A 0 
common 0 
human 0 
skin 1
tumour 1
is 0 
caused 0 
by 0 
activating 0 
mutations 0 
in 0 
beta-catenin 0 
. 0 

WNT 0 
signalling 0 
orchestrates 0 
a 0 
number 0 
of 0 
developmental 0 
programs 0 
. 0 

In 0 
response 0 
to 0 
this 0 
stimulus 0 
, 0 
cytoplasmic 0 
beta-catenin 0 
-LRB- 0 
encoded 0 
by 0 
CTNNB1 0 
-RRB- 0 
is 0 
stabilized 0 
, 0 
enabling 0 
downstream 0 
transcriptional 0 
activation 0 
by 0 
members 0 
of 0 
the 0 
LEF 0 
/ 0 
TCF 0 
family 0 
. 0 

One 0 
of 0 
the 0 
target 0 
genes 0 
for 0 
beta-catenin 0 
/ 0 
TCF 0 
encodes 0 
c-MYC 0 
, 0 
explaining 0 
why 0 
constitutive 0 
activation 0 
of 0 
the 0 
WNT 0 
pathway 0 
can 0 
lead 0 
to 0 
cancer 1
, 0 
particularly 0 
in 0 
the 0 
colon 0
. 0 

Most 0 
colon 1
cancers 1
arise 0 
from 0 
mutations 0 
in 0 
the 0 
gene 0 
encoding 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
, 0 
a 0 
protein 0 
required 0 
for 0 
ubiquitin-mediated 0 
degradation 0 
of 0 
beta-catenin 0 
, 0 
but 0 
a 0 
small 0 
percentage 0 
of 0 
colon 1
and 1
some 1
other 1
cancers 1
harbour 0 
beta-catenin-stabilizing 0 
mutations 0 
. 0 

Recently 0 
, 0 
we 0 
discovered 0 
that 0 
transgenic 0 
mice 0 
expressing 0 
an 0 
activated 0 
beta-catenin 0 
are 0 
predisposed 0 
to 0 
developing 0 
skin 1
tumours 1
resembling 0 
pilomatricomas 1
. 0 

Given 0 
that 0 
the 0 
skin 0 
of 0 
these 0 
adult 0 
mice 0 
also 0 
exhibits 0 
signs 0 
of 0 
de 0 
novo 0 
hair-follicle 0 
morphogenesis 0 
, 0 
we 0 
wondered 0 
whether 0 
human 0 
pilomatricomas 1
might 0 
originate 0 
from 0 
hair 0 
matrix 0 
cells 0 
and 0 
whether 0 
they 0 
might 0 
possess 0 
beta-catenin-stabilizing 0 
mutations 0 
. 0 

Here 0 
, 0 
we 0 
explore 0 
the 0 
cell 0 
origin 0 
and 0 
aetiology 0 
of 0 
this 0 
common 0 
human 0 
skin 1
tumour 1
. 0 

We 0 
found 0 
nuclear 0 
LEF-1 0 
in 0 
the 0 
dividing 0 
tumour 1
cells 0 
, 0 
providing 0 
biochemical 0 
evidence 0 
that 0 
pilomatricomas 1
are 0 
derived 0 
from 0 
hair 0 
matrix 0 
cells 0 
. 0 

At 0 
least 0 
_NUM2 0 
% 0 
of 0 
these 0 
tumours 1
possess 0 
mutations 0 
affecting 0 
the 0 
amino-terminal 0 
segment 0 
, 0 
normally 0 
involved 0 
in 0 
phosphorylation-dependent 0 
, 0 
ubiquitin-mediated 0 
degradation 0 
of 0 
the 0 
protein 0 
. 0 

This 0 
percentage 0 
of 0 
CTNNB1 0 
mutations 0 
is 0 
greater 0 
than 0 
in 0 
all 0 
other 0 
human 0 
tumours 1
examined 0 
thus 0 
far 0 
, 0 
and 0 
directly 0 
implicates 0 
beta-catenin 0 
/ 0 
LEF 0 
misregulation 0 
as 0 
the 0 
major 0 
cause 0 
of 0 
hair 0 
matrix 0 
cell 0 
tumorigenesis 0 
in 0 
humans 0 
. 0 
. 0 

HFE 0 
mutations 0 
analysis 0 
in 0 
_NUM3 0 
hemochromatosis 1
probands 0 
: 0 
evidence 0 
for 0 
S65C 0 
implication 0 
in 0 
mild 0 
form 0 
of 0 
hemochromatosis 1
. 0 

Hereditary 1
hemochromatosis 1
-LRB- 0 
HH 1
-RRB- 0 
is 0 
a 0 
common 0 
autosomal 1
recessive 1
genetic 1
disorder 1
of 0 
iron 0 
metabolism 0 
. 0 

The 0 
HFE 0 
candidate 0 
gene 0 
encoding 0 
an 0 
HLA 0 
class 0 
I-like 0 
protein 0 
involved 0 
in 0 
HH 1
was 0 
identified 0 
in 0 
_NUM4 0 
. 0 

Two 0 
missense 0 
mutations 0 
have 0 
been 0 
described 0 
C282Y 0 
, 0 
accounting 0 
for 0 
_NUM2 0 
% 0 
to 0 
_NUM2 0 
% 0 
of 0 
HH 1
chromosomes 0 
, 0 
and 0 
H63D 0 
, 0 
which 0 
is 0 
associated 0 
with 0 
a 0 
milder 0 
form 0 
of 0 
the 0 
disease 0 
representing 0 
_NUM2 0 
% 0 
to 0 
_NUM2 0 
% 0 
of 0 
non-C282Y 0 
HH 1
chromosomes 0 
. 0 

We 0 
report 0 
here 0 
on 0 
the 0 
analysis 0 
of 0 
C282Y 0 
, 0 
H63D 0 
, 0 
and 0 
the 0 
193A 0 
-- 0 
> 0 
T 0 
substitution 0 
leading 0 
to 0 
the 0 
S65C 0 
missense 0 
substitution 0 
in 0 
a 0 
large 0 
series 0 
of 0 
probands 0 
and 0 
controls 0 
. 0 

The 0 
results 0 
confirm 0 
that 0 
the 0 
C282Y 0 
substitution 0 
was 0 
the 0 
main 0 
mutation 0 
involved 0 
in 0 
hemochromatosis 1
, 0 
accounting 0 
for 0 
_NUM2 0 
% 0 
of 0 
carrier 0 
chromosomes 0 
, 0 
whereas 0 
the 0 
H63D 0 
substitution 0 
represented 0 
_NUM2 0 
% 0 
of 0 
the 0 
HH 1
chromosomes 0 
that 0 
did 0 
not 0 
carry 0 
the 0 
C282Y 0 
mutation 0 
. 0 

In 0 
addition 0 
, 0 
our 0 
screening 0 
showed 0 
that 0 
the 0 
S65C 0 
substitution 0 
was 0 
significantly 0 
enriched 0 
in 0 
probands 0 
with 0 
at 0 
least 0 
one 0 
chromosome 0 
without 0 
an 0 
assigned 0 
mutation 0 
. 0 

This 0 
substitution 0 
accounted 0 
for 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
HH 1
chromosomes 0 
that 0 
were 0 
neither 0 
C282Y 0 
nor 0 
H63D 0 
. 0 

This 0 
enrichment 0 
of 0 
S65C 0 
among 0 
HH 1
chromosomes 0 
suggests 0 
that 0 
the 0 
S65C 0 
substitution 0 
is 0 
associated 0 
with 0 
the 0 
mild 0 
form 0 
of 0 
hemochromatosis 1
. 0 

Germline 0 
BRCA1 0 
alterations 0 
in 0 
a 0 
population-based 0 
series 0 
of 0 
ovarian 1
cancer 1
cases 0 
. 0 

The 0 
objective 0 
of 0 
this 0 
study 0 
was 0 
to 0 
provide 0 
more 0 
accurate 0 
frequency 0 
estimates 0 
of 0 
breast 1
cancer 1
susceptibility 0 
gene 0 
_NUM1 0 
-LRB- 0 
BRCA1 0 
-RRB- 0 
germline 0 
alterations 0 
in 0 
the 0 
ovarian 1
cancer 1
population 0 
. 0 

To 0 
achieve 0 
this 0 
, 0 
we 0 
determined 0 
the 0 
prevalence 0 
of 0 
BRCA1 0 
alterations 0 
in 0 
a 0 
population-based 0 
series 0 
of 0 
consecutive 0 
ovarian 1
cancer 1
cases 0 
. 0 

This 0 
is 0 
the 0 
first 0 
population-based 0 
ovarian 1
cancer 1
study 0 
reporting 0 
BRCA1 0 
alterations 0 
derived 0 
from 0 
a 0 
comprehensive 0 
screen 0 
of 0 
the 0 
entire 0 
coding 0 
region 0 
. 0 

One 0 
hundred 0 
and 0 
seven 0 
ovarian 1
cancer 1
cases 0 
were 0 
analyzed 0 
for 0 
BRCA1 0 
alterations 0 
using 0 
the 0 
RNase 0 
mismatch 0 
cleavage 0 
assay 0 
followed 0 
by 0 
direct 0 
sequencing 0 
. 0 

Two 0 
truncating 0 
mutations 0 
, 0 
962del4 0 
and 0 
3600del11 0 
, 0 
were 0 
identified 0 
. 0 

Both 0 
patients 0 
had 0 
a 0 
family 0 
history 0 
of 0 
breast 1
or 1
ovarian 1
cancer 1
. 0 

Several 0 
novel 0 
as 0 
well 0 
as 0 
previously 0 
reported 0 
uncharacterized 0 
variants 0 
were 0 
also 0 
identified 0 
, 0 
some 0 
of 0 
which 0 
were 0 
associated 0 
with 0 
a 0 
family 0 
history 0 
of 0 
cancer 1
. 0 

The 0 
frequency 0 
distribution 0 
of 0 
common 0 
polymorphisms 0 
was 0 
determined 0 
in 0 
the 0 
_NUM2 0 
Caucasian 0 
cancer 1
cases 0 
in 0 
this 0 
series 0 
and 0 
_NUM2 0 
sister 0 
controls 0 
using 0 
allele-specific 0 
amplification 0 
. 0 

The 0 
rare 0 
form 0 
of 0 
the 0 
Q356R 0 
polymorphism 0 
was 0 
significantly 0 
-LRB- 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
associated 0 
with 0 
a 0 
family 0 
history 0 
of 0 
ovarian 1
cancer 1
, 0 
suggesting 0 
that 0 
this 0 
polymorphism 0 
may 0 
influence 0 
ovarian 1
cancer 1
risk 0 
. 0 

In 0 
summary 0 
, 0 
our 0 
data 0 
suggest 0 
a 0 
role 0 
for 0 
some 0 
uncharacterized 0 
variants 0 
and 0 
rare 0 
forms 0 
of 0 
polymorphisms 0 
in 0 
determining 0 
ovarian 1
cancer 1
risk 0 
, 0 
and 0 
highlight 0 
the 0 
necessity 0 
to 0 
screen 0 
for 0 
missense 0 
alterations 0 
as 0 
well 0 
as 0 
truncating 0 
mutations 0 
in 0 
this 0 
population 0 
. 0 

Identification 0 
of 0 
APC2 0 
, 0 
a 0 
homologue 0 
of 0 
the 0 
adenomatous 1
polyposis 1
coli 1
tumour 1
suppressor 0 
. 0 

The 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 1
APC 1
-RRB- 1
tumour 1
suppressor 0 
protein 0 
controls 0 
the 0 
Wnt 0 
signalling 0 
pathway 0 
by 0 
forming 0 
a 0 
complex 0 
with 0 
glycogen 0 
synthase 0 
kinase 0 
3beta 0 
-LRB- 0 
GSK-3beta 0 
-RRB- 0 
, 0 
axin 0 
/ 0 
conductin 0 
and 0 
betacatenin 0 
. 0 

Complex 0 
formation 0 
induces 0 
the 0 
rapid 0 
degradation 0 
of 0 
betacatenin 0 
. 0 

In 0 
colon 1
carcinoma 1
cells 0 
, 0 
loss 0 
of 0 
APC 0 
leads 0 
to 0 
the 0 
accumulation 0 
of 0 
betacatenin 0 
in 0 
the 0 
nucleus 0 
, 0 
where 0 
it 0 
binds 0 
to 0 
and 0 
activates 0 
the 0 
Tcf-4 0 
transcription 0 
factor 0 
-LRB- 0 
reviewed 0 
in 0 
-LSB- 0 
_NUM1 0 
-RSB- 0 
-LSB- 0 
_NUM1 0 
-RSB- 0 
-RRB- 0 
. 0 

Here 0 
, 0 
we 0 
report 0 
the 0 
identification 0 
and 0 
genomic 0 
structure 0 
of 0 
APC 0 
homologues 0 
. 0 

Mammalian 0 
APC2 0 
, 0 
which 0 
closely 0 
resembles 0 
APC 0 
in 0 
overall 0 
domain 0 
structure 0 
, 0 
was 0 
functionally 0 
analyzed 0 
and 0 
shown 0 
to 0 
contain 0 
two 0 
SAMP 0 
domains 0 
, 0 
both 0 
of 0 
which 0 
are 0 
required 0 
for 0 
binding 0 
to 0 
conductin 0 
. 0 

Like 0 
APC 0 
, 0 
APC2 0 
regulates 0 
the 0 
formation 0 
of 0 
active 0 
betacatenin-Tcf 0 
complexes 0 
, 0 
as 0 
demonstrated 0 
using 0 
transient 0 
transcriptional 0 
activation 0 
assays 0 
in 0 
APC 0 
- 0 
/ 0 
- 0 
colon 1
carcinoma 1
cells 0 
. 0 

Human 0 
APC2 0 
maps 0 
to 0 
chromosome 0 
19p13 0 
. 0 

_NUM1 0 
. 0 

APC 0 
and 0 
APC2 0 
may 0 
therefore 0 
have 0 
comparable 0 
functions 0 
in 0 
development 0 
and 0 
cancer 1
. 0 

Familial 1
deficiency 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
associated 0 
with 0 
recurrent 0 
bacteremic 1
infections 1
due 1
to 1
Neisseria 1
. 0 

The 0 
serum 0 
of 0 
a 0 
29-year 0 
old 0 
woman 0 
with 0 
a 0 
recent 0 
episode 0 
of 0 
disseminated 1
gonococcal 1
infection 1
and 0 
a 0 
history 0 
of 0 
meningococcal 1
meningitis 1
and 0 
arthritis 1
as 0 
a 0 
child 0 
was 0 
found 0 
to 0 
lack 0 
serum 0 
hemolytic 0 
complement 0 
activity 0 
. 0 

The 0 
seventh 0 
component 0 
of 0 
complement 0 
-LRB- 0 
C7 0 
-RRB- 0 
was 0 
not 0 
detected 0 
by 0 
functional 0 
or 0 
immunochemical 0 
assays 0 
, 0 
whereas 0 
other 0 
components 0 
were 0 
normal 0 
by 0 
hemolytic 0 
and 0 
immunochemical 0 
assessment 0 
. 0 

Her 0 
fresh 0 
serum 0 
lacked 0 
complement-mediated 0 
bactericidal 0 
activity 0 
against 0 
Neisseria 0 
gonorrhoeae 0 
, 0 
but 0 
the 0 
addition 0 
of 0 
fresh 0 
normal 0 
serum 0 
or 0 
purified 0 
C7 0 
restored 0 
bactericidal 0 
activity 0 
as 0 
well 0 
as 0 
hemolytic 0 
activity 0 
. 0 

The 0 
absence 1
of 1
functional 1
C7 1
activity 0 
could 0 
not 0 
be 0 
accounted 0 
for 0 
on 0 
the 0 
basis 0 
of 0 
an 0 
inhibitor 0 
. 0 

Opsonization 0 
and 0 
generation 0 
of 0 
chemotactic 0 
activity 0 
functioned 0 
normally 0 
. 0 

Complete 1
absence 1
of 1
C7 1
was 0 
also 0 
found 0 
in 0 
one 0 
sibling 0 
who 0 
had 0 
the 0 
clinical 0 
syndrome 0 
of 0 
meningococcal 1
meningitis 1
and 0 
arthritis 1
as 0 
a 0 
child 0 
and 0 
in 0 
this 0 
siblings 0 
clinically 0 
well 0 
eight-year-old 0 
son 0 
. 0 

HLA 0 
histocompatibility 0 
typing 0 
of 0 
the 0 
family 0 
members 0 
did 0 
not 0 
demonstrate 0 
evidence 0 
for 0 
genetic 0 
linkage 0 
of 0 
C7 1
deficiency 1
with 0 
the 0 
major 0 
histocompatibility 0 
loci 0 
. 0 

This 0 
report 0 
represents 0 
the 0 
first 0 
cases 0 
of 0 
C7 1
deficiency 1
associated 0 
with 0 
infectious 0 
complications 0 
and 0 
suggests 0 
that 0 
bactericidal 0 
activity 0 
may 0 
be 0 
important 0 
in 0 
host 0 
defense 0 
against 0 
bacteremic 1
neisseria 1
infections 1
. 0 

GCH1 0 
mutation 0 
in 0 
a 0 
patient 0 
with 0 
adult-onset 0 
oromandibular 1
dystonia 1
. 0 

The 0 
authors 0 
report 0 
a 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
of 0 
GCH1 0 
in 0 
a 0 
patient 0 
with 0 
adult-onset 0 
oromandibular 1
dystonia 1
and 0 
no 0 
obvious 0 
family 0 
history 0 
of 0 
dystonia 1
. 0 

The 0 
patient 0 
responded 0 
positively 0 
to 0 
treatment 0 
with 0 
L-dopa 0 
. 0 

These 0 
findings 0 
demonstrate 0 
that 0 
GCH1 0 
mutations 0 
must 0 
be 0 
considered 0 
even 0 
in 0 
patients 0 
with 0 
dystonic 1
symptoms 0 
not 0 
typical 0 
of 0 
dopa-responsive 1
dystonia 1
. 0 

The 0 
hereditary 1
hemochromatosis 1
protein 0 
, 0 
HFE 0 
, 0 
specifically 0 
regulates 0 
transferrin-mediated 0 
iron 0 
uptake 0 
in 0 
HeLa 0 
cells 0 
. 0 

HFE 0 
is 0 
the 0 
protein 0 
product 0 
of 0 
the 0 
gene 0 
mutated 0 
in 0 
the 0 
autosomal 1
recessive 1
disease 1
hereditary 1
hemochromatosis 1
-LRB- 0 
Feder 0 
, 0 
J. 0 
N. 0 
, 0 
Gnirke 0 
, 0 
A. 0 
, 0 
Thomas 0 
, 0 
W. 0 
, 0 
Tsuchihashi 0 
, 0 
Z. 0 
, 0 
Ruddy 0 
, 0 
D. 0 
A. 0 
, 0 
Basava 0 
, 0 
A. 0 
, 0 
Dormishian 0 
, 0 
F. 0 
, 0 
Domingo 0 
, 0 
R. 0 
J. 0 
, 0 
Ellis 0 
, 0 
M. 0 
C. 0 
, 0 
Fullan 0 
, 0 
A. 0 
, 0 
Hinton 0 
, 0 
L. 0 
M. 0 
, 0 
Jones 0 
, 0 
N. 0 
L. 0 
, 0 
Kimmel 0 
, 0 
B. 0 
E. 0 
, 0 
Kronmal 0 
, 0 
G. 0 
S. 0 
, 0 
Lauer 0 
, 0 
P. 0 
, 0 
Lee 0 
, 0 
V. 0 
K. 0 
, 0 
Loeb 0 
, 0 
D. 0 
B. 0 
, 0 
Mapa 0 
, 0 
F. 0 
A. 0 
, 0 
McClelland 0 
, 0 
E. 0 
, 0 
Meyer 0 
, 0 
N. 0 
C. 0 
, 0 
Mintier 0 
, 0 
G. 0 
A. 0 
, 0 
Moeller 0 
, 0 
N. 0 
, 0 
Moore 0 
, 0 
T. 0 
, 0 
Morikang 0 
, 0 
E. 0 
, 0 
Prasss 0 
, 0 
C. 0 
E 0 
. 0 

, 0 
Quintana 0 
, 0 
L. 0 
, 0 
Starnes 0 
, 0 
S. 0 
M 0 
. 0 

, 0 
Schatzman 0 
, 0 
R. 0 
C 0 
. 0 

, 0 
Brunke 0 
, 0 
K. 0 
J 0 
. 0 

, 0 
Drayna 0 
, 0 
D. 0 
T. 0 
, 0 
Risch 0 
, 0 
N. 0 
J 0 
. 0 

, 0 
Bacon 0 
, 0 
B. 0 
R 0 
. 0 

, 0 
and 0 
Wolff 0 
, 0 
R. 0 
R 0 
. 0 

-LRB- 0 
_NUM4 0 
-RRB- 0 
Nat 0 
. 0 

Genet 0 
. 0 

_NUM2 0 
, 0 
399-408 0 
-RRB- 0 
. 0 

At 0 
the 0 
cell 0 
surface 0 
, 0 
HFE 0 
complexes 0 
with 0 
transferrin 0 
receptor 0 
-LRB- 0 
TfR 0 
-RRB- 0 
, 0 
increasing 0 
the 0 
dissociation 0 
constant 0 
of 0 
transferrin 0 
-LRB- 0 
Tf 0 
-RRB- 0 
for 0 
its 0 
receptor 0 
10-fold 0 
-LRB- 0 
Gross 0 
, 0 
C. 0 
N 0 
. 0 

, 0 
Irrinki 0 
, 0 
A. 0 
, 0 
Feder 0 
, 0 
J. 0 
N 0 
. 0 

, 0 
and 0 
Enns 0 
, 0 
C 0 
. 0 

A 0 
. 0 

-LRB- 0 
_NUM4 0 
-RRB- 0 
J. 0 
Biol 0 
. 0 

Chem 0 
. 0 

_NUM3 0 
, 0 
22068-22074 0 
; 0 
Feder 0 
, 0 
J. 0 
N. 0 
, 0 
Penny 0 
, 0 
D. 0 
M. 0 
, 0 
Irrinki 0 
, 0 
A. 0 
, 0 
Lee 0 
, 0 
V. 0 
K. 0 
, 0 
Lebron 0 
, 0 
J. 0 
A. 0 
, 0 
Watson 0 
, 0 
N. 0 
, 0 
Tsuchihashi 0 
, 0 
Z. 0 
, 0 
Sigal 0 
, 0 
E. 0 
, 0 
Bjorkman 0 
, 0 
P. 0 
J. 0 
, 0 
and 0 
Schatzman 0 
, 0 
R. 0 
C. 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
Proc 0 
. 0 

Natl 0 
. 0 

Acad 0 
. 0 

Sci 0 
. 0 

U 0 
S 0 
A 0 
_NUM2 0 
, 0 
1472-1477 0 
-RRB- 0 
. 0 

HFE 0 
does 0 
not 0 
remain 0 
at 0 
the 0 
cell 0 
surface 0 
, 0 
but 0 
traffics 0 
with 0 
TfR 0 
to 0 
Tf-positive 0 
internal 0 
compartments 0 
-LRB- 0 
Gross 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

Using 0 
a 0 
HeLa 0 
cell 0 
line 0 
in 0 
which 0 
the 0 
expression 0 
of 0 
HFE 0 
is 0 
controlled 0 
by 0 
tetracycline 0 
, 0 
we 0 
show 0 
that 0 
the 0 
expression 0 
of 0 
HFE 0 
reduces 0 
55Fe 0 
uptake 0 
from 0 
Tf 0 
by 0 
_NUM2 0 
% 0 
but 0 
does 0 
not 0 
affect 0 
the 0 
endocytic 0 
or 0 
exocytic 0 
rates 0 
of 0 
TfR 0 
cycling 0 
. 0 

Therefore 0 
, 0 
HFE 0 
appears 0 
to 0 
reduce 0 
cellular 0 
acquisition 0 
of 0 
iron 0 
from 0 
Tf 0 
within 0 
endocytic 0 
compartments 0 
. 0 

HFE 0 
specifically 0 
reduces 0 
iron 0 
uptake 0 
from 0 
Tf 0 
, 0 
as 0 
non-Tf-mediated 0 
iron 0 
uptake 0 
from 0 
Fe-nitrilotriacetic 0 
acid 0 
is 0 
not 0 
altered 0 
. 0 

These 0 
results 0 
explain 0 
the 0 
decreased 0 
ferritin 0 
levels 0 
seen 0 
in 0 
our 0 
HeLa 0 
cell 0 
system 0 
and 0 
demonstrate 0 
the 0 
specific 0 
control 0 
of 0 
HFE 0 
over 0 
the 0 
Tf-mediated 0 
pathway 0 
of 0 
iron 0 
uptake 0 
. 0 

These 0 
results 0 
also 0 
have 0 
implications 0 
for 0 
the 0 
understanding 0 
of 0 
cellular 0 
iron 0 
homeostasis 0 
in 0 
organs 0 
such 0 
as 0 
the 0 
liver 0 
, 0 
pancreas 0 
, 0 
heart 0 
, 0 
and 0 
spleen 0 
that 0 
are 0 
iron 0 
loaded 0 
in 0 
hereditary 1
hemochromatotic 1
individuals 0 
lacking 0 
functional 0 
HFE 0 
. 0 

Mutation 0 
and 0 
haplotype 0 
studies 0 
of 0 
familial 1
Mediterranean 1
fever 1
reveal 0 
new 0 
ancestral 0 
relationships 0 
and 0 
evidence 0 
for 0 
a 0 
high 0 
carrier 0 
frequency 0 
with 0 
reduced 0 
penetrance 0 
in 0 
the 0 
Ashkenazi 0 
Jewish 0 
population 0 
. 0 

Familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
is 0 
a 0 
recessive 1
disorder 1
characterized 0 
by 0 
episodes 0 
of 0 
fever 0 
with 0 
serositis 1
or 0 
synovitis 1
. 0 

The 0 
FMF 1
gene 0 
-LRB- 0 
MEFV 0 
-RRB- 0 
was 0 
cloned 0 
recently 0 
, 0 
and 0 
four 0 
missense 0 
mutations 0 
were 0 
identified 0 
. 0 

Here 0 
we 0 
present 0 
data 0 
from 0 
non-Ashkenazi 0 
Jewish 0 
and 0 
Arab 0 
patients 0 
in 0 
whom 0 
we 0 
had 0 
not 0 
originally 0 
found 0 
mutations 0 
and 0 
from 0 
a 0 
new 0 
, 0 
more 0 
ethnically 0 
diverse 0 
panel 0 
. 0 

Among 0 
_NUM2 0 
symptomatic 0 
mutation-positive 0 
individuals 0 
, 0 
_NUM2 0 
mutations 0 
accounted 0 
for 0 
_NUM2 0 
% 0 
of 0 
carrier 0 
chromosomes 0 
. 0 

Of 0 
the 0 
two 0 
mutations 0 
that 0 
are 0 
novel 0 
, 0 
one 0 
alters 0 
the 0 
same 0 
residue 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
as 0 
a 0 
previously 0 
known 0 
mutation 0 
, 0 
and 0 
the 0 
other 0 
-LRB- 0 
P369S 0 
-RRB- 0 
is 0 
located 0 
in 0 
exon 0 
_NUM1 0 
. 0 

Consistent 0 
with 0 
another 0 
recent 0 
report 0 
, 0 
the 0 
E148Q 0 
mutation 0 
was 0 
observed 0 
in 0 
patients 0 
of 0 
several 0 
ethnicities 0 
and 0 
on 0 
multiple 0 
microsatellite 0 
haplotypes 0 
, 0 
but 0 
haplotype 0 
data 0 
indicate 0 
an 0 
ancestral 0 
relationships 0 
between 0 
non-Jewish 0 
Italian 0 
and 0 
Ashkenazi 0 
Jewish 0 
patients 0 
with 0 
FMF 1
and 0 
other 0 
affected 0 
populations 0 
. 0 

Among 0 
approximately 0 
_NUM3 0 
anonymous 0 
Ashkenazi 0 
Jewish 0 
DNA 0 
samples 0 
, 0 
the 0 
MEFV 0 
carrier 0 
frequency 0 
was 0 
_NUM2 0 
% 0 
, 0 
with 0 
E148Q 0 
the 0 
most 0 
common 0 
mutation 0 
. 0 

Several 0 
lines 0 
of 0 
evidence 0 
indicate 0 
reduced 0 
penetrance 0 
among 0 
Ashkenazi 0 
Jews 0 
, 0 
especially 0 
for 0 
E148Q 0 
, 0 
P369S 0 
, 0 
and 0 
K695R 0 
. 0 

Nevertheless 0 
, 0 
E148Q 0 
helps 0 
account 0 
for 0 
recessive 0 
inheritance 0 
in 0 
an 0 
Ashkenazi 0 
family 0 
previously 0 
reported 0 
as 0 
an 0 
unusual 0 
case 0 
of 0 
dominantly 0 
inherited 0 
FMF 1
. 0 

The 0 
presence 0 
of 0 
three 0 
frequent 0 
MEFV 0 
mutations 0 
in 0 
multiple 0 
Mediterranean 0 
populations 0 
strongly 0 
suggests 0 
a 0 
heterozygote 0 
advantage 0 
in 0 
this 0 
geographic 0 
region 0 
. 0 

Autoimmune 1
lymphoproliferative 1
syndrome 1
with 0 
defective 0 
Fas 0 
: 0 
genotype 0 
influences 0 
penetrance 0 
. 0 

Autoimmune 1
lymphoproliferative 1
syndrome 1
-LRB- 0 
ALPS 1
-RRB- 0 
is 0 
a 0 
disorder 1
of 1
lymphocyte 1
homeostasis 1
and 1
immunological 1
tolerance 1
. 0 

Most 0 
patients 0 
have 0 
a 0 
heterozygous 0 
mutation 0 
in 0 
the 0 
APT1 0 
gene 0 
, 0 
which 0 
encodes 0 
Fas 0 
-LRB- 0 
CD95 0 
, 0 
APO-1 0 
-RRB- 0 
, 0 
mediator 0 
of 0 
an 0 
apoptotic 0 
pathway 0 
crucial 0 
to 0 
lymphocyte 0 
homeostasis 0 
. 0 

Of 0 
_NUM2 0 
unique 0 
APT1 0 
mutations 0 
in 0 
unrelated 0 
ALPS 1
probands 0 
, 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
occurred 0 
in 0 
exons 0 
7-9 0 
, 0 
which 0 
encode 0 
the 0 
intracellular 0 
portion 0 
of 0 
Fas 0 
. 0 

In 0 
vitro 0 
, 0 
activated 0 
lymphocytes 0 
from 0 
all 0 
_NUM2 0 
patients 0 
showed 0 
apoptotic 0 
defects 0 
when 0 
exposed 0 
to 0 
an 0 
anti-Fas 0 
agonist 0 
monoclonal 0 
antibody 0 
. 0 

Similar 0 
defects 0 
were 0 
found 0 
in 0 
a 0 
Fas-negative 0 
cell 0 
line 0 
transfected 0 
with 0 
cDNAs 0 
bearing 0 
each 0 
of 0 
the 0 
mutations 0 
. 0 

In 0 
cotransfection 0 
experiments 0 
, 0 
Fas 0 
constructs 0 
with 0 
either 0 
intra 0 
- 0 
or 0 
extracellular 0 
mutations 0 
caused 0 
dominant 0 
inhibition 0 
of 0 
apoptosis 0 
mediated 0 
by 0 
wild-type 0 
Fas 0 
. 0 

Two 0 
missense 0 
Fas 0 
variants 0 
, 0 
not 0 
restricted 0 
to 0 
patients 0 
with 0 
ALPS 1
, 0 
were 0 
identified 0 
. 0 

Variant 0 
A 0 
-LRB- 0 
-1 0 
-RRB- 0 
T 0 
at 0 
the 0 
Fas 0 
signal-sequence 0 
cleavage 0 
site 0 
, 0 
which 0 
mediates 0 
apoptosis 0 
less 0 
well 0 
than 0 
wild-type 0 
Fas 0 
and 0 
is 0 
partially 0 
inhibitory 0 
, 0 
was 0 
present 0 
in 0 
_NUM2 0 
% 0 
of 0 
African 0 
American 0 
alleles 0 
. 0 

Among 0 
the 0 
ALPS 1
associated 0 
Fas 0 
mutants 0 
, 0 
dominant 0 
inhibition 0 
of 0 
apoptosis 0 
was 0 
much 0 
more 0 
pronounced 0 
in 0 
mutants 0 
affecting 0 
the 0 
intracellular 0 
, 0 
versus 0 
extracellular 0 
, 0 
portion 0 
of 0 
the 0 
Fas 0 
receptor 0 
. 0 

Mutations 0 
causing 0 
disruption 0 
of 0 
the 0 
intracellular 0 
Fas 0 
death 0 
domain 0 
also 0 
showed 0 
a 0 
higher 0 
penetrance 0 
of 0 
ALPS 1
phenotype 0 
features 0 
in 0 
mutation-bearing 0 
relatives 0 
. 0 

Significant 0 
ALPS 1
related 0 
morbidity 0 
occurred 0 
in 0 
_NUM2 0 
% 0 
of 0 
relatives 0 
with 0 
intracellular 0 
mutations 0 
, 0 
versus 0 
_NUM1 0 
% 0 
of 0 
relatives 0 
with 0 
extracellular 0 
mutations 0 
. 0 

Thus 0 
, 0 
the 0 
location 0 
of 0 
mutations 0 
within 0 
APT1 0 
strongly 0 
influences 0 
the 0 
development 0 
and 0 
the 0 
severity 0 
of 0 
ALPS 1
. 0 

Mutational 0 
analysis 0 
and 0 
genotype-phenotype 0 
correlation 0 
of 0 
_NUM2 0 
unrelated 0 
Japanese 0 
patients 0 
with 0 
X-linked 1
adrenoleukodystrophy 1
. 0 

BACKGROUND 0 
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
is 0 
an 0 
inherited 1
disease 1
characterized 0 
by 0 
progressive 0 
neurologic 1
dysfunction 1
, 0 
occasionally 0 
associated 0 
with 0 
adrenal 1
insufficiency 1
. 0 

The 0 
classic 0 
form 0 
of 0 
ALD 1
usually 0 
has 0 
onset 0 
in 0 
childhood 0
-LRB- 0 
childhood 1
cerebral 1
ALD 1
-RRB- 0 
, 0 
with 0 
rapid 0 
neurologic 1
deterioration 1
leading 0 
to 0 
a 0 
vegetative 0 
state 0 
. 0 

Adult-onset 0 
cerebral 1
ALD 1
also 0 
presents 0 
with 0 
rapidly 0 
progressive 0 
neurologic 1
dysfunction 1
. 0 

Milder 0 
phenotypes 0 
such 0 
as 0 
adrenomyeloneuropathy 1
and 0 
Addison 1
disease 1
only 0 
also 0 
have 0 
been 0 
recognized 0 
. 0 

Despite 0 
discovery 0 
of 0 
the 0 
causative 0 
gene 0 
, 0 
a 0 
molecular 0 
basis 0 
for 0 
the 0 
diverse 0 
clinical 0 
presentations 0 
remains 0 
to 0 
be 0 
elucidated 0 
. 0 

OBJECTIVES 0 
To 0 
conduct 0 
mutational 0 
analyses 0 
in 0 
_NUM2 0 
Japanese 0 
patients 0 
with 0 
ALD 1
from 0 
_NUM2 0 
unrelated 0 
families 0 
, 0 
to 0 
obtain 0 
knowledge 0 
of 0 
the 0 
spectrum 0 
of 0 
mutations 0 
in 0 
this 0 
gene 0 
, 0 
and 0 
to 0 
study 0 
genotype-phenotype 0 
correlations 0 
in 0 
Japanese 0 
patients 0 
. 0 

METHODS 0 
The 0 
_NUM2 0 
patients 0 
comprised 0 
_NUM2 0 
patients 0 
with 0 
childhood 1
cerebral 1
ALD 1
, 0 
_NUM2 0 
patients 0 
with 0 
adult-onset 0 
cerebral 1
ALD 1
, 0 
and 0 
_NUM1 0 
patients 0 
with 0 
adrenomyeloneuropathy 1
. 0 

We 0 
conducted 0 
detailed 0 
mutational 0 
analyses 0 
of 0 
_NUM2 0 
unrelated 0 
Japanese 0 
patients 0 
with 0 
ALD 1
by 0 
genomic 0 
Southern 0 
blot 0 
analysis 0 
and 0 
direct 0 
nucleotide 0 
sequence 0 
analysis 0 
of 0 
reverse 0 
transcriptase-polymerase 0 
chain 0 
reaction 0 
products 0 
derived 0 
from 0 
total 0 
RNA 0 
that 0 
was 0 
extracted 0 
from 0 
cultured 0 
skin 0 
fibroblasts 0 
, 0 
lymphoblastoid 0 
cells 0 
, 0 
or 0 
peripheral 0 
blood 0 
leukocytes 0 
. 0 

RESULTS 0 
Three 0 
patients 0 
with 0 
adult-onset 0 
cerebral 1
ALD 1
were 0 
identified 0 
as 0 
having 0 
large 0 
genomic 0 
rearrangements 0 
. 0 

The 0 
remaining 0 
_NUM2 0 
patients 0 
were 0 
identified 0 
as 0 
having 0 
_NUM2 0 
independent 0 
mutations 0 
, 0 
including 0 
_NUM2 0 
novel 0 
mutations 0 
resulting 0 
in 0 
small 0 
nucleotide 0 
alterations 0 
in 0 
the 0 
ALD 1
gene 0 
. 0 

Eighteen 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
mutations 0 
were 0 
missense 0 
mutations 0 
. 0 

Most 0 
missense 0 
mutations 0 
involved 0 
amino 0 
acids 0 
conserved 0 
in 0 
homologous 0 
gene 0 
products 0 
, 0 
including 0 
PMP70 0 
, 0 
mALDRP 0 
, 0 
and 0 
Pxa1p 0 
. 0 

The 0 
_DS 0 
dinucleotide 0 
deletion 0 
at 0 
position 0 
1081-1082 0 
, 0 
which 0 
has 0 
been 0 
reported 0 
previously 0 
to 0 
be 0 
the 0 
most 0 
common 0 
mutation 0 
in 0 
white 0 
patients 0 
-LRB- 0 
_NUM2 0 
% 0 
-17 0 
% 0 
-RRB- 0 
, 0 
was 0 
also 0 
identified 0 
as 0 
the 0 
most 0 
common 0 
mutation 0 
in 0 
Japanese 0 
patients 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

All 0 
phenotypes 0 
were 0 
associated 0 
with 0 
mutations 0 
resulting 0 
in 0 
protein 0 
truncation 0 
or 0 
subtle 0 
amino 0 
acid 0 
changes 0 
. 0 

There 0 
were 0 
no 0 
differences 0 
in 0 
phenotypic 0 
expressions 0 
between 0 
missense 0 
mutations 0 
involving 0 
conserved 0 
amino 0 
acids 0 
and 0 
those 0 
involving 0 
nonconserved 0 
amino 0 
acids 0 
. 0 

CONCLUSIONS 0 
There 0 
are 0 
no 0 
obvious 0 
correlations 0 
between 0 
the 0 
phenotypes 0 
of 0 
patients 0 
with 0 
ALD 1
and 0 
their 0 
genotypes 0 
, 0 
suggesting 0 
that 0 
other 0 
genetic 0 
or 0 
environmental 0 
factors 0 
modify 0 
the 0 
phenotypic 0 
expressions 0 
of 0 
ALD 1
. 0 
. 0 

Absence 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
in 0 
a 0 
patient 0 
with 0 
chronic 1
meningococcemia 1
presenting 0 
as 0 
vasculitis 1
. 0 

A 0 
previously 0 
healthy 0 
40-year-old 0 
man 0 
presenting 0 
with 0 
fever 1
, 0 
arthritis 1
, 0 
and 0 
cutaneous 1
vasculitis 1
was 0 
found 0 
to 0 
have 0 
chronic 1
meningococcemia 1
. 0 

Evaluation 0 
of 0 
his 0 
complement 0 
system 0 
showed 0 
an 0 
absence 0 
of 0 
functional 0 
and 0 
antigenic 0 
C7 0 
, 0 
compatible 0 
with 0 
a 0 
complete 0 
deficiency 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
. 0 

Study 0 
of 0 
the 0 
patients 0 
family 0 
spanning 0 
four 0 
generations 0 
showed 0 
heterozygous 0 
deficiency 1
of 1
C7 1
in 0 
five 0 
members 0 
. 0 

Chronic 1
neisserial 1
infection 1
can 0 
be 0 
associated 0 
with 0 
C7 1
deficiency 1
and 0 
must 0 
be 0 
distinguished 0 
from 0 
other 0 
causes 0 
of 0 
cutaneous 1
vasculitis 1
. 0 
. 0 

Genotype 0 
and 0 
phenotype 0 
in 0 
patients 0 
with 0 
dihydropyrimidine 1
dehydrogenase 1
deficiency 1
. 0 

Dihydropyrimidine 1
dehydrogenase 1
-LRB- 1
DPD 1
-RRB- 1
deficiency 1
is 0 
an 0 
autosomal 1
recessive 1
disease 1
characterised 0 
by 0 
thymine-uraciluria 0 
in 0 
homozygous 0 
deficient 0 
patients 0 
and 0 
has 0 
been 0 
associated 0 
with 0 
a 0 
variable 0 
clinical 0 
phenotype 0 
. 0 

In 0 
order 0 
to 0 
understand 0 
the 0 
genetic 0 
and 0 
phenotypic 0 
basis 0 
for 0 
DPD 1
deficiency 1
, 0 
we 0 
have 0 
reviewed 0 
_NUM2 0 
families 0 
presenting 0 
_NUM2 0 
patients 0 
with 0 
complete 0 
deficiency 1
of 1
DPD 1
. 0 

In 0 
this 0 
group 0 
of 0 
patients 0 
, 0 
_NUM1 0 
different 0 
mutations 0 
have 0 
been 0 
identified 0 
, 0 
including 0 
_NUM1 0 
deletions 0 
-LSB- 0 
295-298delTCAT 0 
, 0 
1897delC 0 
-RSB- 0 
, 0 
_NUM1 0 
splice-site 0 
mutation 0 
-LSB- 0 
IVS14 0 
+ 0 
1G 0 
> 0 
A 0 
-RRB- 0 
-RSB- 0 
and 0 
_NUM1 0 
missense 0 
mutations 0 
-LRB- 0 
85T 0 
> 0 
C 0 
, 0 
703C 0 
> 0 
T 0 
, 0 
2658G 0 
> 0 
A 0 
, 0 
2983G 0 
> 0 
T 0 
-RRB- 0 
. 0 

Analysis 0 
of 0 
the 0 
prevalence 0 
of 0 
the 0 
various 0 
mutations 0 
among 0 
DPD 1
patients 0 
has 0 
shown 0 
that 0 
the 0 
G 0 
-- 0 
> 0 
A 0 
point 0 
mutation 0 
in 0 
the 0 
invariant 0 
splice 0 
donor 0 
site 0 
is 0 
by 0 
far 0 
the 0 
most 0 
common 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
whereas 0 
the 0 
other 0 
six 0 
mutations 0 
are 0 
less 0 
frequently 0 
observed 0 
. 0 

A 0 
large 0 
phenotypic 0 
variability 0 
has 0 
been 0 
observed 0 
, 0 
with 0 
convulsive 1
disorders 1
, 0 
motor 1
retardation 1
and 0 
mental 1
retardation 1
being 0 
the 0 
most 0 
abundant 0 
manifestations 0 
. 0 

A 0 
clear 0 
correlation 0 
between 0 
the 0 
genotype 0 
and 0 
phenotype 0 
has 0 
not 0 
been 0 
established 0 
. 0 

An 0 
altered 0 
beta-alanine 0 
, 0 
uracil 0 
and 0 
thymine 0 
homeostasis 0 
might 0 
underlie 0 
the 0 
various 0 
clinical 1
abnormalities 1
encountered 0 
in 0 
patients 0 
with 0 
DPD 1
deficiency 1
. 0 

Molecular 0 
characterization 0 
of 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
by 0 
natural 0 
and 0 
amplification 0 
created 0 
restriction 0 
sites 0 
: 0 
five 0 
mutations 0 
account 0 
for 0 
most 0 
G6PD 1
deficiency 1
cases 0 
in 0 
Taiwan 0 
. 0 

We 0 
have 0 
developed 0 
a 0 
rapid 0 
and 0 
simple 0 
method 0 
to 0 
diagnose 0 
the 0 
molecular 0 
defects 0 
of 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
Chinese 0 
in 0 
Taiwan 0 
. 0 

This 0 
method 0 
involves 0 
the 0 
selective 0 
amplification 0 
of 0 
a 0 
DNA 0 
fragment 0 
from 0 
human 0 
G6PD 0
gene 0 
with 0 
specific 0 
oligonucleotide 0 
primers 0 
followed 0 
by 0 
digestion 0 
with 0 
restriction 0 
enzymes 0 
that 0 
recognize 0 
artificially 0 
created 0 
or 0 
naturally 0 
occurring 0 
restriction 0 
sites 0 
. 0 

Ninety-four 0 
Chinese 0 
males 0 
with 0 
G6PD 1
deficiency 1
were 0 
studied 0 
. 0 

The 0 
results 0 
show 0 
that 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
of 0 
_NUM2 0 
-RRB- 0 
were 0 
G 0 
to 0 
T 0 
mutation 0 
at 0 
nucleotide 0 
-LRB- 0 
nt 0 
-RRB- 0 
_NUM4 0 
, 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM2 0 
of 0 
_NUM2 0 
-RRB- 0 
were 0 
G 0 
to 0 
A 0 
mutation 0 
at 0 
nt 0 
_NUM4 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
were 0 
A 0 
to 0 
G 0 
mutation 0 
at 0 
nt 0 
_NUM3 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
were 0 
A 0 
to 0 
G 0 
mutation 0 
at 0 
nt 0 
_NUM2 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
were 0 
C 0 
to 0 
T 0 
mutation 0 
at 0 
nt 0 
_NUM4 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
was 0 
G 0 
to 0 
T 0 
mutation 0 
at 0 
nt 0 
_NUM3 0 
, 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
was 0 
G 0 
to 0 
A 0 
mutation 0 
at 0 
nt 0 
_NUM3 0 
. 0 

These 0 
results 0 
show 0 
that 0 
the 0 
former 0 
five 0 
mutations 0 
account 0 
for 0 
more 0 
than 0 
_NUM2 0 
% 0 
of 0 
G6PD 1
deficiency 1
cases 0 
in 0 
Taiwan 0 
. 0 

Aside 0 
from 0 
showing 0 
that 0 
G 0 
to 0 
T 0 
change 0 
at 0 
nt 0 
_NUM4 0 
is 0 
the 0 
most 0 
common 0 
mutation 0 
, 0 
our 0 
research 0 
indicates 0 
that 0 
nt 0 
_NUM3 0 
mutation 0 
is 0 
a 0 
frequent 0 
mutation 0 
among 0 
Chinese 0 
in 0 
Taiwan 0 
. 0 

We 0 
compared 0 
G6PD 0 
activity 0 
among 0 
different 0 
mutations 0 
, 0 
without 0 
discovering 0 
significant 0 
differences 0 
between 0 
them 0 
. 0 

Homozygous 1
hypobetalipoproteinemia 1
: 0 
a 0 
disease 0 
distinct 0 
from 0 
abetalipoproproteinemia 1
at 0 
the 0 
molecular 0 
level 0 
. 0 

apoB 0 
DNA 0 
, 0 
RNA 0 
, 0 
and 0 
protein 0 
from 0 
two 0 
patients 0 
with 0 
homozygous 1
hypobetalipoproteinemia 1
-LRB- 0 
HBL 1
-RRB- 0 
were 0 
evaluated 0 
and 0 
compared 0 
with 0 
normal 0 
individuals 0 
. 0 

Southern 0 
blot 0 
analysis 0 
with 0 
_NUM2 0 
different 0 
cDNA 0 
probes 0 
revealed 0 
a 0 
normal 0 
gene 0 
without 0 
major 0 
insertions 0 
, 0 
deletions 0 
, 0 
or 0 
rearrangements 0 
. 0 

Northern 0 
and 0 
slot 0 
blot 0 
analyses 0 
of 0 
total 0 
liver 0 
mRNA 0 
from 0 
HBL 1
patients 0 
documented 0 
a 0 
normal 0 
size 0 
apoB 0 
mRNA 0 
that 0 
was 0 
present 0 
in 0 
greatly 0 
reduced 0 
quantities 0 
. 0 

ApoB 0 
protein 0 
was 0 
detected 0 
within 0 
HBL 1
hepatocytes 0 
utilizing 0 
immunohistochemical 0 
techniques 0 
; 0 
however 0 
, 0 
it 0 
was 0 
markedly 0 
reduced 0 
in 0 
quantity 0 
when 0 
compared 0 
with 0 
control 0 
samples 0 
. 0 

No 0 
apoB 0 
was 0 
detectable 0 
in 0 
the 0 
plasma 0 
of 0 
HBL 1
individuals 0 
with 0 
an 0 
ELISA 0 
assay 0 
. 0 

These 0 
data 0 
are 0 
most 0 
consistent 0 
with 0 
a 0 
mutation 0 
in 0 
the 0 
coding 0 
portion 0 
of 0 
the 0 
apoB 0 
gene 0 
in 0 
HBL 1
patients 0 
, 0 
leading 0 
to 0 
an 0 
abnormal 0 
apoB 0 
protein 0 
and 0 
apoB 0 
mRNA 0 
instability 0 
. 0 

These 0 
results 0 
are 0 
distinct 0 
from 0 
those 0 
previously 0 
noted 0 
in 0 
abetalipoproteinemia 1
, 0 
which 0 
was 0 
characterized 0 
by 0 
an 0 
elevated 0 
level 0 
of 0 
hepatic 0 
apoB 0 
mRNA 0 
and 0 
accumulation 0 
of 0 
intracellular 0 
hepatic 0 
apoB 0 
protein 0 
. 0 
. 0 

A 0 
population-based 0 
study 0 
of 0 
the 0 
clinical 0 
expression 0 
of 0 
the 0 
hemochromatosis 1
gene 0 
. 0 

BACKGROUND 0 
AND 0 
METHODS 0 
Hereditary 1
hemochromatosis 1
is 0 
associated 0 
with 0 
homozygosity 0 
for 0 
the 0 
C282Y 0 
mutation 0 
in 0 
the 0 
hemochromatosis 1
-LRB- 0 
HFE 0 
-RRB- 0 
gene 0 
on 0 
chromosome 0 
_NUM1 0 
, 0 
elevated 0 
serum 0 
transferrin 0 
saturation 0 
, 0 
and 0 
excess 1
iron 1
deposits 1
throughout 0 
the 0 
body 0 
. 0 

To 0 
assess 0 
the 0 
prevalence 0 
and 0 
clinical 0 
expression 0 
of 0 
the 0 
HFE 0 
gene 0 
, 0 
we 0 
conducted 0 
a 0 
population-based 0 
study 0 
in 0 
Busselton 0 
, 0 
Australia 0 
. 0 

In 0 
_NUM4 0 
, 0 
we 0 
obtained 0 
blood 0 
samples 0 
for 0 
the 0 
determination 0 
of 0 
serum 0 
transferrin 0 
saturation 0 
and 0 
ferritin 0 
levels 0 
and 0 
the 0 
presence 0 
or 0 
absence 0 
of 0 
the 0 
C282Y 0 
mutation 0 
and 0 
the 0 
H63D 0 
mutation 0 
-LRB- 0 
which 0 
may 0 
contribute 0 
to 0 
increased 0 
hepatic 0 
iron 0 
levels 0 
-RRB- 0 
in 0 
_NUM4 0 
unrelated 0 
white 0 
adults 0 
. 0 

We 0 
evaluated 0 
all 0 
subjects 0 
who 0 
had 0 
persistently 0 
elevated 0 
transferrin-saturation 0 
values 0 
-LRB- 0 
_NUM2 0 
percent 0 
or 0 
higher 0 
-RRB- 0 
or 0 
were 0 
homozygous 0 
for 0 
the 0 
C282Y 0 
mutation 0 
. 0 

We 0 
recommended 0 
liver 0 
biopsy 0 
for 0 
subjects 0 
with 0 
serum 0 
ferritin 0 
levels 0 
of 0 
_NUM3 0 
ng 0 
per 0 
milliliter 0 
or 0 
higher 0 
. 0 

The 0 
subjects 0 
were 0 
followed 0 
for 0 
up 0 
to 0 
four 0 
years 0 
. 0 

RESULTS 0 
Sixteen 0 
of 0 
the 0 
subjects 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
percent 0 
-RRB- 0 
were 0 
homozygous 0 
for 0 
the 0 
C282Y 0 
mutation 0 
, 0 
and 0 
_NUM3 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
percent 0 
-RRB- 0 
were 0 
heterozygous 0 
. 0 

The 0 
serum 0 
transferrin 0 
saturation 0 
was 0 
_NUM2 0 
percent 0 
or 0 
higher 0 
in 0 
_NUM2 0 
of 0 
the 0 
_NUM2 0 
who 0 
were 0 
homozygous 0 
; 0 
in 0 
_NUM1 0 
subject 0 
it 0 
was 0 
_NUM2 0 
percent 0 
. 0 

Four 0 
of 0 
the 0 
homozygous 0 
subjects 0 
had 0 
previously 0 
been 0 
given 0 
a 0 
diagnosis 0 
of 0 
hemochromatosis 1
, 0 
and 0 
_NUM2 0 
had 0 
not 0 
. 0 

Seven 0 
of 0 
these 0 
_NUM2 0 
patients 0 
had 0 
elevated 0 
serum 0 
ferritin 0 
levels 0 
in 0 
_NUM4 0 
; 0 
_NUM1 0 
of 0 
the 0 
_NUM1 0 
had 0 
further 0 
increases 0 
in 0 
_NUM4 0 
, 0 
and 0 
_NUM1 0 
had 0 
a 0 
decrease 0 
, 0 
although 0 
the 0 
value 0 
remained 0 
elevated 0 
. 0 

The 0 
serum 0 
ferritin 0 
levels 0 
in 0 
the 0 
four 0 
other 0 
homozygous 0 
patients 0 
remained 0 
in 0 
the 0 
normal 0 
range 0 
. 0 

Eleven 0 
of 0 
the 0 
_NUM2 0 
homozygous 0 
subjects 0 
underwent 0 
liver 0 
biopsy 0 
; 0 
_NUM1 0 
had 0 
hepatic 1
fibrosis 1
, 0 
and 0 
_NUM1 0 
, 0 
who 0 
had 0 
a 0 
history 0 
of 0 
excessive 1
alcohol 1
consumption 1
, 0 
had 0 
cirrhosis 1
and 0 
mild 0 
microvesicular 1
steatosis 1
. 0 

Eight 0 
of 0 
the 0 
_NUM2 0 
homozygous 0 
subjects 0 
had 0 
clinical 0 
findings 0 
that 0 
were 0 
consistent 0 
with 0 
the 0 
presence 0 
of 0 
hereditary 1
hemochromatosis 1
, 0 
such 0 
as 0 
hepatomegaly 1
, 0 
skin 1
pigmentation 1
, 0 
and 0 
arthritis 1
. 0 

CONCLUSIONS 0 
In 0 
a 0 
population 0 
of 0 
white 0 
adults 0 
of 0 
northern 0 
European 0 
ancestry 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
percent 0 
were 0 
homozygous 0 
for 0 
the 0 
C282Y 0 
mutation 0 
in 0 
the 0 
HFE 0 
gene 0 
. 0 

However 0 
, 0 
only 0 
half 0 
of 0 
those 0 
who 0 
were 0 
homozygous 0 
had 0 
clinical 0 
features 0 
of 0 
hemochromatosis 1
, 0 
and 0 
one 0 
quarter 0 
had 0 
serum 0 
ferritin 0 
levels 0 
that 0 
remained 0 
normal 0 
over 0 
a 0 
four-year 0 
period 0 
. 0 

Overexpression 0 
of 0 
DM20 0 
messenger 0 
RNA 0 
in 0 
two 0 
brothers 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 

Pelizaeus-Merzbacher 1
disease 1
is 0 
a 0 
rare 1
, 1
sex-linked 1
recessive 1
, 1
dysmyelinating 1
disease 1
of 1
the 1
central 1
nervous 1
system 1
that 0 
has 0 
been 0 
associated 0 
with 0 
mutations 0 
in 0 
the 0 
myelin 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
. 0 

Only 0 
_NUM2 0 
% 0 
of 0 
patients 0 
studied 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
have 0 
exonic 0 
mutations 0 
in 0 
this 0 
gene 0 
, 0 
the 0 
underlying 0 
cause 0 
of 0 
the 0 
disease 0 
in 0 
the 0 
remaining 0 
patients 0 
is 0 
unknown 0 
. 0 

The 0 
PLP 0 
gene 0 
encodes 0 
two 0 
major 0 
alternatively 0 
spliced 0 
transcripts 0 
called 0 
PLP 0 
and 0 
DM20 0 
. 0 

PLP 0 
messenger 0 
RNA 0 
is 0 
specifically 0 
expressed 0 
in 0 
central 0 
nervous 0 
system 0 
tissue 0 
, 0 
whereas 0 
DM20 0 
messenger 0 
RNA 0 
is 0 
found 0 
in 0 
central 0 
nervous 0 
system 0 
, 0 
cardiac 0 
, 0 
and 0 
other 0 
tissues 0 
. 0 

We 0 
studied 0 
cultured 0 
skin 0 
fibroblasts 0 
from 0 
_NUM1 0 
brothers 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
who 0 
exhibited 0 
no 0 
detectable 0 
exonic 0 
mutation 0 
of 0 
the 0 
PLP 0 
gene 0 
. 0 

Examination 0 
of 0 
RNA 0 
from 0 
these 0 
cells 0 
showed 0 
that 0 
the 0 
level 0 
of 0 
DM20 0 
messenger 0 
RNA 0 
is 0 
elevated 0 
sixfold 0 
relative 0 
to 0 
male 0 
control 0 
skin 0 
fibroblasts 0 
. 0 

An 0 
unrelated 0 
female 0 
carrier 0 
, 0 
also 0 
with 0 
no 0 
detectable 0 
exonic 0 
mutation 0 
, 0 
showed 0 
a 0 
threefold 0 
increase 0 
in 0 
DM20 0 
messenger 0 
RNA 0 
in 0 
cultured 0 
skin 0 
fibroblasts 0 
. 0 

Our 0 
findings 0 
suggest 0 
that 0 
in 0 
some 0 
patients 0 
, 0 
Pelizaeus-Merzbacher 1
disease 1
is 0 
caused 0 
by 0 
overexpression 0 
of 0 
PLP 0 
gene 0 
transcripts 0 
, 0 
and 0 
that 0 
in 0 
these 0 
families 0 
a 0 
_NUM2 0 
% 0 
increase 0 
of 0 
DM20 0 
messenger 0 
RNA 0 
in 0 
females 0 
, 0 
relative 0 
to 0 
the 0 
increase 0 
in 0 
affected 0 
males 0 
, 0 
can 0 
identify 0 
a 0 
female 0 
carrier 0 
. 0 
. 0 

Homozygosity 0 
for 0 
a 0 
novel 0 
DTDST 0 
mutation 0 
in 0 
a 0 
child 0 
with 0 
a 0 
` 0 
broad 0 
bone-platyspondylic 0 
' 0 
variant 0 
of 0 
diastrophic 1
dysplasia 1
. 0 

Atypical 0 
or 0 
variant 0 
forms 0 
of 0 
well-known 0 
chondrodysplasias 1
may 0 
pose 0 
diagnostic 0 
problems 0 
. 0 

We 0 
report 0 
on 0 
a 0 
girl 0 
with 0 
clinical 0 
features 0 
suggesting 0 
diastrophic 1
dysplasia 1
but 0 
with 0 
unusual 0 
radiographic 0 
features 0 
including 0 
severe 0 
platyspondyly 1
, 0 
wide 0 
metaphyses 0 
, 0 
and 0 
fibular 0 
overgrowth 0 
, 0 
which 0 
are 0 
partially 0 
reminiscent 0 
of 0 
metatropic 1
dysplasia 1
. 0 

The 0 
diagnosis 0 
was 0 
clarified 0 
by 0 
molecular 0 
analysis 0 
of 0 
the 0 
DTDST 0 
gene 0 
, 0 
which 0 
revealed 0 
homozygosity 0 
for 0 
a 0 
previously 0 
undescribed 0 
mutation 0 
leading 0 
to 0 
a 0 
Q454P 0 
substitution 0 
in 0 
the 0 
10th 0 
transmembrane 0 
domain 0 
of 0 
the 0 
DTDST 0 
sulfate 0 
transporter 0 
. 0 

Molecular 0 
analysis 0 
may 0 
be 0 
of 0 
particular 0 
value 0 
in 0 
such 0 
atypical 0 
cases 0 
. 0 
. 0 

Carrier 0 
detection 0 
and 0 
prenatal 0 
diagnosis 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
using 0 
a 0 
combination 0 
of 0 
anonymous 0 
DNA 0 
polymorphisms 0 
and 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
cDNA 0 
. 0 

We 0 
report 0 
carrier 0 
identification 0 
and 0 
a 0 
prenatal 0 
diagnosis 0 
using 0 
DNA 0 
polymorphisms 0 
in 0 
_NUM1 0 
families 0 
with 0 
X-linked 1
Pelizaeus-Merzbacher 1
disease 1
-LRB- 0 
PMD 1
-RRB- 0 
. 0 

In 0 
both 0 
families 0 
, 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
in 0 
the 0 
single 0 
affected 0 
male 0 
could 0 
be 0 
traced 0 
back 0 
to 0 
his 0 
unaffected 0 
maternal 0 
grandfather 0 
. 0 

Therefore 0 
, 0 
each 0 
family 0 
contains 0 
a 0 
new 0 
mutation 0 
. 0 

In 0 
the 0 
case 0 
of 0 
the 0 
prenatal 0 
diagnosis 0 
, 0 
the 0 
fetus 0 
was 0 
shown 0 
by 0 
cytogenetic 0 
analysis 0 
to 0 
be 0 
a 0 
female 0 
, 0 
who 0 
we 0 
predict 0 
will 0 
be 0 
a 0 
noncarrier 0 
of 0 
PMD 1
based 0 
on 0 
her 0 
genotype 0 
with 0 
the 0 
PLP 0 
intragenic 0 
polymorphism 0 
. 0 
. 0 

Gardner 1
syndrome 1
in 0 
a 0 
boy 0 
with 0 
interstitial 0 
deletion 0 
of 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
. 0 

We 0 
described 0 
a 0 
15-year-old 0 
boy 0 
with 0 
Gardner 1
syndrome 1
-LRB- 0 
GS 1
-RRB- 0 
, 0 
mental 1
retardation 1
, 0 
and 0 
craniofacial 1
abnormalities 1
. 0 

High-resolution 0 
banding 0 
analysis 0 
showed 0 
an 0 
interstitial 0 
deletion 0 
of 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
-LRB- 0 
_AN 0 
. 0 

_NUM1 0 
-- 0 
_AN 0 
_NUM1 0 
-- 0 
_AN 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

The 0 
breakpoints 0 
in 0 
the 0 
present 0 
case 0 
and 0 
in 0 
_NUM1 0 
previously 0 
reported 0 
5q 0 
- 0 
patients 0 
with 0 
adenomatous 1
polyposis 1
coli 1
suggest 0 
that 0 
the 0 
gene 0 
responsible 0 
for 0 
GS 1
/ 0 
or 0 
familial 1
polyposis 1
coli 1
-LRB- 0 
FPC 1
-RRB- 0 
is 0 
in 0 
the 0 
5q22 0 
region 0 
, 0 
a 0 
result 0 
consistent 0 
with 0 
the 0 
findings 0 
of 0 
linkage 0 
studies 0 
Type 1
I 1
human 1
complement 1
C2 1
deficiency 1
. 0 

A 0 
28-base 0 
pair 0 
gene 0 
deletion 0 
causes 0 
skipping 0 
of 0 
exon 0 
_NUM1 0 
during 0 
RNA 0 
splicing 0 
. 0 

Two 0 
variants 0 
of 0 
a 0 
genetic 0 
deficiency 1
of 1
complement 1
protein 1
C2 1
-LRB- 0 
C2D 0 
-RRB- 0 
have 0 
been 0 
previously 0 
identified 0 
. 0 

No 0 
C2 0 
protein 0 
translation 0 
is 0 
detected 0 
in 0 
type 0 
I 0 
deficiency 0 
, 0 
while 0 
type 0 
II 0 
deficiency 0 
is 0 
characterized 0 
by 0 
a 0 
selective 0 
block 0 
in 0 
C2 0 
secretion 0 
. 0 

Type 1
I 1
C2 1
deficiency 1
was 0 
described 0 
in 0 
a 0 
family 0 
in 0 
which 0 
the 0 
C2 0 
null 0 
allele 0 
-LRB- 0 
C2Q0 0 
-RRB- 0 
is 0 
associated 0 
with 0 
the 0 
major 0 
histocompatibility 0 
haplotype 0 
/ 0 
complotype 0 
HLA-A25 0 
, 0 
_AN 0 
, 0 
C2Q0 0 
, 0 
BfS 0 
, 0 
C4A4 0 
, 0 
C4B2 0 
, 0 
Drw2 0 
; 0 
this 0 
extended 0 
haplotype 0 
occurs 0 
in 0 
over 0 
_NUM2 0 
% 0 
of 0 
C2-deficient 1
individuals 0 
-LRB- 0 
common 0 
complotype 0 
/ 0 
haplotype 0 
-RRB- 0 
. 0 

To 0 
determine 0 
the 0 
molecular 0 
basis 0 
of 0 
type 1
I 1
C2 1
deficiency 1
, 0 
the 0 
C2 0 
gene 0 
and 0 
cDNA 0 
were 0 
characterized 0 
from 0 
a 0 
homozygous 0 
type 1
I 1
C2-deficient 1
individual 0 
with 0 
the 0 
common 0 
associated 0 
haplotype 0 
/ 0 
complotype 0 
. 0 

We 0 
found 0 
a 0 
28-base 0 
pair 0 
deletion 0 
in 0 
the 0 
type 0
I 0 
C2Q0 0 
gene 0 
, 0 
beginning 0 
_NUM1 0 
base 0 
pairs 0 
upstream 0 
of 0 
the 0 
3-end 0 
of 0 
exon 0 
_NUM1 0 
, 0 
that 0 
generates 0 
a 0 
C2 0 
transcript 0 
with 0 
a 0 
complete 0 
deletion 0 
of 0 
exon 0 
_NUM1 0 
-LRB- 0 
_NUM3 0 
base 0 
pair 0 
-RRB- 0 
and 0 
a 0 
premature 0 
termination 0 
codon 0 
. 0 

In 0 
studies 0 
of 0 
eight 0 
kindred 0 
, 0 
the 0 
28-base 0 
pair 0 
deletion 0 
was 0 
observed 0 
in 0 
all 0 
C2Q0 0 
alleles 0 
associated 0 
with 0 
the 0 
common 0 
type 0
I 0 
deficient 0 
complotype 0 
/ 0 
haplotype 0 
; 0 
this 0 
deletion 0 
was 0 
not 0 
present 0 
in 0 
normal 0 
C2 0 
nor 0 
in 0 
type 1
II 1
C2-deficient 1
genes 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
_NUM1 0 
-RRB- 0 
type 1
I 1
human 1
complement 1
C2 1
deficiency 1
is 0 
caused 0 
by 0 
a 0 
28-base 0 
pair 0 
genomic 0 
deletion 0 
that 0 
causes 0 
skipping 0 
of 0 
exon 0 
_NUM1 0 
during 0 
RNA 0 
splicing 0 
, 0 
resulting 0 
in 0 
generation 0 
of 0 
a 0 
premature 0 
termination 0 
codon 0 
, 0 
_NUM1 0 
-RRB- 0 
the 0 
28-base 0 
pair 0 
deletion 0 
in 0 
the 0 
type 0 
I 0 
C2Q0 0 
gene 0 
is 0 
strongly 0 
associated 0 
with 0 
the 0 
HLA 0 
haplotype 0 
/ 0 
complotype 0 
_AN 0 
, 0 
_AN 0 
, 0 
C2Q0 0 
, 0 
BfS 0 
, 0 
C4A4 0 
, 0 
C4B2 0 
, 0 
Drw2 0 
, 0 
suggesting 0 
that 0 
all 0 
C2-deficient 1
individuals 0 
with 0 
this 0 
haplotype 0 
/ 0 
complotype 0 
will 0 
harbor 0 
the 0 
28-base 0 
pair 0 
C2 0 
gene 0 
deletion 0 
, 0 
and 0 
_NUM1 0 
-RRB- 0 
type 1
II 1
C2 1
deficiency 1
is 0 
caused 0 
by 0 
a 0 
different 0 
, 0 
as 0 
yet 0 
uncharacterized 0 
, 0 
molecular 0 
genetic 1
defect 1
. 0 
. 0 

-LRB- 0 
Over 0 
-RRB- 0 
correction 0 
of 0 
FMR1 1
deficiency 1
with 0 
YAC 0 
transgenics 0 
: 0 
behavioral 0 
and 0 
physical 0 
features 0 
. 0 

Fragile 1
X 1
syndrome 1
is 0 
a 0 
common 0 
cause 0 
of 0 
mental 1
retardation 1
involving 0 
loss 0 
of 0 
expression 0 
of 0 
the 0 
FMR1 0 
gene 0 
. 0 

The 0 
role 0 
of 0 
FMR1 0 
remains 0 
undetermined 0 
but 0 
the 0 
protein 0 
appears 0 
to 0 
be 0 
involved 0 
in 0 
RNA 0 
metabolism 0 
. 0 

Fmr1 0 
knockout 0 
mice 0 
exhibit 0 
a 0 
phenotype 0 
with 0 
some 0 
similarities 0 
to 0 
humans 0 
, 0 
such 0 
as 0 
macroorchidism 1
and 0 
behavioral 0 
abnormalities 0 
. 0 

As 0 
a 0 
step 0 
toward 0 
understanding 0 
the 0 
function 0 
of 0 
FMR1 0 
and 0 
the 0 
determination 0 
of 0 
the 0 
potential 0 
for 0 
therapeutic 0 
approaches 0 
to 0 
fragile 1
X 1
syndrome 1
, 0 
yeast 0 
artificial 0 
chromosome 0 
-LRB- 0 
YAC 0 
-RRB- 0 
transgenic 0 
mice 0 
were 0 
generated 0 
in 0 
order 0 
to 0 
determine 0 
whether 0 
the 0 
Fmr1 0 
knockout 0 
mouse 0 
phenotype 0 
could 0 
be 0 
rescued 0 
. 0 

Several 0 
transgenic 0 
lines 0 
were 0 
generated 0 
that 0 
carried 0 
the 0 
entire 0 
FMR1 0 
locus 0 
with 0 
extensive 0 
amounts 0 
of 0 
flanking 0 
sequence 0 
. 0 

We 0 
observed 0 
that 0 
the 0 
YAC 0 
transgene 0 
supported 0 
production 0 
of 0 
the 0 
human 0 
protein 0 
-LRB- 0 
FMRP 0 
-RRB- 0 
which 0 
was 0 
present 0 
at 0 
levels 0 
_NUM2 0 
to 0 
_NUM2 0 
times 0 
that 0 
of 0 
endogenous 0 
protein 0 
and 0 
was 0 
expressed 0 
in 0 
a 0 
cell 0 
- 0 
and 0 
tissue-specific 0 
manner 0 
. 0 

Macro-orchidism 0 
was 0 
absent 0 
in 0 
knockout 0 
mice 0 
carrying 0 
the 0 
YAC 0 
transgene 0 
indicating 0 
functional 0 
rescue 0 
by 0 
the 0 
human 0 
protein 0 
. 0 

Given 0 
the 0 
complex 0 
behavioral 0 
phenotype 0 
in 0 
fragile 1
X 1
patients 0 
and 0 
the 0 
mild 0 
phenotype 0 
previously 0 
reported 0 
for 0 
the 0 
Fmr1 0 
knockout 0 
mouse 0 
, 0 
we 0 
performed 0 
a 0 
more 0 
thorough 0 
evaluation 0 
of 0 
the 0 
Fmr1 0 
knockout 0 
phenotype 0 
using 0 
additional 0 
behavioral 0 
assays 0 
that 0 
had 0 
not 0 
previously 0 
been 0 
reported 0 
for 0 
this 0 
animal 0 
model 0 
. 0 

The 0 
mouse 0 
displayed 0 
reduced 0 
anxiety 1
related 0 
responses 0 
with 0 
increased 0 
exploratory 0 
behavior 0 
. 0 

FMR1 0 
YAC 0 
transgenic 0 
mice 0 
overexpressing 0 
the 0 
human 0 
protein 0 
did 0 
produce 0 
opposing 0 
behavioral 0 
responses 0 
and 0 
additional 0 
abnormal 0 
behaviors 0 
were 0 
also 0 
observed 0 
. 0 

These 0 
findings 0 
have 0 
significant 0 
implications 0 
for 0 
gene 0 
therapy 0 
for 0 
fragile 1
X 1
syndrome 1
since 0 
overexpression 0 
of 0 
the 0 
gene 0 
may 0 
harbor 0 
its 0 
own 0 
phenotype 0 
. 0 
. 0 

Fabry 1
disease 1
: 0 
identification 0 
of 0 
novel 0 
alpha-galactosidase 0 
A 0 
mutations 0 
and 0 
molecular 0 
carrier 0 
detection 0 
by 0 
use 0 
of 0 
fluorescent 0 
chemical 0 
cleavage 0 
of 0 
mismatches 0 
. 0 

Fabry 1
disease 1
-LRB- 0 
FD 1
-RRB- 0 
-LRB- 0 
angiokeratoma 1
corporis 1
diffusum 1
-RRB- 0 
is 0 
an 0 
X-linked 1
inborn 1
error 1
of 1
glycosphingolipid 1
metabolism 1
caused 0 
by 0 
defects 0 
in 0 
the 0 
lysosomal 0 
alpha-galactosidase 0 
A 0 
gene 0 
-LRB- 0 
GLA 0 
-RRB- 0 
. 0 

The 0 
enzymatic 0 
defect 0 
leads 0 
to 0 
the 0 
systemic 0 
accumulation 0 
of 0 
neutral 0 
glycosphingolipids 0 
with 0 
terminal 0 
alpha-galactosyl 0 
moieties 0 
. 0 

Clinically 0 
, 0 
affected 0 
hemizygous 0 
males 0 
have 0 
angiokeratoma 1
, 0 
severe 1
acroparesthesia 1
, 0 
renal 1
failure 1
, 0 
and 0 
vasculopathy 1
of 1
the 1
heart 1
and 1
brain 1
. 0 

While 0 
demonstration 0 
of 0 
alpha-galactosidase 1
deficiency 1
in 0 
leukocytes 0 
is 0 
diagnostic 0 
in 0 
affected 0 
males 0 
, 0 
enzymatic 0 
detection 0 
of 0 
female 0 
carriers 0 
is 0 
often 0 
inconclusive 0 
, 0 
due 0 
to 0 
random 0 
X-chromosomal 0 
inactivation 0 
, 0 
underlining 0 
the 0 
need 0 
of 0 
molecular 0 
investigations 0 
for 0 
accurate 0 
genetic 0 
counseling 0 
. 0 

By 0 
use 0 
of 0 
chemical 0 
cleavage 0 
of 0 
mismatches 0 
adapted 0 
to 0 
fluorescence-based 0 
detection 0 
systems 0 
, 0 
we 0 
have 0 
characterized 0 
the 0 
mutations 0 
underlying 0 
alpha-Gal 1
A 1
deficiency 1
in 0 
_NUM2 0 
individuals 0 
from 0 
six 0 
unrelated 0 
families 0 
with 0 
FD 1
. 0 

The 0 
mutational 0 
spectrum 0 
included 0 
five 0 
missense 0 
mutations 0 
-LRB- 0 
C202W 0 
, 0 
C223G 0 
, 0 
N224D 0 
, 0 
R301Q 0 
, 0 
and 0 
Q327K 0 
-RRB- 0 
and 0 
one 0 
splice-site 0 
mutation 0 
-LSB- 0 
IVS3 0 
G 0 
-LRB- 0 
-1 0 
-RRB- 0 
-- 0 
> 0 
C 0 
-RSB- 0 
. 0 

Studies 0 
at 0 
the 0 
mRNA 0 
level 0 
showed 0 
that 0 
the 0 
latter 0 
led 0 
to 0 
altered 0 
pre-mRNA 0 
splicing 0 
with 0 
consequent 0 
alteration 0 
of 0 
the 0 
mRNA 0 
translational 0 
reading 0 
frame 0 
and 0 
generation 0 
of 0 
a 0 
premature 0 
termination 0 
codon 0 
of 0 
translation 0 
. 0 

By 0 
use 0 
of 0 
this 0 
strategy 0 
, 0 
carrier 0 
status 0 
was 0 
accurately 0 
assessed 0 
in 0 
all 0 
seven 0 
at-risk 0 
females 0 
tested 0 
, 0 
whereas 0 
enzymatic 0 
dosages 0 
failed 0 
to 0 
diagnose 0 
or 0 
exclude 0 
heterozygosity 0 
. 0 
. 0 

Evidence 0 
for 0 
linkage 0 
of 0 
bipolar 1
disorder 1
to 0 
chromosome 0 
_NUM2 0 
with 0 
a 0 
parent-of-origin 0 
effect 0 
. 0 

A 0 
susceptibility 0 
gene 0 
on 0 
chromosome 0 
_NUM2 0 
and 0 
a 0 
parent-of-origin 0 
effect 0 
have 0 
been 0 
suggested 0 
for 0 
bipolar 1
affective 1
disorder 1
-LRB- 0 
BPAD 1
-RRB- 0 
. 0 

We 0 
have 0 
studied 0 
_NUM2 0 
nuclear 0 
families 0 
selected 0 
for 0 
apparent 0 
unilineal 0 
transmission 0 
of 0 
the 0 
BPAD 1
phenotype 0 
, 0 
by 0 
using 0 
_NUM2 0 
polymorphic 0 
markers 0 
spanning 0 
chromosome 0 
_NUM2 0 
. 0 

Evidence 0 
for 0 
linkage 0 
was 0 
tested 0 
with 0 
affected-sib-pair 0 
and 0 
LOD 0 
score 0 
methods 0 
under 0 
two 0 
definitions 0 
of 0 
the 0 
affected 0 
phenotype 0 
. 0 

The 0 
affected-sibpair 0 
analyses 0 
indicated 0 
excess 0 
allele 0 
sharing 0 
for 0 
markers 0 
on 0 
18p 0 
within 0 
the 0 
region 0 
reported 0 
previously 0 
. 0 

The 0 
greatest 0 
sharing 0 
was 0 
at 0 
D18S37 0 
_NUM2 0 
% 0 
in 0 
bipolar 0 
and 0 
recurrent 0 
unipolar 0 
-LRB- 0 
RUP 0 
-RRB- 0 
sib 0 
pairs 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM4 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
excess 0 
sharing 0 
of 0 
the 0 
paternally 0 
, 0 
but 0 
not 0 
maternally 0 
, 0 
transmitted 0 
alleles 0 
was 0 
observed 0 
at 0 
three 0 
markers 0 
on 0 
18q 0 
at 0 
D18S41 0 
, 0 
_NUM2 0 
bipolar 0 
and 0 
RUP 0 
sib 0 
pairs 0 
were 0 
concordant 0 
for 0 
paternally 0 
transmitted 0 
alleles 0 
, 0 
and 0 
_NUM2 0 
pairs 0 
were 0 
discordant 0 
-LRB- 0 
P 0 
= 0 
_NUM4 0 
-RRB- 0 
. 0 

The 0 
evidence 0 
for 0 
linkage 0 
to 0 
loci 0 
on 0 
both 0 
18p 0 
and 0 
18q 0 
was 0 
strongest 0 
in 0 
the 0 
_NUM2 0 
paternal 0 
pedigrees 0 
, 0 
i. 0 
e 0 
e. 0 
, 0 
those 0 
in 0 
which 0 
the 0 
father 0 
or 0 
one 0 
of 0 
the 0 
fathers 0 
sibs 0 
is 0 
affected 0 
. 0 

In 0 
these 0 
pedigrees 0 
, 0 
the 0 
greatest 0 
allele 0 
sharing 0 
-LRB- 0 
_NUM2 0 
% 0 
; 0 
P 0 
= 0 
. 0 

_NUM5 0 
-RRB- 0 
and 0 
the 0 
highest 0 
LOD 0 
score 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
; 0 
phi 0 
= 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
were 0 
observed 0 
at 0 
D18S41 0 
. 0 

Our 0 
results 0 
provide 0 
further 0 
support 0 
for 0 
linkage 0 
of 0 
BPAD 1
to 0 
chromosome 0 
_NUM2 0 
and 0 
the 0 
first 0 
molecular 0 
evidence 0 
for 0 
a 0 
parent-of-origin 0 
effect 0 
operating 0 
in 0 
this 0 
disorder 0 
. 0 

The 0 
number 0 
of 0 
loci 0 
involved 0 
, 0 
and 0 
their 0 
precise 0 
location 0 
, 0 
require 0 
further 0 
study 0 
BRCA1 0 
mutations 0 
in 0 
a 0 
population-based 0 
sample 0 
of 0 
young 0 
women 0 
with 0 
breast 1
cancer 1
. 0 

BACKGROUND 0 
. 0 

Inherited 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
are 0 
associated 0 
with 0 
a 0 
high 0 
risk 0 
of 0 
breast 1
and 1
ovarian 1
cancer 1
in 0 
some 0 
families 0 
. 0 

However 0 
, 0 
little 0 
is 0 
known 0 
about 0 
the 0 
contribution 0 
of 0 
BRCA1 0 
mutations 0 
to 0 
breast 1
cancer 1
in 0 
the 0 
general 0 
population 0 
. 0 

We 0 
analyzed 0 
DNA 0 
samples 0 
from 0 
women 0 
enrolled 0 
in 0 
a 0 
population-based 0 
study 0 
of 0 
early-onset 0 
breast 1
cancer 1
to 0 
assess 0 
the 0 
spectrum 0 
and 0 
frequency 0 
of 0 
germ-line 0 
BRCA1 0 
mutations 0 
in 0 
young 0 
women 0 
with 0 
breast 1
cancer 1
. 0 

METHODS 0 
. 0 

We 0 
studied 0 
_NUM2 0 
women 0 
in 0 
whom 0 
breast 1
cancer 1
was 0 
diagnosed 0 
before 0 
the 0 
age 0 
of 0 
_NUM2 0 
, 0 
and 0 
who 0 
were 0 
not 0 
selected 0 
on 0 
the 0 
basis 0 
of 0 
family 0 
history 0 
. 0 

Genomic 0 
DNA 0 
was 0 
studied 0 
for 0 
BRCA1 0 
mutations 0 
by 0 
analysis 0 
involving 0 
single-strand 0 
conformation 0 
polymorphisms 0 
and 0 
with 0 
allele-specific 0 
assays 0 
. 0 

Alterations 0 
were 0 
defined 0 
by 0 
DNA 0 
sequencing 0 
. 0 

RESULTS 0 
. 0 

Germ-line 0 
BRCA1 0 
mutations 0 
were 0 
identified 0 
in 0 
_NUM1 0 
of 0 
the 0 
_NUM2 0 
women 0 
. 0 

Four 0 
additional 0 
rare 0 
sequence 0 
variants 0 
of 0 
unknown 0 
functional 0 
importance 0 
were 0 
also 0 
identified 0 
. 0 

Two 0 
of 0 
the 0 
mutations 0 
and 0 
three 0 
of 0 
the 0 
rare 0 
sequence 0 
variants 0 
were 0 
found 0 
among 0 
the 0 
_NUM2 0 
women 0 
who 0 
reported 0 
no 0 
family 0 
history 0 
of 0 
breast 1
or 1
ovarian 1
cancer 1
. 0 

None 0 
of 0 
the 0 
mutations 0 
and 0 
only 0 
one 0 
of 0 
the 0 
rare 0 
variants 0 
was 0 
identified 0 
in 0 
a 0 
reference 0 
population 0 
of 0 
_NUM2 0 
unrelated 0 
subjects 0 
. 0 

CONCLUSIONS 0 
. 0 

Alterations 0 
in 0 
BRCA1 0 
were 0 
identified 0 
in 0 
approximately 0 
_NUM2 0 
percent 0 
of 0 
this 0 
cohort 0 
of 0 
young 0 
women 0 
with 0 
breast 1
cancer 1
. 0 

The 0 
risk 0 
of 0 
harboring 0 
a 0 
mutation 0 
was 0 
not 0 
limited 0 
to 0 
women 0 
with 0 
family 0 
histories 0 
of 0 
breast 1
or 1
ovarian 1
cancer 1
. 0 

These 0 
results 0 
represent 0 
a 0 
minimal 0 
estimate 0 
of 0 
the 0 
frequency 0 
of 0 
BRCA1 0 
mutations 0 
in 0 
this 0 
population 0 
. 0 

Comprehensive 0 
methods 0 
of 0 
identifying 0 
BRCA1 0 
mutations 0 
and 0 
understanding 0 
their 0 
importance 0 
will 0 
be 0 
needed 0 
before 0 
testing 0 
of 0 
women 0 
in 0 
the 0 
general 0 
population 0 
can 0 
be 0 
undertaken 0 
. 0 
. 0 

Retinoschisin 0 
, 0 
the 0 
X-linked 1
retinoschisis 1
protein 0 
, 0 
is 0 
a 0 
secreted 0 
photoreceptor 0 
protein 0 
, 0 
and 0 
is 0 
expressed 0 
and 0 
released 0 
by 0 
Weri-Rb1 0 
cells 0 
. 0 

X-linked 1
retinoschisis 1
is 0 
characterized 0 
by 0 
microcystic-like 0 
changes 0 
of 0 
the 0 
macular 0 
region 0 
and 0 
schisis 0 
within 0 
the 0 
inner 0 
retinal 0 
layers 0 
, 0 
leading 0 
to 0 
visual 1
deterioration 1
in 0 
males 0 
. 0 

Many 0 
missense 0 
and 0 
protein-truncating 0 
mutations 0 
of 0 
the 0 
causative 0 
gene 0 
RS1 0 
have 0 
now 0 
been 0 
identified 0 
and 0 
are 0 
thought 0 
to 0 
be 0 
inactivating 0 
. 0 

RS1 0 
encodes 0 
a 0 
_NUM3 0 
amino 0 
acid 0 
protein 0 
, 0 
retinoschisin 0 
, 0 
which 0 
contains 0 
a 0 
discoidin 0 
domain 0 
but 0 
is 0 
of 0 
unknown 0 
function 0 
. 0 

We 0 
have 0 
generated 0 
a 0 
polyclonal 0 
antibody 0 
against 0 
a 0 
peptide 0 
from 0 
a 0 
unique 0 
region 0 
within 0 
retinoschisin 0 
, 0 
which 0 
detects 0 
a 0 
protein 0 
of 0 
approximately 0 
_NUM2 0 
kDa 0 
in 0 
retinal 0 
samples 0 
reduced 0 
with 0 
dithiothreitol 0 
, 0 
but 0 
multimers 0 
sized 0 
> 0 
_NUM2 0 
kDa 0 
under 0 
non-reducing 0 
conditions 0 
. 0 

A 0 
screen 0 
of 0 
human 0 
tissues 0 
with 0 
this 0 
antibody 0 
reveals 0 
retinoschisin 0 
to 0 
be 0 
retina 0 
specific 0 
and 0 
the 0 
antibody 0 
detects 0 
a 0 
protein 0 
of 0 
similar 0 
size 0 
in 0 
bovine 0 
and 0 
murine 0 
retinae 0 
. 0 

We 0 
investigated 0 
the 0 
expression 0 
pattern 0 
in 0 
the 0 
retina 0 
of 0 
both 0 
RS1 0 
mRNA 0 
-LRB- 0 
using 0 
in 0 
situ 0 
hybridization 0 
with 0 
riboprobes 0 
-RRB- 0 
and 0 
retinoschisin 0 
-LRB- 0 
using 0 
immunohistochemistry 0 
-RRB- 0 
. 0 

The 0 
antisense 0 
riboprobe 0 
detected 0 
RS1 0 
mRNA 0 
only 0 
in 0 
the 0 
photoreceptor 0 
layer 0 
but 0 
the 0 
protein 0 
product 0 
of 0 
the 0 
gene 0 
was 0 
present 0 
both 0 
in 0 
the 0 
photoreceptors 0 
and 0 
within 0 
the 0 
inner 0 
portions 0 
of 0 
the 0 
retina 0 
. 0 

Furthermore 0 
, 0 
differentiated 0 
retinoblastoma 1
cells 0 
-LRB- 0 
Weri-Rb1 0 
cells 0 
-RRB- 0 
were 0 
found 0 
to 0 
express 0 
RS1 0 
mRNA 0 
and 0 
to 0 
release 0 
retinoschisin 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
retinoschisin 0 
is 0 
released 0 
by 0 
photo-receptors 0 
and 0 
has 0 
functions 0 
within 0 
the 0 
inner 0 
retinal 0 
layers 0 
. 0 

Thus 0 
, 0 
X-linked 1
retinoschisis 1
is 0 
caused 0 
by 0 
abnormalities 0 
in 0 
a 0 
putative 0 
secreted 0 
photoreceptor 0 
protein 0 
and 0 
is 0 
the 0 
first 0 
example 0 
of 0 
a 0 
secreted 0 
photo-receptor 0 
protein 0 
associated 0 
with 0 
a 0 
retinal 1
dystrophy 1
. 0 
. 0 

Aberrant 0 
splicing 0 
of 0 
the 0 
CHM 1
gene 0 
is 0 
a 0 
significant 0 
cause 0 
of 0 
choroideremia 1
. 0 

Choroideremia 1
-LRB- 0 
CHM 1
-RRB- 0 
is 0 
an 0 
X-linked 1
progressive 1
degeneration 1
of 1
the 1
choroid 1
and 1
retina 1
. 0 

_NUM2 0 
% 0 
of 0 
unrelated 0 
male 0 
patients 0 
carry 0 
deletions 0 
of 0 
the 0 
partially 0 
cloned 0 
CHM 1
gene 0 
. 0 

In 0 
Finland 0 
, 0 
there 0 
are 0 
more 0 
than 0 
_NUM3 0 
living 0 
CHM 1
patients 0 
belonging 0 
to 0 
eight 0 
apparently 0 
unrelated 0 
pedigrees 0 
. 0 

Molecular 0 
deletions 0 
involving 0 
the 0 
CHM 1
gene 0 
have 0 
been 0 
detected 0 
in 0 
three 0 
families 0 
. 0 

We 0 
have 0 
screened 0 
the 0 
remaining 0 
five 0 
families 0 
for 0 
point 0 
mutations 0 
. 0 

In 0 
one 0 
large 0 
family 0 
a 0 
single 0 
nucleotide 0 
-LRB- 0 
T 0 
-RRB- 0 
insertion 0 
into 0 
the 0 
donor 0 
splice 0 
site 0 
of 0 
exon 0 
C 0 
leads 0 
to 0 
two 0 
aberrantly 0 
spliced 0 
mRNAs 0 
both 0 
producing 0 
a 0 
premature 0 
stop 0 
codon 0 
. 0 

The 0 
mutation 0 
can 0 
be 0 
assayed 0 
easily 0 
by 0 
amplification 0 
and 0 
digestion 0 
with 0 
Msel 0 
. 0 

Our 0 
findings 0 
provide 0 
additional 0 
evidence 0 
for 0 
the 0 
pathogenetic 0 
role 0 
of 0 
CHM 1
mutations 0 
and 0 
provide 0 
a 0 
diagnostic 0 
tool 0 
for 0 
one 0 
fifth 0 
of 0 
the 0 
worlds 0 
known 0 
CHM 1
patients 0 
. 0 
. 0 

X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
: 0 
a 0 
novel 0 
mutation 0 
of 0 
the 0 
ALD 1
gene 0 
in 0 
_NUM1 0 
members 0 
of 0 
a 0 
family 0 
presenting 0 
with 0 
_NUM1 0 
different 0 
phenotypes 0 
. 0 

Fragments 0 
of 0 
the 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
cDNA 0 
from 0 
a 0 
patient 0 
with 0 
adolescent 1
ALD 1
were 0 
amplified 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
and 0 
subcloned 0 
. 0 

Bidirectional 0 
sequencing 0 
of 0 
the 0 
entire 0 
coding 0 
ALD 1
gene 0 
disclosed 0 
a 0 
cytosine 0 
to 0 
guanine 0 
transversion 0 
at 0 
nucleotide 0 
_NUM4 0 
in 0 
exon 0 
five 0 
, 0 
resulting 0 
in 0 
substitution 0 
of 0 
proline 0 
_NUM3 0 
by 0 
arginine 0 
. 0 

Five 0 
of 0 
nine 0 
siblings 0 
of 0 
the 0 
patient 0 
, 0 
comprising 0 
two 0 
cerebral 1
ALD 1
, 0 
one 0 
adrenomyeloneuropathy 1
, 0 
one 0 
Addison 1
only 1
as 0 
well 0 
as 0 
the 0 
symptomatic 0 
mother 0 
-LRB- 0 
all 0 
accumulating 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
-RRB- 0 
carried 0 
this 0 
mutation 0 
, 0 
which 0 
was 0 
not 0 
found 0 
in 0 
the 0 
unaffected 0 
persons 0 
, 0 
in 0 
five 0 
unrelated 0 
ALD 1
patients 0 
, 0 
and 0 
in 0 
twenty 0 
controls 0 
. 0 

We 0 
propose 0 
that 0 
this 0 
missense 0 
mutation 0 
generated 0 
the 0 
disease 0 
per 0 
se 0 
as 0 
well 0 
as 0 
the 0 
metabolic 0 
defect 0 
; 0 
the 0 
different 0 
phenotypes 0 
, 0 
however 0 
, 0 
must 0 
have 0 
originated 0 
by 0 
means 0 
of 0 
additional 0 
pathogenetic 0 
factors 0 
. 0 
. 0 

Statistical 0 
analysis 0 
of 0 
the 0 
two 0 
stage 0 
mutation 0 
model 0 
in 0 
von 1
Hippel-Lindau 1
disease 1
, 0 
and 0 
in 0 
sporadic 1
cerebellar 1
haemangioblastoma 1
and 0 
renal 1
cell 1
carcinoma 1
. 0 

Analysis 0 
of 0 
the 0 
age 0 
incidence 0 
curves 0 
for 0 
unilateral 1
and 1
bilateral 1
retinoblastoma 1
led 0 
Knudson 0 
to 0 
propose 0 
that 0 
hereditary 1
tumours 1
may 0 
arise 0 
by 0 
a 0 
single 0 
event 0 
and 0 
sporadic 1
tumours 1
by 0 
a 0 
two 0 
stage 0 
mutation 0 
process 0 
. 0 

It 0 
has 0 
been 0 
suggested 0 
recently 0 
that 0 
sporadic 1
renal 1
cell 1
carcinoma 1
may 0 
arise 0 
from 0 
a 0 
two 0 
stage 0 
mutation 0 
process 0 
. 0 

We 0 
analysed 0 
the 0 
age 0 
incidence 0 
curves 0 
for 0 
symptomatic 0 
renal 1
cell 1
carcinoma 1
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
and 0 
cerebellar 1
haemangioblastoma 1
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
in 0 
_NUM3 0 
patients 0 
with 0 
von 1
Hippel-Lindau 1
-LRB- 1
VHL 1
-RRB- 1
disease 1
, 0 
and 0 
compared 0 
them 0 
to 0 
_NUM3 0 
patients 0 
with 0 
sporadic 1
renal 1
cell 1
carcinoma 1
and 0 
_NUM2 0 
patients 0 
with 0 
sporadic 1
cerebellar 1
haemangioblastoma 1
. 0 

The 0 
age 0 
incidence 0 
curves 0 
for 0 
renal 1
cell 1
carcinoma 1
and 0 
cerebellar 1
haemangioblastoma 1
in 0 
VHL 1
disease 1
were 0 
compatible 0 
with 0 
a 0 
single 0 
mutation 0 
model 0 
, 0 
whereas 0 
the 0 
age 0 
incidence 0 
curves 0 
for 0 
sporadic 1
renal 1
cell 1
carcinoma 1
and 0 
cerebellar 1
haemangioblastoma 1
suggested 0 
a 0 
two 0 
stage 0 
mutation 0 
process 0 
. 0 

These 0 
data 0 
are 0 
compatible 0 
with 0 
the 0 
VHL 1
gene 0 
functioning 0 
as 0 
a 0 
recessive 0 
tumour 1
suppressor 0 
gene 0 
. 0 

Sporadic 1
cerebellar 1
haemangioblastoma 1
and 0 
some 0 
renal 1
cell 1
carcinoma 1
may 0 
arise 0 
from 0 
somatic 0 
mutations 0 
inactivating 0 
both 0 
alleles 0 
at 0 
the 0 
VHL 1
locus 0 
. 0 
. 0 

Characterization 0 
of 0 
a 0 
germline 0 
mosaicism 0 
in 0 
families 0 
with 0 
Lowe 1
syndrome 1
, 0 
and 0 
identification 0 
of 0 
seven 0 
novel 0 
mutations 0 
in 0 
the 0 
OCRL1 0 
gene 0 
. 0 

The 0 
oculocerebrorenal 1
syndrome 1
of 1
Lowe 1
-LRB- 0 
OCRL 1
-RRB- 0 
is 0 
an 0 
X-linked 1
disorder 1
characterized 0 
by 0 
major 0 
abnormalities 1
of 1
eyes 1
, 1
nervous 1
system 1
, 1
and 1
kidneys 1
. 0 

Mutations 0 
in 0 
the 0 
OCRL1 0 
gene 0 
have 0 
been 0 
associated 0 
with 0 
the 0 
disease 0 
. 0 

OCRL1 0 
encodes 0 
a 0 
phosphatidylinositol 0 
_NUM1 0 
, 0 
5-biphosphate 0 
-LRB- 0 
PtdIns 0 
-LSB- 0 
_NUM1 0 
, 0 
_NUM1 0 
-RSB- 0 
P2 0 
-RRB- 0 
5-phosphatase 0 
. 0 

We 0 
have 0 
examined 0 
the 0 
OCRL1 0 
gene 0 
in 0 
eight 0 
unrelated 0 
patients 0 
with 0 
OCRL 1
and 0 
have 0 
found 0 
seven 0 
new 0 
mutations 0 
and 0 
one 0 
recurrent 0 
in-frame 0 
deletion 0 
. 0 

Among 0 
the 0 
new 0 
mutations 0 
, 0 
two 0 
nonsense 0 
mutations 0 
-LRB- 0 
R317X 0 
and 0 
E558X 0 
-RRB- 0 
and 0 
three 0 
other 0 
frameshift 0 
mutations 0 
caused 0 
premature 0 
termination 0 
of 0 
the 0 
protein 0 
. 0 

A 0 
missense 0 
mutation 0 
, 0 
R483G 0 
, 0 
was 0 
located 0 
in 0 
the 0 
highly 0 
conserved 0 
PtdIns 0 
-LRB- 0 
_NUM1 0 
, 0 
_NUM1 0 
-RRB- 0 
P2 0 
5-phosphatase 0 
domain 0 
. 0 

Finally 0 
, 0 
one 0 
frameshift 0 
mutation 0 
, 0 
2799delC 0 
, 0 
modifies 0 
the 0 
C-terminal 0 
part 0 
of 0 
OCRL1 0 
, 0 
with 0 
an 0 
extension 0 
of 0 
six 0 
amino 0 
acids 0 
. 0 

Altogether 0 
, 0 
_NUM2 0 
% 0 
of 0 
missense 0 
mutations 0 
are 0 
located 0 
in 0 
exon 0 
_NUM2 0 
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
all 0 
mutations 0 
cluster 0 
in 0 
exons 0 
11-15 0 
. 0 

We 0 
also 0 
identified 0 
two 0 
new 0 
microsatellite 0 
markers 0 
for 0 
the 0 
OCRL1 0 
locus 0 
, 0 
and 0 
we 0 
detected 0 
a 0 
germline 0 
mosaicism 0 
in 0 
one 0 
family 0 
. 0 

This 0 
observation 0 
has 0 
direct 0 
implications 0 
for 0 
genetic 0 
counseling 0 
of 0 
Lowe 1
syndrome 1
families 0 
. 0 
. 0 

Aminoglycoside 0 
antibiotics 0 
restore 0 
dystrophin 0 
function 0 
to 0 
skeletal 0 
muscles 0 
of 0 
mdx 0 
mice 0 
. 0 

Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
dystrophin 0 
gene 0 
, 0 
leading 0 
to 0 
the 0 
absence 0 
of 0 
the 0 
dystrophin 0 
protein 0 
in 0 
striated 0 
muscle 0 
. 0 

A 0 
significant 0 
number 0 
of 0 
these 0 
mutations 0 
are 0 
premature 0 
stop 0 
codons 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
the 0 
observation 0 
that 0 
aminoglycoside 0 
treatment 0 
can 0 
suppress 0 
stop 0 
codons 0 
in 0 
cultured 0 
cells 0 
, 0 
we 0 
tested 0 
the 0 
effect 0 
of 0 
gentamicin 0 
on 0 
cultured 0 
muscle 0 
cells 0 
from 0 
the 0 
mdx 0 
mouse 0 
- 0 
an 0 
animal 0 
model 0 
for 0 
DMD 1
that 0 
possesses 0 
a 0 
premature 0 
stop 0 
codon 0 
in 0 
the 0 
dystrophin 0 
gene 0 
. 0 

Exposure 0 
of 0 
mdx 0 
myotubes 0 
to 0 
gentamicin 0 
led 0 
to 0 
the 0 
expression 0 
and 0 
localization 0 
of 0 
dystrophin 0 
to 0 
the 0 
cell 0 
membrane 0 
. 0 

We 0 
then 0 
evaluated 0 
the 0 
effects 0 
of 0 
differing 0 
dosages 0 
of 0 
gentamicin 0 
on 0 
expression 0 
and 0 
functional 0 
protection 0 
of 0 
the 0 
muscles 0 
of 0 
mdx 0 
mice 0 
. 0 

We 0 
identified 0 
a 0 
treatment 0 
regimen 0 
that 0 
resulted 0 
in 0 
the 0 
presence 0 
of 0 
dystrophin 0 
in 0 
the 0 
cell 0 
membrane 0 
in 0 
all 0 
striated 0 
muscles 0 
examined 0 
and 0 
that 0 
provided 0 
functional 0 
protection 0 
against 0 
muscular 1
injury 1
. 0 

To 0 
our 0 
knowledge 0 
, 0 
our 0 
results 0 
are 0 
the 0 
first 0 
to 0 
demonstrate 0 
that 0 
aminoglycosides 0 
can 0 
suppress 0 
stop 0 
codons 0 
not 0 
only 0 
in 0 
vitro 0 
but 0 
also 0 
in 0 
vivo 0 
. 0 

Furthermore 0 
, 0 
these 0 
results 0 
raise 0 
the 0 
possibility 0 
of 0 
a 0 
novel 0 
treatment 0 
regimen 0 
for 0 
muscular 1
dystrophy 1
and 0 
other 0 
diseases 0 
caused 0 
by 0 
premature 0 
stop 0 
codon 0 
mutations 0 
. 0 

This 0 
treatment 0 
could 0 
prove 0 
effective 0 
in 0 
up 0 
to 0 
_NUM2 0 
% 0 
of 0 
patients 0 
with 0 
DMD 1
. 0 
. 0 

Molecular 0 
and 0 
metabolic 0
basis 0 
for 0 
the 0 
metabolic 1
disorder 1
normotriglyceridemic 1
abetalipoproteinemia 1
. 0 

We 0 
have 0 
previously 0 
described 0 
a 0 
disorder 0 
, 0 
normotriglyceridemic 1
abetalipoproteinemia 1
, 0 
that 0 
is 0 
characterized 0 
by 0 
the 0 
virtual 0 
absence 0 
of 0 
plasma 0 
low 0 
density 0 
lipoproteins 0 
and 0 
complete 0 
absence 0 
of 0 
apoB-100 0 
, 0 
but 0 
with 0 
apparently 0 
normal 0 
secretion 0 
of 0 
triglyceride-rich 0 
lipoproteins 0 
containing 0 
apoB-48 0 
. 0 

The 0 
patients 0 
plasma 0 
lipoproteins 0 
were 0 
shown 0 
on 0 
polyacrylamide 0 
gels 0 
and 0 
by 0 
antibody 0 
mapping 0 
to 0 
have 0 
a 0 
new 0 
truncated 0 
apoB 0 
variant 0 
, 0 
apoB-50 0 
, 0 
circulating 0 
along 0 
with 0 
her 0 
apoB-48 0 
. 0 

We 0 
have 0 
found 0 
this 0 
individual 0 
to 0 
be 0 
homozygous 0
for 0 
a 0 
single 0 
C-to-T 0 
nucleotide 0 
substitution 0 
at 0 
apoB 0 
codon 0 
_NUM4 0 
, 0 
which 0 
produces 0 
a 0 
premature 0 
in-frame 0 
stop 0 
codon 0 
. 0 

Thus 0 
, 0 
this 0 
is 0 
a 0 
rare 0 
example 0 
of 0 
homozygous 1
hypobetalipoproteinemia 1
. 0 

Electron 0 
photomicrographs 0 
revealed 0 
that 0 
the 0 
diameters 0 
of 0 
particles 0 
in 0 
the 0 
d 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM3 0 
g 0 
/ 0 
ml 0 
lipoprotein 0 
fraction 0 
, 0 
in 0 
both 0 
the 0 
postprandial 0 
and 0 
postabsorptive 0 
state 0 
, 0 
are 0 
bimodally 0 
distributed 0 
. 0 

The 0 
molar 0 
ratio 0 
of 0 
apoE 0 
to 0 
apoB 0 
in 0 
these 0 
particles 0 
is 0 
_NUM1 0 
. 0 

_NUM1 0 
_NUM1 0 
, 0 
similar 0 
to 0 
normal 0 
VLDL 0 
. 0 

The 0 
plasma 0 
LDL 0 
interval 0 
contains 0 
both 0 
spherical 0 
and 0 
cuboidal 0 
particles 0 
. 0 

Autologous 0 
reinfusion 0 
of 0 
labeled 0 
d 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM3 0 
g 0 
/ 0 
ml 0 
lipoproteins 0 
showed 0 
exponential 0 
disappearance 0 
from 0 
plasma 0 
, 0 
with 0 
an 0 
apparent 0 
half-removal 0 
time 0 
of 0 
_NUM2 0 
min 0 
, 0 
somewhat 0 
slower 0 
than 0 
for 0 
normal 0 
chylomicrons 0 
but 0 
within 0 
the 0 
normal 0 
range 0 
for 0 
VLDL 0 
. 0 

The 0 
calculated 0 
production 0 
rate 0 
for 0 
apoB 0 
was 0 
within 0 
the 0 
normal 0 
range 0 
in 0 
this 0 
subject 0 
. 0 

von 1
Willebrand 1
disease 1
type 1
B 1
: 0 
a 0 
missense 0 
mutation 0 
selectively 0 
abolishes 0 
ristocetin-induced 0 
von 1
Willebrand 1
factor 0 
binding 0 
to 0 
platelet 0 
glycoprotein 0 
Ib 0 
. 0 

von 1
Willebrand 1
factor 0 
-LRB- 0 
vWF 0 
-RRB- 0 
is 0 
a 0 
multimeric 0 
glycoprotein 0 
that 0 
mediates 0 
the 0 
adhesion 0 
of 0 
platelets 0 
to 0 
the 0 
subendothelium 0 
by 0 
binding 0 
to 0 
platelet 0 
glycoprotein 0 
Ib 0 
. 0 

For 0 
human 0 
vWF 0 
, 0 
this 0 
interaction 0 
can 0 
be 0 
induced 0 
in 0 
vitro 0 
by 0 
the 0 
antibiotic 0 
ristocetin 0 
or 0 
the 0 
snake 0 
venom 0 
protein 0 
botrocetin 0 
. 0 

A 0 
missense 0 
mutation 0 
, 0 
Gly-561 0 
-- 0 
> 0 
Ser 0 
, 0 
was 0 
identified 0 
within 0 
the 0 
proposed 0 
glycoprotein 0 
Ib 0 
binding 0 
domain 0 
of 0 
vWF 0 
in 0 
the 0 
proband 0 
with 0 
von 1
Willebrand 1
disease 1
type 1
B 1
, 0 
a 0 
unique 0 
variant 0 
characterized 0 
by 0 
no 0 
ristocetin-induced 0 
, 0 
but 0 
normal 0 
botrocetin-induced 0 
, 0 
binding 0 
to 0 
glycoprotein 0 
Ib 0 
. 0 

The 0 
corresponding 0 
mutant 0 
recombinant 0 
protein 0 
, 0 
rvWF 0 
-LRB- 0 
G561S 0 
-RRB- 0 
, 0 
formed 0 
normal 0 
multimers 0 
and 0 
exhibited 0 
the 0 
same 0 
functional 0 
defect 0 
as 0 
the 0 
patients 0 
plasma 0 
vWF 0 
, 0 
confirming 0 
that 0 
this 0 
mutation 0 
causes 0 
von 1
Willebrand 1
disease 1
type 1
B 1
. 0 

These 0 
data 0 
show 0 
that 0 
botrocetin 0 
and 0 
ristocetin 0 
cofactor 0 
activities 0 
of 0 
vWF 0 
can 0 
be 0 
dissociated 0 
by 0 
a 0 
point 0 
mutation 0 
and 0 
confirm 0 
that 0 
these 0 
mediators 0 
promote 0 
vWF 0 
binding 0 
to 0 
platelets 0 
by 0 
different 0 
mechanisms 0 
. 0 

The 0 
normal 0 
botrocetin-induced 0 
binding 0 
and 0 
the 0 
defective 0 
ristocetin-induced 0 
binding 0 
of 0 
rvWF 0 
-LRB- 0 
G561S 0 
-RRB- 0 
suggest 0 
that 0 
the 0 
primary 0 
defect 0 
in 0 
von 1
Willebrand 1
disease 1
type 1
B 1
may 0 
be 0 
a 0 
failure 0 
of 0 
normal 0 
allosteric 0 
regulation 0 
of 0 
the 0 
glycoprotein 0 
Ib 0 
binding 0 
function 0 
of 0 
vWF 0 
. 0 
. 0 

A 0 
high 0 
incidence 0 
of 0 
BRCA1 0 
mutations 0 
in 0 
_NUM2 0 
breast-ovarian 1
cancer 1
families 0 
. 0 

We 0 
have 0 
analyzed 0 
_NUM2 0 
breast-ovarian 1
cancer 1
families 0 
, 0 
the 0 
majority 0 
of 0 
which 0 
show 0 
positive 0 
evidence 0 
of 0 
linkage 0 
to 0 
chromosome 0 
17q12 0 
for 0 
germ-line 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
. 0 

BRCA1 0 
mutations 0 
cosegregating 0 
with 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
were 0 
identified 0 
in 0 
_NUM2 0 
families 0 
, 0 
including 0 
_NUM1 0 
family 0 
with 0 
a 0 
case 0 
of 0 
male 1
breast 1
cancer 1
. 0 

Nine 0 
of 0 
these 0 
mutations 0 
have 0 
not 0 
been 0 
reported 0 
previously 0 
. 0 

The 0 
majority 0 
of 0 
mutations 0 
were 0 
found 0 
to 0 
generate 0 
a 0 
premature 0 
stop 0 
codon 0 
leading 0 
to 0 
the 0 
formation 0 
of 0 
a 0 
truncated 0 
BRCA1 0 
protein 0 
of 0 
_NUM1 0 
% 0 
-88 0 
% 0 
of 0 
the 0 
expected 0 
normal 0 
length 0 
. 0 

Two 0 
mutations 0 
altered 0 
the 0 
RING 0 
finger 0 
domain 0 
. 0 

Sequencing 0 
of 0 
genomic 0 
DNA 0 
led 0 
to 0 
the 0 
identification 0 
of 0 
a 0 
mutation 0 
in 0 
the 0 
coding 0 
region 0 
of 0 
BRCA1 0 
in 0 
_NUM2 0 
families 0 
, 0 
and 0 
cDNA 0 
analysis 0 
revealed 0 
an 0 
abnormal 0 
or 0 
missing 0 
BRCA1 0 
transcript 0 
in 0 
_NUM1 0 
of 0 
the 0 
_NUM1 0 
remaining 0 
families 0 
. 0 

A 0 
total 0 
of 0 
eight 0 
mutations 0 
were 0 
associated 0 
with 0 
a 0 
reduced 0 
quantity 0 
of 0 
BRCA1 0 
transcript 0 
. 0 

We 0 
were 0 
unable 0 
to 0 
detect 0 
BRCA1 0 
mutations 0 
in 0 
_NUM1 0 
of 0 
the 0 
_NUM2 0 
families 0 
, 0 
but 0 
only 0 
_NUM1 0 
of 0 
these 0 
was 0 
clearly 0 
linked 0 
to 0 
BRCA1 0 
. 0 

It 0 
is 0 
expected 0 
that 0 
the 0 
majority 0 
of 0 
clear 0 
examples 0 
of 0 
the 0 
breast-ovarian 1
syndrome 1
will 0 
be 0 
associated 0 
with 0 
germ-line 0 
mutations 0 
in 0 
the 0 
coding 0 
region 0 
of 0 
BRCA1 0 
. 0 
. 0 

Assignment 0 
of 0 
the 0 
human 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
gene 0 
SGLT1 0 
to 0 
chromosome 0 
22q13 0 
.1 0 
. 0 

The 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
gene 0 
SGLT1 0 
encodes 0 
the 0 
primary 0 
carrier 0 
protein 0 
responsible 0 
for 0 
the 0 
uptake 0 
of 0 
the 0 
dietary 0 
sugars 0 
glucose 0 
and 0 
galactose 0 
from 0 
the 0 
intestinal 0 
lumen 0 
. 0 

SGLT1 0 
transport 0 
activity 0 
is 0 
currently 0 
exploited 0 
in 0 
oral 0 
rehydration 0 
therapy 0 
. 0 

The 0 
75-kDa 0 
glycoprotein 0 
is 0 
localized 0 
in 0 
the 0 
brush 0 
border 0 
of 0 
the 0 
intestinal 0 
epithelium 0 
and 0 
is 0 
predicted 0 
to 0 
comprise 0 
_NUM2 0 
membrane 0 
spans 0 
. 0 

In 0 
two 0 
patients 0 
with 0 
the 0 
autosomal 1
recessive 1
disease 1
glucose 1
/ 1
galactose 1
malabsorption 1
, 0 
the 0 
underlying 0 
cause 0 
was 0 
found 0 
to 0 
be 0 
a 0 
missense 0 
mutation 0 
in 0 
SGLT1 0 
, 0 
and 0 
the 0 
Asp28 0 
-- 0 
> 0 
Asn 0 
change 0 
was 0 
demonstrated 0 
in 0 
vitro 0 
to 0 
eliminate 0 
SGLT1 0 
transport 0 
activity 0 
. 0 

The 0 
SGLT1 0 
gene 0 
was 0 
previously 0 
shown 0 
to 0 
reside 0 
on 0 
the 0 
distal 0 
q 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
-- 0 
> 0 
qter 0 
-RRB- 0 
. 0 

We 0 
have 0 
used 0 
a 0 
cosmid 0 
probe 0 
for 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
, 0 
which 0 
refines 0 
the 0 
localization 0 
to 0 
22q13 0 
. 0 

_NUM1 0 
, 0 
and 0 
provide 0 
an 0 
example 0 
of 0 
the 0 
utility 0 
of 0 
the 0 
SGLT1 0 
probe 0 
as 0 
a 0 
diagnostic 0 
for 0 
genetic 1
diseases 1
associated 0 
with 0 
translocations 0 
of 0 
chromosome 0 
_NUM2 0 
. 0 

A 0 
pseudodeficiency 0 
allele 0 
common 0 
in 0 
non-Jewish 0 
Tay-Sachs 1
carriers 0 
: 0 
implications 0 
for 0 
carrier 0 
screening 0 
. 0 

Deficiency 1
of 1
beta-hexosaminidase 1
A 1
-LRB- 0 
Hex 0 
A 0 
-RRB- 0 
activity 0 
typically 0 
results 0 
in 0 
Tay-Sachs 1
disease 1
. 0 

However 0 
, 0 
healthy 0 
subjects 0 
found 0 
to 0 
be 0 
deficient 1
in 1
Hex 1
A 1
activity 0 
-LRB- 0 
i. 0 
e. 0 
, 0 
pseudodeficient 0 
-RRB- 0 
by 0 
means 0 
of 0 
in 0 
vitro 0 
biochemical 0 
tests 0 
have 0 
been 0 
described 0 
. 0 

We 0 
analyzed 0 
the 0 
HEXA 0 
gene 0 
of 0 
one 0 
pseudodeficient 0 
subject 0 
and 0 
identified 0 
both 0 
a 0 
C739-to-T 0 
substitution 0 
that 0 
changes 0 
Arg247 0 
-- 0 
Trp 0 
on 0 
one 0 
allele 0 
and 0 
a 0 
previously 0 
identified 0 
Tay-Sachs 1
disease 1
mutation 0 
on 0 
the 0 
second 0 
allele 0 
. 0 

Six 0 
additional 0 
pseudodeficient 0 
subjects 0 
were 0 
found 0 
to 0 
have 0 
the 0 
C739-to-T 0 
mutation 0 
. 0 

This 0 
allele 0 
accounted 0 
for 0 
_NUM2 0 
% 0 
-LRB- 0 
20 0 
/ 0 
62 0 
-RRB- 0 
of 0 
non-Jewish 0 
enzyme-defined 0 
Tay-Sachs 1
disease 1
carriers 0 
but 0 
for 0 
none 0 
of 0 
_NUM2 0 
Jewish 0 
enzyme-defined 0 
carriers 0 
who 0 
did 0 
not 0 
have 0 
one 0 
of 0 
three 0 
known 0 
mutations 0 
common 0 
to 0 
this 0 
group 0 
. 0 

The 0 
C739-to-T 0 
allele 0 
, 0 
together 0 
with 0 
a 0 
'' 0 
true 0 
'' 0 
Tay-Sachs 1
disease 1
allele 0 
, 0 
causes 0 
Hex 0 
A 0 
pseudodeficiency 0 
. 0 

Given 0 
both 0 
the 0 
large 0 
proportion 0 
of 0 
non-Jewish 0 
carriers 0 
with 0 
this 0 
allele 0 
and 0 
that 0 
standard 0 
biochemical 0 
screening 0 
can 0 
not 0 
differentiate 0 
between 0 
heterozygotes 0 
for 0 
the 0 
C739-to-T 0 
mutations 0 
and 0 
Tay-Sachs 1
disease 1
carriers 0 
, 0 
DNA 0 
testing 0 
for 0 
this 0 
mutation 0 
in 0 
at-risk 0 
couples 0 
is 0 
essential 0 
. 0 

The 0 
presence 0 
of 0 
two 0 
different 0 
infantile 0 
Tay-Sachs 1
disease 1
mutations 0 
in 0 
a 0 
Cajun 0 
population 0 
. 0 

A 0 
study 0 
was 0 
undertaken 0 
to 0 
characterize 0 
the 0 
mutation 0 
-LRB- 0 
s 0 
-RRB- 0 
responsible 0 
for 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
in 0 
a 0 
Cajun 0 
population 0 
in 0 
southwest 0 
Louisiana 0 
and 0 
to 0 
identify 0 
the 0 
origins 0 
of 0 
these 0 
mutations 0 
. 0 

Eleven 0 
of 0 
_NUM2 0 
infantile 0 
TSD 1
alleles 0 
examined 0 
in 0 
six 0 
families 0 
had 0 
the 0 
beta-hexosaminidase 0 
A 0 
-LRB- 0 
Hex 0 
A 0 
-RRB- 0 
alpha-subunit 0 
exon 0 
_NUM2 0 
insertion 0 
mutation 0 
that 0 
is 0 
present 0 
in 0 
approximately 0 
_NUM2 0 
% 0 
of 0 
Ashkenazi 0 
Jewish 0 
TSD 1
heterozygotes 0 
. 0 

The 0 
mutation 0 
in 0 
the 0 
remaining 0 
allele 0 
was 0 
a 0 
single-base 0 
transition 0 
in 0 
the 0 
donor 0 
splice 0 
site 0 
of 0 
the 0 
alpha-subunit 0 
intron 0 
_NUM1 0 
. 0 

To 0 
determine 0 
the 0 
origins 0 
of 0 
these 0 
two 0 
mutations 0 
in 0 
the 0 
Cajun 0 
population 0 
, 0 
the 0 
TSD 1
carrier 0 
status 0 
was 0 
enzymatically 0 
determined 0 
for 0 
_NUM2 0 
members 0 
of 0 
four 0 
of 0 
the 0 
six 0 
families 0 
, 0 
and 0 
extensive 0 
pedigrees 0 
were 0 
constructed 0 
for 0 
all 0 
carriers 0 
. 0 

A 0 
single 0 
ancestral 0 
couple 0 
from 0 
France 0 
was 0 
found 0 
to 0 
be 0 
common 0 
to 0 
most 0 
of 0 
the 0 
carriers 0 
of 0 
the 0 
exon 0 
_NUM2 0 
insertion 0 
. 0 

Pedigree 0 
data 0 
suggest 0 
that 0 
this 0 
mutation 0 
has 0 
been 0 
in 0 
the 0 
Cajun 0 
population 0 
since 0 
its 0 
founding 0 
over 0 
_NUM1 0 
centuries 0 
ago 0 
and 0 
that 0 
it 0 
may 0 
be 0 
widely 0 
distributed 0 
within 0 
the 0 
population 0 
. 0 

In 0 
contrast 0 
, 0 
the 0 
intron 0 
_NUM1 0 
mutation 0 
apparently 0 
was 0 
introduced 0 
within 0 
the 0 
last 0 
century 0 
and 0 
probably 0 
is 0 
limited 0 
to 0 
a 0 
few 0 
Louisiana 0 
families 0 
. 0 
. 0 

Canavan 1
disease 1
: 0 
genomic 0 
organization 0 
and 0 
localization 0 
of 0 
human 0 
ASPA 0 
to 0 
17p13-ter 0 
and 0 
conservation 0 
of 0 
the 0 
ASPA 0 
gene 0 
during 0 
evolution 0 
. 0 

Canavan 1
disease 1
, 0 
or 0 
spongy 1
degeneration 1
of 1
the 1
brain 1
, 0 
is 0 
a 0 
severe 0 
leukodystrophy 1
caused 0 
by 0 
the 0 
deficiency 1
of 1
aspartoacylase 1
-LRB- 0 
ASPA 0 
-RRB- 0 
. 0 

Recently 0 
, 0 
a 0 
missense 0 
mutation 0 
was 0 
identified 0 
in 0 
human 0 
ASPA 0 
coding 0 
sequence 0 
from 0 
patients 0 
with 0 
Canavan 1
disease 1
. 0 

The 0 
human 0 
ASPA 0 
gene 0 
has 0 
been 0 
cloned 0 
and 0 
found 0 
to 0 
span 0 
_NUM2 0 
kb 0 
of 0 
the 0 
genome 0 
. 0 

Human 0 
aspartoacylase 0 
is 0 
coded 0 
by 0 
six 0 
exons 0 
intervened 0 
by 0 
five 0 
introns 0 
. 0 

The 0 
exons 0 
vary 0 
from 0 
_NUM2 0 
-LRB- 0 
exon 0 
III 0 
-RRB- 0 
to 0 
_NUM3 0 
-LRB- 0 
exon 0 
VI 0 
-RRB- 0 
bases 0 
. 0 

The 0 
exon 0 
/ 0 
intron 0 
splice 0 
junction 0 
sites 0 
follow 0 
the 0 
gt 0 
/ 0 
ag 0 
consensus 0 
sequence 0 
rule 0 
. 0 

Southern 0 
blot 0 
analysis 0 
of 0 
genomic 0 
DNA 0 
from 0 
human 0 
/ 0 
mouse 0 
somatic 0 
cell 0 
hybrid 0 
cell 0 
lines 0 
localized 0 
ASPA 0 
to 0 
human 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
human 0 
ASPA 0 
locus 0 
was 0 
further 0 
mapped 0 
in 0 
the 0 
17p13-ter 0 
region 0 
by 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
. 0 

The 0 
bovine 0 
aspa 0 
gene 0 
has 0 
also 0 
been 0 
cloned 0 
, 0 
and 0 
its 0 
exon 0 
/ 0 
intron 0 
organization 0 
is 0 
identical 0 
to 0 
that 0 
of 0 
the 0 
human 0 
gene 0 
. 0 

The 0 
500-base 0 
sequence 0 
upstream 0 
of 0 
the 0 
initiator 0 
_DS 0 
codon 0 
in 0 
the 0 
human 0 
gene 0 
and 0 
that 0 
in 0 
the 0 
bovine 0 
gene 0 
are 0 
_NUM2 0 
% 0 
identical 0 
. 0 

Human 0 
ASPA 0 
coding 0 
sequences 0 
cross-hybridize 0 
with 0 
genomic 0 
DNA 0 
from 0 
yeast 0 
, 0 
chicken 0 
, 0 
rabbit 0 
, 0 
cow 0 
, 0 
dog 0 
, 0 
mouse 0 
, 0 
rat 0 
, 0 
and 0 
monkey 0 
. 0 

The 0 
specificity 0 
of 0 
cross-species 0 
hybridization 0 
of 0 
coding 0 
sequences 0 
suggests 0 
that 0 
aspartoacylase 0 
has 0 
been 0 
conserved 0 
during 0 
evolution 0 
. 0 

It 0 
should 0 
now 0 
be 0 
possible 0 
to 0 
identify 0 
mutations 0 
in 0 
the 0 
noncoding 0 
genomic 0 
sequences 0 
that 0 
lead 0 
to 0 
Canavan 1
disease 1
and 0 
to 0 
study 0 
the 0 
regulation 0 
of 0 
ASPA 0 
. 0 
. 0 

Adrenoleukodystrophy 1
: 0 
survey 0 
of 0 
_NUM3 0 
cases 0 
: 0 
biochemistry 0 
, 0 
diagnosis 0 
, 0 
and 0 
therapy 0 
. 0 

Adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
is 0 
a 0 
genetically 0 
determined 0 
disorder 0 
associated 0 
with 0 
progressive 1
central 1
demyelination 1
and 0 
adrenal 1
cortical 1
insufficiency 1
. 0 

All 0 
affected 0 
persons 0 
show 0 
increased 0 
levels 0 
of 0 
saturated 0 
unbranched 0 
very-long-chain 0 
fatty 0 
acids 0 
, 0 
particularly 0 
hexacosanoate 0 
-LRB- 0 
_AN 0 
_NUM1 0 
-RRB- 0 
, 0 
because 0 
of 0 
impaired 0 
capacity 0 
to 0 
degrade 0 
these 0 
acids 0 
. 0 

This 0 
degradation 0 
normally 0 
takes 0 
place 0 
in 0 
a 0 
subcellular 0 
organelle 0 
called 0 
the 0 
peroxisome 0 
, 0 
and 0 
ALD 1
, 0 
together 0 
with 0 
Zellwegers 1
cerebrohepatorenal 1
syndrome 1
, 0 
is 0 
now 0 
considered 0 
to 0 
belong 0 
to 0 
the 0 
newly 0 
formed 0 
category 0 
of 0 
peroxisomal 1
disorders 1
. 0 

Biochemical 0 
assays 0 
permit 0 
prenatal 0 
diagnosis 0 
, 0 
as 0 
well 0 
as 0 
identification 0 
of 0 
most 0 
heterozygotes 0 
. 0 

We 0 
have 0 
identified 0 
_NUM3 0 
patients 0 
with 0 
ALD 1
in 0 
_NUM3 0 
kindreds 0 
. 0 

These 0 
patients 0 
show 0 
a 0 
wide 0 
phenotypic 0 
variation 0 
. 0 

Sixty 0 
percent 0 
of 0 
patients 0 
had 0 
childhood 0 
ALD 1
and 0 
_NUM2 0 
% 0 
adrenomyeloneuropathy 1
, 0 
both 0 
of 0 
which 0 
are 0 
X-linked 0 
, 0 
with 0 
the 0 
gene 0 
mapped 0 
to 0 
Xq28 0 
. 0 

Neonatal 1
ALD 1
, 0 
a 0 
distinct 0 
entity 0 
with 0 
autosomal 0 
recessive 0 
inheritance 0 
and 0 
points 0 
of 0 
resemblance 0 
to 0 
Zellwegers 1
syndrome 1
, 0 
accounted 0 
for 0 
_NUM1 0 
% 0 
of 0 
the 0 
cases 0 
. 0 

Although 0 
excess 0 
_AN 0 
_NUM1 0 
in 0 
the 0 
brain 0 
of 0 
patients 0 
with 0 
ALD 1
is 0 
partially 0 
of 0 
dietary 0 
origin 0 
, 0 
dietary 0 
_AN 0 
_NUM1 0 
restriction 0 
did 0 
not 0 
produce 0 
clear 0 
benefit 0 
. 0 

Bone 0 
marrow 0 
transplant 0 
lowered 0 
the 0 
plasma 0 
_AN 0 
_NUM1 0 
level 0 
but 0 
failed 0 
to 0 
arrest 0 
neurological 0 
progression 0 
. 0 
. 0 

French 0 
Machado-Joseph 1
disease 1
patients 0 
do 0 
not 0 
exhibit 0 
gametic 0 
segregation 0 
distortion 0 
: 0 
a 0 
sperm 0 
typing 0 
analysis 0 
. 0 

Segregation 0 
distortion 0 
has 0 
been 0 
reported 0 
to 0 
occur 0 
in 0 
a 0 
number 0 
of 0 
the 0 
trinucleotide 1
repeat 1
disorders 1
. 0 

On 0 
the 0 
basis 0 
of 0 
a 0 
sperm 0 
typing 0 
study 0 
performed 0 
in 0 
patients 0 
of 0 
Japanese 0 
descent 0 
with 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
, 0 
it 0 
was 0 
reported 0 
that 0 
disease 0 
alleles 0 
are 0 
preferentially 0 
transmitted 0 
during 0 
meiosis 0 
. 0 

We 0 
performed 0 
a 0 
sperm 0 
typing 0 
study 0 
of 0 
five 0 
MJD 1
patients 0 
of 0 
French 0 
descent 0 
and 0 
analysis 0 
of 0 
the 0 
pooled 0 
data 0 
shows 0 
a 0 
ratio 0 
of 0 
mutant 0 
to 0 
normal 0 
alleles 0 
of 0 
_NUM3 0 
_NUM3 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
which 0 
does 0 
not 0 
support 0 
meiotic 0 
segregation 0 
distortion 0 
. 0 

To 0 
confirm 0 
these 0 
results 0 
, 0 
sperm 0 
typing 0 
analysis 0 
was 0 
also 0 
performed 0 
using 0 
a 0 
polymorphic 0 
marker 0 
, 0 
D14S1050 0 
, 0 
closely 0 
linked 0 
to 0 
the 0 
MJD1 0 
gene 0 
. 0 

Among 0 
_NUM3 0 
sperm 0 
analyzed 0 
, 0 
the 0 
allele 0 
linked 0 
to 0 
the 0 
disease 0 
chromosome 0 
was 0 
detected 0 
in 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
samples 0 
and 0 
the 0 
allele 0 
linked 0 
to 0 
the 0 
normal 0 
chromosome 0 
was 0 
found 0 
in 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
sperm 0 
. 0 

The 0 
difference 0 
in 0 
frequency 0 
of 0 
these 0 
two 0 
alleles 0 
is 0 
not 0 
significant 0 
-LRB- 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM4 0 
-RRB- 0 
. 0 

Likelihood-based 0 
analysis 0 
of 0 
segregation 0 
distortion 0 
in 0 
the 0 
single 0 
sperm 0 
data 0 
using 0 
the 0 
SPERMSEG 0 
program 0 
also 0 
showed 0 
no 0 
support 0 
for 0 
segregation 0 
distortion 0 
at 0 
the 0 
gamete 0 
level 0 
in 0 
this 0 
patient 0 
population 0 
. 0 

The 0 
previous 0 
report 0 
on 0 
the 0 
Japanese 0 
patients 0 
also 0 
suggested 0 
that 0 
disease 0 
allele 0 
stability 0 
may 0 
be 0 
influenced 0 
by 0 
a 0 
trans 0 
effect 0 
of 0 
an 0 
intragenic 0 
polymorphism 0 
-LRB- 0 
_NUM3 0 
G 0 
/ 0 
C 0 
-RRB- 0 
in 0 
the 0 
wild-type 0 
allele 0 
. 0 

All 0 
of 0 
the 0 
French 0 
patients 0 
were 0 
heterozygous 0 
for 0 
this 0 
polymorphism 0 
. 0 

However 0 
, 0 
analysis 0 
of 0 
the 0 
variance 0 
in 0 
repeat 0 
number 0 
in 0 
sperm 0 
from 0 
the 0 
French 0 
MJD 1
patients 0 
overlapped 0 
significantly 0 
with 0 
the 0 
variance 0 
in 0 
repeat 0 
number 0 
observed 0 
in 0 
the 0 
C 0 
/ 0 
C 0 
homozygous 0 
Japanese 0 
patients 0 
. 0 

Nebulin 0 
seen 0 
in 0 
DMD 1
males 0 
including 0 
one 0 
patient 0 
with 0 
a 0 
large 0 
DNA 0 
deletion 0 
encompassing 0 
the 0 
DMD 1
gene 0 
. 0 

The 0 
presence 0 
of 0 
nebulin 0 
in 0 
a 0 
muscle 0 
specimen 0 
from 0 
a 0 
patient 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
due 0 
to 0 
a 0 
large 0 
deletion 0 
precludes 0 
the 0 
possibility 0 
that 0 
this 0 
protein 0 
is 0 
the 0 
DMD 1
gene 0 
product 0 
. 0 
. 0 

The 0 
human 0 
gene 0 
for 0 
alkaptonuria 1
-LRB- 0 
AKU 1
-RRB- 0 
maps 0 
to 0 
chromosome 0 
3q 0 
. 0 

Alkaptonuria 1
-LRB- 0 
AKU 1
; 0 
McKusick 0 
no. 0 
_NUM6 0 
-RRB- 0 
is 0 
a 0 
rare 0 
autosomal 1
recessive 1
disorder 1
caused 0 
by 0 
the 0 
lack 0 
of 0 
homogentisic 0 
acid 0 
oxidase 0 
activity 0 
. 0 

Patients 0 
excrete 0 
large 0 
amounts 0 
of 0 
homogentisic 0 
acid 0 
in 0 
their 0 
urine 0 
and 0 
a 0 
black 0 
ochronotic 0 
pigment 0 
is 0 
deposited 0 
in 0 
their 0 
cartilage 0 
and 0 
collagenous 0 
tissues 0 
. 0 

Ochronosis 1
is 0 
the 0 
predominant 0 
clinical 0 
complication 0 
of 0 
the 0 
disease 0 
leading 0 
to 0 
ochronotic 1
arthropathy 1
, 0 
dark 0 
urine 0 
, 0 
pigment 0 
changes 0 
of 0 
the 0 
skin 0 
, 0 
and 0 
other 0 
clinical 0 
features 0 
. 0 

A 0 
mutation 0 
causing 0 
alkaptonuria 1
in 0 
the 0 
mouse 0 
has 0 
mapped 0 
to 0 
chromosome 0 
_NUM2 0 
. 0 

Considering 0 
conserved 0 
synteny 0 
, 0 
we 0 
were 0 
able 0 
to 0 
map 0 
the 0 
human 0 
gene 0 
to 0 
chromosome 0 
3q 0 
in 0 
six 0 
alkaptonuria 1
pedigrees 0 
of 0 
Slovak 0 
origin 0 
. 0 
. 0 

The 0 
APC 1
gene 0 
, 0 
responsible 0 
for 0 
familial 1
adenomatous 1
polyposis 1
, 0 
is 0 
mutated 0 
in 0 
human 0 
gastric 1
cancer 1
. 0 

Although 0 
gastric 1
cancer 1
is 0 
the 0 
most 0 
common 0 
cancer 1
in 0 
the 0 
world 0 
, 0 
genetic 0 
changes 0 
during 0 
its 0 
carcinogenesis 0 
are 0 
not 0 
well 0 
understood 0 
. 0 

Since 0 
some 0 
gastric 1
cancers 1
are 0 
considered 0 
to 0 
originate 0 
from 0 
the 0 
intestinal 0 
metaplasia 0 
, 0 
it 0 
is 0 
likely 0 
that 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
, 0 
the 0 
mutation 0 
of 0 
which 0 
causes 0 
adenomatous 1
polyps 1
in 1
the 1
colon 1
, 0 
is 0 
associated 0 
with 0 
carcinogenesis 0 
of 0 
gastric 1
cancer 1
. 0 

Based 0 
on 0 
this 0 
idea 0 
, 0 
DNAs 0 
isolated 0 
from 0 
gastric 1
cancers 1
were 0 
examined 0 
by 0 
means 0 
of 0 
a 0 
RNase 0 
protection 0 
analysis 0 
coupled 0 
with 0 
polymerase 0 
chain 0 
reaction 0 
followed 0 
by 0 
sequencing 0 
of 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
products 0 
. 0 

By 0 
screening 0 
nearly 0 
one-half 0 
of 0 
the 0 
coding 0 
region 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
_NUM2 0 
tumors 1
, 0 
somatic 0 
mutations 0 
were 0 
detected 0 
in 0 
three 0 
tumors 1
a 0 
missense 0 
mutation 0 
, 0 
a 0 
nonsense 0 
mutation 0 
, 0 
and 0 
a 0 
5-base 0 
pair 0 
deletion 0 
resulting 0 
in 0 
a 0 
frame 0 
shift 0 
which 0 
causes 0 
truncation 0 
of 0 
the 0 
gene 0 
product 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
the 0 
mutation 0 
of 0 
the 0 
APC 1
gene 0 
also 0 
plays 0 
an 0 
important 0 
role 0 
during 0 
the 0 
carcinogenesis 0 
of 0 
at 0 
least 0 
some 0 
gastric 1
cancers 1
. 0 
. 0 

Molecular 0 
epidemiology 0 
of 0 
C9 1
deficiency 1
heterozygotes 0 
with 0 
an 0 
Arg95Stop 0 
mutation 0 
of 0 
the 0 
C9 0 
gene 0 
in 0 
Japan 0 
. 0 

Deficiency 1
of 1
the 1
ninth 1
component 1
of 1
human 1
complement 1
-LRB- 0 
C9 0 
-RRB- 0 
is 0 
the 0 
most 0 
common 0 
complement 1
deficiency 1
in 0 
Japan 0 
, 0 
with 0 
an 0 
incidence 0 
of 0 
approximately 0 
one 0 
homozygote 0 
in 0 
_NUM4 0 
, 0 
but 0 
is 0 
very 0 
rare 0 
in 0 
other 0 
countries 0 
. 0 

Genetic 0 
analyses 0 
of 0 
Japanese 0 
C9 1
deficiency 1
have 0 
shown 0 
that 0 
a 0 
C-to-T 0 
transition 0 
leading 0 
to 0 
_DS 0 
stop 0 
codon 0 
for 0 
Arg95 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
C9 0
gene 0 
-LRB- 0 
Arg95Stop 0 
-RRB- 0 
is 0 
common 0 
in 0 
Japanese 0 
C9 1
deficiency 1
. 0 

To 0 
determine 0 
the 0 
prevalence 0 
of 0 
heterozygous 0 
carriers 0 
of 0 
the 0 
Arg95Stop 0 
mutation 0 
in 0 
a 0 
Japanese 0 
population 0 
, 0 
we 0 
collected 0 
DNA 0 
samples 0 
from 0 
_NUM3 0 
individuals 0 
in 0 
two 0 
of 0 
the 0 
four 0 
main 0 
islands 0 
of 0 
Japan 0 
. 0 

Heterozygote 0 
detection 0 
was 0 
performed 0 
with 0 
an 0 
allele-specific 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
system 0 
designed 0 
to 0 
detect 0 
exclusively 0 
only 0 
one 0 
of 0 
the 0 
normal 0 
and 0 
mutant 0 
alleles 0 
, 0 
followed 0 
by 0 
confirmation 0 
with 0 
PCR 0 
/ 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
analysis 0 
and 0 
direct 0 
sequencing 0 
. 0 

Twenty 0 
individuals 0 
were 0 
heterozygous 0 
for 0 
the 0 
Arg95Stop 0 
mutation 0 
. 0 

None 0 
was 0 
homozygous 0 
. 0 

The 0 
prevalence 0 
of 0 
carriers 0 
of 0 
the 0 
Arg95Stop 0 
mutation 0 
was 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
20 0 
/ 0 
300 0 
-RRB- 0 
. 0 

An 0 
estimated 0 
frequency 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
% 0 
-RRB- 0 
of 0 
complete 0 
C9 1
deficiency 1
due 0 
to 0 
homozygous 0 
Arg95Stop 0 
mutation 0 
was 0 
consistent 0 
with 0 
frequencies 0 
determined 0 
by 0 
serological 0 
studies 0 
Molecular 0 
analysis 0 
of 0 
a 0 
female 0 
Lesch-Nyhan 1
patient 0 
. 0 

We 0 
report 0 
the 0 
identification 0 
of 0 
a 0 
female 0 
patient 0 
with 0 
the 0 
X-linked 0 
recessive 0 
Lesch-Nyhan 1
syndrome 1
-LRB- 0 
hypoxanthine 1
phosphoribosyltransferase 1
-LSB- 1
HPRT 1
-RSB- 1
deficiency 1
-RRB- 0 
. 0 

Cytogenetic 0 
and 0 
carrier 0 
studies 0 
revealed 0 
structurally 0 
normal 0 
chromosomes 0 
for 0 
this 0 
patient 0 
and 0 
her 0 
parents 0 
and 0 
demonstrated 0 
that 0 
this 0 
mutation 0 
arose 0 
through 0 
a 0 
de 0 
novo 0 
gametic 0 
event 0 
. 0 

Comparison 0 
of 0 
this 0 
patients 0 
DNA 0 
with 0 
the 0 
DNA 0 
of 0 
her 0 
parents 0 
revealed 0 
that 0 
a 0 
microdeletion 0 
, 0 
which 0 
occurred 0 
within 0 
a 0 
maternal 0 
gamete 0 
and 0 
involved 0 
the 0 
entire 0 
HPRT 0 
gene 0 
, 0 
was 0 
partially 0 
responsible 0 
for 0 
the 0 
disease 0 
in 0 
this 0 
patient 0 
. 0 

Somatic 0 
cell 0 
hybrids 0 
, 0 
generated 0 
to 0 
separate 0 
maternal 0 
and 0 
paternal 0 
X 0 
chromosomes 0 
, 0 
showed 0 
that 0 
expression 0 
of 0 
two 0 
additional 0 
X-linked 0
enzymes 0 
, 0 
phosphoglycerate 0 
kinase 0 
and 0 
glucose-6-phosphate 0 
dehydrogenase 0 
, 0 
were 0 
expressed 0 
only 0 
in 0 
cells 0 
that 0 
contained 0 
the 0 
maternal 0 
X 0 
chromosome 0 
, 0 
suggesting 0 
the 0 
presence 0 
of 0 
a 0 
functionally 0 
inactive 0 
paternal 0 
X 0 
chromosome 0 
. 0 

Furthermore 0 
, 0 
comparison 0 
of 0 
methylation 0 
patterns 0 
within 0 
a 0 
region 0 
of 0 
the 0 
HPRT 0 
gene 0 
known 0 
to 0 
be 0 
important 0 
in 0 
gene 0 
regulation 0 
revealed 0 
differences 0 
between 0 
DNA 0 
from 0 
the 0 
father 0 
and 0 
the 0 
patient 0 
, 0 
in 0 
keeping 0 
with 0 
an 0 
active 0 
HPRT 0 
locus 0 
in 0 
the 0 
father 0 
and 0 
an 0 
inactive 0 
HPRT 0 
locus 0 
in 0 
the 0 
patient 0 
. 0 

Together 0 
these 0 
data 0 
indicate 0 
that 0 
nonrandom 0 
inactivation 0 
of 0 
the 0 
cytogenetically 0 
normal 0 
paternal 0 
X 0 
chromosome 0 
and 0 
a 0 
microdeletion 0 
of 0 
the 0 
HPRT 0 
gene 0 
on 0 
an 0 
active 0 
maternal 0 
X 0 
chromosome 0 
were 0 
responsible 0 
for 0 
the 0 
absence 0 
of 0 
HPRT 0 
in 0 
this 0 
patient 0 
. 0 
. 0 

Changes 0 
at 0 
_AN 0 
of 0 
emerin 0 
weaken 0 
its 0 
protein-protein 0 
interactions 0 
resulting 0 
in 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
. 0 

Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
is 0 
an 0 
X-linked 1
recessive 1
muscular 1
dystrophy 1
characterized 0 
by 0 
early 0 
contractures 1
of 1
the 1
elbows 1
, 1
Achilles 1
tendons 1
and 1
spine 1
, 0 
slowly 0 
progressive 0 
muscle 1
wasting 1
and 0 
weakness 1
, 0 
and 0 
cardiomyopathy 1
associated 0 
with 0 
cardiac 1
conduction 1
defects 1
. 0 

The 0 
emerin 0 
gene 0 
has 0 
been 0 
mapped 0 
to 0 
Xq28 0 
and 0 
encodes 0 
a 0 
34-kDa 0 
serine-rich 0 
protein 0 
, 0 
emerin 0 
, 0 
which 0 
has 0 
been 0 
localized 0 
to 0 
the 0 
nuclear 0 
envelope 0 
in 0 
a 0 
wide 0 
variety 0 
of 0 
tissues 0 
, 0 
including 0 
skeletal 0 
and 0 
cardiac 0 
muscle 0 
. 0 

Mutations 0 
spanning 0 
the 0 
emerin 0 
gene 0 
have 0 
been 0 
identified 0 
in 0 
patients 0 
with 0 
EDMD 1
. 0 

We 0 
present 0 
here 0 
the 0 
effect 0 
, 0 
on 0 
emerin 0 
protein 0 
expression 0 
, 0 
of 0 
two 0 
missense 0 
mutations 0 
identified 0 
in 0 
unrelated 0 
EDMD 1
patients 0 
. 0 

These 0 
alterations 0 
predict 0 
the 0 
replacement 0 
of 0 
a 0 
proline 0 
residue 0 
at 0 
position 0 
_NUM3 0 
with 0 
either 0 
a 0 
histidine 0 
or 0 
a 0 
threonine 0 
. 0 

Biochemical 0 
analysis 0 
has 0 
demonstrated 0 
that 0 
the 0 
mobility 0 
and 0 
expression 0 
levels 0 
of 0 
the 0 
mutant 0 
forms 0 
of 0 
emerin 0 
are 0 
indistinguishable 0 
from 0 
that 0 
of 0 
wild-type 0 
emerin 0 
, 0 
but 0 
that 0 
they 0 
have 0 
weakened 0 
interactions 0 
with 0 
nuclear 0 
lamina 0 
components 0 
. 0 

In 0 
comparison 0 
with 0 
the 0 
usual 0 
EDMD 1
phenotype 0 
, 0 
patients 0 
with 0 
_AN 0 
missense 0 
mutations 0 
have 0 
a 0 
later 0 
age 0 
at 0 
onset 0 
of 0 
first 0 
symptoms 0 
, 0 
elbow 1
contractures 1
, 0 
ankle 1
contractures 1
, 0 
upper 1
limb 1
weakness 1
and 0 
lower 1
limb 1
weakness 1
, 0 
but 0 
there 0 
is 0 
no 0 
difference 0 
for 0 
the 0 
age 0 
at 0 
onset 0 
of 0 
cardiac 1
involvement 1
. 0 

This 0 
is 0 
the 0 
first 0 
report 0 
of 0 
protein 0 
studies 0 
on 0 
patients 0 
with 0 
missense 0 
mutations 0 
resulting 0 
in 0 
the 0 
clinical 0 
features 0 
of 0 
EDMD 1
. 0 

These 0 
studies 0 
demonstrate 0 
the 0 
importance 0 
of 0 
proline 0 
_NUM3 0 
for 0 
the 0 
proper 0 
structure 0 
/ 0 
function 0 
of 0 
emerin 0 
. 0 
. 0 

Decreased 0 
expression 0 
of 0 
BRCA1 0 
accelerates 0 
growth 0 
and 0 
is 0 
often 0 
present 0 
during 0 
sporadic 1
breast 1
cancer 1
progression 0 
. 0 

We 0 
have 0 
characterized 0 
expression 0 
of 0 
the 0 
familial 1
breast 1
and 1
ovarian 1
cancer 1
gene 0 
, 0 
BRCA1 0 
, 0 
in 0 
cases 0 
of 0 
non-hereditary 1
-LRB- 1
sporadic 1
-RRB- 1
breast 1
cancer 1
and 0 
analyzed 0 
the 0 
effect 0 
of 0 
antisense 0 
inhibition 0 
of 0 
BRCA1 0 
on 0 
the 0 
proliferative 0 
rate 0 
of 0 
mammary 0 
epithelial 0 
cells 0 
. 0 

BRCA1 0 
mRNA 0 
levels 0 
are 0 
markedly 0 
decreased 0 
during 0 
the 0 
transition 0 
from 0 
carcinoma 1
in 1
situ 1
to 0 
invasive 1
cancer 1
. 0 

Experimental 0 
inhibition 0 
of 0 
BRCA1 0 
expression 0 
with 0 
antisense 0 
oligonucleotides 0 
produced 0 
accelerated 0 
growth 0 
of 0 
normal 0 
and 0 
malignant 0 
mammary 0 
cells 0 
, 0 
but 0 
had 0 
no 0 
effect 0 
on 0 
non-mammary 0 
epithelial 0 
cells 0 
. 0 

These 0 
studies 0 
suggest 0 
that 0 
BRCA1 0 
may 0 
normally 0 
serve 0 
as 0 
a 0 
negative 0 
regulator 0 
of 0 
mammary 0 
epithelial 0 
cell 0 
growth 0 
whose 0 
function 0 
is 0 
compromised 0 
in 0 
breast 1
cancer 1
either 0 
by 0 
direct 0 
mutation 0 
or 0 
alterations 0 
in 0 
gene 0 
expression 0 
. 0 
. 0 

Additional 0 
copies 0 
of 0 
the 0 
proteolipid 0 
protein 0 
gene 0 
causing 0 
Pelizaeus-Merzbacher 1
disease 1
arise 0 
by 0 
separate 0 
integration 0 
into 0 
the 0 
X 0 
chromosome 0 
. 0 

The 0 
proteolipid 0 
protein 0 
gene 0 
-LRB- 0 
PLP 0 
-RRB- 0 
is 0 
normally 0 
present 0 
at 0 
chromosome 0 
Xq22 0 
. 0 

Mutations 0 
and 0 
duplications 0 
of 0 
this 0 
gene 0 
are 0 
associated 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
-LRB- 0 
PMD 1
-RRB- 0 
. 0 

Here 0 
we 0 
describe 0 
two 0 
new 0 
families 0 
in 0 
which 0 
males 0 
affected 0 
with 0 
PMD 1
were 0 
found 0 
to 0 
have 0 
a 0 
copy 0 
of 0 
PLP 0 
on 0 
the 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
, 0 
in 0 
addition 0 
to 0 
a 0 
normal 0 
copy 0 
on 0 
Xq22 0 
. 0 

In 0 
the 0 
first 0 
family 0 
, 0 
the 0 
extra 0 
copy 0 
was 0 
first 0 
detected 0 
by 0 
the 0 
presence 0 
of 0 
heterozygosity 0 
of 0 
the 0 
AhaII 0 
dimorphism 0 
within 0 
the 0 
PLP 0 
gene 0 
. 0 

The 0 
results 0 
of 0 
FISH 0 
analysis 0 
showed 0 
an 0 
additional 0 
copy 0 
of 0 
PLP 0 
in 0 
Xp22 0 
. 0 

_NUM1 0 
, 0 
although 0 
no 0 
chromosomal 0 
rearrangements 0 
could 0 
be 0 
detected 0 
by 0 
standard 0 
karyotype 0 
analysis 0 
. 0 

Another 0 
three 0 
affected 0 
males 0 
from 0 
the 0 
family 0 
had 0 
similar 0 
findings 0 
. 0 

In 0 
a 0 
second 0 
unrelated 0 
family 0 
with 0 
signs 0 
of 0 
PMD 1
, 0 
cytogenetic 0 
analysis 0 
showed 0 
a 0 
pericentric 0 
inversion 0 
of 0 
the 0 
X 0 
chromosome 0 
. 0 

In 0 
the 0 
inv 0 
-LRB- 0 
X 0 
-RRB- 0 
carried 0 
by 0 
several 0 
affected 0 
family 0 
members 0 
, 0 
FISH 0 
showed 0 
PLP 0 
signals 0 
at 0 
Xp11 0 
. 0 

_NUM1 0 
and 0 
Xq22 0 
. 0 

A 0 
third 0 
family 0 
has 0 
previously 0 
been 0 
reported 0 
, 0 
in 0 
which 0 
affected 0 
members 0 
had 0 
an 0 
extra 0 
copy 0 
of 0 
the 0 
PLP 0 
gene 0 
detected 0 
at 0 
Xq26 0 
in 0 
a 0 
chromosome 0 
with 0 
an 0 
otherwise 0 
normal 0 
banding 0 
pattern 0 
. 0 

The 0 
identification 0 
of 0 
three 0 
separate 0 
families 0 
in 0 
which 0 
PLP 0 
is 0 
duplicated 0 
at 0 
a 0 
noncontiguous 0 
site 0 
suggests 0 
that 0 
such 0 
duplications 0 
could 0 
be 0 
a 0 
relatively 0 
common 0 
but 0 
previously 0 
undetected 0 
cause 0 
of 0 
genetic 1
disorders 1
. 0 

Linkage 0 
relationships 0 
of 0 
the 0 
apolipoprotein 0 
C1 0 
gene 0 
and 0 
a 0 
cytochrome 0 
_AN 0 
gene 0 
-LRB- 0 
CYP2A 0 
-RRB- 0 
to 0 
myotonic 1
dystrophy 1
. 0 

We 0 
have 0 
studied 0 
the 0 
genetic 0 
linkage 0 
of 0 
two 0 
markers 0 
, 0 
the 0 
apolipoprotein 0 
C1 0 
-LRB- 0 
APOC1 0 
-RRB- 0 
gene 0 
and 0 
a 0 
cytochrome 0 
_AN 0 
-LRB- 0 
CYP2A 0 
-RRB- 0 
gene 0 
, 0 
in 0 
relation 0 
to 0 
the 0 
gene 0 
for 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

A 0 
peak 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
_NUM1 0 
cM 0 
was 0 
observed 0 
for 0 
APOC1-DM 0 
, 0 
with 0 
a 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
_NUM1 0 
cM 0 
for 0 
CYP2A-DM 0 
. 0 

These 0 
two 0 
markers 0 
also 0 
show 0 
close 0 
linkage 0 
to 0 
each 0 
other 0 
-LRB- 0 
theta 0 
max 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
Zmax 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

From 0 
examination 0 
of 0 
the 0 
genotypes 0 
of 0 
the 0 
recombinant 0 
individuals 0 
, 0 
CYP2A 0 
appears 0 
to 0 
map 0 
proximal 0 
to 0 
DM 0 
because 0 
in 0 
one 0 
recombinant 0 
individual 0 
CYP2A 0 
, 0 
APOC2 0 
and 0 
CKMM 0 
had 0 
all 0 
recombined 0 
with 0 
DM 0 
. 0 

Evidence 0 
from 0 
another 0 
CYP2A-DM 0 
recombinant 0 
individual 0 
places 0 
CYP2A 0 
proximal 0 
to 0 
APOC2 0 
and 0 
CKMM 0 
. 0 

Localisation 0 
of 0 
CYP2A 0 
on 0 
a 0 
panel 0 
of 0 
somatic 0 
cell 0 
hybrids 0 
also 0 
suggests 0 
that 0 
it 0 
is 0 
proximal 0 
to 0 
DM 0 
and 0 
APOC2 0 
/ 0 
C1 0 
/ 0 
E 0 
gene 0 
cluster 0 
. 0 

beta-galactosidase 0 
gene 0 
mutations 0 
affecting 0 
the 0 
lysosomal 0 
enzyme 0 
and 0 
the 0 
elastin-binding 0 
protein 0 
in 0 
GM1-gangliosidosis 1
patients 0 
with 0 
cardiac 1
involvement 1
. 0 

GM1-gangliosidosis 1
is 0 
a 0 
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
deficiency 1
of 1
acid 1
beta-galactosidase 1
-LRB- 0 
GLB1 0 
-RRB- 0 
. 0 

We 0 
report 0 
five 0 
new 0 
beta-galactosidase 0 
gene 0 
mutations 0 
in 0 
nine 0 
Italian 0 
patients 0 
and 0 
one 0 
fetus 0 
, 0 
segregating 0 
in 0 
seven 0 
unrelated 0 
families 0 
. 0 

Six 0 
of 0 
the 0 
eight 0 
patients 0 
with 0 
the 0 
infantile 0 
, 0 
severe 0 
form 0 
of 0 
the 0 
disease 0 
presented 0 
cardiac 1
involvement 1
, 0 
a 0 
feature 0 
rarely 0 
associated 0 
with 0 
GM1-gangliosidosis 1
. 0 

Molecular 0 
analysis 0 
of 0 
the 0 
patients 0 
RNA 0 
and 0 
DNA 0 
identified 0 
two 0 
new 0 
RNA 0 
splicing 0 
defects 0 
, 0 
three 0 
new 0 
and 0 
three 0 
previously 0 
described 0 
amino 0 
acid 0 
substitutions 0 
. 0 

Interestingly 0 
, 0 
all 0 
patients 0 
with 0 
cardiac 1
involvement 1
were 0 
homozygous 0 
for 0 
one 0 
of 0 
these 0 
mutations 0 
R59H 0 
, 0 
Y591C 0 
, 0 
Y591N 0 
, 0 
or 0 
IVS14-2A 0 
> 0 
G 0 
. 0 

In 0 
contrast 0 
, 0 
all 0 
other 0 
patients 0 
were 0 
compound 0 
heterozygous 0 
for 0 
one 0 
of 0 
the 0 
following 0 
mutations 0 
R201H 0 
, 0 
R482H 0 
, 0 
G579D 0 
, 0 
IVS8 0 
+ 0 
2T 0 
> 0 
C. 0 
Although 0 
we 0 
could 0 
not 0 
directly 0 
correlate 0 
the 0 
presence 0 
of 0 
cardiac 1
abnormalities 1
with 0 
specific 0 
genetic 1
lesions 1
, 0 
the 0 
mutations 0 
identified 0 
in 0 
patients 0 
with 0 
cardiomyopathy 1
fell 0 
in 0 
the 0 
GLB1 0 
cDNA 0 
region 0 
common 0 
to 0 
the 0 
lysosomal 0 
enzyme 0 
and 0 
the 0 
Hbeta-Gal-related 0 
protein 0 
, 0 
also 0 
known 0 
as 0 
the 0 
elastin 0 
binding 0 
protein 0 
-LRB- 0 
EBP 0 
-RRB- 0 
. 0 

Consequently 0 
, 0 
both 0 
molecules 0 
are 0 
affected 0 
by 0 
the 0 
mutations 0 
, 0 
and 0 
they 0 
may 0 
contribute 0 
differently 0 
to 0 
the 0 
occurrence 0 
of 0 
specific 0 
clinical 0 
manifestations 0 
. 0 
. 0 

Exclusion 0 
of 0 
linkage 0 
between 0 
familial 1
Mediterranean 1
fever 1
and 0 
the 0 
human 0 
serum 0 
amyloid 0 
A 0 
-LRB- 0 
SAA 0 
-RRB- 0 
gene 0 
cluster 0 
. 0 

We 0 
studied 0 
the 0 
relationship 0 
between 0 
the 0 
autosomal 0 
recessive 0 
trait 0 
familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
and 0 
the 0 
serum 0 
amyloid 0 
A 0 
-LRB- 0 
SAA 0 
-RRB- 0 
genes 0 
by 0 
comparing 0 
alleles 0 
of 0 
a 0 
highly 0 
polymorphic 0 
dinucleotide 0 
repeat 0 
and 0 
a 0 
conventional 0 
restriction 0 
fragment 0 
length 0 
polymorphism 0 
-LRB- 0 
RFLP 0 
-RRB- 0 
in 0 
the 0 
SAA 0 
gene 0 
cluster 0 
in 0 
Israeli 0 
FMF 1
kindreds 0 
. 0 

By 0 
haplotype 0 
analysis 0 
, 0 
our 0 
data 0 
indicate 0 
a 0 
minimum 0 
crossover 0 
frequency 0 
of 0 
_NUM2 0 
% 0 
between 0 
the 0 
SAA 0 
gene 0 
marker 0 
and 0 
FMF 1
. 0 

By 0 
conventional 0 
linkage 0 
analysis 0 
this 0 
eliminates 0 
a 0 
minimum 0 
of 0 
_NUM2 0 
. 0 

_NUM1 0 
cM 0 
including 0 
and 0 
surrounding 0 
the 0 
SAA 0 
gene 0 
cluster 0 
as 0 
the 0 
site 0 
of 0 
the 0 
FMF 1
mutation 0 
although 0 
SAA 0 
proteins 0 
are 0 
prominent 0 
physiologic 0 
markers 0 
of 0 
the 0 
acute 0 
attacks 0 
. 0 

Mice 0 
deficient 1
in 1
Six5 1
develop 0 
cataracts 1
: 0 
implications 0 
for 0 
myotonic 1
dystrophy 1
. 0 

Expansion 0 
of 0 
a 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
the 0 
_NUM1 0 
UTR 0 
of 0 
the 0 
gene 0 
DMPK 0 
at 0 
the 0 
DM1 0 
locus 0 
on 0 
chromosome 0 
_NUM2 0 
causes 0 
myotonic 1
dystrophy 1
, 0 
a 0 
dominantly 1
inherited 1
disease 1
characterized 0 
by 0 
skeletal 0 
muscle 1
dystrophy 1
and 0 
myotonia 1
, 0 
cataracts 1
and 0 
cardiac 1
conduction 1
defects 1
. 0 

Targeted 0 
deletion 0 
of 0 
Dm15 0 
, 0 
the 0 
mouse 0 
orthologue 0 
of 0 
human 0 
DMPK 0 
, 0 
produced 0 
mice 0 
with 0 
a 0 
mild 0 
myopathy 1
and 0 
cardiac 1
conduction 1
abnormalities 1
, 0 
but 0 
without 0 
other 0 
features 0 
of 0 
myotonic 1
dystrophy 1
, 0 
such 0 
as 0 
myotonia 1
and 0 
cataracts 1
. 0 

We 0 
, 0 
and 0 
others 0 
, 0 
have 0 
demonstrated 0 
that 0 
repeat 0 
expansion 0 
decreases 0 
expression 0 
of 0 
the 0 
adjacent 0 
gene 0 
SIX5 0
-LRB- 0 
refs 0 
_NUM1 0 
, 0 
_NUM1 0 
-RRB- 0 
, 0 
which 0 
encodes 0 
a 0 
homeodomain 0 
transcription 0 
factor 0 
. 0 

To 0 
determine 0 
whether 0 
SIX5 1
deficiency 1
contributes 0 
to 0 
the 0 
myotonic 1
dystrophy 1
phenotype 0 
, 0 
we 0 
disrupted 0 
mouse 0 
Six5 0 
by 0 
replacing 0 
the 0 
first 0 
exon 0 
with 0 
a 0 
beta-galactosidase 0 
reporter 0 
. 0 

Six5-mutant 0 
mice 0 
showed 0 
reporter 0 
expression 0 
in 0 
multiple 0 
tissues 0 
, 0 
including 0 
the 0 
developing 0 
lens 0 
. 0 

Homozygous 0 
mutant 0 
mice 0 
had 0 
no 0 
apparent 0 
abnormalities 1
of 1
skeletal 1
muscle 1
function 1
, 0 
but 0 
developed 0 
lenticular 1
opacities 1
at 0 
a 0 
higher 0 
rate 0 
than 0 
controls 0 
. 0 

Our 0 
results 0 
suggest 0 
that 0 
SIX5 1
deficiency 1
contributes 0 
to 0 
the 0 
cataract 1
phenotype 0 
in 0 
myotonic 1
dystrophy 1
, 0 
and 0 
that 0 
myotonic 1
dystrophy 1
represents 0 
a 0 
multigenic 1
disorder 1
. 0 
. 0 

Screening 0 
for 0 
germ-line 0 
mutations 0 
in 0 
familial 1
adenomatous 1
polyposis 1
patients 0 
: 0 
_NUM2 0 
new 0 
patients 0 
and 0 
a 0 
summary 0 
of 0 
_NUM3 0 
unrelated 0 
patients 0 
. 0 

We 0 
report 0 
here 0 
the 0 
result 0 
of 0 
a 0 
screening 0 
for 0 
germ-line 0 
mutations 0 
in 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
in 0 
_NUM2 0 
new 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
patients 0 
as 0 
well 0 
as 0 
a 0 
summary 0 
of 0 
the 0 
results 0 
of 0 
_NUM3 0 
patients 0 
. 0 

Examination 0 
of 0 
the 0 
entire 0 
coding 0 
region 0 
of 0 
the 0 
APC 1
gene 0 
, 0 
based 0 
on 0 
a 0 
ribonuclease 0 
protection 0 
assay 0 
coupled 0 
with 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
, 0 
disclosed 0 
mutations 0 
that 0 
were 0 
considered 0 
to 0 
cause 0 
significant 0 
defects 0 
in 0 
the 0 
APC 1
product 0 
in 0 
_NUM2 0 
of 0 
_NUM3 0 
unrelated 0 
FAP 1
patients 0 
. 0 

Our 0 
findings 0 
revealed 0 
the 0 
following 0 
characteristics 0 
of 0 
the 0 
germ-line 0 
mutations 0 
of 0 
APC 1
_NUM1 0 
-RRB- 0 
the 0 
great 0 
majority 0 
of 0 
the 0 
mutations 0 
were 0 
found 0 
to 0 
truncate 0 
the 0 
APC 0 
product 0 
; 0 
_NUM1 0 
-RRB- 0 
almost 0 
all 0 
of 0 
the 0 
mutations 0 
were 0 
located 0 
within 0 
the 0 
first 0 
half 0 
of 0 
the 0 
coding 0 
region 0 
; 0 
_NUM1 0 
-RRB- 0 
no 0 
correlation 0 
was 0 
observed 0 
between 0 
the 0 
locations 0 
of 0 
germ-line 0 
mutations 0 
and 0 
extracolonic 0 
manifestations 0 
in 0 
FAP 1
patients 0 
; 0 
_NUM1 0 
-RRB- 0 
more 0 
than 0 
_NUM2 0 
% 0 
of 0 
base 0 
substitutions 0 
in 0 
the 0 
APC 1
gene 0 
were 0 
from 0 
cytosine 0 
to 0 
other 0 
nucleotides 0 
, 0 
nearly 0 
one-third 0 
of 0 
which 0 
occurred 0 
at 0 
the 0 
GpG 0 
site 0 
. 0 

Our 0 
results 0 
provide 0 
information 0 
helpful 0 
to 0 
an 0 
understanding 0 
of 0 
the 0 
APC 1
gene 0 
and 0 
will 0 
also 0 
contribute 0 
to 0 
presymptomatic 0 
diagnosis 0 
of 0 
members 0 
in 0 
FAP 1
families 0 
. 0 
. 0 

Hereditary 0 
deficiency 1
of 1
C5 1
in 0 
association 0 
with 0 
discoid 1
lupus 1
erythematosus 1
. 0 

A 0 
29-year-old 0 
woman 0 
with 0 
discoid 1
lupus 1
erythematosus 1
had 0 
undetectable 0 
classic 0 
pathway 0 
complement 0 
activity 0 
. 0 

Hypocomplementemia 1
was 0 
due 0 
to 0 
selective 0 
deficiency 1
of 1
C5 1
. 0 

One 0 
of 0 
her 0 
children 0 
was 0 
also 0 
deficient 0 
. 0 

To 0 
our 0 
knowledge 0 
this 0 
is 0 
the 0 
first 0 
documented 0 
case 0 
of 0 
an 0 
association 0 
between 0 
discoid 1
lupus 1
erythematosus 1
and 0 
C5 1
deficiency 1
. 0 
. 0 

Isolation 0 
, 0 
genomic 0 
organization 0 
, 0 
and 0 
expression 0 
analysis 0 
of 0 
the 0 
mouse 0 
and 0 
rat 0 
homologs 0 
of 0 
MEFV 0 
, 0 
the 0 
gene 0 
for 0 
familial 1
mediterranean 1
fever 1
. 0 

Familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
is 0 
a 0 
recessive 1
disorder 1
characterized 0 
by 0 
episodes 0 
of 0 
fever 1
with 0 
serositis 1
or 0 
synovitis 1
. 0 

Recently 0 
the 0 
FMF 1
gene 0 
-LRB- 0 
MEFV 0 
-RRB- 0 
was 0 
cloned 0 
; 0 
the 0 
protein 0 
product 0 
, 0 
pyrin 0 
/ 0 
marenostrin 0 
, 0 
is 0 
thought 0 
to 0 
regulate 0 
inflammation 0 
in 0 
myeloid 0 
cells 0 
. 0 

In 0 
this 0 
manuscript 0 
we 0 
report 0 
the 0 
mouse 0 
and 0 
rat 0 
homologs 0 
of 0 
MEFV 0 
. 0 

The 0 
murine 0 
gene 0 
contains 0 
ten 0 
exons 0 
with 0 
a 0 
coding 0 
sequence 0 
of 0 
_NUM4 0 
bp 0 
, 0 
while 0 
the 0 
rat 0 
homolog 0 
has 0 
nine 0 
exons 0 
with 0 
a 0 
coding 0 
sequence 0 
of 0 
_NUM4 0 
bp 0 
. 0 

A 0 
considerable 0 
amino 0 
acid 0 
sequence 0 
homology 0 
was 0 
observed 0 
between 0 
the 0 
mouse 0 
and 0 
human 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
identity 0 
and 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
similarity 0 
-RRB- 0 
and 0 
between 0 
the 0 
mouse 0 
and 0 
rat 0 
genes 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
identity 0 
and 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
similarity 0 
-RRB- 0 
. 0 

The 0 
predicted 0 
rodent 0 
proteins 0 
have 0 
several 0 
important 0 
domains 0 
and 0 
signals 0 
found 0 
in 0 
human 0 
pyrin 0 
, 0 
including 0 
a 0 
B-box 0 
zinc 0 
finger 0 
domain 0 
, 0 
Robbins-Dingwall 0 
nuclear 0 
localization 0 
signal 0 
, 0 
and 0 
coiled-coil 0 
domain 0 
. 0 

However 0 
, 0 
perhaps 0 
because 0 
of 0 
an 0 
ancient 0 
frame-shift 0 
mutation 0 
, 0 
neither 0 
the 0 
mouse 0 
nor 0 
the 0 
rat 0 
protein 0 
has 0 
an 0 
intact 0 
C-terminal 0 
_AN 0 
. 0 

_NUM1 0 
domain 0 
, 0 
in 0 
which 0 
most 0 
FMF 1
associated 0 
mutations 0 
have 0 
been 0 
found 0 
in 0 
human 0 
MEFV 0 
. 0 

Nevertheless 0 
, 0 
like 0 
the 0 
human 0 
gene 0 
, 0 
mouse 0 
Mefv 0 
is 0 
expressed 0 
in 0 
peripheral 0 
blood 0 
granulocytes 0 
but 0 
not 0 
lymphocytes 0 
. 0 

Consistent 0 
with 0 
its 0 
expression 0 
in 0 
granulocytes 0 
, 0 
Mefv 0 
was 0 
detected 0 
at 0 
high 0 
levels 0 
in 0 
the 0 
primary 0 
follicles 0 
and 0 
marginal 0 
zones 0 
of 0 
the 0 
splenic 0 
white 0 
pulp 0 
. 0 

Mefv 0 
is 0 
localized 0 
on 0 
mouse 0 
Chromosome 0 
-LRB- 0 
Chr 0 
-RRB- 0 
_NUM2 0 
, 0 
region 0 
A3-B1 0 
, 0 
extending 0 
a 0 
region 0 
of 0 
synteny 0 
with 0 
human 0 
Chr 0 
16p13 0 
. 0 

_NUM1 0 
. 0 

Development 0 
of 0 
knockout 0 
and 0 
knockin 0 
mouse 0 
models 0 
may 0 
provide 0 
further 0 
insights 0 
into 0 
the 0 
functional 0 
evolution 0 
of 0 
this 0 
gene 0 
. 0 

Analysis 0 
of 0 
X-chromosome 0 
inactivation 0 
and 0 
presumptive 0 
expression 0 
of 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
gene 0 
in 0 
hematopoietic 0 
cell 0 
lineages 0 
of 0 
a 0 
thrombocytopenic 0 
carrier 0 
female 0 
of 0 
WAS 1
. 0 

We 0 
report 0 
on 0 
a 0 
thrombocytopenic 1
female 0 
belonging 0 
to 0 
a 0 
pedigree 0 
with 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
. 0 

Restriction 0 
fragment 0 
length 0 
polymorphism 0 
-LRB- 0 
RFLP 0 
-RRB- 0 
analysis 0 
with 0 
probe 0 
_AN 0 
beta 0 
, 0 
closely 0 
linked 0 
to 0 
the 0 
WAS 1
gene 0 
, 0 
demonstrated 0 
that 0 
she 0 
is 0 
a 0 
carrier 0 
of 0 
WAS 1
. 0 

Both 0 
small-sized 0 
and 0 
normal-sized 0 
platelets 0 
were 0 
present 0 
, 0 
suggesting 0 
that 0 
, 0 
unlike 0 
the 0 
vast 0 
majority 0 
of 0 
WAS 1
carriers 0 
, 0 
she 0 
does 0 
not 0 
manifest 0 
nonrandom 0 
X-chromosome 0 
inactivation 0 
in 0 
the 0 
thrombopoietic 0 
cell 0 
lineage 0 
. 0 

Study 0 
of 0 
X-chromosome 0 
inactivation 0 
by 0 
means 0 
of 0 
RFLP 0 
and 0 
methylation 0 
analysis 0 
demonstrated 0 
that 0 
the 0 
pattern 0 
of 0 
X-chromosome 0 
inactivation 0 
was 0 
nonrandom 0 
in 0 
T 0 
lymphocytes 0 
, 0 
but 0 
random 0 
in 0 
granulocytes 0 
. 0 

While 0 
this 0 
is 0 
the 0 
first 0 
complete 0 
report 0 
on 0 
the 0 
occurrence 0 
of 0 
thrombocytopenia 1
in 0 
a 0 
carrier 0 
female 0 
of 0 
WAS 1
as 0 
the 0 
result 0 
of 0 
atypical 0 
lyonization 0 
, 0 
it 0 
also 0 
suggests 0 
that 0 
expression 0 
of 0 
the 0 
WAS 1
gene 0 
occurs 0 
at 0 
-LRB- 0 
or 0 
extends 0 
up 0 
to 0 
-RRB- 0 
a 0 
later 0 
stage 0 
than 0 
the 0 
multipotent 0 
stem 0 
cell 0 
along 0 
the 0 
hematopoietic 0 
differentiation 0 
pathway 0 
. 0 
. 0 

hCds1-mediated 0 
phosphorylation 0 
of 0 
BRCA1 0 
regulates 0 
the 0 
DNA 0 
damage 0 
response 0 
. 0 

Mutations 0 
in 0 
the 0 
BRCA1 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
tumour 1
suppressor 0 
gene 0 
are 0 
found 0 
in 0 
almost 0 
all 0 
of 0 
the 0 
families 0 
with 0 
inherited 1
breast 1
and 1
ovarian 1
cancers 1
and 0 
about 0 
half 0 
of 0 
the 0 
families 0 
with 0 
only 0 
breast 1
cancer 1
. 0 

Although 0 
the 0 
biochemical 0 
function 0 
of 0 
BRCA1 0 
is 0 
not 0 
well 0 
understood 0 
, 0 
it 0 
is 0 
important 0 
for 0 
DNA 0 
damage 0 
repair 0 
and 0 
cell-cycle 0 
checkpoint 0 
. 0 

BRCA1 0 
exists 0 
in 0 
nuclear 0 
foci 0 
but 0 
is 0 
hyperphosphorylated 0 
and 0 
disperses 0 
after 0 
DNA 0 
damage 0 
. 0 

It 0 
is 0 
not 0 
known 0 
whether 0 
BRCA1 0 
phosphorylation 0 
and 0 
dispersion 0 
and 0 
its 0 
function 0 
in 0 
DNA 0 
damage 0 
response 0 
are 0 
related 0 
. 0 

In 0 
yeast 0 
the 0 
DNA 0 
damage 0 
response 0 
and 0 
the 0 
replication-block 0 
checkpoint 0 
are 0 
mediated 0 
partly 0 
through 0 
the 0 
Cds1 0 
kinase 0 
family 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
the 0 
human 0 
Cds1 0 
kinase 0 
-LRB- 0 
hCds1 0 
/ 0 
Chk2 0 
-RRB- 0 
regulates 0 
BRCA1 0 
function 0 
after 0 
DNA 0 
damage 0 
by 0 
phosphorylating 0 
serine 0 
_NUM3 0 
of 0 
BRCA1 0 
. 0 

We 0 
show 0 
that 0 
hCds1 0 
and 0 
BRCA1 0 
interact 0 
and 0 
co-localize 0 
within 0 
discrete 0 
nuclear 0 
foci 0 
but 0 
separate 0 
after 0 
gamma 0 
irradiation 0 
. 0 

Phosphorylation 0 
of 0 
BRCA1 0 
at 0 
serine 0 
_NUM3 0 
is 0 
required 0 
for 0 
the 0 
release 0 
of 0 
BRCA1 0 
from 0 
hCds1 0 
. 0 

This 0 
phosphorylation 0 
is 0 
also 0 
important 0 
for 0 
the 0 
ability 0 
of 0 
BRCA1 0 
to 0 
restore 0 
survival 0 
after 0 
DNA 0 
damage 0 
in 0 
the 0 
BRCA1-mutated 0 
cell 0 
line 0 
HCC1937 0 
. 0 
. 0 

Ataxin-3 0 
with 0 
an 0 
altered 0 
conformation 0 
that 0 
exposes 0 
the 0 
polyglutamine 0 
domain 0 
is 0 
associated 0 
with 0 
the 0 
nuclear 0 
matrix 0 
. 0 

Spinocerebellar 1
ataxia 1
type-3 1
or 0 
Machado-Joseph 1
disease 1
-LRB- 0 
SCA3 1
/ 0 
MJD 1
-RRB- 0 
is 0 
a 0 
member 0 
of 0 
the 0 
CAG 1
/ 1
polyglutamine 1
repeat 1
disease 1
family 0 
. 0 

In 0 
this 0 
family 0 
of 0 
disorders 0 
, 0 
a 0 
normally 0 
polymorphic 0 
_DS 0 
repeat 0 
becomes 0 
expanded 0 
, 0 
resulting 0 
in 0 
expression 0 
of 0 
an 0 
expanded 0 
polyglutamine 0
domain 0 
in 0 
the 0 
disease 0 
gene 0 
product 0 
. 0 

Experimental 0 
models 0 
of 0 
polyglutamine 1
disease 1
implicate 0 
the 0 
nucleus 0 
in 0 
pathogenesis 0 
; 0 
however 0 
, 0 
the 0 
link 0 
between 0 
intranuclear 0 
expression 0 
of 0 
expanded 0 
polyglutamine 0 
and 0 
neuronal 1
dysfunction 1
remains 0 
unclear 0 
. 0 

Here 0 
we 0 
demonstrate 0 
that 0 
ataxin-3 0 
, 0 
the 0 
disease 0 
protein 0 
in 0 
SCA3 1
/ 0 
MJD 1
, 0 
adopts 0 
a 0 
unique 0 
conformation 0 
when 0 
expressed 0 
within 0 
the 0 
nucleus 0 
of 0 
transfected 0 
cells 0 
. 0 

The 0 
monoclonal 0 
antibody 0 
1C2 0 
is 0 
known 0 
preferentially 0 
to 0 
bind 0 
expanded 0 
polyglutamine 0 
, 0 
but 0 
we 0 
find 0 
that 0 
it 0 
also 0 
binds 0 
a 0 
fragment 0 
of 0 
ataxin-3 0 
containing 0 
a 0 
normal 0 
glutamine 0 
repeat 0 
. 0 

In 0 
addition 0 
, 0 
expression 0 
of 0 
ataxin-3 0 
within 0 
the 0 
nucleus 0 
exposes 0 
the 0 
glutamine 0 
domain 0 
of 0 
the 0 
full-length 0 
non-pathological 0 
protein 0 
, 0 
allowing 0 
it 0 
to 0 
bind 0 
the 0 
monoclonal 0 
antibody 0 
1C2 0 
. 0 

Fractionation 0 
and 0 
immunochemical 0 
experiments 0 
indicate 0 
that 0 
this 0 
novel 0 
conformation 0 
of 0 
intranuclear 0 
ataxin-3 0 
is 0 
not 0 
due 0 
to 0 
proteolysis 0 
, 0 
suggesting 0 
instead 0 
that 0 
association 0 
with 0 
nuclear 0 
protein 0 
-LRB- 0 
s 0 
-RRB- 0 
alters 0 
the 0 
structure 0 
of 0 
full-length 0 
ataxin-3 0 
which 0 
exposes 0 
the 0 
polyglutamine 0 
domain 0 
. 0 

This 0 
conformationally 0 
altered 0 
ataxin-3 0 
is 0 
bound 0 
to 0 
the 0 
nuclear 0 
matrix 0 
. 0 

The 0 
pathological 0 
form 0 
of 0 
ataxin-3 0 
with 0 
an 0 
expanded 0 
polyglutamine 0 
domain 0 
also 0 
associates 0 
with 0 
the 0 
nuclear 0 
matrix 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
an 0 
early 0 
event 0 
in 0 
the 0 
pathogenesis 0 
of 0 
SCA3 1
/ 0 
MJD 1
may 0 
be 0 
an 0 
altered 0 
conformation 0 
of 0 
ataxin-3 0 
within 0 
the 0 
nucleus 0 
that 0 
exposes 0 
the 0 
polyglutamine 0 
domain 0 
. 0 
. 0 

A 0 
zinc 0 
finger 0 
truncation 0 
of 0 
murine 0 
WT1 0 
results 0 
in 0 
the 0 
characteristic 0 
urogenital 1
abnormalities 1
of 0 
Denys-Drash 1
syndrome 1
. 0 

The 0 
Wilms 1
tumor 1
- 0 
suppressor 0 
gene 0 
, 0 
WT1 0
, 0 
plays 0 
a 0 
key 0 
role 0 
in 0 
urogenital 0 
development 0 
, 0 
and 0 
WT1 1
dysfunction 1
is 0 
implicated 0 
in 0 
both 0 
neoplastic 1
-LRB- 0 
Wilms 1
tumor 1
, 0 
mesothelioma 1
, 0 
leukemias 1
, 0 
and 0 
breast 1
cancer 1
-RRB- 0 
and 0 
nonneoplastic 1
-LRB- 0 
glomerulosclerosis 1
-RRB- 0 
disease 0 
. 0 

The 0 
analysis 0 
of 0 
diseases 0 
linked 0 
specifically 0 
with 0 
WT1 0 
mutations 0 
, 0 
such 0 
as 0 
Denys-Drash 1
syndrome 1
-LRB- 0 
DDS 1
-RRB- 0 
, 0 
can 0 
provide 0 
valuable 0 
insight 0 
concerning 0 
the 0 
role 0 
of 0 
WT1 0 
in 0 
development 0 
and 0 
disease 0 
. 0 

DDS 1
is 0 
a 0 
rare 0 
childhood 0 
disease 0 
characterized 0 
by 0 
a 0 
nephropathy 1
involving 0 
mesangial 1
sclerosis 1
, 0 
XY 0 
pseudohermaphroditism 1
, 0 
and 0 
/ 0 
or 0 
Wilms 1
tumor 1
-LRB- 0 
WT 1
-RRB- 0 
. 0 

DDS 1
patients 0 
are 0 
constitutionally 0 
heterozygous 0 
for 0 
exonic 0 
point 0 
mutations 0 
in 0 
WT1 0 
, 0 
which 0 
include 0 
mutations 0 
predicted 0 
to 0 
truncate 0 
the 0 
protein 0 
within 0 
the 0 
C-terminal 0 
zinc 0 
finger 0 
-LRB- 0 
ZF 0 
-RRB- 0 
region 0 
. 0 

We 0 
report 0 
that 0 
heterozygosity 0 
for 0 
a 0 
targeted 0 
murine 0 
Wt1 0 
allele 0 
, 0 
Wt1 0 
-LRB- 0 
tmT396 0 
-RRB- 0 
, 0 
which 0 
truncates 0 
ZF3 0 
at 0 
codon 0 
_NUM3 0 
, 0 
induces 0 
mesangial 1
sclerosis 1
characteristic 0 
of 0 
DDS 1
in 0 
adult 0 
heterozygous 0 
and 0 
chimeric 0 
mice 0 
. 0 

Male 1
genital 1
defects 1
also 0 
were 0 
evident 0 
and 0 
there 0 
was 0 
a 0 
single 0 
case 0 
of 0 
Wilms 1
tumor 1
in 0 
which 0 
the 0 
transcript 0 
of 0 
the 0 
nontargeted 0 
allele 0 
showed 0 
an 0 
exon 0 
_NUM1 0 
skipping 0 
event 0 
, 0 
implying 0 
a 0 
causal 0 
link 0 
between 0 
Wt1 1
dysfunction 1
and 0 
Wilms 1
tumorigenesis 1
in 0 
mice 0 
. 0 

However 0 
, 0 
the 0 
mutant 0 
WT1 0 
-LRB- 0 
tmT396 0 
-RRB- 0 
protein 0 
accounted 0 
for 0 
only 0 
_NUM1 0 
% 0 
of 0 
WT1 0 
in 0 
both 0 
heterozygous 0 
embryonic 0 
stem 0 
cells 0 
and 0 
the 0 
WT 1
. 0 

This 0 
has 0 
implications 0 
regarding 0 
the 0 
mechanism 0 
by 0 
which 0 
the 0 
mutant 0 
allele 0 
exerts 0 
its 0 
effect 0 
. 0 

Heterogeneity 0 
of 0 
`` 0 
Mediterranean 0 
type 0 
'' 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
Spain 0 
and 0 
description 0 
of 0 
two 0 
new 0 
variants 0 
associated 0 
with 0 
favism 1
. 0 

Glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
; 0 
EC 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM2 0 
from 0 
thirty-six 0 
unrelated 0 
Spanish 0 
males 0 
was 0 
partially 0 
purified 0 
from 0 
blood 0 
, 0 
and 0 
the 0 
variants 0 
were 0 
characterized 0 
biochemically 0 
and 0 
electrophoretically 0 
according 0 
to 0 
the 0 
methods 0 
recommended 0 
by 0 
the 0 
world 0 
Health 0 
Organization 0 
. 0 

Subjects 0 
were 0 
from 0 
multiple 0 
geographic 0 
regions 0 
within 0 
Spain 0 
, 0 
and 0 
all 0 
suffered 0 
from 0 
hemolytic 1
anemia 1
, 0 
either 0 
acute 0 
-LRB- 0 
_NUM2 0 
cases 0 
-RRB- 0 
or 0 
chronic 0 
nonspherocytic 0 
-LRB- 0 
_NUM1 0 
cases 0 
-RRB- 0 
. 0 

Almost 0 
all 0 
the 0 
variants 0 
studied 0 
presented 0 
residual 0 
erythrocyte 0 
G6PD 0 
activity 0 
ranging 0 
from 0 
_NUM1 0 
to 0 
_NUM2 0 
% 0 
of 0 
normal 0 
, 0 
and 0 
five 0 
different 0 
mutants 0 
were 0 
responsible 0 
for 0 
the 0 
deficient 0
phenotype 0 
. 0 

Three 0 
variants 0 
were 0 
similar 0 
to 0 
others 0 
previously 0 
described 0 
G6PD 0 
Mediterranean 0 
-LRB- 0 
_NUM2 0 
cases 0 
-RRB- 0 
, 0 
G6PD 0 
Athens-like 0 
-LRB- 0 
_NUM1 0 
cases 0 
-RRB- 0 
, 0 
and 0 
G6PD 0 
Union 0 
-LRB- 0 
_NUM1 0 
cases 0 
-RRB- 0 
. 0 

The 0 
remaining 0 
variants 0 
were 0 
different 0 
from 0 
the 0 
numerous 0 
variants 0 
already 0 
reported 0 
and 0 
have 0 
been 0 
considered 0 
as 0 
new 0 
mutants 0 
. 0 

Provisionally 0 
they 0 
are 0 
called 0 
G6PD 0 
Betica 0 
-LRB- 0 
_NUM2 0 
cases 0 
-RRB- 0 
and 0 
G6PD 0 
Menorca 0 
-LRB- 0 
_NUM1 0 
case 0 
-RRB- 0 
. 0 

The 0 
present 0 
study 0 
constitutes 0 
the 0 
first 0 
attempt 0 
to 0 
characterize 0 
the 0 
deficient 1
G6PD 1
variants 0 
found 0 
in 0 
Spain 0 
and 0 
supplies 0 
new 0 
data 0 
on 0 
the 0 
relationship 0 
between 0 
molecular 0 
characteristics 0 
of 0 
deficient 0 
variants 0 
and 0 
their 0 
clinical 0 
manifestations 0 
. 0 

The 0 
most 0 
important 0 
findings 0 
can 0 
be 0 
summarized 0 
as 0 
follows 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
The 0 
Spanish 0 
population 0 
is 0 
characterized 0 
by 0 
an 0 
important 0 
heterogeneity 0 
in 0 
G6PD 1
deficiency 1
. 0 

-LRB- 0 
_NUM1 0 
-RRB- 0 
Although 0 
G6PD 0 
Mediterranean 0 
is 0 
very 0 
frequent 0 
, 0 
it 0 
presents 0 
a 0 
relatively 0 
high 0 
degree 0 
of 0 
polymorphism 0 
. 0 

-LRB- 0 
_NUM1 0 
-RRB- 0 
Favism 1
has 0 
been 0 
observed 0 
associated 0 
with 0 
all 0 
kinds 0 
of 0 
variants 0 
described 0 
here 0 
. 0 

-LRB- 0 
_NUM1 0 
-RRB- 0 
G6PD 0 
Betica 0 
, 0 
which 0 
is 0 
the 0 
most 0 
frequent 0 
variant 0 
found 0 
in 0 
subjects 0 
of 0 
Southern 0 
Spanish 0 
origin 0 
, 0 
has 0 
been 0 
observed 0 
associated 0 
with 0 
favism 1
in 0 
all 0 
cases 0 
except 0 
one 0 
. 0 

Early 0 
onset 0 
of 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
in 0 
a 0 
boy 0 
with 0 
emerin 0 
gene 0 
deletion 0 
. 0 

A 0 
boy 0 
developed 0 
contractures 1
of 1
the 1
Achilles 1
tendons 1
at 0 
_NUM1 0 
years 0 
and 0 
of 0 
the 0 
postcervical 0 
muscles 0 
at 0 
_NUM1 0 
years 0 
, 0 
although 0 
neither 0 
contractures 1
of 1
the 1
elbows 1
nor 0 
cardiac 1
abnormality 1
were 0 
recognized 0 
by 0 
the 0 
age 0 
of 0 
_NUM1 0 
years 0 
. 0 

Muscle 0 
computed 0 
tomography 0 
scanning 0 
revealed 0 
changes 0 
characteristic 0 
of 0 
muscle 0 
involvement 0 
. 0 

Emerin 0 
was 0 
not 0 
detected 0 
in 0 
the 0 
biopsied 0 
muscle 0 
, 0 
and 0 
RT-PCR 0 
and 0 
PCR-based 0 
genomic 0 
DNA 0 
analyses 0 
of 0 
the 0 
emerin 0 
gene 0 
demonstrated 0 
no 0 
amplification 0 
product 0 
in 0 
the 0 
patient 0 
. 0 

These 0 
results 0 
confirmed 0 
the 0 
diagnosis 0 
of 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
, 0 
and 0 
reinforce 0 
the 0 
necessity 0 
of 0 
molecular 0 
genetic 0 
diagnosis 0 
of 0 
the 0 
membrane 0 
protein 0 
emerin 0 
in 0 
younger 0 
patients 0 
with 0 
possible 0 
EDMD 1
before 0 
appearance 0 
of 0 
the 0 
typical 0 
symptoms 0 
, 0 
to 0 
avoid 0 
sudden 1
cardiac 1
death 1
. 0 
. 0 

PRAD1 0 
, 0 
a 0 
candidate 0 
BCL1 0 
oncogene 0 
: 0 
mapping 0 
and 0 
expression 0 
in 0 
centrocytic 1
lymphoma 1
. 0 

Rearrangement 0 
of 0 
the 0 
BCL1 0 
-LRB- 0 
B-cell 0 
lymphoma 0 
_NUM1 0 
-RRB- 0 
region 0 
on 0 
chromosome 0 
11q13 0 
appears 0 
to 0 
be 0 
highly 0 
characteristic 0 
of 0 
centrocytic 1
lymphoma 1
and 0 
also 0 
is 0 
found 0 
infrequently 0 
in 0 
other 0 
B-cell 1
neoplasms 1
. 0 

Rearrangement 0 
is 0 
thought 0 
to 0 
deregulate 0 
a 0 
nearby 0 
protooncogene 0 
, 0 
but 0 
transcribed 0 
sequences 0 
in 0 
the 0 
immediate 0 
vicinity 0 
of 0 
BCL1 0 
breakpoints 0 
had 0 
not 0 
been 0 
identified 0 
. 0 

PRAD1 0 
, 0 
previously 0 
designated 0 
D11S287E 0 
, 0 
was 0 
identified 0 
on 0 
11q13 0 
as 0 
a 0 
chromosomal 0 
breakpoint 0 
region 0 
rearranged 0 
with 0 
the 0 
parathyroid 0
hormone 0 
gene 0 
in 0 
a 0 
subset 0 
of 0 
parathyroid 1
adenomas 1
; 0 
this 0 
highly 0 
conserved 0 
putative 0 
oncogene 0 
, 0 
which 0 
encodes 0 
a 0 
novel 0 
cyclin 0 
, 0 
has 0 
been 0 
linked 0 
to 0 
BCL1 0 
and 0 
implicated 0 
also 0 
in 0 
subsets 0 
of 0 
breast 1
and 1
squamous 1
cell 1
neoplasms 1
with 0 
11q13 0 
amplification 0 
. 0 

We 0 
report 0 
pulsed-field 0 
gel 0 
electrophoresis 0 
data 0 
showing 0 
BCL1 0 
and 0 
PRAD1 0 
to 0 
be 0 
no 0 
more 0 
than 0 
_NUM3 0 
kilobases 0 
apart 0 
. 0 

PRAD1 0 
mRNA 0 
is 0 
abundantly 0 
expressed 0 
in 0 
seven 0 
of 0 
seven 0 
centrocytic 1
lymphomas 1
-LRB- 0 
Kiel 0 
classification 0 
-RRB- 0 
, 0 
in 0 
contrast 0 
to 0 
_NUM2 0 
closely 0 
related 0 
but 0 
noncentrocytic 1
lymphomas 1
. 0 

Three 0 
of 0 
the 0 
seven 0 
centrocytic 1
lymphomas 1
had 0 
detectable 0 
BCL1 0 
DNA 0 
rearrangement 0 
. 0 

Also 0 
, 0 
two 0 
unusual 0 
cases 0 
of 0 
CLL 0 
with 0 
BCL1 0 
rearrangement 0 
overexpressed 0 
PRAD1 0 
, 0 
in 0 
contrast 0 
to 0 
five 0 
CLL 0 
controls 0 
. 0 

Thus 0 
, 0 
PRAD1 0 
is 0 
an 0 
excellent 0 
candidate 0 
'' 0 
BCL1 0 
oncogene 0 
. 0 
'' 0 

Its 0 
overexpression 0 
may 0 
be 0 
a 0 
key 0 
consequence 0 
of 0 
rearrangement 0 
of 0 
the 0 
BCL1 0 
vicinity 0 
in 0 
B-cell 1
neoplasms 1
and 0 
a 0 
unifying 0 
pathogenetic 0 
feature 0 
in 0 
centrocytic 1
lymphoma 1
. 0 

Adrenoleukodystrophy 1
: 0 
increased 0 
plasma 0 
content 0 
of 0 
saturated 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
. 0 

With 0 
a 0 
new 0 
method 0 
we 0 
measured 0 
the 0 
saturated 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
in 0 
the 0 
plasma 0 
of 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
hemizygotes 0 
, 0 
ALD 1
heterozygotes 0 
, 0 
and 0 
controls 0 
. 0 

ALD 1
hemizygotes 0 
showed 0 
increased 0 
levels 0 
of 0 
hexacosanoate 0 
-LRB- 0 
_AN 0 
fatty 0 
acid 0 
-RRB- 0 
which 0 
represented 0 
_NUM1 0 
. 0 

_NUM3 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM4 0 
% 0 
-LRB- 0 
SEM 0 
-RRB- 0 
of 0 
total 0 
fatty 0 
acids 0 
, 0 
compared 0 
to 0 
_NUM1 0 
. 0 

_NUM3 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM4 0 
% 0 
in 0 
the 0 
controls 0 
. 0 

_AN 0 
, 0 
_AN 0 
, 0 
and 0 
_AN 0 
fatty 0 
acids 0 
were 0 
also 0 
increased 0 
, 0 
but 0 
the 0 
_AN 0 
and 0 
_AN 0 
fatty 0 
acids 0 
were 0 
normal 0 
. 0 

_AN 0 
levels 0 
were 0 
also 0 
increased 0 
in 0 
most 0 
ALD 1
heterozygotes 0 
, 0 
with 0 
a 0 
mean 0 
level 0 
_NUM1 0 
. 0 

_NUM3 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM4 0 
% 0 
of 0 
total 0 
fatty 0 
acids 0 
. 0 

The 0 
technique 0 
can 0 
be 0 
used 0 
for 0 
diagnosis 0 
and 0 
carrier 0 
identification 0 
, 0 
and 0 
in 0 
the 0 
evaluation 0 
of 0 
therapy 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
deficiency 1
inhibits 0 
in 0 
vitro 0 
growth 0 
of 0 
Plasmodium 0 
falciparum 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
; 1
EC 1
-RRB- 1
-deficient 1
red 0 
blood 0 
cells 0 
from 0 
male 0 
hemizygotes 0 
and 0 
female 0 
heterozygotes 0 
from 0 
the 0 
island 0 
of 0 
Sardinia 0 
were 0 
studied 0 
for 0 
their 0 
ability 0 
to 0 
support 0 
growth 0 
in 0 
vitro 0 
of 0 
the 0 
malaria 1
causing 0 
organism 0 
Plasmodium 0 
falciparum 0 
. 0 

Parasite 0 
growth 0 
was 0 
approximately 0 
one-third 0 
of 0 
normal 0 
in 0 
both 0 
hemi 0 
- 0 
and 0 
heterozygotes 0 
for 0 
G6PD 1
deficiency 1
. 0 

In 0 
Sardinians 0 
with 0 
the 0 
beta 0 
0-thalassemia 0 
trait 0 
, 0 
parasite 0 
growth 0 
was 0 
normal 0 
except 0 
when 0 
G6PD 1
deficiency 1
occurred 0 
together 0 
with 0 
the 0 
thalassemia 1
trait 0 
. 0 

The 0 
data 0 
support 0 
the 0 
hypothesis 0 
that 0 
G6PD 1
deficiency 1
may 0 
confer 0 
a 0 
selective 0 
advantage 0 
in 0 
a 0 
malarious 1
area 0 
; 0 
the 0 
female 0 
heterozygote 0 
may 0 
be 0 
at 0 
a 0 
particular 0 
advantage 0 
because 0 
resistance 0 
to 0 
malaria 1
equals 0 
that 0 
of 0 
male 0 
hemizygotes 0 
, 0 
but 0 
the 0 
risk 0 
of 0 
fatal 1
hemolysis 1
may 0 
be 0 
less 0 
. 0 

However 0 
, 0 
more 0 
female 0 
heterozygotes 0 
must 0 
be 0 
studied 0 
to 0 
confirm 0 
this 0 
hypothesis 0 
. 0 

No 0 
protective 0 
effect 0 
of 0 
beta 0 
0-thalassemia 0 
trait 0 
could 0 
be 0 
demonstrated 0 
in 0 
vitro 0 
. 0 

Heterozygous 1
C2 1
deficiency 1
associated 0 
with 0 
angioedema 1
, 0 
myasthenia 1
gravis 1
, 0 
and 0 
systemic 1
lupus 1
erythematosus 1
. 0 

We 0 
describe 0 
a 0 
patient 0 
with 0 
myasthenia 1
gravis 1
, 0 
systemic 1
lupus 1
erythematosus 1
, 0 
and 0 
angioedema 1
associated 0 
with 0 
heterozygous 0 
complement 1
factor 1
_NUM1 1
-LRB- 1
C2 1
-RRB- 1
deficiency 1
. 0 

The 0 
significance 0 
of 0 
this 0 
association 0 
is 0 
controversial 0 
, 0 
though 0 
the 0 
association 0 
of 0 
C2 1
deficiency 1
with 0 
certain 0 
histocompatibility 0 
antigens 0 
suggests 0 
possible 0 
linkage 0 
to 0 
immune 0 
response 0 
genes 0 
. 0 

To 0 
our 0 
knowledge 0 
this 0 
is 0 
the 0 
first 0 
report 0 
of 0 
heterozygous 0 
C2 1
deficiency 1
in 0 
association 0 
with 0 
this 0 
combination 0 
of 0 
autoimmune 1
disorders 1
, 0 
and 0 
we 0 
discuss 0 
the 0 
aetiological 0 
implications 0 
. 0 
. 0 

Inherited 0 
C3 1
deficiency 1
with 0 
recurrent 0 
infections 0 
and 0 
glomerulonephritis 1
. 0 

A 0 
10-year-old 0 
Laotian 0 
boy 0 
had 0 
homozygous 0 
deficiency 1
of 1
the 1
third 1
component 1
of 1
complement 1
and 0 
recurrent 0 
bacterial 1
infections 1
beginning 0 
at 0 
age 0 
_NUM1 0 
months 0 
. 0 

Cellular 0 
and 0 
humoral 0 
immunity 0 
were 0 
normal 0 
, 0 
as 0 
were 0 
polymorphonuclear 0 
leukocyte 0 
chemotaxis 0 
and 0 
bactericidal 0 
activities 0 
. 0 

Serum 0 
complement-mediated 0 
hemolytic 0 
, 0 
chemotactic 0 
, 0 
and 0 
opsonic 0 
activities 0 
were 0 
deficient 0 
. 0 

In 0 
vitro 0 
addition 0 
of 0 
purified 0 
C3 0 
to 0 
patient 0 
serum 0 
restored 0 
hemolytic 0 
complement 0 
to 0 
normal 0 
levels 0 
, 0 
and 0 
plasma 0 
infusion 0 
during 0 
each 0 
of 0 
four 0 
episodes 0 
of 0 
pneumonia 1
significantly 0 
enhanced 0 
serum 0 
opsonic 0 
activity 0 
for 0 
as 0 
long 0 
as 0 
_NUM2 0 
hours 0 
. 0 

A 0 
renal 0 
biopsy 0 
specimen 0 
revealed 0 
mesangiopathic 1
glomerulonephritis 1
, 0 
although 0 
significant 0 
levels 0 
of 0 
circulating 0 
IgG 0 
immune 0 
complexes 0 
were 0 
not 0 
detected 0 
. 0 

These 0 
findings 0 
further 0 
support 0 
the 0 
association 0 
of 0 
C3 1
deficiency 1
with 0 
immune-complex 1
disease 1
and 0 
suggest 0 
that 0 
plasma 0 
infusion 0 
may 0 
be 0 
an 0 
adjunct 0 
to 0 
antibiotic 0 
therapy 0 
in 0 
the 0 
management 0 
of 0 
severe 0 
pyogenic 1
infections 1
in 0 
patients 0 
with 0 
C3 1
deficiency 1
. 0 
. 0 

Southern 0 
analysis 0 
reveals 0 
a 0 
large 0 
deletion 0 
at 0 
the 0 
hypoxanthine 0 
phosphoribosyltransferase 0 
locus 0 
in 0 
a 0 
patient 0 
with 0 
Lesch-Nyhan 1
syndrome 1
. 0 

Whole 0 
genomic 0 
hprt 0 
clones 0 
were 0 
used 0 
in 0 
Southern 0 
analysis 0 
to 0 
screen 0 
the 0 
integrity 0 
of 0 
the 0 
hprt 0 
gene 0 
in 0 
a 0 
family 0 
that 0 
includes 0 
a 0 
patient 0 
with 0 
HPRT 1
enzyme 1
deficiency 1
causal 0 
to 0 
Lesch-Nyhan 1
syndrome 1
. 0 

A 0 
_NUM1 0 
kb 0 
DNA 0 
sequence 0 
deletion 0 
was 0 
found 0 
to 0 
have 0 
its 0 
endpoints 0 
in 0 
the 0 
first 0 
and 0 
third 0 
introns 0 
. 0 

The 0 
probes 0 
identified 0 
the 0 
carrier 0 
status 0 
of 0 
female 0 
family 0 
members 0 
, 0 
aided 0 
by 0 
an 0 
RFLP 0 
carried 0 
by 0 
the 0 
mothers 0 
normal 0 
X-chromosome 0 
. 0 
. 0 

Association 0 
of 0 
BRCA1 0 
with 0 
the 0 
hRad50-hMre11-p95 0 
complex 0 
and 0 
the 0 
DNA 0 
damage 0 
response 0 
. 0 

BRCA1 0 
encodes 0 
a 0 
tumor 1
suppressor 0 
that 0 
is 0 
mutated 0 
in 0 
familial 1
breast 1
and 1
ovarian 1
cancers 1
. 0 

Here 0 
, 0 
it 0 
is 0 
shown 0 
that 0 
BRCA1 0 
interacts 0 
in 0 
vitro 0 
and 0 
in 0 
vivo 0 
with 0 
hRad50 0 
, 0 
which 0 
forms 0 
a 0 
complex 0 
with 0 
hMre11 0 
and 0 
p95 0 
/ 0 
nibrin 0 
. 0 

Upon 0 
irradiation 0 
, 0 
BRCA1 0 
was 0 
detected 0 
in 0 
discrete 0 
foci 0 
in 0 
the 0 
nucleus 0 
, 0 
which 0 
colocalize 0 
with 0 
hRad50 0 
. 0 

Formation 0 
of 0 
irradiation-induced 0 
foci 0 
positive 0 
for 0 
BRCA1 0 
, 0 
hRad50 0 
, 0 
hMre11 0 
, 0 
or 0 
_AN 0 
was 0 
dramatically 0 
reduced 0 
in 0 
HCC 0 
/ 0 
1937 0 
breast 1
cancer 1
cells 0 
carrying 0 
a 0 
homozygous 0 
mutation 0 
in 0 
BRCA1 0 
but 0 
was 0 
restored 0 
by 0 
transfection 0 
of 0 
wild-type 0 
BRCA1 0 
. 0 

Ectopic 0 
expression 0 
of 0 
wild-type 0 
, 0 
but 0 
not 0 
mutated 0 
, 0 
BRCA1 0 
in 0 
these 0 
cells 0 
rendered 0 
them 0 
less 0 
sensitive 0 
to 0 
the 0 
DNA 0 
damage 0 
agent 0 
, 0 
methyl 0 
methanesulfonate 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
BRCA1 0 
is 0 
important 0 
for 0 
the 0 
cellular 0 
responses 0 
to 0 
DNA 0 
damage 0 
that 0 
are 0 
mediated 0 
by 0 
the 0 
hRad50-hMre11-p95 0 
complex 0 
. 0 
. 0 

Nebulin 0 
and 0 
titin 0 
expression 0 
in 0 
Duchenne 1
muscular 1
dystrophy 1
appears 0 
normal 0 
. 0 

Monoclonal 0 
antibodies 0 
which 0 
recognize 0 
different 0 
epitopes 0 
on 0 
either 0 
titin 0 
or 0 
nebulin 0 
show 0 
normal 0 
staining 0 
patterns 0 
on 0 
frozen 0 
sections 0 
of 0 
three 0 
muscle 0 
biopsies 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

Gel 0 
electrophoresis 0 
and 0 
immunoblotting 0 
performed 0 
on 0 
two 0 
of 0 
these 0 
muscle 0 
biopsies 0 
show 0 
the 0 
normal 0 
pattern 0 
of 0 
titin 0 
and 0 
nebulin 0 
polypeptides 0 
. 0 

Since 0 
the 0 
donor 0 
of 0 
one 0 
of 0 
these 0 
biopsies 0 
has 0 
a 0 
large 0 
deletion 0 
of 0 
the 0 
5-region 0 
of 0 
the 0 
DMD 1
gene 0 
, 0 
our 0 
results 0 
argue 0 
against 0 
the 0 
recent 0 
proposal 0 
that 0 
nebulin 0 
is 0 
the 0 
gene 0 
mutated 0 
in 0 
DMD 1
. 0 
. 0 

Myotonic 1
dystrophy 1
kinase 0 
is 0 
a 0 
component 0 
of 0 
neuromuscular 0 
junctions 0 
. 0 

The 0 
clinical 0 
manifestation 0 
of 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
correlated 0 
to 0 
the 0 
extent 0 
of 0 
expansion 0 
of 0 
an 0 
unstable 0 
-LSB- 0 
_DS 0 
-RSB- 0 
n 0 
DNA 0 
motif 0 
. 0 

Recent 0 
studies 0 
have 0 
demonstrated 0 
that 0 
this 0 
trinucleotide 0 
motif 0 
forms 0 
part 0 
of 0 
the 0 
last 0 
, 0 
_NUM1 0 
untranslated 0 
exon 0 
of 0 
a 0 
gene 0 
which 0 
potentially 0 
encodes 0 
multiple 0 
protein 0 
isoforms 0 
of 0 
a 0 
serine 0 
/ 0 
threonine 0 
protein 0 
kinase 0 
-LRB- 0 
myotonic 1
dystrophy 1
protein 0 
kinase 0 
, 0 
DM-PK 0 
-RRB- 0 
. 0 

We 0 
report 0 
here 0 
on 0 
the 0 
development 0 
of 0 
antisera 0 
against 0 
synthetic 0 
DM-PK 0 
peptide 0 
antigens 0 
and 0 
their 0 
use 0 
in 0 
biochemical 0 
and 0 
histochemical 0 
studies 0 
. 0 

Immunoreactive 0 
DM-kinase 0 
protein 0 
of 0 
_NUM2 0 
kD 0 
is 0 
present 0 
at 0 
low 0 
levels 0 
in 0 
skeletal 0 
and 0 
cardiac 0 
muscle 0 
extracts 0 
of 0 
DM 1
patients 0 
and 0 
normal 0 
controls 0 
. 0 

Immunohistochemical 0 
staining 0 
revealed 0 
that 0 
DM-PK 0 
is 0 
localised 0 
prominently 0 
at 0 
sites 0 
of 0 
neuromuscular 0 
and 0 
myotendinous 0 
junctions 0 
-LRB- 0 
NMJs 0 
and 0 
MTJs 0 
-RRB- 0 
of 0 
human 0 
and 0 
rodent 0 
skeletal 0 
muscles 0 
. 0 

Furthermore 0 
, 0 
very 0 
low 0 
levels 0 
of 0 
immunoreactive 0 
DM-PK 0 
protein 0 
are 0 
present 0 
in 0 
the 0 
sarcoplasm 0 
of 0 
predominantly 0 
type 0 
I 0 
fibres 0 
in 0 
various 0 
muscles 0 
. 0 

Strikingly 0 
, 0 
presence 0 
of 0 
the 0 
protein 0 
can 0 
also 0 
be 0 
demonstrated 0 
for 0 
NMJs 0 
of 0 
muscular 0 
tissues 0 
of 0 
adult 0 
and 0 
congenital 0 
cases 0 
of 0 
DM 1
, 0 
with 0 
no 0 
gross 0 
changes 0 
in 0 
structural 0 
organisation 0 
. 0 

Our 0 
findings 0 
provide 0 
a 0 
basis 0 
for 0 
further 0 
characterisation 0 
of 0 
the 0 
role 0 
of 0 
the 0 
kinase 0 
in 0 
protein 0 
assembly 0 
processes 0 
or 0 
signal 0 
mediation 0 
at 0 
synaptic 0 
sites 0 
and 0 
ultimately 0 
for 0 
the 0 
understanding 0 
of 0 
the 0 
complex 0 
pathophysiology 0 
of 0 
DM 1
. 0 
. 0 

New 0 
genetic 0 
variants 0 
of 0 
glucose 0 
6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
in 0 
Italy 0 
. 0 

Six 0 
new 0 
variants 0 
of 0 
human 0 
erythrocyte 0 
G6PD 0 
have 0 
been 0 
characterized 0 
. 0 

All 0 
of 0 
them 0 
were 0 
found 0 
in 0 
Italian 0 
males 0 
and 0 
all 0 
were 0 
associated 0 
with 0 
enzyme 1
deficiency 1
, 0 
but 0 
only 0 
two 0 
with 0 
signs 0 
of 0 
haemolysis 1
. 0 

These 0 
and 0 
other 0 
variants 0 
reported 0 
in 0 
the 0 
literature 0 
, 0 
which 0 
must 0 
thus 0 
far 0 
be 0 
regarded 0 
as 0 
sporadic 0 
, 0 
are 0 
found 0 
to 0 
map 0 
in 0 
parts 0 
of 0 
Italy 0 
where 0 
common 0 
types 0 
of 0 
G6PD 1
deficiency 1
are 0 
also 0 
prevalent 0 
. 0 
. 0 

ATM-heterozygous 0 
germline 0 
mutations 0 
contribute 0 
to 0 
breast 1
cancer 1
susceptibility 0 
. 0 

Approximately 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-1 0 
% 0 
of 0 
the 0 
general 0 
population 0 
has 0 
been 0 
estimated 0 
to 0 
be 0 
heterozygous 0 
for 0 
a 0 
germline 0 
mutation 0 
in 0 
the 0 
ATM 0 
gene 0 
. 0 

Mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
are 0 
responsible 0 
for 0 
the 0 
autosomal 1
recessive 1
disorder 1
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
-LRB- 0 
MIM 0 
_NUM6 0 
-RRB- 0 
. 0 

The 0 
finding 0 
that 0 
ATM-heterozygotes 0 
have 0 
an 0 
increased 0 
relative 0 
risk 0 
for 0 
breast 1
cancer 1
was 0 
supported 0 
by 0 
some 0 
studies 0 
but 0 
not 0 
confirmed 0 
by 0 
others 0 
. 0 

In 0 
view 0 
of 0 
this 0 
discrepancy 0 
, 0 
we 0 
examined 0 
the 0 
frequency 0 
of 0 
ATM 0 
germline 0 
mutations 0 
in 0 
a 0 
selected 0 
group 0 
of 0 
Dutch 0 
patients 0 
with 0 
breast 1
cancer 1
. 0 

We 0 
have 0 
analyzed 0 
ATM 0 
germline 0 
mutations 0 
in 0 
normal 0 
blood 0 
lymphocytes 0 
, 0 
using 0 
the 0 
protein-truncation 0 
test 0 
followed 0 
by 0 
genomic-sequence 0 
analysis 0 
. 0 

A 0 
high 0 
percentage 0 
of 0 
ATM 0 
germline 0 
mutations 0 
was 0 
demonstrated 0 
among 0 
patients 0 
with 0 
sporadic 1
breast 1
cancer 1
. 0 

The 0 
_NUM2 0 
patients 0 
included 0 
in 0 
this 0 
study 0 
had 0 
developed 0 
breast 1
cancer 1
at 0 
age 0 
< 0 
_NUM2 0 
and 0 
had 0 
survived 0 
> 0 
/ 0 
= 0 
_NUM1 0 
years 0 
-LRB- 0 
mean 0 
_NUM2 0 
years 0 
-RRB- 0 
, 0 
and 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
patients 0 
a 0 
contralateral 0 
breast 0 
tumor 0 
had 0 
been 0 
diagnosed 0 
. 0 

Among 0 
these 0 
patients 0 
we 0 
identified 0 
seven 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
ATM 0 
germline 0 
mutations 0 
, 0 
of 0 
which 0 
five 0 
are 0 
distinct 0 
. 0 

One 0 
splice-site 0 
mutation 0 
-LRB- 0 
IVS10-6T 0 
-- 0 
> 0 
G 0 
-RRB- 0 
was 0 
detected 0 
three 0 
times 0 
in 0 
our 0 
series 0 
. 0 

Four 0 
heterozygous 0 
carriers 0 
were 0 
patients 0 
with 0 
bilateral 0 
breast 0 
cancer 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
the 0 
mutations 0 
identified 0 
in 0 
this 0 
study 0 
are 0 
'' 0 
A-T 0 
disease-causing 0 
'' 0 
mutations 0 
that 0 
might 0 
be 0 
associated 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
breast 0 
cancer 0 
in 0 
heterozygotes 0 
. 0 

We 0 
conclude 0 
that 0 
ATM 0 
heterozygotes 0 
have 0 
an 0 
approximately 0 
ninefold-increased 0 
risk 0 
of 0 
developing 0 
a 0 
type 0 
of 0 
breast 0 
cancer 0 
characterized 0 
by 0 
frequent 0 
bilateral 0 
occurrence 0 
, 0 
early 0 
age 0 
at 0 
onset 0 
, 0 
and 0 
long-term 0 
survival 0 
. 0 

The 0 
specific 0 
characteristics 0 
of 0 
our 0 
population 0 
of 0 
patients 0 
may 0 
explain 0 
why 0 
such 0 
a 0 
high 0 
frequency 0 
was 0 
not 0 
found 0 
in 0 
other 0 
series 0 
. 0 

Autoimmune 1
lymphoproliferative 1
syndrome 1
-LRB- 0 
ALPS 1
-RRB- 0 
in 0 
a 0 
child 0 
from 0 
consanguineous 0 
parents 0 
: 0 
a 0 
dominant 0 
or 0 
recessive 0 
disease 0 
? 0 

Autoimmune 1
lymphoproliferative 1
syndrome 1
-LRB- 0 
ALPS 1
-RRB- 0 
is 0 
characterized 0 
by 0 
autoimmune 0 
features 0 
and 0 
lymphoproliferations 0 
and 0 
is 0 
generally 0 
caused 0 
by 0 
defective 0 
Fas-mediated 0 
apoptosis 0 
. 0 

This 0 
report 0 
describes 0 
a 0 
child 0 
with 0 
clinical 0 
features 0 
of 0 
ALPS 1
without 0 
detectable 0 
Fas 0 
expression 0 
on 0 
freshly 0 
isolated 0 
blood 0 
leukocytes 0 
. 0 

Detection 0 
of 0 
FAS 0 
transcripts 0 
via 0 
real-time 0 
quantitative 0 
PCR 0 
made 0 
a 0 
severe 0 
transcriptional 0 
defect 0 
unlikely 0 
. 0 

Sequencing 0 
of 0 
the 0 
FAS 0 
gene 0 
revealed 0 
a 0 
20-nucleotide 0 
duplication 0 
in 0 
the 0 
last 0 
exon 0 
affecting 0 
the 0 
cytoplasmic 0 
signaling 0 
domain 0 
. 0 

The 0 
patient 0 
was 0 
homozygous 0 
for 0 
this 0 
mutation 0 
, 0 
whereas 0 
the 0 
consanguineous 0 
parents 0 
and 0 
the 0 
siblings 0 
were 0 
heterozygous 0 
. 0 

The 0 
patient 0 
reported 0 
here 0 
is 0 
a 0 
human 0 
homologue 0 
of 0 
the 0 
Fas-null 0 
mouse 0 
, 0 
inasmuch 0 
as 0 
she 0 
carries 0 
an 0 
autosomal 0 
homozygous 0 
mutation 0 
in 0 
the 0 
FAS 0 
gene 0 
and 0 
she 0 
shows 0 
the 0 
severe 0 
and 0 
accelerated 0 
ALPS 1
phenotype 0 
. 0 

The 0 
heterozygous 0 
family 0 
members 0 
did 0 
not 0 
have 0 
the 0 
ALPS 1
phenotype 0 
, 0 
indicating 0 
that 0 
the 0 
disease-causing 0 
FAS 0 
mutation 0 
in 0 
this 0 
family 0 
is 0 
autosomal 0 
recessive 0 
. 0 
. 0 

A 0 
prevalent 0 
mutation 0 
for 0 
galactosemia 1
among 0 
black 0 
Americans 0 
. 0 

OBJECTIVE 0 
To 0 
define 0 
the 0 
mutation 0 
causing 0 
galactosemia 1
in 0 
patients 0 
of 0 
black 0 
American 0 
origin 0 
who 0 
have 0 
no 0 
galactose-1-phosphate 0 
uridyltransferase 0 
-LRB- 0 
GALT 0 
-RRB- 0 
activity 0 
in 0 
erythrocytes 0 
but 0 
good 0 
clinical 0 
outcome 0 
. 0 

METHODS 0 
We 0 
discovered 0 
a 0 
mutation 0 
caused 0 
by 0 
a 0 
C 0 
-- 0 
> 0 
T 0 
transition 0 
at 0 
base-pair 0 
_NUM4 0 
of 0 
the 0 
GALT 0 
gene 0 
that 0 
results 0 
in 0 
a 0 
serine-to-leucine 0 
substitution 0 
at 0 
codon 0 
_NUM3 0 
-LRB- 0 
S135L 0 
-RRB- 0 
. 0 

We 0 
developed 0 
a 0 
method 0 
with 0 
which 0 
to 0 
screen 0 
populations 0 
for 0 
its 0 
prevalence 0 
. 0 

We 0 
compared 0 
galactose-1-phosphate 0 
uridyltransferase 0 
among 0 
erythrocytes 0 
, 0 
leukocytes 0 
, 0 
and 0 
transformed 0 
lymphoblasts 0 
, 0 
as 0 
well 0 
as 0 
total 0 
body 0 
oxidation 0 
of 0 
D 0 
- 0 
-LRB- 0 
13C 0 
-RRB- 0 
- 0 
galactose 0 
to 0 
13CO2 0 
among 0 
three 0 
genotypes 0 
for 0 
GALT 0 
-LRB- 0 
S135L 0 
/ 0 
S135L 0 
, 0 
Q188R 0 
/ 0 
Q188R 0 
, 0 
and 0 
Normal 0 
/ 0 
Normal 0 
-RRB- 0 
. 0 

RESULTS 0 
We 0 
found 0 
a 0 
_NUM2 0 
% 0 
prevalence 0 
of 0 
the 0 
S135L 0 
mutation 0 
among 0 
_NUM2 0 
black 0 
American 0 
patients 0 
with 0 
classic 1
galactosemia 1
and 0 
a 0 
_NUM1 0 
% 0 
prevalence 0 
in 0 
a 0 
population 0 
of 0 
_NUM2 0 
black 0 
Americans 0 
without 0 
galactosemia 1
. 0 

The 0 
S135L 0 
mutation 0 
was 0 
not 0 
found 0 
in 0 
_NUM2 0 
white 0 
patients 0 
with 0 
G 0 
/ 0 
G 0 
galactosemia 1
nor 0 
in 0 
_NUM2 0 
white 0 
control 0 
subjects 0 
without 0 
galactosemia 1
. 0 

We 0 
found 0 
normal 0 
whole 0 
body 0 
oxidation 0 
of 0 
D 0 
- 0 
-LRB- 0 
13C 0 
-RRB- 0 
- 0 
galactose 0 
by 0 
the 0 
patient 0 
homozygous 0 
for 0 
S135L 0 
and 0 
various 0 
degrees 0 
of 0 
enzyme 0 
impairment 0 
among 0 
different 0 
tissues 0 
. 0 

CONCLUSIONS 0 
The 0 
S135L 0 
mutation 0 
in 0 
the 0 
GALT 0 
gene 0 
is 0 
a 0 
prevalent 0 
cause 0 
of 0 
galactosemia 1
among 0 
black 0 
patients 0 
. 0 

Because 0 
GALT 0 
activity 0 
varies 0 
in 0 
different 0 
tissues 0 
of 0 
patients 0 
homozygous 0 
for 0 
S135L 0 
, 0 
they 0 
may 0 
have 0 
a 0 
better 0 
clinical 0 
outcome 0 
than 0 
patients 0 
who 0 
are 0 
homozygous 0 
for 0 
Q188R 0 
when 0 
both 0 
are 0 
treated 0 
from 0 
infancy 0 
. 0 
. 0 

Constitutive 0 
and 0 
regulated 0 
modes 0 
of 0 
splicing 0 
produce 0 
six 0 
major 0 
myotonic 1
dystrophy 1
protein 0 
kinase 0 
-LRB- 0 
DMPK 0 
-RRB- 0 
isoforms 0 
with 0 
distinct 0 
properties 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
the 0 
most 0 
prevalent 0 
inherited 1
neuromuscular 1
disease 1
in 0 
adults 0 
. 0 

The 0 
genetic 1
defect 1
is 0 
a 0 
_DS 0 
triplet 0 
repeat 0 
expansion 0 
in 0 
the 0 
3-untranslated 0 
region 0 
of 0 
the 0 
myotonic 1
dystrophy 1
protein 0 
kinase 0 
-LRB- 0 
DMPK 0 
-RRB- 0 
gene 0 
, 0 
consisting 0 
of 0 
_NUM2 0 
exons 0 
. 0 

Using 0 
a 0 
transgenic 0 
DMPK-overexpressor 0 
mouse 0 
model 0 
, 0 
we 0 
demonstrate 0 
here 0 
that 0 
the 0 
endogenous 0 
mouse 0 
DMPK 0 
gene 0 
and 0 
the 0 
human 0 
DMPK 0 
transgene 0 
produce 0 
six 0 
major 0 
alternatively 0 
spliced 0 
mRNAs 0 
which 0 
have 0 
almost 0 
identical 0 
cell 0 
type-dependent 0 
distribution 0 
frequencies 0 
and 0 
expression 0 
patterns 0 
. 0 

Use 0 
of 0 
a 0 
cryptic 0 
_NUM1 0 
splice 0 
site 0 
in 0 
exon 0 
_NUM1 0 
, 0 
which 0 
results 0 
in 0 
absence 0 
or 0 
presence 0 
of 0 
_NUM2 0 
nucleotides 0 
specifying 0 
a 0 
VSGGG 0 
peptide 0 
motif 0 
, 0 
and 0 
/ 0 
or 0 
use 0 
of 0 
a 0 
cryptic 0 
_NUM1 0 
splice 0 
site 0 
in 0 
exon 0 
_NUM2 0 
, 0 
which 0 
leads 0 
to 0 
a 0 
frameshift 0 
in 0 
the 0 
mRNA 0 
reading 0 
frame 0 
, 0 
occur 0 
as 0 
independent 0 
stochastic 0 
events 0 
in 0 
all 0 
tissues 0 
examined 0 
. 0 

In 0 
contrast 0 
, 0 
the 0 
excision 0 
of 0 
exons 0 
13 0 
/ 0 
14 0 
that 0 
causes 0 
a 0 
frameshift 0 
and 0 
creates 0 
a 0 
C-terminally 0 
truncated 0 
protein 0 
is 0 
clearly 0 
cell 0 
type 0 
dependent 0 
and 0 
occurs 0 
predominantly 0 
in 0 
smooth 0 
muscle 0 
. 0 

We 0 
generated 0 
all 0 
six 0 
full-length 0 
mouse 0 
cDNAs 0 
that 0 
result 0 
from 0 
combinations 0 
of 0 
these 0 
three 0 
major 0 
splicing 0 
events 0 
and 0 
show 0 
that 0 
their 0 
transfection 0 
into 0 
cells 0 
in 0 
culture 0 
leads 0 
to 0 
production 0 
of 0 
four 0 
different 0 
approximately 0 
_NUM2 0 
kDa 0 
full-length 0 
-LRB- 0 
heart 0 
- 0 
, 0 
skeletal 0 
muscle 0 
- 0 
or 0 
brain-specific 0 
-RRB- 0 
and 0 
two 0 
C-terminally 0 
truncated 0 
approximately 0 
_NUM2 0 
kDa 0 
-LRB- 0 
smooth 0 
muscle-specific 0 
-RRB- 0 
isoforms 0 
. 0 

Information 0 
on 0 
DMPK 0 
mRNA 0 
and 0 
protein 0 
isoform 0 
expression 0 
patterns 0 
will 0 
be 0 
useful 0 
for 0 
recognizing 0 
differential 0 
effects 0 
of 0 
-LRB- 0 
_DS 0 
-RRB- 0 
-LRB- 0 
n 0 
-RRB- 0 
expansion 0 
in 0 
DM 1
manifestation 0 
. 0 
. 0 

Linkage 0 
analysis 0 
in 0 
a 0 
large 0 
Brazilian 0 
family 0 
with 0 
van 1
der 1
Woude 1
syndrome 1
suggests 0 
the 0 
existence 0 
of 0 
a 0 
susceptibility 0 
locus 0 
for 0 
cleft 1
palate 1
at 0 
17p11.2-11 0 
.1 0 
. 0 

van 1
der 1
Woude 1
syndrome 1
-LRB- 0 
VWS 1
-RRB- 0 
, 0 
which 0 
has 0 
been 0 
mapped 0 
to 0 
1q32-41 0 
, 0 
is 0 
characterized 0 
by 0 
pits 1
and 1
/ 1
or 1
sinuses 1
of 1
the 1
lower 1
lip 1
, 0 
cleft 1
lip 1
/ 1
palate 1
-LRB- 0 
CL 1
/ 1
P 1
-RRB- 0 
, 0 
cleft 1
palate 1
-LRB- 0 
CP 1
-RRB- 0 
, 0 
bifid 1
uvula 1
, 0 
and 0 
hypodontia 1
-LRB- 0 
H 1
-RRB- 0 
. 0 

The 0 
expression 0 
of 0 
VWS 1
, 0 
which 0 
has 0 
incomplete 0 
penetrance 0 
, 0 
is 0 
highly 0 
variable 0 
. 0 

Both 0 
the 0 
occurrence 0 
of 0 
CL 1
/ 1
P 1
and 0 
CP 1
within 0 
the 0 
same 0 
genealogy 0 
and 0 
a 0 
recurrence 0 
risk 0 
< 0 
_NUM2 0 
% 0 
for 0 
CP 1
among 0 
descendants 0 
with 0 
VWS 1
have 0 
suggested 0 
that 0 
the 0 
development 0 
of 0 
clefts 1
in 0 
this 0 
syndrome 0 
is 0 
influenced 0 
by 0 
modifying 0 
genes 0 
at 0 
other 0 
loci 0 
. 0 

To 0 
test 0 
this 0 
hypothesis 0 
, 0 
we 0 
have 0 
conducted 0 
linkage 0 
analysis 0 
in 0 
a 0 
large 0 
Brazilian 0 
kindred 0 
with 0 
VWS 1
, 0 
considering 0 
as 0 
affected 0 
the 0 
individuals 0 
with 0 
CP 1
, 0 
regardless 0 
of 0 
whether 0 
it 0 
is 0 
associated 0 
with 0 
other 0 
clinical 0 
signs 0 
of 0 
VWS 1
. 0 

Our 0 
results 0 
suggest 0 
that 0 
a 0 
gene 0 
at 0 
17p11 0 
. 0 

2-11 0 
2-11 0 
. 0 

_NUM1 0 
, 0 
together 0 
with 0 
the 0 
VWS 1
gene 0 
at 0 
1p32-41 0 
, 0 
enhances 0 
the 0 
probability 0 
of 0 
CP 1
in 0 
an 0 
individual 0 
carrying 0 
the 0 
two 0 
at-risk 0 
genes 0 
. 0 

If 0 
this 0 
hypothesis 0 
is 0 
confirmed 0 
in 0 
other 0 
VWS 1
pedigrees 0 
, 0 
it 0 
will 0 
represent 0 
one 0 
of 0 
the 0 
first 0 
examples 0 
of 0 
a 0 
gene 0 
, 0 
mapped 0 
through 0 
linkage 0 
analysis 0 
, 0 
which 0 
modifies 0 
the 0 
expression 0 
of 0 
a 0 
major 0 
gene 0 
. 0 

Diverse 0 
point 0 
mutations 0 
in 0 
the 0 
human 0 
glucose-6-phosphate 0 
dehydrogenase 0 
gene 0 
cause 0 
enzyme 1
deficiency 1
and 0 
mild 0 
or 0 
severe 0 
hemolytic 1
anemia 1
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
; 1
EC 1
-RRB- 1
deficiency 1
is 0 
a 0 
common 0 
genetic 1
abnormality 1
affecting 0 
an 0 
estimated 0 
_NUM3 0 
million 0 
people 0 
worldwide 0 
. 0 

Clinical 0 
and 0 
biochemical 0 
analyses 0 
have 0 
identified 0 
many 0 
variants 0 
exhibiting 0 
a 0 
range 0 
of 0 
phenotypes 0 
, 0 
which 0 
have 0 
been 0 
well 0 
characterized 0 
from 0 
the 0 
hematological 0 
point 0 
of 0 
view 0 
. 0 

However 0 
, 0 
until 0 
now 0 
, 0 
their 0 
precise 0 
molecular 0 
basis 0 
has 0 
remained 0 
unknown 0 
. 0 

We 0 
have 0 
cloned 0 
and 0 
sequenced 0 
seven 0 
mutant 0 
G6PD 0 
alleles 0 
. 0 

In 0 
the 0 
nondeficient 0 
polymorphic 0 
African 0 
variant 0 
G6PD 0 
A 0 
we 0 
have 0 
found 0 
a 0 
single 0 
point 0 
mutation 0 
. 0 

The 0 
other 0 
six 0 
mutants 0 
investigated 0 
were 0 
all 0 
associated 0 
with 0 
enzyme 1
deficiency 1
. 0 

In 0 
one 0 
of 0 
the 0 
commonest 0 
, 0 
G6PD 0 
Mediterranean 0 
, 0 
which 0 
is 0 
associated 0 
with 0 
favism 1
among 0 
other 0 
clinical 0 
manifestations 0 
, 0 
a 0 
single 0 
amino 0 
acid 0 
replacement 0 
was 0 
found 0 
-LRB- 0 
serine 0 
-- 0 
phenylalanine 0 
-RRB- 0 
it 0 
must 0 
be 0 
responsible 0 
for 0 
the 0 
decreased 0 
stability 0 
and 0 
the 0 
reduced 0 
catalytic 0 
efficiency 0 
of 0 
this 0 
enzyme 0 
. 0 

Single 0 
point 0 
mutations 0 
were 0 
also 0 
found 0 
in 0 
G6PD 0 
Metaponto 0 
-LRB- 0 
Southern 0 
Italy 0 
-RRB- 0 
and 0 
in 0 
G6PD 0 
Ilesha 0 
-LRB- 0 
Nigeria 0 
-RRB- 0 
, 0 
which 0 
are 0 
asymptomatic 0 
, 0 
and 0 
in 0 
G6PD 0 
Chatham 0 
, 0 
which 0 
was 0 
observed 0 
in 0 
an 0 
Indian 0 
boy 0 
with 0 
neonatal 1
jaundice 1
. 0 

In 0 
G6PD 0 
'' 0 
Matera 0 
, 0 
'' 0 
which 0 
is 0 
now 0 
known 0 
to 0 
be 0 
the 0 
same 0 
as 0 
G6PD 0 
A 0 
- 0 
, 0 
two 0 
separate 0 
point 0 
mutations 0 
were 0 
found 0 
, 0 
one 0 
of 0 
which 0 
is 0 
the 0 
same 0 
as 0 
in 0 
G6PD 0 
A 0 
. 0 

In 0 
G6PD 0 
Santiago 0 
, 0 
a 0 
de 0 
novo 0 
mutation 0 
-LRB- 0 
glycine 0 
-- 0 
arginine 0 
-RRB- 0 
is 0 
associated 0 
with 0 
severe 0 
chronic 0 
hemolytic 1
anemia 1
. 0 

The 0 
mutations 0 
observed 0 
show 0 
a 0 
striking 0 
predominance 0 
of 0 
C 0 
-- 0 
T 0 
transitions 0 
, 0 
with 0 
_DS 0 
doublets 0 
involved 0 
in 0 
four 0 
of 0 
seven 0 
cases 0 
. 0 

Thus 0 
, 0 
diverse 0 
point 0 
mutations 0 
may 0 
account 0 
largely 0 
for 0 
the 0 
phenotypic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
. 0 

Increased 0 
high-density 0 
lipoprotein 0 
levels 0 
caused 0 
by 0 
a 0 
common 0 
cholesteryl-ester 0 
transfer 0 
protein 0 
gene 0 
mutation 0 
. 0 

BACKGROUND 0 
AND 0 
METHODS 0 
. 0 

The 0 
plasma 0 
cholesteryl-ester 0 
transfer 0 
protein 0 
-LRB- 0 
CETP 0
-RRB- 0 
catalyzes 0 
the 0 
transfer 0 
of 0 
cholesteryl 0 
esters 0 
from 0 
high-density 0 
lipoprotein 0 
-LRB- 0 
HDL 0 
-RRB- 0 
to 0 
other 0 
lipoproteins 0 
. 0 

We 0 
recently 0 
described 0 
a 0 
Japanese 0 
family 0 
with 0 
increased 0 
HDL 0 
levels 0 
and 0 
CETP 1
deficiency 1
due 0 
to 0 
a 0 
splicing 0 
defect 0 
of 0 
the 0 
CETP 0
gene 0 
. 0 

To 0 
assess 0 
the 0 
frequency 0 
and 0 
phenotype 0 
of 0 
this 0 
condition 0 
, 0 
we 0 
screened 0 
_NUM2 0 
additional 0 
families 0 
with 0 
high 0 
HDL 0 
levels 0 
by 0 
means 0 
of 0 
a 0 
radioimmunoassay 0 
for 0 
CETP 0
and 0 
DNA 0 
analysis 0 
. 0 

RESULTS 0 
. 0 

We 0 
found 0 
the 0 
same 0 
CETP 0
gene 0 
mutation 0 
in 0 
four 0 
families 0 
from 0 
three 0 
different 0 
regions 0 
of 0 
Japan 0 
. 0 

Analysis 0 
of 0 
restriction-fragment-length 0 
polymorphisms 0 
of 0 
the 0 
mutant 0 
CETP 0
allele 0 
showed 0 
that 0 
all 0 
probands 0 
were 0 
homozygous 0 
for 0 
the 0 
identical 0 
haplotype 0 
. 0 

Family 0 
members 0 
homozygous 0 
for 0 
CETP 1
deficiency 1
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
had 0 
moderate 0 
hypercholesterolemia 1
-LRB- 0 
mean 0 
total 0 
cholesterol 0 
level 0 
-LSB- 0 
+ 0 
/ 0 
- 0 
SD 0 
-RSB- 0 
, 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
mmol 0 
per 0 
liter 0 
-RRB- 0 
, 0 
markedly 0 
increased 0 
levels 0 
of 0 
HDL 0 
cholesterol 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
mmol 0 
per 0 
liter 0 
-RRB- 0 
and 0 
apolipoprotein 0 
A-I 0 
, 0 
and 0 
decreased 0 
levels 0 
of 0 
low-density 0 
lipoprotein 0 
cholesterol 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
mmol 0 
per 0 
liter 0 
-RRB- 0 
and 0 
apolipoprotein 0 
B. 0 
Members 0 
heterozygous 0 
for 0 
the 0 
deficiency 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
, 0 
whose 0 
CETP 0
levels 0 
were 0 
in 0 
the 0 
lower 0 
part 0 
of 0 
the 0 
normal 0 
range 0 
, 0 
had 0 
moderately 0 
increased 0 
levels 0 
of 0 
HDL 0 
cholesterol 0 
and 0 
apolipoprotein 0 
A-I 0 
and 0 
an 0 
increased 0 
ratio 0 
of 0 
HDL 0 
subclass 0 
_NUM1 0 
to 0 
HDL 0 
subclass 0 
_NUM1 0 
, 0 
as 0 
compared 0 
with 0 
unaffected 0 
family 0 
members 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM1 0 
vs. 0 
_NUM1 0 
. 0 

_NUM1 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

CETP 1
deficiency 1
was 0 
not 0 
found 0 
in 0 
six 0 
unrelated 0 
subjects 0 
with 0 
elevated 0 
HDL 0 
cholesterol 0 
levels 0 
who 0 
were 0 
from 0 
different 0 
parts 0 
of 0 
the 0 
United 0 
States 0 
. 0 

CONCLUSIONS 0 
. 0 

CETP 1
deficiency 1
appears 0 
to 0 
be 0 
a 0 
frequent 0 
cause 0 
of 0 
increased 0 
HDL 0 
levels 0 
in 0 
the 0 
population 0 
of 0 
Japan 0 
, 0 
possibly 0 
because 0 
of 0 
a 0 
founder 0 
effect 0 
. 0 

The 0 
results 0 
that 0 
we 0 
observed 0 
in 0 
heterozygotes 0 
suggest 0 
that 0 
CETP 0 
normally 0 
plays 0 
a 0 
part 0 
in 0 
the 0 
regulation 0 
of 0 
levels 0 
of 0 
HDL 0 
subclass 0 
_NUM1 0 
. 0 

There 0 
was 0 
no 0 
evidence 0 
of 0 
premature 1
atherosclerosis 1
in 0 
the 0 
families 0 
with 0 
CETP 1
deficiency 1
. 0 

In 0 
fact 0 
, 0 
the 0 
lipoprotein 0 
profile 0 
of 0 
persons 0 
with 0 
CETP 1
deficiency 1
is 0 
potentially 0 
antiatherogenic 0 
and 0 
may 0 
be 0 
associated 0 
with 0 
an 0 
increased 0 
life 0 
span 0 
. 0 

Hereditary 0 
deficiency 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
and 0 
recurrent 0 
meningococcal 1
infection 1
: 0 
investigations 0 
of 0 
an 0 
Irish 0 
family 0 
using 0 
a 0 
novel 0 
haemolytic 0 
screening 0 
assay 0 
for 0 
complement 0 
activity 0 
and 0 
C7 0 
M 0 
/ 0 
N 0 
allotyping 0 
. 0 

Terminal 1
complement 1
component 1
deficiency 1
predisposes 0 
to 0 
meningococcal 1
infection 1
and 0 
is 0 
inherited 0 
in 0 
an 0 
autosomal 0 
co-dominant 0 
manner 0 
. 0 

An 0 
Irish 0 
family 0 
is 0 
described 0 
, 0 
in 0 
which 0 
_NUM1 0 
of 0 
_NUM1 0 
brothers 0 
had 0 
recurrent 0 
meningococcal 1
infection 1
. 0 

A 0 
novel 0 
screening 0 
assay 0 
was 0 
used 0 
to 0 
investigate 0 
for 0 
terminal 1
complement 1
deficiency 1
and 0 
the 0 
_NUM1 0 
affected 0 
brothers 0 
were 0 
found 0 
to 0 
be 0 
completely 1
deficient 1
in 1
the 1
seventh 1
component 1
of 1
complement 1
-LRB- 0 
C7 0
-RRB- 0 
. 0 

Enzyme-linked 0 
immunosorbent 0 
assay 0 
for 0 
C7 0
revealed 0 
lower 0 
than 0 
normal 0 
levels 0 
in 0 
the 0 
remaining 0 
brother 0 
and 0 
parents 0 
. 0 

C7 0
M 0 
/ 0 
N 0 
protein 0 
polymorphism 0 
allotyping 0 
, 0 
used 0 
to 0 
investigate 0 
the 0 
segregation 0 
of 0 
the 0 
C7 1
deficiency 1
genes 0 
, 0 
showed 0 
that 0 
the 0 
apparently 0 
complement 0 
sufficient 0 
brother 0 
was 0 
heterozygous 0 
C7 1
deficient 1
and 0 
a 0 
carrier 0 
of 0 
one 0 
of 0 
the 0 
deficiency 0 
genes 0 
. 0 

Complement 0 
screening 0 
should 0 
be 0 
carried 0 
out 0 
in 0 
any 0 
individual 0 
suffering 0 
recurrent 0 
meningococcal 1
infection 1
or 0 
infection 0 
with 0 
an 0 
uncommon 0 
meningococcal 1
serogroup 0 
. 0 

Identification 0 
of 0 
complement 1
deficient 1
patients 0 
allows 0 
the 0 
implementation 0 
of 0 
strategies 0 
to 0 
prevent 0 
recurrent 0 
infection 0 
. 0 
. 0 

Mild 0 
and 0 
severe 0 
muscular 1
dystrophy 1
associated 0 
with 0 
deletions 0 
in 0 
Xp21 0 
of 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 

We 0 
have 0 
analysed 0 
over 0 
_NUM3 0 
patients 0 
suffering 0 
from 0 
Duchenne 1
or 1
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
or 0 
BMD 1
-RRB- 0 
. 0 

Deletions 0 
have 0 
been 0 
characterised 0 
which 0 
encompass 0 
either 0 
the 0 
pERT87 0 
-LRB- 0 
DXS164 0 
-RRB- 0 
locus 0 
only 0 
, 0 
the 0 
XJ1 0 
. 0 

_NUM1 0 
-LRB- 0 
DXS206 0 
-RRB- 0 
and 0 
HIP25 0 
loci 0 
only 0 
, 0 
or 0 
all 0 
three 0 
loci 0 
. 0 

These 0 
loci 0 
have 0 
been 0 
shown 0 
to 0 
lie 0 
within 0 
the 0 
DMD 1
region 0 
covering 0 
several 0 
hundred 0 
kilobases 0 
-LRB- 0 
kb 0 
-RRB- 0 
of 0 
DNA 0 
. 0 

One 0 
mildly 0 
affected 0 
BMD 1
patient 0 
possesses 0 
a 0 
deletion 0 
of 0 
at 0 
least 0 
_NUM3 0 
kb 0 
including 0 
exons 0 
of 0 
the 0 
DMD 1
gene 0 
. 0 

Other 0 
patients 0 
with 0 
similar 0 
exon 0 
deletions 0 
, 0 
or 0 
smaller 0 
deletions 0 
, 0 
show 0 
the 0 
more 0 
severe 0 
phenotype 0 
typical 0 
of 0 
DMD 1
. 0 

We 0 
conclude 0 
from 0 
these 0 
studies 0 
that 0 
the 0 
severity 0 
of 0 
the 0 
clinical 0 
phenotype 0 
can 0 
not 0 
be 0 
explained 0 
on 0 
the 0 
basis 0 
of 0 
the 0 
size 0 
of 0 
the 0 
deletion 0 
. 0 

We 0 
discuss 0 
this 0 
in 0 
the 0 
context 0 
of 0 
candidate 0 
gene 0 
sequences 0 
. 0 

Meiotic 0 
segregation 0 
analysis 0 
of 0 
RB1 0 
alleles 0 
in 0 
retinoblastoma 1
pedigrees 0 
by 0 
use 0 
of 0 
single-sperm 0 
typing 0 
. 0 

In 0 
hereditary 1
retinoblastoma 1
, 0 
different 0 
epidemiological 0 
studies 0 
have 0 
indicated 0 
a 0 
preferential 0 
paternal 0 
transmission 0 
of 0 
mutant 0 
retinoblastoma 1
alleles 0 
to 0 
offspring 0 
, 0 
suggesting 0 
the 0 
occurrence 0 
of 0 
a 0 
meiotic 0 
drive 0 
. 0 

To 0 
investigate 0 
this 0 
mechanism 0 
, 0 
we 0 
analyzed 0 
sperm 0 
samples 0 
from 0 
six 0 
individuals 0 
from 0 
five 0 
unrelated 0 
families 0 
affected 0 
with 0 
hereditary 1
retinoblastoma 1
. 0 

Single-sperm 0 
typing 0 
techniques 0 
were 0 
performed 0 
for 0 
each 0 
sample 0 
by 0 
study 0 
of 0 
two 0 
informative 0 
short 0 
tandem 0 
repeats 0 
located 0 
either 0 
in 0 
or 0 
close 0 
to 0 
the 0 
retinoblastoma 1
gene 0 
-LRB- 0 
RB1 0 
-RRB- 0 
. 0 

The 0 
segregation 0 
probability 0 
of 0 
mutant 0 
RB1 0 
alleles 0 
in 0 
sperm 0 
samples 0 
was 0 
assessed 0 
by 0 
use 0 
of 0 
the 0 
SPERMSEG 0 
program 0 
, 0 
which 0 
includes 0 
experimental 0 
parameters 0 
, 0 
recombination 0 
fractions 0 
between 0 
the 0 
markers 0 
, 0 
and 0 
segregation 0 
parameters 0 
. 0 

A 0 
total 0 
of 0 
_NUM1 0 
, 0 
_NUM3 0 
single 0 
sperm 0 
from 0 
the 0 
six 0 
donors 0 
were 0 
analyzed 0 
. 0 

We 0 
detected 0 
a 0 
significant 0 
segregation 0 
distortion 0 
in 0 
the 0 
data 0 
as 0 
a 0 
whole 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM4 0 
-RRB- 0 
and 0 
a 0 
significant 0 
heterogeneity 0 
in 0 
the 0 
segregation 0 
rate 0 
across 0 
donors 0 
-LRB- 0 
. 0 

_NUM4 0 
-RRB- 0 
. 0 

Further 0 
analysis 0 
shows 0 
that 0 
this 0 
result 0 
can 0 
be 0 
explained 0 
by 0 
segregation 0 
distortion 0 
in 0 
favor 0 
of 0 
the 0 
normal 0 
allele 0 
in 0 
one 0 
donor 0 
only 0 
and 0 
that 0 
it 0 
does 0 
not 0 
provide 0 
evidence 0 
of 0 
a 0 
significant 0 
segregation 0 
distortion 0 
in 0 
the 0 
other 0 
donors 0 
. 0 

The 0 
segregation 0 
distortion 0 
favoring 0 
the 0 
mutant 0 
RB1 0 
allele 0 
does 0 
not 0 
seem 0 
to 0 
occur 0 
during 0 
spermatogenesis 0 
, 0 
and 0 
, 0 
thus 0 
, 0 
meiotic 0 
drive 0 
may 0 
result 0 
either 0 
from 0 
various 0 
mechanisms 0 
, 0 
including 0 
a 0 
fertilization 0 
advantage 0 
or 0 
a 0 
better 0 
mobility 0 
in 0 
sperm 0 
bearing 0 
a 0 
mutant 0 
RB1 0 
gene 0 
, 0 
or 0 
from 0 
the 0 
existence 0 
of 0 
a 0 
defectively 0 
imprinted 0 
gene 0 
located 0 
on 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 

Functional 0 
differences 0 
of 0 
the 0 
PDS 1
gene 0 
product 0 
are 0 
associated 0 
with 0 
phenotypic 0 
variation 0 
in 0 
patients 0 
with 0 
Pendred 1
syndrome 1
and 0 
non-syndromic 1
hearing 1
loss 1
-LRB- 0 
DFNB4 1
-RRB- 0 
. 0 

The 0 
PDS 1
gene 0 
encodes 0 
a 0 
transmembrane 0 
protein 0 
, 0 
known 0 
as 0 
pendrin 0 
, 0 
which 0 
functions 0 
as 0 
a 0 
transporter 0 
of 0 
iodide 0 
and 0 
chloride 0 
. 0 

Mutations 0 
in 0 
this 0 
gene 0 
are 0 
responsible 0 
for 0 
Pendred 1
syndrome 1
and 0 
autosomal 1
recessive 1
non-syndromic 1
hearing 1
loss 1
at 0 
the 0 
DFNB4 1
locus 0 
on 0 
chromosome 0 
7q31 0 
. 0 

A 0 
screen 0 
of 0 
_NUM2 0 
individuals 0 
from 0 
the 0 
midwestern 0 
USA 0 
with 0 
non-syndromic 1
hearing 1
loss 1
and 0 
dilated 0 
vestibular 0 
aqueducts 0 
identified 0 
three 0 
people 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
with 0 
PDS 1
mutations 0 
. 0 

To 0 
determine 0 
whether 0 
PDS 1
mutations 0 
in 0 
individuals 0 
with 0 
Pendred 1
syndrome 1
differ 0 
functionally 0 
from 0 
PDS 1
mutations 0 
in 0 
individuals 0 
with 0 
non-syndromic 1
hearing 1
loss 1
, 0 
we 0 
compared 0 
three 0 
common 0 
Pendred 1
syndrome 1
allele 0 
variants 0 
-LRB- 0 
L236P 0 
, 0 
T416P 0 
and 0 
E384G 0 
-RRB- 0 
, 0 
with 0 
three 0 
PDS 1
mutations 0 
reported 0 
only 0 
in 0 
individuals 0 
with 0 
non-syndromic 1
hearing 1
loss 1
-LRB- 0 
V480D 0 
, 0 
V653A 0 
and 0 
I490L 0 
/ 0 
G497S 0 
-RRB- 0 
. 0 

The 0 
mutations 0 
associated 0 
with 0 
Pendred 1
syndrome 1
have 0 
complete 0 
loss 0 
of 0 
pendrin-induced 0 
chloride 0 
and 0 
iodide 0 
transport 0 
, 0 
while 0 
alleles 0 
unique 0 
to 0 
people 0 
with 0 
DFNB4 1
are 0 
able 0 
to 0 
transport 0 
both 0 
iodide 0 
and 0 
chloride 0 
, 0 
albeit 0 
at 0 
a 0 
much 0 
lower 0 
level 0 
than 0 
wild-type 0 
pendrin 0 
. 0 

We 0 
hypothesize 0 
that 0 
this 0 
residual 0 
level 0 
of 0 
anion 0 
transport 0 
is 0 
sufficient 0 
to 0 
eliminate 0 
or 0 
postpone 0 
the 0 
onset 0 
of 0 
goiter 1
in 0 
individuals 0 
with 0 
DFNB4 1
. 0 

We 0 
propose 0 
a 0 
model 0 
for 0 
pendrin 0 
function 0 
in 0 
the 0 
thyroid 0 
in 0 
which 0 
pendrin 0 
transports 0 
iodide 0 
across 0 
the 0 
apical 0 
membrane 0 
of 0 
the 0 
thyrocyte 0 
into 0 
the 0 
colloid 0 
space 0 
. 0 
. 0 

Late-onset 0 
metachromatic 1
leukodystrophy 1
: 0 
molecular 0 
pathology 0 
in 0 
two 0 
siblings 0 
. 0 

We 0 
report 0 
on 0 
a 0 
new 0 
allele 0 
at 0 
the 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
locus 0 
causing 0 
late-onset 0 
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
. 0 

In 0 
that 0 
allele 0 
arginine84 0 
, 0 
a 0 
residue 0 
that 0 
is 0 
highly 0 
conserved 0 
in 0 
the 0 
arylsulfatase 0 
gene 0 
family 0 
, 0 
is 0 
replaced 0 
by 0 
glutamine 0 
. 0 

In 0 
contrast 0 
to 0 
alleles 0 
that 0 
cause 0 
early-onset 0 
MLD 1
, 0 
the 0 
arginine84 0 
to 0 
glutamine 0 
substitution 0 
is 0 
associated 0 
with 0 
some 0 
residual 0 
ARSA 0 
activity 0 
. 0 

A 0 
comparison 0 
of 0 
genotypes 0 
, 0 
ARSA 0 
activities 0 
, 0 
and 0 
clinical 0 
data 0 
on 0 
_NUM1 0 
individuals 0 
carrying 0 
the 0 
allele 0 
of 0 
_NUM2 0 
patients 0 
with 0 
MLD 1
examined 0 
, 0 
further 0 
validates 0 
the 0 
concept 0 
that 0 
different 0 
degrees 0 
of 0 
residual 0 
ARSA 0 
activity 0 
are 0 
the 0 
basis 0 
of 0 
phenotypical 0 
variation 0 
in 0 
MLD 1
. 0 
. 0 

Defective 0 
CD95 0 
/ 0 
APO 0 
-1 0 
/ 0 
Fas 0 
signal 0 
complex 0 
formation 0 
in 0 
the 0 
human 0 
autoimmune 1
lymphoproliferative 1
syndrome 1
, 1
type 1
Ia 1
. 0 

Heterozygous 0 
mutations 0 
in 0 
the 0 
CD95 0 
-LRB- 0 
APO-1 0 
/ 0 
Fas 0 
-RRB- 0 
receptor 0 
occur 0 
in 0 
most 0 
individuals 0 
with 0 
autoimmune 1
lymphoproliferative 1
syndrome 1
-LRB- 0 
ALPS 1
-RRB- 0 
and 0 
dominantly 0 
interfere 0 
with 0 
apoptosis 0 
by 0 
an 0 
unknown 0 
mechanism 0 
. 0 

We 0 
show 0 
that 0 
local 0 
or 0 
global 0 
alterations 0 
in 0 
the 0 
structure 0 
of 0 
the 0 
cytoplasmic 0 
death 0 
domain 0 
from 0 
nine 0 
independent 0 
ALPS 1
CD95 0 
death-domain 0 
mutations 0 
result 0 
in 0 
a 0 
failure 0 
to 0 
bind 0 
the 0 
FADD 0 
/ 0 
MORT1 0 
signaling 0 
protein 0 
. 0 

Despite 0 
heterozygosity 0 
for 0 
the 0 
abnormal 0 
allele 0 
, 0 
lymphocytes 0 
from 0 
ALPS 1
patients 0 
showed 0 
markedly 0 
decreased 0 
FADD 0 
association 0 
and 0 
a 0 
loss 0 
of 0 
caspase 0 
recruitment 0 
and 0 
activation 0 
after 0 
CD95 0 
crosslinking 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
intracytoplasmic 0 
CD95 0 
mutations 0 
in 0 
ALPS 1
impair 0 
apoptosis 0 
chiefly 0 
by 0 
disrupting 0 
death-domain 0 
interactions 0 
with 0 
the 0 
signaling 0 
protein 0 
FADD 0 
/ 0 
MORT1 0 
. 0 
. 0 

Classical 1
galactosemia 1
and 0 
mutations 0 
at 0 
the 0 
galactose-1-phosphate 0 
uridyl 0 
transferase 0 
-LRB- 0 
GALT 0 
-RRB- 0 
gene 0 
. 0 

Classical 1
galactosemia 1
is 0 
caused 0 
by 0 
a 0 
deficiency 0 
in 0 
activity 0 
of 0 
the 0 
enzyme 0 
galactose-1-phosphate 0 
uridyl 0 
transferase 0 
-LRB- 0 
GALT 0 
-RRB- 0 
, 0 
which 0 
, 0 
in 0 
turn 0 
, 0 
is 0 
caused 0 
by 0 
mutations 0 
at 0 
the 0 
GALT 0 
gene 0 
. 0 

The 0 
disorder 0 
exhibits 0 
considerable 0 
allelic 0 
heterogeneity 0 
and 0 
, 0 
at 0 
the 0 
end 0 
of 0 
_NUM4 0 
, 0 
more 0 
than 0 
_NUM3 0 
different 0 
base 0 
changes 0 
were 0 
recorded 0 
in 0 
_NUM2 0 
different 0 
populations 0 
and 0 
ethnic 0 
groups 0 
in 0 
_NUM2 0 
countries 0 
worldwide 0 
. 0 

The 0 
mutations 0 
most 0 
frequently 0 
cited 0 
are 0 
Q188R 0 
, 0 
K285N 0 
, 0 
S135L 0 
, 0 
and 0 
N314D 0 
. 0 

Q188R 0 
is 0 
the 0 
most 0 
common 0 
mutation 0 
in 0 
European 0 
populations 0 
or 0 
in 0 
those 0 
predominantly 0 
of 0 
European 0 
descent 0 
. 0 

Overall 0 
, 0 
it 0 
accounts 0 
for 0 
60-70 0 
% 0 
of 0 
mutant 0 
chromosomes 0 
, 0 
but 0 
there 0 
are 0 
significant 0 
differences 0 
in 0 
its 0 
relative 0 
frequency 0 
in 0 
individual 0 
populations 0 
. 0 

Individuals 0 
homoallelic 0 
for 0 
Q188R 0 
tend 0 
to 0 
have 0 
a 0 
severe 0 
phenotype 0 
and 0 
this 0 
is 0 
in 0 
keeping 0 
with 0 
the 0 
virtually 0 
complete 0 
loss 0 
of 0 
enzyme 0 
activity 0 
observed 0 
in 0 
in 0 
vitro 0 
expression 0 
systems 0 
. 0 

Globally 0 
, 0 
K285N 0 
is 0 
rarer 0 
, 0 
but 0 
in 0 
many 0 
European 0 
populations 0 
it 0 
can 0 
be 0 
found 0 
on 0 
25-40 0 
% 0 
of 0 
mutant 0 
chromosomes 0 
. 0 

It 0 
is 0 
invariably 0 
associated 0 
with 0 
a 0 
severe 0 
phenotype 0 
. 0 

S135L 0 
is 0 
found 0 
almost 0 
exclusively 0 
in 0 
African 0 
Americans 0 
. 0 

In 0 
vitro 0 
expression 0 
results 0 
are 0 
discrepant 0 
, 0 
but 0 
some 0 
individuals 0 
carrying 0 
S135L 0 
appear 0 
to 0 
exhibit 0 
GALT 0 
activity 0 
in 0 
some 0 
tissues 0 
. 0 

Duarte 0 
_NUM1 0 
-LRB- 0 
or 0 
Los 0 
Angeles 0 
-RRB- 0 
and 0 
Duarte 0 
_NUM1 0 
-LRB- 0 
or 0 
Duarte 0 
-RRB- 0 
variants 0 
carry 0 
the 0 
same 0 
amino 0 
acid 0 
substitution 0 
, 0 
N314D 0 
, 0 
even 0 
though 0 
D1 0 
is 0 
associated 0 
with 0 
increased 0 
erythrocyte 0 
GALT 0 
activity 0 
and 0 
D2 0 
with 0 
reduced 0 
activity 0 
. 0 

N314D 0 
is 0 
in 0 
linkage 0 
disequilibrium 0 
with 0 
other 0 
base 0 
changes 0 
that 0 
differ 0 
on 0 
the 0 
D1 0 
and 0 
D2 0 
alleles 0 
. 0 

N314D 0 
does 0 
not 0 
impair 0 
GALT 0 
activity 0 
in 0 
in 0 
vitro 0 
expression 0 
systems 0 
. 0 

However 0 
, 0 
there 0 
are 0 
differences 0 
in 0 
the 0 
abundance 0 
of 0 
GALT 0 
protein 0 
in 0 
lymphoblastoid 0 
cells 0 
lines 0 
from 0 
D2 0 
and 0 
D1 0 
individuals 0 
. 0 

It 0 
is 0 
unclear 0 
whether 0 
the 0 
specific 0 
molecular 0 
changes 0 
that 0 
distinguish 0 
the 0 
D1 0 
and 0 
D2 0 
alleles 0 
account 0 
for 0 
the 0 
different 0 
activities 0 
. 0 

The 0 
considerable 0 
genetic 0 
heterogeneity 0 
documented 0 
to 0 
date 0 
undoubtedly 0 
contributes 0 
to 0 
the 0 
phenotypic 0 
heterogeneity 0 
that 0 
is 0 
observed 0 
in 0 
galactosemia 1
. 0 

The 0 
additional 0 
effects 0 
of 0 
nonallelic 0 
variation 0 
and 0 
other 0 
constitutional 0 
factors 0 
on 0 
phenotypic 0 
variability 0 
remain 0 
to 0 
be 0 
elucidated 0 
. 0 
. 0 

X-linked 1
retinoschisis 1
with 0 
point 0 
mutations 0 
in 0 
the 0 
XLRS1 0 
gene 0 
. 0 

BACKGROUND 0 
X-linked 1
retinoschisis 1
-LRB- 0 
XLRS 1
-RRB- 0 
is 0 
a 0 
relatively 0 
rare 0 
vitreoretinal 1
dystrophy 1
that 0 
causes 0 
visual 1
loss 1
in 0 
young 0 
men 0 
. 0 

Recently 0 
, 0 
a 0 
gene 0 
responsible 0 
for 0 
this 0 
disease 0 
, 0 
designated 0 
XLRS1 0 
, 0 
was 0 
identified 0 
, 0 
and 0 
several 0 
deleterious 0 
gene 0 
mutations 0 
were 0 
reported 0 
. 0 

OBJECTIVE 0 
To 0 
analyze 0 
Japanese 0 
patients 0 
clinically 0 
diagnosed 0 
as 0 
having 0 
XLRS 1
formutational 0 
changes 0 
in 0 
the 0 
XLRS1 0 
gene 0 
. 0 

METHODS 0 
Ten 0 
patients 0 
with 0 
XLRS 1
underwent 0 
full 0 
ophthalmologic 0 
examination 0 
, 0 
including 0 
slitlamp 0 
biomicroscopy 0 
and 0 
dilated 0 
funduscopy 0 
. 0 

Genomic 0 
DNA 0 
was 0 
isolated 0 
from 0 
leukocytes 0 
, 0 
and 0 
all 0 
exons 0 
of 0 
the 0 
XLRS1 0 
gene 0 
were 0 
amplified 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
and 0 
analyzed 0 
using 0 
a 0 
direct 0 
sequencing 0 
method 0 
. 0 

RESULTS 0 
Point 0 
mutations 0 
in 0 
the 0 
XLRS1 0 
gene 0 
were 0 
identified 0 
in 0 
all 0 
_NUM2 0 
patients 0 
. 0 

The 0 
mutations 0 
were 0 
identical 0 
in 0 
each 0 
of 0 
_NUM1 0 
pairs 0 
of 0 
brothers 0 
. 0 

Six 0 
of 0 
the 0 
point 0 
mutations 0 
represented 0 
missense 0 
mutations 0 
, 0 
_NUM1 0 
was 0 
a 0 
nonsense 0 
mutation 0 
, 0 
and 0 
_NUM1 0 
was 0 
a 0 
frameshift 0 
mutation 0 
. 0 

Five 0 
of 0 
the 0 
mutations 0 
are 0 
newly 0 
reported 0 
herein 0 
. 0 

CONCLUSIONS 0 
The 0 
discovery 0 
of 0 
new 0 
point 0 
mutations 0 
in 0 
this 0 
study 0 
increases 0 
the 0 
available 0 
information 0 
regarding 0 
the 0 
spectrum 0 
of 0 
genetic 1
abnormalities 1
and 0 
clinical 0 
manifestations 0 
of 0 
XLRS 1
. 0 

However 0 
, 0 
the 0 
limited 0 
data 0 
failed 0 
to 0 
reveal 0 
a 0 
correlation 0 
between 0 
mutation 0 
and 0 
disease 0 
phenotype 0 
. 0 

CLINICAL 0 
RELEVANCE 0 
Identification 0 
of 0 
mutations 0 
in 0 
the 0 
XLRS1 0 
gene 0 
and 0 
expanded 0 
information 0 
on 0 
clinical 0 
manifestations 0 
will 0 
facilitate 0 
early 0 
diagnosis 0 
, 0 
appropriate 0 
early 0 
therapy 0 
, 0 
and 0 
genetic 0 
counseling 0 
regarding 0 
the 0 
prognosis 0 
of 0 
XLRS 1
. 0 
. 0 

Relationship 0 
among 0 
genotype 0 
, 0 
biochemical 0 
phenotype 0 
, 0 
and 0 
cognitive 0 
performance 0 
in 0 
females 0 
with 0 
phenylalanine 1
hydroxylase 1
deficiency 1
: 0 
report 0 
from 0 
the 0 
Maternal 1
Phenylketonuria 1
Collaborative 0 
Study 0 
. 0 

OBJECTIVE 0 
To 0 
examine 0 
the 0 
relationship 0 
of 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
genotypes 0 
to 0 
biochemical 0 
phenotype 0 
and 0 
cognitive 0 
development 0 
in 0 
maternal 1
phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
. 0 

METHODOLOGY 0 
PAH 0 
gene 0 
mutations 0 
were 0 
examined 0 
in 0 
_NUM3 0 
hyperphenylalaninemic 1
females 0 
enrolled 0 
in 0 
the 0 
Maternal 1
PKU 1
Collaborative 0 
Study 0 
-LRB- 0 
MPKUCS 0 
-RRB- 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
different 0 
mutations 0 
were 0 
detected 0 
, 0 
and 0 
complete 0 
genotype 0 
was 0 
obtained 0 
in 0 
_NUM3 0 
individuals 0 
. 0 

Based 0 
on 0 
previous 0 
knowledge 0 
about 0 
mutation-phenotype 0 
associations 0 
, 0 
_NUM2 0 
of 0 
the 0 
mutations 0 
could 0 
be 0 
assigned 0 
to 0 
one 0 
of 0 
four 0 
classes 0 
of 0 
severity 0 
-LRB- 0 
severe 0 
PKU 1
, 0 
moderate 0 
PKU 1
, 0 
mild 0 
PKU 1
, 0 
and 0 
mild 1
hyperphenylalaninemia 1
-LSB- 0 
MHP 1
-RSB- 0 
-RRB- 0 
. 0 

Then 0 
, 0 
_NUM3 0 
MPKUCS 0 
subjects 0 
were 0 
grouped 0 
according 0 
to 0 
the 0 
various 0 
combinations 0 
of 0 
mutation 0 
classifications 0 
. 0 

The 0 
sample 0 
sizes 0 
were 0 
large 0 
enough 0 
for 0 
statistical 0 
testing 0 
in 0 
four 0 
groups 0 
with 0 
at 0 
least 0 
one 0 
mutation 0 
that 0 
completely 0 
abolishes 0 
enzyme 0 
activity 0 
. 0 

These 0 
patients 0 
are 0 
considered 0 
functionally 0 
hemizygous 0 
. 0 

RESULTS 0 
The 0 
biochemical 0 
phenotype 0 
predicted 0 
from 0 
the 0 
genotype 0 
in 0 
functionally 0 
hemizygous 0 
patients 0 
was 0 
related 0 
significantly 0 
to 0 
the 0 
assigned 0 
phenylalanine 0 
level 0 
. 0 

Cognitive 0 
performance 0 
-LRB- 0 
IQ 0 
-RRB- 0 
was 0 
also 0 
significantly 0 
related 0 
to 0 
genotype 0 
. 0 

The 0 
IQ 0 
of 0 
PAH-deficient 1
mothers 0 
with 0 
a 0 
severe 0 
PKU 1
mutation 0 
in 0 
combination 0 
with 0 
a 0 
MHP 1
mutation 0 
or 0 
a 0 
mild 0 
PKU 1
mutation 0 
was 0 
_NUM2 0 
and 0 
_NUM2 0 
, 0 
respectively 0 
, 0 
whereas 0 
the 0 
IQ 0 
of 0 
PKU 1
mothers 0 
with 0 
two 0 
severe 0 
PKU 1
mutations 0 
or 0 
with 0 
one 0 
severe 0 
and 0 
one 0 
moderate 0 
PKU 1
mutation 0 
was 0 
_NUM2 0 
and 0 
_NUM2 0 
, 0 
respectively 0 
. 0 

Of 0 
the 0 
patients 0 
with 0 
PKU 1
, 0 
_NUM2 0 
% 0 
had 0 
been 0 
treated 0 
during 0 
childhood 0 
. 0 

Those 0 
who 0 
were 0 
untreated 0 
or 0 
treated 0 
late 0 
had 0 
lower 0 
than 0 
average 0 
IQ 0 
scores 0 
for 0 
their 0 
group 0 
of 0 
mutation 0 
combinations 0 
. 0 

Females 0 
with 0 
moderate 0 
or 0 
mild 0 
PKU 1
who 0 
were 0 
treated 0 
early 0 
and 0 
treated 0 
for 0 
> 0 
_NUM1 0 
years 0 
showed 0 
IQ 0 
scores 0 
_NUM2 0 
points 0 
above 0 
average 0 
for 0 
their 0 
group 0 
. 0 

CONCLUSIONS 0 
The 0 
reproductive 0 
outcome 0 
in 0 
maternal 1
phenylketonuria 1
is 0 
dependent 0 
on 0 
prenatal 0 
metabolic 0 
control 0 
and 0 
postnatal 0 
environmental 0 
circumstances 0 
. 0 

Both 0 
factors 0 
depend 0 
on 0 
the 0 
intellectual 0 
resources 0 
of 0 
the 0 
mother 0 
with 0 
PKU 1
. 0 

The 0 
significant 0 
relationship 0 
among 0 
genotype 0 
, 0 
biochemical 0 
phenotype 0 
, 0 
and 0 
cognitive 0 
performance 0 
observed 0 
in 0 
the 0 
present 0 
study 0 
is 0 
of 0 
importance 0 
for 0 
the 0 
development 0 
of 0 
an 0 
optimal 0 
strategy 0 
for 0 
future 0 
treatment 0 
of 0 
females 0 
with 0 
PKU 1
who 0 
plan 0 
pregnancy 0 
. 0 
. 0 

Uncoupling 0 
of 0 
hypomyelination 1
and 0 
glial 1
cell 1
death 1
by 0 
a 0 
mutation 0 
in 0 
the 0 
proteolipid 0 
protein 0 
gene 0 
. 0 

Proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
; 0 
M 0 
-LRB- 0 
r 0 
-RRB- 0 
_NUM2 0 
, 0 
_NUM3 0 
-RRB- 0 
is 0 
a 0 
highly 0 
conserved 0 
major 0 
polytopic 0 
membrane 0 
protein 0 
in 0 
myelin 0 
but 0 
its 0 
cellular 0 
function 0 
remains 0 
obscure 0 
. 0 

Neurological 0 
mutant 0 
mice 0 
can 0 
often 0 
provide 0 
model 0 
systems 0 
for 0 
human 0 
genetic 1
disorders 1
. 0 

Mutations 0 
of 0 
the 0 
X-chromosome-linked 0 
PLP 0 
gene 0 
are 0 
lethal 0 
, 0 
identified 0 
first 0 
in 0 
the 0 
jimpy 0 
mouse 0 
and 0 
subsequently 0 
in 0 
patients 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 

The 0 
unexplained 0 
phenotype 0 
of 0 
these 0 
mutations 0 
includes 0 
degeneration 1
and 1
premature 1
cell 1
death 1
of 1
oligodendrocytes 1
with 0 
associated 0 
hypomyelination 1
. 0 

Here 0 
we 0 
show 0 
that 0 
a 0 
new 0 
mouse 0 
mutant 0 
rumpshaker 0 
is 0 
defined 0 
by 0 
the 0 
amino-acid 0 
substitution 0 
Ile-to-Thr 0 
at 0 
residue 0 
_NUM3 0 
in 0 
a 0 
membrane-embedded 0 
domain 0 
of 0 
PLP 0 
. 0 

Surprisingly 0 
, 0 
rumpshaker 0 
mice 0 
, 0 
although 0 
myelin-deficient 1
, 0 
have 0 
normal 0 
longevity 0 
and 0 
a 0 
full 0 
complement 0 
of 0 
morphologically 0 
normal 0 
oligodendrocytes 0 
. 0 

Hypomyelination 1
can 0 
thus 0 
be 0 
genetically 0 
separated 0 
from 0 
the 0 
PLP-dependent 0 
oligodendrocyte 1
degeneration 1
. 0 

We 0 
suggest 0 
that 0 
PLP 0 
has 0 
a 0 
vital 0 
function 0 
in 0 
glial 0 
cell 0 
development 0 
, 0 
distinct 0 
from 0 
its 0 
later 0 
role 0 
in 0 
myelin 0 
assembly 0 
, 0 
and 0 
that 0 
this 0 
dichotomy 0 
of 0 
action 0 
may 0 
explain 0 
the 0 
clinical 0 
spectrum 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 
. 0 

Mutational 0 
analysis 0 
of 0 
the 0 
HGO 0 
gene 0 
in 0 
Finnish 0 
alkaptonuria 1
patients 0 
. 0 

Alkaptonuria 1
-LRB- 0 
AKU 1
-RRB- 0 
, 0 
the 0 
prototypic 0 
inborn 1
error 1
of 1
metabolism 1
, 0 
has 0 
recently 0 
been 0 
shown 0 
to 0 
be 0 
caused 0 
by 0 
loss 0 
of 0 
function 0 
mutations 0 
in 0 
the 0 
homogentisate-1 0 
, 0 
2-dioxygenase 0 
gene 0 
-LRB- 0 
HGO 0 
-RRB- 0 
. 0 

So 0 
far 0 
_NUM2 0 
mutations 0 
have 0 
been 0 
characterised 0 
in 0 
AKU 1
patients 0 
of 0 
different 0 
ethnic 0 
origin 0 
. 0 

We 0 
describe 0 
three 0 
novel 0 
mutations 0 
-LRB- 0 
R58fs 0 
, 0 
R330S 0 
, 0 
and 0 
H371R 0 
-RRB- 0 
and 0 
one 0 
common 0 
AKU 1
mutation 0 
-LRB- 0 
M368V 0 
-RRB- 0 
, 0 
detected 0 
by 0 
mutational 0 
and 0 
polymorphism 0 
analysis 0 
of 0 
the 0 
HGO 0 
gene 0 
in 0 
five 0 
Finnish 0 
AKU 1
pedigrees 0 
. 0 

The 0 
three 0 
novel 0 
AKU 1
mutations 0 
are 0 
most 0 
likely 0 
specific 0 
for 0 
the 0 
Finnish 0 
population 0 
and 0 
have 0 
originated 0 
recently 0 
. 0 
. 0 

Putative 0 
X-linked 1
adrenoleukodystrophy 1
gene 0 
shares 0 
unexpected 0 
homology 0 
with 0 
ABC 0 
transporters 0 
. 0 

Adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
is 0 
an 0 
X-linked 1
disease 1
affecting 0 
1 0 
/ 0 
20 0 
, 0 
_NUM3 0 
males 0 
either 0 
as 0 
cerebral 1
ALD 1
in 0 
childhood 0 
or 0 
as 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
in 0 
adults 0 
. 0 

Childhood 0 
ALD 1
is 0 
the 0 
more 0 
severe 0 
form 0 
, 0 
with 0 
onset 0 
of 0 
neurological 0 
symptoms 0 
between 0 
5-12 0 
years 0 
of 0 
age 0 
. 0 

Central 1
nervous 1
system 1
demyelination 1
progresses 0 
rapidly 0 
and 0 
death 0 
occurs 0 
within 0 
a 0 
few 0 
years 0 
. 0 

AMN 1
is 0 
a 0 
milder 0 
form 0 
of 0 
the 0 
disease 0 
with 0 
onset 0 
at 0 
15-30 0 
years 0 
of 0 
age 0 
and 0 
a 0 
more 0 
progressive 0 
course 0 
. 0 

Adrenal 1
insufficiency 1
-LRB- 0 
Addisons 1
disease 1
-RRB- 0 
may 0 
remain 0 
the 0 
only 0 
clinical 0 
manifestation 0 
of 0 
ALD 1
. 0 

The 0 
principal 0 
biochemical 0 
abnormality 0 
of 0 
ALD 1
is 0 
the 0 
accumulation 0 
of 0 
very-long-chain 0 
fatty 0 
acids 0 
-LRB- 0 
VLCFA 0 
-RRB- 0 
because 0 
of 0 
impaired 0 
beta-oxidation 0 
in 0 
peroxisomes 0 
. 0 

The 0 
normal 0 
oxidation 0 
of 0 
VLCFA-CoA 0 
in 0 
patients 0 
fibroblasts 0 
suggested 0 
that 0 
the 0 
gene 0 
coding 0 
for 0 
the 0 
VLCFA-CoA 0 
synthetase 0 
could 0 
be 0 
a 0 
candidate 0 
gene 0 
for 0 
ALD 1
. 0 

Here 0 
we 0 
use 0 
positional 0 
cloning 0 
to 0 
identify 0 
a 0 
gene 0 
partially 0 
deleted 0 
in 0 
_NUM1 0 
of 0 
_NUM2 0 
independent 0 
patients 0 
with 0 
ALD 1
. 0 

In 0 
familial 0 
cases 0 
, 0 
the 0 
deletions 0 
segregated 0 
with 0 
the 0 
disease 0 
. 0 

An 0 
identical 0 
deletion 0 
was 0 
detected 0 
in 0 
two 0 
brothers 0 
presenting 0 
with 0 
different 0 
clinical 0 
ALD 1
phenotypes 0 
. 0 

Candidate 0 
exons 0 
were 0 
identified 0 
by 0 
computer 0 
analysis 0 
of 0 
genomic 0 
sequences 0 
and 0 
used 0 
to 0 
isolate 0 
complementary 0 
DNAs 0 
by 0 
exon 0 
connection 0 
and 0 
screening 0 
of 0 
cDNA 0 
libraries 0 
. 0 

The 0 
deduced 0 
protein 0 
sequence 0 
shows 0 
significant 0 
sequence 0 
identity 0 
to 0 
a 0 
peroxisomal 0 
membrane 0 
protein 0 
of 0 
M 0 
-LRB- 0 
r 0 
-RRB- 0 
70K 0 
that 0 
is 0 
involved 0 
in 0 
peroxisome 0 
biogenesis 0 
and 0 
belongs 0 
to 0 
the 0 
ATP-binding 0 
cassette 0 
superfamily 0 
of 0 
transporters 0 
. 0 
. 0 

Cardiac 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
channel 0 
dysfunction 0 
in 0 
Brugada 1
syndrome 1
is 0 
aggravated 0 
by 0 
beta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
- 0 
subunit 0 
. 0 

BACKGROUND 0 
Mutations 0 
in 0 
the 0 
gene 0 
encoding 0 
the 0 
human 0 
cardiac 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
channel 0 
alpha-subunit 0 
-LRB- 0 
hH1 0 
-RRB- 0 
are 0 
responsible 0 
for 0 
chromosome 0 
3-linked 0 
congenital 1
long-QT 1
syndrome 1
-LRB- 0 
LQT3 1
-RRB- 0 
and 0 
idiopathic 1
ventricular 1
fibrillation 1
-LRB- 0 
IVF 1
-RRB- 0 
. 0 

An 0 
auxiliary 0 
beta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
- 0 
subunit 0 
, 0 
widely 0 
expressed 0 
in 0 
excitable 0 
tissues 0 
, 0 
shifts 0 
the 0 
voltage 0 
dependence 0 
of 0 
steady-state 0 
inactivation 0 
toward 0 
more 0 
negative 0 
potentials 0 
and 0 
restores 0 
normal 0 
gating 0 
kinetics 0 
of 0 
brain 0 
and 0 
skeletal 0 
muscle 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
channels 0 
expressed 0 
in 0 
Xenopus 0 
oocytes 0 
but 0 
has 0 
little 0 
if 0 
any 0 
functional 0 
effect 0 
on 0 
the 0 
cardiac 0 
isoform 0 
. 0 

Here 0 
, 0 
we 0 
characterize 0 
the 0 
altered 0 
effects 0 
of 0 
a 0 
human 0 
beta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
- 0 
subunit 0 
-LRB- 0 
hbeta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-RRB- 0 
on 0 
the 0 
heterologously 0 
expressed 0 
hH1 0 
mutation 0 
-LRB- 0 
T1620M 0 
-RRB- 0 
previously 0 
associated 0 
with 0 
IVF 1
. 0 

METHODS 0 
AND 0 
RESULTS 0 
When 0 
expressed 0 
alone 0 
in 0 
Xenopus 0 
oocytes 0 
, 0 
T1620M 0 
exhibited 0 
no 0 
persistent 0 
currents 0 
, 0 
in 0 
contrast 0 
to 0 
the 0 
LQT3 1
mutant 0 
channels 0 
, 0 
but 0 
the 0 
midpoint 0 
of 0 
steady-state 0 
inactivation 0 
-LRB- 0 
V 0 
-LRB- 0 
1 0 
/ 0 
2 0 
-RRB- 0 
-RRB- 0 
was 0 
significantly 0 
shifted 0 
toward 0 
more 0 
positive 0 
potentials 0 
than 0 
for 0 
wild-type 0 
hH1 0 
. 0 

Coexpression 0 
of 0 
hbeta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
did 0 
not 0 
significantly 0 
alter 0 
current 0 
decay 0 
or 0 
recovery 0 
from 0 
inactivation 0 
of 0 
wild-type 0 
hH1 0 
; 0 
however 0 
, 0 
it 0 
further 0 
shifted 0 
the 0 
V 0 
-LRB- 0 
1 0 
/ 0 
2 0 
-RRB- 0 
and 0 
accelerated 0 
the 0 
recovery 0 
from 0 
inactivation 0 
of 0 
T1620M 0 
. 0 

Oocyte 0 
macropatch 0 
analysis 0 
revealed 0 
that 0 
the 0 
activation 0 
kinetics 0 
of 0 
T1620M 0 
were 0 
normal 0 
. 0 

CONCLUSIONS 0 
It 0 
is 0 
suggested 0 
that 0 
coexpression 0 
of 0 
hbeta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
exposes 0 
a 0 
more 0 
severe 0 
functional 0 
defect 0 
that 0 
results 0 
in 0 
a 0 
greater 0 
overlap 0 
in 0 
the 0 
relationship 0 
between 0 
channel 0 
inactivation 0 
and 0 
activation 0 
-LRB- 0 
window 0 
current 0 
-RRB- 0 
in 0 
T1620M 0 
, 0 
which 0 
is 0 
proposed 0 
to 0 
be 0 
a 0 
potential 0 
pathophysiological 0 
mechanism 0 
of 0 
IVF 1
in 0 
vivo 0 
. 0 

One 0 
possible 0 
explanation 0 
for 0 
our 0 
finding 0 
is 0 
an 0 
altered 0 
alpha 0 
- 0 
/ 0 
beta 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
- 0 
subunit 0 
association 0 
in 0 
the 0 
mutant 0 
. 0 
. 0 

Autosomal 1
recessive 1
familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
with 0 
continued 0 
secretion 0 
of 0 
mutant 0 
weakly 0 
active 0 
vasopressin 0 
. 0 

Familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
is 0 
an 0 
autosomal 1
dominant 1
disorder 1
characterized 0 
by 0 
post-natal 0 
development 0 
of 0 
arginine 1
vasopressin 1
-LRB- 1
AVP 1
-RRB- 1
deficiency 1
due 0 
to 0 
mutations 0 
in 0 
the 0 
AVP 0 
gene 0 
. 0 

All 0 
published 0 
mutations 0 
affect 0 
the 0 
signal 0 
peptide 0 
or 0 
the 0 
neurophysin-II 0 
carrier 0 
protein 0 
and 0 
are 0 
presumed 0 
to 0 
interfere 0 
with 0 
processing 0 
of 0 
the 0 
preprohormone 0 
, 0 
leading 0 
to 0 
neuronal 1
damage 1
. 0 

We 0 
studied 0 
an 0 
unusual 0 
Palestinian 0 
family 0 
consisting 0 
of 0 
asymptomatic 0 
first 0 
cousin 0 
parents 0 
and 0 
three 0 
children 0 
affected 0 
with 0 
neurohypophyseal 1
diabetes 1
insipidus 1
, 0 
suggesting 0 
autosomal 0 
recessive 0 
inheritance 0 
. 0 

All 0 
three 0 
affected 0 
children 0 
were 0 
homozygous 0 
and 0 
the 0 
parents 0 
heterozygous 0 
for 0 
a 0 
single 0 
novel 0 
mutation 0 
-LRB- 0 
_AN 0 
- 0 
> 0 
T 0 
-RRB- 0 
in 0 
exon 0 
_NUM1 0 
, 0 
replacing 0 
Pro7 0 
of 0 
mature 0 
AVP 0 
with 0 
Leu 0 
-LRB- 0 
Leu-AVP 0 
-RRB- 0 
. 0 

Leu-AVP 0 
was 0 
a 0 
weak 0 
agonist 0 
with 0 
approximately 0 
30-fold 0 
reduced 0 
binding 0 
to 0 
the 0 
human 0 
V2 0 
receptor 0 
. 0 

Measured 0 
by 0 
radioimmunoassay 0 
with 0 
a 0 
synthetic 0 
Leu-AVP 0 
standard 0 
, 0 
serum 0 
Leu-AVP 0 
levels 0 
were 0 
elevated 0 
in 0 
all 0 
three 0 
children 0 
and 0 
further 0 
increased 0 
during 0 
water 0 
deprivation 0 
to 0 
as 0 
high 0 
as 0 
_NUM2 0 
times 0 
normal 0 
. 0 

The 0 
youngest 0 
child 0 
-LRB- 0 
_NUM1 0 
years 0 
old 0 
-RRB- 0 
was 0 
only 0 
mildly 0 
affected 0 
but 0 
had 0 
Leu-AVP 0 
levels 0 
similar 0 
to 0 
her 0 
severely 0 
affected 0 
8-year-old 0 
brother 0 
, 0 
suggesting 0 
that 0 
unknown 0 
mechanisms 0 
may 0 
partially 0 
compensate 0 
for 0 
a 0 
deficiency 1
of 1
active 1
AVP 1
in 0 
very 0 
young 0 
children 0 
. 0 
. 0 

Autosomal 0 
dominant 0 
aniridia 1
linked 0 
to 0 
the 0 
chromosome 0 
11p13 0 
markers 0 
catalase 0 
and 0 
D11S151 0 
in 0 
a 0 
large 0 
Dutch 0 
family 0 
. 0 

In 0 
a 0 
large 0 
pedigree 0 
with 0 
autosomal 0 
dominant 0 
aniridia 1
, 0 
we 0 
found 0 
close 0 
linkage 0 
between 0 
the 0 
aniridia 1
locus 0 
AN2 0 
and 0 
the 0 
markers 0 
catalase 0 
-LRB- 0 
_DS 0 
-RRB- 0 
-LRB- 0 
zeta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
D11S151 0 
-LRB- 0 
zeta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
flanking 0 
the 0 
AN2 0 
locus 0 
on 0 
11p13 0 
. 0 

Positive 0 
lod 0 
scores 0 
were 0 
also 0 
obtained 0 
for 0 
the 0 
11p13 0 
-- 0 
11p14 0 
markers 0 
D11S16 0 
and 0 
FSHB 0 
with 0 
the 0 
linkage 0 
group 0 
CAT 0 
/ 0 
AN2 0 
/ 0 
D11S151 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
autosomal 0 
dominant 0 
aniridia 1
in 0 
this 0 
family 0 
is 0 
due 0 
to 0 
a 0 
mutation 0 
at 0 
the 0 
AN2 0 
locus 0 
on 0 
11p13 0 
. 0 

We 0 
have 0 
excluded 0 
linkage 0 
-LRB- 0 
zeta 0 
less 0 
than 0 
-2 0 
at 0 
theta 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
between 0 
the 0 
aniridia 1
and 0 
the 0 
chromosome 0 
2p25 0 
marker 0 
D2S1 0 
-LRB- 0 
linked 0 
to 0 
ACP1 0 
-RRB- 0 
. 0 

Knobloch 1
syndrome 1
involving 0 
midline 1
scalp 1
defect 1
of 1
the 1
frontal 1
region 1
. 0 

We 0 
report 0 
on 0 
a 0 
4-year-old 0 
boy 0 
with 0 
Knobloch 1
syndrome 1
. 0 

He 0 
has 0 
vitreoretinal 1
degeneration 1
, 0 
high 1
myopia 1
, 0 
cataract 1
, 0 
telecanthus 1
, 0 
hypertelorism 1
, 0 
and 0 
a 0 
high-arched 1
palate 1
. 0 

He 0 
also 0 
has 0 
a 0 
defect 1
of 1
the 1
anterior 1
midline 1
scalp 1
with 0 
involvement 0 
of 0 
the 0 
frontal 0 
bone 0 
as 0 
documented 0 
by 0 
a 0 
computed 0 
tomography 0 
-LRB- 0 
_DS 0 
-RRB- 0 
scan 0 
. 0 

The 0 
brain 0 
was 0 
normal 0 
on 0 
_DS 0 
scan 0 
and 0 
magnetic 0 
resonance 0 
imaging 0 
. 0 

We 0 
present 0 
a 0 
review 0 
of 0 
the 0 
_NUM2 0 
published 0 
cases 0 
with 0 
this 0 
syndrome 0 
. 0 

Our 0 
patient 0 
illustrates 0 
the 0 
importance 0 
of 0 
investigating 0 
for 0 
underlying 0 
ocular 0 
and 0 
central 0 
nervous 0 
system 0 
pathology 0 
whenever 0 
midline 1
scalp 1
defects 1
are 0 
present 0 
. 0 
. 0 

Pendred 1
syndrome 1
: 0 
phenotypic 0 
variability 0 
in 0 
two 0 
families 0 
carrying 0 
the 0 
same 0 
PDS 1
missense 0 
mutation 0 
. 0 

Pendred 1
syndrome 1
comprises 0 
congenital 1
sensorineural 1
hearing 1
loss 1
, 0 
thyroid 1
goiter 1
, 0 
and 0 
positive 0 
perchlorate 0 
discharge 0 
test 0 
. 0 

Recently 0 
, 0 
this 0 
autosomal 1
recessive 1
disorder 1
was 0 
shown 0 
to 0 
be 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
PDS 1
gene 0 
, 0 
which 0 
encodes 0 
an 0 
anion 0 
transporter 0 
called 0 
pendrin 0 
. 0 

Molecular 0 
analysis 0 
of 0 
the 0 
PDS 1
gene 0 
was 0 
performed 0 
in 0 
two 0 
consanguineous 0 
large 0 
families 0 
from 0 
Southern 0 
Tunisia 0 
comprising 0 
a 0 
total 0 
of 0 
_NUM2 0 
individuals 0 
affected 0 
with 0 
profound 0 
congenital 1
deafness 1
; 0 
the 0 
same 0 
missense 0 
mutation 0 
, 0 
L445W 0 
, 0 
was 0 
identified 0 
in 0 
all 0 
affected 0 
individuals 0 
. 0 

A 0 
widened 1
vestibular 1
aqueduct 1
was 0 
found 0 
in 0 
all 0 
patients 0 
who 0 
underwent 0 
computed 0 
tomography 0 
-LRB- 0 
_DS 0 
-RRB- 0 
scan 0 
exploration 0 
of 0 
the 0 
inner 0 
ear 0 
. 0 

In 0 
contrast 0 
, 0 
goiter 1
was 0 
present 0 
in 0 
only 0 
_NUM2 0 
affected 0 
individuals 0 
, 0 
who 0 
interestingly 0 
had 0 
a 0 
normal 0 
result 0 
of 0 
the 0 
perchlorate 0 
discharge 0 
test 0 
whenever 0 
performed 0 
. 0 

The 0 
present 0 
results 0 
question 0 
the 0 
sensitivity 0 
of 0 
the 0 
perchlorate 0 
test 0 
for 0 
the 0 
diagnosis 0 
of 0 
Pendred 1
syndrome 1
and 0 
support 0 
the 0 
use 0 
of 0 
a 0 
molecular 0 
analysis 0 
of 0 
the 0 
PDS 1
gene 0 
in 0 
the 0 
assessment 0 
of 0 
individuals 0 
with 0 
severe 0 
to 0 
profound 0 
congenital 1
hearing 1
loss 1
associated 0 
with 0 
inner 1
ear 1
morphological 1
anomaly 1
even 0 
in 0 
the 0 
absence 0 
of 0 
a 0 
thyroid 1
goiter 1
. 0 
. 0 

The 0 
type 0 
of 0 
somatic 0 
mutation 0 
at 0 
APC 0 
in 0 
familial 1
adenomatous 1
polyposis 1
is 0 
determined 0 
by 0 
the 0 
site 0 
of 0 
the 0 
germline 0 
mutation 0 
: 0 
a 0 
new 0 
facet 0 
to 0 
Knudson 0 
's 0 
` 0 
two-hit 0 
' 0 
hypothesis 0 
. 0 

APC 0 
is 0 
often 0 
cited 0 
as 0 
a 0 
prime 0 
example 0 
of 0 
a 0 
tumor 1
suppressor 0 
gene 0 
. 0 

Truncating 0 
germline 0 
and 0 
somatic 0 
mutations 0 
-LRB- 0 
or 0 
, 0 
infrequently 0 
, 0 
allelic 0 
loss 0 
-RRB- 0 
occur 0 
in 0 
tumors 1
in 0 
FAP 1
-LRB- 0 
familial 1
adenomatous 1
polyposis 1
-RRB- 0 
. 0 

Most 0 
sporadic 1
colorectal 1
cancers 1
also 0 
have 0 
two 0 
APC 1
mutations 0 
. 0 

Clues 0 
from 0 
attenuated 1
polyposis 1
, 0 
missense 0 
germline 0 
variants 0 
with 0 
mild 0 
disease 0 
and 0 
the 0 
somatic 0 
mutation 0 
cluster 0 
region 0 
-LRB- 0 
codons 0 
_NUM1 0 
, 0 
250-1 0 
, 0 
_NUM3 0 
-RRB- 0 
indicate 0 
, 0 
however 0 
, 0 
that 0 
APC 1
mutations 0 
might 0 
not 0 
result 0 
in 0 
simple 0 
loss 0 
of 0 
protein 0 
function 0 
. 0 

We 0 
have 0 
found 0 
that 0 
FAP 1
patients 0 
with 0 
germline 0 
APC 1
mutations 0 
within 0 
a 0 
small 0 
region 0 
-LRB- 0 
codons 0 
_NUM1 0 
, 0 
194-1 0 
, 0 
_NUM3 0 
at 0 
most 0 
-RRB- 0 
mainly 0 
show 0 
allelic 0 
loss 0 
in 0 
their 0 
colorectal 1
adenomas 1
, 0 
in 0 
contrast 0 
to 0 
other 0 
FAP 1
patients 0 
, 0 
whose 0 
second 0 
hits 0 
tend 0 
to 0 
occur 0 
by 0 
truncating 0 
mutations 0 
in 0 
the 0 
mutation 0 
cluster 0 
region 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
different 0 
APC 1
mutations 0 
provide 0 
cells 0 
with 0 
different 0 
selective 0 
advantages 0 
, 0 
with 0 
mutations 0 
close 0 
to 0 
codon 0 
_NUM1 0 
, 0 
_NUM3 0 
providing 0 
the 0 
greatest 0 
advantage 0 
. 0 

Allelic 0 
loss 0 
is 0 
selected 0 
strongly 0 
in 0 
cells 0 
with 0 
one 0 
mutation 0 
near 0 
codon 0 
_NUM1 0 
, 0 
_NUM3 0 
. 0 

A 0 
different 0 
germline-somatic 0 
APC 1
mutation 0 
association 0 
exists 0 
in 0 
FAP 1
desmoids 1
. 0 

APC 0 
is 0 
not 0 
, 0 
therefore 0 
, 0 
a 0 
classical 0 
tumor 1
suppressor 0 
. 0 

Our 0 
findings 0 
also 0 
indicate 0 
a 0 
new 0 
mechanism 0 
for 0 
disease 0 
severity 0 
if 0 
a 0 
broader 0 
spectrum 0 
of 0 
mutations 0 
is 0 
selected 0 
in 0 
tumors 1
, 0 
the 0 
somatic 0 
mutation 0 
rate 0 
is 0 
effectively 0 
higher 0 
and 0 
more 0 
tumors 1
grow 0 
. 0 
. 0 

Purification 0 
of 0 
human 0 
very-long-chain 0 
acyl-coenzyme 0 
A 0 
dehydrogenase 0 
and 0 
characterization 0 
of 0 
its 0 
deficiency 0 
in 0 
seven 0 
patients 0 
. 0 

Mitochondrial 0 
very-long-chain 0 
acyl-coenzyme 0 
A 0 
dehydrogenase 0 
-LRB- 0 
VLCAD 0
-RRB- 0 
was 0 
purified 0 
from 0 
human 0 
liver 0 
. 0 

The 0 
molecular 0 
masses 0 
of 0 
the 0 
native 0 
enzyme 0 
and 0 
the 0 
subunit 0 
were 0 
estimated 0 
to 0 
be 0 
_NUM3 0 
and 0 
_NUM2 0 
kD 0 
, 0 
respectively 0 
. 0 

The 0 
enzyme 0 
was 0 
found 0 
to 0 
catalyze 0 
the 0 
major 0 
part 0 
of 0 
mitochondrial 0 
palmitoylcoenzyme 0 
A 0 
dehydrogenation 0 
in 0 
liver 0 
, 0 
heart 0 
, 0 
skeletal 0 
muscle 0 
, 0 
and 0 
skin 0 
fibroblasts 0 
-LRB- 0 
89-97 0 
, 0 
86-99 0 
, 0 
96-99 0 
, 0 
and 0 
78-87 0 
% 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

Skin 0 
fibroblasts 0 
from 0 
_NUM2 0 
patients 0 
suspected 0 
of 0 
having 0 
a 0 
disorder 0 
of 0 
mitochondrial 0 
beta-oxidation 0 
were 0 
analyzed 0 
for 0 
VLCAD 0
protein 0 
using 0 
immunoblotting 0 
, 0 
and 0 
_NUM1 0 
of 0 
them 0 
contained 0 
undetectable 0 
or 0 
trace 0 
levels 0 
of 0 
the 0 
enzyme 0 
. 0 

The 0 
seven 0 
deficient 0 
fibroblast 0 
lines 0 
were 0 
characterized 0 
by 0 
measuring 0 
acyl-coenzyme 0 
A 0 
dehydrogenation 0 
activities 0 
, 0 
overall 0 
palmitic 0 
acid 0 
oxidation 0 
, 0 
and 0 
VLCAD 0
protein 0 
synthesis 0 
using 0 
pulse-chase 0 
, 0 
further 0 
confirming 0 
the 0 
diagnosis 0 
of 0 
VLCAD 1
deficiency 1
. 0 

These 0 
results 0 
suggested 0 
the 0 
heterogenous 0 
nature 0 
of 0 
the 0 
mutations 0 
causing 0 
the 0 
deficiency 0 
in 0 
the 0 
seven 0 
patients 0 
. 0 

Clinically 0 
, 0 
all 0 
patients 0 
with 0 
VLCAD 1
deficiency 1
exhibited 0 
cardiac 1
disease 1
. 0 

At 0 
least 0 
four 0 
of 0 
them 0 
presented 0 
with 0 
hypertrophic 1
cardiomyopathy 1
. 0 

This 0 
frequency 0 
-LRB- 0 
> 0 
_NUM2 0 
% 0 
-RRB- 0 
was 0 
much 0 
higher 0 
than 0 
that 0 
observed 0 
in 0 
patients 0 
with 0 
other 0 
disorders 0 
of 0 
mitochondrial 0 
long-chain 0 
fatty 0 
acid 0 
oxidation 0 
that 0 
may 0 
be 0 
accompanied 0 
by 0 
cardiac 1
disease 1
in 0 
infants 0 
. 0 
. 0 

A 0 
germ 0 
line 0 
mutation 0 
within 0 
the 0 
coding 0 
sequence 0 
for 0 
the 0 
putative 0 
5-phosphoribosyl-1-pyrophosphate 0 
binding 0 
site 0 
of 0 
hypoxanthine-guanine 0 
phosphoribosyltransferase 0 
-LRB- 0 
HPRT 0 
-RRB- 0 
in 0 
a 0 
Lesch-Nyhan 1
patient 0 
: 0 
missense 0 
mutations 0 
within 0 
a 0 
functionally 0 
important 0 
region 0 
probably 0 
cause 0 
disease 0 
. 0 

Lesch-Nyhan 1
syndrome 1
caused 0 
by 0 
a 0 
complete 1
deficiency 1
of 1
hypoxanthine 1
guanine 1
phosphoribosyltransferase 1
-LRB- 0 
HPRT 0 
-RRB- 0 
is 0 
the 0 
result 0 
of 0 
a 0 
heterogeneous 0 
group 0 
of 0 
germ 0 
line 0 
mutations 0 
. 0 

Identification 0 
of 0 
each 0 
mutant 0 
gene 0 
provides 0 
valuable 0 
information 0 
as 0 
to 0 
the 0 
type 0 
of 0 
mutation 0 
that 0 
occurs 0 
spontaneously 0 
. 0 

We 0 
report 0 
here 0 
a 0 
newly 0 
identified 0 
HPRT 0 
mutation 0 
in 0 
a 0 
Japanese 0 
patient 0 
with 0 
Lesch-Nyhan 1
syndrome 1
. 0 

This 0 
gene 0 
, 0 
designated 0 
HPRT 0
Tokyo 0 
, 0 
had 0 
a 0 
single 0 
nucleotide 0 
change 0 
from 0 
G 0 
to 0 
A 0 
, 0 
as 0 
identified 0 
by 0 
sequencing 0 
cDNA 0 
amplified 0 
by 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
. 0 

Allele 0 
specific 0 
oligonucleotide 0 
hybridization 0 
analysis 0 
using 0 
amplified 0 
genomic 0 
DNA 0 
showed 0 
that 0 
the 0 
mutant 0 
gene 0 
was 0 
transmitted 0 
from 0 
the 0 
maternal 0 
germ 0 
line 0 
. 0 

This 0 
mutation 0 
would 0 
lead 0 
to 0 
an 0 
amino 0 
acid 0 
substitution 0 
of 0 
Asp 0 
for 0 
Gly 0 
at 0 
the 0 
amino 0 
acid 0 
position 0 
_NUM3 0 
located 0 
within 0 
the 0 
putative 0 
5-phosphoribosyl-1-pyrophosphate 0 
-LRB- 0 
PRPP 0 
-RRB- 0 
binding 0 
region 0 
. 0 

Missense 0 
mutations 0 
in 0 
human 0 
HPRT 1
deficient 1
patients 0 
thus 0 
far 0 
reported 0 
tend 0 
to 0 
accumulate 0 
in 0 
this 0 
functionally 0 
active 0 
region 0 
. 0 

However 0 
, 0 
a 0 
comparison 0 
of 0 
the 0 
data 0 
suggested 0 
that 0 
both 0 
missense 0 
and 0 
synonymous 0 
mutations 0 
can 0 
occur 0 
at 0 
any 0 
coding 0 
sequence 0 
of 0 
the 0 
human 0 
germ 0 
line 0 
HPRT 0 
gene 0 
, 0 
but 0 
that 0 
a 0 
limited 0 
percentage 0 
of 0 
all 0 
the 0 
missense 0 
mutations 0 
cause 0 
disease 0 
. 0 

The 0 
probability 0 
that 0 
a 0 
mutation 0 
will 0 
cause 0 
disease 0 
tends 0 
to 0 
be 0 
higher 0 
when 0 
the 0 
missense 0 
mutation 0 
is 0 
within 0 
a 0 
functionally 0 
important 0 
sequence 0 
. 0 
. 0 

In 0 
vitro 0 
and 0 
in 0 
vivo 0 
correlations 0 
for 0 
I65T 0 
and 0 
M1V 0 
mutations 0 
at 0 
the 0 
phenylalanine 0 
hydroxylase 0 
locus 0 
. 0 

Mutations 0 
at 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
locus 0 
are 0 
the 0 
major 0 
cause 0 
of 0 
hyperphenylalaninemia 1
. 0 

We 0 
have 0 
previously 0 
described 0 
four 0 
mutations 0 
-LRB- 0 
M1V 0 
, 0 
IVS12nt1 0 
, 0 
R408W 0 
, 0 
and 0 
S349P 0 
-RRB- 0 
at 0 
the 0 
PAH 0 
locus 0 
in 0 
French 0 
Canadians 0 
with 0 
ancestry 0 
in 0 
eastern 0 
Quebec 0 
. 0 

Here 0 
we 0 
report 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
identification 0 
of 0 
another 0 
mutation 0 
, 0 
on 0 
a 0 
haplotype 0 
_NUM1 0 
chromosome 0 
, 0 
which 0 
converts 0 
codon 0 
_NUM2 0 
from 0 
isoleucine 0 
-LRB- 0 
_DS 0 
-RRB- 0 
to 0 
threonine 0 
-LRB- 0 
_DS 0 
-RRB- 0 
, 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
expression 0 
analysis 0 
of 0 
the 0 
I65T 0 
mutation 0 
in 0 
COS 0 
cells 0 
demonstrating 0 
_NUM2 0 
% 0 
loss 0 
of 0 
both 0 
immunoreactive 0 
protein 0 
and 0 
enzyme 0 
activity 0 
, 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
expression 0 
analysis 0 
of 0 
the 0 
most 0 
prevalent 0 
PKU 1
allele 0 
-LRB- 0 
M1V 0 
-RRB- 0 
in 0 
eastern 0 
Quebec 0 
, 0 
showing 0 
nondetectable 0 
levels 0 
of 0 
PAH 0 
protein 0 
and 0 
activity 0 
, 0 
a 0 
finding 0 
compatible 0 
with 0 
a 0 
mutation 0 
in 0 
the 0 
translation 0 
initiation 0 
codon 0 
. 0 

Homozygosity 0 
for 0 
M1V 0 
and 0 
codominant 0 
inheritance 0 
of 0 
I65T 0 
/ 0 
R408W 0 
were 0 
both 0 
associated 0 
with 0 
classical 1
phenylketonuria 1
. 0 
. 0 

Experimental 0 
hemochromatosis 1
due 0 
to 0 
MHC 0 
class 0 
I 0 
HFE 1
deficiency 1
: 0 
immune 0 
status 0 
and 0 
iron 0 
metabolism 0 
. 0 

The 0 
puzzling 0 
linkage 0 
between 0 
genetic 0 
hemochromatosis 1
and 0 
histocompatibility 0 
loci 0 
became 0 
even 0 
more 0 
so 0 
when 0 
the 0 
gene 0 
involved 0 
, 0 
HFE 0 
, 0 
was 0 
identified 0 
. 0 

Indeed 0 
, 0 
within 0 
the 0 
well 0 
defined 0 
, 0 
mainly 0 
peptide-binding 0 
, 0 
MHC 0 
class 0 
I 0 
family 0 
of 0 
molecules 0 
, 0 
HFE 0 
seems 0 
to 0 
perform 0 
an 0 
unusual 0 
yet 0 
essential 0 
function 0 
. 0 

As 0 
yet 0 
, 0 
our 0 
understanding 0 
of 0 
HFE 0 
function 0 
in 0 
iron 0 
homeostasis 0 
is 0 
only 0 
partial 0 
; 0 
an 0 
even 0 
more 0 
open 0 
question 0 
is 0 
its 0 
possible 0 
role 0 
in 0 
the 0 
immune 0 
system 0 
. 0 

To 0 
advance 0 
on 0 
both 0 
of 0 
these 0 
avenues 0 
, 0 
we 0 
report 0 
the 0 
deletion 0 
of 0 
HFE 0 
alpha1 0 
and 0 
alpha2 0 
putative 0 
ligand 0 
binding 0 
domains 0 
in 0 
vivo 0 
. 0 

HFE-deficient 1
animals 0 
were 0 
analyzed 0 
for 0 
a 0 
comprehensive 0 
set 0 
of 0 
metabolic 0 
and 0 
immune 0 
parameters 0 
. 0 

Faithfully 0 
mimicking 0 
human 0 
hemochromatosis 1
, 0 
mice 0 
homozygous 0 
for 0 
this 0 
deletion 0 
develop 0 
iron 0 
overload 0 
, 0 
characterized 0 
by 0 
a 0 
higher 0 
plasma 0 
iron 0 
content 0 
and 0 
a 0 
raised 0 
transferrin 0 
saturation 0 
as 0 
well 0 
as 0 
an 0 
elevated 0 
hepatic 0 
iron 0 
load 0 
. 0 

The 0 
primary 0 
defect 0 
could 0 
, 0 
indeed 0 
, 0 
be 0 
traced 0 
to 0 
an 0 
augmented 0 
duodenal 0 
iron 0 
absorption 0 
. 0 

In 0 
parallel 0 
, 0 
measurement 0 
of 0 
the 0 
gut 0 
mucosal 0 
iron 0 
content 0 
as 0 
well 0 
as 0 
iron 0 
regulatory 0 
proteins 0 
allows 0 
a 0 
more 0 
informed 0 
evaluation 0 
of 0 
various 0 
hypotheses 0 
regarding 0 
the 0 
precise 0 
role 0 
of 0 
HFE 0 
in 0 
iron 0 
homeostasis 0 
. 0 

Finally 0 
, 0 
an 0 
extensive 0 
phenotyping 0 
of 0 
primary 0 
and 0 
secondary 0 
lymphoid 0 
organs 0 
including 0 
the 0 
gut 0 
provides 0 
no 0 
compelling 0 
evidence 0 
for 0 
an 0 
obvious 0 
immune-linked 0 
function 0 
for 0 
HFE 0 
. 0 
. 0 

-LSB- 0 
Genetic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
: 0 
mutant 0 
alleles 0 
of 0 
G6PD 0
in 0 
the 0 
Shekii 0 
district 0 
of 0 
Azerbaijan 0 
-RSB- 0 
Examination 0 
on 0 
G6PD 1
deficiency 1
in 0 
_NUM3 0 
patients 0 
of 0 
Shekii 0 
district 0 
hospital 0 
-LRB- 0 
Azerbaijan 0 
-RRB- 0 
revealed 0 
_NUM2 0 
hemi 0 
- 0 
, 0 
_NUM1 0 
homo 0 
- 0 
and 0 
_NUM1 0 
heterozygotic 0 
carriers 0 
of 0 
the 0 
defect 0 
. 0 

Gd 0 
- 0 
frequency 0 
, 0 
calculated 0 
from 0 
the 0 
data 0 
obtained 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
may 0 
be 0 
compared 0 
to 0 
neighbouring 0 
regions 0 
frequencies 0 
-LRB- 0 
6-30 0 
% 0 
-RRB- 0 
. 0 

Carriers 0 
of 0 
G6PD 1
deficiency 1
are 0 
residents 0 
of 0 
_NUM2 0 
villages 0 
located 0 
in 0 
Alasani-Aphtalan 0 
valley 0 
, 0 
highly 0 
endemic 0 
with 0 
malaria 1
in 0 
the 0 
past 0 
; 0 
nearly 0 
all 0 
marriages 0 
are 0 
endogamic 0 
. 0 

Physico-chemical 0 
and 0 
kinetic 0 
study 0 
of 0 
_NUM2 0 
mutant 0 
forms 0 
of 0 
G6PD 0
, 0 
according 0 
to 0 
WHO 0 
program 0 
, 0 
led 0 
to 0 
identification 0 
of 0 
_NUM1 0 
variants 0 
of 0 
the 0 
II 0 
class 0 
-LRB- 0 
Shekii 0 
, 0 
Bideiz 0 
, 0 
Shirin-Bulakh 0 
, 0 
Okhut 0 
I 0 
and 0 
Zakataly 0 
-RRB- 0 
and 0 
_NUM1 0 
variants 0 
of 0 
the 0 
III 0 
class 0 
-LRB- 0 
Okhut 0 
II 0 
and 0 
Martinique-like 0 
-RRB- 0 
. 0 

Resemblance 0 
of 0 
the 0 
majority 0 
of 0 
variants 0 
in 0 
electrophoretic 0 
mobility 0 
and 0 
the 0 
level 0 
of 0 
erythrocyte 0 
enzyme 0 
activity 0 
permit 0 
to 0 
suggest 0 
the 0 
existence 0 
of 0 
a 0 
common 0 
parental 0 
mutant 0 
G6PD 0
allele 0 
distributed 0 
in 0 
this 0 
area 0 
. 0 

-LSB- 0 
Gd 0 
- 0 
allele 0 
distribution 0 
patterns 0 
in 0 
Azerbaijan 0 
. 0 

III 0 
. 0 

The 0 
identification 0 
of 0 
mutant 0 
forms 0 
of 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-RSB- 0 
In 0 
_NUM2 0 
families 0 
with 0 
G6PD 1
deficiency 1
living 0 
in 0 
_NUM1 0 
settlements 0 
of 0 
Shekii 0 
district 0 
of 0 
Azerbaijan 0 
_NUM2 0 
G6PD 0 
variants 0 
of 0 
II 0 
and 0 
III 0 
classes 0 
differing 0 
by 0 
kinetic 0 
properties 0 
were 0 
identified 0 
according 0 
WHO 0 
program 0 
. 0 

_NUM1 0 
of 0 
them 0 
are 0 
characterized 0 
with 0 
the 0 
same 0 
electrophoretic 0 
mobility 0 
. 0 

Comparison 0 
of 0 
G6PD 0 
spectra 0 
in 0 
two 0 
subpopulations 0 
and 0 
in 0 
a 0 
mixed 0 
group 0 
permits 0 
to 0 
make 0 
a 0 
conclusion 0 
about 0 
existence 0 
of 0 
common 0 
and 0 
rare 0 
G6PD 0 
alleles 0 
in 0 
examined 0 
population 0 
. 0 

They 0 
distribute 0 
by 0 
gene 0 
drift 0 
supported 0 
by 0 
natural 0 
selection 0 
. 0 

Among 0 
_NUM1 0 
samples 0 
of 0 
G6PD 0 
with 0 
normal 0 
and 0 
increased 0 
activity 0 
two 0 
new 0 
variants 0 
of 0 
IV 0 
class 0 
-- 0 
Nukha 0 
and 0 
Bash-Kungut 0 
-- 0 
were 0 
found 0 
. 0 
. 0 

Determination 0 
of 0 
carrier 0 
status 0 
for 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
by 0 
flow 0 
cytometric 0 
analysis 0 
of 0 
Wiskott-Aldrich 1
syndrome 1
protein 0 
expression 0 
in 0 
peripheral 0 
blood 0 
mononuclear 0 
cells 0 
. 0 

The 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
is 0 
caused 0 
by 0 
defects 0 
in 0 
the 0 
WAS 1
protein 0 
-LRB- 0 
WASP 0 
-RRB- 0 
gene 0 
on 0 
the 0 
X 0 
chromosome 0 
. 0 

Previous 0 
study 0 
disclosed 0 
that 0 
flow 0 
cytometric 0 
analysis 0 
of 0 
intracellular 0 
WASP 0 
expression 0 
-LRB- 0 
FCM-WASP 0 
analysis 0 
-RRB- 0 
in 0 
lymphocytes 0 
was 0 
useful 0 
for 0 
the 0 
diagnosis 0 
of 0 
WAS 1
patients 0 
. 0 

Lymphocytes 0 
from 0 
all 0 
WAS 1
patients 0 
showed 0 
WASPdim 0 
instead 0 
of 0 
WASPbright 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
FCM-WASP 0 
analysis 0 
in 0 
monocytes 0 
could 0 
be 0 
a 0 
useful 0 
tool 0 
for 0 
the 0 
WAS 1
carrier 0 
diagnosis 0 
. 0 

Monocytes 0 
from 0 
all 0 
nine 0 
WAS 1
carriers 0 
showed 0 
varied 0 
population 0 
of 0 
WASPdim 0 
together 0 
with 0 
WASPbright 0 
. 0 

None 0 
of 0 
control 0 
individuals 0 
possessed 0 
the 0 
WASPdim 0 
population 0 
. 0 

In 0 
contrast 0 
, 0 
lymphocytes 0 
from 0 
all 0 
the 0 
carriers 0 
except 0 
two 0 
lacked 0 
the 0 
WASPdim 0 
population 0 
. 0 

The 0 
difference 0 
of 0 
the 0 
WASPdim 0 
population 0 
in 0 
monocytes 0 
and 0 
lymphocytes 0 
observed 0 
in 0 
WAS 1
carriers 0 
suggests 0 
that 0 
WASP 0 
plays 0 
a 0 
more 0 
critical 0 
role 0 
in 0 
the 0 
development 0 
of 0 
lymphocytes 0 
than 0 
in 0 
that 0 
of 0 
monocytes 0 
. 0 

The 0 
present 0 
studies 0 
suggest 0 
that 0 
a 0 
skewed 0 
X-chromosomal 0 
inactivation 0 
pattern 0 
observed 0 
in 0 
WAS 1
carrier 0 
peripheral 0 
blood 0 
cells 0 
is 0 
not 0 
fixed 0 
at 0 
the 0 
hemopoietic 0 
stem 0 
cell 0 
level 0 
but 0 
progresses 0 
after 0 
the 0 
lineage 0 
commitment 0 
. 0 
. 0 

Linkage 0 
of 0 
DNA 0 
markers 0 
at 0 
Xq28 0 
to 0 
adrenoleukodystrophy 1
and 0 
adrenomyeloneuropathy 1
present 0 
within 0 
the 0 
same 0 
family 0 
. 0 

We 0 
present 0 
a 0 
large 0 
kindred 0 
that 0 
contained 0 
patients 0 
with 0 
either 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
or 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
. 0 

The 0 
pedigree 0 
clearly 0 
supported 0 
the 0 
X-linked 0 
mode 0 
of 0 
inheritance 0 
of 0 
the 0 
nonneonatal 0 
form 0 
of 0 
ALD 1
/ 0 
AMN 1
. 0 

Analysis 0 
with 0 
DNA 0 
markers 0 
at 0 
Xq28 0 
suggested 0 
segregation 0 
of 0 
both 0 
ALD 1
and 0 
AMN 1
with 0 
an 0 
identical 0 
haplotype 0 
. 0 

This 0 
indicated 0 
that 0 
nonneonatal 0 
ALD 1
and 0 
AMN 1
are 0 
caused 0 
by 0 
a 0 
mutation 0 
in 0 
the 0 
same 0 
gene 0 
at 0 
Xq28 0 
. 0 

It 0 
showed 0 
, 0 
furthermore 0 
, 0 
that 0 
phenotypic 0 
differences 0 
between 0 
ALD 1
and 0 
AMN 1
are 0 
not 0 
necessarily 0 
the 0 
consequence 0 
of 0 
allelic 0 
heterogeneity 0 
due 0 
to 0 
different 0 
mutations 0 
within 0 
the 0 
same 0 
gene 0 
. 0 

The 0 
maximal 0 
lod 0 
score 0 
for 0 
linkage 0 
of 0 
the 0 
ALD 1
/ 0 
AMN 1
gene 0 
and 0 
the 0 
multiallelic 0 
anonymous 0 
DNA 0 
marker 0 
at 0 
DXS52 0 
was 0 
_NUM1 0 
. 0 

_NUM1 0 
at 0 
a 0 
recombination 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

This 0 
made 0 
a 0 
prenatal 0 
or 0 
presymptomatic 0 
diagnosis 0 
and 0 
heterozygote 0 
detection 0 
by 0 
DNA 0 
analysis 0 
with 0 
this 0 
marker 0 
reliable 0 
. 0 

Further 0 
investigation 0 
of 0 
the 0 
HEXA 0 
gene 0 
intron 0 
_NUM1 0 
donor 0 
splice 0 
site 0 
mutation 0 
frequently 0 
found 0 
in 0 
non-Jewish 0 
Tay-Sachs 1
disease 1
patients 0 
from 0 
the 0 
British 0 
Isles 0 
. 0 

In 0 
a 0 
previous 0 
study 0 
we 0 
found 0 
that 0 
a 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
causing 0 
mutation 0 
in 0 
the 0 
intron 0 
_NUM1 0 
donor 0 
splice 0 
site 0 
of 0 
the 0 
HEXA 0 
gene 0 
occurs 0 
at 0 
high 0 
frequency 0 
in 0 
non-Jewish 0 
patients 0 
and 0 
carriers 0 
from 0 
the 0 
British 0 
Isles 0 
. 0 

It 0 
was 0 
found 0 
more 0 
frequently 0 
in 0 
subjects 0 
of 0 
Irish 0 
, 0 
Scottish 0 
, 0 
and 0 
Welsh 0 
origin 0 
compared 0 
with 0 
English 0 
origin 0 
-LRB- 0 
_NUM2 0 
% 0 
and 0 
_NUM2 0 
% 0 
respectively 0 
-RRB- 0 
. 0 

We 0 
have 0 
now 0 
tested 0 
, 0 
in 0 
a 0 
blind 0 
study 0 
, 0 
_NUM2 0 
American 0 
TSD 1
carriers 0 
and 0 
_NUM2 0 
non-carriers 0 
who 0 
have 0 
British 0 
ancestry 0 
for 0 
the 0 
intron 0 
_NUM1 0 
splice 0 
site 0 
mutation 0 
. 0 

Six 0 
of 0 
the 0 
carriers 0 
and 0 
none 0 
of 0 
the 0 
controls 0 
were 0 
positive 0 
for 0 
the 0 
mutation 0 
. 0 

All 0 
six 0 
had 0 
Irish 0 
ancestry 0 
, 0 
compared 0 
with 0 
nine 0 
of 0 
the 0 
_NUM2 0 
other 0 
-LRB- 0 
intron 0 
_NUM1 0 
mutation 0 
negative 0 
-RRB- 0 
TSD 1
carriers 0 
-LRB- 0 
p 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

These 0 
results 0 
confirm 0 
the 0 
previously 0 
found 0 
high 0 
frequency 0 
of 0 
the 0 
intron 0 
_NUM1 0 
mutation 0 
in 0 
non-Jewish 0 
TSD 1
families 0 
of 0 
British 0 
Isles 0 
, 0 
particularly 0 
Irish 0 
, 0 
origin 0 
, 0 
and 0 
reinforce 0 
the 0 
need 0 
to 0 
screen 0 
such 0 
families 0 
for 0 
this 0 
mutation 0 
. 0 

The 0 
murine 0 
homologues 0 
of 0 
the 0 
Huntington 1
disease 1
gene 0 
-LRB- 0 
Hdh 0 
-RRB- 0 
and 0 
the 0 
alpha-adducin 0 
gene 0 
-LRB- 0 
Add1 0 
-RRB- 0 
map 0 
to 0 
mouse 0 
chromosome 0 
_NUM1 0 
within 0 
a 0 
region 0 
of 0 
conserved 0 
synteny 0 
with 0 
human 0 
chromosome 0 
4p16 0 
.3 0 
. 0 

Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
is 0 
a 0 
severe 0 
autosomal 1
dominant 1
neurodegenerative 1
disorder 1
associated 0 
with 0 
a 0 
novel 0 
gene 0 
-LRB- 0 
IT15 0 
-RRB- 0 
. 0 

Recently 0 
, 0 
we 0 
reported 0 
the 0 
cloning 0 
of 0 
Hdh 0 
, 0 
the 0 
murine 0 
homologue 0 
of 0 
IT15 0 
. 0 

Here 0 
, 0 
using 0 
an 0 
interspecific 0 
backcross 0 
, 0 
we 0 
have 0 
mapped 0 
both 0 
Hdh 0 
and 0 
the 0 
mouse 0 
homologue 0 
of 0 
human 0 
alpha-adducin 0 
-LRB- 0 
Add1 0 
-RRB- 0 
, 0 
a 0 
membrane-associated 0 
cytoskeletal 0 
protein 0 
gene 0 
. 0 

Both 0 
of 0 
these 0 
genes 0 
map 0 
in 0 
the 0 
same 0 
position 0 
on 0 
mouse 0 
chromosome 0 
_NUM1 0 
in 0 
a 0 
region 0 
associated 0 
with 0 
ancestral 0 
chromosomal 0 
rearrangements 0 
and 0 
show 0 
no 0 
recombination 0 
with 0 
D5H4S43 0 
, 0 
D5H4S115 0 
, 0 
and 0 
D5H4S62 0 
, 0 
the 0 
murine 0 
homologues 0 
of 0 
D4S43 0 
, 0 
D4S115 0 
, 0 
and 0 
D4S62 0 
, 0 
respectively 0 
. 0 

Further 0 
mapping 0 
studies 0 
of 0 
humans 0 
, 0 
mice 0 
, 0 
and 0 
other 0 
mammalian 0 
species 0 
should 0 
reveal 0 
the 0 
nature 0 
of 0 
the 0 
rearrangements 0 
affecting 0 
this 0 
chromosomal 0 
segment 0 
during 0 
mammalian 0 
evolution 0 
. 0 
. 0 

Linkage 0 
analysis 0 
of 0 
the 0 
apolipoprotein 0 
C2 0 
gene 0 
and 0 
myotonic 1
dystrophy 1
on 0 
human 0 
chromosome 0 
_NUM2 0 
reveals 0 
linkage 0 
disequilibrium 0 
in 0 
a 0 
French-Canadian 0 
population 0 
. 0 

The 0 
gene 0 
for 0 
human 0 
apolipoprotein 0 
C2 0 
-LRB- 0 
APOC2 0 
-RRB- 0 
, 0 
situated 0 
on 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
, 0 
is 0 
closely 0 
linked 0 
to 0 
the 0 
gene 0 
for 0 
the 0 
most 0 
common 0 
form 0 
of 0 
adult 0 
muscular 1
dystrophy 1
, 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

Six 0 
APOC2 0 
RFLPs 0 
-LRB- 0 
TaqI 0 
, 0 
BglI 0 
, 0 
BanI 0 
, 0 
BamHI 0 
, 0 
NcoI 0 
, 0 
and 0 
AvaII 0 
-RRB- 0 
have 0 
been 0 
identified 0 
to 0 
date 0 
. 0 

We 0 
have 0 
conducted 0 
a 0 
comprehensive 0 
DM 1
linkage 0 
study 0 
utilizing 0 
all 0 
six 0 
RFLPs 0 
and 0 
involving 0 
_NUM2 0 
families 0 
and 0 
_NUM3 0 
individuals 0 
. 0 

The 0 
most 0 
informative 0 
RFLPs 0 
are 0 
, 0 
in 0 
descending 0 
order 0 
, 0 
NcoI 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
BglI 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
AvaII 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
BanI 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
TaqI 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
and 0 
BamHI 0 
-LRB- 0 
lod 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

A 0 
substantial 0 
increase 0 
in 0 
the 0 
lod 0 
scores 0 
over 0 
those 0 
seen 0 
with 0 
the 0 
individual 0 
RFLPs 0 
was 0 
obtained 0 
when 0 
the 0 
linkage 0 
of 0 
the 0 
entire 0 
APOC2 0 
haplotype 0 
-LRB- 0 
composed 0 
of 0 
the 0 
six 0 
RFLPs 0 
-RRB- 0 
was 0 
studied 0 
-LRB- 0 
lod 0 
= 0 
_NUM2 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

We 0 
have 0 
observed 0 
significant 0 
inter-APOC2 0 
RFLP 0 
linkage 0 
disequilibrium 0 
. 0 

Consequently 0 
, 0 
the 0 
three 0 
most 0 
informative 0 
RFLPs 0 
have 0 
been 0 
found 0 
to 0 
be 0 
BanI 0 
, 0 
TaqI 0 
, 0 
and 0 
either 0 
BglI 0 
, 0 
AvaII 0 
, 0 
or 0 
NcoI 0 
polymorphisms 0 
. 0 

We 0 
also 0 
demonstrate 0 
linkage 0 
disequilibrium 0 
between 0 
DM 1
and 0 
APOC2 0 
in 0 
our 0 
French-Canadian 0 
population 0 
-LRB- 0 
standardized 0 
disequilibrium 0 
constant 0 
phi 0 
= 0 
. 0 

_NUM2 0 
, 0 
chi 0 
_NUM1 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
df 0 
= 0 
_NUM1 0 
, 0 
P 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

This 0 
represents 0 
the 0 
first 0 
evidence 0 
of 0 
linkage 0 
disequilibrium 0 
between 0 
APOC2 0 
and 0 
the 0 
DM 0 
locus 0 
. 0 

A 0 
retrospective 0 
anonymous 0 
pilot 0 
study 0 
in 0 
screening 0 
newborns 0 
for 0 
HFE 0 
mutations 0 
in 0 
Scandinavian 0 
populations 0 
. 0 

We 0 
have 0 
retrospectively 0 
analyzed 0 
_NUM3 0 
random 0 
anonymized 0 
dried 0 
blood 0 
spot 0 
-LRB- 0 
DBS 0 
-RRB- 0 
samples 0 
from 0 
neonatal 0 
screening 0 
programs 0 
in 0 
Scandinavia 0 
for 0 
mutations 0 
in 0 
HFE 0 
, 0 
the 0 
candidate 0 
gene 0 
for 0 
hemochromatosis 1
. 0 

We 0 
have 0 
found 0 
C282Y 0 
allele 0 
frequencies 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
+ 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
-LRB- 0 
-1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
in 0 
Greenland 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
+ 0 
/ 0 
-1 0 
. 0 

_NUM1 0 
% 0 
in 0 
Iceland 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
+ 0 
/ 0 
-2 0 
. 0 

_NUM1 0 
% 0 
in 0 
the 0 
Faeroe 0 
Islands 0 
, 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
+ 0 
/ 0 
-2 0 
. 0 

_NUM1 0 
% 0 
in 0 
Denmark 0 
. 0 

The 0 
high 0 
prevalence 0 
of 0 
HFE 0 
mutations 0 
in 0 
Denmark 0 
suggests 0 
that 0 
population 0 
screening 0 
for 0 
the 0 
C282Y 0 
mutation 0 
could 0 
be 0 
highly 0 
advantageous 0 
in 0 
terms 0 
of 0 
preventive 0 
health 0 
care 0 
. 0 

Long-term 0 
follow-up 0 
evaluation 0 
of 0 
C282Y 0 
homozygotes 0 
and 0 
H63D 0 
/ 0 
C282Y 0 
compound 0 
heterozygotes 0 
will 0 
give 0 
an 0 
indication 0 
of 0 
the 0 
penetrance 0 
of 0 
the 0 
mutations 0 
. 0 

Hereditary 0 
TP53 0 
codon 0 
_NUM3 0 
and 0 
somatic 0 
P16INK4A 0 
codon 0 
_NUM2 0 
mutations 0 
in 0 
a 0 
Li-Fraumeni 1
syndrome 1
family 0 
. 0 

Li-Fraumeni 1
syndrome 1
is 0 
an 0 
autosomal 1
dominant 1
disorder 1
that 0 
is 0 
characterized 0 
by 0 
various 0 
types 0 
of 0 
cancer 1
in 0 
childhood 0 
and 0 
adult 0 
cases 0 
. 0 

Although 0 
hereditary 0 
TP53 0 
mutation 0 
is 0 
very 0 
rare 0 
in 0 
different 0 
human 0 
cancers 1
, 0 
it 0 
has 0 
been 0 
frequently 0 
reported 0 
in 0 
Li-Fraumeni 1
syndrome 1
. 0 

On 0 
the 0 
other 0 
hand 0 
, 0 
hereditary 0 
mutations 0 
of 0 
TP57KIP2 0 
, 0 
P15INK4B 0 
, 0 
and 0 
P16INK4A 0 
, 0 
which 0 
affect 0 
the 0 
cell 0 
cycle 0 
similar 0 
to 0 
TP53 0 
, 0 
were 0 
observed 0 
in 0 
some 0 
types 0 
of 0 
cancer 1
. 0 

In 0 
a 0 
Turkish 0 
family 0 
with 0 
the 0 
diagnosis 0 
of 0 
Li-Fraumeni 1
syndrome 1
, 0 
we 0 
analyzed 0 
the 0 
mutation 0 
pattern 0 
of 0 
TP53 0 
, 0 
P57KIP2 0 
, 0 
P15INK4B 0 
, 0 
and 0 
P16INK4A 0 
in 0 
the 0 
peripheral 0 
blood 0 
, 0 
and 0 
loss 0 
of 0 
heterozygosity 0 
-LRB- 0 
homo 0 
/ 0 
hemizygous 0 
deletion 0 
-RRB- 0 
pattern 0 
of 0 
TP53 0 
and 0 
P15INK4B 0 
/ 0 
P16INK4A 0 
in 0 
two 0 
tumor 1
tissues 0 
. 0 

The 0 
propositus 0 
had 0 
a 0 
seminoma 1
, 0 
his 0 
daughter 0 
a 0 
medulloblastoma 1
, 0 
and 0 
one 0 
of 0 
his 0 
healthy 0 
cousins 0 
, 0 
a 0 
TP53 0 
codon 0 
_NUM3 0 
missense 0 
point 0 
mutation 0 
-LRB- 0 
_DS 0 
-- 0 
> 0 
_DS 0 
; 0 
Lys 0 
-- 0 
> 0 
Ile 0 
-RRB- 0 
in 0 
the 0 
peripheral 0 
blood 0 
cells 0 
. 0 

Tumor 0 
tissue 0 
obtained 0 
from 0 
the 0 
propositus 0 
with 0 
the 0 
seminoma 1
revealed 0 
loss 0 
of 0 
heterozygosity 0 
in 0 
the 0 
TP53 0 
gene 0 
. 0 

In 0 
the 0 
analyses 0 
of 0 
tumor 1
tissues 0 
from 0 
the 0 
propositus 0 
and 0 
his 0 
daughter 0 
, 0 
a 0 
P16INK4A 0 
codon 0 
_NUM2 0 
missense 0 
point 0 
mutation 0 
-LRB- 0 
_DS 0 
-- 0 
> 0 
_DS 0 
; 0 
Ala 0 
-- 0 
> 0 
Glu 0 
-RRB- 0 
was 0 
observed 0 
with 0 
the 0 
hereditary 0 
TP53 0 
mutation 0 
. 0 

P16INK4A 0 
codon 0 
_NUM2 0 
mutation 0 
observed 0 
in 0 
our 0 
family 0 
is 0 
a 0 
novel 0 
mutation 0 
in 0 
Li-Fraumeni 1
syndrome 1
. 0 

No 0 
other 0 
gene 0 
alteration 0 
in 0 
TP53 0 
, 0 
P57KIP2 0 
, 0 
P15INK4B 0 
, 0 
and 0 
P16INK4A 0 
was 0 
observed 0 
. 0 

Existence 0 
of 0 
the 0 
P16INK4A 0 
mutation 0 
and 0 
the 0 
hereditary 0 
TP53 0 
mutation 0 
with 0 
or 0 
without 0 
loss 0 
of 0 
heterozygosity 0 
in 0 
the 0 
TP53 0 
gene 0 
-LRB- 0 
seminoma 1
/ 0 
medulloblastoma 1
-RRB- 0 
may 0 
be 0 
evidence 0 
for 0 
a 0 
common 0 
mechanism 0 
involved 0 
in 0 
tumorogenesis 1
. 0 

The 0 
gene 0 
alterations 0 
in 0 
TP53 0 
and 0 
P16INK4A 0 
genes 0 
may 0 
be 0 
used 0 
as 0 
tumor 1
markers 0 
in 0 
our 0 
family 0 
. 0 
. 0 

An 0 
amino-acid 0 
substitution 0 
involved 0 
in 0 
phenylketonuria 1
is 0 
in 0 
linkage 0 
disequilibrium 0 
with 0 
DNA 0 
haplotype 0 
_NUM1 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
human 1
genetic 1
disorder 1
caused 0 
by 0 
a 0 
deficiency 1
of 1
hepatic 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
, 0 
phenylalanine 0 
4-monooxygenase 0 
, 0 
EC 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

PKU 1
is 0 
a 0 
common 0 
inborn 1
error 1
of 1
amino-acid 1
metabolism 1
in 0 
caucasian 0 
populations 0 
and 0 
approximately 0 
_NUM1 0 
in 0 
_NUM2 0 
individuals 0 
are 0 
carriers 0 
of 0 
a 0 
PKU 1
allele 0 
. 0 

To 0 
define 0 
the 0 
molecular 0 
basis 0 
of 0 
PKU 1
, 0 
we 0 
characterized 0 
twelve 0 
restriction 0 
fragment-length 0 
polymorphism 0 
-LRB- 0 
RFLP 0 
-RRB- 0 
haplotypes 0 
of 0 
the 0 
PAH 0 
locus 0 
in 0 
the 0 
northern 0 
European 0 
population 0 
and 0 
observed 0 
that 0 
_NUM2 0 
% 0 
of 0 
the 0 
PKU 1
alleles 0 
in 0 
this 0 
population 0 
are 0 
confined 0 
to 0 
four 0 
common 0 
RFLP 0 
haplotypes 0 
. 0 

We 0 
have 0 
recently 0 
reported 0 
a 0 
splicing 0 
mutation 0 
in 0 
the 0 
PAH 0 
gene 0 
that 0 
is 0 
associated 0 
with 0 
RFLP 0 
haplotype 0 
_NUM1 0 
which 0 
is 0 
present 0 
at 0 
about 0 
_NUM2 0 
% 0 
of 0 
mutant 0 
alleles 0 
. 0 

We 0 
now 0 
report 0 
the 0 
molecular 1
lesion 1
associated 0 
with 0 
the 0 
RFLP 0 
haplotype 0 
_NUM1 0 
mutant 0 
allele 0 
. 0 

This 0 
defect 0 
is 0 
caused 0 
by 0 
a 0 
C-to-T 0 
transition 0 
in 0 
exon 0 
_NUM2 0 
resulting 0 
in 0 
an 0 
amino-acid 0 
substitution 0 
-LRB- 0 
Arg 0 
to 0 
Trp 0 
-RRB- 0 
at 0 
residue 0 
_NUM3 0 
of 0 
PAH 0 
. 0 

Direct 0 
hybridization 0 
analysis 0 
of 0 
the 0 
point 0 
mutation 0 
using 0 
a 0 
specific 0 
oligonucleotide 0 
probe 0 
demonstrated 0 
that 0 
this 0 
mutation 0 
is 0 
also 0 
in 0 
linkage 0 
disequilibrium 0 
with 0 
RFLP 0 
haplotype 0 
_NUM1 0 
alleles 0 
that 0 
make 0 
up 0 
about 0 
_NUM2 0 
% 0 
of 0 
mutant 0 
PAH 0 
genes 0 
The 0 
effects 0 
of 0 
dystrophin 0 
gene 0 
mutations 0 
on 0 
the 0 
ERG 0 
in 0 
mice 0 
and 0 
humans 0 
. 0 

PURPOSE 0 
. 0 

The 0 
authors 0 
earlier 0 
findings 0 
of 0 
a 0 
negative 0 
electroretinogram 0 
-LRB- 0 
ERG 0 
-RRB- 0 
in 0 
a 0 
boy 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
led 0 
them 0 
to 0 
investigate 0 
dystrophin 0 
gene 0 
deletions 0 
and 0 
ERGs 0 
in 0 
five 0 
boys 0 
with 0 
DMD 1
. 0 

The 0 
authors 0 
wanted 0 
to 0 
determined 0 
whether 0 
there 0 
were 0 
similar 0 
ERG 0 
findings 0 
in 0 
an 0 
animal 0 
model 0 
for 0 
DMD 1
, 0 
the 0 
mdx 0 
mouse 0 
. 0 

METHODS 0 
. 0 

Ganzfeld 0 
ERGs 0 
were 0 
recorded 0 
in 0 
five 0 
boys 0 
with 0 
DMD 1
after 0 
a 0 
complete 0 
ophthalmic 0 
examination 0 
. 0 

The 0 
dystrophin 0 
gene 0 
was 0 
analyzed 0 
by 0 
Southern 0 
blot 0 
hybridization 0 
. 0 

ERGs 0 
were 0 
recorded 0 
in 0 
anesthetized 0 
mdx 0 
and 0 
control 0 
mice 0 
with 0 
a 0 
modified 0 
Grass 0 
photostimulator 0 
-LRB- 0 
Grass 0 
Instrument 0 
Company 0 
, 0 
Quincy 0 
, 0 
MA 0 
-RRB- 0 
. 0 

RESULTS 0 
. 0 

Ophthalmic 0 
examinations 0 
in 0 
all 0 
five 0 
boys 0 
had 0 
normal 0 
findings 0 
, 0 
yet 0 
an 0 
abnormal 0 
negative 0 
ERG 0 
was 0 
recorded 0 
for 0 
each 0 
subject 0 
. 0 

The 0 
subjects 0 
gene 0 
deletions 0 
were 0 
variable 0 
, 0 
ranging 0 
from 0 
large 0 
deletions 0 
to 0 
no 0 
detectable 0 
deletions 0 
. 0 

The 0 
ERGs 0 
of 0 
the 0 
mdx 0 
mice 0 
were 0 
normal 0 
and 0 
did 0 
not 0 
differ 0 
significantly 0 
from 0 
those 0 
of 0 
the 0 
control 0 
mice 0 
. 0 

CONCLUSIONS 0 
. 0 

The 0 
authors 0 
believe 0 
the 0 
unique 0 
ERG 0 
recorded 0 
for 0 
the 0 
human 0 
subjects 0 
is 0 
a 0 
manifestation 0 
of 0 
DMD 1
associated 0 
with 0 
defects 0 
at 0 
the 0 
dystrophin 0 
gene 0 
locus 0 
and 0 
represents 0 
a 0 
new 0 
clinical 0 
entity 0 
. 0 

The 0 
ERG 0 
of 0 
the 0 
mdx 0 
mouse 0 
may 0 
be 0 
spared 0 
for 0 
several 0 
reasons 0 
, 0 
including 0 
milder 0 
effects 0 
of 0 
the 0 
mouse 0 
gene 0 
defect 0 
, 0 
differences 0 
in 0 
muscle 0 
and 0 
retinal 0 
gene 0 
product 0 
, 0 
or 0 
species 0 
differences 0 
in 0 
the 0 
biochemical 0 
role 0 
of 0 
dystrophin 0 
. 0 

The 0 
ERG 0 
shows 0 
promise 0 
of 0 
becoming 0 
a 0 
noninvasive 0 
diagnostic 0 
tool 0 
for 0 
DMD 1
and 0 
its 0 
milder 0 
allelic 0 
forms 0 
. 0 
. 0 

Eight 0 
novel 0 
inactivating 0 
germ 0 
line 0 
mutations 0 
at 0 
the 0 
APC 1
gene 0 
identified 0 
by 0 
denaturing 0 
gradient 0 
gel 0 
electrophoresis 0 
. 0 

Familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
is 0 
a 0 
dominantly 0 
inherited 0 
condition 0 
predisposing 0 
to 0 
colorectal 1
cancer 1
. 0 

The 0 
recent 0 
isolation 0 
of 0 
the 0 
responsible 0 
gene 0 
-LRB- 0 
adenomatous 1
polyposis 1
coli 1
or 0 
APC 1
-RRB- 0 
has 0 
facilitated 0 
the 0 
search 0 
for 0 
germ 0 
line 0 
mutations 0 
in 0 
affected 0 
individuals 0 
. 0 

Previous 0 
authors 0 
have 0 
used 0 
the 0 
RNase 0 
protection 0 
assay 0 
and 0 
the 0 
single-strand 0 
conformation 0 
polymorphisms 0 
procedure 0 
to 0 
screen 0 
for 0 
mutations 0 
. 0 

In 0 
this 0 
study 0 
we 0 
used 0 
denaturing 0 
gradient 0 
gel 0 
electrophoresis 0 
-LRB- 0 
DGGE 0 
-RRB- 0 
. 0 

DGGE 0 
analysis 0 
of 0 
_NUM2 0 
APC 1
exons 0 
-LRB- 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM2 0 
, 0 
_NUM2 0 
, 0 
_NUM2 0 
, 0 
_NUM2 0 
, 0 
and 0 
part 0 
of 0 
_NUM2 0 
-RRB- 0 
in 0 
_NUM2 0 
unrelated 0 
Dutch 0 
FAP 1
patients 0 
has 0 
led 0 
to 0 
the 0 
identification 0 
of 0 
eight 0 
novel 0 
germ 0 
line 0 
mutations 0 
resulting 0 
in 0 
stop 0 
codons 0 
or 0 
frameshifts 0 
. 0 

The 0 
results 0 
reported 0 
here 0 
indicate 0 
that 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
familial 1
adenomatous 1
polyposis 1
is 0 
caused 0 
by 0 
an 0 
extremely 0 
heterogeneous 0 
spectrum 0 
of 0 
point 0 
mutations 0 
; 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
all 0 
the 0 
mutations 0 
found 0 
in 0 
this 0 
study 0 
are 0 
chain 0 
terminating 0 
; 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
DGGE 0 
represents 0 
a 0 
rapid 0 
and 0 
sensitive 0 
technique 0 
for 0 
the 0 
detection 0 
of 0 
mutations 0 
in 0 
the 0 
unusually 0 
large 0 
APC 1
gene 0 
. 0 

An 0 
extension 0 
of 0 
the 0 
DGGE 0 
analysis 0 
to 0 
the 0 
entire 0 
coding 0 
region 0 
in 0 
a 0 
sufficient 0 
number 0 
of 0 
clinically 0 
well-characterized 0 
, 0 
unrelated 0 
patients 0 
will 0 
facilitate 0 
the 0 
establishment 0 
of 0 
genotype-phenotype 0 
correlations 0 
. 0 

On 0 
the 0 
other 0 
hand 0 
, 0 
the 0 
occurrence 0 
of 0 
an 0 
extremely 0 
heterogeneous 0 
spectrum 0 
of 0 
mutations 0 
spread 0 
throughout 0 
the 0 
entire 0 
length 0 
of 0 
the 0 
large 0 
APC 1
gene 0 
among 0 
the 0 
FAP 1
patients 0 
indicates 0 
that 0 
this 0 
approach 0 
may 0 
not 0 
be 0 
useful 0 
as 0 
a 0 
rapid 0 
presymptomatic 0 
diagnostic 0 
procedure 0 
in 0 
a 0 
routine 0 
laboratory 0 
. 0 

Nevertheless 0 
, 0 
the 0 
above 0 
DGGE 0 
approach 0 
has 0 
incidentally 0 
led 0 
to 0 
the 0 
identification 0 
of 0 
a 0 
common 0 
polymorphism 0 
in 0 
exon 0 
_NUM2 0 
. 0 

Such 0 
intragenic 0 
polymorphisms 0 
offer 0 
a 0 
practical 0 
approach 0 
to 0 
a 0 
more 0 
rapid 0 
procedure 0 
for 0 
presymptomatic 0 
diagnosis 0 
of 0 
FAP 1
by 0 
linkage 0 
analysis 0 
in 0 
informative 0 
families 0 
. 0 
. 0 

Novel 0 
mutations 0 
in 0 
XLRS1 0 
causing 0 
retinoschisis 1
, 0 
including 0 
first 0 
evidence 0 
of 0 
putative 0 
leader 0 
sequence 0 
change 0 
. 0 

Juvenile 1
retinoschisis 1
is 0 
an 0 
X-linked 1
recessive 1
disease 1
caused 0 
by 0 
mutations 0 
in 0 
the 0 
XLRS1 0 
gene 0 
. 0 

We 0 
screened 0 
_NUM2 0 
new 0 
unrelated 0 
patients 0 
and 0 
families 0 
for 0 
XLRS1 0 
mutations 0 
in 0 
addition 0 
to 0 
previously 0 
reported 0 
mutations 0 
for 0 
_NUM2 0 
of 0 
our 0 
families 0 
-LRB- 0 
Retinoschisis 1
Consortium 0 
, 0 
Hum 0 
Mol 0 
Genet 0 
_NUM4 0 
; 0 
_NUM1 0 
1185-1192 0 
-RRB- 0 
. 0 

Twenty-three 0 
different 0 
mutations 0 
including 0 
_NUM2 0 
novel 0 
ones 0 
were 0 
identified 0 
in 0 
_NUM2 0 
patients 0 
. 0 

Mutations 0 
identified 0 
in 0 
this 0 
study 0 
include 0 
_NUM2 0 
missense 0 
mutations 0 
, 0 
two 0 
nonsense 0 
mutations 0 
, 0 
one 0 
intragenic 0 
deletion 0 
, 0 
four 0 
microdeletions 0 
, 0 
one 0 
insertion 0 
, 0 
and 0 
one 0 
intronic 0 
sequence 0 
substitution 0 
that 0 
is 0 
likely 0 
to 0 
result 0 
in 0 
a 0 
splice 0 
site 0 
defect 0 
. 0 

Two 0 
novel 0 
mutations 0 
, 0 
c. 0 
38T 0 
-- 0 
> 0 
C 0 
-LRB- 0 
L13P 0 
-RRB- 0 
and 0 
c. 0 
667T 0 
-- 0 
> 0 
C 0 
-LRB- 0 
C223R 0 
-RRB- 0 
, 0 
respectively 0 
, 0 
present 0 
the 0 
first 0 
genetic 0 
evidence 0 
for 0 
the 0 
functional 0 
significance 0 
of 0 
the 0 
putative 0 
leader 0 
peptide 0 
sequence 0 
and 0 
for 0 
the 0 
functional 0 
significance 0 
at 0 
the 0 
carboxyl 0 
terminal 0 
of 0 
the 0 
XLRS1 0 
protein 0 
beyond 0 
the 0 
discoidin 0 
domain 0 
. 0 

Mutations 0 
in 0 
_NUM2 0 
of 0 
the 0 
families 0 
were 0 
localized 0 
to 0 
exons 0 
4-6 0 
, 0 
emphasizing 0 
the 0 
critical 0 
functional 0 
significance 0 
of 0 
the 0 
discoidin 0 
domain 0 
of 0 
the 0 
XLRS1 0 
protein 0 
Clinical 0 
use 0 
of 0 
DNA 0 
markers 0 
linked 0 
to 0 
the 0 
gene 0 
for 0 
Duchenne 1
muscular 1
dystrophy 1
. 0 

Seventy 0 
families 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
known 0 
to 0 
the 0 
Institute 0 
of 0 
Child 0 
Health 0 
fall 0 
into 0 
three 0 
categories 0 
with 0 
respect 0 
to 0 
potential 0 
linkage 0 
analysis 0 
with 0 
the 0 
X 0 
chromosome 0 
DNA 0 
markers 0 
RC8 0 
and 0 
L1 0 
. 0 

_NUM2 0 
that 0 
bridge 0 
the 0 
DMD 1
gene 0 
. 0 

Families 0 
in 0 
which 0 
there 0 
is 0 
at 0 
least 0 
one 0 
obligatory 0 
female 0 
heterozygote 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

Here 0 
prediction 0 
and 0 
exclusion 0 
of 0 
DMD 1
gene 0 
transmission 0 
may 0 
be 0 
possible 0 
, 0 
the 0 
accuracy 0 
being 0 
dependent 0 
on 0 
the 0 
closeness 0 
of 0 
the 0 
linkage 0 
of 0 
the 0 
DNA 0 
marker 0 
-LRB- 0 
s 0 
-RRB- 0 
to 0 
the 0 
DMD 1
gene 0 
; 0 
an 0 
illustrative 0 
case 0 
is 0 
reported 0 
. 0 

Families 0 
in 0 
which 0 
there 0 
is 0 
a 0 
single 0 
affected 0 
boy 0 
, 0 
who 0 
also 0 
has 0 
one 0 
or 0 
more 0 
healthy 0 
brothers 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

Given 0 
an 0 
informative 0 
restriction 0 
fragment 0 
length 0 
polymorphism 0 
-LRB- 0 
RFLP 0 
-RRB- 0 
, 0 
the 0 
probability 0 
that 0 
the 0 
boy 0 
represents 0 
a 0 
new 0 
mutation 0 
can 0 
be 0 
reassessed 0 
; 0 
it 0 
is 0 
also 0 
possible 0 
to 0 
exclude 0 
the 0 
DMD 1
gene 0 
in 0 
a 0 
sister 0 
. 0 

Families 0 
with 0 
a 0 
single 0 
affected 0 
boy 0 
with 0 
no 0 
brother 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

Here 0 
exclusion 0 
of 0 
the 0 
DMD 1
gene 0 
in 0 
a 0 
sister 0 
may 0 
be 0 
possible 0 
. 0 

Only 0 
in 0 
one 0 
family 0 
was 0 
there 0 
no 0 
possibility 0 
of 0 
useful 0 
linkage 0 
analysis 0 
. 0 

The 0 
linkage 0 
analysis 0 
required 0 
is 0 
described 0 
, 0 
and 0 
the 0 
need 0 
to 0 
check 0 
DMD 1
families 0 
for 0 
informative 0 
RFLPs 0 
is 0 
stressed 0 
. 0 

Molecular 0 
characterization 0 
of 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
patients 0 
of 0 
Chinese 0 
descent 0 
and 0 
identification 0 
of 0 
new 0 
base 0 
substitutions 0 
in 0 
the 0 
human 0 
G6PD 0 
gene 0 
. 0 

The 0 
underlying 0 
DNA 0 
changes 0 
associated 0 
with 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
-deficient 1
Asians 0 
have 0 
not 0 
been 0 
extensively 0 
investigated 0 
. 0 

To 0 
fill 0 
this 0 
gap 0 
, 0 
we 0 
sequenced 0 
the 0 
G6PD 0 
gene 0 
of 0 
_NUM2 0 
G6PD-deficient 1
Chinese 0 
whose 0 
G6PD 0 
was 0 
well 0 
characterized 0 
biochemically 0 
. 0 

DNA 0 
samples 0 
were 0 
obtained 0 
from 0 
peripheral 0 
blood 0 
of 0 
these 0 
individuals 0 
for 0 
sequencing 0 
using 0 
a 0 
direct 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
sequencing 0 
procedure 0 
. 0 

From 0 
these 0 
_NUM2 0 
samples 0 
, 0 
we 0 
have 0 
identified 0 
five 0 
different 0 
types 0 
of 0 
nucleotide 0 
substitutions 0 
in 0 
the 0 
G6PD 0 
gene 0 
at 0 
cDNA 0 
_NUM4 0 
from 0 
G 0 
to 0 
A 0 
-LRB- 0 
Arg 0 
to 0 
His 0 
-RRB- 0 
; 0 
at 0 
cDNA 0 
_NUM4 0 
from 0 
G 0 
to 0 
T 0 
-LRB- 0 
Arg 0 
to 0 
Leu 0 
-RRB- 0 
; 0 
at 0 
cDNA 0 
_NUM4 0 
from 0 
C 0 
to 0 
T 0 
-LRB- 0 
Leu 0 
to 0 
Phe 0 
-RRB- 0 
; 0 
at 0 
cDNA 0 
_NUM3 0 
from 0 
G 0 
to 0 
T 0 
-LRB- 0 
Gly 0 
to 0 
Val 0 
-RRB- 0 
; 0 
at 0 
cDNA 0 
_NUM2 0 
from 0 
A 0 
to 0 
G 0 
-LRB- 0 
His 0 
to 0 
Arg 0 
-RRB- 0 
. 0 

These 0 
five 0 
nucleotide 0 
substitutions 0 
account 0 
for 0 
over 0 
_NUM2 0 
% 0 
of 0 
our 0 
_NUM2 0 
G6PD-deficient 1
samples 0 
and 0 
these 0 
substitutions 0 
have 0 
not 0 
been 0 
reported 0 
in 0 
non-Asians 0 
. 0 

The 0 
substitutions 0 
found 0 
at 0 
cDNA 0 
_NUM3 0 
and 0 
cDNA 0 
_NUM4 0 
are 0 
new 0 
findings 0 
. 0 

The 0 
substitutions 0 
at 0 
cDNA 0 
_NUM4 0 
and 0 
_NUM4 0 
account 0 
for 0 
over 0 
_NUM2 0 
% 0 
of 0 
the 0 
_NUM2 0 
samples 0 
examined 0 
indicating 0 
a 0 
high 0 
prevalence 0 
of 0 
these 0 
two 0 
alleles 0 
among 0 
G6PD-deficient 1
Chinese 0 
. 0 

Our 0 
findings 0 
add 0 
support 0 
to 0 
the 0 
notion 0 
that 0 
diverse 0 
point 0 
mutations 0 
may 0 
account 0 
largely 0 
for 0 
much 0 
of 0 
the 0 
phenotypic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
. 0 
. 0 

Norrie 1
disease 1
gene 0 
: 0 
characterization 0 
of 0 
deletions 0 
and 0 
possible 0 
function 0 
. 0 

Positional 0 
cloning 0 
experiments 0 
have 0 
resulted 0 
recently 0 
in 0 
the 0 
isolation 0 
of 0 
a 0 
candidate 0 
gene 0 
for 0 
Norrie 1
disease 1
-LRB- 0 
pseudoglioma 1
; 0 
NDP 1
-RRB- 0 
, 0 
a 0 
severe 0 
X-linked 1
neurodevelopmental 1
disorder 1
. 0 

Here 0 
we 0 
report 0 
the 0 
isolation 0 
and 0 
analysis 0 
of 0 
human 0 
genomic 0 
DNA 0 
clones 0 
encompassing 0 
the 0 
NDP 1
gene 0 
. 0 

The 0 
gene 0 
spans 0 
_NUM2 0 
kb 0 
and 0 
consists 0 
of 0 
_NUM1 0 
exons 0 
, 0 
the 0 
first 0 
of 0 
which 0 
is 0 
entirely 0 
contained 0 
within 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
. 0 

Detailed 0 
analysis 0 
of 0 
genomic 0 
deletions 0 
in 0 
Norrie 1
patients 0 
shows 0 
that 0 
they 0 
are 0 
heterogeneous 0 
, 0 
both 0 
in 0 
size 0 
and 0 
in 0 
position 0 
. 0 

By 0 
PCR 0 
analysis 0 
, 0 
we 0 
found 0 
that 0 
expression 0 
of 0 
the 0 
NDP 1
gene 0 
was 0 
not 0 
confined 0 
to 0 
the 0 
eye 0 
or 0 
to 0 
the 0 
brain 0 
. 0 

An 0 
extensive 0 
DNA 0 
and 0 
protein 0 
sequence 0 
comparison 0 
between 0 
the 0 
human 0 
NDP 1
gene 0 
and 0 
related 0 
genes 0 
from 0 
the 0 
database 0 
revealed 0 
homology 0 
with 0 
cysteine-rich 0 
protein-binding 0 
domains 0 
of 0 
immediate 0 
-- 0 
early 0 
genes 0 
implicated 0 
in 0 
the 0 
regulation 0 
of 0 
cell 0 
proliferation 0 
. 0 

We 0 
propose 0 
that 0 
NDP 0 
is 0 
a 0 
molecule 0 
related 0 
in 0 
function 0 
to 0 
these 0 
genes 0 
and 0 
may 0 
be 0 
involved 0 
in 0 
a 0 
pathway 0 
that 0 
regulates 0 
neural 0 
cell 0 
differentiation 0 
and 0 
proliferation 0 
. 0 
. 0 

Prenatal 0 
diagnosis 0 
of 0 
Wolman 1
disease 1
. 0 

Two 0 
pregnancies 0 
at 0 
risk 0 
for 0 
Wolman 1
disease 1
were 0 
monitored 0 
by 0 
assay 0 
and 0 
electrophoresis 0 
of 0 
acid 0 
lipase 0 
in 0 
cultured 0 
amniotic-fluid 0 
cells 0 
. 0 

Cells 0 
from 0 
patient 0 
_NUM1 0 
had 0 
_NUM1 0 
% 0 
of 0 
control 0 
levels 0 
of 0 
acid 0 
lipase 0 
, 0 
using 0 
14C-triolein 0 
as 0 
substrate 0 
; 0 
however 0 
, 0 
when 0 
artificial 0 
substrates 0 
-LRB- 0 
esters 0 
of 0 
4-methylumbelliferone 0 
and 0 
p-nitrophenol 0 
-RRB- 0 
were 0 
used 0 
to 0 
measure 0 
acid 0 
lipase 0 
, 0 
these 0 
cells 0 
had 0 
_NUM2 0 
% 0 
of 0 
control 0 
levels 0 
. 0 

Electrophoresis 0 
of 0 
cell 0 
extracts 0 
revealed 0 
the 0 
absence 0 
of 0 
the 0 
A 0 
form 0 
of 0 
acid 0 
lipase 0 
, 0 
consistent 0 
with 0 
the 0 
diagnosis 0 
of 0 
Wolman 1
disease 1
. 0 

Analysis 0 
of 0 
fetal 0 
tissues 0 
following 0 
prostaglandin 0 
termination 0 
of 0 
this 0 
pregnancy 0 
confirmed 0 
the 0 
diagnosis 0 
. 0 

Assay 0 
of 0 
fetal-skin 0 
fibroblasts 0 
with 0 
14C-triolein 0 
, 0 
as 0 
well 0 
as 0 
with 0 
artificial 0 
substrates 0 
, 0 
showed 0 
marked 0 
deficiency 0 
of 0 
acid 0 
lipase 0 
activity 0 
. 0 

Electrophoresis 0 
of 0 
fetal-tissue 0 
extracts 0 
also 0 
demonstrated 0 
the 0 
absence 0 
of 0 
the 0 
A 0 
form 0 
of 0 
acid 0 
lipase 0 
. 0 

Amniotic-fluid 0 
cells 0 
from 0 
patient 0 
_NUM1 0 
showed 0 
normal 0 
levels 0 
of 0 
acid 0 
lipase 0 
with 0 
all 0 
substrates 0 
tested 0 
; 0 
the 0 
electrophoretic 0 
pattern 0 
of 0 
acid 0 
lipase 0 
was 0 
normal 0 
. 0 

The 0 
results 0 
suggest 0 
that 0 
the 0 
prenatal 0 
diagnosis 0 
of 0 
Wolman 1
disease 1
be 0 
made 0 
using 0 
the 0 
radioassay 0 
of 0 
acid 0 
lipase 0 
and 0 
/ 0 
or 0 
electrophoresis 0 
. 0 
. 0 

Somatic 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
in 0 
sporadic 1
ovarian 1
tumours 1
. 0 

The 0 
BRCA1 0 
gene 0 
on 0 
chromosome 0 
17q21 0 
is 0 
responsible 0 
for 0 
an 0 
autosomal 1
dominant 1
syndrome 1
of 0 
increased 0 
susceptibility 0 
to 0 
breast 1
and 1
ovarian 1
cancer 1
but 0 
no 0 
somatic 0 
mutations 0 
in 0 
tumours 1
have 0 
yet 0 
been 0 
described 0 
. 0 

To 0 
study 0 
the 0 
potential 0 
role 0 
of 0 
BRCA1 0 
in 0 
sporadic 0 
carcinogenesis 0 
, 0 
we 0 
analysed 0 
the 0 
genomic 0 
DNA 0 
of 0 
tumour 1
and 0 
normal 0 
fractions 0 
of 0 
_NUM2 0 
ovarian 1
cancers 1
for 0 
mutations 0 
in 0 
BRCA1 0 
using 0 
the 0 
single-strand 0 
conformation 0 
polymorphism 0 
technique 0 
. 0 

We 0 
now 0 
describe 0 
somatic 0 
mutations 0 
in 0 
the 0 
DNA 0 
of 0 
four 0 
tumours 1
which 0 
also 0 
had 0 
loss 0 
of 0 
heterozygosity 0 
-LRB- 0 
LOH 0 
-RRB- 0 
at 0 
a 0 
BRCA1 0 
intragenic 0 
marker 0 
. 0 

Our 0 
data 0 
support 0 
a 0 
tumour 1
suppressor 0 
mechanism 0 
for 0 
BRCA1 0 
; 0 
somatic 0 
mutations 0 
and 0 
LOH 0 
may 0 
result 0 
in 0 
inactivation 0 
of 0 
BRCA1 0 
in 0 
at 0 
least 0 
a 0 
small 0 
number 0 
of 0 
ovarian 1
cancers 1
. 0 
. 0 

Skewed 0 
X 0 
inactivation 0 
in 0 
a 0 
female 0 
MZ 0 
twin 0 
results 0 
in 0 
Duchenne 1
muscular 1
dystrophy 1
. 0 

One 0 
of 0 
female 0 
MZ 0 
twins 0 
presented 0 
with 0 
muscular 1
dystrophy 1
. 0 

Physical 0 
examination 0 
, 0 
creatine 0 
phosphokinase 0 
levels 0 
, 0 
and 0 
muscle 0 
biopsy 0 
were 0 
consistent 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

However 0 
, 0 
because 0 
of 0 
her 0 
sex 0 
she 0 
was 0 
diagnosed 0 
as 0 
having 0 
limb-girdle 1
muscular 1
dystrophy 1
. 0 

With 0 
cDNA 0 
probes 0 
to 0 
the 0 
DMD 1
gene 0 
, 0 
a 0 
gene 0 
deletion 0 
was 0 
detected 0 
in 0 
the 0 
twins 0 
and 0 
their 0 
mother 0 
. 0 

The 0 
de 0 
novo 0 
mutation 0 
which 0 
arose 0 
in 0 
the 0 
mother 0 
was 0 
shown 0 
by 0 
novel 0 
junction 0 
fragments 0 
generated 0 
by 0 
HindIII 0 
, 0 
PstI 0 
, 0 
or 0 
TaqI 0 
when 0 
probed 0 
with 0 
cDNA8 0 
. 0 

Additional 0 
evidence 0 
of 0 
a 0 
large 0 
gene 0 
deletion 0 
was 0 
given 0 
by 0 
novel 0 
SfiI 0 
junction 0 
fragments 0 
detected 0 
by 0 
probes 0 
_AN 0 
, 0 
J-Bir 0 
, 0 
and 0 
J-66 0 
on 0 
pulsed-field 0 
gel 0 
electrophoresis 0 
-LRB- 0 
PFGE 0 
-RRB- 0 
. 0 

Immunoblot 0 
analysis 0 
of 0 
muscle 0 
from 0 
the 0 
affected 0 
twin 0 
showed 0 
dystrophin 0 
of 0 
normal 0 
size 0 
but 0 
of 0 
reduced 0 
amount 0 
. 0 

Immunofluorescent 0 
visualization 0 
of 0 
dystrophin 0 
revealed 0 
foci 0 
of 0 
dystrophin-positive 0 
fibers 0 
adjacent 0 
to 0 
foci 0 
of 0 
dystrophin-negative 0 
fibers 0 
. 0 

These 0 
data 0 
indicate 0 
that 0 
the 0 
affected 0 
twin 0 
is 0 
a 0 
manifesting 0 
carrier 0 
of 0 
an 0 
abnormal 0 
DMD 1
gene 0 
, 0 
her 0 
myopathy 1
being 0 
a 0 
direct 0 
result 0 
of 0 
underexpression 0 
of 0 
dystrophin 0 
. 0 

Cytogenetic 0 
analysis 0 
revealed 0 
normal 0 
karyotypes 0 
, 0 
eliminating 0 
the 0 
possibility 0 
of 0 
a 0 
translocation 0 
affecting 0 
DMD 1
gene 0 
function 0 
. 0 

Both 0 
linkage 0 
analysis 0 
and 0 
DNA 0 
fingerprint 0 
analysis 0 
revealed 0 
that 0 
each 0 
twin 0 
has 0 
two 0 
different 0 
X 0 
chromosomes 0 
, 0 
eliminating 0 
the 0 
possibility 0 
of 0 
uniparental 1
disomy 1
as 0 
a 0 
mechanism 0 
for 0 
DMD 1
expression 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
methylation 0 
differences 0 
of 0 
the 0 
paternal 0 
and 0 
maternal 0 
X 0 
chromosomes 0 
in 0 
these 0 
MZ 0 
twins 0 
, 0 
we 0 
propose 0 
uneven 0 
lyonization 0 
-LRB- 0 
X 0 
chromosome 0 
inactivation 0 
-RRB- 0 
as 0 
the 0 
underlying 0 
mechanism 0 
for 0 
disease 0 
expression 0 
in 0 
the 0 
affected 0 
female 0 
. 0 
. 0 

Coincident 0 
Kaposi 1
sarcoma 1
and 0 
T-cell 1
lymphoma 1
in 0 
a 0 
patient 0 
with 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
. 0 

A 0 
_NUM2 0 
year 0 
old 0 
male 0 
with 0 
a 0 
history 0 
of 0 
eczema 1
, 0 
recurrent 0 
mild 0 
infections 0 
, 0 
and 0 
thrombocytopenia 1
consistent 0 
with 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
presented 0 
with 0 
a 0 
mediastinal 0 
mass 0 
, 0 
generalized 0 
lymphadenopathy 1
, 0 
splenomegaly 1
, 0 
and 0 
severe 0 
thrombocytopenia 1
. 0 

Studies 0 
of 0 
immune 0 
function 0 
including 0 
immunoglobulin 0 
levels 0 
and 0 
T-cell 0 
subsets 0 
were 0 
normal 0 
. 0 

Furthermore 0 
, 0 
his 0 
T 0 
lymphocytes 0 
proliferated 0 
normally 0 
in 0 
response 0 
to 0 
phytohemagglutinin 0 
, 0 
concanavalin 0 
A 0 
, 0 
and 0 
the 0 
combination 0 
of 0 
neuraminidase 0 
/ 0 
galactose 0 
oxidase 0 
. 0 

However 0 
, 0 
their 0 
proliferative 0 
responses 0 
to 0 
anti-CD43 0 
antibody 0 
and 0 
periodate 0 
were 0 
diminished 0 
, 0 
consistent 0 
with 0 
the 0 
clinical 0 
diagnosis 0 
of 0 
WAS 1
. 0 

An 0 
initial 0 
inguinal 0 
lymph 0 
node 0 
biopsy 0 
surprisingly 0 
revealed 0 
Kaposi 1
sarcoma 1
. 0 

However 0 
, 0 
following 0 
splenectomy 0 
to 0 
increase 0 
the 0 
platelet 0 
count 0 
, 0 
biopsy 0 
of 0 
the 0 
mediastinal 0 
mass 0 
revealed 0 
T-cell 1
large 1
cell 1
lymphoma 1
. 0 

Studies 0 
of 0 
biopsied 0 
tissue 0 
for 0 
the 0 
presence 0 
of 0 
Epstein-Barr 1
virus 1
and 0 
cytomegalovirus 1
were 0 
negative 0 
, 0 
as 0 
were 0 
studies 0 
of 0 
blood 0 
, 0 
including 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
, 0 
for 0 
the 0 
presence 0 
of 0 
the 0 
human 1
immunodeficiency 1
virus 1
-LRB- 0 
HIV 1
-RRB- 0 
. 0 

This 0 
is 0 
the 0 
first 0 
report 0 
of 0 
Kaposi 1
sarcoma 1
arising 0 
in 0 
a 0 
patient 0 
with 0 
a 0 
congenital 1
immunodeficiency 1
syndrome 1
. 0 

Although 0 
Kaposi 1
sarcoma 1
can 0 
arise 0 
in 0 
the 0 
face 0 
of 0 
the 0 
severe 0 
immunosuppression 0 
that 0 
follows 0 
allograft 0 
transplantation 0 
and 0 
in 0 
patients 0 
infected 0 
with 0 
HIV 1
, 0 
we 0 
postulate 0 
that 0 
longevity 0 
in 0 
the 0 
face 0 
of 0 
mild 0 
immunosuppression 0 
was 0 
the 0 
major 0 
factor 0 
in 0 
the 0 
development 0 
of 0 
Kaposi 1
sarcoma 1
in 0 
this 0 
patient 0 
. 0 
. 0 

Treatment 0 
of 0 
cerebrotendinous 1
xanthomatosis 1
: 0 
effects 0 
of 0 
chenodeoxycholic 0 
acid 0 
, 0 
pravastatin 0 
, 0 
and 0 
combined 0 
use 0 
. 0 

Treatments 0 
by 0 
oral 0 
administration 0 
of 0 
chenodeoxycholic 0 
acid 0 
-LRB- 0 
CDCA 0 
-RRB- 0 
alone 0 
, 0 
3-hydroxy-3-methylglutaryl 0 
-LRB- 0 
HMG 0 
-RRB- 0 
CoA 0 
reductase 0 
inhibitor 0 
-LRB- 0 
pravastatin 0 
-RRB- 0 
alone 0 
, 0 
and 0 
combination 0 
of 0 
the 0 
two 0 
drugs 0 
were 0 
attempted 0 
for 0 
_NUM1 0 
patients 0 
with 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
. 0 

CDCA 0 
treatment 0 
at 0 
a 0 
dose 0 
of 0 
_NUM3 0 
mg 0 
/ 0 
day 0 
reduced 0 
serum 0 
cholestanol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
reduction 0 
-RRB- 0 
, 0 
lathosterol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
campesterol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
sitosterol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
. 0 

However 0 
, 0 
the 0 
sera 0 
of 0 
the 0 
patients 0 
changed 0 
to 0 
be 0 
'' 0 
atherogenic 0 
'' 0 
; 0 
total 0 
cholesterol 0 
, 0 
triglyceride 0 
and 0 
low-density 0 
lipoprotein 0 
-LRB- 0 
LDL 0 
-RRB- 0 
- 0 
cholesterol 0 
were 0 
increased 0 
, 0 
while 0 
high-density 0 
lipoprotein 0 
-LRB- 0 
HDL 0 
-RRB- 0 
- 0 
cholesterol 0 
was 0 
decreased 0 
. 0 

Contrarily 0 
, 0 
pravastatin 0 
at 0 
a 0 
dose 0 
of 0 
_NUM2 0 
mg 0 
/ 0 
day 0 
improved 0 
the 0 
sera 0 
of 0 
the 0 
patients 0 
to 0 
be 0 
markedly 0 
'' 0 
anti-atherogenic 0 
'' 0 
, 0 
but 0 
the 0 
reductions 0 
of 0 
cholestanol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
lathosterol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
campesterol 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
sitosterol 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
were 0 
inadequate 0 
. 0 

Combined 0 
treatment 0 
with 0 
CDCA 0 
and 0 
pravastatin 0 
showed 0 
good 0 
overlapping 0 
of 0 
the 0 
effects 0 
of 0 
each 0 
drug 0 
alone 0 
. 0 

The 0 
sera 0 
of 0 
the 0 
patients 0 
were 0 
apparently 0 
more 0 
'' 0 
anti-atherogenic 0 
'' 0 
than 0 
those 0 
after 0 
CDCA 0 
treatment 0 
. 0 

Serum 0 
cholestanol 0 
concentration 0 
was 0 
still 0 
_NUM1 0 
. 0 

_NUM1 0 
times 0 
higher 0 
than 0 
in 0 
controls 0 
, 0 
but 0 
the 0 
serum 0 
lathosterol 0 
level 0 
was 0 
within 0 
the 0 
normal 0 
range 0 
, 0 
indicating 0 
that 0 
the 0 
enhancement 0 
of 0 
overall 0 
cholesterol 0 
synthesis 0 
in 0 
the 0 
patients 0 
was 0 
sufficiently 0 
suppressed 0 
. 0 

Plant 0 
sterol 0 
levels 0 
were 0 
also 0 
within 0 
the 0 
normal 0 
range 0 
. 0 

The 0 
combination 0 
of 0 
CDCA 0 
and 0 
pravastatin 0 
was 0 
a 0 
good 0 
treatment 0 
for 0 
CTX 1
, 0 
based 0 
on 0 
the 0 
improvement 0 
of 0 
serum 0 
lipoprotein 0 
metabolism 0 
, 0 
the 0 
suppression 0 
of 0 
cholesterol 0 
synthesis 0 
, 0 
and 0 
reductions 0 
of 0 
cholestanol 0 
and 0 
plant 0 
sterol 0 
levels 0 
. 0 

In 0 
all 0 
of 0 
_NUM1 0 
patients 0 
, 0 
the 0 
progression 0 
of 0 
disease 0 
was 0 
arrested 0 
, 0 
but 0 
dramatic 0 
effects 0 
on 0 
clinical 0 
manifestations 0 
, 0 
xanthoma 1
, 0 
and 0 
electrophysiological 0 
findings 0 
could 0 
not 0 
be 0 
found 0 
after 0 
the 0 
treatment 0 
of 0 
these 0 
drugs 0 
Combined 1
genetic 1
deficiency 1
of 1
C6 1
and 1
C7 1
in 0 
man 0 
. 0 

By 0 
routine 0 
screening 0 
of 0 
sera 0 
, 0 
a 0 
subject 0 
was 0 
discovered 0 
who 0 
showed 0 
a 0 
sub-total 1
deficiency 1
of 1
C6 1
and 1
C7 1
. 0 

No 0 
clinical 0 
disease 0 
was 0 
associated 0 
with 0 
this 0 
deficiency 0 
which 0 
was 0 
transmitted 0 
through 0 
the 0 
subjects 0 
family 0 
as 0 
a 0 
single 0 
genetic 0 
characteristic 0 
, 0 
the 0 
C6 1
deficiency 1
being 0 
associated 0 
with 0 
a 0 
silent 0 
allele 0 
at 0 
the 0 
structural 0 
locus 0 
. 0 

The 0 
propositus 0 
was 0 
found 0 
to 0 
have 0 
low 0 
quantities 0 
of 0 
an 0 
abnormal 0 
C6 0 
which 0 
was 0 
both 0 
antigenically 0 
deficient 0 
and 0 
smaller 0 
in 0 
size 0 
than 0 
normal 0 
C6 0 
-LRB- 0 
_NUM3 0 
, 0 
_NUM3 0 
daltons 0 
compared 0 
with 0 
_NUM3 0 
, 0 
_NUM3 0 
daltons 0 
-RRB- 0 
and 0 
small 0 
quantities 0 
of 0 
apparently 0 
normal 0 
C7 0 
. 0 

It 0 
is 0 
concluded 0 
that 0 
the 0 
most 0 
likely 0 
explanation 0 
for 0 
this 0 
defect 0 
is 0 
that 0 
the 0 
subject 0 
has 0 
a 0 
structural 0 
mutation 0 
in 0 
his 0 
C6 0 
gene 0 
which 0 
produces 0 
hyopsynthesis 0 
not 0 
only 0 
of 0 
C6 0 
but 0 
also 0 
of 0 
the 0 
closely 0 
linked 0 
gene 0 
for 0 
C7 0 
. 0 

These 0 
findings 0 
suggest 0 
the 0 
possibility 0 
that 0 
C6 0 
and 0 
C7 0 
may 0 
function 0 
as 0 
a 0 
single 0 
genetic 0 
unit 0 
and 0 
that 0 
the 0 
primary 0 
transcript 0 
copied 0 
from 0 
the 0 
genome 0 
includes 0 
information 0 
for 0 
both 0 
proteins 0 
. 0 
. 0 

Partial 0 
deletion 0 
8q 0 
without 0 
Langer-Giedion 1
syndrome 1
: 0 
a 0 
recognisable 0 
syndrome 0 
. 0 

We 0 
report 0 
two 0 
de 0 
novo 0 
cases 0 
of 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
pter 0 
-- 0 
_AN 0 
. 0 

_NUM1 0 
-RRB- 0 
with 0 
breakpoints 0 
involving 0 
the 0 
distal 0 
part 0 
of 0 
band 0 
8q24 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

The 0 
clinical 0 
features 0 
were 0 
similar 0 
and 0 
there 0 
were 0 
no 0 
obvious 0 
stigmata 0 
of 0 
Langer-Giedion 1
syndrome 1
-LRB- 0 
LGS 1
-RRB- 0 
. 0 

There 0 
are 0 
three 0 
other 0 
cases 0 
reported 0 
with 0 
a 0 
deletion 0 
of 0 
chromosome 0 
_NUM1 0 
at 0 
approximately 0 
the 0 
same 0 
breakpoint 0 
, 0 
one 0 
without 0 
LGS 1
and 0 
some 0 
similarities 0 
to 0 
our 0 
cases 0 
, 0 
the 0 
other 0 
two 0 
with 0 
LGS 1
. 0 

Our 0 
findings 0 
would 0 
support 0 
the 0 
observation 0 
that 0 
the 0 
critical 0 
segment 0 
for 0 
the 0 
assignment 0 
of 0 
LGS 1
is 0 
proximal 0 
to 0 
or 0 
involves 0 
the 0 
proximal 0 
part 0 
of 0 
8q24 0 
. 0 

_NUM1 0 
, 0 
but 0 
a 0 
review 0 
of 0 
published 0 
reports 0 
suggests 0 
that 0 
the 0 
aetiology 0 
of 0 
LGS 1
may 0 
be 0 
a 0 
more 0 
complex 0 
issue 0 
Iron-dependent 0 
self-assembly 0 
of 0 
recombinant 0 
yeast 0 
frataxin 0 
: 0 
implications 0 
for 0 
Friedreich 1
ataxia 1
. 0 

Frataxin 1
deficiency 1
is 0 
the 0 
primary 0 
cause 0 
of 0 
Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
, 0 
an 0 
autosomal 1
recessive 1
cardiodegenerative 1
and 1
neurodegenerative 1
disease 1
. 0 

Frataxin 0 
is 0 
a 0 
nuclear-encoded 0 
mitochondrial 0
protein 0 
that 0 
is 0 
widely 0 
conserved 0 
among 0 
eukaryotes 0 
. 0 

Genetic 0 
inactivation 0 
of 0 
the 0 
yeast 0 
frataxin 0 
homologue 0 
-LRB- 0 
Yfh1p 0 
-RRB- 0 
results 0 
in 0 
mitochondrial 1
iron 1
accumulation 1
and 0 
hypersensitivity 1
to 1
oxidative 1
stress 1
. 0 

Increased 0 
iron 0 
deposition 0 
and 0 
evidence 0 
of 0 
oxidative 0 
damage 0 
have 0 
also 0 
been 0 
observed 0 
in 0 
cardiac 0 
tissue 0 
and 0 
cultured 0 
fibroblasts 0 
from 0 
patients 0 
with 0 
FRDA 1
. 0 

These 0 
findings 0 
indicate 0 
that 0 
frataxin 0 
is 0 
essential 0 
for 0 
mitochondrial 0 
iron 0 
homeostasis 0 
and 0 
protection 0 
from 0 
iron-induced 0 
formation 0 
of 0 
free 0 
radicals 0 
. 0 

The 0 
functional 0 
mechanism 0 
of 0 
frataxin 0 
, 0 
however 0 
, 0 
is 0 
still 0 
unknown 0 
. 0 

We 0 
have 0 
expressed 0 
the 0 
mature 0 
form 0 
of 0 
Yfh1p 0 
-LRB- 0 
mYfh1p 0 
-RRB- 0 
in 0 
Escherichia 0 
coli 0 
and 0 
have 0 
analyzed 0 
its 0 
function 0 
in 0 
vitro 0 
. 0 

Isolated 0 
mYfh1p 0 
is 0 
a 0 
soluble 0 
monomer 0 
-LRB- 0 
_NUM2 0 
, 0 
_NUM3 0 
Da 0 
-RRB- 0 
that 0 
contains 0 
no 0 
iron 0 
and 0 
shows 0 
no 0 
significant 0 
tendency 0 
to 0 
self-associate 0 
. 0 

Aerobic 0 
addition 0 
of 0 
ferrous 0 
iron 0 
to 0 
mYfh1p 0 
results 0 
in 0 
assembly 0 
of 0 
regular 0 
spherical 0 
multimers 0 
with 0 
a 0 
molecular 0 
mass 0 
of 0 
approximately 0 
_NUM1 0 
. 0 

_NUM1 0 
MDa 0 
-LRB- 0 
megadaltons 0 
-RRB- 0 
and 0 
a 0 
diameter 0 
of 0 
_NUM2 0 
+ 0 
/ 0 
-2 0 
nm 0 
. 0 

Each 0 
multimer 0 
consists 0 
of 0 
approximately 0 
_NUM2 0 
subunits 0 
and 0 
can 0 
sequester 0 
> 0 
_NUM1 0 
, 0 
_NUM3 0 
atoms 0 
of 0 
iron 0 
. 0 

Titration 0 
of 0 
mYfh1p 0 
with 0 
increasing 0 
iron 0 
concentrations 0 
supports 0 
a 0 
stepwise 0 
mechanism 0 
of 0 
multimer 0 
assembly 0 
. 0 

Sequential 0 
addition 0 
of 0 
an 0 
iron 0 
chelator 0 
and 0 
a 0 
reducing 0 
agent 0 
results 0 
in 0 
quantitative 0 
iron 0 
release 0 
with 0 
concomitant 0 
disassembly 0 
of 0 
the 0 
multimer 0 
, 0 
indicating 0 
that 0 
mYfh1p 0 
sequesters 0 
iron 0 
in 0 
an 0 
available 0 
form 0 
. 0 

In 0 
yeast 0 
mitochondria 0 
, 0 
native 0 
mYfh1p 0 
exists 0 
as 0 
monomer 0 
and 0 
a 0 
higher-order 0 
species 0 
with 0 
a 0 
molecular 0 
weight 0 
> 0 
_NUM3 0 
, 0 
_NUM3 0 
. 0 

After 0 
addition 0 
of 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
Fe 0 
to 0 
the 0 
medium 0 
, 0 
immunoprecipitates 0 
of 0 
this 0 
species 0 
contain 0 
> 0 
_NUM2 0 
atoms 0 
of 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
Fe 0 
per 0 
molecule 0 
of 0 
mYfh1p 0 
. 0 

We 0 
propose 0 
that 0 
iron-dependent 0 
self-assembly 0 
of 0 
recombinant 0 
mYfh1p 0 
reflects 0 
a 0 
physiological 0 
role 0 
for 0 
frataxin 0 
in 0 
mitochondrial 0 
iron 0 
sequestration 0 
and 0 
bioavailability 0 
. 0 
. 0 

Human 0 
mutations 0 
in 0 
glucose 0 
6-phosphate 0 
dehydrogenase 0 
reflect 0 
evolutionary 0 
history 0 
. 0 

Glucose 0 
6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
is 0 
a 0 
cytosolic 0 
enzyme 0 
encoded 0 
by 0 
a 0 
housekeeping 0 
X-linked 0 
gene 0 
whose 0 
main 0 
function 0 
is 0 
to 0 
produce 0 
NADPH 0 
, 0 
a 0 
key 0 
electron 0 
donor 0 
in 0 
the 0 
defense 0 
against 0 
oxidizing 0 
agents 0 
and 0 
in 0 
reductive 0 
biosynthetic 0 
reactions 0 
. 0 

Inherited 0 
G6PD 1
deficiency 1
is 0 
associated 0 
with 0 
either 0 
episodic 1
hemolytic 1
anemia 1
-LRB- 0 
triggered 0 
by 0 
fava 0 
beans 0 
or 0 
other 0 
agents 0 
-RRB- 0 
or 0 
life-long 1
hemolytic 1
anemia 1
. 0 

We 0 
show 0 
here 0 
that 0 
an 0 
evolutionary 0 
analysis 0 
is 0 
a 0 
key 0 
to 0 
understanding 0 
the 0 
biology 0 
of 0 
a 0 
housekeeping 0 
gene 0 
. 0 

From 0 
the 0 
alignment 0 
of 0 
the 0 
amino 0 
acid 0 
-LRB- 0 
aa 0 
-RRB- 0 
sequence 0 
of 0 
_NUM2 0 
glucose 0 
6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
species 0 
from 0 
_NUM2 0 
different 0 
organisms 0 
, 0 
we 0 
found 0 
a 0 
striking 0 
correlation 0 
between 0 
the 0 
aa 0 
replacements 0 
that 0 
cause 0 
G6PD 1
deficiency 1
in 0 
humans 0 
and 0 
the 0 
sequence 0 
conservation 0 
of 0 
G6PD 0
two-thirds 0 
of 0 
such 0 
replacements 0 
are 0 
in 0 
highly 0 
and 0 
moderately 0 
conserved 0 
-LRB- 0 
50-99 0 
% 0 
-RRB- 0 
aa 0 
; 0 
relatively 0 
few 0 
are 0 
in 0 
fully 0 
conserved 0 
aa 0 
-LRB- 0 
where 0 
they 0 
might 0 
be 0 
lethal 0 
-RRB- 0 
or 0 
in 0 
poorly 0 
conserved 0 
aa 0 
, 0 
where 0 
presumably 0 
they 0 
simply 0 
would 0 
not 0 
cause 0 
G6PD 1
deficiency 1
. 0 

This 0 
is 0 
consistent 0 
with 0 
the 0 
notion 0 
that 0 
all 0 
human 0 
mutants 0 
have 0 
residual 0 
enzyme 0 
activity 0 
and 0 
that 0 
null 0 
mutations 0 
are 0 
lethal 0 
at 0 
some 0 
stage 0 
of 0 
development 0 
. 0 

Comparing 0 
the 0 
distribution 0 
of 0 
mutations 0 
in 0 
a 0 
human 0 
housekeeping 0 
gene 0 
with 0 
evolutionary 0 
conservation 0 
is 0 
a 0 
useful 0 
tool 0 
for 0 
pinpointing 0 
amino 0 
acid 0 
residues 0 
important 0 
for 0 
the 0 
stability 0 
or 0 
the 0 
function 0 
of 0 
the 0 
corresponding 0 
protein 0 
. 0 

In 0 
view 0 
of 0 
the 0 
current 0 
explosive 0 
increase 0 
in 0 
full 0 
genome 0 
sequencing 0 
projects 0 
, 0 
this 0 
tool 0 
will 0 
become 0 
rapidly 0 
available 0 
for 0 
numerous 0 
other 0 
genes 0 
. 0 
. 0 

Regionally 0 
clustered 0 
APC 1
mutations 0 
are 0 
associated 0 
with 0 
a 0 
severe 0 
phenotype 0 
and 0 
occur 0 
at 0 
a 0 
high 0 
frequency 0 
in 0 
new 0 
mutation 0 
cases 0 
of 0 
adenomatous 1
polyposis 1
coli 1
. 0 

Germline 0 
mutation 0 
in 0 
APC 0 
at 0 
5q21-22 0 
results 0 
in 0 
the 0 
dominantly 0 
inherited 0 
syndrome 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
. 0 

Somatic 0 
mutation 0 
in 0 
this 0 
gene 0 
is 0 
an 0 
early 0 
event 0 
in 0 
colorectal 0 
tumourigenesis 0 
. 0 

Both 0 
types 0 
of 0 
mutation 0 
are 0 
concentrated 0 
in 0 
the 0 
_NUM1 0 
half 0 
of 0 
exon 0 
_NUM2 0 
. 0 

We 0 
have 0 
used 0 
single 0 
strand 0 
conformational 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
and 0 
heteroduplex 0 
analysis 0 
to 0 
screen 0 
for 0 
variants 0 
in 0 
this 0 
region 0 
of 0 
the 0 
gene 0 
in 0 
a 0 
total 0 
of 0 
_NUM2 0 
affected 0 
but 0 
unrelated 0 
individuals 0 
. 0 

Eighteen 0 
patients 0 
had 0 
no 0 
family 0 
history 0 
of 0 
the 0 
disease 0 
; 0 
of 0 
these 0 
_NUM2 0 
were 0 
classified 0 
as 0 
having 0 
a 0 
severe 0 
phenotype 0 
, 0 
based 0 
on 0 
an 0 
early 0 
age 0 
at 0 
presentation 0 
or 0 
cancer 1
development 0 
. 0 

This 0 
compared 0 
with 0 
_NUM1 0 
of 0 
_NUM2 0 
familial 0 
cases 0 
. 0 

A 0 
_NUM1 0 
bp 0 
deletion 0 
at 0 
codon 0 
_NUM4 0 
reported 0 
to 0 
occur 0 
in 0 
10-15 0 
% 0 
of 0 
unselected 0 
APC 1
patients 0 
worldwide 0 
, 0 
was 0 
found 0 
in 0 
_NUM1 0 
of 0 
the 0 
_NUM2 0 
new 0 
mutation 0 
cases 0 
and 0 
_NUM1 0 
of 0 
the 0 
_NUM2 0 
familial 0 
cases 0 
all 0 
nine 0 
were 0 
classed 0 
as 0 
severe 0 
. 0 

A 0 
further 0 
_NUM1 0 
new 0 
mutations 0 
and 0 
_NUM1 0 
familial 0 
mutation 0 
were 0 
located 0 
downstream 0 
from 0 
codon 0 
_NUM4 0 
, 0 
these 0 
individuals 0 
similarly 0 
being 0 
classed 0 
as 0 
phenotypically 0 
severe 0 
. 0 

In 0 
contrast 0 
all 0 
of 0 
the 0 
APC 1
mutations 0 
detected 0 
in 0 
affected 0 
individuals 0 
with 0 
an 0 
average 0 
phenotype 0 
were 0 
located 0 
prior 0 
to 0 
codon 0 
_NUM4 0 
. 0 

The 0 
frequent 0 
association 0 
of 0 
a 0 
severe 0 
phenotype 0 
with 0 
fresh 0 
mutation 0 
may 0 
explain 0 
the 0 
apparent 0 
conflict 0 
of 0 
a 0 
high 0 
mutation 0 
rate 0 
-LRB- 0 
20-30 0 
% 0 
-RRB- 0 
in 0 
a 0 
condition 0 
, 0 
which 0 
on 0 
average 0 
, 0 
is 0 
lethal 0 
at 0 
a 0 
post-reproductive 0 
age 0 
. 0 
. 0 

Analysis 0 
of 0 
alkaptonuria 1
-LRB- 0 
AKU 1
-RRB- 0 
mutations 0 
and 0 
polymorphisms 0 
reveals 0 
that 0 
the 0 
_DS 0 
sequence 0 
motif 0 
is 0 
a 0 
mutational 0 
hot 0 
spot 0 
in 0 
the 0 
homogentisate 0 
_MT 0 
dioxygenase 0 
gene 0 
-LRB- 0 
HGO 0 
-RRB- 0 
. 0 

We 0 
recently 0 
showed 0 
that 0 
alkaptonuria 1
-LRB- 0 
AKU 1
-RRB- 0 
is 0 
caused 0 
by 0 
loss-of-function 0 
mutations 0 
in 0 
the 0 
homogentisate 0 
_NUM1 0 
, 0 
_NUM1 0 
dioxygenase 0 
gene 0 
-LRB- 0 
HGO 0 
-RRB- 0 
. 0 

Herein 0 
we 0 
describe 0 
haplotype 0 
and 0 
mutational 0 
analyses 0 
of 0 
HGO 0 
in 0 
seven 0 
new 0 
AKU 1
pedigrees 0 
. 0 

These 0 
analyses 0 
identified 0 
two 0 
novel 0 
single-nucleotide 0 
polymorphisms 0 
-LRB- 0 
INV4 0 
+ 0 
31A 0 
-- 0 
> 0 
G 0 
and 0 
INV11 0 
+ 0 
18A 0 
-- 0 
> 0 
G 0 
-RRB- 0 
and 0 
six 0 
novel 0 
AKU 1
mutations 0 
-LRB- 0 
INV1-1G 0 
-- 0 
> 0 
A 0 
, 0 
W60G 0 
, 0 
Y62C 0 
, 0 
A122D 0 
, 0 
P230T 0 
, 0 
and 0 
D291E 0 
-RRB- 0 
, 0 
which 0 
further 0 
illustrates 0 
the 0 
remarkable 0 
allelic 0 
heterogeneity 0 
found 0 
in 0 
AKU 1
. 0 

Reexamination 0 
of 0 
all 0 
_NUM2 0 
mutations 0 
and 0 
polymorphisms 0 
thus 0 
far 0 
described 0 
in 0 
HGO 0 
shows 0 
that 0 
these 0 
nucleotide 0 
changes 0 
are 0 
not 0 
randomly 0 
distributed 0 
; 0 
the 0 
_DS 0 
sequence 0 
motif 0 
and 0 
its 0 
inverted 0 
complement 0 
, 0 
_DS 0 
, 0 
are 0 
preferentially 0 
mutated 0 
. 0 

These 0 
analyses 0 
also 0 
demonstrated 0 
that 0 
the 0 
nucleotide 0 
substitutions 0 
in 0 
HGO 0 
do 0 
not 0 
involve 0 
CpG 0 
dinucleotides 0 
, 0 
which 0 
illustrates 0 
important 0 
differences 0 
between 0 
HGO 0 
and 0 
other 0 
genes 0 
for 0 
the 0 
occurrence 0 
of 0 
mutation 0 
at 0 
specific 0 
short-sequence 0 
motifs 0 
. 0 

Because 0 
the 0 
_DS 0 
sequence 0 
motifs 0 
comprise 0 
a 0 
significant 0 
proportion 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
of 0 
all 0 
mutated 0 
bases 0 
that 0 
have 0 
been 0 
observed 0 
in 0 
HGO 0 
, 0 
we 0 
conclude 0 
that 0 
the 0 
_DS 0 
triplet 0 
is 0 
a 0 
mutational 0 
hot 0 
spot 0 
in 0 
HGO 0 
. 0 

Further 0 
evidence 0 
for 0 
heterogeneity 0 
of 0 
glucose-6-phosphate 1
dehydrogenase 1
deficiency 1
in 0 
Papua 0 
New 0 
Guinea 0 
. 0 

Four 0 
new 0 
G6PD 0
variants 0 
have 0 
been 0 
characterized 0 
in 0 
individuals 0 
from 0 
Papua 0 
New 0 
Guinea 0 
. 0 

This 0 
study 0 
demonstrates 0 
that 0 
the 0 
previously 0 
reported 0 
Markham 0 
variant 0 
and 0 
the 0 
newly 0 
characterized 0 
Salata 0 
variant 0 
may 0 
be 0 
widely 0 
distributed 0 
in 0 
Papua 0 
New 0 
Guinea 0 
. 0 

Th 0 
data 0 
presented 0 
here 0 
together 0 
with 0 
those 0 
of 0 
previously 0 
published 0 
studies 0 
demonstrate 0 
a 0 
degree 0 
of 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
that 0 
is 0 
much 0 
higher 0 
than 0 
that 0 
in 0 
other 0 
regions 0 
of 0 
the 0 
world 0 
where 0 
G6PD 1
deficiency 1
is 0 
common 0 
. 0 
. 0 

Overgrowth 1
of 1
oral 1
mucosa 1
and 1
facial 1
skin 1
, 0 
a 0 
novel 0 
feature 0 
of 0 
aspartylglucosaminuria 1
. 0 

Aspartylglucosaminuria 1
-LRB- 0 
AGU 1
-RRB- 0 
is 0 
a 0 
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
deficiency 1
of 1
aspartylglucosaminidase 1
-LRB- 0 
_DS 0 
-RRB- 0 
. 0 

The 0 
main 0 
symptom 0 
is 0 
progressive 0 
mental 1
retardation 1
. 0 

A 0 
spectrum 0 
of 0 
different 0 
mutations 0 
has 0 
been 0 
reported 0 
in 0 
this 0 
disease 0 
, 0 
one 0 
missense 0 
mutation 0 
-LRB- 0 
Cys163Ser 0 
-RRB- 0 
being 0 
responsible 0 
for 0 
the 0 
majority 0 
of 0 
Finnish 0 
cases 0 
. 0 

We 0 
were 0 
able 0 
to 0 
examine 0 
_NUM2 0 
Finnish 0 
AGU 1
patients 0 
for 0 
changes 0 
in 0 
the 0 
oral 0 
mucosa 0 
and 0 
_NUM2 0 
of 0 
these 0 
for 0 
changes 0 
in 0 
facial 0
skin 0 
. 0 

Biopsy 0 
specimens 0 
of 0 
_NUM2 0 
oral 0 
lesions 0 
, 0 
_NUM2 0 
of 0 
them 0 
associated 0 
with 0 
the 0 
teeth 0 
, 0 
plus 0 
two 0 
facial 1
lesions 1
were 0 
studied 0 
histologically 0 
. 0 

Immunohistochemical 0 
staining 0 
for 0 
_DS 0 
was 0 
performed 0 
on 0 
_NUM2 0 
oral 0 
specimens 0 
. 0 

Skin 0 
was 0 
seborrhoeic 0 
in 0 
adolescent 0 
and 0 
adult 0 
patients 0 
, 0 
with 0 
erythema 1
of 1
the 1
facial 1
skin 1
already 0 
common 0 
in 0 
childhood 0 
. 0 

Of 0 
_NUM2 0 
patients 0 
, 0 
nine 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
had 0 
facial 1
angiofibromas 1
, 0 
tumours 1
primarily 0 
occurring 0 
in 0 
association 0 
with 0 
tuberous 1
sclerosis 1
. 0 

Oedemic 1
buccal 1
mucosa 1
-LRB- 0 
leucoedema 1
-RRB- 0 
and 0 
gingival 1
overgrowths 1
were 0 
more 0 
frequent 0 
in 0 
AGU 1
patients 0 
than 0 
in 0 
controls 0 
-LRB- 0 
p 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

Of 0 
_NUM2 0 
oral 1
mucosal 1
lesions 1
studied 0 
histologically 0 
, 0 
_NUM2 0 
represented 0 
fibroepithelial 1
or 1
epithelial 1
hyperplasias 1
and 0 
were 0 
reactive 0 
in 0 
nature 0 
. 0 

Cytoplasmic 0 
vacuolisation 0 
was 0 
evident 0 
in 0 
four 0 
. 0 

Immunohistochemically 0 
, 0 
expression 0 
of 0 
_DS 0 
in 0 
AGU 1
patients 0 
mucosal 1
lesions 1
did 0 
not 0 
differ 0 
from 0 
that 0 
seen 0 
in 0 
corresponding 0 
lesions 0 
of 0 
normal 0 
subjects 0 
. 0 

Thus 0 
, 0 
the 0 
high 0 
frequency 0 
of 0 
mucosal 1
overgrowth 1
in 0 
AGU 1
patients 0 
does 0 
not 0 
appear 0 
to 0 
be 0 
directly 0 
associated 0 
with 0 
lysosomal 0 
storage 0 
or 0 
with 0 
alterations 0 
in 0 
the 0 
level 0 
of 0 
_DS 0 
expression 0 
. 0 

Molecular 0 
characterization 0 
of 0 
galactosemia 1
-LRB- 0 
type 0 
_NUM1 0 
-RRB- 0 
mutations 0 
in 0 
Japanese 0 
. 0 

We 0 
characterized 0 
two 0 
novel 0 
mutations 0 
of 0 
the 0 
galactose-1-phosphate 0 
uridyltransferase 0 
-LRB- 0 
GALT 0
-RRB- 0 
gene 0 
in 0 
two 0 
Japanese 0 
patients 0 
with 0 
GALT 1
deficiency 1
and 0 
identified 0 
N314D 0 
and 0 
R333W 0 
mutations 0 
, 0 
previously 0 
found 0 
in 0 
Caucasians 0 
. 0 

One 0 
novel 0 
missense 0 
mutation 0 
was 0 
an 0 
G-to-A 0 
transition 0 
in 0 
exon 0 
_NUM1 0 
, 0 
resulting 0 
in 0 
the 0 
substitution 0 
of 0 
arginine 0 
by 0 
histidine 0 
at 0 
the 0 
codon 0 
_NUM3 0 
-LRB- 0 
R231H 0 
-RRB- 0 
. 0 

GALT 0
activity 0 
of 0 
the 0 
R231H 0 
mutant 0 
construct 0 
was 0 
reduced 0 
to 0 
_NUM2 0 
% 0 
of 0 
normal 0 
controls 0 
in 0 
a 0 
COS 0 
cell 0 
expression 0 
system 0 
. 0 

The 0 
other 0 
was 0 
a 0 
splicing 0 
mutation 0 
, 0 
an 0 
A-to-G 0 
transition 0 
at 0 
the 0 
38th 0 
nucleotide 0 
in 0 
exon 0 
_NUM1 0 
-LRB- 0 
318A 0 
-- 0 
> 0 
G 0 
-RRB- 0 
, 0 
resulting 0 
in 0 
a 0 
38-bp 0 
deletion 0 
in 0 
the 0 
GALT 0
cDNA 0 
by 0 
activating 0 
a 0 
cryptic 0 
splice 0 
acceptor 0 
site 0 
. 0 

In 0 
seven 0 
Japanese 0 
families 0 
-LRB- 0 
_NUM2 0 
alleles 0 
for 0 
classic 0 
form 0 
and 0 
one 0 
allele 0 
for 0 
Duarte 0 
variant 0 
-RRB- 0 
with 0 
GALT 1
deficiency 1
, 0 
the 0 
R231H 0 
and 0 
318A 0 
-- 0 
> 0 
G 0 
mutations 0 
were 0 
found 0 
only 0 
on 0 
both 0 
alleles 0 
of 0 
the 0 
proband 0 
. 0 

The 0 
N314D 0 
and 0 
R333W 0 
mutations 0 
were 0 
found 0 
on 0 
one 0 
allele 0 
each 0 
. 0 

The 0 
Q188R 0 
was 0 
prevalent 0 
in 0 
the 0 
United 0 
States 0 
but 0 
not 0 
in 0 
Japanese 0 
patients 0 
. 0 

The 0 
N314D 0 
mutation 0 
was 0 
associated 0 
with 0 
the 0 
Duarte 0 
variant 0 
in 0 
Japanese 0 
persons 0 
, 0 
as 0 
well 0 
as 0 
in 0 
the 0 
United 0 
States 0 
. 0 

We 0 
speculate 0 
that 0 
classic 1
galactosemia 1
mutations 0 
appear 0 
to 0 
differ 0 
between 0 
Japanese 0 
and 0 
Caucasian 0 
patients 0 
. 0 

Our 0 
limited 0 
data 0 
set 0 
on 0 
galactosemia 1
mutations 0 
in 0 
Japanese 0 
suggests 0 
that 0 
the 0 
N314D 0 
GALT 0 
mutation 0 
encoding 0 
the 0 
Duarte 0 
variant 0 
arose 0 
before 0 
Asian 0 
and 0 
Caucasian 0 
people 0 
diverged 0 
and 0 
that 0 
classic 1
galactosemia 1
mutations 0 
arose 0 
and 0 
/ 0 
or 0 
accumulated 0 
after 0 
the 0 
divergence 0 
of 0 
Asian 0 
and 0 
Caucasian 0 
populations 0 
. 0 
. 0 

Linkage 0 
disequilibrium 0 
mapping 0 
in 0 
isolated 0 
founder 0 
populations 0 
: 0 
diastrophic 1
dysplasia 1
in 0 
Finland 0 
. 0 

Linkage 0 
disequilibrium 0 
mapping 0 
in 0 
isolated 0 
populations 0 
provides 0 
a 0 
powerful 0 
tool 0 
for 0 
fine 0 
structure 0 
localization 0 
of 0 
disease 0 
genes 0 
. 0 

Here 0 
, 0 
Luria 0 
and 0 
Delbrucks 0 
classical 0 
methods 0 
for 0 
analysing 0 
bacterial 0 
cultures 0 
are 0 
adapted 0 
to 0 
the 0 
study 0 
of 0 
human 0 
isolated 0 
founder 0 
populations 0 
in 0 
order 0 
to 0 
estimate 0 
-LRB- 0 
i 0 
-RRB- 0 
the 0 
recombination 0 
fraction 0 
between 0 
a 0 
disease 0 
locus 0 
and 0 
a 0 
marker 0 
; 0 
-LRB- 0 
ii 0 
-RRB- 0 
the 0 
expected 0 
degree 0 
of 0 
allelic 0 
homogeneity 0 
in 0 
a 0 
population 0 
; 0 
and 0 
-LRB- 0 
iii 0 
-RRB- 0 
the 0 
mutation 0 
rate 0 
of 0 
marker 0 
loci 0 
. 0 

Using 0 
these 0 
methods 0 
, 0 
we 0 
report 0 
striking 0 
linkage 0 
disequilibrium 0 
for 0 
diastrophic 1
dysplasia 1
-LRB- 0 
DTD 1
-RRB- 0 
in 0 
Finland 0 
indicating 0 
that 0 
the 0 
DTD 1
gene 0 
should 0 
lie 0 
within 0 
_NUM1 0 
. 0 

_NUM2 0 
centimorgans 0 
-LRB- 0 
or 0 
about 0 
_NUM2 0 
kilobases 0 
-RRB- 0 
of 0 
the 0 
CSF1R 0 
gene 0 
. 0 

Predictions 0 
about 0 
allelic 0 
homogeneity 0 
in 0 
Finland 0 
and 0 
mutation 0 
rates 0 
in 0 
simple 0 
sequence 0 
repeats 0 
are 0 
confirmed 0 
by 0 
independent 0 
observations 0 
. 0 

Mutations 0 
in 0 
TNFRSF11A 0 
, 0 
affecting 0 
the 0 
signal 0 
peptide 0 
of 0 
RANK 0 
, 0 
cause 0 
familial 1
expansile 1
osteolysis 1
. 0 

Familial 1
expansile 1
osteolysis 1
-LRB- 0 
FEO 1
, 0 
MIM 0 
_NUM6 0 
-RRB- 0 
is 0 
a 0 
rare 0 
, 0 
autosomal 1
dominant 1
bone 1
disorder 1
characterized 0 
by 0 
focal 0 
areas 0 
of 0 
increased 1
bone 1
remodelling 1
. 0 

The 0 
osteolytic 1
lesions 1
, 0 
which 0 
develop 0 
usually 0 
in 0 
the 0 
long 0 
bones 0 
during 0 
early 0 
adulthood 0 
, 0 
show 0 
increased 0 
osteoblast 0 
and 0 
osteoclast 0 
activity 0 
. 0 

Our 0 
previous 0 
linkage 0 
studies 0 
mapped 0 
the 0 
gene 0 
responsible 0 
for 0 
FEO 1
to 0 
an 0 
interval 0 
of 0 
less 0 
than 0 
_NUM1 0 
cM 0 
between 0 
D18S64 0 
and 0 
D18S51 0 
on 0 
chromosome 0 
18q21 0 
. 0 

2-21 0 
2-21 0 
. 0 

_NUM1 0 
in 0 
a 0 
large 0 
Northern 0 
Irish 0 
family 0 
. 0 

The 0 
gene 0 
encoding 0 
receptor 0 
activator 0 
of 0 
nuclear 0 
factor-kappa 0 
B 0 
-LRB- 0 
RANK 0 
; 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
TNFRSF11A 0 
, 0 
maps 0 
to 0 
this 0 
region 0 
. 0 

RANK 0 
is 0 
essential 0 
in 0 
osteoclast 0 
formation 0 
. 0 

We 0 
identified 0 
two 0 
heterozygous 0 
insertion 0 
mutations 0 
in 0 
exon 0 
_NUM1 0 
of 0 
TNFRSF11A 0 
in 0 
affected 0 
members 0 
of 0 
four 0 
families 0 
with 0 
FEO 1
or 0 
familial 1
Paget 1
disease 1
of 1
bone 1
-LRB- 0 
PDB 1
-RRB- 0 
. 0 

One 0 
was 0 
a 0 
duplication 0 
of 0 
_NUM2 0 
bases 0 
and 0 
the 0 
other 0 
a 0 
duplication 0 
of 0 
_NUM2 0 
bases 0 
, 0 
both 0 
of 0 
which 0 
affected 0 
the 0 
signal 0 
peptide 0 
region 0 
of 0 
the 0 
RANK 0 
molecule 0 
. 0 

Expression 0 
of 0 
recombinant 0 
forms 0 
of 0 
the 0 
mutant 0 
RANK 0 
proteins 0 
revealed 0 
perturbations 0 
in 0 
expression 0 
levels 0 
and 0 
lack 0 
of 0 
normal 0 
cleavage 0 
of 0 
the 0 
signal 0 
peptide 0 
. 0 

Both 0 
mutations 0 
caused 0 
an 0 
increase 0 
in 0 
RANK-mediated 0 
nuclear 0 
factor-kappaB 0 
-LRB- 0 
NF-kappaB 0 
-RRB- 0 
signalling 0 
in 0 
vitro 0 
, 0 
consistent 0 
with 0 
the 0 
presence 0 
of 0 
an 0 
activating 0 
mutation 0 
. 0 

Adrenoleukodystrophy-related 0 
protein 0 
can 0 
compensate 0 
functionally 0 
for 0 
adrenoleukodystrophy 1
protein 1
deficiency 1
-LRB- 0 
X-ALD 1
-RRB- 0 
: 0 
implications 0 
for 0 
therapy 0 
. 0 

Inherited 1
defects 1
in 0 
the 0 
peroxisomal 0 
ATP-binding 0 
cassette 0 
-LRB- 0 
ABC 0 
-RRB- 0 
transporter 0 
adrenoleukodystrophy 1
protein 0 
-LRB- 0 
ALDP 0 
-RRB- 0 
lead 0 
to 0 
the 0 
lethal 0 
peroxisomal 1
disorder 1
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
X-ALD 1
-RRB- 0 
, 0 
for 0 
which 0 
no 0 
efficient 0 
treatment 0 
has 0 
been 0 
established 0 
so 0 
far 0 
. 0 

Three 0 
other 0 
peroxisomal 0 
ABC 0 
transporters 0 
currently 0 
are 0 
known 0 
adrenoleukodystrophy-related 0 
protein 0 
-LRB- 0 
ALDRP 0 
-RRB- 0 
, 0 
_NUM2 0 
kDa 0 
peroxisomal 0 
membrane 0 
protein 0 
-LRB- 0 
PMP70 0 
-RRB- 0 
and 0 
PMP70 0 
- 0 
related 0 
protein 0 
. 0 

By 0 
using 0 
transient 0 
and 0 
stable 0 
overexpression 0 
of 0 
human 0 
cDNAs 0 
encoding 0 
ALDP 0 
and 0 
its 0 
closest 0 
relative 0 
ALDRP 0 
, 0 
we 0 
could 0 
restore 0 
the 0 
impaired 0 
peroxisomal 0 
beta-oxidation 0 
in 0 
fibroblasts 0 
of 0 
X-ALD 1
patients 0 
. 0 

The 0 
pathognomonic 0 
accumulation 0 
of 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
could 0 
also 0 
be 0 
prevented 0 
by 0 
overexpression 0 
of 0 
ALDRP 0 
in 0 
immortalized 0 
X-ALD 1
cells 0 
. 0 

Immunofluorescence 0 
analysis 0 
demonstrated 0 
that 0 
the 0 
functional 0 
replacement 0 
of 0 
ALDP 0 
by 0 
ALDRP 0 
was 0 
not 0 
due 0 
to 0 
stabilization 0 
of 0 
the 0 
mutated 0 
ALDP 0 
itself 0 
. 0 

Moreover 0 
, 0 
we 0 
were 0 
able 0 
to 0 
restore 0 
the 0 
peroxisomal 0 
beta-oxidation 0 
defect 0 
in 0 
the 0 
liver 0 
of 0 
ALDP-deficient 0 
mice 0 
by 0 
stimulation 0 
of 0 
ALDRP 0 
and 0 
PMP70 0 
gene 0 
expression 0 
through 0 
a 0 
dietary 0 
treatment 0 
with 0 
the 0 
peroxisome 0 
proliferator 0 
fenofibrate 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
a 0 
correction 0 
of 0 
the 0 
biochemical 0 
defect 0 
in 0 
X-ALD 0 
could 0 
be 0 
possible 0 
by 0 
drug-induced 0 
overexpression 0 
or 0 
ectopic 0 
expression 0 
of 0 
ALDRP 0 
. 0 
. 0 

The 0 
normal 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
allele 0 
, 0 
or 0 
a 0 
closely 0 
linked 0 
gene 0 
, 0 
influences 0 
age 0 
at 0 
onset 0 
of 0 
HD 1
. 0 

We 0 
evaluated 0 
the 0 
hypothesis 0 
that 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
is 0 
influenced 0 
by 0 
the 0 
normal 0 
HD 1
allele 0 
by 0 
comparing 0 
transmission 0 
patterns 0 
of 0 
genetically 0 
linked 0 
markers 0 
at 0 
the 0 
D4S10 0 
locus 0 
in 0 
the 0 
normal 0 
parent 0 
against 0 
age 0 
at 0 
onset 0 
in 0 
the 0 
affected 0 
offspring 0 
. 0 

Analysis 0 
of 0 
information 0 
from 0 
_NUM2 0 
sibships 0 
in 0 
_NUM2 0 
kindreds 0 
showed 0 
a 0 
significant 0 
tendency 0 
for 0 
sibs 0 
who 0 
have 0 
similar 0 
onset 0 
ages 0 
to 0 
share 0 
the 0 
same 0 
D4S10 0 
allele 0 
from 0 
the 0 
normal 0 
parent 0 
. 0 

Affected 0 
sibs 0 
who 0 
inherited 0 
different 0 
D4S10 0 
alleles 0 
from 0 
the 0 
normal 0 
parent 0 
tended 0 
to 0 
have 0 
more 0 
variable 0 
ages 0 
at 0 
onset 0 
. 0 

These 0 
findings 0 
suggest 0 
that 0 
the 0 
expression 0 
of 0 
HD 1
is 0 
modulated 0 
by 0 
the 0 
normal 0 
HD 1
allele 0 
or 0 
by 0 
a 0 
closely 0 
linked 0 
locus 0 
. 0 
. 0 

Synergistic 0 
effect 0 
of 0 
histone 0 
hyperacetylation 0 
and 0 
DNA 0 
demethylation 0 
in 0 
the 0 
reactivation 0 
of 0 
the 0 
FMR1 0 
gene 0 
. 0 

Most 0 
fragile 1
X 1
syndrome 1
patients 0 
have 0 
expansion 0 
of 0 
a 0 
-LRB- 0 
_DS 0 
-RRB- 0 
-LRB- 0 
n 0 
-RRB- 0 
sequence 0 
with 0 
> 0 
_NUM3 0 
repeats 0 
-LRB- 0 
full 0 
mutation 0 
-RRB- 0 
in 0 
the 0 
FMR1 0 
gene 0 
responsible 0 
for 0 
this 0 
condition 0 
. 0 

Hypermethylation 0 
of 0 
the 0 
expanded 0 
repeat 0 
and 0 
of 0 
the 0 
FMR1 0 
promoter 0 
is 0 
almost 0 
always 0 
present 0 
and 0 
apparently 0 
suppresses 0 
transcription 0 
, 0 
resulting 0 
in 0 
absence 0 
of 0 
the 0 
FMR1 0 
protein 0 
. 0 

We 0 
recently 0 
showed 0 
that 0 
transcriptional 0 
reactivation 0 
of 0 
FMR1 0 
full 0 
mutations 0 
can 0 
be 0 
achieved 0 
by 0 
inducing 0 
DNA 0 
demethylation 0 
with 0 
5-azadeoxycytidine 0 
-LRB- 0 
5-azadC 0 
-RRB- 0 
. 0 

The 0 
level 0 
of 0 
histone 0 
acetylation 0 
is 0 
another 0 
important 0 
factor 0 
in 0 
regulating 0 
gene 0 
expression 0 
; 0 
therefore 0 
, 0 
we 0 
treated 0 
lymphoblastoid 0 
cell 0 
lines 0 
of 0 
non-mosaic 0 
full 0 
mutation 0 
patients 0 
with 0 
three 0 
drugs 0 
capable 0 
of 0 
inducing 0 
histone 0 
hyperacetylation 0 
. 0 

We 0 
observed 0 
a 0 
consistent 0 
, 0 
although 0 
modest 0 
, 0 
reactivation 0 
of 0 
the 0 
FMR1 0 
gene 0 
with 0 
4-phenylbutyrate 0 
, 0 
sodium 0 
butyrate 0 
and 0 
trichostatin 0 
A 0 
, 0 
as 0 
shown 0 
by 0 
RT-PCR 0 
. 0 

However 0 
, 0 
we 0 
report 0 
that 0 
combining 0 
these 0 
drugs 0 
with 0 
5-azadC 0 
results 0 
in 0 
a 0 
_NUM1 0 
- 0 
to 0 
5-fold 0 
increase 0 
in 0 
FMR1 0 
mRNA 0 
levels 0 
obtained 0 
with 0 
5-azadC 0 
alone 0 
, 0 
thus 0 
showing 0 
a 0 
marked 0 
synergistic 0 
effect 0 
of 0 
histone 0 
hyperacetylation 0 
and 0 
DNA 0 
demethylation 0 
in 0 
the 0 
reactivation 0 
of 0 
FMR1 0 
full 0 
mutations 0 
. 0 
. 0 

Genetic 0 
heterogeneity 0 
in 0 
X-linked 1
amelogenesis 1
imperfecta 1
. 0 

The 0 
AMELX 0 
gene 0 
located 0 
at 0 
Xp22 0 
. 0 

1-p22 0 
. 0 

_NUM1 0 
encodes 0 
for 0 
the 0 
enamel 0 
protein 0 
amelogenin 0 
and 0 
has 0 
been 0 
implicated 0 
as 0 
the 0 
gene 0 
responsible 0 
for 0 
the 0 
inherited 1
dental 1
abnormality 1
X-linked 1
amelogenesis 1
imperfecta 1
-LRB- 0 
XAI 1
-RRB- 0 
. 0 

Three 0 
families 0 
with 0 
XAI 1
have 0 
been 0 
investigated 0 
using 0 
polymorphic 0 
DNA 0 
markers 0 
flanking 0 
the 0 
position 0 
of 0 
AMELX 0 
. 0 

Using 0 
two-point 0 
linkage 0 
analysis 0 
, 0 
linkage 0 
was 0 
established 0 
between 0 
XAI 1
and 0 
several 0 
of 0 
these 0 
markers 0 
in 0 
two 0 
families 0 
, 0 
with 0 
a 0 
combined 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
for 0 
DXS16 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

This 0 
supports 0 
the 0 
involvement 0 
of 0 
AMELX 0 
, 0 
located 0 
close 0 
to 0 
DXS16 0 
, 0 
in 0 
the 0 
XAI 1
disease 1
process 0 
-LRB- 0 
AIH1 0 
-RRB- 0 
in 0 
those 0 
families 0 
. 0 

Using 0 
multipoint 0 
linkage 0 
analysis 0 
, 0 
the 0 
combined 0 
maximum 0 
lod 0 
score 0 
for 0 
these 0 
two 0 
families 0 
was 0 
_NUM1 0 
. 0 

_NUM2 0 
for 0 
a 0 
location 0 
of 0 
AIH1 0 
at 0 
_NUM1 0 
cM 0 
distal 0 
to 0 
DXS16 0 
. 0 

The 0 
support 0 
interval 0 
around 0 
this 0 
location 0 
extended 0 
about 0 
_NUM1 0 
cM 0 
proximal 0 
to 0 
DXS92 0 
, 0 
and 0 
the 0 
AIH1 0 
location 0 
could 0 
not 0 
be 0 
precisely 0 
defined 0 
by 0 
multipoint 0 
mapping 0 
. 0 

Study 0 
of 0 
recombination 0 
events 0 
indicated 0 
that 0 
AIH1 0 
lies 0 
in 0 
the 0 
interval 0 
between 0 
DXS143 0 
and 0 
DXS85 0 
. 0 

There 0 
was 0 
significant 0 
evidence 0 
against 0 
linkage 0 
to 0 
this 0 
region 0 
in 0 
the 0 
third 0 
family 0 
, 0 
indicating 0 
locus 0 
heterogeneity 0 
in 0 
XAI 1
. 0 

Further 0 
analysis 0 
with 0 
markers 0 
on 0 
the 0 
long 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
showed 0 
evidence 0 
of 0 
linkage 0 
to 0 
DXS144E 0 
and 0 
F9 0 
with 0 
no 0 
recombination 0 
with 0 
either 0 
of 0 
these 0 
markers 0 
. 0 

Two-point 0 
analysis 0 
gave 0 
a 0 
peak 0 
lod 0 
score 0 
at 0 
DXS144E 0 
with 0 
a 0 
maximum 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
, 0 
with 0 
a 0 
peak 0 
lod 0 
score 0 
in 0 
multipoint 0 
linkage 0 
analysis 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

The 0 
support 0 
interval 0 
extended 0 
_NUM1 0 
cM 0 
proximal 0 
to 0 
DXS144E 0 
and 0 
_NUM2 0 
cM 0 
distal 0 
to 0 
F9 0 
. 0 

-LRB- 0 
ABSTRACT 0 
TRUNCATED 0 
_DS 0 
_NUM3 0 
WORDS 0 
-RRB- 0 
. 0 

Anonymous 0 
marker 0 
loci 0 
within 0 
_NUM3 0 
kb 0 
of 0 
HLA-A 0 
generate 0 
haplotypes 0 
in 0 
linkage 0 
disequilibrium 0 
with 0 
the 0 
hemochromatosis 1
gene 0 
-LRB- 0 
HFE 0 
-RRB- 0 
The 0 
hemochromatosis 1
gene 0 
-LRB- 0 
HFE 0 
-RRB- 0 
maps 0 
to 0 
6p21 0 
. 0 

_NUM1 0 
and 0 
is 0 
less 0 
than 0 
_NUM1 0 
cM 0 
from 0 
the 0 
HLA 0 
class 0 
I 0 
genes 0 
; 0 
however 0 
, 0 
the 0 
precise 0 
physical 0 
location 0 
of 0 
the 0 
gene 0 
has 0 
remained 0 
elusive 0 
and 0 
controversial 0 
. 0 

The 0 
unambiguous 0 
identification 0 
of 0 
a 0 
crossover 0 
event 0 
within 0 
hemochromatosis 1
families 0 
is 0 
very 0 
difficult 0 
; 0 
it 0 
is 0 
particularly 0 
hampered 0 
by 0 
the 0 
variability 0 
of 0 
the 0 
phenotypic 0 
expression 0 
as 0 
well 0 
as 0 
by 0 
the 0 
sex 0 
- 0 
and 0 
age-related 0 
penetrance 0 
of 0 
the 0 
disease 0 
. 0 

For 0 
these 0 
practical 0 
considerations 0 
, 0 
traditional 0 
linkage 0 
analysis 0 
could 0 
prove 0 
of 0 
limited 0 
value 0 
in 0 
further 0 
refining 0 
the 0 
extrapolated 0 
physical 0 
position 0 
of 0 
HFE 0 
. 0 

We 0 
therefore 0 
embarked 0 
upon 0 
a 0 
linkage-disequilibrium 0 
analysis 0 
of 0 
HFE 0 
and 0 
normal 0 
chromosomes 0 
from 0 
the 0 
Brittany 0 
population 0 
. 0 

In 0 
the 0 
present 0 
report 0 
, 0 
_NUM2 0 
hemochromatosis 1
families 0 
yielding 0 
_NUM3 0 
hemochromatosis 1
chromosomes 0 
and 0 
_NUM3 0 
normal 0 
chromosomes 0 
were 0 
RFLP-typed 0 
with 0 
a 0 
battery 0 
of 0 
probes 0 
, 0 
including 0 
two 0 
newly 0 
derived 0 
polymorphic 0 
markers 0 
from 0 
the 0 
_NUM1 0 
. 0 

_NUM1 0 
and 0 
HLA-F 0 
loci 0 
located 0 
_NUM3 0 
and 0 
_NUM3 0 
kb 0 
telomeric 0 
to 0 
HLA-A 0 
, 0 
respectively 0 
. 0 

The 0 
results 0 
suggest 0 
a 0 
strong 0 
peak 0 
of 0 
existing 0 
linkage 0 
disequilibrium 0 
focused 0 
within 0 
the 0 
i82-to-6 0 
. 0 

_NUM1 0 
interval 0 
-LRB- 0 
approximately 0 
_NUM3 0 
kb 0 
-RRB- 0 
. 0 

The 0 
zone 0 
of 0 
linkage 0 
disequilibrium 0 
is 0 
flanked 0 
by 0 
the 0 
_AN 0 
locus 0 
, 0 
positioned 0 
_NUM2 0 
kb 0 
proximal 0 
to 0 
_AN 0 
, 0 
and 0 
the 0 
HLA-F 0 
gene 0 
, 0 
found 0 
_NUM3 0 
kb 0 
distal 0 
to 0 
HLA-A 0 
, 0 
markers 0 
of 0 
which 0 
display 0 
no 0 
significant 0 
association 0 
with 0 
HFE 0 
. 0 

These 0 
data 0 
support 0 
the 0 
possibility 0 
that 0 
HFE 0 
resides 0 
within 0 
the 0 
400-kb 0 
expanse 0 
of 0 
DNA 0 
between 0 
_AN 0 
and 0 
HLA-F 0 
. 0 

Alternatively 0 
, 0 
the 0 
very 0 
tight 0 
association 0 
of 0 
HLA-A3 0 
and 0 
allele 0 
_NUM1 0 
of 0 
the 0 
_NUM1 0 
. 0 

_NUM1 0 
locus 0 
, 0 
both 0 
of 0 
which 0 
are 0 
comprised 0 
by 0 
the 0 
major 0 
ancestral 0 
or 0 
founder 0 
HFE 0 
haplotype 0 
in 0 
Brittany 0 
, 0 
supports 0 
the 0 
possibility 0 
that 0 
the 0 
disease 0 
gene 0 
may 0 
reside 0 
immediately 0 
telomeric 0 
to 0 
the 0 
_NUM1 0 
. 0 

_NUM1 0 
locus 0 
within 0 
the 0 
linkage-disequilibrium 0 
zone 0 
. 0 

Additionally 0 
, 0 
hemochromatosis 1
haplotypes 0 
possessing 0 
HLA-A11 0 
and 0 
the 0 
low-frequency 0 
HLA-F 0 
polymorphism 0 
-LRB- 0 
allele 0 
_NUM1 0 
-RRB- 0 
are 0 
supportive 0 
of 0 
a 0 
separate 0 
founder 0 
chromosome 0 
containing 0 
a 0 
second 0 
, 0 
independently 0 
arising 0 
mutant 0 
allele 0 
. 0 

Overall 0 
, 0 
the 0 
establishment 0 
of 0 
a 0 
likely 0 
'' 0 
hemochromatosis 1
critical 0 
region 0 
'' 0 
centromeric 0 
boundary 0 
and 0 
the 0 
identification 0 
of 0 
a 0 
linkage-disequilibrium 0 
zone 0 
both 0 
significantly 0 
contribute 0 
to 0 
a 0 
reduction 0 
in 0 
the 0 
amount 0 
of 0 
DNA 0 
required 0 
to 0 
be 0 
searched 0 
for 0 
novel 0 
coding 0 
sequences 0 
constituting 0 
the 0 
HFE 1
defect 1
Natural 0 
selection 0 
of 0 
hemi 0 
- 0 
and 0 
heterozygotes 0 
for 0 
G6PD 1
deficiency 1
in 0 
Africa 0 
by 0 
resistance 0 
to 0 
severe 0 
malaria 1
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
, 0 
the 0 
most 0 
common 0 
enzymopathy 1
of 0 
humans 0 
, 0 
affects 0 
over 0 
_NUM3 0 
million 0 
people 0 
. 0 

The 0 
geographical 0 
correlation 0 
of 0 
its 0 
distribution 0 
with 0 
the 0 
historical 0 
endemicity 0 
of 0 
malaria 1
suggests 0 
that 0 
this 0 
disorder 0 
has 0 
risen 0 
in 0 
frequency 0 
through 0 
natural 0 
selection 0 
by 0 
malaria 1
. 0 

However 0 
, 0 
attempts 0 
to 0 
confirm 0 
that 0 
G6PD 1
deficiency 1
is 0 
protective 0 
in 0 
case-control 0 
studies 0 
of 0 
malaria 1
have 0 
yielded 0 
conflicting 0 
results 0 
. 0 

Hence 0 
, 0 
for 0 
this 0 
X-linked 1
disorder 1
, 0 
it 0 
is 0 
unclear 0 
whether 0 
both 0 
male 0 
hemizygotes 0 
and 0 
female 0 
heterozygotes 0 
are 0 
protected 0 
or 0 
, 0 
as 0 
frequently 0 
suggested 0 
, 0 
only 0 
females 0 
. 0 

Furthermore 0 
, 0 
how 0 
much 0 
protection 0 
may 0 
be 0 
afforded 0 
is 0 
unknown 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
, 0 
in 0 
two 0 
large 0 
case-control 0 
studies 0 
of 0 
over 0 
_NUM1 0 
, 0 
_NUM3 0 
African 0 
children 0 
, 0 
the 0 
common 0 
African 0 
form 0 
of 0 
G6PD 1
deficiency 1
-LRB- 0 
G6PD 1
A- 1
-RRB- 0 
is 0 
associated 0 
with 0 
a 0 
46-58 0 
% 0 
reduction 0 
in 0 
risk 0 
of 0 
severe 0 
malaria 1
for 0 
both 0 
female 0 
heterozygotes 0 
and 0 
male 0 
hemizygotes 0 
. 0 

A 0 
mathematical 0 
model 0 
incorporating 0 
the 0 
measured 0 
selective 0 
advantage 0 
against 0 
malaria 1
suggests 0 
that 0 
a 0 
counterbalancing 0 
selective 0 
disadvantage 0 
, 0 
associated 0 
with 0 
this 0 
enzyme 1
deficiency 1
, 0 
has 0 
retarded 0 
its 0 
rise 0 
in 0 
frequency 0 
in 0 
malaria 1
endemic 0 
regions 0 
. 0 

Although 0 
G6PD 1
deficiency 1
is 0 
now 0 
regarded 0 
as 0 
a 0 
generally 0 
benign 0 
disorder 0 
, 0 
in 0 
earlier 0 
environmental 0 
conditions 0 
it 0 
could 0 
have 0 
been 0 
significantly 0 
disadvantageous 0 
. 0 
. 0 

Prader-Willi 1
syndrome 1
and 0 
chromosome 0
_NUM2 0 
. 0 

A 0 
clinical 0 
discussion 0 
of 0 
_NUM2 0 
cases 0 
. 0 

A 0 
chromosome 1
_NUM2 1
anomaly 1
was 0 
observed 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
patients 0 
, 0 
_NUM2 0 
of 0 
whom 0 
were 0 
clinically 0 
suspected 0 
of 0 
having 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

The 0 
clinical 0 
features 0 
of 0 
eight 0 
cases 0 
with 0 
15q11-12 0 
deletion 0 
were 0 
very 0 
similar 0 
to 0 
those 0 
originally 0 
described 0 
in 0 
PWS 1
. 0 

On 0 
the 0 
other 0 
hand 0 
, 0 
the 0 
group 0 
of 0 
normal 0 
karyotype 0 
patients 0 
is 0 
heterogeneous 0 
, 0 
and 0 
their 0 
features 0 
do 0 
not 0 
strictly 0 
correspond 0 
to 0 
the 0 
clinical 0 
definition 0 
of 0 
PWS 1
. 0 

However 0 
, 0 
the 0 
hypothesis 0 
that 0 
PWS 1
is 0 
associated 0 
with 0 
deletion 0 
of 0 
15q11-12 0 
can 0 
neither 0 
explain 0 
the 0 
apparently 0 
balanced 0 
translocations 0 
of 0 
chromosome 0 
_NUM2 0 
nor 0 
account 0 
for 0 
the 0 
small 0 
supernumerary 0 
metacentric 0 
chromosomes 0 
corresponding 0 
to 0 
an 0 
isochromosome 0 
_NUM2 0 
for 0 
band 0 
15q11 0 
observed 0 
in 0 
some 0 
cases 0 
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
phenylketonuria 1
and 0 
related 0 
hyperphenylalaninemias 1
: 0 
mutations 0 
and 0 
polymorphisms 0 
in 0 
the 0 
human 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
. 0 

Mutations 0 
in 0 
the 0 
human 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
producing 0 
phenylketonuria 1
or 0 
hyperphenylalaninemia 1
have 0 
now 0 
been 0 
identified 0 
in 0 
many 0 
patients 0 
from 0 
various 0 
ethnic 0 
groups 0 
. 0 

These 0 
mutations 0 
all 0 
exhibit 0 
a 0 
high 0 
degree 0 
of 0 
association 0 
with 0 
specific 0 
restriction 0 
fragment-length 0 
polymorphism 0 
haplotypes 0 
at 0 
the 0 
PAH 0 
locus 0 
. 0 

About 0 
_NUM2 0 
of 0 
these 0 
mutations 0 
are 0 
single-base 0 
substitutions 0 
, 0 
including 0 
six 0 
nonsense 0 
mutations 0 
and 0 
eight 0 
splicing 0 
mutations 0 
, 0 
with 0 
the 0 
remainder 0 
being 0 
missense 0 
mutations 0 
. 0 

One 0 
splicing 0 
mutation 0 
results 0 
in 0 
a 0 
_NUM1 0 
amino 0 
acid 0 
in-frame 0 
insertion 0 
. 0 

Two 0 
or 0 
_NUM1 0 
large 0 
deletions 0 
, 0 
_NUM1 0 
single 0 
codon 0 
deletions 0 
, 0 
and 0 
_NUM1 0 
single 0 
base 0 
deletions 0 
have 0 
been 0 
found 0 
. 0 

Twelve 0 
of 0 
the 0 
missense 0 
mutations 0 
apparently 0 
result 0 
from 0 
the 0 
methylation 0 
and 0 
subsequent 0 
deamination 0 
of 0 
highly 0 
mutagenic 0 
CpG 0 
dinucleotides 0 
. 0 

Recurrent 0 
mutation 0 
has 0 
been 0 
observed 0 
at 0 
several 0 
of 0 
these 0 
sites 0 
, 0 
producing 0 
associations 0 
with 0 
different 0 
haplotypes 0 
in 0 
different 0 
populations 0 
. 0 

About 0 
half 0 
of 0 
all 0 
missense 0 
mutations 0 
have 0 
been 0 
examined 0 
by 0 
in 0 
vitro 0 
expression 0 
analysis 0 
, 0 
and 0 
a 0 
significant 0 
correlation 0 
has 0 
been 0 
observed 0 
between 0 
residual 0 
PAH 0 
activity 0 
and 0 
disease 0 
phenotype 0 
. 0 

Since 0 
continuing 0 
advances 0 
in 0 
molecular 0 
methodologies 0 
have 0 
dramatically 0 
accelerated 0 
the 0 
rate 0 
in 0 
which 0 
new 0 
mutations 0 
are 0 
being 0 
identified 0 
and 0 
characterized 0 
, 0 
this 0 
register 0 
of 0 
mutations 0 
will 0 
be 0 
updated 0 
periodically 0 
. 0 
. 0 

The 0 
intron 0 
_NUM1 0 
donor 0 
splice 0 
site 0 
transition 0 
: 0 
a 0 
second 0 
Tay-Sachs 1
disease 1
mutation 0 
in 0 
French 0 
Canada 0 
. 0 

Mutations 0 
at 0 
the 0 
hexosaminidase 0 
A 0 
-LRB- 0 
HEXA 0 
-RRB- 0 
gene 0 
which 0 
cause 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
have 0 
elevated 0 
frequency 0 
in 0 
the 0 
Ashkenazi 0 
Jewish 0 
and 0 
French-Canadian 0 
populations 0 
. 0 

We 0 
report 0 
a 0 
novel 0 
TSD 1
allele 0 
in 0 
the 0 
French-Canadian 0 
population 0 
associated 0 
with 0 
the 0 
infantile 0 
form 0 
of 0 
the 0 
disease 0 
. 0 

The 0 
mutation 0 
, 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
at 0 
the 0 
+ 0 
_NUM1 0 
position 0 
of 0 
intron 0 
_NUM1 0 
, 0 
abolishes 0 
the 0 
donor 0 
splice 0 
site 0 
. 0 

Cultured 0 
human 0 
fibroblasts 0 
from 0 
a 0 
compound 0 
heterozygote 0 
for 0 
this 0 
transition 0 
-LRB- 0 
and 0 
for 0 
a 0 
deletion 0 
mutation 0 
-RRB- 0 
produce 0 
no 0 
detectable 0 
HEXA 0 
mRNA 0 
. 0 

The 0 
intron 0 
_NUM1 0 
+ 0 
_NUM1 0 
mutation 0 
occurs 0 
in 0 
the 0 
base 0 
adjacent 0 
to 0 
the 0 
site 0 
of 0 
the 0 
adult-onset 0 
TSD 1
mutation 0 
-LRB- 0 
G805A 0 
-RRB- 0 
. 0 

In 0 
both 0 
mutations 0 
a 0 
restriction 0 
site 0 
for 0 
the 0 
endonuclease 0 
EcoRII 0 
is 0 
abolished 0 
. 0 

Unambiguous 0 
diagnosis 0 
, 0 
therefore 0 
, 0 
requires 0 
allele-specific 0 
oligonucleotide 0 
hybridization 0 
to 0 
distinguish 0 
between 0 
these 0 
two 0 
mutant 0 
alleles 0 
. 0 

The 0 
intron 0 
_NUM1 0 
+ 0 
_NUM1 0 
mutation 0 
has 0 
been 0 
detected 0 
in 0 
three 0 
unrelated 0 
families 0 
. 0 

Obligate 0 
heterozygotes 0 
for 0 
the 0 
intron 0 
_NUM1 0 
+ 0 
_NUM1 0 
mutation 0 
were 0 
born 0 
in 0 
the 0 
Saguenay-Lac-St-Jean 0 
region 0 
of 0 
Quebec 0 
. 0 

The 0 
most 0 
recent 0 
ancestors 0 
common 0 
to 0 
obligate 0 
carriers 0 
of 0 
this 0 
mutation 0 
were 0 
from 0 
the 0 
Charlevoix 0 
region 0 
of 0 
the 0 
province 0 
of 0 
Quebec 0 
. 0 

This 0 
mutation 0 
thus 0 
has 0 
a 0 
different 0 
geographic 0 
centre 0 
of 0 
diffusion 0 
and 0 
is 0 
probably 0 
less 0 
common 0 
than 0 
the 0 
exon 0 
_NUM1 0 
deletion 0 
TSD 1
mutation 0 
in 0 
French 0 
Canadians 0 
. 0 

Neither 0 
mutation 0 
has 0 
been 0 
detected 0 
in 0 
France 0 
, 0 
the 0 
ancestral 0 
homeland 0 
of 0 
French 0 
Canada 0 
. 0 
. 0 

Recessively 0 
inherited 0 
multiple 1
epiphyseal 1
dysplasia 1
with 0 
normal 0 
stature 0 
, 0 
club 1
foot 1
, 0 
and 0 
double 1
layered 1
patella 1
caused 0 
by 0 
a 0 
DTDST 0 
mutation 0 
. 0 

We 0 
have 0 
observed 0 
over 0 
_NUM2 0 
different 0 
mutations 0 
in 0 
the 0 
diastrophic 1
dysplasia 1
sulphate 0 
transporter 0 
gene 0 
-LRB- 0 
DTDST 0 
-RRB- 0 
in 0 
association 0 
with 0 
the 0 
recessive 1
disorders 1
achondrogenesis 1
1B 1
, 0 
atelosteogenesis 1
_NUM1 1
, 0 
and 0 
diastrophic 1
dysplasia 1
. 0 

The 0 
c862t 0 
-LRB- 0 
R279W 0 
-RRB- 0 
transition 0 
is 0 
the 0 
most 0 
common 0 
mutation 0 
in 0 
non-Finnish 0 
patients 0 
, 0 
but 0 
in 0 
these 0 
disorders 0 
it 0 
is 0 
usually 0 
combined 0 
with 0 
other 0 
DTDST 0 
mutations 0 
. 0 

We 0 
had 0 
not 0 
seen 0 
a 0 
case 0 
of 0 
homozygosity 0 
for 0 
c862t 0 
-LRB- 0 
R279W 0 
-RRB- 0 
until 0 
we 0 
analysed 0 
DNA 0 
from 0 
a 0 
_NUM2 0 
year 0 
old 0 
male 0 
with 0 
tall-normal 0 
stature 0 
-LRB- 0 
_NUM3 0 
cm 0 
-RRB- 0 
who 0 
asked 0 
for 0 
genetic 0 
counselling 0 
for 0 
suspected 0 
multiple 1
epiphyseal 1
dysplasia 1
. 0 

He 0 
was 0 
treated 0 
for 0 
club 1
foot 1
and 0 
hip 1
dysplasia 1
at 0 
birth 0 
. 0 

Skeletal 0 
changes 0 
consistent 0 
with 0 
multiple 1
epiphyseal 1
dysplasia 1
, 0 
with 0 
the 0 
peculiar 0 
finding 0 
of 0 
a 0 
double 1
layered 1
patella 1
, 0 
were 0 
recognised 0 
during 0 
childhood 0 
. 0 

Cleft 1
palate 1
, 0 
swelling 1
of 1
the 1
ear 1
pinna 1
, 0 
and 0 
hitch 1
hiker 1
thumb 1
were 0 
absent 0 
. 0 

He 0 
was 0 
found 0 
to 0 
be 0 
homozygous 0 
, 0 
and 0 
both 0 
healthy 0 
parents 0 
heterozygous 0 
, 0 
for 0 
the 0 
R279W 0 
mutation 0 
in 0 
DTDST 0
, 0 
and 0 
his 0 
fibroblasts 0 
showed 0 
a 0 
sulphate 0 
incorporation 0 
defect 0 
typical 0 
of 0 
DTDST 1
disorders 1
. 0 

Counselling 0 
was 0 
given 0 
for 0 
a 0 
recessive 1
disorder 1
, 0 
thereby 0 
considerably 0 
reducing 0 
the 0 
probability 0 
of 0 
affected 0 
offspring 0 
. 0 

Multiple 1
epiphyseal 1
dysplasia 1
is 0 
more 0 
frequently 0 
caused 0 
by 0 
dominant 0 
mutations 0 
in 0 
the 0 
COMP 0 
-LRB- 0 
EDM1 1
, 0 
McKusick 0 
_NUM6 0 
-RRB- 0 
and 0 
COL9A2 0 
genes 0 
-LRB- 0 
EDM2 1
, 0 
McKusick 0 
_NUM6 0 
-RRB- 0 
. 0 

A 0 
few 0 
other 0 
patients 0 
and 0 
families 0 
with 0 
features 0 
similar 0 
to 0 
our 0 
proband 0 
have 0 
been 0 
described 0 
previously 0 
and 0 
considered 0 
to 0 
have 0 
autosomal 0 
recessive 0 
MED 1
-LRB- 0 
EDM4 1
, 0 
McKusick 0 
_NUM6 0 
-RRB- 0 
. 0 

This 0 
observation 0 
confirms 0 
the 0 
existence 0 
of 0 
this 0 
entity 0 
and 0 
assigns 0 
it 0 
to 0 
the 0 
phenotypic 0 
spectrum 0 
associated 0 
with 0 
mutations 0 
at 0 
the 0 
DTDST 0 
locus 0 
. 0 
. 0 

Myotonic 1
dystrophy 1
: 0 
size 0 
- 0 
and 0 
sex-dependent 0 
dynamics 0 
of 0 
_DS 0 
meiotic 0 
instability 0 
, 0 
and 0 
somatic 0 
mosaicism 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
a 0 
progressive 0 
neuromuscular 1
disorder 1
which 0 
results 0 
from 0 
elongations 0 
of 0 
an 0 
unstable 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
, 0 
located 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
the 0 
DM 1
gene 0 
. 0 

A 0 
correlation 0 
has 0 
been 0 
demonstrated 0 
between 0 
the 0 
increase 0 
in 0 
the 0 
repeat 0 
number 0 
of 0 
this 0 
sequence 0 
and 0 
the 0 
severity 0 
of 0 
the 0 
disease 0 
. 0 

However 0 
, 0 
the 0 
clinical 0 
status 0 
of 0 
patients 0 
can 0 
not 0 
be 0 
unambiguously 0 
ascertained 0 
solely 0 
on 0 
the 0 
basis 0 
of 0 
the 0 
number 0 
of 0 
_DS 0 
repeats 0 
. 0 

Moreover 0 
, 0 
the 0 
exclusive 0 
maternal 0 
inheritance 0 
of 0 
the 0 
congenital 0 
form 0 
remains 0 
unexplained 0 
. 0 

Our 0 
observation 0 
of 0 
differently 0 
sized 0 
repeats 0 
in 0 
various 0 
DM 1
tissues 0 
from 0 
the 0 
same 0 
individual 0 
may 0 
explain 0 
why 0 
the 0 
size 0 
of 0 
the 0 
mutation 0 
observed 0 
in 0 
lymphocytes 0 
does 0 
not 0 
necessarily 0 
correlate 0 
with 0 
the 0 
severity 0 
and 0 
nature 0 
of 0 
symptoms 0 
. 0 

Through 0 
a 0 
molecular 0 
and 0 
genetic 0 
study 0 
of 0 
_NUM3 0 
families 0 
including 0 
_NUM3 0 
DM 1
patients 0 
, 0 
we 0 
have 0 
investigated 0 
the 0 
dynamics 0 
of 0 
the 0 
_DS 0 
repeat 0 
meiotic 0 
instability 0 
. 0 

A 0 
positive 0 
correlation 0 
between 0 
the 0 
size 0 
of 0 
the 0 
repeat 0 
and 0 
the 0 
intergenerational 0 
enlargement 0 
was 0 
observed 0 
similarly 0 
through 0 
male 0 
and 0 
female 0 
meioses 0 
for 0 
< 0 
or 0 
= 0 
_NUM1 0 
. 0 

5-kb 0 
_DS 0 
sequences 0 
. 0 

Beyond 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
, 0 
the 0 
intergenerational 0 
variation 0 
was 0 
more 0 
important 0 
through 0 
female 0 
meioses 0 
, 0 
whereas 0 
a 0 
tendency 0 
to 0 
compression 0 
was 0 
observed 0 
almost 0 
exclusively 0 
in 0 
male 0 
meioses 0 
, 0 
for 0 
> 0 
or 0 
= 0 
_NUM1 0 
. 0 

5-kb 0 
fragments 0 
. 0 

This 0 
implies 0 
a 0 
size 0 
- 0 
and 0 
sex-dependent 0 
meiotic 0 
instability 0 
. 0 

Moreover 0 
, 0 
segregation 0 
analysis 0 
supports 0 
the 0 
hypothesis 0 
of 0 
a 0 
maternal 0 
as 0 
well 0 
as 0 
a 0 
familial 0 
predisposition 0 
for 0 
the 0 
occurrence 0 
of 0 
the 0 
congenital 0 
form 0 
. 0 

Finally 0 
, 0 
this 0 
analysis 0 
reveals 0 
a 0 
significant 0 
excess 0 
of 0 
transmitting 0 
grandfathers 0 
partially 0 
accounted 0 
for 0 
by 0 
increased 0 
fertility 0 
in 0 
affected 0 
males 0 
Fatal 0 
pyoderma 1
gangrenosum 1
in 0 
association 0 
with 0 
C7 1
deficiency 1
. 0 

Although 0 
pyoderma 1
gangrenosum 1
-LRB- 0 
PG 1
-RRB- 0 
is 0 
often 0 
associated 0 
with 0 
systemic 1
diseases 1
, 0 
it 0 
has 0 
not 0 
been 0 
reported 0 
in 0 
association 0 
with 0 
congenital 1
complement 1
deficiencies 1
. 0 

We 0 
describe 0 
an 0 
aggressive 0 
and 0 
ultimately 0 
fatal 0 
case 0 
of 0 
PG 1
in 0 
a 0 
patient 0 
with 0 
a 0 
congenital 0 
C7 1
deficiency 1
. 0 

Deficiencies 1
of 1
C7 1
can 0 
be 0 
associated 0 
with 0 
decreased 0 
neutrophil 0 
chemotaxis 0 
, 0 
phagocytosis 0 
, 0 
and 0 
opsonization 0 
, 0 
similar 0 
to 0 
the 0 
immunologic 1
abnormalities 1
described 0 
in 0 
patients 0 
with 0 
PG 1
. 0 

Our 0 
patients 0 
decreased 0 
complement 0 
level 0 
, 0 
if 0 
not 0 
directly 0 
related 0 
to 0 
the 0 
development 0 
of 0 
PG 1
, 0 
may 0 
have 0 
contributed 0 
to 0 
the 0 
aggressive 0 
nature 0 
of 0 
her 0 
disease 0 
. 0 
. 0 

Emerin 1
deficiency 1
at 0 
the 0 
nuclear 0 
membrane 0 
in 0 
patients 0 
with 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
. 0 

Mutations 0 
in 0 
the 0 
STA 0 
gene 0 
at 0 
the 0 
Xq28 0 
locus 0 
have 0 
been 0 
found 0 
in 0 
patients 0 
with 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
. 0 

This 0 
gene 0 
encodes 0 
a 0 
hitherto 0 
unknown 0 
protein 0 
named 0 
emerin 0 
. 0 

To 0 
elucidate 0 
the 0 
subcellular 0 
localization 0 
of 0 
emerin 0 
, 0 
we 0 
raised 0 
two 0 
antisera 0 
against 0 
synthetic 0 
peptide 0 
fragments 0 
predicted 0 
from 0 
emerin 0 
cDNA 0 
. 0 

Using 0 
both 0 
antisera 0 
, 0 
we 0 
found 0 
positive 0 
nuclear 0 
membrane 0 
staining 0 
in 0 
skeletal 0 
, 0 
cardiac 0 
and 0 
smooth 0 
muscles 0 
in 0 
the 0 
normal 0 
controls 0 
and 0 
in 0 
patients 0 
with 0 
neuromuscular 1
diseases 1
other 0 
than 0 
EDMD 1
. 0 

In 0 
contrast 0 
, 0 
a 0 
deficiency 0 
in 0 
immunofluorescent 0 
staining 0 
of 0 
skeletal 0 
and 0 
cardiac 0 
muscle 0 
from 0 
EDMD 1
patients 0 
was 0 
observed 0 
. 0 

A 0 
_NUM2 0 
kD 0 
protein 0 
is 0 
immunoreactive 0 
with 0 
the 0 
antisera 0 
-- 0 
the 0 
protein 0 
is 0 
equivalent 0 
to 0 
that 0 
predicted 0 
for 0 
emerin 0 
. 0 

Together 0 
, 0 
our 0 
findings 0 
suggest 0 
the 0 
specific 0 
deficiency 1
of 1
emerin 1
in 0 
the 0 
nuclear 0 
membrane 0 
of 0 
muscle 0 
cells 0 
in 0 
patients 0 
with 0 
EDMD 1
. 0 
. 0 

A 0 
p16INK4a-insensitive 0 
CDK4 0 
mutant 0 
targeted 0 
by 0 
cytolytic 0 
T 0 
lymphocytes 0 
in 0 
a 0 
human 0 
melanoma 1
. 0 

A 0 
mutated 0 
cyclin-dependent 0 
kinase 0 
_NUM1 0 
-LRB- 0 
CDK4 0 
-RRB- 0 
was 0 
identified 0 
as 0 
a 0 
tumor 1
specific 0 
antigen 0 
recognized 0 
by 0 
HLA-A2 0 
. 0 

1-restricted 0 
autologous 0 
cytolytic 0 
T 0 
lymphocytes 0 
-LRB- 0 
CTLs 0 
-RRB- 0 
in 0 
a 0 
human 0 
melanoma 1
. 0 

The 0 
mutated 0 
CDK4 0 
allele 0 
was 0 
present 0 
in 0 
autologous 0 
cultured 0 
melanoma 1
cells 0 
and 0 
metastasis 0 
tissue 0 
, 0 
but 0 
not 0 
in 0 
the 0 
patients 0 
lymphocytes 0 
. 0 

The 0 
mutation 0 
, 0 
an 0 
arginine-to-cysteine 0 
exchange 0 
at 0 
residue 0 
_NUM2 0 
, 0 
was 0 
part 0 
of 0 
the 0 
CDK4 0 
peptide 0 
recognized 0 
by 0 
CTLs 0 
and 0 
prevented 0 
binding 0 
of 0 
the 0 
CDK4 0 
inhibitor 0 
p16INK4a 0 
, 0 
but 0 
not 0 
of 0 
_AN 0 
or 0 
of 0 
p27KIP1 0 
. 0 

The 0 
same 0 
mutation 0 
was 0 
found 0 
in 0 
one 0 
additional 0 
melanoma 1
among 0 
_NUM2 0 
melanomas 1
analyzed 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
mutation 0 
of 0 
CDK4 0 
can 0 
create 0 
a 0 
tumor 1
specific 0 
antigen 0 
and 0 
can 0 
disrupt 0 
the 0 
cell-cycle 0 
regulation 0 
exerted 0 
by 0 
the 0 
tumor 1
suppressor 0 
p16INK4a 0 
. 0 
. 0 

Molecular 0 
analysis 0 
in 0 
familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
: 0 
early 0 
diagnosis 0 
of 0 
an 0 
asymptomatic 0 
carrier 0 
. 0 

Familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
-LRB- 0 
FNDI 1
-RRB- 0 
is 0 
an 0 
inherited 0 
deficiency 1
of 1
the 1
hormone 1
arginine 1
vasopressin 1
-LRB- 0 
AVP 0 
-RRB- 0 
and 0 
is 0 
transmitted 0 
as 0 
an 0 
autosomal 0 
dominant 0 
trait 0 
. 0 

In 0 
the 0 
present 0 
study 0 
we 0 
have 0 
analyzed 0 
the 0 
AVP-neurophysin 0 
II 0 
-LRB- 0 
AVP-NPII 0 
-RRB- 0 
gene 0 
in 0 
a 0 
Spanish 0 
kindred 0 
. 0 

Studies 0 
were 0 
performed 0 
on 0 
seven 0 
members 0 
-LRB- 0 
four 0 
clinically 0 
affected 0 
-RRB- 0 
of 0 
the 0 
family 0 
. 0 

Patients 0 
were 0 
diagnosed 0 
at 0 
the 0 
Hospital 0 
Universitario 0 
Gregorio 0 
Maranon 0 
-LRB- 0 
Madrid 0 
, 0 
Spain 0 
-RRB- 0 
. 0 

The 0 
entire 0 
coding 0 
region 0 
of 0 
the 0 
AVP-NPII 0 
gene 0 
of 0 
all 0 
family 0 
members 0 
was 0 
amplified 0 
by 0 
PCR 0 
and 0 
sequenced 0 
. 0 

All 0 
affected 0 
individuals 0 
presented 0 
a 0 
missense 0 
mutation 0 
-LRB- 0 
_AN 0 
-- 0 
> 0 
A 0 
-RRB- 0 
that 0 
replaces 0 
glycine 0 
at 0 
position 0 
_NUM2 0 
with 0 
arginine 0 
within 0 
the 0 
NPII 0 
domain 0 
. 0 

The 0 
substitution 0 
was 0 
confirmed 0 
by 0 
restriction 0 
endonuclease 0 
analysis 0 
and 0 
was 0 
present 0 
in 0 
heterozygosis 0 
. 0 

Additionally 0 
, 0 
one 0 
of 0 
the 0 
asymptomatic 0 
relatives 0 
-LRB- 0 
a 0 
girl 0 
_NUM1 0 
months 0 
old 0 
at 0 
the 0 
time 0 
of 0 
study 0 
-RRB- 0 
was 0 
identified 0 
as 0 
carrier 0 
of 0 
the 0 
same 0 
mutation 0 
and 0 
developed 0 
the 0 
disease 0 
_NUM1 0 
months 0 
later 0 
. 0 

The 0 
alteration 0 
found 0 
in 0 
the 0 
second 0 
exon 0 
of 0 
the 0 
gene 0 
in 0 
this 0 
family 0 
seems 0 
to 0 
be 0 
responsible 0 
for 0 
the 0 
disease 0 
, 0 
as 0 
all 0 
individuals 0 
harboring 0 
the 0 
mutation 0 
had 0 
been 0 
previously 0 
diagnosed 0 
or 0 
have 0 
eventually 0 
developed 0 
FNDI 1
. 0 

Identification 0 
of 0 
the 0 
molecular 0 
defect 0 
underlying 0 
FNDI 1
in 0 
affected 0 
families 0 
is 0 
a 0 
powerful 0 
tool 0 
for 0 
early 0 
asymptomatic 0 
diagnosis 0 
in 0 
infants 0 
. 0 
. 0 

Sialophorin 0 
, 0 
a 0 
surface 0 
sialoglycoprotein 0 
defective 0 
in 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
, 0 
is 0 
involved 0 
in 0 
human 0 
T 0 
lymphocyte 0 
proliferation 0 
. 0 

The 0 
mAb 0 
_AN 0 
was 0 
used 0 
to 0 
determine 0 
the 0 
distribution 0 
and 0 
the 0 
function 0 
of 0 
sialophorin 0 
, 0 
the 0 
heavily 0 
glycosylated 0 
surface 0 
molecule 0 
that 0 
is 0 
deficient 0 
/ 0 
defective 0 
in 0 
lymphocytes 0 
of 0 
patients 0 
with 0 
the 0 
X-linked 1
immunodeficiency 1
Wiskott-Aldrich 1
syndrome 1
. 0 

Dual-parameter 0 
FACS 0 
analysis 0 
indicated 0 
that 0 
sialophorin 0 
is 0 
expressed 0 
on 0 
CD4 0 
+ 0 
and 0 
CD8 0 
+ 0 
lymphocytes 0 
, 0 
on 0 
a 0 
subpopulation 0 
of 0 
peripheral 0 
blood 0 
B 0 
lymphocytes 0 
, 0 
on 0 
all 0 
thymocytes 0 
, 0 
and 0 
on 0 
a 0 
subpopulation 0 
of 0 
bone 0 
marrow 0 
cells 0 
. 0 

Functional 0 
studies 0 
demonstrated 0 
that 0 
_AN 0 
mAb 0 
stimulates 0 
the 0 
proliferation 0 
of 0 
peripheral 0 
blood 0 
T 0 
lymphocytes 0 
as 0 
measured 0 
by 0 
stimulation 0 
of 0 
-LSB- 0 
3H 0 
-RSB- 0 
thymidine 0 
incorporation 0 
. 0 

The 0 
time 0 
course 0 
and 0 
magnitude 0 
of 0 
increased 0 
-LSB- 0 
3H 0 
-RSB- 0 
thymidine 0 
incorporation 0 
by 0 
T 0 
lymphocytes 0 
in 0 
response 0 
to 0 
_AN 0 
mAb 0 
paralleled 0 
that 0 
induced 0 
by 0 
anti-CD3 0 
mAb 0 
. 0 

Effective 0 
stimulation 0 
was 0 
dependent 0 
on 0 
the 0 
presence 0 
of 0 
monocytes 0 
and 0 
the 0 
Fc 0 
portion 0 
of 0 
_AN 0 
mAb 0 
. 0 

Stimulation 0 
of 0 
lymphocytes 0 
by 0 
_AN 0 
, 0 
like 0 
stimulation 0 
by 0 
anti-CD3 0 
mAb 0 
, 0 
involves 0 
increased 0 
expression 0 
of 0 
4F2 0 
, 0 
HLA-DR 0 
, 0 
and 0 
IL-2-R 0 
. 0 

These 0 
observations 0 
suggest 0 
that 0 
sialophorin 0 
functions 0 
in 0 
T 0 
cell 0 
activation 0 
. 0 
. 0 

Characterization 0 
of 0 
the 0 
rat 0 
spinocerebellar 0 
ataxia 0 
type 0 
_NUM1 0 
gene 0 
. 0 

Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
belongs 0 
to 0 
a 0 
group 0 
of 0 
clinically 0 
and 0 
genetically 0 
heterogeneous 0 
neurodegenerative 1
disorders 1
characterized 0 
by 0 
progressive 1
cerebellar 1
ataxia 1
. 0 

The 0 
disease-causing 0 
mutation 0 
has 0 
recently 0 
been 0 
identified 0 
as 0 
an 0 
unstable 0 
and 0 
expanded 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
trinucleotide 0 
repeat 0 
in 0 
a 0 
novel 0 
gene 0 
of 0 
unknown 0 
function 0 
. 0 

In 0 
Caucasians 0 
, 0 
repeat 0 
expansions 0 
in 0 
the 0 
MJD1 0 
gene 0 
have 0 
also 0 
been 0 
found 0 
in 0 
patients 0 
with 0 
the 0 
clinically 0 
distinct 0 
autosomal 0 
dominant 0 
spinocerebellar 1
ataxia 1
type 1
_NUM1 1
-LRB- 0 
SCA3 1
-RRB- 0 
. 0 

In 0 
order 0 
to 0 
gain 0 
insight 0 
into 0 
the 0 
biology 0 
of 0 
the 0 
MJD1 0 
/ 0 
SCA3 0 
gene 0 
we 0 
cloned 0 
the 0 
rat 0 
homologue 0 
and 0 
studied 0 
its 0 
expression 0 
. 0 

The 0 
rat 0 
and 0 
human 0 
ataxin-3 0 
genes 0 
are 0 
highly 0 
homologous 0 
with 0 
an 0 
overall 0 
sequence 0 
identity 0 
of 0 
approximately 0 
_NUM2 0 
% 0 
. 0 

However 0 
, 0 
the 0 
C-terminal 0 
end 0 
of 0 
the 0 
putative 0 
protein 0 
differs 0 
strongly 0 
from 0 
the 0 
published 0 
human 0 
sequence 0 
. 0 

The 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
block 0 
in 0 
the 0 
rat 0 
cDNA 0 
consists 0 
of 0 
just 0 
three 0 
interrupted 0 
units 0 
suggesting 0 
that 0 
a 0 
long 0 
polyglutamine 0 
stretch 0 
is 0 
not 0 
essential 0 
for 0 
the 0 
normal 0 
function 0 
of 0 
the 0 
ataxin-3 0 
protein 0 
in 0 
rodents 0 
. 0 

The 0 
expression 0 
pattern 0 
of 0 
the 0 
SCA3 0 
gene 0 
in 0 
various 0 
rat 0 
and 0 
human 0 
tissues 0 
was 0 
investigated 0 
by 0 
Northern 0 
blot 0 
analyses 0 
. 0 

The 0 
mature 0 
transcript 0 
is 0 
approximately 0 
_NUM1 0 
kb 0 
in 0 
length 0 
. 0 

In 0 
rat 0 
testis 0 
, 0 
a 0 
smaller 0 
transcript 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
was 0 
identified 0 
. 0 

Transcription 0 
of 0 
rsca3 0 
was 0 
detected 0 
in 0 
most 0 
rat 0 
tissues 0 
including 0 
brain 0 
. 0 

Analyzing 0 
the 0 
expression 0 
level 0 
of 0 
the 0 
SCA3 0 
gene 0 
in 0 
several 0 
human 0 
brain 0 
sections 0 
revealed 0 
no 0 
significant 0 
higher 0 
mRNA 0 
level 0 
in 0 
regions 0 
predominantly 0 
affected 0 
in 0 
MJD 1
. 0 

Thus 0 
additional 0 
molecules 0 
and 0 
/ 0 
or 0 
regulatory 0 
events 0 
are 0 
necessary 0 
to 0 
explain 0 
the 0 
exclusive 0 
degeneration 1
of 1
certain 1
brain 1
areas 1
. 0 

The 0 
alveolar 1
rhabdomyosarcoma 1
PAX3 0 
/ 0 
FKHR 0 
fusion 0 
protein 0 
is 0 
a 0 
transcriptional 0 
activator 0 
. 0 

Chimeric 0 
transcription 0 
factors 0 
, 0 
created 0 
by 0 
gene 0 
fusions 0 
as 0 
the 0 
result 0 
of 0 
chromosomal 0 
translocations 0 
, 0 
have 0 
been 0 
implicated 0 
in 0 
the 0 
pathogenesis 0 
of 0 
several 0 
pathologically 0 
disparate 0 
solid 1
tumors 1
. 0 

The 0 
PAX3 0 
/ 0 
FKHR 0 
fusion 0 
gene 0 
, 0 
formed 0 
by 0 
a 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
-RRB- 0 
in 0 
alveolar 1
rhabdomyosarcoma 1
, 0 
encodes 0 
a 0 
hybrid 0 
protein 0 
that 0 
contains 0 
both 0 
PAX3 0 
DNA 0 
binding 0 
domains 0 
, 0 
the 0 
paired 0 
box 0 
and 0 
homeodomain 0 
, 0 
linked 0 
to 0 
the 0 
bisected 0 
DNA 0 
binding 0 
domain 0 
of 0 
FKHR 0 
, 0 
a 0 
member 0 
of 0 
the 0 
forkhead 0 
family 0 
of 0 
transcription 0 
factors 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
PAX3 0 
and 0 
PAX3 0 
/ 0 
FKHR 0 
display 0 
similar 0 
, 0 
but 0 
not 0 
identical 0 
transactivation 0 
activities 0 
when 0 
tested 0 
with 0 
model 0 
Pax 0 
recognition 0 
sequences 0 
. 0 

No 0 
functional 0 
role 0 
could 0 
be 0 
ascribed 0 
solely 0 
to 0 
the 0 
residual 0 
FKHR 0 
binding 0 
domain 0 
present 0 
in 0 
the 0 
fusion 0 
protein 0 
, 0 
but 0 
FKHR 0 
was 0 
found 0 
to 0 
contribute 0 
a 0 
strong 0 
carboxyl 0 
terminal 0 
activation 0 
domain 0 
replacing 0 
the 0 
one 0 
located 0 
in 0 
the 0 
unrearranged 0 
PAX3 0 
gene 0 
. 0 

We 0 
show 0 
that 0 
the 0 
native 0 
PAX3 0 
/ 0 
FKHR 0 
protein 0 
present 0 
in 0 
tumor 1
cells 0 
with 0 
this 0 
translocation 0 
has 0 
transcriptional 0 
characteristics 0 
similar 0 
to 0 
the 0 
in 0 
vitro 0 
expressed 0 
protein 0 
. 0 

The 0 
ability 0 
of 0 
the 0 
PAX3 0 
/ 0 
FKHR 0 
hybrid 0 
protein 0 
to 0 
bind 0 
DNA 0 
in 0 
a 0 
sequence 0 
specific 0 
manner 0 
and 0 
to 0 
transactivate 0 
the 0 
expression 0 
of 0 
artificial 0 
reporter 0 
genes 0 
suggests 0 
that 0 
its 0 
aberrant 0 
expression 0 
could 0 
subvert 0 
the 0 
transcriptional 0 
programs 0 
that 0 
normally 0 
control 0 
the 0 
growth 0 
, 0 
differentiation 0 
, 0 
and 0 
survival 0 
of 0 
primitive 0 
myogenic 0 
precursors 0 
in 0 
vivo 0 
. 0 
. 0 

Myotonia 1
levior 1
is 0 
a 0 
chloride 1
channel 1
disorder 1
. 0 

The 0 
group 0 
of 0 
dominant 1
non-dystrophic 1
myotonias 1
, 0 
comprising 0 
disorders 0 
characterized 0 
by 0 
clinically 0 
similar 0 
forms 0 
of 0 
myogenic 0 
muscle 0 
stiffness 0 
, 0 
is 0 
genetically 0 
inhomogeneous 0 
. 0 

Dominant 1
myotonia 1
congenita 1
-LRB- 0 
Thomsens 1
disease 1
-RRB- 0 
is 0 
linked 0 
to 0 
CLCN1 0 
, 0 
the 0 
gene 0 
encoding 0 
the 0 
major 0 
muscle 0 
chloride 0 
channel 0 
, 0 
localized 0 
on 0 
chromosome 0 
7q35 0 
. 0 

In 0 
contrast 0 
, 0 
dominant 1
myotonias 1
sensitive 0 
to 0 
potassium 0 
are 0 
caused 0 
by 0 
point 0 
mutations 0 
in 0 
SCN4A 0 
on 0 
chromosome 0 
17q 0 
, 0 
the 0 
gene 0 
for 0 
the 0 
alpha 0 
subunit 0 
of 0 
the 0 
adult 0 
skeletal 0 
muscle 0 
sodium 0 
channel 0 
. 0 

No 0 
linkage 0 
or 0 
molecular 0 
genetic 0 
data 0 
are 0 
as 0 
yet 0 
available 0 
on 0 
myotonia 1
levior 1
characterized 0 
by 0 
milder 0 
symptoms 0 
and 0 
later 0 
onset 0 
of 0 
myotonia 1
than 0 
in 0 
Thomsens 1
disease 1
, 0 
and 0 
absence 0 
of 0 
muscle 1
hypertrophy 1
. 0 

We 0 
report 0 
a 0 
CLCN1 0 
Gln-552-Arg 0 
substitution 0 
for 0 
a 0 
family 0 
with 0 
dominant 0 
inheritance 0 
previously 0 
diagnosed 0 
to 0 
have 0 
myotonia 1
levior 1
. 0 

Thus 0 
, 0 
this 0 
disorder 0 
appears 0 
as 0 
a 0 
variant 0 
of 0 
Thomsens 1
disease 1
due 0 
to 0 
mutations 0 
leading 0 
to 0 
low 0 
clinical 0 
expressivity 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
report 0 
a 0 
novel 0 
Ile-290-Met 0 
CLCN1 0 
mutation 0 
for 0 
a 0 
typical 0 
Thomsen 0 
pedigree 0 
. 0 

In 0 
another 0 
family 0 
previously 0 
diagnosed 0 
as 0 
having 0 
Thomsens 1
disease 1
, 0 
we 0 
unexpectedly 0 
found 0 
a 0 
CLCN1 0 
_NUM2 0 
bp 0 
deletion 0 
known 0 
to 0 
cause 0 
recessive 1
myotonia 1
, 0 
and 0 
a 0 
rare 0 
Trp-118-Gly 0 
polymorphism 0 
. 0 
. 0 

Markedly 0 
accelerated 0 
catabolism 0 
of 0 
apolipoprotein 0 
A-II 0 
-LRB- 0 
ApoA-II 0 
-RRB- 0 
and 0 
high 0 
density 0 
lipoproteins 0 
containing 0 
ApoA-II 0 
in 0 
classic 0 
lecithin 0 
: 0 
cholesterol 1
acyltransferase 1
deficiency 1
and 0 
fish-eye 1
disease 1
. 0 

Classic 1
-LRB- 1
complete 1
-RRB- 1
lecithin 1
cholesterol 1
acyltransferase 1
-LRB- 1
LCAT 1
-RRB- 1
deficiency 1
and 0 
Fish-eye 1
disease 1
-LRB- 0 
partial 1
LCAT 1
deficiency 1
-RRB- 0 
are 0 
genetic 0 
syndromes 0 
associated 0 
with 0 
markedly 0 
decreased 0 
plasma 0 
levels 0 
of 0 
high 0 
density 0 
lipoprotein 0 
-LRB- 0 
HDL 0 
-RRB- 0 
cholesterol 0 
but 0 
not 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
atherosclerotic 1
cardiovascular 1
disease 1
. 0 

We 0 
investigated 0 
the 0 
metabolism 0 
of 0 
the 0 
HDL 0 
apolipoproteins 0 
-LRB- 0 
apo 0 
-RRB- 0 
apoA-I 0 
and 0 
apoA-II 0 
in 0 
a 0 
total 0 
of 0 
five 0 
patients 0 
with 0 
LCAT 1
deficiency 1
, 0 
one 0 
with 0 
classic 1
LCAT 1
deficiency 1
and 0 
four 0 
with 0 
Fish-eye 1
disease 1
. 0 

Plasma 0 
levels 0 
of 0 
apoA-II 0 
were 0 
decreased 0 
to 0 
a 0 
proportionately 0 
greater 0 
extent 0 
-LRB- 0 
_NUM2 0 
% 0 
of 0 
normal 0 
-RRB- 0 
than 0 
apoA-I 0 
-LRB- 0 
_NUM2 0 
% 0 
of 0 
normal 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
plasma 0 
concentrations 0 
of 0 
HDL 0 
particles 0 
containing 0 
both 0 
apoA-I 0 
and 0 
apoA-II 0 
-LRB- 0 
LpA-I 0 
A-II 0 
-RRB- 0 
were 0 
much 0 
lower 0 
-LRB- 0 
_NUM2 0 
% 0 
of 0 
normal 0 
-RRB- 0 
than 0 
those 0 
of 0 
particles 0 
containing 0 
only 0 
apoA-I 0 
-LRB- 0 
LpA-I 0 
-RRB- 0 
-LRB- 0 
_NUM2 0 
% 0 
of 0 
normal 0 
-RRB- 0 
. 0 

The 0 
metabolic 0 
basis 0 
for 0 
the 0 
low 0 
levels 0 
of 0 
apoA-II 0 
and 0 
LpA-I 0 
A-II 0 
was 0 
investigated 0 
in 0 
all 0 
five 0 
patients 0 
using 0 
both 0 
exogenous 0 
radiotracer 0 
and 0 
endogenous 0 
stable 0 
isotope 0 
labeling 0 
techniques 0 
. 0 

The 0 
mean 0 
plasma 0 
residence 0 
time 0 
of 0 
apoA-I 0 
was 0 
decreased 0 
at 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
d 0 
-LRB- 0 
controls 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
days 0 
-RRB- 0 
; 0 
however 0 
, 0 
the 0 
residence 0 
time 0 
of 0 
apoA-II 0 
was 0 
even 0 
shorter 0 
at 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
d 0 
-LRB- 0 
controls 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM2 0 
d 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
catabolism 0 
of 0 
apoA-I 0 
in 0 
LpA-I 0 
A-II 0 
was 0 
substantially 0 
faster 0 
than 0 
that 0 
of 0 
apoA-I 0 
in 0 
LpA-I 0 
. 0 

In 0 
summary 0 
, 0 
genetic 0 
syndromes 0 
of 0 
either 0 
complete 1
or 1
partial 1
LCAT 1
deficiency 1
result 0 
in 0 
low 0 
levels 0 
of 0 
HDL 0 
through 0 
preferential 0 
hypercatabolism 0 
of 0 
apoA-II 0 
and 0 
HDL 0 
particles 0 
containing 0 
apoA-II 0 
. 0 

Because 0 
LpA-I 0 
has 0 
been 0 
proposed 0 
to 0 
be 0 
more 0 
protective 0 
than 0 
LpA-I 0 
A-II 0 
against 0 
atherosclerosis 1
, 0 
this 0 
selective 0 
effect 0 
on 0 
the 0 
metabolism 0 
of 0 
LpA-I 0 
A-II 0 
may 0 
provide 0 
a 0 
potential 0 
explanation 0 
why 0 
patients 0 
with 0 
classic 1
LCAT 1
deficiency 1
and 0 
Fish-eye 1
disease 1
are 0 
not 0 
at 0 
increased 0 
risk 0 
for 0 
premature 0 
atherosclerosis 1
despite 0 
markedly 0 
decreased 0 
levels 0 
of 0 
HDL 0 
cholesterol 0 
and 0 
apoA-I 0 
The 0 
identical 0 
_NUM1 0 
' 0 
splice-site 0 
acceptor 0 
mutation 0 
in 0 
five 0 
attenuated 1
APC 1
families 0 
from 0 
Newfoundland 0 
demonstrates 0 
a 0 
founder 0 
effect 0 
. 0 

Inherited 0 
mutations 0 
of 0 
the 0 
APC 1
gene 0 
predispose 0 
carriers 0 
to 0 
multiple 0 
adenomatous 1
polyps 1
of 1
the 1
colon 1
and 1
rectum 1
and 0 
to 0 
colorectal 1
cancer 1
. 0 

Mutations 0 
located 0 
at 0 
the 0 
extreme 0 
_NUM1 0 
end 0 
of 0 
the 0 
APC 1
gene 0 
, 0 
however 0 
, 0 
are 0 
associated 0 
with 0 
a 0 
less 0 
severe 0 
disease 0 
known 0 
as 0 
attenuated 1
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
AAPC 1
-RRB- 0 
. 0 

Many 0 
individuals 0 
with 0 
AAPC 1
develop 0 
relatively 0 
few 0 
colorectal 1
polyps 1
but 0 
are 0 
still 0 
at 0 
high 0 
risk 0 
for 0 
colorectal 1
cancer 1
. 0 

We 0 
report 0 
here 0 
the 0 
identification 0 
of 0 
a 0 
_NUM1 0 
APC 1
germline 0 
mutation 0 
in 0 
five 0 
separately 0 
ascertained 0 
AAPC 1
families 0 
from 0 
Newfoundland 0 
, 0 
Canada 0 
. 0 

This 0 
disease-causing 0 
mutation 0 
is 0 
a 0 
single 0 
basepair 0 
change 0 
-LRB- 0 
G 0 
to 0 
A 0 
-RRB- 0 
in 0 
the 0 
splice-acceptor 0 
region 0 
of 0 
APC 1
intron 0 
_NUM1 0 
that 0 
creates 0 
a 0 
mutant 0 
RNA 0 
without 0 
exon 0 
_NUM1 0 
of 0 
APC 1
. 0 

The 0 
observation 0 
of 0 
the 0 
same 0 
APC 1
mutation 0 
in 0 
five 0 
families 0 
from 0 
the 0 
same 0 
geographic 0 
area 0 
demonstrates 0 
a 0 
founder 0 
effect 0 
. 0 

Furthermore 0 
, 0 
the 0 
identification 0 
of 0 
this 0 
germline 0 
mutation 0 
strengthens 0 
the 0 
correlation 0 
between 0 
the 0 
_NUM1 0 
location 0 
of 0 
an 0 
APC 0 
disease-causing 0 
mutation 0 
and 0 
the 0 
attenuated 1
polyposis 1
phenotype 0 
. 0 
. 0 

Linkage 0 
of 0 
aspartylglucosaminuria 1
-LRB- 0 
AGU 1
-RRB- 0 
to 0 
marker 0 
loci 0 
on 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
. 0 

Aspartylglucosaminuria 1
-LRB- 0 
AGU 1
-RRB- 0 
is 0 
caused 0 
by 0 
deficient 0 
activity 0 
of 0 
the 0 
enzyme 0 
aspartylglucosaminidase 0 
-LRB- 0 
_DS 0 
-RRB- 0 
. 0 

The 0 
structural 0 
gene 0 
for 0 
_DS 0 
has 0 
been 0 
assigned 0 
to 0 
the 0 
region 0 
4q21-qter 0 
of 0 
chromosome 0 
_NUM1 0 
. 0 

We 0 
have 0 
studied 0 
the 0 
map 0 
position 0 
of 0 
the 0 
AGU 1
locus 0 
in 0 
relation 0 
to 0 
other 0 
marker 0 
loci 0 
on 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
using 0 
linkage 0 
analyses 0 
. 0 

Restriction 0 
fragment 0 
length 0 
polymorphism 0 
alleles 0 
for 0 
the 0 
ADH2 0 
, 0 
ADH3 0 
, 0 
EGF 0 
, 0 
FG 0 
alpha 0 
and 0 
FG 0 
beta 0 
loci 0 
and 0 
blood 0 
group 0 
antigens 0 
for 0 
the 0 
MNS 0 
locus 0 
were 0 
determined 0 
in 0 
a 0 
panel 0 
of 0 
_NUM2 0 
Finnish 0 
AGU 1
families 0 
. 0 

The 0 
heterozygous 0 
family 0 
members 0 
were 0 
identified 0 
by 0 
reduced 0 
activity 0 
of 0 
_DS 0 
in 0 
lymphocytes 0 
. 0 

Linkage 0 
studies 0 
were 0 
performed 0 
using 0 
both 0 
pairwise 0 
and 0 
multipoint 0 
analyses 0 
. 0 

Loose 0 
linkage 0 
of 0 
the 0 
AGU 0 
locus 0 
to 0 
the 0 
FG 0 
and 0 
MNS 0 
loci 0 
was 0 
observed 0 
-LRB- 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

Multipoint 0 
analysis 0 
to 0 
the 0 
fixed 0 
map 0 
-LSB- 0 
ADH 0 
- 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
- 0 
EGF 0 
- 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
- 0 
FG 0 
- 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
- 0 
MNS 0 
-RSB- 0 
suggests 0 
that 0 
the 0 
location 0 
of 0 
the 0 
AGU 0 
locus 0 
is 0 
_NUM1 0 
. 0 

05-0 0 
. 0 

_NUM2 0 
recombination 0 
units 0 
distal 0 
to 0 
MNS 0 
-LRB- 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

The 0 
order 0 
cen-ADH-EGF-FG-MNS-AGU 0 
is 0 
_NUM2 0 
times 0 
more 0 
likely 0 
than 0 
the 0 
next 0 
best 0 
order 0 
cen-ADH-EGF-AGU-FG-MNS 0 
. 0 

Linkage 0 
analysis 0 
in 0 
X-linked 1
adrenoleukodystrophy 1
and 0 
application 0 
in 0 
post 0 
- 0 
and 0 
prenatal 0 
diagnosis 0 
. 0 

We 0 
have 0 
performed 0 
linkage 0 
analysis 0 
with 0 
the 0 
DNA 0 
markers 0 
DXS52 0 
and 0 
the 0 
clotting 0 
factor 0 
VIII 0 
gene 0 
-LRB- 0 
F8C 0 
-RRB- 0 
, 0 
in 0 
several 0 
large 0 
families 0 
with 0 
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
. 0 

The 0 
tight 0 
linkage 0 
to 0 
DXS52 0 
could 0 
be 0 
extended 0 
giving 0 
a 0 
maximal 0 
LOD 0 
score 0 
of 0 
_NUM2 0 
. 0 

_NUM1 0 
at 0 
_NUM1 0 
cM 0 
. 0 

F8C 0 
was 0 
also 0 
tightly 0 
linked 0 
to 0 
ALD 1
with 0 
a 0 
maximal 0 
LOD 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
without 0 
recombination 0 
. 0 

Multipoint 0 
linkage 0 
analysis 0 
with 0 
the 0 
markers 0 
DXS304 0 
, 0 
DXS52 0 
, 0 
and 0 
F8C 0 
indicated 0 
that 0 
both 0 
the 0 
gene 0 
for 0 
ALD 1
and 0 
for 0 
F8C 0 
are 0 
distal 0 
to 0 
DXS52 0 
. 0 

In 0 
four 0 
patients 0 
with 0 
ALD 1
, 0 
no 0 
major 0 
structural 0 
rearrangement 0 
in 0 
the 0 
Xqter 0 
region 0 
was 0 
observed 0 
; 0 
in 0 
particular 0 
, 0 
there 0 
were 0 
no 0 
abnormalities 1
in 1
the 1
vision 1
blindness 1
genes 1
. 0 

DNA 0 
analysis 0 
appeared 0 
to 0 
be 0 
of 0 
use 0 
in 0 
determination 0 
of 0 
the 0 
carrier 0 
status 0 
of 0 
females 0 
at 0 
risk 0 
, 0 
for 0 
the 0 
determination 0 
of 0 
the 0 
origin 0 
of 0 
the 0 
mutation 0 
in 0 
a 0 
particular 0 
family 0 
, 0 
and 0 
for 0 
prenatal 0 
diagnosis 0 
. 0 

Multicentric 0 
origin 0 
of 0 
hemochromatosis 1
gene 0 
-LRB- 0 
HFE 0 
-RRB- 0 
mutations 0 
. 0 

Genetic 1
hemochromatosis 1
-LRB- 0 
GH 1
-RRB- 0 
is 0 
believed 0 
to 0 
be 0 
a 0 
disease 0 
restricted 0 
to 0 
those 0 
of 0 
European 0 
ancestry 0 
. 0 

In 0 
northwestern 0 
Europe 0 
, 0 
> 0 
_NUM2 0 
% 0 
of 0 
GH 1
patients 0 
are 0 
homozygous 0 
for 0 
one 0 
mutation 0 
, 0 
the 0 
substitution 0 
of 0 
tyrosine 0 
for 0 
cysteine 0 
at 0 
position 0 
_NUM3 0 
-LRB- 0 
C282Y 0 
-RRB- 0 
in 0 
the 0 
unprocessed 0 
protein 0 
. 0 

In 0 
a 0 
proportion 0 
of 0 
GH 1
patients 0 
, 0 
two 0 
mutations 0 
are 0 
present 0 
, 0 
C282Y 0 
and 0 
H63D 0 
. 0 

The 0 
clinical 0 
significance 0 
of 0 
this 0 
second 0 
mutation 0 
is 0 
such 0 
that 0 
it 0 
appears 0 
to 0 
predispose 0 
_NUM1 0 
% 0 
-2 0 
% 0 
of 0 
compound 0 
heterozygotes 0 
to 0 
expression 0 
of 0 
the 0 
disease 0 
. 0 

The 0 
distribution 0 
of 0 
the 0 
two 0 
mutations 0 
differ 0 
, 0 
C282Y 0 
being 0 
limited 0 
to 0 
those 0 
of 0 
northwestern 0 
European 0 
ancestry 0 
and 0 
H63D 0 
being 0 
found 0 
at 0 
allele 0 
frequencies 0 
> 0 
_NUM1 0 
% 0 
, 0 
in 0 
Europe 0 
, 0 
in 0 
countries 0 
bordering 0 
the 0 
Mediterranean 0 
, 0 
in 0 
the 0 
Middle 0 
East 0 
, 0 
and 0 
in 0 
the 0 
Indian 0 
subcontinent 0 
. 0 

The 0 
C282Y 0 
mutation 0 
occurs 0 
on 0 
a 0 
haplotype 0 
that 0 
extends 0 
< 0 
/ 0 
= 0 
_NUM1 0 
Mb 0 
, 0 
suggesting 0 
that 0 
this 0 
mutation 0 
has 0 
arisen 0 
during 0 
the 0 
past 0 
_NUM1 0 
, 0 
_NUM3 0 
years 0 
. 0 

The 0 
H63D 0 
mutation 0 
is 0 
older 0 
and 0 
does 0 
not 0 
occur 0 
on 0 
such 0 
a 0 
large 0 
extended 0 
haplotype 0 
, 0 
the 0 
haplotype 0 
in 0 
this 0 
case 0 
extending 0 
< 0 
/ 0 
= 0 
_NUM3 0 
kb 0 
. 0 

Here 0 
we 0 
report 0 
the 0 
finding 0 
of 0 
the 0 
H63D 0 
and 0 
C282Y 0 
mutations 0 
on 0 
new 0 
haplotypes 0 
. 0 

In 0 
Sri 0 
Lanka 0 
we 0 
have 0 
found 0 
H63D 0 
on 0 
three 0 
new 0 
haplotypes 0 
and 0 
have 0 
found 0 
C282Y 0 
on 0 
one 0 
new 0 
haplotype 0 
, 0 
demonstrating 0 
that 0 
these 0 
mutations 0 
have 0 
arisen 0 
independently 0 
on 0 
this 0 
island 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
the 0 
HFE 0 
gene 0 
has 0 
been 0 
the 0 
subject 0 
of 0 
selection 0 
pressure 0 
. 0 

These 0 
selection 0 
pressures 0 
could 0 
be 0 
due 0 
to 0 
infectious 1
diseases 1
, 0 
environmental 0 
conditions 0 
, 0 
or 0 
other 0 
genetic 1
disorders 1
such 0 
as 0 
anemia 1
. 0 

Identification 0 
and 0 
localization 0 
of 0 
mutations 0 
at 0 
the 0 
Lesch-Nyhan 1
locus 0 
by 0 
ribonuclease 0 
A 0 
cleavage 0 
. 0 

Many 0 
mutations 0 
leading 0 
to 0 
human 0 
disease 0 
are 0 
the 0 
result 0 
of 0 
single 0 
DNA 0 
base 0 
pair 0 
changes 0 
that 0 
can 0 
not 0 
be 0 
identified 0 
by 0 
Southern 0 
analysis 0 
. 0 

This 0 
has 0 
prompted 0 
the 0 
development 0 
of 0 
alternative 0 
assays 0 
for 0 
point 0 
mutation 0 
detection 0 
. 0 

The 0 
recently 0 
described 0 
ribonuclease 0 
A 0 
cleavage 0 
procedure 0 
, 0 
with 0 
a 0 
polyuridylic 0 
acid-paper 0 
affinity 0 
chromatography 0 
step 0 
, 0 
has 0 
been 0 
used 0 
to 0 
identify 0 
the 0 
mutational 0 
lesions 0 
in 0 
the 0 
hypoxanthine 0 
phosphoribosyltransferase 0 
-LRB- 0 
HPRT 0 
-RRB- 0 
messenger 0 
RNAs 0 
of 0 
patients 0 
with 0 
Lesch-Nyhan 1
syndrome 1
. 0 

Distinctive 0 
ribonuclease 0 
A 0 
cleavage 0 
patterns 0 
were 0 
identified 0 
in 0 
messenger 0 
RNA 0 
from 0 
_NUM1 0 
of 0 
_NUM2 0 
Lesch-Nyhan 1
patients 0 
who 0 
were 0 
chosen 0 
because 0 
no 0 
HPRT 0 
Southern 0 
or 0 
Northern 0 
blotting 0 
pattern 0 
changes 0 
had 0 
been 0 
found 0 
. 0 

This 0 
approach 0 
now 0 
allows 0 
HPRT 0 
mutation 0 
detection 0 
in 0 
_NUM2 0 
percent 0 
of 0 
the 0 
cases 0 
of 0 
Lesch-Nyhan 1
syndrome 1
. 0 

The 0 
polyuridylic 0 
acid-paper 0 
affinity 0 
procedure 0 
provides 0 
a 0 
general 0 
method 0 
for 0 
analysis 0 
of 0 
low 0 
abundance 0 
messenger 0 
RNAs 0 
. 0 
. 0 

MEFV-Gene 0 
analysis 0 
in 0 
armenian 0 
patients 0 
with 0 
Familial 1
Mediterranean 1
fever 1
: 0 
diagnostic 0 
value 0 
and 0 
unfavorable 0 
renal 0 
prognosis 0 
of 0 
the 0 
M694V 0 
homozygous 0 
genotype-genetic 0 
and 0 
therapeutic 0 
implications 0 
. 0 

Familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
is 0 
a 0 
recessively 1
inherited 1
disorder 1
that 0 
is 0 
common 0 
in 0 
patients 0 
of 0 
Armenian 0 
ancestry 0 
. 0 

To 0 
date 0 
, 0 
its 0 
diagnosis 0 
, 0 
which 0 
can 0 
be 0 
made 0 
only 0 
retrospectively 0 
, 0 
is 0 
one 0 
of 0 
exclusion 0 
, 0 
based 0 
entirely 0 
on 0 
nonspecific 0 
clinical 0 
signs 0 
that 0 
result 0 
from 0 
serosal 1
inflammation 1
and 0 
that 0 
may 0 
lead 0 
to 0 
unnecessary 0 
surgery 0 
. 0 

Renal 1
amyloidosis 1
, 0 
prevented 0 
by 0 
colchicine 0 
, 0 
is 0 
the 0 
most 0 
severe 0 
complication 0 
of 0 
FMF 1
, 0 
a 0 
disorder 0 
associated 0 
with 0 
mutations 0 
in 0 
the 0 
MEFV 0 
gene 0 
. 0 

To 0 
evaluate 0 
the 0 
diagnostic 0 
and 0 
prognostic 0 
value 0 
of 0 
MEFV-gene 0 
analysis 0 
, 0 
we 0 
investigated 0 
_NUM2 0 
Armenian 0 
FMF 1
patients 0 
from 0 
_NUM2 0 
unrelated 0 
families 0 
that 0 
were 0 
not 0 
selected 0 
through 0 
genetic-linkage 0 
analysis 0 
. 0 

Eight 0 
mutations 0 
, 0 
one 0 
of 0 
which 0 
-LRB- 0 
R408Q 0 
-RRB- 0 
is 0 
new 0 
, 0 
were 0 
found 0 
to 0 
account 0 
for 0 
_NUM2 0 
% 0 
of 0 
the 0 
_NUM3 0 
independent 0 
FMF 1
alleles 0 
, 0 
with 0 
both 0 
FMF 1
alleles 0 
identified 0 
in 0 
_NUM2 0 
% 0 
of 0 
the 0 
patients 0 
. 0 

In 0 
several 0 
instances 0 
, 0 
family 0 
studies 0 
provided 0 
molecular 0 
evidence 0 
for 0 
pseudodominant 0 
transmission 0 
and 0 
incomplete 0 
penetrance 0 
of 0 
the 0 
disease 0 
phenotype 0 
. 0 

The 0 
M694V 0 
homozygous 0 
genotype 0 
was 0 
found 0 
to 0 
be 0 
associated 0 
with 0 
a 0 
higher 0 
prevalence 0 
of 0 
renal 1
amyloidosis 1
and 0 
arthritis 1
, 0 
compared 0 
with 0 
other 0 
genotypes 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM4 0 
and 0 
P 0 
= 0 
. 0 

_NUM3 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

The 0 
demonstration 0 
of 0 
both 0 
the 0 
diagnostic 0 
and 0 
prognostic 0 
value 0 
of 0 
MEFV 0 
analysis 0 
and 0 
particular 0 
modes 0 
of 0 
inheritance 0 
should 0 
lead 0 
to 0 
new 0 
ways 0 
for 0 
management 0 
of 0 
FMF-including 0 
genetic 0 
counseling 0 
and 0 
therapeutic 0 
decisions 0 
in 0 
affected 0 
families 0 
. 0 

Identification 0 
and 0 
localization 0 
of 0 
huntingtin 0 
in 0 
brain 0 
and 0 
human 0 
lymphoblastoid 0 
cell 0 
lines 0 
with 0 
anti-fusion 0 
protein 0 
antibodies 0 
. 0 

The 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
phenotype 0 
is 0 
associated 0 
with 0 
expansion 0 
of 0 
a 0 
trinucleotide 0 
repeat 0 
in 0 
the 0 
IT15 0 
gene 0 
, 0 
which 0 
is 0 
predicted 0 
to 0 
encode 0 
a 0 
348-kDa 0 
protein 0 
named 0 
huntington 0 
. 0 

We 0 
used 0 
polyclonal 0 
and 0 
monoclonal 0 
anti-fusion 0 
protein 0 
antibodies 0 
to 0 
identify 0 
native 0 
huntingtin 0 
in 0 
rat 0 
, 0 
monkey 0 
, 0 
and 0 
human 0 
. 0 

Western 0 
blots 0 
revealed 0 
a 0 
protein 0 
with 0 
the 0 
expected 0 
molecular 0 
weight 0 
which 0 
is 0 
present 0 
in 0 
the 0 
soluble 0 
fraction 0 
of 0 
rat 0 
and 0 
monkey 0 
brain 0 
tissues 0 
and 0 
lymphoblastoid 0 
cells 0 
from 0 
control 0 
cases 0 
. 0 

In 0 
lymphoblastoid 0 
cell 0 
lines 0 
from 0 
juvenile-onset 0 
heterozygote 0 
HD 1
cases 0 
, 0 
both 0 
normal 0 
and 0 
mutant 0 
huntingtin 0 
are 0 
expressed 0 
, 0 
and 0 
increasing 0 
repeat 0 
expansion 0 
leads 0 
to 0 
lower 0 
levels 0 
of 0 
the 0 
mutant 0 
protein 0 
. 0 

Immunocytochemistry 0 
indicates 0 
that 0 
huntingtin 0 
is 0 
located 0 
in 0 
neurons 0 
throughout 0 
the 0 
brain 0 
, 0 
with 0 
the 0 
highest 0 
levels 0 
evident 0 
in 0 
larger 0 
neurons 0 
. 0 

In 0 
the 0 
human 0 
striatum 0 
, 0 
huntingtin 0 
is 0 
enriched 0 
in 0 
a 0 
patch-like 0 
distribution 0 
, 0 
potentially 0 
corresponding 0 
to 0 
the 0 
first 0 
areas 0 
affected 0 
in 0 
HD 1
. 0 

Subcellular 0 
localization 0 
of 0 
huntingtin 0 
is 0 
consistent 0 
with 0 
a 0 
cytosolic 0 
protein 0 
primarily 0 
found 0 
in 0 
somatodendritic 0 
regions 0 
. 0 

Huntingtin 0 
appears 0 
to 0 
particularly 0 
associate 0 
with 0 
microtubules 0 
, 0 
although 0 
some 0 
is 0 
also 0 
associated 0 
with 0 
synaptic 0 
vesicles 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
the 0 
localization 0 
of 0 
huntingtin 0 
in 0 
association 0 
with 0 
microtubules 0 
, 0 
we 0 
speculate 0 
that 0 
the 0 
mutation 0 
impairs 0 
the 0 
cytoskeletal 0 
anchoring 0 
or 0 
transport 0 
of 0 
mitochondria 0 
, 0 
vesicles 0 
, 0 
or 0 
other 0 
organelles 0 
or 0 
molecules 0 
. 0 
. 0 

Correlation 0 
between 0 
the 0 
location 0 
of 0 
germ-line 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
and 0 
the 0 
number 0 
of 0 
colorectal 1
polyps 1
in 0 
familial 1
adenomatous 1
polyposis 1
patients 0 
. 0 

Recently 0 
we 0 
have 0 
isolated 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
which 0 
causes 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
, 0 
and 0 
its 0 
germ-line 0 
mutations 0 
in 0 
a 0 
substantial 0 
number 0 
of 0 
FAP 1
patients 0 
have 0 
been 0 
identified 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
this 0 
information 0 
, 0 
we 0 
compared 0 
the 0 
location 0 
of 0 
germ-line 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
in 0 
_NUM2 0 
unrelated 0 
patients 0 
-LRB- 0 
_NUM2 0 
of 0 
whom 0 
have 0 
been 0 
reported 0 
previously 0 
-RRB- 0 
with 0 
the 0 
number 0 
of 0 
colorectal 1
polyps 1
developed 0 
in 0 
FAP 1
patients 0 
; 0 
_NUM2 0 
were 0 
sparse 0 
types 0 
and 0 
five 0 
were 0 
profuse 0 
types 0 
. 0 

All 0 
but 0 
one 0 
of 0 
the 0 
mutations 0 
were 0 
considered 0 
to 0 
cause 0 
truncation 0 
of 0 
the 0 
gene 0 
product 0 
by 0 
frame-shift 0 
due 0 
to 0 
deletion 0 
-LRB- 0 
_NUM2 0 
cases 0 
-RRB- 0 
or 0 
nonsense 0 
mutation 0 
-LRB- 0 
seven 0 
cases 0 
-RRB- 0 
. 0 

The 0 
location 0 
of 0 
the 0 
germ-line 0 
mutations 0 
seems 0 
to 0 
correlate 0 
with 0 
the 0 
two 0 
clinical 0 
types 0 
; 0 
germ-line 0 
mutations 0 
in 0 
five 0 
FAP 1
patients 0 
with 0 
profuse 0 
polyps 1
were 0 
observed 0 
between 0 
codon 0 
_NUM4 0 
and 0 
codon 0 
_NUM4 0 
, 0 
whereas 0 
mutations 0 
in 0 
_NUM2 0 
FAP 1
patients 0 
with 0 
fewer 0 
polyps 1
were 0 
observed 0 
in 0 
the 0 
other 0 
regions 0 
of 0 
the 0 
APC 1
gene 0 
. 0 

The 0 
result 0 
suggests 0 
that 0 
the 0 
number 0 
of 0 
colorectal 1
polyps 1
in 0 
FAP 1
patients 0 
may 0 
be 0 
associated 0 
with 0 
a 0 
difference 0 
in 0 
the 0 
stability 0 
or 0 
biological 0 
function 0 
of 0 
the 0 
truncated 0 
APC 1
protein 0 
. 0 
. 0 

Duchenne 1
/ 1
Becker 1
muscular 1
dystrophy 1
: 0 
correlation 0 
of 0 
phenotype 0 
by 0 
electroretinography 0 
with 0 
sites 0 
of 0 
dystrophin 0 
mutations 0 
. 0 

The 0 
dark-adapted 0 
electroretinogram 0 
-LRB- 0 
ERG 0 
-RRB- 0 
of 0 
patients 0 
with 0 
Duchenne 1
and 1
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
/ 0 
BMD 1
-RRB- 0 
shows 0 
a 0 
marked 0 
reduction 0 
in 0 
b-wave 0 
amplitude 0 
. 0 

Genotype-phenotype 0 
studies 0 
of 0 
mouse 0 
models 0 
for 0 
DMD 1
show 0 
position-specific 0 
effects 0 
of 0 
the 0 
mutations 0 
upon 0 
the 0 
phenotype 0 
mice 0 
with 0 
_NUM1 0 
defects 0 
of 0 
dystrophin 0 
have 0 
normal 0 
ERGs 0 
, 0 
those 0 
with 0 
defects 0 
in 0 
the 0 
central 0 
region 0 
have 0 
a 0 
normal 0 
b-wave 0 
amplitude 0 
associated 0 
with 0 
prolonged 0 
implicit 0 
times 0 
for 0 
both 0 
the 0 
b-wave 0 
and 0 
oscillatory 0 
potentials 0 
, 0 
and 0 
mice 0 
with 0 
_NUM1 0 
defects 0 
have 0 
a 0 
phenotype 0 
similar 0 
to 0 
that 0 
seen 0 
in 0 
DMD 1
/ 0 
BMD 1
patients 0 
. 0 

The 0 
mouse 0 
studies 0 
suggest 0 
a 0 
key 0 
role 0 
for 0 
the 0 
carboxyl 0 
terminal 0 
dystrophin 0 
isoform 0 
, 0 
Dp260 0 
, 0 
in 0 
retinal 0 
electrophysiology 0 
. 0 

We 0 
have 0 
undertaken 0 
a 0 
systematic 0 
evaluation 0 
of 0 
DMD 1
/ 0 
BMD 1
patients 0 
through 0 
clinical 0 
examination 0 
and 0 
review 0 
of 0 
the 0 
literature 0 
in 0 
order 0 
to 0 
determine 0 
whether 0 
the 0 
position-specific 0 
effects 0 
of 0 
mutations 0 
noted 0 
in 0 
the 0 
mouse 0 
are 0 
present 0 
in 0 
man 0 
. 0 

We 0 
have 0 
found 0 
that 0 
, 0 
in 0 
man 0 
, 0 
a 0 
wider 0 
variation 0 
of 0 
DMD 1
defects 1
correlate 0 
with 0 
reductions 0 
in 0 
the 0 
b-wave 0 
amplitude 0 
. 0 

Individuals 0 
with 0 
normal 0 
ERGs 0 
have 0 
mutations 0 
predominantly 0 
located 0 
_NUM1 0 
of 0 
the 0 
transcript 0 
initiation 0 
site 0 
of 0 
Dp260 0 
. 0 

Our 0 
results 0 
suggest 0 
that 0 
the 0 
most 0 
important 0 
determinant 0 
in 0 
the 0 
ERG 0 
b-wave 0 
phenotype 0 
is 0 
the 0 
mutation 0 
position 0 
, 0 
rather 0 
than 0 
muscle 1
disease 1
severity 0 
. 0 

Forty-six 0 
per 0 
cent 0 
of 0 
patients 0 
with 0 
mutations 0 
_NUM1 0 
of 0 
the 0 
Dp260 0 
transcript 0 
start 0 
site 0 
have 0 
abnormal 0 
ERGs 0 
, 0 
as 0 
opposed 0 
to 0 
_NUM2 0 
% 0 
with 0 
more 0 
distal 0 
mutations 0 
. 0 

The 0 
human 0 
genotype-phenotype 0 
correlations 0 
are 0 
consistent 0 
with 0 
a 0 
role 0 
for 0 
Dp260 0 
in 0 
normal 0 
retinal 0 
electrophysiology 0 
and 0 
may 0 
also 0 
reflect 0 
the 0 
expression 0 
of 0 
other 0 
C-terminal 0 
dystrophin 0 
isoforms 0 
and 0 
their 0 
contributions 0 
to 0 
retinal 0 
signal 0 
transmission 0 
. 0 
. 0 

Molecular 0 
characterization 0 
of 0 
two 0 
galactosemia 1
mutations 0 
and 0 
one 0 
polymorphism 0 
: 0 
implications 0 
for 0 
structure-function 0 
analysis 0 
of 0 
human 0 
galactose-1-phosphate 0 
uridyltransferase 0 
. 0 

We 0 
report 0 
here 0 
the 0 
molecular 0 
characterization 0 
of 0 
two 0 
galactosemia 1
mutations 0 
, 0 
L74P 0 
and 0 
F171S 0 
, 0 
and 0 
one 0 
polymorphism 0 
, 0 
S135L 0 
, 0 
in 0 
human 0 
galactose-1-phosphate 0 
uridyltransferase 0 
-LRB- 0 
GALT 0 
-RRB- 0 
. 0 

Both 0 
galactosemia 1
mutations 0 
result 0 
in 0 
reduced 0 
enzymatic 0 
activity 0 
when 0 
reconstructed 0 
in 0 
the 0 
cDNA 0 
and 0 
overexpressed 0 
. 0 

The 0 
polymorphism 0 
, 0 
in 0 
contrast 0 
, 0 
has 0 
near 0 
normal 0 
activity 0 
. 0 

Both 0 
mutations 0 
affect 0 
evolutionarily 0 
conserved 0 
residues 0 
, 0 
suggesting 0 
that 0 
they 0 
are 0 
functionally 0 
important 0 
, 0 
while 0 
the 0 
polymorphism 0 
occurs 0 
in 0 
a 0 
nonconserved 0 
domain 0 
which 0 
is 0 
presumably 0 
not 0 
critical 0 
for 0 
enzymatic 0 
function 0 
. 0 

The 0 
F171S 0 
mutation 0 
is 0 
close 0 
to 0 
the 0 
putative 0 
active-site 0 
nucleophile 0 
. 0 

Our 0 
data 0 
further 0 
support 0 
the 0 
notion 0 
of 0 
molecular 0 
heterogeneity 0 
of 0 
galactosemia 1
and 0 
suggest 0 
that 0 
galactosemia 1
mutations 0 
and 0 
GALT 0 
polymorphisms 0 
may 0 
be 0 
useful 0 
tools 0 
in 0 
highlighting 0 
different 0 
functional 0 
domains 0 
in 0 
human 0 
GALT 0 
. 0 
. 0 

Gaucher 1
disease 1
: 0 
the 0 
origins 0 
of 0 
the 0 
Ashkenazi 0 
Jewish 0 
N370S 0 
and 0 
84GG 0 
acid 0 
beta-glucosidase 0 
mutations 0 
. 0 

Type 0 
_NUM1 0 
Gaucher 1
disease 1
-LRB- 0 
GD 1
-RRB- 0 
, 0 
a 0 
non-neuronopathic 0 
lysosomal 1
storage 1
disorder 1
, 0 
results 0 
from 0 
the 0 
deficient 0 
activity 0 
of 0 
acid 0 
beta-glucosidase 0 
-LRB- 0 
GBA 0 
-RRB- 0 
. 0 

Type 0 
_NUM1 0 
disease 0 
is 0 
panethnic 0 
but 0 
is 0 
more 0 
prevalent 0 
in 0 
individuals 0 
of 0 
Ashkenazi 0 
Jewish 0 
-LRB- 0 
AJ 0 
-RRB- 0 
descent 0 
. 0 

Of 0 
the 0 
causative 0 
GBA 0 
mutations 0 
, 0 
N370S 0 
is 0 
particularly 0 
frequent 0 
in 0 
the 0 
AJ 0 
population 0 
, 0 
-LRB- 0 
q 0 
approximately 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
whereas 0 
the 0 
84GG 0 
insertion 0 
-LRB- 0 
q 0 
approximately 0 
. 0 

_NUM3 0 
-RRB- 0 
occurs 0 
exclusively 0 
in 0 
the 0 
Ashkenazim 0 
. 0 

To 0 
investigate 0 
the 0 
genetic 0 
history 0 
of 0 
these 0 
mutations 0 
in 0 
the 0 
AJ 0 
population 0 
, 0 
short 0 
tandem 0 
repeat 0 
-LRB- 0 
STR 0 
-RRB- 0 
markers 0 
were 0 
used 0 
to 0 
map 0 
a 0 
_NUM1 0 
. 0 

3-cM 0 
region 0 
containing 0 
the 0 
GBA 0 
locus 0 
and 0 
to 0 
genotype 0 
_NUM3 0 
AJ 0 
N370S 0 
chromosomes 0 
, 0 
_NUM2 0 
European 0 
non-Jewish 0 
N370S 0 
chromosomes 0 
, 0 
and 0 
_NUM2 0 
AJ 0 
84GG 0 
chromosomes 0 
. 0 

A 0 
highly 0 
conserved 0 
haplotype 0 
at 0 
four 0 
markers 0 
flanking 0 
GBA 0 
-LRB- 0 
PKLR 0 
, 0 
D1S1595 0 
, 0 
D1S2721 0 
, 0 
and 0 
D1S2777 0 
-RRB- 0 
was 0 
observed 0 
on 0 
both 0 
the 0 
AJ 0 
chromosomes 0 
and 0 
the 0 
non-Jewish 0 
N370S 0 
chromosomes 0 
, 0 
suggesting 0 
the 0 
occurrence 0 
of 0 
a 0 
founder 0 
common 0 
to 0 
both 0 
populations 0 
. 0 

Of 0 
note 0 
, 0 
the 0 
presence 0 
of 0 
different 0 
divergent 0 
haplotypes 0 
suggested 0 
the 0 
occurrence 0 
of 0 
de 0 
novo 0 
, 0 
recurrent 0 
N370S 0 
mutations 0 
. 0 

In 0 
contrast 0 
, 0 
a 0 
different 0 
conserved 0 
haplotype 0 
at 0 
these 0 
markers 0 
was 0 
identified 0 
on 0 
the 0 
84GG 0 
chromosomes 0 
, 0 
which 0 
was 0 
unique 0 
to 0 
the 0 
AJ 0 
population 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
the 0 
linkage 0 
disequilibrium 0 
-LRB- 0 
LD 0 
-RRB- 0 
delta 0 
values 0 
, 0 
the 0 
non-Jewish 0 
European 0 
N370S 0 
chromosomes 0 
had 0 
greater 0 
haplotype 0 
diversity 0 
and 0 
less 0 
LD 0 
at 0 
the 0 
markers 0 
flanking 0 
the 0 
conserved 0 
haplotype 0 
than 0 
did 0 
the 0 
AJ 0 
N370S 0 
chromosomes 0 
. 0 

This 0 
finding 0 
is 0 
consistent 0 
with 0 
the 0 
presence 0 
of 0 
the 0 
N370S 0 
mutation 0 
in 0 
the 0 
non-Jewish 0 
European 0 
population 0 
prior 0 
to 0 
the 0 
founding 0 
of 0 
the 0 
AJ 0 
population 0 
. 0 

Coalescence 0 
analyses 0 
for 0 
the 0 
N370S 0 
and 0 
84GG 0 
mutations 0 
estimated 0 
similar 0 
coalescence 0 
times 0 
, 0 
of 0 
_NUM2 0 
and 0 
_FN 0 
generations 0 
ago 0 
, 0 
respectively 0 
. 0 

The 0 
results 0 
of 0 
these 0 
studies 0 
are 0 
consistent 0 
with 0 
a 0 
significant 0 
bottleneck 0 
occurring 0 
in 0 
the 0 
AJ 0 
population 0 
during 0 
the 0 
first 0 
millennium 0 
, 0 
when 0 
the 0 
population 0 
became 0 
established 0 
in 0 
Europe 0 
. 0 

Investigation 0 
of 0 
thermoregulatory 0 
characteristics 0 
in 0 
patients 0 
with 0 
Prader-Willi 1
syndrome 1
. 0 

A 0 
survey 0 
instrument 0 
is 0 
used 0 
to 0 
assess 0 
temperature 0 
regulation 0 
characteristics 0 
in 0 
children 0 
with 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
compared 0 
to 0 
_NUM1 0 
control 0 
groups 0 
sibs 0 
of 0 
PWS 1
patients 0 
-LRB- 0 
SIB 0 
-RRB- 0 
, 0 
neurodevelopmentally 1
handicapped 1
children 0 
-LRB- 0 
ND 0 
-RRB- 0 
, 0 
and 0 
age 0 
and 0 
gender 0 
matched 0 
well 0 
children 0 
-LRB- 0 
WC 0 
-RRB- 0 
. 0 

Significant 0 
differences 0 
were 0 
found 0 
between 0 
PWS 1
patients 0 
, 0 
SIB 0 
controls 0 
, 0 
and 0 
WC 0 
controls 0 
in 0 
the 0 
prevalence 0 
of 0 
febrile 0 
convulsions 0 
, 0 
fever-associated 0 
symptoms 0 
, 0 
and 0 
temperature 0 
less 0 
than 0 
_NUM2 0 
degrees 0 
F. 0 
No 0 
differences 0 
were 0 
noted 0 
in 0 
any 0 
variable 0 
between 0 
the 0 
PWS 1
patients 0 
and 0 
the 0 
ND 0 
controls 0 
, 0 
suggesting 0 
that 0 
these 0 
abnormalities 0 
are 0 
not 0 
unique 0 
to 0 
PWS 1
, 0 
but 0 
can 0 
occur 0 
in 0 
any 0 
neurodevelopmentally 1
handicapped 1
individual 0 
, 0 
further 0 
suggesting 0 
these 0 
do 0 
not 0 
necessarily 0 
reflect 0 
syndrome-specific 0 
hypothalamic 1
abnormalities 1
. 0 
. 0 

Abnormal 0 
high 0 
density 0 
lipoproteins 0 
in 0 
cerebrotendinous 1
xanthomatosis 1
. 0 

The 0 
plasma 0 
lipoprotein 0 
profiles 0 
and 0 
high 0 
density 0 
lipoproteins 0 
-LRB- 0 
HDL 0 
-RRB- 0 
were 0 
characterized 0 
in 0 
patients 0 
with 0 
the 0 
genetic 1
disease 1
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
. 0 

Abnormalities 1
in 1
the 1
HDL 1
may 0 
contribute 0 
to 0 
their 0 
increased 0 
atherogenesis 0 
and 0 
excessive 0 
deposits 0 
of 0 
tissue 0 
sterols 0 
in 0 
the 0 
presence 0 
of 0 
low 0 
or 0 
low-normal 0 
concentrations 0 
of 0 
plasma 0 
cholesterol 0 
-LRB- 0 
_NUM3 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
-RRB- 0 
and 0 
low 0 
density 0 
lipoproteins 0 
-LRB- 0 
LDL 0 
-RRB- 0 
. 0 

The 0 
mean 0 
HDL-cholesterol 0 
concentration 0 
in 0 
the 0 
CTX 1
plasmas 0 
was 0 
_NUM2 0 
. 0 

_NUM1 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM1 0 
mg 0 
/ 0 
dl 0 
, 0 
about 0 
one-third 0 
the 0 
normal 0 
value 0 
. 0 

The 0 
low 0 
HDL-cholesterol 0 
reflects 0 
a 0 
low 0 
concentration 0 
and 0 
an 0 
abnormal 0 
lipid 0 
composition 0 
of 0 
the 0 
plasma 0 
HDL 0 
. 0 

Relative 0 
to 0 
normal 0 
HDL 0 
, 0 
the 0 
cholesteryl 0 
esters 0 
are 0 
low 0 
, 0 
free 0 
cholesterol 0 
and 0 
phospholipids 0 
essentially 0 
normal 0 
, 0 
and 0 
triglycerides 0 
increased 0 
. 0 

The 0 
ratio 0 
of 0 
apoprotein 0 
-LRB- 0 
apo 0 
-RRB- 0 
to 0 
total 0 
cholesterol 0 
in 0 
the 0 
HDL 0 
of 0 
CTX 1
was 0 
two 0 
to 0 
three 0 
times 0 
greater 0 
than 0 
normal 0 
. 0 

In 0 
the 0 
CTX 1
HDL 0 
, 0 
the 0 
ratio 0 
of 0 
apoAI 0 
to 0 
apoAII 0 
was 0 
high 0 
, 0 
the 0 
proportion 0 
of 0 
apoC 0 
low 0 
, 0 
and 0 
a 0 
normally 0 
minor 0 
form 0 
of 0 
apoAI 0 
increased 0 
relative 0 
to 0 
other 0 
forms 0 
. 0 

The 0 
HDL 0 
in 0 
electron 0 
micrographs 0 
appeared 0 
normal 0 
morphologically 0 
and 0 
in 0 
particle 0 
size 0 
. 0 

The 0 
abnormalities 0 
in 0 
lipoprotein 0 
distribution 0 
profile 0 
and 0 
composition 0 
of 0 
the 0 
plasma 0 
HDL 0 
result 0 
from 0 
metabolic 0 
defects 0 
that 0 
are 0 
not 0 
understood 0 
but 0 
may 0 
be 0 
linked 0 
to 0 
the 0 
genetic 1
defect 1
in 0 
bile 0 
acid 0 
synthesis 0 
in 0 
CTX 1
. 0 

As 0 
a 0 
consequence 0 
, 0 
it 0 
is 0 
probable 0 
that 0 
the 0 
normal 0 
functions 0 
of 0 
the 0 
HDL 0 
, 0 
possibly 0 
including 0 
modulation 0 
of 0 
LDL-cholesterol 0 
uptake 0 
and 0 
the 0 
removal 0 
of 0 
excess 0 
cholesterol 0 
from 0 
peripheral 0 
tissues 0 
, 0 
are 0 
perturbed 0 
significantly 0 
in 0 
this 0 
disease 0 
. 0 

Splicing 0 
defects 0 
in 0 
the 0 
ataxia-telangiectasia 1
gene 0 
, 0 
ATM 0 
: 0 
underlying 0 
mutations 0 
and 0 
consequences 0 
. 0 

Mutations 0 
resulting 0 
in 0 
defective 0 
splicing 0 
constitute 0 
a 0 
significant 0 
proportion 0 
-LRB- 0 
30 0 
/ 0 
62 0 
-LSB- 0 
_NUM2 0 
% 0 
-RSB- 0 
-RRB- 0 
of 0 
a 0 
new 0 
series 0 
of 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
in 0 
patients 0 
with 0 
ataxia-telangiectasia 1
-LRB- 0 
_DS 0 
-RRB- 0 
that 0 
were 0 
detected 0 
by 0 
the 0 
protein-truncation 0 
assay 0 
followed 0 
by 0 
sequence 0 
analysis 0 
of 0 
genomic 0 
DNA 0 
. 0 

Fewer 0 
than 0 
half 0 
of 0 
the 0 
splicing 0 
mutations 0 
involved 0 
the 0 
canonical 0 
_DS 0 
splice-acceptor 0 
site 0 
or 0 
_DS 0 
splice-donor 0 
site 0 
. 0 

A 0 
higher 0 
percentage 0 
of 0 
mutations 0 
occurred 0 
at 0 
less 0 
stringently 0 
conserved 0 
sites 0 
, 0 
including 0 
silent 0 
mutations 0 
of 0 
the 0 
last 0 
nucleotide 0 
of 0 
exons 0 
, 0 
mutations 0 
in 0 
nucleotides 0 
other 0 
than 0 
the 0 
conserved 0 
_DS 0 
and 0 
_DS 0 
in 0 
the 0 
consensus 0 
splice 0 
sites 0 
, 0 
and 0 
creation 0 
of 0 
splice-acceptor 0 
or 0 
splice-donor 0 
sites 0 
in 0 
either 0 
introns 0 
or 0 
exons 0 
. 0 

These 0 
splicing 0 
mutations 0 
led 0 
to 0 
a 0 
variety 0 
of 0 
consequences 0 
, 0 
including 0 
exon 0 
skipping 0 
and 0 
, 0 
to 0 
a 0 
lesser 0 
degree 0 
, 0 
intron 0 
retention 0 
, 0 
activation 0 
of 0 
cryptic 0 
splice 0 
sites 0 
, 0 
or 0 
creation 0 
of 0 
new 0 
splice 0 
sites 0 
. 0 

In 0 
addition 0 
, 0 
_NUM1 0 
of 0 
_NUM2 0 
nonsense 0 
mutations 0 
and 0 
_NUM1 0 
missense 0 
mutation 0 
were 0 
associated 0 
with 0 
deletion 0 
in 0 
the 0 
cDNA 0 
of 0 
the 0 
exons 0 
in 0 
which 0 
the 0 
mutations 0 
occurred 0 
. 0 

No 0 
ATM 0 
protein 0 
was 0 
detected 0 
by 0 
western 0 
blotting 0 
in 0 
any 0 
_DS 0 
cell 0 
line 0 
in 0 
which 0 
splicing 0 
mutations 0 
were 0 
identified 0 
. 0 

Several 0 
cases 0 
of 0 
exon 0 
skipping 0 
in 0 
both 0 
normal 0 
controls 0 
and 0 
patients 0 
for 0 
whom 0 
no 0 
underlying 0 
defect 0 
could 0 
be 0 
found 0 
in 0 
genomic 0 
DNA 0 
were 0 
also 0 
observed 0 
, 0 
suggesting 0 
caution 0 
in 0 
the 0 
interpretation 0 
of 0 
exon 0 
deletions 0 
observed 0 
in 0 
ATM 0 
cDNA 0 
when 0 
there 0 
is 0 
no 0 
accompanying 0 
identification 0 
of 0 
genomic 0 
mutations 0 
. 0 
. 0 

Mutations 0 
of 0 
the 0 
cathepsin 0 
C 0 
gene 0 
are 0 
responsible 0 
for 0 
Papillon-Lefevre 1
syndrome 1
. 0 

Papillon-Lefevre 1
syndrome 1
-LRB- 0 
PLS 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
characterised 0 
by 0 
palmoplantar 1
hyperkeratosis 1
and 0 
severe 0 
early 0 
onset 0 
periodontitis 1
that 0 
results 0 
in 0 
the 0 
premature 0 
loss 0 
of 0 
the 0 
primary 0 
and 0 
secondary 0 
dentitions 0 
. 0 

A 0 
major 0 
gene 0 
locus 0 
for 0 
PLS 1
has 0 
been 0 
mapped 0 
to 0 
a 0 
_NUM1 0 
. 0 

_NUM1 0 
cM 0 
interval 0 
on 0 
chromosome 0 
11q14 0 
. 0 

Correlation 0 
of 0 
physical 0 
and 0 
genetic 0 
maps 0 
of 0 
this 0 
interval 0 
indicate 0 
it 0 
includes 0 
at 0 
least 0 
_NUM2 0 
ESTs 0 
and 0 
six 0 
known 0 
genes 0 
including 0 
the 0 
lysosomal 0 
protease 0 
cathepsin 0 
C 0 
gene 0 
-LRB- 0 
CTSC 0 
-RRB- 0 
. 0 

The 0 
CTSC 0 
message 0 
is 0 
expressed 0 
at 0 
high 0 
levels 0 
in 0 
a 0 
variety 0 
of 0 
immune 0 
cells 0 
including 0 
polymorphonuclear 0 
leucocytes 0 
, 0 
macrophages 0 
, 0 
and 0 
their 0 
precursors 0 
. 0 

By 0 
RT-PCR 0 
, 0 
we 0 
found 0 
CTSC 0 
is 0 
also 0 
expressed 0 
in 0 
epithelial 0 
regions 0 
commonly 0 
affected 0 
by 0 
PLS 1
, 0 
including 0 
the 0 
palms 0 
, 0 
soles 0 
, 0 
knees 0 
, 0 
and 0 
oral 0 
keratinised 0 
gingiva 0 
. 0 

The 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
CTSC 0 
gene 0 
consists 0 
of 0 
two 0 
exons 0 
. 0 

Sequence 0 
analysis 0 
of 0 
CTSC 0 
from 0 
subjects 0 
affected 0 
with 0 
PLS 1
from 0 
five 0 
consanguineous 0 
Turkish 0 
families 0 
identified 0 
four 0 
different 0 
mutations 0 
. 0 

An 0 
exon 0 
_NUM1 0 
nonsense 0 
mutation 0 
-LRB- 0 
856C 0 
-- 0 
> 0 
T 0 
-RRB- 0 
introduces 0 
a 0 
premature 0 
stop 0 
codon 0 
at 0 
amino 0 
acid 0 
_NUM3 0 
. 0 

Three 0 
exon 0 
_NUM1 0 
mutations 0 
were 0 
identified 0 
, 0 
including 0 
a 0 
single 0 
nucleotide 0 
deletion 0 
-LRB- 0 
2692delA 0 
-RRB- 0 
of 0 
codon 0 
_NUM3 0 
introducing 0 
a 0 
frameshift 0 
and 0 
premature 0 
termination 0 
codon 0 
, 0 
a 0 
_NUM1 0 
bp 0 
deletion 0 
-LRB- 0 
2673-2674delCT 0 
-RRB- 0 
that 0 
results 0 
in 0 
introduction 0 
of 0 
a 0 
stop 0 
codon 0 
at 0 
amino 0 
acid 0 
_NUM3 0 
, 0 
and 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
substitution 0 
in 0 
codon 0 
_NUM3 0 
-LRB- 0 
2931G 0 
-- 0 
> 0 
A 0 
-RRB- 0 
introducing 0 
a 0 
premature 0 
termination 0 
codon 0 
. 0 

All 0 
PLS 1
patients 0 
were 0 
homozygous 0 
for 0 
cathepsin 0 
C 0 
mutations 0 
inherited 0 
from 0 
a 0 
common 0 
ancestor 0 
. 0 

Parents 0 
and 0 
sibs 0 
heterozygous 0 
for 0 
cathepsin 0 
C 0 
mutations 0 
do 0 
not 0 
show 0 
either 0 
the 0 
palmoplantar 1
hyperkeratosis 1
or 0 
severe 0 
early 0 
onset 0 
periodontitis 1
characteristic 0 
of 0 
PLS 1
. 0 

A 0 
more 0 
complete 0 
understanding 0 
of 0 
the 0 
functional 0 
physiology 0 
of 0 
cathepsin 0 
C 0 
carries 0 
significant 0 
implications 0 
for 0 
understanding 0 
normal 0 
and 0 
abnormal 0 
skin 0 
development 0 
and 0 
periodontal 1
disease 1
susceptibility 0 
Identification 0 
of 0 
a 0 
single 0 
nucleotide 0 
change 0 
in 0 
the 0 
hypoxanthine-guanine 0 
phosphoribosyltransferase 0 
gene 0 
-LRB- 0 
HPRTYale 0 
-RRB- 0 
responsible 0 
for 0 
Lesch-Nyhan 1
syndrome 1
. 0 

Complete 0 
deficiency 1
of 1
hypoxanthine-guanine 1
phosphoribosyltransferase 1
-LRB- 0 
HPRT 0 
-RRB- 0 
causes 0 
the 0 
Lesch-Nyhan 1
syndrome 1
. 0 

Previous 0 
characterization 0 
of 0 
a 0 
mutant 0 
form 0 
of 0 
HPRT 0 
, 0 
HPRTYale 0 
, 0 
from 0 
a 0 
subject 0 
with 0 
the 0 
Lesch-Nyhan 1
syndrome 1
revealed 0 
normal 0 
mRNA 0 
and 0 
protein 0 
concentrations 0 
, 0 
no 0 
residual 0 
catalytic 0 
activity 0 
, 0 
and 0 
cathodal 0 
migration 0 
upon 0 
PAGE 0 
. 0 

We 0 
have 0 
cloned 0 
and 0 
sequenced 0 
HPRTYale 0 
cDNA 0 
. 0 

The 0 
nucleotide 0 
sequence 0 
of 0 
full-length 0 
HPRTYale 0 
cDNA 0 
revealed 0 
a 0 
single 0 
nucleotide 0 
substitution 0 
compared 0 
with 0 
normal 0 
HPRT 0 
cDNA 0 
G 0 
-- 0 
C 0 
at 0 
nucleotide 0 
position 0 
_NUM3 0 
. 0 

This 0 
transversion 0 
predicts 0 
substitution 0 
of 0 
arginine 0 
for 0 
glycine 0 
at 0 
amino 0 
acid 0 
position 0 
_NUM2 0 
, 0 
explaining 0 
the 0 
cathodal 0 
migration 0 
of 0 
HPRTYale 0 
. 0 

Chou-Fasman 0 
secondary 0 
structure 0 
analysis 0 
predicts 0 
a 0 
change 0 
in 0 
the 0 
probability 0 
of 0 
beta-turn 0 
formation 0 
in 0 
the 0 
region 0 
containing 0 
the 0 
mutation 0 
. 0 

Inclusion 0 
of 0 
the 0 
bulky 0 
arginine 0 
side 0 
chain 0 
in 0 
place 0 
of 0 
glycine 0 
probably 0 
disrupts 0 
protein 0 
folding 0 
as 0 
well 0 
. 0 

Cloning 0 
mutant 0 
forms 0 
of 0 
cDNA 0 
allows 0 
identification 0 
of 0 
specific 0 
mutations 0 
, 0 
provides 0 
insight 0 
into 0 
mutational 0 
mechanisms 0 
, 0 
and 0 
facilitates 0 
structure-function 0 
analysis 0 
of 0 
mutant 0 
proteins 0 
. 0 
. 0 

Molecular 0 
detection 0 
of 0 
chromosomal 0 
translocations 0 
that 0 
disrupt 0 
the 0 
putative 0 
retinoblastoma 1
susceptibility 0 
locus 0 
. 0 

A 0 
candidate 0 
DNA 0 
sequence 0 
with 0 
many 0 
of 0 
the 0 
properties 0 
predicted 0 
for 0 
the 0 
retinoblastoma 1
susceptibility 0 
-LRB- 0 
RB1 0 
-RRB- 0 
locus 0 
has 0 
been 0 
cloned 0 
-LRB- 0 
S. 0 
H. 0 
Friend 0 
, 0 
R. 0 
Bernards 0 
, 0 
S. 0 
Rogelj 0 
, 0 
R. 0 
A. 0 
Weinberg 0 
, 0 
J. 0 
M. 0 
Rapaport 0 
, 0 
D. 0 
M. 0 
Albert 0 
, 0 
and 0 
T. 0 
P. 0 
Dryja 0 
, 0 
Nature 0 
-LSB- 0 
London 0 
-RSB- 0 
_NUM3 0 
643-645 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

The 0 
large 0 
size 0 
of 0 
this 0 
gene 0 
-LRB- 0 
ca. 0 
_NUM3 0 
kilobases 0 
-LSB- 0 
kb 0 
-RSB- 0 
-RRB- 0 
and 0 
its 0 
multiple 0 
dispersed 0 
exons 0 
-LRB- 0 
Wiggs 0 
et 0 
al. 0 
, 0 
N. 0 
Engl 0 
. 0 

J. 0 
Med 0 
. 0 

_NUM3 0 
151-157 0 
, 0 
_NUM4 0 
-RRB- 0 
complicate 0 
molecular 0 
screening 0 
strategies 0 
important 0 
in 0 
prenatal 0 
and 0 
presymptomatic 0 
diagnosis 0 
and 0 
in 0 
carrier 0 
detection 0 
. 0 

Here 0 
we 0 
used 0 
field 0 
inversion 0 
gel 0 
electrophoresis 0 
-LRB- 0 
FIGE 0 
-RRB- 0 
to 0 
construct 0 
a 0 
restriction 0 
map 0 
of 0 
approximately 0 
_NUM1 0 
, 0 
_NUM3 0 
kb 0 
of 0 
DNA 0 
surrounding 0 
the 0 
RB1 0 
locus 0 
and 0 
to 0 
detect 0 
the 0 
translocation 0 
breakpoints 0 
in 0 
three 0 
retinoblastoma 1
patients 0 
. 0 

DNA 0 
probes 0 
from 0 
either 0 
the 0 
_NUM1 0 
or 0 
_NUM1 0 
end 0 
of 0 
the 0 
gene 0 
were 0 
used 0 
to 0 
detect 0 
a 0 
250-kb 0 
EagI 0 
restriction 0 
fragment 0 
in 0 
DNA 0 
from 0 
unaffected 0 
individuals 0 
. 0 

Both 0 
probes 0 
identified 0 
an 0 
additional 0 
hybridizing 0 
fragment 0 
in 0 
the 0 
DNA 0 
from 0 
each 0 
patient 0 
, 0 
permitting 0 
the 0 
breakpoints 0 
in 0 
all 0 
three 0 
to 0 
be 0 
mapped 0 
within 0 
the 0 
cloned 0 
RB1 0 
gene 0 
. 0 

Analysis 0 
of 0 
the 0 
breakpoint 0 
in 0 
one 0 
translocation 0 
cell 0 
line 0 
allowed 0 
the 0 
RB1 0 
gene 0 
to 0 
be 0 
oriented 0 
with 0 
its 0 
_NUM1 0 
end 0 
toward 0 
the 0 
centromere 0 
. 0 

The 0 
_NUM1 0 
end 0 
of 0 
the 0 
gene 0 
also 0 
appeared 0 
to 0 
be 0 
associated 0 
with 0 
a 0 
clustering 0 
of 0 
sites 0 
for 0 
several 0 
infrequently 0 
cleaving 0 
restriction 0 
enzymes 0 
, 0 
indicating 0 
the 0 
presence 0 
of 0 
an 0 
HpaII 0 
tiny 0 
fragment 0 
island 0 
. 0 

The 0 
detection 0 
and 0 
mapping 0 
of 0 
the 0 
translocation 0 
breakpoints 0 
of 0 
all 0 
three 0 
retinoblastoma 1
patients 0 
to 0 
within 0 
the 0 
putative 0 
RB1 0 
gene 0 
substantiated 0 
the 0 
authenticity 0 
of 0 
this 0 
candidate 0 
sequence 0 
and 0 
demonstrated 0 
the 0 
utility 0 
of 0 
FIGE 0 
in 0 
detecting 0 
chromosomal 0 
rearrangements 0 
affecting 0 
this 0 
locus 0 
. 0 

Constitutional 0 
mutations 0 
in 0 
the 0 
WT1 0 
gene 0 
in 0 
patients 0 
with 0 
Denys-Drash 1
syndrome 1
. 0 

The 0 
Denys-Drash 1
syndrome 1
is 0 
characterised 0 
by 0 
a 0 
typical 0 
nephropathy 1
, 0 
genital 1
abnormalities 1
and 0 
also 0 
predisposes 0 
to 0 
the 0 
development 0 
of 0 
Wilms 1
tumor 1
. 0 

These 0 
patients 0 
eventually 0 
go 0 
into 0 
end 0 
stage 0 
renal 1
failure 1
. 0 

A 0 
candidate 0 
Wilms 1
tumor 1
gene 0 
, 0 
WT1 0 
, 0 
from 0 
the 0 
11p13 0 
chromosome 0 
region 0 
has 0 
recently 0 
been 0 
cloned 0 
. 0 

We 0 
have 0 
analysed 0 
the 0 
DNA 0 
sequence 0 
in 0 
constitutional 0 
cells 0 
from 0 
eight 0 
patients 0 
and 0 
have 0 
shown 0 
heterozygous 0 
mutations 0 
in 0 
six 0 
of 0 
them 0 
. 0 

Four 0 
of 0 
the 0 
mutations 0 
were 0 
in 0 
exon 0 
_NUM1 0 
, 0 
all 0 
resulting 0 
in 0 
missense 0 
mutations 0 
. 0 

Three 0 
were 0 
at 0 
nucleotide 0 
position 0 
_NUM4 0 
resulting 0 
in 0 
an 0 
arg 0 
> 0 
trp 0 
amino 0 
acid 0 
change 0 
. 0 

The 0 
other 0 
was 0 
at 0 
position 0 
_NUM4 0 
converting 0 
an 0 
asp 0 
> 0 
asn 0 
in 0 
the 0 
predicted 0 
resultant 0 
protein 0 
. 0 

One 0 
patient 0 
had 0 
a 0 
missense 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
, 0 
converting 0 
an 0 
arg 0 
> 0 
his 0 
. 0 

A 0 
single 0 
base 0 
pair 0 
insertion 0 
at 0 
nucleotide 0 
position 0 
_NUM3 0 
in 0 
exon 0 
_NUM1 0 
resulted 0 
in 0 
the 0 
generation 0 
of 0 
a 0 
premature 0 
stop 0 
codon 0 
in 0 
the 0 
last 0 
patient 0 
. 0 

We 0 
were 0 
unable 0 
to 0 
find 0 
a 0 
mutation 0 
in 0 
one 0 
patient 0 
despite 0 
complete 0 
sequencing 0 
of 0 
the 0 
genomic 0 
sequence 0 
of 0 
the 0 
gene 0 
. 0 

The 0 
last 0 
patient 0 
carried 0 
a 0 
constitutional 0 
deletion 0 
of 0 
the 0 
11p13 0 
region 0 
and 0 
no 0 
additional 0 
mutation 0 
was 0 
found 0 
. 0 

There 0 
was 0 
no 0 
obvious 0 
correlation 0 
between 0 
the 0 
type 0 
of 0 
mutation 0 
and 0 
phenotypic 0 
expression 0 
. 0 

These 0 
results 0 
further 0 
demonstrate 0 
that 0 
the 0 
WT1 0 
gene 0 
is 0 
important 0 
in 0 
both 0 
the 0 
development 0 
of 0 
the 0 
kidney 0 
and 0 
the 0 
genito-urinary 0 
system 0 
. 0 
. 0 

Four 0 
novel 0 
PEPD 0 
alleles 0 
causing 0 
prolidase 1
deficiency 1
. 0 

Mutations 0 
at 0 
the 0 
PEPD 0 
locus 0 
cause 0 
prolidase 1
deficiency 1
-LRB- 0 
McKusick 0 
_NUM6 0 
-RRB- 0 
, 0 
a 0 
rare 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
iminodipeptiduria 1
, 0 
skin 1
ulcers 1
, 0 
mental 1
retardation 1
, 0 
and 0 
recurrent 0 
infections 0 
. 0 

Four 0 
PEPD 0 
mutations 0 
from 0 
five 0 
severely 0 
affected 0 
individuals 0 
were 0 
characterized 0 
by 0 
analysis 0 
of 0 
reverse-transcribed 0 
, 0 
PCR-amplified 0 
-LRB- 0 
RT-PCR 0 
-RRB- 0 
cDNA 0 
. 0 

We 0 
used 0 
SSCP 0 
analysis 0 
on 0 
four 0 
overlapping 0 
cDNA 0 
fragments 0 
covering 0 
the 0 
entire 0 
coding 0 
region 0 
of 0 
the 0 
PEPD 0 
gene 0 
and 0 
detected 0 
abnormal 0 
SSCP 0 
bands 0 
for 0 
the 0 
fragment 0 
spanning 0 
all 0 
or 0 
part 0 
of 0 
exons 0 
13-15 0 
in 0 
three 0 
of 0 
the 0 
probands 0 
. 0 

Direct 0 
sequencing 0 
of 0 
the 0 
mutant 0 
cDNAs 0 
showed 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
, 0 
_NUM4 0 
substitution 0 
-LRB- 0 
G448R 0 
-RRB- 0 
in 0 
two 0 
patients 0 
and 0 
a 0 
3-bp 0 
deletion 0 
-LRB- 0 
delta 0 
_AN 0 
or 0 
delta 0 
_AN 0 
-RRB- 0 
in 0 
another 0 
. 0 

In 0 
the 0 
other 0 
two 0 
probands 0 
the 0 
amplified 0 
products 0 
were 0 
of 0 
reduced 0 
size 0 
. 0 

Direct 0 
sequencing 0 
of 0 
these 0 
mutant 0 
cDNAs 0 
revealed 0 
a 0 
deletion 0 
of 0 
exon 0 
_NUM1 0 
in 0 
one 0 
patient 0 
and 0 
of 0 
exon 0 
_NUM1 0 
in 0 
the 0 
other 0 
. 0 

Intronic 0 
sequences 0 
flanking 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
were 0 
identified 0 
using 0 
inverse 0 
PCR 0 
followed 0 
by 0 
direct 0 
sequencing 0 
. 0 

Conventional 0 
PCR 0 
and 0 
direct 0 
sequencing 0 
then 0 
established 0 
the 0 
intron-exon 0 
borders 0 
of 0 
the 0 
mutant 0 
genomic 0 
DNA 0 
revealing 0 
two 0 
splice 0 
acceptor 0 
mutations 0 
a 0 
G 0 
-- 0 
> 0 
C 0 
substitution 0 
at 0 
position 0 
-1 0 
of 0 
intron 0 
_NUM1 0 
and 0 
an 0 
A 0 
-- 0 
> 0 
G 0 
substitution 0 
at 0 
position 0 
-2 0 
of 0 
intron 0 
_NUM1 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
the 0 
severe 0 
form 0 
of 0 
prolidase 1
deficiency 1
is 0 
caused 0 
by 0 
multiple 0 
PEPD 0 
alleles 0 
. 0 

In 0 
this 0 
report 0 
we 0 
attempt 0 
to 0 
begin 0 
the 0 
process 0 
of 0 
describing 0 
these 0 
alleles 0 
and 0 
cataloging 0 
their 0 
phenotypic 0 
expression 0 
. 0 
. 0 

Translocation 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
.1 0 
; 0 
_AN 0 
-RRB- 0 
associated 0 
with 0 
familial 0 
isolated 1
aniridia 1
. 0 

A 0 
father 0 
and 0 
daughter 0 
with 0 
isolated 1
aniridia 1
were 0 
observed 0 
to 0 
have 0 
an 0 
apparently 0 
balanced 0 
, 0 
reciprocal 0 
translocation 0 
involving 0 
chromosomes 0 
_NUM1 0 
and 0 
_NUM2 0 
-LSB- 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

_NUM1 0 
; 0 
_AN 0 
-RRB- 0 
-RSB- 0 
. 0 

No 0 
other 0 
clinical 0 
characteristics 0 
often 0 
associated 0 
with 0 
the 0 
deletion 0 
of 0 
11p13 0 
were 0 
observed 0 
in 0 
this 0 
family 0 
. 0 

This 0 
finding 0 
, 0 
in 0 
association 0 
with 0 
_NUM1 0 
other 0 
instances 0 
of 0 
single 0 
breaks 0 
at 0 
11p13 0 
and 0 
aniridia 1
, 0 
supports 0 
the 0 
assignment 0 
of 0 
AN2 0 
to 0 
11p13 0 
. 0 

Genotype-phenotype 0 
analysis 0 
in 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
and 0 
identification 0 
of 0 
a 0 
missense 0 
mutation 0 
associated 0 
with 0 
a 0 
milder 0 
phenotype 0 
. 0 

Direct 0 
sequencing 0 
of 0 
the 0 
emerin 0 
gene 0 
in 0 
_NUM2 0 
families 0 
with 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EMD 1
-RRB- 0 
revealed 0 
mutations 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
confirming 0 
that 0 
emerin 0 
mutations 0 
can 0 
be 0 
identified 0 
in 0 
the 0 
majority 0 
of 0 
families 0 
with 0 
X-linked 1
EMD 1
. 0 

Most 0 
emerin 0 
mutations 0 
result 0 
in 0 
absence 0 
of 0 
the 0 
protein 0 
. 0 

In 0 
this 0 
study 0 
three 0 
mutations 0 
-LRB- 0 
a 0 
missense 0 
mutation 0 
Pro183Thr 0 
and 0 
two 0 
in-frame 0 
deletions 0 
removing 0 
residues 0 
95-99 0 
and 0 
236-241 0 
, 0 
respectively 0 
-RRB- 0 
were 0 
unusual 0 
in 0 
being 0 
associated 0 
with 0 
expression 0 
of 0 
mutant 0 
protein 0 
. 0 

The 0 
phenotype 0 
in 0 
these 0 
families 0 
was 0 
compared 0 
in 0 
detail 0 
with 0 
the 0 
clinical 0 
features 0 
in 0 
cases 0 
with 0 
typical 0 
null 0 
mutations 0 
. 0 

For 0 
the 0 
in-frame 0 
deletions 0 
there 0 
were 0 
no 0 
significant 0 
differences 0 
. 0 

In 0 
the 0 
family 0 
with 0 
the 0 
missense 0 
mutation 0 
the 0 
phenotype 0 
was 0 
milder 0 
. 0 

Age 0 
at 0 
onset 0 
was 0 
later 0 
for 0 
first 0 
symptoms 0 
and 0 
for 0 
development 0 
of 0 
ankle 1
contractures 1
and 0 
muscle 1
weakness 1
. 0 

These 0 
findings 0 
have 0 
diagnostic 0 
implications 0 
as 0 
well 0 
as 0 
pointing 0 
to 0 
functionally 0 
important 0 
regions 0 
of 0 
the 0 
emerin 0 
protein 0 
. 0 
. 0 

Asef 0 
, 0 
a 0 
link 0 
between 0 
the 0 
tumor 1
suppressor 0 
APC 0 
and 0 
G-protein 0 
signaling 0 
. 0 

The 0 
adenomatous 1
polyposis 1
coli 1
gene 0 
-LRB- 0 
APC 0 
-RRB- 0 
is 0 
mutated 0 
in 0 
familial 1
adenomatous 1
polyposis 1
and 0 
in 0 
sporadic 0 
colorectal 1
tumors 1
. 0 

Here 0 
the 0 
APC 1
gene 0 
product 0 
is 0 
shown 0 
to 0 
bind 0 
through 0 
its 0 
armadillo 0 
repeat 0 
domain 0 
to 0 
a 0 
Rac-specific 0 
guanine 0 
nucleotide 0 
exchange 0 
factor 0 
-LRB- 0 
GEF 0 
-RRB- 0 
, 0 
termed 0 
Asef 0 
. 0 

Endogenous 0 
APC 0 
colocalized 0 
with 0 
Asef 0 
in 0 
mouse 0 
colon 0 
epithelial 0 
cells 0 
and 0 
neuronal 0 
cells 0 
. 0 

Furthermore 0 
, 0 
APC 0 
enhanced 0 
the 0 
GEF 0 
activity 0 
of 0 
Asef 0 
and 0 
stimulated 0 
Asef-mediated 0 
cell 0 
flattening 0 
, 0 
membrane 0 
ruffling 0 
, 0 
and 0 
lamellipodia 0 
formation 0 
in 0 
MDCK 0 
cells 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
the 0 
APC-Asef 0 
complex 0 
may 0 
regulate 0 
the 0 
actin 0 
cytoskeletal 0 
network 0 
, 0 
cell 0 
morphology 0 
and 0 
migration 0 
, 0 
and 0 
neuronal 0 
function 0 
. 0 
. 0 

Localization 0 
of 0 
the 0 
region 0 
homologous 0 
to 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
locus 0 
on 0 
the 0 
mouse 0 
X 0 
chromosome 0 
. 0 

Recent 0 
progress 0 
has 0 
resulted 0 
in 0 
part 0 
of 0 
the 0 
gene 0 
mutated 0 
in 0 
Duchenne 1
and 1
the 1
milder 1
Becker 1
muscular 1
dystrophies 1
being 0 
cloned 0 
and 0 
has 0 
suggested 0 
that 0 
the 0 
gene 0 
itself 0 
extends 0 
over 0 
_NUM1 0 
, 0 
_NUM3 0 
to 0 
_NUM1 0 
, 0 
_NUM3 0 
kilobases 0 
-LRB- 0 
kb 0 
-RRB- 0 
. 0 

To 0 
study 0 
how 0 
mutations 0 
in 0 
this 0 
gene 0 
affect 0 
muscle 0 
development 0 
and 0 
integrity 0 
, 0 
it 0 
would 0 
be 0 
of 0 
interest 0 
to 0 
have 0 
available 0 
a 0 
mouse 0 
model 0 
of 0 
the 0 
human 0 
disease 0 
. 0 

The 0 
mouse 0 
mdx 0 
mutation 0 
affects 0 
muscle 0 
and 0 
confers 0 
a 0 
mild 0 
dystrophic 1
syndrome 1
, 0 
but 0 
it 0 
is 0 
not 0 
clear 0 
whether 0 
this 0 
mutation 0 
is 0 
equivalent 0 
to 0 
Duchenne 1
/ 1
Becker 1
muscular 1
dystrophy 1
in 0 
man 0 
. 0 

Here 0 
we 0 
describe 0 
the 0 
use 0 
of 0 
two 0 
sequences 0 
from 0 
the 0 
human 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
that 0 
cross-hybridize 0 
to 0 
mouse 0 
X-linked 0 
sequences 0 
to 0 
localize 0 
the 0 
gene 0 
homologous 0 
to 0 
DMD 1
in 0 
the 0 
mouse 0 
. 0 

Both 0 
sequences 0 
map 0 
to 0 
the 0 
region 0 
of 0 
_NUM2 0 
centimorgan 0 
lying 0 
between 0 
the 0 
Tabby 0 
-LRB- 0 
Ta 0 
-RRB- 0 
and 0 
St14-1 0 
-LRB- 0 
DxPas8 0 
-RRB- 0 
loci 0 
, 0 
close 0 
to 0 
the 0 
phosphorylase 0 
b 0 
kinase 0 
locus 0 
-LRB- 0 
Phk 0 
-RRB- 0 
. 0 

By 0 
analogy 0 
with 0 
the 0 
human 0 
X-chromosome 0 
, 0 
we 0 
conclude 0 
that 0 
the 0 
region 0 
in 0 
the 0 
mouse 0 
around 0 
the 0 
G6pd 0 
and 0 
St14-1 0 
loci 0 
may 0 
contain 0 
two 0 
genes 0 
corresponding 0 
to 0 
distinct 0 
human 0 
myopathies 1
Emery 1
Dreifuss 1
muscular 1
dystrophy 1
which 0 
is 0 
known 0 
to 0 
be 0 
closely 0 
linked 0 
to 0 
St14-1 0 
in 0 
man 0 
and 0 
the 0 
DMD 1
homologue 0 
described 0 
here 0 
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
hexosaminidase 1
A 1
deficiency 1
and 0 
pseudodeficiency 0 
in 0 
the 0 
Berks 0 
County 0 
Pennsylvania 0 
Dutch 0 
. 0 

Following 0 
the 0 
birth 0 
of 0 
two 0 
infants 0 
with 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
, 0 
a 0 
non-Jewish 0 
, 0 
Pennsylvania 0 
Dutch 0 
kindred 0 
was 0 
screened 0 
for 0 
TSD 1
carriers 0 
using 0 
the 0 
biochemical 0 
assay 0 
. 0 

A 0 
high 0 
frequency 0 
of 0 
individuals 0 
who 0 
appeared 0 
to 0 
be 0 
TSD 1
heterozygotes 0 
was 0 
detected 0 
-LRB- 0 
Kelly 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

Clinical 0 
and 0 
biochemical 0 
evidence 0 
suggested 0 
that 0 
the 0 
increased 0 
carrier 0 
frequency 0 
was 0 
due 0 
to 0 
at 0 
least 0 
two 0 
altered 0 
alleles 0 
for 0 
the 0 
hexosaminidase 0 
A 0 
alpha-subunit 0 
. 0 

We 0 
now 0 
report 0 
two 0 
mutant 0 
alleles 0 
in 0 
this 0 
Pennsylvania 0 
Dutch 0 
kindred 0 
, 0 
and 0 
one 0 
polymorphism 0 
. 0 

One 0 
allele 0 
, 0 
reported 0 
originally 0 
in 0 
a 0 
French 0 
TSD 1
patient 0 
-LRB- 0 
Akli 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
, 0 
is 0 
a 0 
_DS 0 
-- 0 
> 0 
_DS 0 
transition 0 
at 0 
the 0 
donor 0 
splice-site 0 
of 0 
intron 0 
_NUM1 0 
. 0 

The 0 
second 0 
, 0 
a 0 
C 0 
-- 0 
> 0 
T 0 
transition 0 
at 0 
nucleotide 0 
_NUM3 0 
-LRB- 0 
Arg247Trp 0 
-RRB- 0 
, 0 
has 0 
been 0 
shown 0 
by 0 
Triggs-Raine 0 
et 0 
al. 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
to 0 
be 0 
a 0 
clinically 0 
benign 0 
'' 0 
pseudodeficient 0 
'' 0 
allele 0 
associated 0 
with 0 
reduced 0 
enzyme 0 
activity 0 
against 0 
artificial 0 
substrate 0 
. 0 

Finally 0 
, 0 
a 0 
polymorphism 0 
-LSB- 0 
G 0 
-- 0 
> 0 
A 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
-RSB- 0 
, 0 
which 0 
leaves 0 
valine 0 
at 0 
codon 0 
_NUM3 0 
unchanged 0 
, 0 
is 0 
described 0 
. 0 

Gene 0 
transfer 0 
and 0 
expression 0 
of 0 
human 0 
phenylalanine 0 
hydroxylase 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
caused 0 
by 0 
a 0 
genetic 0 
deficiency 1
of 1
the 1
enzyme 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

A 0 
full-length 0 
complementary 0 
DNA 0 
clone 0 
of 0 
human 0 
PAH 0 
was 0 
inserted 0 
into 0 
a 0 
eukaryotic 0 
expression 0 
vector 0 
and 0 
transferred 0 
into 0 
mouse 0 
NIH3T3 0 
cells 0 
which 0 
do 0 
not 0 
normally 0 
express 0 
PAH 0 
. 0 

The 0 
transformed 0 
mouse 0 
cells 0 
expressed 0 
PAH 0 
messenger 0 
RNA 0 
, 0 
immunoreactive 0 
protein 0 
, 0 
and 0 
enzymatic 0 
activity 0 
that 0 
are 0 
characteristic 0 
of 0 
the 0 
normal 0 
human 0 
liver 0 
products 0 
, 0 
demonstrating 0 
that 0 
a 0 
single 0 
gene 0 
contains 0 
all 0 
of 0 
the 0 
necessary 0 
genetic 0 
information 0 
to 0 
code 0 
for 0 
functional 0 
PAH 0 
. 0 

These 0 
results 0 
support 0 
the 0 
use 0 
of 0 
the 0 
human 0 
PAH 0 
probe 0 
in 0 
prenatal 0 
diagnosis 0 
and 0 
detection 0 
of 0 
carriers 0 
, 0 
to 0 
provide 0 
new 0 
opportunities 0 
for 0 
the 0 
biochemical 0 
characterization 0 
of 0 
normal 0 
and 0 
mutant 0 
enzymes 0 
, 0 
and 0 
in 0 
the 0 
investigation 0 
of 0 
alternative 0 
genetic 0 
therapies 0 
for 0 
PKU 1
. 0 
. 0 

Macular 1
dystrophy 1
associated 0 
with 0 
mutations 0 
at 0 
codon 0 
_NUM3 0 
in 0 
the 0 
human 0 
retinal 1
degeneration 1
slow 0 
gene 0 
. 0 

BACKGROUND 0 
Recently 0 
, 0 
mutations 0 
in 0 
the 0 
retinal 1
degeneration 1
slow 0 
-LRB- 0 
rds 0 
-RRB- 0 
gene 0 
which 0 
codes 0 
for 0 
peripherin-rds 0 
have 0 
been 0 
implicated 0 
as 0 
a 0 
cause 0 
of 0 
autosomal 1
dominant 1
retinitis 1
pigmentosa 1
. 0 

Because 0 
this 0 
gene 0 
is 0 
expressed 0 
in 0 
both 0 
rods 0 
and 0 
cones 0 
, 0 
mutations 0 
in 0 
the 0 
rds 0 
gene 0 
might 0 
be 0 
expected 0 
to 0 
cause 0 
degeneration 0 
affecting 0 
either 0 
the 0 
scotopic 0 
or 0 
photopic 0 
systems 0 
. 0 

Mutations 0 
at 0 
codon 0 
_NUM3 0 
of 0 
the 0 
rds 0 
gene 0 
have 0 
been 0 
identified 0 
in 0 
three 0 
families 0 
with 0 
autosomal 0 
dominantly 0 
inherited 0 
, 0 
progressive 0 
macular 1
dystrophy 1
. 0 

METHODS 0 
Affected 0 
individuals 0 
underwent 0 
ophthalmic 0 
examination 0 
, 0 
scotopic 0 
perimetry 0 
, 0 
dark 0 
adaptometry 0 
, 0 
measurement 0 
of 0 
color-contrast 0 
sensitivity 0 
, 0 
and 0 
electroretinography 0 
to 0 
characterize 0 
the 0 
photoreceptor 0 
dysfunction 0 
. 0 

RESULTS 0 
In 0 
all 0 
but 0 
one 0 
affected 0 
member 0 
, 0 
symptoms 0 
of 0 
progressive 0 
central 0 
visual 1
loss 1
developed 0 
in 0 
the 0 
third 0 
or 0 
fourth 0 
decade 0 
of 0 
life 0 
accompanied 0 
by 0 
central 1
scotoma 1
and 0 
well-demarcated 0 
atrophy 1
of 1
the 1
retinal 1
pigment 1
epithelium 1
and 0 
choriocapillaris 1
of 1
the 1
macula 1
. 0 

In 0 
general 0 
, 0 
cone 0 
and 0 
rod 0 
thresholds 0 
were 0 
elevated 0 
, 0 
and 0 
color-contrast 0 
sensitivity 0 
was 0 
absent 0 
in 0 
the 0 
central 0 
visual 0 
field 0 
. 0 

Peripherally 0 
, 0 
the 0 
scotopic 0 
sensitivities 0 
were 0 
normal 0 
, 0 
as 0 
was 0 
the 0 
recovery 0 
from 0 
bleach 0 
. 0 

Cone 0 
electroretinograms 0 
were 0 
diminished 0 
in 0 
amplitude 0 
, 0 
and 0 
delayed 0 
in 0 
all 0 
affected 0 
adults 0 
except 0 
one 0 
. 0 

Rod 0 
electroretinograms 0 
were 0 
normal 0 
or 0 
near 0 
normal 0 
in 0 
amplitude 0 
, 0 
and 0 
had 0 
normal 0 
implicit 0 
times 0 
. 0 

Affected 0 
asymptomatic 0 
children 0 
had 0 
macular 0
changes 0 
, 0 
abnormal 0 
color-contrast 0 
sensitivity 0 
, 0 
and 0 
reduced 0 
pattern 0 
and 0 
cone 0 
electroretinograms 0 
. 0 

CONCLUSION 0 
These 0 
results 0 
indicate 0 
that 0 
mutations 0 
in 0 
the 0 
rds 0 
gene 0 
can 0 
be 0 
expressed 0 
as 0 
a 0 
macular 1
dystrophy 1
, 0 
with 0 
evidence 0 
of 0 
primary 0 
cone 1
dysfunction 1
and 0 
preservation 0 
of 0 
peripheral 0 
rod 0 
function 0 
. 0 
. 0 

Glucose 0 
6-phosphate 0 
dehydrogenase 0 
variants 0 
: 0 
Gd 0 
-LRB- 0 
+ 0 
-RRB- 0 
Alexandra 0 
associated 0 
with 0 
neonatal 1
jaundice 1
and 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Camperdown 0 
in 0 
a 0 
young 0 
man 0 
with 0 
lamellar 1
cataracts 1
. 0 

Two 0 
male 0 
subjects 0 
are 0 
described 0 
, 0 
with 0 
unusual 0 
clinical 0 
presentations 0 
and 0 
with 0 
hitherto 0 
undescribed 0 
G6PD 0 
variants 0 
. 0 

The 0 
first 0 
, 0 
of 0 
Italian 0 
extraction 0 
, 0 
suffered 0 
from 0 
severe 0 
neonatal 1
jaundice 1
following 0 
maternal 0 
ingestion 0 
of 0 
fresh 0 
broad 0 
beans 0 
-LRB- 0 
Vicia 0 
fava 0 
-RRB- 0 
both 0 
prenatally 0 
and 0 
postnatally 0 
the 0 
expression 0 
of 0 
the 0 
enzymatic 0 
defect 0 
was 0 
much 0 
more 0 
severe 0 
in 0 
the 0 
neonatal 0 
period 0 
than 0 
on 0 
retesting 0 
in 0 
adolescence 0 
, 0 
when 0 
biochemical 0 
characterization 0 
showed 0 
unique 0 
features 0 
which 0 
justify 0 
designation 0 
as 0 
a 0 
new 0 
variant 0 
Gd 0 
-LRB- 0 
+ 0 
-RRB- 0 
Alexandra 0 
. 0 

The 0 
second 0 
patient 0 
, 0 
a 0 
boy 0 
of 0 
Maltese 0 
extraction 0 
who 0 
was 0 
found 0 
to 0 
have 0 
bilateral 1
lamellar 1
cataracts 1
at 0 
the 0 
age 0 
of 0 
_NUM1 0 
years 0 
, 0 
was 0 
identified 0 
as 0 
G6PD 1
deficient 1
only 0 
as 0 
a 0 
result 0 
of 0 
a 0 
survey 0 
of 0 
children 0 
of 0 
Mediterranean 0 
origin 0 
with 0 
unexplained 0 
cataract 1
formation 0 
; 0 
he 0 
has 0 
approximately 0 
_NUM2 0 
% 0 
of 0 
normal 0 
enzyme 0 
activity 0 
, 0 
with 0 
another 0 
unique 0 
combination 0 
of 0 
biochemical 0 
characteristics 0 
which 0 
has 0 
led 0 
to 0 
its 0 
designation 0 
as 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Camperdown 0 
. 0 

Although 0 
this 0 
association 0 
may 0 
be 0 
coincidental 0 
, 0 
it 0 
prompts 0 
further 0 
attention 0 
to 0 
the 0 
possibility 0 
that 0 
under 0 
certain 0 
circumstances 0 
G6PD 1
deficiency 1
may 0 
favor 0 
cataract 1
formation 0 
. 0 

The 0 
two 0 
cases 0 
illustrate 0 
the 0 
value 0 
of 0 
characterization 0 
of 0 
the 0 
mutant 0 
enzyme 0 
whenever 0 
unexpected 0 
clinical 0 
or 0 
laboratory 0 
results 0 
are 0 
obtained 0 
. 0 
. 0 

DNA 0 
restriction 0 
fragments 0 
associated 0 
with 0 
alpha 0 
1-antitrypsin 0 
indicate 0 
a 0 
single 0 
origin 0 
for 0 
deficiency 0
allele 0 
PI 0 
Z 0 
. 0 

The 0 
alpha 0 
1-protease 0 
inhibitor 0 
, 0 
or 0 
alpha-antitrypsin 0 
-LRB- 0 
_DS 0 
-RRB- 0 
, 0 
a 0 
major 0 
plasma 0 
inhibitor 0 
of 0 
leukocyte 0 
elastase 0 
and 0 
bacterial 0 
proteases 0 
, 0 
is 0 
encoded 0 
at 0 
the 0 
PI 0 
locus 0 
on 0 
chromosome 0 
_NUM2 0 
-LRB- 0 
14q24 0 
. 0 

3-q32 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

A 0 
deficiency 1
of 1
_DS 1
in 0 
individuals 0 
homozygous 0 
for 0 
the 0 
PI 0 
Z 0 
allele 0 
occurs 0 
in 0 
about 0 
_NUM1 0 
in 0 
_NUM1 0 
, 0 
000-8 0 
, 0 
_NUM3 0 
caucasians 0 
and 0 
is 0 
associated 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
early 0 
adult 0 
onset 0 
emphysema 1
and 0 
liver 1
disease 1
in 0 
childhood 0 
. 0 

We 0 
have 0 
now 0 
used 0 
DNA 0 
polymorphisms 0 
associated 0 
with 0 
the 0 
_DS 0 
gene 0 
to 0 
investigate 0 
the 0 
origin 0 
of 0 
the 0 
PI 0 
Z 0 
allele 0 
. 0 

Using 0 
two 0 
genomic 0 
probes 0 
extending 0 
into 0 
the 0 
_NUM1 0 
and 0 
_NUM1 0 
flanking 0 
regions 0 
, 0 
respectively 0 
, 0 
we 0 
have 0 
identified 0 
eight 0 
polymorphic 0 
restriction 0 
sites 0 
. 0 

Extensive 0 
linkage 0 
disequilibrium 0 
occurs 0 
throughout 0 
the 0 
probed 0 
region 0 
with 0 
the 0 
PI 0 
Z 0 
allele 0 
, 0 
but 0 
not 0 
with 0 
normal 0 
PI 0 
M 0 
alleles 0 
. 0 

The 0 
Z 0 
allele 0 
occurs 0 
mainly 0 
with 0 
one 0 
haplotype 0 
, 0 
indicating 0 
a 0 
single 0 
, 0 
relatively 0 
recent 0 
, 0 
origin 0 
in 0 
caucasians 0 
Myotonic 1
dystrophy 1
in 0 
transgenic 0 
mice 0 
expressing 0 
an 0 
expanded 0 
CUG 0 
repeat 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
, 0 
the 0 
most 0 
common 0 
form 0 
of 0 
muscular 1
dystrophy 1
in 0 
adult 0 
humans 0 
, 0 
results 0 
from 0 
expansion 0 
of 0 
a 0 
_DS 0 
repeat 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
the 0 
DMPK 0 
gene 0 
. 0 

The 0 
mutant 0 
DMPK 0 
messenger 0 
RNA 0 
-LRB- 0 
mRNA 0 
-RRB- 0 
contains 0 
an 0 
expanded 0 
CUG 0 
repeat 0 
and 0 
is 0 
retained 0 
in 0 
the 0 
nucleus 0 
. 0 

We 0 
have 0 
expressed 0 
an 0 
untranslated 0 
CUG 0 
repeat 0 
in 0 
an 0 
unrelated 0 
mRNA 0 
in 0 
transgenic 0 
mice 0 
. 0 

Mice 0 
that 0 
expressed 0 
expanded 0 
CUG 0 
repeats 0 
developed 0 
myotonia 1
and 0 
myopathy 1
, 0 
whereas 0 
mice 0 
expressing 0 
a 0 
nonexpanded 0 
repeat 0 
did 0 
not 0 
. 0 

Thus 0 
, 0 
transcripts 0 
with 0 
expanded 0 
CUG 0 
repeats 0 
are 0 
sufficient 0 
to 0 
generate 0 
a 0 
DM 1
phenotype 0 
. 0 

This 0 
result 0 
supports 0 
a 0 
role 0 
for 0 
RNA 0 
gain 0 
of 0 
function 0 
in 0 
disease 0 
pathogenesis 0 
. 0 
. 0 

Submicroscopic 0 
deletion 0 
in 0 
cousins 0 
with 0 
Prader-Willi 1
syndrome 1
causes 0 
a 0 
grandmatrilineal 0 
inheritance 0 
pattern 0 
: 0 
effects 0 
of 0 
imprinting 0 
. 0 

The 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
critical 0 
region 0 
on 0 
15q11-q13 0 
is 0 
subject 0 
to 0 
imprinting 0 
. 0 

PWS 1
becomes 0 
apparent 0 
when 0 
genes 0 
on 0 
the 0 
paternally 0 
inherited 0 
chromosome 0 
are 0 
not 0 
expressed 0 
. 0 

Familial 1
PWS 1
is 0 
rare 0 
. 0 

We 0 
report 0 
on 0 
a 0 
family 0 
in 0 
which 0 
a 0 
male 0 
and 0 
a 0 
female 0 
paternal 0 
first 0 
cousin 0 
both 0 
have 0 
PWS 1
with 0 
cytogenetically 0 
normal 0 
karyotypes 0 
. 0 

Fluorescence 0 
in 0 
situ 0 
hybridization 0 
-LRB- 0 
FISH 0 
-RRB- 0 
analysis 0 
shows 0 
a 0 
submicroscopic 0 
deletion 0 
of 0 
SNRPN 0 
, 0 
but 0 
not 0 
the 0 
closely 0 
associated 0 
loci 0 
D15S10 0 
, 0 
D15S11 0 
, 0 
D15S63 0 
, 0 
and 0 
GABRB3 0 
. 0 

The 0 
cousins 0 
fathers 0 
and 0 
two 0 
paternal 0 
aunts 0 
have 0 
the 0 
same 0 
deletion 0 
and 0 
are 0 
clinically 0 
normal 0 
. 0 

The 0 
grandmother 0 
of 0 
the 0 
cousins 0 
is 0 
deceased 0 
and 0 
not 0 
available 0 
for 0 
study 0 
, 0 
and 0 
their 0 
grandfather 0 
is 0 
not 0 
deleted 0 
for 0 
SNRPN 0 
. 0 

DNA 0 
methylation 0 
analysis 0 
of 0 
D15S63 0 
is 0 
consistent 0 
with 0 
an 0 
abnormality 0 
of 0 
the 0 
imprinting 0 
center 0 
associated 0 
with 0 
PWS 1
. 0 
'' 0 

Grandmatrilineal 0 
'' 0 
inheritance 0 
occurs 0 
when 0 
a 0 
woman 0 
with 0 
deletion 0 
of 0 
an 0 
imprinted 0 
, 0 
paternally 0 
expressed 0 
gene 0 
is 0 
at 0 
risk 0 
of 0 
having 0 
affected 0 
grandchildren 0 
through 0 
her 0 
sons 0 
. 0 

In 0 
this 0 
case 0 
, 0 
PWS 1
does 0 
not 0 
become 0 
evident 0 
as 0 
long 0 
as 0 
the 0 
deletion 0 
is 0 
passed 0 
through 0 
the 0 
matrilineal 0 
line 0 
. 0 

This 0 
represents 0 
a 0 
unique 0 
inheritance 0 
pattern 0 
due 0 
to 0 
imprinting 0 
. 0 
. 0 

Expression 0 
and 0 
imprinting 0 
of 0 
MAGEL2 0 
suggest 0 
a 0 
role 0 
in 0 
Prader-willi 1
syndrome 1
and 0 
the 0 
homologous 0 
murine 0 
imprinting 0 
phenotype 0 
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
is 0 
caused 0 
by 0 
the 0 
loss 0 
of 0 
expression 0 
of 0 
imprinted 0 
genes 0 
in 0 
chromosome 0 
15q11-q13 0 
. 0 

Affected 0 
individuals 0 
exhibit 0 
neonatal 1
hypotonia 1
, 0 
developmental 1
delay 1
and 0 
childhood-onset 1
obesity 1
. 0 

Necdin 0 
, 0 
a 0 
protein 0 
implicated 0 
in 0 
the 0 
terminal 0 
differentiation 0 
of 0 
neurons 0 
, 0 
is 0 
the 0 
only 0 
PWS 1
candidate 0 
gene 0 
to 0 
reduce 0 
viability 0 
when 0 
disrupted 0 
in 0 
a 0 
mouse 0 
model 0 
. 0 

In 0 
this 0 
study 0 
, 0 
we 0 
have 0 
characterized 0 
MAGEL2 0 
-LRB- 0 
also 0 
known 0 
as 0 
NDNL1 0 
-RRB- 0 
, 0 
a 0 
gene 0 
with 0 
_NUM2 0 
% 0 
amino 0 
acid 0 
sequence 0 
similarity 0 
to 0 
necdin 0 
and 0 
located 0 
_NUM2 0 
kb 0 
distal 0 
to 0 
NDN 0 
in 0 
the 0 
PWS 1
deletion 0 
region 0 
. 0 

MAGEL2 0 
is 0 
expressed 0 
predominantly 0 
in 0 
brain 0 
, 0 
the 0 
primary 0 
tissue 0 
affected 0 
in 0 
PWS 1
and 0 
in 0 
several 0 
fetal 0 
tissues 0 
as 0 
shown 0 
by 0 
northern 0 
blot 0 
analysis 0 
. 0 

MAGEL2 0 
is 0 
imprinted 0 
with 0 
monoallelic 0 
expression 0 
in 0 
control 0 
brain 0 
, 0 
and 0 
paternal-only 0 
expression 0 
in 0 
the 0 
central 0 
nervous 0 
system 0 
as 0 
demonstrated 0 
by 0 
its 0 
lack 0 
of 0 
expression 0 
in 0 
brain 0 
from 0 
a 0 
PWS 1
affected 0 
individual 0 
. 0 

The 0 
orthologous 0 
mouse 0 
gene 0 
-LRB- 0 
Magel2 0 
-RRB- 0 
is 0 
located 0 
within 0 
_NUM3 0 
kb 0 
of 0 
NDN 0 
, 0 
is 0 
imprinted 0 
with 0 
paternal-only 0 
expression 0 
and 0 
is 0 
expressed 0 
predominantly 0 
in 0 
late 0 
developmental 0 
stages 0 
and 0 
adult 0 
brain 0 
as 0 
shown 0 
by 0 
northern 0 
blotting 0 
, 0 
RT-PCR 0 
and 0 
whole-mount 0 
RNA 0 
in 0 
situ 0 
hybridization 0 
. 0 

Magel2 0 
distribution 0 
partially 0 
overlaps 0 
that 0 
of 0 
NDN 0 
, 0 
with 0 
strong 0 
expression 0 
being 0 
detected 0 
in 0 
the 0 
central 0 
nervous 0 
system 0 
in 0 
mid-gestation 0 
mouse 0 
embryos 0 
by 0 
in 0 
situ 0 
hybridization 0 
. 0 

We 0 
hypothesize 0 
that 0 
, 0 
although 0 
loss 0 
of 0 
necdin 0 
expression 0 
may 0 
be 0 
important 0 
in 0 
the 0 
neonatal 0 
presentation 0 
of 0 
PWS 1
, 0 
loss 0 
of 0 
MAGEL2 0 
may 0 
be 0 
critical 0 
to 0 
abnormalities 1
in 1
brain 1
development 1
and 0 
dysmorphic 1
features 1
in 0 
individuals 0 
with 0 
PWS 1
. 0 
. 0 

A 0 
single 0 
origin 0 
of 0 
phenylketonuria 1
in 0 
Yemenite 0 
Jews 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
a 0 
metabolic 1
disease 1
caused 0 
by 0 
recessive 0 
mutations 0 
of 0 
the 0 
gene 0 
encoding 0 
the 0 
hepatic 0 
enzyme 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

The 0 
incidence 0 
of 0 
PKU 1
varies 0 
widely 0 
across 0 
different 0 
geographic 0 
areas 0 
, 0 
and 0 
is 0 
highest 0 
-LRB- 0 
about 0 
_NUM1 0 
in 0 
_NUM1 0 
, 0 
_NUM3 0 
live 0 
births 0 
-RRB- 0 
in 0 
Ireland 0 
and 0 
western 0 
Scotland 0 
, 0 
and 0 
among 0 
Yemenite 0 
Jews 0 
. 0 

A 0 
limited 0 
number 0 
of 0 
point 0 
mutations 0 
account 0 
for 0 
most 0 
of 0 
the 0 
PKU 1
cases 0 
in 0 
the 0 
European 0 
population 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
a 0 
single 0 
molecular 0 
defect 0 
-- 0 
a 0 
deletion 0 
spanning 0 
the 0 
third 0 
exon 0 
of 0 
the 0 
PAH 0 
gene 0 
-- 0 
is 0 
responsible 0 
for 0 
all 0 
the 0 
PKU 1
cases 0 
among 0 
the 0 
Yemenite 0 
Jews 0 
. 0 

Examination 0 
of 0 
a 0 
random 0 
sample 0 
of 0 
Yemenite 0 
Jews 0 
using 0 
a 0 
molecular 0 
probe 0 
that 0 
detects 0 
the 0 
carriers 0 
of 0 
this 0 
deletion 0 
indicated 0 
a 0 
high 0 
frequency 0 
of 0 
the 0 
defective 0 
gene 0 
in 0 
this 0 
community 0 
. 0 

Although 0 
the 0 
deleted 0 
PAH 0 
gene 0 
was 0 
traced 0 
to 0 
_NUM2 0 
different 0 
locations 0 
throughout 0 
Yemen 0 
, 0 
family 0 
histories 0 
and 0 
official 0 
documents 0 
of 0 
the 0 
Yemenite 0 
Jewish 0 
community 0 
showed 0 
that 0 
the 0 
common 0 
ancestor 0 
of 0 
all 0 
the 0 
carriers 0 
of 0 
this 0 
genetic 1
defect 1
lived 0 
in 0 
Sana 0 
, 0 
the 0 
capital 0 
of 0 
Yemen 0 
, 0 
before 0 
the 0 
eighteenth 0 
century 0 
. 0 
. 0 

High 0 
resolution 0 
genetic 0 
analysis 0 
suggests 0 
one 0 
ancestral 0 
predisposing 0 
haplotype 0 
for 0 
the 0 
origin 0 
of 0 
the 0 
myotonic 1
dystrophy 1
mutation 0 
. 0 

The 0 
mutation 0 
causing 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
has 0 
been 0 
identified 0 
as 0 
an 0 
amplification 0 
of 0 
an 0 
unstable 0 
trinucleotide 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
in 0 
over 0 
_NUM2 0 
% 0 
of 0 
the 0 
global 0 
DM 1
population 0 
. 0 

It 0 
is 0 
in 0 
complete 0 
linkage 0 
disequilibrium 0 
with 0 
an 0 
Alu 0 
element 0 
polymorphism 0 
within 0 
the 0 
DM 1
kinase 0 
gene 0 
, 0 
suggesting 0 
that 0 
DM 1
is 0 
a 0 
consequence 0 
of 0 
one 0 
or 0 
few 0 
ancestral 0 
mutations 0 
. 0 

A 0 
recent 0 
analysis 0 
utilizing 0 
this 0 
polymorphism 0 
as 0 
well 0 
as 0 
a 0 
flanking 0 
dinucleotide 0 
marker 0 
, 0 
suggested 0 
that 0 
similar 0 
to 0 
Fragile 1
X 1
syndrome 1
, 0 
DM 1
exhibited 0 
a 0 
founder 0 
effect 0 
-LRB- 0 
Imbert 0 
et 0 
al. 0 
, 0 
_NUM4 0 
Nature 0 
Genet 0 
. 0 

_NUM1 0 
, 0 
72-76 0 
-RRB- 0 
. 0 

In 0 
contrast 0 
, 0 
the 0 
low 0 
reproductive 0 
fitness 0 
of 0 
individuals 0 
with 0 
congenital 0 
DM 1
-LRB- 0 
the 0 
endpoint 0 
of 0 
genetic 0 
anticipation 0 
in 0 
myotonic 1
dystrophy 1
-RRB- 0 
suggests 0 
a 0 
higher 0 
rate 0 
of 0 
new 0 
mutations 0 
. 0 

We 0 
present 0 
a 0 
high 0 
resolution 0 
genetic 0 
analysis 0 
of 0 
the 0 
DM 1
locus 0 
using 0 
PCR 0 
based 0 
assays 0 
of 0 
nine 0 
polymorphisms 0 
, 0 
spanning 0 
a 0 
physical 0 
distance 0 
of 0 
_NUM2 0 
kb 0 
, 0 
within 0 
and 0 
immediately 0 
flanking 0 
the 0 
DM 1
kinase 0 
gene 0 
. 0 

The 0 
persistent 0 
complete 0 
allelic 0 
association 0 
of 0 
the 0 
DM 1
mutation 0 
with 0 
all 0 
these 0 
polymorphisms 0 
provides 0 
further 0 
support 0 
to 0 
previous 0 
observations 0 
and 0 
suggests 0 
more 0 
strongly 0 
that 0 
the 0 
DM 1
mutation 0 
occurred 0 
on 0 
the 0 
background 0 
of 0 
a 0 
particular 0 
haplotype 0 
in 0 
which 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
became 0 
inherently 0 
unstable 0 
and 0 
therefore 0 
predisposed 0 
to 0 
amplification 0 
. 0 

Identification 0 
and 0 
rapid 0 
detection 0 
of 0 
three 0 
Tay-Sachs 1
mutations 0 
in 0 
the 0 
Moroccan 0 
Jewish 0 
population 0 
. 0 

Infantile 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
HEXA 0 
gene 0 
that 0 
result 0 
in 0 
the 0 
complete 0 
absence 0 
of 0 
beta-hexosaminidase 0 
A 0 
activity 0 
. 0 

It 0 
is 0 
well 0 
known 0 
that 0 
an 0 
elevated 0 
frequency 0 
of 0 
TSD 1
mutations 0 
exists 0 
among 0 
Ashkenazi 0 
Jews 0 
. 0 

More 0 
recently 0 
it 0 
has 0 
become 0 
apparent 0 
that 0 
elevated 0 
carrier 0 
frequencies 0 
for 0 
TSD 1
also 0 
occur 0 
in 0 
several 0 
other 0 
ethnic 0 
groups 0 
, 0 
including 0 
Moroccan 0 
Jews 0 
, 0 
a 0 
subgroup 0 
of 0 
Sephardic 0 
Jews 0 
. 0 

Elsewhere 0 
we 0 
reported 0 
an 0 
in-frame 0 
deletion 0 
of 0 
one 0 
of 0 
the 0 
two 0 
adjacent 0 
phenylalanine 0 
codons 0 
at 0 
position 0 
_NUM3 0 
or 0 
_NUM3 0 
-LRB- 0 
delta 0 
F304 0 
/ 0 
305 0 
-RRB- 0 
in 0 
one 0 
HEXA 0 
allele 0 
of 0 
a 0 
Moroccan 0 
Jewish 0 
TSD 1
patient 0 
and 0 
in 0 
three 0 
obligate 0 
carriers 0 
from 0 
six 0 
unrelated 0 
Moroccan 0 
Jewish 0 
families 0 
. 0 

We 0 
have 0 
now 0 
identified 0 
two 0 
additional 0 
mutations 0 
within 0 
exon 0 
_NUM1 0 
of 0 
the 0 
HEXA 0 
gene 0 
that 0 
account 0 
for 0 
the 0 
remaining 0 
TSD 1
alleles 0 
in 0 
the 0 
patient 0 
and 0 
carriers 0 
. 0 

One 0 
of 0 
the 0 
mutations 0 
is 0 
a 0 
novel 0 
C-to-G 0 
transversion 0 
, 0 
resulting 0 
in 0 
a 0 
replacement 0 
of 0 
Tyr180 0 
by 0 
a 0 
stop 0 
codon 0 
. 0 

The 0 
other 0 
mutation 0 
is 0 
a 0 
G-to-A 0 
transition 0 
resulting 0 
in 0 
an 0 
Arg170-to-Gln 0 
substitution 0 
. 0 

This 0 
mutation 0 
is 0 
at 0 
a 0 
CpG 0 
site 0 
in 0 
a 0 
Japanese 0 
infant 0 
with 0 
Tay-Sachs 1
disease 1
and 0 
was 0 
described 0 
elsewhere 0 
. 0 

Analysis 0 
of 0 
nine 0 
obligate 0 
carriers 0 
from 0 
seven 0 
unrelated 0 
families 0 
showed 0 
that 0 
four 0 
harbor 0 
the 0 
delta 0 
F304 0 
/ 0 
305 0 
mutation 0 
, 0 
two 0 
the 0 
Arg170 0 
-- 0 
Gln 0 
mutation 0 
, 0 
and 0 
one 0 
the 0 
Tyr180 0 
-- 0 
Stop 0 
mutation 0 
. 0 

We 0 
also 0 
have 0 
developed 0 
rapid 0 
, 0 
nonradioactive 0 
assays 0 
for 0 
the 0 
detection 0 
of 0 
each 0 
mutation 0 
, 0 
which 0 
should 0 
be 0 
helpful 0 
for 0 
carrier 0 
screening 0 
. 0 
. 0 

Mapping 0 
of 0 
the 0 
mouse 0 
homologue 0 
of 0 
the 0 
Wilson 1
disease 1
gene 0 
to 0 
mouse 0 
chromosome 0 
_NUM1 0 
. 0 

ATP7B 0 
, 0 
the 0 
gene 0 
altered 0 
in 0 
Wilson 1
disease 1
-LRB- 0 
WD 1
-RRB- 0 
patients 0 
, 0 
lies 0 
in 0 
a 0 
block 0 
of 0 
homology 0 
shared 0 
between 0 
human 0 
chromosome 0 
13q14 0 
and 0 
the 0 
central 0 
region 0 
of 0 
mouse 0 
chromosome 0 
_NUM2 0 
. 0 

However 0 
, 0 
we 0 
have 0 
mapped 0 
the 0 
murine 0 
homologue 0 
of 0 
ATP7B 0 
-LRB- 0 
Atp7b 0 
-RRB- 0 
to 0 
mouse 0 
chromosome 0 
_NUM1 0 
by 0 
somatic 0 
cell 0 
hybrid 0 
analysis 0 
. 0 

Analysis 0 
of 0 
_NUM2 0 
interspecific 0 
backcross 0 
offspring 0 
was 0 
used 0 
to 0 
position 0 
Atp7b 0 
close 0 
to 0 
D8Mit3 0 
and 0 
another 0 
ATPase 0 
locus 0 
, 0 
Atp4b 0 
, 0 
on 0 
mouse 0 
chromosome 0 
_NUM1 0 
. 0 

ATP4B 0 
lies 0 
in 0 
13q34 0 
and 0 
is 0 
separated 0 
from 0 
ATP7B 0 
by 0 
several 0 
loci 0 
whose 0 
mouse 0 
homologues 0 
map 0 
to 0 
mouse 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
assignment 0 
of 0 
Atp7b 0 
to 0 
mouse 0 
chromosome 0 
_NUM1 0 
identifies 0 
a 0 
previously 0 
unrecognized 0 
region 0 
of 0 
homology 0 
between 0 
this 0 
chromosome 0 
and 0 
human 0 
chromosome 0 
_NUM2 0 
. 0 

This 0 
assignment 0 
suggests 0 
a 0 
possible 0 
location 0 
for 0 
the 0 
toxic 0 
milk 0 
mutation 0 
in 0 
the 0 
mouse 0 
, 0 
which 0 
has 0 
been 0 
proposed 0 
as 0 
a 0 
homologue 0 
of 0 
WD 1
. 0 
. 0 

Characteristics 0 
of 0 
intergenerational 0 
contractions 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
myotonic 1
dystrophy 1
. 0 

In 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
, 0 
the 0 
size 0 
of 0 
a 0 
_DS 0 
repeat 0 
in 0 
the 0 
DM 1
kinase 0 
gene 0 
generally 0 
increases 0 
in 0 
successive 0 
generations 0 
with 0 
clinical 0 
evidence 0 
of 0 
anticipation 0 
. 0 

However 0 
, 0 
there 0 
have 0 
also 0 
been 0 
cases 0 
with 0 
an 0 
intergenerational 0 
contraction 0 
of 0 
the 0 
repeat 0 
. 0 

We 0 
examined 0 
_NUM1 0 
, 0 
_NUM3 0 
DM 1
parent-offspring 0 
pairs 0 
, 0 
of 0 
which 0 
_NUM2 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
showed 0 
such 0 
contractions 0 
in 0 
peripheral 0 
blood 0 
leukocytes 0 
-LRB- 0 
PBL 0 
-RRB- 0 
. 0 

In 0 
_NUM2 0 
of 0 
the 0 
_NUM2 0 
pairs 0 
, 0 
clinical 0 
data 0 
allowed 0 
an 0 
analysis 0 
of 0 
their 0 
anticipation 0 
status 0 
. 0 

It 0 
is 0 
surprising 0 
that 0 
anticipation 0 
occurred 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
these 0 
_NUM2 0 
pairs 0 
, 0 
while 0 
none 0 
clearly 0 
showed 0 
a 0 
later 0 
onset 0 
of 0 
DM 1
in 0 
the 0 
symptomatic 0 
offspring 0 
. 0 

The 0 
contraction 0 
occurred 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM3 0 
paternal 0 
transmissions 0 
and 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM1 0 
% 0 
-RRB- 0 
of 0 
_NUM3 0 
maternal 0 
transmissions 0 
. 0 

Anticipation 0 
was 0 
observed 0 
more 0 
frequently 0 
in 0 
maternal 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
than 0 
in 0 
paternal 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
transmissions 0 
-LRB- 0 
P 0 
< 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

The 0 
parental 0 
repeat 0 
size 0 
correlated 0 
with 0 
the 0 
size 0 
of 0 
intergenerational 0 
contraction 0 
-LRB- 0 
r2 0 
= 0 
. 0 

_NUM2 0 
, 0 
P 0 
< 0 
< 0 
. 0 

_NUM3 0 
-RRB- 0 
, 0 
and 0 
the 0 
slope 0 
of 0 
linear 0 
regression 0 
was 0 
steeper 0 
in 0 
paternal 0 
-LRB- 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
than 0 
in 0 
maternal 0 
-LRB- 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
transmissions 0 
-LRB- 0 
P 0 
< 0 
< 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

Sixteen 0 
DM 1
parents 0 
had 0 
multiple 0 
DM 1
offspring 0 
with 0 
the 0 
_DS 0 
repeat 0 
contractions 0 
. 0 

This 0 
frequency 0 
was 0 
higher 0 
than 0 
the 0 
frequency 0 
expected 0 
from 0 
the 0 
probability 0 
of 0 
the 0 
repeat 0 
contractions 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
the 0 
size 0 
of 0 
DM 1
sib 0 
population 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
DM 1
offspring 0 
per 0 
DM 1
parent 0 
, 0 
in 0 
_NUM3 0 
DM 1
parents 0 
-RRB- 0 
. 0 

We 0 
conclude 0 
that 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
intergenerational 0 
contractions 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
leukocyte 0 
DNA 0 
frequently 0 
accompanies 0 
apparent 0 
anticipation 0 
, 0 
especially 0 
when 0 
DM 1
is 0 
maternally 0 
transmitted 0 
, 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
the 0 
paternal 0 
origin 0 
of 0 
the 0 
repeat 0 
and 0 
the 0 
presence 0 
of 0 
the 0 
repeat 0 
contraction 0 
in 0 
a 0 
sibling 0 
increase 0 
the 0 
probability 0 
of 0 
the 0 
_DS 0 
repeat 0 
contraction 0 
Splice-site 0 
mutation 0 
in 0 
the 0 
PDS 1
gene 0 
may 0 
result 0 
in 0 
intrafamilial 0 
variability 0 
for 0 
deafness 1
in 0 
Pendred 1
syndrome 1
. 0 

Pendred 1
syndrome 1
is 0 
a 0 
recessive 1
inherited 1
disorder 1
that 0 
consists 0 
of 0 
developmental 1
abnormalities 1
of 1
the 1
cochlea 1
, 0 
sensorineural 1
hearing 1
loss 1
, 0 
and 0 
diffuse 1
thyroid 1
enlargement 1
-LRB- 0 
goiter 1
-RRB- 0 
. 0 

This 0 
disorder 0 
may 0 
account 0 
for 0 
up 0 
to 0 
_NUM2 0 
% 0 
of 0 
cases 0 
of 0 
hereditary 1
deafness 1
. 0 

The 0 
disease 0 
gene 0 
-LRB- 0 
PDS 1
-RRB- 0 
has 0 
been 0 
mapped 0 
to 0 
chromosome 0 
7q22-q31 0 
, 0 
and 0 
encodes 0 
a 0 
chloride-iodide 0 
transport 0 
protein 0 
. 0 

We 0 
performed 0 
mutation 0 
analysis 0 
of 0 
individual 0 
exons 0 
of 0 
the 0 
PDS 1
gene 0 
in 0 
one 0 
Spanish 0 
family 0 
that 0 
shows 0 
intrafamilial 0 
variability 0 
of 0 
the 0 
deafness 1
phenotype 0 
-LRB- 0 
two 0 
patients 0 
with 0 
profound 0 
and 0 
one 0 
with 0 
moderate-severe 0 
deafness 1
-RRB- 0 
. 0 

We 0 
identified 0 
a 0 
new 0 
splice-site 0 
mutation 0 
affecting 0 
intron 0 
_NUM1 0 
of 0 
the 0 
PDS 1
gene 0 
, 0 
at 0 
nucleotide 0 
position 0 
_NUM3 0 
+ 0 
_NUM1 0 
. 0 

RNA 0 
analysis 0 
from 0 
lymphocytes 0 
of 0 
the 0 
affected 0 
patients 0 
showed 0 
that 0 
mutation 0 
_NUM3 0 
+ 0 
7A 0 
-- 0 
> 0 
G 0 
generates 0 
a 0 
new 0 
donor 0 
splice 0 
site 0 
, 0 
leading 0 
to 0 
an 0 
mRNA 0 
with 0 
an 0 
insertion 0 
of 0 
six 0 
nucleotides 0 
from 0 
intron 0 
_NUM1 0 
of 0 
PDS 1
. 0 

Since 0 
the 0 
newly 0 
created 0 
donor 0 
splice 0 
site 0 
is 0 
likely 0 
to 0 
compete 0 
with 0 
the 0 
normal 0 
one 0 
, 0 
variations 0 
of 0 
the 0 
levels 0 
of 0 
normal 0 
and 0 
aberrant 0 
transcripts 0 
of 0 
the 0 
PDS 0 
gene 0 
in 0 
the 0 
cochlea 0 
may 0 
explain 0 
the 0 
variability 0 
in 0 
the 0 
deafness 1
presentation 0 
. 0 
. 0 

Heterozygous 0 
loss 0 
of 0 
Six5 0 
in 0 
mice 0 
is 0 
sufficient 0 
to 0 
cause 0 
ocular 0 
cataracts 1
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disorder 1
characterized 0 
by 0 
skeletal 0 
muscle 1
wasting 1
, 0 
myotonia 1
, 0 
cardiac 1
arrhythmia 1
, 0 
hyperinsulinaemia 1
, 0 
mental 1
retardation 1
and 0 
ocular 0 
cataracts 1
. 0 

The 0 
genetic 1
defect 1
in 0 
DM 1
is 0 
a 0 
_DS 0 
repeat 0 
expansion 0 
located 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
DMPK 0 
and 0 
_NUM1 0 
of 0 
a 0 
homeodomain-encoding 0 
gene 0 
, 0 
SIX5 0 
-LRB- 0 
formerly 0 
DMAHP 0 
; 0 
refs 0 
2-5 0 
-RRB- 0 
. 0 

There 0 
are 0 
three 0 
mechanisms 0 
by 0 
which 0 
_DS 0 
expansion 0 
can 0 
result 0 
in 0 
DM 1
. 0 

First 0 
, 0 
repeat 0 
expansion 0 
may 0 
alter 0 
the 0 
processing 0 
or 0 
transport 0 
of 0 
the 0 
mutant 0 
DMPK 0 
mRNA 0 
and 0 
consequently 0 
reduce 0 
DMPK 0 
levels 0 
. 0 

Second 0 
, 0 
_DS 0 
expansion 0 
may 0 
establish 0 
a 0 
region 0 
of 0 
heterochromatin 0 
_NUM1 0 
of 0 
the 0 
repeat 0 
sequence 0 
and 0 
decrease 0 
SIX5 0 
transcription 0 
. 0 

Third 0 
, 0 
toxic 0 
effects 0 
of 0 
the 0 
repeat 0 
expansion 0 
may 0 
be 0 
intrinsic 0 
to 0 
the 0 
repeated 0 
elements 0 
at 0 
the 0 
level 0 
of 0 
DNA 0 
or 0 
RNA 0 
-LRB- 0 
refs 0 
_NUM2 0 
, 0 
_NUM2 0 
-RRB- 0 
. 0 

Previous 0 
studies 0 
have 0 
demonstrated 0 
that 0 
a 0 
dose-dependent 0 
loss 0 
of 0 
Dm15 0 
-LRB- 0 
the 0 
mouse 0 
DMPK 0 
homologue 0 
-RRB- 0 
in 0 
mice 0 
produces 0 
a 0 
partial 0 
DM 1
phenotype 0 
characterized 0 
by 0 
decreased 0 
development 0 
of 0 
skeletal 0 
muscle 0 
force 0 
and 0 
cardiac 1
conduction 1
disorders 1
. 0 

To 0 
test 0 
the 0 
role 0 
of 0 
Six5 0 
loss 0 
in 0 
DM 1
, 0 
we 0 
have 0 
analysed 0 
a 0 
strain 0 
of 0 
mice 0 
in 0 
which 0 
Six5 0 
was 0 
deleted 0 
. 0 

Our 0 
results 0 
demonstrate 0 
that 0 
the 0 
rate 0 
and 0 
severity 0 
of 0 
cataract 1
formation 0 
is 0 
inversely 0 
related 0 
to 0 
Six5 0 
dosage 0 
and 0 
is 0 
temporally 0 
progressive 0 
. 0 

Six5 0 
+ 0 
/ 0 
- 0 
and 0 
Six5 0 
- 0 
/ 0 
- 0 
mice 0 
show 0 
increased 0 
steady-state 0 
levels 0 
of 0 
the 0 
Na 0 
+ 0 
/ 0 
K 0 
+ 0 
- 0 
ATPase 0 
alpha-1 0 
subunit 0 
and 0 
decreased 0 
Dm15 0 
mRNA 0 
levels 0 
. 0 

Thus 0 
, 0 
altered 0 
ion 0 
homeostasis 0 
within 0 
the 0 
lens 0 
may 0 
contribute 0 
to 0 
cataract 1
formation 0 
. 0 

As 0 
ocular 0 
cataracts 1
are 0 
a 0 
characteristic 0 
feature 0 
of 0 
DM 1
, 0 
these 0 
results 0 
demonstrate 0 
that 0 
decreased 0 
SIX5 0 
transcription 0 
is 0 
important 0 
in 0 
the 0 
aetiology 0 
of 0 
DM 1
. 0 

Our 0 
data 0 
support 0 
the 0 
hypothesis 0 
that 0 
DM 1
is 0 
a 0 
contiguous 0 
gene 0 
syndrome 0 
associated 0 
with 0 
the 0 
partial 0 
loss 0 
of 0 
both 0 
DMPK 0 
and 0 
SIX5 0 
. 0 
. 0 

Cis 0 
and 0 
trans 0 
effects 0 
of 0 
the 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
mutation 0 
in 0 
a 0 
cell 0 
culture 0 
model 0 
. 0 

The 0 
mutation 0 
causing 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
has 0 
been 0 
identified 0 
as 0 
a 0 
_DS 0 
expansion 0 
in 0 
the 0 
3-untranslated 0 
region 0 
-LRB- 0 
3-UTR 0 
-RRB- 0 
of 0 
the 0 
DM 1
protein 0 
kinase 0 
gene 0 
-LRB- 0 
DMPK 0 
-RRB- 0 
, 0 
but 0 
the 0 
mechanism 0 
-LRB- 0 
s 0 
-RRB- 0 
of 0 
pathogenesis 0 
remain 0 
unknown 0 
. 0 

Studies 0 
using 0 
DM 1
patient 0 
materials 0 
have 0 
often 0 
produced 0 
confusing 0 
results 0 
. 0 

Therefore 0 
, 0 
to 0 
study 0 
the 0 
effects 0 
of 0 
the 0 
DM 1
mutation 0 
in 0 
a 0 
controlled 0 
environment 0 
, 0 
we 0 
have 0 
established 0 
a 0 
cell 0 
culture 0 
model 0 
system 0 
using 0 
C2C12 0 
mouse 0 
myoblasts 0 
. 0 

By 0 
expressing 0 
chimeric 0 
reporter 0 
constructs 0 
containing 0 
a 0 
reporter 0 
gene 0 
fused 0 
to 0 
a 0 
human 0 
DMPK 0 
3-UTR 0 
, 0 
we 0 
identified 0 
both 0 
cis 0 
and 0 
trans 0 
effects 0 
that 0 
are 0 
mediated 0 
by 0 
the 0 
DM 1
mutation 0 
. 0 

Our 0 
data 0 
show 0 
that 0 
a 0 
mutant 0 
DMPK 0 
3-UTR 0 
, 0 
with 0 
as 0 
few 0 
as 0 
_NUM2 0 
CTGs 0 
, 0 
had 0 
a 0 
negative 0 
cis 0 
effect 0 
on 0 
protein 0 
expression 0 
and 0 
resulted 0 
in 0 
the 0 
aggregation 0 
of 0 
reporter 0 
transcripts 0 
into 0 
discrete 0 
nuclear 0 
foci 0 
. 0 

We 0 
determined 0 
by 0 
deletion 0 
analysis 0 
that 0 
an 0 
expanded 0 
-LRB- 0 
_DS 0 
-RRB- 0 
-LRB- 0 
n 0 
-RRB- 0 
tract 0 
alone 0 
was 0 
sufficient 0 
to 0 
mediate 0 
these 0 
cis 0 
effects 0 
. 0 

Furthermore 0 
, 0 
in 0 
contrast 0 
to 0 
the 0 
normal 0 
DMPK 0 
3-UTR 0 
mRNA 0 
, 0 
a 0 
mutant 0 
DMPK 0 
3-UTR 0 
mRNA 0 
with 0 
-LRB- 0 
CUG 0 
-RRB- 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
selectively 0 
inhibited 0 
myogenic 0 
differentiation 0 
of 0 
C2C12 0 
myoblasts 0 
. 0 

Genetic 0 
analysis 0 
and 0 
the 0 
Cre 0 
- 0 
loxP 0 
system 0 
were 0 
used 0 
to 0 
clearly 0 
demonstrate 0 
that 0 
the 0 
myoblast 0 
fusion 0 
defect 0 
could 0 
be 0 
rescued 0 
by 0 
eliminating 0 
the 0 
expression 0 
of 0 
the 0 
mutant 0 
DMPK 0 
3-UTR 0 
transcript 0 
. 0 

Characterization 0 
of 0 
spontaneous 0 
deletion 0 
events 0 
mapped 0 
the 0 
inhibitory 0 
effect 0 
to 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
-LRB- 0 
n 0 
-RRB- 0 
expansion 0 
and 0 
/ 0 
or 0 
the 0 
_NUM1 0 
end 0 
of 0 
the 0 
DMPK 0 
3-UTR 0 
. 0 

These 0 
results 0 
provide 0 
evidence 0 
that 0 
the 0 
DM 1
mutation 0 
acts 0 
in 0 
cis 0 
to 0 
reduce 0 
protein 0 
production 0 
-LRB- 0 
consistent 0 
with 0 
DMPK 1
haploinsufficiency 1
-RRB- 0 
and 0 
in 0 
trans 0 
as 0 
a 0 
riboregulator 0 
to 0 
inhibit 0 
myogenesis 0 
. 0 
. 0 

Intelligence 0 
quotient 0 
profile 0 
in 0 
myotonic 1
dystrophy 1
, 0 
intergenerational 0 
deficit 0 
, 0 
and 0 
correlation 0 
with 0 
_DS 0 
amplification 0 
. 0 

An 0 
abbreviated 0 
Wechsler 0 
Adult 0 
Intelligence 0 
Scale 0 
Revised 0 
-LRB- 0 
WAIS-R 0 
-RRB- 0 
was 0 
used 0 
to 0 
assess 0 
verbal 0 
and 0 
arithmetical 0 
cognitive 0 
performance 0 
in 0 
_NUM2 0 
subjects 0 
with 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
, 0 
covering 0 
all 0 
grades 0 
of 0 
disease 0 
severity 0 
, 0 
and 0 
_NUM2 0 
controls 0 
at 0 
_NUM2 0 
% 0 
risk 0 
of 0 
inheriting 0 
DM 1
. 0 

Scaled 0 
scores 0 
from 0 
the 0 
assessment 0 
were 0 
converted 0 
into 0 
an 0 
intelligence 0 
quotient 0 
-LRB- 0 
IQ 0 
-RRB- 0 
estimation 0 
on 0 
each 0 
person 0 
. 0 

Significant 0 
IQ 0 
differences 0 
were 0 
found 0 
between 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
all 0 
_NUM2 0 
DM 1
subjects 0 
-LRB- 0 
mean 0 
_NUM2 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
and 0 
_NUM2 0 
controls 0 
-LRB- 0 
_NUM3 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
with 0 
no 0 
sex 0 
differences 0 
in 0 
either 0 
group 0 
; 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
_NUM2 0 
affected 0 
parents 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
and 0 
their 0 
affected 0 
children 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
where 0 
significance 0 
was 0 
dependent 0 
on 0 
parental 0 
sex 0 
being 0 
female 0 
; 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
_NUM2 0 
pairs 0 
of 0 
affected 0 
sibs 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
and 0 
their 0 
normal 0 
sibs 0 
-LRB- 0 
_NUM3 0 
. 0 

_NUM1 0 
, 0 
SD 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

IQ 0 
steadily 0 
declined 0 
as 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
the 0 
age 0 
of 0 
onset 0 
of 0 
signs 0 
and 0 
symptoms 0 
decreased 0 
, 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
the 0 
_DS 0 
expansion 0 
size 0 
increased 0 
. 0 

The 0 
correlation 0 
appeared 0 
to 0 
be 0 
more 0 
linear 0 
with 0 
age 0 
of 0 
onset 0 
. 0 

The 0 
correlation 0 
of 0 
IQ 0 
difference 0 
and 0 
_DS 0 
expansion 0 
difference 0 
in 0 
both 0 
the 0 
DM 1
parent-child 0 
pairs 0 
and 0 
normal 0 
sib-affected 0 
sib 0 
pairs 0 
was 0 
poor 0 
, 0 
indicating 0 
that 0 
_DS 0 
expansion 0 
is 0 
not 0 
a 0 
reliable 0 
predictor 0 
of 0 
IQ 0 
either 0 
in 0 
individual 0 
persons 0 
or 0 
families 0 
. 0 

Further 0 
analysis 0 
of 0 
cognitive 0 
function 0 
in 0 
DM 1
is 0 
required 0 
to 0 
clarify 0 
specific 0 
deficits 0 
characteristic 0 
of 0 
this 0 
patient 0 
group 0 
Complement 1
factor 1
_NUM1 1
deficiency 1
: 0 
a 0 
clinical 0 
and 0 
serological 0 
family 0 
study 0 
. 0 

Inherited 1
complement 1
deficiencies 1
are 0 
associated 0 
with 0 
a 0 
variety 0 
of 0 
connective 0 
tissue 0 
diseases 0 
. 0 

A 0 
family 0 
with 0 
inherited 1
deficiency 1
of 1
complement 1
factor 1
_NUM1 1
-LRB- 0 
C2 0
-RRB- 0 
is 0 
described 0 
in 0 
which 0 
two 0 
family 0 
members 0 
with 0 
homozygous 0 
C2 1
deficiency 1
developed 0 
cutaneous 1
vasculitis 1
and 0 
sicca 1
syndrome 1
. 0 

The 0 
other 0 
family 0 
members 0 
had 0 
heterozygous 0 
C2 1
deficiency 1
and 0 
each 0 
member 0 
had 0 
the 0 
HLA-A25 0 
, 0 
_AN 0 
, 0 
DR2 0 
-LRB- 0 
_AN 0 
-RRB- 0 
haplotype 0 
. 0 

The 0 
mother 0 
had 0 
seropositive 1
rheumatoid 1
arthritis 1
. 0 

Further 0 
studies 0 
showed 0 
the 0 
presence 0 
of 0 
cryoglobulins 0 
, 0 
antibodies 0 
against 0 
endothelial 0 
cells 0 
, 0 
and 0 
anticardiolipin 0 
antibodies 0 
. 0 
. 0 

Oncogenic 0 
point 0 
mutations 0 
in 0 
exon 0 
_NUM2 0 
of 0 
the 0 
RB1 0 
gene 0 
in 0 
families 0 
showing 0 
incomplete 0 
penetrance 0 
and 0 
mild 0 
expression 0 
of 0 
the 0 
retinoblastoma 1
phenotype 0 
. 0 

The 0 
retinoblastoma 1
predisposition 0 
gene 0 
, 0 
RB1 0 
, 0 
segregates 0 
as 0 
an 0 
autosomal 0 
dominant 0 
trait 0 
with 0 
high 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
penetrance 0 
. 0 

Certain 0 
families 0 
, 0 
however 0 
, 0 
show 0 
an 0 
unusual 0 
low-penetrance 0 
phenotype 0 
with 0 
many 0 
individuals 0 
being 0 
unaffected 0 
, 0 
unilaterally 0 
affected 0 
, 0 
or 0 
with 0 
evidence 0 
of 0 
spontaneously 0 
regressed 0 
tumors 1
. 0 

We 0 
have 0 
used 0 
single-strand 0 
conformation 0 
polymorphism 0 
analysis 0 
and 0 
PCR 0 
sequencing 0 
to 0 
study 0 
two 0 
such 0 
families 0 
. 0 

Mutations 0 
were 0 
found 0 
in 0 
exon 0 
_NUM2 0 
of 0 
RB1 0 
in 0 
both 0 
cases 0 
. 0 

In 0 
one 0 
family 0 
a 0 
C 0 
-- 0 
T 0 
transition 0 
in 0 
codon 0 
_NUM3 0 
converts 0 
an 0 
arginine 0 
-LRB- 0 
_DS 0 
-RRB- 0 
to 0 
a 0 
tryptophan 0 
-LRB- 0 
_DS 0 
-RRB- 0 
codon 0 
. 0 

In 0 
this 0 
family 0 
, 0 
incomplete 0 
penetrance 0 
and 0 
mild 0 
phenotypic 0 
expression 0 
were 0 
observed 0 
in 0 
virtually 0 
all 0 
patients 0 
, 0 
possibly 0 
indicating 0 
that 0 
single 0 
amino 0 
acid 0 
changes 0 
may 0 
modify 0 
protein 0 
structure 0 
/ 0 
function 0 
such 0 
that 0 
tumorigenesis 0 
is 0 
not 0 
inevitable 0 
. 0 

In 0 
the 0 
second 0 
family 0 
the 0 
mutation 0 
in 0 
codon 0 
_NUM3 0 
is 0 
a 0 
G 0 
-- 0 
T 0 
transversion 0 
that 0 
converts 0 
a 0 
glutamine 0 
-LRB- 0 
_DS 0 
-RRB- 0 
to 0 
a 0 
stop 0 
-LRB- 0 
_DS 0 
-RRB- 0 
codon 0 
. 0 

However 0 
, 0 
this 0 
mutation 0 
also 0 
occurs 0 
near 0 
a 0 
potential 0 
cryptic 0 
splice 0 
acceptor 0 
site 0 
, 0 
raising 0 
the 0 
possibility 0 
of 0 
alternative 0 
splicing 0 
resulting 0 
in 0 
a 0 
less 0 
severely 0 
disrupted 0 
protein 0 
. 0 
. 0 

Identification 0 
of 0 
a 0 
novel 0 
R21X 0 
mutation 0 
in 0 
the 0 
liver-type 0 
arginase 0 
gene 0 
-LRB- 0 
ARG1 0 
-RRB- 0 
in 0 
four 0 
Portuguese 0 
patients 0 
with 0 
argininemia 1
. 0 

Argininemia 1
is 0 
a 0 
rare 0 
autossomal 1
recessive 1
disorder 1
caused 0 
by 0 
deficiency 1
in 1
the 1
cytosolic 1
liver-type 1
arginase 1
enzyme 1
-LRB- 0 
L-arginine 0 
urea-hydrolase 0 
; 0 
E. 0 
C. 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

In 0 
order 0 
to 0 
investigate 0 
the 0 
molecular 0 
basis 0 
for 0 
argininemia 1
in 0 
four 0 
unrelated 0 
Portuguese 0 
patients 0 
-LRB- 0 
two 0 
from 0 
northern 0 
Portugal 0 
and 0 
two 0 
from 0 
Madeira 0 
Island 0 
-RRB- 0 
we 0 
performed 0 
a 0 
DNA 0 
sequence 0 
analysis 0 
of 0 
all 0 
the 0 
exons 0 
and 0 
exon 0 
/ 0 
intron 0 
boundaries 0 
of 0 
the 0 
liver-type 0 
arginase 0 
gene 0 
-LRB- 0 
ARG1 0 
-RRB- 0 
. 0 

All 0 
patients 0 
were 0 
found 0 
to 0 
be 0 
homozygous 0 
for 0 
a 0 
newly 0 
identified 0 
C 0 
- 0 
> 0 
T 0 
transition 0 
in 0 
codon 0 
_NUM2 0 
-LRB- 0 
exon 0 
_NUM1 0 
-RRB- 0 
substituting 0 
arginine 0 
for 0 
a 0 
premature 0 
stop 0 
codon 0 
-LRB- 0 
R21X 0 
_DS 0 
to 0 
_DS 0 
-RRB- 0 
and 0 
generating 0 
a 0 
NlaIII 0 
restriction 0 
site 0 
. 0 

Restriction 0 
digestion 0 
following 0 
PCR 0 
amplification 0 
of 0 
ARG1 0 
exon 0 
_NUM1 0 
confirmed 0 
the 0 
presence 0 
of 0 
the 0 
mutation 0 
. 0 

A 0 
mutation 0 
in 0 
the 0 
pleckstrin 0 
homology 0 
-LRB- 0 
PH 0 
-RRB- 0 
domain 0 
of 0 
the 0 
FGD1 0 
gene 0 
in 0 
an 0 
Italian 0 
family 0 
with 0 
faciogenital 1
dysplasia 1
-LRB- 0 
Aarskog-Scott 1
syndrome 1
-RRB- 0 
. 0 

Aarskog-Scott 1
Syndrome 1
-LRB- 0 
AAS 1
-RRB- 0 
is 0 
an 0 
X-linked 1
disorder 1
characterised 0 
by 0 
short 1
stature 1
and 0 
multiple 0 
facial 1
, 1
limb 1
and 1
genital 1
abnormalities 1
. 0 

A 0 
gene 0 
, 0 
FGD1 0 
, 0 
altered 0 
in 0 
a 0 
patient 0 
with 0 
AAS 1
phenotype 0 
, 0 
has 0 
been 0 
identified 0 
and 0 
found 0 
to 0 
encode 0 
a 0 
protein 0 
with 0 
homology 0 
to 0 
Rho 0 
/ 0 
Rac 0 
guanine 0 
nucleotide 0 
exchange 0 
factors 0 
-LRB- 0 
Rho 0 
/ 0 
Rac 0 
GEF 0 
-RRB- 0 
. 0 

However 0 
, 0 
since 0 
this 0 
original 0 
report 0 
on 0 
identification 0 
of 0 
a 0 
mutated 0 
FGD1 0 
gene 0 
in 0 
an 0 
AAS 1
patient 0 
, 0 
no 0 
additional 0 
mutations 0 
in 0 
the 0 
FGD1 0 
gene 0 
have 0 
been 0 
described 0 
. 0 

We 0 
analysed 0 
_NUM2 0 
independent 0 
patients 0 
with 0 
clinical 0 
diagnosis 0 
of 0 
AAS 1
. 0 

One 0 
patient 0 
presented 0 
a 0 
mutation 0 
that 0 
results 0 
in 0 
a 0 
nucleotide 0 
change 0 
in 0 
exon 0 
_NUM2 0 
of 0 
the 0 
FGD1 0 
gene 0 
-LRB- 0 
_AN 0 
> 0 
A 0 
-RRB- 0 
substituting 0 
a 0 
Gln 0 
for 0 
Arg 0 
in 0 
position 0 
_NUM3 0 
. 0 

The 0 
mutation 0 
was 0 
found 0 
to 0 
segregate 0 
with 0 
the 0 
AAS 1
phenotype 0 
in 0 
affected 0 
males 0 
and 0 
carrier 0 
females 0 
in 0 
the 0 
family 0 
of 0 
this 0 
patient 0 
. 0 

Interestingly 0 
, 0 
Arg-610 0 
is 0 
located 0 
within 0 
one 0 
of 0 
the 0 
two 0 
pleckstrin 0 
homology 0 
-LRB- 0 
PH 0 
-RRB- 0 
domains 0 
of 0 
the 0 
FGD1 0 
gene 0 
and 0 
it 0 
corresponds 0 
to 0 
a 0 
highly 0 
conserved 0 
residue 0 
which 0 
has 0 
been 0 
involved 0 
in 0 
InsP 0 
binding 0 
in 0 
PH 0 
domains 0 
of 0 
other 0 
proteins 0 
. 0 

The 0 
same 0 
residue 0 
is 0 
often 0 
mutated 0 
in 0 
the 0 
Brutons 0 
tyrosine 0 
kinase 0 
-LRB- 0 
Btk 0 
-RRB- 0 
gene 0 
in 0 
patients 0 
with 0 
an 0 
X-linked 1
agammaglobulinemia 1
. 0 

The 0 
Arg610Gln 0 
mutation 0 
represents 0 
the 0 
first 0 
case 0 
of 0 
a 0 
mutation 0 
in 0 
the 0 
PH 0 
domain 0 
of 0 
the 0 
FGD1 0 
gene 0 
and 0 
additional 0 
evidence 0 
that 0 
mutations 0 
in 0 
PH 0 
domains 0 
can 0 
be 0 
associated 0 
to 0 
human 0 
diseases 0 
. 0 
. 0 

Localization 0 
of 0 
histidase 0 
to 0 
human 0 
chromosome 0 
region 0 
12q22 0 
-- 0 
_AN 0 
.1 0 
and 0 
mouse 0 
chromosome 0 
region 0 
10C2 0 
-- 0 
D1 0 
. 0 

The 0 
human 0 
gene 0 
for 0 
histidase 0 
-LRB- 0 
histidine 0 
ammonia-lyase 0 
; 0 
HAL 0 
-RRB- 0 
, 0 
the 0 
enzyme 0 
deficient 0 
in 0 
histidinemia 1
, 0 
was 0 
assigned 0 
to 0 
human 0 
chromosome 0 
_NUM2 0 
by 0 
Southern 0 
blot 0 
analysis 0 
of 0 
human 0 
X 0 
mouse 0 
somatic 0 
cell 0 
hybrid 0 
DNA 0 
. 0 

The 0 
gene 0 
was 0 
sublocalized 0 
to 0 
region 0 
12q22 0 
-- 0 
_AN 0 
. 0 

_NUM1 0 
by 0 
in 0 
situ 0 
hybridization 0 
, 0 
using 0 
a 0 
human 0 
histidase 0 
cDNA 0 
. 0 

The 0 
homologous 0 
locus 0 
in 0 
the 0 
mouse 0 
-LRB- 0 
Hal 0 
-RRB- 0 
was 0 
mapped 0 
to 0 
region 0 
10C2 0 
-- 0 
D1 0 
by 0 
in 0 
situ 0 
hybridization 0 
, 0 
using 0 
a 0 
cell 0 
line 0 
from 0 
a 0 
mouse 0 
homozygous 0 
for 0 
a 0 
_NUM1 0 
. 0 

_NUM2 0 
Robertsonian 0 
translocation 0 
. 0 

These 0 
assignments 0 
extend 0 
the 0 
conserved 0 
syntenic 0 
region 0 
between 0 
human 0 
chromosome 0 
_NUM2 0 
and 0 
mouse 0 
chromosome 0 
_NUM2 0 
that 0 
includes 0 
the 0 
genes 0 
for 0 
phenylalanine 0 
hydroxylase 0 
, 0 
gamma 0 
interferon 0 
, 0 
peptidase 0 
, 0 
and 0 
citrate 0 
synthase 0 
. 0 

The 0 
localization 0 
of 0 
histidase 0 
to 0 
mouse 0 
chromosome 0 
_NUM2 0 
suggests 0 
that 0 
the 0 
histidase 0 
regulatory 0 
locus 0 
-LRB- 0 
Hsd 0 
-RRB- 0 
and 0 
the 0 
histidinemia 0 
mutation 0 
-LRB- 0 
his 0 
-RRB- 0 
, 0 
which 0 
are 0 
both 0 
known 0 
to 0 
be 0 
on 0 
chromosome 0 
_NUM2 0 
, 0 
may 0 
be 0 
alleles 0 
of 0 
the 0 
histidase 0 
structural 0 
gene 0 
locus 0 
. 0 

Noninvasive 0 
test 0 
for 0 
fragile 1
X 1
syndrome 1
, 0 
using 0 
hair 0 
root 0 
analysis 0 
. 0 

Identification 0 
of 0 
the 0 
FMR1 0 
gene 0 
and 0 
the 0 
repeat-amplification 0 
mechanism 0 
causing 0 
fragile 1
X 1
syndrome 1
led 0 
to 0 
development 0 
of 0 
reliable 0 
DNA-based 0 
diagnostic 0 
methods 0 
, 0 
including 0 
Southern 0 
blot 0 
hybridization 0 
and 0 
PCR 0 
. 0 

Both 0 
methods 0 
are 0 
performed 0 
on 0 
DNA 0 
isolated 0 
from 0 
peripheral 0 
blood 0 
cells 0 
and 0 
measure 0 
the 0 
repeat 0 
size 0 
in 0 
FMR1 0 
. 0 

Using 0 
an 0 
immunocytochemical 0 
technique 0 
on 0 
blood 0 
smears 0 
, 0 
we 0 
recently 0 
developed 0 
a 0 
novel 0 
test 0 
for 0 
identification 0 
of 0 
patients 0 
with 0 
fragile 1
X 1
syndrome 1
. 0 

This 0 
method 0 
, 0 
also 0 
called 0 
'' 0 
antibody 0 
test 0 
, 0 
'' 0 
uses 0 
monoclonal 0 
antibodies 0 
against 0 
the 0 
FMR1 0 
gene 0 
product 0 
-LRB- 0 
FMRP 0 
-RRB- 0 
and 0 
is 0 
based 0 
on 0 
absence 0 
of 0 
FMRP 0 
in 0 
patients 0 
cells 0 
. 0 

Here 0 
we 0 
describe 0 
a 0 
new 0 
diagnostic 0 
test 0 
to 0 
identify 0 
male 0 
patients 0 
with 0 
fragile 1
X 1
syndrome 1
, 0 
on 0 
the 0 
basis 0 
of 0 
lack 0 
of 0 
FMRP 0 
in 0 
their 0 
hair 0 
roots 0 
. 0 

Expression 0 
of 0 
FMRP 0 
in 0 
hair 0 
roots 0 
was 0 
studied 0 
by 0 
use 0 
of 0 
an 0 
FMRP-specific 0 
antibody 0 
test 0 
, 0 
and 0 
the 0 
percentage 0 
of 0 
FMRP-expressing 0 
hair 0 
roots 0 
in 0 
controls 0 
and 0 
in 0 
male 0 
fragile 1
X 1
patients 0 
was 0 
determined 0 
. 0 

Control 0 
individuals 0 
showed 0 
clear 0 
expression 0 
of 0 
FMRP 0 
in 0 
nearly 0 
every 0 
hair 0 
root 0 
, 0 
whereas 0 
male 0 
fragile 1
X 1
patients 0 
lacked 0 
expression 0 
of 0 
FMRP 0 
in 0 
almost 0 
all 0 
their 0 
hair 0 
roots 0 
. 0 

Mentally 1
retarded 1
female 0 
patients 0 
with 0 
a 0 
full 0 
mutation 0 
showed 0 
FMRP 0 
expression 0 
in 0 
only 0 
some 0 
of 0 
their 0 
hair 0 
roots 0 
-LRB- 0 
< 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
and 0 
no 0 
overlap 0 
with 0 
normal 0 
female 0 
controls 0 
was 0 
observed 0 
. 0 

The 0 
advantages 0 
of 0 
this 0 
test 0 
are 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
plucking 0 
of 0 
hair 0 
follicles 0 
does 0 
no 0 
appreciable 0 
harm 0 
to 0 
the 0 
mentally 1
retarded 1
patient 0 
, 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
hairs 0 
can 0 
be 0 
sent 0 
in 0 
a 0 
simple 0 
envelope 0 
to 0 
a 0 
diagnostic 0 
center 0 
, 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
the 0 
result 0 
of 0 
the 0 
test 0 
is 0 
available 0 
within 0 
_NUM1 0 
h 0 
of 0 
plucking 0 
. 0 

In 0 
addition 0 
, 0 
this 0 
test 0 
enabled 0 
us 0 
to 0 
identify 0 
two 0 
fragile 1
X 1
patients 0 
who 0 
did 0 
not 0 
show 0 
the 0 
full 0 
mutation 0 
by 0 
analysis 0 
of 0 
DNA 0 
isolated 0 
from 0 
blood 0 
cells 0 
. 0 
. 0 

Pelizaeus-Merzbacher 1
disease 1
: 0 
detection 0 
of 0 
mutations 0 
Thr181 0 
-- 0 
Pro 0 
and 0 
Leu223 0 
-- 0 
Pro 0 
in 0 
the 0 
proteolipid 0 
protein 0 
gene 0 
, 0 
and 0 
prenatal 0 
diagnosis 0 
. 0 

A 0 
family 0 
with 0 
an 0 
apparent 0 
history 0 
of 0 
X-linked 0 
Pelizaeus-Merzbacher 1
disease 1
presented 0 
for 0 
genetic 0 
counseling 0 
, 0 
requesting 0 
carrier 0 
detection 0 
and 0 
prenatal 0 
diagnosis 0 
. 0 

RFLP 0 
analysis 0 
using 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
probe 0 
was 0 
uninformative 0 
in 0 
this 0 
family 0 
. 0 

A 0 
prenatal 0 
diagnosis 0 
on 0 
a 0 
chorionic 0 
villus 0 
sample 0 
-LRB- 0 
CVS 0 
-RRB- 0 
was 0 
carried 0 
out 0 
using 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
analysis 0 
of 0 
a 0 
variant 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
PLP 0 
gene 0 
. 0 

The 0 
fetus 0 
was 0 
predicted 0 
to 0 
be 0 
unaffected 0 
. 0 

Sequencing 0 
of 0 
the 0 
exon 0 
from 0 
the 0 
CVS 0 
, 0 
the 0 
predicted-carrier 0 
mother 0 
, 0 
and 0 
the 0 
obligate-carrier 0 
grandmother 0 
revealed 0 
an 0 
A-to-C 0 
change 0 
at 0 
nucleotide 0 
_NUM3 0 
in 0 
the 0 
two 0 
women 0 
but 0 
not 0 
in 0 
the 0 
fetus 0 
. 0 

As 0 
this 0 
change 0 
results 0 
in 0 
a 0 
Thr-to-Pro 0 
change 0 
at 0 
amino 0 
acid 0 
_NUM3 0 
in 0 
a 0 
region 0 
of 0 
the 0 
gene 0 
predicted 0 
to 0 
be 0 
part 0 
of 0 
a 0 
transmembrane 0 
segment 0 
, 0 
it 0 
was 0 
concluded 0 
that 0 
this 0 
was 0 
the 0 
mutation 0 
causing 0 
the 0 
disease 0 
in 0 
this 0 
family 0 
. 0 

In 0 
addition 0 
, 0 
in 0 
a 0 
second 0 
family 0 
, 0 
an 0 
exon 0 
_NUM1 0 
variant 0 
band 0 
pattern 0 
on 0 
SSCP 0 
analysis 0 
was 0 
shown 0 
by 0 
sequencing 0 
to 0 
be 0 
due 0 
to 0 
a 0 
T-to-C 0 
change 0 
at 0 
nucleotide 0 
_NUM3 0 
. 0 

This 0 
results 0 
in 0 
a 0 
Leu-to-Pro 0 
change 0 
in 0 
a 0 
carrier 0 
mother 0 
and 0 
in 0 
her 0 
two 0 
affected 0 
sons 0 
. 0 

These 0 
results 0 
provide 0 
further 0 
examples 0 
of 0 
mutations 0 
in 0 
PLP 0 
that 0 
cause 0 
Pelizaeus-Merzbacher 1
disease 1
and 0 
illustrate 0 
the 0 
value 0 
of 0 
SSCP 0 
in 0 
genetic 0 
analysis 0 
. 0 
. 0 

A 0 
normal 0 
male 0 
with 0 
an 0 
inherited 0 
deletion 0 
of 0 
one 0 
exon 0 
within 0 
the 0 
DMD 1
gene 0 
. 0 

We 0 
describe 0 
two 0 
brothers 0 
with 0 
identical 0 
inherited 0 
deletions 0 
of 0 
one 0 
single 0 
exon 0 
within 0 
the 0 
middle 0 
of 0 
the 0 
DMD 1
gene 0 
; 0 
one 0 
brother 0 
has 0 
Becker 1
muscular 1
dystrophy 1
diagnosed 0 
at 0 
_NUM2 0 
years 0 
of 0 
age 0 
, 0 
whereas 0 
the 0 
older 0 
brother 0 
is 0 
normal 0 
at 0 
_NUM2 0 
. 0 

These 0 
results 0 
have 0 
implications 0 
for 0 
genetic 0 
counselling 0 
and 0 
prenatal 0 
diagnosis 0 
in 0 
families 0 
with 0 
Becker 1
muscular 1
dystrophy 1
. 0 
. 0 

Small 0 
deletions 0 
in 0 
the 0 
type 0 
II 0 
collagen 0 
triple 0 
helix 0 
produce 0 
kniest 1
dysplasia 1
. 0 

Kniest 1
dysplasia 1
is 0 
a 0 
moderately 0 
severe 0 
type 1
II 1
collagenopathy 1
, 0 
characterized 0 
by 0 
short 0 
trunk 0 
and 0 
limbs 0 
, 0 
kyphoscoliosis 1
, 0 
midface 1
hypoplasia 1
, 0 
severe 0 
myopia 1
, 0 
and 0 
hearing 1
loss 1
. 0 

Mutations 0 
in 0 
the 0 
gene 0 
that 0 
encodes 0 
type 0 
II 0 
collagen 0 
-LRB- 0 
COL2A1 0 
-RRB- 0 
, 0 
the 0 
predominant 0 
protein 0 
of 0 
cartilage 0 
, 0 
have 0 
been 0 
identified 0 
in 0 
a 0 
number 0 
of 0 
individuals 0 
with 0 
Kniest 1
dysplasia 1
. 0 

All 0 
but 0 
two 0 
of 0 
these 0 
previously 0 
described 0 
mutations 0 
cause 0 
in-frame 0 
deletions 0 
in 0 
type 0 
II 0 
collagen 0 
, 0 
either 0 
by 0 
small 0 
deletions 0 
in 0 
the 0 
gene 0 
or 0 
splice 0 
site 0 
alterations 0 
. 0 

Furthermore 0 
, 0 
all 0 
but 0 
one 0 
of 0 
these 0 
mutations 0 
is 0 
located 0 
between 0 
exons 0 
_NUM2 0 
and 0 
_NUM2 0 
in 0 
the 0 
COL2A1 0 
gene 0 
. 0 

We 0 
used 0 
heteroduplex 0 
analysis 0 
to 0 
identify 0 
sequence 0 
anomalies 0 
in 0 
five 0 
individuals 0 
with 0 
Kniest 1
dysplasia 1
. 0 

Sequencing 0 
of 0 
the 0 
index 0 
patients 0 
genomic 0 
DNA 0 
identified 0 
four 0 
new 0 
dominant 0 
mutations 0 
in 0 
COL2A1 0 
that 0 
result 0 
in 0 
Kniest 1
dysplasia 1
a 0 
21-bp 0 
deletion 0 
in 0 
exon 0 
_NUM2 0 
, 0 
an 0 
18-bp 0 
deletion 0 
in 0 
exon 0 
_NUM2 0 
, 0 
and 0 
4-bp 0 
deletions 0 
in 0 
the 0 
splice 0 
donor 0 
sites 0 
of 0 
introns 0 
_NUM2 0 
and 0 
_NUM2 0 
. 0 

A 0 
previously 0 
described 0 
28-bp 0 
deletion 0 
at 0 
the 0 
COL2A1 0 
exon 0 
12-intron 0 
_NUM2 0 
junction 0 
, 0 
deleting 0 
the 0 
splice 0 
donor 0 
site 0 
, 0 
was 0 
identified 0 
in 0 
the 0 
fifth 0 
case 0 
. 0 

The 0 
latter 0 
three 0 
mutations 0 
are 0 
predicted 0 
to 0 
result 0 
in 0 
exon 0 
skipping 0 
in 0 
the 0 
mRNA 0 
encoded 0 
from 0 
the 0 
mutant 0 
allele 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
Kniest 1
dysplasia 1
results 0 
from 0 
shorter 0 
type 0 
II 0 
collagen 0 
monomers 0 
, 0 
and 0 
support 0 
the 0 
hypothesis 0 
that 0 
alteration 0 
of 0 
a 0 
specific 0 
COL2A1 0 
domain 0 
, 0 
which 0 
may 0 
span 0 
from 0 
exons 0 
_NUM2 0 
to 0 
_NUM2 0 
, 0 
leads 0 
to 0 
the 0 
Kniest 1
dysplasia 1
phenotype 0 
. 0 
. 0 

Adenomatous 1
polyposis 1
coli 1
and 0 
a 0 
cytogenetic 0 
deletion 0 
of 0 
chromosome 0 
_NUM1 0 
resulting 0 
from 0 
a 0 
maternal 0 
intrachromosomal 0 
insertion 0 
. 0 

We 0 
present 0 
the 0 
clinical 0 
and 0 
laboratory 0 
findings 0 
in 0 
an 0 
institutionalised 0 
adult 0 
patient 0 
originally 0 
referred 0 
for 0 
autism 1
. 0 

A 0 
high 0 
risk 0 
of 0 
colorectal 1
cancer 1
was 0 
predicted 0 
when 0 
an 0 
interstitial 0 
deletion 0 
of 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
, 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
q15q22 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
was 0 
detected 0 
in 0 
her 0 
lymphocytes 0 
and 0 
deletion 0 
of 0 
the 0 
MCC 0 
and 0 
APC 1
genes 0 
confirmed 0 
by 0 
molecular 0 
analysis 0 
. 0 

Adenomatous 1
polyposis 1
coli 1
and 0 
carcinoma 1
of 1
the 1
rectum 1
were 0 
subsequently 0 
diagnosed 0 
in 0 
the 0 
patient 0 
. 0 

She 0 
was 0 
profoundly 0 
mentally 1
retarded 1
, 0 
autistic 1
, 0 
and 0 
had 0 
minor 0 
dysmorphic 1
features 1
consistent 0 
with 0 
those 0 
of 0 
previous 0 
patients 0 
with 0 
similar 0 
deletions 0 
. 0 

The 0 
deletion 0 
arose 0 
as 0 
a 0 
result 0 
of 0 
recombination 0 
within 0 
the 0 
small 0 
insertion 0 
loop 0 
formed 0 
at 0 
meiosis 0 
by 0 
the 0 
direct 0 
insertion 0 
-LRB- 0 
dir 0 
ins 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

3q14 0 
. 0 

2q15 0 
-RRB- 0 
-RRB- 0 
found 0 
in 0 
the 0 
patients 0 
mother 0 
. 0 

This 0 
family 0 
further 0 
confirms 0 
the 0 
cytogenetic 0 
mapping 0 
of 0 
both 0 
MCC 0 
and 0 
APC 1
genes 0 
to 0 
5q22 0 
and 0 
comparison 0 
with 0 
other 0 
recent 0 
cases 0 
suggests 0 
that 0 
both 0 
genes 0 
and 0 
their 0 
closely 0 
linked 0 
markers 0 
lie 0 
within 0 
the 0 
5q22 0 
. 0 

_NUM1 0 
subband 0 
Somatic 0 
mutations 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
colorectal 1
tumors 1
: 0 
mutation 0 
cluster 0 
region 0 
in 0 
the 0 
APC 1
gene 0 
. 0 

We 0 
examined 0 
somatic 0 
mutations 0 
of 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
in 0 
_NUM2 0 
colorectal 1
tumors 1
-LRB- 0 
_NUM2 0 
adenomas 1
and 0 
_NUM2 0 
carcinomas 1
-RRB- 0 
developed 0 
in 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
and 0 
non-FAP 0 
patients 0 
. 0 

In 0 
addition 0 
to 0 
loss 0 
of 0 
heterozygosity 0 
-LRB- 0 
LOH 0 
-RRB- 0 
at 0 
the 0 
APC 1
locus 0 
in 0 
_NUM2 0 
tumors 1
, 0 
_NUM2 0 
other 0 
somatic 0 
mutations 0 
were 0 
detected 0 
. 0 

Twenty-one 0 
of 0 
them 0 
were 0 
point 0 
mutations 0 
; 0 
_NUM2 0 
nonsense 0 
and 0 
two 0 
missense 0 
mutations 0 
, 0 
and 0 
three 0 
occurred 0 
in 0 
introns 0 
at 0 
the 0 
splicing 0 
site 0 
. 0 

Twenty-two 0 
tumors 1
had 0 
frameshift 0 
mutations 0 
due 0 
to 0 
deletion 0 
or 0 
insertion 0 
; 0 
nineteen 0 
of 0 
them 0 
were 0 
deletions 0 
of 0 
one 0 
to 0 
_NUM2 0 
bp 0 
and 0 
three 0 
were 0 
a 0 
1-bp 0 
insertion 0 
. 0 

One 0 
tumor 1
had 0 
a 0 
1-bp 0 
deletion 0 
in 0 
an 0 
intron 0 
near 0 
the 0 
splicing 0 
site 0 
. 0 

Hence 0 
, 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
mutations 0 
resulted 0 
in 0 
truncation 0 
of 0 
the 0 
APC 1
protein 0 
. 0 

Over 0 
_NUM2 0 
% 0 
of 0 
the 0 
somatic 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
were 0 
clustered 0 
within 0 
a 0 
small 0 
region 0 
of 0 
exon 0 
_NUM2 0 
, 0 
designated 0 
as 0 
MCR 0 
-LRB- 0 
mutation 0 
cluster 0 
region 0 
-RRB- 0 
, 0 
which 0 
accounted 0 
for 0 
less 0 
than 0 
_NUM2 0 
% 0 
of 0 
the 0 
coding 0 
region 0 
. 0 

Combining 0 
these 0 
data 0 
and 0 
the 0 
results 0 
of 0 
LOH 0 
, 0 
more 0 
than 0 
_NUM2 0 
% 0 
of 0 
tumors 1
-LRB- 0 
_NUM2 0 
adenomas 1
and 0 
_NUM2 0 
carcinomas 1
-RRB- 0 
had 0 
at 0 
least 0 
one 0 
mutation 0 
in 0 
the 0 
APC 1
gene 0 
, 0 
of 0 
which 0 
more 0 
than 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM1 0 
adenomas 1
and 0 
_NUM2 0 
carcinomas 1
-RRB- 0 
had 0 
two 0 
mutations 0 
. 0 

These 0 
results 0 
strongly 0 
suggest 0 
that 0 
somatic 0 
mutations 0 
of 0 
the 0 
APC 1
gene 0 
are 0 
associated 0 
with 0 
development 0 
of 0 
a 0 
great 0 
majority 0 
of 0 
colorectal 1
tumors 1
. 0 
. 0 

Identification 0 
of 0 
an 0 
altered 0 
splice 0 
site 0 
in 0 
Ashkenazi 0 
Tay-Sachs 1
disease 1
. 0 

Tay-Sachs 1
disease 1
is 0 
an 0 
autosomal 1
recessive 1
genetic 1
disorder 1
resulting 0 
from 0 
mutation 0 
of 0 
the 0 
HEXA 0 
gene 0 
encoding 0 
the 0 
alpha-subunit 0 
of 0 
the 0 
lysosomal 0 
enzyme 0 
, 0 
beta-N-acetylhexosaminidase 0 
A 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

A 0 
relatively 0 
high 0 
frequency 0 
of 0 
carriers 0 
-LRB- 0 
1 0 
/ 0 
27 0 
-RRB- 0 
of 0 
a 0 
lethal 0 
, 0 
infantile 0 
form 0 
of 0 
the 0 
disease 0 
is 0 
found 0 
in 0 
the 0 
Ashkenazi 0 
Jewish 0 
population 0 
, 0 
but 0 
it 0 
is 0 
not 0 
yet 0 
evident 0 
whether 0 
this 0 
has 0 
resulted 0 
from 0 
a 0 
founder 0 
effect 0 
and 0 
random 0 
genetic 0 
drift 0 
or 0 
from 0 
a 0 
selective 0 
advantage 0 
of 0 
heterozygotes 0 
. 0 

We 0 
have 0 
identified 0 
a 0 
single-base 0 
mutation 0 
in 0 
a 0 
cloned 0 
fragment 0 
of 0 
the 0 
HEXA 0 
gene 0 
from 0 
an 0 
Ashkenazi 0 
Jewish 0 
patient 0 
. 0 

This 0 
change 0 
, 0 
the 0 
substitution 0 
of 0 
a 0 
C 0 
for 0 
G 0 
in 0 
the 0 
first 0 
nucleotide 0 
of 0 
intron 0 
_NUM2 0 
is 0 
expected 0 
to 0 
result 0 
in 0 
defective 0 
splicing 0 
of 0 
the 0 
messenger 0 
RNA 0 
. 0 

A 0 
test 0 
for 0 
the 0 
mutant 0 
allele 0 
based 0 
on 0 
amplification 0 
of 0 
DNA 0 
by 0 
the 0 
polymerase 0 
chain 0 
rection 0 
and 0 
cleavage 0 
of 0 
a 0 
DdeI 0 
restriction 0 
site 0 
generated 0 
by 0 
the 0 
mutation 0 
revealed 0 
that 0 
this 0 
case 0 
and 0 
two 0 
other 0 
cases 0 
of 0 
the 0 
Ashkenazi 0 
, 0 
infantile 0 
form 0 
of 0 
Tay-Sachs 1
disease 1
are 0 
heterozygous 0 
for 0 
two 0 
different 0 
mutations 0 
. 0 

The 0 
occurrence 0 
of 0 
multiple 0 
mutant 0 
alleles 0 
warrants 0 
further 0 
examination 0 
of 0 
the 0 
selective 0 
advantage 0 
hypothesis 0 
. 0 
. 0 

Coats 1
disease 1
of 0 
the 0 
retina 0 
-LRB- 0 
unilateral 1
retinal 1
telangiectasis 1
-RRB- 0 
caused 0 
by 0 
somatic 0 
mutation 0 
in 0 
the 0 
NDP 0 
gene 0 
: 0 
a 0 
role 0 
for 0 
norrin 0 
in 0 
retinal 0 
angiogenesis 0 
. 0 

Coats 1
disease 1
is 0 
characterized 0 
by 0 
abnormal 1
retinal 1
vascular 1
development 1
-LRB- 0 
so-called 0 
retinal 1
telangiectasis 1
-RRB- 0 
which 0 
results 0 
in 0 
massive 0 
intraretinal 1
and 1
subretinal 1
lipid 1
accumulation 1
-LRB- 0 
exudative 1
retinal 1
detachment 1
-RRB- 0 
. 0 

The 0 
classical 0 
form 0 
of 0 
Coats 1
disease 1
is 0 
almost 0 
invariably 0 
isolated 0 
, 0 
unilateral 0 
and 0 
seen 0 
in 0 
males 0 
. 0 

A 0 
female 0 
with 0 
a 0 
unilateral 0 
variant 0 
of 0 
Coats 1
disease 1
gave 0 
birth 0 
to 0 
a 0 
son 0 
affected 0 
by 0 
Norrie 1
disease 1
. 0 

Both 0 
carried 0 
a 0 
missense 0 
mutation 0 
within 0 
the 0 
NDP 0 
gene 0 
on 0 
chromosome 0 
Xp11 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

Subsequently 0 
analysis 0 
of 0 
the 0 
retinas 0 
of 0 
nine 0 
enucleated 0 
eyes 0 
from 0 
males 0 
with 0 
Coats 1
disease 1
demonstrated 0 
in 0 
one 0 
a 0 
somatic 0 
mutation 0 
in 0 
the 0 
NDP 0 
gene 0 
which 0 
was 0 
not 0 
present 0 
within 0 
non-retinal 0 
tissue 0 
. 0 

We 0 
suggest 0 
that 0 
Coats 1
telangiectasis 1
is 0 
secondary 0 
to 0 
somatic 0 
mutation 0 
in 0 
the 0 
NDP 0 
gene 0 
which 0 
results 0 
in 0 
a 0 
deficiency 1
of 1
norrin 1
-LRB- 0 
the 0 
protein 0 
product 0 
of 0 
the 0 
NDP 0 
gene 0 
-RRB- 0 
within 0 
the 0 
developing 0 
retina 0 
. 0 

This 0 
supports 0 
recent 0 
observations 0 
that 0 
the 0 
protein 0 
is 0 
critical 0 
for 0 
normal 0 
retinal 0 
vasculogenesis 0 
. 0 

Trisomy 1
_NUM2 1
with 0 
loss 0 
of 0 
the 0 
paternal 0 
_NUM2 0 
as 0 
a 0 
cause 0 
of 0 
Prader-Willi 1
syndrome 1
due 0 
to 0 
maternal 1
disomy 1
. 0 

Uniparental 1
disomy 1
has 0 
recently 0 
been 0 
recognized 0 
to 0 
cause 0 
human 0 
disorders 0 
, 0 
including 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

We 0 
describe 0 
a 0 
particularly 0 
instructive 0 
case 0 
which 0 
raises 0 
important 0 
issues 0 
concerning 0 
the 0 
mechanisms 0 
producing 0 
uniparental 1
disomy 1
and 0 
whose 0 
evaluation 0 
provides 0 
evidence 0 
that 0 
trisomy 0 
may 0 
precede 0 
uniparental 1
disomy 1
in 0 
a 0 
fetus 0 
. 0 

Chorionic 0 
villus 0 
sampling 0 
performed 0 
for 0 
advanced 0 
maternal 0 
age 0 
revealed 0 
trisomy 1
_NUM2 1
in 0 
all 0 
direct 0 
and 0 
cultured 0 
cells 0 
, 0 
though 0 
the 0 
fetus 0 
appeared 0 
normal 0 
. 0 

Chromosome 0 
analysis 0 
of 0 
amniocytes 0 
obtained 0 
at 0 
_NUM2 0 
wk 0 
was 0 
normal 0 
in 0 
over 0 
_NUM3 0 
cells 0 
studied 0 
. 0 

The 0 
child 0 
was 0 
hypotonic 1
at 0 
birth 0 
, 0 
and 0 
high-resolution 0 
banding 0 
failed 0 
to 0 
reveal 0 
the 0 
deletion 0 
of 0 
15q11-13 0 
, 0 
a 0 
deletion 0 
which 0 
is 0 
found 0 
in 0 
_NUM2 0 
% 0 
-70 0 
% 0 
of 0 
patients 0 
with 0 
PWS 1
. 0 

Over 0 
time 0 
, 0 
typical 0 
features 0 
of 0 
PWS 1
developed 0 
. 0 

Molecular 0 
genetic 0 
analysis 0 
using 0 
probes 0 
for 0 
chromosome 0 
_NUM2 0 
revealed 0 
maternal 0 
disomy 0 
. 0 

Maternal 0 
nondisjunction 0 
with 0 
fertilization 0 
of 0 
a 0 
disomic 0 
egg 0 
by 0 
a 0 
normal 0 
sperm 0 
, 0 
followed 0 
by 0 
loss 0 
of 0 
the 0 
paternal 0 
_NUM2 0 
, 0 
is 0 
a 0 
likely 0 
cause 0 
of 0 
confined 0 
placental 0 
mosaicism 0 
and 0 
uniparental 1
disomy 1
in 0 
this 0 
case 0 
of 0 
PWS 1
, 0 
and 0 
advanced 0 
maternal 0 
age 0 
may 0 
be 0 
a 0 
predisposing 0 
factor 0 
. 0 
. 0 

Genetic 0 
defect 1
in 1
secretion 1
of 1
complement 1
C5 1
in 0 
mice 0 
. 0 

A 0 
genetic 0 
deficiency 1
of 1
the 1
fifth 1
-LRB- 1
C5 1
-RRB- 1
component 1
of 1
complement1-3 1
, 0 
a 0 
serum 0 
glycoprotein 0 
of 0 
molecular 0 
weight 0 
-LRB- 0 
MW 0 
-RRB- 0 
_NUM3 0 
, 0 
_NUM3 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
has 0 
been 0 
found 0 
in 0 
_NUM2 0 
% 0 
of 0 
inbred 0 
strains 0 
of 0 
mice3 0 
. 0 

Sera 0 
of 0 
deficient 0 
mice 0 
lack 0 
detectable 0 
C5 0
activity 0 
and 0 
protein2 0 
, 0 
_NUM1 0 
. 0 

In 0 
addition 0 
deficient 0 
mice 0 
produce 0 
antibody 0 
to 0 
mouse 0 
C5 0
when 0 
injected 0 
with 0 
sera 0 
from 0 
C5 0
sufficient 0 
-LRB- 0 
normal 0 
-RRB- 0 
strains 0 
. 0 

Levy 0 
et 0 
al. 0 
_NUM1 0 
showed 0 
that 0 
somatic 0 
cell 0 
hybrids 0 
between 0 
C5 0
deficient 0 
-LRB- 0 
_AN 0 
. 0 

D2 0 
/ 0 
old 0 
line 0 
-RRB- 0 
macrophages 0 
and 0 
either 0 
C5 0
sufficient 0 
-LRB- 0 
_AN 0 
. 0 

D2 0 
/ 0 
new 0 
line 0 
-RRB- 0 
mouse 0 
kidney 0 
or 0 
chicken 0 
erythroblasts 0 
secreted 0 
haemolytically 0 
active 0 
mouse 0 
C5 0
in 0 
vitro 0 
. 0 

Several 0 
possible 0 
molecular 0 
mechanisms 0 
to 0 
account 0 
for 0 
the 0 
findings 0 
were 0 
considered 0 
, 0 
but 0 
insufficient 0 
direct 0 
data 0 
were 0 
available 0 
to 0 
choose 0 
among 0 
them 0 
. 0 

We 0 
recently 0 
reported 0 
that 0 
mouse 0 
-LRB- 0 
CD 0 
. 0 

_NUM1 0 
strain 0 
-RRB- 0 
peritoneal 0 
cells 0 
in 0 
culture 0 
synthesise 0 
and 0 
secrete 0 
a 0 
single 0 
chain 0 
precursor 0 
, 0 
pro-C5 0 
-LRB- 0 
MW 0 
approximately 0 
_NUM3 0 
, 0 
_NUM3 0 
-RRB- 0 
, 0 
of 0 
the 0 
two-chain 0 
-LRB- 0 
alpha 0 
chain 0 
, 0 
_NUM3 0 
, 0 
_NUM3 0 
and 0 
beta 0 
chain 0 
_NUM2 0 
, 0 
_NUM3 0 
MW 0 
-RRB- 0 
C5 0
protein6 0 
. 0 

Radiolabelled 0 
precursor 0 
C5 0
was 0 
contained 0 
within 0 
the 0 
cells 0 
and 0 
was 0 
secreted 0 
into 0 
the 0 
tissue 0 
culture 0 
media 0 
. 0 

Using 0 
similar 0 
methods 0 
, 0 
we 0 
now 0 
find 0 
that 0 
C5 1
deficiency 1
in 0 
each 0 
of 0 
five 0 
different 0 
mouse 0 
strains 0 
-LRB- 0 
AKR 0 
, 0 
SWR 0 
, 0 
DBA 0 
/ 0 
2J8 0 
A 0 
/ 0 
HeJ 0 
and 0 
_AN 0 
. 0 

D2 0 
/ 0 
old 0 
line 0 
-RRB- 0 
is 0 
due 0 
to 0 
a 0 
failure 0 
in 0 
secretion 0 
of 0 
C5 0 
protein 0 
and 0 
not 0 
to 0 
a 0 
failure 0 
in 0 
biosynthesis 0 
of 0 
pro-C5 0 
WASP 0 
gene 0 
mutations 0 
in 0 
Wiskott-Aldrich 1
syndrome 1
and 0 
X-linked 1
thrombocytopenia 1
. 0 

The 0 
WASP 0 
gene 0 
has 0 
been 0 
recently 0 
cloned 0 
from 0 
Xp11 0 
. 0 

_NUM2 0 
and 0 
shown 0 
to 0 
be 0 
mutated 0 
in 0 
three 0 
patients 0 
with 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
. 0 

We 0 
have 0 
developed 0 
a 0 
screening 0 
protocol 0 
for 0 
identifying 0 
WASP 0 
gene 0 
alterations 0 
in 0 
genomic 0 
DNA 0 
and 0 
have 0 
identified 0 
a 0 
spectrum 0 
of 0 
novel 0 
mutations 0 
in 0 
_NUM2 0 
additional 0 
unrelated 0 
families 0 
. 0 

These 0 
missense 0 
, 0 
nonsense 0 
and 0 
frameshift 0 
mutations 0 
involve 0 
eight 0 
of 0 
the 0 
_NUM2 0 
exons 0 
of 0 
the 0 
gene 0 
. 0 

Two 0 
mutations 0 
creating 0 
premature 0 
termination 0 
codons 0 
were 0 
associated 0 
with 0 
lack 0 
of 0 
detectable 0 
mRNA 0 
on 0 
Northern 0 
blots 0 
. 0 

Four 0 
amino 0 
acid 0 
substitutions 0 
, 0 
Leu27Phe 0 
, 0 
Thr48Ile 0 
, 0 
Val75Met 0 
and 0 
Arg477Lys 0 
, 0 
were 0 
found 0 
in 0 
patients 0 
with 0 
congenital 1
thrombocytopenia 1
and 0 
no 0 
clinically 0 
evident 0 
immune 0 
defect 0 
indicating 0 
that 0 
the 0 
WASP 0 
gene 0 
is 0 
the 0 
site 0 
for 0 
mutations 0 
in 0 
X-linked 1
thrombocytopenia 1
as 0 
well 0 
as 0 
in 0 
WAS 1
. 0 

A 0 
T-cell 0 
line 0 
from 0 
a 0 
WAS 1
patient 0 
contained 0 
two 0 
independent 0 
DNA 0 
alterations 0 
, 0 
a 0 
constitutional 0 
frameshift 0 
mutation 0 
, 0 
also 0 
present 0 
in 0 
peripheral 0 
blood 0 
leukocytes 0 
from 0 
the 0 
patient 0 
, 0 
and 0 
compensatory 0 
splice 0 
site 0 
mutation 0 
unique 0 
to 0 
the 0 
cell 0 
line 0 
. 0 

The 0 
distribution 0 
of 0 
eight 0 
missense 0 
mutations 0 
provides 0 
valuable 0 
information 0 
on 0 
amino 0 
acids 0 
which 0 
are 0 
essential 0 
for 0 
normal 0 
protein 0 
function 0 
, 0 
and 0 
suggests 0 
that 0 
sites 0 
in 0 
the 0 
first 0 
two 0 
exons 0 
are 0 
hot-spots 0 
for 0 
mutation 0 
. 0 

Detection 0 
of 0 
a 0 
nonsense 0 
mutation 0 
in 0 
the 0 
dystrophin 0 
gene 0 
by 0 
multiple 0 
SSCP 0 
. 0 

A 0 
combination 0 
of 0 
multiplex 0 
PCR 0 
with 0 
the 0 
single 0 
strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
technique 0 
was 0 
employed 0 
to 0 
screen 0 
for 0 
point 0 
mutations 0 
in 0 
the 0 
human 0 
dystrophin 0 
gene 0 
. 0 

Co-amplification 0 
of 0 
_NUM2 0 
exons 0 
from 0 
genomic 0 
DNA 0 
of 0 
Duchenne 1
and 1
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
/ 0 
BMD 1
-RRB- 0 
patients 0 
with 0 
no 0 
deletion 0 
or 0 
duplication 0 
was 0 
performed 0 
and 0 
the 0 
samples 0 
subjected 0 
to 0 
multiple 0 
SSCP 0 
analysis 0 
. 0 

We 0 
report 0 
the 0 
case 0 
of 0 
a 0 
nonsense 0 
mutation 0 
in 0 
a 0 
Duchenne 1
patient 0 
identified 0 
by 0 
this 0 
approach 0 
. 0 

The 0 
mutation 0 
introduces 0 
a 0 
termination 0 
codon 0 
within 0 
exon 0 
_NUM1 0 
of 0 
the 0 
dystrophin 0 
gene 0 
. 0 

It 0 
is 0 
predicted 0 
to 0 
cause 0 
a 0 
very 0 
premature 0 
translational 0 
termination 0 
accounting 0 
for 0 
the 0 
severe 0 
phenotype 0 
observed 0 
. 0 

The 0 
patient 0 
inherited 0 
this 0 
mutation 0 
from 0 
his 0 
mother 0 
. 0 

In 0 
addition 0 
the 0 
analysis 0 
revealed 0 
_NUM1 0 
polymorphisms 0 
useful 0 
for 0 
internal 0 
control 0 
. 0 
. 0 

Molecular 0 
mechanisms 0 
of 0 
oncogenic 0 
mutations 0 
in 0 
tumors 1
from 0 
patients 0 
with 0 
bilateral 1
and 1
unilateral 1
retinoblastoma 1
. 0 

The 0 
RB1 0 
gene 0 
from 0 
_NUM2 0 
human 0 
retinoblastoma 1
tumors 1
has 0 
been 0 
analyzed 0 
exon-by-exon 0 
with 0 
the 0 
single-strand 0 
conformation 0 
polymorphism 0 
technique 0 
. 0 

Mutations 0 
were 0 
found 0 
in 0 
all 0 
tumors 1
, 0 
and 0 
one-third 0 
of 0 
the 0 
tumors 1
had 0 
independent 0 
mutations 0 
in 0 
both 0 
alleles 0 
neither 0 
of 0 
which 0 
were 0 
found 0 
in 0 
the 0 
germ 0 
line 0 
, 0 
confirming 0 
their 0 
true 0 
sporadic 0 
nature 0 
. 0 

In 0 
the 0 
remaining 0 
two-thirds 0 
of 0 
the 0 
tumors 1
only 0 
one 0 
mutation 0 
was 0 
found 0 
, 0 
consistent 0 
with 0 
the 0 
loss-of-heterozygosity 0 
theory 0 
of 0 
tumorigenesis 0 
. 0 

Point 0 
mutations 0 
, 0 
the 0 
majority 0 
of 0 
which 0 
were 0 
C 0 
-- 0 
> 0 
T 0 
transitions 0 
, 0 
were 0 
the 0 
most 0 
common 0 
abnormality 0 
and 0 
usually 0 
resulted 0 
in 0 
the 0 
conversion 0 
of 0 
an 0 
arginine 0 
codon 0 
to 0 
a 0 
stop 0 
codon 0 
. 0 

Small 0 
deletions 0 
were 0 
the 0 
second 0 
most 0 
common 0 
abnormality 0 
and 0 
most 0 
often 0 
created 0 
a 0 
downstream 0 
stop 0 
codon 0 
as 0 
the 0 
result 0 
of 0 
a 0 
reading 0 
frameshift 0 
. 0 

Deletions 0 
and 0 
point 0 
mutations 0 
also 0 
affected 0 
splice 0 
junctions 0 
. 0 

Direct 0 
repeats 0 
were 0 
present 0 
at 0 
the 0 
breakpoint 0 
junctions 0 
in 0 
the 0 
majority 0 
of 0 
deletions 0 
, 0 
supporting 0 
a 0 
slipped-mispairing 0 
mechanism 0 
. 0 

Point 0 
mutations 0 
generally 0 
produced 0 
DNA 0 
sequences 0 
which 0 
resulted 0 
in 0 
perfect 0 
homology 0 
with 0 
endogenous 0 
sequences 0 
which 0 
lay 0 
within 0 
_NUM2 0 
bp 0 
. 0 
. 0 

PAX6 0 
gene 0 
dosage 0 
effect 0 
in 0 
a 0 
family 0 
with 0 
congenital 1
cataracts 1
, 0 
aniridia 1
, 0 
anophthalmia 1
and 0 
central 1
nervous 1
system 1
defects 1
. 0 

The 0 
human 0 
eye 0 
malformation 0 
aniridia 1
results 0 
from 0 
haploinsufficiency 1
of 1
PAX6 1
, 0 
a 0 
paired 0 
box 0 
DNA-binding 0 
protein 0 
. 0 

To 0 
study 0 
this 0 
dosage 0 
effect 0 
, 0 
we 0 
characterized 0 
two 0 
PAX6 0 
mutations 0 
in 0 
a 0 
family 0 
segregating 0 
aniridia 1
and 0 
a 0 
milder 0 
syndrome 0 
consisting 0 
of 0 
congenital 1
cataracts 1
and 0 
late 0 
onset 0 
corneal 1
dystrophy 1
. 0 

The 0 
nonsense 0 
mutations 0 
, 0 
at 0 
codons 0 
_NUM3 0 
and 0 
_NUM3 0 
, 0 
truncate 0 
PAX6 0 
within 0 
the 0 
N-terminal 0 
paired 0 
and 0 
C-terminal 0 
PST 0 
domains 0 
, 0 
respectively 0 
. 0 

The 0 
wild-type 0 
PST 0 
domain 0 
activates 0 
transcription 0 
autonomously 0 
and 0 
the 0 
mutant 0 
form 0 
has 0 
partial 0 
activity 0 
. 0 

A 0 
compound 0 
heterozygote 0 
had 0 
severe 0 
craniofacial 1
and 1
central 1
nervous 1
system 1
defects 1
and 0 
no 1
eyes 1
. 0 

The 0 
pattern 0 
of 0 
malformations 0 
is 0 
similar 0 
to 0 
that 0 
in 0 
homozygous 0 
Sey 0 
mice 0 
and 0 
suggests 0 
a 0 
critical 0 
role 0 
for 0 
PAX6 0 
in 0 
controlling 0 
the 0 
migration 0 
and 0 
differentiation 0 
of 0 
specific 0 
neuronal 0 
progenitor 0 
cells 0 
in 0 
the 0 
brain 0 
. 0 
. 0 

Hereditary 1
C7 1
deficiency 1
. 0 

Diagnosis 0 
and 0 
HLA 0 
studies 0 
in 0 
a 0 
French-Canadian 0 
family 0 
. 0 

The 0 
serum 0 
of 0 
a 0 
44-yr-old 0 
woman 0 
of 0 
French-Canadian 0 
descent 0 
having 0 
a 0 
B-27 0 
positive 0 
ankylosing 1
spondylitis 1
was 0 
deficient 1
in 1
the 1
seventh 1
component 1
of 1
complement 1
-LRB- 0 
C7 0
-RRB- 0 
as 0 
determined 0 
by 0 
hemolytic 0 
and 0 
immunochemical 0 
methods 0 
. 0 

No 0 
inhibitor 0 
against 0 
C7 0
was 0 
detected 0 
, 0 
and 0 
the 0 
levels 0 
of 0 
all 0 
other 0 
complement 0 
components 0 
were 0 
normal 0 
. 0 

No 0 
deficiency 0 
in 0 
the 0 
opsonic 0 
activity 0 
of 0 
the 0 
serum 0 
was 0 
found 0 
, 0 
and 0 
the 0 
results 0 
of 0 
basic 0 
coagulation 0 
studies 0 
of 0 
the 0 
plasma 0 
were 0 
normal 0 
. 0 

On 0 
investigation 0 
of 0 
the 0 
patients 0 
family 0 
, 0 
two 0 
sisters 0 
were 0 
found 0 
to 0 
have 0 
the 0 
same 0 
deficiency 0 
but 0 
were 0 
otherwise 0 
in 0 
good 0 
health 0 
. 0 

The 0 
seven 0 
other 0 
siblings 0 
were 0 
heterozygous 0 
for 0 
C7 1
deficiency 1
, 0 
while 0 
the 0 
paternal 0 
aunt 0 
had 0 
a 0 
normal 0 
C7 0 
level 0 
. 0 

In 0 
the 0 
third 0 
generation 0 
, 0 
six 0 
children 0 
of 0 
the 0 
three 0 
homozygous 0 
sisters 0 
and 0 
five 0 
children 0 
of 0 
heterozygotes 0 
were 0 
available 0 
for 0 
testing 0 
. 0 

Studies 0 
of 0 
the 0 
HLA 0 
antigens 0 
in 0 
all 0 
the 0 
_NUM2 0 
subjects 0 
and 0 
in 0 
three 0 
spouses 0 
indicated 0 
no 0 
close 0 
linkage 0 
between 0 
the 0 
CM 1
deficienty 1
and 0 
the 0 
HLA 0 
system 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
simultaneous 0 
occurrence 0 
of 0 
two 0 
hereditary 0 
complement 1
deficiencies 1
-LRB- 1
C2 1
and 1
C7 1
-RRB- 1
was 0 
discovered 0 
in 0 
one 0 
family 0 
of 0 
this 0 
remarkable 0 
kindred 0 
. 0 
. 0 

Alstrom 1
syndrome 1
: 0 
further 0 
evidence 0 
for 0 
linkage 0 
to 0 
human 0 
chromosome 0 
2p13 0 
. 0 

Alstrom 1
syndrome 1
is 0 
a 0 
rare 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
retinal 1
degeneration 1
, 0 
sensorineural 1
hearing 1
loss 1
, 0 
early-onset 0 
obesity 1
, 0 
and 0 
non-insulin-dependent 1
diabetes 1
mellitus 1
. 0 

The 0 
gene 0 
for 0 
Alstrom 1
syndrome 1
-LRB- 0 
ALMS1 0 
-RRB- 0 
has 0 
been 0 
previously 0 
localized 0 
to 0 
human 0 
chromosome 0 
2p13 0 
by 0 
homozygosity 0 
mapping 0 
in 0 
two 0 
distinct 0 
isolated 0 
populations 0 
- 0 
French 0 
Acadian 0 
and 0 
North 0 
African 0 
. 0 

Pair-wise 0 
analyses 0 
resulted 0 
in 0 
maximum 0 
lod 0 
-LRB- 0 
logarithm 0 
of 0 
the 0 
odds 0 
ratio 0 
-RRB- 0 
scores 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
, 0 
respectively 0 
. 0 

To 0 
confirm 0 
these 0 
findings 0 
, 0 
a 0 
large 0 
linkage 0 
study 0 
was 0 
performed 0 
in 0 
twelve 0 
additional 0 
families 0 
segregating 0 
for 0 
Alstrom 1
syndrome 1
. 0 

A 0 
maximum 0 
two-point 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
-LRB- 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
for 0 
marker 0 
D2S2110 0 
and 0 
a 0 
maximum 0 
cumulative 0 
multipoint 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
for 0 
marker 0 
D2S2110 0 
were 0 
observed 0 
, 0 
further 0 
supporting 0 
linkage 0 
to 0 
chromosome 0 
2p13 0 
. 0 

No 0 
evidence 0 
of 0 
genetic 0 
heterogeneity 0 
was 0 
observed 0 
in 0 
these 0 
families 0 
. 0 

Meiotic 0 
recombination 0 
events 0 
have 0 
localized 0 
the 0 
critical 0 
region 0 
containing 0 
ALMS1 0 
to 0 
a 0 
_NUM1 0 
. 0 

1-cM 0 
interval 0 
flanked 0 
by 0 
markers 0 
D2S327 0 
and 0 
D2S286 0 
. 0 

A 0 
fine 0 
resolution 0 
radiation 0 
hybrid 0 
map 0 
of 0 
_NUM2 0 
genes 0 
and 0 
markers 0 
has 0 
been 0 
constructed 0 
. 0 

Haplotype 0 
and 0 
multipoint 0 
linkage 0 
analysis 0 
in 0 
Finnish 0 
choroideremia 1
families 0 
. 0 

Multipoint 0 
linkage 0 
analysis 0 
of 0 
choroideremia 1
-LRB- 0 
TCD 1
-RRB- 0 
and 0 
seven 0 
X 0 
chromosomal 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
-LRB- 0 
RFLPs 0 
-RRB- 0 
was 0 
carried 0 
out 0 
in 0 
_NUM2 0 
Finnish 0 
TCD 1
families 0 
. 0 

The 0 
data 0 
place 0 
TCD 1
distal 0 
to 0 
PGK 0 
and 0 
DXS72 0 
, 0 
very 0 
close 0 
to 0 
DXYS1 0 
and 0 
DXYS5 0 
-LRB- 0 
Zmax 0 
= 0 
_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
-RRB- 0 
and 0 
proximal 0 
to 0 
DXYS4 0 
and 0 
DXYS12 0 
. 0 

This 0 
agrees 0 
with 0 
the 0 
data 0 
obtained 0 
from 0 
other 0 
linkage 0 
studies 0 
and 0 
from 0 
physical 0 
mapping 0 
. 0 

All 0 
the 0 
TCD 1
males 0 
and 0 
carrier 0 
females 0 
studied 0 
have 0 
the 0 
same 0 
DXYS1 0 
allele 0 
in 0 
coupling 0 
with 0 
TCD 1
. 0 

In 0 
Northeastern 0 
Finland 0 
, 0 
66 0 
/ 0 
69 0 
chromosomes 0 
carrying 0 
TCD 1
had 0 
the 0 
same 0 
haplotype 0 
at 0 
loci 0 
DXS72 0 
, 0 
DXYS1 0 
, 0 
DXYS4 0 
, 0 
and 0 
DXYS12 0 
. 0 

The 0 
same 0 
haplotype 0 
is 0 
seen 0 
in 0 
only 0 
15 0 
/ 0 
99 0 
chromosomes 0 
not 0 
carrying 0 
TCD 1
. 0 

Moreover 0 
, 0 
in 0 
71 0 
/ 0 
104 0 
non-TCD 0 
chromosomes 0 
, 0 
the 0 
haplotype 0 
at 0 
six 0 
marker 0 
loci 0 
is 0 
different 0 
from 0 
those 0 
seen 0 
in 0 
any 0 
of 0 
the 0 
_NUM2 0 
TCD 1
chromosomes 0 
. 0 

This 0 
supports 0 
the 0 
previously 0 
described 0 
hypothesis 0 
that 0 
the 0 
large 0 
Northern 0 
Finnish 0 
choroideremia 1
pedigrees 0 
, 0 
comprising 0 
a 0 
total 0 
of 0 
over 0 
_NUM2 0 
living 0 
patients 0 
representing 0 
more 0 
than 0 
a 0 
fifth 0 
of 0 
all 0 
TCD 1
patients 0 
described 0 
worldwide 0 
, 0 
carry 0 
the 0 
same 0 
mutation 0 
. 0 

These 0 
linkage 0 
and 0 
haplotype 0 
data 0 
provide 0 
improved 0 
opportunities 0 
for 0 
prenatal 0 
diagnosis 0 
based 0 
on 0 
RFLP 0 
studies 0 
. 0 
. 0 

Genetic 0 
heterogeneity 0 
at 0 
the 0 
glucose-6-phosphate 0 
dehydrogenase 0 
locus 0 
in 0 
southern 0 
Italy 0 
: 0 
a 0 
study 0 
on 0 
a 0 
population 0 
from 0 
the 0 
Matera 0 
district 0 
. 0 

Glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
has 0 
been 0 
analyzed 0 
by 0 
gel 0 
electrophoresis 0 
and 0 
by 0 
quantitative 0 
assay 0 
in 0 
an 0 
unselected 0 
sample 0 
of 0 
_NUM4 0 
schoolboys 0 
from 0 
the 0 
province 0 
of 0 
Matera 0 
-LRB- 0 
Lucania 0 
-RRB- 0 
in 0 
southern 0 
Italy 0 
. 0 

We 0 
have 0 
identified 0 
_NUM2 0 
subjects 0 
with 0 
a 0 
G6PD 0
variant 0 
. 0 

Of 0 
these 0 
, 0 
_NUM2 0 
had 0 
severe 0 
G6PD 1
deficiency 1
, 0 
nine 0 
had 0 
mild 0 
to 0 
moderate 0 
deficiency 0 
, 0 
and 0 
three 0 
had 0 
a 0 
non-deficient 0 
electrophoretic 0 
variant 0 
. 0 

The 0 
overall 0 
rate 0 
of 0 
G6PD 1
deficiency 1
was 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
. 0 

The 0 
frequency 0 
of 0 
G6PD 1
deficiency 1
, 0 
ranging 0 
from 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
on 0 
the 0 
Ionian 0 
Coast 0 
to 0 
zero 0 
on 0 
the 0 
eastern 0 
side 0 
of 0 
the 0 
Lucanian 0 
Apennines 0 
, 0 
appears 0 
to 0 
be 0 
inversely 0 
related 0 
to 0 
the 0 
distance 0 
of 0 
each 0 
town 0 
examined 0 
from 0 
the 0 
Ionian 0 
Coast 0 
, 0 
suggesting 0 
that 0 
this 0 
geographic 0 
distribution 0 
may 0 
reflect 0 
, 0 
at 0 
least 0 
in 0 
part 0 
, 0 
gene 0 
flow 0 
from 0 
Greek 0 
settlers 0 
. 0 

Biochemical 0 
characterization 0 
has 0 
shown 0 
that 0 
most 0 
of 0 
the 0 
G6PD 1
deficiency 1
in 0 
this 0 
population 0 
is 0 
accounted 0 
for 0 
by 0 
G6PD 0
Mediterranean 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
have 0 
found 0 
several 0 
examples 0 
of 0 
two 0 
other 0 
known 0 
polymorphic 0 
variants 0 
-LRB- 0 
G6PD 0
Cagliari 0 
and 0 
G6PD 0
A 0 
- 0 
-RRB- 0 
; 0 
three 0 
new 0 
polymorphic 0 
variants 0 
, 0 
G6PD 0
Metaponto 0 
-LRB- 0 
class 0 
III 0 
-RRB- 0 
, 0 
G6PD 0
Montalbano 0 
-LRB- 0 
class 0 
III 0 
-RRB- 0 
, 0 
and 0 
G6PD 0
Pisticci 0 
-LRB- 0 
class 0 
IV 0 
-RRB- 0 
; 0 
and 0 
two 0 
sporadic 0 
variants 0 
, 0 
G6PD 0
Tursi 0 
-LRB- 0 
class 0 
III 0 
-RRB- 0 
and 0 
G6PD 0
Ferrandina 0 
-LRB- 0 
class 0 
II 0 
-RRB- 0 
. 0 

These 0 
data 0 
provide 0 
further 0 
evidence 0 
for 0 
the 0 
marked 0 
genetic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
within 0 
a 0 
relatively 0 
narrow 0 
geographic 0 
area 0 
and 0 
they 0 
prove 0 
the 0 
presence 0 
in 0 
the 0 
Italian 0 
peninsula 0 
of 0 
a 0 
gene 0 
-LRB- 0 
GdA 0 
- 0 
-RRB- 0 
regarded 0 
as 0 
characteristically 0 
African 0 
. 0 

Defective 0 
CTLA-4 0 
cycling 0 
pathway 0 
in 0 
Chediak-Higashi 1
syndrome 1
: 0 
a 0 
possible 0 
mechanism 0 
for 0 
deregulation 0 
of 0 
T 0 
lymphocyte 0 
activation 0 
. 0 

Cytotoxic 0 
T 0 
lymphocyte-associated 0 
antigen 0 
_NUM1 0 
-LRB- 0 
CTLA-4 0 
, 0 
also 0 
known 0 
as 0 
CD152 0 
-RRB- 0 
has 0 
been 0 
shown 0 
to 0 
play 0 
a 0 
major 0 
role 0 
in 0 
the 0 
regulation 0 
of 0 
T 0 
cell 0 
activation 0 
. 0 

Its 0 
membrane 0 
expression 0 
is 0 
highly 0 
regulated 0 
by 0 
endocytosis 0 
and 0 
trafficking 0 
through 0 
the 0 
secretory 0 
lysosome 0 
pathway 0 
. 0 

Chediak-Higashi 1
syndrome 1
-LRB- 0 
CHS 1
-RRB- 0 
is 0 
an 0 
inherited 1
disorder 1
caused 0 
by 0 
mutations 0 
in 0 
the 0 
lysosomal 0 
trafficking 0 
regulator 0 
gene 0 
, 0 
LYST 0 
. 0 

It 0 
results 0 
in 0 
defective 0 
membrane 0 
targeting 0 
of 0 
the 0 
proteins 0 
present 0 
in 0 
secretory 0 
lysosomes 0 
, 0 
and 0 
it 0 
is 0 
associated 0 
with 0 
a 0 
variety 0 
of 0 
features 0 
, 0 
including 0 
a 0 
lymphoproliferative 1
syndrome 1
with 0 
hemophagocytosis 1
. 0 

The 0 
murine 0 
equivalent 0 
of 0 
CHS 1
, 0 
beige 0 
mice 0 
, 0 
present 0 
similar 0 
characteristics 0 
but 0 
do 0 
not 0 
develop 0 
the 0 
lymphoproliferative 1
syndrome 1
. 0 

We 0 
show 0 
herein 0 
that 0 
CTLA-4 0 
is 0 
present 0 
in 0 
enlarged 0 
, 0 
abnormal 0 
vesicles 0 
in 0 
CHS 1
T 0 
cells 0 
and 0 
is 0 
not 0 
properly 0 
expressed 0 
at 0 
the 0 
cell 0 
surface 0 
after 0 
T 0 
cell 0 
activation 0 
, 0 
whereas 0 
its 0 
surface 0 
expression 0 
is 0 
not 0 
impaired 0 
. 0 

It 0 
is 0 
therefore 0 
proposed 0 
that 0 
the 0 
defective 0 
surface 0 
expression 0 
of 0 
CTLA-4 0 
by 0 
CHS 1
T 0 
cells 0 
is 0 
involved 0 
in 0 
the 0 
generation 0 
of 0 
lymphoproliferative 1
disease 1
. 0 

This 0 
observation 0 
may 0 
provide 0 
insight 0 
into 0 
the 0 
role 0 
of 0 
CTLA-4 0 
in 0 
humans 0 
. 0 
. 0 

Beta-catenin 0 
accumulation 0 
and 0 
mutation 0 
of 0 
the 0 
CTNNB1 0 
gene 0 
in 0 
hepatoblastoma 1
. 0 

Hepatoblastoma 1
is 0 
a 0 
rare 0 
malignant 1
tumor 1
of 1
the 1
liver 1
that 0 
occurs 0 
in 0 
children 0 
at 0 
an 0 
average 0 
age 0 
of 0 
_NUM1 0 
to 0 
_NUM1 0 
years 0 
. 0 

Epidemiologic 0 
studies 0 
have 0 
shown 0 
an 0 
increased 0 
frequency 0 
of 0 
this 0 
tumor 1
type 0 
in 0 
families 0 
affected 0 
by 0 
adenomatous 1
polyposis 1
coli 1
. 0 

In 0 
addition 0 
to 0 
the 0 
epidemiologic 0 
data 0 
, 0 
molecular 0 
genetic 0 
studies 0 
suggest 0 
that 0 
inactivation 0 
of 0 
the 0 
APC 1
tumor 1
suppressor 0 
may 0 
be 0 
involved 0 
in 0 
hepatoblastoma 1
tumorigenesis 0 
. 0 

A 0 
major 0 
function 0 
of 0 
APC 0 
is 0 
the 0 
downregulation 0 
of 0 
beta-catenin 0 
, 0 
a 0 
transcription-activating 0 
protein 0 
with 0 
oncogenic 0 
potential 0 
. 0 

In 0 
an 0 
ongoing 0 
immunohistochemical 0 
study 0 
of 0 
beta-catenin 0 
expression 0 
in 0 
sporadic 0 
cases 0 
of 0 
tumor 1
types 0 
that 0 
are 0 
associated 0 
with 0 
adenomatous 1
polyposis 1
coli 1
, 0 
we 0 
observed 0 
increased 0 
beta-catenin 0 
levels 0 
in 0 
the 0 
cytoplasm 0 
and 0 
in 0 
the 0 
nuclei 0 
of 0 
three 0 
investigated 0 
hepatoblastomas 1
. 0 

Sequencing 0 
of 0 
exon 0 
_NUM1 0 
of 0 
the 0 
beta-catenin 0 
gene 0 
-LRB- 0 
CTNNB1 0 
-RRB- 0 
revealed 0 
an 0 
activating 0 
mutation 0 
in 0 
one 0 
of 0 
the 0 
tumor 1
samples 0 
. 0 

Our 0 
data 0 
indicate 0 
for 0 
the 0 
first 0 
time 0 
that 0 
beta-catenin 0 
accumulation 0 
may 0 
play 0 
a 0 
role 0 
in 0 
the 0 
development 0 
of 0 
hepatoblastoma 1
and 0 
that 0 
activating 0 
mutations 0 
of 0 
the 0 
beta-catenin 0 
gene 0 
may 0 
substitute 0 
biallelic 0 
APC 0 
inactivation 0 
in 0 
this 0 
tumor 1
type 0 
. 0 

Genes 0 
Chromosomes 0 
Cancer 0 
_NUM2 0 
399-402 0 
, 0 
_NUM4 0 
. 0 
. 0 

Sequence 0 
of 0 
DNA 0 
flanking 0 
the 0 
exons 0 
of 0 
the 0 
HEXA 0 
gene 0 
, 0 
and 0 
identification 0 
of 0 
mutations 0 
in 0 
Tay-Sachs 1
disease 1
. 0 

The 0 
rapid 0 
identification 0 
of 0 
mutations 0 
causing 0 
Tay-Sachs 1
disease 1
requires 0 
the 0 
capacity 0 
to 0 
readily 0 
screen 0 
the 0 
regions 0 
of 0 
the 0 
HEXA 0 
gene 0 
most 0 
likely 0 
to 0 
be 0 
affected 0 
by 0 
mutation 0 
. 0 

We 0 
have 0 
sequenced 0 
the 0 
portions 0 
of 0 
the 0 
introns 0 
flanking 0 
each 0 
of 0 
the 0 
_NUM2 0 
HEXA 0 
exons 0 
in 0 
order 0 
to 0 
specify 0 
oligonucleotide 0 
primers 0 
for 0 
the 0 
PCR-dependent 0 
amplification 0 
of 0 
each 0 
exon 0 
and 0 
splice-junction 0 
sequence 0 
. 0 

The 0 
amplified 0 
products 0 
were 0 
analyzed 0 
, 0 
by 0 
electrophoresis 0 
in 0 
nondenaturing 0 
polyacrylamide 0 
gels 0 
, 0 
for 0 
the 0 
presence 0 
of 0 
either 0 
heteroduplexes 0 
, 0 
derived 0 
from 0 
the 0 
annealing 0 
of 0 
normal 0 
and 0 
mutant 0 
DNA 0 
strands 0 
, 0 
or 0 
single-strand 0 
conformational 0 
polymorphisms 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
, 0 
derived 0 
from 0 
the 0 
renaturation 0 
of 0 
single-stranded 0 
DNA 0 
. 0 

Five 0 
novel 0 
mutations 0 
from 0 
Tay-Sachs 1
disease 1
patients 0 
were 0 
detected 0 
a 0 
5-bp 0 
deletion 0 
of 0 
_DS 0 
in 0 
IVS-9 0 
; 0 
a 0 
2-bp 0 
deletion 0 
of 0 
_DS 0 
in 0 
exon 0 
_NUM1 0 
; 0 
_AN 0 
to 0 
A 0 
, 0 
giving 0 
a 0 
stop 0 
codon 0 
in 0 
exon 0 
_NUM1 0 
; 0 
_AN 0 
to 0 
T 0 
in 0 
exon 0 
_NUM1 0 
, 0 
producing 0 
the 0 
third 0 
amino 0 
acid 0 
substitution 0 
detected 0 
at 0 
this 0 
site 0 
; 0 
and 0 
G 0 
to 0 
C 0 
at 0 
position 0 
_NUM1 0 
of 0 
IVS-2 0 
, 0 
expected 0 
to 0 
produce 0 
abnormal 0 
splicing 0 
. 0 

In 0 
addition 0 
, 0 
two 0 
mutations 0 
, 0 
-LRB- 0 
_AN 0 
to 0 
A 0 
in 0 
exon 0 
_NUM2 0 
and 0 
a 0 
4-bp 0 
insertion 0 
in 0 
exon 0 
_NUM2 0 
-RRB- 0 
that 0 
have 0 
previously 0 
been 0 
reported 0 
were 0 
identified 0 
. 0 
. 0 

In 0 
vivo 0 
modulation 0 
of 0 
Hmgic 0 
reduces 0 
obesity 1
. 0 

The 0 
HMGI 0 
family 0 
of 0 
proteins 0 
consists 0 
of 0 
three 0 
members 0 
, 0 
HMGIC 0 
, 0 
HMGI 0 
and 0 
HMGI 0 
-LRB- 0 
Y 0 
-RRB- 0 
, 0 
that 0 
function 0 
as 0 
architectural 0 
factors 0 
and 0 
are 0 
essential 0 
components 0 
of 0 
the 0 
enhancesome 0 
. 0 

HMGIC 0 
is 0 
predominantly 0 
expressed 0 
in 0 
proliferating 0 
, 0 
undifferentiated 0 
mesenchymal 0
cells 0 
and 0 
is 0 
not 0 
detected 0 
in 0 
adult 0 
tissues 0 
. 0 

It 0 
is 0 
disrupted 0 
and 0 
misexpressed 0 
in 0 
a 0 
number 0 
of 0 
mesenchymal 1
tumour 1
cell 0 
types 0 
, 0 
including 0 
fat-cell 1
tumours 1
-LRB- 0 
lipomas 1
-RRB- 0 
. 0 

In 0 
addition 0 
Hmgic 0 
- 0 
/ 0 
- 0 
mice 0 
have 0 
a 0 
deficiency 0 
in 0 
fat 0 
tissue 0 
. 0 

To 0 
study 0 
its 0 
role 0 
in 0 
adipogenesis 0 
and 0 
obesity 1
, 0 
we 0 
examined 0 
Hmgic 0 
expression 0 
in 0 
the 0 
adipose 0 
tissue 0 
of 0 
adult 0 
, 0 
obese 1
mice 0 
. 0 

Mice 0 
with 0 
a 0 
partial 1
or 1
complete 1
deficiency 1
of 1
Hmgic 1
resisted 0 
diet-induced 0 
obesity 1
. 0 

Disruption 0 
of 0 
Hmgic 0 
caused 0 
a 0 
reduction 0 
in 0 
the 0 
obesity 1
induced 0 
by 0 
leptin 1
deficiency 1
-LRB- 0 
Lepob 0 
/ 0 
Lepob 0 
-RRB- 0 
in 0 
a 0 
gene-dose-dependent 0 
manner 0 
. 0 

Our 0 
studies 0 
implicate 0 
a 0 
role 0 
for 0 
HMGIC 0 
in 0 
fat-cell 0 
proliferation 0 
, 0 
indicating 0 
that 0 
it 0 
may 0 
be 0 
an 0 
adipose-specific 0 
target 0 
for 0 
the 0 
treatment 0 
of 0 
obesity 1
. 0 
. 0 

Prenatal 0 
diagnosis 0 
by 0 
FISH 0 
in 0 
a 0 
family 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
caused 0 
by 0 
duplication 0 
of 0 
PLP 0 
gene 0 
. 0 

A 0 
diagnosis 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
-LRB- 0 
MIM 0 
_NUM6 0 
-RRB- 0 
was 0 
made 0 
in 0 
a 0 
young 0 
boy 0 
. 0 

No 0 
mutation 0 
in 0 
the 0 
coding 0 
region 0 
of 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
had 0 
been 0 
found 0 
. 0 

The 0 
boys 0 
maternal 0 
aunt 0 
came 0 
for 0 
prenatal 0 
diagnosis 0 
when 0 
_NUM2 0 
+ 0 
weeks 0 
pregnant 0 
and 0 
carrying 0 
a 0 
male 0 
fetus 0 
. 0 

Samples 0 
were 0 
tested 0 
for 0 
duplication 0 
of 0 
the 0 
PLP 0 
gene 0 
, 0 
by 0 
interphase 0 
FISH 0 
, 0 
in 0 
lymphocyte 0 
preparations 0 
from 0 
the 0 
proband 0 
, 0 
his 0 
aunt 0 
and 0 
an 0 
amniotic 0 
fluid 0 
cell 0 
preparation 0 
from 0 
the 0 
fetus 0 
. 0 

The 0 
proband 0 
was 0 
found 0 
to 0 
carry 0 
the 0 
duplication 0 
, 0 
thus 0 
confirming 0 
the 0 
diagnosis 0 
of 0 
Pelizaeus 1
Merzbacher 1
disease 1
, 0 
but 0 
neither 0 
the 0 
aunt 0 
nor 0 
the 0 
fetus 0 
carried 0 
a 0 
duplication 0 
. 0 
. 0 

Somatic 0 
rearrangement 0 
of 0 
chromosome 0 
_NUM2 0 
in 0 
human 0 
lymphocytes 0 
. 0 

Ataxia-telangiectasia 1
is 0 
a 0 
rare 0 
genetic 1
disorder 1
associated 0 
with 0 
immune 1
deficiency 1
, 0 
chromosome 1
instability 1
, 0 
and 0 
a 0 
predisposition 0 
to 0 
lymphoid 1
malignancy 1
. 0 

We 0 
have 0 
detected 0 
chromosomally 0 
anomalous 0 
clones 0 
of 0 
lymphocytes 0 
in 0 
eight 0 
patients 0 
with 0 
this 0 
disorder 0 
. 0 

Chromosome 0 
banding 0 
disclosed 0 
that 0 
the 0 
clones 0 
are 0 
consistently 0 
marked 0 
by 0 
structural 0 
rearrangement 0 
of 0 
the 0 
long 0 
arm 0 
-LRB- 0 
q 0 
-RRB- 0 
of 0 
chromosome 0 
_NUM2 0 
. 0 

A 0 
translocation 0 
involving 0 
14q 0 
was 0 
found 0 
in 0 
clones 0 
obtained 0 
from 0 
seven 0 
of 0 
the 0 
eight 0 
patients 0 
whereas 0 
a 0 
ring 0 
_NUM2 0 
chromosome 0 
was 0 
found 0 
in 0 
a 0 
clone 0 
obtained 0 
from 0 
the 0 
other 0 
. 0 

These 0 
findings 0 
as 0 
well 0 
as 0 
data 0 
obtained 0 
by 0 
others 0 
for 0 
patients 0 
with 0 
ataxia-telangiectasia 1
suggest 0 
that 0 
structural 0 
rearrangement 0 
of 0 
14q 0 
is 0 
the 0 
initial 0 
chromosomal 0 
change 0 
in 0 
lymphocyte 0 
clones 0 
of 0 
patients 0 
with 0 
this 0 
disorder 0 
. 0 

Chromosomes 0 
of 0 
lymphocytes 0 
from 0 
one 0 
of 0 
the 0 
patients 0 
were 0 
studied 0 
before 0 
and 0 
after 0 
the 0 
onset 0 
of 0 
chronic 1
lymphocytic 1
leukemia 1
. 0 

Before 0 
leukemia 1
was 0 
diagnosed 0 
, 0 
the 0 
patient 0 
had 0 
a 0 
lymphocyte 0 
clone 0 
with 0 
a 0 
14q 0 
translocation 0 
. 0 

This 0 
clone 0 
appears 0 
to 0 
have 0 
given 0 
rise 0 
to 0 
the 0 
leukemic 1
cells 0 
. 0 

We 0 
hypothesize 0 
that 0 
structural 0 
rearrangement 0 
of 0 
14q 0 
is 0 
directly 0 
related 0 
to 0 
abnormal 0 
growth 0 
of 0 
lymphocytes 0 
and 0 
that 0 
it 0 
may 0 
be 0 
a 0 
step 0 
toward 0 
the 0 
development 0 
of 0 
lymphoid 1
malignancies 1
. 0 

Increasing 0 
evidence 0 
, 0 
provided 0 
by 0 
others 0 
, 0 
for 0 
the 0 
nonrandom 0 
involvement 0 
of 0 
14q 0 
in 0 
African-type 0 
Burkitts 1
lymphoma 1
and 0 
other 0 
lymphoid 1
neoplasms 1
further 0 
strengthens 0 
this 0 
hypothesis 0 
. 0 
. 0 

Two 0 
missense 0 
mutations 0 
causing 0 
mild 0 
hyperphenylalaninemia 1
associated 0 
with 0 
DNA 0 
haplotype 0 
_NUM2 0 
. 0 

The 0 
genetic 1
defects 1
responsible 0 
for 0 
most 0 
phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
and 0 
hyperphenylalaninemia 1
-LRB- 0 
HPA 1
-RRB- 0 
cases 0 
are 0 
located 0 
in 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
gene 0 
. 0 

Approximately 0 
50-60 0 
mutations 0 
have 0 
been 0 
reported 0 
in 0 
Caucasians 0 
and 0 
are 0 
reflected 0 
in 0 
a 0 
wide 0 
range 0 
of 0 
clinical 0 
severities 0 
. 0 

Most 0 
mutations 0 
are 0 
linked 0 
to 0 
specific 0 
haplotypes 0 
, 0 
as 0 
defined 0 
by 0 
eight 0 
polymorphic 0 
restriction 0 
sites 0 
in 0 
the 0 
PAH 0 
gene 0 
. 0 

We 0 
hypothesized 0 
that 0 
there 0 
is 0 
at 0 
least 0 
one 0 
mild 0 
mutation 0 
linked 0 
to 0 
haplotype 0 
_NUM2 0 
in 0 
the 0 
Swedish 0 
PKU 1
/ 0 
HPA 1
population 0 
, 0 
since 0 
_NUM1 0 
of 0 
_NUM1 0 
patients 0 
carrying 0 
haplotype 0 
_NUM2 0 
had 0 
mild 0 
HPA 1
. 0 

Sequence 0 
analysis 0 
revealed 0 
a 0 
C-to-G 0 
transversion 0 
at 0 
the 0 
second 0 
base 0 
of 0 
codon 0 
_NUM3 0 
, 0 
resulting 0 
in 0 
a 0 
substitution 0 
of 0 
glycine 0 
for 0 
alanine 0 
, 0 
in 0 
four 0 
mutant 0 
haplotype 0 
_NUM2 0 
genes 0 
, 0 
and 0 
a 0 
G-to-A 0 
transition 0 
at 0 
the 0 
second 0 
base 0 
of 0 
codon 0 
_NUM3 0 
, 0 
resulting 0 
in 0 
a 0 
substitution 0 
of 0 
glutamine 0 
for 0 
arginine 0 
, 0 
in 0 
another 0 
three 0 
mutant 0 
haplotype 0 
_NUM2 0 
genes 0 
. 0 

These 0 
mutations 0 
segregated 0 
with 0 
mutant 0 
haplotype 0 
_NUM2 0 
alleles 0 
in 0 
nuclear 0 
families 0 
but 0 
were 0 
not 0 
present 0 
on 0 
normal 0 
or 0 
other 0 
mutant 0 
alleles 0 
. 0 

Both 0 
mutations 0 
were 0 
tested 0 
in 0 
a 0 
eukaryotic 0 
expression 0 
system 0 
in 0 
which 0 
enzyme 0 
activities 0 
of 0 
different 0 
mutant 0 
PAH 0 
enzymes 0 
reflect 0 
the 0 
relative 0 
severities 0 
of 0 
the 0 
mutations 0 
, 0 
although 0 
these 0 
in 0 
vitro 0 
activities 0 
can 0 
not 0 
be 0 
translated 0 
directly 0 
into 0 
in 0 
vivo 0 
hepatic 0 
activities 0 
. 0 

The 0 
A322G 0 
mutant 0 
PAH 0 
had 0 
about 0 
_NUM2 0 
% 0 
and 0 
the 0 
R408Q 0 
mutant 0 
PAH 0 
about 0 
_NUM2 0 
% 0 
of 0 
the 0 
wild-type 0 
PAH 0 
enzyme 0 
activity 0 
. 0 

These 0 
in 0 
vitro 0 
activities 0 
are 0 
the 0 
highest 0 
reported 0 
for 0 
mutant 0 
PAH 0 
enzymes 0 
produced 0 
in 0 
the 0 
same 0 
expression 0 
system 0 
. 0 

-LRB- 0 
ABSTRACT 0 
TRUNCATED 0 
_DS 0 
_NUM3 0 
WORDS 0 
-RRB- 0 
. 0 

Genomic 0 
organization 0 
of 0 
the 0 
adrenoleukodystrophy 1
gene 0 
. 0 

Adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
, 0 
the 0 
most 0 
frequent 0 
peroxisomal 1
disorder 1
, 0 
is 0 
a 0 
severe 0 
neurodegenerative 1
disease 1
associated 0 
with 0 
an 0 
impairment 1
of 1
very 1
long 1
chain 1
fatty 1
acids 1
beta-oxidation 1
. 0 

We 0 
have 0 
recently 0 
identified 0 
by 0 
positional 0 
cloning 0 
the 0 
gene 0 
responsible 0 
for 0 
ALD 1
, 0 
located 0 
in 0 
Xq28 0 
. 0 

It 0 
encodes 0 
a 0 
new 0 
member 0 
of 0 
the 0 
'' 0 
ABC 0 
'' 0 
superfamily 0 
of 0 
membrane-associated 0 
transporters 0 
that 0 
shows 0 
, 0 
in 0 
particular 0 
, 0 
significant 0 
homology 0 
to 0 
the 0 
70-kDa 0 
peroxisomal 0 
membrane 0 
protein 0 
-LRB- 0 
PMP70 0 
-RRB- 0 
. 0 

We 0 
report 0 
here 0 
a 0 
detailed 0 
characterization 0 
of 0 
the 0 
ALD 1
gene 0 
structure 0 
. 0 

It 0 
extends 0 
over 0 
_NUM2 0 
kb 0 
and 0 
consists 0 
of 0 
_NUM2 0 
exons 0 
. 0 

To 0 
facilitate 0 
the 0 
detection 0 
of 0 
mutations 0 
in 0 
ALD 1
patients 0 
, 0 
we 0 
have 0 
determined 0 
the 0 
intronic 0 
sequences 0 
flanking 0 
the 0 
exons 0 
as 0 
well 0 
as 0 
the 0 
sequence 0 
of 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
and 0 
of 0 
the 0 
immediate 0 
_NUM1 0 
promoter 0 
region 0 
. 0 

Sequences 0 
present 0 
in 0 
distal 0 
exons 0 
cross-hybridize 0 
strongly 0 
to 0 
additional 0 
sequences 0 
in 0 
the 0 
human 0 
genome 0 
. 0 

The 0 
ALD 1
gene 0 
has 0 
been 0 
positioned 0 
on 0 
a 0 
pulsed-field 0 
map 0 
between 0 
DXS15 0 
and 0 
the 0 
L1CAM 0 
gene 0 
, 0 
about 0 
_NUM3 0 
kb 0 
upstream 0 
from 0 
the 0 
color 0 
pigment 0 
genes 0 
. 0 

The 0 
frequent 0 
occurrence 0 
of 0 
color 0 
vision 0 
anomalies 0 
observed 0 
in 0 
patients 0 
with 0 
adrenomyeloneuropathy 1
-LRB- 0 
the 0 
adult 0 
onset 0 
form 0 
of 0 
ALD 1
-RRB- 0 
thus 0 
does 0 
not 0 
represent 0 
a 0 
contiguous 1
gene 1
syndrome 1
but 0 
a 0 
secondary 0 
manifestation 0 
of 0 
ALD 1
. 0 
. 0 

BRCA1 0 
interacts 0 
with 0 
components 0 
of 0 
the 0 
histone 0 
deacetylase 0 
complex 0 
. 0 

Germ-line 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
tumor 0 
suppressor 0 
gene 0 
are 0 
associated 0 
with 0 
an 0 
increased 0 
susceptibility 0 
to 0 
breast 1
and 1
ovarian 1
cancer 1
. 0 

BRCA1 0 
contains 0 
a 0 
carboxyl-terminal 0 
domain 0 
-LRB- 0 
BRCT 0 
-RRB- 0 
that 0 
is 0 
shared 0 
with 0 
several 0 
other 0 
proteins 0 
involved 0 
in 0 
maintaining 0 
genome 0 
integrity 0 
. 0 

In 0 
an 0 
effort 0 
to 0 
understand 0 
the 0 
function 0 
of 0 
BRCA1 0 
, 0 
we 0 
sought 0 
to 0 
isolate 0 
proteins 0 
that 0 
interact 0 
with 0 
the 0 
BRCT 0 
domain 0 
. 0 

Purified 0 
BRCT 0 
polypeptide 0 
was 0 
used 0 
as 0 
a 0 
probe 0 
to 0 
screen 0 
a 0 
human 0 
placenta 0 
cDNA 0 
expression 0 
library 0 
by 0 
Far 0 
Western 0 
analysis 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
BRCA1 0 
interacts 0 
in 0 
vivo 0 
and 0 
in 0 
vitro 0 
with 0 
the 0 
Rb-binding 0 
proteins 0 
, 0 
RbAp46 0 
and 0 
RbAp48 0 
, 0 
as 0 
well 0 
as 0 
with 0 
Rb 0 
. 0 

Moreover 0 
, 0 
the 0 
BRCT 0 
domain 0 
associates 0 
with 0 
the 0 
histone 0 
deacetylases 0 
HDAC1 0 
and 0 
HDAC2 0 
. 0 

These 0 
results 0 
demonstrate 0 
that 0 
BRCA1 0 
interacts 0 
with 0 
components 0 
of 0 
the 0 
histone 0 
deacetylase 0 
complex 0 
, 0 
and 0 
therefore 0 
may 0 
explain 0 
the 0 
involvement 0 
of 0 
BRCA1 0 
in 0 
multiple 0 
processes 0 
such 0 
as 0 
transcription 0 
, 0 
DNA 0 
repair 0 
, 0 
and 0 
recombination 0 
. 0 
. 0 

Deletion 0 
of 0 
the 0 
KIT 0 
and 0 
PDGFRA 0 
genes 0 
in 0 
a 0 
patient 0 
with 0 
piebaldism 1
. 0 

We 0 
have 0 
previously 0 
shown 0 
that 0 
human 0 
piebaldism 1
results 0 
from 0 
mutations 0 
of 0 
the 0 
KIT 0 
gene 0 
, 0 
which 0 
encodes 0 
the 0 
receptor 0 
for 0 
the 0 
mast 0 
/ 0 
stem 0 
cell 0 
growth 0 
factor 0 
and 0 
is 0 
located 0 
in 0 
chromosome 0 
segment 0 
4q12 0 
. 0 

Using 0 
DNA 0 
of 0 
a 0 
patient 0 
with 0 
piebaldism 1
, 0 
mental 1
retardation 1
, 0 
and 0 
multiple 1
congenital 1
anomalies 1
associated 0 
with 0 
a 0 
_NUM2 0 
, 0 
XY 0 
, 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
q12q21 0 
. 0 

_NUM1 0 
-RRB- 0 
karyotype 0 
, 0 
we 0 
carried 0 
out 0 
quantitative 0 
Southern 0 
blot 0 
hybridization 0 
analyses 0 
of 0 
the 0 
KIT 0 
gene 0 
and 0 
the 0 
adjacent 0 
PDGFRA 0 
-LRB- 0 
platelet-derived 0 
growth 0 
factor 0 
receptor 0 
alpha 0 
subunit 0 
-RRB- 0 
genes 0 
. 0 

The 0 
patient 0 
was 0 
hemizygous 0 
for 0 
both 0 
the 0 
KIT 0 
and 0 
PDGFRA 0 
genes 0 
, 0 
indicating 0 
that 0 
both 0 
of 0 
these 0 
genes 0 
are 0 
included 0 
within 0 
the 0 
deleted 0 
region 0 
. 0 

Therefore 0 
, 0 
deletion 0 
of 0 
the 0 
KIT 0 
and 0 
PDGFRA 0 
genes 0 
may 0 
account 0 
for 0 
the 0 
piebald 1
phenotype 0 
in 0 
this 0 
patient 0 
. 0 

Glucose-6-phosphate 0 
dehydrogenase 0 
variants 0 
and 0 
their 0 
frequency 0 
in 0 
Guangdong 0 
, 0 
China 0 
. 0 

Erythrocyte 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
was 0 
characterized 0 
in 0 
blood 0 
samples 0 
obtained 0 
from 0 
_NUM2 0 
randomly 0 
selected 0 
males 0 
with 0 
enzyme 1
deficiency 1
from 0 
various 0 
regions 0 
of 0 
Guangdong 0 
Province 0 
, 0 
China 0 
. 0 

Nine 0 
new 0 
variants 0 
-LRB- 0 
Gd 0 
Kaiping 0 
, 0 
Gd 0 
Boluo 0 
, 0 
Gd 0 
Huiyang 0 
, 0 
Gd 0 
Gaomin 0 
, 0 
Gd 0 
Qing-Baijiang 0 
, 0 
Gd 0 
Gaozhou 0 
, 0 
Gd 0 
Huazhou 0 
, 0 
Gd 0 
Nanhai 0 
, 0 
and 0 
Gd 0 
Guangzhou 0 
-RRB- 0 
were 0 
identified 0 
. 0 

Of 0 
the 0 
_NUM2 0 
variants 0 
found 0 
in 0 
this 0 
province 0 
, 0 
Gd 0 
Kaiping 0 
, 0 
Gd 0 
Taiwan-Hakka 0 
, 0 
Gd 0 
Haad 0 
Yai 0 
, 0 
Gd 0 
Haad 0 
Yai-like 0 
and 0 
Gd 0 
Huiyang 0 
occurred 0 
most 0 
frequently 0 
. 0 

The 0 
frequency 0 
of 0 
each 0 
variant 0 
was 0 
calculated 0 
. 0 

The 0 
results 0 
demonstrated 0 
that 0 
the 0 
genetic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
was 0 
high 0 
in 0 
this 0 
area 0 
. 0 
. 0 

A 0 
common 0 
molecular 0 
basis 0 
for 0 
rearrangement 1
disorders 1
on 0 
chromosome 0 
22q11 0 
. 0 

The 0 
chromosome 0 
22q11 0 
region 0 
is 0 
susceptible 0 
to 0 
rearrangements 0 
that 0 
are 0 
associated 0 
with 0 
congenital 1
anomaly 1
disorders 1
and 0 
malignant 1
tumors 1
. 0 

Three 0 
congenital 1
anomaly 1
disorders 1
, 0 
cat-eye 1
syndrome 1
, 0 
der 1
-LRB- 1
-RRB- 1
syndrome 1
and 0 
velo-cardio-facial 1
syndrome 1
/ 0 
DiGeorge 1
syndrome 1
-LRB- 0 
VCFS 1
/ 0 
DGS 1
-RRB- 0 
are 0 
associated 0 
with 0 
tetrasomy 0 
, 0 
trisomy 0 
or 0 
monosomy 0 
, 0 
respectively 0 
, 0 
for 0 
part 0 
of 0 
chromosome 0 
22q11 0 
. 0 

VCFS 1
/ 0 
DGS 1
is 0 
the 0 
most 0 
common 0 
syndrome 0 
associated 0 
with 0 
22q11 0 
rearrangements 0 
. 0 

In 0 
order 0 
to 0 
determine 0 
whether 0 
there 0 
are 0 
particular 0 
regions 0 
on 0 
22q11 0 
that 0 
are 0 
prone 0 
to 0 
rearrangements 0 
, 0 
the 0 
deletion 0 
end-points 0 
in 0 
a 0 
large 0 
number 0 
of 0 
VCFS 1
/ 0 
DGS 1
patients 0 
were 0 
defined 0 
by 0 
haplotype 0 
analysis 0 
. 0 

Most 0 
VCFS 1
/ 0 
DGS 1
patients 0 
have 0 
a 0 
similar 0 
_NUM1 0 
Mb 0 
deletion 0 
, 0 
some 0 
have 0 
a 0 
nested 0 
distal 0 
deletion 0 
breakpoint 0 
resulting 0 
in 0 
a 0 
_NUM1 0 
. 0 

_NUM1 0 
Mb 0 
deletion 0 
and 0 
a 0 
few 0 
rare 0 
patients 0 
have 0 
unique 0 
deletions 0 
or 0 
translocations 0 
. 0 

The 0 
high 0 
prevalence 0 
of 0 
the 0 
disorder 0 
in 0 
the 0 
population 0 
and 0 
the 0 
fact 0 
that 0 
most 0 
cases 0 
occur 0 
sporadically 0 
suggest 0 
that 0 
sequences 0 
at 0 
or 0 
near 0 
the 0 
breakpoints 0 
confer 0 
susceptibility 0 
to 0 
chromosome 0 
rearrangements 0 
. 0 

To 0 
investigate 0 
this 0 
hypothesis 0 
, 0 
we 0 
developed 0 
hamster-human 0 
somatic 0 
hybrid 0 
cell 0 
lines 0 
from 0 
VCFS 1
/ 0 
DGS 1
patients 0 
with 0 
all 0 
three 0 
classes 0 
of 0 
deletions 0 
and 0 
we 0 
now 0 
show 0 
that 0 
the 0 
breakpoints 0 
occur 0 
within 0 
similar 0 
low 0 
copy 0 
repeats 0 
, 0 
termed 0 
LCR22s 0 
. 0 

To 0 
support 0 
this 0 
idea 0 
further 0 
, 0 
we 0 
identified 0 
a 0 
family 0 
that 0 
carries 0 
an 0 
interstitial 0 
duplication 0 
of 0 
the 0 
same 0 
_NUM1 0 
Mb 0 
region 0 
that 0 
is 0 
deleted 0 
in 0 
VCFS 1
/ 0 
DGS 1
patients 0 
. 0 

We 0 
present 0 
models 0 
to 0 
explain 0 
how 0 
the 0 
LCR22s 0 
can 0 
mediate 0 
different 0 
homologous 0 
recombination 0 
events 0 
, 0 
thereby 0 
generating 0 
a 0 
number 0 
of 0 
rearrangements 0 
that 0 
are 0 
associated 0 
with 0 
congenital 1
anomaly 1
disorders 1
. 0 

We 0 
identified 0 
five 0 
additional 0 
copies 0 
of 0 
the 0 
LCR22 0 
on 0 
22q11 0 
that 0 
may 0 
mediate 0 
other 0 
rearrangements 0 
leading 0 
to 0 
disease 0 
. 0 

Typical 0 
and 0 
partial 0 
cat 1
eye 1
syndrome 1
: 0 
identification 0 
of 0 
the 0 
marker 0 
chromosome 0 
by 0 
FISH 0 
. 0 

Three 0 
children 0 
are 0 
reported 0 
with 0 
typical 0 
cat 1
eye 1
syndrome 1
-LRB- 0 
CES 1
-RRB- 0 
and 0 
three 0 
more 0 
children 0 
with 0 
partial 0 
CES 1
because 0 
of 0 
absence 0 
of 0 
coloboma 0 
, 0 
in 0 
which 0 
the 0 
supernumerary 0 
marker 0 
chromosome 0 
was 0 
studied 0 
by 0 
FISH 0 
. 0 

Using 0 
a 0 
genomic 0 
library 0 
, 0 
and 0 
also 0 
a 0 
centromeric 0 
and 0 
particularly 0 
a 0 
cosmid 0 
probe 0 
of 0 
22q11 0 
, 0 
partial 0 
tetrasomy 1
was 0 
shown 0 
in 0 
all 0 
cases 0 
. 0 
. 0 

An 0 
intrachromosomal 0 
insertion 0 
causing 0 
5q22 0 
deletion 0 
and 0 
familial 1
adenomatous 1
polyposis 1
coli 1
in 0 
two 0 
generations 0 
. 0 

We 0 
report 0 
familial 1
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
FAPC 1
-RRB- 0 
with 0 
epidermoid 1
cysts 1
, 0 
osteomata 1
, 0 
and 0 
areas 0 
of 0 
congenital 1
hypertrophy 1
of 1
the 1
retinal 1
pigment 1
epithelium 1
-LRB- 0 
CHRPEs 1
-RRB- 0 
in 0 
a 0 
male 0 
patient 0 
and 0 
his 0 
maternal 0 
aunt 0 
, 0 
both 0 
of 0 
whom 0 
suffered 0 
a 0 
mild 0 
to 0 
moderate 0 
degree 0 
of 0 
mental 1
handicap 1
. 0 

Both 0 
had 0 
an 0 
interstitial 0 
deletion 0 
of 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
-LRB- 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
q22q23 0 
. 0 

_NUM1 0 
-RRB- 0 
-RRB- 0 
. 0 

Two 0 
other 0 
normal 0 
family 0 
members 0 
had 0 
the 0 
underlying 0 
direct 0 
insertion 0 
of 0 
chromosome 0 
_NUM1 0 
-LRB- 0 
dir 0 
ins 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

3q22q23 0 
3q22q23 0 
. 0 

_NUM1 0 
-RRB- 0 
-RRB- 0 
. 0 

Molecular 0 
genetic 0 
and 0 
fluorescent 0 
hybridisation 0 
studies 0 
have 0 
shown 0 
that 0 
loci 0 
D5S37 0 
and 0 
D5S98 0 
are 0 
outside 0 
the 0 
deletion 0 
whereas 0 
loci 0 
detected 0 
by 0 
probes 0 
EF5 0 
. 0 

_NUM2 0 
and 0 
YN5 0 
. 0 

_NUM2 0 
are 0 
lost 0 
. 0 

As 0 
expected 0 
, 0 
the 0 
molecular 0 
analyses 0 
indicate 0 
loss 0 
of 0 
one 0 
allele 0 
at 0 
the 0 
MCC 0 
and 0 
APC 1
loci 0 
. 0 

The 0 
APC 1
gene 0 
is 0 
located 0 
within 0 
band 0 
5q22 0 
. 0 

Familial 0 
direct 0 
insertions 0 
should 0 
be 0 
considered 0 
as 0 
a 0 
cause 0 
of 0 
recurrent 0 
microdeletion 0 
syndromes 0 
. 0 

Cloning 0 
of 0 
the 0 
Huntington 1
disease 1
region 0 
in 0 
yeast 0 
artificial 0 
chromosomes 0 
. 0 

The 0 
gene 0 
responsible 0 
for 0 
Huntington 1
disease 1
has 0 
been 0 
localized 0 
to 0 
a 0 
_NUM1 0 
. 0 

_NUM1 0 
million 0 
base 0 
pair 0 
-LRB- 0 
Mb 0 
-RRB- 0 
region 0 
between 0 
the 0 
loci 0 
D4S10 0 
and 0 
D4S168 0 
on 0 
the 0 
short 0 
arm 0 
of 0 
chromosome 0 
_NUM1 0 
. 0 

As 0 
part 0 
of 0 
a 0 
strategy 0 
to 0 
clone 0 
the 0 
HD 1
gene 0 
on 0 
the 0 
basis 0 
of 0 
its 0 
chromosomal 0 
location 0 
, 0 
we 0 
isolated 0 
genomic 0 
DNA 0 
from 0 
the 0 
HD 1
region 0 
as 0 
a 0 
set 0 
of 0 
overlapping 0 
yeast 0 
artificial 0 
chromosome 0 
-LRB- 0 
YAC 0 
-RRB- 0 
clones 0 
. 0 

Twenty-eight 0 
YAC 0 
clones 0 
were 0 
identified 0 
by 0 
screening 0 
human 0 
YAC 0 
libraries 0 
with 0 
twelve 0 
PCR-based 0 
sequence-tagged 0 
sites 0 
-LRB- 0 
STSs 0 
-RRB- 0 
from 0 
the 0 
region 0 
. 0 

We 0 
assembled 0 
the 0 
YAC 0 
clones 0 
into 0 
overlapping 0 
sets 0 
by 0 
hybridizing 0 
them 0 
to 0 
a 0 
large 0 
number 0 
of 0 
DNA 0 
probes 0 
from 0 
the 0 
HD 1
region 0 
, 0 
including 0 
the 0 
STSs 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
isolated 0 
the 0 
ends 0 
of 0 
the 0 
human 0 
DNA 0 
inserts 0 
of 0 
most 0 
of 0 
the 0 
YAC 0 
clones 0 
to 0 
assist 0 
in 0 
the 0 
construction 0 
of 0 
the 0 
contig 0 
. 0 

Although 0 
almost 0 
half 0 
of 0 
the 0 
YACs 0 
appear 0 
to 0 
contain 0 
chimeric 0 
inserts 0 
and 0 
several 0 
contain 0 
internal 0 
deletions 0 
or 0 
other 0 
rearrangements 0 
, 0 
we 0 
were 0 
able 0 
to 0 
obtain 0 
over 0 
_NUM1 0 
. 0 

_NUM1 0 
Mb 0 
of 0 
the 0 
HD 1
region 0 
in 0 
YACs 0 
, 0 
including 0 
one 0 
continuous 0 
segment 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
Mb 0 
covering 0 
the 0 
region 0 
that 0 
most 0 
likely 0 
contains 0 
the 0 
HD 1
gene 0 
. 0 

Ten 0 
of 0 
the 0 
twenty 0 
eight 0 
YAC 0 
clones 0 
comprise 0 
a 0 
minimal 0 
set 0 
spanning 0 
the 0 
_NUM1 0 
. 0 

_NUM1 0 
Mb 0 
. 0 

These 0 
clones 0 
provide 0 
reagents 0 
for 0 
the 0 
complete 0 
characterization 0 
of 0 
this 0 
region 0 
of 0 
the 0 
genome 0 
and 0 
for 0 
the 0 
eventual 0 
isolation 0 
of 0 
the 0 
HD 1
gene 0 
. 0 

Three 0 
novel 0 
mutations 0 
in 0 
five 0 
unrelated 0 
subjects 0 
with 0 
hereditary 0 
protein 1
S 1
deficiency 1
type 1
I 1
. 0 

A 0 
panel 0 
of 0 
eight 0 
unrelated 0 
subjects 0 
with 0 
inherited 0 
type 1
I 1
protein 1
S 1
deficiency 1
was 0 
screened 0 
for 0 
mutations 0 
in 0 
the 0 
PROS1 0 
gene 0 
. 0 

In 0 
five 0 
subjects 0 
an 0 
abnormality 0 
was 0 
found 0 
but 0 
mutations 0 
were 0 
not 0 
detected 0 
in 0 
the 0 
remaining 0 
three 0 
subjects 0 
. 0 

Two 0 
subjects 0 
shared 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
at 0 
position 0 
+ 0 
_NUM1 0 
of 0 
the 0 
donor 0 
splice 0 
site 0 
consensus 0 
sequence 0 
of 0 
intron 0 
_NUM2 0 
. 0 

Also 0 
in 0 
two 0 
subjects 0 
an 0 
A 0 
-- 0 
> 0 
T 0 
transversion 0 
was 0 
detected 0 
in 0 
the 0 
stopcodon 0 
of 0 
the 0 
PROS1 0 
gene 0 
; 0 
this 0 
transversion 0 
predicts 0 
a 0 
protein 0
S 0 
molecule 0 
that 0 
is 0 
extended 0 
by 0 
_NUM2 0 
amino 0 
acids 0 
. 0 

The 0 
fifth 0 
subject 0 
was 0 
found 0 
to 0 
possess 0 
two 0 
sequence 0 
abnormalities 0 
. 0 

One 0 
allele 0 
carried 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
near 0 
the 0 
donor 0 
splice 0 
junction 0 
of 0 
intron 0 
_NUM1 0 
, 0 
but 0 
this 0 
abnormality 0 
is 0 
probably 0 
neutral 0 
, 0 
since 0 
it 0 
was 0 
inherited 0 
from 0 
the 0 
parent 0 
with 0 
normal 0 
protein 0
S 0 
antigen 0 
levels 0 
. 0 

In 0 
the 0 
other 0 
allele 0 
a 0 
single 0 
T 0 
insertion 0 
in 0 
codon 0 
-25 0 
was 0 
found 0 
. 0 

Analysis 0 
of 0 
platelet 0 
RNA 0 
showed 0 
that 0 
only 0 
the 0 
mRNA 0 
with 0 
the 0 
A 0 
-- 0 
> 0 
T 0 
mutation 0 
in 0 
the 0 
stopcodon 0 
is 0 
present 0 
in 0 
amounts 0 
comparable 0 
to 0 
wildtype 0 
RNA 0 
. 0 

mRNA 0 
from 0 
the 0 
alleles 0 
with 0 
the 0 
other 0 
two 0 
mutations 0 
was 0 
either 0 
undetectable 0 
or 0 
present 0 
in 0 
greatly 0 
reduced 0 
amounts 0 
. 0 

The 0 
latter 0 
indicates 0 
that 0 
a 0 
mRNA 0 
based 0 
approach 0 
is 0 
not 0 
feasible 0 
for 0 
the 0 
genetic 0 
analysis 0 
of 0 
protein 1
S 1
deficiency 1
type 1
I 1
. 0 
. 0 

A 0 
potential 0 
animal 0 
model 0 
for 0 
Lesch-Nyhan 1
syndrome 1
through 0 
introduction 0 
of 0 
HPRT 0 
mutations 0 
into 0 
mice 0 
. 0 

The 0 
human 0 
Lesch-Nyhan 1
syndrome 1
is 0 
a 0 
rare 0 
neurological 1
and 1
behavioural 1
disorder 1
, 0 
affecting 0 
only 0 
males 0 
, 0 
which 0 
is 0 
caused 0 
by 0 
an 0 
inherited 1
deficiency 1
in 0 
the 0 
level 0 
of 0 
activity 0 
of 0 
the 0 
purine 0 
salvage 0 
enzyme 0 
hypoxanthine-guanosine 0 
phosphoribosyl 0 
transferase 0 
-LRB- 0 
HPRT 0 
-RRB- 0 
. 0 

How 0 
the 0 
resulting 0 
alterations 0 
in 0 
purine 0 
metabolism 0 
lead 0 
to 0 
the 0 
severe 0 
symptoms 0 
characteristic 0 
of 0 
Lesch-Nyhan 1
patients 0 
is 0 
still 0 
not 0 
understood 0 
. 0 

No 0 
mutations 0 
at 0 
the 0 
Hprt 0 
locus 0 
leading 0 
to 0 
loss 0 
of 0 
activity 0 
have 0 
been 0 
described 0 
in 0 
laboratory 0 
animals 0 
. 0 

To 0 
derive 0 
an 0 
animal 0 
model 0 
for 0 
the 0 
Lesch-Nyhan 1
syndrome 1
, 0 
we 0 
have 0 
used 0 
cultured 0 
mouse 0 
embryonic 0 
stem 0 
cells 0 
, 0 
mutagenized 0 
by 0 
retroviral 0 
insertion 0 
and 0 
selected 0 
for 0 
loss 0 
of 0 
HPRT 0 
activity 0 
, 0 
to 0 
construct 0 
chimaeric 0 
mice 0 
. 0 

Two 0 
clonal 0 
lines 0 
carrying 0 
different 0 
mutant 0 
Hprt 0 
alleles 0 
have 0 
given 0 
rise 0 
to 0 
germ 0 
cells 0 
in 0 
chimaeras 0 
, 0 
allowing 0 
the 0 
derivation 0 
of 0 
strains 0 
of 0 
mutant 0 
mice 0 
having 0 
the 0 
same 0 
biochemical 0 
defect 0 
as 0 
Lesch-Nyhan 1
patients 0 
. 0 

Male 0 
mice 0 
carrying 0 
the 0 
mutant 0 
alleles 0 
are 0 
viable 0 
and 0 
analysis 0 
of 0 
their 0 
cells 0 
shows 0 
a 0 
total 0 
lack 0 
of 0 
HPRT 0 
activity 0 
. 0 
. 0 

Duplicational 0 
mutation 0 
at 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
locus 0 
: 0 
its 0 
frequency 0 
, 0 
distribution 0 
, 0 
origin 0 
, 0 
and 0 
phenotypegenotype 0 
correlation 0 
. 0 

Partial 0 
gene 0 
deletion 0 
is 0 
the 0 
major 0 
cause 0 
of 0 
mutation 0 
leading 0 
to 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
and 0 
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
BMD 1
-RRB- 0 
. 0 

Partial 0 
gene 0 
duplication 0 
has 0 
also 0 
been 0 
recognized 0 
in 0 
a 0 
few 0 
cases 0 
. 0 

We 0 
have 0 
conducted 0 
a 0 
survey 0 
for 0 
duplication 0 
in 0 
_NUM2 0 
unrelated 0 
nondeletion 0 
patients 0 
, 0 
analyzed 0 
by 0 
Southern 0 
blot 0 
hybridization 0 
with 0 
clones 0 
representing 0 
the 0 
entire 0 
DMD 1
cDNA 0 
. 0 

With 0 
careful 0 
quantitative 0 
analysis 0 
of 0 
hybridization 0 
band 0 
intensity 0 
, 0 
_NUM2 0 
cases 0 
were 0 
found 0 
to 0 
carry 0 
a 0 
duplication 0 
of 0 
part 0 
of 0 
the 0 
gene 0 
, 0 
a 0 
frequency 0 
of 0 
_NUM2 0 
% 0 
for 0 
nondeletion 0 
cases 0 
-LRB- 0 
10 0 
/ 0 
72 0 
-RRB- 0 
, 0 
or 0 
_NUM1 0 
% 0 
for 0 
all 0 
cases 0 
-LRB- 0 
10 0 
/ 0 
181 0 
-RRB- 0 
. 0 

The 0 
extent 0 
of 0 
these 0 
duplications 0 
has 0 
been 0 
characterized 0 
according 0 
to 0 
the 0 
published 0 
exon-containing 0 
HindIII 0 
fragment 0 
map 0 
, 0 
and 0 
in 0 
six 0 
of 0 
the 0 
_NUM2 0 
duplications 0 
a 0 
novel 0 
restriction 0 
fragment 0 
that 0 
spanned 0 
the 0 
duplication 0 
junction 0 
was 0 
detected 0 
. 0 

The 0 
resulting 0 
translational 0 
reading 0 
frame 0 
of 0 
mRNA 0 
has 0 
been 0 
predicted 0 
for 0 
nine 0 
duplications 0 
. 0 

A 0 
shift 0 
of 0 
the 0 
reading 0 
frame 0 
was 0 
predicted 0 
in 0 
four 0 
of 0 
the 0 
six 0 
DMD 1
cases 0 
and 0 
in 0 
one 0 
of 0 
the 0 
two 0 
intermediate 0 
cases 0 
, 0 
while 0 
the 0 
reading 0 
frame 0 
remained 0 
uninterrupted 0 
in 0 
both 0 
BMD 1
cases 0 
. 0 

RFLP 0 
and 0 
quantitative 0 
Southern 0 
blot 0 
analyses 0 
revealed 0 
a 0 
grandpaternal 0 
origin 0 
of 0 
duplication 0 
in 0 
four 0 
families 0 
and 0 
grandmaternal 0 
origin 0 
in 0 
one 0 
family 0 
. 0 

In 0 
all 0 
five 0 
families 0 
, 0 
the 0 
duplication 0 
was 0 
found 0 
to 0 
originate 0 
from 0 
a 0 
single 0 
X 0 
chromosome 0 
. 0 

Unequal 0 
sister-chromatid 0 
exchange 0 
is 0 
proposed 0 
to 0 
be 0 
the 0 
mechanism 0 
for 0 
the 0 
formation 0 
of 0 
these 0 
duplications 0 
. 0 
. 0 

Molecular 0 
evidence 0 
for 0 
new 0 
mutation 0 
at 0 
the 0 
hprt 0 
locus 0 
in 0 
Lesch-Nyhan 1
patients 0 
. 0 

Hypoxanthine-guanine 0 
phosphoribosyltransferase 0 
-LRB- 0 
HPRT 0
; 0 
EC2 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
which 0 
functions 0 
in 0 
the 0 
metabolic 0 
salvage 0 
of 0 
purines 0 
, 0 
is 0 
encoded 0 
by 0 
an 0 
X-linked 0 
gene 0 
in 0 
man 0 
. 0 

Partial 0 
HPRT 1
deficiencies 1
are 0 
associated 0 
with 0 
gouty 1
arthritis 1
, 0 
while 0 
absence 0 
of 0 
activity 0 
results 0 
in 0 
Lesch-Nyhan 1
syndrome 1
-LRB- 0 
L-N 1
-RRB- 0 
. 0 

L-N 1
patients 0 
fail 0 
to 0 
reproduce 0 
and 0 
the 0 
heterozygous 0 
state 0 
appears 0 
to 0 
confer 0 
no 0 
selective 0 
advantage 0 
. 0 

Thus 0 
, 0 
Haldanes 0 
principle 0 
predicts 0 
that 0 
new 0 
mutations 0 
at 0 
the 0 
hprt 0 
locus 0 
must 0 
occur 0 
frequently 0 
in 0 
order 0 
for 0 
L-N 1
syndrome 1
to 0 
be 0 
maintained 0 
in 0 
the 0 
population 0 
. 0 

This 0 
constant 0 
introduction 0 
of 0 
new 0 
mutations 0 
would 0 
be 0 
expected 0 
to 0 
result 0 
in 0 
a 0 
heterogeneous 0 
collection 0 
of 0 
genetic 1
lesions 1
, 0 
some 0 
of 0 
which 0 
may 0 
be 0 
novel 0 
. 0 

As 0 
we 0 
report 0 
here 0 
, 0 
the 0 
mutations 0 
in 0 
the 0 
hprt 0 
gene 0 
of 0 
seven 0 
L-N 1
patients 0 
, 0 
selected 0 
from 0 
an 0 
initial 0 
survey 0 
of 0 
_NUM2 0 
patients 0 
, 0 
have 0 
been 0 
characterized 0 
and 0 
all 0 
were 0 
found 0 
to 0 
be 0 
distinctly 0 
different 0 
, 0 
as 0 
predicted 0 
. 0 

The 0 
origin 0 
of 0 
one 0 
unusual 0 
mutation 0 
has 0 
been 0 
identified 0 
by 0 
analysis 0 
of 0 
DNA 0 
from 0 
four 0 
generations 0 
of 0 
family 0 
members 0 
. 0 

Further 0 
molecular 0 
analysis 0 
of 0 
the 0 
origin 0 
of 0 
new 0 
mutations 0 
at 0 
the 0 
hprt 0 
locus 0 
should 0 
aid 0 
in 0 
resolving 0 
the 0 
issue 0 
of 0 
an 0 
apparent 0 
difference 0 
in 0 
the 0 
frequency 0 
of 0 
hprt 0 
mutations 0 
in 0 
males 0 
and 0 
females 0 
The 0 
mapping 0 
of 0 
a 0 
cDNA 0 
from 0 
the 0 
human 0 
X-linked 1
Duchenne 1
muscular 1
dystrophy 1
gene 0 
to 0 
the 0 
mouse 0 
X 0 
chromosome 0 
. 0 

The 0 
recent 0 
discovery 0 
of 0 
sequences 0 
at 0 
the 0 
site 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
in 0 
humans 0 
has 0 
opened 0 
up 0 
the 0 
possibility 0 
of 0 
a 0 
detailed 0 
molecular 0 
analysis 0 
of 0 
the 0 
genes 0 
in 0 
humans 0 
and 0 
in 0 
related 0 
mammalian 0 
species 0 
. 0 

Until 0 
relatively 0 
recently 0 
, 0 
there 0 
was 0 
no 0 
obvious 0 
mouse 0 
model 0 
of 0 
this 0 
genetic 1
disease 1
for 0 
the 0 
development 0 
of 0 
therapeutic 0 
strategies 0 
. 0 

The 0 
identification 0 
of 0 
a 0 
mouse 0 
X-linked 0 
mutant 0 
showing 0 
muscular 1
dystrophy 1
, 0 
mdx 0 
, 0 
has 0 
provided 0 
a 0 
candidate 0 
mouse 0 
genetic 0 
homologue 0 
to 0 
the 0 
DMD 1
locus 0 
; 0 
the 0 
relatively 0 
mild 0 
pathological 0 
features 0 
of 0 
mdx 0 
suggest 0 
it 0 
may 0 
have 0 
more 0 
in 0 
common 0 
with 0 
mutations 0 
of 0 
the 0 
Becker 1
muscular 1
dystrophy 1
type 0 
at 0 
the 0 
same 0 
human 0 
locus 0 
, 0 
however 0 
. 0 

But 0 
the 0 
close 0 
genetic 0 
linkage 0 
of 0 
mdx 0 
to 0 
G6PD 0 
and 0 
Hprt 0 
on 0 
the 0 
mouse 0 
X 0 
chromosome 0 
, 0 
coupled 0 
with 0 
its 0 
comparatively 0 
mild 0 
pathology 0 
, 0 
have 0 
suggested 0 
that 0 
the 0 
mdx 0 
mutation 0 
may 0 
instead 0 
correspond 0 
to 0 
Emery 1
Dreifuss 1
muscular 1
dystrophy 1
which 0 
itself 0 
is 0 
closely 0 
linked 0 
to 0 
DNA 0 
markers 0 
at 0 
Xq28-qter 0 
in 0 
the 0 
region 0 
of 0 
G6PD 0 
on 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 

Using 0 
an 0 
interspecific 0 
mouse 0 
domesticus 0 
/ 0 
spretus 0 
cross 0 
, 0 
segregating 0 
for 0 
a 0 
variety 0 
of 0 
markers 0 
on 0 
the 0 
mouse 0 
X 0 
chromosome 0 
, 0 
we 0 
have 0 
positioned 0 
on 0 
the 0 
mouse 0 
X 0 
chromosome 0 
sequences 0 
homologous 0 
to 0 
a 0 
DMD 1
cDNA 0 
clone 0 
. 0 

These 0 
sequences 0 
map 0 
provocatively 0 
close 0 
to 0 
the 0 
mdx 0 
mutation 0 
and 0 
unexpectedly 0 
distant 0 
from 0 
sparse 0 
fur 0 
, 0 
spf 0 
, 0 
the 0 
mouse 0 
homologue 0 
of 0 
OTC 0 
-LRB- 0 
ornithine 0 
transcarbamylase 0 
-RRB- 0 
which 0 
is 0 
closely 0 
linked 0 
to 0 
DMD 1
on 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 
. 0 

Identification 0 
of 0 
the 0 
mutation 0 
in 0 
the 0 
alkaptonuria 1
mouse 0 
model 0 
. 0 

Alkaptonuria 1
-LRB- 0 
aku 1
-RRB- 0 
, 0 
an 0 
inborn 1
error 1
of 1
metabolism 1
caused 0 
by 0 
the 0 
loss 0 
of 0 
homogentisate 0 
_NUM1 0 
, 0 
2-dioxygenase 0 
-LRB- 0 
HGD 0 
-RRB- 0 
, 0 
has 0 
been 0 
described 0 
in 0 
a 0 
mouse 0 
model 0 
created 0 
by 0 
ethylnitrosourea 0 
mutagenesis 0 
but 0 
the 0 
mutation 0 
in 0 
these 0 
mice 0 
has 0 
not 0 
previously 0 
been 0 
identified 0 
. 0 

We 0 
used 0 
RT-PCR 0 
to 0 
amplify 0 
the 0 
Hgd 0 
cDNA 0 
from 0 
Hgd 0 
-LRB- 0 
aku 0 
-RRB- 0 
/ 0 
Hgd 0 
-LRB- 0 
aku 0 
-RRB- 0 
mice 0 
. 0 

Two 0 
products 0 
shorter 0 
than 0 
the 0 
wild-type 0 
product 0 
were 0 
amplified 0 
. 0 

Restriction 0 
mapping 0 
and 0 
DNA 0 
sequencing 0 
were 0 
then 0 
used 0 
to 0 
identify 0 
the 0 
Hgd 0 
-LRB- 0 
aku 0 
-RRB- 0 
mouse 0 
mutation 0 
, 0 
found 0 
to 0 
be 0 
a 0 
single 0 
base 0 
change 0 
in 0 
a 0 
splice 0 
donor 0 
consensus 0 
sequence 0 
, 0 
causing 0 
exon 0 
skipping 0 
and 0 
frame-shifted 0 
products 0 
. 0 

This 0 
base 0 
change 0 
allowed 0 
us 0 
to 0 
create 0 
a 0 
non-radioactive 0 
genotyping 0 
assay 0 
for 0 
this 0 
allele 0 
. 0 

Common 0 
sequence 0 
motifs 0 
at 0 
the 0 
rearrangement 0 
sites 0 
of 0 
a 0 
constitutional 0 
X 0 
/ 0 
autosome 0 
translocation 0 
and 0 
associated 0 
deletion 0 
. 0 

Reciprocal 0 
chromosome 0 
translocations 0 
are 0 
common 0 
de 0 
novo 0 
rearrangements 0 
that 0 
occur 0 
randomly 0 
throughout 0 
the 0 
human 0 
genome 0 
. 0 

To 0 
learn 0 
about 0 
causative 0 
mechanisms 0 
, 0 
we 0 
have 0 
cloned 0 
and 0 
sequenced 0 
the 0 
breakpoints 0 
of 0 
a 0 
cytologically 0 
balanced 0 
constitutional 0 
reciprocal 0 
translocation 0 
, 0 
t 0 
-LRB- 0 
X 0 
; 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

_NUM1 0 
; 0 
_AN 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
present 0 
in 0 
a 0 
girl 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

Physical 0 
mapping 0 
of 0 
the 0 
derivative 0 
chromosomes 0 
, 0 
after 0 
their 0 
separation 0 
in 0 
somatic 0 
cell 0 
hybrids 0 
, 0 
reveals 0 
that 0 
the 0 
translocation 0 
disrupts 0 
the 0 
DMD 1
gene 0 
in 0 
Xp21 0 
within 0 
the 0 
18-kb 0 
intron 0 
_NUM2 0 
. 0 

Restriction 0 
mapping 0 
and 0 
sequencing 0 
of 0 
clones 0 
that 0 
span 0 
both 0 
translocation 0 
breakpoints 0 
as 0 
well 0 
as 0 
the 0 
corresponding 0 
normal 0 
regions 0 
indicate 0 
the 0 
loss 0 
of 0 
approximately 0 
_NUM1 0 
kb 0 
in 0 
the 0 
formation 0 
of 0 
the 0 
derivative 0 
X 0 
chromosome 0 
, 0 
with 0 
4-6 0 
bp 0 
deleted 0 
from 0 
chromosome 0 
_NUM1 0 
. 0 

RFLP 0 
and 0 
Southern 0 
analyses 0 
indicate 0 
that 0 
the 0 
de 0 
novo 0 
translocation 0 
is 0 
a 0 
paternal 0 
origin 0 
and 0 
that 0 
the 0 
fathers 0 
X 0 
chromosome 0 
contains 0 
the 0 
DNA 0 
that 0 
is 0 
deleted 0 
in 0 
the 0 
derivative 0 
X. 0 
Most 0 
likely 0 
, 0 
deletion 0 
and 0 
translation 0 
arose 0 
simultaneously 0 
from 0 
a 0 
complex 0 
rearrangement 0 
event 0 
that 0 
involves 0 
three 0 
chromosomal 0 
breakpoints 0 
. 0 

Short 0 
regions 0 
of 0 
sequence 0 
homology 0 
were 0 
present 0 
at 0 
the 0 
three 0 
sites 0 
. 0 

A 0 
5-bp 0 
sequence 0 
, 0 
_DS 0 
, 0 
found 0 
exactly 0 
at 0 
the 0 
translocation 0 
breakpoints 0 
on 0 
both 0 
normal 0 
chromosomes 0 
X 0 
and 0 
_NUM1 0 
, 0 
has 0 
been 0 
preserved 0 
only 0 
on 0 
the 0 
der 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
chromosome 0 
. 0 

It 0 
is 0 
likely 0 
that 0 
the 0 
X-derived 0 
sequence 0 
_DS 0 
has 0 
been 0 
lost 0 
in 0 
the 0 
formation 0 
of 0 
the 0 
der 0 
-LRB- 0 
X 0 
-RRB- 0 
chromosome 0 
, 0 
as 0 
it 0 
matches 0 
an 0 
inverted 0 
_DS 0 
sequence 0 
present 0 
on 0 
the 0 
opposite 0 
strand 0 
exactly 0 
at 0 
the 0 
other 0 
end 0 
of 0 
the 0 
deleted 0 
5-kb 0 
fragment 0 
. 0 

The 0 
human 0 
factor 0 
IX 0 
gene 0 
as 0 
germline 0 
mutagen 0 
test 0 
: 0 
samples 0 
from 0 
Mainland 0 
China 0 
have 0 
the 0 
putatively 0 
endogenous 0 
pattern 0 
of 0 
mutation 0 
. 0 

Germline 0 
mutations 0 
are 0 
the 0 
major 0 
source 0 
of 0 
genetic 0 
variation 0 
that 0 
allows 0 
a 0 
species 0 
to 0 
evolve 0 
over 0 
time 0 
but 0 
at 0 
the 0 
cost 0 
of 0 
Mendelian 1
disease 1
and 0 
genetic 0 
predisposition 0 
to 0 
multifactorial 1
diseases 1
. 0 

Previous 0 
analyses 0 
have 0 
revealed 0 
that 0 
the 0 
pattern 0 
of 0 
germline 0 
mutations 0 
in 0 
the 0 
factor 0 
IX 0 
gene 0 
-LRB- 0 
F9 0 
-RRB- 0 
is 0 
similar 0 
among 0 
a 0 
variety 0 
of 0 
ethnically 0 
and 0 
geographically 0 
diverse 0 
populations 0 
and 0 
compatible 0 
with 0 
the 0 
ancient 0 
pattern 0 
that 0 
has 0 
shaped 0 
the 0 
mammalian 0 
genome 0 
. 0 

Here 0 
, 0 
we 0 
compare 0 
the 0 
pattern 0 
of 0 
germline 0 
mutation 0 
in 0 
a 0 
population 0 
of 0 
hemophilia 1
B 1
patients 0 
from 0 
Mainland 0 
China 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
to 0 
that 0 
in 0 
U. 0 
S. 0 
Caucasians 0 
, 0 
Blacks 0 
, 0 
and 0 
Mexican 0 
Hispanics 0 
and 0 
stratify 0 
by 0 
disease 0 
severity 0 
and 0 
ethnicity 0 
. 0 

The 0 
similar 0 
pattern 0 
of 0 
germline 0 
mutation 0 
in 0 
all 0 
ethnic 0 
groups 0 
studied 0 
to 0 
date 0 
provides 0 
additional 0 
data 0 
compatible 0 
with 0 
the 0 
inference 0 
that 0 
endogenous 0 
processes 0 
predominate 0 
in 0 
germline 0 
mutations 0 
. 0 

Phenotype 0 
heterogeneity 0 
among 0 
hemizygotes 0 
in 0 
a 0 
family 0 
biochemically 0 
screened 0 
for 0 
adrenoleukodystrophy 1
. 0 

We 0 
report 0 
on 0 
two 0 
clinically 0 
, 0 
neurologically 0 
normal 0 
relatives 0 
of 0 
a 0 
boy 0 
affected 0 
by 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
; 0 
they 0 
were 0 
found 0 
repeatedly 0 
to 0 
have 0 
the 0 
biochemical 0 
defect 0 
of 0 
an 0 
ALD 1
hemizygote 0 
. 0 

The 0 
assay 0 
consisted 0 
in 0 
the 0 
determination 0 
of 0 
very-long-chain 0 
fatty 0 
acids 0 
in 0 
lyophilized 0 
and 0 
reconstituted 0 
plasma 0 
. 0 

While 0 
no 0 
evidence 0 
of 0 
neurologic 1
disease 1
-LRB- 0 
leukodystrophy 1
or 0 
myeloneuropathy 1
-RRB- 0 
was 0 
present 0 
in 0 
these 0 
hemizygotes 0 
, 0 
adrenocortical 1
insufficiency 1
provoking 0 
compensatory 0 
high 0 
ACTH 0 
release 0 
was 0 
found 0 
in 0 
both 0 
. 0 

These 0 
findings 0 
should 0 
be 0 
taken 0 
into 0 
consideration 0 
when 0 
counseling 0 
families 0 
in 0 
which 0 
cases 0 
with 0 
clinically 0 
expressed 0 
ALD 1
are 0 
represented 0 
in 0 
several 0 
generations 0 
. 0 
. 0 

Novel 0 
mutations 0 
of 0 
the 0 
ATP7B 0 
gene 0 
in 0 
Japanese 0 
patients 0 
with 0 
Wilson 1
disease 1
. 0 

Wilson 1
disease 1
-LRB- 0 
WD 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
copper 0 
accumulation 0 
in 0 
the 0 
liver 0 
, 0 
brain 0 
, 0 
kidneys 0 
, 0 
and 0 
corneas 0 
, 0 
and 0 
culminating 0 
in 0 
copper 0 
toxication 0 
in 0 
these 0 
organs 0 
. 0 

In 0 
this 0 
study 0 
, 0 
we 0 
analyzed 0 
mutations 0 
of 0 
the 0 
responsible 0 
gene 0 
, 0 
ATP7B 0 
, 0 
in 0 
four 0 
Japanese 0 
patients 0 
with 0 
WD 1
. 0 

By 0 
direct 0 
sequencing 0 
, 0 
we 0 
identified 0 
five 0 
mutations 0 
, 0 
of 0 
which 0 
two 0 
were 0 
novel 0 
, 0 
and 0 
_NUM2 0 
polymorphisms 0 
, 0 
of 0 
which 0 
_NUM1 0 
were 0 
novel 0 
. 0 

The 0 
mutations 0 
2871delC 0 
and 0 
2513delA 0 
shift 0 
the 0 
reading 0 
frame 0 
so 0 
that 0 
truncated 0 
abnormal 0 
protein 0 
is 0 
expected 0 
. 0 

In 0 
contrast 0 
to 0 
these 0 
mutations 0 
found 0 
in 0 
patients 0 
with 0 
hepatic-type 0 
of 0 
early 0 
onset 0 
, 0 
the 0 
mutations 0 
A874V 0 
, 0 
R778L 0 
, 0 
and 0 
3892delGTC 0 
were 0 
either 0 
missense 0 
mutations 0 
or 0 
in 0 
frame 0 
1-amino 0 
acid 0 
deletion 0 
, 0 
and 0 
occurred 0 
in 0 
the 0 
patients 0 
with 0 
hepato-neurologic 0 
type 0 
of 0 
late 0 
onset 0 
. 0 

The 0 
mutations 0 
2871delC 0 
and 0 
R778L 0 
have 0 
been 0 
previously 0 
reported 0 
in 0 
a 0 
relatively 0 
large 0 
number 0 
of 0 
Japanese 0 
patients 0 
. 0 

In 0 
particular 0 
, 0 
R778L 0 
is 0 
known 0 
to 0 
be 0 
more 0 
prevalent 0 
in 0 
Asian 0 
countries 0 
than 0 
in 0 
other 0 
countries 0 
of 0 
the 0 
world 0 
. 0 

Our 0 
data 0 
are 0 
compatible 0 
with 0 
the 0 
hypothesis 0 
that 0 
the 0 
mutations 0 
tend 0 
to 0 
occur 0 
in 0 
a 0 
population-specific 0 
manner 0 
. 0 

Therefore 0 
, 0 
the 0 
accumulation 0 
of 0 
the 0 
types 0 
of 0 
mutations 0 
in 0 
Japanese 0 
patients 0 
with 0 
WD 1
will 0 
facilitate 0 
the 0 
fast 0 
and 0 
effective 0 
genetic 0 
diagnosis 0 
of 0 
WD 1
in 0 
Japanese 0 
patients 0 
. 0 
. 0 

Structural 0 
analysis 0 
of 0 
the 0 
_NUM1 0 
' 0 
region 0 
of 0 
mouse 0 
and 0 
human 0 
Huntington 1
disease 1
genes 0 
reveals 0 
conservation 0 
of 0 
putative 0 
promoter 0 
region 0 
and 0 
di 0 
- 0 
and 0 
trinucleotide 0 
polymorphisms 0 
. 0 

We 0 
have 0 
previously 0 
cloned 0 
and 0 
characterized 0 
the 0 
murine 0 
homologue 0 
of 0 
the 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
gene 0 
and 0 
shown 0 
that 0 
it 0 
maps 0 
to 0 
mouse 0 
chromosome 0 
_NUM1 0 
within 0 
a 0 
region 0 
of 0 
conserved 0 
synteny 0 
with 0 
human 0 
chromosome 0 
4p16 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

Here 0 
we 0 
present 0 
a 0 
detailed 0 
comparison 0 
of 0 
the 0 
sequence 0 
of 0 
the 0 
putative 0 
promoter 0 
and 0 
the 0 
organization 0 
of 0 
the 0 
_NUM1 0 
genomic 0 
region 0 
of 0 
the 0 
murine 0 
-LRB- 0 
Hdh 0 
-RRB- 0 
and 0 
human 0 
HD 1
genes 0 
encompassing 0 
the 0 
first 0 
five 0 
exons 0 
. 0 

We 0 
show 0 
that 0 
in 0 
this 0 
region 0 
these 0 
two 0 
genes 0 
share 0 
identical 0 
exon 0 
boundaries 0 
, 0 
but 0 
have 0 
different-size 0 
introns 0 
. 0 

Two 0 
dinucleotide 0 
-LRB- 0 
_DS 0 
-RRB- 0 
and 0 
one 0 
trinucleotide 0 
intronic 0 
polymorphism 0 
in 0 
Hdh 0 
and 0 
an 0 
intronic 0 
_DS 0 
polymorphism 0 
in 0 
the 0 
HD 1
gene 0 
were 0 
identified 0 
. 0 

Comparison 0 
of 0 
940-bp 0 
sequence 0 
_NUM1 0 
to 0 
the 0 
putative 0 
translation 0 
start 0 
site 0 
reveals 0 
a 0 
highly 0 
conserved 0 
region 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
nucleotide 0 
identity 0 
-RRB- 0 
between 0 
Hdh 0 
and 0 
the 0 
HD 1
gene 0 
from 0 
nucleotide 0 
-56 0 
to 0 
-206 0 
-LRB- 0 
of 0 
Hdh 0 
-RRB- 0 
. 0 

Neither 0 
Hdh 0 
nor 0 
the 0 
HD 1
gene 0 
have 0 
typical 0 
_DS 0 
or 0 
_DS 0 
elements 0 
, 0 
but 0 
both 0 
show 0 
one 0 
putative 0 
AP2 0 
binding 0 
site 0 
and 0 
numerous 0 
potential 0 
Sp1 0 
binding 0 
sites 0 
. 0 

The 0 
high 0 
sequence 0 
identity 0 
between 0 
Hdh 0 
and 0 
the 0 
HD 1
gene 0 
for 0 
approximately 0 
_NUM3 0 
bp 0 
_NUM1 0 
to 0 
the 0 
putative 0 
translation 0 
start 0 
site 0 
indicates 0 
that 0 
these 0 
sequences 0 
may 0 
play 0 
a 0 
role 0 
in 0 
regulating 0 
expression 0 
of 0 
the 0 
Huntington 1
disease 1
gene 0 
Complement 1
deficiency 1
and 0 
nephritis 1
. 0 

A 0 
report 0 
of 0 
a 0 
family 0 
. 0 

A 0 
family 0 
is 0 
described 0 
in 0 
which 0 
three 0 
children 0 
had 0 
homozygous 0 
deficiency 1
of 1
C3 1
and 0 
in 0 
which 0 
both 0 
parents 0 
and 0 
two 0 
other 0 
children 0 
were 0 
heterozygous 0 
for 0 
the 0 
C3 0
null 0 
gene 0 
. 0 

One 0 
child 0 
with 0 
heterozygous 0 
C3 1
deficiency 1
was 0 
found 0 
to 0 
have 0 
membranoproliferative 0 
glomerulonephritis 1
; 0 
proteinuria 1
and 0 
/ 0 
or 0 
microscopical 0 
haematuria 1
was 0 
present 0 
in 0 
all 0 
three 0 
homozygous 0 
C3-deficient 1
children 0 
. 0 

All 0 
children 0 
with 0 
homozygous 0 
or 0 
heterozygous 0 
C3 1
deficiency 1
were 0 
, 0 
to 0 
a 0 
varying 0 
degree 0 
, 0 
susceptible 0 
to 0 
infection 0 
. 0 

The 0 
only 0 
child 0 
of 0 
the 0 
family 0 
with 0 
normal 0 
complement 0 
had 0 
no 0 
increased 0 
risk 0 
of 0 
infection 0 
and 0 
no 0 
renal 1
disease 1
. 0 

This 0 
family 0 
study 0 
provides 0 
further 0 
support 0 
for 0 
the 0 
proposal 0 
that 0 
C3 1
deficiency 1
predisposes 0 
to 0 
nephritis 1
. 0 
. 0 

Cytogenetic 0 
investigations 0 
in 0 
families 0 
with 0 
ataxia-telangiectasia 1
. 0 

Chromosomal 0 
studies 0 
were 0 
performed 0 
on 0 
peripheral 0 
blood 0 
lymphocytes 0 
and 0 
cultured 0 
skin 0 
fibroblasts 0 
from 0 
five 0 
Israeli-Moroccan 0 
families 0 
with 0 
ataxia-telangiectasia 1
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
individuals 0 
, 0 
including 0 
seven 0 
propositi 0 
, 0 
was 0 
investigated 0 
. 0 

Among 0 
the 0 
probands 0 
, 0 
significantly 0 
elevated 0 
rates 0 
of 0 
chromosome 0 
damage 0 
were 0 
observed 0 
in 0 
both 0 
blood 0 
and 0 
skin 0 
. 0 

Skin 0 
fibroblasts 0 
of 0 
affected 0 
individuals 0 
showed 0 
several 0 
orders 0 
of 0 
magnitude 0 
more 0 
chromosome 0 
breakage 0 
than 0 
lymphocytes 0 
. 0 

Increased 0 
rates 0 
of 0 
chromosome 0 
damage 0 
were 0 
also 0 
observed 0 
in 0 
the 0 
fibroblasts 0 
of 0 
some 0 
phenotypically 0 
normal 0 
family 0 
members 0 
-LRB- 0 
obligate 0 
heterozygotes 0 
and 0 
sibs 0 
-RRB- 0 
when 0 
compared 0 
to 0 
normal 0 
controls 0 
. 0 

An 0 
apparent 0 
abnormal 0 
clone 0 
of 0 
cells 0 
, 0 
possessing 0 
a 0 
large 0 
acrocentric 0 
marker 0 
chromosome 0 
-LRB- 0 
14q 0 
+ 0 
-RRB- 0 
, 0 
was 0 
observed 0 
in 0 
varying 0 
proportions 0 
among 0 
cells 0 
of 0 
all 0 
the 0 
propositi 0 
-LRB- 0 
2-5 0 
% 0 
of 0 
lymphocytes 0 
; 0 
1-9 0 
% 0 
of 0 
fibroblasts 0 
-RRB- 0 
. 0 
. 0 

Predominance 0 
of 0 
the 0 
adrenomyeloneuropathy 1
phenotype 0 
of 0 
X-linked 1
adrenoleukodystrophy 1
in 0 
The 0 
Netherlands 0 
: 0 
a 0 
survey 0 
of 0 
_NUM2 0 
kindreds 0 
. 0 

X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
X-ALD 1
-RRB- 0 
is 0 
an 0 
inherited 1
disorder 1
of 0 
peroxisomal 0 
beta-oxidation 0 
associated 0 
with 0 
accumulation 0 
of 0 
saturated 0 
very 0 
long-chain 0 
fatty 0 
acids 0 
, 0 
which 0 
results 0 
in 0 
central 0 
and 0 
peripheral 0 
demyelination 1
and 0 
in 0 
impaired 1
function 1
of 1
adrenal 1
cortex 1
and 1
testes 1
. 0 

The 0 
phenotypic 0 
expression 0 
is 0 
highly 0 
variable 0 
, 0 
childhood 1
cerebral 1
ALD 1
-LRB- 0 
CCALD 1
-RRB- 0 
and 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
being 0 
the 0 
main 0 
variants 0 
. 0 

We 0 
explored 0 
the 0 
_NUM2 0 
Dutch 0 
kindreds 0 
well 0 
known 0 
to 0 
the 0 
Dutch 0 
X-ALD 1
/ 0 
AMN 1
Study 0 
Group 0 
and 0 
phenotyped 0 
_NUM2 0 
male 0 
patients 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
had 0 
AMN 1
and 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
CCALD 1
or 0 
adolescent 1
cerebral 1
ALD 1
-LRB- 0 
AdolCALD 1
-RRB- 0 
. 0 

These 0 
percentages 0 
differ 0 
significantly 0 
from 0 
previous 0 
reports 0 
, 0 
in 0 
which 0 
_NUM2 0 
to 0 
_NUM2 0 
% 0 
of 0 
the 0 
patients 0 
developed 0 
AMN 1
and 0 
_NUM2 0 
to 0 
_NUM2 0 
% 0 
CCALD 1
or 0 
AdolCALD 1
. 0 

Our 0 
findings 0 
indicate 0 
that 0 
-- 0 
at 0 
least 0 
in 0 
the 0 
Netherlands 0 
-- 0 
AMN 1
may 0 
be 0 
the 0 
most 0 
frequent 0 
phenotype 0 
of 0 
X-ALD 1
. 0 
. 0 

Three 0 
novel 0 
aniridia 1
mutations 0 
in 0 
the 0 
human 0 
PAX6 0 
gene 0 
. 0 

Aniridia 1
-LRB- 0 
iris 1
hypoplasia 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
congenital 1
disorder 1
of 1
the 1
eye 1
. 0 

Mutations 0 
in 0 
the 0 
human 0 
aniridia 1
-LRB- 0 
PAX6 0 
-RRB- 0 
gene 0 
have 0 
now 0 
been 0 
identified 0 
in 0 
many 0 
patients 0 
from 0 
various 0 
ethnic 0 
groups 0 
. 0 

In 0 
the 0 
study 0 
reported 0 
here 0 
we 0 
describe 0 
PAX6 0 
mutations 0 
in 0 
one 0 
sporadic 0 
and 0 
five 0 
familial 0 
cases 0 
with 0 
aniridia 1
. 0 

Of 0 
the 0 
four 0 
different 0 
mutations 0 
identified 0 
, 0 
one 0 
was 0 
identical 0 
to 0 
a 0 
previously 0 
reported 0 
mutation 0 
-LRB- 0 
C 0 
-- 0 
> 0 
T 0 
transition 0 
at 0 
codon 0 
_NUM3 0 
-RRB- 0 
, 0 
and 0 
three 0 
were 0 
novel 0 
two 0 
in 0 
the 0 
glycine-rich 0 
region 0 
and 0 
one 0 
in 0 
the 0 
proline 0 
/ 0 
serine 0 
/ 0 
threonine-rich 0 
-LRB- 0 
PST 0 
-RRB- 0 
region 0 
. 0 

One 0 
PAX6 0 
mutation 0 
found 0 
in 0 
the 0 
PST 0 
region 0 
was 0 
associated 0 
with 0 
cataracts 1
in 0 
an 0 
aniridia 1
family 0 
. 0 

Another 0 
splice 0 
mutation 0 
in 0 
the 0 
PST 0 
domain 0 
occurred 0 
in 0 
an 0 
aniridia 1
patient 0 
with 0 
anosmia 1
-LRB- 0 
inability 0 
to 0 
smell 0 
-RRB- 0 
. 0 

The 0 
six 0 
new 0 
aniridia 1
cases 0 
reported 0 
here 0 
have 0 
mutations 0 
predicted 0 
to 0 
generate 0 
incomplete 0 
PAX6 0 
proteins 0 
. 0 

These 0 
results 0 
support 0 
the 0 
theory 0 
that 0 
human 0 
aniridia 1
is 0 
caused 0 
by 0 
haploinsufficiency 1
of 1
PAX6 1
. 0 
. 0 

Hepatoblastoma 1
, 0 
pigmented 1
ocular 1
fundus 1
lesions 1
and 0 
jaw 1
lesions 1
in 0 
Gardner 1
syndrome 1
. 0 

Hepatoblastoma 1
is 0 
a 0 
rare 0 
neoplasm 1
of 0 
infants 0 
and 0 
children 0 
only 0 
recently 0 
documented 0 
in 0 
association 0 
with 0 
hereditary 1
adenomatous 1
polyposis 1
of 1
the 1
colon 1
-LSB- 0 
Kingston 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RSB- 0 
. 0 

We 0 
report 0 
four 0 
children 0 
with 0 
hepatoblastoma 1
from 0 
four 0 
unrelated 0 
families 0 
with 0 
Gardner 1
syndrome 1
-LRB- 0 
GS 1
-RRB- 0 
. 0 

One 0 
child 0 
, 0 
now 0 
_NUM2 0 
years 0 
old 0 
, 0 
survived 0 
after 0 
a 0 
resection 0 
of 0 
a 0 
hepatoblastoma 1
in 0 
infancy 0 
and 0 
recently 0 
was 0 
found 0 
to 0 
have 0 
GS 1
. 0 

He 0 
has 0 
an 0 
associated 0 
odontoma 1
and 0 
pigmented 1
ocular 1
fundus 1
lesions 1
, 0 
both 0 
of 0 
which 0 
have 0 
been 0 
shown 0 
to 0 
be 0 
clinical 0 
markers 0 
of 0 
GS 1
. 0 

Many 0 
individuals 0 
in 0 
these 0 
four 0 
GS 1
families 0 
, 0 
both 0 
affected 0 
and 0 
at 0 
risk 0 
, 0 
have 0 
osteomatous 1
jaw 1
lesions 1
and 0 
pigmented 1
ocular 1
fundus 1
lesions 1
. 0 

A 0 
search 0 
for 0 
colonic 1
polyps 1
should 0 
be 0 
made 0 
in 0 
families 0 
of 0 
infants 0 
and 0 
children 0 
with 0 
hepatoblastoma 1
. 0 

If 0 
the 0 
child 0 
survives 0 
, 0 
he 0 
or 0 
she 0 
should 0 
be 0 
monitored 0 
for 0 
the 0 
later 0 
appearance 0 
of 0 
colonic 1
polyps 1
. 0 

The 0 
finding 0 
of 0 
jaw 1
lesions 1
and 0 
/ 0 
or 0 
pigmented 1
ocular 1
fundus 1
lesions 1
in 0 
relatives 0 
at 0 
risk 0 
are 0 
indications 0 
of 0 
the 0 
possible 0 
presence 0 
of 0 
the 0 
GS 1
gene 0 
. 0 

Mutation 0 
spectrum 0 
in 0 
the 0 
CHM 1
gene 0 
of 0 
Danish 0 
and 0 
Swedish 0 
choroideremia 1
patients 0 
. 0 

The 0 
recent 0 
isolation 0 
of 0 
the 0 
complete 0 
open 0 
reading 0 
frame 0 
of 0 
the 0 
choroideremia 1
-LRB- 0 
CHM 1
-RRB- 0 
gene 0 
and 0 
the 0 
characterization 0 
of 0 
the 0 
exon-intron 0 
boundaries 0 
has 0 
paved 0 
the 0 
way 0 
to 0 
mutation 0 
detection 0 
in 0 
patients 0 
with 0 
classical 0 
choroideremia 1
. 0 

We 0 
have 0 
performed 0 
mutation 0 
screening 0 
in 0 
patients 0 
from 0 
_NUM2 0 
Danish 0 
and 0 
Swedish 0 
families 0 
by 0 
using 0 
Southern 0 
blot 0 
hybridization 0 
and 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
PCR-SSCP 0 
-RRB- 0 
technique 0 
. 0 

Causative 0 
mutations 0 
in 0 
the 0 
CHM 1
gene 0 
were 0 
detected 0 
in 0 
at 0 
least 0 
_NUM2 0 
families 0 
, 0 
indicating 0 
that 0 
a 0 
substantial 0 
part 0 
of 0 
the 0 
mutations 0 
can 0 
be 0 
identified 0 
by 0 
this 0 
approach 0 
. 0 

In 0 
four 0 
of 0 
these 0 
families 0 
deletions 0 
of 0 
different 0 
sizes 0 
were 0 
found 0 
. 0 

Thus 0 
, 0 
in 0 
one 0 
patient 0 
, 0 
the 0 
deletion 0 
resulted 0 
in 0 
the 0 
absence 0 
of 0 
only 0 
one 0 
exon 0 
, 0 
while 0 
in 0 
another 0 
the 0 
deletion 0 
comprised 0 
the 0 
entire 0 
CHM 1
gene 0 
. 0 

Mapping 0 
of 0 
the 0 
deletion 0 
endpoints 0 
in 0 
these 0 
four 0 
patients 0 
and 0 
in 0 
another 0 
_NUM2 0 
male 0 
patients 0 
with 0 
sizeable 0 
deletions 0 
enabled 0 
us 0 
to 0 
construct 0 
a 0 
very 0 
detailed 0 
map 0 
of 0 
intervals 0 
_NUM1 0 
and 0 
_NUM1 0 
of 0 
Xq21 0 
. 0 

In 0 
the 0 
remaining 0 
_NUM2 0 
Danish 0 
and 0 
Swedish 0 
families 0 
at 0 
least 0 
_NUM1 0 
causative 0 
mutations 0 
were 0 
found 0 
by 0 
PCR-SSCP 0 
analysis 0 
and 0 
direct 0 
sequencing 0 
. 0 

Interestingly 0 
, 0 
all 0 
CHM 1
gene 0 
mutations 0 
detected 0 
thus 0 
far 0 
in 0 
choroideremia 1
patients 0 
give 0 
rise 0 
to 0 
the 0 
introduction 0 
of 0 
a 0 
premature 0 
stop 0 
codon 0 
. 0 
. 0 

Diverse 0 
point 0 
mutations 0 
result 0 
in 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
polymorphism 0 
in 0 
Taiwan 0 
. 0 

Glucose-6-PHOSPHATE 1
dehydrogenase 1
-LRB- 1
G6PD 1
; 1
EC 1
-RRB- 1
deficiency 1
is 0 
the 0 
most 0 
common 0 
human 0 
enzymopathy 1
, 0 
affecting 0 
more 0 
than 0 
_NUM3 0 
million 0 
people 0 
worldwide 0 
. 0 

Although 0 
greater 0 
than 0 
_NUM3 0 
variants 0 
have 0 
been 0 
described 0 
based 0 
on 0 
clinical 0 
and 0 
biochemical 0 
criteria 0 
, 0 
little 0 
is 0 
known 0 
about 0 
the 0 
molecular 0 
basis 0 
of 0 
these 0 
G6PD 1
deficiencies 1
. 0 

Recently 0 
, 0 
the 0 
gene 0 
that 0 
encodes 0 
human 0 
G6PD 0
has 0 
been 0 
cloned 0 
and 0 
sequenced 0 
, 0 
which 0 
enables 0 
us 0 
to 0 
examine 0 
directly 0 
the 0 
heterogeneity 0 
of 0 
G6PD 0
at 0 
the 0 
DNA 0 
level 0 
. 0 

During 0 
the 0 
past 0 
_NUM2 0 
years 0 
, 0 
we 0 
examined 0 
the 0 
G6PD 0
activity 0 
in 0 
_NUM2 0 
, 0 
_NUM3 0 
newborn 0 
Chinese 0 
infants 0 
-LRB- 0 
_NUM2 0 
, 0 
_NUM3 0 
males 0 
and 0 
_NUM1 0 
, 0 
_NUM3 0 
females 0 
-RRB- 0 
and 0 
identified 0 
_NUM3 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
males 0 
and 0 
_NUM3 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
females 0 
having 0 
low 0 
G6PD 0
activity 0 
. 0 

The 0 
G6PD 0
gene 0 
from 0 
_NUM2 0 
randomly 0 
selected 0 
affected 0 
individuals 0 
and 0 
their 0 
relatives 0 
was 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
amplified 0 
, 0 
subcloned 0 
, 0 
and 0 
sequenced 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
at 0 
least 0 
four 0 
types 0 
of 0 
mutation 0 
are 0 
responsible 0 
for 0 
the 0 
G6PD 0
polymorphism 0 
in 0 
Taiwan 0 
. 0 

The 0 
first 0 
type 0 
of 0 
mutation 0 
-LRB- 0 
_NUM3 0 
G 0 
-- 0 
A 0 
-RRB- 0 
was 0 
found 0 
in 0 
an 0 
affected 0 
Chinese 0 
with 0 
a 0 
G 0 
to 0 
A 0 
change 0 
at 0 
nucleotide 0 
_NUM3 0 
, 0 
which 0 
results 0 
in 0 
a 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Gly 0 
to 0 
Ser 0 
substitution 0 
. 0 

The 0 
second 0 
type 0 
of 0 
mutation 0 
-LRB- 0 
_NUM3 0 
A 0 
-- 0 
G 0 
-RRB- 0 
is 0 
a 0 
novel 0 
mutation 0 
that 0 
has 0 
not 0 
been 0 
reported 0 
in 0 
any 0 
other 0 
ethnic 0 
group 0 
and 0 
was 0 
identified 0 
in 0 
two 0 
affected 0 
Chinese 0 
. 0 

This 0 
mutation 0 
causes 0 
an 0 
A 0 
to 0 
G 0 
change 0 
at 0 
nucleotide 0 
position 0 
_NUM3 0 
, 0 
producing 0 
an 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Asn 0 
to 0 
Asp 0 
substitution 0 
. 0 

Interestingly 0 
, 0 
the 0 
_NUM3 0 
G 0 
-- 0 
A 0 
and 0 
_NUM3 0 
A 0 
-- 0 
G 0 
mutations 0 
create 0 
Alu 0 
I 0 
and 0 
Ava 0 
II 0 
recognition 0 
sites 0 
, 0 
respectively 0 
, 0 
which 0 
enabled 0 
us 0 
to 0 
rapidly 0 
detect 0 
these 0 
two 0 
mutations 0 
by 0 
PCR 0 
/ 0 
restriction 0 
enzyme 0 
-LRB- 0 
RE 0 
-RRB- 0 
digestion 0 
method 0 
. 0 

The 0 
third 0 
mutation 0 
-LRB- 0 
_NUM4 0 
G 0 
-- 0 
T 0 
-RRB- 0 
was 0 
found 0 
in 0 
four 0 
affected 0 
Chinese 0 
. 0 

This 0 
mutation 0 
causes 0 
a 0 
G 0 
to 0 
T 0 
change 0 
at 0 
nucleotide 0 
position 0 
_NUM4 0 
that 0 
results 0 
in 0 
an 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Arg 0 
to 0 
Leu 0 
substitution 0 
. 0 

The 0 
_NUM4 0 
G 0 
-- 0 
T 0 
mutation 0 
seems 0 
to 0 
be 0 
the 0 
dominant 0 
allele 0 
that 0 
causes 0 
G6PD 1
deficiency 1
in 0 
Taiwan 0 
. 0 

Finally 0 
, 0 
two 0 
affected 0 
Chinese 0 
were 0 
identified 0 
as 0 
having 0 
the 0 
fourth 0 
mutation 0 
-LRB- 0 
_NUM4 0 
G 0 
-- 0 
A 0 
-RRB- 0 
. 0 

This 0 
mutation 0 
causes 0 
a 0 
G 0 
to 0 
A 0 
change 0 
at 0 
nucleotide 0 
_NUM4 0 
that 0 
produces 0 
an 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Arg 0 
to 0 
His 0 
substitution 0 
. 0 

Our 0 
studies 0 
provide 0 
the 0 
direct 0 
proof 0 
of 0 
the 0 
genetic 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
in 0 
the 0 
Chinese 0 
populations 0 
of 0 
Taiwan 0 
and 0 
the 0 
PCR 0 
/ 0 
RE 0 
digestion 0 
method 0 
is 0 
suitable 0 
for 0 
simultaneous 0 
detection 0 
of 0 
the 0 
_NUM3 0 
G 0 
-- 0 
A 0 
and 0 
_NUM3 0 
A 0 
-- 0 
G 0 
mutations 0 
. 0 

Fas 0 
preassociation 0 
required 0 
for 0 
apoptosis 0 
signaling 0 
and 0 
dominant 0 
inhibition 0 
by 0 
pathogenic 0 
mutations 0 
. 0 

Heterozygous 0 
mutations 0 
encoding 0 
abnormal 0 
forms 0 
of 0 
the 0 
death 0 
receptor 0 
Fas 0 
dominantly 0 
interfere 0 
with 0 
Fas-induced 0 
lymphocyte 0 
apoptosis 0 
in 0 
human 0 
autoimmune 1
lymphoproliferative 1
syndrome 1
. 0 

This 0 
effect 0 
, 0 
rather 0 
than 0 
depending 0 
on 0 
ligand-induced 0 
receptor 0 
oligomerization 0 
, 0 
was 0 
found 0 
to 0 
stem 0 
from 0 
ligand 0 
- 0 
independent 0 
interaction 0 
of 0 
wild-type 0 
and 0 
mutant 0 
Fas 0 
receptors 0 
through 0 
a 0 
specific 0 
region 0 
in 0 
the 0 
extracellular 0 
domain 0 
. 0 

Preassociated 0 
Fas 0 
complexes 0 
were 0 
found 0 
in 0 
living 0 
cells 0 
by 0 
means 0 
of 0 
fluorescence 0 
resonance 0 
energy 0 
transfer 0 
between 0 
variants 0 
of 0 
green 0 
fluorescent 0 
protein 0 
. 0 

These 0 
results 0 
show 0 
that 0 
formation 0 
of 0 
preassociated 0 
receptor 0 
complexes 0 
is 0 
necessary 0 
for 0 
Fas 0 
signaling 0 
and 0 
dominant 0 
interference 0 
in 0 
human 0 
disease 0 
. 0 
. 0 

Familial 1
Mediterranean 1
fever 1
in 0 
the 0 
colchicine 0 
era 0 
: 0 
the 0 
fate 0 
of 0 
one 0 
family 0 
. 0 

In 0 
order 0 
to 0 
demonstrate 0 
the 0 
effect 0 
of 0 
prophylactic 0 
colchicine 0 
treatment 0 
on 0 
the 0 
natural 0 
history 0 
of 0 
familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
, 0 
a 0 
family 0 
is 0 
presented 0 
with 0 
_NUM1 0 
out 0 
of 0 
_NUM1 0 
siblings 0 
affected 0 
by 0 
FMF 1
. 0 

Each 0 
patient 0 
represents 0 
a 0 
different 0 
stage 0 
of 0 
the 0 
amyloidotic 1
kidney 1
disease 1
of 0 
FMF 1
and 0 
the 0 
effect 0 
of 0 
continuous 0 
colchicine 0 
treatment 0 
on 0 
its 0 
course 0 
. 0 

Considered 0 
together 0 
, 0 
the 0 
members 0 
of 0 
this 0 
family 0 
present 0 
an 0 
almost 0 
complete 0 
clinical 0 
, 0 
genetic 0 
, 0 
and 0 
behavioral 0 
picture 0 
of 0 
the 0 
disease 0 
. 0 
. 0 

Two 0 
new 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
mutations 0 
in 0 
a 0 
juvenile 0 
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
patient 0 
. 0 

Fragments 0 
of 0 
the 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
gene 0 
from 0 
a 0 
patient 0 
with 0 
juvenile-onset 0 
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
were 0 
amplified 0 
by 0 
PCR 0 
and 0 
ligated 0 
into 0 
MP13 0 
cloning 0 
vectors 0 
. 0 

Clones 0 
hybridizing 0 
with 0 
cDNA 0 
for 0 
human 0 
ARSA 0 
were 0 
selected 0 
, 0 
examined 0 
for 0 
appropriate 0 
size 0 
inserts 0 
, 0 
and 0 
used 0 
to 0 
prepare 0 
single-stranded 0 
phage 0 
DNA 0 
. 0 

Examination 0 
of 0 
the 0 
entire 0 
coding 0 
and 0 
most 0 
of 0 
the 0 
intronic 0 
sequence 0 
revealed 0 
two 0 
putative 0 
disease-related 0 
mutations 0 
. 0 

One 0 
, 0 
a 0 
point 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
, 0 
resulted 0 
in 0 
the 0 
substitution 0 
of 0 
isoleucine 0 
by 0 
serine 0 
. 0 

Introduction 0 
of 0 
this 0 
alteration 0 
into 0 
the 0 
normal 0 
ARSA 0 
cDNA 0 
sequence 0 
resulted 0 
in 0 
a 0 
substantial 0 
decrease 0 
in 0 
ARSA 0 
activity 0 
on 0 
transient 0 
expression 0 
in 0 
cultured 0 
baby 0 
hamster 0 
kidney 0 
cells 0 
. 0 

About 0 
_NUM1 0 
% 0 
of 0 
the 0 
control 0 
expression 0 
was 0 
observed 0 
, 0 
suggesting 0 
a 0 
small 0 
residual 0 
activity 0 
in 0 
the 0 
mutated 0 
ARSA 0 
. 0 

The 0 
second 0 
mutation 0 
, 0 
a 0 
G-to-A 0 
transition 0 
, 0 
occurred 0 
in 0 
the 0 
other 0 
allele 0 
and 0 
resulted 0 
in 0 
an 0 
altered 0 
splice-recognition 0 
sequence 0 
between 0 
exon 0 
_NUM1 0 
and 0 
the 0 
following 0 
intron 0 
. 0 

The 0 
mutation 0 
also 0 
resulted 0 
in 0 
the 0 
loss 0 
of 0 
a 0 
restriction 0 
site 0 
. 0 

Apparently 0 
normal 0 
levels 0 
of 0 
mRNA 0 
were 0 
generated 0 
from 0 
this 0 
allele 0 
, 0 
but 0 
no 0 
ARSA 0 
activity 0 
or 0 
immuno-cross-reactive 0 
material 0 
could 0 
be 0 
detected 0 
. 0 

A 0 
collection 0 
of 0 
DNA 0 
samples 0 
from 0 
known 0 
or 0 
suspected 0 
MLD 1
patients 0 
, 0 
members 0 
of 0 
their 0 
families 0 
, 0 
and 0 
normal 0 
controls 0 
was 0 
screened 0 
for 0 
these 0 
mutations 0 
. 0 

Four 0 
additional 0 
individuals 0 
carrying 0 
each 0 
of 0 
the 0 
mutations 0 
were 0 
found 0 
among 0 
the 0 
nearly 0 
_NUM3 0 
MLD 1
patients 0 
in 0 
the 0 
sample 0 
. 0 

Gene 0 
segregation 0 
in 0 
the 0 
original 0 
patients 0 
family 0 
was 0 
consistent 0 
with 0 
available 0 
clinical 0 
and 0 
biochemical 0 
data 0 
. 0 

No 0 
individuals 0 
homozygous 0 
for 0 
either 0 
of 0 
these 0 
two 0 
mutations 0 
were 0 
identified 0 
. 0 

However 0 
, 0 
combinations 0 
with 0 
other 0 
MLD 1
mutations 0 
suggest 0 
that 0 
the 0 
point 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
does 0 
result 0 
in 0 
some 0 
residual 0 
enzyme 0 
activity 0 
and 0 
is 0 
associated 0 
with 0 
late-onset 0 
forms 0 
of 0 
the 0 
disease 0 
. 0 

The 0 
splice-site 0 
mutation 0 
following 0 
exon 0 
_NUM1 0 
produces 0 
late-infantile 0 
MLD 1
when 0 
combined 0 
with 0 
other 0 
enzyme-null 0 
mutations 0 
, 0 
implying 0 
that 0 
it 0 
is 0 
completely 0 
silent 0 
enzymatically 0 
. 0 
. 0 

Null 0 
mutation 0 
of 0 
the 0 
murine 0 
ATP7B 0 
-LRB- 0 
Wilson 1
disease 1
-RRB- 0 
gene 0 
results 0 
in 0 
intracellular 1
copper 1
accumulation 1
and 0 
late-onset 1
hepatic 1
nodular 1
transformation 1
. 0 

The 0 
Atp7b 0 
protein 0 
is 0 
a 0 
copper-transporting 0 
ATPase 0 
expressed 0 
predominantly 0 
in 0 
the 0 
liver 0 
and 0 
to 0 
a 0 
lesser 0 
extent 0 
in 0 
most 0 
other 0 
tissues 0 
. 0 

Mutations 0 
in 0 
the 0 
ATP7B 0 
gene 0 
lead 0 
to 0 
Wilson 1
disease 1
, 0 
a 0 
copper 1
toxicity 1
disorder 1
characterized 0 
by 0 
dramatic 0 
build-up 0 
of 0 
intracellular 0 
hepatic 0
copper 0 
with 0 
subsequent 0 
hepatic 1
and 1
neuro-logical 1
abnormalities 1
. 0 

Using 0 
homologous 0 
recombination 0 
to 0 
disrupt 0 
the 0 
normal 0 
translation 0 
of 0 
ATP7B 0 
, 0 
we 0 
have 0 
generated 0 
a 0 
strain 0 
of 0 
mice 0 
that 0 
are 0 
homozygous 0 
mutants 0 
-LRB- 0 
null 0 
-RRB- 0 
for 0 
the 0 
Wilson 1
disease 1
gene 0 
. 0 

The 0 
ATP7B 0 
null 0 
mice 0 
display 0 
a 0 
gradual 0 
accumulation 0 
of 0 
hepatic 0 
copper 0
that 0 
increases 0 
to 0 
a 0 
level 0 
60-fold 0 
greater 0 
than 0 
normal 0 
by 0 
_NUM1 0 
months 0 
of 0 
age 0 
. 0 

An 0 
increase 0 
in 0 
copper 0
concentration 0 
was 0 
also 0 
observed 0 
in 0 
the 0 
kidney 0 
, 0 
brain 0 
, 0 
placenta 0 
and 0 
lactating 0 
mammary 0 
glands 0 
of 0 
homo-zygous 0 
mutants 0 
, 0 
although 0 
milk 0 
from 0 
the 0 
mutant 0 
glands 0 
was 0 
copper 1
deficient 1
. 0 

Morphological 1
abnormalities 1
resembling 0 
cirrhosis 1
developed 0 
in 0 
the 0 
majority 0 
of 0 
the 0 
livers 0 
from 0 
homozygous 0 
mutants 0 
older 0 
than 0 
_NUM1 0 
months 0 
of 0 
age 0 
. 0 

Progeny 0 
of 0 
the 0 
homozygous 0 
mutant 0 
females 0 
demonstrated 0 
neurological 1
abnormalities 1
and 0 
growth 1
retardation 1
characteristic 0 
of 0 
copper 1
deficiency 1
. 0 

Copper 0 
concentration 0 
in 0 
the 0 
livers 0 
of 0 
the 0 
newborn 0 
homozygous 0 
null 0 
mutants 0 
was 0 
decreased 0 
dramatically 0 
. 0 

In 0 
summary 0 
, 0 
inactivation 0 
of 0 
the 0 
murine 0 
ATP7B 0 
gene 0 
produces 0 
a 0 
form 0 
of 0 
cirrhotic 1
liver 1
disease 1
that 0 
resembles 0 
Wilson 1
disease 1
in 0 
humans 0 
and 0 
the 0 
toxic 0 
milk 0 
phenotype 0 
in 0 
the 0 
mouse 0 
. 0 
. 0 

Adrenoleukodystrophy 1
and 0 
adrenomyeloneuropathy 1
associated 0 
with 0 
partial 0 
adrenal 1
insufficiency 1
in 0 
three 0 
generations 0 
of 0 
a 0 
kindred 0 
. 0 

Four 0 
cases 0 
of 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
and 0 
one 0 
case 0 
of 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
have 0 
developed 0 
in 0 
a 0 
kindred 0 
over 0 
three 0 
generations 0 
demonstrating 0 
that 0 
AMN 1
is 0 
a 0 
clinical 0 
variant 0 
of 0 
ALD 1
. 0 

Pituitary-adrenal 0 
function 0 
studies 0 
were 0 
performed 0 
in 0 
_NUM2 0 
family 0 
members 0 
, 0 
including 0 
two 0 
affected 0 
males 0 
and 0 
four 0 
females 0 
identified 0 
as 0 
carriers 0 
of 0 
ALD 1
/ 0 
AMN 1
. 0 

No 0 
pituitary-adrenal 1
abnormality 1
was 0 
found 0 
in 0 
the 0 
carriers 0 
. 0 

However 0 
, 0 
basal 0 
morning 0 
plasma 0 
adrenocorticotropic 0 
hormone 0 
-LRB- 0 
ACTH 0 
-RRB- 0 
levels 0 
were 0 
markedly 0 
elevated 0 
in 0 
the 0 
two 0 
males 0 
with 0 
ALD 1
and 0 
AMN 1
, 0 
despite 0 
the 0 
fact 0 
that 0 
they 0 
had 0 
no 0 
clinical 0 
signs 0 
of 0 
adrenal 1
insufficiency 1
and 0 
that 0 
morning 0 
plasma 0 
cortisol 0 
levels 0 
and 0 
their 0 
response 0 
to 0 
maximal 0 
exogenous 0 
ACTH 0 
stimulation 0 
appeared 0 
to 0 
be 0 
normal 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
integrated 0 
24-hour 0 
response 0 
to 0 
the 0 
administration 0 
were 0 
also 0 
subnormal 0 
in 0 
these 0 
two 0 
cases 0 
. 0 

Thus 0 
, 0 
people 0 
with 0 
ALD 1
and 0 
AMN 1
may 0 
have 0 
subclinical 0 
partial 0 
adrenocrotical 1
insufficiency 1
. 0 

No 0 
other 0 
endocrinologic 1
dysfunction 1
was 0 
identified 0 
. 0 
. 0 

Identification 0 
of 0 
mutations 0 
in 0 
the 0 
ALD 0 
gene 0 
of 0 
_NUM2 0 
families 0 
with 0 
adrenoleukodystrophy 1
/ 0 
adrenomyeloneuropathy 1
. 0 

Adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
, 0 
an 0 
X-linked 1
inherited 1
metabolic 1
disorder 1
, 0 
is 0 
the 0 
most 0 
frequent 0 
inborn 1
peroxisomal 1
disease 1
. 0 

It 0 
leads 0 
to 0 
demyelination 1
in 1
the 1
central 1
and 1
peripheral 1
nervous 1
system 1
. 0 

Defective 0 
beta-oxidation 0 
of 0 
saturated 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
-LRB- 0 
VLCFAs 0 
; 0 
_AN 0 
0-C26 0 
_NUM1 0 
-RRB- 0 
in 0 
peroxisomes 0 
has 0 
been 0 
shown 0 
to 0 
lead 0 
to 0 
an 0 
accumulation 0 
of 0 
VLCFAs 0 
in 0 
leukoid 0 
areas 0 
of 0 
the 0 
central 0 
nervous 0 
system 0 
, 0 
peripheral 0 
nerves 0 
, 0 
adrenal 0 
gland 0 
, 0 
and 0 
blood 0 
. 0 

The 0 
ALD 1
gene 0 
has 0 
been 0 
recently 0 
identified 0 
and 0 
encodes 0 
a 0 
745-amino-acid 0 
protein 0 
. 0 

We 0 
screened 0 
patients 0 
with 0 
adrenoleukodystrophy 1
/ 0 
adrenomyeloneuropathy 1
-LRB- 0 
ALD 1
/ 0 
AMN 1
-RRB- 0 
from 0 
_NUM2 0 
kindreds 0 
for 0 
mutations 0 
in 0 
the 0 
ALD 1
gene 0 
. 0 

Eleven 0 
missense 0 
and 0 
two 0 
nonsense 0 
mutations 0 
, 0 
five 0 
deletions 0 
, 0 
and 0 
one 0 
insertion 0 
were 0 
detected 0 
by 0 
direct 0 
sequencing 0 
of 0 
eight 0 
reverse 0 
transcribed 0 
fragments 0 
of 0 
the 0 
ALD 1
gene 0 
mRNA 0 
. 0 

Four 0 
mutations 0 
could 0 
be 0 
shown 0 
to 0 
be 0 
de 0 
novo 0 
. 0 

All 0 
mutations 0 
could 0 
be 0 
confirmed 0 
in 0 
carriers 0 
by 0 
sequencing 0 
genomic 0 
DNA 0 
. 0 

No 0 
correlation 0 
between 0 
the 0 
type 0 
of 0 
mutation 0 
and 0 
the 0 
severity 0 
of 0 
the 0 
phenotype 0 
could 0 
be 0 
observed 0 
. 0 

The 0 
mutations 0 
were 0 
not 0 
detected 0 
in 0 
the 0 
ALD 1
gene 0 
of 0 
_NUM2 0 
healthy 0 
persons 0 
. 0 
. 0 

Gonosomal 0 
mosaicism 0 
in 0 
myotonic 1
dystrophy 1
patients 0 
: 0 
involvement 0 
of 0 
mitotic 0 
events 0 
in 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
variation 0 
and 0 
selection 0 
against 0 
extreme 0 
expansion 0 
in 0 
sperm 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
caused 0 
by 0 
abnormal 0 
expansion 0 
of 0 
a 0 
polymorphic 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
, 0 
located 0 
in 0 
the 0 
DM 1
protein 0 
kinase 0 
gene 0 
. 0 

We 0 
determined 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
lengths 0 
in 0 
a 0 
broad 0 
range 0 
of 0 
tissue 0 
DNAs 0 
from 0 
patients 0 
with 0 
mild 0 
, 0 
classical 0 
, 0 
or 0 
congenital 0 
manifestation 0 
of 0 
DM 1
. 0 

Differences 0 
in 0 
the 0 
repeat 0 
length 0 
were 0 
seen 0 
in 0 
somatic 0 
tissues 0 
from 0 
single 0 
DM 1
individuals 0 
and 0 
twins 0 
. 0 

Repeats 0 
appeared 0 
to 0 
expand 0 
to 0 
a 0 
similar 0 
extent 0 
in 0 
tissues 0 
originating 0 
from 0 
the 0 
same 0 
embryonal 0 
origin 0 
. 0 

In 0 
most 0 
male 0 
patients 0 
carrying 0 
intermediate 0 
- 0 
or 0 
small-sized 0 
expansions 0 
in 0 
blood 0 
, 0 
the 0 
repeat 0 
lengths 0 
covered 0 
a 0 
markedly 0 
wider 0 
range 0 
in 0 
sperm 0 
. 0 

In 0 
contrast 0 
, 0 
male 0 
patients 0 
with 0 
large 0 
allele 0 
expansions 0 
in 0 
blood 0 
-LRB- 0 
> 0 
_NUM3 0 
CTGs 0 
-RRB- 0 
had 0 
similar 0 
or 0 
smaller 0 
repeats 0 
in 0 
sperm 0 
, 0 
when 0 
detectable 0 
. 0 

Sperm 0 
alleles 0 
with 0 
> 0 
_NUM1 0 
, 0 
_NUM3 0 
CTGs 0 
were 0 
not 0 
seen 0 
. 0 

We 0 
conclude 0 
that 0 
DM 1
patients 0 
can 0 
be 0 
considered 0 
gonosomal 0 
mosaics 0 
, 0 
i. 0 
e 0 
e. 0 
, 0 
combined 0 
somatic 0 
and 0 
germ-line 0 
tissue 0 
mosaics 0 
. 0 

Most 0 
remarkably 0 
, 0 
we 0 
observed 0 
multiple 0 
cases 0 
where 0 
the 0 
length 0 
distributions 0 
of 0 
intermediate 0 
- 0 
or 0 
small-sized 0 
alleles 0 
in 0 
fathers 0 
sperm 0 
were 0 
significantly 0 
different 0 
from 0 
that 0 
in 0 
their 0 
offsprings 0 
blood 0 
. 0 

Our 0 
combined 0 
findings 0 
indicate 0 
that 0 
intergenerational 0 
length 0 
changes 0 
in 0 
the 0 
unstable 0 
_DS 0 
repeat 0 
are 0 
most 0 
likely 0 
to 0 
occur 0 
during 0 
early 0 
embryonic 0 
mitotic 0 
divisions 0 
in 0 
both 0 
somatic 0 
and 0 
germ-line 0 
tissue 0 
formation 0 
. 0 

Both 0 
the 0 
initial 0 
_DS 0 
length 0 
, 0 
the 0 
overall 0 
number 0 
of 0 
cell 0 
divisions 0 
involved 0 
in 0 
tissue 0 
formation 0 
, 0 
and 0 
perhaps 0 
a 0 
specific 0 
selection 0 
process 0 
in 0 
spermatogenesis 0 
may 0 
influence 0 
the 0 
dynamics 0 
of 0 
this 0 
process 0 
. 0 

A 0 
model 0 
explaining 0 
mitotic 0 
instability 0 
and 0 
sex-dependent 0 
segregation 0 
phenomena 0 
in 0 
DM 1
manifestation 0 
is 0 
discussed 0 
Combined 0 
analysis 0 
of 0 
hereditary 1
prostate 1
cancer 1
linkage 0 
to 0 
1q24-25 0 
: 0 
results 0 
from 0 
_NUM3 0 
hereditary 1
prostate 1
cancer 1
families 0 
from 0 
the 0 
International 0 
Consortium 0 
for 0 
Prostate 1
Cancer 1
Genetics 0 
. 0 

A 0 
previous 0 
linkage 0 
study 0 
provided 0 
evidence 0 
for 0 
a 0 
prostate 1
cancer 1
susceptibility 0 
locus 0 
at 0 
1q24-25 0 
. 0 

Subsequent 0 
reports 0 
in 0 
additional 0 
collections 0 
of 0 
families 0 
have 0 
yielded 0 
conflicting 0 
results 0 
. 0 

In 0 
addition 0 
, 0 
evidence 0 
for 0 
locus 0 
heterogeneity 0 
has 0 
been 0 
provided 0 
by 0 
the 0 
identification 0 
of 0 
other 0 
putative 0 
hereditary 1
prostate 1
cancer 1
loci 0 
on 0 
Xq27-28 0 
, 0 
1q42-43 0 
, 0 
and 0 
1p36 0 
. 0 

The 0 
present 0 
study 0 
describes 0 
a 0 
combined 0 
analysis 0 
for 0 
six 0 
markers 0 
in 0 
the 0 
1q24-25 0 
region 0 
in 0 
_NUM3 0 
families 0 
affected 0 
by 0 
hereditary 1
prostate 1
cancer 1
and 0 
ascertained 0 
by 0 
the 0 
members 0 
of 0 
the 0 
International 0 
Consortium 0 
for 0 
Prostate 1
Cancer 1
Genetics 0 
-LRB- 0 
ICPCG 0 
-RRB- 0 
from 0 
North 0 
America 0 
, 0 
Australia 0 
, 0 
Finland 0 
, 0 
Norway 0 
, 0 
Sweden 0 
, 0 
and 0 
the 0 
United 0 
Kingdom 0 
. 0 

Overall 0 
, 0 
there 0 
was 0 
some 0 
evidence 0 
for 0 
linkage 0 
, 0 
with 0 
a 0 
peak 0 
parametric 0 
multipoint 0 
LOD 0 
score 0 
assuming 0 
heterogeneity 0 
-LRB- 0 
HLOD 0 
-RRB- 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
at 0 
D1S212 0 
. 0 

The 0 
estimated 0 
proportion 0 
of 0 
families 0 
-LRB- 0 
alpha 0 
-RRB- 0 
linked 0 
to 0 
the 0 
locus 0 
was 0 
. 0 

_NUM2 0 
-LRB- 0 
1-LOD 0 
support 0 
interval 0 
. 0 

_NUM2 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

This 0 
evidence 0 
was 0 
not 0 
observed 0 
by 0 
a 0 
nonparametric 0 
approach 0 
, 0 
presumably 0 
because 0 
of 0 
the 0 
extensive 0 
heterogeneity 0 
. 0 

Further 0 
parametric 0 
analysis 0 
revealed 0 
a 0 
significant 0 
effect 0 
of 0 
the 0 
presence 0 
of 0 
male-to-male 0 
disease 0 
transmission 0 
within 0 
the 0 
families 0 
. 0 

In 0 
the 0 
subset 0 
of 0 
_NUM3 0 
such 0 
families 0 
, 0 
the 0 
peak 0 
HLOD 0 
was 0 
_NUM1 0 
. 0 

In 0 
the 0 
subset 0 
of 0 
_NUM3 0 
such 0 
families 0 
, 0 
the 0 
peak 0 
HLOD 0 
was 0 
_NUM1 0 
. 0 

_NUM2 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM4 0 
-RRB- 0 
and 0 
alpha 0 
= 0 
. 0 

_NUM2 0 
-LRB- 0 
1-LOD 0 
support 0 
interval 0 
. 0 

_NUM2 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
compared 0 
with 0 
HLODs 0 
of 0 
_NUM1 0 
in 0 
the 0 
remaining 0 
_NUM3 0 
families 0 
. 0 

Within 0 
the 0 
families 0 
with 0 
male-to-male 0 
disease 0 
transmission 0 
, 0 
alpha 0 
increased 0 
with 0 
the 0 
early 0 
mean 0 
age 0 
at 0 
diagnosis 0 
-LRB- 0 
< 0 
_NUM2 0 
years 0 
, 0 
alpha 0 
= 0 
. 0 

_NUM2 0 
, 0 
with 0 
1-LOD 0 
support 0 
interval 0 
. 0 

_NUM2 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
the 0 
number 0 
of 0 
affected 0 
family 0 
members 0 
-LRB- 0 
five 0 
or 0 
more 0 
family 0 
members 0 
, 0 
alpha 0 
= 0 
. 0 

_NUM2 0 
, 0 
with 0 
1-LOD 0 
support 0 
interval 0 
. 0 

_NUM2 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

The 0 
highest 0 
value 0 
of 0 
alpha 0 
was 0 
observed 0 
for 0 
the 0 
_NUM2 0 
families 0 
that 0 
met 0 
all 0 
three 0 
criteria 0 
-LRB- 0 
peak 0 
HLOD 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
P 0 
= 0 
. 0 

_NUM3 0 
, 0 
alpha 0 
= 0 
. 0 

_NUM2 0 
, 0 
with 0 
1-LOD 0 
support 0 
interval 0 
. 0 

_NUM2 0 
- 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

These 0 
results 0 
support 0 
the 0 
finding 0 
of 0 
a 0 
prostate 1
cancer 1
susceptibility 0 
gene 0 
linked 0 
to 0 
1q24-25 0 
, 0 
albeit 0 
in 0 
a 0 
defined 0 
subset 0 
of 0 
prostate 1
cancer 1
families 0 
. 0 

Although 0 
HPC1 0 
accounts 0 
for 0 
only 0 
a 0 
small 0 
proportion 0 
of 0 
all 0 
families 0 
affected 0 
by 0 
hereditary 1
prostate 1
cancer 1
, 0 
it 0 
appears 0 
to 0 
play 0 
a 0 
more 0 
prominent 0 
role 0 
in 0 
the 0 
subset 0 
of 0 
families 0 
with 0 
several 0 
members 0 
affected 0 
at 0 
an 0 
early 0 
age 0 
and 0 
with 0 
male-to-male 0 
disease 0 
transmission 0 
. 0 

A 0 
novel 0 
disease 0 
with 0 
deficiency 1
of 1
mitochondrial 1
very-long-chain 1
acyl-CoA 1
dehydrogenase 1
. 0 

Palmitoyl-CoA 0 
dehydrogenase 0 
activity 0 
in 0 
skin 0 
fibroblasts 0 
from 0 
seven 0 
patients 0 
with 0 
unidentified 0 
defects 0 
of 0 
fatty 0 
acid 0 
oxidation 0 
was 0 
measured 0 
in 0 
the 0 
presence 0 
and 0 
absence 0 
of 0 
antibodies 0 
against 0 
medium-chain 0 
, 0 
long-chain 0 
, 0 
and 0 
very-long-chain 0 
acyl-CoA 0 
dehydrogenases 0 
-LRB- 0 
VLCAD 0
-RRB- 0 
. 0 

Two 0 
of 0 
the 0 
patients 0 
, 0 
4-5 0 
month 0 
old 0 
boys 0 
, 0 
were 0 
found 0 
to 0 
have 0 
a 0 
novel 0 
disease 0 
, 0 
VLCAD 1
deficiency 1
, 0 
as 0 
judged 0 
from 0 
the 0 
results 0 
of 0 
very 0 
low 0 
palmitoyl-CoA 0 
dehydrogenase 0 
activity 0 
and 0 
the 0 
lack 0 
of 0 
immunoreactivity 0 
toward 0 
antibody 0 
raised 0 
to 0 
purified 0 
VLCAD 0 
. 0 
. 0 

Inherited 0 
WT1 0 
mutation 0 
in 0 
Denys-Drash 1
syndrome 1
. 0 

Patients 0 
with 0 
the 0 
Denys-Drash 1
syndrome 1
-LRB- 0 
Wilms 1
tumor 1
, 0 
genital 1
anomalies 1
, 0 
and 0 
nephropathy 1
-RRB- 0 
have 0 
been 0 
demonstrated 0 
to 0 
carry 0 
de 0 
novo 0 
constitutional 0 
mutations 0 
in 0 
WT1 0 
, 0 
the 0 
Wilms 1
tumor 1
gene 0 
at 0 
chromosome 0 
11p13 0 
. 0 

We 0 
report 0 
three 0 
new 0 
cases 0 
, 0 
two 0 
carrying 0 
a 0 
previously 0 
described 0 
WT1 0 
exon 0 
_NUM1 0 
mutation 0 
and 0 
one 0 
with 0 
a 0 
novel 0 
WT1 0 
exon 0 
_NUM1 0 
mutation 0 
. 0 

However 0 
, 0 
unlike 0 
patients 0 
in 0 
previous 0 
reports 0 
, 0 
one 0 
of 0 
our 0 
three 0 
patients 0 
inherited 0 
the 0 
affected 0 
allele 0 
from 0 
his 0 
phenotypically 0 
unaffected 0 
father 0 
. 0 

This 0 
observation 0 
indicates 0 
that 0 
the 0 
WT1 0 
exon 0 
_NUM1 0 
mutation 0 
affecting 0 
394Arg 0 
demonstrated 0 
in 0 
over 0 
one-half 0 
of 0 
the 0 
patients 0 
with 0 
the 0 
Denys-Drash 1
syndrome 1
may 0 
exhibit 0 
incomplete 0 
penetrance 0 
. 0 

Consequently 0 
, 0 
familial 0 
studies 0 
in 0 
patients 0 
affected 0 
by 0 
this 0 
syndrome 0 
are 0 
recommended 0 
. 0 
. 0 

Glucose 1
/ 1
galactose 1
malabsorption 1
caused 0 
by 0 
a 0 
defect 0 
in 0 
the 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
. 0 

Glucose 1
/ 1
galactose 1
malabsorption 1
-LRB- 0 
GGM 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disease 1
manifesting 0 
within 0 
the 0 
first 0 
weeks 0 
of 0 
life 0 
and 0 
characterized 0 
by 0 
a 0 
selective 0 
failure 0 
to 0 
absorb 0 
dietary 0 
glucose 0 
and 0 
galactose 0 
from 0 
the 0 
intestine 0 
. 0 

The 0 
consequent 0 
severe 0 
diarrhoea 1
and 0 
dehydration 1
are 0 
usually 0 
fatal 0 
unless 0 
these 0 
sugars 0 
are 0 
eliminated 0 
from 0 
the 0 
diet 0 
. 0 

Intestinal 0 
biopsies 0 
of 0 
GGM 1
patients 0 
have 0 
revealed 0 
a 0 
specific 0 
defect 0 
in 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
- 0 
dependent 0 
absorption 0 
of 0 
glucose 0 
in 0 
the 0 
brush 0 
border 0 
. 0 

Normal 0 
glucose 0 
absorption 0 
is 0 
mediated 0 
by 0 
the 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
in 0 
the 0 
brush 0 
border 0 
membrane 0 
of 0 
the 0 
intestinal 0 
epithelium 0 
. 0 

Cellular 0 
influx 0 
is 0 
driven 0 
by 0 
the 0 
transmembrane 0 
Na 0 
+ 0 
electrochemical 0 
potential 0 
gradient 0 
; 0 
thereafter 0 
the 0 
sugar 0 
moves 0 
to 0 
the 0 
blood 0 
across 0 
the 0 
basolateral 0 
membrane 0 
via 0 
the 0 
facilitated 0 
glucose 0 
carrier 0 
. 0 

We 0 
have 0 
previously 0 
cloned 0 
and 0 
sequenced 0 
a 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
from 0 
normal 0 
human 0 
ileum 0 
and 0 
shown 0 
that 0 
this 0 
gene 0 
, 0 
SGLT1 0 
, 0 
resides 0 
on 0 
the 0 
distal 0 
q 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
. 0 

We 0 
have 0 
now 0 
amplified 0 
SGLT1 0 
complementary 0 
DNA 0 
and 0 
genomic 0 
DNA 0 
from 0 
members 0 
of 0 
a 0 
family 0 
affected 0 
with 0 
GGM 1
by 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
. 0 

Sequence 0 
analysis 0 
of 0 
the 0 
amplified 0 
products 0 
has 0 
revealed 0 
a 0 
single 0 
missense 0 
mutation 0 
in 0 
SGLT1 0 
which 0 
cosegregates 0 
with 0 
the 0 
GGM 1
phenotype 0 
and 0 
results 0 
in 0 
a 0 
complete 0 
loss 0 
of 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
- 0 
dependent 0 
glucose 0 
transport 0 
in 0 
Xenopus 0 
oocytes 0 
injected 0 
with 0 
this 0 
complementary 0 
RNA 0 
. 0 
. 0 

Atm 0 
and 0 
Bax 0 
cooperate 0 
in 0 
ionizing 0 
radiation-induced 0 
apoptosis 0 
in 0 
the 0 
central 0 
nervous 0 
system 0 
. 0 

Ataxia-telangiectasia 1
is 0 
a 0 
hereditary 1
multisystemic 1
disease 1
resulting 0 
from 0 
mutations 0 
of 0 
ataxia 1
telangiectasia 1
, 0 
mutated 0 
-LRB- 0 
ATM 0 
-RRB- 0 
and 0 
is 0 
characterized 0 
by 0 
neurodegeneration 1
, 0 
cancer 1
, 0 
immune 1
defects 1
, 0 
and 0 
hypersensitivity 1
to 1
ionizing 1
radiation 1
. 0 

The 0 
molecular 0 
details 0 
of 0 
ATM 0 
function 0 
in 0 
the 0 
nervous 0 
system 0 
are 0 
unclear 0 
, 0 
although 0 
the 0 
neurological 1
lesion 1
in 0 
ataxia-telangiectasia 1
becomes 0 
apparent 0 
early 0 
in 0 
life 0 
, 0 
suggesting 0 
a 0 
developmental 0 
origin 0 
. 0 

The 0 
central 0 
nervous 0 
system 0 
-LRB- 0 
CNS 0 
-RRB- 0 
of 0 
Atm-null 0 
mice 0 
shows 0 
a 0 
pronounced 0 
defect 0 
in 0 
apoptosis 0 
induced 0 
by 0 
genotoxic 0 
stress 0 
, 0 
suggesting 0 
ATM 0 
functions 0 
to 0 
eliminate 0 
neurons 0 
with 0 
excessive 0 
genomic 0 
damage 0 
. 0 

Here 0 
, 0 
we 0 
report 0 
that 0 
the 0 
death 0 
effector 0 
Bax 0 
is 0 
required 0 
for 0 
a 0 
large 0 
proportion 0 
of 0 
Atm-dependent 0 
apoptosis 0 
in 0 
the 0 
developing 0 
CNS 0 
after 0 
ionizing 0 
radiation 0 
-LRB- 0 
IR 0 
-RRB- 0 
. 0 

Although 0 
many 0 
of 0 
the 0 
same 0 
regions 0 
of 0 
the 0 
CNS 0 
in 0 
both 0 
Bax 0 
- 0 
/ 0 
- 0 
and 0 
Atm 0 
- 0 
/ 0 
- 0 
mice 0 
were 0 
radioresistant 0 
, 0 
mice 0 
nullizygous 0 
for 0 
both 0 
Bax 0 
and 0 
Atm 0 
showed 0 
additional 0 
reduction 0 
in 0 
IR-induced 0 
apoptosis 0 
in 0 
the 0 
CNS 0 
. 0 

Therefore 0 
, 0 
although 0 
the 0 
major 0 
IR-induced 0 
apoptotic 0 
pathway 0 
in 0 
the 0 
CNS 0 
requires 0 
Atm 0 
and 0 
Bax 0 
, 0 
a 0 
p53-dependent 0 
collateral 0 
pathway 0 
exists 0 
that 0 
has 0 
both 0 
Atm 0 
- 0 
and 0 
Bax-independent 0 
branches 0 
. 0 

Further 0 
, 0 
Atm 0 
- 0 
and 0 
Bax-dependent 0 
apoptosis 0 
in 0 
the 0 
CNS 0 
also 0 
required 0 
caspase-3 0 
activation 0 
. 0 

These 0 
data 0 
implicate 0 
Bax 0 
and 0 
caspase-3 0 
as 0 
death 0 
effectors 0 
in 0 
neurodegenerative 0 
pathways 0 
. 0 
. 0 

Novel 0 
Tay-Sachs 1
disease 1
mutations 0 
from 0 
China 0 
. 0 

We 0 
describe 0 
three 0 
HEXA 0 
mutations 0 
associated 0 
with 0 
infantile 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
in 0 
three 0 
unrelated 0 
nonconsanguineous 0 
Chinese 0 
families 0 
. 0 

Novel 0 
mutations 0 
were 0 
found 0 
in 0 
two 0 
of 0 
these 0 
families 0 
. 0 

The 0 
third 0 
is 0 
a 0 
previously 0 
reported 0 
mutation 0 
-LRB- 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
at 0 
nt 0 
_NUM4 0 
-RRB- 0 
-LRB- 0 
Nakano 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

Direct 0 
sequencing 0 
of 0 
PCR 0 
products 0 
identified 0 
a 0 
novel 0 
insertion 0 
of 0 
an 0 
A 0 
after 0 
nt 0 
_NUM3 0 
in 0 
family 0 
_NUM1 0 
. 0 

This 0 
change 0 
generates 0 
an 0 
early 0 
termination 0 
codon 0 
_NUM1 0 
bp 0 
downstream 0 
from 0 
the 0 
insertion 0 
site 0 
. 0 

Allele-specific 0 
oligonucleotide 0 
hybridization 0 
confirmed 0 
homozygosity 0 
in 0 
the 0 
proband 0 
. 0 

Single 0 
strand 0 
conformational 0 
polymorphism 0 
analysis 0 
and 0 
direct 0 
sequencing 0 
of 0 
amplified 0 
exon 0 
_NUM2 0 
revealed 0 
a 0 
T 0 
-- 0 
> 0 
C 0 
transition 0 
at 0 
nt 0 
_NUM4 0 
with 0 
the 0 
corresponding 0 
amino 0 
acid 0 
substitution 0 
W485R 0 
in 0 
the 0 
second 0 
family 0 
. 0 

This 0 
mutation 0 
creates 0 
an 0 
Fnu4HI 0 
restriction 0 
site 0 
. 0 

The 0 
proband 0 
is 0 
homozygous 0 
for 0 
this 0 
allele 0 
. 0 

When 0 
the 0 
site-specific 0 
mutagenized 0 
alpha 0 
cDNA 0 
carrying 0 
the 0 
T 0 
-- 0 
> 0 
C 0 
transition 0 
at 0 
nt 0 
_NUM4 0 
was 0 
expressed 0 
in 0 
COS 0 
_NUM1 0 
cells 0 
hexosaminidase 0 
S 0 
activity 0 
was 0 
not 0 
detectable 0 
above 0 
background 0 
. 0 

A 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
at 0 
nt 0 
_NUM4 0 
-LRB- 0 
exon 0 
_NUM2 0 
-RRB- 0 
corresponding 0 
to 0 
the 0 
E482K 0 
substitution 0 
was 0 
found 0 
in 0 
the 0 
third 0 
family 0 
. 0 

This 0 
mutation 0 
occurs 0 
at 0 
a 0 
CpG 0 
dinucleotide 0 
. 0 

It 0 
has 0 
been 0 
reported 0 
in 0 
an 0 
Italian 0 
TSD 1
proband 0 
and 0 
causes 0 
defective 0 
intracellular 0 
transport 0 
of 0 
the 0 
alpha-subunit 0 
from 0 
the 0 
rough 0 
endoplasmic 0 
reticulum 0 
to 0 
the 0 
Golgi 0 
apparatus 0 
. 0 

Glucose 1
6-phosphate 1
dehydrogenase 1
deficiency 1
and 0 
incidence 0 
of 0 
hematologic 1
malignancy 1
. 0 

We 0 
have 0 
evaluated 0 
the 0 
hypothesis 0 
of 0 
a 0 
negative 0 
association 0 
between 0 
glucose 1
6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
and 0 
cancer 1
in 0 
a 0 
cohort 0 
of 0 
_NUM3 0 
Sardinian 0 
males 0 
with 0 
hematological 1
malignancies 1
. 0 

The 0 
frequency 0 
of 0 
G6PD 1
deficiency 1
in 0 
the 0 
patients 0 
was 0 
not 0 
different 0 
from 0 
the 0 
incidence 0 
in 0 
a 0 
group 0 
of 0 
_NUM2 0 
, 0 
_NUM3 0 
controls 0 
. 0 

The 0 
same 0 
conclusion 0 
resulted 0 
from 0 
the 0 
comparison 0 
of 0 
the 0 
frequency 0 
of 0 
expression 0 
of 0 
the 0 
GdB 0 
gene 0 
in 0 
_NUM2 0 
heterozygous 0 
women 0 
having 0 
a 0 
clonal 0 
hematologic 1
disease 1
and 0 
a 0 
control 0 
group 0 
of 0 
_NUM2 0 
healthy 0 
heterozygotes 0 
. 0 

Therefore 0 
at 0 
present 0 
there 0 
is 0 
no 0 
evidence 0 
that 0 
G6PD 1
deficiency 1
has 0 
a 0 
protective 0 
effect 0 
against 0 
development 0 
of 0 
hematologic 1
neoplasms 1
. 0 
. 0 

A 0 
physical 0 
map 0 
and 0 
candidate 0 
genes 0 
in 0 
the 0 
BRCA1 0 
region 0 
on 0 
chromosome 0 
17q12-21 0 
. 0 

We 0 
have 0 
constructed 0 
a 0 
physical 0 
map 0 
of 0 
a 0 
_NUM1 0 
cM 0 
region 0 
on 0 
chromosome 0 
17q12-21 0 
that 0 
contains 0 
the 0 
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
gene 0 
BRCA1 0 
. 0 

The 0 
map 0 
comprises 0 
a 0 
contig 0 
of 0 
_NUM3 0 
overlapping 0 
yeast 0 
artificial 0 
chromosomes 0 
and 0 
P1 0 
clones 0 
, 0 
onto 0 
which 0 
we 0 
have 0 
placed 0 
_NUM3 0 
PCR 0 
markers 0 
. 0 

We 0 
have 0 
localized 0 
more 0 
than 0 
_NUM2 0 
genes 0 
on 0 
this 0 
map 0 
, 0 
ten 0 
of 0 
which 0 
had 0 
not 0 
been 0 
mapped 0 
to 0 
the 0 
region 0 
previously 0 
, 0 
and 0 
have 0 
isolated 0 
_NUM2 0 
cDNA 0 
clones 0 
representing 0 
partial 0 
sequences 0 
of 0 
as 0 
yet 0 
unidentified 0 
genes 0 
. 0 

Two 0 
genes 0 
that 0 
lie 0 
within 0 
a 0 
narrow 0 
region 0 
defined 0 
by 0 
meiotic 0 
breakpoints 0 
in 0 
BRCA1 0 
patients 0 
have 0 
been 0 
sequenced 0 
in 0 
breast 1
cancer 1
patients 0 
without 0 
revealing 0 
any 0 
deleterious 0 
mutations 0 
. 0 

These 0 
new 0 
reagents 0 
should 0 
facilitate 0 
the 0 
identification 0 
of 0 
BRCA1 0 
. 0 
. 0 

Sulfate 0 
transport 0 
is 0 
not 0 
impaired 0 
in 0 
pendred 1
syndrome 1
thyrocytes 0 
. 0 

Pendred 1
syndrome 1
is 0 
the 0 
most 0 
common 0 
form 0 
of 0 
syndromic 1
deafness 1
, 0 
characterized 0 
by 0 
dyshormonogenic 1
goiter 1
associated 0 
with 0 
sensory-neural 1
deafness 1
. 0 

The 0 
gene 0 
responsible 0 
for 0 
the 0 
disease 0 
-LRB- 0 
PDS 1
-RRB- 0 
has 0 
been 0 
cloned 0 
, 0 
but 0 
its 0 
function 0 
is 0 
as 0 
yet 0 
unknown 0 
and 0 
the 0 
connection 0 
between 0 
thyroid 1
goiter 1
and 0 
sensory-neural 1
deafness 1
remains 0 
an 0 
enigma 0 
. 0 

PDS 0 
codes 0 
for 0 
a 0 
novel 0 
protein 0 
, 0 
pendrin 0 
, 0 
which 0 
is 0 
closely 0 
related 0 
to 0 
a 0 
number 0 
of 0 
sufate 0 
transporters 0 
. 0 

Mechanisms 0 
by 0 
which 0 
abnormal 0 
sulfate 0 
transport 0 
could 0 
deleteriously 0 
affect 0 
iodide 0 
organification 0 
have 0 
been 0 
proposed 0 
. 0 

We 0 
tested 0 
sulfate 0 
transport 0 
in 0 
thyrocytes 0 
obtained 0 
from 0 
Pendred 1
syndrome 1
patients 0 
and 0 
found 0 
that 0 
it 0 
was 0 
not 0 
defective 0 
. 0 

This 0 
suggests 0 
that 0 
pendrin 0 
in 0 
fact 0 
may 0 
not 0 
be 0 
a 0 
sulfate 0 
transporter 0 
, 0 
and 0 
emphasizes 0 
the 0 
importance 0 
of 0 
functional 0 
studies 0 
on 0 
this 0 
novel 0 
protein 0 
. 0 
. 0 

Spinal 1
xanthomatosis 1
: 0 
a 0 
variant 0 
of 0 
cerebrotendinous 1
xanthomatosis 1
. 0 

We 0 
describe 0 
seven 0 
Dutch 0 
patients 0 
from 0 
six 0 
families 0 
with 0 
a 0 
slowly 0 
progressive 0 
, 0 
mainly 0 
spinal 1
cord 1
syndrome 1
that 0 
remained 0 
for 0 
many 0 
years 0 
the 0 
sole 0 
expression 0 
of 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
. 0 

MRI 0 
demonstrated 0 
white 1
matter 1
abnormalities 1
in 0 
the 0 
lateral 0 
and 0 
dorsal 0 
columns 0 
of 0 
the 0 
spinal 0
cord 0 
. 0 

Post-mortem 0 
examination 0 
of 0 
one 0 
of 0 
the 0 
patients 0 
showed 0 
extensive 0 
myelin 0 
loss 0 
in 0 
these 0 
columns 0 
. 0 

An 0 
array 0 
of 0 
genotypes 0 
was 0 
found 0 
in 0 
these 0 
patients 0 
. 0 

We 0 
conclude 0 
that 0 
spinal 1
xanthomatosis 1
is 0 
a 0 
clinical 0 
and 0 
radiological 0 
separate 0 
entity 0 
of 0 
CTX 1
that 0 
should 0 
be 0 
included 0 
in 0 
the 0 
differential 0 
diagnosis 0 
of 0 
chronic 1
myelopathy 1
. 0 
. 0 

The 0 
exon 0 
_NUM2 0 
duplication 0 
in 0 
the 0 
BRCA1 0 
gene 0 
is 0 
a 0 
founder 0 
mutation 0 
present 0 
in 0 
geographically 0 
diverse 0 
populations 0 
. 0 

The 0 
BRCA1 0 
Exon 0 
_NUM2 0 
Duplication 0 
Screening 0 
Group 0 
. 0 

Recently 0 
, 0 
a 0 
6-kb 0 
duplication 0 
of 0 
exon 0 
_NUM2 0 
, 0 
which 0 
creates 0 
a 0 
frameshift 0 
in 0 
the 0 
coding 0 
sequence 0 
of 0 
the 0 
BRCA1 0 
gene 0 
, 0 
has 0 
been 0 
described 0 
in 0 
three 0 
unrelated 0 
U. 0 
S 0 
S. 0 
families 0 
of 0 
European 0 
ancestry 0 
and 0 
in 0 
one 0 
Portuguese 0 
family 0 
. 0 

Here 0 
, 0 
our 0 
goal 0 
was 0 
to 0 
estimate 0 
the 0 
frequency 0 
and 0 
geographic 0 
diversity 0 
of 0 
carriers 0 
of 0 
this 0 
duplication 0 
. 0 

To 0 
do 0 
this 0 
, 0 
a 0 
collaborative 0 
screening 0 
study 0 
was 0 
set 0 
up 0 
that 0 
involved 0 
_NUM2 0 
institutions 0 
from 0 
_NUM2 0 
countries 0 
and 0 
included 0 
_NUM1 0 
, 0 
_NUM3 0 
unrelated 0 
individuals 0 
with 0 
a 0 
family 0 
history 0 
of 0 
the 0 
disease 0 
and 0 
_NUM3 0 
early-onset 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
cases 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
additional 0 
families 0 
carrying 0 
this 0 
mutation 0 
were 0 
identified 0 
in 0 
Australia 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
Belgium 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
Canada 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
Great 0 
Britain 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
and 0 
the 0 
United 0 
States 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
. 0 

Haplotyping 0 
showed 0 
that 0 
they 0 
are 0 
likely 0 
to 0 
derive 0 
from 0 
a 0 
common 0 
ancestor 0 
, 0 
possibly 0 
of 0 
northern 0 
British 0 
origin 0 
. 0 

Our 0 
results 0 
demonstrate 0 
that 0 
it 0 
is 0 
strongly 0 
advisable 0 
, 0 
for 0 
laboratories 0 
carrying 0 
out 0 
screening 0 
either 0 
in 0 
English-speaking 0 
countries 0 
or 0 
in 0 
countries 0 
with 0 
historical 0 
links 0 
with 0 
Britain 0 
, 0 
to 0 
include 0 
within 0 
their 0 
BRCA1 0 
screening 0 
protocols 0 
the 0 
polymerase 0 
chain 0 
reaction-based 0 
assay 0 
described 0 
in 0 
this 0 
report 0 
. 0 

Germline 0 
mutations 0 
of 0 
the 0 
BRCA1 0 
gene 0 
in 0 
breast 1
and 1
ovarian 1
cancer 1
families 0 
provide 0 
evidence 0 
for 0 
a 0 
genotype-phenotype 0 
correlation 0 
. 0 

Mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
, 0 
discovered 0 
in 0 
_NUM4 0 
, 0 
are 0 
associated 0 
with 0 
an 0 
80-90 0 
% 0 
lifetime 0 
risk 0 
of 0 
breast 1
cancer 1
. 0 

We 0 
have 0 
analysed 0 
_NUM2 0 
families 0 
with 0 
a 0 
history 0 
of 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
for 0 
germline 0 
mutations 0 
in 0 
BRCA1 0 
. 0 

Twenty-two 0 
different 0 
mutations 0 
were 0 
detected 0 
in 0 
_NUM2 0 
families 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
of 0 
which 0 
_NUM2 0 
are 0 
previously 0 
unreported 0 
. 0 

We 0 
observed 0 
a 0 
significant 0 
correlation 0 
between 0 
the 0 
location 0 
of 0 
the 0 
mutation 0 
in 0 
the 0 
gene 0 
and 0 
the 0 
ratio 0 
of 0 
breast 1
to 1
ovarian 1
cancer 1
incidence 0 
within 0 
each 0 
family 0 
. 0 

Our 0 
data 0 
suggest 0 
a 0 
transition 0 
in 0 
risk 0 
such 0 
that 0 
mutations 0 
in 0 
the 0 
_NUM1 0 
third 0 
of 0 
the 0 
gene 0 
are 0 
associated 0 
with 0 
a 0 
lower 0 
proportion 0 
of 0 
ovarian 1
cancer 1
. 0 

Haplotype 0 
analysis 0 
supports 0 
previous 0 
data 0 
which 0 
suggest 0 
some 0 
BRCA1 0 
mutation 0 
carriers 0 
have 0 
common 0 
ancestors 0 
; 0 
however 0 
, 0 
we 0 
have 0 
found 0 
at 0 
least 0 
two 0 
examples 0 
where 0 
recurrent 0 
mutations 0 
appear 0 
to 0 
have 0 
arisen 0 
independently 0 
. 0 
. 0 

Inactivation 0 
of 0 
the 0 
Friedreich 1
ataxia 1
mouse 0 
gene 0 
leads 0 
to 0 
early 0 
embryonic 1
lethality 1
without 0 
iron 0 
accumulation 0 
. 0 

Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
, 0 
the 0 
most 0 
common 0 
autosomal 1
recessive 1
ataxia 1
, 0 
is 0 
caused 0 
in 0 
almost 0 
all 0 
cases 0 
by 0 
homozygous 0 
intronic 0 
expansions 0 
resulting 0 
in 0 
the 0 
loss 0 
of 0 
frataxin 0 
, 0 
a 0 
mitochondrial 0 
protein 0 
conserved 0 
through 0 
evolution 0 
, 0 
and 0 
involved 0 
in 0 
mitochondrial 0 
iron 0 
homeostasis 0 
. 0 

Yeast 0 
knockout 0 
models 0 
, 0 
and 0 
histological 0 
and 0 
biochemical 0 
data 0 
from 0 
patient 0 
heart 0 
biopsies 0 
or 0 
autopsies 0 
indicate 0 
that 0 
the 0 
frataxin 0 
defect 0 
causes 0 
a 0 
specific 0 
iron-sulfur 1
protein 1
deficiency 1
and 0 
mitochondrial 0 
iron 0 
accumulation 0 
leading 0 
to 0 
the 0 
pathological 0 
changes 0 
. 0 

Affected 0 
human 0 
tissues 0 
are 0 
rarely 0 
available 0 
to 0 
further 0 
examine 0 
this 0 
hypothesis 0 
. 0 

To 0 
study 0 
the 0 
mechanism 0 
of 0 
the 0 
disease 0 
, 0 
we 0 
generated 0 
a 0 
mouse 0 
model 0 
by 0 
deletion 0 
of 0 
exon 0 
_NUM1 0 
leading 0 
to 0 
inactivation 0 
of 0 
the 0 
Frda 1
gene 0 
product 0 
. 0 

We 0 
show 0 
that 0 
homozygous 0 
deletions 0 
cause 0 
embryonic 1
lethality 1
a 0 
few 0 
days 0 
after 0 
implantation 0 
, 0 
demonstrating 0 
an 0 
important 0 
role 0 
for 0 
frataxin 0 
during 0 
early 0 
development 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
the 0 
milder 0 
phenotype 0 
in 0 
humans 0 
is 0 
due 0 
to 0 
residual 0 
frataxin 0 
expression 0 
associated 0 
with 0 
the 0 
expansion 0 
mutations 0 
. 0 

Surprisingly 0 
, 0 
in 0 
the 0 
frataxin 0 
knockout 0 
mouse 0 
, 0 
no 0 
iron 0 
accumulation 0 
was 0 
observed 0 
during 0 
embryonic 0 
resorption 0 
, 0 
suggesting 0 
that 0 
cell 0 
death 0 
could 0 
be 0 
due 0 
to 0 
a 0 
mechanism 0 
independent 0 
of 0 
iron 0 
accumulation 0 
. 0 
. 0 

A 0 
glycine250 0 
-- 0 
> 0 
aspartate 0 
substitution 0 
in 0 
the 0 
alpha-subunit 0 
of 0 
hexosaminidase 0 
A 0 
causes 0 
juvenile-onset 0 
Tay-Sachs 1
disease 1
in 0 
a 0 
Lebanese-Canadian 0 
family 0 
. 0 

The 0 
mutation 0 
causing 0 
juvenile 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
in 0 
two 0 
sibs 0 
of 0 
Lebanese-Maronite 0 
origin 0 
is 0 
described 0 
. 0 

An 0 
mRNA-containing 0 
extract 0 
of 0 
cultured 0 
fibroblasts 0 
obtained 0 
from 0 
one 0 
of 0 
the 0 
probands 0 
was 0 
used 0 
as 0 
a 0 
template 0 
to 0 
amplify 0 
the 0 
coding 0 
sequence 0 
of 0 
the 0 
hexosaminidase 0 
A 0 
-LRB- 0 
Hex 0 
A 0 
-RRB- 0 
alpha-subunit 0 
. 0 

Sequencing 0 
of 0 
amplified 0 
cDNA 0 
fragments 0 
revealed 0 
a 0 
single 0 
alteration 0 
, 0 
guanine 0 
to 0 
adenine 0 
at 0 
nt 0 
_NUM3 0 
creating 0 
a 0 
G250D 0 
mutation 0 
. 0 

The 0 
mutation 0 
introduces 0 
a 0 
new 0 
recognition 0 
site 0 
for 0 
the 0 
restriction 0 
enzyme 0 
Eco 0 
RV 0 
, 0 
permitting 0 
identification 0 
of 0 
heterozygotes 0 
for 0 
this 0 
allele 0 
following 0 
PCR 0 
amplification 0 
and 0 
Eco 0 
RV 0 
digestion 0 
of 0 
exon 0 
_NUM1 0 
sequences 0 
from 0 
genomic 0 
DNA 0 
templates 0 
. 0 

In 0 
order 0 
to 0 
test 0 
the 0 
effect 0 
of 0 
this 0 
substitution 0 
, 0 
an 0 
in 0 
vitro 0 
mutagenized 0 
cDNA 0 
construct 0 
was 0 
introduced 0 
into 0 
a 0 
mammalian 0 
expression 0 
vector 0 
and 0 
transfected 0 
into 0 
monkey 0 
Cos-1 0 
cells 0 
separately 0 
or 0 
along 0 
with 0 
a 0 
beta-cDNA 0 
expression 0 
vector 0 
. 0 

When 0 
the 0 
mutant 0 
alpha-cDNA 0 
was 0 
the 0 
only 0 
gene 0 
introduced 0 
into 0 
COS 0 
cells 0 
no 0 
enzymatic 0 
activity 0 
above 0 
endogenous 0 
COS 0 
cell 0 
activity 0 
was 0 
detected 0 
. 0 

Cotransfection 0 
of 0 
normal 0 
alpha-cDNA 0 
and 0 
beta-cDNA 0 
followed 0 
by 0 
immunoprecipitation 0 
of 0 
human 0 
Hex 0 
A 0 
resulted 0 
in 0 
20-fold 0 
increase 0 
in 0 
the 0 
ratio 0 
between 0 
positive 0 
and 0 
negative 0 
-LRB- 0 
mock 0 
transfection 0 
-RRB- 0 
control 0 
values 0 
. 0 

This 0 
allowed 0 
the 0 
detection 0 
of 0 
some 0 
residual 0 
activity 0 
-LRB- 0 
_NUM2 0 
% 0 
of 0 
the 0 
positive 0 
control 0 
-RRB- 0 
when 0 
the 0 
mutant 0 
alpha-cDNA 0 
replaced 0 
its 0 
wild-type 0 
counterpart 0 
. 0 

The 0 
predicted 0 
protein 0 
environment 0 
in 0 
which 0 
the 0 
mutation 0 
occurs 0 
is 0 
compared 0 
to 0 
that 0 
of 0 
the 0 
adult-onset 0 
Tay-Sachs 1
disease 1
mutation 0 
caused 0 
by 0 
a 0 
Gly269 0 
-- 0 
> 0 
Ser 0 
substitution 0 
in 0 
exon 0 
_NUM1 0 
. 0 

-LRB- 0 
ABSTRACT 0 
TRUNCATED 0 
_DS 0 
_NUM3 0 
WORDS 0 
-RRB- 0 
. 0 

Restriction 0 
of 0 
ocular 0 
fundus 0 
lesions 0 
to 0 
a 0 
specific 0 
subgroup 0 
of 0 
APC 1
mutations 0 
in 0 
adenomatous 1
polyposis 1
coli 1
patients 0 
. 0 

In 0 
humans 0 
, 0 
alteration 0 
of 0 
the 0 
tumor 1
suppressor 0 
gene 0 
, 0 
APC 1
, 0 
causes 0 
adenomatous 1
polyposis 1
coli 1
, 0 
a 0 
condition 0 
causing 0 
predisposition 0 
to 0 
colorectal 1
cancer 1
. 0 

The 0 
syndrome 0 
inconsistently 0 
associates 0 
characteristic 0 
patches 0 
of 0 
congenital 1
hypertrophy 1
of 1
the 1
retinal 1
pigment 1
epithelium 1
-LRB- 0 
CHRPE 1
-RRB- 0 
. 0 

Ocular 0 
examination 0 
revealed 0 
that 0 
patients 0 
expressing 0 
CHRPE 1
tend 0 
to 0 
cluster 0 
within 0 
specific 0 
families 0 
. 0 

The 0 
exact 0 
APC 1
mutation 0 
was 0 
identified 0 
in 0 
_NUM2 0 
unrelated 0 
patients 0 
. 0 

In 0 
all 0 
cases 0 
these 0 
mutations 0 
were 0 
predicted 0 
to 0 
lead 0 
to 0 
the 0 
synthesis 0 
of 0 
a 0 
truncated 0 
protein 0 
. 0 

The 0 
extent 0 
of 0 
CHRPE 1
was 0 
found 0 
to 0 
be 0 
dependent 0 
on 0 
the 0 
position 0 
of 0 
the 0 
mutation 0 
along 0 
the 0 
coding 0 
sequence 0 
. 0 

CHRPE 1
lesions 0 
are 0 
almost 0 
always 0 
absent 0 
if 0 
the 0 
mutation 0 
occurs 0 
before 0 
exon 0 
_NUM1 0 
, 0 
but 0 
are 0 
systematically 0 
present 0 
if 0 
it 0 
occurs 0 
after 0 
this 0 
exon 0 
. 0 

Thus 0 
, 0 
the 0 
range 0 
of 0 
phenotypic 0 
expression 0 
observed 0 
among 0 
affected 0 
patients 0 
may 0 
result 0 
in 0 
part 0 
from 0 
different 0 
allelic 0 
manifestations 0 
of 0 
APC 1
mutations 0 
. 0 
. 0 

Linkage 0 
analysis 0 
of 0 
_NUM2 0 
Canadian 0 
breast 1
and 1
breast-ovarian 1
cancer 1
families 0 
. 0 

We 0 
have 0 
examined 0 
_NUM2 0 
Canadian 0 
families 0 
with 0 
hereditary 1
breast 1
or 1
ovarian 1
cancer 1
for 0 
linkage 0 
to 0 
markers 0 
flanking 0 
the 0 
BRCA1 0 
gene 0 
on 0 
chromosome 0 
17q12-q21 0 
. 0 

Of 0 
the 0 
_NUM2 0 
families 0 
that 0 
contain 0 
cases 0 
of 0 
ovarian 1
cancer 1
, 0 
_NUM2 0 
% 0 
were 0 
estimated 0 
to 0 
be 0 
linked 0 
to 0 
BRCA1 0 
. 0 

In 0 
contrast 0 
, 0 
there 0 
was 0 
no 0 
overall 0 
evidence 0 
of 0 
linkage 0 
in 0 
the 0 
group 0 
of 0 
_NUM2 0 
families 0 
with 0 
breast 1
cancer 1
without 0 
ovarian 1
cancer 1
. 0 

A 0 
genetic 0 
recombinant 0 
in 0 
a 0 
breast-ovarian 1
cancer 1
family 0 
indicates 0 
a 0 
placement 0 
of 0 
BRCA1 0 
telomeric 0 
to 0 
D17S776 0 
, 0 
and 0 
helps 0 
to 0 
define 0 
the 0 
region 0 
of 0 
assignment 0 
of 0 
the 0 
cancer 1
susceptibility 0 
gene 0 
. 0 

Other 0 
cancers 1
of 0 
interest 0 
that 0 
appeared 0 
in 0 
the 0 
BRCA1-linked 0 
families 0 
included 0 
primary 1
peritoneal 1
cancer 1
, 0 
cancer 1
of 1
the 1
fallopian 1
tube 1
, 0 
and 0 
malignant 1
melanoma 1
. 0 
. 0 

Malignant 1
neoplasms 1
in 0 
the 0 
families 0 
of 0 
patients 0 
with 0 
ataxia-telangiectasia 1
. 0 

Ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
syndrome 1
associated 0 
with 0 
a 0 
greatly 0 
increased 0 
incidence 0 
of 0 
malignant 1
neoplasms 1
in 0 
homozygous 0 
affected 0 
individuals 0 
. 0 

Heterozygotes 0 
for 0 
the 0 
gene 0 
for 0 
A-T 1
are 0 
thought 0 
to 0 
comprise 0 
about 0 
_NUM1 0 
% 0 
of 0 
the 0 
general 0 
population 0 
and 0 
, 0 
therefore 0 
, 0 
it 0 
is 0 
important 0 
to 0 
know 0 
whether 0 
this 0 
gene 0 
also 0 
predisposes 0 
the 0 
heterozygous 0 
carrier 0 
to 0 
cancers 1
. 0 

Heterozygous 0 
carriers 0 
of 0 
this 0 
gene 0 
are 0 
common 0 
among 0 
the 0 
close 0 
relatives 0 
of 0 
patients 0 
with 0 
A-T 1
, 0 
although 0 
individual 0 
carriers 0 
can 0 
not 0 
be 0 
identified 0 
by 0 
any 0 
clinical 0 
criterion 0 
or 0 
laboratory 0 
test 0 
. 0 

For 0 
this 0 
reason 0 
, 0 
we 0 
compared 0 
the 0 
incidence 0 
of 0 
death 0 
from 0 
malignant 1
neoplasms 1
in 0 
_NUM1 0 
families 0 
of 0 
patients 0 
with 0 
A-T 1
to 0 
that 0 
expected 0 
in 0 
a 0 
random 0 
sample 0 
of 0 
the 0 
general 0 
population 0 
. 0 

There 0 
were 0 
_NUM2 0 
deaths 0 
from 0 
malignant 1
neoplasms 1
in 0 
relatives 0 
dying 0 
before 0 
age 0 
_NUM2 0 
, 0 
compared 0 
to 0 
_NUM2 0 
. 0 

_NUM1 0 
expected 0 
-LRB- 0 
p 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

For 0 
A-T 1
heterozygotes 0 
younger 0 
than 0 
age 0 
_NUM2 0 
, 0 
the 0 
risk 0 
of 0 
dying 0 
from 0 
a 0 
malignant 1
neoplasm 1
was 0 
estimated 0 
to 0 
be 0 
greater 0 
than 0 
_NUM1 0 
times 0 
the 0 
risk 0 
for 0 
the 0 
general 0 
population 0 
. 0 

A-T 1
heterozygotes 0 
may 0 
comprise 0 
more 0 
than 0 
_NUM1 0 
% 0 
of 0 
all 0 
persons 0 
dying 0 
from 0 
a 0 
cancer 1
before 0 
age 0 
_NUM2 0 
. 0 

The 0 
incidence 0 
of 0 
ovarian 1
, 1
gastric 1
, 1
and 1
biliary 1
system 1
carcinomas 1
and 0 
of 0 
leukemia 1
and 0 
lymphoma 1
was 0 
increased 0 
in 0 
these 0 
A-T 1
families 0 
. 0 

Other 0 
neoplasms 1
that 0 
may 0 
be 0 
associated 0 
with 0 
this 0 
gene 0 
in 0 
heterozygotes 0 
include 0 
pancreatic 1
, 1
basal 1
cell 1
, 1
colonic 1
, 1
breast 1
, 1
and 1
cervical 1
carcinomas 1
. 0 

Molecular 0 
genetics 0 
of 0 
PKU 1
in 0 
eastern 0 
Europe 0 
: 0 
a 0 
nonsense 0 
mutation 0 
associated 0 
with 0 
haplotype 0 
_NUM1 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
a 0 
genetic 1
disorder 1
secondary 0 
to 0 
a 0 
deficiency 1
of 1
hepatic 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

Several 0 
mutations 0 
in 0 
the 0 
PAH 0 
gene 0 
have 0 
recently 0 
been 0 
reported 0 
, 0 
and 0 
linkage 0 
disequilibrium 0 
was 0 
observed 0 
between 0 
RFLP 0 
haplotypes 0 
and 0 
specific 0 
mutations 0 
. 0 

A 0 
new 0 
molecular 1
lesion 1
has 0 
been 0 
identified 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
PAH 0 
gene 0 
in 0 
a 0 
Hungarian 0 
PKU 1
patient 0 
by 0 
direct 0 
sequencing 0 
of 0 
PCR-amplified 0 
DNA 0 
. 0 

The 0 
C-to-T 0 
transition 0 
causes 0 
the 0 
substitution 0 
of 0 
Arg243 0 
to 0 
a 0 
termination 0 
codon 0 
, 0 
and 0 
the 0 
mutant 0 
allele 0 
is 0 
associated 0 
with 0 
haplotype 0 
_NUM1 0 
of 0 
the 0 
PAH 0 
gene 0 
. 0 

The 0 
mutation 0 
is 0 
present 0 
in 0 
two 0 
of 0 
nine 0 
mutant 0 
haplotype 0 
_NUM1 0 
alleles 0 
among 0 
Eastern 0 
Europeans 0 
and 0 
is 0 
not 0 
present 0 
among 0 
Western 0 
Europeans 0 
and 0 
Asians 0 
. 0 

The 0 
rarity 0 
of 0 
this 0 
mutant 0 
allele 0 
and 0 
its 0 
restricted 0 
geographic 0 
distribution 0 
suggest 0 
that 0 
the 0 
mutational 0 
event 0 
occurred 0 
recently 0 
on 0 
a 0 
normal 0 
haplotype 0 
_NUM1 0 
background 0 
in 0 
Eastern 0 
Europe 0 
. 0 
. 0 

Isolation 0 
of 0 
the 0 
mouse 0 
homologue 0 
of 0 
BRCA1 0 
and 0 
genetic 0 
mapping 0 
to 0 
mouse 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
BRCA1 0 
gene 0 
is 0 
in 0 
large 0 
part 0 
responsible 0 
for 0 
hereditary 1
human 1
breast 1
and 1
ovarian 1
cancer 1
. 0 

Here 0 
we 0 
report 0 
the 0 
isolation 0 
of 0 
the 0 
murine 0 
Brca1 0 
homologue 0 
cDNA 0 
clones 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
identified 0 
genomic 0 
P1 0 
clones 0 
that 0 
contain 0 
most 0 
, 0 
if 0 
not 0 
all 0 
, 0 
of 0 
the 0 
mouse 0 
Brca1 0 
locus 0 
. 0 

DNA 0 
sequence 0 
analysis 0 
revealed 0 
that 0 
the 0 
mouse 0 
and 0 
human 0 
coding 0 
regions 0 
are 0 
_NUM2 0 
% 0 
identical 0 
at 0 
the 0 
nucleotide 0 
level 0 
while 0 
the 0 
predicted 0 
amino 0 
acid 0 
identity 0 
is 0 
only 0 
_NUM2 0 
% 0 
. 0 

A 0 
DNA 0 
sequence 0 
variant 0 
in 0 
the 0 
Brca1 0 
locus 0 
was 0 
identified 0 
and 0 
used 0 
to 0 
map 0 
this 0 
gene 0 
on 0 
a 0 
-LRB- 0 
Mus 0 
m. 0 
musculus 0 
Czech 0 
II 0 
x 0 
C57BL 0 
/ 0 
KsJ 0 
-RRB- 0 
F1 0 
x 0 
C57BL 0 
/ 0 
KsJ 0 
intersubspecific 0 
backcross 0 
to 0 
distal 0 
mouse 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
mapping 0 
of 0 
this 0 
gene 0 
to 0 
a 0 
region 0 
highly 0 
syntenic 0 
with 0 
human 0 
chromosome 0 
_NUM2 0 
, 0 
coupled 0 
with 0 
Southern 0 
and 0 
Northern 0 
analyses 0 
, 0 
confirms 0 
that 0 
we 0 
isolated 0 
the 0 
murine 0 
Brca1 0 
homologue 0 
rather 0 
than 0 
a 0 
related 0 
RING 0 
finger 0 
gene 0 
. 0 

The 0 
isolation 0 
of 0 
the 0 
mouse 0 
Brca1 0 
homologue 0 
will 0 
facilitate 0 
the 0 
creation 0 
of 0 
mouse 0 
models 0 
for 0 
germline 0 
BRCA1 1
defects 1
. 0 
. 0 

Human 0 
deficiency 1
of 1
the 1
sixth 1
component 1
of 1
complement 1
in 0 
a 0 
patient 0 
with 0 
meningococcal 1
meningitis 1
and 0 
no 0 
haemostasis 1
abnormality 1
. 0 

A 0 
case 0 
of 0 
human 0 
complete 0 
C6 1
deficiency 1
is 0 
reported 0 
. 0 

The 0 
patient 0 
, 0 
a 0 
_NUM2 0 
year 0 
old 0 
white 0 
male 0 
, 0 
was 0 
seen 0 
on 0 
the 0 
occasion 0 
of 0 
an 0 
isolated 0 
episode 0 
of 0 
meningococcal 1
meningitis 1
. 0 

Serum 0 
complement 0 
hemolytic 0 
and 0 
bactericidal 0 
activities 0 
were 0 
lacking 0 
and 0 
could 0 
be 0 
restored 0 
to 0 
normal 0 
by 0 
addition 0 
of 0 
appropriate 0 
amounts 0 
of 0 
purified 0 
C6 0 
. 0 

No 0 
hemostatic 1
abnormalities 1
were 0 
observed 0 
. 0 
. 0 

The 0 
Wiskott-Aldrich 1
syndrome 1
: 0 
refinement 0 
of 0 
the 0 
localization 0 
on 0 
Xp 0 
and 0 
identification 0 
of 0 
another 0 
closely 0 
linked 0 
marker 0 
locus 0 
, 0 
OATL1 0 
. 0 

The 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
has 0 
previously 0 
been 0 
mapped 0 
to 0 
the 0 
proximal 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
between 0 
the 0 
DXS14 0 
and 0 
DXS7 0 
loci 0 
. 0 

In 0 
this 0 
study 0 
, 0 
further 0 
segregation 0 
analysis 0 
has 0 
been 0 
performed 0 
using 0 
a 0 
newly 0 
identified 0 
WAS 1
family 0 
as 0 
well 0 
as 0 
an 0 
additional 0 
marker 0 
probe 0 
, 0 
HOATL1 0 
. 0 

The 0 
results 0 
indicate 0 
close 0 
linkage 0 
between 0 
the 0 
WAS 1
and 0 
OATL1 0 
loci 0 
-LRB- 0 
Z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
localize 0 
the 0 
TIMP 0 
, 0 
OATL1 0 
, 0 
DXS255 0 
, 0 
and 0 
WAS 1
loci 0 
distal 0 
to 0 
DXS146 0 
and 0 
the 0 
OATL1 0 
and 0 
WAS 1
loci 0 
proximal 0 
to 0 
TIMP 0 
. 0 

These 0 
linkage 0 
data 0 
narrow 0 
the 0 
boundaries 0 
within 0 
which 0 
the 0 
WAS 1
locus 0 
maps 0 
to 0 
the 0 
chromosomal 0 
region 0 
bracketed 0 
by 0 
TIMP 0 
and 0 
DXS146 0 
and 0 
support 0 
the 0 
loci 0 
order 0 
Xpter-DXS7-TIMP 0 
- 0 
-LRB- 0 
OATL1 0 
, 0 
WAS 0 
, 0 
DXS255 0 
-RRB- 0 
- 0 
DXS146 0 
. 0 

Hereditary 1
deficiency 1
of 1
the 1
third 1
component 1
of 1
complement 1
in 0 
a 0 
child 0 
with 0 
fever 1
, 0 
skin 1
rash 1
, 0 
and 0 
arthralgias 1
: 0 
response 0 
to 0 
transfusion 0 
of 0 
whole 0 
blood 0 
. 0 

A 0 
previously 0 
well 0 
34-month-old 0 
male 0 
presenting 0 
with 0 
fever 1
, 0 
skin 1
rash 1
, 0 
and 0 
arthralgias 1
was 0 
found 0 
to 0 
lack 0 
C3 0 
by 0 
immunochemical 0 
-LRB- 0 
undetectable 0 
-RRB- 0 
and 0 
hemolytic 0 
-LRB- 0 
_NUM1 0 
% 0 
normal 0 
-RRB- 0 
assays 0 
. 0 

No 0 
infectious 0 
agent 0 
could 0 
be 0 
demonstrated 0 
. 0 

Protein 0 
levels 0 
of 0 
Clq 0 
. 0 

C4 0 
, 0 
C5 0 
, 0 
properdin 0 
, 0 
and 0 
C3b-INA 0 
and 0 
hemolytic 0 
activities 0 
of 0 
complement 0 
components 0 
C1 0 
to 0 
C9 0 
except 0 
C3 0 
were 0 
normal 0 
or 0 
elevated 0 
; 0 
total 0 
hemolytic 0 
complement 0 
activity 0 
was 0 
_NUM2 0 
% 0 
of 0 
normal 0 
and 0 
was 0 
reconstituted 0 
by 0 
purified 0 
C3 0 
. 0 

Properdin 0 
factor 0 
B 0 
was 0 
_NUM3 0 
-LRB- 0 
normal 0 
_NUM3 0 
to 0 
_NUM3 0 
-RRB- 0 
mug 0 
/ 0 
ml 0 
, 0 
and 0 
was 0 
not 0 
cleaver 0 
upon 0 
addition 0 
of 0 
zymosan 0 
or 0 
cobra 0 
venom 0 
factor 0 
. 0 

The 0 
serum 0 
had 0 
normal 0 
immune 0 
adherence 0 
activity 0 
, 0 
but 0 
was 0 
deficient 0 
in 0 
ability 0 
to 0 
opsonize 0 
Candida 0 
albicans 0 
for 0 
uptake 0 
and 0 
Escherichia 0 
coli 0 
for 0 
killing 0 
by 0 
neurophils 0 
, 0 
generate 0 
neutrophil 0 
chemotactic 0 
factors 0 
and 0 
inhibit 0 
the 0 
growth 0 
of 0 
E. 0 
coli 0 
; 0 
these 0 
activities 0 
were 0 
restored 0 
by 0 
purified 0 
C3 0 
. 0 

A 0 
transfusion 0 
of 0 
_NUM3 0 
ml 0 
1-hour-old 0 
normal 0 
whole 0 
blood 0 
on 0 
the 0 
fifty-second 0 
day 0 
resulted 0 
in 0 
transitory 0 
elevation 0 
of 0 
the 0 
C3 0 
level 0 
to 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
with 0 
a 0 
fall-off 0 
-LRB- 0 
approximately 0 
2 1 0 
/ 0 
2 0 
% 0 
per 0 
hour 0 
-RRB- 0 
to 0 
undetectable 0 
levels 0 
by 0 
_NUM2 0 
hours 0 
; 0 
it 0 
was 0 
followed 0 
by 0 
disappearance 0 
of 0 
the 0 
skin 1
rash 1
and 0 
arthralgias 1
and 0 
return 0 
to 0 
normal 0 
of 0 
the 0 
previously 0 
elevated 0 
temperature 0 
and 0 
CRP 0 
levels 0 
. 0 

C3 0 
levels 0 
in 0 
family 0 
members 0 
-LRB- 0 
seven 0 
of 0 
_NUM2 0 
half-normal 0 
-RRB- 0 
, 0 
lack 0 
of 0 
anti-C3 0 
activity 0 
, 0 
normal 0 
C3b-INA 0 
levels 0 
and 0 
a 0 
normal 0 
rate 0 
of 0 
catabolism 0 
of 0 
transfused 0 
C3 0 
indicated 0 
that 0 
the 0 
deficiency 0 
was 0 
inherited 0 
with 0 
autosomal 0 
codominance 0 
and 0 
involved 0 
decreased 1
synthesis 1
of 1
C3 1
. 0 

Thus 0 
, 0 
this 0 
child 0 
is 0 
a 0 
unique 0 
individual 0 
with 0 
inherited 1
C3 1
deficiency 1
presenting 0 
with 0 
absence 0 
of 0 
repeated 0 
infections 0 
, 0 
whose 0 
symptoms 0 
of 0 
fever 1
, 0 
skin 1
rash 1
, 0 
and 0 
arthralgia 1
were 0 
abated 0 
by 0 
whole 0 
blood 0 
transfusion 0 
. 0 
. 0 

Cloning 0 
of 0 
breakpoints 0 
of 0 
a 0 
chromosome 0 
translocation 0 
identifies 0 
the 0 
AN2 0 
locus 0 
. 0 

Chromosome 0 
translocations 0 
involving 0 
11p13 0 
have 0 
been 0 
associated 0 
with 0 
familial 1
aniridia 1
in 0 
two 0 
kindreds 0 
highlighting 0 
the 0 
chromosomal 0 
localization 0 
of 0 
the 0 
AN2 0 
locus 0 
. 0 

This 0 
locus 0 
is 0 
also 0 
part 0 
of 0 
the 0 
WAGR 1
complex 0 
-LRB- 0 
Wilms 1
tumor 1
, 0 
aniridia 1
, 0 
genitourinary 1
abnormalities 1
, 0 
and 0 
mental 1
retardation 1
-RRB- 0 
. 0 

In 0 
one 0 
kindred 0 
, 0 
the 0 
translocation 0 
is 0 
associated 0 
with 0 
a 0 
deletion 0 
, 0 
and 0 
probes 0 
for 0 
this 0 
region 0 
were 0 
used 0 
to 0 
identify 0 
and 0 
clone 0 
the 0 
breakpoints 0 
of 0 
the 0 
translocation 0 
in 0 
the 0 
second 0 
kindred 0 
. 0 

Comparison 0 
of 0 
phage 0 
restriction 0 
maps 0 
exclude 0 
the 0 
presence 0 
of 0 
any 0 
sizable 0 
deletion 0 
in 0 
this 0 
case 0 
. 0 

Sequences 0 
at 0 
the 0 
chromosome 0 
_NUM2 0 
breakpoint 0 
are 0 
conserved 0 
in 0 
multiple 0 
species 0 
, 0 
suggesting 0 
that 0 
the 0 
translocation 0 
falls 0 
within 0 
the 0 
AN2 0 
gene 0 
. 0 
. 0 

Study 0 
of 0 
the 0 
voltage-gated 0 
sodium 0 
channel 0 
beta 0 
_NUM1 0 
subunit 0 
gene 0 
-LRB- 0 
SCN1B 0 
-RRB- 0 
in 0 
the 0 
benign 1
familial 1
infantile 1
convulsions 1
syndrome 1
-LRB- 0 
BFIC 1
-RRB- 0 
. 0 

Benign 1
familial 1
infantile 1
convulsions 1
-LRB- 0 
BFIC 1
-RRB- 0 
is 0 
a 0 
rare 0 
autosomal 1
dominant 1
epilepsy 1
syndrome 1
. 0 

This 0 
syndrome 0 
has 0 
been 0 
recently 0 
described 0 
in 0 
Italian 0 
and 0 
French 0 
pedigrees 0 
. 0 

Patients 0 
present 0 
with 0 
partial 0 
, 0 
then 0 
generalized 0 
seizures 0 
, 0 
with 0 
onset 0 
at 0 
age 0 
three 0 
months 0 
. 0 

The 0 
seizures 0 
usually 0 
spontaneously 0 
cease 0 
after 0 
one 0 
year 0 
without 0 
treatment 0 
, 0 
leaving 0 
no 0 
neurological 1
abnormalities 1
. 0 

We 0 
have 0 
mapped 0 
BFIC 1
to 0 
chromosome 0 
19q 0 
in 0 
five 0 
Italian 0 
pedigrees 0 
. 0 

The 0 
sodium 0 
channel 0 
beta1 0 
subunit 0 
gene 0 
-LRB- 0 
SCN1B 0 
-RRB- 0 
maps 0 
to 0 
this 0 
candidate 0 
region 0 
and 0 
has 0 
been 0 
shown 0 
to 0 
be 0 
involved 0 
in 0 
one 0 
Australian 0 
pedigree 0 
with 0 
generalized 1
epilepsy 1
and 1
febrile 1
seizures 1
plus 1
-LRB- 0 
GEFS 0 
+ 0 
-RRB- 0 
. 0 

In 0 
this 0 
family 0 
, 0 
a 0 
missense 0 
mutation 0 
in 0 
SCN1B 0 
cosegregates 0 
with 0 
the 0 
GEFS 0 
+ 0 
phenotype 0 
. 0 

BFIC 1
and 0 
GEFS 0 
+ 0 
have 0 
clinical 0 
features 0 
in 0 
common 0 
, 0 
therefore 0 
SCN1B 0 
is 0 
a 0 
candidate 0 
gene 0 
for 0 
BFIC 1
. 0 

We 0 
studied 0 
SCN1B 0 
exons 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
and 0 
_NUM1 0 
, 0 
using 0 
four 0 
SSCP 0 
methods 0 
in 0 
_NUM2 0 
Caucasian 0 
BFIC 1
probands 0 
of 0 
Western 0 
Europe 0 
. 0 

We 0 
found 0 
no 0 
exon 0 
variants 0 
. 0 

One 0 
variant 0 
was 0 
identified 0 
in 0 
intron 0 
_NUM1 0 
-LRB- 0 
IVS5-10C 0 
> 0 
G 0 
-RRB- 0 
, 0 
which 0 
did 0 
not 0 
segregate 0 
with 0 
BFIC 1
and 0 
was 0 
observed 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
controls 0 
. 0 

A 0 
second 0 
variant 0 
in 0 
intron 0 
_NUM1 0 
was 0 
identified 0 
-LRB- 0 
IVS5 0 
+ 0 
30G 0 
> 0 
A 0 
-RRB- 0 
. 0 

It 0 
was 0 
rare 0 
, 0 
as 0 
not 0 
observed 0 
in 0 
controls 0 
, 0 
but 0 
not 0 
segregating 0 
with 0 
the 0 
BFIC 1
phenotype 0 
. 0 

Brain 1
disease 1
and 0 
molecular 0 
analysis 0 
in 0 
myotonic 1
dystrophy 1
. 0 

Abnormal 0 
amplification 0 
of 0 
a 0 
_DS 0 
repeat 0 
on 0 
chromosome 0 
_NUM2 0 
is 0 
the 0 
molecular 0 
basis 0 
of 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

Expansion 0 
of 0 
the 0 
repeat 0 
has 0 
been 0 
correlated 0 
with 0 
severity 0 
of 0 
several 0 
clinical 0 
features 0 
of 0 
the 0 
disease 0 
. 0 

We 0 
performed 0 
extensive 0 
cognitive 0 
testing 0 
, 0 
cerebral 0 
magnetic 0 
resonance 0 
imaging 0 
-LRB- 0 
MRI 0 
-RRB- 0 
and 0 
a 0 
molecular 0 
analysis 0 
in 0 
_NUM2 0 
cases 0 
of 0 
DM 1
to 0 
determine 0 
the 0 
relationship 0 
between 0 
the 0 
molecular 0 
defect 0 
and 0 
brain 1
disease 1
. 0 

Performance 0 
in 0 
two 0 
or 0 
more 0 
cognitive 0 
tests 0 
was 0 
pathological 0 
in 0 
_NUM2 0 
cases 0 
. 0 

Fourteen 0 
patients 0 
had 0 
subcortical 0 
white 1
matter 1
lesions 1
on 0 
MRI 0 
, 0 
_NUM2 0 
had 0 
cerebral 1
atrophy 1
. 0 

Amplification 0 
of 0 
the 0 
_DS 0 
repeat 0 
showed 0 
a 0 
strong 0 
correlation 0 
with 0 
cognitive 0 
test 0 
deficits 0 
when 0 
exceeding 0 
a 0 
length 0 
of 0 
over 0 
_NUM4 0 
trinucleotides 0 
. 0 

MRI 0 
lesions 0 
were 0 
associated 0 
with 0 
impaired 0 
psychometric 0 
performance 0 
, 0 
but 0 
MRI 0 
and 0 
molecular 0 
findings 0 
were 0 
only 0 
weakly 0 
related 0 
. 0 

Disease 0 
duration 0 
influenced 0 
the 0 
appearance 0 
and 0 
amount 0 
of 0 
white 1
matter 1
lesions 1
on 0 
MRI 0 
. 0 

Quantification 0 
of 0 
_DS 0 
repeat 0 
size 0 
may 0 
allow 0 
an 0 
early 0 
estimate 0 
on 0 
the 0 
probability 0 
of 0 
brain 0 
involvement 0 
in 0 
DM 1
; 0 
cognitive 1
dysfunction 1
is 0 
associated 0 
with 0 
white 1
matter 1
lesions 1
and 0 
cerebral 1
atrophy 1
later 0 
on 0 
in 0 
the 0 
course 0 
. 0 
. 0 

A 0 
highly 0 
accurate 0 
, 0 
low 0 
cost 0 
test 0 
for 0 
BRCA1 0 
mutations 0 
. 0 

The 0 
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
syndrome 1
is 0 
associated 0 
with 0 
a 0 
high 0 
frequency 0 
of 0 
BRCA1 0 
mutations 0 
. 0 

However 0 
, 0 
the 0 
widespread 0 
use 0 
of 0 
BRCA1 0 
testing 0 
has 0 
been 0 
limited 0 
to 0 
date 0 
by 0 
three 0 
principal 0 
concerns 0 
the 0 
fear 0 
of 0 
loss 0 
of 0 
health 0 
and 0 
life 0 
insurance 0 
, 0 
the 0 
uncertain 0 
clinical 0 
value 0 
of 0 
a 0 
positive 0 
test 0 
result 0 
, 0 
and 0 
the 0 
current 0 
lack 0 
of 0 
an 0 
inexpensive 0 
and 0 
sensitive 0 
screening 0 
test 0 
for 0 
BRCA1 0 
mutations 0 
. 0 

We 0 
have 0 
developed 0 
an 0 
inexpensive 0 
system 0 
for 0 
gene 0 
mutational 0 
scanning 0 
, 0 
based 0 
on 0 
a 0 
combination 0 
of 0 
extensive 0 
multiplex 0 
PCR 0 
amplification 0 
and 0 
two 0 
dimensional 0 
electrophoresis 0 
. 0 

The 0 
efficiency 0 
of 0 
this 0 
system 0 
, 0 
as 0 
a 0 
screening 0 
test 0 
for 0 
BRCA1 0 
mutations 0 
, 0 
was 0 
evaluated 0 
in 0 
a 0 
panel 0 
of 0 
_NUM2 0 
samples 0 
from 0 
high 0 
risk 0 
women 0 
, 0 
_NUM2 0 
of 0 
which 0 
contained 0 
a 0 
previously 0 
identified 0 
mutation 0 
in 0 
BRCA1 0 
. 0 

All 0 
_NUM2 0 
mutations 0 
were 0 
identified 0 
, 0 
as 0 
well 0 
as 0 
an 0 
additional 0 
five 0 
that 0 
had 0 
previously 0 
escaped 0 
detection 0 
. 0 

In 0 
addition 0 
to 0 
the 0 
_NUM2 0 
mutations 0 
, 0 
a 0 
total 0 
of 0 
_NUM2 0 
different 0 
polymorphic 0 
variants 0 
were 0 
scored 0 
, 0 
most 0 
of 0 
which 0 
were 0 
recurring 0 
. 0 

All 0 
were 0 
confirmed 0 
by 0 
nucleotide 0 
sequencing 0 
. 0 

The 0 
cost 0 
of 0 
screening 0 
per 0 
sample 0 
was 0 
calculated 0 
to 0 
be 0 
approximately 0 
US 0 
$ 0 
_NUM2 0 
for 0 
the 0 
manual 0 
technique 0 
used 0 
in 0 
this 0 
study 0 
, 0 
and 0 
may 0 
be 0 
reduced 0 
to 0 
approximately 0 
US 0 
$ 0 
_NUM2 0 
with 0 
the 0 
introduction 0 
of 0 
commercially 0 
available 0 
PCR 0 
robotics 0 
and 0 
fluorescent 0 
imaging 0 
. 0 

Implementation 0 
of 0 
this 0 
method 0 
of 0 
mutation 0 
screening 0 
in 0 
the 0 
research 0 
and 0 
clinical 0 
setting 0 
should 0 
permit 0 
rapid 0 
accrual 0 
of 0 
quantitative 0 
data 0 
on 0 
genotype-phenotype 0 
associations 0 
for 0 
the 0 
evaluation 0 
of 0 
diagnostic 0 
testing 0 
. 0 
. 0 

Germline 0 
mutations 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
Korean 0 
familial 1
adenomatous 1
polyposis 1
patients 0 
. 0 

We 0 
extensively 0 
analyzed 0 
genomic 0 
DNA 0 
and 0 
messenger 0 
RNA 0 
-LRB- 0 
mRNA 0 
-RRB- 0 
from 0 
_NUM2 0 
unrelated 0 
Korean 0 
patients 0 
with 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
for 0 
identification 0 
of 0 
germline 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
mutations 0 
. 0 

We 0 
adopted 0 
both 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
analysis 0 
and 0 
a 0 
method 0 
of 0 
analysis 0 
involving 0 
the 0 
reverse 0 
transcription-polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
RT-PCR 0 
-RRB- 0 
followed 0 
by 0 
a 0 
protein 0 
truncation 0 
test 0 
-LRB- 0 
PTT 0 
-RRB- 0 
. 0 

DNA 0 
sequencing 0 
confirmed 0 
all 0 
alterations 0 
represented 0 
by 0 
aberrant 0 
bands 0 
. 0 

Germline 0 
mutations 0 
were 0 
identified 0 
in 0 
_NUM2 0 
patients 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

Nineteen 0 
of 0 
the 0 
detected 0 
mutations 0 
were 0 
presumed 0 
to 0 
be 0 
novel 0 
, 0 
thus 0 
emphasizing 0 
the 0 
heterogeneity 0 
of 0 
the 0 
mutational 0 
spectrum 0 
in 0 
Korean 0 
FAP 1
patients 0 
. 0 

In 0 
the 0 
initial 0 
_NUM2 0 
patients 0 
, 0 
SSCP 0 
analysis 0 
was 0 
followed 0 
by 0 
PTT 0 
for 0 
those 0 
patients 0 
for 0 
whom 0 
no 0 
detectable 0 
mutations 0 
were 0 
found 0 
by 0 
SSCP 0 
. 0 

Using 0 
this 0 
combined 0 
approach 0 
, 0 
we 0 
identified 0 
germline 0 
APC 1
gene 0 
mutations 0 
in 0 
_NUM2 0 
of 0 
the 0 
_NUM2 0 
FAP 1
patients 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
including 0 
_NUM1 0 
patients 0 
in 0 
whom 0 
SSCP 0 
analysis 0 
failed 0 
to 0 
distinguish 0 
the 0 
mutant 0 
allele 0 
. 0 

In 0 
the 0 
_NUM2 0 
later 0 
patients 0 
, 0 
we 0 
identified 0 
truncating 0 
mutations 0 
in 0 
_NUM1 0 
patients 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
using 0 
PTT 0 
only 0 
. 0 

Our 0 
results 0 
confirm 0 
that 0 
the 0 
mutation 0 
detection 0 
rate 0 
with 0 
PTT 0 
was 0 
superior 0 
to 0 
that 0 
with 0 
SSCP 0 
, 0 
and 0 
suggest 0 
that 0 
PTT 0 
would 0 
be 0 
a 0 
more 0 
practical 0 
screening 0 
method 0 
to 0 
detect 0 
germline 0 
mutations 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
FAP 1
patients 0 
. 0 

Homozygosity 0 
mapping 0 
in 0 
a 0 
family 0 
with 0 
microcephaly 1
, 0 
mental 1
retardation 1
, 0 
and 0 
short 1
stature 1
to 0 
a 0 
Cohen 1
syndrome 1
region 0 
on 0 
8q21.3-8q22 0 
.1 0 
: 0 
redefining 0 
a 0 
clinical 0 
entity 0 
. 0 

A 0 
syndrome 0 
of 0 
microcephaly 1
, 0 
progressive 0 
postnatal 1
growth 1
deficiency 1
, 0 
and 0 
mental 1
retardation 1
was 0 
observed 0 
in 0 
two 0 
brothers 0 
and 0 
their 0 
cousin 0 
from 0 
a 0 
multiply 0 
consanguineous 0 
kindred 0 
of 0 
Lebanese 0 
descent 0 
. 0 

Hypotonia 1
, 0 
chorioretinal 1
dystrophy 1
, 0 
and 0 
myopia 1
were 0 
also 0 
identified 0 
. 0 

The 0 
severity 0 
of 0 
the 0 
condition 0 
varied 0 
among 0 
the 0 
closely 0 
related 0 
patients 0 
. 0 

Because 0 
of 0 
absence 0 
of 0 
a 0 
distinctive 0 
facial 0 
appearance 0 
, 0 
the 0 
degree 0 
of 0 
mental 1
retardation 1
, 0 
and 0 
short 1
stature 1
, 0 
the 0 
initially 0 
considered 0 
clinical 0 
diagnosis 0 
of 0 
Cohen 1
syndrome 1
was 0 
withdrawn 0 
and 0 
a 0 
novel 0 
genetic 0 
entity 0 
was 0 
assumed 0 
. 0 

Homozygosity 0 
mapping 0 
in 0 
this 0 
family 0 
assigned 0 
the 0 
gene 0 
to 0 
a 0 
_NUM2 0 
. 0 

8-cM 0 
region 0 
on 0 
the 0 
chromosome 0 
band 0 
8q21 0 
. 0 

_NUM1 0 
-22 0 
. 0 

_NUM1 0 
, 0 
between 0 
the 0 
microsatellites 0 
at 0 
D8S270 0 
and 0 
D8S514 0 
. 0 

The 0 
maximum 0 
two-point 0 
LOD 0 
score 0 
was 0 
found 0 
for 0 
marker 0 
at 0 
D8S267 0 
-LRB- 0 
Zmax 0 
= 0 
_NUM1 0 
. 0 
. 0 

_NUM3 0 
at 0 
Omax 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Intriguingly 0 
enough 0 
, 0 
the 0 
identified 0 
gene 0 
region 0 
overlaps 0 
the 0 
refined 0 
gene 0 
region 0 
for 0 
Cohen 1
syndrome 1
-LRB- 0 
COH1 0 
-RRB- 0 
-LSB- 0 
Kolehmainen 0 
et 0 
al. 0 
, 0 
_NUM4 0 
Euro 0 
J 0 
Hum 0 
Genet 0 
_NUM1 0 
206-213 0 
-RSB- 0 
. 0 

This 0 
fact 0 
encourages 0 
the 0 
hypothesis 0 
that 0 
the 0 
described 0 
kindred 0 
segregates 0 
for 0 
a 0 
variant 0 
of 0 
Cohen 1
syndrome 1
and 0 
suggests 0 
a 0 
redefinition 0 
of 0 
its 0 
phenotype 0 
Spontaneous 0 
reversion 0 
of 0 
novel 0 
Lesch-Nyhan 1
mutation 0 
by 0 
HPRT 0 
gene 0 
rearrangement 0 
. 0 

Molecular 0 
analysis 0 
of 0 
an 0 
unusual 0 
patient 0 
with 0 
the 0 
Lesch-Nyhan 1
syndrome 1
has 0 
suggested 0 
that 0 
the 0 
mutation 0 
is 0 
due 0 
to 0 
a 0 
partial 0 
HPRT 0 
gene 0 
duplication 0 
. 0 

We 0 
now 0 
report 0 
the 0 
cloning 0 
and 0 
sequencing 0 
of 0 
the 0 
mutant 0 
HPRT 0 
cDNA 0 
which 0 
shows 0 
the 0 
precise 0 
duplication 0 
of 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
. 0 

This 0 
mutation 0 
is 0 
the 0 
result 0 
of 0 
an 0 
internal 0 
duplication 0 
of 0 
16-20 0 
kilobases 0 
of 0 
the 0 
gene 0 
. 0 

The 0 
structure 0 
of 0 
the 0 
mutant 0 
gene 0 
suggests 0 
that 0 
the 0 
duplication 0 
was 0 
not 0 
generated 0 
by 0 
a 0 
single 0 
unequal 0 
crossing-over 0 
event 0 
between 0 
two 0 
normal 0 
HPRT 0 
alleles 0 
. 0 

Growth 0 
of 0 
Epstein-Barr 1
virus-transformed 0 
lymphoblasts 0 
from 0 
this 0 
patient 0 
in 0 
selective 0 
medium 0 
has 0 
permitted 0 
isolation 0 
of 0 
spontaneous 0 
HPRT 0 
+ 0 
revertants 0 
of 0 
this 0 
mutation 0 
. 0 

The 0 
reversion 0 
event 0 
involves 0 
a 0 
second 0 
major 0 
HPRT 0 
gene 0 
rearrangement 0 
where 0 
most 0 
or 0 
all 0 
of 0 
the 0 
duplicated 0 
portion 0 
of 0 
the 0 
mutant 0 
gene 0 
is 0 
deleted 0 
. 0 

The 0 
original 0 
mutation 0 
therefore 0 
has 0 
the 0 
potential 0 
for 0 
spontaneous 0 
somatic 0 
reversion 0 
. 0 

This 0 
may 0 
explain 0 
the 0 
relatively 0 
mild 0 
symptoms 0 
of 0 
the 0 
Lesch-Nyhan 1
syndrome 1
exhibited 0 
by 0 
this 0 
patient 0 
. 0 
. 0 

Nephropathy 1
in 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
. 0 

Nephropathy 1
was 0 
detected 0 
in 0 
five 0 
of 0 
_NUM2 0 
patients 0 
with 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
who 0 
were 0 
participating 0 
in 0 
a 0 
study 0 
of 0 
transfer 0 
factor 0 
-LRB- 0 
TF 0 
-RRB- 0 
therapy 0 
. 0 

In 0 
two 0 
patients 0 
, 0 
nephropathy 1
was 0 
present 0 
before 0 
TF 0 
and 0 
did 0 
not 0 
appear 0 
changed 0 
by 0 
TF 0 
therapy 0 
. 0 

One 0 
of 0 
these 0 
patients 0 
subsequently 0 
developed 0 
progressive 0 
renal 1
failure 1
requiring 0 
dialysis 0 
beginning 0 
5 1 0 
/ 0 
2 0 
years 0 
after 0 
TF 0 
therapy 0 
. 0 

In 0 
two 0 
patients 0 
, 0 
decreased 0 
renal 0
function 0 
appeared 0 
very 0 
soon 0 
after 0 
the 0 
administration 0 
of 0 
TF 0 
. 0 

One 0 
patient 0 
showed 0 
gradually 0 
decreasing 0 
renal 0
function 0 
beginning 0 
after 0 
two 0 
years 0 
of 0 
TF 0 
therapy 0 
. 0 

An 0 
additional 0 
patient 0 
was 0 
identified 0 
who 0 
died 0 
with 0 
renal 1
failure 1
without 0 
having 0 
received 0 
TF 0 
. 0 

The 0 
results 0 
suggest 0 
that 0 
renal 1
failure 1
occurs 0 
in 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
more 0 
frequently 0 
than 0 
generally 0 
recognized 0 
and 0 
that 0 
administration 0 
of 0 
TF 0 
may 0 
precipitate 0 
or 0 
accelerate 0 
the 0 
renal 1
disease 1
in 0 
patients 0 
with 0 
this 0 
syndrome 0 
. 0 
. 0 

Aniridia 1
associated 0 
cytogenetic 0 
rearrangements 0 
suggest 0 
that 0 
a 0 
position 0 
effect 0 
may 0 
cause 0 
the 0 
mutant 0 
phenotype 0 
. 0 

Current 0 
evidence 0 
suggests 0 
that 0 
aniridia 1
-LRB- 0 
absence 1
of 1
iris 1
-RRB- 0 
is 0 
caused 0 
by 0 
loss 0 
of 0 
function 0 
of 0 
one 0 
copy 0 
of 0 
the 0 
PAX6 0 
gene 0 
, 0 
which 0 
maps 0 
to 0 
11p13 0 
. 0 

We 0 
present 0 
the 0 
further 0 
characterisation 0 
of 0 
two 0 
aniridia 1
pedigrees 0 
in 0 
which 0 
the 0 
disease 0 
segregates 0 
with 0 
chromosomal 0 
rearrangements 0 
which 0 
involve 0 
11p13 0 
but 0 
do 0 
not 0 
disrupt 0 
the 0 
PAX6 0 
gene 0 
. 0 

We 0 
have 0 
isolated 0 
three 0 
human 0 
YAC 0 
clones 0 
which 0 
encompass 0 
the 0 
PAX6 0 
locus 0 
and 0 
we 0 
have 0 
used 0 
these 0 
to 0 
show 0 
that 0 
in 0 
both 0 
cases 0 
the 0 
chromosomal 0 
breakpoint 0 
is 0 
at 0 
least 0 
_NUM2 0 
kb 0 
distal 0 
of 0 
the 0 
_NUM1 0 
end 0 
of 0 
PAX6 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
open 0 
reading 0 
frame 0 
of 0 
PAX6 0 
is 0 
apparently 0 
free 0 
of 0 
mutations 0 
. 0 

We 0 
propose 0 
that 0 
the 0 
PAX6 0 
gene 0 
on 0 
the 0 
rearranged 0 
chromosome 0 
_NUM2 0 
is 0 
in 0 
an 0 
inappropriate 0 
chromatin 0 
environment 0 
for 0 
normal 0 
expression 0 
and 0 
therefore 0 
that 0 
a 0 
position 0 
effect 0 
is 0 
the 0 
underlying 0 
mechanism 0 
of 0 
disease 0 
in 0 
these 0 
families 0 
. 0 
. 0 

Genetic 0 
cholesteryl 1
ester 1
transfer 1
protein 1
deficiency 1
caused 0 
by 0 
two 0 
prevalent 0 
mutations 0 
as 0 
a 0 
major 0 
determinant 0 
of 0 
increased 0 
levels 0 
of 0 
high 0 
density 0 
lipoprotein 0 
cholesterol 0 
. 0 

Genetic 0 
determinants 0 
of 0 
HDL 0 
cholesterol 0 
-LRB- 0 
HDL-C 0 
-RRB- 0 
levels 0 
in 0 
the 0 
general 0 
population 0 
are 0 
poorly 0 
understood 0 
. 0 

We 0 
previously 0 
described 0 
plasma 0 
cholesteryl 1
ester 1
transfer 1
protein 1
-LRB- 1
CETP 1
-RRB- 1
deficiency 1
due 0 
to 0 
an 0 
intron 0 
_NUM2 0 
G 0 
-LRB- 0 
+ 0 
_NUM1 0 
-RRB- 0 
- 0 
to-A 0 
mutation 0 
-LRB- 0 
Int14 0 
A 0 
-RRB- 0 
in 0 
several 0 
families 0 
with 0 
very 0 
high 0 
HDL-C 0 
levels 0 
in 0 
Japan 0 
. 0 

Subjects 0 
with 0 
HDL-C 0 
> 0 
or 0 
= 0 
_NUM3 0 
mg 0 
/ 0 
dl 0 
-LRB- 0 
n 0 
= 0 
_NUM3 0 
-RRB- 0 
were 0 
screened 0 
by 0 
PCR 0 
single 0 
strand 0 
conformational 0 
polymorphism 0 
analysis 0 
of 0 
the 0 
CETP 0
gene 0 
. 0 

Two 0 
other 0 
mutations 0 
were 0 
identified 0 
by 0 
DNA 0 
sequencing 0 
or 0 
primer-mediated 0 
restriction 0 
map 0 
modification 0 
of 0 
PCR 0 
products 0 
a 0 
novel 0 
intron 0 
_NUM2 0 
splice 0 
donor 0 
site 0 
mutation 0 
caused 0 
by 0 
a 0 
T 0 
insertion 0 
at 0 
position 0 
+ 0 
_NUM1 0 
from 0 
the 0 
exon14 0 
/ 0 
intron14 0 
boundary 0 
-LRB- 0 
Int14 0 
T 0 
-RRB- 0 
and 0 
a 0 
missense 0 
mutation 0 
-LRB- 0 
Asp442 0 
to 0 
Gly 0 
-RRB- 0 
within 0 
exon 0 
_NUM2 0 
-LRB- 0 
D442G 0 
-RRB- 0 
. 0 

The 0 
Int14 0 
T 0 
mutation 0 
was 0 
only 0 
found 0 
in 0 
one 0 
family 0 
. 0 

However 0 
, 0 
the 0 
D442G 0 
and 0 
Int14 0 
A 0 
mutations 0 
were 0 
highly 0 
prevalent 0 
in 0 
subjects 0 
with 0 
HDL-C 0 
> 0 
or 0 
= 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
, 0 
with 0 
combined 0 
allele 0 
frequencies 0 
of 0 
_NUM1 0 
% 0 
, 0 
_NUM2 0 
% 0 
, 0 
_NUM2 0 
% 0 
and 0 
_NUM2 0 
% 0 
for 0 
HDL-C 0 
60-79 0 
, 0 
80-99 0 
, 0 
100-119 0 
, 0 
and 0 
> 0 
or 0 
= 0 
_NUM3 0 
mg 0 
/ 0 
dl 0 
, 0 
respectively 0 
. 0 

Furthermore 0 
, 0 
prevalences 0 
of 0 
the 0 
D442G 0 
and 0 
Int14 0 
A 0 
mutations 0 
were 0 
extremely 0 
high 0 
in 0 
a 0 
general 0 
sample 0 
of 0 
Japanese 0 
men 0 
-LRB- 0 
n 0 
= 0 
_NUM3 0 
-RRB- 0 
, 0 
with 0 
heterozygote 0 
frequencies 0 
of 0 
_NUM1 0 
% 0 
and 0 
_NUM1 0 
% 0 
, 0 
respectively 0 
. 0 

These 0 
two 0 
mutations 0 
accounted 0 
for 0 
about 0 
_NUM2 0 
% 0 
of 0 
the 0 
total 0 
variance 0 
of 0 
HDL-C 0 
in 0 
this 0 
population 0 
. 0 

The 0 
phenotype 0 
in 0 
a 0 
genetic 0 
compound 0 
heterozygote 0 
-LRB- 0 
Int14 0 
T 0 
and 0 
Int14 0 
A 0 
-RRB- 0 
was 0 
similar 0 
to 0 
that 0 
of 0 
Int14 0 
A 0 
homozygotes 0 
-LRB- 0 
no 0 
detectable 0 
CETP 0
and 0 
markedly 0 
increased 0 
HDL-C 0 
-RRB- 0 
, 0 
indicating 0 
that 0 
the 0 
Int14 0 
T 0 
produces 0 
a 0 
null 0 
allele 0 
. 0 

In 0 
four 0 
D442G 0 
homozygotes 0 
, 0 
mean 0 
HDL-C 0 
levels 0 
-LRB- 0 
_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
-RRB- 0 
were 0 
lower 0 
than 0 
in 0 
Int14 0 
A 0 
homozygotes 0 
-LRB- 0 
_NUM3 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
-RRB- 0 
, 0 
reflecting 0 
residual 0 
CETP 0
activity 0 
in 0 
plasma 0 
. 0 

In 0 
_NUM2 0 
D442G 0 
heterozygotes 0 
, 0 
mean 0 
HDL-C 0 
levels 0 
were 0 
_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
, 0 
similar 0 
to 0 
the 0 
level 0 
in 0 
D442G 0 
homozygotes 0 
, 0 
and 0 
significantly 0 
greater 0 
than 0 
mean 0 
HDL-C 0 
levels 0 
in 0 
Int14 0 
A 0 
heterozygotes 0 
-LRB- 0 
_NUM2 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
mg 0 
/ 0 
dl 0 
-RRB- 0 
. 0 

Thus 0 
, 0 
the 0 
D442G 0 
mutation 0 
acts 0 
differently 0 
to 0 
the 0 
null 0 
mutations 0 
with 0 
weaker 0 
effects 0 
on 0 
HDL 0 
in 0 
the 0 
homozygous 0 
state 0 
and 0 
stronger 0 
effects 0 
in 0 
the 0 
heterozygotes 0 
, 0 
suggesting 0 
dominant 0 
expression 0 
of 0 
a 0 
partially 0 
defective 0 
allele 0 
. 0 

CETP 1
deficiency 1
, 0 
reflecting 0 
two 0 
prevalent 0 
mutations 0 
-LRB- 0 
D442G 0 
and 0 
Int14 0 
A 0 
-RRB- 0 
, 0 
is 0 
the 0 
first 0 
example 0 
of 0 
a 0 
genetic 1
deficiency 1
state 0 
which 0 
is 0 
sufficiently 0 
common 0 
to 0 
explain 0 
a 0 
significant 0 
fraction 0 
of 0 
the 0 
variation 0 
in 0 
HDL-C 0 
in 0 
the 0 
general 0 
population 0 
. 0 
. 0 

X-linked 1
glucose-6-phosphate 1
dehydrogenase 1
deficiency 1
in 0 
Mus 0 
musculus 0 
. 0 

A 0 
mouse 0 
with 0 
X-linked 1
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
has 0 
been 0 
recovered 0 
in 0 
offspring 0 
of 0 
1-ethyl-1-nitrosourea-treated 0 
male 0 
mice 0 
. 0 

The 0 
activity 0 
alteration 0 
was 0 
detected 0 
in 0 
blood 0 
but 0 
can 0 
also 0 
be 0 
observed 0 
in 0 
other 0 
tissue 0 
extracts 0 
. 0 

Hemizygous 0 
, 0 
heterozygous 0 
, 0 
and 0 
homozygous 0 
mutants 0 
have 0 
, 0 
respectively 0 
, 0 
about 0 
_NUM2 0 
, 0 
_NUM2 0 
, 0 
and 0 
_NUM2 0 
% 0 
G6PD 0 
remaining 0 
activity 0 
in 0 
the 0 
blood 0 
as 0 
compared 0 
to 0 
the 0 
wild 0 
type 0 
. 0 

Erythrocyte 0 
indices 0 
did 0 
not 0 
show 0 
differences 0 
between 0 
mutants 0 
and 0 
wild 0 
types 0 
. 0 

The 0 
mutation 0 
does 0 
not 0 
affect 0 
the 0 
electrophoretic 0 
migration 0 
, 0 
the 0 
isoelectric 0 
point 0 
, 0 
or 0 
the 0 
thermal 0 
stability 0 
. 0 

Kinetic 0 
properties 0 
, 0 
such 0 
as 0 
the 0 
Km 0 
for 0 
glucose-6-phosphate 0 
or 0 
for 0 
NADP 0 
and 0 
the 0 
relative 0 
utilization 0 
of 0 
substrate 0 
analogues 0 
, 0 
showed 0 
no 0 
differences 0 
between 0 
wild 0 
types 0 
and 0 
mutants 0 
with 0 
the 0 
exception 0 
of 0 
the 0 
relative 0 
utilization 0 
of 0 
deamino-NADP 0 
which 0 
was 0 
significantly 0 
lower 0 
in 0 
mutants 0 
. 0 

This 0 
is 0 
presently 0 
the 0 
only 0 
animal 0 
model 0 
for 0 
X-linked 1
G6PD 1
deficiency 1
in 0 
humans 0 
. 0 
. 0 

Human 0 
glycine 0 
decarboxylase 0 
gene 0 
-LRB- 0 
GLDC 0 
-RRB- 0 
and 0 
its 0 
highly 0 
conserved 0 
processed 0 
pseudogene 0 
-LRB- 0 
psiGLDC 0 
-RRB- 0 
: 0 
their 0 
structure 0 
and 0 
expression 0 
, 0 
and 0 
the 0 
identification 0 
of 0 
a 0 
large 0 
deletion 0 
in 0 
a 0 
family 0 
with 0 
nonketotic 1
hyperglycinemia 1
. 0 

Mutations 0 
in 0 
the 0 
glycine 0 
decarboxylase 0 
gene 0 
-LRB- 0 
GLDC 0 
-RRB- 0 
cause 0 
nonketotic 1
hyperglycinemia 1
-LRB- 0 
NKH 1
-RRB- 0 
, 0 
an 0 
in-born 1
error 1
of 1
metabolism 1
characterized 0 
by 0 
severe 0 
neurological 1
disturbance 1
. 0 

We 0 
have 0 
determined 0 
the 0 
structure 0 
of 0 
GLDC 0 
and 0 
of 0 
its 0 
pseudogene 0 
-LRB- 0 
psiGLDC 0 
-RRB- 0 
and 0 
studied 0 
their 0 
expression 0 
for 0 
a 0 
molecular 0 
analysis 0 
of 0 
NKH 1
. 0 

The 0 
GLDC 0 
gene 0 
spans 0 
at 0 
least 0 
_NUM3 0 
kb 0 
and 0 
consists 0 
of 0 
_NUM2 0 
exons 0 
. 0 

All 0 
donor 0 
and 0 
acceptor 0 
sites 0 
adhere 0 
to 0 
the 0 
canonical 0 
GT-AG 0 
rule 0 
, 0 
except 0 
for 0 
the 0 
donor 0 
site 0 
of 0 
intron 0 
_NUM2 0 
, 0 
where 0 
a 0 
variant 0 
form 0 
_DS 0 
is 0 
used 0 
instead 0 
of 0 
_DS 0 
. 0 

The 0 
transcription 0 
initiation 0 
site 0 
has 0 
been 0 
assigned 0 
to 0 
a 0 
residue 0 
_NUM3 0 
bp 0 
upstream 0 
from 0 
the 0 
translation 0 
initiation 0 
triplet 0 
by 0 
primer 0 
extension 0 
analysis 0 
. 0 

The 0 
psiGLDC 0 
gene 0 
has 0 
no 0 
intron 0 
and 0 
shares 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
homology 0 
with 0 
the 0 
coding 0 
region 0 
of 0 
functional 0 
GLDC 0 
, 0 
suggesting 0 
that 0 
psiGLDC 0 
is 0 
a 0 
processed 0 
pseudogene 0 
that 0 
arose 0 
from 0 
the 0 
GLDC 0 
transcript 0 
about 0 
4-8 0 
million 0 
years 0 
ago 0 
. 0 

RNA 0 
blotting 0 
analysis 0 
has 0 
revealed 0 
that 0 
GLDC 0 
is 0 
expressed 0 
in 0 
human 0 
liver 0 
, 0 
kidney 0 
, 0 
brain 0 
, 0 
and 0 
placenta 0 
. 0 

We 0 
have 0 
also 0 
examined 0 
a 0 
patient 0 
with 0 
NKH 1
with 0 
no 0 
detectable 0 
GLDC 0 
mRNA 0 
in 0 
his 0 
lymphoblasts 0 
. 0 

Exons 0 
1-3 0 
of 0 
the 0 
functional 0 
GLDC 0 
gene 0 
from 0 
this 0 
patient 0 
are 0 
not 0 
amplified 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
, 0 
whereas 0 
those 0 
from 0 
control 0 
subjects 0 
are 0 
. 0 

These 0 
results 0 
suggest 0 
a 0 
large 0 
homozygous 0 
deletion 0 
-LRB- 0 
at 0 
least 0 
_NUM2 0 
kb 0 
-RRB- 0 
in 0 
the 0 
patient 0 
. 0 

Furthermore 0 
, 0 
we 0 
have 0 
devised 0 
a 0 
semi-quantitative 0 
PCR 0 
to 0 
estimate 0 
the 0 
number 0 
of 0 
GLDC 0 
alleles 0 
by 0 
using 0 
psiGLDC 0 
as 0 
an 0 
internal 0 
control 0 
and 0 
have 0 
confirmed 0 
the 0 
homozygosity 0 
and 0 
heterozygosity 0 
of 0 
the 0 
deletion 0 
in 0 
the 0 
patient 0 
and 0 
his 0 
parents 0 
, 0 
respectively 0 
. 0 

Structural 0 
information 0 
of 0 
GLDC 0 
and 0 
psiGLDC 0 
should 0 
facilitate 0 
the 0 
molecular 0 
analysis 0 
of 0 
NKH 1
. 0 

Growth 1
retardation 1
and 0 
tumour 1
inhibition 0 
by 0 
BRCA1 0 
. 0 

Inherited 0 
mutations 0 
in 0 
BRCA1 0 
predispose 0 
to 0 
breast 1
and 1
ovarian 1
cancer 1
, 0 
but 0 
the 0 
role 0 
of 0 
BRCA1 0 
in 0 
sporadic 0 
breast 1
and 1
ovarian 1
cancer 1
has 0 
previously 0 
been 0 
elusive 0 
. 0 

Here 0 
, 0 
we 0 
show 0 
that 0 
retroviral 0 
transfer 0 
of 0 
the 0 
wild-type 0 
BRCA1 0 
gene 0 
inhibits 0 
growth 0 
in 0 
vitro 0 
of 0 
all 0 
breast 1
and 1
ovarian 1
cancer 1
cell 0 
lines 0 
tested 0 
, 0 
but 0 
not 0 
colon 1
or 1
lung 1
cancer 1
cells 0 
or 0 
fibroblasts 0 
. 0 

Mutant 0 
BRCA1 0 
has 0 
no 0 
effect 0 
on 0 
growth 0 
of 0 
breast 1
cancer 1
cells 0 
; 0 
ovarian 1
cancer 1
cell 0 
growth 0 
is 0 
not 0 
affected 0 
by 0 
BRCA1 0 
mutations 0 
in 0 
the 0 
_NUM1 0 
portion 0 
of 0 
the 0 
gene 0 
, 0 
but 0 
is 0 
inhibited 0 
by 0 
_NUM1 0 
BRCA1 0 
mutations 0 
. 0 

Development 0 
of 0 
MCF-7 1
tumours 1
in 0 
nude 0 
mice 0 
is 0 
inhibited 0 
when 0 
MCF-7 0
cells 0 
are 0 
transfected 0 
with 0 
wild-type 0 
, 0 
but 0 
not 0 
mutant 0 
, 0 
BRCA1 0 
. 0 

Most 0 
importantly 0 
, 0 
among 0 
mice 0 
with 0 
established 0 
MCF-7 1
tumours 1
, 0 
peritoneal 0 
treatment 0 
with 0 
a 0 
retroviral 0 
vector 0 
expressing 0 
wild-type 0 
BRCA1 0 
significantly 0 
inhibits 0 
tumour 1
growth 0 
and 0 
increased 0 
survival 0 
. 0 
. 0 

Striking 0 
prevalence 0 
of 0 
ankylosing 1
spondylitis 1
in 0 
`` 0 
healthy 0 
'' 0 
_AN 0 
positive 0 
males 0 
and 0 
females 0 
. 0 

Ankylosing 1
spondylitis 1
is 0 
diagnosed 0 
once 0 
or 0 
twice 0 
in 0 
each 0 
_NUM4 0 
males 0 
and 0 
one 0 
tenth 0 
as 0 
frequently 0 
in 0 
females 0 
, 0 
but 0 
the 0 
true 0 
prevalence 0 
is 0 
unknown 0 
. 0 

Indentification 0 
of 0 
genetic 0 
marker 0 
, 0 
HL-A 0 
_AN 0 
, 0 
for 0 
susceptible 0 
persons 0 
has 0 
provided 0 
a 0 
tool 0 
facilitating 0 
epidemiologic 0 
studies 0 
and 0 
allowing 0 
identification 0 
of 0 
'' 0 
control 0 
'' 0 
populations 0 
without 0 
the 0 
marker 0 
. 0 

Evaluation 0 
by 0 
postal 0 
questionnaires 0 
, 0 
and 0 
pelvic 0 
radiography 0 
of 0 
_NUM2 0 
HL-A 0 
27W-positive 0 
blood 0 
donors 0 
selected 0 
from 0 
a 0 
group 0 
of 0 
apparently 0 
healthy 0 
subjects 0 
revealed 0 
_NUM2 0 
who 0 
satisfied 0 
the 0 
criteria 0 
for 0 
definite 0 
ankylosing 1
spondylitis 1
. 0 

The 0 
prevalence 0 
was 0 
similar 0 
in 0 
both 0 
sexes 0 
. 0 

One 0 
hundred 0 
and 0 
twenty-six 0 
W27-negative 0 
controls 0 
matched 0 
for 0 
race 0 
, 0 
sex 0 
, 0 
and 0 
age 0 
failed 0 
to 0 
yield 0 
a 0 
single 0 
case 0 
. 0 

For 0 
a 0 
person 0 
of 0 
either 0 
sex 0 
with 0 
HL-A 0 
_AN 0 
, 0 
there 0 
appears 0 
to 0 
be 0 
about 0 
a 0 
_NUM2 0 
per 0 
cent 0 
chance 0 
that 0 
ankylosing 1
spondylitis 1
will 0 
develop 0 
, 0 
suggesting 0 
a 0 
prevalence 0 
of 0 
_NUM2 0 
to 0 
_NUM2 0 
per 0 
thousand 0 
. 0 

Hitherto 0 
accepted 0 
figures 0 
may 0 
underestimate 0 
the 0 
frequency 0 
by 0 
a 0 
factor 0 
of 0 
_NUM2 0 
to 0 
_NUM2 0 
. 0 
. 0 

Rapid 0 
detection 0 
of 0 
BRCA1 0 
mutations 0 
by 0 
the 0 
protein 0 
truncation 0 
test 0 
. 0 

More 0 
than 0 
_NUM2 0 
% 0 
of 0 
the 0 
reported 0 
mutations 0 
in 0 
the 0 
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
gene 0 
, 0 
BRCA1 0 
, 0 
result 0 
in 0 
truncated 0 
proteins 0 
. 0 

We 0 
have 0 
used 0 
the 0 
protein 0 
truncation 0 
test 0 
-LRB- 0 
PTT 0 
-RRB- 0 
to 0 
screen 0 
for 0 
mutations 0 
in 0 
exon 0 
_NUM2 0 
, 0 
which 0 
encodes 0 
_NUM2 0 
% 0 
of 0 
BRCA1 0 
. 0 

In 0 
_NUM2 0 
patients 0 
from 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
families 0 
we 0 
found 0 
six 0 
novel 0 
mutations 0 
two 0 
single 0 
nucleotide 0 
insertions 0 
, 0 
three 0 
small 0 
deletions 0 
-LRB- 0 
1-5 0 
bp 0 
-RRB- 0 
and 0 
a 0 
nonsense 0 
mutation 0 
identified 0 
two 0 
unrelated 0 
families 0 
. 0 

Furthermore 0 
, 0 
we 0 
were 0 
able 0 
to 0 
amplify 0 
the 0 
remaining 0 
coding 0 
region 0 
by 0 
RT-PCR 0 
using 0 
lymphocyte 0 
RNA 0 
. 0 

Combined 0 
with 0 
PTT 0 
, 0 
we 0 
detected 0 
aberrantly 0 
spliced 0 
products 0 
affecting 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
in 0 
one 0 
of 0 
two 0 
BRCA1-linked 0 
families 0 
examined 0 
. 0 

The 0 
protein 0 
truncation 0 
test 0 
promises 0 
to 0 
become 0 
a 0 
valuable 0 
technique 0 
in 0 
detecting 0 
BRCA1 0 
mutations 0 
. 0 
. 0 

New 0 
variant 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
in 0 
a 0 
family 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 

A 0 
C 0 
-- 0 
greater 0 
than 0 
G 0 
transversion 0 
has 0 
been 0 
found 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
PLP 0 
gene 0 
of 0 
affected 0 
males 0 
and 0 
their 0 
mother 0 
in 0 
a 0 
single 0 
sibship 0 
with 0 
Pelizaeus-merzbacher 1
disease 1
-LRB- 0 
PMD 1
-RRB- 0 
. 0 

The 0 
transversion 0 
should 0 
not 0 
result 0 
in 0 
an 0 
amino 0 
acid 0 
change 0 
in 0 
the 0 
protein 0 
but 0 
it 0 
does 0 
result 0 
in 0 
the 0 
loss 0 
of 0 
a 0 
HaeIII 0 
restriction 0 
endonuclease 0 
cleavage 0 
site 0 
. 0 

It 0 
is 0 
concordant 0 
with 0 
the 0 
disease 0 
in 0 
this 0 
family 0 
. 0 

One-hundred-ten 0 
unrelated 0 
X 0 
chromosomes 0 
are 0 
negative 0 
for 0 
this 0 
mutation 0 
. 0 

No 0 
other 0 
sequence 0 
defect 0 
was 0 
found 0 
in 0 
the 0 
PLP 0 
exons 0 
of 0 
the 0 
affected 0 
males 0 
. 0 

The 0 
cause 0 
of 0 
disease 0 
in 0 
this 0 
family 0 
remains 0 
unknown 0 
, 0 
but 0 
the 0 
association 0 
between 0 
this 0 
rare 0 
mutation 0 
and 0 
PMD 1
is 0 
intriguing 0 
. 0 

The 0 
mutation 0 
can 0 
serve 0 
as 0 
a 0 
marker 0 
for 0 
following 0 
segregation 0 
of 0 
the 0 
PLP 0 
gene 0 
. 0 
. 0 

Variants 0 
of 0 
erythrocyte 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
in 0 
Bulgarian 0 
populations 0 
. 0 

Ten 0 
variants 0 
of 0 
erythrocyte 0 
glucose-6-phosphate 0 
dehydrogenase 0 
were 0 
identified 0 
in 0 
_NUM2 0 
patients 0 
with 0 
G6PD 1
deficiency 1
from 0 
three 0 
districts 0 
of 0 
Bulgaria 0 
. 0 

Corinth-like 0 
and 0 
Fayoum-like 0 
variants 0 
were 0 
the 0 
most 0 
frequent 0 
; 0 
Mediterranean 0 
, 0 
Ohut 0 
II 0 
, 0 
Kilgore 0 
, 0 
Boston 0 
, 0 
Poznan 0 
, 0 
and 0 
Panay 0 
variants 0 
and 0 
two 0 
new 0 
variants 0 
, 0 
Petrich 0 
and 0 
Gotze 0 
Delchev 0 
, 0 
were 0 
each 0 
found 0 
in 0 
one 0 
or 0 
two 0 
carriers 0 
. 0 

No 0 
correlation 0 
was 0 
revealed 0 
between 0 
clinical 0 
and 0 
biochemical 0 
polymorphism 0 
. 0 
. 0 

The 0 
C282Y 0 
mutation 0 
causing 0 
hereditary 1
hemochromatosis 1
does 0 
not 0 
produce 0 
a 0 
null 0 
allele 0 
. 0 

Targeted 0 
mutagenesis 0 
was 0 
used 0 
to 0 
produce 0 
two 0 
mutations 0 
in 0 
the 0 
murine 0 
hemochromatosis 1
gene 0 
-LRB- 0 
Hfe 0 
-RRB- 0 
locus 0 
. 0 

The 0 
first 0 
mutation 0 
deletes 0 
a 0 
large 0 
portion 0 
of 0 
the 0 
coding 0 
sequence 0 
, 0 
generating 0 
a 0 
null 0 
allele 0 
. 0 

The 0 
second 0 
mutation 0 
introduces 0 
a 0 
missense 0 
mutation 0 
-LRB- 0 
C282Y 0 
-RRB- 0 
into 0 
the 0 
Hfe 0 
locus 0 
, 0 
but 0 
otherwise 0 
leaves 0 
the 0 
gene 0 
intact 0 
. 0 

This 0 
mutation 0 
is 0 
identical 0 
to 0 
the 0 
disease-causing 0 
mutation 0 
in 0 
patients 0 
with 0 
hereditary 1
hemochromatosis 1
. 0 

Mice 0 
carrying 0 
each 0 
of 0 
the 0 
two 0 
mutations 0 
were 0 
bred 0 
and 0 
analyzed 0 
. 0 

Homozygosity 0 
for 0 
either 0 
mutation 0 
results 0 
in 0 
postnatal 0 
iron 0 
loading 0 
. 0 

The 0 
effects 0 
of 0 
the 0 
null 0 
mutation 0 
are 0 
more 0 
severe 0 
than 0 
the 0 
effects 0 
of 0 
the 0 
C282Y 0 
mutation 0 
. 0 

Mice 0 
heterozygous 0 
for 0 
either 0 
mutation 0 
accumulate 0 
more 0 
iron 0 
than 0 
normal 0 
controls 0 
. 0 

Interestingly 0 
, 0 
although 0 
liver 0 
iron 0 
stores 0 
are 0 
greatly 0 
increased 0 
, 0 
splenic 0 
iron 0 
is 0 
decreased 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
C282Y 0 
mutation 0 
does 0 
not 0 
result 0 
in 0 
a 0 
null 0 
allele 0 
. 0 
. 0 

Regional 0 
localisation 0 
of 0 
the 0 
Friedreich 1
ataxia 1
locus 0 
to 0 
human 0 
chromosome 0 
9q13 0 
-- 0 
_AN 0 
.1 0 
. 0 

We 0 
have 0 
previously 0 
assigned 0 
the 0 
Friedreich 1
ataxia 1
locus 0 
-LRB- 0 
FRDA 0 
-RRB- 0 
to 0 
chromosome 0 
_NUM1 0 
; 0 
the 0 
current 0 
maximal 0 
lod 0 
score 0 
between 0 
FRDA 0 
and 0 
MCT112 0 
-LRB- 0 
D9S15 0 
-RRB- 0 
is 0 
greater 0 
than 0 
_NUM2 0 
at 0 
a 0 
recombination 0 
fraction 0 
of 0 
theta 0 
= 0 
_NUM1 0 
. 0 

The 0 
physical 0 
assignment 0 
of 0 
the 0 
locus 0 
defined 0 
by 0 
MCT112 0 
, 0 
and 0 
hence 0 
FRDA 0 
, 0 
has 0 
not 0 
been 0 
determined 0 
, 0 
although 0 
linkage 0 
analysis 0 
of 0 
MCT112 0 
with 0 
other 0 
chromosome 0 
_NUM1 0 
markers 0 
inferred 0 
a 0 
location 0 
close 0 
to 0 
the 0 
centromere 0 
. 0 

We 0 
have 0 
used 0 
in 0 
situ 0 
hybridisation 0 
with 0 
MCT112 0 
, 0 
a 0 
corresponding 0 
cosmid 0 
MJ1 0 
, 0 
and 0 
DR47 0 
-LRB- 0 
D9S5 0 
-RRB- 0 
, 0 
coupled 0 
with 0 
mapping 0 
studies 0 
on 0 
hybrid 0 
cell 0 
panels 0 
, 0 
to 0 
define 0 
more 0 
precisely 0 
the 0 
location 0 
of 0 
the 0 
disease 0 
locus 0 
. 0 

The 0 
in 0 
situ 0 
location 0 
of 0 
all 0 
three 0 
probes 0 
is 0 
9q13 0 
-- 0 
_AN 0 
. 0 

_NUM1 0 
, 0 
distal 0 
to 0 
the 0 
variable 0 
heterochromatin 0 
region 0 
. 0 

Physical 0 
assignment 0 
of 0 
FRDA 0 
will 0 
allow 0 
us 0 
to 0 
identify 0 
hybrid 0 
cell 0 
lines 0 
containing 0 
the 0 
mutated 0 
gene 0 
. 0 

Mxi1 0 
mutations 0 
in 0 
human 0 
neurofibrosarcomas 1
. 0 

Mxi1 0 
is 0 
thought 0 
to 0 
negatively 0 
regulate 0 
Myc 0 
function 0 
and 0 
may 0 
therefore 0 
be 0 
a 0 
potential 0 
tumor 1
suppressor 0 
gene 0 
. 0 

Little 0 
effort 0 
has 0 
yet 0 
been 0 
made 0 
to 0 
find 0 
alterations 0 
involving 0 
this 0 
gene 0 
in 0 
human 0 
solid 1
tumors 1
. 0 

We 0 
screened 0 
_NUM2 0 
human 0 
gastric 1
cancers 1
, 0 
_NUM1 0 
esophageal 1
cancers 1
, 0 
_NUM2 0 
bone 1
and 1
soft 1
tissue 1
tumors 1
of 0 
various 0 
types 0 
, 0 
including 0 
_NUM1 0 
neurofibrosarcomas 1
. 0 

We 0 
also 0 
examined 0 
_NUM2 0 
human 0 
tumor 1
cell 0 
lines 0 
consisting 0 
of 0 
_NUM2 0 
esophageal 1
cancers 1
, 0 
_NUM1 0 
glioma 1
/ 0 
glioblastomas 1
and 0 
_NUM2 0 
others 0 
for 0 
Mxi1 0 
mutations 0 
in 0 
exons 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
-LRB- 0 
HLH 0 
domain 0 
-RRB- 0 
, 0 
_NUM1 0 
and 0 
_NUM1 0 
. 0 

Polymerase 0 
chain 0 
reaction-single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
PCR-SSCP 0 
-RRB- 0 
and 0 
subsequent 0 
sequencing 0 
revealed 0 
three 0 
distinct 0 
polymorphisms 0 
in 0 
the 0 
intron-exon 0 
boundary 0 
upstream 0 
from 0 
exon 0 
_NUM1 0 
. 0 

We 0 
discovered 0 
a 0 
missense 0 
mutation 0 
, 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Ala 0 
_NUM2 0 
Val 0 
-RRB- 0 
, 0 
in 0 
exon 0 
_NUM1 0 
in 0 
a 0 
neurofibrosarcoma 1
patient 0 
-LRB- 0 
case 0 
_NUM1 0 
-RRB- 0 
, 0 
two 0 
missense 0 
mutations 0 
, 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Lys 0 
_NUM3 0 
Gln 0 
-RRB- 0 
and 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Glu 0 
_NUM3 0 
Gly 0 
-RRB- 0 
in 0 
exon 0 
_NUM1 0 
of 0 
another 0 
neurofibrosarcoma 1
patient 0 
-LRB- 0 
case 0 
_NUM1 0 
-RRB- 0 
, 0 
and 0 
_NUM1 0 
amino 0 
acid 0 
substitutions 0 
, 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Val 0 
_NUM3 0 
Ala 0 
-RRB- 0 
, 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Val 0 
_NUM3 0 
Ala 0 
-RRB- 0 
and 0 
_DS 0 
to 0 
_DS 0 
-LRB- 0 
Phe 0 
_NUM3 0 
Leu 0 
-RRB- 0 
, 0 
in 0 
a 0 
third 0 
neurofibrosarcoma 1
patient 0 
-LRB- 0 
case 0 
_NUM1 0 
-RRB- 0 
. 0 

In 0 
case 0 
_NUM1 0 
, 0 
loss 0 
of 0 
heterozygosity 0 
was 0 
also 0 
demonstrated 0 
by 0 
informative 0 
-LRB- 0 
_DS 0 
-RRB- 0 
_NUM1 0 
/ 0 
-LRB- 0 
_DS 0 
-RRB- 0 
_NUM1 0 
polymorphism 0 
. 0 

Our 0 
data 0 
demonstrate 0 
that 0 
mutations 0 
occur 0 
in 0 
the 0 
Mxi1 0 
gene 0 
in 0 
neurofibrosarcoma 1
. 0 

Missense 0 
mutations 0 
in 0 
the 0 
functional 0 
domain 0 
of 0 
Mxi1 0 
in 0 
these 0 
cases 0 
may 0 
be 0 
involved 0 
in 0 
the 0 
pathogenesis 0 
of 0 
neurofibrosarcoma 1
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
essential 1
fructosuria 1
: 0 
molecular 0 
cloning 0 
and 0 
mutational 0 
analysis 0 
of 0 
human 0 
ketohexokinase 0 
-LRB- 0 
fructokinase 0 
-RRB- 0 
. 0 

Essential 1
fructosuria 1
is 0 
one 0 
of 0 
the 0 
oldest 0 
known 0 
inborn 1
errors 1
of 1
metabolism 1
. 0 

It 0 
is 0 
a 0 
benign 0 
condition 0 
which 0 
is 0 
believed 0 
to 0 
result 0 
from 0 
deficiency 1
of 1
hepatic 1
fructokinase 1
-LRB- 0 
ketohexokinase 0 
, 0 
KHK 0 
, 0 
E. 0 
C. 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

This 0 
enzyme 0 
catalyses 0 
the 0 
first 0 
step 0 
of 0 
metabolism 0 
of 0 
dietary 0 
fructose 0 
, 0 
conversion 0 
of 0 
fructose 0 
to 0 
fructose-1-phosphate 0 
. 0 

Despite 0 
the 0 
early 0 
recognition 0 
of 0 
this 0 
disorder 0 
, 0 
the 0 
primary 0 
structure 0 
of 0 
human 0 
KHK 0 
and 0 
the 0 
molecular 0 
basis 0 
of 0 
essential 1
fructosuria 1
have 0 
not 0 
been 0 
previously 0 
defined 0 
. 0 

In 0 
this 0 
report 0 
, 0 
the 0 
isolation 0 
and 0 
sequencing 0 
of 0 
full-length 0 
cDNA 0 
clones 0 
encoding 0 
human 0 
ketohexokinase 0 
are 0 
described 0 
. 0 

Alternative 0 
mRNA 0 
species 0 
and 0 
alternative 0 
KHK 0 
isozymes 0 
are 0 
produced 0 
by 0 
alternative 0 
polyadenylation 0 
and 0 
splicing 0 
of 0 
the 0 
KHK 0 
gene 0 
. 0 

The 0 
KHK 0 
proteins 0 
show 0 
a 0 
high 0 
level 0 
of 0 
sequence 0 
conservation 0 
relative 0 
to 0 
rat 0 
KHK 0 
. 0 

Direct 0 
evidence 0 
that 0 
mutation 0 
of 0 
the 0 
KHK 0 
structural 0 
gene 0 
is 0 
the 0 
cause 0 
of 0 
essential 1
fructosuria 1
was 0 
also 0 
obtained 0 
. 0 

In 0 
a 0 
well-characterized 0 
family 0 
, 0 
in 0 
which 0 
three 0 
of 0 
eight 0 
siblings 0 
have 0 
fructosuria 1
, 0 
all 0 
affected 0 
individuals 0 
are 0 
compound 0 
heterozygotes 0 
for 0 
two 0 
mutations 0 
Gly40Arg 0 
and 0 
Ala43Thr 0 
. 0 

Both 0 
mutations 0 
result 0 
from 0 
G 0 
-- 0 
> 0 
A 0 
transitions 0 
, 0 
and 0 
each 0 
alters 0 
the 0 
same 0 
conserved 0 
region 0 
of 0 
the 0 
KHK 0 
protein 0 
. 0 

Neither 0 
mutation 0 
was 0 
seen 0 
in 0 
a 0 
sample 0 
of 0 
_NUM2 0 
unrelated 0 
control 0 
individuals 0 
. 0 

An 0 
additional 0 
conservative 0 
amino 0 
acid 0 
change 0 
-LRB- 0 
Val49IIe 0 
-RRB- 0 
was 0 
present 0 
on 0 
the 0 
KHK 0 
allele 0 
bearing 0 
Ala43Thr 0 
Loss 0 
of 0 
the 0 
ataxia-telangiectasia 1
gene 0 
product 0 
causes 0 
oxidative 0 
damage 0 
in 0 
target 0 
organs 0 
. 0 

Ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
is 0 
characterized 0 
by 0 
a 0 
markedly 0 
increased 0 
sensitivity 0 
to 0 
ionizing 0 
radiation 0 
, 0 
increased 0 
incidence 0 
of 0 
cancer 1
, 0 
and 0 
neurodegeneration 1
, 0 
especially 0 
of 0 
the 0 
cerebellar 0 
Purkinje 0 
cells 0 
. 0 

Ionizing 0 
radiation 0 
oxidizes 0 
macromolecules 0 
and 0 
causes 0 
tissue 0 
damage 0 
through 0 
the 0 
generation 0 
of 0 
reactive 0 
oxygen 0 
species 0 
-LRB- 0 
ROS 0 
-RRB- 0 
. 0 

We 0 
therefore 0 
hypothesized 0 
that 0 
A-T 1
is 0 
due 0 
to 0 
oxidative 0 
damage 0 
resulting 0 
from 0 
loss 0 
of 0 
function 0 
of 0 
the 0 
A-T 1
gene 0 
product 0 
. 0 

To 0 
assess 0 
this 0 
hypothesis 0 
, 0 
we 0 
employed 0 
an 0 
animal 0 
model 0 
of 0 
A-T 1
, 0 
the 0 
mouse 0 
with 0 
a 0 
disrupted 0 
Atm 0 
gene 0 
. 0 

We 0 
show 0 
that 0 
organs 0 
which 0 
develop 0 
pathologic 0 
changes 0 
in 0 
the 0 
Atm-deficient 0 
mice 0 
are 0 
targets 0 
of 0 
oxidative 0 
damage 0 
, 0 
and 0 
that 0 
cerebellar 0 
Purkinje 0 
cells 0 
are 0 
particularly 0 
affected 0 
. 0 

These 0 
observations 0 
provide 0 
a 0 
mechanistic 0 
basis 0 
for 0 
the 0 
A-T 1
phenotype 0 
and 0 
lay 0 
a 0 
rational 0 
foundation 0 
for 0 
therapeutic 0 
intervention 0 
. 0 
. 0 

Family 0 
studies 0 
in 0 
Bechterew's 1
syndrome 1
-LRB- 0 
ankylosing 1
spondylitis 1
-RRB- 0 
III 0 
. 0 

Genetics 0 
. 0 

The 0 
results 0 
of 0 
segregation 0 
analyses 0 
in 0 
_NUM2 0 
families 0 
where 0 
the 0 
proband 0 
had 0 
ankylosing 1
spondylitis 1
, 0 
are 0 
presented 0 
. 0 

Of 0 
the 0 
_NUM3 0 
adult 0 
, 0 
living 0 
first 0 
degree 0 
relatives 0 
, 0 
approximately 0 
_NUM2 0 
% 0 
cooperated 0 
in 0 
the 0 
study 0 
. 0 

Clinical 0 
and 0 
radiographical 0 
examinations 0 
were 0 
performed 0 
and 0 
HLA 0 
typing 0 
was 0 
conducted 0 
. 0 

The 0 
results 0 
were 0 
in 0 
agreement 0 
with 0 
our 0 
hypothesis 0 
that 0 
ankylosing 1
spondylitis 1
is 0 
part 0 
of 0 
a 0 
syndrome 0 
where 0 
different 0 
genetic 0 
factors 0 
interact 0 
. 0 

Such 0 
known 0 
factors 0 
are 0 
HLA 0 
_AN 0 
associated 0 
disease 0 
susceptibility 0 
, 0 
susceptibility 0 
to 0 
psoriatic 1
arthropathy 1
and 0 
susceptibility 0 
to 0 
entero-arthropathy 1
. 0 

Radiographical 0 
sacro-iliitis 1
was 0 
restricted 0 
to 0 
HLA 0 
_AN 0 
positive 0 
relatives 0 
, 0 
and 0 
was 0 
more 0 
frequently 0 
found 0 
in 0 
relatives 0 
to 0 
probands 0 
with 0 
psoriasis 1
than 0 
in 0 
relatives 0 
to 0 
probands 0 
without 0 
psoriasis 1
. 0 

Environmental 0 
factors 0 
-LRB- 0 
intestinal 0 
bacteria 0 
-RRB- 0 
are 0 
known 0 
to 0 
trigger 0 
the 0 
disease 0 
at 0 
least 0 
in 0 
some 0 
persons 0 
, 0 
and 0 
we 0 
have 0 
postulated 0 
that 0 
all 0 
or 0 
most 0 
of 0 
them 0 
have 0 
the 0 
predisposition 0 
to 0 
develop 0 
disease 0 
. 0 

Thus 0 
, 0 
the 0 
syndrome 0 
has 0 
a 0 
multifactorial 0 
etiology 0 
. 0 

The 0 
phenotypic 0 
expressions 0 
of 0 
the 0 
different 0 
genetic 0 
predispositions 0 
involved 0 
, 0 
include 0 
sacro-iliitis 1
, 0 
psoriasis 1
, 0 
acute 1
anterior 1
uveitis 1
, 0 
peripheral 0 
arthropathy 1
and 0 
inflammatory 1
bowel 1
disease 1
. 0 

We 0 
suggest 0 
the 0 
descriptive 0 
name 0 
HEREDITARY 1
MULTIFOCAL 1
RELAPSING 1
INFLAMMATION 1
-LRB- 0 
HEMRI 1
-RRB- 0 
for 0 
this 0 
syndrome 0 
. 0 

Ankylosing 1
spondylitis 1
, 0 
psoriatic 1
arthropathy 1
and 0 
entero-arthropathy 1
may 0 
be 0 
regarded 0 
as 0 
clinical 0 
sub-types 0 
of 0 
the 0 
syndrome 0 
. 0 
. 0 

Chromosome 0 
mapping 0 
of 0 
the 0 
rod 0 
photoreceptor 0 
cGMP 0 
phosphodiesterase 0 
beta-subunit 0 
gene 0 
in 0 
mouse 0 
and 0 
human 0 
: 0 
tight 0 
linkage 0 
to 0 
the 0 
Huntington 1
disease 1
region 0 
-LRB- 0 
4p16 0 
.3 0 
-RRB- 0 
. 0 

The 0 
retinal 1
degeneration 1
mouse 0 
-LRB- 0 
gene 0 
symbol 0 
, 0 
rd 0 
-RRB- 0 
is 0 
an 0 
animal 0 
model 0 
for 0 
certain 0 
forms 0 
of 0 
human 0 
hereditary 1
retinopathies 1
. 0 

Recent 0 
findings 0 
of 0 
a 0 
nonsense 0 
mutation 0 
in 0 
the 0 
rd 0 
mouse 0 
PDE 0 
beta-subunit 0 
gene 0 
-LRB- 0 
Pdeb 0 
-RRB- 0 
prompted 0 
us 0 
to 0 
investigate 0 
the 0 
chromosome 0 
locations 0 
of 0 
the 0 
mouse 0 
and 0 
human 0 
genes 0 
. 0 

We 0 
have 0 
utilized 0 
backcross 0 
analysis 0 
in 0 
mice 0 
to 0 
verify 0 
and 0 
define 0 
more 0 
precisely 0 
the 0 
location 0 
of 0 
the 0 
Pdeb 0 
locus 0 
_NUM1 0 
. 0 

_NUM1 0 
+ 0 
/ 0 
- 0 
_NUM1 0 
. 0 

_NUM1 0 
cM 0 
distal 0 
of 0 
Mgsa 0 
on 0 
mouse 0 
chromosome 0 
_NUM1 0 
. 0 

We 0 
have 0 
determined 0 
that 0 
the 0 
human 0 
gene 0 
-LRB- 0 
PDEB 0 
-RRB- 0 
maps 0 
to 0 
4p16 0 
. 0 

_NUM1 0 
, 0 
very 0 
close 0 
to 0 
the 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
region 0 
. 0 

Analysis 0 
of 0 
the 0 
comparative 0 
map 0 
for 0 
mice 0 
and 0 
humans 0 
shows 0 
that 0 
the 0 
mouse 0 
homologue 0 
of 0 
the 0 
HD 1
gene 0 
will 0 
reside 0 
on 0 
chromosome 0 
_NUM1 0 
. 0 

Linkage 0 
of 0 
the 0 
mouse 0 
Pdeb 0 
locus 0 
with 0 
other 0 
homologues 0 
in 0 
the 0 
human 0 
4p16 0 
. 0 

_NUM1 0 
region 0 
is 0 
maintained 0 
but 0 
gene 0 
order 0 
is 0 
not 0 
, 0 
suggesting 0 
at 0 
least 0 
three 0 
possible 0 
sites 0 
for 0 
the 0 
corresponding 0 
mouse 0 
HD 1
gene 0 
. 0 

Hereditary 1
deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
in 0 
man 0 
. 0 

II 0 
. 0 

Biological 0 
properties 0 
of 0 
C5-deficient 1
human 0 
serum 0 
. 0 

The 0 
first 0 
known 0 
human 0 
kindred 0 
with 0 
hereditary 1
deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
-LRB- 0 
C5 0 
-RRB- 0 
was 0 
documented 0 
in 0 
the 0 
accompanying 0 
report 0 
. 0 

This 0 
study 0 
examines 0 
several 0 
biological 0 
properties 0 
of 0 
C5-deficient 1
-LRB- 0 
C5D 1
-RRB- 0 
human 0 
serum 0 
, 0 
particularly 0 
sera 0 
obtained 0 
from 0 
two 0 
C5D 1
homozygotes 0 
. 0 

The 0 
proband 0 
, 0 
who 0 
has 0 
inactive 0 
systemic 1
lupus 1
erythematosus 1
is 0 
completely 0 
lacking 0 
C5 0
, 0 
while 0 
her 0 
healthy 0 
half-sister 0 
has 0 
1-2 0 
% 0 
of 0 
normal 0 
levels 0 
. 0 

Both 0 
sera 0 
were 0 
severely 0 
impaired 0 
in 0 
their 0 
ability 0 
to 0 
generate 0 
chemotactic 0 
activity 0 
for 0 
normal 0 
human 0 
neutrophils 0 
upon 0 
incubation 0 
with 0 
aggregated 0 
human 0 
gamma-globulin 0 
or 0 
Escherichia 0 
coli 0 
endotoxin 0 
. 0 

This 0 
function 0 
was 0 
fully 0 
restored 0 
in 0 
the 0 
siblings 0 
serum 0 
, 0 
and 0 
substantially 0 
improved 0 
in 0 
the 0 
probands 0 
serum 0 
, 0 
by 0 
addition 0 
of 0 
highly 0 
purified 0 
human 0 
C5 0
to 0 
normal 0 
serum 0 
concentrations 0 
. 0 

Sera 0 
from 0 
eight 0 
family 0 
members 0 
who 0 
were 0 
apparently 0 
heterozygous 0 
for 0 
C5 1
deficiency 1
gave 0 
normal 0 
chemotactic 0 
scores 0 
. 0 

The 0 
ability 0 
of 0 
C5D 1
serum 0 
to 0 
opsonize 0 
Saccharomyces 0 
cerevisiae 0 
-LRB- 0 
bakers 0 
yeast 0 
-RRB- 0 
or 0 
Candida 0 
albicans 0 
for 0 
ingestion 0 
by 0 
normal 0 
neutrophils 0 
was 0 
completely 0 
normal 0 
. 0 

In 0 
addition 0 
, 0 
C5D 1
serum 0 
was 0 
capable 0 
of 0 
promoting 0 
normal 0 
phagocytosis 0 
and 0 
intracellular 0 
killing 0 
of 0 
Staphylococcus 0 
aureus 0 
. 0 

The 0 
probands 0 
serum 0 
was 0 
incapable 0 
of 0 
mediating 0 
lysis 0 
of 0 
erythrocytes 0 
from 0 
a 0 
patient 0 
with 0 
paroxysmal 1
nocturnal 1
hemoglobinuria 1
in 0 
both 0 
the 0 
sucrose 0 
hemolysia 0 
and 0 
acid 0 
hemolysis 0 
tests 0 
, 0 
and 0 
also 0 
lacked 0 
bactericidal 0 
activity 0 
against 0 
sensitized 0 
or 0 
unsensitized 0 
Salmonella 0 
typhi 0 
. 0 

The 0 
siblings 0 
serum 0 
, 0 
containing 0 
only 0 
1-2 0 
% 0 
of 0 
normal 0 
C5 0 
, 0 
effectively 0 
lysed 0 
S. 0 
typhi 0 
, 0 
but 0 
only 0 
at 0 
eightfold 0 
lower 0 
serum 0 
dilutions 0 
as 0 
compared 0 
to 0 
normals 0 
. 0 

These 0 
findings 0 
underscore 0 
the 0 
critical 0 
role 0 
of 0 
C5 0 
in 0 
the 0 
generation 0 
of 0 
chemotactic 0 
activity 0 
and 0 
in 0 
cytolytic 0 
reactions 0 
, 0 
as 0 
opposed 0 
to 0 
a 0 
nonobligatory 0 
or 0 
minimal 0 
role 0 
in 0 
opsonization 0 
, 0 
at 0 
least 0 
for 0 
the 0 
organisms 0 
under 0 
study 0 
. 0 
. 0 

The 0 
gene 0 
for 0 
familial 1
Mediterranean 1
fever 1
, 0 
MEFV 0 
, 0 
is 0 
expressed 0 
in 0 
early 0 
leukocyte 0 
development 0 
and 0 
is 0 
regulated 0 
in 0 
response 0 
to 0 
inflammatory 0 
mediators 0 
. 0 

Familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
is 0 
a 0 
recessive 1
disorder 1
characterized 0 
by 0 
episodes 0 
of 0 
fever 1
and 0 
neutrophil-mediated 1
serosal 1
inflammation 1
. 0 

We 0 
recently 0 
identified 0 
the 0 
gene 0 
causing 0 
FMF 1
, 0 
designated 0 
MEFV 0 
, 0 
and 0 
found 0 
it 0 
to 0 
be 0 
expressed 0 
in 0 
mature 0 
neutrophils 0 
, 0 
suggesting 0 
that 0 
it 0 
functions 0 
as 0 
an 0 
inflammatory 0 
regulator 0 
. 0 

To 0 
facilitate 0 
our 0 
understanding 0 
of 0 
the 0 
normal 0 
function 0 
of 0 
MEFV 0 
, 0 
we 0 
extended 0 
our 0 
previous 0 
studies 0 
. 0 

MEFV 0 
messenger 0 
RNA 0 
was 0 
detected 0 
by 0 
reverse 0 
transcriptase-polymerase 0 
chain 0 
reaction 0 
in 0 
bone 0 
marrow 0 
leukocytes 0 
, 0 
with 0 
differential 0 
expression 0 
observed 0 
among 0 
cells 0 
by 0 
in 0 
situ 0 
hybridization 0 
. 0 

CD34 0 
hematopoietic 0 
stem-cell 0 
cultures 0 
induced 0 
toward 0 
the 0 
granulocytic 0 
lineage 0 
expressed 0 
MEFV 0 
at 0 
the 0 
myelocyte 0 
stage 0 
, 0 
concurrently 0 
with 0 
lineage 0 
commitment 0 
. 0 

The 0 
prepromyelocytic 0 
cell 0 
line 0 
HL60 0 
expressed 0 
MEFV 0 
only 0 
at 0 
granulocytic 0 
and 0 
monocytic 0 
differentiation 0 
. 0 

MEFV 0 
was 0 
also 0 
expressed 0 
in 0 
the 0 
monocytic 0 
cell 0 
lines 0 
_AN 0 
and 0 
THP-1 0 
. 0 

Among 0 
peripheral 0 
blood 0 
leukocytes 0 
, 0 
MEFV 0 
expression 0 
was 0 
detected 0 
in 0 
neutrophils 0 
, 0 
eosinophils 0 
, 0 
and 0 
to 0 
varying 0 
degrees 0 
, 0 
monocytes 0 
. 0 

Consistent 0 
with 0 
the 0 
tissue 0 
specificity 0 
of 0 
expression 0 
, 0 
complete 0 
sequencing 0 
and 0 
analysis 0 
of 0 
upstream 0 
regulatory 0 
regions 0 
of 0 
MEFV 0 
revealed 0 
homology 0 
to 0 
myeloid-specific 0 
promoters 0 
and 0 
to 0 
more 0 
broadly 0 
expressed 0 
inflammatory 0 
promoter 0 
elements 0 
. 0 

In 0 
vitro 0 
stimulation 0 
of 0 
monocytes 0 
with 0 
the 0 
proinflammatory 0 
agents 0 
interferon 0 
-LRB- 0 
IFN 0 
-RRB- 0 
gamma 0 
, 0 
tumor 1
necrosis 0 
factor 0 
, 0 
and 0 
lipopolysaccharide 0 
induced 0 
MEFV 0 
expression 0 
, 0 
whereas 0 
the 0 
antiinflammatory 0 
cytokines 0 
interleukin 0 
-LRB- 0 
IL 0 
-RRB- 0 
_NUM1 0 
, 0 
IL-10 0 
, 0 
and 0 
transforming 0 
growth 0 
factor 0 
beta 0 
inhibited 0 
such 0 
expression 0 
. 0 

Induction 0 
by 0 
IFN-gamma 0 
occurred 0 
rapidly 0 
and 0 
was 0 
resistant 0 
to 0 
cycloheximide 0 
. 0 

IFN-alpha 0 
also 0 
induced 0 
MEFV 0 
expression 0 
. 0 

In 0 
granulocytes 0 
, 0 
MEFV 0 
was 0 
up-regulated 0 
by 0 
IFN-gamma 0 
and 0 
the 0 
combination 0 
of 0 
IFN-alpha 0 
and 0 
colchicine 0 
. 0 

These 0 
results 0 
refine 0 
understanding 0 
of 0 
MEFV 0 
by 0 
placing 0 
the 0 
gene 0 
in 0 
the 0 
myelomonocytic-specific 0 
proinflammatory 0 
pathway 0 
and 0 
identifying 0 
it 0 
as 0 
an 0 
IFN-gamma 0 
immediate 0 
early 0 
gene 0 
. 0 
. 0 

Spectrum 0 
of 0 
hSNF5 0 
/ 0 
INI1 0 
somatic 0 
mutations 0 
in 0 
human 0 
cancer 1
and 0 
genotype-phenotype 0 
correlations 0 
. 0 

The 0 
hSNF5 0 
/ 0 
INI1 0 
gene 0 
which 0 
encodes 0 
a 0 
member 0 
of 0 
the 0 
SWI 0 
/ 0 
SNF 0 
chromatin 0 
ATP-dependent 0 
remodeling 0 
complex 0 
, 0 
is 0 
a 0 
new 0 
tumor 1
suppressor 0 
gene 0 
localized 0 
on 0 
chromosome 0 
22q11 0 
. 0 

_NUM1 0 
and 0 
recently 0 
shown 0 
to 0 
be 0 
mutated 0 
in 0 
malignant 1
rhabdoid 1
tumors 1
. 0 

We 0 
have 0 
searched 0 
for 0 
hSNF5 0 
/ 0 
INI1 0 
mutations 0 
in 0 
_NUM3 0 
tumors 1
of 0 
various 0 
origins 0 
using 0 
a 0 
screening 0 
method 0 
based 0 
on 0 
denaturing 0 
high-performance 0 
liquid 0 
chromatography 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
homozygous 0 
deletions 0 
and 0 
_NUM2 0 
point 0 
alterations 0 
were 0 
identified 0 
. 0 

Point 0 
mutations 0 
were 0 
scattered 0 
along 0 
the 0 
coding 0 
sequence 0 
and 0 
included 0 
_NUM2 0 
nonsense 0 
, 0 
_NUM2 0 
frameshift 0 
, 0 
three 0 
splice 0 
site 0 
, 0 
two 0 
missense 0 
and 0 
one 0 
editing 0 
mutations 0 
. 0 

Mutations 0 
were 0 
retrieved 0 
in 0 
most 0 
rhabdoid 1
tumors 1
, 0 
whatever 0 
their 0 
sites 0 
of 0 
occurrence 0 
, 0 
indicating 0 
the 0 
common 0 
pathogenetic 0 
origin 0 
of 0 
these 0 
tumors 1
. 0 

Recurrent 0 
hSNF5 0 
/ 0 
INI1 0 
alterations 0 
were 0 
also 0 
observed 0 
in 0 
choroid 1
plexus 1
carcinomas 1
and 0 
in 0 
a 0 
subset 0 
of 0 
central 0 
primitive 0 
neuroectodermal 1
tumors 1
-LRB- 0 
cPNETs 0 
-RRB- 0 
and 0 
medulloblastomas 1
. 0 

In 0 
contrast 0 
, 0 
hSNF5 0 
/ 0 
INI1 0 
point 0 
mutations 0 
were 0 
not 0 
detected 0 
in 0 
breast 1
cancers 1
, 0 
Wilms 1
tumors 1
, 0 
gliomas 1
, 0 
ependymomas 1
, 0 
sarcomas 1
and 0 
other 0 
tumor 1
types 0 
, 0 
even 0 
though 0 
most 0 
analyzed 0 
cases 0 
harbored 0 
loss 0 
of 0 
heterozygosity 0 
at 0 
22q11 0 
. 0 

_NUM1 0 
loci 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
rhabdoid 1
tumors 1
, 0 
choroid 1
plexus 1
carcinomas 1
and 0 
a 0 
subset 0 
of 0 
medulloblastomas 1
and 0 
cPNETs 0 
share 0 
common 0 
pathways 0 
of 0 
oncogenesis 0 
related 0 
to 0 
hSNF5 0 
/ 0 
INI1 0 
alteration 0 
and 0 
that 0 
hSNF5 0 
/ 0 
INI1 0 
mutations 0 
define 0 
a 0 
genetically 0 
homogeneous 0 
family 0 
of 0 
highly 0 
aggressive 0 
cancers 1
mainly 0 
occurring 0 
in 0 
young 0 
children 0 
and 0 
frequently 0 
, 0 
but 0 
not 0 
always 0 
, 0 
exhibiting 0 
a 0 
rhabdoid 1
phenotype 0 
Heterogeneity 0 
of 0 
glucose-6-phosphate 1
dehydrogenase 1
deficiency 1
in 0 
Algeria 0 
. 0 

Study 0 
in 0 
Northern 0 
Algeria 0 
with 0 
description 0 
of 0 
five 0 
new 0 
variants 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
was 0 
found 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
male 0 
population 0 
living 0 
in 0 
the 0 
urban 0 
area 0 
of 0 
Algiers 0 
. 0 

The 0 
deficient 0 
subjects 0 
originated 0 
from 0 
multiple 0 
geographic 0 
regions 0 
of 0 
Northern 0 
Algeria 0 
, 0 
with 0 
prevalence 0 
of 0 
individuals 0 
of 0 
Berber-Kabyle 0 
origin 0 
. 0 

Red 0 
blood 0 
cell 0 
G6PD 0
was 0 
partially 0 
purified 0 
and 0 
characterized 0 
in 0 
deficient 0 
males 0 
from 0 
_NUM2 0 
families 0 
, 0 
and 0 
six 0 
different 0 
variants 0 
were 0 
found 0 
. 0 

Among 0 
them 0 
, 0 
only 0 
one 0 
, 0 
the 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Kabyle 0 
variant 0 
, 0 
had 0 
been 0 
previously 0 
described 0 
. 0 

It 0 
was 0 
detected 0 
in 0 
nine 0 
families 0 
. 0 

The 0 
other 0 
five 0 
variants 0 
were 0 
new 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Laghouat 0 
-LRB- 0 
four 0 
cases 0 
-RRB- 0 
, 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Blida 0 
-LRB- 0 
one 0 
case 0 
-RRB- 0 
, 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Thenia 0 
-LRB- 0 
one 0 
case 0 
-RRB- 0 
, 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Titteri 0 
-LRB- 0 
one 0 
case 0 
-RRB- 0 
, 0 
and 0 
Gd 0 
-LRB- 0 
- 0 
-RRB- 0 
Alger 0 
-LRB- 0 
two 0 
brothers 0 
-RRB- 0 
. 0 

Strikingly 0 
, 0 
the 0 
common 0 
Mediterranean 0 
variant 0 
was 0 
not 0 
found 0 
. 0 

G6PD 1
deficiency 1
is 0 
heterogeneous 0 
in 0 
northern 0 
Algeria 0 
where 0 
autochtonous 0 
variants 0 
seem 0 
to 0 
prevail 0 
. 0 

The 0 
Kabyle 0 
variant 0 
may 0 
be 0 
common 0 
in 0 
this 0 
country 0 
. 0 

Fragile 1
X 1
syndrome 1
without 0 
_DS 0 
amplification 0 
has 0 
an 0 
FMR1 0 
deletion 0 
. 0 

We 0 
describe 0 
a 0 
patient 0 
with 0 
typical 0 
clinical 0 
features 0 
of 0 
the 0 
fragile 1
X 1
syndrome 1
, 0 
but 0 
without 0 
cytogenetic 0 
expression 0 
of 0 
the 0 
fragile 1
X 1
or 0 
an 0 
amplified 0 
_DS 0 
trinucleotide 0 
repeat 0 
fragment 0 
. 0 

The 0 
patient 0 
has 0 
a 0 
previously 0 
uncharacterized 0 
submicroscopic 0 
deletion 0 
encompassing 0 
the 0 
_DS 0 
repeat 0 
, 0 
the 0 
entire 0 
FMR1 0 
gene 0 
and 0 
about 0 
_NUM1 0 
. 0 

_NUM1 0 
megabases 0 
of 0 
flanking 0 
sequences 0 
. 0 

This 0 
finding 0 
confirms 0 
that 0 
the 0 
fragile 1
X 1
phenotype 0 
can 0 
exist 0 
, 0 
without 0 
amplification 0 
of 0 
the 0 
_DS 0 
repeat 0 
or 0 
cytogenetic 0 
expression 0 
of 0 
the 0 
fragile 1
X 1
, 0 
and 0 
that 0 
fragile 1
X 1
syndrome 1
is 0 
a 0 
genetically 0 
homogeneous 0 
disorder 0 
involving 0 
FMR1 0 
. 0 

We 0 
also 0 
found 0 
random 0 
X-inactivation 0 
in 0 
the 0 
mother 0 
of 0 
the 0 
patient 0 
who 0 
was 0 
shown 0 
to 0 
be 0 
a 0 
carrier 0 
of 0 
this 0 
deletion 0 
. 0 

Confirmation 0 
of 0 
linkage 0 
of 0 
Van 1
der 1
Woude 1
syndrome 1
to 0 
chromosome 0 
1q32 0 
: 0 
evidence 0 
of 0 
association 0 
with 0 
STR 0 
alleles 0 
suggests 0 
possible 0 
unique 0 
origin 0 
of 0 
the 0 
disease 0 
mutation 0 
. 0 

Van 1
der 1
Woude 1
syndrome 1
-LRB- 0 
VWS 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
craniofacial 1
disorder 1
with 0 
high 0 
penetrance 0 
and 0 
variable 0 
expression 0 
. 0 

Its 0 
clinical 0 
features 0 
are 0 
variably 0 
expressed 0 
, 0 
but 0 
include 0 
cleft 1
lip 1
and 0 
/ 0 
or 0 
cleft 1
palate 1
, 0 
lip 1
pits 1
and 0 
hypodontia 1
. 0 

All 0 
VWS 1
families 0 
studied 0 
to 0 
date 0 
map 0 
the 0 
disease 0 
gene 0 
to 0 
a 0 
< 0 
_NUM1 0 
cM 0 
region 0 
of 0 
chromosome 0 
1q32 0 
, 0 
with 0 
no 0 
evidence 0 
of 0 
locus 0 
heterogeneity 0 
. 0 

The 0 
aim 0 
of 0 
this 0 
study 0 
is 0 
to 0 
refine 0 
the 0 
localization 0 
of 0 
the 0 
VWS 1
gene 0 
and 0 
to 0 
further 0 
assess 0 
possible 0 
heterogeneity 0 
. 0 

We 0 
analyzed 0 
four 0 
multiplex 0 
VWS 1
families 0 
. 0 

All 0 
available 0 
members 0 
were 0 
clinically 0 
assessed 0 
and 0 
genotyped 0 
for 0 
_NUM2 0 
short 0 
tandem 0 
repeat 0 
markers 0 
on 0 
chromosome 0 
_NUM1 0 
in 0 
the 0 
VWS 1
candidate 0 
gene 0 
region 0 
. 0 

We 0 
performed 0 
two-point 0 
and 0 
multipoint 0 
limit 0 
of 0 
detection 0 
-LRB- 0 
LOD 0 
-RRB- 0 
score 0 
analyses 0 
using 0 
a 0 
high 0 
penetrance 0 
autosomal 0 
dominant 0 
model 0 
. 0 

All 0 
families 0 
showed 0 
positive 0 
LOD 0 
scores 0 
without 0 
any 0 
recombination 0 
in 0 
the 0 
candidate 0 
region 0 
. 0 

The 0 
largest 0 
two-point 0 
LOD 0 
score 0 
was 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

Our 0 
assay 0 
method 0 
for 0 
short 0 
tandem 0 
repeat 0 
-LRB- 0 
STR 0 
-RRB- 0 
markers 0 
provided 0 
highly 0 
accurate 0 
size 0 
estimation 0 
of 0 
marker 0 
allele 0 
fragment 0 
sizes 0 
, 0 
and 0 
therefore 0 
enabled 0 
us 0 
to 0 
determine 0 
the 0 
specific 0 
alleles 0 
segregating 0 
with 0 
the 0 
VWS 1
gene 0 
in 0 
each 0 
of 0 
our 0 
four 0 
families 0 
. 0 

We 0 
observed 0 
a 0 
striking 0 
pattern 0 
of 0 
STR 0 
allele 0 
sharing 0 
at 0 
several 0 
closely 0 
linked 0 
loci 0 
among 0 
our 0 
four 0 
Caucasian 0 
VWS 1
families 0 
recruited 0 
at 0 
three 0 
different 0 
locations 0 
in 0 
the 0 
US 0 
. 0 

These 0 
results 0 
suggest 0 
the 0 
possibility 0 
of 0 
a 0 
unique 0 
origin 0 
for 0 
a 0 
mutation 0 
responsible 0 
for 0 
many 0 
or 0 
most 0 
cases 0 
of 0 
VWS 1
. 0 

The 0 
carrier 0 
frequency 0 
of 0 
the 0 
BRCA1 0 
185delAG 0 
mutation 0 
is 0 
approximately 0 
_NUM1 0 
percent 0 
in 0 
Ashkenazi 0 
Jewish 0 
individuals 0 
. 0 

Since 0 
BRCA1 0 
, 0 
the 0 
first 0 
major 0 
gene 0 
responsible 0 
for 0 
inherited 1
breast 1
cancer 1
, 0 
was 0 
cloned 0 
, 0 
more 0 
than 0 
_NUM2 0 
unique 0 
mutations 0 
have 0 
been 0 
detected 0 
in 0 
the 0 
germline 0 
of 0 
individuals 0 
with 0 
breast 1
and 1
ovarian 1
cancer 1
. 0 

In 0 
high-risk 0 
pedigrees 0 
, 0 
female 0 
carriers 0 
of 0 
BRCA1 0 
mutations 0 
have 0 
an 0 
80-90 0 
% 0 
lifetime 0 
risk 0 
of 0 
breast 1
cancer 1
, 0 
and 0 
a 0 
40-50 0 
% 0 
risk 0 
of 0 
ovarian 1
cancer 1
. 0 

However 0 
, 0 
the 0 
mutation 0 
stats 0 
of 0 
individuals 0 
unselected 0 
for 0 
breast 1
or 1
ovarian 1
cancer 1
has 0 
not 0 
been 0 
determined 0 
, 0 
and 0 
it 0 
is 0 
not 0 
known 0 
whether 0 
mutations 0 
in 0 
such 0 
individuals 0 
confer 0 
the 0 
same 0 
risk 0 
of 0 
cancer 1
as 0 
in 0 
individuals 0 
from 0 
the 0 
high-risk 0 
families 0 
studied 0 
so 0 
far 0 
. 0 

Following 0 
the 0 
finding 0 
of 0 
a 0 
185delAG 0 
frameshift 0 
mutation 0 
in 0 
several 0 
Ashkenazi 0 
Jewish 0 
breast 0 
/ 0 
ovarian 0 
families 0 
, 0 
we 0 
have 0 
determined 0 
the 0 
frequency 0 
of 0 
this 0 
mutation 0 
in 0 
_NUM3 0 
Ashkenazim 0 
seeking 0 
genetic 0 
testing 0 
for 0 
conditions 0 
unrelated 0 
to 0 
cancer 1
, 0 
and 0 
in 0 
_NUM3 0 
reference 0 
individuals 0 
not 0 
selected 0 
for 0 
ethnic 0 
origin 0 
. 0 

We 0 
observed 0 
the 0 
185delAG 0 
mutation 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
Ashkenazim 0 
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
limit 0 
, 0 
_NUM1 0 
. 0 

4-1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
in 0 
none 0 
of 0 
the 0 
reference 0 
samples 0 
. 0 

Our 0 
results 0 
suggest 0 
that 0 
one 0 
in 0 
a 0 
hundred 0 
women 0 
of 0 
Ashkenazi 0 
descent 0 
may 0 
be 0 
at 0 
especially 0 
high 0 
risk 0 
of 0 
developing 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
. 0 

Targeted 0 
modification 0 
of 0 
the 0 
apolipoprotein 0 
B 0 
gene 0 
results 0 
in 0 
hypobetalipoproteinemia 1
and 0 
developmental 1
abnormalities 1
in 0 
mice 0 
. 0 

Familial 1
hypobetalipoproteinemia 1
is 0 
an 0 
autosomal 1
codominant 1
disorder 1
resulting 0 
in 0 
a 0 
dramatic 0 
reduction 0 
in 0 
plasma 0 
concentrations 0 
of 0 
apolipoprotein 0 
-LRB- 0 
apo 0 
-RRB- 0 
B 0 
, 0 
cholesterol 0 
, 0 
and 0 
beta-migrating 0 
lipoproteins 0 
. 0 

A 0 
benefit 0 
of 0 
hypobetalipoproteinemia 1
is 0 
that 0 
mildly 0 
affected 0 
individuals 0 
may 0 
be 0 
protected 0 
from 0 
coronary 1
vascular 1
disease 1
. 0 

We 0 
have 0 
used 0 
gene 0 
targeting 0 
to 0 
generate 0 
mice 0 
with 0 
a 0 
modified 0 
Apob 0 
allele 0 
. 0 

Mice 0 
containing 0 
this 0 
allele 0 
display 0 
all 0 
of 0 
the 0 
hallmarks 0 
of 0 
human 0 
hypobetalipoproteinemia 1
they 0 
produce 0 
a 0 
truncated 0 
apoB 0 
protein 0 
, 0 
apoB70 0 
, 0 
and 0 
have 0 
markedly 0 
decreased 0 
plasma 0 
concentrations 0 
of 0 
apoB 0 
, 0 
beta-lipoproteins 0 
, 0 
and 0 
total 0 
cholesterol 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
mice 0 
manifest 0 
several 0 
characteristics 0 
that 0 
are 0 
occasionally 0 
observed 0 
in 0 
human 0 
hypobetalipoproteinemia 1
, 0 
including 0 
reduced 0 
plasma 0 
triglyceride 0 
concentrations 0 
, 0 
fasting 0 
chylomicronemia 1
, 0 
and 0 
reduced 0 
high 0 
density 0 
lipoprotein 0 
cholesterol 0 
. 0 

An 0 
unexpected 0 
finding 0 
is 0 
that 0 
the 0 
modified 0 
Apob 0 
allele 0 
is 0 
strongly 0 
associated 0 
with 0 
exencephalus 1
and 0 
hydrocephalus 1
. 0 

These 0 
mice 0 
should 0 
help 0 
increase 0 
our 0 
understanding 0 
of 0 
hypobetalipoproteinemia 1
, 0 
atherogenesis 1
, 0 
and 0 
the 0 
etiology 0 
of 0 
exencephalus 1
and 0 
hydrocephalus 1
. 0 
. 0 

Common 0 
mutations 0 
in 0 
BRCA1 0 
and 0 
BRCA2 0 
do 0 
not 0 
contribute 0 
to 0 
early 0 
prostate 1
cancer 1
in 0 
Jewish 0 
men 0 
. 0 

BACKGROUND 0 
Families 0 
with 0 
a 0 
high 0 
incidence 0 
of 0 
hereditary 1
breast 1
cancer 1
, 0 
and 0 
subsequently 0 
shown 0 
to 0 
have 0 
terminating 0 
mutations 0 
in 0 
BRCA1 0 
or 0 
BRCA2 0 
, 0 
appear 0 
to 0 
have 0 
a 0 
higher 0 
incidence 0 
of 0 
prostate 1
cancer 1
among 0 
male 0 
relatives 0 
. 0 

We 0 
aimed 0 
to 0 
determine 0 
whether 0 
the 0 
common 0 
germline 0 
mutations 0 
of 0 
BRCA1 0 
or 0 
BRCA2 0 
in 0 
Ashkenazi 0 
Jewish 0 
men 0 
predisposed 0 
them 0 
to 0 
prostate 1
cancer 1
. 0 

METHODS 0 
We 0 
examined 0 
genomic 0 
DNA 0 
from 0 
_NUM2 0 
-LRB- 0 
for 0 
BRCA1 0 
185delAG 0 
-RRB- 0 
or 0 
_NUM2 0 
-LRB- 0 
for 0 
BRCA2 0 
6174delT 0 
-RRB- 0 
Ashkenazi 0 
Jewish 0 
prostate 1
cancer 1
patients 0 
, 0 
most 0 
of 0 
whom 0 
were 0 
treated 0 
at 0 
a 0 
relatively 0 
young 0 
age 0 
, 0 
for 0 
the 0 
most 0 
common 0 
germline 0 
mutation 0 
in 0 
each 0 
gene 0 
seen 0 
in 0 
the 0 
Ashkenazi 0 
population 0 
. 0 

RESULTS 0 
Our 0 
study 0 
should 0 
have 0 
been 0 
able 0 
to 0 
detect 0 
a 0 
4-5-fold 0 
increase 0 
in 0 
the 0 
risk 0 
of 0 
prostate 1
cancer 1
due 0 
to 0 
mutation 0 
of 0 
BRCA1 0 
or 0 
BRCA2 0 
. 0 

However 0 
, 0 
only 0 
one 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
% 0 
; 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
, 0 
0-3 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
of 0 
the 0 
patients 0 
was 0 
heterozygous 0 
for 0 
the 0 
BRCA1 0 
mutant 0 
allele 0 
, 0 
and 0 
only 0 
two 0 
were 0 
heterozygous 0 
for 0 
the 0 
BRCA2 0 
mutation 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
; 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
, 0 
0-6 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
. 0 

CONCLUSIONS 0 
The 0 
incidence 0 
of 0 
each 0 
of 0 
the 0 
germline 0 
mutations 0 
in 0 
these 0 
prostate 1
cancer 1
patients 0 
closely 0 
matched 0 
their 0 
incidence 0 
-LRB- 0 
about 0 
_NUM1 0 
% 0 
-RRB- 0 
in 0 
the 0 
general 0 
Ashkenazi 0 
Jewish 0 
population 0 
. 0 

This 0 
suggests 0 
that 0 
unlike 0 
cases 0 
of 0 
breast 1
and 1
ovarian 1
cancers 1
, 0 
mutations 0 
in 0 
BRCA1 0 
or 0 
BRCA2 0 
do 0 
not 0 
significantly 0 
predispose 0 
men 0 
to 0 
prostate 1
cancer 1
Two 0 
new 0 
variants 0 
of 0 
glucose-6-phosphate 0 
dehydrogenase 0 
associated 0 
with 0 
hereditary 1
non-spherocytic 1
hemolytic 1
anemia 1
: 0 
G6PD 0 
Wayne 0 
and 0 
G6PD 0 
Huron 0 
. 0 

Two 0 
new 0 
deficient 0 
variants 0 
of 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
causing 0 
hereditary 1
nonspherocytic 1
hemolytic 1
anemia 1
-LRB- 0 
HNSHA 1
-RRB- 0 
are 0 
described 0 
. 0 

Both 0 
of 0 
these 0 
are 0 
unique 0 
and 0 
they 0 
have 0 
been 0 
named 0 
G6PD 0
Wayne 0 
and 0 
G6PD 0
Huron 0 
. 0 

Patients 0 
with 0 
G6PD 0
Wayne 0 
underwent 0 
splenectomy 0 
and 0 
no 0 
objective 0 
improvement 0 
was 0 
noted 0 
. 0 

The 0 
patients 0 
with 0 
G6PD 0
Huron 0 
were 0 
under 0 
medical 0 
observation 0 
for 0 
a 0 
considerable 0 
period 0 
of 0 
time 0 
without 0 
the 0 
diagnosis 0 
of 0 
G6PD 1
deficiency 1
being 0 
entertained 0 
because 0 
the 0 
family 0 
was 0 
of 0 
Northern 0 
European 0 
origin 0 
. 0 

Since 0 
sporadic 0 
variants 0 
of 0 
G6PD 0 
causing 0 
HNSHA 1
show 0 
no 0 
special 0 
racial 0 
predilection 0 
, 0 
the 0 
diagnosis 0 
of 0 
G6PD 1
deficiency 1
should 0 
always 0 
be 0 
considered 0 
in 0 
patients 0 
with 0 
this 0 
syndrome 0 
. 0 
. 0 

The 0 
Tay-Sachs 1
disease 1
gene 0 
in 0 
North 0 
American 0 
Jewish 0 
populations 0 
: 0 
geographic 0 
variations 0 
and 0 
origin 0 
. 0 

From 0 
data 0 
collected 0 
in 0 
a 0 
North 0 
American 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
heterozygote 0 
screening 0 
program 0 
, 0 
the 0 
TSD 1
carrier 0 
frequency 0 
among 0 
_NUM2 0 
, 0 
_NUM3 0 
Jewish 0 
individuals 0 
was 0 
found 0 
to 0 
be 0 
. 0 

_NUM4 0 
-LRB- 0 
_NUM1 0 
in 0 
_NUM2 0 
individuals 0 
-RRB- 0 
. 0 

This 0 
frequency 0 
is 0 
consistent 0 
with 0 
earlier 0 
estimates 0 
based 0 
on 0 
TSD 1
incidence 0 
data 0 
. 0 

TSD 1
carrier 0 
frequencies 0 
were 0 
then 0 
examined 0 
by 0 
single 0 
country 0 
and 0 
single 0 
region 0 
of 0 
origin 0 
in 0 
_NUM2 0 
, 0 
_NUM3 0 
Jews 0 
within 0 
this 0 
sample 0 
for 0 
whom 0 
such 0 
data 0 
were 0 
available 0 
for 0 
analysis 0 
. 0 

Jews 0 
with 0 
Polish 0 
and 0 
/ 0 
or 0 
Russian 0 
ancestry 0 
constituted 0 
_NUM2 0 
% 0 
of 0 
this 0 
sample 0 
and 0 
had 0 
a 0 
TSD 1
carrier 0 
frequency 0 
of 0 
. 0 

_NUM4 0 
. 0 

No 0 
TSD 1
carriers 0 
were 0 
observed 0 
among 0 
the 0 
_NUM3 0 
Jews 0 
of 0 
Near 0 
Eastern 0 
origins 0 
. 0 

Relative 0 
to 0 
Jews 0 
of 0 
Polish 0 
and 0 
Russian 0 
origins 0 
, 0 
there 0 
was 0 
at 0 
least 0 
a 0 
twofold 0 
increase 0 
in 0 
the 0 
TSD 1
carrier 0 
frequency 0 
in 0 
Jews 0 
of 0 
Austrian 0 
, 0 
Hungarian 0 
, 0 
and 0 
Czechoslovakian 0 
origins 0 
-LRB- 0 
P 0 
less 0 
than 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

These 0 
findings 0 
suggest 0 
that 0 
the 0 
TSD 1
gene 0 
proliferated 0 
among 0 
the 0 
antecedents 0 
of 0 
modern 0 
Ashkenazi 0 
Jewry 0 
after 0 
the 0 
Second 0 
Diaspora 0 
-LRB- 0 
_NUM2 0 
A. 0 
D. 0 
-RRB- 0 
and 0 
before 0 
their 0 
major 0 
migrations 0 
to 0 
regions 0 
of 0 
Poland 0 
and 0 
Russia 0 
-LRB- 0 
before 0 
_NUM4 0 
A. 0 
D. 0 
-RRB- 0 
. 0 

Novel 0 
inherited 0 
mutations 0 
and 0 
variable 0 
expressivity 0 
of 0 
BRCA1 0 
alleles 0 
, 0 
including 0 
the 0 
founder 0 
mutation 0 
185delAG 0 
in 0 
Ashkenazi 0 
Jewish 0 
families 0 
. 0 

Thirty-seven 0 
families 0 
with 0 
four 0 
or 0 
more 0 
cases 0 
of 0 
breast 1
cancer 1
or 0 
breast 1
and 1
ovarian 1
cancer 1
were 0 
analyzed 0 
for 0 
mutations 0 
in 0 
BRCA1 0 
. 0 

Twelve 0 
different 0 
germ-line 0 
mutations 0 
, 0 
four 0 
novel 0 
and 0 
eight 0 
previously 0 
observed 0 
, 0 
were 0 
detected 0 
in 0 
_NUM2 0 
families 0 
. 0 

Five 0 
families 0 
of 0 
Ashkenazi 0 
Jewish 0 
descent 0 
carried 0 
the 0 
185delAG 0 
mutation 0 
and 0 
shared 0 
the 0 
same 0 
haplotype 0 
at 0 
eight 0 
polymorphic 0 
markers 0 
spanning 0 
approximately 0 
_NUM3 0 
kb 0 
at 0 
BRCA1 0 
. 0 

Expressivity 0 
of 0 
185delAG 0 
in 0 
these 0 
families 0 
varied 0 
, 0 
from 0 
early-onset 0 
breast 1
cancer 1
without 0 
ovarian 1
cancer 1
. 0 

Mutation 0 
4184delTCAA 0 
occurred 0 
independently 0 
in 0 
two 0 
families 0 
. 0 

In 0 
one 0 
family 0 
, 0 
penetrance 0 
was 0 
complete 0 
, 0 
with 0 
females 0 
developing 0 
early-onset 0 
breast 1
cancer 1
or 0 
ovarian 1
cancer 1
and 0 
the 0 
male 0 
carrier 0 
developing 0 
prostatic 1
cancer 1
, 0 
whereas 0 
, 0 
in 0 
the 0 
other 0 
family 0 
, 0 
penetrance 0 
was 0 
incomplete 0 
and 0 
only 0 
breast 1
cancer 1
occurred 0 
, 0 
diagnosed 0 
at 0 
ages 0 
38-81 0 
years 0 
. 0 

Two 0 
novel 0 
nonsense 0 
mutations 0 
led 0 
to 0 
the 0 
loss 0 
of 0 
mutant 0 
BRCA1 0 
transcript 0 
in 0 
families 0 
with 0 
_NUM2 0 
and 0 
_NUM1 0 
cases 0 
of 0 
early-onset 0 
breast 1
cancer 1
and 0 
ovarian 1
cancer 1
. 0 

A 0 
665-nt 0 
segment 0 
of 0 
the 0 
BRCA1 0 
3-UTR 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
of 0 
genomic 0 
sequence 0 
including 0 
the 0 
putative 0 
promoter 0 
region 0 
were 0 
invariant 0 
by 0 
single-strand 0 
conformation 0 
analysis 0 
in 0 
_NUM2 0 
families 0 
without 0 
coding-sequence 0 
mutations 0 
. 0 

Overall 0 
in 0 
our 0 
series 0 
, 0 
BRCA1 0 
mutations 0 
have 0 
been 0 
detected 0 
in 0 
_NUM2 0 
families 0 
_NUM2 0 
with 0 
positive 0 
BRCA1 0 
lod 0 
scores 0 
, 0 
_NUM1 0 
with 0 
negative 0 
lod 0 
scores 0 
-LRB- 0 
reflecting 0 
multiple 0 
sporadic 0 
breast 1
cancers 1
-RRB- 0 
, 0 
and 0 
_NUM1 0 
not 0 
tested 0 
for 0 
linkage 0 
. 0 

Three 0 
other 0 
families 0 
have 0 
positive 0 
lod 0 
scores 0 
for 0 
linkage 0 
to 0 
BRCA2 0 
, 0 
but 0 
_NUM2 0 
families 0 
without 0 
detected 0 
BRCA1 0 
mutations 0 
have 0 
negative 0 
lod 0 
scores 0 
for 0 
both 0 
BRCA1 0 
and 0 
BRCA2 0 
. 0 

Transgenic 0 
mice 0 
carrying 0 
large 0 
human 0 
genomic 0 
sequences 0 
with 0 
expanded 0 
_DS 0 
repeat 0 
mimic 0 
closely 0 
the 0 
DM 1
_DS 0 
repeat 0 
intergenerational 0 
and 0 
somatic 0 
instability 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
caused 0 
by 0 
a 0 
_DS 0 
repeat 0 
expansion 0 
in 0 
the 0 
3UTR 0 
of 0 
the 0 
DM 1
protein 0 
kinase 0 
-LRB- 0 
DMPK 0 
-RRB- 0 
gene 0 
. 0 

A 0 
very 0 
high 0 
level 0 
of 0 
instability 0 
is 0 
observed 0 
through 0 
successive 0 
generations 0 
and 0 
the 0 
size 0 
of 0 
the 0 
repeat 0 
is 0 
generally 0 
correlated 0 
with 0 
the 0 
severity 0 
of 0 
the 0 
disease 0 
and 0 
with 0 
age 0 
at 0 
onset 0 
. 0 

Furthermore 0 
, 0 
tissues 0 
from 0 
DM 1
patients 0 
exhibit 0 
somatic 0 
mosaicism 0 
that 0 
increases 0 
with 0 
age 0 
. 0 

We 0 
generated 0 
transgenic 0 
mice 0 
carrying 0 
large 0 
human 0 
genomic 0 
sequences 0 
with 0 
_NUM2 0 
, 0 
_NUM2 0 
or 0 
> 0 
_NUM3 0 
_DS 0 
, 0 
cloned 0 
from 0 
patients 0 
from 0 
the 0 
same 0 
affected 0 
DM 1
family 0 
. 0 

Using 0 
large 0 
human 0 
flanking 0 
sequences 0 
and 0 
a 0 
large 0 
amplification 0 
, 0 
we 0 
demonstrate 0 
that 0 
the 0 
intergenerational 0 
_DS 0 
repeat 0 
instability 0 
is 0 
reproduced 0 
in 0 
mice 0 
, 0 
with 0 
a 0 
strong 0 
bias 0 
towards 0 
expansions 0 
and 0 
with 0 
the 0 
same 0 
sex 0 
- 0 
and 0 
size-dependent 0 
characteristics 0 
as 0 
in 0 
humans 0 
. 0 

Moreover 0 
, 0 
a 0 
high 0 
level 0 
of 0 
instability 0 
, 0 
increasing 0 
with 0 
age 0 
, 0 
can 0 
be 0 
observed 0 
in 0 
tissues 0 
and 0 
in 0 
sperm 0 
. 0 

Although 0 
we 0 
did 0 
not 0 
observe 0 
dramatic 0 
expansions 0 
-LRB- 0 
or 0 
big 0 
jumps 0 
over 0 
several 0 
hundred 0 
_DS 0 
repeats 0 
-RRB- 0 
as 0 
in 0 
congenital 0 
forms 0 
of 0 
DM 1
, 0 
our 0 
model 0 
carrying 0 
> 0 
_NUM3 0 
_DS 0 
is 0 
the 0 
first 0 
to 0 
show 0 
instability 0 
so 0 
close 0 
to 0 
the 0 
human 0 
DM 1
situation 0 
. 0 

Our 0 
three 0 
models 0 
carrying 0 
different 0 
sizes 0 
of 0 
_DS 0 
repeat 0 
provide 0 
insight 0 
on 0 
the 0 
different 0 
factors 0 
modulating 0 
the 0 
_DS 0 
repeat 0 
instability 0 
. 0 
. 0 

Linkage 0 
of 0 
gene 0 
for 0 
C2 1
deficiency 1
and 0 
the 0 
major 0 
histocompatibility 0 
complex 0 
MHC 0 
in 0 
man 0 
. 0 

Family 0 
study 0 
of 0 
a 0 
further 0 
case 0 
. 0 

Close 0 
linkage 0 
between 0 
HL-A 0 
and 0 
C2 1
deficiency 1
was 0 
first 0 
reported 0 
by 0 
FU 0 
and 0 
co-workers 0 
in 0 
_NUM4 0 
. 0 

We 0 
present 0 
here 0 
a 0 
pedigree 0 
of 0 
a 0 
31-year-old 0 
C2-deficient 1
individual 0 
with 0 
clinical 0 
manifestations 0 
of 0 
Hodgkins 1
disease 1
. 0 

The 0 
following 0 
markers 0 
were 0 
tested 0 
C2 0
levels 0 
, 0 
factor 0 
B 0 
polymorphism 0 
, 0 
blood 0 
groups 0 
, 0 
and 0 
enzyme 0 
typing 0 
. 0 

In 0 
addition 0 
to 0 
close 0 
linkage 0 
between 0 
HL-A 0 
and 0 
C2 1
deficiency 1
, 0 
both 0 
parents 0 
were 0 
heterozygous 0 
for 0 
Bf 0 
-LRB- 0 
HL-A 0 
linked 0 
, 0 
electrophoretic 0 
variation 0 
of 0 
B 0 
-RRB- 0 
. 0 

The 0 
two 0 
HL-A 0 
haplotypes 0 
closely 0 
linked 0 
to 0 
C2 1
deficiency 1
are 0 
different 0 
_NUM1 0 
, 0 
_AN 0 
and 0 
_AN 0 
, 0 
_AN 0 
. 0 

They 0 
share 0 
, 0 
however 0 
, 0 
the 0 
SD2 0 
antigen 0 
_AN 0 
and 0 
the 0 
LD 0 
type 0 
7a 0 
. 0 
. 0 

Age 0 
of 0 
onset 0 
in 0 
Huntington 1
disease 1
: 0 
sex 0 
specific 0 
influence 0 
of 0 
apolipoprotein 0 
E 0 
genotype 0 
and 0 
normal 0 
_DS 0 
repeat 0 
length 0 
. 0 

Age 0 
of 0 
onset 0 
-LRB- 0 
AO 0 
-RRB- 0 
of 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
is 0 
known 0 
to 0 
be 0 
correlated 0 
with 0 
the 0 
length 0 
of 0 
an 0 
expanded 0 
_DS 0 
repeat 0 
in 0 
the 0 
HD 1
gene 0 
. 0 

Apolipoprotein 0 
E 0 
-LRB- 0 
APOE 0 
-RRB- 0 
genotype 0 
, 0 
in 0 
turn 0 
, 0 
is 0 
known 0 
to 0 
influence 0 
AO 0 
in 0 
Alzheimer 1
disease 1
, 0 
rendering 0 
the 0 
APOE 0 
gene 0 
a 0 
likely 0 
candidate 0 
to 0 
affect 0 
AO 0 
in 0 
other 0 
neurological 1
diseases 1
too 0 
. 0 

We 0 
therefore 0 
determined 0 
APOE 0 
genotype 0 
and 0 
normal 0 
_DS 0 
repeat 0 
length 0 
in 0 
the 0 
HD 1
gene 0 
for 0 
_NUM3 0 
HD 1
patients 0 
who 0 
were 0 
previously 0 
analysed 0 
with 0 
respect 0 
to 0 
_DS 0 
repeat 0 
length 0 
. 0 

Genotyping 0 
for 0 
APOE 0 
was 0 
performed 0 
blind 0 
to 0 
clinical 0 
information 0 
. 0 

In 0 
addition 0 
to 0 
highlighting 0 
the 0 
effect 0 
of 0 
the 0 
normal 0 
repeat 0 
length 0 
upon 0 
AO 0 
in 0 
maternally 0 
inherited 0 
HD 1
and 0 
in 0 
male 0 
patients 0 
, 0 
we 0 
show 0 
that 0 
the 0 
APOE 0 
epsilon2epsilon3 0 
genotype 0 
is 0 
associated 0 
with 0 
significantly 0 
earlier 0 
AO 0 
in 0 
males 0 
than 0 
in 0 
females 0 
. 0 

Such 0 
a 0 
sex 0 
difference 0 
in 0 
AO 0 
was 0 
not 0 
apparent 0 
for 0 
any 0 
of 0 
the 0 
other 0 
APOE 0 
genotypes 0 
. 0 

Our 0 
findings 0 
suggest 0 
that 0 
subtle 0 
differences 0 
in 0 
the 0 
course 0 
of 0 
the 0 
neurodegeneration 1
in 0 
HD 1
may 0 
allow 0 
interacting 0 
genes 0 
to 0 
exert 0 
gender 0 
specific 0 
effects 0 
upon 0 
AO 0 
. 0 

Genetic 0 
linkage 0 
map 0 
of 0 
six 0 
polymorphic 0 
DNA 0 
markers 0 
around 0 
the 0 
gene 0 
for 0 
familial 1
adenomatous 1
polyposis 1
on 0 
chromosome 0 
_NUM1 0 
. 0 

A 0 
genetic 0 
linkage 0 
map 0 
of 0 
six 0 
polymorphic 0 
DNA 0 
markers 0 
close 0 
to 0 
the 0 
gene 0 
-LRB- 0 
APC 0 
-RRB- 0 
for 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
on 0 
chromosome 0 
5q 0 
is 0 
reported 0 
. 0 

One 0 
hundred 0 
fifty-five 0 
typed 0 
members 0 
of 0 
nine 0 
FAP 1
kindred 0 
provided 0 
more 0 
than 0 
_NUM2 0 
meioses 0 
for 0 
linkage 0 
analysis 0 
. 0 

A 0 
number 0 
of 0 
crucial 0 
recombination 0 
events 0 
have 0 
been 0 
identified 0 
which 0 
are 0 
informative 0 
at 0 
three 0 
or 0 
more 0 
loci 0 
, 0 
allowing 0 
confident 0 
ordering 0 
of 0 
parts 0 
of 0 
the 0 
map 0 
. 0 

There 0 
was 0 
no 0 
evidence 0 
of 0 
genetic 0 
heterogeneity 0 
, 0 
with 0 
all 0 
families 0 
showing 0 
linkage 0 
of 0 
at 0 
least 0 
one 0 
chromosome 0 
_NUM1 0 
marker 0 
to 0 
the 0 
gene 0 
. 0 

Recombination 0 
data 0 
and 0 
two-point 0 
linkage 0 
analysis 0 
support 0 
a 0 
locus 0 
order 0 
of 0 
centromere-pi 0 
227-C11P11-ECB27-L5 0 
. 0 

62-APC-EF5 0 
62-APC-EF5 0 
. 0 

44-YN5 0 
44-YN5 0 
. 0 

48-telomer 0 
e 0 
, 0 
although 0 
EF5 0 
. 0 

_NUM2 0 
could 0 
lie 0 
in 0 
the 0 
interval 0 
L5 0 
. 0 

62-APC 0 
or 0 
ECB27-L5 0 
. 0 

_NUM2 0 
. 0 

No 0 
recombinants 0 
were 0 
identified 0 
between 0 
APC 0 
and 0 
either 0 
EF5 0 
. 0 

_NUM2 0 
or 0 
YN5 0 
. 0 

_NUM2 0 
, 0 
but 0 
published 0 
deletion 0 
mapping 0 
in 0 
colorectal 1
carcinomas 1
and 0 
linkage 0 
analysis 0 
in 0 
FAP 1
suggest 0 
that 0 
YN5 0 
. 0 

_NUM2 0 
is 0 
1-3 0 
cM 0 
from 0 
APC 1
. 0 

The 0 
present 0 
study 0 
suggests 0 
that 0 
YN5 0 
. 0 

_NUM2 0 
and 0 
L5 0 
. 0 

_NUM2 0 
delineate 0 
a 0 
small 0 
region 0 
of 0 
chromosome 0 
_NUM1 0 
within 0 
which 0 
the 0 
EF5 0 
. 0 

_NUM2 0 
locus 0 
lies 0 
very 0 
close 0 
to 0 
the 0 
APC 0 
gene 0 
. 0 

These 0 
data 0 
not 0 
only 0 
allow 0 
use 0 
of 0 
flanking 0 
markers 0 
for 0 
presymptomatic 0 
diagnosis 0 
of 0 
FAP 1
but 0 
also 0 
provide 0 
a 0 
high-density 0 
map 0 
of 0 
the 0 
region 0 
for 0 
isolation 0 
of 0 
the 0 
APC 1
gene 0 
itself 0 
and 0 
for 0 
further 0 
assessment 0 
of 0 
the 0 
role 0 
of 0 
chromosome 0 
_NUM1 0 
deletions 0 
in 0 
the 0 
biology 0 
of 0 
sporadic 0 
colorectal 1
cancer 1
. 0 

Detection 0 
of 0 
a 0 
novel 0 
arginine 0 
vasopressin 0 
defect 0 
by 0 
dideoxy 0 
fingerprinting 0 
. 0 

Autosomal 1
dominant 1
neurohypophyseal 1
diabetes 1
insipidus 1
is 0 
a 0 
familial 0 
form 0 
of 0 
diabetes 1
insipidus 1
. 0 

This 0 
disorder 0 
is 0 
associated 0 
with 0 
variable 0 
levels 0 
of 0 
arginine 0 
vasopressin 0 
-LRB- 0 
AVP 0 
-RRB- 0 
and 0 
diabetes 1
insipidus 1
of 0 
varying 0 
severity 0 
, 0 
which 0 
responds 0 
to 0 
exogenous 0 
AVP 0 
. 0 

To 0 
determine 0 
the 0 
molecular 0 
basis 0 
of 0 
autosomal 1
dominant 1
neurohypophyseal 1
diabetes 1
insipidus 1
, 0 
the 0 
AVP 0 
genes 0 
of 0 
members 0 
of 0 
a 0 
large 0 
kindred 0 
were 0 
analyzed 0 
. 0 

A 0 
new 0 
method 0 
, 0 
called 0 
dideoxy 0 
fingerprinting 0 
, 0 
was 0 
used 0 
to 0 
detect 0 
an 0 
AVP 0 
mutation 0 
that 0 
was 0 
characterized 0 
by 0 
DNA 0 
sequencing 0 
. 0 

The 0 
novel 0 
defect 0 
found 0 
changes 0 
the 0 
last 0 
codon 0 
of 0 
the 0 
AVP 0 
signal 0 
peptide 0 
from 0 
alanine 0 
to 0 
threonine 0 
, 0 
which 0 
should 0 
perturb 0 
cleavage 0 
of 0 
mature 0 
AVP 0 
from 0 
its 0 
precursor 0 
protein 0 
and 0 
inhibit 0 
its 0 
secretion 0 
or 0 
action 0 
. 0 
. 0 

Association 0 
of 0 
the 0 
APC 1
tumor 1
suppressor 0 
protein 0 
with 0 
catenins 0 
. 0 

Mutations 0 
of 0 
APC 0 
appear 0 
to 0 
initiate 0 
sporadic 0 
and 0 
inherited 0 
forms 0 
of 0 
human 0 
colorectal 1
cancer 1
. 0 

Although 0 
these 0 
mutations 0 
have 0 
been 0 
well 0 
characterized 0 
, 0 
little 0 
is 0 
known 0 
about 0 
the 0 
function 0 
of 0 
the 0 
APC 1
gene 0 
product 0 
. 0 

Two 0 
cellular 0 
proteins 0 
that 0 
associate 0 
with 0 
APC 1
were 0 
identified 0 
by 0 
nucleotide 0 
sequence 0 
analysis 0 
and 0 
peptide 0 
mapping 0 
as 0 
the 0 
E-cadherin-associated 0 
proteins 0 
alpha 0 
- 0 
and 0 
beta-catenin 0 
. 0 

A 0 
27-residue 0 
fragment 0 
of 0 
APC 0 
containing 0 
a 0 
15-amino 0 
acid 0 
repeat 0 
was 0 
sufficient 0 
for 0 
the 0 
interaction 0 
with 0 
the 0 
catenins 0 
. 0 

These 0 
results 0 
suggest 0 
an 0 
important 0 
link 0 
between 0 
tumor 1
initiation 0 
and 0 
cell 0 
adhesion 0 
. 0 
. 0 

Myotonic 1
dystrophy 1
is 0 
closely 0 
linked 0 
to 0 
the 0 
gene 0 
for 0 
muscle-type 0 
creatine 0 
kinase 0 
-LRB- 0 
CKMM 0 
-RRB- 0 
. 0 

We 0 
have 0 
studied 0 
genetic 0 
linkage 0 
between 0 
the 0 
gene 0 
for 0 
creatine 0 
kinase 0 
muscle 0 
type 0 
-LRB- 0 
CKMM 0 
-RRB- 0 
and 0 
the 0 
gene 0 
for 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

In 0 
a 0 
panel 0 
of 0 
_NUM2 0 
myotonic 1
dystrophy 1
families 0 
from 0 
Canada 0 
and 0 
the 0 
Netherlands 0 
, 0 
a 0 
maximum 0 
lod 0 
score 0 
-LRB- 0 
Zmax 0 
-RRB- 0 
of 0 
_NUM2 0 
. 0 

_NUM1 0 
at 0 
a 0 
recombination 0 
frequency 0 
-LRB- 0 
theta 0 
-RRB- 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
was 0 
obtained 0 
. 0 

Tight 0 
linkage 0 
was 0 
also 0 
demonstrated 0 
for 0 
CKMM 0 
and 0 
the 0 
gene 0 
for 0 
apolipoprotein 0 
C2 0 
-LRB- 0 
ApoC2 0 
-RRB- 0 
. 0 

This 0 
establishes 0 
CKMM 0 
as 0 
a 0 
useful 0 
marker 0 
for 0 
myotonic 1
dystrophy 1
Discordant 0 
clinical 0 
outcome 0 
in 0 
myotonic 1
dystrophy 1
relatives 0 
showing 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
> 0 
_NUM3 0 
repeats 0 
. 0 

A 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
family 0 
is 0 
described 0 
in 0 
which 0 
discordant 0 
DM 1
phenotypes 0 
were 0 
found 0 
in 0 
the 0 
children 0 
of 0 
two 0 
affected 0 
sisters 0 
with 0 
similar 0 
_DS 0 
expansion 0 
and 0 
clinical 0 
manifestations 0 
. 0 

In 0 
this 0 
family 0 
, 0 
congenital 0 
as 0 
well 0 
as 0 
early 0 
severe 0 
childhood 0 
and 0 
later 0 
childhood 0 
onset 0 
DM 1
coexist 0 
. 0 

This 0 
observation 0 
strengthens 0 
the 0 
limited 0 
ability 0 
of 0 
lymphocytes 0 
_DS 0 
repeat 0 
number 0 
analysis 0 
in 0 
predicting 0 
genotype-phenotype 0 
correlations 0 
in 0 
DM 1
patients 0 
. 0 
. 0 

Constitutional 0 
von 1
Hippel-Lindau 1
-LRB- 0 
VHL 1
-RRB- 0 
gene 0 
deletions 0 
detected 0 
in 0 
VHL 1
families 0 
by 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
. 0 

von 1
Hippel-Lindau 1
-LRB- 1
VHL 1
-RRB- 1
disease 1
is 0 
an 0 
autosomal 1
dominantly 1
inherited 1
cancer 1
syndrome 1
predisposing 0 
to 0 
a 0 
variety 0 
of 0 
tumor 1
types 0 
that 0 
include 0 
retinal 0 
hemangioblastomas 1
, 0 
hemangioblastomas 1
of 0 
the 0 
central 0 
nervous 0 
system 0 
, 0 
renal 1
cell 1
carcinomas 1
, 0 
pancreatic 1
cysts 1
and 1
tumors 1
, 0 
pheochromocytomas 1
, 0 
endolymphatic 1
sac 1
tumors 1
, 0 
and 0 
epididymal 1
cystadenomas 1
-LSB- 0 
W. 0 
M. 0 
Linehan 0 
et 0 
al. 0 
, 0 
J. 0 
Am 0 
. 0 

Med 0 
. 0 

Assoc. 0 
, 0 
_NUM3 0 
564-570 0 
, 0 
_NUM4 0 
; 0 
E. 0 
A. 0 
Maher 0 
and 0 
W. 0 
G. 0 
Kaelin 0 
, 0 
Jr. 0 
, 0 
Medicine 0 
-LRB- 0 
Baltimore 0 
-RRB- 0 
, 0 
_NUM2 0 
381-391 0 
, 0 
_NUM4 0 
; 0 
W. 0 
M. 0 
Linehan 0 
and 0 
R. 0 
D. 0 
Klausner 0 
, 0 
In 0 
B. 0 
Vogelstein 0 
and 0 
K. 0 
Kinzler 0 
-LRB- 0 
eds 0 
. 0 
-RRB- 0 

, 0 
The 0 
Genetic 0 
Basis 0 
of 0 
Human 0 
Cancer 0 
, 0 
pp. 0 
455-473 0 
, 0 
McGraw-Hill 0 
, 0 
_NUM4 0 
-RSB- 0 
. 0 

The 0 
VHL 1
gene 0 
was 0 
localized 0 
to 0 
chromosome 0 
3p25-26 0 
and 0 
cloned 0 
-LSB- 0 
F. 0 
Latif 0 
et 0 
al. 0 
, 0 
Science 0 
-LRB- 0 
Washington 0 
DC 0 
-RRB- 0 
, 0 
_NUM3 0 
1317-1320 0 
, 0 
_NUM4 0 
-RSB- 0 
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
VHL 1
gene 0 
have 0 
been 0 
detected 0 
in 0 
the 0 
majority 0 
of 0 
VHL 1
kindreds 0 
. 0 

The 0 
reported 0 
frequency 0 
of 0 
detection 0 
of 0 
VHL 1
germline 0 
mutations 0 
has 0 
varied 0 
from 0 
_NUM2 0 
to 0 
_NUM2 0 
% 0 
-LRB- 0 
J. 0 
M. 0 
Whaley 0 
et 0 
al. 0 
, 0 
Am 0 
. 0 

J. 0 
Hum 0 
. 0 

Genet. 0 
, 0 
_NUM2 0 
1092-1102 0 
, 0 
_NUM4 0 
; 0 
Clinical 0 
Research 0 
Group 0 
for 0 
Japan 0 
, 0 
Hum 0 
. 0 

Mol 0 
. 0 

Genet. 0 
, 0 
_NUM1 0 
2233-2237 0 
, 0 
_NUM4 0 
; 0 
F. 0 
Chen 0 
et 0 
al. 0 
, 0 
Hum 0 
. 0 

Mutat. 0 
, 0 
_NUM1 0 
66-75 0 
, 0 
_NUM4 0 
; 0 
E. 0 
R. 0 
Maher 0 
et 0 
al. 0 
, 0 
J. 0 
Med 0 
. 0 

Genet. 0 
, 0 
_NUM2 0 
328-332 0 
, 0 
_NUM4 0 
; 0 
B. 0 
Zbar 0 
, 0 
Cancer 0 
Surv. 0 
, 0 
_NUM2 0 
219-232 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

Recently 0 
a 0 
quantitative 0 
Southern 0 
blotting 0 
procedure 0 
was 0 
found 0 
to 0 
improve 0 
this 0 
frequency 0 
-LRB- 0 
C. 0 
Stolle 0 
et 0 
al. 0 
, 0 
Hum 0 
. 0 

Mutat. 0 
, 0 
_NUM2 0 
417-423 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
we 0 
report 0 
the 0 
use 0 
of 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
-LRB- 0 
FISH 0 
-RRB- 0 
as 0 
a 0 
method 0 
to 0 
detect 0 
and 0 
characterize 0 
VHL 1
germline 0 
deletions 0 
. 0 

We 0 
reexamined 0 
a 0 
group 0 
of 0 
VHL 1
patients 0 
shown 0 
previously 0 
by 0 
single-strand 0 
conformation 0 
and 0 
sequencing 0 
analysis 0 
not 0 
to 0 
harbor 0 
point 0 
mutations 0 
in 0 
the 0 
VHL 1
locus 0 
. 0 

We 0 
found 0 
constitutional 0 
deletions 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
VHL 1
patients 0 
in 0 
this 0 
group 0 
using 0 
cosmid 0 
and 0 
P1 0 
probes 0 
that 0 
cover 0 
the 0 
VHL 1
locus 0 
. 0 

We 0 
then 0 
tested 0 
six 0 
phenotypically 0 
normal 0 
offspring 0 
from 0 
four 0 
of 0 
these 0 
VHL 1
families 0 
two 0 
were 0 
found 0 
to 0 
carry 0 
the 0 
deletion 0 
and 0 
the 0 
other 0 
four 0 
were 0 
deletion-free 0 
. 0 

In 0 
addition 0 
, 0 
germline 0 
mosaicism 0 
of 0 
the 0 
VHL 1
gene 0 
was 0 
identified 0 
in 0 
one 0 
family 0 
. 0 

In 0 
sum 0 
, 0 
FISH 0 
was 0 
found 0 
to 0 
be 0 
a 0 
simple 0 
and 0 
reliable 0 
method 0 
to 0 
detect 0 
VHL 1
germline 0 
deletions 0 
and 0 
practically 0 
useful 0 
in 0 
cases 0 
where 0 
other 0 
methods 0 
of 0 
screening 0 
have 0 
failed 0 
to 0 
detect 0 
a 0 
VHL 1
gene 1
abnormality 1
Aberrant 0 
subcellular 0 
localization 0 
of 0 
BRCA1 0 
in 0 
breast 1
cancer 1
. 0 

The 0 
BRCA1 0 
gene 0 
product 0 
was 0 
identified 0 
as 0 
a 0 
220-kilodalton 0 
nuclear 0 
phosphoprotein 0 
in 0 
normal 0 
cells 0 
, 0 
including 0 
breast 0 
ductal 0 
epithelial 0 
cells 0 
, 0 
and 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
tumor 1
cell 0 
lines 0 
derived 0 
from 0 
tissues 0 
other 0 
than 0 
breast 0
and 0 
ovary 0 
. 0 

In 0 
_NUM2 0 
of 0 
_NUM2 0 
breast 1
and 1
ovarian 1
cancer 1
lines 0 
and 0 
_NUM2 0 
of 0 
_NUM2 0 
samples 0 
of 0 
cells 0 
obtained 0 
from 0 
malignant 0 
effusions 0 
, 0 
however 0 
, 0 
BRCA1 0 
localized 0 
mainly 0 
in 0 
cytoplasm 0 
. 0 

Absence 0 
of 0 
BRCA1 0 
or 0 
aberrant 0 
subcellular 0 
location 0 
was 0 
also 0 
observed 0 
to 0 
a 0 
variable 0 
extent 0 
in 0 
histological 0 
sections 0 
of 0 
many 0 
breast 1
cancer 1
biopsies 0 
. 0 

These 0 
findings 0 
suggest 0 
that 0 
BRCA1 1
abnormalities 1
may 0 
be 0 
involved 0 
in 0 
the 0 
pathogenesis 0 
of 0 
many 0 
breast 1
cancers 1
, 0 
sporadic 0 
as 0 
well 0 
as 0 
familial 0 
. 0 
. 0 

HLA 0 
_AN 0 
and 0 
the 0 
genetics 0 
of 0 
ankylosing 1
spondylitis 1
. 0 

One 0 
hundred 0 
and 0 
twenty-eight 0 
of 0 
_NUM3 0 
patients 0 
with 0 
ankylosing 1
spondylitis 1
-LRB- 0 
AS 1
-RRB- 0 
were 0 
found 0 
to 0 
be 0 
HLA 0 
_AN 0 
positive 0 
. 0 

Five 0 
patients 0 
had 0 
evidence 0 
of 0 
a 0 
sero-negative 0 
peripheral 1
arthritis 1
resembling 0 
peripheral 1
psoriatic 1
arthritis 1
and 0 
_NUM1 0 
of 0 
these 0 
were 0 
_AN 0 
negative 0 
. 0 

One 0 
further 0 
_AN 0 
negative 0 
patients 0 
had 0 
a 0 
sister 0 
with 0 
ankylosing 1
spondylitis 1
and 0 
ulcerative 1
colitis 1
and 0 
a 0 
mother 0 
with 0 
ulcerative 1
colitis 1
. 0 

There 0 
was 0 
evidence 0 
of 0 
a 0 
somewhat 0 
later 0 
age 0 
of 0 
onset 0 
of 0 
symptoms 0 
in 0 
_AN 0 
negative 0 
patients 0 
. 0 

These 0 
findings 0 
are 0 
interpreted 0 
as 0 
suggesting 0 
some 0 
degree 0 
of 0 
clinical 0 
and 0 
genetic 0 
heterogeneity 0 
in 0 
ankylosing 1
spondylitis 1
with 0 
genes 0 
for 0 
psoriasis 1
and 0 
inflammatory 1
bowel 1
disease 1
being 0 
important 0 
in 0 
some 0 
individuals 0 
, 0 
particularly 0 
those 0 
who 0 
are 0 
_AN 0 
negative 0 
. 0 

Twenty-five 0 
first-degree 0 
relatives 0 
with 0 
ankylosing 1
spondylitis 1
were 0 
all 0 
_AN 0 
positive 0 
. 0 

The 0 
only 0 
instance 0 
of 0 
disassociation 0 
of 0 
_AN 0 
and 0 
spondylitis 1
in 0 
a 0 
family 0 
was 0 
where 0 
the 0 
proband 0 
had 0 
ulcerative 1
colitis 1
as 0 
well 0 
as 0 
spondylitis 1
. 0 

Of 0 
_NUM2 0 
_AN 0 
positive 0 
fathers 0 
_NUM1 0 
could 0 
be 0 
diagnosed 0 
as 0 
having 0 
definite 0 
ankylosing 1
spondylitis 1
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

These 0 
findings 0 
are 0 
thought 0 
to 0 
provide 0 
evidence 0 
against 0 
the 0 
concept 0 
that 0 
the 0 
gene 0 
for 0 
ankylosing 1
spondylitis 1
is 0 
not 0 
_AN 0 
but 0 
a 0 
closely 0 
linked 0 
gene 0 
and 0 
favour 0 
the 0 
occurrence 0 
of 0 
an 0 
environmental 0 
event 0 
affecting 0 
approximately 0 
one-fifth 0 
of 0 
_AN 0 
positive 0 
males 0 
to 0 
result 0 
in 0 
disease 0 
. 0 
. 0 

Late 0 
infantile 0 
metachromatic 1
leukodystrophy 1
in 0 
Israel 0 
. 0 

Metachromatic 1
Leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
is 0 
a 0 
neurodegenerative 1
disease 1
in 0 
which 0 
the 0 
lysosomal 0 
enzyme 0 
, 0 
Aryl 0 
sulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
is 0 
deficient 0 
. 0 

The 0 
disease 0 
is 0 
inherited 0 
as 0 
an 0 
autosomal 0 
recessive 0 
trait 0 
and 0 
its 0 
frequency 0 
is 0 
estimated 0 
to 0 
be 0 
1 0 
/ 0 
40 0 
, 0 
_NUM3 0 
live 0 
births 0 
. 0 

The 0 
gene 0 
of 0 
ARSA 0 
has 0 
been 0 
cloned 0 
and 0 
up 0 
to 0 
now 0 
eight 0 
mutations 0 
causing 0 
MLD 1
have 0 
been 0 
reported 0 
. 0 

Another 0 
mutation 0 
, 0 
PD 0 
, 0 
leads 0 
to 0 
the 0 
deficiency 0 
of 0 
the 0 
enzyme 0 
in 0 
vitro 0 
-LRB- 0 
pseudodeficiency 0 
-RRB- 0 
without 0 
any 0 
known 0 
clinical 0 
effect 0 
. 0 

The 0 
PD 0 
mutation 0 
is 0 
frequent 0 
in 0 
all 0 
populations 0 
. 0 

In 0 
Israel 0 
, 0 
late 0 
infantile 0 
MLD 1
was 0 
found 0 
to 0 
be 0 
very 0 
frequent 0 
in 0 
a 0 
small 0 
Jewish 0 
isolate 0 
, 0 
the 0 
Habbanite 0 
Jews 0 
-LRB- 0 
1 0 
/ 0 
75 0 
live 0 
births 0 
-RRB- 0 
. 0 

The 0 
molecular 0 
analysis 0 
demonstrated 0 
that 0 
in 0 
the 0 
Habbanite 0 
population 0 
, 0 
the 0 
mutation 0 
occurred 0 
on 0 
an 0 
allele 0 
with 0 
the 0 
PD 0 
mutation 0 
. 0 

The 0 
loss 0 
of 0 
ARSA 0 
activity 0 
is 0 
due 0 
to 0 
a 0 
point 0 
mutation 0 
C 0 
> 0 
T 0 
leading 0 
to 0 
a 0 
change 0 
of 0 
proline 0 
to 0 
leucine 0 
. 0 

MLD 1
is 0 
also 0 
frequent 0 
among 0 
Moslem 0 
Arabs 0 
in 0 
Jerusalem 0 
. 0 

The 0 
mutation 0 
is 0 
a 0 
transition 0 
G 0 
> 0 
A 0 
destroying 0 
the 0 
splice 0 
donor 0 
site 0 
of 0 
exon 0 
_NUM1 0 
. 0 

This 0 
mutation 0 
has 0 
been 0 
reported 0 
in 0 
patients 0 
with 0 
the 0 
late 0 
infantile 0 
MLD 1
from 0 
different 0 
ethnic 0 
groups 0 
. 0 

The 0 
Christian 0 
Arabs 0 
in 0 
Israel 0 
also 0 
have 0 
a 0 
high 0 
incidence 0 
of 0 
the 0 
disease 0 
-LRB- 0 
1 0 
/ 0 
10 0 
, 0 
_NUM3 0 
live 0 
births 0 
-RRB- 0 
; 0 
the 0 
mutation 0 
in 0 
this 0 
population 0 
is 0 
still 0 
unknown 0 
. 0 

Knowledge 0 
of 0 
the 0 
different 0 
mutations 0 
causing 0 
MLD 1
in 0 
these 0 
defined 0 
populations 0 
will 0 
allow 0 
a 0 
carrier 0 
screening 0 
program 0 
to 0 
be 0 
carried 0 
out 0 
and 0 
prevent 0 
the 0 
birth 0 
of 0 
additional 0 
affected 0 
children 0 
. 0 
. 0 

Genomic 0 
rearrangements 0 
of 0 
the 0 
APC 1
tumor 1
suppressor 0 
gene 0 
in 0 
familial 1
adenomatous 1
polyposis 1
. 0 

Germline 0 
mutations 0 
of 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 1
APC 1
-RRB- 1
tumor 1
suppressor 0 
gene 0 
result 0 
in 0 
the 0 
hereditary 1
colorectal 1
cancer 1
syndrome 1
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

Almost 0 
all 0 
APC 1
mutations 0 
that 0 
have 0 
been 0 
identified 0 
are 0 
single-nucleotide 0 
alterations 0 
, 0 
small 0 
insertions 0 
, 0 
or 0 
small 0 
deletions 0 
that 0 
would 0 
truncate 0 
the 0 
protein 0 
product 0 
of 0 
the 0 
gene 0 
. 0 

No 0 
well-characterized 0 
intragenic 0 
rearrangement 0 
of 0 
APC 0 
has 0 
been 0 
described 0 
, 0 
and 0 
the 0 
prevalence 0 
of 0 
this 0 
type 0 
of 0 
mutation 0 
in 0 
FAP 1
patients 0 
is 0 
not 0 
clear 0 
. 0 

We 0 
screened 0 
_NUM2 0 
potential 0 
FAP 1
families 0 
and 0 
identified 0 
_NUM2 0 
different 0 
germline 0 
APC 1
mutations 0 
in 0 
_NUM2 0 
families 0 
. 0 

Four 0 
of 0 
these 0 
mutations 0 
were 0 
genomic 0 
rearrangements 0 
resulting 0 
from 0 
homologous 0 
and 0 
nonhomologous 0 
recombinations 0 
mediated 0 
by 0 
Alu 0 
elements 0 
. 0 

Two 0 
of 0 
these 0 
four 0 
rearrangements 0 
were 0 
complex 0 
, 0 
involving 0 
deletion 0 
and 0 
insertion 0 
of 0 
nucleotides 0 
. 0 

Of 0 
these 0 
four 0 
rearrangements 0 
, 0 
one 0 
resulted 0 
in 0 
the 0 
deletion 0 
of 0 
exons 0 
_NUM2 0 
and 0 
_NUM2 0 
and 0 
two 0 
others 0 
resulted 0 
in 0 
either 0 
complete 0 
or 0 
partial 0 
deletion 0 
of 0 
exon 0 
_NUM2 0 
. 0 

The 0 
fourth 0 
rearrangement 0 
grossly 0 
altered 0 
the 0 
sequence 0 
within 0 
intron 0 
_NUM2 0 
. 0 

Although 0 
this 0 
rearrangement 0 
did 0 
not 0 
affect 0 
any 0 
coding 0 
sequence 0 
of 0 
APC 1
at 0 
the 0 
genomic 0 
DNA 0 
level 0 
, 0 
it 0 
caused 0 
inappropriate 0 
splicing 0 
of 0 
exon 0 
_NUM2 0 
. 0 

These 0 
rearrangements 0 
were 0 
initially 0 
revealed 0 
by 0 
analyzing 0 
cDNAs 0 
and 0 
could 0 
not 0 
have 0 
been 0 
identified 0 
by 0 
using 0 
mutation 0 
detection 0 
methods 0 
that 0 
screened 0 
each 0 
exon 0 
individually 0 
. 0 

The 0 
identification 0 
of 0 
a 0 
rearrangement 0 
that 0 
did 0 
not 0 
alter 0 
any 0 
coding 0 
exons 0 
yet 0 
affected 0 
the 0 
splicing 0 
further 0 
underscores 0 
the 0 
importance 0 
of 0 
using 0 
cDNA 0 
for 0 
mutation 0 
analysis 0 
. 0 

The 0 
identification 0 
of 0 
four 0 
genomic 0 
rearrangements 0 
among 0 
_NUM2 0 
mutations 0 
suggests 0 
that 0 
genomic 0 
rearrangements 0 
are 0 
frequent 0 
germline 0 
APC 0 
mutations 0 
. 0 
. 0 

Familial 1
male 1
breast 1
cancer 1
is 0 
not 0 
linked 0 
to 0 
the 0 
BRCA1 0 
locus 0 
on 0 
chromosome 0 
17q 0 
. 0 

Breast 1
cancer 1
in 0 
men 0 
is 0 
about 0 
a 0 
hundredfold 0 
less 0 
common 0 
than 0 
in 0 
women 0 
and 0 
this 0 
has 0 
hindered 0 
research 0 
into 0 
its 0 
genetic 0 
basis 0 
. 0 

We 0 
have 0 
examined 0 
_NUM2 0 
families 0 
with 0 
at 0 
least 0 
one 0 
case 0 
of 0 
male 1
breast 1
cancer 1
for 0 
linkage 0 
to 0 
the 0 
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
locus 0 
, 0 
BRCA1 0 
, 0 
on 0 
chromosome 0 
17q 0 
. 0 

We 0 
found 0 
strong 0 
evidence 0 
against 0 
linkage 0 
to 0 
BRCA1 0 
-LRB- 0 
lod 0 
score-16 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
the 0 
best 0 
estimate 0 
of 0 
the 0 
proportion 0 
of 0 
linked 0 
families 0 
was 0 
_NUM1 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
0-18 0 
% 0 
-RRB- 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
there 0 
is 0 
a 0 
gene 0 
-LRB- 0 
s 0 
-RRB- 0 
other 0 
than 0 
BRCA1 0 
which 0 
predisposes 0 
to 0 
early-onset 0 
breast 1
cancer 1
in 0 
women 0 
and 0 
which 0 
confers 0 
a 0 
higher 0 
risk 0 
of 0 
male 1
breast 1
cancer 1
. 0 

Identification 0 
of 0 
additional 0 
pedigrees 0 
that 0 
include 0 
cases 0 
of 0 
male 1
breast 1
cancer 1
may 0 
therefore 0 
facilitate 0 
the 0 
mapping 0 
and 0 
isolation 0 
of 0 
this 0 
gene 0 
. 0 

Evidence 0 
for 0 
inter-generational 0 
instability 0 
in 0 
the 0 
_DS 0 
repeat 0 
in 0 
the 0 
MJD1 0 
gene 0 
and 0 
for 0 
conserved 0 
haplotypes 0 
at 0 
flanking 0 
markers 0 
amongst 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
with 0 
Machado-Joseph 1
disease 1
. 0 

The 0 
size 0 
of 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
array 0 
in 0 
the 0 
_NUM1 0 
' 0 
end 0 
of 0 
the 0 
MJD1 0 
gene 0 
and 0 
the 0 
haplotype 0 
at 0 
a 0 
series 0 
of 0 
microsatellite 0 
markers 0 
surrounding 0 
the 0 
MJD1 0 
gene 0 
were 0 
examined 0 
in 0 
a 0 
large 0 
cohort 0 
of 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
affected 0 
with 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
. 0 

Our 0 
data 0 
provide 0 
five 0 
novel 0 
observations 0 
. 0 

First 0 
, 0 
MJD 1
is 0 
associated 0 
with 0 
expansion 0 
fo 0 
the 0 
array 0 
from 0 
the 0 
normal 0 
range 0 
of 0 
14-37 0 
repeats 0 
to 0 
68-84 0 
repeats 0 
in 0 
most 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
, 0 
but 0 
no 0 
subjects 0 
were 0 
observed 0 
with 0 
expansions 0 
intermediate 0 
in 0 
size 0 
between 0 
those 0 
of 0 
the 0 
normal 0 
and 0 
MJD 1
affected 0 
groups 0 
. 0 

Second 0 
, 0 
the 0 
expanded 0 
allele 0 
associated 0 
with 0 
MJD 1
displays 0 
inter-generational 0 
instability 0 
, 0 
particularly 0 
in 0 
male 0 
meioses 0 
, 0 
and 0 
this 0 
instability 0 
was 0 
associated 0 
with 0 
the 0 
clinical 0 
phenomenon 0 
of 0 
anticipation 0 
. 0 

Third 0 
, 0 
the 0 
size 0 
of 0 
the 0 
expanded 0 
allele 0 
is 0 
not 0 
only 0 
inversely 0 
correlated 0 
with 0 
the 0 
age-of-onset 0 
of 0 
MJD 1
-LRB- 0 
r 0 
= 0 
-0.738 0 
, 0 
p 0 
< 0 
_FN 0 
-RRB- 0 
, 0 
but 0 
is 0 
also 0 
correlated 0 
with 0 
the 0 
frequency 0 
of 0 
other 0 
clinical 0 
features 0 
-LSB- 0 
e.g. 0 
pseudoexophthalmos 0 
and 0 
pyramidal 0 
signs 0 
were 0 
more 0 
frequent 0 
in 0 
subjects 0 
with 0 
large 0 
repeats 0 
-LRB- 0 
p 0 
< 0 
_FN 0 
and 0 
p 0 
< 0 
_FN 0 
respectively 0 
-RRB- 0 
-RSB- 0 
. 0 

Fourth 0 
, 0 
the 0 
disease 0 
phenotype 0 
is 0 
significantly 0 
more 0 
severe 0 
and 0 
had 0 
an 0 
early 0 
age 0 
of 0 
onset 0 
-LRB- 0 
_NUM2 0 
years 0 
-RRB- 0 
in 0 
a 0 
subject 0 
homozygous 0 
for 0 
the 0 
expanded 0 
allele 0 
, 0 
which 0 
contrasts 0 
with 0 
Huntington 1
disease 1
and 0 
suggests 0 
that 0 
the 0 
expanded 0 
allele 0 
in 0 
the 0 
MJD1 0 
gene 0 
could 0 
exert 0 
its 0 
effect 0 
either 0 
by 0 
a 0 
dominant 0 
negative 0 
effect 0 
-LRB- 0 
putatively 0 
excluded 0 
in 0 
HD 1
-RRB- 0 
or 0 
by 0 
a 0 
gain 0 
of 0 
function 0 
effect 0 
as 0 
proposed 0 
for 0 
HD 1
. 0 

Finally 0 
, 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
affected 0 
with 0 
MJD 1
share 0 
haplotypes 0 
at 0 
several 0 
markers 0 
surrounding 0 
the 0 
MJD1 0 
gene 0 
, 0 
which 0 
are 0 
uncommon 0 
in 0 
the 0 
normal 0 
Japanese 0 
and 0 
Caucasian 0 
population 0 
, 0 
and 0 
which 0 
suggests 0 
the 0 
existence 0 
either 0 
of 0 
common 0 
founders 0 
in 0 
these 0 
populations 0 
or 0 
of 0 
chromosomes 0 
susceptible 0 
to 0 
pathologic 0 
expansion 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
the 0 
MJD1 0 
gene 0 
. 0 

Familial 0 
Prader-Willi 1
syndrome 1
with 0 
apparently 0 
normal 0 
chromosomes 0 
. 0 

We 0 
report 0 
on 0 
_NUM1 0 
sibs 0 
-LRB- 0 
2F 0 
, 0 
2M 0 
-RRB- 0 
with 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

Diagnosis 0 
was 0 
made 0 
clinically 0 
on 0 
the 0 
basis 0 
of 0 
history 0 
, 0 
behavior 0 
, 0 
and 0 
physical 0 
findings 0 
in 0 
_NUM1 0 
of 0 
the 0 
sibs 0 
. 0 

The 0 
other 0 
child 0 
had 0 
died 0 
at 0 
age 0 
_NUM2 0 
months 0 
with 0 
a 0 
history 0 
and 0 
clinical 0 
findings 0 
typical 0 
of 0 
first 0 
phase 0 
of 0 
PWS 1
. 0 

Results 0 
of 0 
chromosome 0 
studies 0 
on 0 
the 0 
parents 0 
and 0 
surviving 0 
sibs 0 
were 0 
normal 0 
. 0 

The 0 
implications 0 
of 0 
this 0 
unusual 0 
familial 0 
occurrence 0 
for 0 
our 0 
understanding 0 
of 0 
PWS 1
are 0 
discussed 0 
. 0 
. 0 

Age 0 
at 0 
diagnosis 0 
as 0 
an 0 
indicator 0 
of 0 
eligibility 0 
for 0 
BRCA1 0 
DNA 0 
testing 0 
in 0 
familial 1
breast 1
cancer 1
. 0 

We 0 
searched 0 
for 0 
criteria 0 
that 0 
could 0 
indicate 0 
breast 1
cancer 1
families 0 
with 0 
a 0 
high 0 
prior 0 
probability 0 
of 0 
being 0 
caused 0 
by 0 
the 0 
breast 1
/ 1
ovarian 1
cancer 1
susceptibility 0 
locus 0 
BRCA1 0 
on 0 
chromosome 0 
_NUM2 0 
. 0 

To 0 
this 0 
end 0 
, 0 
we 0 
performed 0 
a 0 
linkage 0 
study 0 
with 0 
_NUM2 0 
consecutively 0 
collected 0 
Dutch 0 
breast 1
cancer 1
families 0 
, 0 
including 0 
_NUM2 0 
with 0 
at 0 
least 0 
one 0 
case 0 
of 0 
ovarian 1
cancer 1
. 0 

We 0 
used 0 
an 0 
intake 0 
cut-off 0 
of 0 
at 0 
least 0 
three 0 
first-degree 0 
relatives 0 
with 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
at 0 
any 0 
age 0 
. 0 

Significant 0 
evidence 0 
for 0 
linkage 0 
was 0 
found 0 
only 0 
among 0 
the 0 
_NUM2 0 
breast 1
cancer 1
families 0 
with 0 
a 0 
mean 0 
age 0 
at 0 
diagnosis 0 
of 0 
less 0 
than 0 
_NUM2 0 
years 0 
. 0 

An 0 
unexpectedly 0 
low 0 
proportion 0 
of 0 
the 0 
breast-ovarian 1
cancer 1
families 0 
were 0 
estimated 0 
to 0 
be 0 
linked 0 
to 0 
BRCA1 0 
, 0 
which 0 
could 0 
be 0 
due 0 
to 0 
a 0 
founder 0 
effect 0 
in 0 
the 0 
Dutch 0 
population 0 
. 0 

Given 0 
the 0 
expected 0 
logistical 0 
problems 0 
in 0 
clinical 0 
management 0 
now 0 
that 0 
BRCA1 0 
has 0 
been 0 
identified 0 
, 0 
we 0 
propose 0 
an 0 
interim 0 
period 0 
in 0 
which 0 
only 0 
families 0 
with 0 
a 0 
strong 0 
positive 0 
family 0 
history 0 
for 0 
early 0 
onset 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
will 0 
be 0 
offered 0 
BRCA1 0 
mutation 0 
testing 0 
. 0 
. 0 

Some 0 
Mexican 0 
glucose-6-phosphate 0 
dehydrogenase 0 
variants 0 
revisited 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
appears 0 
to 0 
be 0 
fairly 0 
common 0 
in 0 
Mexico 0 
. 0 

We 0 
have 0 
now 0 
examined 0 
the 0 
DNA 0 
of 0 
three 0 
previously 0 
reported 0 
electrophoretically 0 
fast 0 
Mexican 0 
G6PD 0
variants 0 
, 0 
- 0 
G6PD 0
Distrito 0 
Federal 0 
, 0 
G6PD 0
Tepic 0 
, 0 
and 0 
G6PD 0
Castilla 0 
. 0 

All 0 
three 0 
of 0 
these 0 
variants 0 
, 0 
believed 0 
on 0 
the 0 
basis 0 
of 0 
biochemical 0 
characterization 0 
and 0 
population 0 
origin 0 
to 0 
be 0 
unique 0 
, 0 
have 0 
the 0 
G 0 
-- 0 
A 0 
transition 0 
at 0 
nucleotide 0 
_NUM3 0 
and 0 
the 0 
A 0 
-- 0 
G 0 
transition 0 
at 0 
nucleotide 0 
_NUM3 0 
, 0 
mutations 0 
that 0 
we 0 
now 0 
recognize 0 
to 0 
be 0 
characteristic 0 
of 0 
G6PD 0
A 0 
- 0 
. 0 

Two 0 
other 0 
Mexican 0 
males 0 
with 0 
G6PD 1
deficiency 1
were 0 
found 0 
to 0 
have 0 
the 0 
same 0 
mutation 0 
. 0 

All 0 
five 0 
have 0 
the 0 
-LRB- 0 
NlaIII 0 
/ 0 
FokI 0 
/ 0 
PvuII 0 
/ 0 
PstI 0 
-RRB- 0 
haplotype 0 
characteristic 0 
of 0 
G6PD 0 
A 0 
- 0 
in 0 
Africa 0 
. 0 

Since 0 
the 0 
PvuII 0 
+ 0 
genotype 0 
seems 0 
to 0 
be 0 
rare 0 
in 0 
Europe 0 
, 0 
we 0 
conclude 0 
that 0 
all 0 
of 0 
these 0 
G6PD 0 
A 0 
- 0 
genes 0 
had 0 
their 0 
ancient 0 
origin 0 
in 0 
Africa 0 
, 0 
although 0 
in 0 
many 0 
of 0 
the 0 
Mexican 0 
patients 0 
with 0 
G6PD 0 
A 0 
-202 0 
A 0 
/ 0 
376G 0 
the 0 
gene 0 
may 0 
have 0 
been 0 
imported 0 
more 0 
recently 0 
from 0 
Spain 0 
, 0 
where 0 
this 0 
variant 0 
, 0 
formerly 0 
known 0 
as 0 
G6PD 0 
Betica 0 
, 0 
is 0 
also 0 
prevalent 0 
. 0 
. 0 

Inactivation 0 
of 0 
germline 0 
mutant 0 
APC 1
alleles 0 
by 0 
attenuated 0
somatic 0 
mutations 0 
: 0 
a 0 
molecular 0 
genetic 0 
mechanism 0 
for 0 
attenuated 1
familial 1
adenomatous 1
polyposis 1
. 0 

Germline 0 
mutations 0 
of 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 1
APC 1
-RRB- 1
tumor 1
suppressor 0 
gene 0 
result 0 
in 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

Patients 0 
with 0 
FAP 1
typically 0 
develop 0 
hundreds 0 
to 0 
thousands 0 
of 0 
benign 1
colorectal 1
tumors 1
and 0 
early-onset 0 
colorectal 1
cancer 1
. 0 

A 0 
subset 0 
of 0 
germline 0 
APC 1
mutations 0 
results 0 
in 0 
an 0 
attenuated 1
FAP 1
-LRB- 0 
AFAP 1
-RRB- 0 
phenotype 0 
, 0 
in 0 
which 0 
patients 0 
develop 0 
fewer 0 
tumors 1
and 0 
develop 0 
them 0 
at 0 
an 0 
older 0 
age 0 
. 0 

Although 0 
a 0 
genotype-phenotype 0 
correlation 0 
between 0 
the 0 
locations 0 
of 0 
APC 1
germline 0 
mutations 0 
and 0 
the 0 
development 0 
of 0 
AFAP 1
has 0 
been 0 
well 0 
documented 0 
, 0 
the 0 
mechanism 0 
for 0 
AFAP 1
has 0 
not 0 
been 0 
well 0 
defined 0 
. 0 

We 0 
investigated 0 
the 0 
mechanism 0 
for 0 
AFAP 1
in 0 
patients 0 
carrying 0 
a 0 
mutant 0 
APC 1
allele 0 
-LRB- 0 
APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
-RRB- 0 
that 0 
has 0 
a 0 
mutation 0 
in 0 
the 0 
alternatively 0 
spliced 0 
region 0 
of 0 
exon 0 
_NUM1 0 
. 0 

APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
was 0 
found 0 
to 0 
down-regulate 0 
beta-catenin-regulated 0 
transcription 0 
, 0 
the 0 
major 0 
tumor 1
suppressor 0 
function 0 
of 0 
APC 1
, 0 
as 0 
did 0 
the 0 
wild-type 0 
APC 0 
. 0 

Mutation 0 
analysis 0 
showed 0 
that 0 
both 0 
APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
and 0 
the 0 
wild-type 0 
APC 0 
alleles 0 
were 0 
somatically 0 
mutated 0 
in 0 
most 0 
colorectal 1
tumors 1
from 0 
these 0 
patients 0 
. 0 

Functional 0 
analysis 0 
showed 0 
that 0 
4666insA 0 
, 0 
a 0 
common 0 
somatic 0 
mutation 0 
in 0 
APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
in 0 
these 0 
tumors 1
, 0 
did 0 
not 0 
inactivate 0 
the 0 
wild-type 0 
APC 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
carriers 0 
of 0 
APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
develop 0 
fewer 0 
colorectal 1
tumors 1
than 0 
do 0 
typical 0 
patients 0 
with 0 
FAP 1
because 0 
somatic 0 
inactivation 0 
of 0 
both 0 
APC 1
alleles 0 
is 0 
necessary 0 
for 0 
colorectal 0
tumorigenesis 0 
. 0 

However 0 
, 0 
these 0 
patients 0 
develop 0 
colorectal 1
tumors 1
more 0 
frequently 0 
than 0 
does 0 
the 0 
general 0 
population 0 
because 0 
APC 0 
-LRB- 0 
AS9 0 
-RRB- 0 
is 0 
inactivated 0 
by 0 
mutations 0 
that 0 
do 0 
not 0 
inactivate 0 
the 0 
wild-type 0 
APC 0 
. 0 
. 0 

Submicroscopic 0 
deletions 0 
at 0 
the 0 
WAGR 1
locus 0 
, 0 
revealed 0 
by 0 
nonradioactive 0 
in 0 
situ 0 
hybridization 0 
. 0 

Fluorescence 0 
in 0 
situ 0 
hybridization 0 
-LRB- 0 
FISH 0 
-RRB- 0 
with 0 
biotin-labeled 0 
probes 0 
mapping 0 
to 0 
11p13 0 
has 0 
been 0 
used 0 
for 0 
the 0 
molecular 0 
analysis 0 
of 0 
deletions 0 
of 0 
the 0 
WAGR 1
-LRB- 0 
Wilms 1
tumor 1
, 0 
aniridia 1
, 0 
genitourinary 1
abnormalities 1
, 0 
and 0 
mental 1
retardation 1
-RRB- 0 
locus 0 
. 0 

We 0 
have 0 
detected 0 
a 0 
submicroscopic 0 
11p13 0 
deletion 0 
in 0 
a 0 
child 0 
with 0 
inherited 0 
aniridia 1
who 0 
subsequently 0 
presented 0 
with 0 
Wilms 1
tumor 1
in 0 
a 0 
horseshoe 0 
kidney 0 
, 0 
only 0 
revealed 0 
at 0 
surgery 0 
. 0 

The 0 
mother 0 
, 0 
who 0 
has 0 
aniridia 1
, 0 
was 0 
also 0 
found 0 
to 0 
carry 0 
a 0 
deletion 0 
including 0 
both 0 
the 0 
aniridia 1
candidate 0 
gene 0 
-LRB- 0 
AN2 0 
-RRB- 0 
and 0 
the 0 
Wilms 1
tumor 1
predisposition 0 
gene 0 
-LRB- 0 
WT1 0 
-RRB- 0 
. 0 

This 0 
is 0 
therefore 0 
a 0 
rare 0 
case 0 
of 0 
an 0 
inherited 0 
WAGR 1
deletion 0 
. 0 

Wilms 1
tumor 1
has 0 
so 0 
far 0 
only 0 
been 0 
associated 0 
with 0 
sporadic 0 
de 0 
novo 0 
aniridia 1
cases 0 
. 0 

We 0 
have 0 
shown 0 
that 0 
a 0 
cosmid 0 
probe 0 
for 0 
a 0 
candidate 0 
aniridia 1
gene 0 
, 0 
homologous 0 
to 0 
the 0 
mouse 0 
Pax-6 0 
gene 0 
, 0 
is 0 
deleted 0 
in 0 
cell 0 
lines 0 
from 0 
aniridia 1
patients 0 
with 0 
previously 0 
characterized 0 
deletions 0 
at 0 
11p13 0 
, 0 
while 0 
another 0 
cosmid 0 
marker 0 
mapping 0 
between 0 
two 0 
aniridia 1
associated 0 
translocation 0 
breakpoints 0 
-LRB- 0 
and 0 
hence 0 
a 0 
second 0 
candidate 0 
marker 0 
-RRB- 0 
is 0 
present 0 
on 0 
both 0 
chromosomes 0 
. 0 

These 0 
results 0 
support 0 
the 0 
Pax-6 0 
homologue 0 
as 0 
a 0 
strong 0 
candidate 0 
for 0 
the 0 
AN2 0 
gene 0 
. 0 

FISH 0 
with 0 
cosmid 0 
probes 0 
has 0 
proved 0 
to 0 
be 0 
a 0 
fast 0 
and 0 
reliable 0 
technique 0 
for 0 
the 0 
molecular 0 
analysis 0 
of 0 
deletions 0 
. 0 

It 0 
can 0 
be 0 
used 0 
with 0 
limited 0 
amounts 0 
of 0 
material 0 
and 0 
has 0 
strong 0 
potential 0 
for 0 
clinical 0 
applications 0 
. 0 
. 0 

Haplotype 0 
studies 0 
in 0 
Wilson 1
disease 1
. 0 

In 0 
_NUM2 0 
families 0 
with 0 
Wilson 1
disease 1
, 0 
we 0 
have 0 
studied 0 
DNA 0 
haplotypes 0 
of 0 
dinucleotide 0 
repeat 0 
polymorphisms 0 
-LRB- 0 
_DS 0 
repeats 0 
-RRB- 0 
in 0 
the 0 
13q14 0 
. 0 

_NUM1 0 
region 0 
, 0 
to 0 
examine 0 
these 0 
markers 0 
for 0 
association 0 
with 0 
the 0 
Wilson 1
disease 1
gene 0 
-LRB- 0 
WND 1
-RRB- 0 
. 0 

In 0 
addition 0 
to 0 
a 0 
marker 0 
-LRB- 0 
D13S133 0 
-RRB- 0 
described 0 
elsewhere 0 
, 0 
we 0 
have 0 
developed 0 
three 0 
new 0 
highly 0 
polymorphic 0 
markers 0 
-LRB- 0 
D13S314 0 
, 0 
D13S315 0 
, 0 
and 0 
D13S316 0 
-RRB- 0 
close 0 
to 0 
the 0 
WND 1
locus 0 
. 0 

We 0 
have 0 
examined 0 
the 0 
distribution 0 
of 0 
marker 0 
alleles 0 
at 0 
the 0 
loci 0 
studied 0 
and 0 
have 0 
found 0 
that 0 
D13S314 0 
, 0 
D13S133 0 
, 0 
and 0 
D13S316 0 
each 0 
show 0 
nonrandom 0 
distribution 0 
on 0 
chromosomes 0 
carrying 0 
the 0 
WND 1
mutation 0 
. 0 

We 0 
have 0 
studied 0 
haplotypes 0 
of 0 
these 0 
three 0 
markers 0 
and 0 
have 0 
found 0 
that 0 
there 0 
are 0 
highly 0 
significant 0 
differences 0 
between 0 
WND 1
and 0 
normal 0 
haplotypes 0 
in 0 
northern 0 
European 0 
families 0 
. 0 

These 0 
findings 0 
have 0 
important 0 
implications 0 
for 0 
mutation 0 
detection 0 
and 0 
molecular 0 
diagnosis 0 
in 0 
families 0 
with 0 
Wilson 1
disease 1
. 0 

Growth 0 
hormone 0 
treatment 0 
increases 0 
CO 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
response 0 
, 0 
ventilation 0 
and 0 
central 0 
inspiratory 0 
drive 0 
in 0 
children 0 
with 0 
Prader-Willi 1
syndrome 1
. 0 

We 0 
studied 0 
whether 0 
the 0 
beneficial 0 
effects 0 
of 0 
growth 0 
hormone 0 
-LRB- 0 
GH 0 
-RRB- 0 
treatment 0 
on 0 
growth 0 
and 0 
body 0 
composition 0 
in 0 
PWS 1
are 0 
accompanied 0 
by 0 
an 0 
improvement 0 
in 0 
respiratory 0 
function 0 
. 0 

We 0 
measured 0 
resting 0 
ventilation 0 
, 0 
airway 0 
occlusion 0 
pressure 0 
-LRB- 0 
P 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
-RRB- 0 
and 0 
ventilatory 0 
response 0 
to 0 
CO 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
in 0 
nine 0 
children 0 
, 0 
aged 0 
7-14 0 
years 0 
, 0 
before 0 
and 0 
6-9 0 
months 0 
after 0 
the 0 
start 0 
of 0 
GH 0 
treatment 0 
. 0 

During 0 
GH 0 
treatment 0 
, 0 
resting 0 
ventilation 0 
increased 0 
by 0 
_NUM2 0 
% 0 
, 0 
P 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
by 0 
_NUM2 0 
% 0 
and 0 
the 0 
response 0 
to 0 
CO 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
by 0 
_NUM2 0 
% 0 
-LRB- 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
, 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

This 0 
observed 0 
increase 0 
in 0 
ventilatory 0 
output 0 
was 0 
not 0 
correlated 0 
to 0 
changes 0 
in 0 
body 0 
mass 0 
index 0 
. 0 

CONCLUSION 0 
Treatment 0 
of 0 
children 0 
with 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
seems 0 
to 0 
have 0 
a 0 
stimulatory 0 
effect 0 
on 0 
central 0 
respiratory 0 
structures 0 
. 0 

The 0 
observed 0 
increase 0 
in 0 
ventilation 0 
and 0 
inspiratory 0 
drive 0 
may 0 
contribute 0 
to 0 
the 0 
improved 0 
activity 0 
level 0 
reported 0 
by 0 
parents 0 
of 0 
PWS 1
children 0 
during 0 
growth 0 
hormone 0 
therapy 0 
Somatic 0 
von 1
Hippel-Lindau 1
mutation 0 
in 0 
clear 0 
cell 0 
papillary 1
cystadenoma 1
of 1
the 1
epididymis 1
. 0 

Papillary 1
cystadenoma 1
of 1
the 1
epididymis 1
is 0 
an 0 
uncommon 0 
benign 0 
lesion 0 
that 0 
may 0 
occur 0 
sporadically 0 
or 0 
as 0 
a 0 
manifestation 0 
of 0 
von 1
Hippel-Lindau 1
-LRB- 1
VHL 1
-RRB- 1
disease 1
. 0 

Neither 0 
immunohistochemical 0 
studies 0 
nor 0 
molecular 0 
genetic 0 
analyses 0 
of 0 
the 0 
VHL 1
gene 0 
have 0 
been 0 
reported 0 
previously 0 
for 0 
this 0 
lesion 0 
. 0 

The 0 
authors 0 
describe 0 
two 0 
cases 0 
of 0 
clear 0 
cell 0 
papillary 1
cystadenoma 1
of 1
the 1
epididymis 1
, 0 
both 0 
of 0 
which 0 
were 0 
initially 0 
confused 0 
with 0 
metastatic 1
renal 1
cell 1
carcinoma 1
. 0 

Both 0 
lesions 0 
showed 0 
positive 0 
immunohistochemical 0 
staining 0 
for 0 
low 0 
and 0 
intermediate 0 
molecular 0 
weight 0 
keratins 0 
-LRB- 0 
Cam 0 
_NUM1 0 
. 0 

_NUM1 0 
and 0 
AE1 0 
/ 0 
AE3 0 
-RRB- 0 
, 0 
EMA 0 
, 0 
vimentin 0 
, 0 
alpha 0 
1-antitrypsin 0 
, 0 
and 0 
alpha 0 
1-antichymotrypsin 0 
. 0 

Each 0 
was 0 
negative 0 
for 0 
CEA 0 
. 0 

Because 0 
clear 0 
cell 0 
papillary 1
cystadenoma 1
is 0 
similar 0 
to 0 
renal 1
cell 1
carcinoma 1
histologically 0 
, 0 
and 0 
because 0 
both 0 
occur 0 
as 0 
components 0 
of 0 
the 0 
von 1
Hippel-Lindau 1
disease 1
complex 0 
, 0 
the 0 
authors 0 
analyzed 0 
both 0 
cases 0 
for 0 
the 0 
presence 0 
of 0 
mutations 0 
in 0 
the 0 
VHL 1
gene 0 
. 0 

A 0 
somatic 0 
VHL 1
gene 0 
mutation 0 
was 0 
detected 0 
in 0 
one 0 
of 0 
the 0 
two 0 
tumors 1
by 0 
polymerase 0 
chain 0 
reaction 0 
followed 0 
by 0 
single-strand 0 
conformation 0 
polymorphism 0 
analysis 0 
. 0 

Direct 0 
sequencing 0 
revealed 0 
a 0 
cytosine 0 
to 0 
thymine 0 
transition 0 
at 0 
nucleotide 0 
_NUM3 0 
, 0 
resulting 0 
in 0 
the 0 
replacement 0 
of 0 
an 0 
arginine 0 
with 0 
a 0 
stop 0 
codon 0 
after 0 
the 0 
sixth 0 
amino 0 
acid 0 
of 0 
exon 0 
_NUM1 0 
. 0 

As 0 
the 0 
VHL 1
gene 0 
is 0 
believed 0 
to 0 
function 0 
as 0 
a 0 
tumor 1
suppressor 0 
gene 0 
, 0 
VHL 1
gene 0 
mutations 0 
may 0 
play 0 
a 0 
role 0 
in 0 
the 0 
initiation 0 
of 0 
tumorigenesis 0 
in 0 
sporadic 0 
cystadenomas 1
of 1
the 1
epididymis 1
. 0 

An 0 
evaluation 0 
of 0 
genetic 0 
heterogeneity 0 
in 0 
_NUM3 0 
breast-ovarian 1
cancer 1
families 0 
. 0 

Breast 1
Cancer 1
Linkage 0 
Consortium 0 
. 0 

The 0 
breast-ovary 1
cancer-family 1
syndrome 1
is 0 
a 0 
dominant 0 
predisposition 0 
to 0 
cancer 1
of 1
the 1
breast 1
and 1
ovaries 1
which 0 
has 0 
been 0 
mapped 0 
to 0 
chromosome 0 
region 0 
17q12-q21 0 
. 0 

The 0 
majority 0 
, 0 
but 0 
not 0 
all 0 
, 0 
of 0 
breast-ovary 1
cancer 1
families 0 
show 0 
linkage 0 
to 0 
this 0 
susceptibility 0 
locus 0 
, 0 
designated 0 
BRCA1 0 
. 0 

We 0 
report 0 
here 0 
the 0 
results 0 
of 0 
a 0 
linkage 0 
analysis 0 
of 0 
_NUM3 0 
families 0 
with 0 
both 0 
breast 1
and 1
ovarian 1
cancer 1
. 0 

These 0 
families 0 
contain 0 
either 0 
a 0 
total 0 
of 0 
three 0 
or 0 
more 0 
cases 0 
of 0 
early-onset 0 
-LRB- 0 
before 0 
age 0 
_NUM2 0 
years 0 
-RRB- 0 
breast 1
cancer 1
or 0 
ovarian 1
cancer 1
. 0 

All 0 
families 0 
contained 0 
at 0 
least 0 
one 0 
case 0 
of 0 
ovarian 1
cancer 1
. 0 

Overall 0 
, 0 
an 0 
estimated 0 
_NUM2 0 
% 0 
of 0 
the 0 
_NUM3 0 
families 0 
are 0 
linked 0 
to 0 
the 0 
BRCA1 0 
locus 0 
. 0 

None 0 
of 0 
the 0 
_NUM2 0 
families 0 
with 0 
cases 0 
of 0 
male 1
breast 1
cancer 1
appear 0 
to 0 
be 0 
linked 0 
, 0 
but 0 
it 0 
is 0 
estimated 0 
that 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
_NUM2 0 
% 0 
-100 0 
% 0 
-RRB- 0 
of 0 
families 0 
with 0 
no 0 
male 1
breast 1
cancer 1
and 0 
with 0 
two 0 
or 0 
more 0 
ovarian 1
cancers 1
are 0 
linked 0 
to 0 
BRCA1 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
the 0 
breast-ovarian 1
cancer-family 1
syndrome 1
is 0 
genetically 0 
heterogeneous 0 
. 0 

However 0 
, 0 
the 0 
large 0 
majority 0 
of 0 
families 0 
with 0 
early-onset 0 
breast 1
cancer 1
and 0 
with 0 
two 0 
or 0 
more 0 
cases 0 
of 0 
ovarian 1
cancer 1
are 0 
likely 0 
to 0 
be 0 
due 0 
to 0 
BRCA1 0 
mutations 0 
. 0 
. 0 

Genetic 0 
analysis 0 
in 0 
families 0 
with 0 
van 1
der 1
Woude 1
syndrome 1
. 0 

We 0 
have 0 
brought 0 
together 0 
information 0 
on 0 
_NUM3 0 
affected 0 
individuals 0 
in 0 
_NUM3 0 
families 0 
-LRB- 0 
including 0 
three 0 
new 0 
pedigrees 0 
-RRB- 0 
reported 0 
in 0 
the 0 
_NUM3 0 
year 0 
period 0 
since 0 
_NUM4 0 
when 0 
Demarquay 0 
first 0 
described 0 
a 0 
family 0 
with 0 
what 0 
was 0 
later 0 
called 0 
van 1
der 1
Woude 1
syndrome 1
-LRB- 0 
VWS 1
-RRB- 0 
. 0 

Both 0 
types 0 
of 0 
oral 1
cleft 1
, 0 
cleft 1
palate 1
-LRB- 0 
CP 1
-RRB- 0 
and 0 
cleft 1
lip 1
with 0 
or 0 
without 0 
CP 1
-LRB- 0 
CLP 1
-RRB- 0 
, 0 
segregate 0 
in 0 
these 0 
families 0 
together 0 
with 0 
lower 0 
lip 1
pits 1
or 0 
fistulae 1
in 0 
an 0 
autosomal 0 
dominant 0 
mode 0 
with 0 
high 0 
penetrance 0 
estimated 0 
to 0 
be 0 
K 0 
= 0 
. 0 

_NUM2 0 
and 0 
. 0 

_NUM2 0 
by 0 
different 0 
methods 0 
. 0 

Cleft 0 
types 0 
-LRB- 0 
CLP 1
and 0 
CP 1
-RRB- 0 
occur 0 
in 0 
VWS 1
in 0 
the 0 
same 0 
proportions 0 
as 0 
in 0 
the 0 
general 0 
non-VWS 0 
population 0 
, 0 
ie 0 
, 0 
about 0 
twice 0 
as 0 
many 0 
cleft-bearing 0 
individuals 0 
have 0 
CLP 1
as 0 
have 0 
CP 1
. 0 

On 0 
the 0 
other 0 
hand 0 
, 0 
we 0 
do 0 
not 0 
find 0 
the 0 
usually 0 
observed 0 
excess 0 
of 0 
females 0 
with 0 
CP 1
and 0 
excess 0 
of 0 
males 0 
with 0 
CLP 1
; 0 
in 0 
VWS 1
the 0 
sex 0 
ratios 0 
are 0 
more 0 
nearly 0 
equal 0 
. 0 

Lip 1
pits 1
also 0 
are 0 
equally 0 
distributed 0 
between 0 
the 0 
sexes 0 
. 0 

Affected 0 
males 0 
and 0 
females 0 
are 0 
equally 0 
likely 0 
to 0 
transmit 0 
VWS 1
. 0 

However 0 
, 0 
there 0 
is 0 
an 0 
excess 0 
of 0 
less 0 
severely 0 
affected 0 
individuals 0 
among 0 
transmitters 0 
and 0 
a 0 
deficiency 0 
of 0 
more 0 
severely 0 
affected 0 
, 0 
brought 0 
about 0 
by 0 
a 0 
proband 0 
bias 0 
and 0 
differential 0 
fecundity 0 
. 0 

The 0 
expression 0 
of 0 
VWS 1
is 0 
significantly 0 
modified 0 
by 0 
the 0 
genetic 0 
background 0 
More 0 
extreme 0 
phenotypes 0 
in 0 
parents 0 
tend 0 
to 0 
produce 0 
more 0 
extreme 0 
expression 0 
in 0 
their 0 
children 0 
. 0 

For 0 
a 0 
VWS 1
gene 0 
carrier 0 
the 0 
relative 0 
risk 0 
of 0 
transmitting 0 
a 0 
cleft 0 
is 0 
_NUM2 0 
. 0 

_NUM2 0 
% 0 
; 0 
that 0 
of 0 
transmitting 0 
lower 0 
lip 1
pits 1
is 0 
_NUM2 0 
. 0 

_NUM2 0 
% 0 
. 0 

Three 0 
pedigrees 0 
of 0 
lip 1
pits 1
in 0 
the 0 
literature 0 
show 0 
no 0 
clefts 0 
among 0 
a 0 
significant 0 
number 0 
of 0 
affected 0 
individuals 0 
. 0 

Control 0 
of 0 
gene 0 
expression 0 
in 0 
VWS 1
in 0 
the 0 
three 0 
target 0 
tissues 0 
appears 0 
to 0 
be 0 
independent 0 
and 0 
separately 0 
designated 0 
. 0 

Mutation 0 
rate 0 
of 0 
the 0 
VWS 1
gene 0 
is 0 
calculated 0 
to 0 
be 0 
_NUM1 0 
. 0 

_NUM1 0 
X 0 
_NUM2 0 
-LRB- 0 
-5 0 
-RRB- 0 
Molecular 0 
and 0 
phenotypic 0 
analysis 0 
of 0 
patients 0 
with 0 
deletions 0 
within 0 
the 0 
deletion-rich 0 
region 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
. 0 

Eighty 0 
unrelated 0 
individuals 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
or 0 
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
BMD 1
-RRB- 0 
were 0 
found 0 
to 0 
have 0 
deletions 0 
in 0 
the 0 
major 0 
deletion-rich 0 
region 0 
of 0 
the 0 
DMD 1
locus 0 
. 0 

This 0 
region 0 
includes 0 
the 0 
last 0 
five 0 
exons 0 
detected 0 
by 0 
cDNA5b-7 0 
, 0 
all 0 
exons 0 
detected 0 
by 0 
cDNA8 0 
, 0 
and 0 
the 0 
first 0 
two 0 
exons 0 
detected 0 
by 0 
cDNA9 0 
. 0 

These 0 
_NUM2 0 
individuals 0 
account 0 
for 0 
approximately 0 
_NUM2 0 
% 0 
of 0 
_NUM3 0 
deletions 0 
of 0 
the 0 
gene 0 
, 0 
detected 0 
among 0 
_NUM3 0 
patients 0 
analyzed 0 
with 0 
the 0 
entire 0 
dystrophin 0 
cDNA 0 
. 0 

Endpoints 0 
for 0 
many 0 
of 0 
these 0 
deletions 0 
were 0 
further 0 
characterized 0 
using 0 
two 0 
genomic 0 
probes 0 
, 0 
_AN 0 
-LRB- 0 
DXS269 0 
; 0 
Wapenaar 0 
et 0 
al. 0 
-RRB- 0 
and 0 
GMGX11 0 
-LRB- 0 
DXS239 0 
; 0 
present 0 
paper 0 
-RRB- 0 
. 0 

Clinical 0 
findings 0 
are 0 
presented 0 
for 0 
all 0 
_NUM2 0 
patients 0 
allowing 0 
a 0 
correlation 0 
of 0 
phenotypic 0 
severity 0 
with 0 
the 0 
genotype 0 
. 0 

Thirty-eight 0 
independent 0 
patients 0 
were 0 
old 0 
enough 0 
to 0 
be 0 
classified 0 
as 0 
DMD 1
, 0 
BMD 1
, 0 
or 0 
intermediate 0 
phenotype 0 
and 0 
had 0 
deletions 0 
of 0 
exons 0 
with 0 
sequenced 0 
intron 0 
/ 0 
exon 0 
boundaries 0 
. 0 

Of 0 
these 0 
, 0 
eight 0 
BMD 1
patients 0 
and 0 
one 0 
intermediate 0 
patient 0 
had 0 
gene 0 
deletions 0 
predicted 0 
to 0 
leave 0 
the 0 
reading 0 
frame 0 
intact 0 
, 0 
while 0 
_NUM2 0 
DMD 1
patients 0 
, 0 
_NUM1 0 
intermediate 0 
patients 0 
, 0 
and 0 
_NUM1 0 
BMD 1
patient 0 
had 0 
gene 0 
deletions 0 
predicted 0 
to 0 
disrupt 0 
the 0 
reading 0 
frame 0 
. 0 

Thus 0 
, 0 
with 0 
two 0 
exceptions 0 
, 0 
frameshift 0 
deletions 0 
of 0 
the 0 
gene 0 
resulted 0 
in 0 
more 0 
severe 0 
phenotype 0 
than 0 
did 0 
in-frame 0 
deletions 0 
. 0 

This 0 
is 0 
in 0 
agreement 0 
with 0 
recent 0 
findings 0 
by 0 
Baumbach 0 
et 0 
al. 0 
and 0 
Koenig 0 
et 0 
al. 0 
but 0 
is 0 
in 0 
contrast 0 
to 0 
findings 0 
, 0 
by 0 
Malhotra 0 
et 0 
al. 0 
at 0 
the 0 
_NUM1 0 
' 0 
end 0 
of 0 
the 0 
gene 0 
. 0 

Proteolipoprotein 0 
gene 0 
analysis 0 
in 0 
_NUM2 0 
patients 0 
with 0 
sporadic 0 
Pelizaeus-Merzbacher 1
Disease 1
: 0 
duplications 0 
, 0 
the 0 
major 0 
cause 0 
of 0 
the 0 
disease 0 
, 0 
originate 0 
more 0 
frequently 0 
in 0 
male 0 
germ 0 
cells 0 
, 0 
but 0 
point 0 
mutations 0 
do 0 
not 0 
. 0 

The 0 
Clinical 0 
European 0 
Network 0 
on 0 
Brain 1
Dysmyelinating 1
Disease 1
. 0 

Pelizaeus-Merzbacher 1
Disease 1
-LRB- 0 
PMD 1
-RRB- 0 
is 0 
an 0 
X-linked 1
developmental 1
defect 1
of 1
myelination 1
affecting 0 
the 0 
central 0 
nervous 0 
system 0 
and 0 
segregating 0 
with 0 
the 0 
proteolipoprotein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
locus 0 
. 0 

Investigating 0 
_NUM2 0 
strictly 0 
selected 0 
sporadic 0 
cases 0 
of 0 
PMD 1
, 0 
we 0 
found 0 
PLP 0 
mutations 0 
in 0 
_NUM2 0 
% 0 
; 0 
complete 0 
PLP-gene 0 
duplications 0 
were 0 
the 0 
most 0 
frequent 0 
abnormality 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
whereas 0 
point 0 
mutations 0 
in 0 
coding 0 
or 0 
splice-site 0 
regions 0 
of 0 
the 0 
gene 0 
were 0 
involved 0 
less 0 
frequently 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

We 0 
analyzed 0 
the 0 
maternal 0 
status 0 
of 0 
_NUM2 0 
cases 0 
to 0 
determine 0 
the 0 
origin 0 
of 0 
both 0 
types 0 
of 0 
PLP 0 
mutation 0 
, 0 
since 0 
this 0 
is 0 
relevant 0 
to 0 
genetic 0 
counseling 0 
. 0 

In 0 
the 0 
_NUM2 0 
point 0 
mutations 0 
, 0 
_NUM2 0 
% 0 
of 0 
mothers 0 
were 0 
heterozygous 0 
for 0 
the 0 
mutation 0 
, 0 
a 0 
value 0 
identical 0 
to 0 
the 0 
two-thirds 0 
of 0 
carrier 0 
mothers 0 
that 0 
would 0 
be 0 
expected 0 
if 0 
there 0 
were 0 
an 0 
equal 0 
mutation 0 
rate 0 
in 0 
male 0 
and 0 
female 0 
germ 0 
cells 0 
. 0 

In 0 
sharp 0 
contrast 0 
, 0 
among 0 
the 0 
_NUM2 0 
duplicated 0 
cases 0 
, 0 
_NUM2 0 
% 0 
of 0 
mothers 0 
were 0 
carriers 0 
, 0 
a 0 
value 0 
significantly 0 
-LRB- 0 
chi2 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
P 0 
< 0 
. 0 

_NUM2 0 
-RRB- 0 
in 0 
favor 0 
of 0 
a 0 
male 0 
bias 0 
, 0 
with 0 
an 0 
estimation 0 
of 0 
the 0 
male 0 
/ 0 
female 0 
mutation 0 
frequency 0 
-LRB- 0 
k 0 
-RRB- 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

Moreover 0 
, 0 
we 0 
observed 0 
the 0 
occurrence 0 
of 0 
de 0 
novo 0 
mutations 0 
between 0 
parental 0 
and 0 
grandparental 0 
generations 0 
in 0 
_NUM2 0 
three-generation 0 
families 0 
, 0 
which 0 
allowed 0 
a 0 
direct 0 
estimation 0 
of 0 
the 0 
k 0 
value 0 
-LRB- 0 
k 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

Again 0 
, 0 
a 0 
significant 0 
male 0 
mutation 0 
imbalance 0 
was 0 
observed 0 
only 0 
for 0 
the 0 
duplications 0 
. 0 

Haplotype 0 
analysis 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
in 0 
Turkish 0 
phenylketonuria 1
families 0 
. 0 

We 0 
have 0 
estimated 0 
the 0 
haplotype 0 
distribution 0 
of 0 
mutant 0 
and 0 
normal 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
alleles 0 
for 0 
_NUM2 0 
Turkish 0 
phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
families 0 
_NUM2 0 
normal 0 
and 0 
_NUM2 0 
mutated 0 
PAH 0 
alleles 0 
could 0 
be 0 
identified 0 
. 0 

Of 0 
the 0 
latter 0 
, 0 
the 0 
most 0 
prevalent 0 
were 0 
associated 0 
with 0 
haplotype 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
, 0 
while 0 
the 0 
normal 0 
alleles 0 
were 0 
preferentially 0 
associated 0 
with 0 
haplotype 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

Of 0 
the 0 
_NUM2 0 
different 0 
haplotypes 0 
observed 0 
, 0 
_NUM1 0 
have 0 
not 0 
been 0 
described 0 
previously 0 
. 0 

The 0 
haplotype 0 
distribution 0 
differed 0 
significantly 0 
from 0 
that 0 
of 0 
the 0 
Northern 0 
European 0 
population 0 
. 0 

Two 0 
of 0 
the 0 
eight 0 
polymorphic 0 
sites 0 
were 0 
in 0 
association 0 
with 0 
PKU 1
. 0 

No 0 
deletions 0 
of 0 
exon 0 
sequences 0 
were 0 
found 0 
in 0 
the 0 
families 0 
analysed 0 
. 0 

Cloning 0 
of 0 
human 0 
very-long-chain 0 
acyl-coenzyme 0 
A 0 
dehydrogenase 0 
and 0 
molecular 0 
characterization 0 
of 0 
its 0 
deficiency 0 
in 0 
two 0 
patients 0 
. 0 

Two 0 
overlapping 0 
cDNA 0 
clones 0 
-LRB- 0 
_NUM1 0 
, 0 
_NUM3 0 
bp 0 
and 0 
_NUM3 0 
bp 0 
, 0 
respectively 0 
-RRB- 0 
encoding 0 
the 0 
precursor 0 
of 0 
human 0 
mitochondrial 0 
very-long-chain 0 
acyl-coenzyme 0 
A 0 
dehydrogenase 0 
-LRB- 0 
VLCAD 0 
-RRB- 0 
were 0 
cloned 0 
and 0 
sequenced 0 
. 0 

The 0 
cDNA 0 
inserts 0 
of 0 
these 0 
clones 0 
together 0 
encompass 0 
a 0 
region 0 
of 0 
_NUM1 0 
, 0 
_NUM3 0 
bases 0 
, 0 
encoding 0 
the 0 
entire 0 
protein 0 
of 0 
_NUM3 0 
amino 0 
acids 0 
, 0 
including 0 
a 0 
40-amino 0 
acid 0 
leader 0 
peptide 0 
and 0 
a 0 
615-amino 0 
acid 0 
mature 0 
polypeptide 0 
. 0 

PCR-amplified 0 
VLCAD 0 
cDNAs 0 
were 0 
sequenced 0 
in 0 
cultured 0 
fibroblasts 0 
from 0 
two 0 
VLCAD-deficient 1
patients 0 
. 0 

In 0 
both 0 
patients 0 
, 0 
a 0 
105-bp 0 
deletion 0 
encompassing 0 
bases 0 
1078-1182 0 
in 0 
VLCAD 0
cDNA 0 
was 0 
identified 0 
. 0 

The 0 
deletion 0 
seems 0 
to 0 
occur 0 
due 0 
to 0 
exon 0 
skipping 0 
during 0 
processing 0 
of 0 
VLCAD 0
pre-mRNA 0 
. 0 

This 0 
is 0 
the 0 
first 0 
demonstration 0 
of 0 
a 0 
mutation 0 
causing 0 
VLCAD 1
deficiency 1
. 0 

Quantitative 0 
cDNA 0 
expression 0 
of 0 
normal 0 
human 0 
VLCAD 0 
was 0 
performed 0 
in 0 
the 0 
patients 0 
fibroblasts 0 
, 0 
using 0 
vaccinia 0 
viral 0 
system 0 
, 0 
which 0 
demonstrated 0 
that 0 
the 0 
deficiency 1
of 1
the 1
normal 1
VLCAD 1
protein 1
causes 0 
impaired 0 
long-chain 0 
fatty 0 
acid 0 
beta-oxidation 0 
activity 0 
in 0 
the 0 
patients 0 
fibroblasts 0 
. 0 

In 0 
patient 0 
fibroblasts 0 
, 0 
raising 0 
VLCAD 0
activity 0 
to 0 
approximately 0 
_NUM2 0 
% 0 
of 0 
normal 0 
control 0 
fibroblast 0 
activity 0 
raised 0 
palmitic 0 
acid 0 
beta-oxidation 0 
flux 0 
to 0 
the 0 
level 0 
found 0 
in 0 
control 0 
fibroblasts 0 
, 0 
which 0 
may 0 
offer 0 
important 0 
information 0 
for 0 
the 0 
rational 0 
design 0 
of 0 
future 0 
somatic 0 
gene 0 
therapy 0 
for 0 
VLCAD 1
deficiency 1
. 0 
. 0 

Mutations 0 
in 0 
the 0 
RB1 0 
gene 0 
and 0 
their 0 
effects 0 
on 0 
transcription 0 
. 0 

Inactivation 0 
of 0 
both 0 
alleles 0 
of 0 
the 0 
RB1 0 
gene 0 
during 0 
normal 0 
retinal 0 
development 0 
initiates 0 
the 0 
formation 0 
of 0 
a 0 
retinoblastoma 1
-LRB- 1
RB 1
-RRB- 1
tumor 1
. 0 

To 0 
identify 0 
the 0 
mutations 0 
which 0 
inactivate 0 
RB1 0 
, 0 
_NUM2 0 
RB 1
tumors 1
isolated 0 
from 0 
_NUM2 0 
patients 0 
were 0 
analyzed 0 
with 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
or 0 
an 0 
RNase 0 
protection 0 
assay 0 
or 0 
both 0 
. 0 

Mutations 0 
were 0 
identified 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
RB 1
tumors 1
; 0 
in 0 
_NUM1 0 
tumors 1
, 0 
the 0 
precise 0 
errors 0 
in 0 
nucleotide 0 
sequence 0 
were 0 
characterized 0 
. 0 

Each 0 
of 0 
four 0 
germ 0 
line 0 
mutations 0 
involved 0 
a 0 
small 0 
deletion 0 
or 0 
duplication 0 
, 0 
while 0 
three 0 
somatic 0 
mutations 0 
were 0 
point 0 
mutations 0 
leading 0 
to 0 
splice 0 
alterations 0 
and 0 
loss 0 
of 0 
an 0 
exon 0 
from 0 
the 0 
mature 0 
RB1 0 
mRNA 0 
. 0 

We 0 
were 0 
unable 0 
to 0 
detect 0 
expression 0 
of 0 
the 0 
mutant 0 
allele 0 
in 0 
lymphoblasts 0 
of 0 
three 0 
bilaterally 0 
affected 0 
patients 0 
, 0 
although 0 
the 0 
mutation 0 
was 0 
present 0 
in 0 
the 0 
genomic 0 
DNA 0 
and 0 
transcripts 0 
containing 0 
the 0 
mutations 0 
were 0 
obvious 0 
in 0 
the 0 
RB 1
tumors 1
in 0 
the 0 
absence 0 
of 0 
a 0 
normal 0 
RB1 0 
allele 0 
. 0 

The 0 
variations 0 
in 0 
the 0 
level 0 
of 0 
expression 0 
of 0 
mutant 0 
transcripts 0 
suggest 0 
deregulation 0 
of 0 
RB1 0 
transcription 0 
in 0 
the 0 
absence 0 
of 0 
a 0 
functional 0 
RB1 0 
gene 0 
product 0 
. 0 
. 0 

Resolution 0 
of 0 
the 0 
two 0 
loci 0 
for 0 
autosomal 0 
dominant 0 
aniridia 1
, 0 
AN1 0 
and 0 
AN2 0 
, 0 
to 0 
a 0 
single 0 
locus 0 
on 0 
chromosome 0 
11p13 0 
. 0 

Two 0 
distinct 0 
loci 0 
have 0 
been 0 
proposed 0 
for 0 
aniridia 1
; 0 
AN1 0 
for 0 
autosomal 0 
dominant 0 
aniridia 1
on 0 
chromosome 0 
2p 0 
and 0 
AN2 0 
for 0 
the 0 
aniridia 1
in 0 
the 0 
WAGR 1
contiguous 1
gene 1
syndrome 1
on 0 
chromosome 0 
11p13 0 
. 0 

In 0 
this 0 
report 0 
, 0 
the 0 
kindred 0 
segregating 0 
for 0 
autosomal 0 
dominant 0 
aniridia 1
, 0 
which 0 
suggested 0 
linkage 0 
to 0 
acid 0 
phosphatase-1 0 
-LRB- 0 
ACP1 0 
-RRB- 0 
and 0 
led 0 
to 0 
the 0 
assignment 0 
of 0 
the 0 
AN1 0 
locus 0 
on 0 
chromosome 0 
2p 0 
, 0 
has 0 
been 0 
updated 0 
and 0 
expanded 0 
. 0 

Linkage 0 
analysis 0 
between 0 
the 0 
aniridia 1
phenotype 0 
and 0 
ACP1 0 
does 0 
not 0 
support 0 
the 0 
original 0 
linkage 0 
results 0 
, 0 
excluding 0 
linkage 0 
up 0 
to 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
with 0 
Z 0 
= 0 
-2 0 
. 0 

Tests 0 
for 0 
linkage 0 
to 0 
other 0 
chromosome 0 
2p 0 
markers 0 
. 0 

APOB 0 
, 0 
D2S71 0 
, 0 
D2S5 0 
, 0 
and 0 
D2S1 0 
, 0 
also 0 
excluded 0 
linkage 0 
to 0 
aniridia 1
. 0 

Markers 0 
that 0 
have 0 
been 0 
isolated 0 
from 0 
the 0 
chromosome 0 
11p13 0 
region 0 
were 0 
then 0 
analyzed 0 
in 0 
this 0 
aniridia 1
family 0 
. 0 

Two 0 
RFLPs 0 
at 0 
the 0 
D11S323 0 
locus 0 
give 0 
significant 0 
evidence 0 
for 0 
linkage 0 
. 0 

The 0 
PvuII 0 
polymorphism 0 
detected 0 
by 0 
probe 0 
p5S1 0 
. 0 

_NUM1 0 
detects 0 
no 0 
recombinants 0 
, 0 
with 0 
a 0 
maximum 0 
lod 0 
score 0 
of 0 
Z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

The 0 
HaeIII 0 
polymorphism 0 
detected 0 
by 0 
the 0 
probe 0 
p5BE1 0 
. 0 

_NUM1 0 
gives 0 
a 0 
maximum 0 
lod 0 
score 0 
of 0 
Z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

Locus 0 
D11S325 0 
gives 0 
a 0 
lod 0 
score 0 
of 0 
Z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
a 0 
locus 0 
for 0 
aniridia 1
-LRB- 0 
AN1 0 
-RRB- 0 
on 0 
chromosome 0 
2p 0 
has 0 
been 0 
misassigned 0 
and 0 
that 0 
this 0 
autosomal 0 
dominant 0 
aniridia 1
family 0 
is 0 
segregating 0 
for 0 
an 0 
aniridia 1
mutation 0 
linked 0 
to 0 
markers 0 
in 0 
the 0 
11p13 0 
region 0 
. 0 

_DS 0 
to 0 
_DS 0 
transition 0 
at 0 
a 0 
splice 0 
donor 0 
site 0 
causes 0 
skipping 0 
of 0 
the 0 
preceding 0 
exon 0 
in 0 
phenylketonuria 1
. 0 

Classical 1
Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
human 1
genetic 1
disorder 1
caused 0 
by 0 
a 0 
deficiency 1
of 1
hepatic 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

We 0 
isolated 0 
several 0 
mutant 0 
PAH 0 
cDNA 0 
clones 0 
from 0 
a 0 
PKU 1
carrier 0 
individual 0 
and 0 
showed 0 
that 0 
they 0 
contained 0 
an 0 
internal 0 
_NUM3 0 
base 0 
pair 0 
deletion 0 
, 0 
corresponding 0 
precisely 0 
to 0 
exon 0 
_NUM2 0 
of 0 
the 0 
human 0 
chromosomal 0 
PAH 0 
gene 0 
. 0 

The 0 
deletion 0 
causes 0 
the 0 
synthesis 0 
of 0 
a 0 
truncated 0 
protein 0 
lacking 0 
the 0 
C-terminal 0 
_NUM2 0 
amino 0 
acids 0 
. 0 

Gene 0 
transfer 0 
and 0 
expression 0 
studies 0 
using 0 
the 0 
mutant 0 
PAH 0 
cDNA 0 
indicated 0 
that 0 
the 0 
deletion 0 
abolishes 0 
PAH 0 
activity 0 
in 0 
the 0 
cell 0 
as 0 
a 0 
result 0 
of 0 
protein 0 
instability 0 
. 0 

To 0 
determine 0 
the 0 
molecular 0 
basis 0 
of 0 
the 0 
deletion 0 
, 0 
the 0 
mutant 0 
chromosomal 0 
PAH 0 
gene 0 
was 0 
isolated 0 
from 0 
this 0 
individual 0 
and 0 
shown 0 
to 0 
contain 0 
a 0 
_DS 0 
-- 0 
greater 0 
than 0 
_DS 0 
substitution 0 
at 0 
the 0 
_NUM1 0 
splice 0 
donor 0 
site 0 
of 0 
intron 0 
_NUM2 0 
. 0 

Thus 0 
, 0 
the 0 
consequence 0 
of 0 
the 0 
splice 0 
donor 0 
site 0 
mutation 0 
in 0 
the 0 
human 0 
liver 0 
is 0 
the 0 
skipping 0 
of 0 
the 0 
preceding 0 
exon 0 
during 0 
RNA 0 
splicing 0 
. 0 
. 0 

Clinical 0 
and 0 
molecular 0 
genetic 0 
analysis 0 
of 0 
_NUM2 0 
Wolfram 1
syndrome 1
kindreds 0 
demonstrating 0 
a 0 
wide 0 
spectrum 0 
of 0 
mutations 0 
in 0 
WFS1 0 
. 0 

Wolfram 1
syndrome 1
is 0 
an 0 
autosomal 1
recessive 1
neurodegenerative 1
disorder 1
characterized 0 
by 0 
juvenile-onset 1
diabetes 1
mellitus 1
and 0 
progressive 0 
optic 1
atrophy 1
. 0 

mtDNA 0 
deletions 0 
have 0 
been 0 
described 0 
, 0 
and 0 
a 0 
gene 0 
-LRB- 0 
WFS1 0 
-RRB- 0 
recently 0 
has 0 
been 0 
identified 0 
, 0 
on 0 
chromosome 0 
4p16 0 
, 0 
encoding 0 
a 0 
predicted 0 
_NUM3 0 
amino 0 
acid 0 
transmembrane 0 
protein 0 
. 0 

Direct 0 
DNA 0 
sequencing 0 
was 0 
done 0 
to 0 
screen 0 
the 0 
entire 0 
coding 0 
region 0 
of 0 
the 0 
WFS1 0 
gene 0 
in 0 
_NUM2 0 
patients 0 
from 0 
_NUM2 0 
British 0 
kindreds 0 
with 0 
Wolfram 1
syndrome 1
. 0 

DNA 0 
was 0 
also 0 
screened 0 
for 0 
structural 0 
rearrangements 0 
-LRB- 0 
deletions 0 
and 0 
duplications 0 
-RRB- 0 
and 0 
point 0 
mutations 0 
in 0 
mtDNA 0 
. 0 

No 0 
pathogenic 0 
mtDNA 0 
mutations 0 
were 0 
found 0 
in 0 
our 0 
cohort 0 
. 0 

We 0 
identified 0 
_NUM2 0 
mutations 0 
in 0 
the 0 
WFS1 0 
gene 0 
_NUM1 0 
nonsense 0 
mutations 0 
, 0 
_NUM1 0 
missense 0 
mutations 0 
, 0 
_NUM1 0 
in-frame 0 
deletions 0 
, 0 
_NUM1 0 
in-frame 0 
insertion 0 
, 0 
and 0 
_NUM1 0 
frameshift 0 
mutations 0 
. 0 

Of 0 
these 0 
, 0 
_NUM2 0 
were 0 
novel 0 
mutations 0 
, 0 
and 0 
most 0 
occurred 0 
in 0 
exon 0 
_NUM1 0 
. 0 

The 0 
majority 0 
of 0 
patients 0 
were 0 
compound 0 
heterozygotes 0 
for 0 
two 0 
mutations 0 
, 0 
and 0 
there 0 
was 0 
no 0 
common 0 
founder 0 
mutation 0 
. 0 

The 0 
data 0 
were 0 
also 0 
analyzed 0 
for 0 
genotype-phenotype 0 
relationships 0 
. 0 

Although 0 
some 0 
interesting 0 
cases 0 
were 0 
noted 0 
, 0 
consideration 0 
of 0 
the 0 
small 0 
sample 0 
size 0 
and 0 
frequency 0 
of 0 
each 0 
mutation 0 
indicated 0 
no 0 
clear-cut 0 
correlations 0 
between 0 
any 0 
of 0 
the 0 
observed 0 
mutations 0 
and 0 
disease 0 
severity 0 
. 0 

There 0 
were 0 
no 0 
obvious 0 
mutation 0 
hot 0 
spots 0 
or 0 
clusters 0 
. 0 

Hence 0 
, 0 
molecular 0 
screening 0 
for 0 
Wolfram 1
syndrome 1
in 0 
affected 0 
families 0 
and 0 
for 0 
Wolfram 1
syndrome 1
carrier 0 
status 0 
in 0 
subjects 0 
with 0 
psychiatric 1
disorders 1
or 0 
diabetes 1
mellitus 1
will 0 
require 0 
complete 0 
analysis 0 
of 0 
exon 0 
_NUM1 0 
and 0 
upstream 0 
exons 0 
. 0 
. 0 

Maternal 1
uniparental 1
disomy 1
for 1
chromosome 1
_NUM2 1
in 0 
a 0 
boy 0 
with 0 
a 0 
normal 0 
karyotype 0 
. 0 

We 0 
report 0 
on 0 
a 0 
boy 0 
with 0 
a 0 
maternal 1
uniparental 1
disomy 1
for 1
chromosome 1
_NUM2 1
-LRB- 0 
UPD 1
-LRB- 0 
_NUM2 0 
-RRB- 0 
-RRB- 0 
. 0 

At 0 
_NUM1 0 
years 0 
of 0 
age 0 
he 0 
was 0 
referred 0 
to 0 
us 0 
by 0 
the 0 
paediatrician 0 
because 0 
of 0 
symptoms 0 
of 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

He 0 
showed 0 
short 1
stature 1
, 0 
obesity 1
, 0 
mild 0 
developmental 1
delay 1
, 0 
cryptorchidism 1
, 0 
and 0 
some 0 
mild 0 
dysmorphic 1
features 1
. 0 

The 0 
history 0 
further 0 
indicated 0 
intrauterine 1
growth 1
retardation 1
at 0 
the 0 
end 0 
of 0 
the 0 
pregnancy 0 
. 0 

His 0 
mother 0 
was 0 
_NUM2 0 
years 0 
of 0 
age 0 
at 0 
the 0 
time 0 
of 0 
his 0 
birth 0 
. 0 

After 0 
birth 0 
he 0 
showed 0 
hypotonia 1
with 0 
poor 0 
sucking 0 
, 0 
for 0 
which 0 
gavage 0 
feeding 0 
was 0 
needed 0 
. 0 

Motor 0 
development 0 
was 0 
delayed 0 
. 0 

After 0 
_NUM1 0 
year 0 
he 0 
became 0 
obese 1
despite 0 
a 0 
normal 0 
appetite 0 
. 0 

Recurrent 0 
middle 1
ear 1
infections 1
, 0 
a 0 
high 0 
pain 0 
threshold 0 
, 0 
and 0 
a 0 
great 0 
skill 0 
with 0 
jigsaw 0 
puzzles 0 
were 0 
reported 0 
. 0 

There 0 
were 0 
no 0 
behavioural 0 
problems 0 
or 0 
sleep 0 
disturbance 0 
. 0 

Chromosomal 0 
analysis 0 
was 0 
normal 0 
-LRB- 0 
_NUM2 0 
, 0 
XY 0 
-RRB- 0 
. 0 

DNA 0 
analysis 0 
for 0 
Prader-Willi 1
syndrome 1
showed 0 
no 0 
abnormalities 0 
. 0 

Two 0 
years 0 
later 0 
he 0 
was 0 
re-examined 0 
because 0 
we 0 
thought 0 
his 0 
features 0 
fitted 0 
the 0 
PWS 1
like 0 
phenotype 0 
associated 0 
with 0 
maternal 0 
UPD 1
-LRB- 0 
_NUM2 0 
-RRB- 0 
. 0 

At 0 
that 0 
time 0 
precocious 0 
puberty 0 
was 0 
evident 0 
. 0 

DNA 0 
analysis 0 
showed 0 
maternal 1
heterodisomy 1
for 0 
chromosome 0 
_NUM2 0 
. 0 

In 0 
all 0 
the 0 
previously 0 
described 0 
_NUM2 0 
cases 0 
with 0 
maternal 0 
UPD 1
-LRB- 0 
_NUM2 0 
-RRB- 0 
, 0 
a 0 
Robertsonian 0 
translocation 0 
involving 0 
chromosome 0 
_NUM2 0 
was 0 
detected 0 
cytogenetically 0 
before 0 
DNA 0 
analysis 0 
. 0 

This 0 
is 0 
the 0 
first 0 
report 0 
of 0 
diagnosis 0 
of 0 
maternal 0 
UPD 1
-LRB- 0 
_NUM2 0 
-RRB- 0 
based 0 
on 0 
clinical 0 
features 0 
. 0 

This 0 
finding 0 
underlines 0 
the 0 
importance 0 
of 0 
DNA 0 
analysis 0 
for 0 
maternal 0 
UPD 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
in 0 
patients 0 
with 0 
a 0 
similar 0 
PWS 1
like 0 
phenotype 0 
even 0 
without 0 
previous 0 
identification 0 
of 0 
a 0 
Robertsonian 0 
translocation 0 
involving 0 
chromosome 0 
_NUM2 0 
. 0 
. 0 

Detection 0 
of 0 
eight 0 
BRCA1 0 
mutations 0 
in 0 
_NUM2 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
, 0 
including 0 
_NUM1 0 
family 0 
with 0 
male 1
breast 1
cancer 1
. 0 

Genetic 0 
epidemiological 0 
evidence 0 
suggests 0 
that 0 
mutations 0 
in 0 
BRCA1 0 
may 0 
be 0 
responsible 0 
for 0 
approximately 0 
one 0 
half 0 
of 0 
early 0 
onset 0 
familial 1
breast 1
cancer 1
and 0 
the 0 
majority 0 
of 0 
familial 1
breast 1
/ 1
ovarian 1
cancer 1
. 0 

The 0 
recent 0 
cloning 0 
of 0 
BRCA1 0 
allows 0 
for 0 
the 0 
direct 0 
detection 0 
of 0 
mutations 0 
, 0 
but 0 
the 0 
feasibility 0 
of 0 
presymptomatic 0 
screening 0 
for 0 
cancer 1
susceptibility 0 
is 0 
unknown 0 
. 0 

We 0 
analyzed 0 
genomic 0 
DNA 0 
from 0 
one 0 
affected 0 
individual 0 
from 0 
each 0 
of 0 
_NUM2 0 
families 0 
with 0 
at 0 
least 0 
three 0 
cases 0 
of 0 
ovarian 1
or 1
breast 1
cancer 1
, 0 
using 0 
SSCP 0 
assays 0 
. 0 

Variant 0 
SSCP 0 
bands 0 
were 0 
subcloned 0 
and 0 
sequenced 0 
. 0 

Allele-specific 0 
oligonucleotide 0 
hybridization 0 
was 0 
used 0 
to 0 
verify 0 
sequence 0 
changes 0 
and 0 
to 0 
screen 0 
DNA 0 
from 0 
control 0 
individuals 0 
. 0 

Six 0 
frameshift 0 
and 0 
two 0 
missense 0 
mutations 0 
were 0 
detected 0 
in 0 
_NUM2 0 
different 0 
families 0 
. 0 

A 0 
frameshift 0 
mutation 0 
was 0 
detected 0 
in 0 
a 0 
male 0 
proband 0 
affected 0 
with 0 
both 0 
breast 1
and 1
prostate 1
cancer 1
. 0 

A 0 
40-bp 0 
deletion 0 
was 0 
detected 0 
in 0 
a 0 
patient 0 
who 0 
developed 0 
intra-abdominal 1
carcinomatosis 1
_NUM1 0 
year 0 
after 0 
prophylactic 0 
oophorectomy 0 
. 0 

Mutations 0 
were 0 
detected 0 
throughout 0 
the 0 
gene 0 
, 0 
and 0 
only 0 
one 0 
was 0 
detected 0 
in 0 
more 0 
than 0 
a 0 
single 0 
family 0 
. 0 

These 0 
results 0 
provide 0 
further 0 
evidence 0 
that 0 
inherited 1
breast 1
and 1
ovarian 1
cancer 1
can 0 
occur 0 
as 0 
a 0 
consequence 0 
of 0 
a 0 
wide 0 
array 0 
of 0 
BRCA1 0 
mutations 0 
. 0 

These 0 
results 0 
suggests 0 
that 0 
development 0 
of 0 
a 0 
screening 0 
test 0 
for 0 
BRCA1 0 
mutations 0 
will 0 
be 0 
technically 0 
challenging 0 
. 0 

The 0 
finding 0 
of 0 
a 0 
mutation 0 
in 0 
a 0 
family 0 
with 0 
male 1
breast 1
cancer 1
, 0 
not 0 
previously 0 
thought 0 
to 0 
be 0 
related 0 
to 0 
BRCA1 0 
, 0 
also 0 
illustrates 0 
the 0 
potential 0 
difficulties 0 
of 0 
genetic 0 
counseling 0 
for 0 
individuals 0 
known 0 
to 0 
carry 0 
mutations 0 
. 0 
. 0 

Color 1
vision 1
defects 1
in 0 
adrenomyeloneuropathy 1
. 0 

The 0 
relationship 0 
between 0 
abnormal 1
color 1
vision 1
and 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
was 0 
investigated 0 
in 0 
_NUM2 0 
AMN 1
patients 0 
and 0 
_NUM2 0 
age-matched 0 
controls 0 
by 0 
using 0 
the 0 
Farnsworth-Munsell 0 
_NUM3 0 
Hue 0 
test 0 
. 0 

Twelve 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
patients 0 
showed 0 
test 0 
scores 0 
significantly 0 
above 0 
normal 0 
. 0 

The 0 
axes 0 
of 0 
bipolarity 0 
determined 0 
by 0 
the 0 
testing 0 
differed 0 
widely 0 
between 0 
the 0 
patients 0 
with 0 
abnormal 0 
scores 0 
, 0 
compatible 0 
with 0 
the 0 
notion 0 
that 0 
different 0 
alterations 0 
in 0 
visual 0 
pigment 0 
genes 0 
occur 0 
in 0 
different 0 
AMN 1
kindreds 0 
. 0 

These 0 
observations 0 
confirm 0 
our 0 
earlier 0 
impression 0 
that 0 
the 0 
frequency 0 
of 0 
abnormal 1
color 1
vision 1
is 0 
increased 0 
in 0 
these 0 
kindreds 0 
, 0 
and 0 
it 0 
supports 0 
our 0 
contentions 0 
that 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
AMN 1
-LRB- 0 
and 0 
its 0 
companion 0 
, 0 
adrenoleukodystrophy 1
-RRB- 0 
are 0 
very 0 
closely 0 
linked 0 
to 0 
the 0 
visual 0 
pigment 0 
loci 0 
at 0 
Xq28 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
this 0 
proximity 0 
might 0 
provide 0 
the 0 
opportunity 0 
to 0 
observe 0 
contiguous 1
gene 1
defects 1
. 0 
. 0 

Patterns 0 
of 0 
exon 0 
deletions 0 
in 0 
Duchenne 1
and 1
Becker 1
muscular 1
dystrophy 1
. 0 

A 0 
panel 0 
of 0 
patients 0 
with 0 
Duchenne 1
and 1
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
and 0 
BMD 1
-RRB- 0 
has 0 
been 0 
screened 0 
with 0 
the 0 
cDNA 0 
probes 0 
Cf56a 0 
and 0 
Cf23a 0 
, 0 
which 0 
detect 0 
exons 0 
in 0 
the 0 
central 0 
part 0 
of 0 
the 0 
DMD 1
gene 0 
. 0 

One 0 
or 0 
more 0 
exons 0 
were 0 
deleted 0 
in 0 
_NUM2 0 
% 0 
of 0 
patients 0 
. 0 

The 0 
deletions 0 
were 0 
mapped 0 
and 0 
prove 0 
to 0 
be 0 
heterogeneous 0 
in 0 
size 0 
and 0 
extent 0 
, 0 
particularly 0 
in 0 
DMD 1
. 0 

Deletions 0 
specific 0 
to 0 
DMD 1
and 0 
to 0 
BMD 1
are 0 
described 0 
. 0 

Half 0 
of 0 
all 0 
BMD 1
patients 0 
have 0 
a 0 
deletion 0 
of 0 
one 0 
particular 0 
small 0 
group 0 
of 0 
exons 0 
; 0 
smaller 0 
deletions 0 
within 0 
this 0 
same 0 
group 0 
produce 0 
the 0 
more 0 
severe 0 
DMD 1
. 0 
. 0 

The 0 
LEC 0 
rat 0 
has 0 
a 0 
deletion 0 
in 0 
the 0 
copper 0 
transporting 0 
ATPase 0 
gene 0 
homologous 0 
to 0 
the 0 
Wilson 1
disease 1
gene 0 
. 0 

The 0 
Long-Evans 0 
Cinnamon 0 
-LRB- 0 
LEC 0 
-RRB- 0 
rat 0 
shows 0 
similarity 0 
to 0 
Wilson 1
disease 1
in 0 
many 0 
clinical 0 
and 0 
biochemical 0 
features 0 
. 0 

We 0 
have 0 
cloned 0 
cDNAs 0 
for 0 
the 0 
rat 0 
gene 0 
-LRB- 0 
Atp7b 0 
-RRB- 0 
homologous 0 
to 0 
the 0 
human 0 
Wilson 1
disease 1
gene 0 
-LRB- 0 
ATP7B 0 
-RRB- 0 
and 0 
have 0 
used 0 
them 0 
to 0 
identify 0 
a 0 
partial 0 
deletion 0 
in 0 
the 0 
Atp7b 0 
gene 0 
in 0 
the 0 
LEC 0 
rat 0 
. 0 

The 0 
deletion 0 
removes 0 
at 0 
least 0 
_NUM3 0 
bp 0 
of 0 
the 0 
coding 0 
region 0 
at 0 
the 0 
_NUM1 0 
end 0 
, 0 
includes 0 
the 0 
crucial 0 
ATP 0 
binding 0 
domain 0 
and 0 
extends 0 
downstream 0 
of 0 
the 0 
gene 0 
. 0 

Our 0 
results 0 
provide 0 
convincing 0 
evidence 0 
for 0 
defining 0 
the 0 
LEC 0 
rat 0 
as 0 
an 0 
animal 0 
model 0 
for 0 
Wilson 1
disease 1
. 0 

This 0 
model 0 
will 0 
be 0 
important 0 
for 0 
studying 0 
liver 0 
pathophysiology 0 
, 0 
for 0 
developing 0 
therapy 0 
for 0 
Wilson 1
disease 1
and 0 
for 0 
studying 0 
the 0 
pathway 0 
of 0 
copper 0 
transport 0 
and 0 
its 0 
possible 0 
interaction 0 
with 0 
other 0 
heavy 0 
metals 0 
. 0 
. 0 

Detection 0 
of 0 
a 0 
new 0 
submicroscopic 0 
Norrie 1
disease 1
deletion 0 
interval 0 
with 0 
a 0 
novel 0 
DNA 0 
probe 0 
isolated 0 
by 0 
differential 0 
Alu 0 
PCR 0 
fingerprint 0 
cloning 0 
. 0 

Differential 0 
Alu 0 
PCR 0 
fingerprint 0 
cloning 0 
was 0 
used 0 
to 0 
isolate 0 
a 0 
DNA 0 
probe 0 
from 0 
the 0 
Xp11 0 
. 0 

_NUM1 0 
-- 0 
> 0 
_AN 0 
. 0 

_NUM2 0 
region 0 
of 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 

This 0 
novel 0 
sequence 0 
, 0 
cpXr318 0 
-LRB- 0 
DXS742 0 
-RRB- 0 
, 0 
detects 0 
a 0 
new 0 
submicroscopic 0 
deletion 0 
interval 0 
at 0 
the 0 
Norrie 1
disease 1
locus 0 
-LRB- 0 
NDP 0 
-RRB- 0 
. 0 

Combining 0 
our 0 
data 0 
with 0 
the 0 
consensus 0 
genetic 0 
map 0 
of 0 
the 0 
proximal 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
, 0 
we 0 
propose 0 
the 0 
physical 0 
order 0 
Xcen-DXS14-DXS255 0 
- 0 
-LRB- 0 
DXS426 0 
, 0 
TIMP 0 
-RRB- 0 
- 0 
-LRB- 0 
DXS742 0 
- 0 
-LRB- 0 
-LSB- 0 
MAOB-MAOA-DXS7 0 
-RSB- 0 
, 0 
NDP 0 
-RRB- 0 
- 0 
DXS77-DXS228 0 
-RRB- 0 
- 0 
DXS209-DXS148-DXS196 0 
- 0 
+ 0 
+ 0 
+ 0 
Xpter 0 
. 0 

The 0 
cpXr318 0 
probe 0 
and 0 
a 0 
subclone 0 
from 0 
a 0 
cosmid 0 
corresponding 0 
to 0 
the 0 
DXS7 0 
locus 0 
were 0 
converted 0 
into 0 
sequence-tagged 0 
sites 0 
. 0 

Finally 0 
, 0 
DXS742 0 
, 0 
DSX7 0 
, 0 
DXS77 0 
, 0 
and 0 
MAOA 0 
were 0 
integrated 0 
into 0 
a 0 
physical 0 
map 0 
spanning 0 
the 0 
Norrie 1
disease 1
locus 0 
Genetic 0 
analysis 0 
of 0 
a 0 
Japanese 0 
family 0 
with 0 
normotriglyceridemic 1
abetalipoproteinemia 1
indicates 0 
a 0 
lack 0 
of 0 
linkage 0 
to 0 
the 0 
apolipoprotein 0 
B 0 
gene 0 
. 0 

Normotriglyceridemic 1
abetalipoproteinemia 1
is 0 
a 0 
rare 0 
familial 1
disorder 1
characterized 0 
by 0 
an 0 
isolated 0 
deficiency 1
of 1
apoB-100 1
. 0 

We 0 
have 0 
previously 0 
reported 0 
a 0 
patient 0 
with 0 
this 0 
disease 0 
, 0 
who 0 
had 0 
normal 0 
apoB-48 0 
but 0 
no 0 
apoB-100 0 
. 0 

To 0 
elucidate 0 
the 0 
genetic 1
abnormalities 1
in 0 
this 0 
family 0 
, 0 
we 0 
studied 0 
the 0 
linkage 0 
of 0 
apoB 0 
gene 0 
using 0 
three 0 
genetic 0 
markers 0 
. 0 

The 0 
proband 0 
and 0 
her 0 
affected 0 
brother 0 
showed 0 
completely 0 
different 0 
apoB 0 
gene 0 
alleles 0 
, 0 
suggesting 0 
that 0 
the 0 
apoB 0 
gene 0 
itself 0 
is 0 
not 0 
related 0 
to 0 
this 0 
disorder 0 
in 0 
this 0 
family 0 
. 0 

By 0 
contrast 0 
, 0 
an 0 
American 0 
case 0 
had 0 
a 0 
point 0 
substitution 0 
in 0 
the 0 
apoB 0 
gene 0 
generating 0 
an 0 
in-frame 0 
stop 0 
codon 0 
. 0 

These 0 
results 0 
indicate 0 
that 0 
this 0 
disorder 0 
can 0 
be 0 
caused 0 
by 0 
defect 0 
-LRB- 0 
s 0 
-RRB- 0 
of 0 
either 0 
an 0 
apoB 0 
gene 0 
or 0 
other 0 
genes 0 
. 0 
. 0 

Founder 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
in 0 
Polish 0 
families 0 
with 0 
breast-ovarian 1
cancer 1
. 0 

We 0 
have 0 
undertaken 0 
a 0 
hospital-based 0 
study 0 
, 0 
to 0 
identify 0 
possible 0 
BRCA1 0 
and 0 
BRCA2 0 
founder 0 
mutations 0 
in 0 
the 0 
Polish 0 
population 0 
. 0 

The 0 
study 0 
group 0 
consisted 0 
of 0 
_NUM2 0 
Polish 0 
families 0 
with 0 
cancer 1
who 0 
have 0 
at 0 
least 0 
three 0 
related 0 
females 0 
affected 0 
with 0 
breast 1
or 1
ovarian 1
cancer 1
and 0 
who 0 
had 0 
cancer 1
diagnosed 0 
, 0 
in 0 
at 0 
least 0 
one 0 
of 0 
the 0 
three 0 
affected 0 
females 0 
, 0 
at 0 
age 0 
< 0 
_NUM2 0 
years 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
families 0 
had 0 
both 0 
breast 1
and 1
ovarian 1
cancers 1
, 0 
_NUM1 0 
families 0 
had 0 
ovarian 1
cancers 1
only 0 
, 0 
and 0 
_NUM2 0 
families 0 
had 0 
breast 1
cancers 1
only 0 
. 0 

Genomic 0 
DNA 0 
was 0 
prepared 0 
from 0 
the 0 
peripheral 0 
blood 0 
leukocytes 0 
of 0 
at 0 
least 0 
one 0 
affected 0 
woman 0 
from 0 
each 0 
family 0 
. 0 

The 0 
entire 0 
coding 0 
region 0 
of 0 
BRCA1 0
and 0 
BRCA2 0 
was 0 
screened 0 
for 0 
the 0 
presence 0 
of 0 
germline 0 
mutations 0 
, 0 
by 0 
use 0 
of 0 
SSCP 0 
followed 0 
by 0 
direct 0 
sequencing 0 
of 0 
observed 0 
variants 0 
. 0 

Mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
_NUM2 0 
families 0 
studied 0 
. 0 

All 0 
but 0 
one 0 
of 0 
the 0 
mutations 0 
were 0 
detected 0 
within 0 
the 0 
BRCA1 0
gene 0 
. 0 

BRCA1 1
abnormalities 1
were 0 
identified 0 
in 0 
all 0 
four 0 
families 0 
with 0 
ovarian 1
cancer 1
only 0 
, 0 
in 0 
_NUM2 0 
% 0 
of 0 
_NUM2 0 
families 0 
with 0 
both 0 
breast 1
and 1
ovarian 1
cancer 1
, 0 
and 0 
in 0 
_NUM2 0 
% 0 
of 0 
_NUM2 0 
families 0 
with 0 
breast 1
cancer 1
only 0 
. 0 

The 0 
single 0 
family 0 
with 0 
a 0 
BRCA2 0 
mutation 0 
had 0 
the 0 
breast-ovarian 1
cancer 1
syndrome 1
. 0 

Seven 0 
distinct 0 
mutations 0 
were 0 
identified 0 
; 0 
five 0 
of 0 
these 0 
occurred 0 
in 0 
two 0 
or 0 
more 0 
families 0 
. 0 

In 0 
total 0 
, 0 
recurrent 0 
mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
_NUM2 0 
families 0 
with 0 
detected 0 
mutations 0 
. 0 

Three 0 
BRCA1 1
abnormalities 1
- 0 
5382insC 0 
, 0 
C61G 0 
, 0 
and 0 
4153delA 0 
- 0 
accounted 0 
for 0 
_NUM2 0 
% 0 
, 0 
_NUM2 0 
% 0 
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
the 0 
identified 0 
mutations 0 
, 0 
respectively 0 
. 0 
. 0 

New 0 
founder 0 
haplotypes 0 
at 0 
the 0 
myotonic 1
dystrophy 1
locus 0 
in 0 
southern 0 
Africa 0 
. 0 

The 0 
association 0 
between 0 
normal 0 
alleles 0 
at 0 
the 0 
_DS 0 
repeat 0 
and 0 
two 0 
nearby 0 
polymorphisms 0 
in 0 
the 0 
myotonin 0 
protein 0 
kinase 0 
gene 0 
, 0 
the 0 
Alu 0 
insertion 0 
/ 0 
deletion 0 
polymorphism 0 
and 0 
the 0 
myotonic 1
dystrophy 1
kinase 0 
-LRB- 0 
DMK 0 
-RRB- 0 
-LRB- 0 
G 0 
/ 0 
T 0 
-RRB- 0 
intron 0 
9 0 
/ 0 
HinfI 0 
polymorphism 0 
, 0 
has 0 
been 0 
analyzed 0 
in 0 
South 0 
African 0 
Negroids 0 
, 0 
a 0 
population 0 
in 0 
which 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
has 0 
not 0 
been 0 
described 0 
. 0 

South 0 
African 0 
Negroids 0 
have 0 
a 0 
_DS 0 
allelic 0 
distribution 0 
that 0 
is 0 
significantly 0 
different 0 
from 0 
that 0 
in 0 
Caucasoids 0 
and 0 
Japanese 0 
the 0 
_DS 0 
repeat 0 
lengths 0 
of 0 
> 0 
or 0 
= 0 
_NUM2 0 
are 0 
very 0 
rare 0 
. 0 

The 0 
striking 0 
linkage 0 
disequilibrium 0 
between 0 
specific 0 
alleles 0 
at 0 
the 0 
Alu 0 
polymorphism 0 
-LRB- 0 
Alu 0 
-LRB- 0 
ins 0 
-RRB- 0 
and 0 
Alu 0 
-LRB- 0 
del 0 
-RRB- 0 
-RRB- 0 
, 0 
the 0 
HinfI 0 
polymorphism 0 
-LRB- 0 
HinfI-1 0 
and 0 
HinfI-2 0 
-RRB- 0 
, 0 
and 0 
the 0 
_DS 0 
repeat 0 
polymorphism 0 
seen 0 
in 0 
Caucasoid 0 
-LRB- 0 
Europeans 0 
and 0 
Canadians 0 
-RRB- 0 
populations 0 
was 0 
also 0 
found 0 
in 0 
the 0 
South 0 
African 0 
Negroid 0 
population 0 
. 0 

Numerous 0 
haplotypes 0 
, 0 
not 0 
previously 0 
described 0 
in 0 
Europeans 0 
, 0 
were 0 
, 0 
however 0 
, 0 
found 0 
. 0 

It 0 
thus 0 
seems 0 
likely 0 
that 0 
only 0 
a 0 
small 0 
number 0 
of 0 
these 0 
'' 0 
African 0 
'' 0 
chromosomes 0 
were 0 
present 0 
in 0 
the 0 
progenitors 0 
of 0 
all 0 
non-African 0 
peoples 0 
. 0 

These 0 
data 0 
provide 0 
support 0 
for 0 
the 0 
'' 0 
out 0 
of 0 
Africa 0 
'' 0 
model 0 
for 0 
the 0 
origin 0 
of 0 
modern 0 
humans 0 
and 0 
suggest 0 
that 0 
the 0 
rare 0 
ancestral 0 
DM 1
mutation 0 
event 0 
may 0 
have 0 
occurred 0 
after 0 
the 0 
migration 0 
from 0 
Africa 0 
, 0 
hence 0 
the 0 
absence 0 
of 0 
DM 1
in 0 
sub-Saharan 0 
Negroid 0 
peoples 0 
. 0 
. 0 

Marked 0 
phenotypic 0 
heterogeneity 0 
associated 0 
with 0 
expansion 0 
of 0 
a 0 
_DS 0 
repeat 0 
sequence 0 
at 0 
the 0 
spinocerebellar 1
ataxia 1
_NUM1 1
/ 1
Machado-Joseph 1
disease 1
locus 0 
. 0 

The 0 
spinocerebellar 1
ataxia 1
_NUM1 1
locus 0 
-LRB- 0 
SCA3 1
-RRB- 0 
for 0 
type 1
I 1
autosomal 1
dominant 1
cerebellar 1
ataxia 1
-LRB- 0 
ADCA 1
type 1
I 1
-RRB- 0 
, 0 
a 0 
clinically 0 
and 0 
genetically 0 
heterogeneous 0 
group 0 
of 0 
neurodegenerative 1
disorders 1
, 0 
has 0 
been 0 
mapped 0 
to 0 
chromosome 0 
14q32 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

ADCA 1
type 1
I 1
patients 0 
from 0 
families 0 
segregating 0 
SCA3 1
share 0 
clinical 0 
features 0 
in 0 
common 0 
with 0 
those 0 
with 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
, 0 
the 0 
gene 0 
of 0 
which 0 
maps 0 
to 0 
the 0 
same 0 
region 0 
. 0 

We 0 
show 0 
here 0 
that 0 
the 0 
disease 0 
gene 0 
segregating 0 
in 0 
each 0 
of 0 
three 0 
French 0 
ADCA 1
type 1
I 1
kindreds 0 
and 0 
in 0 
a 0 
French 0 
family 0 
with 0 
neuropathological 0 
findings 0 
suggesting 0 
the 0 
ataxochoreic 0 
form 0 
of 0 
dentatorubropallidoluysian 1
atrophy 1
carries 0 
an 0 
expanded 0 
_DS 0 
repeat 0 
sequence 0 
located 0 
at 0 
the 0 
same 0 
locus 0 
as 0 
that 0 
for 0 
MJD 1
. 0 

Analysis 0 
of 0 
the 0 
mutation 0 
in 0 
these 0 
families 0 
shows 0 
a 0 
strong 0 
negative 0 
correlation 0 
between 0 
size 0 
of 0 
the 0 
expanded 0 
_DS 0 
repeat 0 
and 0 
age 0 
at 0 
onset 0 
of 0 
clinical 0 
disease 0 
. 0 

Instability 0 
of 0 
the 0 
expanded 0 
triplet 0 
repeat 0 
was 0 
not 0 
found 0 
to 0 
be 0 
affected 0 
by 0 
sex 0 
of 0 
the 0 
parent 0 
transmitting 0 
the 0 
mutation 0 
. 0 

Evidence 0 
was 0 
found 0 
for 0 
somatic 0 
and 0 
gonadal 0 
mosaicism 0 
for 0 
alleles 0 
carrying 0 
expanded 0 
trinucleotide 0 
repeats 0 
. 0 

The 0 
red-green 0 
visual 0 
pigment 0 
gene 0 
region 0 
in 0 
adrenoleukodystrophy 1
. 0 

Although 0 
recent 0 
data 0 
established 0 
that 0 
a 0 
specific 0 
very-long-chain 0 
fatty 0 
acyl-CoA 0 
synthetase 0 
is 0 
defective 0 
in 0 
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
, 0 
the 0 
ALD 1
gene 0 
is 0 
still 0 
unidentified 0 
. 0 

The 0 
ALD 1
locus 0 
has 0 
been 0 
mapped 0 
to 0 
Xq28 0 
, 0 
like 0 
the 0 
red 0 
and 0 
green 0 
color 0 
pigment 0 
genes 0 
. 0 

Abnormal 1
color 1
vision 1
has 0 
been 0 
observed 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
patients 0 
with 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
, 0 
a 0 
milder 0 
form 0 
of 0 
ALD 1
. 0 

Furthermore 0 
, 0 
rearrangements 0 
of 0 
the 0 
color 0 
vision 0 
gene 0 
cluster 0 
were 0 
found 0 
in 0 
four 0 
of 0 
eight 0 
ALD 1
kindreds 0 
. 0 

This 0 
led 0 
us 0 
to 0 
propose 0 
that 0 
a 0 
single 0 
DNA 0 
rearrangement 0 
could 0 
underlie 0 
both 0 
ALD 1
and 0 
abnormal 1
color 1
vision 1
in 0 
these 0 
patients 0 
. 0 

Study 0 
of 0 
_NUM2 0 
French 0 
ALD 1
patients 0 
failed 0 
to 0 
reveal 0 
a 0 
higher 0 
than 0 
expected 0 
frequency 0 
of 0 
green 0 
/ 0 
red 0 
visual 0 
pigment 0 
rearrangements 0 
_NUM1 0 
to 0 
the 0 
red 0 
/ 0 
green 0 
color 0 
vision 0 
gene 0 
complex 0 
. 0 

The 0 
previous 0 
report 0 
of 0 
such 0 
rearrangements 0 
was 0 
based 0 
on 0 
small 0 
numbers 0 
and 0 
lack 0 
of 0 
knowledge 0 
that 0 
the 0 
frequency 0 
of 0 
'' 0 
abnormal 0 
'' 0 
color 0 
vision 0 
arrays 0 
on 0 
molecular 0 
analysis 0 
was 0 
twice 0 
as 0 
high 0 
as 0 
expected 0 
on 0 
the 0 
basis 0 
of 0 
the 0 
frequency 0 
of 0 
phenotypic 1
color 1
vision 1
defects 1
. 0 

The 0 
red 0 
/ 0 
green 0 
color 0 
pigment 0 
-LRB- 0 
R 0 
/ 0 
GCP 0 
-RRB- 0 
region 0 
was 0 
studied 0 
by 0 
pulsed-field 0 
gel 0 
electrophoresis 0 
in 0 
_NUM2 0 
of 0 
these 0 
patients 0 
, 0 
and 0 
we 0 
did 0 
not 0 
find 0 
any 0 
fragment 0 
size 0 
difference 0 
between 0 
the 0 
patients 0 
and 0 
normal 0 
individuals 0 
who 0 
have 0 
the 0 
same 0 
number 0 
of 0 
pigment 0 
genes 0 
. 0 

The 0 
R 0 
/ 0 
GCP 0 
region 0 
was 0 
also 0 
analyzed 0 
in 0 
_NUM2 0 
French 0 
and 0 
seven 0 
North 0 
American 0 
ALD 1
patients 0 
by 0 
using 0 
six 0 
genomic 0 
DNA 0 
probes 0 
, 0 
isolated 0 
from 0 
a 0 
cosmid 0 
walk 0 
, 0 
that 0 
flank 0 
the 0 
color 0 
vision 0 
genes 0 
. 0 

No 0 
deletions 0 
were 0 
found 0 
with 0 
probes 0 
that 0 
lie 0 
_NUM1 0 
of 0 
the 0 
green 0 
pigment 0 
genes 0 
. 0 

One 0 
of 0 
the 0 
eight 0 
previously 0 
reported 0 
ALD 1
individuals 0 
has 0 
a 0 
long 0 
deletion 0 
_NUM1 0 
of 0 
the 0 
red 0 
pigment 0 
gene 0 
, 0 
a 0 
deletion 0 
causing 0 
blue 0 
cone 0 
monochromacy 0 
. 0 

This 0 
finding 0 
and 0 
the 0 
previous 0 
findings 0 
of 0 
a 0 
_NUM2 0 
% 0 
frequency 0 
of 0 
phenotypic 0 
color 0 
vision 0 
defects 0 
in 0 
patients 0 
with 0 
AMN 1
may 0 
suggest 0 
that 0 
the 0 
ALD 1
/ 0 
AMN 1
gene 0 
lies 0 
_NUM1 0 
to 0 
the 0 
red 0 
pigment 0 
gene 0 
and 0 
that 0 
the 0 
frequent 0 
phenotypic 0 
color 1
vision 1
anomalies 1
owe 0 
their 0 
origin 0 
to 0 
deleted 0 
DNA 0 
that 0 
includes 0 
regulatory 0 
genes 0 
for 0 
color 0
vision 0 
. 0 

It 0 
is 0 
possible 0 
, 0 
however 0 
, 0 
that 0 
phenotypic 0 
color 1
vision 1
anomalies 1
in 0 
AMN 1
may 0 
be 0 
phenocopies 0 
secondary 0 
to 0 
retinal 0 
or 0 
neural 0 
involvement 0 
by 0 
the 0 
disease 0 
. 0 

The 0 
single 0 
case 0 
of 0 
blue 0 
cone 0 
monochromacy 0 
may 0 
therefore 0 
be 0 
a 0 
fortuitous 0 
coincidence 0 
of 0 
two 0 
diseases 0 
. 0 
. 0 

Haim-Munk 1
syndrome 1
and 0 
Papillon-Lefevre 1
syndrome 1
are 0 
allelic 0 
mutations 0 
in 0 
cathepsin 0 
C. 0 
Of 0 
the 0 
many 0 
palmoplantar 1
keratoderma 1
-LRB- 1
PPK 1
-RRB- 1
conditions 1
, 0 
only 0 
Papillon-Lefevre 1
syndrome 1
-LRB- 0 
PLS 1
-RRB- 0 
and 0 
Haim-Munk 1
syndrome 1
-LRB- 0 
HMS 1
-RRB- 0 
are 0 
associated 0 
with 0 
premature 0 
periodontal 0 
destruction 0 
. 0 

Although 0 
both 0 
PLS 1
and 0 
HMS 1
share 0 
the 0 
cardinal 0 
features 0 
of 0 
PPK 1
and 0 
severe 0 
periodontitis 1
, 0 
a 0 
number 0 
of 0 
additional 0 
findings 0 
are 0 
reported 0 
in 0 
HMS 1
including 0 
arachnodactyly 1
, 0 
acro-osteolysis 1
, 0 
atrophic 1
changes 1
of 1
the 1
nails 1
, 0 
and 0 
a 0 
radiographic 1
deformity 1
of 1
the 1
fingers 1
. 0 

While 0 
PLS 1
cases 0 
have 0 
been 0 
identified 0 
throughout 0 
the 0 
world 0 
, 0 
HMS 1
has 0 
only 0 
been 0 
described 0 
among 0 
descendants 0 
of 0 
a 0 
religious 0 
isolate 0 
originally 0 
from 0 
Cochin 0 
, 0 
India 0 
. 0 

Parental 0 
consanguinity 0 
is 0 
a 0 
characteristic 0 
of 0 
many 0 
cases 0 
of 0 
both 0 
conditions 0 
. 0 

Although 0 
autosomal 0 
recessive 0 
transmission 0 
of 0 
PLS 1
is 0 
evident 0 
, 0 
a 0 
more 0 
'' 0 
complex 0 
'' 0 
autosomal 0 
recessive 0 
pattern 0 
of 0 
inheritance 0 
with 0 
phenotypic 0 
influences 0 
from 0 
a 0 
closely 0 
linked 0 
modifying 0 
locus 0 
has 0 
been 0 
hypothesised 0 
for 0 
HMS 1
. 0 

Recently 0 
, 0 
mutations 0 
of 0 
the 0 
cathepsin 0 
C 0 
gene 0 
have 0 
been 0 
identified 0 
as 0 
the 0 
underlying 0 
genetic 1
defect 1
in 0 
PLS 1
. 0 

To 0 
determine 0 
if 0 
a 0 
cathepsin 0 
C 0 
mutation 0 
is 0 
also 0 
responsible 0 
for 0 
HMS 1
, 0 
we 0 
sequenced 0 
the 0 
gene 0 
in 0 
affected 0 
and 0 
unaffected 0 
subjects 0 
from 0 
the 0 
Cochin 0 
isolate 0 
in 0 
which 0 
both 0 
the 0 
PLS 1
and 0 
HMS 1
phenotypes 0 
appear 0 
. 0 

Here 0 
we 0 
report 0 
identification 0 
of 0 
a 0 
mutation 0 
of 0 
cathepsin 0 
C 0 
-LRB- 0 
exon 0 
_NUM1 0 
, 0 
2127A 0 
-- 0 
> 0 
G 0 
-RRB- 0 
that 0 
changes 0 
a 0 
highly 0 
conserved 0 
amino 0 
acid 0 
in 0 
the 0 
cathepsin 0 
C 0 
peptide 0 
. 0 

This 0 
mutation 0 
segregates 0 
with 0 
HMS 1
in 0 
four 0 
nuclear 0 
families 0 
. 0 

Additionally 0 
, 0 
the 0 
existence 0 
of 0 
a 0 
shared 0 
common 0 
haplotype 0 
for 0 
genetic 0 
loci 0 
flanking 0 
the 0 
cathepsin 0 
C 0 
gene 0 
suggests 0 
that 0 
affected 0 
subjects 0 
descended 0 
from 0 
the 0 
Cochin 0 
isolate 0 
are 0 
homozygous 0 
for 0 
a 0 
mutation 0 
inherited 0 
'' 0 
identical 0 
by 0 
descent 0 
'' 0 
from 0 
a 0 
common 0 
ancestor 0 
. 0 

This 0 
finding 0 
supports 0 
simple 0 
autosomal 0 
recessive 0 
inheritance 0 
for 0 
HMS 1
in 0 
these 0 
families 0 
. 0 

We 0 
also 0 
report 0 
a 0 
mutation 0 
of 0 
the 0 
same 0 
exon 0 
_NUM1 0 
CTSC 0 
codon 0 
-LRB- 0 
2126C 0 
-- 0 
> 0 
T 0 
-RRB- 0 
in 0 
a 0 
Turkish 0 
family 0 
with 0 
classical 0 
PLS 1
. 0 

These 0 
findings 0 
provide 0 
evidence 0 
that 0 
PLS 1
and 0 
HMS 1
are 0 
allelic 0 
variants 0 
of 0 
cathepsin 0 
C 0 
gene 0 
mutations 0 
. 0 
. 0 

X 0 
inactivation 0 
and 0 
somatic 0 
cell 0 
selection 0 
rescue 0 
female 0 
mice 0 
carrying 0 
a 0 
Piga-null 0 
mutation 0 
. 0 

A 0 
somatic 0 
mutation 0 
in 0 
the 0 
X 0 
linked 0 
PIGA 0 
gene 0 
is 0 
responsible 0 
for 0 
the 0 
deficiency 1
of 1
glycosyl 1
phosphatidylinositol 1
-LRB- 1
GPI 1
-RRB- 1
- 1
anchored 1
proteins 1
on 0 
blood 0 
cells 0 
from 0 
patients 0 
with 0 
paroxysmal 1
nocturnal 1
hemoglobinuria 1
. 0 

No 0 
inherited 0 
form 0 
of 0 
GPI-anchor 1
deficiency 1
has 0 
been 0 
described 0 
. 0 

Because 0 
conventional 0 
Piga 0 
gene 0 
knockout 0 
is 0 
associated 0 
with 0 
high 0 
embryonic 1
lethality 1
in 0 
chimeric 0 
mice 0 
, 0 
we 0 
used 0 
the 0 
Cre 0 
/ 0 
loxP 0 
system 0 
. 0 

We 0 
generated 0 
mice 0 
in 0 
which 0 
two 0 
loxP 0 
sites 0 
flank 0 
part 0 
of 0 
Piga 0 
exon 0 
_NUM1 0 
. 0 

After 0 
crossbreeding 0 
with 0 
female 0 
mice 0 
of 0 
the 0 
EIIa-cre 0 
strain 0 
, 0 
the 0 
floxed 0 
allele 0 
undergoes 0 
Cre-mediated 0 
recombination 0 
with 0 
high 0 
efficiency 0 
during 0 
early 0 
embryonic 0 
development 0 
. 0 

Because 0 
of 0 
X 0 
chromosome 0 
inactivation 0 
, 0 
female 0 
offspring 0 
are 0 
mosaic 0 
for 0 
cells 0 
that 0 
express 0 
or 0 
lack 0 
GPI-linked 0 
proteins 0 
. 0 

Analysis 0 
of 0 
mosaic 0 
mice 0 
showed 0 
that 0 
in 0 
heart 0 
, 0 
lung 0 
, 0 
kidney 0 
, 0 
brain 0 
, 0 
and 0 
liver 0 
, 0 
mainly 0 
wild-type 0 
Piga 0 
is 0 
active 0 
, 0 
suggesting 0 
that 0 
these 0 
tissues 0 
require 0 
GPI-linked 0 
proteins 0 
. 0 

The 0 
salient 0 
exceptions 0 
were 0 
spleen 0 
, 0 
thymus 0 
, 0 
and 0 
red 0 
blood 0 
cells 0 
, 0 
which 0 
had 0 
almost 0 
equal 0 
numbers 0 
of 0 
cells 0 
expressing 0 
the 0 
wild-type 0 
or 0 
the 0 
recombined 0 
allele 0 
, 0 
implying 0 
that 0 
GPI-linked 0 
proteins 0 
are 0 
not 0 
essential 0 
for 0 
the 0 
derivation 0 
of 0 
these 0 
tissues 0 
. 0 

PIGA 0 
-LRB- 0 
- 0 
-RRB- 0 
cells 0 
had 0 
no 0 
growth 0 
advantage 0 
, 0 
suggesting 0 
that 0 
other 0 
factors 0 
are 0 
needed 0 
for 0 
their 0 
clonal 0 
dominance 0 
in 0 
patients 0 
with 0 
paroxysmal 1
nocturnal 1
hemoglobinuria 1
. 0 
. 0 

The 0 
Norrie 1
disease 1
gene 0 
maps 0 
to 0 
a 0 
_NUM3 0 
kb 0 
region 0 
on 0 
chromosome 0 
Xp11 0 
.3 0 
. 0 

Norrie 1
disease 1
is 0 
a 0 
human 0 
X-linked 1
recessive 1
disorder 1
of 0 
unknown 0 
etiology 0 
characterized 0 
by 0 
congenital 1
blindness 1
, 0 
sensory 1
neural 1
deafness 1
and 0 
mental 1
retardation 1
. 0 

This 0 
disease 0 
gene 0 
was 0 
previously 0 
linked 0 
to 0 
the 0 
DXS7 0 
-LRB- 0 
L1 0 
. 0 

_NUM2 0 
-RRB- 0 
locus 0 
and 0 
the 0 
MAO 0 
genes 0 
in 0 
band 0 
Xp11 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

We 0 
report 0 
here 0 
fine 0 
physical 0 
mapping 0 
of 0 
the 0 
obligate 0 
region 0 
containing 0 
the 0 
Norrie 1
disease 1
gene 0 
-LRB- 0 
NDP 0 
-RRB- 0 
defined 0 
by 0 
a 0 
recombination 0 
and 0 
by 0 
the 0 
smallest 0 
submicroscopic 0 
chromosomal 0 
deletion 0 
associated 0 
with 0 
Norrie 1
disease 1
identified 0 
to 0 
date 0 
. 0 

Analysis 0 
, 0 
using 0 
in 0 
addition 0 
two 0 
overlapping 0 
YAC 0 
clones 0 
from 0 
this 0 
region 0 
, 0 
allowed 0 
orientation 0 
of 0 
the 0 
MAOA 0 
and 0 
MAOB 0 
genes 0 
in 0 
a 0 
5-3-3-5 0 
configuration 0 
. 0 

A 0 
recombination 0 
event 0 
between 0 
a 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
polymorphism 0 
in 0 
intron 0 
_NUM1 0 
of 0 
the 0 
MAOB 0 
gene 0 
and 0 
the 0 
NDP 0 
locus 0 
, 0 
in 0 
a 0 
family 0 
previously 0 
reported 0 
to 0 
have 0 
a 0 
recombination 0 
between 0 
DXS7 0 
and 0 
NDP 0 
, 0 
delineates 0 
a 0 
flanking 0 
marker 0 
telomeric 0 
to 0 
this 0 
disease 0 
gene 0 
. 0 

An 0 
anonymous 0 
DNA 0 
probe 0 
, 0 
dc12 0 
, 0 
present 0 
in 0 
one 0 
of 0 
the 0 
YACs 0 
and 0 
in 0 
a 0 
patient 0 
with 0 
a 0 
submicroscopic 0 
deletion 0 
which 0 
includes 0 
MAOA 0 
and 0 
MAOB 0 
but 0 
not 0 
L1 0 
. 0 

_NUM2 0 
, 0 
serves 0 
as 0 
a 0 
flanking 0 
marker 0 
centromeric 0 
to 0 
the 0 
disease 0 
gene 0 
. 0 

An 0 
Alu-PCR 0 
fragment 0 
from 0 
the 0 
right 0 
arm 0 
of 0 
the 0 
MAO 0 
YAC 0 
-LRB- 0 
YMAO 0 
. 0 

AluR 0 
-RRB- 0 
is 0 
not 0 
deleted 0 
in 0 
this 0 
patient 0 
and 0 
also 0 
delineates 0 
the 0 
centromeric 0 
extent 0 
of 0 
the 0 
obligate 0 
disease 0 
region 0 
. 0 

The 0 
apparent 0 
order 0 
of 0 
these 0 
loci 0 
is 0 
telomere 0 
. 0 

DXS7-MAOA-MAOB-NDP-dc12-YMAO 0 
DXS7-MAOA-MAOB-NDP-dc12-YMAO 0 
. 0 

AluR 0 
. 0 

centromere 0 
. 0 

Together 0 
these 0 
data 0 
define 0 
the 0 
obligate 0 
region 0 
containing 0 
the 0 
NDP 0 
gene 0 
to 0 
a 0 
chromosomal 0 
segment 0 
less 0 
than 0 
_NUM3 0 
kb 0 
. 0 

Molecular 0 
genetics 0 
of 0 
the 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
Mediterranean 0 
variant 0 
and 0 
description 0 
of 0 
a 0 
new 0 
G6PD 0 
mutant 0 
, 0 
G6PD 0 
Andalus1361A 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
; 1
E. 1
C. 1
-RRB- 1
deficiency 1
is 0 
the 0 
most 0 
common 0 
human 0 
enzymopathy 1
; 0 
more 0 
than 0 
_NUM3 0 
different 0 
biochemical 0 
variants 0 
of 0 
the 0 
enzyme 0 
have 0 
been 0 
described 0 
. 0 

In 0 
many 0 
parts 0 
of 0 
the 0 
world 0 
the 0 
Mediterranean 0 
type 0 
of 0 
G6PD 1
deficiency 1
is 0 
prevalent 0 
. 0 

However 0 
, 0 
G6PD 0 
Mediterranean 0 
has 0 
come 0 
to 0 
be 0 
regarded 0 
as 0 
a 0 
generic 0 
term 0 
applied 0 
to 0 
similar 0 
G6PD 0 
mutations 0 
thought 0 
, 0 
however 0 
, 0 
to 0 
represent 0 
a 0 
somewhat 0 
heterogeneous 0 
group 0 
. 0 

A 0 
C 0 
-- 0 
T 0 
mutation 0 
at 0 
nucleotide 0 
_NUM3 0 
of 0 
G6PD 0 
Mediterranean 0 
has 0 
been 0 
identified 0 
by 0 
Vulliamy 0 
et 0 
al. 0 
, 0 
and 0 
the 0 
same 0 
mutation 0 
has 0 
been 0 
found 0 
by 0 
De 0 
Vita 0 
et 0 
al. 0 
in 0 
G6PD 0 
Mediterranean 0 
, 0 
G6PD 0 
Sassari 0 
, 0 
and 0 
G6PD 0 
Cagliari 0 
. 0 

The 0 
latter 0 
subjects 0 
had 0 
an 0 
additional 0 
mutation 0 
, 0 
at 0 
nucleotide 0 
_NUM4 0 
, 0 
that 0 
did 0 
not 0 
produce 0 
a 0 
coding 0 
change 0 
. 0 

We 0 
have 0 
examined 0 
genomic 0 
DNA 0 
of 0 
five 0 
patients 0 
-- 0 
four 0 
of 0 
Spanish 0 
origin 0 
and 0 
one 0 
of 0 
Jewish 0 
origin 0 
-- 0 
having 0 
enzymatically 0 
documented 0 
G6PD 0 
Mediterranean 0 
. 0 

All 0 
had 0 
both 0 
the 0 
mutation 0 
at 0 
nucleotide 0 
_NUM3 0 
and 0 
that 0 
at 0 
nucleotide 0 
_NUM4 0 
. 0 

A 0 
sixth 0 
sample 0 
, 0 
resembling 0 
G6PD 0 
Mediterranean 0 
kinetically 0 
but 0 
with 0 
a 0 
slightly 0 
rapid 0 
electrophoretic 0 
mobility 0 
, 0 
was 0 
designated 0 
G6PD 0 
Andalus 0 
and 0 
was 0 
found 0 
to 0 
have 0 
a 0 
different 0 
mutation 0 
, 0 
a 0 
G 0 
-- 0 
A 0 
transition 0 
at 0 
nucleotide 0 
_NUM4 0 
, 0 
producing 0 
an 0 
arginine-to-histidine 0 
substitution 0 
. 0 

These 0 
studies 0 
suggest 0 
that 0 
G6PD 0 
Mediterranean 0 
is 0 
, 0 
after 0 
all 0 
, 0 
relatively 0 
homogeneous 0 
. 0 

Small 0 
nuclear 0 
ribonucleoprotein 0 
polypeptide 0 
N 0 
-LRB- 0 
SNRPN 0 
-RRB- 0 
, 0 
an 0 
expressed 0 
gene 0 
in 0 
the 0 
Prader-Willi 1
syndrome 1
critical 0 
region 0 
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
is 0 
associated 0 
with 0 
paternally 0 
derived 0 
chromosomal 0 
deletions 0 
in 0 
region 0 
15q11-13 0 
or 0 
with 0 
maternal 1
disomy 1
for 1
chromosome 1
_NUM2 1
. 0 

Therefore 0 
, 0 
loss 0 
of 0 
the 0 
expressed 0 
paternal 0 
alleles 0 
of 0 
maternally 0 
imprinted 0 
genes 0 
must 0 
be 0 
responsible 0 
for 0 
the 0 
PWS 1
phenotype 0 
. 0 

We 0 
have 0 
mapped 0 
the 0 
gene 0 
encoding 0 
the 0 
small 0 
nuclear 0 
RNA 0 
associated 0 
polypeptide 0 
SmN 0 
-LRB- 0 
SNRPN 0 
-RRB- 0 
to 0 
human 0 
chromosome 0 
15q12 0 
and 0 
a 0 
processed 0 
pseudogene 0 
SNRPNP1 0 
to 0 
chromosome 0 
region 0 
6pter-p21 0 
. 0 

Furthermore 0 
, 0 
SNRPN 0 
was 0 
mapped 0 
to 0 
the 0 
minimal 0 
deletion 0 
interval 0 
that 0 
is 0 
critical 0 
for 0 
PWS 1
. 0 

The 0 
fact 0 
that 0 
the 0 
mouse 0 
Snrpn 0 
gene 0 
is 0 
maternally 0 
imprinted 0 
in 0 
brain 0 
suggests 0 
that 0 
loss 0 
of 0 
the 0 
paternally 0 
derived 0 
SNRPN 0 
allele 0 
may 0 
be 0 
involved 0 
in 0 
the 0 
PWS 1
phenotype 0 
. 0 
. 0 

Increased 0 
incidence 0 
of 0 
cancer 1
in 0 
patients 0 
with 0 
cartilage-hair 1
hypoplasia 1
. 0 

OBJECTIVE 0 
Previous 0 
reports 0 
have 0 
suggested 0 
an 0 
increased 0 
risk 0 
of 0 
cancer 1
among 0 
patients 0 
with 0 
cartilage-hair 1
hypoplasia 1
-LRB- 0 
CHH 1
-RRB- 0 
. 0 

This 0 
study 0 
was 0 
carried 0 
out 0 
to 0 
further 0 
evaluate 0 
this 0 
risk 0 
among 0 
patients 0 
with 0 
CHH 1
and 0 
their 0 
first-degree 0 
relatives 0 
. 0 

STUDY 0 
DESIGN 0 
One 0 
hundred 0 
twenty-two 0 
patients 0 
with 0 
CHH 1
were 0 
identified 0 
through 0 
_NUM1 0 
countrywide 0 
epidemiologic 0 
surveys 0 
in 0 
_NUM4 0 
and 0 
in 0 
_NUM4 0 
. 0 

Their 0 
parents 0 
and 0 
nonaffected 0 
siblings 0 
were 0 
identified 0 
through 0 
the 0 
Population 0 
Register 0 
Center 0 
. 0 

This 0 
cohort 0 
underwent 0 
follow-up 0 
for 0 
cancer 1
incidence 0 
through 0 
the 0 
Finnish 0 
Cancer 0 
Registry 0 
to 0 
the 0 
end 0 
of 0 
_NUM4 0 
. 0 

RESULTS 0 
A 0 
statistically 0 
significant 0 
excess 0 
risk 0 
of 0 
cancer 1
was 0 
seen 0 
among 0 
the 0 
patients 0 
with 0 
CHH 1
-LRB- 0 
standardized 0 
incidence 0 
ratio 0 
_NUM1 0 
. 0 

_NUM1 0 
, 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
_NUM1 0 
. 0 

_NUM1 0 
to 0 
_NUM2 0 
-RRB- 0 
, 0 
which 0 
was 0 
mainly 0 
attributable 0 
to 0 
non-Hodgkins 1
lymphoma 1
-LRB- 0 
standardized 0 
incidence 0 
ratio 0 
_NUM2 0 
, 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
_NUM2 0 
to 0 
_NUM3 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
a 0 
significant 0 
excess 0 
risk 0 
of 0 
basal 1
cell 1
carcinoma 1
was 0 
seen 0 
-LRB- 0 
standardized 0 
incidence 0 
ratio 0 
_NUM2 0 
, 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
_NUM1 0 
. 0 

_NUM1 0 
to 0 
_NUM3 0 
-RRB- 0 
. 0 

The 0 
cancer 1
incidence 0 
among 0 
the 0 
siblings 0 
or 0 
the 0 
parents 0 
did 0 
not 0 
differ 0 
from 0 
the 0 
average 0 
cancer 1
incidence 0 
in 0 
the 0 
Finnish 0 
population 0 
. 0 

CONCLUSIONS 0 
This 0 
study 0 
confirms 0 
an 0 
increased 0 
risk 0 
of 0 
cancer 1
, 0 
especially 0 
non-Hodgkins 1
lymphoma 1
, 0 
probably 0 
attributable 0 
to 0 
defective 0 
immunity 0 
, 0 
among 0 
patients 0 
with 0 
CHH 1
. 0 

Genetic 0 
polymorphism 0 
of 0 
G6PD 0
in 0 
a 0 
Bulgarian 0 
population 0 
. 0 

Considerable 0 
genetic 0 
heterogeneity 0 
in 0 
G6PD 0
was 0 
found 0 
in 0 
the 0 
Bulgarian 0 
population-14 0 
G6PD 0
variants 0 
isolated 0 
from 0 
_NUM3 0 
hemizygous 0 
carriers 0 
of 0 
G6PD 1
deficiency 1
. 0 

Of 0 
these 0 
, 0 
G6PD 0 
Mediterranean 0 
type 0 
was 0 
a 0 
polymorphic 0 
variant 0 
and 0 
G6PD 0 
Corinth 0 
occurred 0 
with 0 
high 0 
frequency 0 
. 0 

Two 0 
new 0 
variants 0 
were 0 
identified-G6PD 0 
Rudosem 0 
and 0 
G6PD 0 
Nedelino 0 
. 0 

In 0 
a 0 
selected 0 
group 0 
of 0 
_NUM2 0 
subjects 0 
with 0 
clinical 0 
manifestations 0 
, 0 
four 0 
variants 0 
were 0 
established 0 
G6PD 0 
Mediterranian 0 
, 0 
G6PD 0 
Corinth 0 
, 0 
G6PD 0 
Seattle 0 
and 0 
G6PD 0 
Ohut 0 
II 0 
. 0 
. 0 

A 0 
genetic 0 
etiology 0 
for 0 
DiGeorge 1
syndrome 1
: 0 
consistent 0 
deletions 0 
and 0 
microdeletions 0 
of 0 
22q11 0 
. 0 

DiGeorge 1
syndrome 1
-LRB- 0 
DGS 1
-RRB- 0 
, 0 
a 0 
developmental 0 
field 0 
defect 0 
of 0 
the 0 
third 0 
and 0 
fourth 0 
pharyngeal 0 
pouches 0 
, 0 
is 0 
characterized 0 
by 0 
aplasia 1
or 1
hypoplasia 1
of 1
the 1
thymus 1
and 1
parathyroid 1
glands 1
and 0 
by 0 
conotruncal 1
cardiac 1
malformations 1
. 0 

Cytogenetic 0 
studies 0 
support 0 
the 0 
presence 0 
of 0 
a 0 
DGS 1
critical 0 
region 0 
in 0 
band 0 
22q11 0 
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
we 0 
report 0 
the 0 
results 0 
of 0 
clinical 0 
, 0 
cytogenetic 0 
, 0 
and 0 
molecular 0 
studies 0 
of 0 
_NUM2 0 
patients 0 
with 0 
DGS 1
. 0 

Chromosome 0 
analysis 0 
, 0 
utilizing 0 
high-resolution 0 
banding 0 
techniques 0 
, 0 
detected 0 
interstitial 0 
deletions 0 
in 0 
five 0 
probands 0 
and 0 
was 0 
inconclusive 0 
for 0 
a 0 
deletion 0 
in 0 
three 0 
probands 0 
. 0 

The 0 
remaining 0 
six 0 
patients 0 
had 0 
normal 0 
karyotypes 0 
. 0 

In 0 
contrast 0 
, 0 
molecular 0 
analysis 0 
detected 0 
DNA 0 
deletions 0 
in 0 
all 0 
_NUM2 0 
probands 0 
. 0 

Two 0 
of 0 
_NUM2 0 
loci 0 
tested 0 
, 0 
D22S75 0 
and 0 
D22S259 0 
, 0 
are 0 
deleted 0 
in 0 
all 0 
_NUM2 0 
patients 0 
. 0 

A 0 
third 0 
locus 0 
, 0 
D22S66 0 
, 0 
is 0 
deleted 0 
in 0 
the 0 
eight 0 
DGS 1
probands 0 
tested 0 
. 0 

Physical 0 
mapping 0 
using 0 
somatic 0 
cell 0 
hybrids 0 
places 0 
D22S66 0 
between 0 
D22S75 0 
and 0 
D22S259 0 
, 0 
suggesting 0 
that 0 
it 0 
should 0 
be 0 
deleted 0 
in 0 
the 0 
remaining 0 
six 0 
cases 0 
. 0 

Parent-of-origin 0 
studies 0 
were 0 
performed 0 
in 0 
five 0 
families 0 
. 0 

Four 0 
probands 0 
failed 0 
to 0 
inherit 0 
a 0 
maternal 0 
allele 0 
, 0 
and 0 
one 0 
failed 0 
to 0 
inherit 0 
a 0 
paternal 0 
allele 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
these 0 
families 0 
, 0 
and 0 
of 0 
six 0 
maternally 0 
and 0 
five 0 
paternally 0 
derived 0 
unbalanced-translocation 0 
DGS 1
probands 0 
in 0 
the 0 
literature 0 
, 0 
parent 0 
of 0 
origin 0 
or 0 
imprinting 0 
does 0 
not 0 
appear 0 
to 0 
play 0 
an 0 
important 0 
role 0 
in 0 
the 0 
pathogenesis 0 
of 0 
DGS 1
. 0 

Deletion 0 
of 0 
the 0 
same 0 
three 0 
loci 0 
in 0 
all 0 
_NUM2 0 
DGS 1
probands 0 
begins 0 
to 0 
delineate 0 
the 0 
region 0 
of 0 
chromosome 0 
_NUM2 0 
critical 0 
for 0 
DGS 1
and 0 
confirms 0 
the 0 
hypothesis 0 
that 0 
submicroscopic 0 
deletions 0 
of 0 
22q11 0 
are 0 
etiologic 0 
in 0 
the 0 
vast 0 
majority 0 
of 0 
cases 0 
. 0 
. 0 

Characterisation 0 
of 0 
a 0 
new 0 
rare 0 
fragile 0
site 0 
easily 0 
confused 0 
with 0 
the 0 
fragile 1
X 1
. 0 

A 0 
new 0 
fragile 0 
site 0 
-LRB- 0 
FRAXE 0 
-RRB- 0 
in 0 
Xq28 0 
is 0 
described 0 
. 0 

It 0 
appears 0 
to 0 
be 0 
a 0 
typical 0 
folate 0 
sensitive 0 
fragile 0 
site 0 
. 0 

The 0 
fragile 0 
site 0 
is 0 
not 0 
associated 0 
with 0 
mental 1
retardation 1
, 0 
it 0 
does 0 
not 0 
give 0 
abnormal 0 
results 0 
when 0 
subjected 0 
to 0 
Southern 0 
analysis 0 
with 0 
probe 0 
pfxa3 0 
which 0 
detects 0 
the 0 
unstable 0 
DNA 0 
sequence 0 
characteristic 0 
of 0 
fragile 1
X 1
syndrome 1
. 0 

In 0 
situ 0 
hybridization 0 
mapping 0 
locates 0 
the 0 
fragile 0
site 0 
between 0 
_NUM3 0 
kb 0 
and 0 
_NUM3 0 
kb 0 
distal 0 
to 0 
FRAXA 0 
. 0 

The 0 
distinction 0 
between 0 
the 0 
two 0 
fragile 0
sites 0 
is 0 
important 0 
clinically 0 
since 0 
cytogenetic 0 
detection 0 
of 0 
FRAXE 0 
, 0 
without 0 
molecular 0 
analysis 0 
, 0 
could 0 
result 0 
in 0 
misdiagnosis 0 
of 0 
fragile 1
X 1
syndrome 1
. 0 
. 0 

BRCA1 0 
mutations 0 
in 0 
primary 0 
breast 1
and 1
ovarian 1
carcinomas 1
. 0 

Loss 0 
of 0 
heterozygosity 0 
data 0 
from 0 
familial 1
tumors 1
suggest 0 
that 0 
BRCA1 0 
, 0 
a 0 
gene 0 
that 0 
confers 0 
susceptibility 0 
to 0 
ovarian 1
and 1
early-onset 1
breast 1
cancer 1
, 0 
encodes 0 
a 0 
tumor 1
suppressor 0 
. 0 

The 0 
BRCA1 0 
region 0 
is 0 
also 0 
subject 0 
to 0 
allelic 0 
loss 0 
in 0 
sporadic 1
breast 1
and 1
ovarian 1
cancers 1
, 0 
an 0 
indication 0 
that 0 
BRCA1 0 
mutations 0 
may 0 
occur 0 
somatically 0 
in 0 
these 0 
tumors 1
. 0 

The 0 
BRCA1 0 
coding 0 
region 0 
was 0 
examined 0 
for 0 
mutations 0 
in 0 
primary 0 
breast 1
and 1
ovarian 1
tumors 1
that 0 
show 0 
allele 0 
loss 0 
at 0 
the 0 
BRCA1 0 
locus 0 
. 0 

Mutations 0 
were 0 
detected 0 
in 0 
_NUM1 0 
of 0 
_NUM2 0 
breast 0 
and 0 
_NUM1 0 
of 0 
_NUM2 0 
ovarian 1
carcinomas 1
; 0 
all 0 
four 0 
mutations 0 
were 0 
germline 0 
alterations 0 
and 0 
occurred 0 
in 0 
early-onset 0 
cancers 1
. 0 

These 0 
results 0 
suggest 0 
that 0 
mutation 0 
of 0 
BRCA1 0 
may 0 
not 0 
be 0 
critical 0 
in 0 
the 0 
development 0 
of 0 
the 0 
majority 0 
of 0 
breast 1
and 1
ovarian 1
cancers 1
that 0 
arise 0 
in 0 
the 0 
absence 0 
of 0 
a 0 
mutant 0 
germline 0 
allele 0 
. 0 
. 0 

Genomic 0 
structure 0 
of 0 
the 0 
EWS 0 
gene 0 
and 0 
its 0 
relationship 0 
to 0 
EWSR1 0 
, 0 
a 0 
site 0 
of 0 
tumor 1
associated 0 
chromosome 0 
translocation 0 
. 0 

The 0 
EWS 0 
gene 0 
has 0 
been 0 
identified 0 
based 0 
on 0 
its 0 
location 0 
at 0 
the 0 
chromosome 0 
_NUM2 0 
breakpoint 0 
of 0 
the 0 
t 0 
-LRB- 0 
_NUM2 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
-RRB- 0 
translocation 0 
that 0 
characterizes 0 
Ewing 1
sarcoma 1
and 0 
related 0 
neuroectodermal 1
tumors 1
. 0 

The 0 
EWS 0 
gene 0 
spans 0 
about 0 
_NUM2 0 
kb 0 
of 0 
DNA 0 
and 0 
is 0 
encoded 0 
by 0 
_NUM2 0 
exons 0 
. 0 

The 0 
nucleotide 0 
sequence 0 
of 0 
the 0 
exons 0 
is 0 
identical 0 
to 0 
that 0 
of 0 
the 0 
previously 0 
described 0 
cDNA 0 
. 0 

The 0 
first 0 
_NUM1 0 
exons 0 
encode 0 
the 0 
N-terminal 0 
domain 0 
of 0 
EWS 0 
, 0 
which 0 
consists 0 
of 0 
a 0 
repeated 0 
degenerated 0 
polypeptide 0 
of 0 
_NUM1 0 
to 0 
_NUM2 0 
residues 0 
rich 0 
in 0 
tyrosine 0 
, 0 
serine 0 
, 0 
threonine 0 
, 0 
glycine 0 
, 0 
and 0 
glutamine 0 
. 0 

Exons 0 
_NUM2 0 
, 0 
_NUM2 0 
, 0 
and 0 
_NUM2 0 
encode 0 
the 0 
putative 0 
RNA 0 
binding 0 
domain 0 
. 0 

The 0 
three 0 
glycine 0 
- 0 
and 0 
arginine-rich 0 
motifs 0 
of 0 
the 0 
gene 0 
are 0 
mainly 0 
encoded 0 
by 0 
exons 0 
8-9 0 
, 0 
_NUM2 0 
, 0 
and 0 
_NUM2 0 
. 0 

The 0 
DNA 0 
sequence 0 
in 0 
the 0 
_NUM1 0 
region 0 
of 0 
the 0 
gene 0 
has 0 
features 0 
of 0 
a 0 
CpG-rich 0 
island 0 
and 0 
lacks 0 
canonical 0 
promoter 0 
elements 0 
, 0 
such 0 
as 0 
_DS 0 
and 0 
_DS 0 
consensus 0 
sequences 0 
. 0 

Positions 0 
of 0 
the 0 
chromosome 0 
_NUM2 0 
breakpoints 0 
were 0 
determined 0 
for 0 
_NUM2 0 
Ewing 1
tumors 1
. 0 

They 0 
were 0 
localized 0 
in 0 
introns 0 
_NUM1 0 
or 0 
_NUM1 0 
in 0 
_NUM2 0 
cases 0 
and 0 
in 0 
intron 0 
_NUM2 0 
in 0 
_NUM1 0 
case 0 
. 0 
. 0 

PAX6 0 
mutations 0 
in 0 
aniridia 1
. 0 

Aniridia 1
is 0 
a 0 
congenital 1
malformation 1
of 1
the 1
eye 1
, 0 
chiefly 0 
characterised 0 
by 0 
iris 1
hypoplasia 1
, 0 
which 0 
can 0 
cause 0 
blindness 1
. 0 

The 0 
PAX6 0 
gene 0 
was 0 
isolated 0 
as 0 
a 0 
candidate 0 
aniridia 1
gene 0 
by 0 
positional 0 
cloning 0 
from 0 
the 0 
smallest 0 
region 0 
of 0 
overlap 0 
of 0 
aniridia 1
associated 0 
deletions 0 
. 0 

Subsequently 0 
PAX6 0 
intragenic 0 
mutations 0 
were 0 
demonstrated 0 
in 0 
Smalleye 0 
, 0 
a 0 
mouse 0 
mutant 0 
which 0 
is 0 
an 0 
animal 0 
model 0 
for 0 
aniridia 1
, 0 
and 0 
six 0 
human 0 
aniridia 1
patients 0 
. 0 

In 0 
this 0 
paper 0 
we 0 
describe 0 
four 0 
additional 0 
PAX6 0 
point 0 
mutations 0 
in 0 
aniridia 1
patients 0 
, 0 
both 0 
sporadic 0 
and 0 
familial 0 
. 0 

These 0 
mutations 0 
highlight 0 
regions 0 
of 0 
the 0 
gene 0 
which 0 
are 0 
essential 0 
for 0 
normal 0 
PAX6 0 
function 0 
. 0 

In 0 
addition 0 
, 0 
the 0 
frequency 0 
at 0 
which 0 
we 0 
have 0 
found 0 
PAX6 0 
mutations 0 
suggests 0 
that 0 
lesions 0 
in 0 
PAX6 0 
will 0 
account 0 
for 0 
most 0 
cases 0 
of 0 
aniridia 1
. 0 
. 0 

Mutations 0 
in 0 
the 0 
PAX6 0 
gene 0 
in 0 
patients 0 
with 0 
hereditary 0 
aniridia 1
. 0 

The 0 
_NUM2 0 
exons 0 
of 0 
the 0 
PAX6 0 
gene 0 
have 0 
been 0 
analysed 0 
exon-by-exon 0 
using 0 
SSCP 0 
in 0 
_NUM1 0 
aniridia 1
families 0 
. 0 

In 0 
each 0 
family 0 
band 0 
shifts 0 
were 0 
observed 0 
on 0 
the 0 
SSCP 0 
gels 0 
for 0 
only 0 
one 0 
exon 0 
and 0 
direct 0 
PCR-sequencing 0 
revealed 0 
mutations 0 
in 0 
each 0 
case 0 
. 0 

Two 0 
mutations 0 
involved 0 
C 0 
-- 0 
> 0 
T 0 
transitions 0 
in 0 
CGAarg 0 
codons 0 
in 0 
exons 0 
_NUM1 0 
and 0 
_NUM2 0 
. 0 

Another 0 
C 0 
-- 0 
> 0 
T 0 
transition 0 
converted 0 
a 0 
CAG-glutamine 0 
to 0 
a 0 
TAG-stop 0 
in 0 
exon 0 
_NUM1 0 
. 0 

Small 0 
insertions 0 
created 0 
frameshifts 0 
which 0 
produced 0 
downstream 0 
stop 0 
codons 0 
in 0 
another 0 
two 0 
patients 0 
and 0 
an 0 
A 0 
-- 0 
> 0 
T 0 
mutation 0 
disrupted 0 
the 0 
splice 0 
donor 0 
site 0 
of 0 
exon 0 
_NUM1 0 
in 0 
the 0 
remaining 0 
family 0 
. 0 

Thus 0 
, 0 
complete 0 
inactivation 0 
of 0 
the 0 
PAX6 0 
gene 0 
is 0 
predicted 0 
in 0 
all 0 
cases 0 
. 0 

Analysis 0 
of 0 
other 0 
affected 0 
members 0 
of 0 
the 0 
families 0 
showed 0 
that 0 
, 0 
in 0 
each 0 
case 0 
, 0 
all 0 
affected 0 
individuals 0 
carried 0 
the 0 
same 0 
family-specific 0 
mutation 0 
. 0 

One 0 
polymorphism 0 
was 0 
found 0 
in 0 
exon 0 
_NUM1 0 
. 0 

This 0 
data 0 
strongly 0 
supports 0 
the 0 
candidature 0 
of 0 
PAX6 0 
as 0 
the 0 
gene 0 
responsible 0 
for 0 
hereditary 0 
aniridia 1
. 0 
. 0 

Locus 0 
heterogeneity 0 
in 0 
Friedreich 1
ataxia 1
. 0 

Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
is 0 
the 0 
most 0 
common 0 
form 0 
of 0 
autosomal 1
recessive 1
ataxia 1
. 0 

The 0 
disease 0 
locus 0 
was 0 
assigned 0 
to 0 
chromosome 0 
_NUM1 0 
and 0 
the 0 
disease 0 
gene 0 
, 0 
STM7 0 
/ 0 
X25 0 
, 0 
has 0 
been 0 
isolated 0 
. 0 

To 0 
date 0 
most 0 
data 0 
suggest 0 
locus 0 
homogeneity 0 
in 0 
FRDA 1
. 0 

We 0 
now 0 
provide 0 
strong 0 
evidence 0 
of 0 
a 0 
second 0 
FRDA 1
locus 0 
. 0 

Studying 0 
two 0 
siblings 0 
with 0 
FRDA 1
from 0 
two 0 
families 0 
we 0 
did 0 
not 0 
detect 0 
a 0 
mutation 0 
in 0 
STM7 0 
/ 0 
X25 0 
. 0 

Haplotype 0 
analysis 0 
of 0 
the 0 
STM7 0 
/ 0 
X25 0 
region 0 
of 0 
chromosome 0 
_NUM1 0 
demonstrated 0 
that 0 
the 0 
relevant 0 
portion 0 
of 0 
chromosome 0 
_NUM1 0 
differs 0 
in 0 
the 0 
patients 0 
. 0 

Although 0 
the 0 
patients 0 
studied 0 
had 0 
typical 0 
FRDA 1
, 0 
one 0 
sibpair 0 
had 0 
the 0 
uncommon 0 
symptom 0 
of 0 
retained 0 
tendon 0 
reflexes 0 
. 0 

In 0 
order 0 
to 0 
investigate 0 
whether 0 
retained 0 
tendon 0 
reflexes 0 
are 0 
characteristic 0 
of 0 
FRDA 1
caused 0 
by 0 
the 0 
second 0 
locus 0 
, 0 
FRDA2 0 
, 0 
we 0 
studied 0 
an 0 
unrelated 0 
FRDA 1
patient 0 
with 0 
retained 0 
tendon 0 
reflexes 0 
. 0 

The 0 
observation 0 
of 0 
typical 0 
mutations 0 
in 0 
STM7 0 
/ 0 
X25 0 
-LRB- 0 
_DS 0 
expansions 0 
-RRB- 0 
in 0 
this 0 
patient 0 
demonstrates 0 
that 0 
the 0 
two 0 
genetically 0 
different 0 
forms 0 
of 0 
FRDA 1
can 0 
not 0 
be 0 
distinguished 0 
clinically 0 
. 0 
. 0 

Haploinsufficiency 1
of 1
the 1
transcription 1
factors 1
FOXC1 1
and 1
FOXC2 1
results 0 
in 0 
aberrant 0 
ocular 0 
development 0 
. 0 

Anterior 1
segment 1
developmental 1
disorders 1
, 0 
including 0 
Axenfeld-Rieger 1
anomaly 1
-LRB- 0 
ARA 1
-RRB- 0 
, 0 
variably 0 
associate 0 
with 0 
harmfully 0 
elevated 0 
intraocular 0 
pressure 0 
-LRB- 0 
IOP 0 
-RRB- 0 
, 0 
which 0 
causes 0 
glaucoma 1
. 0 

Clinically 0 
observed 0 
dysgenesis 0 
does 0 
not 0 
correlate 0 
with 0 
IOP 0 
, 0 
however 0 
, 0 
and 0 
the 0 
etiology 0 
of 0 
glaucoma 1
development 0 
is 0 
not 0 
understood 0 
. 0 

The 0 
forkhead 0 
transcription 0 
factor 0 
genes 0 
Foxc1 0 
-LRB- 0 
formerly 0 
Mf1 0 
-RRB- 0 
and 0 
Foxc2 0 
-LRB- 0 
formerly 0 
Mfh1 0 
-RRB- 0 
are 0 
expressed 0 
in 0 
the 0 
mesenchyme 0 
from 0 
which 0 
the 0 
ocular 0 
drainage 0 
structures 0 
derive 0 
. 0 

Mutations 0 
in 0 
the 0 
human 0 
homolog 0 
of 0 
Foxc1 0 
, 0 
FKHL7 0 
, 0 
cause 0 
dominant 0 
anterior 1
segment 1
defects 1
and 0 
glaucoma 1
in 0 
various 0 
families 0 
. 0 

We 0 
show 0 
that 0 
Foxc1 0 
-LRB- 0 
+ 0 
/ 0 
- 0 
-RRB- 0 
mice 0 
have 0 
anterior 1
segment 1
abnormalities 1
similar 0 
to 0 
those 0 
reported 0 
in 0 
human 0 
patients 0 
. 0 

These 0 
abnormalities 0 
include 0 
small 0 
or 0 
absent 0 
Schlemms 0 
canal 0 
, 0 
aberrantly 0 
developed 0 
trabecular 0 
meshwork 0 
, 0 
iris 1
hypoplasia 1
, 0 
severely 0 
eccentric 0 
pupils 0 
and 0 
displaced 0 
Schwalbes 0 
line 0 
. 0 

The 0 
penetrance 0 
of 0 
clinically 0 
obvious 0 
abnormalities 0 
varies 0 
with 0 
genetic 0 
background 0 
. 0 

In 0 
some 0 
affected 0 
eyes 0 
, 0 
collagen 0 
bundles 0 
were 0 
half 0 
normal 0 
diameter 0 
, 0 
or 0 
collagen 0 
and 0 
elastic 0 
tissue 0 
were 0 
very 0 
sparse 0 
. 0 

Thus 0 
, 0 
abnormalities 0 
in 0 
extracellular 0 
matrix 0 
synthesis 0 
or 0 
organization 0 
may 0 
contribute 0 
to 0 
development 0 
of 0 
the 0 
ocular 0 
phenotypes 0 
. 0 

Despite 0 
the 0 
abnormalities 0 
in 0 
ocular 0 
drainage 0 
structures 0 
in 0 
Foxc1 0 
-LRB- 0 
+ 0 
/ 0 
- 0 
-RRB- 0 
mice 0 
, 0 
IOP 0 
was 0 
normal 0 
in 0 
almost 0 
all 0 
mice 0 
analyzed 0 
, 0 
on 0 
all 0 
genetic 0 
backgrounds 0 
and 0 
at 0 
all 0 
ages 0 
. 0 

Similar 0 
abnormalities 0 
were 0 
found 0 
in 0 
Foxc2 0 
-LRB- 0 
+ 0 
/ 0 
- 0 
-RRB- 0 
mice 0 
, 0 
but 0 
no 0 
disease-associated 0 
mutations 0 
were 0 
identified 0 
in 0 
the 0 
human 0 
homolog 0 
FKHL14 0 
in 0 
_NUM2 0 
ARA 1
patients 0 
. 0 

Foxc1 0 
-LRB- 0 
+ 0 
/ 0 
- 0 
-RRB- 0 
and 0 
Foxc2 0 
-LRB- 0 
+ 0 
/ 0 
- 0 
-RRB- 0 
mice 0 
are 0 
useful 0 
models 0 
for 0 
studying 0 
anterior 0 
segment 0 
development 0 
and 0 
its 0 
anomalies 0 
, 0 
and 0 
may 0 
allow 0 
identification 0 
of 0 
genes 0 
that 0 
interact 0 
with 0 
Foxc1 0 
and 0 
Foxc2 0 
-LRB- 0 
or 0 
FKHL7 0 
and 0 
FKHL14 0 
-RRB- 0 
to 0 
produce 0 
a 0 
phenotype 0 
with 0 
elevated 0 
IOP 0 
and 0 
glaucoma 1
. 0 
. 0 

The 0 
dermatofibrosarcoma 1
protuberans 1
associated 0 
collagen 0 
type 0 
Ialpha1 0 
/ 0 
platelet-derived 0 
growth 0 
factor 0 
-LRB- 0 
PDGF 0 
-RRB- 0 
B-chain 0 
fusion 0 
gene 0 
generates 0 
a 0 
transforming 0 
protein 0 
that 0 
is 0 
processed 0 
to 0 
functional 0 
PDGF-BB 0 
. 0 

Dermatofibrosarcoma 1
protuberans 1
-LRB- 0 
DFSP 1
-RRB- 0 
displays 0 
chromosomal 0 
rearrangements 0 
involving 0 
chromosome 0 
_NUM2 0 
and 0 
_NUM2 0 
, 0 
which 0 
fuse 0 
the 0 
collagen 0 
type 0 
Ialpha1 0 
-LRB- 0 
COLIA1 0 
-RRB- 0 
gene 0 
to 0 
the 0 
platelet-derived 0 
growth 0 
factor 0 
-LRB- 0 
PDGF 0 
-RRB- 0 
B-chain 0 
-LRB- 0 
PDGFB 0 
-RRB- 0 
gene 0 
. 0 

To 0 
characterize 0 
the 0 
functional 0 
and 0 
structural 0 
properties 0 
of 0 
the 0 
COLIA1 0 
/ 0 
PDGFB 0 
fusion 0 
protein 0 
, 0 
we 0 
generated 0 
a 0 
stable 0 
NIH3T3 0 
cell 0 
line 0 
that 0 
contained 0 
a 0 
tumor 0 
derived 0 
chimeric 0 
gene 0 
resulting 0 
from 0 
a 0 
COIA1 0 
intron 0 
7-PDGFB 0 
intron 0 
_NUM1 0 
fusion 0 
. 0 

Expression 0 
of 0 
the 0 
fusion 0 
protein 0 
led 0 
to 0 
morphological 0 
transformation 0 
and 0 
increased 0 
growth 0 
rate 0 
of 0 
these 0 
cells 0 
. 0 

The 0 
PDGF 0 
receptor 0 
kinase 0 
inhibitor 0 
CGP57148B 0 
reversed 0 
the 0 
transformed 0 
phenotype 0 
and 0 
reduced 0 
the 0 
growth 0 
rate 0 
of 0 
COLIA1 0 
/ 0 
PDGFB-expressing 0 
cells 0 
but 0 
had 0 
no 0 
effects 0 
on 0 
control 0 
cells 0 
. 0 

The 0 
presence 0 
of 0 
dimeric 0 
COLIA1 0 
/ 0 
PDGFB 0 
precursors 0 
was 0 
demonstrated 0 
through 0 
PDGFB 0 
immunoprecipitations 0 
of 0 
metabolically 0 
labeled 0 
cells 0 
and 0 
also 0 
by 0 
PDGFB 0 
immunoprecipitations 0 
followed 0 
by 0 
immunoblotting 0 
with 0 
COLIA1 0 
antibodies 0 
. 0 

Pulse-chase 0 
studies 0 
demonstrated 0 
that 0 
the 0 
COLIA1 0 
/ 0 
PDGFB 0 
precursor 0 
was 0 
processed 0 
to 0 
an 0 
end 0 
product 0 
that 0 
was 0 
indistinguishable 0 
from 0 
wild-type 0 
PDGF-BB 0 
. 0 

Finally 0 
, 0 
COLIA1 0 
/ 0 
PDGFB-expressing 0 
cells 0 
generated 0 
tumors 1
after 0 
s. 0 
c 0 
c. 0 
injection 0 
into 0 
nude 0 
mice 0 
, 0 
and 0 
tumor 1
growth 0 
was 0 
reduced 0 
by 0 
treatment 0 
with 0 
CGP57148B 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
COLIA1 0 
/ 0 
PDGFB 0 
fusion 0 
associated 0 
with 0 
DFSP 1
contributes 0 
to 0 
tumor 1
development 0 
through 0 
ectopic 0 
production 0 
of 0 
PDGF-BB 0 
and 0 
the 0 
formation 0 
of 0 
an 0 
autocrine 0 
loop 0 
. 0 

Our 0 
findings 0 
, 0 
thus 0 
, 0 
suggest 0 
that 0 
PDGF 0 
receptors 0 
could 0 
be 0 
a 0 
target 0 
for 0 
pharmacological 0 
treatment 0 
of 0 
DFSP 1
and 0 
giant 1
cell 1
fibroblastoma 1
, 0 
e. 0 
g. 0 
, 0 
through 0 
the 0 
use 0 
of 0 
PDGF 0 
receptor 0 
kinase 0 
inhibitors 0 
such 0 
as 0 
CGP57148B 0 
. 0 

Founder 0 
effect 0 
of 0 
a 0 
prevalent 0 
phenylketonuria 1
mutation 0 
in 0 
the 0 
Oriental 0 
population 0 
. 0 

A 0 
missense 0 
mutation 0 
has 0 
been 0 
identified 0 
in 0 
the 0 
human 0 
phenylalanine 0 
hydroxylase 0 
-LSB- 0 
PAH 0 
; 0 
phenylalanine 0 
4-monooxygenase 0 
; 0 
L-phenylalanine 0 
, 0 
tetrahydrobiopterin 0 
oxygen 0 
oxidoreductase 0 
-LRB- 0 
4-hydroxylating 0 
-RRB- 0 
, 0 
EC 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

_NUM2 0 
. 0 

_NUM1 0 
-RSB- 0 
gene 0 
in 0 
a 0 
Chinese 0 
patient 0 
with 0 
classic 0 
phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
. 0 

A 0 
G-to-C 0 
transition 0 
at 0 
the 0 
second 0 
base 0 
of 0 
codon 0 
_NUM3 0 
in 0 
exon 0 
_NUM2 0 
of 0 
the 0 
gene 0 
results 0 
in 0 
the 0 
substitution 0 
of 0 
Pro413 0 
for 0 
Arg413 0 
in 0 
the 0 
mutant 0 
protein 0 
. 0 

This 0 
mutation 0 
-LRB- 0 
R413P 0 
-RRB- 0 
results 0 
in 0 
negligible 0 
enzymatic 0 
activity 0 
when 0 
expressed 0 
in 0 
heterologous 0 
mammalian 0 
cells 0 
and 0 
is 0 
compatible 0 
with 0 
a 0 
classic 0 
PKU 1
phenotype 0 
in 0 
the 0 
patient 0 
. 0 

Population 0 
genetic 0 
studies 0 
reveal 0 
that 0 
this 0 
mutation 0 
is 0 
tightly 0 
linked 0 
to 0 
restriction 0 
fragment 0 
length 0 
polymorphism 0 
haplotype 0 
_NUM1 0 
, 0 
which 0 
is 0 
the 0 
predominant 0 
haplotype 0 
of 0 
the 0 
PAH 0 
locus 0 
in 0 
the 0 
Oriental 0 
population 0 
. 0 

It 0 
accounts 0 
for 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
northern 0 
Chinese 0 
and 0 
_NUM2 0 
% 0 
of 0 
Japanese 0 
PKU 1
alleles 0 
, 0 
but 0 
it 0 
is 0 
rare 0 
in 0 
southern 0 
Chinese 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
is 0 
absent 0 
in 0 
the 0 
Caucasian 0 
population 0 
. 0 

The 0 
data 0 
demonstrate 0 
unambiguously 0 
that 0 
the 0 
mutation 0 
occurred 0 
after 0 
racial 0 
divergence 0 
of 0 
Orientals 0 
and 0 
Caucasians 0 
and 0 
suggest 0 
that 0 
the 0 
allele 0 
has 0 
spread 0 
throughout 0 
the 0 
Orient 0 
by 0 
a 0 
founder 0 
effect 0 
. 0 

Previous 0 
protein 0 
polymorphism 0 
studies 0 
in 0 
eastern 0 
Asia 0 
have 0 
led 0 
to 0 
the 0 
hypothesis 0 
that 0 
'' 0 
northern 0 
Mongoloids 0 
'' 0 
represented 0 
a 0 
founding 0 
population 0 
in 0 
Asia 0 
. 0 

Our 0 
results 0 
are 0 
compatible 0 
with 0 
this 0 
hypothesis 0 
in 0 
that 0 
the 0 
PKU 1
mutation 0 
might 0 
have 0 
occurred 0 
in 0 
northern 0 
Mongoloids 0 
and 0 
subsequently 0 
spread 0 
to 0 
the 0 
Chinese 0 
and 0 
Japanese 0 
populations 0 
. 0 

Late-onset 0 
familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
: 0 
a 0 
subset 0 
with 0 
distinct 0 
clinical 0 
, 0 
demographic 0 
, 0 
and 0 
molecular 0 
genetic 0 
characteristics 0 
. 0 

To 0 
determine 0 
the 0 
prevalence 0 
and 0 
characterize 0 
demographic 0 
, 0 
clinical 0 
, 0 
and 0 
genetic 0 
features 0 
of 0 
familial 1
Mediterranean 1
fever 1
-LRB- 0 
FMF 1
-RRB- 0 
of 0 
late 0 
onset 0 
, 0 
all 0 
patients 0 
experiencing 0 
their 0 
first 0 
FMF 1
attack 0 
at 0 
age 0 
_NUM2 0 
years 0 
or 0 
more 0 
were 0 
identified 0 
using 0 
the 0 
computerized 0 
registry 0 
of 0 
our 0 
FMF 1
clinic 0 
, 0 
and 0 
then 0 
thoroughly 0 
interviewed 0 
and 0 
examined 0 
. 0 

The 0 
control 0 
group 0 
consisted 0 
of 0 
_NUM2 0 
consecutive 0 
FMF 1
patients 0 
, 0 
who 0 
arrived 0 
at 0 
the 0 
FMF 1
clinic 0 
for 0 
their 0 
regular 0 
follow-up 0 
visit 0 
and 0 
were 0 
_NUM2 0 
years 0 
of 0 
age 0 
or 0 
older 0 
at 0 
the 0 
time 0 
of 0 
the 0 
examination 0 
. 0 

The 0 
severity 0 
of 0 
the 0 
disease 0 
in 0 
patients 0 
and 0 
controls 0 
was 0 
determined 0 
using 0 
a 0 
modified 0 
score 0 
, 0 
developed 0 
previously 0 
. 0 

Mutational 0 
analysis 0 
in 0 
the 0 
FMF 1
gene 0 
was 0 
performed 0 
using 0 
a 0 
commercial 0 
kit 0 
. 0 

Only 0 
_NUM2 0 
of 0 
_NUM4 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
patients 0 
had 0 
late-onset 0 
FMF 1
. 0 

These 0 
patients 0 
were 0 
mostly 0 
men 0 
, 0 
of 0 
non-North 0 
African 0 
origin 0 
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
compared 0 
to 0 
controls 0 
. 0 

All 0 
had 0 
abdominal 0 
attacks 0 
and 0 
in 0 
most 0 
these 0 
were 0 
the 0 
only 0 
manifestation 0 
of 0 
their 0 
disease 0 
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
_NUM3 0 
. 0 

None 0 
had 0 
chronic 0 
or 0 
prolonged 0 
manifestations 0 
of 0 
FMF 1
, 0 
for 0 
example 0 
, 0 
amyloidosis 1
, 0 
chronic 1
arthritis 1
, 0 
or 0 
protracted 0 
myalgia 1
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
. 0 

The 0 
response 0 
to 0 
treatment 0 
was 0 
good 0 
despite 0 
using 0 
low 0 
colchicine 0 
dose 0 
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

The 0 
overall 0 
severity 0 
score 0 
indicated 0 
a 0 
mild 0 
disease 0 
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
. 0 

Mutational 0 
analysis 0 
revealed 0 
absence 0 
of 0 
M694V 0 
homozygosity 0 
, 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
compared 0 
to 0 
our 0 
regular 0 
FMF 1
population 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
onset 0 
of 0 
FMF 1
in 0 
a 0 
late 0 
age 0 
defines 0 
a 0 
milder 0 
form 0 
of 0 
disease 0 
with 0 
typical 0 
clinical 0 
, 0 
demographic 0 
, 0 
and 0 
molecular 0 
genetic 0 
characteristics 0 
Structure 0 
of 0 
the 0 
human 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
gene 0 
SGLT1 0 
. 0 

Intestinal 0 
uptake 0 
of 0 
dietary 0 
glucose 0 
and 0 
galactose 0 
is 0 
mediated 0 
by 0 
the 0 
SGLT1 0 
Na 0 
+ 0 
/ 0 
glucose 0 
cotransporter 0 
of 0 
the 0 
brush 0 
border 0 
. 0 

An 0 
SGLT1 0 
missense 0 
mutation 0 
underlies 0 
hereditary 1
glucose 1
/ 1
galactose 1
malabsorption 1
, 0 
characterized 0 
by 0 
potentially 0 
fatal 0 
diarrhea 1
; 0 
conversely 0 
, 0 
oral 0 
rehydration 0 
therapy 0 
exploits 0 
normal 0 
transport 0 
to 0 
alleviate 0 
life-threatening 0 
diarrhea 1
of 0 
infectious 0 
origin 0 
. 0 

We 0 
have 0 
mapped 0 
the 0 
entire 0 
human 0 
SGLT1 0 
Na 0 
+ 0 
/ 0 
glucose 0
cotransporter 0 
gene 0 
from 0 
cosmid 0 
and 0 
lambda 0 
phage 0 
clones 0 
representing 0 
a 0 
genomic 0 
region 0 
of 0 
_NUM3 0 
kilobases 0 
. 0 

Transcription 0 
initiation 0 
occurred 0 
from 0 
a 0 
site 0 
_NUM2 0 
base 0 
pairs 0 
_NUM1 0 
of 0 
a 0 
_DS 0 
sequence 0 
. 0 

All 0 
exon-flanking 0 
regions 0 
were 0 
sequenced 0 
, 0 
and 0 
the 0 
entire 0 
112-kilobase 0 
region 0 
mapped 0 
with 0 
four 0 
restriction 0 
enzymes 0 
. 0 

SGLT1 0 
is 0 
comprised 0 
of 0 
_NUM2 0 
exons 0 
-LRB- 0 
spanning 0 
_NUM2 0 
kilobases 0 
-RRB- 0 
; 0 
a 0 
possible 0 
evolutionary 0 
origin 0 
from 0 
a 0 
six-membrane-span 0 
ancestral 0 
precursor 0 
via 0 
a 0 
gene 0 
duplication 0 
event 0 
is 0 
suggested 0 
from 0 
comparison 0 
of 0 
exons 0 
against 0 
protein 0 
secondary 0 
structure 0 
and 0 
from 0 
sequence 0 
considerations 0 
. 0 

A 0 
new 0 
missense 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
causing 0 
glucose 1
/ 1
galactose 1
malabsorption 1
is 0 
also 0 
described 0 
. 0 

This 0 
is 0 
the 0 
first 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
- 0 
dependent 0 
cotransporter 0 
gene 0 
structure 0 
reported 0 
. 0 

These 0 
data 0 
facilitate 0 
the 0 
search 0 
for 0 
new 0 
glucose 1
/ 1
galactose 1
malabsorption 1
related 0 
mutations 0 
in 0 
this 0 
important 0 
gene 0 
and 0 
provide 0 
a 0 
basis 0 
for 0 
future 0 
evolutionary 0 
comparisons 0 
with 0 
other 0 
Na 0 
-LRB- 0 
+ 0 
-RRB- 0 
- 0 
dependent 0 
cotransporters 0 
. 0 
. 0 

ATM 0 
phosphorylates 0 
p95 0 
/ 0 
nbs1 0 
in 0 
an 0 
S-phase 0 
checkpoint 0 
pathway 0 
. 0 

The 0 
rare 1
diseases 1
ataxia-telangiectasia 1
-LRB- 0 
_DS 1
-RRB- 0 
, 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
, 0 
and 0 
Nijmegen 1
breakage 1
syndrome 1
-LRB- 0 
NBS 1
-RRB- 0 
, 0 
with 0 
mutations 0 
in 0 
the 0 
p95 0 
/ 0 
nbs1 0 
gene 0 
, 0 
share 0 
a 0 
variety 0 
of 0 
phenotypic 1
abnormalities 1
such 0 
as 0 
chromosomal 1
instability 1
, 0 
radiation 0 
sensitivity 0 
and 0 
defects 0 
in 0 
cell-cycle 0 
checkpoints 0 
in 0 
response 0 
to 0 
ionizing 0 
radiation 0 
. 0 

The 0 
ATM 0 
gene 0 
encodes 0 
a 0 
protein 0 
kinase 0 
that 0 
is 0 
activated 0 
by 0 
ionizing 0 
radiation 0 
or 0 
radiomimetic 0 
drugs 0 
, 0 
whereas 0 
p95 0 
/ 0 
nbs1 0 
is 0 
part 0 
of 0 
a 0 
protein 0 
complex 0 
that 0 
is 0 
involved 0 
in 0 
responses 0 
to 0 
DNA 0 
double-strand 0 
breaks 0 
. 0 

Here 0 
, 0 
because 0 
of 0 
the 0 
similarities 0 
between 0 
_DS 0 
and 0 
NBS 1
, 0 
we 0 
evaluated 0 
the 0 
functional 0 
interactions 0 
between 0 
ATM 0 
and 0 
p95 0 
/ 0 
nbs1 0 
. 0 

Activation 0 
of 0 
the 0 
ATM 0 
kinase 0 
by 0 
ionizing 0 
radiation 0 
and 0 
induction 0 
of 0 
ATM-dependent 0 
responses 0 
in 0 
NBS 1
cells 0 
indicated 0 
that 0 
p95 0 
/ 0 
nbs1 0 
may 0 
not 0 
be 0 
required 0 
for 0 
signalling 0 
to 0 
ATM 0 
after 0 
ionizing 0 
radiation 0 
. 0 

However 0 
, 0 
p95 0 
/ 0 
nbs1 0 
was 0 
phosphorylated 0 
on 0 
serine 0 
_NUM3 0 
in 0 
an 0 
ATM-dependent 0 
manner 0 
in 0 
vitro 0 
and 0 
in 0 
vivo 0 
after 0 
ionizing 0 
radiation 0 
. 0 

A 0 
p95 0 
/ 0 
nbs1 0 
construct 0 
mutated 0 
at 0 
the 0 
ATM 0 
phosphorylation 0 
site 0 
abrogated 0 
an 0 
S-phase 0 
checkpoint 0 
induced 0 
by 0 
ionizing 0 
radiation 0 
in 0 
normal 0 
cells 0 
and 0 
failed 0 
to 0 
compensate 0 
for 0 
this 0 
functional 0 
deficiency 0 
in 0 
NBS 1
cells 0 
. 0 

These 0 
observations 0 
link 0 
ATM 0 
and 0 
p95 0 
/ 0 
nbs1 0 
in 0 
a 0 
common 0 
signalling 0 
pathway 0 
and 0 
provide 0 
an 0 
explanation 0 
for 0 
phenotypic 0 
similarities 0 
in 0 
these 0 
two 0 
diseases 0 
. 0 
. 0 

Two 0 
distinct 0 
mutations 0 
at 0 
a 0 
single 0 
BamHI 0 
site 0 
in 0 
phenylketonuria 1
. 0 

Classical 1
phenylketonuria 1
is 0 
an 0 
autosomal 1
recessive 1
disease 1
caused 0 
by 0 
a 0 
deficiency 1
of 1
hepatic 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

The 0 
abolition 0 
of 0 
an 0 
invariant 0 
BamHI 0 
site 0 
located 0 
in 0 
the 0 
coding 0 
sequence 0 
of 0 
the 0 
PAH 0 
gene 0 
-LRB- 0 
exon 0 
_NUM1 0 
-RRB- 0 
led 0 
to 0 
the 0 
recognition 0 
of 0 
two 0 
new 0 
point 0 
mutations 0 
at 0 
codon 0 
_NUM3 0 
and 0 
_NUM3 0 
-LRB- 0 
272gly 0 
-- 0 
stop 0 
and 0 
273ser 0 
-- 0 
phe 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

Both 0 
mutations 0 
were 0 
detected 0 
in 0 
north 0 
eastern 0 
France 0 
or 0 
Belgium 0 
and 0 
occurred 0 
on 0 
the 0 
background 0 
of 0 
RFLP 0 
haplotype 0 
_NUM1 0 
alleles 0 
. 0 

The 0 
present 0 
study 0 
supports 0 
the 0 
view 0 
that 0 
the 0 
clinical 0 
heterogeneity 0 
in 0 
PKU 1
is 0 
accounted 0 
for 0 
by 0 
the 0 
large 0 
variety 0 
of 0 
mutant 0 
genotypes 0 
associated 0 
with 0 
PAH 1
deficiencies 1
. 0 
. 0 

Functional 0 
link 0 
between 0 
ataxia-telangiectasia 1
and 0 
Nijmegen 1
breakage 1
syndrome 1
gene 0 
products 0 
. 0 

Ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
and 0 
Nijmegen 1
breakage 1
syndrome 1
-LRB- 0 
NBS 1
-RRB- 0 
are 0 
recessive 1
genetic 1
disorders 1
with 0 
susceptibility 0 
to 0 
cancer 1
and 0 
similar 0 
cellular 0 
phenotypes 0 
. 0 

The 0 
protein 0 
product 0 
of 0 
the 0 
gene 0 
responsible 0 
for 0 
A-T 1
, 0 
designated 0 
ATM 0 
, 0 
is 0 
a 0 
member 0 
of 0 
a 0 
family 0 
of 0 
kinases 0 
characterized 0 
by 0 
a 0 
carboxy-terminal 0 
phosphatidylinositol 0 
3-kinase-like 0 
domain 0 
. 0 

The 0 
NBS1 0 
protein 0 
is 0 
specifically 0 
mutated 0 
in 0 
patients 0 
with 0 
Nijmegen 1
breakage 1
syndrome 1
and 0 
forms 0 
a 0 
complex 0 
with 0 
the 0 
DNA 0 
repair 0 
proteins 0 
Rad50 0 
and 0 
Mrel1 0 
. 0 

Here 0 
we 0 
show 0 
that 0 
phosphorylation 0 
of 0 
NBS1 0 
, 0 
induced 0 
by 0 
ionizing 0 
radiation 0 
, 0 
requires 0 
catalytically 0 
active 0 
ATM 0 
. 0 

Complexes 0 
containing 0 
ATM 0 
and 0 
NBS1 0 
exist 0 
in 0 
vivo 0 
in 0 
both 0 
untreated 0 
cells 0 
and 0 
cells 0 
treated 0 
with 0 
ionizing 0 
radiation 0 
. 0 

We 0 
have 0 
identified 0 
two 0 
residues 0 
of 0 
NBS1 0 
, 0 
Ser 0 
_NUM3 0 
and 0 
Ser 0 
_NUM3 0 
that 0 
are 0 
phosphorylated 0 
in 0 
vitro 0 
by 0 
ATM 0 
and 0 
whose 0 
modification 0 
in 0 
vivo 0 
is 0 
essential 0 
for 0 
the 0 
cellular 0 
response 0 
to 0 
DNA 0 
damage 0 
. 0 

This 0 
response 0 
includes 0 
S-phase 0 
checkpoint 0 
activation 0 
, 0 
formation 0 
of 0 
the 0 
NBS1 0 
/ 0 
Mrel1 0 
/ 0 
Rad50 0 
nuclear 0 
foci 0 
and 0 
rescue 0 
of 0 
hypersensitivity 1
to 1
ionizing 1
radiation 1
. 0 

Together 0 
, 0 
these 0 
results 0 
demonstrate 0 
a 0 
biochemical 0 
link 0 
between 0 
cell-cycle 0 
checkpoints 0 
activated 0 
by 0 
DNA 0 
damage 0 
and 0 
DNA 0 
repair 0 
in 0 
two 0 
genetic 1
diseases 1
with 0 
overlapping 0 
phenotypes 0 
. 0 
. 0 

Structure 0 
and 0 
genomic 0 
sequence 0 
of 0 
the 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
kinase 0 
-RRB- 0 
gene 0 
. 0 

The 0 
mutation 0 
causing 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
has 0 
recently 0 
been 0 
identified 0 
as 0 
an 0 
unstable 0 
_DS 0 
trinucleotide 0 
repeat 0 
located 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
a 0 
gene 0 
encoding 0 
for 0 
a 0 
protein 0 
with 0 
putative 0 
serine-threonine 0 
protein 0 
kinase 0 
activity 0 
. 0 

In 0 
this 0 
report 0 
we 0 
present 0 
the 0 
genomic 0 
sequences 0 
of 0 
the 0 
human 0 
and 0 
murine 0 
DM 1
kinase 0 
gene 0 
. 0 

A 0 
comparison 0 
of 0 
these 0 
sequences 0 
with 0 
each 0 
other 0 
and 0 
with 0 
known 0 
cDNA 0 
sequences 0 
from 0 
both 0 
species 0 
, 0 
led 0 
us 0 
to 0 
predict 0 
a 0 
translation 0 
initiation 0 
codon 0 
, 0 
as 0 
well 0 
as 0 
determine 0 
the 0 
organization 0 
of 0 
the 0 
DM 1
kinase 0 
gene 0 
. 0 

Several 0 
polymorphisms 0 
within 0 
the 0 
human 0 
DM 1
kinase 0 
gene 0 
have 0 
been 0 
identified 0 
, 0 
and 0 
PCR 0 
assays 0 
to 0 
detect 0 
two 0 
of 0 
these 0 
are 0 
described 0 
. 0 

The 0 
complete 0 
sequence 0 
and 0 
characterization 0 
of 0 
the 0 
structure 0 
of 0 
the 0 
DM 1
kinase 0 
gene 0 
, 0 
as 0 
well 0 
as 0 
the 0 
identification 0 
of 0 
novel 0 
polymorphisms 0 
within 0 
the 0 
gene 0 
, 0 
represent 0 
an 0 
important 0 
step 0 
in 0 
a 0 
further 0 
understanding 0 
of 0 
the 0 
genetics 0 
of 0 
myotonic 1
dystrophy 1
and 0 
the 0 
molecular 0 
biology 0 
of 0 
the 0 
gene 0 
. 0 
. 0 

Identification 0 
of 0 
novel 0 
imprinted 0 
transcripts 0 
in 0 
the 0 
Prader-Willi 1
syndrome 1
and 0 
Angelman 1
syndrome 1
deletion 0 
region 0 
: 0 
further 0 
evidence 0 
for 0 
regional 0 
imprinting 0 
control 0 
. 0 

Deletions 0 
and 0 
other 0 
abnormalities 0 
of 0 
human 0 
chromosome 0 
15q11-q13 0 
are 0 
associated 0 
with 0 
two 0 
developmental 0 
disorders 0 
, 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
and 0 
Angelman 1
syndrome 1
-LRB- 0 
AS 1
-RRB- 0 
. 0 

Loss 0 
of 0 
expression 0 
of 0 
imprinted 0 
, 0 
paternally 0 
expressed 0 
genes 0 
has 0 
been 0 
implicated 0 
in 0 
PWS 1
. 0 

However 0 
, 0 
the 0 
number 0 
of 0 
imprinted 0 
genes 0 
that 0 
contribute 0 
to 0 
PWS 1
, 0 
and 0 
the 0 
range 0 
over 0 
which 0 
the 0 
imprinting 0 
signal 0 
acts 0 
to 0 
silence 0 
one 0 
copy 0 
of 0 
the 0 
gene 0 
in 0 
a 0 
parent-of-origin-specific 0 
manner 0 
, 0 
are 0 
unknown 0 
. 0 

To 0 
identify 0 
additional 0 
imprinted 0 
genes 0 
that 0 
could 0 
contribute 0 
to 0 
the 0 
PWS 1
phenotype 0 
and 0 
to 0 
understand 0 
the 0 
regional 0 
control 0 
of 0 
imprinting 0 
in 0 
15q11-q13 0 
, 0 
we 0 
have 0 
constructed 0 
an 0 
imprinted 0 
transcript 0 
map 0 
of 0 
the 0 
PWS-AS 0 
deletion 0 
interval 0 
. 0 

The 0 
imprinting 0 
status 0 
of 0 
_NUM2 0 
expressed 0 
sequence 0 
tags 0 
derived 0 
from 0 
the 0 
radiation-hybrid 0 
human 0 
transcript 0 
maps 0 
or 0 
physical 0 
maps 0 
was 0 
determined 0 
in 0 
a 0 
reverse 0 
transcriptase-PCR 0 
assay 0 
and 0 
correlated 0 
with 0 
the 0 
position 0 
of 0 
the 0 
transcripts 0 
on 0 
the 0 
physical 0 
map 0 
. 0 

Seven 0 
new 0 
paternally 0 
expressed 0 
transcripts 0 
localize 0 
to 0 
an 0 
approximately 0 
_NUM1 0 
. 0 

5-Mb 0 
domain 0 
surrounding 0 
the 0 
SNRPN-associated 0 
imprinting 0 
center 0 
, 0 
which 0 
already 0 
includes 0 
four 0 
imprinted 0 
, 0 
paternally 0 
expressed 0 
genes 0 
. 0 

All 0 
other 0 
tested 0 
new 0 
transcripts 0 
in 0 
the 0 
deletion 0 
region 0 
were 0 
expressed 0 
from 0 
both 0 
alleles 0 
. 0 

A 0 
domain 0 
of 0 
exclusive 0 
paternal 0 
expression 0 
surrounding 0 
the 0 
imprinting 0 
center 0 
suggests 0 
strong 0 
regional 0 
control 0 
of 0 
the 0 
imprinting 0 
process 0 
. 0 

This 0 
study 0 
provides 0 
the 0 
means 0 
for 0 
further 0 
investigation 0 
of 0 
additional 0 
genes 0 
that 0 
cause 0 
or 0 
modify 0 
the 0 
phenotypes 0 
associated 0 
with 0 
rearrangements 0 
of 0 
15q11-q13 0 
. 0 

Penetrances 0 
of 0 
BRCA1 0 
1675delA 0 
and 0 
1135insA 0 
with 0 
respect 0 
to 0 
breast 1
cancer 1
and 0 
ovarian 1
cancer 1
. 0 

For 0 
genetic 0 
counseling 0 
and 0 
predictive 0 
testing 0 
in 0 
families 0 
with 0 
inherited 1
breast-ovarian 1
cancer 1
, 0 
penetrances 0 
and 0 
expressions 0 
of 0 
the 0 
underlying 0 
mutations 0 
should 0 
be 0 
known 0 
. 0 

We 0 
have 0 
previously 0 
reported 0 
two 0 
BRCA1 0 
founder 0 
mutations 0 
in 0 
the 0 
Norwegian 0 
population 0 
. 0 

Index 0 
cases 0 
for 0 
the 0 
present 0 
study 0 
were 0 
found 0 
two 0 
different 0 
ways 0 
through 0 
a 0 
series 0 
of 0 
consecutive 0 
ovarian 1
cancers 1
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
and 0 
through 0 
our 0 
family 0 
cancer 1
clinic 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

Altogether 0 
, 0 
_NUM2 0 
of 0 
the 0 
patients 0 
had 0 
BRCA1 0 
1675delA 0 
, 0 
and 0 
_NUM2 0 
had 0 
1135insA 0 
. 0 

Their 0 
relatives 0 
were 0 
described 0 
with 0 
respect 0 
to 0 
absence 0 
/ 0 
presence 0 
of 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
. 0 

Of 0 
_NUM3 0 
living 0 
female 0 
relatives 0 
, 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
were 0 
tested 0 
for 0 
the 0 
presence 0 
of 0 
a 0 
mutation 0 
. 0 

No 0 
difference 0 
, 0 
in 0 
penetrance 0 
and 0 
expression 0 
, 0 
between 0 
the 0 
two 0 
mutations 0 
were 0 
found 0 
, 0 
whereas 0 
differences 0 
according 0 
to 0 
method 0 
of 0 
ascertainment 0 
were 0 
seen 0 
. 0 

The 0 
overall 0 
findings 0 
were 0 
that 0 
disease 0 
started 0 
to 0 
occur 0 
at 0 
age 0 
_NUM2 0 
years 0 
and 0 
that 0 
by 0 
age 0 
_NUM2 0 
years 0 
_NUM2 0 
% 0 
of 0 
the 0 
mutation-carrying 0 
women 0 
had 0 
experienced 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
. 0 

More 0 
ovarian 1
cancers 1
than 0 
breast 1
cancers 1
were 0 
recorded 0 
. 0 

Both 0 
penetrance 0 
and 0 
expression 0 
-LRB- 0 
breast 1
cancer 1
vs. 0 
ovarian 1
cancer 1
-RRB- 0 
were 0 
different 0 
from 0 
those 0 
in 0 
reports 0 
of 0 
the 0 
Ashkenazi 0 
founder 0 
mutations 0 
. 0 

Whether 0 
the 0 
reported 0 
differences 0 
reflect 0 
true 0 
differences 0 
and 0 
/ 0 
or 0 
methodological 0 
problems 0 
is 0 
discussed 0 
. 0 

An 0 
observed 0 
excess 0 
of 0 
mutation 0 
carriers 0 
could 0 
not 0 
be 0 
accounted 0 
for 0 
by 0 
methodological 0 
problems 0 
; 0 
possible 0 
explanations 0 
were 0 
a 0 
'' 0 
true 0 
'' 0 
low 0 
penetrance 0 
or 0 
preferential 0 
segregation 0 
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
subtotal 1
complement 1
C6 1
deficiency 1
. 0 

A 0 
carboxy-terminally 0 
truncated 0 
but 0 
functionally 0 
active 0 
C6 0 
. 0 

Individuals 0 
with 0 
subtotal 1
complement 1
C6 1
deficiency 1
possess 0 
a 0 
C6 0 
molecule 0 
that 0 
is 0 
_NUM2 0 
% 0 
shorter 0 
than 0 
normal 0 
C6 0 
and 0 
present 0 
in 0 
low 0 
but 0 
detectable 0 
concentrations 0 
-LRB- 0 
1-2 0 
% 0 
of 0 
the 0 
normal 0 
mean 0 
-RRB- 0 
. 0 

We 0 
now 0 
show 0 
that 0 
this 0 
dysmorphic 0 
C6 0 
is 0 
bactericidally 0 
active 0 
and 0 
lacks 0 
an 0 
epitope 0 
that 0 
was 0 
mapped 0 
to 0 
the 0 
most 0 
carboxy-terminal 0 
part 0 
of 0 
C6 0 
using 0 
C6 0 
cDNA 0 
fragments 0 
expressed 0 
as 0 
fusion 0 
proteins 0 
in 0 
the 0 
pUEX 0 
expression 0 
system 0 
. 0 

We 0 
thus 0 
predicted 0 
that 0 
the 0 
abnormal 0 
C6 0 
molecule 0 
might 0 
be 0 
carboxy-terminally 0 
truncated 0 
and 0 
sought 0 
a 0 
mutation 0 
in 0 
an 0 
area 0 
approximately 0 
_NUM2 0 
% 0 
from 0 
the 0 
carboxy-terminal 0 
end 0 
of 0 
the 0 
coding 0 
sequence 0 
. 0 

By 0 
sequencing 0 
PCR-amplified 0 
products 0 
from 0 
this 0 
region 0 
, 0 
we 0 
found 0 
, 0 
in 0 
three 0 
individuals 0 
from 0 
two 0 
families 0 
, 0 
a 0 
mutation 0 
that 0 
might 0 
plausibly 0 
be 0 
responsible 0 
for 0 
the 0 
defect 0 
. 0 

All 0 
three 0 
have 0 
an 0 
abnormal 0 
_NUM1 0 
splice 0 
donor 0 
site 0 
of 0 
intron 0 
_NUM2 0 
, 0 
which 0 
would 0 
probably 0 
prevent 0 
splicing 0 
. 0 

An 0 
in-frame 0 
stop 0 
codon 0 
is 0 
found 0 
_NUM2 0 
codons 0 
downstream 0 
from 0 
the 0 
intron 0 
boundary 0 
, 0 
which 0 
would 0 
lead 0 
to 0 
a 0 
truncated 0 
polypeptide 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
smaller 0 
than 0 
normal 0 
C6 0 
. 0 

This 0 
result 0 
was 0 
unexpected 0 
, 0 
as 0 
earlier 0 
studies 0 
mapped 0 
the 0 
C5b 0 
binding 0 
site 0 
, 0 
or 0 
a 0 
putative 0 
enzymatic 0 
region 0 
, 0 
to 0 
this 0 
part 0 
of 0 
C6 0 
. 0 

Interestingly 0 
, 0 
all 0 
three 0 
subjects 0 
were 0 
probably 0 
heterozygous 0 
for 0 
both 0 
subtotal 1
C6 1
and 1
complete 1
C6 1
deficiency 1
. 0 

Mutations 0 
of 0 
the 0 
VHL 1
gene 0 
in 0 
sporadic 1
renal 1
cell 1
carcinoma 1
: 0 
definition 0 
of 0 
a 0 
risk 0 
factor 0 
for 0 
VHL 1
patients 0 
to 0 
develop 0 
an 0 
RCC 1
. 0 

To 0 
investigate 0 
the 0 
nature 0 
of 0 
somatic 0 
von 1
Hippel-Lindau 1
-LRB- 0 
VHL 1
-RRB- 0 
mutations 0 
, 0 
we 0 
analyzed 0 
_NUM3 0 
primary 0 
sporadic 0 
human 0 
renal 1
cell 1
carcinomas 1
for 0 
mutations 0 
of 0 
the 0 
VHL 1
tumor 1
suppressor 0 
gene 0 
, 0 
using 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
and 0 
single-strand 0 
conformational 0 
polymorphism 0 
analysis 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
of 0 
DNA 0 
. 0 

We 0 
detected 0 
abnormal 0 
SSCP 0 
pattern 0 
in 0 
_NUM2 0 
samples 0 
. 0 

After 0 
sequencing 0 
, 0 
we 0 
identified 0 
microdeletions 0 
in 0 
_NUM2 0 
% 0 
of 0 
cases 0 
, 0 
microinsertions 0 
in 0 
_NUM2 0 
% 0 
, 0 
nonsense 0 
mutations 0 
in 0 
_NUM1 0 
% 0 
, 0 
and 0 
missense 0 
mutations 0 
in 0 
_NUM2 0 
% 0 
. 0 

Among 0 
these 0 
mutations 0 
, 0 
_NUM2 0 
% 0 
correspond 0 
to 0 
new 0 
mutations 0 
. 0 

VHL 1
mutations 0 
were 0 
found 0 
only 0 
in 0 
the 0 
nonpapillary 1
renal 1
cell 1
carcinoma 1
-LRB- 0 
RCC 1
-RRB- 0 
subtype 0 
, 0 
as 0 
previously 0 
reported 0 
. 0 

To 0 
compare 0 
somatic 0 
and 0 
germline 0 
mutations 0 
, 0 
we 0 
used 0 
the 0 
VHL 1
database 0 
, 0 
which 0 
includes 0 
_NUM3 0 
mutations 0 
. 0 

The 0 
study 0 
of 0 
mutational 0 
events 0 
revealed 0 
a 0 
significant 0 
difference 0 
between 0 
somatic 0 
and 0 
germline 0 
mutations 0 
with 0 
mutations 0 
leading 0 
to 0 
truncated 0 
proteins 0 
observed 0 
in 0 
_NUM2 0 
% 0 
of 0 
somatic 0 
mutations 0 
vs 0 
only 0 
_NUM2 0 
% 0 
in 0 
germline 0 
mutations 0 
-LRB- 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

We 0 
postulated 0 
that 0 
a 0 
specific 0 
pattern 0 
of 0 
VHL 1
mutations 0 
is 0 
associated 0 
with 0 
sporadic 1
RCC 1
. 0 

This 0 
pattern 0 
corresponds 0 
to 0 
mutations 0 
leading 0 
mainly 0 
to 0 
truncated 0 
proteins 0 
with 0 
few 0 
specific 0 
missense 0 
mutations 0 
. 0 

We 0 
then 0 
analyzed 0 
the 0 
occurrence 0 
of 0 
RCC 1
in 0 
VHL 1
families 0 
, 0 
based 0 
on 0 
the 0 
nature 0 
of 0 
mutations 0 
. 0 

We 0 
observed 0 
RCC 1
in 0 
at 0 
least 0 
one 0 
member 0 
of 0 
the 0 
VHL 1
families 0 
in 0 
_NUM2 0 
% 0 
of 0 
cases 0 
with 0 
mutations 0 
leading 0 
to 0 
truncated 0 
proteins 0 
versus 0 
_NUM2 0 
% 0 
in 0 
cases 0 
with 0 
missense 0 
mutations 0 
-LRB- 0 
P 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Thus 0 
, 0 
mutations 0 
resulting 0 
in 0 
truncated 0 
proteins 0 
may 0 
lead 0 
to 0 
a 0 
higher 0 
risk 0 
of 0 
RCC 1
in 0 
VHL 1
patients 0 
Evidence 0 
for 0 
inter-generational 0 
instability 0 
in 0 
the 0 
_DS 0 
repeat 0 
in 0 
the 0 
MJD1 0 
gene 0 
and 0 
for 0 
conserved 0 
haplotypes 0 
at 0 
flanking 0 
markers 0 
amongst 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
with 0 
Machado-Joseph 1
disease 1
. 0 

The 0 
size 0 
of 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
array 0 
in 0 
the 0 
_NUM1 0 
' 0 
end 0 
of 0 
the 0 
MJD1 0 
gene 0 
and 0 
the 0 
haplotype 0 
at 0 
a 0 
series 0 
of 0 
microsatellite 0 
markers 0 
surrounding 0 
the 0 
MJD1 0 
gene 0 
were 0 
examined 0 
in 0 
a 0 
large 0 
cohort 0 
of 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
affected 0 
with 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
. 0 

Our 0 
data 0 
provide 0 
five 0 
novel 0 
observations 0 
. 0 

First 0 
, 0 
MJD 1
is 0 
associated 0 
with 0 
expansion 0 
fo 0 
the 0 
array 0 
from 0 
the 0 
normal 0 
range 0 
of 0 
14-37 0 
repeats 0 
to 0 
68-84 0 
repeats 0 
in 0 
most 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
, 0 
but 0 
no 0 
subjects 0 
were 0 
observed 0 
with 0 
expansions 0 
intermediate 0 
in 0 
size 0 
between 0 
those 0 
of 0 
the 0 
normal 0 
and 0 
MJD 1
affected 0 
groups 0 
. 0 

Second 0 
, 0 
the 0 
expanded 0 
allele 0 
associated 0 
with 0 
MJD 1
displays 0 
inter-generational 0 
instability 0 
, 0 
particularly 0 
in 0 
male 0 
meioses 0 
, 0 
and 0 
this 0 
instability 0 
was 0 
associated 0 
with 0 
the 0 
clinical 0 
phenomenon 0 
of 0 
anticipation 0 
. 0 

Third 0 
, 0 
the 0 
size 0 
of 0 
the 0 
expanded 0 
allele 0 
is 0 
not 0 
only 0 
inversely 0 
correlated 0 
with 0 
the 0 
age-of-onset 0 
of 0 
MJD 1
-LRB- 0 
r 0 
= 0 
-0.738 0 
, 0 
p 0 
< 0 
_FN 0 
-RRB- 0 
, 0 
but 0 
is 0 
also 0 
correlated 0 
with 0 
the 0 
frequency 0 
of 0 
other 0 
clinical 0 
features 0 
-LSB- 0 
e.g. 0 
pseudoexophthalmos 0 
and 0 
pyramidal 0 
signs 0 
were 0 
more 0 
frequent 0 
in 0 
subjects 0 
with 0 
large 0 
repeats 0 
-LRB- 0 
p 0 
< 0 
_FN 0 
and 0 
p 0 
< 0 
_FN 0 
respectively 0 
-RRB- 0 
-RSB- 0 
. 0 

Fourth 0 
, 0 
the 0 
disease 0 
phenotype 0 
is 0 
significantly 0 
more 0 
severe 0 
and 0 
had 0 
an 0 
early 0 
age 0 
of 0 
onset 0 
-LRB- 0 
_NUM2 0 
years 0 
-RRB- 0 
in 0 
a 0 
subject 0 
homozygous 0 
for 0 
the 0 
expanded 0 
allele 0 
, 0 
which 0 
contrasts 0 
with 0 
Huntington 1
disease 1
and 0 
suggests 0 
that 0 
the 0 
expanded 0 
allele 0 
in 0 
the 0 
MJD1 0 
gene 0 
could 0 
exert 0 
its 0 
effect 0 
either 0 
by 0 
a 0 
dominant 0 
negative 0 
effect 0 
-LRB- 0 
putatively 0 
excluded 0 
in 0 
HD 1
-RRB- 0 
or 0 
by 0 
a 0 
gain 0 
of 0 
function 0 
effect 0 
as 0 
proposed 0 
for 0 
HD 1
. 0 

Finally 0 
, 0 
Japanese 0 
and 0 
Caucasian 0 
subjects 0 
affected 0 
with 0 
MJD 1
share 0 
haplotypes 0 
at 0 
several 0 
markers 0 
surrounding 0 
the 0 
MJD1 0 
gene 0 
, 0 
which 0 
are 0 
uncommon 0 
in 0 
the 0 
normal 0 
Japanese 0 
and 0 
Caucasian 0 
population 0 
, 0 
and 0 
which 0 
suggests 0 
the 0 
existence 0 
either 0 
of 0 
common 0 
founders 0 
in 0 
these 0 
populations 0 
or 0 
of 0 
chromosomes 0 
susceptible 0 
to 0 
pathologic 0 
expansion 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
the 0 
MJD1 0 
gene 0 
. 0 

Myotonic 1
dystrophy 1
: 0 
the 0 
role 0 
of 0 
the 0 
CUG 0 
triplet 0 
repeats 0 
in 0 
splicing 0 
of 0 
a 0 
novel 0 
DMPK 0 
exon 0 
and 0 
altered 0 
cytoplasmic 0 
DMPK 0 
mRNA 0 
isoform 0 
ratios 0 
. 0 

The 0 
mechanism 0 
by 0 
which 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
expansion 0 
in 0 
the 0 
_NUM1 0 
UTR 0 
of 0 
the 0 
DMPK 0 
gene 0 
causes 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
unknown 0 
. 0 

We 0 
identified 0 
four 0 
RNA 0 
splicing 0 
factors 0 
-- 0 
hnRNP 0 
C 0 
, 0 
U2AF 0 
-LRB- 0 
U2 0 
auxiliary 0 
factor 0 
-RRB- 0 
, 0 
PTB 0 
-LRB- 0 
polypyrimidine 0 
tract 0 
binding 0 
protein 0 
-RRB- 0 
, 0 
and 0 
PSF 0 
-LRB- 0 
PTB 0 
associated 0 
splicing 0 
factor 0 
-RRB- 0 
-- 0 
that 0 
bind 0 
to 0 
two 0 
short 0 
regions 0 
_NUM1 0 
of 0 
the 0 
-LRB- 0 
CUG 0 
-RRB- 0 
n 0 
, 0 
and 0 
found 0 
a 0 
novel 0 
_NUM1 0 
DMPK 0 
exon 0 
resulting 0 
in 0 
an 0 
mRNA 0 
lacking 0 
the 0 
repeats 0 
. 0 

We 0 
propose 0 
that 0 
the 0 
-LRB- 0 
CUG 0 
-RRB- 0 
n 0 
is 0 
an 0 
essential 0 
cis 0 
acting 0 
element 0 
for 0 
this 0 
splicing 0 
event 0 
. 0 

In 0 
contrast 0 
to 0 
-LRB- 0 
CUG 0 
-RRB- 0 
n 0 
containing 0 
mRNAs 0 
, 0 
the 0 
novel 0 
isoform 0 
is 0 
not 0 
retained 0 
in 0 
the 0 
nucleus 0 
in 0 
DM 1
cells 0 
, 0 
resulting 0 
in 0 
imbalances 0 
in 0 
relative 0 
levels 0 
of 0 
cytoplasmic 0 
DMPK 0 
mRNA 0 
isoforms 0 
and 0 
a 0 
new 0 
dominant 0 
effect 0 
of 0 
the 0 
mutation 0 
on 0 
DMPK 0 
. 0 
. 0 

Mechanism 0 
of 0 
increased 0 
iron 0 
absorption 0 
in 0 
murine 0 
model 0 
of 0 
hereditary 1
hemochromatosis 1
: 0 
increased 0 
duodenal 0 
expression 0 
of 0 
the 0 
iron 0 
transporter 0 
DMT1 0 
. 0 

Hereditary 1
hemochromatosis 1
-LRB- 0 
HH 1
-RRB- 0 
is 0 
a 0 
common 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
tissue 0 
iron 0 
deposition 0 
secondary 0 
to 0 
excessive 0 
dietary 0 
iron 0 
absorption 0 
. 0 

We 0 
recently 0 
reported 0 
that 0 
HFE 0 
, 0 
the 0 
protein 0 
defective 0 
in 0 
HH 1
, 0 
was 0 
physically 0 
associated 0 
with 0 
the 0 
transferrin 0 
receptor 0 
-LRB- 0 
TfR 0 
-RRB- 0 
in 0 
duodenal 0 
crypt 0 
cells 0 
and 0 
proposed 0 
that 0 
mutations 0 
in 0 
HFE 0 
attenuate 0 
the 0 
uptake 0 
of 0 
transferrin-bound 0 
iron 0 
from 0 
plasma 0 
by 0 
duodenal 0 
crypt 0 
cells 0 
, 0 
leading 0 
to 0 
up-regulation 0 
of 0 
transporters 0 
for 0 
dietary 0
iron 0 
. 0 

Here 0 
, 0 
we 0 
tested 0 
the 0 
hypothesis 0 
that 0 
HFE 0 
- 0 
/ 0 
- 0 
mice 0 
have 0 
increased 0 
duodenal 0 
expression 0 
of 0 
the 0 
divalent 0 
metal 0 
transporter 0 
-LRB- 0 
DMT1 0 
-RRB- 0 
. 0 

By 0 
_NUM1 0 
weeks 0 
of 0 
age 0 
, 0 
the 0 
HFE 0 
- 0 
/ 0 
- 0 
mice 0 
demonstrated 0 
iron 0 
loading 0 
when 0 
compared 0 
with 0 
HFE 0 
+ 0 
/ 0 
+ 0 
littermates 0 
, 0 
with 0 
elevated 0 
transferrin 0 
saturations 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
vs. 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
elevated 0 
liver 0 
iron 0 
concentrations 0 
-LRB- 0 
_NUM3 0 
micrograms 0 
vs. 0 
_NUM3 0 
micrograms 0 
-RRB- 0 
. 0 

By 0 
using 0 
Northern 0 
blot 0 
analyses 0 
, 0 
we 0 
quantitated 0 
duodenal 0 
expression 0 
of 0 
both 0 
classes 0 
of 0 
DMT1 0 
transcripts 0 
one 0 
containing 0 
an 0 
iron 0 
responsive 0 
element 0 
-LRB- 0 
IRE 0 
-RRB- 0 
, 0 
called 0 
DMT1 0 
-LRB- 0 
IRE 0 
-RRB- 0 
, 0 
and 0 
one 0 
containing 0 
no 0 
IRE 0 
, 0 
called 0 
DMT1 0 
-LRB- 0 
non-IRE 0 
-RRB- 0 
. 0 

The 0 
positive 0 
control 0 
for 0 
DMT1 0 
up-regulation 0 
was 0 
a 0 
murine 0 
model 0 
of 0 
dietary 1
iron 1
deficiency 1
that 0 
demonstrated 0 
greatly 0 
increased 0 
levels 0 
of 0 
duodenal 0 
DMT1 0 
-LRB- 0 
IRE 0 
-RRB- 0 
mRNA 0 
. 0 

HFE 0 
- 0 
/ 0 
- 0 
mice 0 
also 0 
demonstrated 0 
an 0 
increase 0 
in 0 
duodenal 0 
DMT1 0 
-LRB- 0 
IRE 0 
-RRB- 0 
mRNA 0 
-LRB- 0 
average 0 
_NUM1 0 
. 0 

7-fold 0 
-RRB- 0 
, 0 
despite 0 
their 0 
elevated 0 
transferrin 0 
saturation 0 
and 0 
hepatic 0 
iron 0 
content 0 
. 0 

Duodenal 0 
expression 0 
of 0 
DMT1 0 
-LRB- 0 
non-IRE 0 
-RRB- 0 
was 0 
not 0 
increased 0 
, 0 
nor 0 
was 0 
hepatic 0 
expression 0 
of 0 
DMT1 0 
increased 0 
. 0 

These 0 
data 0 
support 0 
the 0 
model 0 
for 0 
HH 0 
in 0 
which 0 
HFE 0 
mutations 0 
lead 0 
to 0 
inappropriately 0 
low 0 
crypt 0 
cell 0 
iron 0 
, 0 
with 0 
resultant 0 
stabilization 0 
of 0 
DMT1 0 
-LRB- 0 
IRE 0 
-RRB- 0 
mRNA 0 
, 0 
up-regulation 0 
of 0 
DMT1 0 
, 0 
and 0 
increased 0 
absorption 0 
of 0 
dietary 0 
iron 0 
. 0 

Yeast 0 
artificial 0 
chromosomes 0 
for 0 
the 0 
molecular 0 
analysis 0 
of 0 
the 0 
familial 1
polyposis 1
APC 1
gene 0 
region 0 
. 0 

Two 0 
yeast 0 
artificial 0 
chromosomes 0 
-LRB- 0 
YACs 0 
-RRB- 0 
spanning 0 
a 0 
total 0 
distance 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
megabase 0 
pairs 0 
of 0 
DNA 0 
around 0 
the 0 
MCC 0 
-LRB- 0 
for 0 
mutated 0 
in 0 
colorectal 1
carcinoma 1
-RRB- 0 
and 0 
APC 1
-LRB- 0 
for 0 
adenomatous 1
polyposis 1
coli 1
-RRB- 0 
genes 0 
at 0 
5q21 0 
have 0 
been 0 
isolated 0 
and 0 
characterized 0 
. 0 

Starting 0 
from 0 
the 0 
MCC 0 
gene 0 
, 0 
a 0 
strategy 0 
was 0 
undertaken 0 
to 0 
identify 0 
constitutional 0 
submicroscopic 0 
deletions 0 
in 0 
familial 1
adenomatous 1
polyposis 1
patients 0 
that 0 
might 0 
considerably 0 
narrow 0 
down 0 
the 0 
position 0 
of 0 
the 0 
APC 1
gene 0 
. 0 

To 0 
this 0 
end 0 
, 0 
YACs 0 
identified 0 
by 0 
the 0 
MCC 0 
gene 0 
were 0 
screened 0 
across 0 
a 0 
chromosome 0 
5-specific 0 
cosmid 0 
library 0 
to 0 
provide 0 
a 0 
source 0 
of 0 
DNA 0 
probes 0 
for 0 
genomic 0 
scanning 0 
. 0 

The 0 
cosmids 0 
isolated 0 
from 0 
these 0 
experiments 0 
were 0 
used 0 
to 0 
screen 0 
a 0 
panel 0 
of 0 
somatic 0 
cell 0 
hybrids 0 
containing 0 
chromosome 0 
_NUM1 0 
segregated 0 
from 0 
patients 0 
suspected 0 
to 0 
carry 0 
putative 0 
interstitial 0 
deletions 0 
. 0 

This 0 
screening 0 
approach 0 
led 0 
to 0 
the 0 
confirmation 0 
of 0 
a 0 
small 0 
heterozygous 0 
deletion 0 
in 0 
a 0 
polyposis 1
patient 0 
that 0 
overlaps 0 
one 0 
of 0 
the 0 
two 0 
isolated 0 
YACs 0 
. 0 

This 0 
YAC 0 
has 0 
been 0 
shown 0 
to 0 
contain 0 
the 0 
entire 0 
APC 1
gene 0 
, 0 
in 0 
addition 0 
to 0 
a 0 
significant 0 
portion 0 
of 0 
DNA 0 
flanking 0 
the 0 
_NUM1 0 
end 0 
of 0 
the 0 
gene 0 
, 0 
and 0 
should 0 
therefore 0 
prove 0 
a 0 
valuable 0 
resource 0 
for 0 
functional 0 
studies 0 
by 0 
transfer 0 
to 0 
colorectal 1
tumor 1
derived 0 
cell 0 
lines 0 
. 0 

Analbuminemia 1
in 0 
an 0 
American 0 
Indian 0 
girl 0 
. 0 

Analbuminemia 1
was 0 
fortuitously 0 
detected 0 
in 0 
a 0 
nonedematous 0 
12-year-old 0 
American 0 
Indian 0 
girl 0 
with 0 
atopic 1
dermatitis 1
, 0 
mild 0 
bronchial 1
asthma 1
, 0 
a 0 
mild 0 
seizure 1
disorder 1
, 0 
and 0 
hyperlipoproteinemia 1
with 0 
a 0 
corneal 1
arcus 1
. 0 

Immunologic 0 
methods 0 
revealed 0 
trace 0 
amounts 0 
-LRB- 0 
_NUM2 0 
mg 0 
/ 0 
100 0 
ml 0 
-RRB- 0 
of 0 
apparently 0 
normal 0 
serum 0 
albumin 0 
. 0 

The 0 
patients 0 
parents 0 
were 0 
remotely 0 
related 0 
. 0 

The 0 
pedigree 0 
and 0 
clinical 0 
findings 0 
were 0 
compatible 0 
with 0 
autosomal 0 
recessive 0 
transmission 0 
of 0 
analbuminemia 1
. 0 

Heterozygotes 0 
had 0 
subnormal 0 
levels 0 
of 0 
serum 0 
albumin 0 
. 0 

The 0 
Gc-locus 0 
is 0 
closely 0 
linked 0 
to 0 
the 0 
structural 0 
albumin 0 
locus 0 
. 0 

Gc-protein 0 
levels 0 
were 0 
normal 0 
in 0 
the 0 
patient 0 
and 0 
together 0 
with 0 
normal 0 
chromosomal 0 
banding 0 
studies 0 
make 0 
it 0 
unlikely 0 
that 0 
a 0 
chromosomal 0 
deletion 0 
caused 0 
analbuminemia 1
. 0 

Gc-types 0 
in 0 
the 0 
family 0 
were 0 
compatible 0 
with 0 
, 0 
but 0 
did 0 
not 0 
prove 0 
, 0 
linkage 0 
of 0 
analbuminemia 1
to 0 
the 0 
Gc-locus 0 
. 0 

These 0 
findings 0 
suggest 0 
a 0 
'' 0 
thalassemia 1
'' 0 
- 0 
like 0 
mutation 0 
for 0 
this 0 
disorder 0 
. 0 
. 0 

Treatment 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
with 0 
growth 0 
hormone 0 
inhibitors 0 
. 0 

A 0 
controlled 0 
, 0 
double-blind 0 
therapeutic 0 
trial 0 
with 0 
the 0 
drug 0 
mazindol 0 
, 0 
a 0 
growth 0 
hormone 0 
inhibitor 0 
, 0 
was 0 
performed 0 
in 0 
a 0 
pair 0 
of 0 
7 1 0 
/ 0 
2 0 
year-old 0 
monozygotic 0 
twins 0 
, 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

The 0 
rationale 0 
for 0 
this 0 
trial 0 
was 0 
based 0 
on 0 
a 0 
patient 0 
-LRB- 0 
reported 0 
previously 0 
-RRB- 0 
affected 0 
simultaneously 0 
with 0 
DMD 1
and 0 
growth 1
hormone 1
-LRB- 1
GH 1
-RRB- 1
deficiency 1
, 0 
who 0 
is 0 
showing 0 
a 0 
benign 0 
course 0 
of 0 
the 0 
dystrophic 1
process 1
and 0 
is 0 
still 0 
walking 0 
at 0 
_NUM2 0 
years 0 
. 0 

One 0 
of 0 
the 0 
twins 0 
received 0 
_NUM1 0 
mg 0 
of 0 
mazindol 0 
daily 0 
, 0 
while 0 
the 0 
other 0 
received 0 
a 0 
placebo 0 
. 0 

The 0 
assessment 0 
, 0 
repeated 0 
every 0 
_NUM1 0 
months 0 
, 0 
included 0 
weight 0 
and 0 
height 0 
measurements 0 
, 0 
functional 0 
and 0 
motor 0 
ability 0 
tests 0 
, 0 
ergometry 0 
and 0 
determinations 0 
of 0 
serum 0 
enzymes 0 
and 0 
GH 0 
levels 0 
. 0 

After 0 
one 0 
year 0 
of 0 
trial 0 
the 0 
code 0 
was 0 
broken 0 
and 0 
it 0 
was 0 
seen 0 
that 0 
the 0 
twin 0 
under 0 
placebo 0 
treatment 0 
was 0 
strikingly 0 
worse 0 
than 0 
his 0 
brother 0 
, 0 
the 0 
progression 0 
of 0 
whose 0 
condition 0 
was 0 
practically 0 
arrested 0 
. 0 

These 0 
results 0 
strongly 0 
suggest 0 
that 0 
treatment 0 
with 0 
a 0 
GH 0 
inhibitor 0 
is 0 
beneficial 0 
for 0 
DMD 1
patients 0 
. 0 
. 0 

Identification 0 
of 0 
WASP 0 
mutations 0 
in 0 
patients 0 
with 0 
Wiskott-Aldrich 1
syndrome 1
and 0 
isolated 1
thrombocytopenia 1
reveals 0 
allelic 0 
heterogeneity 0 
at 0 
the 0 
WAS 1
locus 0 
. 0 

Mutation 0 
in 0 
the 0 
gene 0 
encoding 0 
the 0 
recently 0 
isolated 0 
WASP 0 
protein 0 
has 0 
now 0 
been 0 
identified 0 
as 0 
the 0 
genetic 1
defect 1
responsible 0 
for 0 
the 0 
X-linked 1
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
, 0 
a 0 
primary 0 
immunodeficiency 1
disease 1
associated 0 
with 0 
extensive 0 
phenotypic 0 
variability 0 
. 0 

To 0 
elucidate 0 
the 0 
range 0 
of 0 
WASP 0 
mutations 0 
responsible 0 
for 0 
WAS 1
, 0 
we 0 
used 0 
PCR-SSCP 0 
analysis 0 
to 0 
screen 0 
for 0 
WASP 0 
gene 0 
mutation 0 
in 0 
_NUM2 0 
unrelated 0 
boys 0 
with 0 
the 0 
diagnosis 0 
of 0 
classical 0 
or 0 
attenuated 0 
WAS 1
or 0 
isolated 1
thrombocytopenia 1
. 0 

All 0 
_NUM2 0 
patients 0 
had 0 
WASP 0 
mutations 0 
, 0 
each 0 
of 0 
which 0 
localized 0 
to 0 
the 0 
initial 0 
three 0 
or 0 
terminal 0 
three 0 
exons 0 
of 0 
the 0 
gene 0 
, 0 
and 0 
the 0 
majority 0 
of 0 
which 0 
were 0 
unique 0 
in 0 
each 0 
case 0 
. 0 

However 0 
, 0 
a 0 
missense 0 
mutation 0 
which 0 
results 0 
in 0 
substitution 0 
of 0 
the 0 
arginine 0 
at 0 
WAS 1
codon 0 
_NUM2 0 
was 0 
identified 0 
in 0 
three 0 
boys 0 
with 0 
severe 0 
WAS 1
as 0 
well 0 
as 0 
in 0 
one 0 
boy 0 
presenting 0 
with 0 
thrombocytopenia 1
alone 0 
. 0 

While 0 
the 0 
three 0 
mutations 0 
found 0 
in 0 
the 0 
isolated 1
thrombocytopenia 1
patients 0 
leave 0 
the 0 
reading 0 
frame 0 
intact 0 
, 0 
about 0 
one-half 0 
of 0 
the 0 
gene 0 
alterations 0 
detected 0 
in 0 
both 0 
severe 0 
and 0 
attenuated 0 
WAS 1
patients 0 
result 0 
in 0 
frameshifted 0 
transcript 0 
and 0 
premature 0 
translation 0 
termination 0 
. 0 

These 0 
findings 0 
therefore 0 
confirm 0 
the 0 
association 0 
of 0 
WAS 1
with 0 
WASP 0 
mutation 0 
and 0 
identify 0 
WASP 0 
mutation 0 
as 0 
a 0 
cause 0 
for 0 
isolated 0 
congenital 1
thrombocytopenia 1
in 0 
males 0 
. 0 

While 0 
the 0 
WASP 0 
gene 0 
defects 0 
responsible 0 
for 0 
isolated 1
thrombocytopenia 1
and 0 
other 0 
mild 0 
presentations 0 
of 0 
WAS 1
do 0 
not 0 
appear 0 
distinct 0 
from 0 
those 0 
resulting 0 
in 0 
severe 0 
WAS 1
, 0 
these 0 
data 0 
indicate 0 
that 0 
analysis 0 
of 0 
WASP 0 
gene 0 
mutation 0 
provides 0 
a 0 
valuable 0 
tool 0 
for 0 
distinguishing 0 
the 0 
spectrum 0 
of 0 
WAS 1
patients 0 
and 0 
the 0 
subset 0 
of 0 
males 0 
with 0 
isolated 1
thrombocytopenia 1
who 0 
represent 0 
mild 0 
cases 0 
of 0 
WAS 1
. 0 
. 0 

Huntington 1
disease 1
without 0 
_DS 0 
expansion 0 
: 0 
phenocopies 0 
or 0 
errors 0 
in 0 
assignment 0 
? 0 

Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
has 0 
been 0 
shown 0 
to 0 
be 0 
associated 0 
with 0 
an 0 
expanded 0 
_DS 0 
repeat 0 
within 0 
a 0 
novel 0 
gene 0 
on 0 
4p16 0 
. 0 

_NUM1 0 
-LRB- 0 
IT15 0 
-RRB- 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
of 0 
_NUM1 0 
, 0 
_NUM3 0 
affected 0 
persons 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
our 0 
cohort 0 
-RRB- 0 
did 0 
not 0 
have 0 
an 0 
expanded 0 
_DS 0 
in 0 
the 0 
disease 0 
range 0 
. 0 

The 0 
reasons 0 
for 0 
not 0 
observing 0 
expansion 0 
in 0 
affected 0 
individuals 0 
are 0 
important 0 
for 0 
determining 0 
the 0 
sensitivity 0 
of 0 
using 0 
repeat 0 
length 0 
both 0 
for 0 
diagnosis 0 
of 0 
affected 0 
patients 0 
and 0 
for 0 
predictive 0 
testing 0 
programs 0 
and 0 
may 0 
have 0 
biological 0 
relevance 0 
for 0 
the 0 
understanding 0 
of 0 
the 0 
molecular 0 
mechanism 0 
underlying 0 
HD 1
. 0 

Here 0 
we 0 
show 0 
that 0 
the 0 
majority 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
of 0 
the 0 
individuals 0 
with 0 
normal 0 
sized 0 
alleles 0 
represent 0 
misdiagnosis 0 
, 0 
sample 0 
mix-up 0 
, 0 
or 0 
clerical 0 
error 0 
. 0 

The 0 
remaining 0 
_NUM2 0 
patients 0 
represent 0 
possible 0 
phenocopies 0 
for 0 
HD 1
. 0 

In 0 
at 0 
least 0 
four 0 
cases 0 
, 0 
family 0 
studies 0 
of 0 
these 0 
phenocopies 0 
excluded 0 
4p16 0 
. 0 

_NUM1 0 
as 0 
the 0 
region 0 
responsible 0 
for 0 
the 0 
phenotype 0 
. 0 

Mutations 0 
in 0 
the 0 
HD 1
gene 0 
that 0 
are 0 
other 0 
than 0 
_DS 0 
expansion 0 
have 0 
not 0 
been 0 
excluded 0 
for 0 
the 0 
remaining 0 
eight 0 
cases 0 
; 0 
however 0 
, 0 
in 0 
as 0 
many 0 
as 0 
seven 0 
of 0 
these 0 
persons 0 
, 0 
retrospective 0 
review 0 
of 0 
these 0 
patients 0 
clinical 0 
features 0 
identified 0 
characteristics 0 
not 0 
typical 0 
for 0 
HD 1
. 0 

This 0 
study 0 
shows 0 
that 0 
on 0 
rare 0 
occasions 0 
mutations 0 
in 0 
other 0 
, 0 
as-yet-undefined 0 
genes 0 
can 0 
present 0 
with 0 
a 0 
clinical 0 
phenotype 0 
very 0 
similar 0 
to 0 
that 0 
of 0 
HD 1
Allelic 0 
exclusion 0 
of 0 
glucose-6-phosphate 0 
dehydrogenase 0 
in 0 
platelets 0 
and 0 
T 0 
lymphocytes 0 
from 0 
a 0 
Wiskott-Aldrich 1
syndrome 1
carrier 0 
. 0 

An 0 
obligate 0 
carrier 0 
of 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
who 0 
was 0 
also 0 
heterozygous 0 
for 0 
the 0 
A 0 
and 0 
B 0 
types 0 
of 0 
X-linked 0 
glucose-6-phosphate 0 
dehydrogenase 0 
was 0 
found 0 
. 0 

With 0 
her 0 
it 0 
became 0 
possible 0 
to 0 
determine 0 
whether 0 
allelic 0 
exclusion 0 
occurs 0 
in 0 
particular 0 
cell-types 0 
of 0 
the 0 
WAS 1
carrier 0 
. 0 

If 0 
so 0 
, 0 
the 0 
remaining 0 
cells 0 
of 0 
a 0 
particular 0 
cell-type 0 
would 0 
express 0 
only 0 
the 0 
normal 0 
X 0 
chromosome 0 
and 0 
only 0 
one 0 
glucose-6-phosphate 0 
dehydrogenase 0 
isoenzyme 0 
would 0 
be 0 
demonstrable 0 
. 0 

This 0 
carrier 0 
had 0 
only 0 
the 0 
B 0 
isoenzyme 0 
of 0 
glucose-6-phosphate 0 
dehydrogenase 0 
in 0 
platelets 0 
and 0 
thymus-derived 0 
T 0 
lymphocytes 0 
, 0 
although 0 
both 0 
isoenzymes 0 
A 0 
and 0 
B 0 
were 0 
present 0 
in 0 
erythrocytes 0 
and 0 
neutrophils 0 
. 0 

These 0 
findings 0 
suggest 0 
that 0 
selection 0 
against 0 
the 0 
WAS 1
gene 0 
occurs 0 
in 0 
platelets 0 
and 0 
thymus-derived 0 
T 0 
lymphocytes 0 
and 0 
that 0 
the 0 
defects 0 
associated 0 
with 0 
WAS 1
expressed 0 
in 0 
these 0 
cell-types 0 
may 0 
be 0 
implicated 0 
in 0 
the 0 
genesis 0 
of 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
. 0 
. 0 

A 0 
novel 0 
mutation 0 
in 0 
the 0 
sodium 0 
/ 0 
iodide 0
symporter 0 
gene 0 
in 0 
the 0 
largest 0 
family 0 
with 0 
iodide 1
transport 1
defect 1
. 0 

We 0 
previously 0 
reported 0 
nine 0 
children 0 
with 0 
an 0 
autosomally 0 
recessive 0 
form 0 
of 0 
congenital 1
hypothyroidism 1
due 0 
to 0 
an 0 
iodide 1
transport 1
defect 1
in 0 
a 0 
large 0 
Hutterite 0 
family 0 
with 0 
extensive 0 
consanguinity 0 
living 0 
in 0 
central 0 
Canada 0 
. 0 

Since 0 
the 0 
original 0 
report 0 
, 0 
we 0 
have 0 
diagnosed 0 
congenital 1
hypothyroidism 1
by 0 
newborn 0 
TSH 0 
screening 0 
in 0 
_NUM1 0 
additional 0 
children 0 
from 0 
the 0 
family 0 
. 0 

We 0 
performed 0 
direct 0 
sequencing 0 
of 0 
the 0 
PCR 0 
products 0 
of 0 
each 0 
NIS 0 
-LRB- 0 
sodium 0 
/ 0 
iodide 0
symporter 0 
-RRB- 0 
gene 0 
exon 0 
with 0 
flanking 0 
introns 0 
amplified 0 
from 0 
genomic 0 
DNA 0 
extracted 0 
from 0 
peripheral 0 
blood 0 
cells 0 
of 0 
the 0 
patients 0 
. 0 

We 0 
identified 0 
a 0 
novel 0 
NIS 0 
gene 0 
mutation 0 
, 0 
G395R 0 
-LRB- 0 
Gly395 0 
-- 0 
> 0 
Arg 0 
; 0 
_DS 0 
-- 0 
> 0 
_DS 0 
-RRB- 0 
, 0 
in 0 
_NUM2 0 
patients 0 
examined 0 
in 0 
the 0 
present 0 
study 0 
. 0 

All 0 
of 0 
the 0 
parents 0 
tested 0 
were 0 
heterozygous 0 
for 0 
the 0 
mutation 0 
, 0 
suggesting 0 
that 0 
the 0 
patients 0 
were 0 
homozygous 0 
. 0 

The 0 
mutation 0 
was 0 
located 0 
in 0 
the 0 
10th 0 
transmembrane 0 
helix 0 
. 0 

Expression 0 
experiments 0 
by 0 
transfection 0 
of 0 
the 0 
mutant 0 
NIS 0 
complimentary 0 
DNA 0 
into 0 
COS-7 0 
cells 0 
showed 0 
no 0 
perchlorate-sensitive 0 
iodide 0
uptake 0 
, 0 
confirming 0 
that 0 
the 0 
mutation 0 
is 0 
the 0 
direct 0 
cause 0 
of 0 
the 0 
iodide 1
transport 1
defect 1
in 0 
these 0 
patients 0 
. 0 

A 0 
patient 0 
who 0 
showed 0 
an 0 
intermediate 0 
saliva 0 
/ 0 
serum 0 
technetium 0 
ratio 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
; 0 
normal 0 
, 0 
> 0 
or 0 
= 0 
_NUM2 0 
-RRB- 0 
and 0 
was 0 
considered 0 
to 0 
have 0 
a 0 
partial 0 
or 0 
less 0 
severe 0 
defect 0 
in 0 
the 0 
previous 0 
report 0 
-LRB- 0 
IX-24 0 
-RRB- 0 
did 0 
not 0 
have 0 
a 0 
NIS 0 
gene 0 
mutation 0 
. 0 

It 0 
is 0 
now 0 
possible 0 
to 0 
use 0 
gene 0 
diagnostics 0 
of 0 
this 0 
unique 0 
NIS 0 
mutation 0 
to 0 
identify 0 
patients 0 
with 0 
congenital 1
hypothyroidism 1
due 0 
to 0 
an 0 
iodide 1
transport 1
defect 1
in 0 
this 0 
family 0 
and 0 
to 0 
determine 0 
the 0 
carrier 0 
state 0 
of 0 
potential 0 
parents 0 
for 0 
genetic 0 
counseling 0 
and 0 
arranging 0 
rapid 0 
and 0 
early 0 
diagnosis 0 
of 0 
their 0 
infants 0 
. 0 

Determination 0 
of 0 
the 0 
mutations 0 
responsible 0 
for 0 
the 0 
Lesch-Nyhan 1
syndrome 1
in 0 
_NUM2 0 
subjects 0 
. 0 

Hypoxanthine 0 
-- 0 
guanine 0 
phosphoribosyltransferase 0 
-LRB- 0 
HPRT 0 
-RRB- 0 
is 0 
a 0 
purine 0 
salvage 0 
enzyme 0 
that 0 
catalyzes 0 
the 0 
conversion 0 
of 0 
hypoxanthine 0 
to 0 
inosine 0 
monophosphate 0 
and 0 
guanine 0 
to 0 
guanosine 0 
monophosphate 0 
. 0 

Previous 0 
studies 0 
of 0 
mutant 0 
HPRT 0 
proteins 0 
analyzed 0 
at 0 
the 0 
molecular 0 
level 0 
have 0 
shown 0 
a 0 
significant 0 
heterogeneity 0 
. 0 

This 0 
investigation 0 
further 0 
verifies 0 
this 0 
heterogeneity 0 
and 0 
identifies 0 
insertions 0 
, 0 
deletions 0 
, 0 
and 0 
point 0 
mutations 0 
. 0 

The 0 
direct 0 
sequencing 0 
of 0 
the 0 
polymerase 0 
chain 0 
reaction-amplified 0 
product 0 
of 0 
reverse-transcribed 0 
HPRT 0 
mRNA 0 
enabled 0 
the 0 
rapid 0 
identification 0 
of 0 
the 0 
mutations 0 
found 0 
in 0 
_NUM2 0 
previously 0 
uncharacterized 0 
cell 0 
lines 0 
derived 0 
from 0 
patients 0 
with 0 
the 0 
Lesch-Nyhan 1
syndrome 1
. 0 
. 0 

A 0 
new 0 
_DS 0 
pattern 0 
in 0 
adrenoleukodystrophy 1
. 0 

A 0 
new 0 
_DS 0 
pattern 0 
was 0 
observed 0 
in 0 
_NUM1 0 
patients 0 
with 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
. 0 

This 0 
pattern 0 
, 0 
which 0 
the 0 
authors 0 
call 0 
Type 0 
II 0 
, 0 
is 0 
characterized 0 
by 0 
the 0 
absence 0 
of 0 
posterior 0 
periventricular 0 
areas 0 
of 0 
decreased 0 
attenuation 0 
around 0 
the 0 
trigone 0 
on 0 
non-contrast 0 
scans 0 
after 0 
contrast 0 
infusion 0 
, 0 
however 0 
, 0 
there 0 
is 0 
striking 0 
enhancement 0 
of 0 
various 0 
white-matter 0 
structures 0 
-LRB- 0 
tracts 0 
or 0 
fiber 0 
systems 0 
-RRB- 0 
such 0 
as 0 
the 0 
internal 0 
capsules 0 
, 0 
corpus 0 
callosum 0 
, 0 
corona 0 
radiata 0 
, 0 
forceps 0 
major 0 
, 0 
and 0 
cerebral 0 
peduncles 0 
. 0 

This 0 
is 0 
different 0 
from 0 
numerous 0 
previous 0 
descriptions 0 
of 0 
the 0 
_DS 0 
pattern 0 
in 0 
ALD 1
. 0 

Type 1
II 1
ALD 1
does 0 
not 0 
appear 0 
to 0 
have 0 
been 0 
seen 0 
in 0 
any 0 
other 0 
leukoencephalopathy 1
and 0 
is 0 
probably 0 
specific 0 
for 0 
a 0 
phenotypic 0 
variant 0 
or 0 
an 0 
evolving 0 
stage 0 
of 0 
ALD 1
. 0 
. 0 

Genetic 0 
analysis 0 
, 0 
phenotypic 0 
diagnosis 0 
, 0 
and 0 
risk 0 
of 0 
venous 1
thrombosis 1
in 0 
families 0 
with 0 
inherited 0 
deficiencies 1
of 1
protein 1
S 1
. 0 
Protein 1
S 1
deficiency 1
is 0 
a 0 
recognized 0 
risk 0 
factor 0 
for 0 
venous 1
thrombosis 1
. 0 

Of 0 
all 0 
the 0 
inherited 0 
thrombophilic 1
conditions 1
, 0 
it 0 
remains 0 
the 0 
most 0 
difficult 0 
to 0 
diagnose 0 
because 0 
of 0 
phenotypic 0 
variability 0 
, 0 
which 0 
can 0 
lead 0 
to 0 
inconclusive 0 
results 0 
. 0 

We 0 
have 0 
overcome 0 
this 0 
problem 0 
by 0 
studying 0 
a 0 
cohort 0 
of 0 
patients 0 
from 0 
a 0 
single 0 
center 0 
where 0 
the 0 
diagnosis 0 
was 0 
confirmed 0 
at 0 
the 0 
genetic 0 
level 0 
. 0 

Twenty-eight 0 
index 0 
patients 0 
with 0 
protein 1
S 1
deficiency 1
and 0 
a 0 
PROS1 1
gene 1
defect 1
were 0 
studied 0 
, 0 
together 0 
with 0 
_NUM3 0 
first-degree 0 
relatives 0 
. 0 

To 0 
avoid 0 
selection 0 
bias 0 
, 0 
we 0 
confined 0 
analysis 0 
of 0 
total 0 
and 0 
free 0 
protein 0 
S 0 
levels 0 
and 0 
thrombotic 0 
risk 0 
to 0 
the 0 
patients 0 
relatives 0 
. 0 

In 0 
this 0 
group 0 
of 0 
relatives 0 
, 0 
a 0 
low 0 
free 0 
protein 0 
S 0 
level 0 
was 0 
the 0 
most 0 
reliable 0 
predictor 0 
of 0 
a 0 
PROS1 1
gene 1
defect 1
-LRB- 0 
sensitivity 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
, 0 
specificity 0 
_NUM3 0 
% 0 
-RRB- 0 
. 0 

First-degree 0 
relatives 0 
with 0 
a 0 
PROS1 1
gene 1
defect 1
had 0 
a 0 
_NUM1 0 
. 0 

0-fold 0 
higher 0 
risk 0 
of 0 
thrombosis 1
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
, 0 
_NUM1 0 
. 0 

5-16 0 
. 0 

_NUM1 0 
-RRB- 0 
than 0 
those 0 
with 0 
a 0 
normal 0 
PROS1 0 
gene 0 
and 0 
no 0 
other 0 
recognized 0 
thrombophilic 1
defect 1
. 0 

Although 0 
pregnancy 0 
/ 0 
puerperium 0 
and 0 
immobility 0 
/ 0 
trauma 1
were 0 
important 0 
precipitating 0 
factors 0 
for 0 
thrombosis 1
, 0 
almost 0 
half 0 
of 0 
the 0 
events 0 
were 0 
spontaneous 0 
. 0 

Relatives 0 
with 0 
splice-site 0 
or 0 
major 0 
structural 0 
defects 1
in 1
the 1
PROS1 1
gene 1
were 0 
more 0 
likely 0 
to 0 
have 0 
had 0 
a 0 
thrombotic 0 
event 0 
and 0 
had 0 
significantly 0 
lower 0 
total 0 
and 0 
free 0 
protein 0 
S 0 
levels 0 
than 0 
those 0 
relatives 0 
having 0 
missense 0 
mutations 0 
. 0 

We 0 
conclude 0 
that 0 
persons 0 
with 0 
PROS1 1
gene 1
defects 1
and 0 
protein 1
S 1
deficiency 1
are 0 
at 0 
increased 0 
risk 0 
of 0 
thrombosis 1
and 0 
that 0 
free 0 
protein 0 
S 0 
estimation 0 
offers 0 
the 0 
most 0 
reliable 0 
way 0 
of 0 
diagnosing 0 
the 0 
deficiency 0 
. 0 

-LRB- 0 
Blood 0 
. 0 

_NUM4 0 
; 0 
_NUM2 0 
1935-1941 0 
-RRB- 0 
. 0 

Severe 0 
clinical 0 
expression 0 
in 0 
X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
. 0 

X-linked 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
is 0 
a 0 
relatively 0 
rare 0 
benign 1
neuromuscular 1
disorder 1
which 0 
can 0 
vary 0 
remarkably 0 
in 0 
onset 0 
, 0 
course 0 
and 0 
severity 0 
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
a 0 
_DS 0 
deletion 0 
spanning 0 
the 0 
nucleotides 0 
631-635 0 
of 0 
the 0 
emerin 0 
gene 0 
caused 0 
an 0 
unusually 0 
severe 0 
disease 0 
phenotype 0 
including 0 
loss 1
of 1
ambulation 1
and 0 
severe 0 
muscle 1
wasting 1
in 0 
two 0 
affected 0 
brothers 0 
. 0 

The 0 
same 0 
mutation 0 
has 0 
been 0 
reported 0 
previously 0 
in 0 
an 0 
unrelated 0 
family 0 
showing 0 
a 0 
significantly 0 
milder 0 
phenotype 0 
. 0 

The 0 
interfamilial 0 
heterogeneity 0 
in 0 
distribution 0 
and 0 
in 0 
severity 0 
of 0 
the 0 
features 0 
in 0 
the 0 
two 0 
families 0 
point 0 
to 0 
environmental 0 
or 0 
genetic 0 
modification 0 
as 0 
the 0 
cause 0 
of 0 
clinical 0 
variability 0 
in 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
. 0 
. 0 

The 0 
gene 0 
for 0 
spinal 1
cerebellar 1
ataxia 1
_NUM1 0 
-LRB- 0 
SCA3 0 
-RRB- 0 
is 0 
located 0 
in 0 
a 0 
region 0 
of 0 
approximately 0 
_NUM1 0 
cM 0 
on 0 
chromosome 0 
14q24.3-q32 0 
.2 0 
. 0 

SCA3 0 
, 0 
the 0 
gene 0 
for 0 
spinal 1
cerebellar 1
ataxia 1
_NUM1 0 
, 0 
was 0 
recently 0 
mapped 0 
to 0 
a 0 
15-cM 0 
interval 0 
between 0 
D14S67 0 
and 0 
D14S81 0 
on 0 
chromosome 0 
14q 0 
, 0 
by 0 
linkage 0 
analysis 0 
in 0 
two 0 
families 0 
of 0 
French 0 
ancestry 0 
. 0 

The 0 
SCA3 0 
candidate 0 
region 0 
has 0 
now 0 
been 0 
refined 0 
by 0 
linkage 0 
analysis 0 
with 0 
four 0 
new 0 
microsatellite 0 
markers 0 
-LRB- 0 
D14S256 0 
, 0 
D14S291 0 
, 0 
D14S280 0 
, 0 
and 0 
AFM343vf1 0 
-RRB- 0 
in 0 
the 0 
same 0 
two 0 
families 0 
, 0 
in 0 
which 0 
_NUM2 0 
additional 0 
individuals 0 
were 0 
genotyped 0 
, 0 
and 0 
in 0 
a 0 
third 0 
French 0 
family 0 
. 0 

Combined 0 
two-point 0 
linkage 0 
analyses 0 
show 0 
that 0 
the 0 
new 0 
markers 0 
, 0 
D14S280 0 
and 0 
AFM343vf1 0 
, 0 
are 0 
tightly 0 
linked 0 
to 0 
the 0 
SCA3 0 
locus 0 
, 0 
with 0 
maximal 0 
lod 0 
scores 0 
, 0 
at 0 
recombination 0 
fraction 0 
, 0 
-LRB- 0 
theta 0 
-RRB- 0 
= 0 
. 0 

_NUM2 0 
, 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
_NUM2 0 
. 0 

_NUM2 0 
, 0 
respectively 0 
. 0 

Combined 0 
multipoint 0 
and 0 
recombinant 0 
haplotype 0 
analyses 0 
localize 0 
the 0 
SCA3 0 
locus 0 
to 0 
a 0 
3-cM 0 
interval 0 
flanked 0 
by 0 
D14S291 0 
and 0 
D14S81 0 
. 0 

The 0 
same 0 
allele 0 
for 0 
D14S280 0 
segregates 0 
with 0 
the 0 
disease 0 
locus 0 
in 0 
the 0 
three 0 
kindreds 0 
. 0 

This 0 
allele 0 
is 0 
frequent 0 
in 0 
the 0 
French 0 
population 0 
, 0 
however 0 
, 0 
and 0 
linkage 0 
disequilibrium 0 
is 0 
not 0 
clearly 0 
established 0 
. 0 

The 0 
SCA3 0 
locus 0 
remains 0 
within 0 
the 0 
29-cM 0 
region 0 
on 0 
14q24 0 
. 0 

3-q32 0 
. 0 

_NUM1 0 
containing 0 
the 0 
gene 0 
for 0 
the 0 
Machado-Joseph 1
disease 1
, 0 
which 0 
is 0 
clinically 0 
related 0 
to 0 
the 0 
phenotype 0 
determined 0 
by 0 
SCA3 0 
, 0 
but 0 
it 0 
can 0 
not 0 
yet 0 
be 0 
concluded 0 
that 0 
both 0 
diseases 0 
result 0 
from 0 
alterations 0 
of 0 
the 0 
same 0 
gene 0 
Huntington 1
disease 1
and 0 
childhood-onset 0 
Tourette 1
syndrome 1
. 0 

A 0 
40-year-old 0 
man 0 
with 0 
childhood-onset 0 
Tourette 1
syndrome 1
-LRB- 0 
TS 1
-RRB- 0 
developed 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
. 0 

We 0 
believe 0 
this 0 
to 0 
be 0 
the 0 
first 0 
reported 0 
case 0 
of 0 
childhood-onset 0 
TS 1
with 0 
adult 0 
onset 0 
HD 1
. 0 

Discovery 0 
of 0 
other 0 
cases 0 
with 0 
both 0 
disorders 0 
may 0 
provide 0 
clues 0 
to 0 
the 0 
pathophysiology 0 
of 0 
both 0 
conditions 0 
. 0 
. 0 

The 0 
protein 0 
deficient 0 
in 0 
Lowe 1
syndrome 1
is 0 
a 0 
phosphatidylinositol-4 0 
,5 0 
- 0 
bisphosphate 0 
5-phosphatase 0 
. 0 

Lowe 1
syndrome 1
, 0 
also 0 
known 0 
as 0 
oculocerebrorenal 1
syndrome 1
, 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
X 0 
chromosome-encoded 0 
OCRL 0 
gene 0 
. 0 

The 0 
OCRL 0 
protein 0 
is 0 
_NUM2 0 
% 0 
identical 0 
to 0 
inositol 0 
polyphosphate 0 
5-phosphatase 0 
II 0 
-LRB- 0 
5-phosphatase 0 
II 0 
-RRB- 0 
from 0 
human 0 
platelets 0 
over 0 
a 0 
span 0 
of 0 
_NUM3 0 
aa 0 
, 0 
suggesting 0 
that 0 
OCRL 0 
may 0 
be 0 
a 0 
similar 0 
enzyme 0 
. 0 

We 0 
engineered 0 
a 0 
construct 0 
of 0 
the 0 
OCRL 0 
cDNA 0 
that 0 
encodes 0 
amino 0 
acids 0 
homologous 0 
to 0 
the 0 
platelet 0 
5-phosphatase 0 
for 0 
expression 0 
in 0 
baculovirus-infected 0 
Sf9 0 
insect 0 
cells 0 
. 0 

This 0 
cDNA 0 
encodes 0 
aa 0 
264-968 0 
of 0 
the 0 
OCRL 0 
protein 0 
. 0 

The 0 
recombinant 0 
protein 0 
was 0 
found 0 
to 0 
catalyze 0 
the 0 
reactions 0 
also 0 
carried 0 
out 0 
by 0 
platelet 0 
5-phosphatase 0 
II 0 
. 0 

Thus 0 
OCRL 0 
converts 0 
inositol 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
5-trisphosphate 0 
to 0 
inositol 0 
_NUM1 0 
, 0 
4-bisphosphate 0 
, 0 
and 0 
it 0 
converts 0 
inositol 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
5-tetrakisphosphate 0 
to 0 
inositol 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
4-trisphosphate 0 
. 0 

Most 0 
important 0 
, 0 
the 0 
enzyme 0 
converts 0 
phosphatidylinositol 0 
_NUM1 0 
, 0 
5-bisphosphate 0 
to 0 
phosphatidylinositol 0 
4-phosphate 0 
. 0 

The 0 
relative 0 
ability 0 
of 0 
OCRL 0 
to 0 
catalyze 0 
the 0 
three 0 
reactions 0 
is 0 
different 0 
from 0 
that 0 
of 0 
5-phosphatase 0 
II 0 
and 0 
from 0 
that 0 
of 0 
another 0 
5-phosphatase 0 
isoenzyme 0 
from 0 
platelets 0 
, 0 
5-phosphatase 0 
I 0 
. 0 

The 0 
recombinant 0 
OCRL 0 
protein 0 
hydrolyzes 0 
the 0 
phospholipid 0 
substrate 0 
_NUM2 0 
- 0 
to 0 
30-fold 0 
better 0 
than 0 
5-phosphatase 0 
II 0 
, 0 
and 0 
5-phosphatase 0 
I 0 
does 0 
not 0 
cleave 0 
the 0 
lipid 0 
at 0 
all 0 
. 0 

We 0 
also 0 
show 0 
that 0 
OCRL 0 
functions 0 
as 0 
a 0 
phosphatidylinositol 0 
_NUM1 0 
, 0 
5-bisphosphate 0 
5-phosphatase 0 
in 0 
OCRL-expressing 0 
Sf9 0 
cells 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
OCRL 0 
is 0 
mainly 0 
a 0 
lipid 0 
phosphatase 0 
that 0 
may 0 
control 0 
cellular 0 
levels 0 
of 0 
a 0 
critical 0 
metabolite 0 
, 0 
phosphatidylinositol 0 
_NUM1 0 
, 0 
5-bisphosphate 0 
. 0 

Deficiency 0 
of 0 
this 0 
enzyme 0 
apparently 0 
causes 0 
the 0 
protean 0 
manifestations 0 
of 0 
Lowe 1
syndrome 1
. 0 
. 0 

Microdeletions 0 
at 0 
chromosome 0 
bands 0 
1q32-q41 0 
as 0 
a 0 
cause 0 
of 0 
Van 1
der 1
Woude 1
syndrome 1
. 0 

Van 1
der 1
Woude 1
syndrome 1
-LRB- 0 
VWS 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disorder 1
comprising 0 
cleft 1
lip 1
and 0 
/ 0 
or 0 
cleft 1
palate 1
and 0 
lip 1
pits 1
. 0 

We 0 
reported 0 
previously 0 
a 0 
family 0 
whose 0 
underlying 0 
mutation 0 
is 0 
a 0 
500-800 0 
kb 0 
deletion 0 
localized 0 
to 0 
chromosome 0 
bands 0 
1q32-q41 0 
-LSB- 0 
Sander 0 
et 0 
al. 0 
, 0 
_NUM4 0 
Hum 0 
Mol 0 
Genet 0 
_NUM1 0 
576-578 0 
-RSB- 0 
. 0 

Along 0 
with 0 
cleft 1
lip 1
/ 1
palate 1
and 0 
lip 1
pits 1
, 0 
affected 0 
relatives 0 
exhibit 0 
developmental 1
delays 1
, 0 
suggesting 0 
that 0 
the 0 
function 0 
of 0 
a 0 
gene 0 
nearby 0 
may 0 
also 0 
be 0 
disrupted 0 
. 0 

To 0 
further 0 
localize 0 
the 0 
VWS 1
gene 0 
we 0 
searched 0 
for 0 
other 0 
deletions 0 
that 0 
cause 0 
VWS 1
. 0 

An 0 
allele 0 
loss 0 
assay 0 
was 0 
performed 0 
using 0 
a 0 
novel 0 
highly 0 
polymorphic 0 
marker 0 
, 0 
D1S3753 0 
. 0 

From 0 
a 0 
panel 0 
of 0 
_NUM2 0 
unrelated 0 
individuals 0 
, 0 
we 0 
detected 0 
an 0 
allele 0 
loss 0 
in 0 
one 0 
family 0 
, 0 
indicating 0 
the 0 
presence 0 
of 0 
a 0 
deletion 0 
. 0 

In 0 
this 0 
family 0 
, 0 
the 0 
phenotype 0 
in 0 
three 0 
generations 0 
of 0 
affected 0 
individuals 0 
was 0 
confined 0 
to 0 
the 0 
cardinal 0 
signs 0 
of 0 
VWS 1
. 0 

Surprisingly 0 
, 0 
mapping 0 
of 0 
the 0 
new 0 
deletion 0 
showed 0 
that 0 
it 0 
extended 0 
_NUM1 0 
. 0 

2-1 0 
Mb 0 
beyond 0 
the 0 
proximal 0 
breakpoint 0 
for 0 
the 0 
deletion 0 
described 0 
previously 0 
. 0 

No 0 
deletions 0 
were 0 
detected 0 
in 0 
seven 0 
cases 0 
of 0 
popliteal 1
pterygia 1
syndrome 1
, 0 
_NUM2 0 
cases 0 
of 0 
mixed 0 
syndromic 1
forms 1
of 1
cleft 1
lip 1
and 1
palate 1
, 0 
and 0 
_NUM3 0 
cases 0 
of 0 
nonsyndromic 1
cleft 1
lip 1
and 1
palate 1
. 0 

Mucopolysaccharidosis 1
type 1
IVA 1
: 0 
common 0 
double 0 
deletion 0 
in 0 
the 0 
N-acetylgalactosamine-6-sulfatase 0 
gene 0 
-LRB- 0 
GALNS 0 
-RRB- 0 
. 0 

Mucopolysaccharidosis 1
IVA 1
-LRB- 0 
MPS 1
IVA 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
caused 0 
by 0 
a 0 
deficiency 1
in 1
N-acetylgalactosamine-6-sulfatase 1
-LRB- 0 
GALNS 0 
-RRB- 0 
. 0 

We 0 
found 0 
two 0 
separate 0 
deletions 0 
of 0 
nearly 0 
_NUM1 0 
. 0 

_NUM1 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
in 0 
the 0 
GALNS 0 
gene 0 
, 0 
including 0 
some 0 
exons 0 
. 0 

There 0 
are 0 
Alu 0 
repetitive 0 
elements 0 
near 0 
the 0 
breakpoints 0 
of 0 
the 0 
_NUM1 0 
. 0 

0-kb 0 
deletion 0 
, 0 
and 0 
this 0 
deletion 0 
resulted 0 
from 0 
an 0 
Alu-Alu 0 
recombination 0 
. 0 

The 0 
other 0 
_NUM1 0 
. 0 

0-kb 0 
deletion 0 
involved 0 
illegitimate 0 
recombinational 0 
events 0 
between 0 
incomplete 0 
short 0 
direct 0 
repeats 0 
of 0 
_NUM1 0 
bp 0 
at 0 
deletion 0 
breakpoints 0 
. 0 

The 0 
same 0 
rearrangement 0 
has 0 
been 0 
observed 0 
in 0 
a 0 
heteroallelic 0 
state 0 
in 0 
four 0 
unrelated 0 
patients 0 
. 0 

This 0 
is 0 
the 0 
first 0 
documentation 0 
of 0 
a 0 
common 0 
double 0 
deletion 0 
a 0 
gene 0 
that 0 
is 0 
not 0 
a 0 
member 0 
of 0 
a 0 
gene 0 
cluster 0 
. 0 

Segregation 0 
analysis 0 
of 0 
a 0 
marker 0 
localised 0 
Xp21.2-Xp21 0 
.3 0 
in 0 
Duchenne 1
and 1
Becker 1
muscular 1
dystrophy 1
families 0 
. 0 

A 0 
DNA 0 
marker 0 
C7 0 
, 0 
localised 0 
Xp21 0 
. 0 

1-Xp21 0 
. 0 

_NUM1 0 
, 0 
has 0 
been 0 
studied 0 
in 0 
kindreds 0 
segregating 0 
for 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
and 0 
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
BMD 1
-RRB- 0 
. 0 

In 0 
DMD 1
families 0 
four 0 
crossovers 0 
were 0 
observed 0 
in 0 
_NUM2 0 
informative 0 
meioses 0 
between 0 
C7 0 
and 0 
the 0 
DMD 1
locus 0 
-LRB- 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
z 0 
max 0 
= 0 
+ 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

In 0 
BMD 1
families 0 
no 0 
recombinants 0 
were 0 
observed 0 
in 0 
the 0 
_NUM2 0 
informative 0 
meioses 0 
studied 0 
. 0 

These 0 
data 0 
are 0 
consistent 0 
with 0 
the 0 
localisation 0 
of 0 
the 0 
mutations 0 
in 0 
these 0 
disorders 0 
being 0 
in 0 
the 0 
same 0 
region 0 
of 0 
Xp21 0 
. 0 

Studies 0 
in 0 
families 0 
also 0 
segregating 0 
for 0 
the 0 
DNA 0 
marker 0 
_NUM3 0 
support 0 
the 0 
previously 0 
reported 0 
physical 0 
order 0 
of 0 
these 0 
loci 0 
as 0 
X 0 
centromere-754-DMD-BMD-C7-X 0 
telomere 0 
. 0 

A 0 
recombination 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
-LRB- 0 
z 0 
max 0 
= 0 
+ 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
was 0 
found 0 
between 0 
DMD-754 0 
by 0 
combining 0 
our 0 
previously 0 
published 0 
data 0 
with 0 
the 0 
data 0 
presented 0 
here 0 
. 0 

C7 0 
and 0 
_NUM3 0 
thus 0 
provide 0 
good 0 
bridging 0 
markers 0 
for 0 
the 0 
diagnosis 0 
of 0 
DMD 1
and 0 
BMD 1
Genetic 0 
analysis 0 
of 0 
the 0 
BRCA1 0 
region 0 
in 0 
a 0 
large 0 
breast 0
/ 0 
ovarian 0 
family 0 
: 0 
refinement 0 
of 0 
the 0 
minimal 0 
region 0 
containing 0 
BRCA1 0 
. 0 

We 0 
have 0 
analyzed 0 
a 0 
single 0 
multi-affected 0 
breast 1
/ 1
ovarian 1
cancer 1
pedigree 0 
-LRB- 0 
BOV3 0 
-RRB- 0 
and 0 
have 0 
shown 0 
consistent 0 
inheritance 0 
of 0 
markers 0 
on 0 
chromosome 0 
17q 0 
with 0 
the 0 
disease 0 
confirming 0 
that 0 
this 0 
family 0 
is 0 
due 0 
to 0 
the 0 
BRCA1 0 
gene 0 
. 0 

Analysis 0 
of 0 
17q 0 
haplotypes 0 
shows 0 
a 0 
recombination 0 
event 0 
in 0 
a 0 
bilateral 0 
breast 1
cancer 1
case 0 
which 0 
suggests 0 
that 0 
the 0 
BRCA1 0 
gene 0 
lies 0 
distal 0 
to 0 
D17S857 0 
; 0 
D17S857 0 
is 0 
thus 0 
the 0 
new 0 
proximal 0 
boundary 0 
for 0 
the 0 
region 0 
containing 0 
BRCA1 0 
. 0 

Combining 0 
this 0 
information 0 
with 0 
previously 0 
published 0 
mapping 0 
information 0 
suggests 0 
that 0 
BRCA1 0 
is 0 
contained 0 
in 0 
a 0 
region 0 
estimated 0 
at 0 
1-1 0 
. 0 

_NUM1 0 
Mb 0 
in 0 
length 0 
. 0 

All 0 
seven 0 
breast 1
tumour 1
/ 0 
blood 0 
pairs 0 
examined 0 
from 0 
this 0 
family 0 
show 0 
loss 0 
of 0 
heterozygosity 0 
in 0 
the 0 
tumours 1
. 0 

The 0 
allel 0 
retained 0 
in 0 
each 0 
tumour 1
was 0 
from 0 
the 0 
disease-bearing 0 
chromosome 0 
implicating 0 
BRCA1 0 
as 0 
a 0 
tumour 1
suppressor 0 
gene 0 
. 0 

We 0 
have 0 
sequenced 0 
the 0 
_NUM2 0 
beta-oestradiol 0 
dehydrogenase 0 
genes 0 
-LRB- 0 
EDH17B1 0 
and 0 
EDH17B2 0 
-RRB- 0 
which 0 
have 0 
been 0 
suggested 0 
as 0 
candidate 0 
genes 0 
for 0 
BRCA1 0 
in 0 
four 0 
members 0 
of 0 
this 0 
family 0 
. 0 

No 0 
germline 0 
mutations 0 
were 0 
detected 0 
. 0 

A 0 
point 0 
mutation 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Met 0 
on 0 
the 0 
alpha 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
integrin 0 
leads 0 
to 0 
the 0 
formation 0 
of 0 
new 0 
human 0 
platelet 0 
alloantigen 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
and 0 
affects 0 
collagen-induced 0 
aggregation 0 
. 0 

A 0 
new 0 
platelet-specific 0 
alloantigen 0 
, 0 
termed 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
, 0 
was 0 
identified 0 
in 0 
a 0 
severe 0 
case 0 
of 0 
neonatal 1
alloimmune 1
thrombocytopenia 1
. 0 

The 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
alloantigen 0 
is 0 
of 0 
low 0 
frequency 0 
-LRB- 0 
1 0 
/ 0 
400 0 
-RRB- 0 
in 0 
the 0 
German 0 
population 0 
. 0 

Immunochemical 0 
studies 0 
demonstrated 0 
that 0 
the 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
epitopes 0 
reside 0 
on 0 
platelet 0 
glycoprotein 0 
-LRB- 0 
GP 0 
-RRB- 0 
Ia 0 
. 0 

Nucleotide 0 
sequence 0 
analysis 0 
of 0 
GPIa 0 
cDNA 0 
derived 0 
from 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
- 0 
positive 0 
platelets 0 
showed 0 
C 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
-- 0 
> 0 
T 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
point 0 
mutation 0 
, 0 
resulting 0 
in 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Met 0 
dimorphism 0 
. 0 

Analysis 0 
of 0 
genomic 0 
DNA 0 
from 0 
_NUM2 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
- 0 
negative 0 
normal 0 
individuals 0 
showed 0 
that 0 
the 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
is 0 
encoded 0 
by 0 
_DS 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
or 0 
_DS 0 
-LRB- 0 
_NUM4 0 
-RRB- 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
. 0 

To 0 
establish 0 
a 0 
DNA 0 
typing 0 
technique 0 
, 0 
we 0 
elucidated 0 
the 0 
organization 0 
of 0 
the 0 
GPIa 0 
gene 0 
adjacent 0 
to 0 
the 0 
polymorphic 0 
bases 0 
. 0 

The 0 
introns 0 
-LRB- 0 
_NUM3 0 
bp 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
-RRB- 0 
encompass 0 
a 0 
142-bp 0 
exon 0 
with 0 
the 0 
_NUM1 0 
polymorphic 0 
bases 0 
_NUM4 0 
and 0 
_NUM4 0 
. 0 

Polymerase 0 
chain 0 
reaction-restriction 0 
fragment 0 
length 0 
polymorphism 0 
analysis 0 
on 0 
DNA 0 
derived 0 
from 0 
_NUM3 0 
donors 0 
using 0 
the 0 
restriction 0 
enzyme 0 
Mae 0 
III 0 
showed 0 
that 0 
the 0 
Met 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
form 0 
of 0 
GPIa 0 
is 0 
restricted 0 
to 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
-LRB- 0 
+ 0 
-RRB- 0 
phenotype 0 
. 0 

Analysis 0 
of 0 
stable 0 
Chinese 0 
hamster 0 
ovary 0 
transfectants 0 
expressing 0 
allele-specific 0 
recombinant 0 
forms 0 
of 0 
GPIa 0 
showed 0 
that 0 
anti-Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
exclusively 0 
reacted 0 
with 0 
the 0 
Glu 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Met 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
, 0 
but 0 
not 0 
with 0 
the 0 
Glu 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
and 0 
the 0 
Lys 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
isoforms 0 
. 0 

In 0 
contrast 0 
, 0 
anti-Br 0 
-LRB- 0 
a 0 
-RRB- 0 
-LRB- 0 
HPA-5b 0 
-RRB- 0 
only 0 
recognized 0 
the 0 
Lys 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
form 0 
, 0 
whereas 0 
anti-Br 0 
-LRB- 0 
b 0 
-RRB- 0 
-LRB- 0 
HPA-5a 0 
-RRB- 0 
reacted 0 
with 0 
both 0 
Glu 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
and 0 
Glu 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Met 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
isoforms 0 
. 0 

These 0 
results 0 
demonstrated 0 
that 0 
the 0 
Met 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
is 0 
responsible 0 
for 0 
formation 0 
of 0 
the 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
alloantigenic 0 
determinants 0 
, 0 
whereas 0 
amino 0 
acid 0 
_NUM3 0 
-LRB- 0 
Lys 0 
or 0 
Glu 0 
-RRB- 0 
specifically 0 
controls 0 
the 0 
expression 0 
of 0 
Br 0 
-LRB- 0 
a 0 
-RRB- 0 
and 0 
Br 0 
-LRB- 0 
b 0 
-RRB- 0 
epitopes 0 
, 0 
respectively 0 
. 0 

Platelet 0 
aggregation 0 
responses 0 
of 0 
Sit 0 
-LRB- 0 
a 0 
-RRB- 0 
-LRB- 0 
+ 0 
-RRB- 0 
individuals 0 
were 0 
diminished 0 
in 0 
response 0 
to 0 
collagen 0 
, 0 
indicating 0 
that 0 
the 0 
Thr 0 
-LRB- 0 
_NUM3 0 
-RRB- 0 
Met 0 
mutation 0 
affects 0 
the 0 
function 0 
of 0 
the 0 
GPIa 0 
/ 0 
IIa 0 
complex 0 
Estimation 0 
of 0 
the 0 
male 0 
to 0 
female 0 
ratio 0 
of 0 
mutation 0 
rates 0 
from 0 
the 0 
segregation 0 
of 0 
X-chromosomal 0 
DNA 0 
haplotypes 0 
in 0 
Duchenne 1
muscular 1
dystrophy 1
families 0 
. 0 

A 0 
novel 0 
procedure 0 
is 0 
presented 0 
to 0 
estimate 0 
the 0 
ratio 0 
of 0 
male 0 
to 0 
female 0 
mutation 0 
rates 0 
for 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

X-specific 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
are 0 
used 0 
to 0 
establish 0 
DNA 0 
haplotypes 0 
in 0 
three-generation 0 
DMD 1
families 0 
. 0 

From 0 
the 0 
proportion 0 
of 0 
DMD 1
patients 0 
who 0 
have 0 
inherited 0 
their 0 
maternal 0 
grandfathers 0 
X 0 
chromosome 0 
, 0 
the 0 
ratio 0 
of 0 
mutation 0 
rates 0 
can 0 
be 0 
calculated 0 
. 0 

In 0 
contrast 0 
to 0 
classical 0 
methods 0 
, 0 
the 0 
proposed 0 
procedure 0 
is 0 
not 0 
restricted 0 
to 0 
sporadic 0 
or 0 
familiar 0 
cases 0 
nor 0 
is 0 
any 0 
information 0 
on 0 
the 0 
carrier 0 
status 0 
of 0 
female 0 
relatives 0 
required 0 
. 0 
. 0 

Genetic 0 
analysis 0 
of 0 
an 0 
inherited 0 
deficiency 1
of 1
the 1
third 1
component 1
of 1
complement 1
in 0 
Brittany 0 
spaniel 0 
dogs 0 
. 0 

Genetically 0 
determined 0 
C3 1
deficiency 1
in 0 
Brittany 0 
spaniel 0 
dogs 0 
shares 0 
a 0 
number 0 
of 0 
biochemical 0 
and 0 
clinical 0 
characteristics 0 
with 0 
the 0 
human 0 
disorder 0 
. 0 

In 0 
humans 0 
, 0 
the 0 
gene 0 
for 0 
C3 1
deficiency 1
is 0 
a 0 
null 0 
gene 0 
that 0 
is 0 
allelic 0 
to 0 
the 0 
structural 0 
gene 0 
for 0 
C3 0
and 0 
is 0 
not 0 
linked 0 
to 0 
the 0 
major 0 
histocompatibility 0 
locus 0 
. 0 

The 0 
current 0 
study 0 
used 0 
allotype 0 
analysis 0 
of 0 
canine 0 
C3 0
in 0 
order 0 
to 0 
demonstrate 0 
that 0 
the 0 
gene 0 
for 0 
C3 1
deficiency 1
in 0 
these 0 
dogs 0 
is 0 
also 0 
a 0 
null 0 
gene 0 
allelic 0 
to 0 
the 0 
structural 0 
gene 0 
for 0 
C3 0
. 0 

In 0 
addition 0 
, 0 
preliminary 0 
pedigree 0 
analysis 0 
suggests 0 
that 0 
the 0 
gene 0 
for 0 
canine 0 
C3 1
deficiency 1
is 0 
apparently 0 
not 0 
closely 0 
linked 0 
to 0 
the 0 
major 0 
histocompatibility 0 
complex 0 
of 0 
the 0 
dog 0 
. 0 

Thus 0 
, 0 
it 0 
appears 0 
that 0 
C3 1
deficiency 1
in 0 
Brittany 0 
spaniel 0 
dogs 0 
not 0 
only 0 
shares 0 
biochemical 0 
and 0 
clinical 0 
features 0 
with 0 
C3 1
deficiency 1
in 0 
humans 0 
, 0 
but 0 
also 0 
shares 0 
some 0 
genetic 0 
characteristics 0 
with 0 
the 0 
human 0 
disorder 0 
. 0 
. 0 

A 0 
novel 0 
frameshift 0 
mutation 0 
in 0 
the 0 
McLeod 1
syndrome 1
gene 0 
in 0 
a 0 
Japanese 0 
family 0 
. 0 

We 0 
report 0 
a 0 
novel 0 
mutation 0 
in 0 
the 0 
XK 0 
gene 0 
-LRB- 0 
XK 0 
-RRB- 0 
in 0 
a 0 
Japanese 0 
patient 0 
with 0 
McLeod 1
syndrome 1
. 0 

A 0 
50-year-old 0 
man 0 
showed 0 
progressive 0 
muscular 1
atrophy 1
, 0 
choreic 1
movement 1
, 0 
elevated 0 
level 0 
of 0 
serum 0 
creatinine 0 
kinase 0 
, 0 
and 0 
acanthocytosis 1
. 0 

The 0 
expression 0 
level 0 
of 0 
all 0 
the 0 
Kell 0 
antigens 0 
in 0 
erythrocyte 0 
was 0 
decreased 0 
and 0 
molecular 0 
analysis 0 
revealed 0 
a 0 
single-base 0 
-LRB- 0 
T 0 
-RRB- 0 
deletion 0 
at 0 
the 0 
nucleotide 0 
position 0 
_NUM4 0 
in 0 
XK 0 
. 0 

This 0 
deletion 0 
caused 0 
a 0 
frameshift 0 
in 0 
translation 0 
, 0 
leading 0 
to 0 
a 0 
premature 0 
stop 0 
codon 0 
at 0 
the 0 
amino 0 
acid 0 
position 0 
_NUM3 0 
. 0 

We 0 
conclude 0 
this 0 
single-base 0 
deletion 0 
causes 0 
defective 0 
Kx 0 
protein 0 
, 0 
which 0 
is 0 
responsible 0 
for 0 
the 0 
McLeod 1
phenotype 0 
in 0 
this 0 
patient 0 
. 0 
. 0 

Alpha-cardiac 0 
actin 0 
is 0 
a 0 
novel 0 
disease 0 
gene 0 
in 0 
familial 1
hypertrophic 1
cardiomyopathy 1
. 0 

We 0 
identified 0 
the 0 
alpha-cardiac 0 
actin 0 
gene 0 
-LRB- 0 
_DS 0 
-RRB- 0 
as 0 
a 0 
novel 0 
disease 0 
gene 0 
in 0 
a 0 
pedigree 0 
suffering 0 
from 0 
familial 1
hypertrophic 1
cardiomyopathy 1
-LRB- 0 
FHC 1
-RRB- 0 
. 0 

Linkage 0 
analyses 0 
excluded 0 
all 0 
the 0 
previously 0 
reported 0 
FHC 1
loci 0 
as 0 
possible 0 
disease 0 
loci 0 
in 0 
the 0 
family 0 
studied 0 
, 0 
with 0 
lod 0 
scores 0 
varying 0 
between 0 
-2 0 
. 0 

_NUM1 0 
and 0 
-6 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

Further 0 
linkage 0 
analyses 0 
of 0 
plausible 0 
candidate 0 
genes 0 
highly 0 
expressed 0 
in 0 
the 0 
adult 0 
human 0 
heart 0 
identified 0 
_DS 0 
as 0 
the 0 
most 0 
likely 0 
disease 0 
gene 0 
, 0 
showing 0 
a 0 
maximal 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

Mutation 0 
analysis 0 
of 0 
_DS 0 
revealed 0 
an 0 
Ala295Ser 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
close 0 
to 0 
_NUM1 0 
missense 0 
mutations 0 
recently 0 
described 0 
to 0 
cause 0 
the 0 
inherited 0 
form 0 
of 0 
idiopathic 1
dilated 1
cardiomyopathy 1
-LRB- 0 
IDC 1
-RRB- 0 
. 0 

The 0 
EWS 0 
gene 0 
, 0 
involved 0 
in 0 
Ewing 1
family 1
of 1
tumors 1
, 0 
malignant 1
melanoma 1
of 1
soft 1
parts 1
and 0 
desmoplastic 1
small 1
round 1
cell 1
tumors 1
, 0 
codes 0 
for 0 
an 0 
RNA 0 
binding 0 
protein 0 
with 0 
novel 0 
regulatory 0 
domains 0 
. 0 

The 0 
EWS 0 
gene 0 
, 0 
which 0 
maps 0 
to 0 
band 0 
_AN 0 
of 0 
human 0 
chromosome 0 
_NUM2 0 
, 0 
is 0 
involved 0 
in 0 
a 0 
wide 0 
variety 0 
of 0 
human 0 
solid 1
tumors 1
including 0 
Ewing 1
sarcoma 1
, 0 
related 0 
primitive 0 
neuroectodermal 1
tumors 1
, 0 
malignant 1
melanoma 1
of 1
soft 1
parts 1
and 0 
desmoplastic 1
small 1
round 1
cell 1
tumors 1
. 0 

In 0 
these 0 
tumors 1
, 0 
the 0 
EWS 0 
is 0 
fused 0 
to 0 
genes 0 
encoding 0 
transcriptional 0 
activators 0 
/ 0 
repressors 0 
, 0 
like 0 
Fli-1 0 
or 0 
erg 0 
or 0 
ATF 0 
_NUM1 0 
or 0 
wt1 0 
. 0 

To 0 
better 0 
understand 0 
the 0 
function 0 
of 0 
the 0 
EWS 0 
protein 0 
, 0 
we 0 
cloned 0 
the 0 
EWS 0 
cDNA 0 
. 0 

Sequence 0 
analysis 0 
of 0 
this 0 
cDNA 0 
revealed 0 
differential 0 
splicing 0 
involving 0 
two 0 
exons 0 
encoding 0 
_NUM2 0 
amino 0 
acids 0 
. 0 

Both 0 
alternatively 0 
spliced 0 
transcripts 0 
, 0 
EWS 0 
and 0 
EWS-b 0 
, 0 
are 0 
expressed 0 
in 0 
a 0 
variety 0 
of 0 
cells 0 
. 0 

Because 0 
EWS 0 
proteins 0 
contain 0 
putative 0 
conserved 0 
RNA 0 
binding 0 
motifs 0 
, 0 
we 0 
studied 0 
the 0 
RNA 0 
binding 0 
properties 0 
of 0 
the 0 
EWS 0 
protein 0 
. 0 

The 0 
EWS-b 0 
protein 0 
binds 0 
to 0 
RNA 0 
in 0 
vitro 0 
and 0 
, 0 
specifically 0 
, 0 
to 0 
poly 0 
G 0 
and 0 
poly 0 
U 0 
. 0 

The 0 
RNA 0 
binding 0 
activity 0 
was 0 
localized 0 
to 0 
the 0 
carboxy 0 
terminal 0 
_NUM2 0 
amino 0 
acids 0 
, 0 
which 0 
constitute 0 
RGG 0 
box 0 
. 0 

Thus 0 
the 0 
amino 0 
terminal 0 
domain 0 
of 0 
EWS 0 
-LRB- 0 
NTD-EWS 0 
-RRB- 0 
, 0 
which 0 
is 0 
involved 0 
in 0 
chromosome 0 
translocation 0 
may 0 
regulate 0 
the 0 
specificity 0 
of 0 
RNA 0 
binding 0 
activity 0 
of 0 
EWS 0 
. 0 

An 0 
EWS-erg 0 
chimeric 0 
protein 0 
, 0 
which 0 
is 0 
found 0 
in 0 
Ewings 1
sarcoma 1
cells 0 
, 0 
functions 0 
as 0 
a 0 
transcriptional 0 
activator 0 
. 0 

Mutational 0 
analysis 0 
of 0 
EWS-erg 0 
chimeric 0 
protein 0 
revealed 0 
that 0 
NTD-EWS 0 
functions 0 
as 0 
a 0 
regulatory 0 
domain 0 
for 0 
the 0 
transcriptional 0 
activation 0 
properties 0 
of 0 
EWS-erg 0 
chimeric 0 
protein 0 
. 0 
. 0 

A 0 
mutation 0 
common 0 
in 0 
non-Jewish 0 
Tay-Sachs 1
disease 1
: 0 
frequency 0 
and 0 
RNA 0 
studies 0 
. 0 

Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
genetic 1
disorder 1
resulting 0 
from 0 
mutation 0 
of 0 
the 0 
HEXA 0 
gene 0 
encoding 0 
the 0 
alpha-subunit 0 
of 0 
the 0 
lysosomal 0 
enzyme 0 
, 0 
beta-N-acetylhexosaminidase 0 
A 0 
-LRB- 0 
Hex 0 
A 0 
-RRB- 0 
. 0 

We 0 
have 0 
discovered 0 
that 0 
a 0 
Tay-Sachs 1
mutation 0 
, 0 
IVS-9 0 
+ 0 
_NUM1 0 
G 0 
-- 0 
> 0 
A 0 
, 0 
first 0 
detected 0 
by 0 
Akli 0 
et 0 
al. 0 
-LRB- 0 
Genomics 0 
_NUM2 0 
124-134 0 
, 0 
_NUM4 0 
-RRB- 0 
, 0 
is 0 
a 0 
common 0 
disease 0 
allele 0 
in 0 
non-Jewish 0 
Caucasians 0 
-LRB- 0 
10 0 
/ 0 
58 0 
alleles 0 
examined 0 
-RRB- 0 
. 0 

A 0 
PCR-based 0 
diagnostic 0 
test 0 
, 0 
which 0 
detects 0 
an 0 
NlaIII 0 
site 0 
generated 0 
by 0 
the 0 
mutation 0 
, 0 
revealed 0 
a 0 
frequency 0 
among 0 
enzyme-defined 0 
carriers 0 
of 0 
9 0 
/ 0 
64 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

Most 0 
of 0 
those 0 
carrying 0 
the 0 
allele 0 
trace 0 
their 0 
origins 0 
to 0 
the 0 
United 0 
Kingdom 0 
, 0 
Ireland 0 
, 0 
or 0 
Western 0 
Europe 0 
. 0 

It 0 
was 0 
not 0 
identified 0 
among 0 
_NUM2 0 
Black 0 
American 0 
TSD 1
alleles 0 
or 0 
in 0 
any 0 
of 0 
_NUM2 0 
Ashkenazi 0 
Jewish 0 
, 0 
enzyme-defined 0 
carriers 0 
who 0 
did 0 
not 0 
carry 0 
any 0 
of 0 
the 0 
mutations 0 
common 0 
to 0 
this 0 
population 0 
. 0 

No 0 
normally 0 
spliced 0 
RNA 0 
was 0 
detected 0 
in 0 
PCR 0 
products 0 
generated 0 
from 0 
reverse 0 
transcription 0 
of 0 
RNA 0 
carrying 0 
the 0 
IVS-9 0 
mutation 0 
. 0 

Instead 0 
, 0 
the 0 
low 0 
levels 0 
of 0 
mRNA 0 
from 0 
this 0 
allele 0 
were 0 
comprised 0 
of 0 
aberrant 0 
species 0 
resulting 0 
from 0 
the 0 
use 0 
of 0 
either 0 
of 0 
two 0 
cryptic 0 
donor 0 
sites 0 
, 0 
one 0 
truncating 0 
exon 0 
_NUM1 0 
and 0 
the 0 
other 0 
within 0 
IVS-9 0 
, 0 
spliced 0 
to 0 
exon 0 
_NUM2 0 
. 0 

Numerous 0 
additional 0 
splice 0 
products 0 
were 0 
detected 0 
, 0 
most 0 
involving 0 
skipping 0 
of 0 
one 0 
or 0 
more 0 
surrounding 0 
exons 0 
. 0 

Together 0 
with 0 
a 0 
recently 0 
identified 0 
allele 0 
responsible 0 
for 0 
Hex 0 
A 0 
pseudodeficiency 0 
-LRB- 0 
Triggs-Raine 0 
et 0 
al. 0 
. 0 

Am 0 
J 0 
Hum 0 
Genet 0 
, 0 
_NUM4 0 
-RRB- 0 
, 0 
these 0 
two 0 
alleles 0 
accounted 0 
for 0 
almost 0 
_NUM2 0 
% 0 
-LRB- 0 
29 0 
/ 0 
64 0 
-RRB- 0 
of 0 
TSD 1
or 0 
carrier 0 
alleles 0 
ascertained 0 
by 0 
enzyme 0 
screening 0 
tests 0 
in 0 
non-Jewish 0 
Caucasians 0 
. 0 
. 0 

Characterization 0 
of 0 
the 0 
myotonic 1
dystrophy 1
region 0 
predicts 0 
multiple 0 
protein 0 
isoform-encoding 0 
mRNAs 0 
. 0 

The 0 
mutation 0 
underlying 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
has 0 
been 0 
identified 0 
as 0 
an 0 
expansion 0 
of 0 
a 0 
polymorphic 0 
CTG-repeat 0 
in 0 
a 0 
gene 0 
encoding 0 
protein 0 
kinase 0 
activity 0 
. 0 

Brain 0 
and 0 
heart 0 
transcripts 0 
of 0 
the 0 
DM-kinase 0 
-LRB- 0 
DMR-B15 0 
-RRB- 0 
gene 0 
are 0 
subject 0 
to 0 
alternative 0 
RNA 0 
splicing 0 
in 0 
both 0 
human 0 
and 0 
mouse 0 
. 0 

The 0 
unstable 0 
-LSB- 0 
_DS 0 
-RSB- 0 
5-30 0 
motif 0 
is 0 
found 0 
uniquely 0 
in 0 
humans 0 
, 0 
although 0 
the 0 
flanking 0 
nucleotides 0 
are 0 
also 0 
present 0 
in 0 
mouse 0 
. 0 

Characterization 0 
of 0 
the 0 
DM 1
region 0 
of 0 
both 0 
species 0 
reveals 0 
another 0 
active 0 
gene 0 
-LRB- 0 
DMR-N9 0 
-RRB- 0 
in 0 
close 0 
proximity 0 
to 0 
the 0 
kinase 0 
gene 0 
. 0 

DMR-N9 0 
transcripts 0 
, 0 
mainly 0 
expressed 0 
in 0 
brain 0 
and 0 
testis 0 
, 0 
possess 0 
a 0 
single 0 
, 0 
large 0 
open 0 
reading 0 
frame 0 
, 0 
but 0 
the 0 
function 0 
of 0 
its 0 
protein 0 
product 0 
is 0 
unknown 0 
. 0 

Clinical 0 
manifestation 0 
of 0 
DM 1
may 0 
be 0 
caused 0 
by 0 
the 0 
expanded 0 
CTG-repeat 0 
compromising 0 
the 0 
-LRB- 0 
alternative 0 
-RRB- 0 
expression 0 
of 0 
DM-kinase 0 
or 0 
DMR-N9 0 
proteins 0 
. 0 
. 0 

Paroxysmal 1
nocturnal 1
haemoglobinuria 1
with 0 
coexisting 0 
deficiency 1
of 1
the 1
ninth 1
component 1
of 1
complement 1
: 0 
lack 0 
of 0 
massive 0 
haemolytic 1
attack 1
. 0 

A 0 
47-year-old 0 
woman 0 
with 0 
paroxysmal 1
nocturnal 1
haemoglobinuria 1
-LRB- 0 
PNH 1
-RRB- 0 
was 0 
found 0 
to 0 
have 0 
an 0 
inherited 1
deficiency 1
in 1
the 1
ninth 1
complement 1
component 1
-LRB- 0 
C9 0 
-RRB- 0 
. 0 

In 0 
complement-sensitivity 0 
lysis 0 
tests 0 
, 0 
_NUM2 0 
% 0 
of 0 
her 0 
erythrocytes 0 
were 0 
markedly 0 
complement-sensitive 0 
-LRB- 0 
PNH-III 0 
-RRB- 0 
. 0 

Laser 0 
cytofluorimetry 0 
with 0 
a 0 
monoclonal 0 
antibody 0 
against 0 
decay-accelerating 0 
factor 0 
-LRB- 0 
DAF 0 
-RRB- 0 
revealed 0 
that 0 
_NUM2 0 
% 0 
of 0 
her 0 
erythrocytes 0 
were 0 
DAF-negative 0 
. 0 

Surprisingly 0 
, 0 
she 0 
has 0 
suffered 0 
only 0 
mild 0 
haemolysis 1
and 0 
has 0 
never 0 
experienced 0 
massive 0 
spontaneous 0 
haemolysis 1
. 0 

Gross 0 
haemoglobinuria 1
and 0 
jaundice 1
occurred 0 
only 0 
after 0 
receiving 0 
postoperative 0 
transfusion 0 
of 0 
whole 0 
blood 0 
. 0 

In 0 
her 0 
serum 0 
, 0 
C9 0 
was 0 
not 0 
detectable 0 
either 0 
by 0 
immunological 0 
or 0 
by 0 
functional 0 
assays 0 
. 0 

Both 0 
the 0 
Ham 0 
test 0 
and 0 
the 0 
sugar 0 
water 0 
test 0 
using 0 
normal 0 
human 0 
serum 0 
or 0 
plasma 0 
yielded 0 
marked 0 
haemolysis 0 
of 0 
the 0 
patients 0 
erythrocytes 0 
. 0 

When 0 
the 0 
patients 0 
serum 0 
or 0 
plasma 0 
was 0 
used 0 
, 0 
only 0 
a 0 
trace 0 
of 0 
lysis 0 
was 0 
detected 0 
. 0 

Addition 0 
of 0 
purified 0 
human 0 
C9 0 
to 0 
her 0 
plasma 0 
fully 0 
restored 0 
haemolysis 0 
. 0 

These 0 
observations 0 
indicated 0 
that 0 
C9 0 
may 0 
play 0 
a 0 
critical 0 
role 0 
in 0 
haemolytic 1
attacks 1
in 0 
patients 0 
with 0 
PNH 1
and 0 
that 0 
characteristic 0 
haemolysis 1
in 0 
PNH 1
may 0 
be 0 
tempered 0 
by 0 
coexisting 0 
C9 1
deficiency 1
. 0 
. 0 

BRCA1 0 
is 0 
associated 0 
with 0 
a 0 
human 0 
SWI 0 
/ 0 
SNF-related 0 
complex 0 
: 0 
linking 0 
chromatin 0 
remodeling 0 
to 0 
breast 1
cancer 1
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
tumor 1
suppressor 0 
gene 0 
, 0 
BRCA1 0 
, 0 
predispose 0 
individuals 0 
to 0 
breast 1
and 1
ovarian 1
cancers 1
. 0 

Using 0 
a 0 
combination 0 
of 0 
affinity 0 
- 0 
and 0 
conventional 0 
chromatographic 0 
techniques 0 
, 0 
we 0 
have 0 
isolated 0 
a 0 
predominant 0 
form 0 
of 0 
a 0 
multiprotein 0 
BRCA1-containing 0 
complex 0 
from 0 
human 0 
cells 0 
displaying 0 
chromatin-remodeling 0 
activity 0 
. 0 

Mass 0 
spectrometric 0 
sequencing 0 
of 0 
components 0 
of 0 
this 0 
complex 0 
indicated 0 
that 0 
BRCA1 0 
is 0 
associated 0 
with 0 
a 0 
SWI 0 
/ 0 
SNF-related 0 
complex 0 
. 0 

We 0 
show 0 
that 0 
BRCA1 0 
can 0 
directly 0 
interact 0 
with 0 
the 0 
BRG1 0 
subunit 0 
of 0 
the 0 
SWI 0 
/ 0 
SNF 0 
complex 0 
. 0 

Moreover 0 
, 0 
p53-mediated 0 
stimulation 0 
of 0 
transcription 0 
by 0 
BRCA1 0 
was 0 
completely 0 
abrogated 0 
by 0 
either 0 
a 0 
dominant-negative 0 
mutant 0 
of 0 
BRG1 0 
or 0 
the 0 
cancer 1
causing 0 
deletion 0 
in 0 
exon 0 
_NUM2 0 
of 0 
BRCA1 0 
. 0 

These 0 
findings 0 
reveal 0 
a 0 
direct 0 
function 0 
for 0 
BRCA1 0 
in 0 
transcriptional 0 
control 0 
through 0 
modulation 0 
of 0 
chromatin 0 
structure 0 
. 0 
. 0 

Germinal 0 
mosaicism 0 
in 0 
a 0 
Duchenne 1
muscular 1
dystrophy 1
family 0 
: 0 
implications 0 
for 0 
genetic 0 
counselling 0 
. 0 

In 0 
this 0 
study 0 
we 0 
describe 0 
a 0 
three-generation 0 
family 0 
in 0 
which 0 
two 0 
siblings 0 
were 0 
affected 0 
by 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

Immunohistochemical 0 
analysis 0 
of 0 
muscle 0 
dystrophin 0 
and 0 
haplotype 0 
analysis 0 
of 0 
the 0 
DMD 1
locus 0 
revealed 0 
that 0 
the 0 
X 0 
chromosome 0 
carrying 0 
the 0 
DMD 1
gene 0 
was 0 
transmitted 0 
from 0 
the 0 
healthy 0 
maternal 0 
grandfather 0 
to 0 
his 0 
three 0 
daughters 0 
, 0 
including 0 
the 0 
probands 0 
mother 0 
. 0 

These 0 
findings 0 
indicate 0 
that 0 
the 0 
grandfather 0 
was 0 
a 0 
germinal 0 
mosaic 0 
for 0 
the 0 
DMD 1
gene 0 
. 0 

The 0 
definition 0 
of 0 
the 0 
carrier 0 
status 0 
in 0 
two 0 
possible 0 
carriers 0 
led 0 
us 0 
to 0 
give 0 
accurate 0 
genetic 0 
counselling 0 
and 0 
to 0 
prevent 0 
the 0 
birth 0 
of 0 
an 0 
affected 0 
boy 0 
. 0 

The 0 
results 0 
of 0 
this 0 
study 0 
demonstrate 0 
the 0 
usefulness 0 
of 0 
haplotype 0 
analysis 0 
and 0 
immunohistochemical 0 
muscle 0 
dystrophin 0 
studies 0 
to 0 
detect 0 
hidden 0 
germinal 0 
mosaicism 0 
and 0 
to 0 
improve 0 
genetic 0 
counselling 0 
. 0 
. 0 

Centrosome 0 
amplification 0 
and 0 
a 0 
defective 0 
G2-M 0 
cell 0 
cycle 0 
checkpoint 0 
induce 0 
genetic 0 
instability 0 
in 0 
BRCA1 0 
exon 0 
_NUM2 0 
isoform-deficient 0 
cells 0 
. 0 

Germline 0 
mutations 0 
of 0 
the 0 
Brca1 0 
tumor 1
suppressor 0 
gene 0 
predispose 0 
women 0 
to 0 
breast 1
and 1
ovarian 1
cancers 1
. 0 

To 0 
study 0 
mechanisms 0 
underlying 0 
BRCA1-related 0 
tumorigenesis 0 
, 0 
we 0 
derived 0 
mouse 0 
embryonic 0 
fibroblast 0 
cells 0 
carrying 0 
a 0 
targeted 0 
deletion 0 
of 0 
exon 0 
_NUM2 0 
of 0 
the 0 
Brca1 0 
gene 0 
. 0 

We 0 
show 0 
that 0 
the 0 
mutant 0 
cells 0 
maintain 0 
an 0 
intact 0 
G1-S 0 
cell 0 
cycle 0 
checkpoint 0 
and 0 
proliferate 0 
poorly 0 
. 0 

However 0 
, 0 
a 0 
defective 0 
G2-M 0 
checkpoint 0 
in 0 
these 0 
cells 0 
is 0 
accompanied 0 
by 0 
extensive 0 
chromosomal 1
abnormalities 1
. 0 

Mutant 0 
fibroblasts 0 
contain 0 
multiple 0 
, 0 
functional 0 
centrosomes 0 
, 0 
which 0 
lead 0 
to 0 
unequal 0 
chromosome 0 
segregation 0 
, 0 
abnormal 0 
nuclear 0 
division 0 
, 0 
and 0 
aneuploidy 1
. 0 

These 0 
data 0 
uncover 0 
an 0 
essential 0 
role 0 
of 0 
BRCA1 0 
in 0 
maintaining 0 
genetic 0 
stability 0 
through 0 
the 0 
regulation 0 
of 0 
centrosome 0 
duplication 0 
and 0 
the 0 
G2-M 0 
checkpoint 0 
and 0 
provide 0 
a 0 
molecular 0 
basis 0 
for 0 
the 0 
role 0 
of 0 
BRCA1 0 
in 0 
tumorigenesis 0 
. 0 
. 0 

Aberrant 0 
splicing 0 
of 0 
phenylalanine 0 
hydroxylase 0 
mRNA 0 
: 0 
the 0 
major 0 
cause 0 
for 0 
phenylketonuria 1
in 0 
parts 0 
of 0 
southern 0 
Europe 0 
. 0 

We 0 
report 0 
a 0 
mutation 0 
within 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
gene 0 
that 0 
causes 0 
aberrant 0 
splicing 0 
of 0 
the 0 
mRNA 0 
and 0 
that 0 
is 0 
in 0 
tight 0 
association 0 
with 0 
chromosomal 0 
haplotypes 0 
_NUM1 0 
, 0 
_NUM2 0 
, 0 
and 0 
_NUM2 0 
. 0 

Because 0 
of 0 
the 0 
high 0 
frequency 0 
of 0 
these 0 
particular 0 
haplotypes 0 
in 0 
Bulgaria 0 
, 0 
Italy 0 
, 0 
and 0 
Turkey 0 
, 0 
it 0 
appears 0 
to 0 
be 0 
one 0 
of 0 
the 0 
more 0 
frequent 0 
defects 0 
in 0 
the 0 
PAH 0 
gene 0 
causing 0 
classical 0 
phenylketonuria 1
in 0 
this 0 
part 0 
of 0 
Europe 0 
. 0 

The 0 
mutation 0 
is 0 
a 0 
G 0 
to 0 
A 0 
transition 0 
at 0 
position 0 
_NUM3 0 
in 0 
intron 0 
_NUM2 0 
of 0 
the 0 
PAH 0 
gene 0 
, 0 
_NUM2 0 
bp 0 
upstream 0 
from 0 
the 0 
intron 0 
10 0 
/ 0 
exon 0 
_NUM2 0 
boundary 0 
. 0 

It 0 
activates 0 
a 0 
cryptic 0 
splice 0 
site 0 
and 0 
results 0 
in 0 
an 0 
in-frame 0 
insertion 0 
of 0 
_NUM1 0 
nucleotides 0 
between 0 
exon 0 
_NUM2 0 
and 0 
exon 0 
_NUM2 0 
of 0 
the 0 
processed 0 
mRNA 0 
. 0 

Normal 0 
amounts 0 
of 0 
liver 0 
PAH 0 
protein 0 
are 0 
present 0 
in 0 
homozygous 0 
patients 0 
, 0 
but 0 
no 0 
catalytic 0 
activity 0 
can 0 
be 0 
detected 0 
. 0 

This 0 
loss 0 
of 0 
enzyme 0 
activity 0 
is 0 
probably 0 
caused 0 
by 0 
conformational 0 
changes 0 
resulting 0 
from 0 
the 0 
insertion 0 
of 0 
three 0 
additional 0 
amino 0 
acids 0 
-LRB- 0 
Gly-Leu-Gln 0 
-RRB- 0 
between 0 
the 0 
normal 0 
sequences 0 
encoded 0 
by 0 
exon 0 
_NUM2 0 
and 0 
exon 0 
_NUM2 0 
. 0 
. 0 

Biochemical 0 
and 0 
structural 0 
analysis 0 
of 0 
missense 0 
mutations 0 
in 0 
N-acetylgalactosamine-6-sulfate 0 
sulfatase 0 
causing 0 
mucopolysaccharidosis 1
IVA 1
phenotypes 0 
. 0 

Mucopolysaccharidosis 1
IVA 1
-LRB- 0 
MPS 1
IVA 1
; 0 
OMIM 0 
# 0 
_NUM6 0 
-RRB- 0 
, 0 
a 0 
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
a 0 
deficiency 1
of 1
N 1
-acetylgalactosamine-6-sulfate 1
sulfatase 1
-LRB- 0 
GALNS 0 
-RRB- 0 
, 0 
has 0 
variable 0 
clinical 0 
phenotypes 0 
. 0 

To 0 
date 0 
we 0 
have 0 
identified 0 
_NUM2 0 
missense 0 
mutations 0 
in 0 
the 0 
GALNS 0 
gene 0 
from 0 
MPS 1
IVA 1
patients 0 
, 0 
but 0 
the 0 
correlation 0 
between 0 
genotype 0 
and 0 
phenotype 0 
has 0 
remained 0 
unclear 0 
. 0 

We 0 
studied 0 
_NUM2 0 
missense 0 
mutations 0 
using 0 
biochemical 0 
approaches 0 
and 0 
_NUM2 0 
missense 0 
mutations 0 
, 0 
using 0 
structural 0 
analyses 0 
. 0 

Fifteen 0 
missense 0 
mutations 0 
and 0 
two 0 
newly 0 
engineered 0 
active 0 
site 0 
mutations 0 
-LRB- 0 
C79S 0 
, 0 
C79T 0 
-RRB- 0 
were 0 
characterized 0 
by 0 
transient 0 
expression 0 
analysis 0 
. 0 

Mutant 0 
proteins 0 
, 0 
except 0 
for 0 
C79S 0 
and 0 
C79T 0 
, 0 
were 0 
destabilized 0 
and 0 
detected 0 
as 0 
insoluble 0 
precursor 0 
forms 0 
while 0 
the 0 
C79S 0 
and 0 
C79T 0 
mutants 0 
were 0 
of 0 
a 0 
soluble 0 
mature 0 
size 0 
. 0 

Mutants 0 
found 0 
in 0 
the 0 
severe 0 
phenotype 0 
had 0 
no 0 
activity 0 
. 0 

Mutants 0 
found 0 
in 0 
the 0 
mild 0 
phenotype 0 
had 0 
a 0 
considerable 0 
residual 0 
activity 0 
-LRB- 0 
_NUM1 0 
. 0 

3-13 0 
. 0 

_NUM1 0 
% 0 
of 0 
wild-type 0 
GALNS 0 
activity 0 
-RRB- 0 
. 0 

Sulfatases 0 
, 0 
including 0 
GALNS 0 
, 0 
are 0 
members 0 
of 0 
a 0 
highly 0 
conserved 0 
gene 0 
family 0 
sharing 0 
an 0 
extensive 0 
sequence 0 
homology 0 
. 0 

Thus 0 
, 0 
a 0 
tertiary 0 
structural 0 
model 0 
of 0 
human 0 
GALNS 0 
was 0 
constructed 0 
from 0 
the 0 
X-ray 0 
crystal 0 
structure 0 
of 0 
N 0 
- 0 
acetylgalacto-samine-4-sulfatase 0 
and 0 
arylsulfatase 0 
A 0 
, 0 
using 0 
homology 0 
modeling 0 
, 0 
and 0 
_NUM2 0 
missense 0 
mutations 0 
were 0 
investigated 0 
. 0 

Consequently 0 
, 0 
we 0 
propose 0 
that 0 
there 0 
are 0 
at 0 
least 0 
three 0 
different 0 
reasons 0 
for 0 
the 0 
severe 0 
phenotype 0 
-LRB- 0 
i 0 
-RRB- 0 
destruction 0 
of 0 
the 0 
hydrophobic 0 
core 0 
or 0 
modification 0 
of 0 
the 0 
packing 0 
; 0 
-LRB- 0 
ii 0 
-RRB- 0 
removal 0 
of 0 
a 0 
salt 0 
bridge 0 
to 0 
destabilize 0 
the 0 
entire 0 
conformation 0 
; 0 
-LRB- 0 
iii 0 
-RRB- 0 
modification 0 
of 0 
the 0 
active 0 
site 0 
. 0 

In 0 
contrast 0 
, 0 
mild 0 
mutations 0 
were 0 
mostly 0 
located 0 
on 0 
the 0 
surface 0 
of 0 
the 0 
GALNS 0 
protein 0 
. 0 

These 0 
studies 0 
shed 0 
further 0 
light 0 
on 0 
the 0 
genotype-phenotype 0 
correlation 0 
of 0 
MPS 1
IVA 1
and 0 
structure-function 0 
relationship 0 
in 0 
the 0 
sulfatase 0 
family 0 
. 0 

Wiskott-Aldrich 1
syndrome 1
: 0 
cellular 0 
impairments 0 
and 0 
their 0 
implication 0 
for 0 
carrier 0 
detection 0 
. 0 

A 0 
family 0 
in 0 
which 0 
two 0 
male 0 
siblings 0 
were 0 
affected 0 
with 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
was 0 
studied 0 
using 0 
G-6-PD 0 
isoenzymes 0 
as 0 
an 0 
X-linked 0 
marker 0 
in 0 
order 0 
to 0 
investigate 0 
the 0 
nature 0 
of 0 
cellular 0 
abnormalities 0 
. 0 

Isolated 0 
peripheral 0 
blood 0 
cell 0 
types 0 
from 0 
the 0 
doubly 0 
heterozygous 0 
mother 0 
of 0 
the 0 
affected 0 
males 0 
seemingly 0 
failed 0 
to 0 
express 0 
the 0 
G-6-PD 0 
allele 0 
in 0 
cis 0 
position 0 
with 0 
the 0 
WAS 1
allele 0 
while 0 
her 0 
cultured 0 
skin 0 
fibroblasts 0 
expressed 0 
both 0 
G-6-PD 0 
alleles 0 
. 0 

Additionally 0 
, 0 
a 0 
histogram 0 
analysis 0 
of 0 
platelet 0 
size 0 
revealed 0 
a 0 
single 0 
population 0 
of 0 
abnormally 0 
small 0 
platelets 0 
in 0 
the 0 
affected 0 
propositus 0 
, 0 
whereas 0 
the 0 
heterozygous 0 
mother 0 
had 0 
no 0 
appreciable 0 
small 0 
platelet 0 
subpopulation 0 
. 0 

In 0 
vitro 0 
culture 0 
of 0 
hemopoietic 0 
progenitor 0 
cells 0 
of 0 
the 0 
heterozygous 0 
mother 0 
showed 0 
that 0 
the 0 
majority 0 
of 0 
progenitor 0 
cells 0 
did 0 
not 0 
express 0 
the 0 
WAS 1
allele 0 
. 0 

However 0 
, 0 
a 0 
small 0 
number 0 
of 0 
cells 0 
expressing 0 
the 0 
G-6-PD 0 
type 0 
linked 0 
with 0 
the 0 
WAS 1
allele 0 
were 0 
detected 0 
. 0 

The 0 
proportion 0 
of 0 
the 0 
latter 0 
progenitors 0 
was 0 
significantly 0 
higher 0 
among 0 
more 0 
primitive 0 
progenitors 0 
-LRB- 0 
those 0 
giving 0 
rise 0 
to 0 
later 0 
appearing 0 
colonies 0 
-RRB- 0 
. 0 

This 0 
observation 0 
suggests 0 
that 0 
selection 0 
against 0 
cells 0 
expressing 0 
the 0 
Wiskott-Aldrich 1
defect 1
takes 0 
place 0 
in 0 
the 0 
hemopoietic 0 
system 0 
of 0 
the 0 
heterozygous 0 
female 0 
and 0 
offers 0 
a 0 
possible 0 
means 0 
of 0 
carrier 0 
detection 0 
in 0 
some 0 
women 0 
. 0 

Linkage 0 
studies 0 
in 0 
this 0 
family 0 
revealed 0 
one 0 
example 0 
of 0 
probable 0 
recombination 0 
between 0 
the 0 
loci 0 
for 0 
WAS 1
and 0 
G-6-PD 0 
among 0 
three 0 
informative 0 
subjects 0 
, 0 
suggesting 0 
that 0 
these 0 
two 0 
loci 0 
may 0 
not 0 
be 0 
closely 0 
linked 0 
on 0 
the 0 
X-chromosome 0 
. 0 
. 0 

Familial 1
deficiency 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
associated 0 
with 0 
recurrent 0 
meningococcal 1
infections 1
. 0 

We 0 
describe 0 
an 0 
11-year-old 0 
girl 0 
suffering 0 
from 0 
recurrent 1
meningitis 1
with 0 
a 0 
complete 0 
absence 1
of 1
the 1
seventh 1
component 1
of 1
complement 1
-LRB- 0 
C7 0
-RRB- 0 
. 0 

Diagnosis 0 
was 0 
established 0 
by 0 
haemolytic 0 
titration 0 
and 0 
western 0 
blotting 0 
. 0 

The 0 
patients 0 
serum 0 
lacked 0 
the 0 
_NUM2 0 
kDa 0 
C7 0
chain 0 
. 0 

Haemolytic 0 
activity 0 
of 0 
serum 0 
was 0 
reconstituted 0 
with 0 
either 0 
pooled 0 
normal 0 
human 0 
serum 0 
or 0 
with 0 
purified 0 
C7 0
. 0 

The 0 
relatives 0 
-LRB- 0 
parents 0 
and 0 
one 0 
sister 0 
-RRB- 0 
had 0 
half-normal 0 
levels 0 
of 0 
both 0 
immunochemically 0 
and 0 
functionally 0 
determined 0 
C7 0
, 0 
indicating 0 
a 0 
heterozygous 0 
state 0 
for 0 
C7 1
deficiency 1
. 0 
. 0 

Non-syndromic 1
hearing 1
loss 1
associated 0 
with 0 
enlarged 1
vestibular 1
aqueduct 1
is 0 
caused 0 
by 0 
PDS 1
mutations 0 
. 0 

Enlarged 1
vestibular 1
aqueduct 1
-LRB- 0 
EVA 1
-RRB- 0 
, 0 
known 0 
as 0 
the 0 
most 0 
common 0 
form 0 
of 0 
inner 1
ear 1
abnormality 1
, 0 
has 0 
recently 0 
been 0 
of 0 
particular 0 
genetic 0 
interest 0 
because 0 
this 0 
anomaly 0 
is 0 
inherited 0 
in 0 
a 0 
recessive 0 
manner 0 
. 0 

The 0 
locus 0 
for 0 
non-syndromic 1
sensorineural 1
hearing 1
loss 1
with 0 
EVA 1
has 0 
been 0 
mapped 0 
to 0 
the 0 
same 0 
chromosomal 0 
region 0 
, 0 
7q31 0 
, 0 
as 0 
the 0 
Pendred 1
syndrome 1
locus 0 
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
seven 0 
mutations 0 
in 0 
the 0 
PDS 1
gene 0 
-LRB- 0 
PDS 0 
-RRB- 0 
, 0 
the 0 
gene 0 
responsible 0 
for 0 
Pendred 1
syndrome 1
, 0 
have 0 
been 0 
found 0 
in 0 
families 0 
of 0 
non-syndromic 1
sensorineural 1
hearing 1
loss 1
with 0 
EVA 1
. 0 

One 0 
family 0 
is 0 
homozygous 0 
, 0 
three 0 
families 0 
are 0 
compound 0 
heterozygotes 0 
, 0 
and 0 
two 0 
families 0 
are 0 
heterozygous 0 
but 0 
with 0 
no 0 
other 0 
mutation 0 
detected 0 
. 0 

The 0 
present 0 
results 0 
provide 0 
evidence 0 
that 0 
mutations 0 
in 0 
PDS 0 
cause 0 
both 0 
syndromic 1
and 1
non-syndromic 1
hearing 1
loss 1
. 0 
. 0 

Deletions 0 
of 0 
a 0 
DNA 0 
sequence 0 
in 0 
retinoblastomas 1
and 0 
mesenchymal 1
tumors 1
: 0 
organization 0 
of 0 
the 0 
sequence 0 
and 0 
its 0 
encoded 0 
protein 0 
. 0 

Retinoblastoma 1
is 0 
a 0 
childhood 1
tumor 1
that 0 
can 0 
arise 0 
because 0 
of 0 
mutant 0 
alleles 0 
acquired 0 
as 0 
somatic 0 
or 0 
germinal 0 
mutations 0 
. 0 

The 0 
mutant 0 
allele 0 
can 0 
be 0 
carried 0 
in 0 
the 0 
germ 0 
line 0 
. 0 

The 0 
mutations 0 
creating 0 
these 0 
alleles 0 
act 0 
by 0 
inactivating 0 
copies 0 
of 0 
a 0 
recessive 0 
oncogene 0 
located 0 
within 0 
band 0 
_AN 0 
of 0 
chromosome 0 
_NUM2 0 
and 0 
termed 0 
the 0 
RB1 0 
locus 0 
. 0 

We 0 
have 0 
reported 0 
isolation 0 
of 0 
a 0 
cDNA 0 
fragment 0 
that 0 
recognizes 0 
chromosomal 0 
sequences 0 
possessing 0 
many 0 
of 0 
the 0 
attributes 0 
of 0 
the 0 
retinoblastoma 1
gene 0 
associated 0 
with 0 
the 0 
RB1 0 
locus 0 
. 0 

We 0 
now 0 
report 0 
that 0 
this 0 
segment 0 
is 0 
additionally 0 
the 0 
target 0 
of 0 
somatic 0 
mutations 0 
in 0 
mesenchymal 1
tumors 1
among 0 
patients 0 
having 0 
no 0 
apparent 0 
predisposition 0 
to 0 
retinoblastoma 1
and 0 
no 0 
previous 0 
evidence 0 
of 0 
retinoblastoma 1
. 0 

These 0 
tumors 1
provide 0 
additional 0 
evidence 0 
that 0 
the 0 
cloned 0 
sequences 0 
are 0 
representative 0 
of 0 
a 0 
gene 0 
that 0 
is 0 
a 0 
frequent 0 
target 0 
of 0 
inactivation 0 
during 0 
tumorigenesis 0 
. 0 

Sequence 0 
analysis 0 
of 0 
this 0 
cDNA 0 
provides 0 
little 0 
insight 0 
into 0 
its 0 
normal 0 
functional 0 
role 0 
. 0 
. 0 

Genetically 0 
determined 0 
low 0 
C4 0 
: 0 
a 0 
predisposing 0 
factor 0 
to 0 
autoimmune 1
chronic 1
active 1
hepatitis 1
. 0 

Of 0 
_NUM2 0 
patients 0 
with 0 
autoimmune 1
chronic 1
active 1
hepatitis 1
-LRB- 0 
CAH 1
-RRB- 0 
starting 0 
in 0 
childhood 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
had 0 
low 0 
C4 0 
and 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
had 0 
low 0 
C3 0 
serum 0 
levels 0 
. 0 

Impaired 0 
hepatic 0 
synthesis 0 
and 0 
immune-consumption 0 
were 0 
unlikely 0 
since 0 
transferrin 0 
levels 0 
were 0 
normal 0 
in 0 
all 0 
patients 0 
, 0 
albumin 0 
levels 0 
were 0 
persistently 0 
low 0 
in 0 
only 0 
_NUM1 0 
, 0 
and 0 
only 0 
_NUM1 0 
had 0 
raised 0 
levels 0 
of 0 
activation 0 
fragment 0 
C3d 0 
. 0 

C4d 0 
was 0 
normal 0 
in 0 
all 0 
patients 0 
studied 0 
. 0 

In 0 
the 0 
families 0 
of 0 
_NUM2 0 
probands 0 
with 0 
low 0 
C4 0 
, 0 
_NUM1 0 
parents 0 
had 0 
low 0 
C4 0 
and 0 
_NUM1 0 
had 0 
levels 0 
which 0 
were 0 
at 0 
the 0 
lower 0 
limit 0 
of 0 
normal 0 
. 0 

_NUM1 0 
of 0 
_NUM2 0 
siblings 0 
from 0 
_NUM1 0 
families 0 
had 0 
low 0 
C4 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
low 0 
C4 0 
levels 0 
in 0 
CAH 1
are 0 
genetically 0 
determined 0 
. 0 

C4 0
phenotyping 0 
in 0 
_NUM2 0 
patients 0 
and 0 
in 0 
_NUM2 0 
parents 0 
showed 0 
that 0 
_NUM2 0 
% 0 
and 0 
_NUM2 0 
% 0 
, 0 
respectively 0 
, 0 
had 0 
null 0 
allotypes 0 
at 0 
either 0 
the 0 
C4A 0 
or 0 
C4B 0 
locus 0 
compared 0 
with 0 
_NUM2 0 
% 0 
in 0 
controls 0 
, 0 
indicating 0 
that 0 
defective 0 
expression 0 
of 0 
structural 0 
genes 0 
may 0 
contribute 0 
to 0 
the 0 
observed 0 
C4 1
deficiency 1
. 0 
. 0 

Tight 0 
linkage 0 
between 0 
myotonic 1
dystrophy 1
and 0 
apolipoprotein 0 
E 0 
genes 0 
revealed 0 
with 0 
allele-specific 0 
oligonucleotides 0 
. 0 

In 0 
_NUM2 0 
families 0 
with 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
a 0 
novel 0 
approach 0 
based 0 
on 0 
use 0 
of 0 
allele-specific 0 
oligonucleotides 0 
has 0 
been 0 
employed 0 
to 0 
study 0 
the 0 
linkage 0 
relationship 0 
between 0 
the 0 
apolipoprotein 0 
E 0 
-LRB- 0 
APOE 0 
-RRB- 0 
gene 0 
and 0 
DM 1
. 0 

Synthetic 0 
oligonucleotides 0 
, 0 
designed 0 
to 0 
discriminate 0 
between 0 
APOE 0 
alleles 0 
epsilon 0 
_NUM1 0 
and 0 
epsilon 0 
_NUM1 0 
, 0 
enabled 0 
us 0 
to 0 
distinguish 0 
heterozygous 0 
carriers 0 
in 0 
a 0 
hybridization 0 
assay 0 
. 0 

In 0 
a 0 
subset 0 
of 0 
families 0 
, 0 
the 0 
relevant 0 
segment 0 
of 0 
the 0 
APOE 0 
gene 0 
was 0 
enzymatically 0 
amplified 0 
to 0 
increase 0 
the 0 
sensitivity 0 
of 0 
the 0 
method 0 
. 0 

For 0 
DM 1
and 0 
APOE 0 
, 0 
a 0 
maximum 0 
lod 0 
score 0 
-LRB- 0 
zmax 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
was 0 
obtained 0 
at 0 
a 0 
recombination 0 
frequency 0 
-LRB- 0 
theta 0 
-RRB- 0 
of 0 
_NUM1 0 
. 0 

_NUM3 0 
-LRB- 0 
male 0 
theta 0 
= 0 
female 0 
theta 0 
-RRB- 0 
. 0 

No 0 
recombination 0 
-LRB- 0 
maximum 0 
lod 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
was 0 
found 0 
between 0 
APOE 0 
and 0 
the 0 
apolipoprotein 0 
CII 0 
-LRB- 0 
APOC2 0 
-RRB- 0 
gene 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
, 0 
in 0 
addition 0 
to 0 
APOC2 0 
, 0 
APOE 0 
is 0 
a 0 
useful 0 
marker 0 
for 0 
presymptomatic 0 
DM 0 
diagnosis 0 
. 0 

Confirmation 0 
of 0 
BRCA1 0 
by 0 
analysis 0 
of 0 
germline 0 
mutations 0 
linked 0 
to 0 
breast 1
and 1
ovarian 1
cancer 1
in 0 
ten 0 
families 0 
. 0 

We 0 
provide 0 
genetic 0 
evidence 0 
supporting 0 
the 0 
identity 0 
of 0 
the 0 
candidate 0 
gene 0 
for 0 
BRCA1 0 
through 0 
the 0 
characterization 0 
of 0 
germline 0 
mutations 0 
in 0 
_NUM2 0 
breast 1
cancer 1
patients 0 
and 0 
_NUM2 0 
ovarian 1
cancer 1
patients 0 
in 0 
ten 0 
families 0 
with 0 
cancer 1
linked 0 
to 0 
chromosome 0 
17q21 0 
. 0 

Nine 0 
different 0 
mutations 0 
were 0 
detected 0 
by 0 
screening 0 
BRCA1 0 
DNA 0 
and 0 
RNA 0 
by 0 
single-strand 0 
conformation 0 
polymorphism 0 
analysis 0 
and 0 
direct 0 
sequencing 0 
. 0 

Seven 0 
mutations 0 
lead 0 
to 0 
protein 0 
truncations 0 
at 0 
sites 0 
throughout 0 
the 0 
gene 0 
. 0 

One 0 
missense 0 
mutation 0 
-LRB- 0 
which 0 
occurred 0 
independently 0 
in 0 
two 0 
families 0 
-RRB- 0 
leads 0 
to 0 
loss 0 
of 0 
a 0 
cysteine 0 
in 0 
the 0 
zinc 0 
binding 0 
domain 0 
. 0 

An 0 
intronic 0 
single 0 
basepair 0 
substitution 0 
destroys 0 
an 0 
acceptor 0 
site 0 
and 0 
activates 0 
a 0 
cryptic 0 
splice 0 
site 0 
, 0 
leading 0 
to 0 
a 0 
_NUM2 0 
basepair 0 
insertion 0 
and 0 
chain 0 
termination 0 
. 0 

The 0 
four 0 
families 0 
with 0 
both 0 
breast 1
and 1
ovarian 1
cancer 1
had 0 
chain 0 
termination 0 
mutations 0 
in 0 
the 0 
N-terminal 0 
half 0 
of 0 
the 0 
protein 0 
. 0 
. 0 

Genetic 0 
instability 0 
in 0 
human 0 
ovarian 1
cancer 1
cell 0 
lines 0 
. 0 

We 0 
have 0 
analyzed 0 
the 0 
stability 0 
of 0 
microsatellites 0 
in 0 
cell 0 
lines 0 
derived 0 
from 0 
human 0 
ovarian 1
cancers 1
and 0 
found 0 
that 0 
_NUM1 0 
out 0 
of 0 
_NUM2 0 
of 0 
the 0 
ovarian 1
tumor 1
cell 0 
lines 0 
are 0 
genetically 0 
unstable 0 
at 0 
the 0 
majority 0 
of 0 
the 0 
loci 0 
analyzed 0 
. 0 

In 0 
clones 0 
and 0 
subclones 0 
derived 0 
serially 0 
from 0 
one 0 
of 0 
these 0 
cell 0 
lines 0 
-LRB- 0 
_NUM4 0 
; 0 
serous 1
cystadenocarcinoma 1
-RRB- 0 
, 0 
a 0 
very 0 
high 0 
proportion 0 
of 0 
microsatellites 0 
distributed 0 
in 0 
many 0 
different 0 
regions 0 
of 0 
the 0 
genome 0 
change 0 
their 0 
size 0 
in 0 
a 0 
mercurial 0 
fashion 0 
. 0 

We 0 
conclude 0 
that 0 
genomic 0 
instability 0 
in 0 
ovarian 1
tumors 1
is 0 
a 0 
dynamic 0 
and 0 
ongoing 0 
process 0 
whose 0 
high 0 
frequency 0 
may 0 
have 0 
been 0 
previously 0 
underestimated 0 
by 0 
PCR-based 0 
allelotyping 0 
of 0 
bulk 0 
tumor 1
tissue 0 
. 0 

We 0 
have 0 
identified 0 
the 0 
source 0 
of 0 
the 0 
genetic 0 
instability 0 
in 0 
one 0 
ovarian 1
tumor 1
as 0 
a 0 
point 0 
mutation 0 
-LRB- 0 
R524P 0 
-RRB- 0 
in 0 
the 0 
human 0 
mismatch-repair 0 
gene 0 
MSH2 0 
-LRB- 0 
Salmonella 0 
MutS 0 
homologue 0 
-RRB- 0 
, 0 
which 0 
has 0 
recently 0 
been 0 
shown 0 
to 0 
be 0 
involved 0 
in 0 
hereditary 1
nonpolyposis 1
colorectal 1
cancer 1
. 0 

Patient 0 
_NUM4 0 
was 0 
a 0 
38-year-old 0 
heterozygote 0 
, 0 
and 0 
her 0 
normal 0 
tissue 0 
carried 0 
both 0 
mutant 0 
and 0 
wild-type 0 
alleles 0 
of 0 
the 0 
human 0 
MSH2 0 
gene 0 
. 0 

However 0 
the 0 
wild-type 0 
allele 0 
was 0 
lost 0 
at 0 
some 0 
point 0 
early 0 
during 0 
tumorigenesis 0 
so 0 
that 0 
DNA 0 
isolated 0 
either 0 
from 0 
the 0 
patients 0 
ovarian 1
tumor 1
or 0 
from 0 
the 0 
_NUM4 0 
cell 0 
line 0 
carries 0 
only 0 
the 0 
mutant 0 
allele 0 
of 0 
the 0 
human 0 
MSH2 0 
gene 0 
. 0 

The 0 
genetic 0 
instability 0 
observed 0 
in 0 
the 0 
tumor 1
and 0 
cell 0 
line 0 
DNA 0 
, 0 
together 0 
with 0 
the 0 
germ-line 0 
mutation 0 
in 0 
a 0 
mismatch-repair 0 
gene 0 
, 0 
suggest 0 
that 0 
the 0 
MSH2 0 
gene 0 
is 0 
involved 0 
in 0 
the 0 
onset 0 
and 0 
/ 0 
or 0 
progression 0 
in 0 
a 0 
subset 0 
of 0 
ovarian 1
cancer 1
. 0 
. 0 

Retroviral-mediated 0 
gene 0 
transfer 0 
of 0 
human 0 
phenylalanine 0 
hydroxylase 0 
into 0 
NIH 0 
3T3 0 
and 0 
hepatoma 1
cells 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
caused 0 
by 0 
deficiency 1
of 1
the 1
hepatic 1
enzyme 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

A 0 
full-length 0 
human 0 
PAH 0 
cDNA 0 
sequence 0 
has 0 
been 0 
inserted 0 
into 0 
pzip-neoSV 0 
-LRB- 0 
X 0 
-RRB- 0 
, 0 
which 0 
is 0 
a 0 
retroviral 0 
vector 0 
containing 0 
the 0 
bacterial 0 
neo 0 
gene 0 
. 0 

The 0 
recombinant 0 
has 0 
been 0 
transfected 0 
into 0 
psi 0 
_NUM1 0 
cells 0 
, 0 
which 0 
provide 0 
synthesis 0 
of 0 
the 0 
retroviral 0 
capsid 0 
. 0 

Recombinant 0 
virus 0 
was 0 
detected 0 
in 0 
the 0 
culture 0 
medium 0 
of 0 
the 0 
transfected 0 
psi 0 
_NUM1 0 
cells 0 
, 0 
which 0 
is 0 
capable 0 
of 0 
transmitting 0 
the 0 
human 0 
PAH 0 
gene 0 
into 0 
mouse 0 
NIH 0 
3T3 0 
cells 0 
by 0 
infection 0 
leading 0 
to 0 
stable 0 
incorporation 0 
of 0 
the 0 
recombinant 0 
provirus 0 
. 0 

Infected 0 
cells 0 
express 0 
PAH 0 
mRNA 0 
, 0 
immunoreactive 0 
PAH 0 
protein 0 
, 0 
and 0 
exhibit 0 
pterin-dependent 0 
phenylalanine 0 
hydroxylase 0 
activity 0 
. 0 

The 0 
recombinant 0 
virus 0 
is 0 
also 0 
capable 0 
of 0 
infecting 0 
a 0 
mouse 0 
hepatoma 1
cell 0 
line 0 
that 0 
does 0 
not 0 
normally 0 
synthesize 0 
PAH 0 
. 0 

PAH 0 
activity 0 
is 0 
present 0 
in 0 
the 0 
cellular 0 
extracts 0 
and 0 
the 0 
entire 0 
hydroxylation 0 
system 0 
is 0 
reconstituted 0 
in 0 
the 0 
hepatoma 1
cells 0 
infected 0 
with 0 
the 0 
recombinant 0 
viruses 0 
. 0 

Thus 0 
, 0 
recombinant 0 
viruses 0 
containing 0 
human 0 
PAH 0 
cDNA 0 
provide 0 
a 0 
means 0 
for 0 
introducing 0 
functional 0 
PAH 0 
into 0 
mammalian 0 
cells 0 
of 0 
hepatic 0 
origin 0 
and 0 
can 0 
potentially 0 
be 0 
introduced 0 
into 0 
whole 0 
animals 0 
as 0 
a 0 
model 0 
for 0 
somatic 0 
gene 0 
therapy 0 
for 0 
PKU 1
. 0 
. 0 

Characterisation 0 
of 0 
molecular 0 
defects 0 
in 0 
X-linked 1
amelogenesis 1
imperfecta 1
-LRB- 0 
AIH1 0 
-RRB- 0 
. 0 

Amelogenins 0 
are 0 
an 0 
heterogenous 0 
family 0 
of 0 
proteins 0 
produced 0 
by 0 
ameloblasts 0 
of 0 
the 0 
enamel 0 
organ 0 
during 0 
tooth 0 
development 0 
. 0 

Disturbances 0 
of 0 
enamel 0 
formation 0 
occur 0 
in 0 
amelogenesis 1
imperfecta 1
, 0 
a 0 
clinically 0 
heterogenous 0 
group 0 
of 0 
inherited 1
disorders 1
characterised 0 
by 0 
defective 0 
enamel 0 
biomineralisation 0 
. 0 

An 0 
amelogenin 0 
gene 0 
, 0 
AMGX 0 
, 0 
has 0 
been 0 
mapped 0 
to 0 
the 0 
short 0 
of 0 
the 0 
X 0 
chromosome 0 
-LRB- 0 
Xp22 0 
. 0 

1-p22 0 
. 0 

_NUM1 0 
-RRB- 0 
and 0 
has 0 
been 0 
implicated 0 
in 0 
the 0 
molecular 0 
pathology 0 
of 0 
X-linked 1
amelogenesis 1
imperfecta 1
-LRB- 0 
AIH1 1
-RRB- 0 
. 0 

We 0 
have 0 
identified 0 
three 0 
families 0 
exhibiting 0 
AIH1 1
and 0 
screened 0 
the 0 
AMGX 0 
gene 0 
for 0 
mutations 0 
using 0 
single-strand 0 
conformational 0 
polymorphism 0 
analysis 0 
and 0 
DNA 0 
sequencing 0 
. 0 

Three 0 
novel 0 
mutations 0 
were 0 
identified 0 
a 0 
C-T 0 
substitution 0 
in 0 
exon 0 
_NUM1 0 
, 0 
and 0 
a 0 
G-T 0 
substitution 0 
and 0 
single 0 
cytosine 0 
deletion 0 
in 0 
exon 0 
_NUM1 0 
, 0 
confirming 0 
the 0 
existence 0 
of 0 
extensive 0 
allelic 0 
heterogeneity 0 
in 0 
this 0 
condition 0 
. 0 

The 0 
identification 0 
of 0 
family-specific 0 
mutations 0 
will 0 
enable 0 
early 0 
identification 0 
of 0 
affected 0 
individuals 0 
and 0 
correlation 0 
of 0 
clinical 0 
phenotype 0 
with 0 
genotype 0 
will 0 
facilitate 0 
an 0 
objective 0 
system 0 
of 0 
disease 0 
classification 0 
. 0 

The 0 
Pendred 1
syndrome 1
gene 0 
encodes 0 
a 0 
chloride-iodide 0 
transport 0 
protein 0 
. 0 

Pendred 1
syndrome 1
is 0 
the 0 
most 0 
common 0 
form 0 
of 0 
syndromic 1
deafness 1
and 0 
characterized 0 
by 0 
congenital 0 
sensorineural 1
hearing 1
loss 1
and 0 
goitre 1
. 0 

This 0 
disorder 0 
was 0 
mapped 0 
to 0 
chromosome 0 
_NUM1 0 
and 0 
the 0 
gene 0 
causing 0 
Pendred 1
syndrome 1
-LRB- 0 
PDS 1
-RRB- 0 
was 0 
subsequently 0 
identified 0 
by 0 
positional 0 
cloning 0 
. 0 

PDS 0 
encodes 0 
a 0 
putative 0 
transmembrane 0 
protein 0 
designated 0 
pendrin 0 
. 0 

Pendrin 0 
is 0 
closely 0 
related 0 
to 0 
a 0 
family 0 
of 0 
sulfate 0 
transport 0 
proteins 0 
that 0 
includes 0 
the 0 
rat 0 
sulfate-anion 0 
transporter 0 
-LRB- 0 
encoded 0 
by 0 
Sat-1 0 
; 0 
_NUM2 0 
% 0 
amino 0 
acid 0 
sequence 0 
identity 0 
-RRB- 0 
, 0 
the 0 
human 0 
diastrophic 1
dysplasia 1
sulfate 0 
transporter 0 
-LRB- 0 
encoded 0 
by 0 
DTD 0 
; 0 
_NUM2 0 
% 0 
-RRB- 0 
and 0 
the 0 
human 0 
sulfate 0 
transporter 0 
downregulated 0 
in 0 
adenoma 1
-LRB- 0 
encoded 0 
by 0 
DRA 0 
; 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
this 0 
homology 0 
and 0 
the 0 
presence 0 
of 0 
a 0 
slightly 0 
modified 0 
sulfate-transporter 0 
signature 0 
sequence 0 
comprising 0 
its 0 
putative 0 
second 0 
transmembrane 0 
domain 0 
, 0 
pendrin 0 
has 0 
been 0 
proposed 0 
to 0 
function 0 
as 0 
a 0 
sulfate 0 
transporter 0 
. 0 

We 0 
were 0 
unable 0 
to 0 
detect 0 
evidence 0 
of 0 
sulfate 0 
transport 0 
following 0 
the 0 
expression 0 
of 0 
pendrin 0 
in 0 
Xenopus 0 
laevis 0 
oocytes 0 
by 0 
microinjection 0 
of 0 
PDS 0 
cRNA 0 
or 0 
in 0 
Sf9 0 
cells 0 
following 0 
infection 0 
with 0 
PDS-recombinant 0 
baculovirus 0 
. 0 

The 0 
rates 0 
of 0 
transport 0 
for 0 
iodide 0 
and 0 
chloride 0 
were 0 
significantly 0 
increased 0 
following 0 
the 0 
expression 0 
of 0 
pendrin 0 
in 0 
both 0 
cell 0 
systems 0 
. 0 

Our 0 
results 0 
demonstrate 0 
that 0 
pendrin 0 
functions 0 
as 0 
a 0 
transporter 0 
of 0 
chloride 0 
and 0 
iodide 0 
, 0 
but 0 
not 0 
sulfate 0 
, 0 
and 0 
may 0 
provide 0 
insight 0 
into 0 
thyroid 0 
physiology 0 
and 0 
the 0 
pathophysiology 0 
of 0 
Pendred 1
syndrome 1
. 0 
. 0 

Linkage 0 
relationship 0 
of 0 
C2 1
deficiency 1
, 0 
HLA 0 
and 0 
glyoxalase 0 
I 0 
loci 0 
. 0 

Immunogenetic 0 
analysis 0 
of 0 
a 0 
homozygous 0 
C2-deficient 1
individual 0 
and 0 
family 0 
members 0 
demonstrated 0 
linkage 0 
of 0 
HLA-A25 0 
, 0 
_AN 0 
and 0 
C2o 0 
. 0 

HLA-D 0 
typing 0 
showed 0 
that 0 
_NUM1 0 
members 0 
typed 0 
with 0 
homozygous 0 
Dw2 0 
typing 0 
cells 0 
from 0 
an 0 
individual 0 
with 0 
C2 1
deficiency 1
but 0 
not 0 
with 0 
Dw2 0 
typing 0 
cells 0 
from 0 
_NUM1 0 
individuals 0 
with 0 
normal 0 
C2 0 
. 0 

The 0 
homozygous 0 
C2-deficient 1
propositus 0 
and 0 
brother 0 
were 0 
HLA-A 0 
and 0 
B 0 
homozygous 0 
but 0 
heterozygous 0 
at 0 
the 0 
HLA-D 0 
and 0 
glyoxalase 0 
I 0 
loci 0 
. 0 

Therefore 0 
, 0 
in 0 
this 0 
family 0 
, 0 
the 0 
C2o 0 
gene 0 
is 0 
linked 0 
with 0 
two 0 
distinct 0 
haplotypes 0 
HLA-A25 0 
, 0 
_AN 0 
, 0 
Dw2 0 
, 0 
GLO1 0 
and 0 
HLA-A25 0 
, 0 
_AN 0 
, 0 
D 0 
unknown 0 
, 0 
GL02 0 
. 0 

These 0 
results 0 
could 0 
be 0 
explained 0 
by 0 
an 0 
ancestral 0 
recombinant 0 
event 0 
, 0 
which 0 
occurred 0 
between 0 
the 0 
C2o 0 
locus 0 
and 0 
HLA-D 0 
locus 0 
in 0 
which 0 
C2o 0 
segregated 0 
with 0 
HLA-B 0 
. 0 

This 0 
would 0 
suggest 0 
that 0 
the 0 
locus 0 
for 0 
the 0 
C2o 0 
gene 0 
maps 0 
between 0 
HLA-B 0 
and 0 
HLA-D 0 
on 0 
the 0 
sixth 0 
chromosome 0 
. 0 
. 0 

A 0 
71-kilodalton 0 
protein 0 
is 0 
a 0 
major 0 
product 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
gene 0 
in 0 
brain 0 
and 0 
other 0 
nonmuscle 0 
tissues 0 
. 0 

The 0 
known 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
products 0 
, 0 
the 0 
muscle 0 
- 0 
and 0 
brain-type 0 
dystrophin 0 
isoforms 0 
, 0 
are 0 
427-kDa 0 
proteins 0 
translated 0 
from 0 
14-kilobase 0 
-LRB- 0 
kb 0 
-RRB- 0 
mRNAs 0 
. 0 

Recently 0 
we 0 
described 0 
a 0 
_NUM1 0 
. 0 

5-kb 0 
mRNA 0 
that 0 
also 0 
is 0 
transcribed 0 
from 0 
the 0 
DMD 1
gene 0 
. 0 

Cloning 0 
and 0 
in 0 
vitro 0 
transcription 0 
and 0 
translation 0 
of 0 
the 0 
entire 0 
coding 0 
region 0 
show 0 
that 0 
the 0 
_NUM1 0 
. 0 

5-kb 0 
mRNA 0 
encodes 0 
a 0 
_NUM2 0 
. 0 

8-kDa 0 
protein 0 
that 0 
is 0 
a 0 
major 0 
product 0 
of 0 
the 0 
DMD 1
gene 0 
. 0 

It 0 
contains 0 
the 0 
C-terminal 0 
and 0 
the 0 
cysteine-rich 0 
domains 0 
of 0 
dystrophin 0 
, 0 
seven 0 
additional 0 
amino 0 
acids 0 
at 0 
the 0 
N 0 
terminus 0 
, 0 
and 0 
some 0 
modifications 0 
formed 0 
by 0 
alternative 0 
splicing 0 
in 0 
the 0 
C-terminal 0 
domain 0 
. 0 

It 0 
lacks 0 
the 0 
entire 0 
large 0 
domain 0 
of 0 
spectrin-like 0 
repeats 0 
and 0 
the 0 
actin-binding 0 
N-terminal 0 
domain 0 
of 0 
dystrophin 0 
. 0 

This 0 
protein 0 
is 0 
the 0 
major 0 
DMD 1
gene 0 
product 0 
in 0 
brain 0 
and 0 
other 0 
nonmuscle 0 
tissues 0 
but 0 
is 0 
undetectable 0 
in 0 
skeletal 0 
muscle 0 
extracts 0 
. 0 

Histidinemia 1
. 0 

Classical 0 
and 0 
atypical 0 
form 0 
in 0 
siblings 0 
. 0 

Two 0 
brothers 0 
, 0 
_NUM1 0 
and 0 
_NUM2 0 
years 0 
old 0 
, 0 
had 0 
histidinemia 1
. 0 

On 0 
the 0 
basis 0 
of 0 
clinical 0 
and 0 
biochemical 0 
observations 0 
, 0 
the 0 
younger 0 
boy 0 
was 0 
considered 0 
to 0 
have 0 
a 0 
classical 0 
type 0 
of 0 
the 0 
disease 0 
, 0 
while 0 
the 0 
older 0 
boy 0 
had 0 
an 0 
atypical 0 
form 0 
characterized 0 
by 0 
partial 0 
impairment 0 
of 0 
the 0 
skin 0 
histidase 0 
activity 0 
and 0 
a 0 
moderately 0 
prolonged 0 
half-life 0 
of 0 
blood 0 
histidine 0 
. 0 

The 0 
mother 0 
is 0 
a 0 
heterozygous 0 
carrier 0 
, 0 
while 0 
the 0 
father 0 
and 0 
sister 0 
seem 0 
to 0 
be 0 
normal 0 
. 0 
. 0 

Hypoxanthine-guanine 1
phosphoribosyltransferase 1
deficiency 1
: 0 
analysis 0 
of 0 
HPRT 0 
mutations 0 
by 0 
direct 0 
sequencing 0 
and 0 
allele-specific 0 
amplification 0 
. 0 

The 0 
Lesch-Nyhan 1
syndrome 1
is 0 
a 0 
severe 0 
X 1
chromosome-linked 1
human 1
disease 1
caused 0 
by 0 
a 0 
virtual 0 
absence 1
of 1
hypoxanthine-guanine 1
phosphoribosyltransferase 1
-LRB- 1
HPRT 1
-RRB- 1
activity 1
. 0 

A 0 
partial 0 
deficiency 0 
in 0 
the 0 
activity 0 
of 0 
this 0 
enzyme 0 
can 0 
result 0 
in 0 
gouty 1
arthritis 1
. 0 

To 0 
determine 0 
the 0 
genetic 0 
basis 0 
for 0 
reduction 0 
or 0 
loss 0 
of 0 
enzyme 0 
activity 0 
, 0 
we 0 
have 0 
amplified 0 
and 0 
sequenced 0 
the 0 
coding 0 
region 0 
of 0 
HPRT 0 
cDNA 0 
from 0 
four 0 
patients 0 
one 0 
with 0 
Lesch-Nyhan 1
syndrome 1
-LRB- 0 
HPRTPerth 0 
-RRB- 0 
and 0 
three 0 
with 0 
partial 1
deficiencies 1
of 1
HPRT 1
activity 1
, 0 
which 0 
have 0 
been 0 
designated 0 
HPRTUrangan 0 
, 0 
HPRTSwan 0 
and 0 
HPRTToowong 0 
. 0 

In 0 
all 0 
four 0 
patients 0 
, 0 
the 0 
only 0 
mutation 0 
identified 0 
was 0 
a 0 
single 0 
base 0 
substitution 0 
in 0 
exons 0 
_NUM1 0 
or 0 
_NUM1 0 
of 0 
the 0 
coding 0 
region 0 
, 0 
which 0 
in 0 
each 0 
case 0 
predicts 0 
a 0 
single 0 
amino 0 
acid 0 
substitution 0 
in 0 
the 0 
translated 0 
protein 0 
. 0 

Each 0 
base 0 
change 0 
was 0 
confirmed 0 
by 0 
allele-specific 0 
amplification 0 
of 0 
the 0 
patients 0 
genomic 0 
DNA 0 
. 0 

It 0 
is 0 
interesting 0 
to 0 
note 0 
that 0 
the 0 
mutation 0 
found 0 
for 0 
HPRTPerth 0 
is 0 
identical 0 
to 0 
that 0 
reported 0 
for 0 
HPRTFlint 0 
. 0 

It 0 
appears 0 
that 0 
the 0 
two 0 
mutations 0 
are 0 
de 0 
novo 0 
events 0 
. 0 
. 0 

Sjogren-Larsson 1
syndrome 1
. 0 

Impaired 0 
fatty 0 
alcohol 0 
oxidation 0 
in 0 
cultured 0 
fibroblasts 0 
due 0 
to 0 
deficient 0 
fatty 0 
alcohol 0 
: 0 
nicotinamide 0 
adenine 0 
dinucleotide 0 
oxidoreductase 0 
activity 0 
. 0 

Lipid 0 
metabolism 0 
was 0 
studied 0 
in 0 
cultured 0 
skin 0 
fibroblasts 0 
from 0 
patients 0 
with 0 
the 0 
inherited 1
disorder 1
, 0 
Sjogren-Larsson 1
syndrome 1
-LRB- 0 
SLS 1
-RRB- 0 
. 0 

Intact 0 
SLS 1
fibroblasts 0 
incubated 0 
in 0 
the 0 
presence 0 
of 0 
-LSB- 0 
1-14C 0 
-RSB- 0 
palmitate 0 
accumulated 0 
more 0 
radioactive 0 
hexadecanol 0 
than 0 
did 0 
normal 0 
cells 0 
, 0 
whereas 0 
incorporation 0 
of 0 
radioactivity 0 
into 0 
other 0 
cellular 0 
lipids 0 
was 0 
unaltered 0 
. 0 

The 0 
hexadecanol 0 
content 0 
of 0 
SLS 1
fibroblasts 0 
was 0 
abnormally 0 
elevated 0 
. 0 

Hexadecanol 0 
accumulation 0 
was 0 
not 0 
due 0 
to 0 
increased 0 
fatty 0 
alcohol 0 
synthesis 0 
nor 0 
its 0 
deficient 0 
utilization 0 
for 0 
glycerol 0 
ether 0 
synthesis 0 
. 0 

The 0 
half-life 0 
of 0 
intracellular 0 
hexadecanol 0 
loaded 0 
into 0 
SLS 1
fibroblasts 0 
was 0 
increased 0 
-LRB- 0 
_NUM2 0 
min 0 
-RRB- 0 
compared 0 
with 0 
normal 0 
-LRB- 0 
_NUM2 0 
min 0 
-RRB- 0 
, 0 
and 0 
intact 0 
SLS 1
fibroblasts 0 
showed 0 
impaired 0 
oxidation 0 
of 0 
-LSB- 0 
14C 0 
-RSB- 0 
- 0 
hexadecanol 0 
to 0 
fatty 0 
acid 0 
. 0 

Fatty 0 
alcohol 0 
NAD 0 
+ 0 
oxidoreductase 0 
, 0 
the 0 
enzyme 0 
catalyzing 0 
this 0 
reaction 0 
, 0 
was 0 
deficient 0 
in 0 
SLS 1
fibroblasts 0 
. 0 

Mean 0 
total 0 
activity 0 
in 0 
SLS 1
fibroblasts 0 
-LRB- 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
was 0 
_NUM2 0 
% 0 
of 0 
that 0 
in 0 
normal 0 
fibroblasts 0 
, 0 
and 0 
palmitoyl 0 
CoA-inhibitable 0 
activity 0 
was 0 
_NUM1 0 
% 0 
of 0 
normal 0 
. 0 

Fibroblasts 0 
from 0 
two 0 
obligate 0 
SLS 1
heterozygotes 0 
had 0 
enzyme 0 
activities 0 
intermediate 0 
between 0 
that 0 
in 0 
normal 0 
fibroblasts 0 
and 0 
individuals 0 
with 0 
SLS 1
. 0 

These 0 
results 0 
suggest 0 
that 0 
the 0 
primary 0 
defect 0 
in 0 
SLS 1
is 0 
deficiency 1
of 1
fatty 1
alcohol 1
NAD 1
+ 1
oxidoreductase 1
. 0 

SLS 1
represents 0 
the 0 
first 0 
inherited 1
disorder 1
in 0 
man 0 
associated 0 
with 0 
an 0 
isolated 0 
abnormality 1
in 1
fatty 1
alcohol 1
metabolism 1
. 0 
. 0 

Glycerol 0 
as 0 
a 0 
correlate 0 
of 0 
impaired 1
glucose 1
tolerance 1
: 0 
dissection 0 
of 0 
a 0 
complex 0 
system 0 
by 0 
use 0 
of 0 
a 0 
simple 0 
genetic 0 
trait 0 
. 0 

Glycerol 0 
kinase 0 
-LRB- 0 
GK 0 
-RRB- 0 
represents 0 
the 0 
primary 0 
entry 0 
of 0 
glycerol 0 
into 0 
glucose 0 
and 0 
triglyceride 0 
metabolism 0 
. 0 

Impaired 1
glucose 1
tolerance 1
-LRB- 0 
IGT 1
-RRB- 0 
and 0 
hypertriglyceridemia 1
are 0 
associated 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
diabetes 1
mellitus 1
and 0 
cardiovascular 1
disease 1
. 0 

The 0 
relationship 0 
between 0 
glycerol 0 
and 0 
the 0 
risk 0 
of 0 
IGT 1
, 0 
however 0 
, 0 
is 0 
poorly 0 
understood 0 
. 0 

We 0 
therefore 0 
undertook 0 
the 0 
study 0 
of 0 
fasting 0 
plasma 0 
glycerol 0 
levels 0 
in 0 
a 0 
cohort 0 
of 0 
_NUM1 0 
, 0 
_NUM3 0 
unrelated 0 
men 0 
and 0 
women 0 
of 0 
French-Canadian 0 
descent 0 
. 0 

Family 0 
screening 0 
in 0 
the 0 
initial 0 
cohort 0 
identified 0 
_NUM2 0 
men 0 
from 0 
five 0 
families 0 
with 0 
severe 0 
hyperglycerolemia 1
-LRB- 0 
values 0 
above 0 
_NUM1 0 
. 0 

_NUM1 0 
mmol 0 
/ 0 
liter 0 
-RRB- 0 
and 0 
demonstrated 0 
an 0 
X-linked 0 
pattern 0 
of 0 
inheritance 0 
. 0 

Linkage 0 
analysis 0 
of 0 
the 0 
data 0 
from 0 
_NUM2 0 
microsatellite 0 
markers 0 
surrounding 0 
the 0 
Xp21 0 
. 0 

_NUM1 0 
GK 0 
gene 0 
resulted 0 
in 0 
a 0 
peak 0 
LOD 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
centered 0 
around 0 
marker 0 
DXS8039 0 
. 0 

In 0 
addition 0 
, 0 
since 0 
all 0 
of 0 
the 0 
families 0 
originated 0 
in 0 
a 0 
population 0 
with 0 
a 0 
proven 0 
founder 0 
effect-the 0 
Saguenay 0 
Lac-St 0 
. 0 

- 0 
Jean 0 
region 0 
of 0 
Quebec-a 0 
common 0 
disease 0 
haplotype 0 
was 0 
sought 0 
. 0 

Indeed 0 
, 0 
a 0 
six-marker 0 
haplotype 0 
extending 0 
over 0 
a 0 
region 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
cM 0 
was 0 
observed 0 
in 0 
all 0 
families 0 
. 0 

Resequencing 0 
of 0 
the 0 
GK 0 
gene 0 
in 0 
family 0 
members 0 
led 0 
to 0 
the 0 
discovery 0 
of 0 
a 0 
N288D 0 
missense 0 
mutation 0 
in 0 
exon 0 
_NUM2 0 
, 0 
which 0 
resulted 0 
in 0 
the 0 
substitution 0 
of 0 
a 0 
highly 0 
conserved 0 
asparagine 0 
residue 0 
by 0 
a 0 
negatively 0 
charged 0 
aspartic 0 
acid 0 
. 0 

Assignment 0 
of 0 
the 0 
aspartylglucosaminidase 0 
gene 0 
-LRB- 0 
_DS 0 
-RRB- 0 
to 0 
4q33 0 
-- 0 
_AN 0 
based 0 
on 0 
decreased 0 
activity 0 
in 0 
a 0 
girl 0 
with 0 
a 0 
_NUM2 0 
, 0 
XX 0 
, 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
-RRB- 0 
karyotype 0 
. 0 

Aspartylglucosaminuria 1
-LRB- 0 
AGU 1
-RRB- 0 
is 0 
a 0 
recessive 0 
autosomally 0 
inherited 0 
lysosomal 1
storage 1
disorder 1
due 0 
to 0 
deficiency 1
of 1
the 1
enzyme 1
aspartylglucosaminidase 1
-LRB- 0 
_DS 0 
-RRB- 0 
. 0 

The 0 
structural 0 
gene 0 
for 0 
this 0 
human 0 
enzyme 0 
-LRB- 0 
_DS 0 
-RRB- 0 
has 0 
been 0 
assigned 0 
to 0 
the 0 
region 0 
4q21 0 
-- 0 
qter 0 
. 0 

We 0 
determined 0 
the 0 
_DS 0 
activity 0 
in 0 
cultured 0 
fibroblasts 0 
of 0 
a 0 
girl 0 
with 0 
a 0 
_NUM2 0 
, 0 
XX 0 
, 0 
del 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
-RRB- 0 
karyotype 0 
. 0 

The 0 
results 0 
indicate 0 
that 0 
the 0 
girl 0 
is 0 
a 0 
hemizygote 0 
for 0 
_DS 0 
, 0 
permitting 0 
the 0 
assignment 0 
of 0 
human 0 
_DS 0 
to 0 
the 0 
region 0 
4q33 0 
-- 0 
qter 0 
. 0 
. 0 

Mutations 0 
in 0 
the 0 
fibrinogen 0 
aalpha 0 
gene 0 
account 0 
for 0 
the 0 
majority 0 
of 0 
cases 0 
of 0 
congenital 1
afibrinogenemia 1
. 0 

Congenital 1
afibrinogenemia 1
is 0 
a 0 
rare 0 
, 0 
autosomal 1
, 1
recessive 1
disorder 1
characterized 0 
by 0 
the 0 
complete 0 
absence 0 
of 0 
detectable 0 
fibrinogen 0 
. 0 

We 0 
previously 0 
identified 0 
the 0 
first 0 
causative 0 
mutations 0 
in 0 
a 0 
nonconsanguineous 0 
Swiss 0 
family 0 
; 0 
the 0 
_NUM1 0 
affected 0 
persons 0 
have 0 
homozygous 0 
deletions 0 
of 0 
approximately 0 
_NUM2 0 
kb 0 
of 0 
the 0 
fibrinogen 0 
alpha 0 
-LRB- 0 
FGA 0 
-RRB- 0 
gene 0 
. 0 

Haplotype 0 
data 0 
implied 0 
that 0 
these 0 
deletions 0 
occurred 0 
on 0 
distinct 0 
ancestral 0 
chromosomes 0 
, 0 
suggesting 0 
that 0 
this 0 
region 0 
may 0 
be 0 
susceptible 0 
to 0 
deletion 0 
by 0 
a 0 
common 0 
mechanism 0 
. 0 

We 0 
subsequently 0 
showed 0 
that 0 
all 0 
the 0 
deletions 0 
were 0 
identical 0 
to 0 
the 0 
base 0 
pair 0 
and 0 
probably 0 
resulted 0 
from 0 
a 0 
nonhomologous 0 
recombination 0 
mediated 0 
by 0 
7-bp 0 
direct 0 
repeats 0 
. 0 

In 0 
this 0 
study 0 
, 0 
we 0 
have 0 
collected 0 
data 0 
on 0 
_NUM2 0 
additional 0 
unrelated 0 
patients 0 
to 0 
identify 0 
the 0 
causative 0 
mutations 0 
and 0 
to 0 
determine 0 
the 0 
prevalence 0 
of 0 
the 0 
11-kb 0 
deletion 0 
. 0 

A 0 
common 0 
recurrent 0 
mutation 0 
, 0 
at 0 
the 0 
donor 0 
splice 0 
site 0 
of 0 
FGA 0 
intron 0 
_NUM1 0 
-LRB- 0 
IVS4 0 
+ 0 
_NUM1 0 
G 0 
> 0 
T 0 
-RRB- 0 
, 0 
accounted 0 
for 0 
_NUM2 0 
of 0 
the 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
alleles 0 
. 0 

One 0 
patient 0 
was 0 
heterozygous 0 
for 0 
the 0 
previously 0 
identified 0 
deletion 0 
. 0 

Three 0 
more 0 
frameshift 0 
mutations 0 
, 0 
_NUM1 0 
nonsense 0 
mutations 0 
, 0 
and 0 
a 0 
second 0 
splice 0 
site 0 
mutation 0 
were 0 
also 0 
identified 0 
. 0 

Consequently 0 
, 0 
_NUM2 0 
% 0 
of 0 
afibrinogenemia 1
alleles 0 
analyzed 0 
to 0 
date 0 
have 0 
truncating 0 
mutations 0 
of 0 
FGA 0 
, 0 
though 0 
mutations 0 
in 0 
all 0 
_NUM1 0 
fibrinogen 0 
genes 0 
, 0 
FGG 0 
, 0 
FGA 0 
, 0 
and 0 
FGB 0 
, 0 
might 0 
be 0 
predicted 0 
to 0 
cause 0 
congenital 1
afibrinogenemia 1
. 0 
. 0 

Utilization 0 
of 0 
purines 0 
by 0 
an 0 
HPRT 0 
variant 0 
in 0 
an 0 
intelligent 0 
, 0 
nonmutilative 0 
patient 0 
with 0 
features 0 
of 0 
the 0 
Lesch-Nyhan 1
syndrome 1
. 0 

The 0 
patient 0 
, 0 
H. 0 
Chr 0 
. 0 

B. 0 
, 0 
was 0 
among 0 
the 0 
first 0 
reported 0 
with 0 
hyperuricemia 1
and 0 
central 1
nervous 1
system 1
symptoms 1
. 0 

He 0 
has 0 
been 0 
found 0 
to 0 
have 0 
a 0 
variant 0 
of 0 
hypoxanthine 0 
guanine 0 
phosphoribosyl 0 
transferase 0 
-LRB- 0 
HPRT 0 
; 0 
E. 0 
C. 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
distinct 0 
from 0 
the 0 
enzyme 0 
present 0 
in 0 
patients 0 
with 0 
the 0 
Lesch-Nyhan 1
syndrome 1
. 0 

The 0 
patient 0 
had 0 
chroeoathetosis 1
, 0 
spasticity 1
, 0 
dysarthric 1
speech 1
, 0 
and 0 
hyperuricemia 1
. 0 

However 0 
, 0 
his 0 
intelligence 0 
was 0 
normal 0 
and 0 
he 0 
had 0 
no 0 
evidence 0 
of 0 
self-mutilation 0 
. 0 

There 0 
was 0 
no 0 
activity 0 
of 0 
HPRT 0 
in 0 
the 0 
lysates 0 
of 0 
erythrocytes 0 
and 0 
cultured 0 
fibroblasts 0 
when 0 
analyzed 0 
in 0 
the 0 
usual 0 
manner 0 
. 0 

Using 0 
a 0 
newly 0 
developed 0 
method 0 
for 0 
the 0 
study 0 
of 0 
purine 0 
metabolism 0 
in 0 
intact 0 
cultured 0 
cells 0 
, 0 
this 0 
patient 0 
was 0 
found 0 
to 0 
metabolize 0 
some 0 
_NUM1 0 
% 0 
of 0 
8-14C-hypoxanthine 0 
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
the 0 
isotope 0 
utilized 0 
was 0 
converted 0 
to 0 
adenine 0 
and 0 
guanine 0 
nucleotides 0 
. 0 

In 0 
contrast 0 
, 0 
cells 0 
from 0 
patients 0 
with 0 
the 0 
Lesch-Nyhan 1
syndrome 1
were 0 
virtually 0 
completely 0 
unable 0 
to 0 
convert 0 
hypoxanthine 0 
to 0 
nucleotides 0 
. 0 

The 0 
patients 0 
fibroblasts 0 
were 0 
even 0 
more 0 
efficient 0 
in 0 
the 0 
metabolism 0 
of 0 
8-14C-guanine 0 
, 0 
which 0 
was 0 
utilized 0 
to 0 
the 0 
extent 0 
of 0 
_NUM2 0 
% 0 
, 0 
over 0 
_NUM2 0 
% 0 
of 0 
which 0 
was 0 
converted 0 
to 0 
guanine 0 
and 0 
adenine 0 
nucleotides 0 
. 0 

The 0 
growth 0 
of 0 
the 0 
cultured 0 
fibroblasts 0 
of 0 
this 0 
patient 0 
was 0 
intermediate 0 
in 0 
media 0 
containing 0 
hypoxanthine 0 
aminopterin 0 
thymidine 0 
-LRB- 0 
HAT 0 
-RRB- 0 
, 0 
whereas 0 
the 0 
growth 0 
of 0 
Lesch-Nyhan 1
cells 0 
was 0 
inhibited 0 
and 0 
normal 0 
cells 0 
grew 0 
normally 0 
. 0 

Similarly 0 
in 0 
8-azaguanine 0 
, 0 
6-thioguanine 0 
, 0 
and 0 
8-azahypoxanthine 0 
, 0 
the 0 
growth 0 
of 0 
the 0 
patients 0 
cells 0 
was 0 
intermediate 0 
between 0 
normal 0 
and 0 
Lesch-Nyhan 1
cells 0 
. 0 

These 0 
observations 0 
provide 0 
further 0 
evidence 0 
for 0 
genetic 0 
heterogeneity 0 
among 0 
patients 0 
with 0 
disorders 0 
in 0 
purine 0 
metabolism 0 
involving 0 
the 0 
HPRT 0 
gene 0 
. 0 

They 0 
document 0 
that 0 
this 0 
famous 0 
patient 0 
did 0 
not 0 
have 0 
the 0 
Lesch-Nyhan 1
syndrome 1
Canavan 1
disease 1
: 0 
mutations 0 
among 0 
Jewish 0 
and 0 
non-Jewish 0 
patients 0 
. 0 

Canavan 1
disease 1
is 0 
an 0 
autosomal 1
recessive 1
leukodystrophy 1
caused 0 
by 0 
the 0 
deficiency 1
of 1
aspartoacylase 1
-LRB- 0 
ASPA 0 
-RRB- 0 
. 0 

Sixty-four 0 
probands 0 
were 0 
analyzed 0 
for 0 
mutations 0 
in 0 
the 0 
ASPA 0 
gene 0 
. 0 

Three 0 
point 0 
mutations 0 
-- 0 
693C 0 
-- 0 
> 0 
A 0 
, 0 
854A 0 
-- 0 
> 0 
C 0 
, 0 
and 0 
914C 0 
-- 0 
> 0 
A 0 
-- 0 
were 0 
identified 0 
in 0 
the 0 
coding 0 
sequence 0 
. 0 

The 0 
693C 0 
-- 0 
> 0 
A 0 
and 0 
914C 0 
-- 0 
> 0 
A 0 
base 0 
changes 0 
, 0 
resulting 0 
in 0 
nonsense 0 
tyr231 0 
-- 0 
> 0 
ter 0 
and 0 
missense 0 
ala305 0 
-- 0 
> 0 
glu 0 
mutations 0 
, 0 
respectively 0 
, 0 
lead 0 
to 0 
complete 0 
loss 0 
of 0 
ASPA 0 
activity 0 
in 0 
in 0 
vitro 0 
expression 0 
studies 0 
. 0 

The 0 
854A 0 
-- 0 
> 0 
C 0 
transversion 0 
converted 0 
glu 0 
to 0 
ala 0 
in 0 
codon 0 
_NUM3 0 
. 0 

The 0 
glu285 0 
-- 0 
> 0 
ala 0 
mutant 0 
ASPA 0 
has 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
activity 0 
expressed 0 
by 0 
the 0 
wild-type 0 
enzyme 0 
. 0 

A 0 
fourth 0 
mutation 0 
, 0 
_NUM3 0 
-- 0 
_NUM1 0 
-LRB- 0 
A 0 
-- 0 
> 0 
G 0 
-RRB- 0 
transition 0 
, 0 
was 0 
identified 0 
at 0 
the 0 
splice-acceptor 0 
site 0 
in 0 
intron 0 
_NUM1 0 
. 0 

The 0 
splice-site 0 
mutation 0 
would 0 
lead 0 
to 0 
skipping 0 
of 0 
exon 0 
_NUM1 0 
, 0 
accompanied 0 
by 0 
a 0 
frameshift 0 
, 0 
and 0 
thus 0 
would 0 
produce 0 
aberrant 0 
ASPA 0 
. 0 

Of 0 
the 0 
_NUM3 0 
unrelated 0 
Canavan 1
chromosomes 0 
analyzed 0 
, 0 
_NUM2 0 
were 0 
from 0 
probands 0 
of 0 
Ashkenazi 0 
Jewish 0 
descent 0 
. 0 

The 0 
glu285 0 
-- 0 
> 0 
ala 0 
mutation 0 
was 0 
predominant 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
in 0 
this 0 
population 0 
, 0 
followed 0 
by 0 
the 0 
tyr231 0 
-- 0 
> 0 
ter 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
_NUM3 0 
-- 0 
_NUM1 0 
-LRB- 0 
A 0 
-- 0 
> 0 
G 0 
-RRB- 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
mutations 0 
. 0 

The 0 
three 0 
mutations 0 
account 0 
for 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
Canavan 1
chromosomes 0 
of 0 
Ashkenazi 0 
Jewish 0 
origin 0 
. 0 

The 0 
ala305 0 
-- 0 
> 0 
glu 0 
mutation 0 
was 0 
found 0 
exclusively 0 
in 0 
non-Jewish 0 
probands 0 
of 0 
European 0 
descent 0 
and 0 
constituted 0 
_NUM2 0 
% 0 
of 0 
the 0 
_NUM2 0 
mutant 0 
chromosomes 0 
. 0 

Predominant 0 
occurrence 0 
of 0 
certain 0 
mutations 0 
among 0 
Ashkenazi 0 
Jewish 0 
and 0 
non-Jewish 0 
patients 0 
with 0 
Canavan 1
disease 1
would 0 
suggest 0 
a 0 
founding-father 0 
effect 0 
in 0 
propagation 0 
of 0 
these 0 
mutant 0 
chromosomes 0 
Identification 0 
of 0 
deletion 0 
mutations 0 
and 0 
three 0 
new 0 
genes 0 
at 0 
the 0 
familial 1
polyposis 1
locus 0 
. 0 

Small 0 
-LRB- 0 
100-260 0 
kb 0 
-RRB- 0 
, 0 
nested 0 
deletions 0 
were 0 
characterized 0 
in 0 
DNA 0 
from 0 
two 0 
unrelated 0 
patients 0 
with 0 
familial 1
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
. 0 

Three 0 
candidate 0 
genes 0 
located 0 
within 0 
the 0 
deleted 0 
region 0 
were 0 
ascertained 0 
and 0 
a 0 
previous 0 
candidate 0 
gene 0 
, 0 
MCC 0 
, 0 
was 0 
shown 0 
to 0 
be 0 
located 0 
outside 0 
the 0 
deleted 0 
region 0 
. 0 

One 0 
of 0 
the 0 
new 0 
genes 0 
contained 0 
sequence 0 
identical 0 
to 0 
SRP19 0 
, 0 
the 0 
gene 0 
coding 0 
for 0 
the 0 
_NUM2 0 
kd 0 
component 0 
of 0 
the 0 
ribosomal 0 
signal 0 
recognition 0 
particle 0 
. 0 

The 0 
second 0 
, 0 
provisionally 0 
designated 0 
DP1 0 
-LRB- 0 
deleted 0 
in 0 
polyposis 0 
_NUM1 0 
-RRB- 0 
, 0 
was 0 
found 0 
to 0 
be 0 
transcribed 0 
in 0 
the 0 
same 0 
orientation 0 
as 0 
MCC 0 
. 0 

Two 0 
other 0 
cDNAs 0 
, 0 
DP2 0 
and 0 
DP3 0 
, 0 
were 0 
found 0 
to 0 
overlap 0 
, 0 
forming 0 
a 0 
single 0 
gene 0 
, 0 
DP2 0 
. 0 

_NUM1 0 
, 0 
that 0 
is 0 
transcribed 0 
in 0 
the 0 
same 0 
orientation 0 
as 0 
SRP19 0 
. 0 

Genotype-phenotype 0 
correlations 0 
in 0 
families 0 
with 0 
deletions 0 
in 0 
the 0 
von 1
Hippel-Lindau 1
-LRB- 0 
VHL 1
-RRB- 0 
gene 0 
. 0 

Von 1
Hippel-Lindau 1
-LRB- 1
VHL 1
-RRB- 1
disease 1
is 0 
a 0 
hereditary 1
tumor 1
syndrome 1
characterized 0 
by 0 
predisposition 0 
for 0 
bilateral 1
and 1
multi-centric 1
hemangioblastoma 1
in 0 
the 0 
retina 0 
and 0 
central 0 
nervous 0 
system 0 
, 0 
pheochromocytoma 1
, 0 
renal 1
cell 1
carcinoma 1
, 0 
and 0 
cysts 1
in 1
the 1
kidney 1
, 1
pancreas 1
, 1
and 1
epididymis 1
. 0 

We 0 
describe 0 
five 0 
families 0 
for 0 
which 0 
direct 0 
sequencing 0 
of 0 
the 0 
coding 0 
region 0 
of 0 
the 0 
VHL 1
gene 0 
had 0 
failed 0 
to 0 
identify 0 
the 0 
family-specific 0 
mutation 0 
. 0 

Further 0 
molecular 0 
analysis 0 
revealed 0 
deletions 0 
involving 0 
the 0 
VHL 1
gene 0 
in 0 
each 0 
of 0 
these 0 
families 0 
. 0 

In 0 
four 0 
families 0 
, 0 
partial 0 
deletions 0 
of 0 
one 0 
or 0 
more 0 
exons 0 
were 0 
detected 0 
by 0 
Southern 0 
blot 0 
analysis 0 
. 0 

In 0 
the 0 
fifth 0 
family 0 
, 0 
FISH 0 
analysis 0 
demonstrated 0 
the 0 
deletion 0 
of 0 
the 0 
entire 0 
VHL 1
gene 0 
. 0 

Our 0 
results 0 
show 0 
that 0 
-LRB- 0 
quantitative 0 
-RRB- 0 
Southern 0 
blot 0 
analysis 0 
is 0 
a 0 
sensitive 0 
method 0 
for 0 
detecting 0 
germline 0 
deletions 0 
of 0 
the 0 
VHL 1
gene 0 
and 0 
should 0 
be 0 
implemented 0 
in 0 
routine 0 
DNA 0 
diagnosis 0 
for 0 
VHL 1
disease 1
. 0 

Our 0 
data 0 
support 0 
the 0 
previously 0 
established 0 
observation 0 
that 0 
families 0 
with 0 
a 0 
germline 0 
deletion 0 
have 0 
a 0 
low 0 
risk 0 
for 0 
pheochromocytoma 1
. 0 

Further 0 
unraveling 0 
of 0 
genotype-phenotype 0 
correlations 0 
in 0 
VHL 1
disease 1
has 0 
revealed 0 
that 0 
families 0 
with 0 
a 0 
full 0 
or 0 
partial 0 
deletion 0 
of 0 
the 0 
VHL 1
gene 0 
exhibit 0 
a 0 
phenotype 0 
with 0 
a 0 
preponderance 0 
of 0 
central 1
nervous 1
system 1
hemangioblastoma 1
. 0 
. 0 

Understanding 0 
the 0 
molecular 0 
basis 0 
of 0 
fragile 1
X 1
syndrome 1
. 0 

Fragile 1
X 1
syndrome 1
, 0 
a 0 
common 0 
form 0 
of 0 
inherited 1
mental 1
retardation 1
, 0 
is 0 
mainly 0 
caused 0 
by 0 
massive 0 
expansion 0 
of 0 
_DS 0 
triplet 0 
repeats 0 
located 0 
in 0 
the 0 
5-untranslated 0 
region 0 
of 0 
the 0 
fragile 1
X 1
mental 1
retardation 1
-LRB- 0 
FMR1 0 
-RRB- 0 
gene 0 
. 0 

In 0 
patients 0 
with 0 
fragile 1
X 1
syndrome 1
, 0 
the 0 
expanded 0 
_DS 0 
triplet 0 
repeats 0 
are 0 
hypermethylated 0 
and 0 
the 0 
expression 0 
of 0 
the 0 
FMR1 0 
gene 0 
is 0 
repressed 0 
, 0 
which 0 
leads 0 
to 0 
the 0 
absence 0 
of 0 
FMR1 0 
protein 0 
-LRB- 0 
FMRP 0 
-RRB- 0 
and 0 
subsequent 0 
mental 1
retardation 1
. 0 

FMRP 0 
is 0 
an 0 
RNA-binding 0 
protein 0 
that 0 
shuttles 0 
between 0 
the 0 
nucleus 0 
and 0 
cytoplasm 0 
. 0 

This 0 
protein 0 
has 0 
been 0 
implicated 0 
in 0 
protein 0 
translation 0 
as 0 
it 0 
is 0 
found 0 
associated 0 
with 0 
polyribosomes 0 
and 0 
the 0 
rough 0 
endoplasmic 0 
reticulum 0 
. 0 

We 0 
discuss 0 
here 0 
the 0 
recent 0 
progress 0 
made 0 
towards 0 
understanding 0 
the 0 
molecular 0 
mechanism 0 
of 0 
_DS 0 
repeat 0 
expansion 0 
and 0 
physiological 0 
function 0 
-LRB- 0 
s 0 
-RRB- 0 
of 0 
FMRP 0 
. 0 

These 0 
studies 0 
will 0 
not 0 
only 0 
help 0 
to 0 
illuminate 0 
the 0 
molecular 0 
basis 0 
of 0 
the 0 
general 0 
class 0 
of 0 
human 0 
diseases 0 
with 0 
trinucleotide 0 
repeat 0 
expansion 0 
but 0 
also 0 
provide 0 
an 0 
avenue 0 
to 0 
understand 0 
aspects 0 
of 0 
human 0 
cognition 0 
and 0 
intelligence 0 
. 0 
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
deficiency 1
in 0 
Papua 0 
New 0 
Guinea 0 
. 0 

The 0 
description 0 
of 0 
_NUM2 0 
new 0 
variants 0 
. 0 

A 0 
total 0 
of 0 
_NUM3 0 
males 0 
from 0 
various 0 
regions 0 
of 0 
Papua 0 
New 0 
Guinea 0 
were 0 
screened 0 
for 0 
red 0 
cell 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
activity 0 
. 0 

Twenty-six 0 
G6PD 1
deficient 1
individuals 0 
were 0 
identified 0 
. 0 

Biochemical 0 
characterization 0 
of 0 
G6PD 0
purified 0 
from 0 
these 0 
subjects 0 
has 0 
revealed 0 
_NUM2 0 
new 0 
variants 0 
and 0 
several 0 
copies 0 
of 0 
previously 0 
described 0 
forms 0 
of 0 
G6PD 0
. 0 

This 0 
study 0 
illustrates 0 
the 0 
extreme 0 
heterogeneity 0 
of 0 
G6PD 1
deficiency 1
among 0 
the 0 
people 0 
of 0 
Papua 0 
New 0 
Guinea 0 
. 0 
. 0 

Regional 0 
mapping 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
and 0 
the 0 
phenylketonuria 1
locus 0 
in 0 
the 0 
human 0 
genome 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
of 0 
amino 0 
acid 0 
metabolism 0 
caused 0 
by 0 
a 0 
deficiency 1
of 1
the 1
hepatic 1
enzyme 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
; 0 
phenylalanine 0 
4-monooxygenase 0 
, 0 
EC 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

_NUM2 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

A 0 
cDNA 0 
clone 0 
for 0 
human 0 
PAH 0 
has 0 
previously 0 
been 0 
used 0 
to 0 
assign 0 
the 0 
corresponding 0 
gene 0 
to 0 
human 0 
chromosome 0 
_NUM2 0 
. 0 

To 0 
define 0 
the 0 
regional 0 
map 0 
position 0 
of 0 
the 0 
disease 0 
locus 0 
and 0 
the 0 
PAH 0 
gene 0 
on 0 
human 0 
chromosome 0 
_NUM2 0 
, 0 
DNA 0 
was 0 
isolated 0 
from 0 
human-hamster 0 
somatic 0 
cell 0 
hybrids 0 
with 0 
various 0 
deletions 0 
of 0 
human 0 
chromosome 0 
_NUM2 0 
and 0 
was 0 
analyzed 0 
by 0 
Southern 0 
blot 0 
analysis 0 
using 0 
the 0 
human 0 
cDNA 0 
PAH 0 
clone 0 
as 0 
a 0 
hybridization 0 
probe 0 
. 0 

From 0 
these 0 
results 0 
, 0 
together 0 
with 0 
detailed 0 
biochemical 0 
and 0 
cytogenetic 0 
characterization 0 
of 0 
the 0 
hybrid 0 
cells 0 
, 0 
the 0 
region 0 
on 0 
chromosome 0 
_NUM2 0 
containing 0 
the 0 
human 0 
PAH 0 
gene 0 
has 0 
been 0 
defined 0 
as 0 
12q14 0 
. 0 

_NUM1 0 
-- 0 
qter 0 
_NUM1 0 
-- 0 
qter 0 
. 0 

The 0 
PAH 0 
map 0 
position 0 
on 0 
chromosome 0 
_NUM2 0 
was 0 
further 0 
localized 0 
by 0 
in 0 
situ 0 
hybridization 0 
of 0 
125I-labeled 0 
human 0 
PAH 0 
cDNA 0 
to 0 
chromosomes 0 
prepared 0 
from 0 
a 0 
human 0 
lymphoblastoid 0 
cell 0 
line 0 
. 0 

Results 0 
of 0 
these 0 
experiments 0 
demonstrated 0 
that 0 
the 0 
region 0 
on 0 
chromosome 0 
_NUM2 0 
containing 0 
the 0 
PAH 0 
gene 0 
and 0 
the 0 
PKU 1
locus 0 
in 0 
man 0 
is 0 
12q22 0 
-- 0 
12q24 0 
. 0 

_NUM1 0 
. 0 

These 0 
results 0 
not 0 
only 0 
provide 0 
a 0 
regionalized 0 
map 0 
position 0 
for 0 
a 0 
major 0 
human 0 
disease 0 
locus 0 
but 0 
also 0 
can 0 
serve 0 
as 0 
a 0 
reference 0 
point 0 
for 0 
linkage 0 
analysis 0 
with 0 
other 0 
DNA 0 
markers 0 
on 0 
human 0 
chromosome 0 
_NUM2 0 
Total 1
deficiency 1
of 1
plasma 1
cholesteryl 1
ester 1
transfer 1
protein 1
in 0 
subjects 0 
homozygous 0 
and 0 
heterozygous 0 
for 0 
the 0 
intron 0 
_NUM2 0 
splicing 0 
defect 0 
. 0 

The 0 
molecular 0 
basis 0 
of 0 
cholesteryl 1
ester 1
transfer 1
protein 1
-LRB- 1
CETP 1
-RRB- 1
deficiency 1
was 0 
investigated 0 
in 0 
_NUM1 0 
unrelated 0 
CETP-deficient 1
families 0 
. 0 

The 0 
high 0 
density 0 
lipoprotein-cholesterol 0 
levels 0 
of 0 
the 0 
probands 0 
exceeded 0 
_NUM3 0 
mg 0 
/ 0 
dl 0 
. 0 

The 0 
plasma 0 
of 0 
the 0 
probands 0 
was 0 
totally 0 
deficient 0 
in 0 
CETP 0 
activity 0 
and 0 
mass 0 
. 0 

The 0 
genomic 0 
DNA 0 
of 0 
the 0 
patients 0 
was 0 
amplified 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
, 0 
using 0 
two 0 
oligonucleotide 0 
primers 0 
located 0 
in 0 
the 0 
intron 0 
_NUM2 0 
and 0 
_NUM2 0 
of 0 
the 0 
CETP 0 
gene 0 
, 0 
and 0 
the 0 
amplified 0 
products 0 
were 0 
directly 0 
sequenced 0 
. 0 

Two 0 
patients 0 
were 0 
homozygous 0 
for 0 
a 0 
G-to-A 0 
change 0 
at 0 
the 0 
5-splice 0 
donor 0 
site 0 
of 0 
the 0 
intron 0 
_NUM2 0 
. 0 

The 0 
G-to-A 0 
change 0 
would 0 
cause 0 
impaired 0 
splicing 0 
of 0 
pre-messenger 0 
RNA 0 
. 0 

The 0 
other 0 
two 0 
probands 0 
were 0 
heterozygous 0 
for 0 
the 0 
mutation 0 
, 0 
but 0 
totally 0 
lacked 0 
CETP 0 
. 0 

Their 0 
lipoprotein 0 
patterns 0 
were 0 
also 0 
similar 0 
to 0 
those 0 
of 0 
the 0 
two 0 
homozygotes 0 
. 0 

Thus 0 
, 0 
other 0 
genetic 1
defects 1
or 0 
metabolic 0 
factors 0 
influencing 0 
CETP 0
expression 0 
are 0 
implicated 0 
. 0 

The 0 
data 0 
suggest 0 
that 0 
the 0 
G-to-A 0 
mutation 0 
may 0 
be 0 
common 0 
in 0 
human 0 
plasma 0 
CETP 1
deficiency 1
. 0 

Furthermore 0 
, 0 
there 0 
could 0 
be 0 
compound 0 
heterozygotes 0 
who 0 
totally 0 
lack 0 
plasma 0 
CETP 0 
and 0 
have 0 
lipoprotein 0 
profiles 0 
similar 0 
to 0 
those 0 
of 0 
homozygotes 0 
. 0 
. 0 

Heterogeneity 0 
of 0 
type 1
I 1
von 1
Willebrand 1
disease 1
: 0 
evidence 0 
for 0 
a 0 
subgroup 0 
with 0 
an 0 
abnormal 0 
von 1
Willebrand 1
factor 0 
. 0 

Type 1
I 1
von 1
Willebrand 1
disease 1
-LRB- 0 
vWD 1
-RRB- 0 
is 0 
characterized 0 
by 0 
equally 0 
low 0 
plasma 0 
concentrations 0 
of 0 
von 1
Willebrand 1
factor 0 
antigen 0 
-LRB- 0 
vWF 0 
Ag 0 
-RRB- 0 
and 0 
ristocetin 0 
cofactor 0 
-LRB- 0 
RiCof 0 
-RRB- 0 
and 0 
by 0 
the 0 
presence 0 
of 0 
all 0 
vWF 0 
multimers 0 
in 0 
sodium 0 
dodecyl 0 
sulfate 0 
-LRB- 0 
SDS 0 
-RRB- 0 
- 0 
agarose 0 
gel 0 
electrophoresis 0 
. 0 

For 0 
_NUM2 0 
patients 0 
-LRB- 0 
_NUM2 0 
kindreds 0 
-RRB- 0 
diagnosed 0 
with 0 
these 0 
criteria 0 
, 0 
we 0 
have 0 
studied 0 
the 0 
platelet 0 
contents 0 
of 0 
vWF 0 
Ag 0 
and 0 
RiCof 0 
and 0 
the 0 
changes 0 
of 0 
these 0 
in 0 
plasma 0 
after 0 
DDAVP 0 
infusion 0 
. 0 

Platelet 0 
vWF 0 
Ag 0 
and 0 
RiCof 0 
were 0 
normal 0 
in 0 
four 0 
kindreds 0 
-LRB- 0 
called 0 
'' 0 
platelet 0 
normal 0 
'' 0 
subgroup 0 
-RRB- 0 
; 0 
following 0 
1-deamino-8-D-arginine 0 
vasopressin 0 
; 0 
plasma 0 
vWF 0 
Ag 0 
, 0 
RiCof 0 
and 0 
the 0 
bleeding 0 
time 0 
-LRB- 0 
BT 0 
-RRB- 0 
became 0 
normal 0 
. 0 

In 0 
six 0 
kindreds 0 
, 0 
platelet 0 
vWF 0 
Ag 0 
and 0 
RiCof 0 
were 0 
equally 0 
low 0 
-LRB- 0 
platelet 0 
low 0 
-RRB- 0 
; 0 
after 0 
DDAVP 0 
, 0 
plasma 0 
vWF 0 
Ag 0 
and 0 
RiCof 0 
remained 0 
low 0 
, 0 
and 0 
the 0 
BT 0 
was 0 
prolonged 0 
. 0 

In 0 
three 0 
additional 0 
kindreds 0 
, 0 
platelets 0 
contained 0 
normal 0 
concentrations 0 
of 0 
vWF 0 
Ag 0 
, 0 
but 0 
RiCof 0 
was 0 
very 0 
low 0 
-LRB- 0 
platelet 0 
discordant 0 
-RRB- 0 
; 0 
even 0 
though 0 
a 0 
complete 0 
set 0 
of 0 
multimers 0 
was 0 
found 0 
in 0 
plasma 0 
and 0 
platelets 0 
, 0 
there 0 
was 0 
a 0 
relatively 0 
small 0 
amount 0 
of 0 
large 0 
multimers 0 
. 0 

After 0 
DDAVP 0 
, 0 
plasma 0 
vWF 0 
Ag 0 
became 0 
normal 0 
, 0 
but 0 
RiCof 0 
remained 0 
low 0 
and 0 
the 0 
BT 0 
was 0 
very 0 
prolonged 0 
. 0 

These 0 
findings 0 
demonstrated 0 
that 0 
there 0 
can 0 
be 0 
an 0 
abnormal 0 
vWF 0 
-LRB- 0 
RiCof 0 
less 0 
than 0 
vWF 0 
Ag 0 
-RRB- 0 
even 0 
in 0 
type 1
I 1
vWD 1
, 0 
coexisting 0 
with 0 
a 0 
complete 0 
set 0 
of 0 
vWF 0 
multimers 0 
-LRB- 0 
platelet 0 
discordant 0 
-RRB- 0 
; 0 
that 0 
the 0 
abnormal 0 
vWF 0 
can 0 
be 0 
shown 0 
more 0 
clearly 0 
in 0 
platelets 0 
than 0 
in 0 
plasma 0 
or 0 
else 0 
in 0 
plasma 0 
after 0 
DDAVP 0 
infusion 0 
; 0 
and 0 
that 0 
DDAVP 0 
normalizes 0 
the 0 
BT 0 
only 0 
in 0 
those 0 
patients 0 
with 0 
normal 0 
platelet 0 
levels 0 
of 0 
both 0 
vWF 0 
Ag 0 
and 0 
RiCof 0 
-LRB- 0 
platelet 0 
normal 0 
-RRB- 0 
. 0 
. 0 

Characterization 0 
of 0 
a 0 
YAC 0 
containing 0 
part 0 
or 0 
all 0 
of 0 
the 0 
Norrie 1
disease 1
locus 0 
. 0 

It 0 
has 0 
been 0 
shown 0 
from 0 
pulsed-field 0 
gel 0 
electrophoresis 0 
-LRB- 0 
PFGE 0 
-RRB- 0 
that 0 
the 0 
monoamine 0 
oxidase 0 
genes 0 
A 0 
and 0 
B 0 
-LRB- 0 
MAOA 0 
& 0 
MAOB 0 
-RRB- 0 
and 0 
DXS7 0 
loci 0 
are 0 
physically 0 
very 0 
close 0 
. 0 

We 0 
have 0 
therefore 0 
extended 0 
studies 0 
on 0 
their 0 
relationship 0 
through 0 
the 0 
characterisation 0 
of 0 
a 0 
_NUM3 0 
kb 0 
YAC 0 
isolated 0 
using 0 
L1 0 
. 0 

_NUM2 0 
-LRB- 0 
recognising 0 
the 0 
DXS7 0 
locus 0 
-RRB- 0 
as 0 
a 0 
probe 0 
. 0 

Restriction 0 
mapping 0 
of 0 
the 0 
YAC 0 
indicates 0 
that 0 
it 0 
contains 0 
both 0 
MAOA 0 
and 0 
MAOB 0 
genes 0 
in 0 
addition 0 
to 0 
the 0 
DXS7 0 
locus 0 
. 0 

The 0 
map 0 
derived 0 
from 0 
the 0 
YL1 0 
. 0 

28-YAC 0 
is 0 
compatible 0 
both 0 
with 0 
the 0 
map 0 
from 0 
an 0 
independently 0 
derived 0 
YAC 0 
carrying 0 
MAOA 0 
and 0 
B 0 
genes 0 
and 0 
with 0 
the 0 
long 0 
range 0 
genomic 0 
map 0 
for 0 
the 0 
region 0 
. 0 

A 0 
series 0 
of 0 
subclones 0 
prepared 0 
from 0 
a 0 
phage 0 
library 0 
-LRB- 0 
lambda 0 
DASH 0 
II 0 
-RRB- 0 
of 0 
the 0 
YAC 0 
have 0 
been 0 
characterised 0 
and 0 
have 0 
been 0 
employed 0 
to 0 
determine 0 
the 0 
end 0 
point 0 
of 0 
the 0 
deletion 0 
of 0 
a 0 
Norrie 1
disease 1
-LRB- 0 
NDP 1
-RRB- 0 
patient 0 
who 0 
has 0 
been 0 
shown 0 
to 0 
lack 0 
both 0 
DXS7 0 
and 0 
MAO 0 
coding 0 
sequences 0 
. 0 

The 0 
pattern 0 
of 0 
retention 0 
of 0 
subclones 0 
in 0 
the 0 
deletion 0 
patient 0 
place 0 
the 0 
end 0 
point 0 
of 0 
the 0 
deletion 0 
within 0 
30-130 0 
kb 0 
of 0 
the 0 
proximal 0 
end 0 
of 0 
the 0 
YAC 0 
. 0 

By 0 
combining 0 
the 0 
data 0 
with 0 
established 0 
recombination 0 
analysis 0 
, 0 
we 0 
provide 0 
evidence 0 
that 0 
all 0 
or 0 
part 0 
of 0 
the 0 
NDP 0 
lies 0 
in 0 
the 0 
interval 0 
of 0 
approximately 0 
250kb 0 
within 0 
the 0 
YAC 0 
. 0 

Identification 0 
of 0 
mutations 0 
in 0 
Danish 0 
choroideremia 1
families 0 
. 0 

We 0 
have 0 
searched 0 
for 0 
mutations 0 
in 0 
the 0 
choroideremia 1
gene 0 
-LRB- 0 
CHM 1
-RRB- 0 
in 0 
patients 0 
from 0 
_NUM2 0 
Danish 0 
families 0 
in 0 
which 0 
CHM 1
is 0 
segregating 0 
. 0 

Employing 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
, 0 
single 0 
strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
analysis 0 
, 0 
and 0 
direct 0 
DNA 0 
sequencing 0 
, 0 
different 0 
mutations 0 
have 0 
been 0 
identified 0 
in 0 
_NUM1 0 
patients 0 
. 0 

All 0 
the 0 
mutations 0 
will 0 
interfere 0 
with 0 
the 0 
correct 0 
translation 0 
of 0 
the 0 
mRNA 0 
predicting 0 
a 0 
truncated 0 
protein 0 
or 0 
no 0 
gene 0 
product 0 
at 0 
all 0 
. 0 
. 0 

G130V 0 
, 0 
a 0 
common 0 
FRDA 1
point 0 
mutation 0 
, 0 
appears 0 
to 0 
have 0 
arisen 0 
from 0 
a 0 
common 0 
founder 0 
. 0 

Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
is 0 
the 0 
most 0 
common 0 
inherited 1
ataxia 1
. 0 

About 0 
_NUM2 0 
% 0 
of 0 
mutant 0 
alleles 0 
have 0 
an 0 
expansion 0 
of 0 
a 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
intron 0 
_NUM1 0 
of 0 
the 0 
affected 0 
gene 0 
, 0 
FRDA 1
. 0 

The 0 
other 0 
_NUM1 0 
% 0 
are 0 
point 0 
mutations 0 
. 0 

Of 0 
the 0 
_NUM2 0 
point 0 
mutations 0 
so 0 
far 0 
described 0 
, 0 
three 0 
appear 0 
to 0 
be 0 
more 0 
common 0 
. 0 

One 0 
of 0 
these 0 
is 0 
the 0 
G130V 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
of 0 
FRDA 0 
. 0 

G130V 0 
, 0 
when 0 
present 0 
with 0 
an 0 
expanded 0 
_DS 0 
repeat 0 
on 0 
the 0 
other 0 
allele 0 
, 0 
is 0 
associated 0 
with 0 
an 0 
atypical 0 
FRDA 0 
phenotype 0 
. 0 

Haplotype 0 
analysis 0 
was 0 
undertaken 0 
on 0 
the 0 
four 0 
families 0 
who 0 
have 0 
been 0 
described 0 
with 0 
this 0 
mutation 0 
. 0 

The 0 
results 0 
suggest 0 
a 0 
common 0 
founder 0 
for 0 
this 0 
mutation 0 
. 0 

Although 0 
marked 0 
differences 0 
in 0 
extragenic 0 
marker 0 
haplotypes 0 
were 0 
seen 0 
in 0 
one 0 
family 0 
, 0 
similar 0 
intragenic 0 
haplotyping 0 
suggests 0 
the 0 
same 0 
mutation 0 
founder 0 
for 0 
this 0 
family 0 
with 0 
the 0 
differences 0 
explicable 0 
by 0 
two 0 
recombination 0 
events 0 
. 0 
. 0 

Frequency 0 
of 0 
exon 0 
_NUM2 0 
missense 0 
mutation 0 
-LRB- 0 
442D 0 
: 0 
G 0 
-RRB- 0 
in 0 
cholesteryl 0 
ester 0 
transfer 0 
protein 0 
gene 0 
in 0 
hyperalphalipoproteinemic 1
Japanese 0 
subjects 0 
. 0 

Cholesteryl 0 
ester 0 
transfer 0 
protein 0 
-LRB- 0 
CETP 0 
-RRB- 0 
transfers 0 
cholesteryl 0 
ester 0 
from 0 
high 0 
density 0 
lipoprotein 0 
-LRB- 0 
HDL 0 
-RRB- 0 
to 0 
apo 0 
B-containing 0 
lipoproteins 0 
. 0 

The 0 
hyperalphalipoproteinemia 1
caused 0 
by 0 
CETP 1
deficiency 1
is 0 
fairly 0 
common 0 
in 0 
Japan 0 
and 0 
one 0 
of 0 
the 0 
most 0 
common 0 
mutations 0 
in 0 
the 0 
CETP 0 
gene 0 
is 0 
the 0 
splicing 0 
defect 0 
of 0 
the 0 
intron 0 
_NUM2 0 
, 0 
the 0 
allelic 0 
frequency 0 
of 0 
which 0 
has 0 
been 0 
shown 0 
to 0 
be 0 
_NUM1 0 
. 0 

_NUM4 0 
in 0 
the 0 
Japanese 0 
general 0 
population 0 
. 0 

Recently 0 
, 0 
we 0 
have 0 
reported 0 
a 0 
missense 0 
mutation 0 
in 0 
exon 0 
_NUM2 0 
of 0 
the 0 
CETP 0 
gene 0 
-LRB- 0 
442D 0 
G 0 
-RRB- 0 
, 0 
showing 0 
a 0 
dominant 0 
effect 0 
on 0 
the 0 
CETP 0 
activity 0 
and 0 
HDL-cholesterol 0 
level 0 
. 0 

In 0 
the 0 
current 0 
study 0 
, 0 
we 0 
determined 0 
the 0 
frequency 0 
of 0 
this 0 
new 0 
mutation 0 
in 0 
Japanese 0 
hyperalphalipoproteinemic 1
-LRB- 0 
HDL-cholesterol 0 
> 0 
or 0 
= 0 
_NUM3 0 
mg 0 
/ 0 
dl 0 
-RRB- 0 
subjects 0 
. 0 

A 0 
rapid 0 
and 0 
easy 0 
screening 0 
method 0 
for 0 
this 0 
new 0 
mutation 0 
was 0 
developed 0 
using 0 
a 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
- 0 
mediated 0 
site-directed 0 
mutagenesis 0 
. 0 

Among 0 
_NUM3 0 
Japanese 0 
hyperalphalipoproteinemic 1
subjects 0 
-LRB- 0 
HDL-cholesterol 0 
; 0 
_NUM3 0 
. 0 

_NUM1 0 
+ 0 
/ 0 
- 0 
_NUM2 0 
. 0 

_NUM1 0 
mg 0 
/ 0 
dl 0 
, 0 
mean 0 
+ 0 
/ 0 
- 0 
S. 0 
D. 0 
-RRB- 0 
without 0 
the 0 
intron 0 
_NUM2 0 
splice 0 
defect 0 
, 0 
three 0 
homozygotes 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
_NUM2 0 
heterozygotes 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
were 0 
found 0 
to 0 
have 0 
the 0 
442D 0 
G 0 
mutation 0 
. 0 

The 0 
relative 0 
allelic 0 
frequency 0 
of 0 
this 0 
mutation 0 
was 0 
calculated 0 
to 0 
be 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

One 0 
of 0 
the 0 
homozygotes 0 
for 0 
the 0 
442D 0 
G 0 
mutation 0 
was 0 
the 0 
patient 0 
previously 0 
described 0 
by 0 
us 0 
as 0 
having 0 
hyperalphalipoproteinemia 1
with 0 
corneal 1
opacity 1
and 0 
coronary 1
heart 1
disease 1
. 0 

This 0 
was 0 
the 0 
first 0 
reported 0 
subject 0 
homozygous 0 
for 0 
the 0 
CETP 1
deficiency 1
who 0 
also 0 
demonstrated 0 
atherosclerotic 1
symptoms 1
. 0 

In 0 
homozygous 0 
subjects 0 
, 0 
CETP 0 
activity 0 
ranged 0 
from 0 
_NUM2 0 
% 0 
to 0 
_NUM2 0 
% 0 
of 0 
the 0 
normal 0 
value 0 
, 0 
which 0 
was 0 
consistent 0 
with 0 
the 0 
results 0 
obtained 0 
from 0 
the 0 
transient 0 
expression 0 
experiment 0 
previously 0 
reported 0 
; 0 
however 0 
, 0 
the 0 
specific 0 
activity 0 
of 0 
CETP 0 
was 0 
not 0 
as 0 
low 0 
as 0 
expected 0 
. 0 

-LRB- 0 
ABSTRACT 0 
TRUNCATED 0 
_DS 0 
_NUM3 0 
WORDS 0 
-RRB- 0 
Fibroblast 0 
growth 0 
factor 0 
homologous 0 
factor 0 
_NUM1 0 
-LRB- 0 
FHF2 0 
-RRB- 0 
: 0 
gene 0 
structure 0 
, 0 
expression 0 
and 0 
mapping 0 
to 0 
the 0 
Borjeson-Forssman-Lehmann 1
syndrome 1
region 0 
in 0 
Xq26 0 
delineated 0 
by 0 
a 0 
duplication 0 
breakpoint 0 
in 0 
a 0 
BFLS 1
like 0 
patient 0 
. 0 

Borjeson-Forssman-Lehmann 1
syndrome 1
-LRB- 0 
BFLS 1
-RRB- 0 
is 0 
a 0 
syndromal 0 
X-linked 1
mental 1
retardation 1
, 0 
which 0 
maps 0 
by 0 
linkage 0 
to 0 
the 0 
_AN 0 
region 0 
of 0 
the 0 
human 0 
X 0 
chromosome 0 
. 0 

We 0 
have 0 
identified 0 
a 0 
male 0 
patient 0 
with 0 
BFLS 1
like 0 
features 0 
and 0 
a 0 
duplication 0 
, 0 
_NUM2 0 
, 0 
Y 0 
, 0 
dup 0 
-LRB- 0 
X 0 
-RRB- 0 
-LRB- 0 
q26q28 0 
-RRB- 0 
, 0 
inherited 0 
from 0 
his 0 
phenotypically 0 
normal 0 
mother 0 
. 0 

Fluorescence 0 
in 0 
situ 0 
hybridisation 0 
using 0 
yeast 0 
artificial 0 
chromosome 0 
clones 0 
from 0 
Xq26 0 
localised 0 
the 0 
duplication 0 
breakpoint 0 
to 0 
an 0 
approximately 0 
400-kb 0 
interval 0 
in 0 
the 0 
Xq26 0 
. 0 

_NUM1 0 
region 0 
between 0 
DXS155 0 
and 0 
DXS294 0 
/ 0 
DXS730 0 
. 0 

Database 0 
searches 0 
and 0 
analysis 0 
of 0 
available 0 
genomic 0 
DNA 0 
sequence 0 
from 0 
the 0 
region 0 
revealed 0 
the 0 
presence 0 
of 0 
the 0 
fibroblast 0 
growth 0 
factor 0 
homologous 0 
factor 0 
gene 0 
, 0 
FHF2 0 
, 0 
within 0 
the 0 
duplication 0 
breakpoint 0 
interval 0 
. 0 

The 0 
gene 0 
structure 0 
of 0 
FHF2 0 
was 0 
determined 0 
and 0 
two 0 
new 0 
exons 0 
were 0 
identified 0 
, 0 
including 0 
a 0 
new 0 
_NUM1 0 
end 0 
exon 0 
, 0 
1B 0 
. 0 

FHF2 0 
is 0 
a 0 
large 0 
gene 0 
extending 0 
over 0 
approximately 0 
_NUM3 0 
kb 0 
in 0 
Xq26 0 
. 0 

_NUM1 0 
and 0 
is 0 
composed 0 
of 0 
at 0 
least 0 
seven 0 
exons 0 
. 0 

It 0 
shows 0 
tissue-specific 0 
alternative 0 
splicing 0 
and 0 
alternative 0 
transcription 0 
starts 0 
. 0 

Northern 0 
blot 0 
hybridisation 0 
showed 0 
highest 0 
expression 0 
in 0 
brain 0 
and 0 
skeletal 0 
muscle 0 
. 0 

The 0 
FHF2 0 
gene 0 
localisation 0 
and 0 
tissue-specific 0 
expression 0 
pattern 0 
suggest 0 
it 0 
to 0 
be 0 
a 0 
candidate 0 
gene 0 
for 0 
familial 0 
cases 0 
of 0 
the 0 
BFLS 1
syndrome 1
and 0 
other 0 
syndromal 0 
and 0 
non-specific 0 
forms 0 
of 0 
X-linked 1
mental 1
retardation 1
mapping 0 
to 0 
the 0 
region 0 
. 0 

Illegitimate 0 
transcription 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
in 0 
lymphocytes 0 
for 0 
identification 0 
of 0 
mutations 0 
in 0 
phenylketonuria 1
. 0 

Taking 0 
advantage 0 
of 0 
the 0 
illegitimate 0 
transcription 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
gene 0 
, 0 
we 0 
have 0 
been 0 
able 0 
to 0 
analyse 0 
the 0 
PAH 0 
cDNA 0 
sequence 0 
of 0 
hyperphenylalaninemic 1
children 0 
in 0 
circulating 0 
lymphocytes 0 
. 0 

Using 0 
this 0 
approach 0 
, 0 
we 0 
have 0 
also 0 
identified 0 
_NUM1 0 
novel 0 
mutations 0 
in 0 
cDNA 0 
from 0 
liver 0 
and 0 
lymphocytes 0 
of 0 
two 0 
patients 0 
. 0 

One 0 
mutation 0 
, 0 
detected 0 
by 0 
the 0 
abnormal 0 
pattern 0 
of 0 
migration 0 
of 0 
an 0 
amplified 0 
fragment 0 
, 0 
is 0 
a 0 
C 0 
to 0 
T 0 
transition 0 
in 0 
the 0 
splice 0 
acceptor 0 
site 0 
of 0 
intron 0 
_NUM2 0 
, 0 
which 0 
resulted 0 
in 0 
the 0 
skipping 0 
of 0 
exon 0 
_NUM2 0 
with 0 
the 0 
premature 0 
termination 0 
of 0 
RNA 0 
translation 0 
downstream 0 
from 0 
exon 0 
_NUM2 0 
-LRB- 0 
-3 0 
IVS10 0 
-RRB- 0 
. 0 

The 0 
other 0 
two 0 
mutations 0 
are 0 
missense 0 
mutations 0 
in 0 
exons 0 
_NUM2 0 
and 0 
_NUM2 0 
-LRB- 0 
respectively 0 
, 0 
L333F 0 
and 0 
E390G 0 
-RRB- 0 
. 0 

The 0 
present 0 
study 0 
supports 0 
the 0 
view 0 
that 0 
circulating 0 
lymphocytes 0 
give 0 
easy 0 
access 0 
to 0 
PAH 0 
gene 0 
transcripts 0 
whose 0 
nucleotide 0 
sequence 0 
is 0 
identical 0 
to 0 
that 0 
reported 0 
in 0 
liver 0 
and 0 
therefore 0 
represent 0 
a 0 
useful 0 
tool 0 
for 0 
molecular 0 
genetic 0 
studies 0 
in 0 
phenylketonuria 1
. 0 
. 0 

Function 0 
of 0 
an 0 
axonal 0 
chemoattractant 0 
modulated 0 
by 0 
metalloprotease 0 
activity 0 
. 0 

The 0 
axonal 0 
chemoattractant 0 
netrin-1 0 
guides 0 
spinal 0 
commissural 0 
axons 0 
by 0 
activating 0 
its 0 
receptor 0 
DCC 0 
-LRB- 0 
Deleted 0 
in 0 
Colorectal 1
Cancer 1
-RRB- 0 
. 0 

We 0 
have 0 
found 0 
that 0 
chemical 0 
inhibitors 0 
of 0 
metalloproteases 0 
potentiate 0 
netrin-mediated 0 
axon 0 
outgrowth 0 
in 0 
vitro 0 
. 0 

We 0 
have 0 
also 0 
found 0 
that 0 
DCC 0 
is 0 
a 0 
substrate 0 
for 0 
metalloprotease-dependent 0 
ectodomain 0 
shedding 0 
, 0 
and 0 
that 0 
the 0 
inhibitors 0 
block 0 
proteolytic 0 
processing 0 
of 0 
DCC 0 
and 0 
cause 0 
an 0 
increase 0 
in 0 
DCC 0 
protein 0 
levels 0 
on 0 
axons 0 
within 0 
spinal 0 
cord 0 
explants 0 
. 0 

Thus 0 
, 0 
potentiation 0 
of 0 
netrin 0 
activity 0 
by 0 
inhibitors 0 
may 0 
result 0 
from 0 
stabilization 0 
of 0 
DCC 0 
on 0 
the 0 
axons 0 
, 0 
and 0 
proteolytic 0 
activity 0 
may 0 
regulate 0 
axon 0 
migration 0 
by 0 
controlling 0 
the 0 
number 0 
of 0 
functional 0 
extracellular 0 
axon 0 
guidance 0 
receptors 0 
. 0 
. 0 

Choroideremia 1
: 0 
close 0 
linkage 0 
to 0 
DXYS1 0 
and 0 
DXYS12 0 
demonstrated 0 
by 0 
segregation 0 
analysis 0 
and 0 
historical-genealogical 0 
evidence 0 
. 0 

Linkage 0 
studies 0 
using 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
were 0 
conducted 0 
in 0 
the 0 
X-linked 1
disorder 1
, 0 
choroideremia 1
, 0 
designated 0 
TCD 1
for 0 
Progressive 1
Tapeto-Choroidal 1
Dystrophy 1
. 0 

Previously 0 
demonstrated 0 
close 0 
linkage 0 
with 0 
locus 0 
DXYS1 0 
was 0 
confirmed 0 
-LRB- 0 
lod 0 
_NUM2 0 
. 0 

_NUM2 0 
at 0 
_NUM1 0 
recombination 0 
distance 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
locus 0 
DXYS12 0 
was 0 
found 0 
to 0 
be 0 
closely 0 
linked 0 
with 0 
TCD 1
-LRB- 0 
lod 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
_NUM1 0 
recombination 0 
distance 0 
-RRB- 0 
. 0 

The 0 
disease 0 
mainly 0 
occurs 0 
in 0 
three 0 
large 0 
kindreds 0 
in 0 
remote 0 
Northern 0 
Finland 0 
. 0 

While 0 
formal 0 
genealogical 0 
proof 0 
is 0 
lacking 0 
, 0 
all 0 
presently 0 
living 0 
-LRB- 0 
more 0 
than 0 
_NUM2 0 
affected 0 
males 0 
and 0 
_NUM3 0 
carrier 0 
females 0 
-RRB- 0 
probably 0 
originate 0 
from 0 
a 0 
common 0 
founder 0 
couple 0 
born 0 
in 0 
_NUM4 0 
and 0 
_NUM4 0 
, 0 
twelve 0 
generations 0 
ago 0 
. 0 

All 0 
_NUM2 0 
patients 0 
and 0 
_NUM2 0 
carriers 0 
tested 0 
from 0 
the 0 
three 0 
kindreds 0 
had 0 
the 0 
same 0 
haplotype 0 
-LRB- 0 
TCD 1
/ 0 
DXYS1 0 
, 0 
11kb 0 
/ 0 
DXYS12 0 
, 0 
_NUM1 0 
. 0 

6kb 0 
-RRB- 0 
. 0 

Given 0 
that 0 
at 0 
least 0 
_NUM3 0 
female 0 
meioses 0 
transmitting 0 
TCD 1
have 0 
occurred 0 
since 0 
_NUM4 0 
in 0 
these 0 
kindreds 0 
, 0 
extremely 0 
close 0 
linkage 0 
between 0 
TCD 1
, 0 
DXYS1 0 
and 0 
DXYS12 0 
is 0 
suggested 0 
. 0 

The 0 
above 0 
haplotype 0 
is 0 
a 0 
very 0 
useful 0 
diagnostic 0 
tool 0 
in 0 
these 0 
TCD 1
families 0 
. 0 

We 0 
suggest 0 
that 0 
our 0 
historical-genealogical 0 
approach 0 
to 0 
linkage 0 
analysis 0 
may 0 
be 0 
possible 0 
elsewhere 0 
in 0 
similar 0 
isolated 0 
populations 0 
Functional 0 
consequences 0 
of 0 
mutations 0 
in 0 
the 0 
early 0 
growth 0 
response 0 
_NUM1 0 
gene 0 
-LRB- 0 
EGR2 0 
-RRB- 0 
correlate 0 
with 0 
severity 0 
of 0 
human 0 
myelinopathies 1
. 0 

The 0 
early 0 
growth 0 
response 0 
_NUM1 0 
gene 0 
-LRB- 0 
EGR2 0 
-RRB- 0 
is 0 
a 0 
Cys2His2zinc 0 
finger 0 
transcription 0 
factor 0 
which 0 
is 0 
thought 0 
to 0 
play 0 
a 0 
role 0 
in 0 
the 0 
regulation 0 
of 0 
peripheral 0 
nervous 0 
system 0 
myelination 0 
. 0 

This 0 
idea 0 
is 0 
based 0 
partly 0 
on 0 
the 0 
phenotype 0 
of 0 
homozygous 0 
Krox20 0 
-LRB- 0 
Egr2 0 
-RRB- 0 
knockout 0 
mice 0 
, 0 
which 0 
display 0 
hypomyelination 1
of 1
the 1
PNS 1
and 0 
a 0 
block 0 
of 0 
Schwann 0 
cells 0 
at 0 
an 0 
early 0 
stage 0 
of 0 
differentiation 0 
. 0 

Mutations 0 
in 0 
the 0 
human 0 
EGR2 0 
gene 0 
have 0 
recently 0 
been 0 
associated 0 
with 0 
the 0 
inherited 1
peripheral 1
neuropathies 1
Charcot-Marie-Tooth 1
type 1
_NUM1 1
, 0 
Dejerine-Sottas 1
syndrome 1
and 0 
congenital 1
hypomyelinating 1
neuropathy 1
. 0 

Three 0 
of 0 
the 0 
four 0 
EGR2 0 
mutations 0 
are 0 
dominant 0 
and 0 
occur 0 
within 0 
the 0 
zinc 0 
finger 0 
DNA-binding 0 
domain 0 
. 0 

The 0 
fourth 0 
mutation 0 
is 0 
recessive 0 
and 0 
affects 0 
the 0 
inhibitory 0 
domain 0 
-LRB- 0 
R1 0 
-RRB- 0 
that 0 
binds 0 
the 0 
NAB 0 
transcriptional 0 
co-repressors 0 
. 0 

A 0 
combination 0 
of 0 
DNA-binding 0 
assays 0 
and 0 
transcriptional 0 
analysis 0 
was 0 
used 0 
to 0 
determine 0 
the 0 
functional 0 
consequences 0 
of 0 
these 0 
mutations 0 
. 0 

The 0 
zinc 0 
finger 0 
mutations 0 
affect 0 
DNA 0 
binding 0 
and 0 
the 0 
amount 0 
of 0 
residual 0 
binding 0 
directly 0 
correlates 0 
with 0 
disease 0 
severity 0 
. 0 

The 0 
R1 0 
domain 0 
mutation 0 
prevents 0 
interaction 0 
of 0 
EGR2 0 
with 0 
the 0 
NAB 0 
co-repressors 0 
and 0 
thereby 0 
increases 0 
transcriptional 0 
activity 0 
. 0 

These 0 
data 0 
provide 0 
insight 0 
into 0 
the 0 
possible 0 
disease 0 
mechanisms 0 
underlying 0 
EGR2 0 
mutations 0 
and 0 
the 0 
reason 0 
for 0 
varying 0 
severity 0 
and 0 
differences 0 
in 0 
inheritance 0 
patterns 0 
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
human 0 
von 1
Willebrand 1
disease 1
: 0 
analysis 0 
of 0 
platelet 0 
von 1
Willebrand 1
factor 0 
mRNA 0 
. 0 

von 1
Willebrand 1
disease 1
-LRB- 0 
vWD 1
-RRB- 0 
, 0 
the 0 
most 0 
common 0 
inherited 1
bleeding 1
disorder 1
in 0 
humans 0 
, 0 
can 0 
result 0 
from 0 
either 0 
a 0 
quantitative 0 
or 0 
a 0 
qualitative 0 
defect 0 
in 0 
the 0 
adhesive 0 
glycoprotein 0 
, 0 
von 1
Willebrand 1
factor 0 
-LRB- 0 
vWF 0 
-RRB- 0 
. 0 

Molecular 0 
studies 0 
of 0 
vWD 1
have 0 
been 0 
limited 0 
by 0 
the 0 
large 0 
size 0 
of 0 
the 0 
vWF 0 
gene 0 
and 0 
difficulty 0 
in 0 
obtaining 0 
the 0 
vWF 0 
mRNA 0 
from 0 
patients 0 
. 0 

By 0 
use 0 
of 0 
an 0 
adaptation 0 
of 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
, 0 
vWF 0 
mRNA 0 
was 0 
amplified 0 
and 0 
sequenced 0 
from 0 
peripheral 0 
blood 0 
platelets 0 
. 0 

A 0 
silent 0 
vWF 0 
allele 0 
was 0 
identified 0 
, 0 
resulting 0 
from 0 
a 0 
cis 0 
defect 0 
in 0 
vWF 0 
mRNA 0 
transcription 0 
or 0 
processing 0 
. 0 

In 0 
two 0 
type 1
IIA 1
vWD 1
patients 0 
, 0 
two 0 
different 0 
but 0 
adjacent 0 
missense 0 
mutations 0 
were 0 
identified 0 
, 0 
the 0 
locations 0 
of 0 
which 0 
may 0 
identify 0 
an 0 
important 0 
vWF 0 
functional 0 
domain 0 
. 0 

Expression 0 
in 0 
heterologous 0 
cells 0 
of 0 
recombinant 0 
vWF 0 
containing 0 
one 0 
of 0 
these 0 
latter 0 
mutations 0 
reproduced 0 
the 0 
characteristic 0 
structural 0 
abnormality 0 
seen 0 
in 0 
type 1
IIA 1
vWD 1
plasma 0 
. 0 
. 0 

A 0 
transgene 0 
insertion 0 
creating 0 
a 0 
heritable 0 
chromosome 0 
deletion 0 
mouse 0 
model 0 
of 0 
Prader-Willi 1
and 1
angelman 1
syndromes 1
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
and 0 
Angelman 1
syndrome 1
-LRB- 0 
AS 1
-RRB- 0 
result 0 
from 0 
the 0 
loss 0 
of 0 
function 0 
of 0 
imprinted 0 
genes 0 
in 0 
human 0 
chromosome 0 
15q11-q13 0 
. 0 

The 0 
central 0 
part 0 
of 0 
mouse 0 
chromosome 0 
_NUM1 0 
is 0 
homologous 0 
to 0 
human 0 
15q11-q13 0 
, 0 
with 0 
conservation 0 
of 0 
both 0 
gene 0 
order 0 
and 0 
imprinted 0 
features 0 
. 0 

We 0 
report 0 
here 0 
the 0 
characterization 0 
of 0 
a 0 
transgene 0 
insertion 0 
-LRB- 0 
Epstein-Barr 0 
virus 0 
Latent 0 
Membrane 0 
Protein 0 
2A 0 
, 0 
LMP2A 0 
-RRB- 0 
into 0 
mouse 0 
chromosome 0 
7C 0 
, 0 
which 0 
has 0 
resulted 0 
in 0 
mouse 0 
models 0 
for 0 
PWS 1
and 0 
AS 1
dependent 0 
on 0 
the 0 
sex 0 
of 0 
the 0 
transmitting 0 
parent 0 
. 0 

Epigenotype 0 
-LRB- 0 
allelic 0 
expression 0 
and 0 
DNA 0 
methylation 0 
-RRB- 0 
and 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
analyses 0 
indicate 0 
that 0 
the 0 
transgene-induced 0 
mutation 0 
has 0 
generated 0 
a 0 
complete 0 
deletion 0 
of 0 
the 0 
PWS 1
/ 0 
AS 1
homologous 0 
region 0 
but 0 
has 0 
not 0 
deleted 0 
flanking 0 
loci 0 
. 0 

Because 0 
the 0 
intact 0 
chromosome 0 
_NUM1 0 
, 0 
opposite 0 
the 0 
deleted 0 
homolog 0 
, 0 
maintains 0 
the 0 
correct 0 
imprint 0 
in 0 
somatic 0 
cells 0 
of 0 
PWS 1
and 0 
AS 1
mice 0 
and 0 
establishes 0 
the 0 
correct 0 
imprint 0 
in 0 
male 0 
and 0 
female 0 
germ 0 
cells 0 
of 0 
AS 1
mice 0 
, 0 
homologous 0 
association 0 
and 0 
replication 0 
asynchrony 0 
are 0 
not 0 
part 0 
of 0 
the 0 
imprinting 0 
mechanism 0 
. 0 

This 0 
heritable-deletion 0 
mouse 0 
model 0 
will 0 
be 0 
particularly 0 
useful 0 
for 0 
the 0 
identification 0 
of 0 
the 0 
etiological 0 
genes 0 
and 0 
mechanisms 0 
, 0 
phenotypic 0 
basis 0 
, 0 
and 0 
investigation 0 
of 0 
therapeutic 0 
approaches 0 
for 0 
PWS 1
. 0 
. 0 

Transgenic 0 
mice 0 
expressing 0 
a 0 
truncated 0 
form 0 
of 0 
the 0 
high 0 
mobility 0 
group 0 
I-C 0 
protein 0 
develop 0 
adiposity 0 
and 0 
an 0 
abnormally 0 
high 0 
prevalence 0 
of 0 
lipomas 1
. 0 

Chromosomal 0 
translocations 0 
in 0 
human 0 
lipomas 1
frequently 0 
create 0 
fusion 0 
transcripts 0 
encoding 0 
high 0 
mobility 0 
group 0 
-LRB- 0 
HMG 0 
-RRB- 0 
I-C 0 
DNA-binding 0 
domains 0 
and 0 
C-terminal 0 
sequences 0 
from 0 
different 0 
presumed 0 
transcription 0 
factors 0 
, 0 
suggesting 0 
a 0 
potential 0 
role 0 
for 0 
HMG 0 
I-C 0 
in 0 
the 0 
development 0 
of 0 
lipomas 1
. 0 

To 0 
evaluate 0 
the 0 
role 0 
of 0 
the 0 
HMG 0 
I-C 0 
component 0 
, 0 
the 0 
three 0 
DNA-binding 0 
domains 0 
of 0 
HMG 0 
I-C 0 
have 0 
now 0 
been 0 
expressed 0 
in 0 
transgenic 0 
mice 0 
. 0 

Despite 0 
the 0 
ubiquitous 0 
expression 0 
of 0 
the 0 
truncated 0 
HMG 0 
I-C 0 
protein 0 
, 0 
the 0 
transgenic 0 
mice 0 
develop 0 
a 0 
selective 0 
abundance 0 
of 0 
fat 0 
tissue 0 
early 0 
in 0 
life 0 
, 0 
show 0 
marked 0 
adipose 1
tissue 1
inflammation 1
, 0 
and 0 
have 0 
an 0 
abnormally 0 
high 0 
incidence 0 
of 0 
lipomas 1
. 0 

These 0 
findings 0 
demonstrate 0 
that 0 
the 0 
DNA-binding 0 
domains 0 
of 0 
HMG 0 
I-C 0 
, 0 
in 0 
the 0 
absence 0 
of 0 
a 0 
C-terminal 0 
fusion 0 
partner 0 
, 0 
are 0 
sufficient 0 
to 0 
perturb 0 
adipogenesis 0 
and 0 
predispose 0 
to 0 
lipomas 1
. 0 

We 0 
provide 0 
data 0 
supporting 0 
the 0 
central 0 
utility 0 
of 0 
this 0 
animal 0 
model 0 
as 0 
a 0 
tool 0 
to 0 
understand 0 
the 0 
molecular 0 
mechanisms 0 
underlying 0 
the 0 
development 0 
of 0 
one 0 
of 0 
the 0 
most 0 
common 0 
kind 0 
of 0 
human 0 
benign 1
tumors 1
. 0 
. 0 

A 0 
common 0 
MSH2 0 
mutation 0 
in 0 
English 0 
and 0 
North 0 
American 0 
HNPCC 1
families 0 
: 0 
origin 0 
, 0 
phenotypic 0 
expression 0 
, 0 
and 0 
sex 0 
specific 0 
differences 0 
in 0 
colorectal 1
cancer 1
. 0 

The 0 
frequency 0 
, 0 
origin 0 
, 0 
and 0 
phenotypic 0 
expression 0 
of 0 
a 0 
germline 0 
MSH2 0 
gene 0 
mutation 0 
previously 0 
identified 0 
in 0 
seven 0 
kindreds 0 
with 0 
hereditary 1
non-polyposis 1
cancer 1
syndrome 1
-LRB- 0 
HNPCC 1
-RRB- 0 
was 0 
investigated 0 
. 0 

The 0 
mutation 0 
-LRB- 0 
A 0 
-- 0 
> 0 
T 0 
at 0 
nt943 0 
+ 0 
_NUM1 0 
-RRB- 0 
disrupts 0 
the 0 
_NUM1 0 
splice 0 
site 0 
of 0 
exon 0 
_NUM1 0 
leading 0 
to 0 
the 0 
deletion 0 
of 0 
this 0 
exon 0 
from 0 
MSH2 0 
mRNA 0 
and 0 
represents 0 
the 0 
only 0 
frequent 0 
MSH2 0 
mutation 0 
so 0 
far 0 
reported 0 
. 0 

Although 0 
this 0 
mutation 0 
was 0 
initially 0 
detected 0 
in 0 
four 0 
of 0 
_NUM2 0 
colorectal 1
cancer 1
families 0 
analysed 0 
from 0 
eastern 0 
England 0 
, 0 
more 0 
extensive 0 
analysis 0 
has 0 
reduced 0 
the 0 
frequency 0 
to 0 
four 0 
of 0 
_NUM2 0 
-LRB- 0 
_NUM1 0 
% 0 
-RRB- 0 
English 0 
HNPCC 1
kindreds 0 
analysed 0 
. 0 

In 0 
contrast 0 
, 0 
the 0 
MSH2 0 
mutation 0 
was 0 
identified 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
separately 0 
identified 0 
colorectal 1
families 0 
from 0 
Newfoundland 0 
. 0 

To 0 
investigate 0 
the 0 
origin 0 
of 0 
this 0 
mutation 0 
in 0 
colorectal 1
cancer 1
families 0 
from 0 
England 0 
-LRB- 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
, 0 
Newfoundland 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
, 0 
and 0 
the 0 
United 0 
States 0 
-LRB- 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
, 0 
haplotype 0 
analysis 0 
using 0 
microsatellite 0 
markers 0 
linked 0 
to 0 
MSH2 0 
was 0 
performed 0 
. 0 

Within 0 
the 0 
English 0 
and 0 
US 0 
families 0 
there 0 
was 0 
little 0 
evidence 0 
for 0 
a 0 
recent 0 
common 0 
origin 0 
of 0 
the 0 
MSH2 0 
splice 0 
site 0 
mutation 0 
in 0 
most 0 
families 0 
. 0 

In 0 
contrast 0 
, 0 
a 0 
common 0 
haplotype 0 
was 0 
identified 0 
at 0 
the 0 
two 0 
flanking 0 
markers 0 
-LRB- 0 
CA5 0 
and 0 
D2S288 0 
-RRB- 0 
in 0 
eight 0 
of 0 
the 0 
Newfoundland 0 
families 0 
. 0 

These 0 
findings 0 
suggested 0 
a 0 
founder 0 
effect 0 
within 0 
Newfoundland 0 
similar 0 
to 0 
that 0 
reported 0 
by 0 
others 0 
for 0 
two 0 
MLH1 0 
mutations 0 
in 0 
Finnish 0 
HNPCC 1
families 0 
. 0 

We 0 
calculated 0 
age 0 
related 0 
risks 0 
of 0 
all 0 
, 0 
colorectal 1
, 1
endometrial 1
, 1
and 1
ovarian 1
cancers 1
in 0 
nt943 0 
+ 0 
_NUM1 0 
A 0 
-- 0 
> 0 
T 0 
MSH2 0 
mutation 0 
carriers 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
for 0 
all 0 
patients 0 
and 0 
for 0 
men 0 
and 0 
women 0 
separately 0 
. 0 

For 0 
both 0 
sexes 0 
combined 0 
, 0 
the 0 
penetrances 0 
at 0 
age 0 
_NUM2 0 
years 0 
for 0 
all 0 
cancers 1
and 0 
for 0 
colorectal 1
cancer 1
were 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
respectively 0 
. 0 

The 0 
risk 0 
of 0 
colorectal 1
cancer 1
was 0 
significantly 0 
higher 0 
-LRB- 0 
p 0 
< 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
in 0 
males 0 
than 0 
females 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
v 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
_NUM1 0 
. 0 

_NUM2 0 
v 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
ages 0 
_NUM2 0 
and 0 
_NUM2 0 
years 0 
, 0 
respectively 0 
-RRB- 0 
. 0 

For 0 
females 0 
there 0 
was 0 
a 0 
high 0 
risk 0 
of 0 
endometrial 1
cancer 1
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
at 0 
age 0 
_NUM2 0 
years 0 
-RRB- 0 
and 0 
premenopausal 1
ovarian 1
cancer 1
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
at 0 
_NUM2 0 
years 0 
-RRB- 0 
. 0 

These 0 
intersex 0 
differences 0 
in 0 
colorectal 1
cancer 1
risks 0 
have 0 
implications 0 
for 0 
screening 0 
programmes 0 
and 0 
for 0 
attempts 0 
to 0 
identify 0 
colorectal 1
cancer 1
susceptibility 0 
modifiers 0 
. 0 

Novel 0 
mutation 0 
at 0 
the 0 
initiation 0 
codon 0 
in 0 
the 0 
Norrie 1
disease 1
gene 0 
in 0 
two 0 
Japanese 0 
families 0 
. 0 

We 0 
have 0 
identified 0 
a 0 
new 0 
mutation 0 
of 0 
Norrie 1
disease 1
-LRB- 0 
ND 1
-RRB- 0 
gene 0 
in 0 
two 0 
Japanese 0 
males 0 
from 0 
unrelated 0 
families 0 
; 0 
they 0 
showed 0 
typical 0 
ocular 0 
features 0 
of 0 
ND 1
but 0 
no 0 
mental 1
retardation 1
or 0 
hearing 1
impairment 1
. 0 

A 0 
mutation 0 
was 0 
found 0 
in 0 
both 0 
patients 0 
at 0 
the 0 
initiation 0 
codon 0 
of 0 
exon 0 
_NUM1 0 
of 0 
the 0 
ND 1
gene 0 
-LRB- 0 
_DS 0 
to 0 
_DS 0 
-RRB- 0 
, 0 
with 0 
otherwise 0 
normal 0 
nucleotide 0 
sequences 0 
. 0 

Their 0 
mothers 0 
had 0 
the 0 
normal 0 
and 0 
mutant 0 
types 0 
of 0 
the 0 
gene 0 
, 0 
which 0 
was 0 
expected 0 
for 0 
heterozygotes 0 
of 0 
the 0 
disease 0 
. 0 

The 0 
mutation 0 
of 0 
the 0 
initiation 0 
codon 0 
would 0 
cause 0 
the 0 
failure 0 
of 0 
ND 1
gene 0 
expression 0 
or 0 
a 0 
defect 0 
in 0 
translation 0 
thereby 0 
truncating 0 
the 0 
amino 0 
terminus 0 
of 0 
ND 1
protein 0 
. 0 

In 0 
view 0 
of 0 
the 0 
rarity 0 
and 0 
marked 0 
heterogeneity 0 
of 0 
mutations 0 
in 0 
the 0 
ND 1
gene 0 
, 0 
the 0 
present 0 
apparently 0 
unrelated 0 
Japanese 0 
families 0 
who 0 
have 0 
lived 0 
in 0 
the 0 
same 0 
area 0 
for 0 
over 0 
two 0 
centuries 0 
presumably 0 
share 0 
the 0 
origin 0 
of 0 
the 0 
mutation 0 
. 0 
. 0 

Haplotype 0 
and 0 
phenotype 0 
analysis 0 
of 0 
six 0 
recurrent 0 
BRCA1 0 
mutations 0 
in 0 
_NUM2 0 
families 0 
: 0 
results 0 
of 0 
an 0 
international 0 
study 0 
. 0 

Several 0 
BRCA1 0 
mutations 0 
have 0 
now 0 
been 0 
found 0 
to 0 
occur 0 
in 0 
geographically 0 
diverse 0 
breast 1
and 1
ovarian 1
cancer 1
families 0 
. 0 

To 0 
investigate 0 
mutation 0 
origin 0 
and 0 
mutation-specific 0 
phenotypes 0 
due 0 
to 0 
BRCA1 0 
, 0 
we 0 
constructed 0 
a 0 
haplotype 0 
of 0 
nine 0 
polymorphic 0 
markers 0 
within 0 
or 0 
immediately 0 
flanking 0 
the 0 
BRCA1 0 
locus 0 
in 0 
a 0 
set 0 
of 0 
_NUM2 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
selected 0 
for 0 
having 0 
one 0 
of 0 
six 0 
recurrent 0 
BRCA1 0 
mutations 0 
. 0 

Tests 0 
of 0 
both 0 
mutations 0 
and 0 
family-specific 0 
differences 0 
in 0 
age 0 
at 0 
diagnosis 0 
were 0 
not 0 
significant 0 
. 0 

A 0 
comparison 0 
of 0 
the 0 
six 0 
mutations 0 
in 0 
the 0 
relative 0 
proportions 0 
of 0 
cases 0 
of 0 
breast 1
and 1
ovarian 1
cancer 1
was 0 
suggestive 0 
of 0 
an 0 
effect 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM3 0 
-RRB- 0 
, 0 
with 0 
_NUM2 0 
% 0 
of 0 
women 0 
presumed 0 
affected 0 
because 0 
of 0 
the 0 
_NUM4 0 
del 0 
_NUM2 0 
BRCA1 0 
mutation 0 
having 0 
ovarian 1
cancer 1
, 0 
compared 0 
with 0 
_NUM2 0 
% 0 
of 0 
affected 0 
women 0 
with 0 
the 0 
splice-site 0 
mutation 0 
in 0 
intron 0 
_NUM1 0 
of 0 
BRCA1 0 
. 0 

For 0 
the 0 
BRCA1 0 
mutations 0 
studied 0 
here 0 
, 0 
the 0 
individual 0 
mutations 0 
are 0 
estimated 0 
to 0 
have 0 
arisen 0 
9-170 0 
generations 0 
ago 0 
. 0 

In 0 
general 0 
, 0 
a 0 
high 0 
degree 0 
of 0 
haplotype 0 
conservation 0 
across 0 
the 0 
region 0 
was 0 
observed 0 
, 0 
with 0 
haplotype 0 
differences 0 
most 0 
often 0 
due 0 
to 0 
mutations 0 
in 0 
the 0 
short-tandem-repeat 0 
markers 0 
, 0 
although 0 
some 0 
likely 0 
instances 0 
of 0 
recombination 0 
also 0 
were 0 
observed 0 
. 0 

For 0 
several 0 
of 0 
the 0 
instances 0 
, 0 
there 0 
was 0 
evidence 0 
for 0 
multiple 0 
, 0 
independent 0 
, 0 
BRCA1 0 
mutational 0 
events 0 
. 0 

A 0 
new 0 
glucose-6-phosphate 0 
dehydrogenase 0 
variant 0 
-LRB- 0 
G6PD 0 
Nagano 0 
-RRB- 0 
associated 0 
with 0 
congenital 1
hemolytic 1
anemia 1
. 0 

A 0 
new 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
variant 0 
associated 0 
with 0 
chronic 1
nonspherocytic 1
hemolytic 1
anemia 1
was 0 
reported 0 
. 0 

The 0 
patient 0 
, 0 
a 0 
6-year-old 0 
Japanese 0 
male 0 
, 0 
was 0 
noticed 0 
to 0 
have 0 
hemolytic 1
anemia 1
soon 0 
after 0 
birth 0 
, 0 
and 0 
a 0 
diagnosis 0 
of 0 
G6PD 1
deficiency 1
was 0 
made 0 
at 0 
the 0 
age 0 
of 0 
_NUM1 0 
. 0 

He 0 
had 0 
episodes 0 
of 0 
hemolytic 1
crisis 1
several 0 
times 0 
after 0 
upper 1
respiratory 1
infection 1
. 0 

G6PD 0 
activity 0 
of 0 
the 0 
patient 0 
was 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
normal 0 
. 0 

The 0 
enzymatic 0 
characteristics 0 
were 0 
examined 0 
when 0 
he 0 
was 0 
_NUM1 0 
years 0 
old 0 
, 0 
and 0 
his 0 
G6PD 0 
showed 0 
faster-than-normal 0 
electrophoretic 0 
mobility 0 
, 0 
low 0 
Km 0 
G6P 0 
, 0 
high 0 
Km 0 
NADP 0 
, 0 
low 0 
Ki 0 
NADPH 0 
, 0 
normal 0 
utilization 0 
of 0 
substrate 0 
analogues 0 
, 0 
heat 0 
instability 0 
, 0 
and 0 
a 0 
normal 0 
pH 0 
optimum 0 
curve 0 
. 0 

From 0 
these 0 
results 0 
, 0 
this 0 
was 0 
considered 0 
to 0 
be 0 
a 0 
new 0 
variant 0 
and 0 
was 0 
designated 0 
G6PD 0 
Nagano 0 
. 0 

Infection-induced 0 
hemolysis 1
and 0 
chronic 1
hemolytic 1
anemia 1
seem 0 
to 0 
be 0 
due 0 
to 0 
markedly 0 
impaired 0 
enzyme 0 
activity 0 
and 0 
thermal 0 
instability 0 
. 0 

Craniofrontonasal 1
dysplasia 1
. 0 

We 0 
report 0 
on 0 
nine 0 
patients 0 
with 0 
craniofrontonasal 1
dysplasia 1
-LRB- 0 
CFND 1
-RRB- 0 
. 0 

Seven 0 
classical 0 
cases 0 
had 0 
facial 0 
features 0 
suggestive 0 
of 0 
frontonasal 1
dysplasia 1
and 0 
coronal 1
craniosynostosis 1
. 0 

Extracranial 1
abnormalities 1
such 0 
as 0 
brittle 1
nails 1
with 1
prominent 1
longitudinal 1
grooves 1
or 0 
syndactyly 1
of 1
fingers 1
and 1
toes 1
were 0 
observed 0 
in 0 
individual 0 
patients 0 
. 0 

In 0 
two 0 
families 0 
the 0 
father 0 
of 0 
classical 0 
cases 0 
showed 0 
a 0 
milder 0 
pattern 0 
of 0 
abnormalities 0 
, 0 
consistent 0 
with 0 
the 0 
diagnosis 0 
. 0 

We 0 
present 0 
a 0 
_NUM1 0 
- 0 
to 0 
13-year 0 
follow-up 0 
on 0 
our 0 
patients 0 
. 0 

Hypotonia 1
and 0 
laxity 1
of 1
joints 1
are 0 
common 0 
and 0 
may 0 
necessitate 0 
supportive 0 
measures 0 
. 0 

Mild 0 
developmental 1
delay 1
was 0 
noted 0 
in 0 
three 0 
out 0 
of 0 
six 0 
classical 0 
cases 0 
studied 0 
in 0 
detail 0 
. 0 

Unlike 0 
almost 0 
all 0 
other 0 
X-linked 1
disorders 1
, 0 
clinical 0 
expression 0 
in 0 
CFND 1
is 0 
generally 0 
much 0 
more 0 
severe 0 
in 0 
females 0 
than 0 
in 0 
males 0 
. 0 

In 0 
contrast 0 
to 0 
previous 0 
reports 0 
of 0 
this 0 
condition 0 
, 0 
one 0 
of 0 
our 0 
severely 0 
affected 0 
cases 0 
is 0 
a 0 
male 0 
. 0 
. 0 

A 0 
new 0 
mutation 0 
in 0 
the 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
gene 0 
in 0 
a 0 
German 0 
family 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 

A 0 
C-to-T 0 
transition 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
PLP 0 
gene 0 
was 0 
found 0 
in 0 
_NUM1 0 
affected 0 
males 0 
and 0 
two 0 
obligate 0 
carriers 0 
in 0 
a 0 
German 0 
family 0 
with 0 
Pelizaeus-Merzbacher 1
disease 1
. 0 

The 0 
mutation 0 
, 0 
which 0 
causes 0 
loss 0 
of 0 
an 0 
HphI 0 
site 0 
and 0 
changes 0 
amino 0 
acid 0 
_NUM3 0 
from 0 
threonine 0 
to 0 
isoleucine 0 
, 0 
was 0 
absent 0 
from 0 
_NUM3 0 
normal 0 
chromosomes 0 
. 0 

There 0 
are 0 
_NUM1 0 
concordances 0 
and 0 
_NUM1 0 
discrepancy 0 
between 0 
these 0 
results 0 
and 0 
those 0 
obtained 0 
by 0 
magnetic 0 
resonance 0 
imaging 0 
in 0 
this 0 
family 0 
. 0 
. 0 

The 0 
Wiskott-Aldrich 1
syndrome 1
and 0 
X-linked 1
congenital 1
thrombocytopenia 1
are 0 
caused 0 
by 0 
mutations 0 
of 0 
the 0 
same 0 
gene 0 
. 0 

The 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
is 0 
an 0 
X-linked 1
recessive 1
disorder 1
characterized 0 
by 0 
thrombocytopenia 1
, 0 
small 0 
platelets 0 
, 0 
eczema 1
, 0 
recurrent 0 
infections 0 
, 0 
and 0 
immunodeficiency 1
. 0 

Besides 0 
the 0 
classic 0 
WAS 1
phenotype 0 
, 0 
there 0 
is 0 
a 0 
group 0 
of 0 
patients 0 
with 0 
congenital 1
X-linked 1
thrombocytopenia 1
-LRB- 0 
XLT 1
-RRB- 0 
who 0 
have 0 
small 0 
platelets 0 
but 0 
only 0 
transient 0 
eczema 1
, 0 
if 0 
any 0 
, 0 
and 0 
minimal 0 
immune 1
deficiency 1
. 0 

Because 0 
the 0 
gene 0 
responsible 0 
for 0 
WAS 1
has 0 
been 0 
sequenced 0 
, 0 
it 0 
was 0 
possible 0 
to 0 
correlate 0 
the 0 
WAS 1
phenotypes 0 
with 0 
WAS 1
gene 0 
mutations 0 
. 0 

Using 0 
a 0 
fingerprinting 0 
screening 0 
technique 0 
, 0 
we 0 
determined 0 
the 0 
approximate 0 
location 0 
of 0 
the 0 
mutation 0 
in 0 
_NUM2 0 
unrelated 0 
WAS 1
patients 0 
with 0 
mild 0 
to 0 
severe 0 
clinical 0 
symptoms 0 
. 0 

Direct 0 
sequence 0 
analysis 0 
of 0 
cDNA 0 
and 0 
genomic 0 
DNA 0 
obtained 0 
from 0 
patient-derived 0 
cell 0 
lines 0 
showed 0 
_NUM2 0 
unique 0 
mutations 0 
distributed 0 
throughout 0 
the 0 
WAS 1
gene 0 
, 0 
including 0 
insertions 0 
, 0 
deletions 0 
, 0 
and 0 
point 0 
mutations 0 
resulting 0 
in 0 
amino 0 
acid 0 
substitutions 0 
, 0 
termination 0 
, 0 
exon 0 
skipping 0 
, 0 
or 0 
splicing 0 
defects 0 
. 0 

Of 0 
_NUM1 0 
unrelated 0 
patients 0 
with 0 
the 0 
XLT 1
phenotype 0 
, 0 
_NUM1 0 
had 0 
missense 0 
mutations 0 
affecting 0 
exon 0 
_NUM1 0 
and 0 
_NUM1 0 
had 0 
a 0 
splice-site 0 
mutation 0 
affecting 0 
exon 0 
_NUM1 0 
. 0 

Patients 0 
with 0 
classic 0 
WAS 1
had 0 
more 0 
complex 0 
mutations 0 
, 0 
resulting 0 
in 0 
termination 0 
codons 0 
, 0 
frameshift 0 
, 0 
and 0 
early 0 
termination 0 
. 0 

These 0 
findings 0 
provide 0 
direct 0 
evidence 0 
that 0 
XLT 1
and 0 
WAS 1
are 0 
caused 0 
by 0 
mutations 0 
of 0 
the 0 
same 0 
gene 0 
and 0 
suggest 0 
that 0 
severe 0 
clinical 0 
phenotypes 0 
are 0 
associated 0 
with 0 
complex 0 
mutations 0 
. 0 
. 0 

A 0 
3-base 0 
pair 0 
in-frame 0 
deletion 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
results 0 
in 0 
a 0 
kinetic 0 
variant 0 
of 0 
phenylketonuria 1
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disease 1
due 0 
to 0 
deficiency 1
of 1
a 1
hepatic 1
enzyme 1
, 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

The 0 
absence 0 
of 0 
PAH 0 
activity 0 
results 0 
in 0 
typical 0 
PKU 1
while 0 
persistence 0 
of 0 
a 0 
residual 0 
enzyme 0 
activity 0 
gives 0 
rise 0 
to 0 
variant 0 
forms 0 
of 0 
the 0 
disease 0 
. 0 

We 0 
report 0 
here 0 
a 0 
3-base 0 
pair 0 
in-frame 0 
deletion 0 
of 0 
the 0 
PAH 0 
gene 0 
-LRB- 0 
delta 0 
_NUM3 0 
-RRB- 0 
in 0 
a 0 
mild 0 
variant 0 
, 0 
with 0 
markedly 0 
reduced 0 
affinity 0 
of 0 
the 0 
enzyme 0 
for 0 
phenylalanine 0 
-LRB- 0 
Km 0 
= 0 
_NUM3 0 
nM 0 
-RRB- 0 
, 0 
and 0 
we 0 
provide 0 
functional 0 
evidence 0 
for 0 
responsibility 0 
of 0 
the 0 
deletion 0 
in 0 
the 0 
mutant 0 
phenotype 0 
. 0 

Since 0 
the 0 
deletion 0 
was 0 
located 0 
in 0 
the 0 
third 0 
exon 0 
of 0 
the 0 
gene 0 
, 0 
which 0 
presents 0 
no 0 
homology 0 
with 0 
other 0 
hydroxylases 0 
, 0 
we 0 
suggest 0 
that 0 
exon 0 
_NUM1 0 
is 0 
involved 0 
in 0 
the 0 
specificity 0 
of 0 
the 0 
enzyme 0 
for 0 
phenylalanine 0 
. 0 

Finally 0 
, 0 
since 0 
none 0 
of 0 
the 0 
_NUM2 0 
PKU 1
patients 0 
tested 0 
were 0 
found 0 
to 0 
carry 0 
this 0 
particular 0 
deletion 0 
, 0 
our 0 
study 0 
suggests 0 
that 0 
this 0 
molecular 0 
event 0 
probably 0 
occurred 0 
recently 0 
on 0 
the 0 
background 0 
of 0 
a 0 
haplotype 0 
_NUM1 0 
gene 0 
in 0 
Portugal 0 
. 0 
. 0 

Friedreich 1
ataxia 1
: 0 
an 0 
overview 0 
. 0 

Friedreich 1
ataxia 1
, 0 
an 0 
autosomal 1
recessive 1
neurodegenerative 1
disease 1
, 0 
is 0 
the 0 
most 0 
common 0 
of 0 
the 0 
inherited 1
ataxias 1
. 0 

The 0 
recent 0 
discovery 0 
of 0 
the 0 
gene 0 
that 0 
is 0 
mutated 0 
in 0 
this 0 
condition 0 
, 0 
FRDA 0 
, 0 
has 0 
led 0 
to 0 
rapid 0 
advances 0 
in 0 
the 0 
understanding 0 
of 0 
the 0 
pathogenesis 0 
of 0 
Friedreich 1
ataxia 1
. 0 

About 0 
_NUM2 0 
% 0 
of 0 
mutant 0 
alleles 0 
have 0 
an 0 
expansion 0 
of 0 
a 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
intron 0 
_NUM1 0 
of 0 
the 0 
gene 0 
. 0 

This 0 
leads 0 
to 0 
reduced 0 
levels 0 
of 0 
the 0 
protein 0 
, 0 
frataxin 0 
. 0 

There 0 
is 0 
mounting 0 
evidence 0 
to 0 
suggest 0 
that 0 
Friedreich 1
ataxia 1
is 0 
the 0 
result 0 
of 0 
accumulation 0 
of 0 
iron 0 
in 0 
mitochondria 0 
leading 0 
to 0 
excess 0 
production 0 
of 0 
free 0 
radicals 0 
, 0 
which 0 
then 0 
results 0 
in 0 
cellular 0 
damage 0 
and 0 
death 0 
. 0 

Currently 0 
there 0 
is 0 
no 0 
known 0 
treatment 0 
that 0 
alters 0 
the 0 
natural 0 
course 0 
of 0 
the 0 
disease 0 
. 0 

The 0 
discovery 0 
of 0 
the 0 
FRDA 1
gene 0 
and 0 
its 0 
possible 0 
function 0 
has 0 
raised 0 
hope 0 
that 0 
rational 0 
therapeutic 0 
strategies 0 
will 0 
be 0 
developed 0 
. 0 
. 0 

Clinical 0 
and 0 
molecular 0 
genetics 0 
of 0 
primary 1
dystonias 1
. 0 

Primary 1
dystonias 1
are 0 
movement 1
disorders 1
with 0 
dystonia 1
as 0 
a 0 
major 0 
symptom 0 
. 0 

They 0 
are 0 
frequently 0 
inherited 0 
as 0 
Mendelian 0 
traits 0 
. 0 

There 0 
are 0 
at 0 
least 0 
eight 0 
clinically 0 
distinct 0 
autosomal 0 
dominant 0 
and 0 
two 0 
X-linked 0 
recessive 0 
forms 0 
. 0 

In 0 
addition 0 
, 0 
pedigree 0 
analyses 0 
suggest 0 
the 0 
occurrence 0 
of 0 
an 0 
autosomal 0 
recessive 0 
variant 0 
. 0 

The 0 
clinical 0 
classification 0 
is 0 
increasingly 0 
being 0 
replaced 0 
by 0 
a 0 
genetic 0 
one 0 
. 0 

To 0 
date 0 
gene 0 
loci 0 
have 0 
been 0 
identified 0 
in 0 
at 0 
least 0 
six 0 
autosomal 0 
dominant 0 
forms 0 
, 0 
i. 0 
e. 0 
, 0 
in 0 
idiopathic 1
torsion 1
dystonia 1
-LRB- 0 
9q34 0 
-RRB- 0 
, 0 
focal 1
dystonia 1
-LRB- 0 
18p 0 
-RRB- 0 
, 0 
adult-onset 0 
idiopathic 1
torsion 1
dystonia 1
of 0 
mixed 0 
type 0 
-LRB- 0 
8p21-q22 0 
-RRB- 0 
, 0 
dopa-responsive 1
dystonia 1
-LRB- 0 
14q22 0 
. 0 

1-q22 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
and 0 
paroxysmal 1
dystonic 1
choreoathetosis 1
-LRB- 0 
2q25-q33 0 
; 0 
1p21-p13 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

Gene 0 
loci 0 
in 0 
the 0 
X-linked 0
recessive 0 
forms 0 
have 0 
been 0 
assigned 0 
to 0 
Xq13 0 
. 0 

_NUM1 0 
in 0 
the 0 
X-linked 1
dystonia 1
parkinsonism 1
syndrome 1
and 0 
to 0 
Xq22 0 
in 0 
X-linked 1
sensorineural 1
deafness 1
, 0 
dystonia 1
, 0 
and 0 
mental 1
retardation 1
. 0 

The 0 
disease 0 
genes 0 
have 0 
been 0 
identified 0 
in 0 
two 0 
autosomal 0 
dominant 0 
forms 0 
and 0 
in 0 
one 0 
X-linked 0 
recessive 0 
form 0 
. 0 

Mutations 0 
in 0 
a 0 
gene 0 
coding 0 
for 0 
an 0 
ATP-binding 0 
protein 0 
were 0 
detected 0 
in 0 
idiopathic 1
torsion 1
dystonia 1
-LRB- 0 
DYT1 0 
-RRB- 0 
, 0 
and 0 
the 0 
GTP 0 
cyclohydrolase 0 
_NUM1 0 
gene 0 
is 0 
mutated 0 
in 0 
dopa-responsive 1
dystonia 1
-LRB- 0 
DYT5 0 
-RRB- 0 
. 0 

In 0 
sensorineural 1
deafness 1
, 0 
dystonia 1
, 0 
and 0 
mental 1
retardation 1
, 0 
mutations 0 
were 0 
found 0 
in 0 
the 0 
gene 0 
DDP 0 
coding 0 
for 0 
a 0 
polypeptide 0 
of 0 
unknown 0 
function 0 
. 0 

This 0 
article 0 
reviews 0 
the 0 
clinical 0 
and 0 
molecular 0 
genetics 0 
of 0 
primary 1
dystonias 1
, 0 
critically 0 
discusses 0 
present 0 
findings 0 
, 0 
and 0 
proposes 0 
referring 0 
to 0 
the 0 
known 0 
forms 0 
, 0 
most 0 
of 0 
which 0 
can 0 
be 0 
distinguished 0 
by 0 
genetic 0 
criteria 0 
, 0 
as 0 
dystonias 1
1-12 1
. 0 

Clinical 0 
and 0 
genetic 0 
study 0 
of 0 
Friedreich 1
ataxia 1
in 0 
an 0 
Australian 0 
population 0 
. 0 

Friedreich 1
ataxia 1
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
caused 0 
by 0 
mutations 0 
in 0 
the 0 
FRDA 1
gene 0 
that 0 
encodes 0 
a 0 
210-amino 0 
acid 0 
protein 0 
called 0 
frataxin 0 
. 0 

An 0 
expansion 0 
of 0 
a 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
intron 0 
_NUM1 0 
of 0 
the 0 
gene 0 
is 0 
present 0 
in 0 
more 0 
than 0 
_NUM2 0 
% 0 
of 0 
mutant 0 
alleles 0 
. 0 

Of 0 
the 0 
_NUM2 0 
people 0 
we 0 
studied 0 
who 0 
have 0 
mutations 0 
in 0 
FRDA 0 
, 0 
_NUM2 0 
are 0 
homozygous 0 
for 0 
an 0 
expanded 0 
_DS 0 
repeat 0 
; 0 
the 0 
other 0 
five 0 
patients 0 
have 0 
an 0 
expansion 0 
in 0 
one 0 
allele 0 
and 0 
a 0 
point 0 
mutation 0 
in 0 
the 0 
other 0 
. 0 

Here 0 
we 0 
present 0 
a 0 
detailed 0 
clinical 0 
and 0 
genetic 0 
study 0 
of 0 
a 0 
subset 0 
of 0 
_NUM2 0 
patients 0 
homozygous 0 
for 0 
an 0 
expansion 0 
of 0 
the 0 
_DS 0 
repeat 0 
. 0 

We 0 
found 0 
a 0 
correlation 0 
between 0 
the 0 
size 0 
of 0 
the 0 
smaller 0 
of 0 
the 0 
two 0 
expanded 0 
alleles 0 
and 0 
age 0 
at 0 
onset 0 
, 0 
age 0 
into 0 
wheelchair 0 
, 0 
scoliosis 1
, 0 
impaired 0 
vibration 0 
sense 0 
, 0 
and 0 
the 0 
presence 0 
of 0 
foot 1
deformity 1
. 0 

There 0 
was 0 
no 0 
significant 0 
correlation 0 
between 0 
the 0 
size 0 
of 0 
the 0 
smaller 0 
allele 0 
and 0 
cardiomyopathy 1
, 0 
diabetes 1
mellitus 1
, 0 
loss 1
of 1
proprioception 1
, 0 
or 0 
bladder 1
symptoms 1
. 0 

The 0 
larger 0 
allele 0 
size 0 
correlated 0 
with 0 
bladder 1
symptoms 1
and 0 
the 0 
presence 0 
of 0 
foot 1
deformity 1
. 0 

The 0 
duration 0 
of 0 
disease 0 
is 0 
correlated 0 
with 0 
wheelchair 0 
use 0 
and 0 
the 0 
presence 0 
of 0 
diabetes 1
, 0 
scoliosis 1
, 0 
bladder 1
symptoms 1
and 0 
impaired 1
proprioception 1
, 0 
and 0 
vibration 0 
sense 0 
but 0 
no 0 
other 0 
complications 0 
studied 0 
. 0 
. 0 

Recurrent 0 
meningococcal 1
meningitis 1
with 0 
absence 1
of 1
the 1
sixth 1
component 1
of 1
complement 1
: 0 
an 0 
evaluation 0 
of 0 
underlying 0 
immunologic 0 
mechanisms 0 
. 0 

A 0 
51 0 
/ 0 
2-year-old 0 
black 0 
girl 0 
with 0 
recurrent 0 
meningococcal 1
meningitis 1
and 0 
absence 1
of 1
the 1
sixth 1
component 1
of 1
complement 1
-LRB- 0 
C6 0 
-RRB- 0 
is 0 
reported 0 
. 0 

To 0 
explore 0 
the 0 
pathogenesis 0 
of 0 
recurrent 0 
neisserial 1
infections 1
in 0 
C6 1
deficiency 1
, 0 
a 0 
detailed 0 
analysis 0 
of 0 
her 0 
immune 0 
competence 0 
was 0 
conducted 0 
. 0 

Her 0 
serum 0 
had 0 
normal 0 
chemotactic 0 
, 0 
opsonic 0 
, 0 
alternative 0 
complement 0 
pathway 0 
, 0 
and 0 
specific 0 
antibody 0 
activity 0 
, 0 
but 0 
lacked 0 
complement-mediated 0 
bacteriolytic 0 
activity 0 
. 0 

In 0 
addition 0 
, 0 
her 0 
C6-deficient 1
serum 0 
was 0 
indistinguishable 0 
from 0 
normal 0 
serum 0 
in 0 
a 0 
complement-dependent 0 
assay 0 
of 0 
phagocyte 0 
bactericidal 0 
activity 0 
. 0 

Absent 0 
bacteriolysis 0 
remains 0 
the 0 
only 0 
consistent 0 
defect 0 
associated 0 
with 0 
recurrent 0 
neisserial 1
infections 1
and 0 
absence 0 
of 0 
one 0 
of 0 
the 0 
late-acting 0 
complement 0 
components 0 
. 0 
. 0 

Mutation 0 
of 0 
the 0 
sterol 0 
27-hydroxylase 0 
gene 0 
-LRB- 0 
CYP27 0 
-RRB- 0 
results 0 
in 0 
truncation 0 
of 0 
mRNA 0 
expressed 0 
in 0 
leucocytes 0 
in 0 
a 0 
Japanese 0 
family 0 
with 0 
cerebrotendinous 1
xanthomatosis 1
. 0 

OBJECTIVES 0 
A 0 
Japanese 0 
family 0 
with 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
was 0 
investigated 0 
for 0 
a 0 
sequence 0 
alteration 0 
in 0 
the 0 
sterol 0 
27-hydroxylase 0 
gene 0 
-LRB- 0 
CYP27 0 
-RRB- 0 
. 0 

The 0 
expression 0 
of 0 
CYP27 0 
has 0 
been 0 
mostly 0 
explored 0 
using 0 
cultured 0 
fibroblasts 0 
, 0 
prompting 0 
the 0 
examination 0 
of 0 
the 0 
transcripts 0 
from 0 
blood 0 
leucocytes 0 
as 0 
a 0 
simple 0 
and 0 
rapid 0 
technique 0 
. 0 

METHODS 0 
An 0 
alteration 0 
in 0 
CYP27 0 
of 0 
the 0 
proband 0 
was 0 
searched 0 
for 0 
by 0 
polymerase 0 
chain 0 
reaction-single 0 
strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
PCR-SSCP 0 
-RRB- 0 
analysis 0 
and 0 
subsequent 0 
sequencing 0 
. 0 

Samples 0 
of 0 
RNA 0 
were 0 
subjected 0 
to 0 
reverse 0 
transcription 0 
PCR 0 
-LRB- 0 
RT-PCR 0 
-RRB- 0 
and 0 
the 0 
product 0 
of 0 
the 0 
proband 0 
was 0 
amplified 0 
with 0 
nested 0 
primers 0 
and 0 
sequenced 0 
. 0 

RESULTS 0 
A 0 
homozygous 0 
G 0 
to 0 
A 0 
transition 0 
at 0 
the 0 
_NUM1 0 
end 0 
of 0 
intron 0 
_NUM1 0 
was 0 
detected 0 
in 0 
the 0 
patient 0 
. 0 

In 0 
RT-PCR 0 
analysis 0 
, 0 
only 0 
a 0 
truncated 0 
transcript 0 
was 0 
detected 0 
in 0 
the 0 
patient 0 
, 0 
whereas 0 
both 0 
normal 0 
and 0 
truncated 0 
transcripts 0 
were 0 
detected 0 
in 0 
the 0 
siblings 0 
. 0 

The 0 
sequencing 0 
of 0 
the 0 
patients 0 
cDNA 0 
fragment 0 
disclosed 0 
a 0 
direct 0 
conjuction 0 
of 0 
exon 0 
_NUM1 0 
and 0 
exon 0 
_NUM1 0 
. 0 

CONCLUSION 0 
The 0 
mutation 0 
at 0 
splice 0 
donor 0 
site 0 
and 0 
the 0 
truncation 0 
of 0 
mRNA 0 
were 0 
identical 0 
with 0 
those 0 
of 0 
a 0 
recently 0 
reported 0 
Italian 0 
patient 0 
, 0 
although 0 
different 0 
in 0 
symptomatology 0 
. 0 

The 0 
application 0 
of 0 
blood 0 
leucocytes 0 
can 0 
be 0 
a 0 
simple 0 
technique 0 
on 0 
analysing 0 
a 0 
constructive 0 
abnormality 1
of 1
CYP27 1
mRNA 0 
. 0 
. 0 

Frequent 0 
detection 0 
of 0 
codon 0 
_NUM3 0 
mutation 0 
in 0 
the 0 
androgen 0 
receptor 0 
gene 0 
in 0 
advanced 1
prostate 1
cancers 1
. 0 

Prostatic 0 
tissue 0 
specimens 0 
derived 0 
from 0 
transurethral 0 
resections 0 
of 0 
patients 0 
with 0 
metastatic 1
prostate 1
cancer 1
were 0 
analyzed 0 
for 0 
genetic 0 
alterations 0 
in 0 
the 0 
hormone-binding 0 
domain 0 
of 0 
the 0 
androgen 0 
receptor 0 
-LRB- 0 
AR 0 
-RRB- 0 
gene 0 
. 0 

Direct 0 
sequencing 0 
of 0 
the 0 
polymerase 0 
chain 0 
reaction-derived 0 
DNAs 0 
of 0 
_NUM1 0 
of 0 
_NUM2 0 
specimens 0 
revealed 0 
a 0 
codon 0 
_NUM3 0 
mutation 0 
-LRB- 0 
_DS 0 
-- 0 
> 0 
_DS 0 
, 0 
Thr 0 
-- 0 
> 0 
Ala 0 
-RRB- 0 
in 0 
the 0 
hormone-binding 0 
domain 0 
of 0 
the 0 
AR 0 
gene 0 
. 0 

This 0 
same 0 
AR 0 
mutation 0 
has 0 
been 0 
reported 0 
previously 0 
in 0 
a 0 
metastatic 1
prostate 1
cancer 1
cell 0 
line 0 
, 0 
LNCaP 0 
, 0 
where 0 
this 0 
mutation 0 
confers 0 
upon 0 
the 0 
AR 0 
an 0 
altered 0 
ligand-binding 0 
specificity 0 
which 0 
is 0 
stimulated 0 
by 0 
estrogens 0 
, 0 
progestagens 0 
, 0 
and 0 
antiandrogens 0 
. 0 

It 0 
is 0 
possible 0 
that 0 
analogous 0 
to 0 
an 0 
activated 0 
/ 0 
altered 0 
growth 0 
factor 0 
receptor 0 
oncogene 0 
, 0 
codon 0 
_NUM3 0 
mutant 0 
AR 0 
with 0 
altered 0 
ligand 0 
binding 0 
may 0 
provide 0 
a 0 
selective 0 
growth 0 
advantage 0 
in 0 
the 0 
genesis 0 
of 0 
a 0 
subset 0 
of 0 
advanced 1
prostate 1
cancer 1
. 0 

Although 0 
estrogens 0 
are 0 
used 0 
infrequently 0 
, 0 
antiandrogens 0 
are 0 
used 0 
increasingly 0 
in 0 
hormonal 0 
therapy 0 
for 0 
patients 0 
with 0 
advanced 1
prostate 1
cancer 1
. 0 

The 0 
stimulatory 0 
effect 0 
of 0 
these 0 
therapeutic 0 
agents 0 
on 0 
the 0 
codon 0 
_NUM3 0 
mutant 0 
AR 0 
further 0 
suggests 0 
that 0 
this 0 
frequently 0 
observed 0 
AR 0 
mutation 0 
may 0 
contribute 0 
to 0 
the 0 
treatment 0 
refractory 0 
disease 0 
. 0 
. 0 

ATM-dependent 0 
phosphorylation 0 
of 0 
nibrin 0 
in 0 
response 0 
to 0 
radiation 0 
exposure 0 
. 0 

Mutations 0 
in 0 
the 0 
gene 0 
ATM 0 
are 0 
responsible 0 
for 0 
the 0 
genetic 1
disorder 1
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
, 0 
which 0 
is 0 
characterized 0 
by 0 
cerebellar 1
dysfunction 1
, 0 
radiosensitivity 0 
, 0 
chromosomal 0 
instability 0 
and 0 
cancer 1
predisposition 0 
. 0 

Both 0 
the 0 
A-T 1
phenotype 0 
and 0 
the 0 
similarity 0 
of 0 
the 0 
ATM 0 
protein 0 
to 0 
other 0 
DNA-damage 0 
sensors 0 
suggests 0 
a 0 
role 0 
for 0 
ATM 0 
in 0 
biochemical 0 
pathways 0 
involved 0 
in 0 
the 0 
recognition 0 
, 0 
signalling 0 
and 0 
repair 0 
of 0 
DNA 0 
double-strand 0 
breaks 0 
-LRB- 0 
DSBs 0 
-RRB- 0 
. 0 

There 0 
are 0 
strong 0 
parallels 0 
between 0 
the 0 
pattern 0 
of 0 
radiosensitivity 0 
, 0 
chromosomal 0 
instability 0 
and 0 
cancer 1
predisposition 0 
in 0 
A-T 1
patients 0 
and 0 
that 0 
in 0 
patients 0 
with 0 
Nijmegen 1
breakage 1
syndrome 1
-LRB- 0 
NBS 1
-RRB- 0 
. 0 

The 0 
protein 0 
defective 0 
in 0 
NBS 1
, 0 
nibrin 0 
-LRB- 0 
encoded 0 
by 0 
NBS1 0 
-RRB- 0 
, 0 
forms 0 
a 0 
complex 0 
with 0 
MRE11 0 
and 0 
RAD50 0 
-LRB- 0 
refs 0 
_NUM1 0 
, 0 
_NUM1 0 
-RRB- 0 
. 0 

This 0 
complex 0 
localizes 0 
to 0 
DSBs 0 
within 0 
_NUM2 0 
minutes 0 
after 0 
cellular 0 
exposure 0 
to 0 
ionizing 0 
radiation 0 
-LRB- 0 
IR 0 
-RRB- 0 
and 0 
is 0 
observed 0 
in 0 
brightly 0 
staining 0 
nuclear 0 
foci 0 
after 0 
a 0 
longer 0 
period 0 
of 0 
time 0 
. 0 

The 0 
overlap 0 
between 0 
clinical 0 
and 0 
cellular 0 
phenotypes 0 
in 0 
A-T 1
and 0 
NBS 1
suggests 0 
that 0 
ATM 0 
and 0 
nibrin 0 
may 0 
function 0 
in 0 
the 0 
same 0 
biochemical 0 
pathway 0 
. 0 

Here 0 
we 0 
demonstrate 0 
that 0 
nibrin 0 
is 0 
phosphorylated 0 
within 0 
one 0 
hour 0 
of 0 
treatment 0 
of 0 
cells 0 
with 0 
IR 0 
. 0 

This 0 
response 0 
is 0 
abrogated 0 
in 0 
A-T 1
cells 0 
that 0 
either 0 
do 0 
not 0 
express 0 
ATM 0 
protein 0 
or 0 
express 0 
near 0 
full-length 0 
mutant 0 
protein 0 
. 0 

We 0 
also 0 
show 0 
that 0 
ATM 0 
physically 0 
interacts 0 
with 0 
and 0 
phosphorylates 0 
nibrin 0 
on 0 
serine 0 
_NUM3 0 
both 0 
in 0 
vivo 0 
and 0 
in 0 
vitro 0 
. 0 

Phosphorylation 0 
of 0 
this 0 
site 0 
appears 0 
to 0 
be 0 
functionally 0 
important 0 
because 0 
mutated 0 
nibrin 0 
-LRB- 0 
S343A 0 
-RRB- 0 
does 0 
not 0 
completely 0 
complement 0 
radiosensitivity 0 
in 0 
NBS 1
cells 0 
. 0 

ATM 0 
phosphorylation 0 
of 0 
nibrin 0 
does 0 
not 0 
affect 0 
nibrin-MRE11-RAD50 0 
association 0 
as 0 
revealed 0 
by 0 
radiation-induced 0 
foci 0 
formation 0 
. 0 

Our 0 
data 0 
provide 0 
a 0 
biochemical 0 
explanation 0 
for 0 
the 0 
similarity 0 
in 0 
phenotype 0 
between 0 
A-T 1
and 0 
NBS 1
. 0 
. 0 

Detection 0 
of 0 
an 0 
unstable 0 
fragment 0 
of 0 
DNA 0 
specific 0 
to 0 
individuals 0 
with 0 
myotonic 1
dystrophy 1
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
the 0 
most 0 
common 0 
form 0 
of 0 
adult 0 
muscular 1
dystrophy 1
, 0 
with 0 
a 0 
prevalence 0 
of 0 
2-14 0 
per 0 
_NUM3 0 
, 0 
_NUM3 0 
individuals 0 
. 0 

The 0 
disease 0 
is 0 
characterized 0 
by 0 
progressive 0 
muscle 1
weakness 1
and 0 
sustained 1
muscle 1
contraction 1
, 0 
often 0 
with 0 
a 0 
wide 0 
range 0 
of 0 
accompanying 0 
symptoms 0 
. 0 

The 0 
age 0 
at 0 
onset 0 
and 0 
severity 0 
of 0 
the 0 
disease 0 
show 0 
extreme 0 
variation 0 
, 0 
both 0 
within 0 
and 0 
between 0 
families 0 
. 0 

Despite 0 
its 0 
clinical 0 
variability 0 
, 0 
this 0 
dominant 0 
condition 0 
segregates 0 
as 0 
a 0 
single 0 
locus 0 
at 0 
chromosome 0 
19q13 0 
. 0 

_NUM1 0 
in 0 
every 0 
population 0 
studied 0 
. 0 

It 0 
is 0 
flanked 0 
by 0 
the 0 
tightly 0 
linked 0 
genetic 0 
markers 0 
ERCC1 0 
proximally 0 
and 0 
D19S51 0 
distally 0 
; 0 
these 0 
define 0 
the 0 
DM 1
critical 0 
region 0 
. 0 

We 0 
report 0 
the 0 
isolation 0 
of 0 
an 0 
expressed 0 
sequence 0 
from 0 
this 0 
region 0 
which 0 
detects 0 
a 0 
DNA 0 
fragment 0 
that 0 
is 0 
larger 0 
in 0 
affected 0 
individuals 0 
than 0 
in 0 
normal 0 
siblings 0 
or 0 
unaffected 0 
controls 0 
. 0 

The 0 
size 0 
of 0 
this 0 
fragment 0 
varies 0 
between 0 
affected 0 
siblings 0 
, 0 
and 0 
increases 0 
in 0 
size 0 
through 0 
generations 0 
in 0 
parallel 0 
with 0 
increasing 0 
severity 0 
of 0 
the 0 
disease 0 
. 0 

We 0 
postulate 0 
that 0 
this 0 
unstable 0 
DNA 0 
sequence 0 
is 0 
the 0 
molecular 0 
feature 0 
that 0 
underlies 0 
DM 1
. 0 

Detection 0 
of 0 
a 0 
novel 0 
missense 0 
mutation 0 
and 0 
second 0 
recurrent 0 
mutation 0 
in 0 
the 0 
CACNA1A 0 
gene 0 
in 0 
individuals 0 
with 0 
EA-2 1
and 0 
FHM 1
. 0 

Mutations 0 
in 0 
the 0 
brain 0 
specific 0 
P 0 
/ 0 
Q 0 
type 0 
Ca2 0 
+ 0 
channel 0 
alpha1 0 
subunit 0 
gene 0 
, 0 
CACNA1A 0 
, 0 
have 0 
been 0 
identified 0 
in 0 
three 0 
clinically 0 
distinct 0 
disorders 0 
, 0 
viz 0 
. 0 

episodic 1
ataxia 1
type 1
_NUM1 1
-LRB- 0 
EA-2 1
-RRB- 0 
, 0 
familial 1
hemiplegic 1
migraine 1
-LRB- 0 
FHM 1
-RRB- 0 
and 0 
spinocerebellar 1
ataxia 1
_NUM1 1
-LRB- 0 
SCA6 1
-RRB- 0 
. 0 

For 0 
individuals 0 
with 0 
EA-2 1
, 0 
the 0 
mutations 0 
described 0 
thus 0 
far 0 
are 0 
presumed 0 
to 0 
result 0 
in 0 
a 0 
truncated 0 
protein 0 
product 0 
. 0 

Several 0 
different 0 
missense 0 
mutations 0 
have 0 
been 0 
identified 0 
in 0 
patients 0 
with 0 
FHM 1
. 0 

At 0 
least 0 
two 0 
of 0 
these 0 
mutations 0 
have 0 
been 0 
identified 0 
on 0 
two 0 
different 0 
chromosome 0 
19p13 0 
haplotypes 0 
and 0 
thus 0 
represent 0 
recurrent 0 
mutations 0 
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
we 0 
have 0 
screened 0 
several 0 
individuals 0 
for 0 
mutations 0 
in 0 
all 0 
_NUM2 0 
exons 0 
in 0 
the 0 
CACNA1A 0 
gene 0 
by 0 
single-strand 0 
conformation 0 
analysis 0 
. 0 

We 0 
have 0 
characterised 0 
a 0 
novel 0 
missense 0 
mutation 0 
, 0 
G5260A 0 
, 0 
in 0 
exon 0 
_NUM2 0 
in 0 
a 0 
family 0 
segregating 0 
for 0 
EA-2 1
. 0 

The 0 
consequence 0 
of 0 
this 0 
mutation 0 
is 0 
an 0 
amino 0 
acid 0 
substitution 0 
at 0 
a 0 
highly 0 
conserved 0 
position 0 
within 0 
the 0 
CACNA1A 0 
gene 0 
. 0 

This 0 
represents 0 
the 0 
first 0 
point 0 
mutation 0 
not 0 
resulting 0 
in 0 
a 0 
proposed 0 
truncated 0 
protein 0 
. 0 

Furthermore 0 
, 0 
this 0 
mutation 0 
has 0 
been 0 
detected 0 
in 0 
a 0 
family 0 
member 0 
with 0 
mild 0 
clinical 0 
signs 0 
including 0 
only 0 
migraine 1
. 0 

Additionally 0 
, 0 
a 0 
second 0 
previously 0 
identified 0 
recurrent 0 
muta 0 
tion 0 
, 0 
C2272T 0 
, 0 
in 0 
exon 0 
_NUM2 0 
has 0 
been 0 
discovered 0 
in 0 
a 0 
patient 0 
with 0 
FHM 1
. 0 
. 0 

Dominant 0 
negative 0 
effect 0 
of 0 
the 0 
APC1309 0 
mutation 0 
: 0 
a 0 
possible 0 
explanation 0 
for 0 
genotype-phenotype 0 
correlations 0 
in 0 
familial 1
adenomatous 1
polyposis 1
. 0 

Inactivation 0 
of 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
product 0 
initiates 0 
colorectal 0 
tumorigenesis 0 
. 0 

Patients 0 
with 0 
familial 1
APC 1
-LRB- 0 
FAP 1
-RRB- 0 
carry 0 
germ-line 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
and 0 
develop 0 
multiple 0 
colorectal 1
adenomas 1
and 0 
subsequent 0 
carcinomas 1
early 0 
in 0 
life 0 
. 0 

The 0 
severity 0 
of 0 
the 0 
disease 0 
correlates 0 
with 0 
the 0 
position 0 
of 0 
the 0 
inherited 0 
APC 1
mutation 0 
-LRB- 0 
genotype-phenotype 0 
correlation 0 
-RRB- 0 
. 0 

Together 0 
with 0 
the 0 
fact 0 
that 0 
both 0 
germ-line 0 
and 0 
sporadic 0 
APC 1
mutations 0 
cluster 0 
in 0 
the 0 
central 0 
region 0 
of 0 
the 0 
APC 1
gene 0 
, 0 
this 0 
points 0 
to 0 
a 0 
dominant 0 
negative 0 
effect 0 
of 0 
certain 0 
APC 1
mutants 0 
. 0 

Loss 0 
of 0 
APC 1
function 0 
was 0 
recently 0 
shown 0 
to 0 
result 0 
in 0 
enhanced 0 
beta-catenin 0 
- 0 
/ 0 
Tcf-mediated 0 
transcription 0 
in 0 
colon 0 
epithelial 0 
cells 0 
. 0 

Here 0 
, 0 
we 0 
provide 0 
experimental 0 
evidence 0 
for 0 
a 0 
dominant 0 
negative 0 
effect 0 
of 0 
APC 1
gene 0 
products 0 
associated 0 
with 0 
severe 0 
polyposis 1
. 0 

Wild-type 0 
APC 1
activity 0 
in 0 
beta-catenin 0 
- 0 
/ 0 
Tcf-mediated 0 
transcription 0 
was 0 
strongly 0 
inhibited 0 
by 0 
a 0 
mutant 0 
APC 1
that 0 
is 0 
truncated 0 
at 0 
codon 0 
_NUM4 0 
. 0 

In 0 
contrast 0 
, 0 
mutant 0 
APC 1
gene 0 
products 0 
that 0 
are 0 
associated 0 
with 0 
attenuated 1
polyposis 1
-LRB- 0 
codon 0 
_NUM3 0 
or 0 
_NUM4 0 
-RRB- 0 
interfered 0 
only 0 
weakly 0 
with 0 
wild-type 0 
APC 1
activity 0 
. 0 

These 0 
results 0 
suggest 0 
a 0 
molecular 0 
explanation 0 
for 0 
the 0 
genotype-phenotype 0 
correlation 0 
in 0 
FAP 1
patients 0 
and 0 
support 0 
the 0 
idea 0 
that 0 
colorectal 1
tumor 1
growth 0 
might 0 
be 0 
, 0 
in 0 
part 0 
, 0 
driven 0 
by 0 
selection 0 
for 0 
a 0 
mutation 0 
in 0 
the 0 
mutation 0 
cluster 0 
region 0 
. 0 
. 0 

Mutation 0 
of 0 
the 0 
KIT 0 
-LRB- 0 
mast 0 
/ 0 
stem 0 
cell 0 
growth 0 
factor 0 
receptor 0 
-RRB- 0 
protooncogene 0 
in 0 
human 0 
piebaldism 1
. 0 

Piebaldism 1
is 0 
an 0 
autosomal 1
dominant 1
genetic 1
disorder 1
characterized 0 
by 0 
cogenital 0 
patches 0 
of 0 
skin 0 
and 0 
hair 0 
from 0 
which 0 
melanocytes 0 
are 0 
completely 0 
absent 0 
. 0 

A 0 
similar 0 
disorder 0 
of 0 
mouse 0 
, 0 
dominant 0 
white 0 
spotting 0 
-LRB- 0 
W 0 
-RRB- 0 
, 0 
results 0 
from 0 
mutations 0 
of 0 
the 0 
c-Kit 0 
protooncogene 0 
, 0 
which 0 
encodes 0 
and 0 
receptor 0 
for 0 
mast 0 
/ 0 
stem 0 
cell 0 
growth 0 
factor 0 
. 0 

We 0 
identified 0 
a 0 
KIT 0 
gene 0 
mutation 0 
in 0 
a 0 
proband 0 
with 0 
classic 0 
autosomal 0 
dominant 0 
piebaldism 1
. 0 

This 0 
mutation 0 
results 0 
in 0 
a 0 
Gly 0 
-- 0 
Arg 0 
substitution 0 
at 0 
codon 0 
_NUM3 0 
, 0 
within 0 
the 0 
tyrosine 0 
kinase 0 
domain 0 
. 0 

This 0 
substitution 0 
was 0 
not 0 
seen 0 
in 0 
any 0 
normal 0 
individuals 0 
and 0 
was 0 
completely 0 
linked 0 
to 0 
the 0 
piebald 1
phenotype 0 
in 0 
the 0 
probands 0 
family 0 
. 0 

Piebaldism 1
in 0 
this 0 
family 0 
thus 0 
appears 0 
to 0 
be 0 
the 0 
human 0 
homologue 0 
to 0 
dominant 0 
white 0 
spotting 0 
-LRB- 0 
W 0 
-RRB- 0 
of 0 
the 0 
mouse 0 
. 0 
. 0 

An 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
missense 0 
mutation 0 
-LRB- 0 
T274M 0 
-RRB- 0 
causing 0 
late-infantile 1
metachromatic 1
leukodystrophy 1
. 0 

Metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
a 0 
deficiency 1
of 1
arylsulfatase 1
A 1
-LRB- 0 
ARSA 0 
; 0 
EC 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

The 0 
_NUM1 0 
ARSA 0 
exons 0 
and 0 
adjacent 0 
intron 0 
boundaries 0 
from 0 
a 0 
patient 0 
with 0 
late-infantile 1
metachromatic 1
leukodystrophy 1
were 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
amplified 0 
in 0 
seven 0 
discrete 0 
reactions 0 
. 0 

Amplified 0 
ARSA 0 
exons 0 
were 0 
analysed 0 
for 0 
the 0 
presence 0 
of 0 
sequence 0 
alterations 0 
by 0 
single-strand 0 
conformation 0 
polymorphism 0 
analysis 0 
, 0 
followed 0 
by 0 
direct 0 
sequencing 0 
of 0 
PCR 0 
products 0 
. 0 

The 0 
patient 0 
was 0 
found 0 
to 0 
be 0 
homozygous 0 
for 0 
a 0 
C 0 
-- 0 
> 0 
T 0 
transition 0 
in 0 
exon 0 
IV 0 
that 0 
results 0 
in 0 
the 0 
substitution 0 
of 0 
a 0 
highly 0 
conserved 0 
threonine 0 
residue 0 
at 0 
amino 0 
acid 0 
_NUM3 0 
with 0 
a 0 
methionine 0 
-LRB- 0 
T274M 0 
-RRB- 0 
. 0 

Analysis 0 
of 0 
a 0 
further 0 
_NUM2 0 
MLD 1
patients 0 
revealed 0 
the 0 
presence 0 
of 0 
five 0 
additional 0 
homozygotes 0 
for 0 
T274M 0 
. 0 

All 0 
_NUM1 0 
T274M 0 
homozygotes 0 
-LRB- 0 
representing 0 
four 0 
families 0 
-RRB- 0 
were 0 
of 0 
Lebanese 0 
descent 0 
, 0 
and 0 
all 0 
were 0 
known 0 
to 0 
be 0 
the 0 
result 0 
of 0 
consanguineous 0 
marriages 0 
. 0 

The 0 
altered 0 
amino 0 
acid 0 
is 0 
rigidly 0 
conserved 0 
among 0 
_NUM2 0 
sulfatases 0 
from 0 
Escherichia 0 
coli 0 
to 0 
humans 0 
; 0 
therefore 0 
, 0 
it 0 
is 0 
most 0 
likely 0 
that 0 
the 0 
resultant 0 
mutant 0 
protein 0 
will 0 
have 0 
little 0 
or 0 
no 0 
enzyme 0 
activity 0 
. 0 

This 0 
is 0 
consistent 0 
with 0 
the 0 
very 0 
low 0 
ARSA 0 
activity 0 
measured 0 
in 0 
these 0 
patients 0 
and 0 
their 0 
uniformly 0 
severe 0 
clinical 0 
presentation 0 
Mutations 0 
in 0 
the 0 
gene 0 
for 0 
X-linked 1
adrenoleukodystrophy 1
in 0 
patients 0 
with 0 
different 0 
clinical 0 
phenotypes 0 
. 0 

Recently 0 
, 0 
the 0 
gene 0 
for 0 
the 0 
most 0 
common 0 
peroxisomal 1
disorder 1
, 0 
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
X-ALD 1
-RRB- 0 
, 0 
has 0 
been 0 
described 0 
encoding 0 
a 0 
peroxisomal 0 
membrane 0 
transporter 0 
protein 0 
. 0 

We 0 
analyzed 0 
the 0 
entire 0 
protein-coding 0 
sequence 0 
of 0 
this 0 
gene 0 
by 0 
reverse-transcription 0 
PCR 0 
, 0 
SSCP 0 
, 0 
and 0 
DNA 0 
sequencing 0 
in 0 
five 0 
patients 0 
with 0 
different 0 
clinical 0 
expression 0 
of 0 
X-ALD 1
and 0 
in 0 
their 0 
female 0 
relatives 0 
; 0 
these 0 
clinical 0 
expressions 0 
were 0 
cerebral 0 
childhood 0 
ALD 1
, 0 
adrenomyeloneuropathy 1
-LRB- 0 
AMN 1
-RRB- 0 
, 0 
and 0 
'' 0 
Addison 1
disease 1
only 1
'' 0 
-LRB- 0 
ADO 1
-RRB- 0 
phenotype 0 
. 0 

In 0 
the 0 
three 0 
patients 0 
exhibiting 0 
the 0 
classical 0 
picture 0 
of 0 
severe 0 
childhood 0 
ALD 1
we 0 
identified 0 
in 0 
the 0 
_NUM1 0 
portion 0 
of 0 
the 0 
X-ALD 1
gene 0 
a 0 
38-bp 0 
deletion 0 
that 0 
causes 0 
a 0 
frameshift 0 
mutation 0 
, 0 
a 0 
3-bp 0 
deletion 0 
leading 0 
to 0 
a 0 
deletion 0 
of 0 
an 0 
amino 0 
acid 0 
in 0 
the 0 
ATP-binding 0 
domain 0 
of 0 
the 0 
ALD 1
protein 0 
, 0 
and 0 
a 0 
missense 0 
mutation 0 
. 0 

In 0 
the 0 
patient 0 
with 0 
the 0 
clinical 0 
phenotype 0 
of 0 
AMN 1
, 0 
a 0 
nonsense 0 
mutation 0 
in 0 
codon 0 
_NUM3 0 
, 0 
along 0 
with 0 
a 0 
second 0 
site 0 
mutation 0 
at 0 
codon 0 
_NUM3 0 
, 0 
was 0 
observed 0 
. 0 

Analysis 0 
of 0 
the 0 
patient 0 
with 0 
the 0 
ADO 1
phenotype 0 
revealed 0 
a 0 
further 0 
missense 0 
mutation 0 
at 0 
a 0 
highly 0 
conserved 0 
position 0 
in 0 
the 0 
ALDP 0 
/ 0 
PMP70 0 
comparison 0 
. 0 

The 0 
disruptive 0 
nature 0 
of 0 
two 0 
mutations 0 
-LRB- 0 
i. 0 
e. 0 
, 0 
the 0 
frameshift 0 
and 0 
the 0 
nonsense 0 
mutation 0 
-RRB- 0 
in 0 
patients 0 
with 0 
biochemically 0 
proved 0 
childhood 0 
ALD 1
and 0 
AMN 1
further 0 
strongly 0 
supports 0 
the 0 
hypothesis 0 
that 0 
alterations 0 
in 0 
this 0 
gene 0 
play 0 
a 0 
crucial 0 
role 0 
in 0 
the 0 
pathogenesis 0 
of 0 
X-ALD 1
. 0 

Since 0 
the 0 
current 0 
biochemical 0 
techniques 0 
for 0 
X-ALD 1
carrier 0 
detection 0 
in 0 
affected 0 
families 0 
lack 0 
sufficient 0 
reliability 0 
, 0 
our 0 
procedure 0 
described 0 
for 0 
systematic 0 
mutation 0 
scanning 0 
is 0 
also 0 
capable 0 
of 0 
improving 0 
genetic 0 
counseling 0 
and 0 
prenatal 0 
diagnosis 0 
Atelosteogenesis 1
type 1
II 1
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
diastrophic 1
dysplasia 1
sulfate-transporter 0 
gene 0 
-LRB- 0 
DTDST 0 
-RRB- 0 
: 0 
evidence 0 
for 0 
a 0 
phenotypic 0 
series 0 
involving 0 
three 0 
chondrodysplasias 1
. 0 

Atelosteogenesis 1
type 1
II 1
-LRB- 0 
AO 1
II 1
-RRB- 0 
is 0 
a 0 
neonatally 0 
lethal 0 
chondrodysplasia 1
whose 0 
clinical 0 
and 0 
histological 0 
characteristics 0 
resemble 0 
those 0 
of 0 
another 0 
chondrodysplasia 1
, 0 
the 0 
much 0 
less 0 
severe 0 
diastrophic 1
dysplasia 1
-LRB- 0 
DTD 1
-RRB- 0 
. 0 

The 0 
similarity 0 
suggests 0 
a 0 
shared 0 
pathogenesis 0 
involving 0 
lesions 0 
in 0 
the 0 
same 0 
biochemical 0 
pathway 0 
and 0 
perhaps 0 
the 0 
same 0 
gene 0 
. 0 

DTD 1
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
recently 0 
identified 0 
diastrophic 1
dysplasia 1
sulfate-transporter 0 
gene 0 
-LRB- 0 
DTDST 0 
-RRB- 0 
. 0 

Here 0 
, 0 
we 0 
report 0 
that 0 
AOII 1
patients 0 
also 0 
have 0 
DTDST 0 
mutations 0 
, 0 
which 0 
lead 0 
to 0 
defective 0 
uptake 0 
of 0 
inorganic 0 
sulfate 0 
and 0 
insufficient 0 
sulfation 0 
of 0 
macromolecules 0 
by 0 
patient 0 
mesenchymal 0 
cells 0 
in 0 
vitro 0 
. 0 

Together 0 
with 0 
our 0 
recent 0 
observation 0 
that 0 
a 0 
third 0 
even 0 
more 0 
severe 0 
chondrodysplasia 1
, 0 
achondrogenesis 0 
type 0 
IB 0 
, 0 
is 0 
also 0 
caused 0 
by 0 
mutations 0 
in 0 
DTDST 0 
, 0 
these 0 
results 0 
demonstrate 0 
a 0 
phenotypic 0 
series 0 
of 0 
three 0 
chondrodysplasias 1
of 0 
increasing 0 
severity 0 
caused 0 
by 0 
lesions 0 
in 0 
a 0 
single 0 
sulfate-transporter 0 
gene 0 
. 0 

The 0 
severity 0 
of 0 
the 0 
phenotype 0 
appears 0 
to 0 
be 0 
correlated 0 
with 0 
the 0 
predicted 0 
effect 0 
of 0 
the 0 
mutations 0 
on 0 
the 0 
residual 0 
activity 0 
of 0 
the 0 
DTDST 0 
protein 0 
. 0 
. 0 

Emerin 1
, 1
deficiency 1
of 0 
which 0 
causes 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
, 0 
is 0 
localized 0 
at 0 
the 0 
inner 0 
nuclear 0 
membrane 0 
. 0 

X-linked 1
recessive 1
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
is 0 
an 0 
inherited 1
muscle 1
disorder 1
characterized 0 
by 0 
the 0 
clinical 0 
triad 0 
of 0 
progressive 0 
wasting 1
of 1
humero-peroneal 1
muscles 1
, 0 
early 0 
contractures 1
of 1
the 1
elbows 1
, 1
Achilles 1
tendons 1
and 1
postcervical 1
muscles 1
, 0 
and 0 
cardiac 1
conduction 1
block 1
with 0 
a 0 
high 0 
risk 0 
of 0 
sudden 1
death 1
. 0 

The 0 
gene 0 
for 0 
EDMD 1
on 0 
Xq28 0 
encodes 0 
a 0 
novel 0 
protein 0 
named 0 
emerin 0 
that 0 
localizes 0 
at 0 
the 0 
nuclear 0 
membrane 0 
of 0 
skeletal 0 
, 0 
cardiac 0 
and 0 
smooth 0 
muscles 0 
and 0 
some 0 
other 0 
non-muscle 0 
tissues 0 
. 0 

To 0 
investigate 0 
a 0 
possible 0 
physiological 0 
role 0 
for 0 
emerin 0 
, 0 
we 0 
examined 0 
the 0 
ultrastructural 0 
localization 0 
of 0 
the 0 
protein 0 
in 0 
human 0 
skeletal 0 
muscle 0 
and 0 
HeLa 0 
cells 0 
, 0 
using 0 
ultrathin 0 
cryosections 0 
. 0 

We 0 
found 0 
that 0 
the 0 
immune-labeled 0 
colloidal 0 
gold 0 
particles 0 
were 0 
localized 0 
on 0 
the 0 
nucleoplasmic 0 
surface 0 
of 0 
the 0 
inner 0 
nuclear 0 
membrane 0 
, 0 
but 0 
not 0 
on 0 
the 0 
nuclear 0 
pore 0 
. 0 

Emerin 0 
stayed 0 
on 0 
the 0 
cytoplasmic 0 
surface 0 
of 0 
the 0 
nuclear 0 
lamina 0 
, 0 
even 0 
after 0 
detergent 0 
treatment 0 
that 0 
solubilizes 0 
membrane 0 
lipids 0 
and 0 
washes 0 
out 0 
membrane 0 
proteins 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
emerin 0 
anchors 0 
at 0 
the 0 
inner 0 
nuclear 0 
membrane 0 
through 0 
the 0 
hydrophobic 0 
stretch 0 
, 0 
and 0 
protrudes 0 
from 0 
the 0 
hydrophilic 0 
region 0 
to 0 
the 0 
nucleoplasm 0 
where 0 
it 0 
interacts 0 
with 0 
the 0 
nuclear 0 
lamina 0 
. 0 

We 0 
speculate 0 
that 0 
emerin 0 
contributes 0 
to 0 
maintain 0 
the 0 
nuclear 0 
structure 0 
and 0 
stability 0 
, 0 
as 0 
well 0 
as 0 
nuclear 0 
functions 0 
, 0 
particularly 0 
in 0 
muscle 0 
tissues 0 
that 0 
have 0 
severe 0 
stress 0 
with 0 
rigorous 0 
contraction-relaxation 0 
movements 0 
and 0 
calcium 0 
flux 0 
. 0 
. 0 

Identification 0 
of 0 
a 0 
common 0 
PEX1 0 
mutation 0 
in 0 
Zellweger 1
syndrome 1
. 0 

The 0 
Zellweger 1
spectrum 1
of 1
disease 1
, 0 
encompassing 0 
Zellweger 1
syndrome 1
and 0 
the 0 
progressively 0 
milder 0 
phenotypes 0 
of 0 
neonatal 1
adrenoleukodystrophy 1
and 0 
infantile 1
Refsum 1
disease 1
, 0 
is 0 
due 0 
to 0 
a 0 
failure 0 
to 0 
form 0 
functional 0 
peroxisomes 0 
. 0 

Cell 0 
fusion 0 
complementation 0 
studies 0 
demonstrated 0 
that 0 
these 0 
diseases 0 
are 0 
genetically 0 
heterogeneous 0 
, 0 
with 0 
two-thirds 0 
of 0 
all 0 
patients 0 
lying 0 
within 0 
a 0 
single 0 
complementation 0 
group 0 
, 0 
CG1 0 
. 0 

Molecular 0 
genetic 0 
and 0 
cell 0 
biology 0 
studies 0 
have 0 
shown 0 
that 0 
PEX1 0 
is 0 
deficient 0 
in 0 
many 0 
CG1 0 
patients 0 
. 0 

However 0 
, 0 
previous 0 
studies 0 
have 0 
focused 0 
on 0 
mildly 0 
affected 0 
patients 0 
and 0 
there 0 
is 0 
still 0 
no 0 
report 0 
of 0 
two 0 
mutant 0 
PEX1 0 
alleles 0 
in 0 
any 0 
Zellweger 1
syndrome 1
patient 0 
. 0 

Furthermore 0 
, 0 
mutations 0 
in 0 
the 0 
PMP70 0 
gene 0 
have 0 
also 0 
been 0 
identified 0 
in 0 
two 0 
Zellweger 1
syndrome 1
patients 0 
from 0 
CG1 0 
, 0 
raising 0 
the 0 
possibility 0 
that 0 
CG1 0 
patients 0 
may 0 
represent 0 
a 0 
mixture 0 
of 0 
PEX1-deficient 0 
and 0 
PMP70-deficient 0 
individuals 0 
. 0 

To 0 
address 0 
the 0 
molecular 0 
basis 0 
of 0 
disease 0 
in 0 
Zellweger 1
syndrome 1
patients 0 
from 0 
CG1 0 
, 0 
we 0 
examined 0 
all 0 
_NUM2 0 
PEX1 0 
exons 0 
in 0 
four 0 
patients 0 
, 0 
including 0 
both 0 
patients 0 
that 0 
have 0 
mutations 0 
in 0 
PMP70 0 
. 0 

PEX1 0 
mutations 0 
were 0 
detected 0 
in 0 
all 0 
four 0 
patients 0 
, 0 
including 0 
a 0 
1-bp 0 
insertion 0 
-LRB- 0 
c. 0 
2097insT 0 
-RRB- 0 
in 0 
exon 0 
_NUM2 0 
that 0 
was 0 
present 0 
in 0 
three 0 
of 0 
the 0 
four 0 
patients 0 
. 0 

Subsequent 0 
studies 0 
demonstrated 0 
that 0 
this 0 
mutation 0 
is 0 
present 0 
in 0 
one-half 0 
of 0 
all 0 
CG1 0 
patients 0 
and 0 
correlates 0 
with 0 
the 0 
Zellweger 1
syndrome 1
phenotype 0 
. 0 

As 0 
this 0 
mutation 0 
leads 0 
to 0 
a 0 
loss 0 
of 0 
protein 0 
function 0 
its 0 
frequency 0 
makes 0 
it 0 
the 0 
most 0 
common 0 
cause 0 
of 0 
Zellweger 1
syndrome 1
, 0 
helping 0 
to 0 
explain 0 
the 0 
high 0 
percentage 0 
of 0 
patients 0 
that 0 
belong 0 
to 0 
CG1 0 
. 0 

Polymorphisms 0 
of 0 
the 0 
CYP2D6 0 
gene 0 
increase 0 
susceptibility 0 
to 0 
ankylosing 1
spondylitis 1
. 0 

Ankylosing 1
spondylitis 1
-LRB- 0 
AS 1
-RRB- 0 
is 0 
a 0 
common 0 
and 0 
highly 0 
familial 0 
rheumatic 1
disorder 1
. 0 

The 0 
sibling 0 
recurrence 0 
risk 0 
ratio 0 
for 0 
the 0 
disease 0 
is 0 
_NUM2 0 
and 0 
heritability 0 
assessed 0 
in 0 
twins 0 
> 0 
_NUM2 0 
% 0 
. 0 

Although 0 
MHC 0 
genes 0 
, 0 
including 0 
HLA-B27 0 
, 0 
contribute 0 
only 0 
20-50 0 
% 0 
of 0 
the 0 
genetic 0 
risk 0 
for 0 
the 0 
disease 0 
, 0 
no 0 
non-MHC 0 
gene 0 
has 0 
yet 0 
been 0 
convincingly 0 
demonstrated 0 
to 0 
influence 0 
either 0 
susceptibility 0 
to 0 
the 0 
disease 0 
or 0 
its 0 
phenotypic 0 
expression 0 
. 0 

Previous 0 
linkage 0 
and 0 
association 0 
studies 0 
have 0 
suggested 0 
the 0 
presence 0 
of 0 
a 0 
susceptibility 0 
gene 0 
for 0 
AS 1
close 0 
to 0 
, 0 
or 0 
within 0 
, 0 
the 0 
cytochrome 0 
_AN 0 
2D6 0 
gene 0 
-LRB- 0 
CYP2D6 0 
, 0 
debrisoquine 0 
hydroxylase 0 
-RRB- 0 
located 0 
at 0 
chromosome 0 
22q13 0 
.1 0 
. 0 

We 0 
performed 0 
a 0 
linkage 0 
study 0 
of 0 
chromosome 0 
_NUM2 0 
in 0 
_NUM3 0 
families 0 
with 0 
AS 1
affected 0 
sibling-pairs 0 
. 0 

Association 0 
of 0 
alleles 0 
of 0 
the 0 
CYP2D6 0 
gene 0 
was 0 
examined 0 
by 0 
both 0 
case-control 0 
and 0 
within-family 0 
means 0 
. 0 

For 0 
case-control 0 
studies 0 
, 0 
_NUM3 0 
unrelated 0 
individuals 0 
with 0 
AS 1
-LRB- 0 
_NUM3 0 
probands 0 
from 0 
sibling-pair 0 
and 0 
parent-case 0 
trio 0 
families 0 
and 0 
_NUM3 0 
unrelated 0 
non-familial 0 
sporadic 0 
cases 0 
-RRB- 0 
and 0 
_NUM3 0 
healthy 0 
ethnically 0 
matched 0 
controls 0 
were 0 
employed 0 
. 0 

For 0 
within-family 0 
association 0 
studies 0 
, 0 
_NUM3 0 
families 0 
including 0 
_NUM3 0 
parent-case 0 
trios 0 
and 0 
_NUM3 0 
affected 0 
sibling-pair 0 
families 0 
were 0 
employed 0 
. 0 

Homozygosity 0 
for 0 
poor 0 
metabolizer 0 
alleles 0 
was 0 
found 0 
to 0 
be 0 
associated 0 
with 0 
AS 1
. 0 

Heterozygosity 0 
for 0 
the 0 
most 0 
frequent 0 
poor 0 
metabolizer 0 
allele 0 
-LRB- 0 
CYP2D6 0 
* 0 
_NUM1 0 
-RRB- 0 
was 0 
not 0 
associated 0 
with 0 
increased 0 
susceptibility 0 
to 0 
AS 1
. 0 

Significant 0 
within-family 0 
association 0 
of 0 
CYP2D6 0 
* 0 
_NUM1 0 
alleles 0 
and 0 
AS 1
was 0 
demonstrated 0 
. 0 

Weak 0 
linkage 0 
was 0 
also 0 
demonstrated 0 
between 0 
CYP2D6 0 
and 0 
AS 1
. 0 

We 0 
postulate 0 
that 0 
altered 0 
metabolism 0 
of 0 
a 0 
natural 0 
toxin 0 
or 0 
antigen 0 
by 0 
the 0 
CYP2D6 0 
gene 0 
may 0 
increase 0 
susceptibility 0 
to 0 
AS 1
. 0 

Molecular 0 
analysis 0 
of 0 
the 0 
genotype-phenotype 0 
relationship 0 
in 0 
factor 1
X 1
deficiency 1
. 0 

Factor 1
X 1
deficiency 1
is 0 
a 0 
rare 0 
haemorrhagic 1
condition 1
, 0 
normally 0 
inherited 0 
as 0 
an 0 
autosomal 0 
recessive 0 
trait 0 
, 0 
in 0 
which 0 
a 0 
variable 0 
clinical 0 
presentation 0 
correlates 0 
poorly 0 
with 0 
laboratory 0 
phenotype 0 
. 0 

The 0 
factor 0
X 0 
-LRB- 0 
_AN 0 
-RRB- 0 
genes 0 
of 0 
_NUM2 0 
unrelated 0 
individuals 0 
with 0 
factor 1
X 1
deficiency 1
-LRB- 0 
_NUM2 0 
familial 0 
and 0 
two 0 
sporadic 0 
cases 0 
-RRB- 0 
were 0 
sequenced 0 
yielding 0 
a 0 
total 0 
of 0 
_NUM2 0 
novel 0 
mutations 0 
. 0 

Family 0 
studies 0 
were 0 
performed 0 
in 0 
order 0 
to 0 
distinguish 0 
the 0 
contributions 0 
of 0 
individual 0 
mutant 0 
_AN 0 
alleles 0 
to 0 
the 0 
clinical 0 
and 0 
laboratory 0 
phenotypes 0 
. 0 

Missense 0 
mutations 0 
were 0 
studied 0 
by 0 
means 0 
of 0 
molecular 0 
modelling 0 
, 0 
whereas 0 
single 0 
basepair 0 
substitutions 0 
in 0 
splice 0 
sites 0 
and 0 
the 0 
_NUM1 0 
flanking 0 
region 0 
were 0 
examined 0 
by 0 
in 0 
vitro 0 
splicing 0 
assay 0 
and 0 
luciferase 0 
reporter 0 
gene 0 
assay 0 
respectively 0 
. 0 

The 0 
deletion 0 
allele 0 
of 0 
a 0 
novel 0 
hexanucleotide 0 
insertion 0 
/ 0 
deletion 0 
polymorphism 0 
in 0 
the 0 
_AN 0 
gene 0 
promoter 0 
region 0 
was 0 
shown 0 
by 0 
reporter 0 
gene 0 
assay 0 
, 0 
to 0 
reduce 0 
promoter 0 
activity 0 
by 0 
approximately 0 
_NUM2 0 
% 0 
. 0 

One 0 
family 0 
manifesting 0 
an 0 
autosomal 0 
dominant 0 
pattern 0 
of 0 
inheritance 0 
possessed 0 
three 0 
clinically 0 
affected 0 
members 0 
who 0 
were 0 
heterozygous 0 
for 0 
a 0 
splice-site 0 
mutation 0 
that 0 
was 0 
predicted 0 
to 0 
lead 0 
to 0 
the 0 
production 0 
of 0 
a 0 
truncated 0 
protein 0 
product 0 
. 0 

A 0 
model 0 
which 0 
accounts 0 
for 0 
the 0 
dominant 0 
negative 0 
effect 0 
of 0 
this 0 
lesion 0 
is 0 
presented 0 
. 0 

Variation 0 
in 0 
the 0 
antigen 0 
level 0 
of 0 
heterozygous 0 
relatives 0 
of 0 
probands 0 
was 0 
found 0 
to 0 
be 0 
significantly 0 
higher 0 
between 0 
families 0 
than 0 
within 0 
families 0 
, 0 
consistent 0 
with 0 
the 0 
view 0 
that 0 
the 0 
nature 0 
of 0 
the 0 
_AN 0 
lesion 0 
-LRB- 0 
s 0 
-RRB- 0 
segregating 0 
in 0 
a 0 
given 0 
family 0 
is 0 
a 0 
prime 0 
determinant 0 
of 0 
the 0 
laboratory 0 
phenotype 0 
. 0 

By 0 
contrast 0 
, 0 
no 0 
such 0 
relationship 0 
could 0 
be 0 
discerned 0 
between 0 
laboratory 0 
phenotype 0 
and 0 
polymorphism 0 
genotype 0 
. 0 
. 0 

Restoration 0 
of 0 
photoreceptor 0 
ultrastructure 0 
and 0 
function 0 
in 0 
retinal 1
degeneration 1
slow 0 
mice 0 
by 0 
gene 0 
therapy 0 
. 0 

The 0 
gene 0 
Prph2 0 
encodes 0 
a 0 
photoreceptor-specific 0 
membrane 0 
glycoprotein 0 
, 0 
peripherin-2 0 
-LRB- 0 
also 0 
known 0 
as 0 
peripherin 0 
/ 0 
rds 0 
-RRB- 0 
, 0 
which 0 
is 0 
inserted 0 
into 0 
the 0 
rims 0 
of 0 
photoreceptor 0
outer 0 
segment 0 
discs 0 
in 0 
a 0 
complex 0 
with 0 
rom-1 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

The 0 
complex 0 
is 0 
necessary 0 
for 0 
the 0 
stabilization 0 
of 0 
the 0 
discs 0 
, 0 
which 0 
are 0 
renewed 0 
constantly 0 
throughout 0 
life 0 
, 0 
and 0 
which 0 
contain 0 
the 0 
visual 0 
pigments 0 
necessary 0 
for 0 
photon 0 
capture 0 
. 0 

Mutations 0 
in 0 
Prph2 0 
have 0 
been 0 
shown 0 
to 0 
result 0 
in 0 
a 0 
variety 0 
of 0 
photoreceptor 1
dystrophies 1
, 0 
including 0 
autosomal 1
dominant 1
retinitis 1
pigmentosa 1
and 0 
macular 1
dystrophy 1
. 0 

A 0 
common 0 
feature 0 
of 0 
these 0 
diseases 0 
is 0 
the 0 
loss 0 
of 0 
photoreceptor 0 
function 0 
, 0 
also 0 
seen 0 
in 0 
the 0 
retinal 1
degeneration 1
slow 0 
-LRB- 0 
rds 0 
or 0 
Prph2 0 
Rd2 0 
/ 0 
Rd2 0 
-RRB- 0 
mouse 0 
, 0 
which 0 
is 0 
homozygous 0 
for 0 
a 0 
null 0 
mutation 0 
in 0 
Prph2 0 
. 0 

It 0 
is 0 
characterized 0 
by 0 
a 0 
complete 0 
failure 0 
to 0 
develop 0 
photoreceptor 0 
discs 0 
and 0 
outer 0 
segments 0 
, 0 
downregulation 0 
of 0 
rhodopsin 0 
and 0 
apoptotic 0 
loss 0 
of 0 
photoreceptor 0 
cells 0 
. 0 

The 0 
electroretinograms 0 
-LRB- 0 
ERGs 0 
-RRB- 0 
of 0 
Prph2Rd2 0 
/ 0 
Rd2 0 
mice 0 
have 0 
greatly 0 
diminished 0 
a-wave 0 
and 0 
b-wave 0 
amplitudes 0 
, 0 
which 0 
decline 0 
to 0 
virtually 0 
undetectable 0 
concentrations 0 
by 0 
two 0 
months 0 
. 0 

Subretinal 0 
injection 0 
of 0 
recombinant 0 
adeno-associated 0 
virus 0 
-LRB- 0 
AAV 0 
-RRB- 0 
encoding 0 
a 0 
Prph2 0 
transgene 0 
results 0 
in 0 
stable 0 
generation 0 
of 0 
outer 0 
segment 0 
structures 0 
and 0 
formation 0 
of 0 
new 0 
stacks 0 
of 0 
discs 0 
containing 0 
both 0 
perpherin-2 0 
and 0 
rhodopsin 0 
, 0 
which 0 
in 0 
many 0 
cases 0 
are 0 
morphologically 0 
similar 0 
to 0 
normal 0 
outer 0 
segments 0 
. 0 

Moreover 0 
, 0 
the 0 
re-establishment 0 
of 0 
the 0 
structural 0 
integrity 0 
of 0 
the 0 
photoreceptor 0 
layer 0 
also 0 
results 0 
in 0 
electrophysiological 0 
correction 0 
. 0 

These 0 
studies 0 
demonstrate 0 
for 0 
the 0 
first 0 
time 0 
that 0 
a 0 
complex 0 
ultrastructural 0 
cell 0 
defect 0 
can 0 
be 0 
corrected 0 
both 0 
morphologically 0 
and 0 
functionally 0 
by 0 
in 0 
vivo 0 
gene 0 
transfer 0 
. 0 
. 0 

Phenylalanine 0 
hydroxylase 0 
gene 0 
haplotypes 0 
in 0 
Polynesians 0 
: 0 
evolutionary 0 
origins 0 
and 0 
absence 0 
of 0 
alleles 0 
associated 0 
with 0 
severe 0 
phenylketonuria 1
. 0 

A 0 
total 0 
of 0 
_NUM3 0 
haplotypes 0 
for 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
gene 0 
locus 0 
were 0 
established 0 
in 0 
five 0 
groups 0 
of 0 
Polynesians 0 
comprising 0 
Samoans 0 
, 0 
Tongans 0 
, 0 
Cook 0 
Islanders 0 
, 0 
Maori 0 
, 0 
and 0 
Niueans 0 
. 0 

Considerable 0 
genetic 0 
continuity 0 
was 0 
demonstrated 0 
between 0 
these 0 
widely 0 
dispersed 0 
populations 0 
, 0 
since 0 
three 0 
common 0 
haplotypes 0 
-LRB- 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
and 0 
_NUM1 0 
-RRB- 0 
constituted 0 
over 0 
_NUM2 0 
% 0 
of 0 
alleles 0 
. 0 

A 0 
control 0 
group 0 
of 0 
individuals 0 
from 0 
Southeast 0 
Asia 0 
shared 0 
the 0 
same 0 
major 0 
haplotypes 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
and 0 
_NUM1 0 
, 0 
with 0 
Polynesians 0 
. 0 

These 0 
data 0 
provide 0 
further 0 
support 0 
for 0 
the 0 
theories 0 
of 0 
genetic 0 
homogeneity 0 
and 0 
of 0 
Asian 0 
affinities 0 
of 0 
the 0 
Polynesian 0 
precursor 0 
populations 0 
. 0 

The 0 
absence 0 
of 0 
severe 0 
phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
in 0 
both 0 
Polynesians 0 
and 0 
Southeast 0 
Asians 0 
is 0 
consistent 0 
with 0 
the 0 
lack 0 
of 0 
PAH 0 
haplotypes 0 
_NUM1 0 
and 0 
_NUM1 0 
, 0 
on 0 
which 0 
the 0 
severe 0 
PKU 1
mutants 0 
have 0 
arisen 0 
among 0 
Caucasians 0 
. 0 
. 0 

cDNA 0 
microarrays 0 
detect 0 
activation 0 
of 0 
a 0 
myogenic 0 
transcription 0 
program 0 
by 0 
the 0 
PAX3-FKHR 0 
fusion 0 
oncogene 0 
. 0 

Alveolar 1
rhabdomyosarcoma 1
is 0 
an 0 
aggressive 0 
pediatric 1
cancer 1
of 1
striated 1
muscle 1
characterized 0 
in 0 
_NUM2 0 
% 0 
of 0 
cases 0 
by 0 
a 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
-RRB- 0 
. 0 

This 0 
results 0 
in 0 
the 0 
fusion 0 
of 0 
PAX3 0 
, 0 
a 0 
developmental 0 
transcription 0 
factor 0 
required 0 
for 0 
limb 0 
myogenesis 0 
, 0 
with 0 
FKHR 0 
, 0 
a 0 
member 0 
of 0 
the 0 
forkhead 0 
family 0 
of 0 
transcription 0 
factors 0 
. 0 

The 0 
resultant 0 
PAX3-FKHR 0 
gene 0 
possesses 0 
transforming 0 
properties 0 
; 0 
however 0 
, 0 
the 0 
effects 0 
of 0 
this 0 
chimeric 0 
oncogene 0 
on 0 
gene 0 
expression 0 
are 0 
largely 0 
unknown 0 
. 0 

To 0 
investigate 0 
the 0 
actions 0 
of 0 
these 0 
transcription 0 
factors 0 
, 0 
both 0 
Pax3 0 
and 0 
PAX3-FKHR 0 
were 0 
introduced 0 
into 0 
NIH 0 
3T3 0 
cells 0 
, 0 
and 0 
the 0 
resultant 0 
gene 0 
expression 0 
changes 0 
were 0 
analyzed 0 
with 0 
a 0 
murine 0 
cDNA 0 
microarray 0 
containing 0 
_NUM1 0 
, 0 
_NUM3 0 
elements 0 
. 0 

We 0 
found 0 
that 0 
PAX3-FKHR 0 
but 0 
not 0 
PAX3 0 
activated 0 
a 0 
myogenic 0 
transcription 0 
program 0 
including 0 
the 0 
induction 0 
of 0 
transcription 0 
factors 0 
MyoD 0 
, 0 
Myogenin 0 
, 0 
Six1 0 
, 0 
and 0 
Slug 0 
as 0 
well 0 
as 0 
a 0 
battery 0 
of 0 
genes 0 
involved 0 
in 0 
several 0 
aspects 0 
of 0 
muscle 0 
function 0 
. 0 

Notable 0 
among 0 
this 0 
group 0 
were 0 
the 0 
growth 0 
factor 0 
gene 0 
Igf2 0 
and 0 
its 0 
binding 0 
protein 0 
Igfbp5 0 
. 0 

Relevance 0 
of 0 
this 0 
model 0 
was 0 
suggested 0 
by 0 
verification 0 
that 0 
three 0 
of 0 
these 0 
genes 0 
-LRB- 0 
IGFBP5 0 
, 0 
HSIX1 0 
, 0 
and 0 
Slug 0 
-RRB- 0 
were 0 
also 0 
expressed 0 
in 0 
alveolar 1
rhabdomyosarcoma 1
cell 0 
lines 0 
. 0 

This 0 
study 0 
utilizes 0 
cDNA 0 
microarrays 0 
to 0 
elucidate 0 
the 0 
pattern 0 
of 0 
gene 0 
expression 0 
induced 0 
by 0 
an 0 
oncogenic 0 
transcription 0 
factor 0 
and 0 
demonstrates 0 
the 0 
profound 0 
myogenic 0 
properties 0 
of 0 
PAX3-FKHR 0 
in 0 
NIH 0 
3T3 0 
cells 0 
. 0 
. 0 

Re-evaluation 0 
of 0 
the 0 
sublocalization 0 
of 0 
esterase 0 
D 0 
and 0 
its 0 
relation 0 
to 0 
the 0 
retinoblastoma 1
locus 0 
by 0 
in 0 
situ 0 
hybridization 0 
. 0 

In 0 
situ 0 
hybridization 0 
of 0 
a 0 
cDNA 0 
probe 0 
for 0 
the 0 
esterase 0 
D 0 
gene 0 
-LRB- 0 
ESD 0 
-RRB- 0 
was 0 
carried 0 
out 0 
on 0 
human 0 
chromosomes 0 
. 0 

The 0 
probe 0 
hybridized 0 
most 0 
strongly 0 
to 0 
13q14 0 
. 0 

_NUM1 0 
and 0 
13q14 0 
. 0 

_NUM1 0 
. 0 

This 0 
observation 0 
raises 0 
doubts 0 
concerning 0 
the 0 
most 0 
recently 0 
published 0 
assignment 0 
of 0 
ESD 0 
to 0 
13q14 0 
. 0 

_NUM1 0 
. 0 

A 0 
deletion 0 
in 0 
an 0 
individual 0 
with 0 
retinoblastoma 1
was 0 
reported 0 
to 0 
separate 0 
the 0 
closely 0 
linked 0 
ESD 0 
and 0 
retinoblastoma 1
-LRB- 0 
RB1 0 
-RRB- 0 
loci 0 
, 0 
placing 0 
ESD 0 
proximal 0 
to 0 
RB1 0 
. 0 

Quantitative 0 
in 0 
situ 0 
hybridization 0 
studies 0 
of 0 
this 0 
deletion 0 
do 0 
not 0 
confirm 0 
this 0 
interpretation 0 
. 0 

Rather 0 
, 0 
they 0 
suggest 0 
that 0 
ESD 0 
is 0 
missing 0 
from 0 
the 0 
deleted 0 
chromosome 0 
_NUM2 0 
and 0 
duplicated 0 
on 0 
the 0 
normal 0 
homolog 0 
. 0 

From 0 
these 0 
findings 0 
, 0 
we 0 
conclude 0 
that 0 
the 0 
deletion 0 
in 0 
this 0 
individual 0 
can 0 
not 0 
be 0 
used 0 
to 0 
determine 0 
the 0 
orientation 0 
nor 0 
the 0 
sublocalization 0 
of 0 
ESD 0 
and 0 
RB1 0 
within 0 
the 0 
13q14 0 
region 0 
. 0 

The 0 
DNA 0 
double-strand 0 
break 0 
repair 0 
gene 0 
hMRE11 0 
is 0 
mutated 0 
in 0 
individuals 0 
with 0 
an 0 
ataxia-telangiectasia-like 1
disorder 1
. 0 

We 0 
show 0 
that 0 
hypomorphic 0 
mutations 0 
in 0 
hMRE11 0 
, 0 
but 0 
not 0 
in 0 
ATM 0 
, 0 
are 0 
present 0 
in 0 
certain 0 
individuals 0 
with 0 
an 0 
ataxia-telangiectasia-like 1
disorder 1
-LRB- 0 
ATLD 1
-RRB- 0 
. 0 

The 0 
cellular 0 
features 0 
resulting 0 
from 0 
these 0 
hMRE11 0 
mutations 0 
are 0 
similar 0 
to 0 
those 0 
seen 0 
in 0 
A-T 1
as 0 
well 0 
as 0 
NBS 1
and 0 
include 0 
hypersensitivity 1
to 1
ionizing 1
radiation 1
, 0 
radioresistant 0 
DNA 0 
synthesis 0 
, 0 
and 0 
abrogation 0 
of 0 
ATM-dependent 0 
events 0 
, 0 
such 0 
as 0 
the 0 
activation 0 
of 0 
Jun 0 
kinase 0 
following 0 
exposure 0 
to 0 
gamma 0 
irradiation 0 
. 0 

Although 0 
the 0 
mutant 0 
hMre11 0 
proteins 0 
retain 0 
some 0 
ability 0 
to 0 
interact 0 
with 0 
hRad50 0 
and 0 
Nbs1 0 
, 0 
formation 0 
of 0 
ionizing 0 
radiation-induced 0 
hMre11 0 
and 0 
Nbs1 0 
foci 0 
was 0 
absent 0 
in 0 
hMRE11 0 
mutant 0 
cells 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
ATM 0 
and 0 
the 0 
hMre11 0 
/ 0 
hRad50 0 
/ 0 
Nbs1 0 
protein 0 
complex 0 
act 0 
in 0 
the 0 
same 0 
DNA 0 
damage 0 
response 0 
pathway 0 
and 0 
link 0 
hMre11 0 
to 0 
the 0 
complex 0 
pathology 0 
of 0 
A-T 1
. 0 
. 0 

Duchenne 1
muscular 1
dystrophy 1
gene 0 
expression 0 
in 0 
normal 0 
and 0 
diseased 0 
human 0 
muscle 0 
. 0 

A 0 
probe 0 
for 0 
the 0 
_NUM1 0 
end 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
was 0 
used 0 
to 0 
study 0 
expression 0 
of 0 
the 0 
gene 0 
in 0 
normal 0 
human 0 
muscle 0 
, 0 
myogenic 0 
cell 0 
cultures 0 
, 0 
and 0 
muscle 0 
from 0 
patients 0 
with 0 
DMD 1
. 0 

Expression 0 
was 0 
found 0 
in 0 
RNA 0 
from 0 
normal 0 
fetal 0 
muscle 0 
, 0 
adult 0 
cardiac 0 
and 0 
skeletal 0 
muscle 0 
, 0 
and 0 
cultured 0 
muscle 0 
after 0 
myoblast 0 
fusion 0 
. 0 

In 0 
DMD 1
muscle 0 
, 0 
expression 0 
of 0 
this 0 
portion 0 
of 0 
the 0 
gene 0 
was 0 
also 0 
revealed 0 
by 0 
in 0 
situ 0 
RNA 0 
hybridization 0 
, 0 
particularly 0 
in 0 
regenerating 0 
muscle 0 
fibers 0 
. 0 
. 0 

Localisation 0 
of 0 
the 0 
Becker 1
muscular 1
dystrophy 1
gene 0 
on 0 
the 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
by 0 
linkage 0 
to 0 
cloned 0 
DNA 0 
sequences 0 
. 0 

A 0 
linkage 0 
study 0 
in 0 
_NUM2 0 
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
BMD 1
-RRB- 0 
kindreds 0 
using 0 
three 0 
cloned 0 
DNA 0 
sequences 0 
from 0 
the 0 
X 0 
chromosome 0 
which 0 
demonstrate 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
-LRB- 0 
RFLPs 0 
-RRB- 0 
, 0 
suggests 0 
that 0 
the 0 
BMD 1
gene 0 
is 0 
located 0 
on 0 
the 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
, 0 
in 0 
the 0 
_AN 0 
region 0 
. 0 

The 0 
genes 0 
for 0 
Becker 1
and 1
Duchenne 1
dystrophies 1
must 0 
therefore 0 
be 0 
closely 0 
linked 0 
, 0 
if 0 
not 0 
allelic 0 
, 0 
and 0 
any 0 
future 0 
DNA 0 
probes 0 
found 0 
to 0 
be 0 
of 0 
practical 0 
use 0 
in 0 
one 0 
disorder 0 
should 0 
be 0 
equally 0 
applicable 0 
to 0 
the 0 
other 0 
. 0 

The 0 
linkage 0 
analysis 0 
also 0 
provides 0 
data 0 
on 0 
the 0 
frequency 0 
of 0 
recombination 0 
along 0 
the 0 
short 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
, 0 
and 0 
across 0 
the 0 
centromeric 0 
region 0 
. 0 
. 0 

Age 0 
of 0 
the 0 
intronic 0 
_DS 0 
triplet 0 
repeat 0 
expansion 0 
mutation 0 
in 0 
Friedreich 1
ataxia 1
. 0 

Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
, 0 
the 0 
most 0 
frequently 0 
inherited 1
ataxia 1
, 0 
is 0 
due 0 
in 0 
the 0 
vast 0 
majority 0 
of 0 
cases 0 
to 0 
a 0 
large 0 
expansion 0 
of 0 
an 0 
intronic 0 
_DS 0 
repeat 0 
. 0 

Using 0 
linkage 0 
disequilibrium 0 
analysis 0 
based 0 
on 0 
haplotype 0 
data 0 
of 0 
seven 0 
polymorphic 0 
markers 0 
close 0 
to 0 
the 0 
frataxin 0 
gene 0 
, 0 
the 0 
age 0 
of 0 
FRDA 1
founding 0 
mutational 0 
event 0 
-LRB- 0 
s 0 
-RRB- 0 
is 0 
estimated 0 
to 0 
be 0 
at 0 
least 0 
_NUM3 0 
+ 0 
/ 0 
-203 0 
generations 0 
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
564-801 0 
g 0 
-RRB- 0 
, 0 
a 0 
dating 0 
which 0 
is 0 
consistent 0 
with 0 
little 0 
or 0 
no 0 
negative 0 
selection 0 
and 0 
provides 0 
further 0 
evidence 0 
for 0 
an 0 
ancient 0 
spread 0 
of 0 
a 0 
pre-mutation 0 
-LRB- 0 
at-risk 0 
alleles 0 
-RRB- 0 
in 0 
western 0 
Europe 0 
. 0 
. 0 

The 0 
human 0 
MAGEL2 0 
gene 0 
and 0 
its 0 
mouse 0 
homologue 0 
are 0 
paternally 0 
expressed 0 
and 0 
mapped 0 
to 0 
the 0 
Prader-Willi 1
region 0 
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
is 0 
a 0 
complex 0 
neurogenetic 1
disorder 1
. 0 

The 0 
phenotype 0 
is 0 
likely 0 
to 0 
be 0 
a 0 
contiguous 1
gene 1
syndrome 1
involving 0 
genes 0 
which 0 
are 0 
paternally 0 
expressed 0 
only 0 
, 0 
located 0 
in 0 
the 0 
human 0 
15q11-q13 0 
region 0 
. 0 

Four 0 
mouse 0 
models 0 
of 0 
PWS 1
have 0 
been 0 
reported 0 
but 0 
these 0 
do 0 
not 0 
definitively 0 
allow 0 
the 0 
delineation 0 
of 0 
the 0 
critical 0 
region 0 
and 0 
the 0 
associated 0 
genes 0 
involved 0 
in 0 
the 0 
aetiology 0 
of 0 
PWS 1
. 0 

Moreover 0 
, 0 
targeted 0 
mutagenesis 0 
of 0 
mouse 0 
homologues 0 
of 0 
the 0 
human 0 
candidate 0 
PWS 1
genes 0 
does 0 
not 0 
appear 0 
to 0 
result 0 
in 0 
any 0 
of 0 
the 0 
features 0 
of 0 
PWS 1
. 0 

Therefore 0 
, 0 
the 0 
isolation 0 
of 0 
new 0 
genes 0 
in 0 
this 0 
region 0 
remains 0 
crucial 0 
for 0 
a 0 
better 0 
understanding 0 
of 0 
the 0 
molecular 0 
basis 0 
of 0 
PWS 1
. 0 

In 0 
this 0 
manuscript 0 
, 0 
we 0 
report 0 
the 0 
characterization 0 
of 0 
MAGEL2 0 
and 0 
its 0 
mouse 0 
homologue 0 
Magel2 0 
. 0 

These 0 
are 0 
located 0 
in 0 
the 0 
human 0 
15q11-q13 0 
and 0 
mouse 0 
7C 0 
regions 0 
, 0 
in 0 
close 0 
proximity 0 
to 0 
NDN 0 
/ 0 
Ndn 0 
. 0 

By 0 
northern 0 
blot 0 
analysis 0 
we 0 
did 0 
not 0 
detect 0 
any 0 
expression 0 
of 0 
MAGEL2 0 
/ 0 
Magel2 0 
but 0 
by 0 
RT-PCR 0 
analysis 0 
, 0 
specific 0 
expression 0 
was 0 
detected 0 
in 0 
fetal 0 
and 0 
adult 0 
brain 0 
and 0 
in 0 
placenta 0 
. 0 

Both 0 
genes 0 
are 0 
intronless 0 
with 0 
tandem 0 
direct 0 
repeat 0 
sequences 0 
contained 0 
within 0 
a 0 
CpG 0 
island 0 
in 0 
the 0 
5-untranscribed 0 
region 0 
. 0 

The 0 
transcripts 0 
encode 0 
putative 0 
proteins 0 
that 0 
are 0 
homologous 0 
to 0 
the 0 
MAGE 0 
proteins 0 
and 0 
NDN 0 
. 0 

Moreover 0 
, 0 
MAGEL2 0 
/ 0 
Magel2 0 
are 0 
expressed 0 
only 0 
from 0 
the 0 
paternal 0 
allele 0 
in 0 
brain 0 
, 0 
suggesting 0 
a 0 
potential 0 
role 0 
in 0 
the 0 
aetiology 0 
of 0 
PWS 1
and 0 
its 0 
mouse 0 
model 0 
, 0 
respectively 0 
. 0 
. 0 

Multiple 0 
origins 0 
for 0 
phenylketonuria 1
in 0 
Europe 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
, 0 
a 0 
disorder 1
of 1
amino 1
acid 1
metabolism 1
prevalent 0 
among 0 
Caucasians 0 
and 0 
other 0 
ethnic 0 
groups 0 
, 0 
is 0 
caused 0 
primarily 0 
by 0 
a 0 
deficiency 1
of 1
the 1
hepatic 1
enzyme 1
phenylalanine 1
hydroxylase 1
-LRB- 0 
PAH 0 
-RRB- 0 
. 0 

PKU 1
is 0 
a 0 
highly 0 
heterogeneous 0 
disorder 0 
, 0 
with 0 
more 0 
than 0 
_NUM2 0 
molecular 0 
lesions 0 
identified 0 
in 0 
the 0 
PAH 0 
gene 0 
. 0 

The 0 
haplotype 0 
associations 0 
, 0 
relative 0 
frequencies 0 
, 0 
and 0 
distributions 0 
of 0 
five 0 
prevalent 0 
PAH 0 
mutations 0 
-LRB- 0 
R158Q 0 
, 0 
R261Q 0 
, 0 
IVS10nt546 0 
, 0 
R408W 0 
, 0 
and 0 
IVS12n1 0 
-RRB- 0 
were 0 
established 0 
in 0 
a 0 
comprehensive 0 
European 0 
sample 0 
population 0 
and 0 
subsequently 0 
were 0 
examined 0 
to 0 
determine 0 
the 0 
potential 0 
roles 0 
of 0 
several 0 
genetic 0 
mechanisms 0 
in 0 
explaining 0 
the 0 
present 0 
distribution 0 
of 0 
the 0 
major 0 
PKU 1
alleles 0 
. 0 

Each 0 
of 0 
these 0 
five 0 
mutations 0 
was 0 
strongly 0 
associated 0 
with 0 
only 0 
one 0 
of 0 
the 0 
more 0 
than 0 
_NUM2 0 
chromosomal 0 
haplotypes 0 
defined 0 
by 0 
eight 0 
RFLPs 0 
in 0 
or 0 
near 0 
the 0 
PAH 0 
gene 0 
. 0 

These 0 
findings 0 
suggest 0 
that 0 
each 0 
of 0 
these 0 
mutations 0 
arose 0 
through 0 
a 0 
single 0 
founding 0 
event 0 
that 0 
occurred 0 
within 0 
time 0 
periods 0 
ranging 0 
from 0 
several 0 
hundred 0 
to 0 
several 0 
thousand 0 
years 0 
ago 0 
. 0 

From 0 
the 0 
significant 0 
differences 0 
observed 0 
in 0 
the 0 
relative 0 
frequencies 0 
and 0 
distributions 0 
of 0 
these 0 
five 0 
alleles 0 
throughout 0 
Europe 0 
, 0 
four 0 
of 0 
these 0 
putative 0 
founding 0 
events 0 
could 0 
be 0 
localized 0 
to 0 
specific 0 
ethnic 0 
subgroups 0 
. 0 

Together 0 
, 0 
these 0 
data 0 
suggest 0 
that 0 
there 0 
were 0 
multiple 0 
, 0 
geographically 0 
and 0 
ethnically 0 
distinct 0 
origins 0 
for 0 
PKU 1
within 0 
the 0 
European 0 
population 0 
. 0 
. 0 

Autoinhibition 0 
and 0 
activation 0 
mechanisms 0 
of 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
protein 0 
. 0 

The 0 
Rho-family 0 
GTPase 0 
, 0 
Cdc42 0 
, 0 
can 0 
regulate 0 
the 0 
actin 0 
cytoskeleton 0 
through 0 
activation 0 
of 0 
Wiskott-Aldrich 1
syndrome 1
protein 0 
-LRB- 0 
WASP 0 
-RRB- 0 
family 0 
members 0 
. 0 

Activation 0 
relieves 0 
an 0 
autoinhibitory 0 
contact 0 
between 0 
the 0 
GTPase-binding 0 
domain 0 
and 0 
the 0 
carboxy-terminal 0 
region 0 
of 0 
WASP 0 
proteins 0 
. 0 

Here 0 
we 0 
report 0 
the 0 
autoinhibited 0 
structure 0 
of 0 
the 0 
GTPase-binding 0 
domain 0 
of 0 
WASP 0 
, 0 
which 0 
can 0 
be 0 
induced 0 
by 0 
the 0 
C-terminal 0 
region 0 
or 0 
by 0 
organic 0 
co-solvents 0 
. 0 

In 0 
the 0 
autoinhibited 0 
complex 0 
, 0 
intramolecular 0 
interactions 0 
with 0 
the 0 
GTPase-binding 0 
domain 0 
occlude 0 
residues 0 
of 0 
the 0 
C 0 
terminus 0 
that 0 
regulate 0 
the 0 
Arp2 0 
/ 0 
3 0 
actin-nucleating 0 
complex 0 
. 0 

Binding 0 
of 0 
Cdc42 0 
to 0 
the 0 
GTPase-binding 0 
domain 0 
causes 0 
a 0 
dramatic 0 
conformational 0 
change 0 
, 0 
resulting 0 
in 0 
disruption 0 
of 0 
the 0 
hydrophobic 0 
core 0 
and 0 
release 0 
of 0 
the 0 
C 0 
terminus 0 
, 0 
enabling 0 
its 0 
interaction 0 
with 0 
the 0 
actin 0 
regulatory 0 
machinery 0 
. 0 

These 0 
data 0 
show 0 
that 0 
intrinsically 0 
unstructured 0 
peptides 0 
such 0 
as 0 
the 0 
GTPase-binding 0 
domain 0 
of 0 
WASP 0 
can 0 
be 0 
induced 0 
into 0 
distinct 0 
structural 0 
and 0 
functional 0 
states 0 
depending 0 
on 0 
context 0 
. 0 
. 0 

Localisation 0 
of 0 
the 0 
gene 0 
for 0 
Norrie 1
disease 1
to 0 
between 0 
DXS7 0 
and 0 
DXS426 0 
on 0 
Xp 0 
. 0 

A 0 
highly 0 
informative 0 
microsatellite 0 
marker 0 
, 0 
DXS426 0 
, 0 
which 0 
maps 0 
proximal 0 
to 0 
DXS7 0 
in 0 
the 0 
interval 0 
Xp11 0 
. 0 

4-Xp11 0 
4-Xp11 0 
. 0 

_NUM2 0 
, 0 
has 0 
been 0 
used 0 
to 0 
refine 0 
further 0 
the 0 
localisation 0 
of 0 
the 0 
gene 0 
for 0 
Norrie 1
disease 1
-LRB- 0 
NDP 1
-RRB- 0 
. 0 

The 0 
results 0 
from 0 
a 0 
multiply 0 
informative 0 
crossover 0 
localize 0 
the 0 
NDP 1
gene 0 
proximal 0 
to 0 
DXS7 0 
. 0 

In 0 
conjunction 0 
with 0 
information 0 
from 0 
_NUM1 0 
NDP 1
patients 0 
who 0 
have 0 
a 0 
deletion 0 
for 0 
DXS7 0 
but 0 
not 0 
for 0 
DSX426 0 
, 0 
our 0 
data 0 
indicate 0 
that 0 
the 0 
NDP 1
gene 0 
lies 0 
between 0 
DXS7 0 
and 0 
DXS426 0 
on 0 
proximal 0 
Xp 0 
. 0 

Molecular 0 
basis 0 
of 0 
human 0 
mitochondrial 0 
very-long-chain 1
acyl-CoA 1
dehydrogenase 1
deficiency 1
causing 0 
cardiomyopathy 1
and 0 
sudden 1
death 1
in 0 
childhood 0 
. 0 

beta-Oxidation 0 
of 0 
long-chain 0 
fatty 0 
acids 0 
provides 0 
the 0 
major 0 
source 0 
of 0 
energy 0 
in 0 
the 0 
heart 0 
. 0 

Defects 0 
in 0 
enzymes 0 
of 0 
the 0 
beta-oxidation 0 
pathway 0 
cause 0 
sudden 1
, 1
unexplained 1
death 1
in 0 
childhood 0 
, 0 
acute 0 
hepatic 1
encephalopathy 1
or 0 
liver 1
failure 1
, 0 
skeletal 1
myopathy 1
, 0 
and 0 
cardiomyopathy 1
. 0 

Very-long-chain 0 
acyl-CoA 0 
dehydrogenase 0 
-LSB- 0 
VLCAD 0
; 0 
very-long-chain-acyl-CoA 0 
-LRB- 0 
acceptor 0 
-RRB- 0 
_NUM1 0 
, 0 
3-oxidoreductase 0 
, 0 
EC 0 
_NUM1 0 
. 0 

_NUM1 0 
_NUM1 0 
. 0 

_NUM2 0 
_NUM2 0 
. 0 

_NUM2 0 
-RSB- 0 
catalyzes 0 
the 0 
first 0 
step 0 
in 0 
beta-oxidation 0 
. 0 

We 0 
have 0 
isolated 0 
the 0 
human 0 
VLCAD 0
cDNA 0 
and 0 
gene 0 
and 0 
determined 0 
the 0 
complete 0 
nucleotide 0 
sequences 0 
. 0 

Polymerase 0 
chain 0 
reaction 0 
amplification 0 
of 0 
VLCAD 0
mRNA 0 
and 0 
genomic 0 
exons 0 
defined 0 
the 0 
molecular 0 
defects 0 
in 0 
two 0 
patients 0 
with 0 
VLCAD 1
deficiency 1
who 0 
presented 0 
with 0 
unexplained 0 
cardiac 1
arrest 1
and 0 
cardiomyopathy 1
. 0 

In 0 
one 0 
, 0 
a 0 
homozygous 0 
mutation 0 
in 0 
the 0 
consensus 0 
dinucleotide 0 
of 0 
the 0 
donor 0 
splice 0 
site 0 
-LRB- 0 
g 0 
+ 0 
_NUM1 0 
-- 0 
> 0 
a 0 
-RRB- 0 
was 0 
associated 0 
with 0 
universal 0 
skipping 0 
of 0 
the 0 
prior 0 
exon 0 
-LRB- 0 
exon 0 
_NUM2 0 
-RRB- 0 
. 0 

The 0 
second 0 
patient 0 
was 0 
a 0 
compound 0 
heterozygote 0 
, 0 
with 0 
a 0 
missense 0 
mutation 0 
, 0 
_AN 0 
-- 0 
> 0 
T 0 
, 0 
changing 0 
the 0 
arginine 0 
at 0 
residue 0 
_NUM3 0 
to 0 
tryptophan 0 
on 0 
one 0 
allele 0 
and 0 
a 0 
single 0 
base 0 
deletion 0 
at 0 
the 0 
intron-exon 0 
_NUM1 0 
boundary 0 
as 0 
the 0 
second 0 
mutation 0 
. 0 

This 0 
initial 0 
delineation 0 
of 0 
human 0 
mutations 0 
in 0 
VLCAD 0
suggests 0 
that 0 
VLCAD 1
deficiency 1
reduces 0 
myocardial 0 
fatty 0 
acid 0 
beta-oxidation 0 
and 0 
energy 0 
production 0 
and 0 
is 0 
associated 0 
with 0 
cardiomyopathy 1
and 0 
sudden 1
death 1
in 0 
childhood 0 
. 0 

An 0 
error 0 
in 0 
dystrophin 0 
mRNA 0 
processing 0 
in 0 
golden 1
retriever 1
muscular 1
dystrophy 1
, 0 
an 0 
animal 0 
homologue 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
. 0 

Golden 1
retriever 1
muscular 1
dystrophy 1
-LRB- 0 
GRMD 1
-RRB- 0 
is 0 
a 0 
spontaneous 0 
, 0 
X-linked 0 
, 0 
progressively 0 
fatal 0 
disease 0 
of 0 
dogs 0 
and 0 
is 0 
also 0 
a 0 
homologue 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

Two-thirds 0 
of 0 
DMD 1
patients 0 
carry 0 
detectable 0 
deletions 0 
in 0 
their 0 
dystrophin 0 
gene 0 
. 0 

The 0 
defect 0 
underlying 0 
the 0 
remaining 0 
one-third 0 
of 0 
DMD 1
patients 0 
is 0 
undetermined 0 
. 0 

Analysis 0 
of 0 
the 0 
canine 0 
dystrophin 0 
gene 0 
in 0 
normal 0 
and 0 
GRMD 1
dogs 0 
has 0 
failed 0 
to 0 
demonstrate 0 
any 0 
detectable 0 
loss 0 
of 0 
exons 0 
. 0 

Here 0 
, 0 
we 0 
have 0 
demonstrated 0 
a 0 
RNA 0 
processing 0 
error 0 
in 0 
GRMD 1
that 0 
results 0 
from 0 
a 0 
single 0 
base 0 
change 0 
in 0 
the 0 
_NUM1 0 
consensus 0 
splice 0 
site 0 
of 0 
intron 0 
_NUM1 0 
. 0 

The 0 
seventh 0 
exon 0 
is 0 
then 0 
skipped 0 
, 0 
which 0 
predicts 0 
a 0 
termination 0 
of 0 
the 0 
dystrophin 0
reading 0 
frame 0 
within 0 
its 0 
N-terminal 0 
domain 0 
in 0 
exon 0 
_NUM1 0 
. 0 

This 0 
is 0 
the 0 
first 0 
example 0 
of 0 
dystrophin 1
deficiency 1
caused 0 
by 0 
a 0 
splice-site 0 
mutation 0 
. 0 
. 0 

Serum 0 
amyloid 0 
A 0 
and 0 
P 0 
protein 0 
genes 0 
in 0 
familial 1
Mediterranean 1
fever 1
. 0 

Two 0 
recent 0 
studies 0 
have 0 
suggested 0 
the 0 
involvement 0 
of 0 
serum 0 
amyloid 0 
A 0 
-LRB- 0 
SAA 0 
-RRB- 0 
and 0 
P 0 
-LRB- 0 
APCS 0 
-RRB- 0 
genes 0 
in 0 
familial 1
Mediterranean 1
fever 1
-LRB- 0 
MEF 1
-RRB- 0 
. 0 

To 0 
test 0 
the 0 
role 0 
of 0 
SAA 0 
and 0 
APCS 0 
in 0 
MEF 1
and 0 
MEF-amyloidosis 1
, 0 
we 0 
studied 0 
_NUM2 0 
informative 0 
families 0 
-LRB- 0 
_NUM2 0 
Armenians 0 
, 0 
_NUM1 0 
non-Ashkenazi 0 
Jews 0 
-RRB- 0 
and 0 
_NUM1 0 
MEF 1
patients 0 
with 0 
amyloidosis 1
using 0 
a 0 
candidate 0 
gene 0 
approach 0 
. 0 

No 0 
evidence 0 
for 0 
any 0 
MEF 1
associated 0 
polymorphism 0 
was 0 
found 0 
in 0 
any 0 
of 0 
the 0 
_NUM2 0 
Armenian 0 
and 0 
Jewish 0 
MEF 1
patients 0 
tested 0 
. 0 

Our 0 
family 0 
studies 0 
allowed 0 
us 0 
to 0 
rule 0 
out 0 
tight 0 
linkage 0 
between 0 
SAA 0 
and 0 
MEF 1
-LRB- 0 
lod 0 
score 0 
= 0 
-2 0 
. 0 

_NUM2 0 
, 0 
theta 0 
less 0 
than 0 
or 0 
equal 0 
to 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

For 0 
APCS 0 
we 0 
found 0 
that 0 
the 0 
allele 0 
frequency 0 
in 0 
the 0 
MEF-amyloidosis 1
patients 0 
was 0 
similar 0 
to 0 
that 0 
in 0 
_NUM2 0 
unrelated 0 
MEF 1
patients 0 
without 0 
amyloidosis 1
and 0 
their 0 
_NUM2 0 
healthy 0 
parents 0 
. 0 

Glucose-6-phosphate 0 
dehydrogenase 0 
variants 0 
from 0 
Italian 0 
subjects 0 
associated 0 
with 0 
severe 1
neonatal 1
jaundice 1
. 0 

Screening 0 
for 0 
the 0 
G6PD 1
deficiency 1
was 0 
carried 0 
out 0 
at 0 
the 0 
Maternity 0 
Division 0 
of 0 
the 0 
Galliera 0 
Hospital 0 
in 0 
Genoa 0 
, 0 
Italy 0 
. 0 

Two 0 
groups 0 
of 0 
subjects 0 
with 0 
hyperbilirubinaemia 1
of 0 
non-immunological 0 
origin 0 
were 0 
examined 0 
-LRB- 0 
a 0 
-RRB- 0 
_NUM3 0 
newborn 0 
babies 0 
of 0 
Sardinian 0 
extraction 0 
-LRB- 0 
on 0 
cord 0 
blood 0 
-RRB- 0 
and 0 
-LRB- 0 
b 0 
-RRB- 0 
_NUM3 0 
newborn 0 
babies 0 
of 0 
south 0 
Italian 0 
ancestry 0 
-LRB- 0 
on 0 
peripheral 0 
blood 0 
-RRB- 0 
. 0 

Among 0 
_NUM3 0 
subjects 0 
, 0 
_NUM2 0 
showed 0 
an 0 
enzyme 0 
deficiency 0 
; 0 
in 0 
_NUM2 0 
the 0 
defect 0 
was 0 
of 0 
the 0 
Mediterranean 0 
type 0 
. 0 

In 0 
one 0 
case 0 
, 0 
previously 0 
described 0 
, 0 
the 0 
enzyme 0 
was 0 
of 0 
the 0 
A 0 
- 0 
type 0 
. 0 

In 0 
the 0 
remaining 0 
cases 0 
three 0 
different 0 
variants 0 
were 0 
identified 0 
. 0 

In 0 
the 0 
present 0 
work 0 
these 0 
three 0 
cases 0 
, 0 
each 0 
with 0 
severe 1
neonatal 1
jaundice 1
, 0 
are 0 
reported 0 
. 0 

Their 0 
parents 0 
originated 0 
from 0 
Calabria 0 
, 0 
from 0 
Sardinia 0 
and 0 
from 0 
Sicily 0 
. 0 

The 0 
abnormal 0 
enzymes 0 
are 0 
respectively 0 
designated 0 
as 0 
GdDcbrousse-like 0 
, 0 
GdGallura 0 
and 0 
GdAgrigento 0 
. 0 
. 0 

Loss 0 
of 0 
normal 0 
allele 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
an 0 
adrenocortical 1
carcinoma 1
from 0 
a 0 
patient 0 
with 0 
familial 1
adenomatous 1
polyposis 1
. 0 

Endocrine 1
neoplasms 1
have 0 
been 0 
reported 0 
occasionally 0 
in 0 
patients 0 
with 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

An 0 
adrenocorotical 1
carcinoma 1
was 0 
studied 0 
in 0 
a 0 
patient 0 
with 0 
a 0 
family 0 
history 0 
of 0 
FAP 1
. 0 

Loss 0 
of 0 
heterozygosity 0 
-LRB- 0 
LOH 0 
-RRB- 0 
in 0 
the 0 
region 0 
close 0 
to 0 
the 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
was 0 
detected 0 
in 0 
this 0 
carcinoma 1
, 0 
and 0 
evidence 0 
was 0 
obtained 0 
that 0 
there 0 
was 0 
a 0 
loss 0 
of 0 
the 0 
normal 0 
allele 0 
of 0 
the 0 
APC 1
gene 0 
. 0 

This 0 
is 0 
the 0 
first 0 
demonstration 0 
of 0 
LOH 0 
at 0 
the 0 
APC 1
locus 0 
in 0 
adrenocortical 1
tumors 1
. 0 

The 0 
present 0 
results 0 
and 0 
our 0 
previous 0 
data 0 
on 0 
LOH 0 
in 0 
a 0 
recurring 0 
desmoid 1
tumor 1
suggest 0 
that 0 
the 0 
heterozygous 0 
mutant 0 
/ 0 
wild-type 0 
condition 0 
of 0 
the 0 
APC 1
gene 0 
may 0 
give 0 
rise 0 
to 0 
benign 1
tumors 1
, 0 
and 0 
that 0 
functional 0 
loss 0 
of 0 
this 0 
gene 0 
leads 0 
to 0 
development 0 
of 0 
tumors 1
not 0 
only 0 
in 0 
the 0 
colon 0 
but 0 
also 0 
in 0 
other 0 
various 0 
parts 0 
of 0 
the 0 
body 0 
in 0 
FAP 1
patients 0 
. 0 
. 0 

Heterozygous 0 
C2-deficiency 1
and 0 
myasthenia 1
gravis 1
. 0 

Complement 1
deficiency 1
states 0 
in 0 
myasthenia 1
gravis 1
-LRB- 0 
MG 1
-RRB- 0 
have 0 
not 0 
been 0 
reported 0 
previously 0 
. 0 

We 0 
describe 0 
a 0 
19-year-old 0 
woman 0 
with 0 
typical 0 
MG 1
and 0 
heterozygous 0 
C2 1
deficiency 1
, 0 
along 0 
with 0 
HLA 0 
typing 0 
of 0 
the 0 
patient 0 
and 0 
her 0 
immediate 0 
family 0 
. 0 
. 0 

Large 0 
heterozygous 0 
deletion 0 
masquerading 0 
as 0 
homozygous 0 
missense 0 
mutation 0 
: 0 
a 0 
pitfall 0 
in 0 
diagnostic 0 
mutation 0 
analysis 0 
. 0 

The 0 
clinical 0 
use 0 
of 0 
molecular 0 
analyses 0 
in 0 
recessive 1
disorders 1
relies 0 
on 0 
the 0 
exact 0 
characterization 0 
of 0 
both 0 
mutant 0 
alleles 0 
in 0 
the 0 
affected 0 
patient 0 
. 0 

This 0 
can 0 
be 0 
problematic 0 
when 0 
only 0 
part 0 
of 0 
the 0 
gene 0 
is 0 
examined 0 
or 0 
when 0 
relevant 0 
DNA 0 
alterations 0 
are 0 
not 0 
recognized 0 
by 0 
standard 0 
methods 0 
. 0 

We 0 
present 0 
a 0 
child 0 
in 0 
whom 0 
phenylketonuria 1
was 0 
apparently 0 
caused 0 
by 0 
homozygosity 0 
for 0 
the 0 
mutation 0 
E390G 0 
in 0 
exon 0 
_NUM2 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0 
-RRB- 0 
gene 0 
. 0 

However 0 
, 0 
the 0 
clinical 0 
severity 0 
of 0 
the 0 
disease 0 
was 0 
not 0 
quite 0 
as 0 
mild 0 
as 0 
expected 0 
, 0 
the 0 
mutation 0 
was 0 
not 0 
identified 0 
in 0 
the 0 
father 0 
despite 0 
confirmed 0 
paternity 0 
, 0 
and 0 
the 0 
paternal 0 
allele 0 
showed 0 
a 0 
highly 0 
unusual 0 
pattern 0 
of 0 
polymorphic 0 
markers 0 
in 0 
the 0 
PAH 0 
gene 0 
. 0 

Presence 0 
of 0 
a 0 
large 0 
deletion 0 
involving 0 
exons 0 
_NUM1 0 
, 0 
_NUM2 0 
and 0 
_NUM2 0 
of 0 
the 0 
phenylalanine 0 
hydroxylase 0 
gene 0 
was 0 
confirmed 0 
by 0 
long-range 0 
PCR 0 
. 0 

Diagnostic 0 
DNA 0 
analyses 0 
should 0 
include 0 
a 0 
comprehensive 0 
examination 0 
of 0 
the 0 
whole 0 
relevant 0 
gene 0 
in 0 
the 0 
patient 0 
and 0 
confirmation 0 
of 0 
carrier 0 
status 0 
in 0 
both 0 
parents 0 
. 0 
. 0 

Two 0 
point 0 
mutations 0 
are 0 
responsible 0 
for 0 
G6PD 0
polymorphism 0 
in 0 
Sardinia 0 
. 0 

The 0 
human 0 
X-linked 0 
gene 0 
encoding 0 
glucose 0 
6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0
-RRB- 0 
is 0 
highly 0 
polymorphic 0 
; 0 
more 0 
than 0 
_NUM3 0 
G6PD 0
variants 0 
have 0 
been 0 
identified 0 
. 0 

G6PD 1
deficiency 1
in 0 
different 0 
geographical 0 
areas 0 
appears 0 
to 0 
have 0 
arisen 0 
through 0 
independent 0 
mutational 0 
events 0 
, 0 
but 0 
within 0 
the 0 
same 0 
population 0 
it 0 
may 0 
also 0 
be 0 
heterogeneous 0 
. 0 

One 0 
example 0 
is 0 
the 0 
island 0 
of 0 
Sardinia 0 
, 0 
where 0 
careful 0 
clinical 0 
and 0 
biochemical 0 
studies 0 
have 0 
identified 0 
four 0 
different 0 
G6PD 0
variants 0 
. 0 

We 0 
cloned 0 
and 0 
sequenced 0 
the 0 
four 0 
G6PD 0
variants 0 
from 0 
Sardinia 0 
and 0 
found 0 
that 0 
only 0 
two 0 
mutations 0 
are 0 
responsible 0 
for 0 
G6PD 1
deficiency 1
in 0 
this 0 
area 0 
one 0 
mutation 0 
is 0 
the 0 
cause 0 
of 0 
the 0 
G6PD 1
Seattle-like 1
phenotype 1
, 0 
a 0 
milder 0 
form 0 
of 0 
G6PD 1
deficiency 1
; 0 
the 0 
other 0 
mutation 0 
is 0 
responsible 0 
for 0 
all 0 
forms 0 
of 0 
very 0 
severe 0 
G6PD 1
deficiency 1
in 0 
Sardinia 0 
and 0 
, 0 
possibly 0 
, 0 
in 0 
the 0 
Mediterranean 0 
. 0 
. 0 

Familial 1
discoid 1
lupus 1
erythematosus 1
associated 0 
with 0 
heterozygote 0 
C2 1
deficiency 1
. 0 

Two 0 
siblings 0 
with 0 
chronic 1
discoid 1
lupus 1
erythematosus 1
and 0 
several 0 
family 0 
members 0 
were 0 
found 0 
with 0 
heterozygous 0 
C2 1
deficiency 1
. 0 

An 0 
association 0 
with 0 
histocompatibility 0 
markers 0 
HLA-B18 0 
and 0 
HLA-Dw2 0 
was 0 
demonstrated 0 
, 0 
and 0 
the 0 
slow 0 
allotype 0 
of 0 
factor 0 
B 0 
was 0 
present 0 
. 0 

Linkage 0 
studies 0 
in 0 
this 0 
family 0 
suggested 0 
a 0 
close 0 
linkage 0 
between 0 
the 0 
C2 1
deficiency 1
gene 0 
and 0 
genes 0 
coding 0 
for 0 
_AN 0 
, 0 
Dw2 0 
, 0 
and 0 
BfS 0 
antigens 0 
. 0 

One 0 
HLA-ACB 0 
/ 0 
DBf 0 
recombinant 0 
was 0 
observed 0 
showing 0 
closer 0 
linkage 0 
between 0 
HLA-D 0 
and 0 
Bf 0 
than 0 
between 0 
HLA-B 0 
and 0 
Bf 0 
. 0 
. 0 

A 0 
strong 0 
candidate 0 
for 0 
the 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
gene 0 
BRCA1 0 
. 0 

A 0 
strong 0 
candidate 0 
for 0 
the 0 
17q-linked 0 
BRCA1 0 
gene 0 
, 0 
which 0 
influences 0 
susceptibility 0 
to 0 
breast 1
and 1
ovarian 1
cancer 1
, 0 
has 0 
been 0 
identified 0 
by 0 
positional 0 
cloning 0 
methods 0 
. 0 

Probable 0 
predisposing 0 
mutations 0 
have 0 
been 0 
detected 0 
in 0 
five 0 
of 0 
eight 0 
kindreds 0 
presumed 0 
to 0 
segregate 0 
BRCA1 0 
susceptibility 0 
alleles 0 
. 0 

The 0 
mutations 0 
include 0 
an 0 
11-base 0 
pair 0 
deletion 0 
, 0 
a 0 
1-base 0 
pair 0 
insertion 0 
, 0 
a 0 
stop 0 
codon 0 
, 0 
a 0 
missense 0 
substitution 0 
, 0 
and 0 
an 0 
inferred 0 
regulatory 0 
mutation 0 
. 0 

The 0 
BRCA1 0 
gene 0 
is 0 
expressed 0 
in 0 
numerous 0 
tissues 0 
, 0 
including 0 
breast 0
and 0 
ovary 0 
, 0 
and 0 
encodes 0 
a 0 
predicted 0 
protein 0 
of 0 
_NUM4 0 
amino 0 
acids 0 
. 0 

This 0 
protein 0 
contains 0 
a 0 
zinc 0 
finger 0 
domain 0 
in 0 
its 0 
amino-terminal 0 
region 0 
, 0 
but 0 
is 0 
otherwise 0 
unrelated 0 
to 0 
previously 0 
described 0 
proteins 0 
. 0 

Identification 0 
of 0 
BRCA1 0 
should 0 
facilitate 0 
early 0 
diagnosis 0 
of 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
in 0 
some 0 
individuals 0 
as 0 
well 0 
as 0 
a 0 
better 0 
understanding 0 
of 0 
breast 1
cancer 1
biology 0 
. 0 
. 0 

Recombinations 0 
in 0 
individuals 0 
homozygous 0 
by 0 
descent 0 
localize 0 
the 0 
Friedreich 1
ataxia 1
locus 0 
in 0 
a 0 
cloned 0 
450-kb 0 
interval 0 
. 0 

The 0 
locus 0 
for 0 
Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
, 0 
a 0 
severe 0 
neurodegenerative 1
disease 1
, 0 
is 0 
tightly 0 
linked 0 
to 0 
markers 0 
D9S5 0 
and 0 
D9S15 0 
, 0 
and 0 
analysis 0 
of 0 
rare 0 
recombination 0 
events 0 
has 0 
suggested 0 
the 0 
order 0 
cen-FRDA-D9S5-D9S15-qter 0 
. 0 

We 0 
report 0 
here 0 
the 0 
construction 0 
of 0 
a 0 
YAC 0 
contig 0 
extending 0 
_NUM3 0 
kb 0 
centromeric 0 
to 0 
D9S5 0 
and 0 
the 0 
isolation 0 
of 0 
five 0 
new 0 
microsatellite 0 
markers 0 
from 0 
this 0 
region 0 
. 0 

In 0 
order 0 
to 0 
map 0 
these 0 
markers 0 
with 0 
respect 0 
to 0 
the 0 
FRDA 1
locus 0 
, 0 
all 0 
within 0 
a 0 
1-cM 0 
confidence 0 
interval 0 
, 0 
we 0 
sought 0 
to 0 
increase 0 
the 0 
genetic 0 
information 0 
of 0 
available 0 
FRDA 1
families 0 
by 0 
considering 0 
homozygosity 0 
by 0 
descent 0 
and 0 
association 0 
with 0 
founder 0 
haplotypes 0 
in 0 
isolated 0 
populations 0 
. 0 

This 0 
approach 0 
allowed 0 
us 0 
to 0 
identify 0 
one 0 
phase-known 0 
recombination 0 
and 0 
one 0 
probable 0 
historic 0 
recombination 0 
on 0 
haplotypes 0 
from 0 
Reunion 0 
Island 0 
patients 0 
, 0 
both 0 
of 0 
which 0 
place 0 
three 0 
of 0 
the 0 
five 0 
markers 0 
proximal 0 
to 0 
FRDA 1
. 0 

This 0 
represents 0 
the 0 
first 0 
identification 0 
of 0 
close 0 
FRDA 1
flanking 0 
markers 0 
on 0 
the 0 
centromeric 0 
side 0 
. 0 

The 0 
two 0 
other 0 
markers 0 
allowed 0 
us 0 
to 0 
narrow 0 
the 0 
breakpoint 0 
of 0 
a 0 
previously 0 
identified 0 
distal 0 
recombination 0 
that 0 
is 0 
> 0 
_NUM3 0 
kb 0 
from 0 
D9S5 0 
-LRB- 0 
26P 0 
-RRB- 0 
. 0 

Taken 0 
together 0 
, 0 
the 0 
results 0 
place 0 
the 0 
FRDA 1
locus 0 
in 0 
a 0 
450-kb 0 
interval 0 
, 0 
which 0 
is 0 
small 0 
enough 0 
for 0 
direct 0 
search 0 
of 0 
candidate 0 
genes 0 
. 0 

A 0 
detailed 0 
rare 0 
cutter 0 
restriction 0 
map 0 
and 0 
a 0 
cosmid 0 
contig 0 
covering 0 
this 0 
interval 0 
were 0 
constructed 0 
and 0 
should 0 
facilitate 0 
the 0 
search 0 
of 0 
genes 0 
in 0 
this 0 
region 0 
. 0 
. 0 

Further 0 
mapping 0 
of 0 
an 0 
ataxia-telangiectasia 1
locus 0 
to 0 
the 0 
chromosome 0 
11q23 0 
region 0 
. 0 

We 0 
recently 0 
mapped 0 
the 0 
gene 0 
for 0 
ataxia-telangiectasia 1
group 0 
A 0 
-LRB- 0 
_DS 1
-RRB- 0 
to 0 
chromosome 0 
11q22-23 0 
by 0 
linkage 0 
analysis 0 
, 0 
using 0 
the 0 
genetic 0 
markers 0 
THY1 0 
and 0 
pYNB3 0 
. 0 

_NUM2 0 
-LRB- 0 
D11S144 0 
-RRB- 0 
. 0 

The 0 
most 0 
likely 0 
order 0 
was 0 
cent-AT-S144-THY1 0 
. 0 

The 0 
present 0 
paper 0 
describes 0 
further 0 
mapping 0 
of 0 
the 0 
_DS 1
locus 0 
by 0 
means 0 
of 0 
a 0 
panel 0 
of 0 
_NUM2 0 
markers 0 
that 0 
span 0 
approximately 0 
_NUM2 0 
cM 0 
in 0 
the 0 
11q22-23 0 
region 0 
centered 0 
around 0 
_AN 0 
and 0 
THY1 0 
. 0 

Location 0 
scores 0 
indicate 0 
that 0 
three 0 
contiguous 0 
subsegments 0 
within 0 
the 0 
-LSB- 0 
S144-THY1 0 
-RSB- 0 
segment 0 
, 0 
as 0 
well 0 
as 0 
three 0 
contiguous 0 
segments 0 
telomeric 0 
to 0 
THY1 0 
, 0 
are 0 
each 0 
unlikely 0 
to 0 
contain 0 
the 0 
_DS 1
locus 0 
, 0 
while 0 
the 0 
more 0 
centromeric 0 
-LSB- 0 
STMY-S144 0 
-RSB- 0 
segment 0 
is 0 
most 0 
likely 0 
to 0 
contain 0 
the 0 
_DS 1
locus 0 
. 0 

These 0 
data 0 
, 0 
together 0 
with 0 
recent 0 
refinements 0 
in 0 
the 0 
linkage 0 
and 0 
physical 0 
maps 0 
of 0 
11q22-23 0 
, 0 
place 0 
the 0 
_DS 0 
locus 0 
at 0 
11q23 0 
. 0 

Proliferation-related 0 
expression 0 
of 0 
p19 0 
/ 0 
nm23 0 
nucleoside 0 
diphosphate 0 
kinase 0 
. 0 

High 0 
level 0 
expression 0 
of 0 
the 0 
nm23-H1 0 
gene 0 
, 0 
which 0 
encodes 0 
for 0 
a 0 
nucleoside 0 
diphosphate 0 
kinase 0 
, 0 
has 0 
been 0 
found 0 
to 0 
correlate 0 
with 0 
diminished 0 
metastasis 0 
in 0 
some 0 
tumors 1
but 0 
not 0 
in 0 
others 0 
. 0 

We 0 
have 0 
previously 0 
identified 0 
the 0 
protein 0 
product 0 
of 0 
the 0 
nm23-H1 0 
gene 0 
in 0 
two-dimensional 0 
electrophoretic 0 
gels 0 
and 0 
have 0 
designated 0 
it 0 
p19 0 
/ 0 
nm23 0 
. 0 

In 0 
neuroblastoma 1
, 0 
higher 0 
levels 0 
of 0 
p19 0 
/ 0 
nm23 0 
, 0 
which 0 
are 0 
associated 0 
with 0 
amplification 0 
of 0 
the 0 
N-myc 0 
oncogene 0 
, 0 
large 0 
tumor 1
mass 0 
, 0 
and 0 
metastasis 0 
, 0 
were 0 
observed 0 
in 0 
advanced 0 
stage 0 
tumors 1
compared 0 
with 0 
limited 0 
stage 0 
disease 0 
. 0 

Because 0 
of 0 
the 0 
variable 0 
expression 0 
of 0 
nm23-H1 0 
in 0 
different 0 
tumors 1
, 0 
we 0 
have 0 
investigated 0 
the 0 
relationship 0 
between 0 
amounts 0 
of 0 
the 0 
protein 0 
and 0 
cell 0 
proliferation 0 
. 0 

The 0 
levels 0 
of 0 
p19 0 
/ 0 
nm23 0 
were 0 
compared 0 
between 0 
resting 0 
and 0 
mitotically 0 
stimulated 0 
normal 0 
human 0 
PBLs 0 
and 0 
in 0 
leukemia 1
cells 0 
. 0 

The 0 
amount 0 
of 0 
p19 0 
/ 0 
nm23 0 
increased 0 
in 0 
normal 0 
lymphocytes 0 
in 0 
response 0 
to 0 
mitotic 0 
stimulation 0 
and 0 
paralleled 0 
the 0 
increase 0 
in 0 
DNA 0 
synthesis 0 
. 0 

In 0 
leukemia 1
cells 0 
obtained 0 
from 0 
patients 0 
with 0 
different 0 
subtypes 0 
of 0 
acute 1
leukemia 1
, 0 
p19 0 
/ 0 
nm23 0 
levels 0 
were 0 
also 0 
increased 0 
relative 0 
to 0 
resting 0 
normal 0 
lymphocytes 0 
. 0 

Treatment 0 
of 0 
mitotically 0 
stimulated 0 
lymphocytes 0 
with 0 
cyclosporin 0 
, 0 
which 0 
inhibits 0 
proliferation 0 
, 0 
blocked 0 
the 0 
increase 0 
in 0 
p19 0 
/ 0 
nm23 0 
; 0 
treatment 0 
of 0 
the 0 
leukemia 1
cell 0 
line 0 
HL-60 0 
with 0 
dimethylsulfoxide 0 
, 0 
which 0 
induces 0 
terminal 0 
differentiation 0 
, 0 
resulted 0 
in 0 
diminished 0 
levels 0 
of 0 
p19 0 
/ 0 
nm23 0 
. 0 

Our 0 
data 0 
therefore 0 
provide 0 
evidence 0 
that 0 
nm23-H1 0 
expression 0 
is 0 
related 0 
to 0 
cell 0 
proliferative 0 
activity 0 
. 0 
. 0 

Carrier 0 
detection 0 
of 0 
pyruvate 1
carboxylase 1
deficiency 1
in 0 
fibroblasts 0 
and 0 
lymphocytes 0 
. 0 

Pyruvate 0 
carboxylase 0 
-LRB- 0 
E. 0 
C. 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
activity 0 
was 0 
determined 0 
in 0 
the 0 
circulating 0 
peripheral 0 
lymphocytes 0 
and 0 
cultured 0 
skin 0 
fibroblasts 0 
from 0 
the 0 
family 0 
of 0 
a 0 
patient 0 
with 0 
hepatic 0 
, 0 
cerebral 0 
, 0 
renal 0 
cortical 0 
, 0 
leukocyte 0 
, 0 
and 0 
fibroblast 0 
pyruvate 1
carboxylase 1
deficiency 1
-LRB- 0 
PC 1
Portland 1
deficiency 1
-RRB- 0 
. 0 

Lymphocyte 0 
activities 0 
were 0 
mother 0 
, 0 
_NUM2 0 
-- 0 
_NUM2 0 
% 0 
; 0 
father 0 
, 0 
_NUM2 0 
-- 0 
_NUM2 0 
% 0 
; 0 
brother 0 
, 0 
_NUM2 0 
-- 0 
_NUM3 0 
% 0 
; 0 
and 0 
sister 0 
, 0 
_NUM2 0 
-- 0 
_NUM2 0 
% 0 
of 0 
the 0 
lowest 0 
normal 0 
. 0 

Fibroblasts 0 
from 0 
the 0 
patients 0 
mother 0 
and 0 
father 0 
had 0 
_NUM2 0 
and 0 
_NUM2 0 
% 0 
, 0 
respectively 0 
, 0 
of 0 
the 0 
activity 0 
of 0 
the 0 
lowest 0 
normal 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
the 0 
disease 0 
is 0 
inherited 0 
in 0 
an 0 
autosomal 0 
recessive 0 
manner 0 
and 0 
that 0 
lymphocytes 0 
and 0 
fibroblasts 0 
can 0 
be 0 
used 0 
to 0 
detect 0 
carriers 0 
. 0 

Neither 0 
pyruvate 0 
carboxylase 0 
nor 0 
mitochondrial 0 
PEPCK 0 
activity 0 
in 0 
lymphocytes 0 
was 0 
increased 0 
by 0 
a 0 
21-hr 0 
fast 0 
. 0 

Complex 1
glycerol 1
kinase 1
deficiency 1
: 0 
molecular-genetic 0 
, 0 
cytogenetic 0 
, 0 
and 0 
clinical 0 
studies 0 
of 0 
five 0 
Japanese 0 
patients 0 
. 0 

Five 0 
male 0 
Japanese 0 
patients 0 
with 0 
complex 1
glycerol 1
kinase 1
deficiency 1
-LRB- 0 
CGKD 1
-RRB- 0 
and 0 
their 0 
relatives 0 
were 0 
studied 0 
clinically 0 
, 0 
cytogenetically 0 
, 0 
and 0 
molecular-genetically 0 
. 0 

All 0 
patients 0 
had 0 
muscular 1
dystrophy 1
or 0 
muscle 1
weakness 1
, 0 
mental 1
retardation 1
, 0 
congenital 1
adrenal 1
hypoplasia 1
, 0 
and 0 
glycerol 1
kinase 1
deficiency 1
. 0 

High-resolution 0 
GTG-banded 0 
chromosomes 0 
showed 0 
a 0 
microdeletion 0 
in 0 
the 0 
Xp21 0 
region 0 
in 0 
all 0 
four 0 
patients 0 
examined 0 
and 0 
in 0 
all 0 
five 0 
mothers 0 
. 0 

Southern 0 
hybridizations 0 
, 0 
after 0 
digestions 0 
by 0 
restriction 0 
endonucleases 0 
, 0 
with 0 
various 0 
cloned 0 
DNAs 0 
-LRB- 0 
D2 0 
, 0 
99-6 0 
, 0 
_AN 0 
, 0 
C7 0 
, 0 
L1-4 0 
, 0 
cDMD13-14 0 
, 0 
J66-HI 0 
, 0 
_AN 0 
, 0 
J-Bir 0 
, 0 
ERT87-30 0 
, 0 
ERT87-15 0 
, 0 
ERT87-8 0 
, 0 
ERT87-1 0 
, 0 
XJ-1 0 
. 0 

_NUM1 0 
, 0 
_NUM3 0 
, 0 
cx5 0 
. 0 

_NUM1 0 
, 0 
and 0 
OTC-1 0 
-RRB- 0 
that 0 
are 0 
located 0 
around 0 
Xp21 0 
also 0 
showed 0 
a 0 
deletion 0 
in 0 
the 0 
genome 0 
of 0 
all 0 
patients 0 
and 0 
mothers 0 
. 0 

Although 0 
the 0 
deletion 0 
differed 0 
in 0 
size 0 
among 0 
patients 0 
, 0 
a 0 
segment 0 
commonly 0 
absent 0 
was 0 
located 0 
between 0 
the 0 
genomic 0 
sequences 0 
corresponding 0 
to 0 
L1-4 0 
and 0 
cDMD13-14 0 
. 0 

This 0 
finding 0 
indicated 0 
that 0 
the 0 
gene 0 
coding 0 
for 0 
glycerol 0 
kinase 0 
-LRB- 0 
GK 0 
-RRB- 0 
is 0 
located 0 
within 0 
this 0 
segment 0 
. 0 

A 0 
comparison 0 
of 0 
the 0 
clinical 0 
manifestations 0 
of 0 
the 0 
present 0 
five 0 
patients 0 
and 0 
reported 0 
CGKD 1
or 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
patients 0 
with 0 
DNA 0 
deletion 0 
suggests 0 
the 0 
existence 0 
of 0 
a 0 
certain 0 
gene 0 
responsible 0 
for 0 
gonadotropin 1
deficiency 1
-LRB- 0 
GTD 1
-RRB- 0 
. 0 

The 0 
result 0 
of 0 
the 0 
present 0 
study 0 
and 0 
results 0 
of 0 
previous 0 
studies 0 
suggest 0 
that 0 
genes 0 
for 0 
ornithine 0 
transcarbamylase 0 
-LRB- 0 
OTC 0 
-RRB- 0 
, 0 
DMD 1
, 0 
and 0 
GK 0 
and 0 
putative 0 
genes 0 
responsible 0 
for 0 
congenital 1
adrenal 1
hypoplasia 1
-LRB- 0 
AHC 1
-RRB- 0 
and 0 
GTD 1
are 0 
arranged 0 
from 0 
telomere 0 
to 0 
centromere 0 
as 0 
pter 0 
-- 0 
GTD 0 
-- 0 
AHC 0 
-- 0 
GK 0 
-- 0 
DMD 0 
-- 0 
OTC 0 
-- 0 
cen 0 
Duchenne 1
muscular 1
dystrophy 1
and 0 
myotonic 1
dystrophy 1
in 0 
the 0 
same 0 
patient 0 
. 0 

We 0 
report 0 
on 0 
the 0 
first 0 
patient 0 
identified 0 
with 0 
myotonic 1
dystrophy 1
and 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
. 0 

The 0 
family 0 
of 0 
the 0 
propositus 0 
had 0 
a 0 
strong 0 
history 0 
of 0 
myotonic 1
dystrophy 1
, 0 
and 0 
there 0 
was 0 
an 0 
intrafamilial 0 
pathological 0 
expansion 0 
of 0 
the 0 
responsible 0 
_DS 0 
repeat 0 
between 0 
the 0 
mildly 0 
affected 0 
mother 0 
-LRB- 0 
_NUM3 0 
repeats 0 
; 0 
normal 0 
_NUM2 0 
repeats 0 
-RRB- 0 
and 0 
her 0 
more 0 
severely 0 
affected 0 
son 0 
-LRB- 0 
_NUM3 0 
repeats 0 
-RRB- 0 
, 0 
and 0 
his 0 
sister 0 
-LRB- 0 
_NUM3 0 
repeats 0 
-RRB- 0 
. 0 

The 0 
propositus 0 
was 0 
an 0 
isolated 0 
case 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
with 0 
marked 0 
dystrophin 1
deficiency 1
in 0 
muscle 0 
biopsy 0 
. 0 

The 0 
patient 0 
was 0 
still 0 
ambulatory 0 
post 0 
age 0 
_NUM2 0 
. 0 

Myotonic 1
dystrophy 1
could 0 
interfere 0 
to 0 
some 0 
extent 0 
with 0 
the 0 
progression 0 
of 0 
Duchenne 1
dystrophy 1
. 0 

However 0 
, 0 
other 0 
interpretations 0 
are 0 
possible 0 
. 0 

Twelve 0 
percent 0 
of 0 
dystrophin 0 
revertant 0 
fibers 0 
as 0 
observed 0 
by 0 
immunohistochemistry 0 
could 0 
be 0 
sufficient 0 
to 0 
ameliorate 0 
typical 0 
DMD 1
clinical 0 
severity 0 
, 0 
or 0 
the 0 
patient 0 
may 0 
present 0 
a 0 
somatic 0 
mosaic 0 
. 0 

The 0 
pathophysiological 0 
interactions 0 
of 0 
these 0 
two 0 
unlinked 0 
disorders 0 
are 0 
discussed 0 
at 0 
the 0 
clinical 0 
and 0 
histopathological 0 
levels 0 
. 0 
. 0 

Autosomal 0 
recessive 0 
transmission 0 
of 0 
hemophilia 1
A 1
due 0 
to 0 
a 0 
von 1
Willebrand 1
factor 0 
mutation 0 
. 0 

The 0 
differential 0 
diagnosis 0 
of 0 
the 0 
genetic 1
bleeding 1
disorders 1
, 0 
hemophilia 1
A 1
and 0 
von 1
Willebrand 1
disease 1
, 0 
is 0 
occasionally 0 
confounded 0 
by 0 
the 0 
close 0 
molecular 0 
relationship 0 
of 0 
coagulation 0 
factor 0 
VIII 0 
and 0 
von 1
Willebrand 1
factor 0 
-LRB- 0 
vWF 0 
-RRB- 0 
. 0 

This 0 
report 0 
describes 0 
the 0 
autosomal 0 
inheritance 0 
of 0 
a 0 
hemophilia 1
A 1
phenotype 0 
due 0 
to 0 
a 0 
mutation 0 
of 0 
vWF 0 
that 0 
results 0 
in 0 
defective 0 
factor 0 
VIII 0 
binding 0 
. 0 

The 0 
proband 0 
was 0 
a 0 
female 0 
patient 0 
with 0 
low 0 
levels 0 
of 0 
factor 0 
VIII 0 
activity 0 
. 0 

Polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
amplification 0 
and 0 
DNA 0 
sequencing 0 
were 0 
employed 0 
to 0 
examine 0 
exons 0 
encoding 0 
the 0 
putative 0 
factor 0 
VIII 0 
binding 0 
domain 0 
of 0 
vWF 0 
. 0 

The 0 
patient 0 
was 0 
found 0 
to 0 
be 0 
homozygous 0 
for 0 
a 0 
single 0 
point 0 
mutation 0 
causing 0 
a 0 
Thr 0 
-- 0 
> 0 
Met 0 
substitution 0 
at 0 
amino 0 
acid 0 
position 0 
_NUM2 0 
in 0 
the 0 
mature 0 
vWF 0 
subunit 0 
. 0 

The 0 
phenotypic 0 
expression 0 
of 0 
the 0 
mutation 0 
was 0 
determined 0 
to 0 
be 0 
recessive 0 
because 0 
heterozygous 0 
family 0 
members 0 
were 0 
clinically 0 
unaffected 0 
. 0 

Recombinant 0 
vWF 0 
containing 0 
the 0 
observed 0 
amino 0 
acid 0 
substitution 0 
was 0 
expressed 0 
in 0 
COS-1 0 
cells 0 
. 0 

The 0 
mutant 0 
vWF 0 
was 0 
processed 0 
and 0 
secreted 0 
normally 0 
, 0 
and 0 
was 0 
functionally 0 
equivalent 0 
to 0 
wild-type 0 
vWF 0 
in 0 
its 0 
ability 0 
to 0 
bind 0 
to 0 
platelets 0 
. 0 

However 0 
, 0 
the 0 
mutant 0 
failed 0 
to 0 
bind 0 
factor 0 
VIII 0 
, 0 
demonstrating 0 
that 0 
the 0 
mutation 0 
was 0 
functionally 0 
related 0 
to 0 
the 0 
observed 0 
hemophilia 1
phenotype 0 
. 0 

The 0 
family 0 
we 0 
describe 0 
demonstrates 0 
the 0 
recessive 0 
inheritance 0 
of 0 
a 0 
recently 0 
recognized 0 
class 0 
of 0 
genetic 0 
bleeding 0 
disorders 0 
, 0 
we 0 
call 0 
'' 0 
autosomal 0 
hemophilia 1
. 0 
'' 0 

We 0 
conclude 0 
that 0 
vWF 0 
mutation 0 
may 0 
be 0 
an 0 
under 0 
recognized 0 
cause 0 
of 0 
hemophilia 1
, 0 
especially 0 
in 0 
cases 0 
where 0 
the 0 
inheritance 0 
pattern 0 
is 0 
not 0 
consistent 0 
with 0 
X-linked 0
transmission 0 
. 0 

Determination 0 
of 0 
_NUM2 0 
X-linked 1
adrenoleukodystrophy 1
mutations 0 
, 0 
including 0 
_NUM2 0 
not 0 
previously 0 
described 0 
. 0 

X-linked 1
Adrenoleukodystrophy 1
-LRB- 0 
X-ALD 1
-RRB- 0 
is 0 
the 0 
most 0 
frequent 0 
peroxisomal 1
disease 1
. 0 

It 0 
mainly 0 
involves 0 
the 0 
nervous 0 
system 0 
white 0 
matter 0 
, 0 
adrenal 0 
cortex 0 
and 0 
testes 0 
. 0 

Several 0 
distinct 0 
clinical 0 
phenotypes 0 
are 0 
known 0 
. 0 

The 0 
principal 0 
biochemical 0 
abnormality 0 
is 0 
the 0 
accumulation 0 
of 0 
saturated 0 
very-long-chain 0 
fatty 0 
acids 0 
-LRB- 0 
VLCFAs 0 
> 0 
_AN 0 
_NUM1 0 
, 0 
mainly 0 
_AN 0 
_NUM1 0 
-RRB- 0 
, 0 
which 0 
is 0 
due 0 
to 0 
impaired 0 
capacity 0 
for 0 
beta-oxidation 0 
in 0 
peroxisomes 0 
. 0 

Diagnosis 0 
is 0 
usually 0 
based 0 
on 0 
the 0 
VLCFA 0 
levels 0 
in 0 
plasma 0 
or 0 
cultured 0 
skin 0 
fibroblasts 0 
in 0 
both 0 
patients 0 
and 0 
carriers 0 
. 0 

In 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
affected 0 
males 0 
, 0 
however 0 
, 0 
the 0 
plasma 0 
_AN 0 
_NUM1 0 
level 0 
is 0 
borderline 0 
normal 0 
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
obligate 0 
female 0 
carriers 0 
have 0 
normal 0 
results 0 
. 0 

Effective 0 
mutation 0 
detection 0 
in 0 
these 0 
families 0 
is 0 
therefore 0 
fundamental 0 
to 0 
unambiguously 0 
determine 0 
the 0 
genetic 0 
status 0 
of 0 
each 0 
individual 0 
at 0 
risk 0 
. 0 

Of 0 
particular 0 
concern 0 
are 0 
female 0 
members 0 
of 0 
kindreds 0 
segregating 0 
X-ALD 1
mutations 0 
, 0 
because 0 
normal 0 
VLCFA 0 
levels 0 
do 0 
not 0 
guarantee 0 
lack 0 
of 0 
carrier 0 
status 0 
. 0 

We 0 
describe 0 
a 0 
fast 0 
method 0 
for 0 
detection 0 
of 0 
X-ALD 1
mutations 0 
. 0 

The 0 
method 0 
is 0 
based 0 
on 0 
SSCP 0 
analysis 0 
of 0 
nested 0 
PCR 0 
fragments 0 
followed 0 
by 0 
sequence-determination 0 
reactions 0 
. 0 

Using 0 
this 0 
methodology 0 
we 0 
have 0 
found 0 
X-ALD 1
mutations 0 
in 0 
_NUM2 0 
kindreds 0 
, 0 
including 0 
_NUM2 0 
not 0 
previously 0 
reported 0 
. 0 

Mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
in 0 
families 0 
with 0 
early-onset 0 
breast 1
and 1
ovarian 1
cancer 1
. 0 

We 0 
analysed 0 
_NUM2 0 
probands 0 
with 0 
a 0 
family 0 
history 0 
of 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
for 0 
germline 0 
mutations 0 
in 0 
the 0 
coding 0 
region 0 
of 0 
the 0 
BRCA1 0 
candidate 0 
gene 0 
, 0 
using 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
analysis 0 
on 0 
PCR-amplified 0 
genomic 0 
DNA 0 
. 0 

A 0 
total 0 
of 0 
eight 0 
putative 0 
disease-causing 0 
alterations 0 
were 0 
identified 0 
four 0 
of 0 
these 0 
are 0 
frameshifts 0 
and 0 
two 0 
are 0 
nonsense 0 
mutations 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
found 0 
two 0 
missense 0 
mutations 0 
, 0 
one 0 
of 0 
which 0 
changes 0 
the 0 
final 0 
cysteine 0 
of 0 
the 0 
BRCA1 0 
zinc 0 
finger 0 
motif 0 
to 0 
glycine 0 
. 0 

These 0 
data 0 
are 0 
consistent 0 
with 0 
a 0 
tumour 1
suppressor 0 
model 0 
, 0 
and 0 
support 0 
the 0 
notion 0 
that 0 
this 0 
candidate 0 
gene 0 
is 0 
in 0 
fact 0 
BRCA1 0 
. 0 

The 0 
heterogeneity 0 
of 0 
mutations 0 
, 0 
coupled 0 
with 0 
the 0 
large 0 
size 0 
of 0 
the 0 
gene 0 
, 0 
indicates 0 
that 0 
clinical 0 
application 0 
of 0 
BRCA1 0 
mutation 0 
testing 0 
will 0 
be 0 
technically 0 
challenging 0 
. 0 
. 0 

Screening 0 
for 0 
carriers 0 
of 0 
Tay-Sachs 1
disease 1
among 0 
Ashkenazi 0 
Jews 0 
. 0 

A 0 
comparison 0 
of 0 
DNA-based 0 
and 0 
enzyme-based 0 
tests 0 
. 0 

BACKGROUND 0 
AND 0 
METHODS 0 
. 0 

The 0 
prevention 0 
of 0 
Tay-Sachs 1
disease 1
-LRB- 0 
GM2 1
gangliosidosis 1
, 1
type 1
_NUM1 1
-RRB- 0 
depends 0 
on 0 
the 0 
identification 0 
of 0 
carriers 0 
of 0 
the 0 
gene 0 
for 0 
this 0 
autosomal 1
recessive 1
disorder 1
. 0 

We 0 
compared 0 
the 0 
enzyme-based 0 
test 0 
widely 0 
used 0 
in 0 
screening 0 
for 0 
Tay-Sachs 1
disease 1
with 0 
a 0 
test 0 
based 0 
on 0 
analysis 0 
of 0 
DNA 0 
. 0 

We 0 
developed 0 
methods 0 
to 0 
detect 0 
the 0 
three 0 
mutations 0 
in 0 
the 0 
HEXA 0 
gene 0 
that 0 
occur 0 
with 0 
high 0 
frequency 0 
among 0 
Ashkenazi 0 
Jews 0 
two 0 
mutations 0 
cause 0 
infantile 0 
Tay-Sachs 1
disease 1
, 0 
and 0 
the 0 
third 0 
causes 0 
the 0 
adult-onset 0 
form 0 
of 0 
the 0 
disease 0 
. 0 

DNA 0 
segments 0 
containing 0 
these 0 
mutation 0 
sites 0 
were 0 
amplified 0 
with 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
and 0 
analyzed 0 
for 0 
the 0 
presence 0 
of 0 
the 0 
mutations 0 
. 0 

RESULTS 0 
. 0 

Among 0 
_NUM2 0 
Ashkenazi 0 
obligate 0 
carriers 0 
of 0 
Tay-Sachs 1
disease 1
, 0 
the 0 
three 0 
specific 0 
mutations 0 
accounted 0 
for 0 
all 0 
but 0 
one 0 
of 0 
the 0 
mutant 0 
alleles 0 
-LRB- 0 
_NUM2 0 
percent 0 
-RRB- 0 
. 0 

In 0 
_NUM3 0 
Ashkenazi 0 
carriers 0 
identified 0 
by 0 
the 0 
enzyme 0 
test 0 
, 0 
DNA 0 
analysis 0 
showed 0 
that 0 
_NUM3 0 
-LRB- 0 
_NUM2 0 
percent 0 
-RRB- 0 
had 0 
one 0 
of 0 
the 0 
identified 0 
mutations 0 
. 0 

Of 0 
the 0 
_NUM3 0 
, 0 
_NUM2 0 
percent 0 
had 0 
the 0 
exon 0 
_NUM2 0 
insertion 0 
mutation 0 
, 0 
_NUM2 0 
percent 0 
had 0 
the 0 
intron 0 
_NUM2 0 
splice-junction 0 
mutation 0 
, 0 
and 0 
_NUM1 0 
percent 0 
had 0 
the 0 
less 0 
severe 0 
exon 0 
_NUM1 0 
mutation 0 
associated 0 
with 0 
adult-onset 0 
disease 0 
. 0 

The 0 
results 0 
of 0 
the 0 
enzyme 0 
tests 0 
in 0 
the 0 
_NUM2 0 
subjects 0 
-LRB- 0 
_NUM2 0 
percent 0 
-RRB- 0 
who 0 
were 0 
defined 0 
as 0 
carriers 0 
but 0 
in 0 
whom 0 
DNA 0 
analysis 0 
did 0 
not 0 
identify 0 
a 0 
mutant 0 
allele 0 
were 0 
probably 0 
false 0 
positive 0 
-LRB- 0 
although 0 
there 0 
remains 0 
some 0 
possibility 0 
of 0 
unidentified 0 
mutations 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
of 0 
_NUM3 0 
persons 0 
defined 0 
as 0 
noncarriers 0 
by 0 
the 0 
enzyme-based 0 
test 0 
, 0 
_NUM1 0 
was 0 
identified 0 
as 0 
a 0 
carrier 0 
by 0 
DNA 0 
analysis 0 
-LRB- 0 
i. 0 
e 0 
e. 0 
, 0 
a 0 
false 0 
negative 0 
enzyme-test 0 
result 0 
-RRB- 0 
. 0 

CONCLUSIONS 0 
. 0 

The 0 
increased 0 
specificity 0 
and 0 
predictive 0 
value 0 
of 0 
the 0 
DNA-based 0 
test 0 
make 0 
it 0 
a 0 
useful 0 
adjunct 0 
to 0 
the 0 
diagnostic 0 
tests 0 
currently 0 
used 0 
to 0 
screen 0 
for 0 
carriers 0 
of 0 
Tay-Sachs 1
disease 1
. 0 

Adrenoleukodystrophy 1
gene 0 
encodes 0 
an 0 
_NUM2 0 
kDa 0 
membrane 0 
protein 0 
. 0 

An 0 
antibody 0 
against 0 
the 0 
synthetic 0 
C-terminal 0 
peptides 0 
deduced 0 
from 0 
the 0 
cDNA 0 
of 0 
the 0 
gene 0 
responsible 0 
for 0 
X-linked 1
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
was 0 
produced 0 
to 0 
characterize 0 
the 0 
product 0 
of 0 
the 0 
ALD 1
gene 0 
. 0 

The 0 
antibody 0 
reacted 0 
with 0 
the 0 
_NUM2 0 
kDa 0 
band 0 
protein 0 
in 0 
control 0 
fibroblasts 0 
, 0 
while 0 
no 0 
bands 0 
were 0 
detected 0 
in 0 
the 0 
fibroblasts 0 
from 0 
a 0 
patient 0 
with 0 
ALD 1
-LRB- 0 
# 0 
_NUM3 0 
-RRB- 0 
, 0 
in 0 
which 0 
mRNA 0 
of 0 
the 0 
ALD 1
gene 0 
was 0 
undetectable 0 
based 0 
on 0 
Northern 0 
blot 0 
analysis 0 
. 0 

The 0 
293T 0 
cells 0 
transfected 0 
with 0 
the 0 
full-coding 0 
cDNA 0 
inserted 0 
in 0 
the 0 
expression 0 
vector 0 
produced 0 
a 0 
new 0 
_NUM2 0 
kDa 0 
protein 0 
, 0 
as 0 
detected 0 
by 0 
Western 0 
blot 0 
. 0 

In 0 
an 0 
immunocytological 0 
study 0 
, 0 
the 0 
staining 0 
was 0 
in 0 
a 0 
punctate 0 
pattern 0 
, 0 
in 0 
the 0 
normal 0 
fibroblasts 0 
. 0 

However 0 
, 0 
there 0 
was 0 
no 0 
punctate 0 
staining 0 
in 0 
the 0 
# 0 
_NUM3 0 
cells 0 
. 0 

These 0 
data 0 
thus 0 
indicate 0 
that 0 
the 0 
ALD 1
gene 0 
encodes 0 
an 0 
_NUM2 0 
kDa 0 
membrane 0 
protein 0 
. 0 
. 0 

Preferential 0 
germline 0 
mutation 0 
of 0 
the 0 
paternal 0 
allele 0 
in 0 
retinoblastoma 1
. 0 

The 0 
event 0 
triggering 0 
malignant 0 
proliferation 0 
in 0 
_NUM2 0 
% 0 
of 0 
retinoblastoma 1
tumours 1
is 0 
loss 0 
of 0 
heterozygosity 0 
for 0 
chromosome 0 
13q14 0 
, 0 
whereby 0 
the 0 
normal 0 
retinoblastoma 1
gene 0 
-LRB- 0 
RB1 0 
-RRB- 0 
allele 0 
is 0 
lost 0 
and 0 
an 0 
already 0 
mutated 0 
RB1 0 
allele 0 
remains 0 
in 0 
the 0 
tumour 1
. 0 

The 0 
first 0 
allele 0 
suffers 0 
a 0 
mutational 0 
event 0 
-- 0 
deletion 0 
, 0 
duplication 0 
or 0 
point 0 
mutation 0 
-LRB- 0 
manuscript 0 
in 0 
preparation 0 
-RRB- 0 
-- 0 
either 0 
in 0 
the 0 
germ 0 
line 0 
-LRB- 0 
all 0 
bilateral 0 
patients 0 
-RRB- 0 
or 0 
in 0 
a 0 
somatic 0 
retinal 0 
cell 0 
-LRB- 0 
most 0 
unilateral 0 
patients 0 
-RRB- 0 
. 0 

Most 0 
bilateral 0 
patients 0 
have 0 
no 0 
family 0 
history 0 
of 0 
retinoblastoma 1
and 0 
are 0 
presumed 0 
to 0 
have 0 
new 0 
germline 0 
mutations 0 
which 0 
arose 0 
in 0 
the 0 
egg 0 
, 0 
sperm 0 
or 0 
early 0 
embryo 0 
. 0 

We 0 
have 0 
determined 0 
the 0 
parental 0 
origin 0 
of 0 
the 0 
retained 0 
allele 0 
in 0 
nine 0 
retinoblastoma 1
tumours 1
from 0 
eight 0 
unrelated 0 
non-familial 0 
cases 0 
by 0 
using 0 
RB1-linked 0 
genetic 0 
markers 0 
. 0 

Six 0 
tumours 1
retained 0 
the 0 
paternal 0 
allele 0 
and 0 
three 0 
retained 0 
the 0 
maternal 0 
allele 0 
. 0 

Of 0 
the 0 
three 0 
unilateral 1
tumours 1
, 0 
only 0 
one 0 
retained 0 
the 0 
paternal 0 
RB1 0 
allele 0 
. 0 

Thus 0 
, 0 
there 0 
is 0 
no 0 
evidence 0 
that 0 
the 0 
paternal 0 
RB1 0 
allele 0 
is 0 
preferentially 0 
retained 0 
in 0 
retinoblastoma 1
, 0 
as 0 
has 0 
been 0 
suggested 0 
to 0 
be 0 
the 0 
case 0 
in 0 
osteosarcoma 1
. 0 

By 0 
contrast 0 
, 0 
tumours 1
from 0 
four 0 
of 0 
the 0 
five 0 
bilateral 0 
patients 0 
retained 0 
the 0 
paternal 0 
RB1 0 
allele 0 
. 0 

This 0 
suggests 0 
either 0 
that 0 
new 0 
germline 0 
RB1 0 
mutations 0 
arise 0 
more 0 
frequently 0 
during 0 
spermatogenesis 0 
than 0 
during 0 
oogenesis 0 
, 0 
or 0 
that 0 
imprinting 0 
in 0 
the 0 
early 0 
embryo 0 
affects 0 
chromosomal 0 
susceptibility 0 
to 0 
mutation 0 
. 0 
. 0 

Mutations 0 
at 0 
the 0 
ataxia-telangiectasia 1
locus 0 
and 0 
clinical 0 
phenotypes 0 
of 0 
A-T 1
patients 0 
. 0 

Mutations 0 
at 0 
the 0 
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
locus 0 
on 0 
chromosome 0 
band 0 
11q22 0 
cause 0 
a 0 
distinctive 0 
autosomal 1
recessive 1
syndrome 1
in 0 
homozygotes 0 
and 0 
predispose 0 
heterozygotes 0 
to 0 
cancer 1
, 0 
ischemic 1
heart 1
disease 1
, 0 
and 0 
early 0 
mortality 0 
. 0 

PCR 0 
amplification 0 
from 0 
genomic 0 
DNA 0 
and 0 
automated 0 
sequencing 0 
of 0 
the 0 
entire 0 
coding 0 
region 0 
-LRB- 0 
_NUM2 0 
exons 0 
-RRB- 0 
and 0 
splice 0 
junctions 0 
detected 0 
_NUM2 0 
mutations 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
in 0 
_NUM2 0 
A-T 1
chromosomes 0 
. 0 

Heteroduplex 0 
analysis 0 
detected 0 
another 0 
_NUM2 0 
mutations 0 
at 0 
the 0 
A-T 1
locus 0 
. 0 

Out 0 
of 0 
a 0 
total 0 
of 0 
_NUM2 0 
unique 0 
mutations 0 
, 0 
_NUM2 0 
were 0 
found 0 
only 0 
in 0 
a 0 
single 0 
family 0 
, 0 
and 0 
_NUM2 0 
had 0 
not 0 
been 0 
reported 0 
previously 0 
. 0 

Most 0 
-LRB- 0 
58 0 
/ 0 
71 0 
, 0 
_NUM2 0 
% 0 
-RRB- 0 
mutations 0 
were 0 
frameshift 0 
and 0 
nonsense 0 
mutations 0 
that 0 
are 0 
predicted 0 
to 0 
cause 0 
truncation 0 
of 0 
the 0 
A-T 1
protein 0 
; 0 
the 0 
less 0 
common 0 
mutation 0 
types 0 
were 0 
missense 0 
-LRB- 0 
9 0 
/ 0 
71 0 
, 0 
_NUM2 0 
% 0 
-RRB- 0 
, 0 
splicing 0 
-LRB- 0 
3 0 
/ 0 
71 0 
, 0 
_NUM1 0 
% 0 
-RRB- 0 
and 0 
one 0 
in-frame 0 
deletion 0 
, 0 
_NUM4 0 
_NUM1 0 
-LRB- 0 
1 0 
/ 0 
71 0 
, 0 
_NUM1 0 
% 0 
-RRB- 0 
. 0 

The 0 
mean 0 
survival 0 
and 0 
height 0 
distribution 0 
of 0 
_NUM3 0 
A-T 1
patients 0 
correlated 0 
significantly 0 
with 0 
the 0 
specific 0 
mutations 0 
present 0 
in 0 
the 0 
patients 0 
. 0 

Patients 0 
homozygous 0 
for 0 
a 0 
single 0 
truncating 0 
mutation 0 
, 0 
typically 0 
near 0 
the 0 
N-terminal 0 
end 0 
of 0 
the 0 
gene 0 
, 0 
or 0 
heterozygous 0 
for 0 
the 0 
in-frame 0 
deletion 0 
_NUM4 0 
_NUM1 0 
, 0 
were 0 
shorter 0 
and 0 
had 0 
significantly 0 
shorter 0 
survival 0 
than 0 
those 0 
heterozygous 0 
for 0 
a 0 
splice 0 
site 0 
or 0 
missense 0 
mutation 0 
, 0 
or 0 
heterozygous 0 
for 0 
two 0 
truncating 0 
mutations 0 
. 0 

Alterations 0 
of 0 
the 0 
length 0 
or 0 
amino 0 
acid 0 
composition 0 
of 0 
the 0 
A-T 1
gene 0 
product 0 
affect 0 
the 0 
A-T 1
clinical 0 
phenotype 0 
in 0 
different 0 
ways 0 
. 0 

Mutation 0 
analysis 0 
at 0 
the 0 
A-T 1
locus 0 
may 0 
help 0 
estimate 0 
the 0 
prognosis 0 
of 0 
A-T 1
patients 0 
. 0 
. 0 

Anticipation 0 
resulting 0 
in 0 
elimination 0 
of 0 
the 0 
myotonic 1
dystrophy 1
gene 0 
: 0 
a 0 
follow 0 
up 0 
study 0 
of 0 
one 0 
extended 0 
family 0 
. 0 

We 0 
have 0 
re-examined 0 
an 0 
extended 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
family 0 
, 0 
previously 0 
described 0 
in 0 
_NUM4 0 
, 0 
in 0 
order 0 
to 0 
study 0 
the 0 
long 0 
term 0 
effects 0 
of 0 
anticipation 0 
in 0 
DM 1
and 0 
in 0 
particular 0 
the 0 
implications 0 
for 0 
families 0 
affected 0 
by 0 
this 0 
disease 0 
. 0 

This 0 
follow 0 
up 0 
study 0 
provides 0 
data 0 
on 0 
_NUM2 0 
gene 0 
carriers 0 
and 0 
_NUM2 0 
asymptomatic 0 
at 0 
risk 0 
family 0 
members 0 
in 0 
five 0 
generations 0 
. 0 

Clinical 0 
anticipation 0 
, 0 
defined 0 
as 0 
the 0 
cascade 0 
of 0 
mild 0 
, 0 
adult 0 
, 0 
childhood 0 
, 0 
or 0 
congenital 1
disease 1
in 0 
subsequent 0 
generations 0 
, 0 
appeared 0 
to 0 
be 0 
a 0 
relentless 0 
process 0 
, 0 
occurring 0 
in 0 
all 0 
affected 0 
branches 0 
of 0 
the 0 
family 0 
. 0 

The 0 
cascade 0 
was 0 
found 0 
to 0 
proceed 0 
asynchronously 0 
in 0 
the 0 
different 0 
branches 0 
, 0 
mainly 0 
because 0 
of 0 
an 0 
unequal 0 
number 0 
of 0 
generations 0 
with 0 
mild 0 
disease 0 
. 0 

The 0 
transition 0 
from 0 
the 0 
mild 0 
to 0 
the 0 
adult 0 
type 0 
was 0 
associated 0 
with 0 
transmission 0 
through 0 
a 0 
male 0 
parent 0 
. 0 

Stable 0 
transmission 0 
of 0 
the 0 
asymptomatic 0 
/ 0 
mild 0 
phenotype 0 
showed 0 
a 0 
female 0 
transmission 0 
bias 0 
. 0 

We 0 
further 0 
examined 0 
the 0 
extent 0 
and 0 
causes 0 
of 0 
gene 0 
loss 0 
in 0 
this 0 
pedigree 0 
. 0 

Gene 0 
loss 0 
in 0 
the 0 
patient 0 
group 0 
was 0 
complete 0 
, 0 
owing 0 
to 0 
infertility 1
of 0 
the 0 
male 0 
patients 0 
with 0 
adult 0 
onset 0 
disease 0 
and 0 
the 0 
fact 0 
that 0 
mentally 1
retarded 1
patients 0 
did 0 
not 0 
procreate 0 
. 0 

Out 0 
of 0 
the 0 
_NUM2 0 
at 0 
risk 0 
subjects 0 
in 0 
the 0 
two 0 
youngest 0 
generations 0 
, 0 
only 0 
one 0 
was 0 
found 0 
to 0 
have 0 
a 0 
full 0 
mutation 0 
. 0 

This 0 
is 0 
the 0 
only 0 
subject 0 
who 0 
may 0 
transmit 0 
the 0 
gene 0 
to 0 
the 0 
sixth 0 
generation 0 
. 0 

No 0 
protomutation 0 
carriers 0 
were 0 
found 0 
in 0 
the 0 
fourth 0 
and 0 
fifth 0 
generations 0 
. 0 

Therefore 0 
it 0 
is 0 
highly 0 
probable 0 
that 0 
the 0 
DM 1
gene 0 
will 0 
be 0 
eliminated 0 
from 0 
this 0 
pedigree 0 
within 0 
one 0 
generation 0 
. 0 

The 0 
high 0 
population 0 
frequency 0 
of 0 
DM 1
can 0 
at 0 
present 0 
not 0 
be 0 
explained 0 
by 0 
the 0 
contribution 0 
of 0 
asymptomatic 0 
cases 0 
in 0 
the 0 
younger 0 
generations 0 
of 0 
known 0 
families 0 
, 0 
but 0 
is 0 
probably 0 
caused 0 
by 0 
the 0 
events 0 
in 0 
the 0 
ancestral 0 
generations 0 
. 0 
. 0 

Exon 0 
_NUM1 0 
mutations 0 
in 0 
the 0 
WT1 0 
gene 0 
, 0 
without 0 
influencing 0 
KTS 0 
splice 0 
isoforms 0 
, 0 
are 0 
also 0 
responsible 0 
for 0 
Frasier 1
syndrome 1
. 0 

We 0 
report 0 
new 0 
mutations 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
WT1 0 
gene 0 
that 0 
did 0 
not 0 
alter 0 
the 0 
ratio 0 
of 0 
+ 0 
/ 0 
- 0 
KTS 0 
splice 0 
isoforms 0 
in 0 
two 0 
unrelated 0 
patients 0 
with 0 
Frasier 1
syndrome 1
-LRB- 0 
FS 1
-RRB- 0 
. 0 

The 0 
mutation 0 
of 0 
intron 0 
_NUM1 0 
inducing 0 
defective 0 
alternative 0 
splicing 0 
was 0 
reported 0 
to 0 
be 0 
responsible 0 
for 0 
this 0 
syndrome 0 
. 0 

The 0 
mutations 0 
found 0 
in 0 
our 0 
cases 0 
occurred 0 
in 0 
the 0 
same 0 
exon 0 
of 0 
the 0 
WT1 0 
gene 0 
as 0 
detected 0 
in 0 
Denys-Drash 1
syndrome 1
-LRB- 0 
DDS 1
-RRB- 0 
and 0 
could 0 
not 0 
be 0 
explained 0 
by 0 
the 0 
previously 0 
proposed 0 
mechanism 0 
. 0 

The 0 
results 0 
suggest 0 
that 0 
the 0 
two 0 
syndromes 0 
originate 0 
from 0 
the 0 
same 0 
WT1 1
gene 1
abnormality 1
. 0 

From 0 
a 0 
molecular 0 
biological 0 
point 0 
of 0 
view 0 
, 0 
we 0 
concluded 0 
that 0 
the 0 
two 0 
diseases 0 
were 0 
not 0 
separable 0 
, 0 
and 0 
that 0 
FS 1
should 0 
be 0 
included 0 
as 0 
an 0 
atypical 0 
form 0 
of 0 
DDS 1
. 0 
. 0 

Deficit 0 
of 0 
in 0 
vivo 0 
mitochondrial 0 
ATP 0 
production 0 
in 0 
patients 0 
with 0 
Friedreich 1
ataxia 1
. 0 

Friedreich 1
ataxia 1
-LRB- 0 
FRDA 1
-RRB- 0 
, 0 
the 0 
most 0 
common 0 
of 0 
the 0 
inherited 1
ataxias 1
, 0 
is 0 
an 0 
autosomal 1
recessive 1
degenerative 1
disorder 1
, 0 
characterized 0 
clinically 0 
by 0 
onset 0 
before 0 
the 0 
age 0 
of 0 
_NUM2 0 
of 0 
progressive 1
gait 1
and 1
limb 1
ataxia 1
, 0 
absence 1
of 1
deep 1
tendon 1
reflexes 1
, 0 
extensor 1
plantar 1
responses 1
, 0 
and 0 
loss 1
of 1
position 1
and 1
vibration 1
sense 1
in 0 
the 0 
lower 0 
limbs 0 
. 0 

FRDA 1
is 0 
caused 0 
by 0 
a 0 
_DS 0 
triplet 0 
expansion 0 
in 0 
the 0 
first 0 
intron 0 
of 0 
the 0 
FRDA 1
gene 0 
on 0 
chromosome 0 
9q13 0 
in 0 
_NUM2 0 
% 0 
of 0 
patients 0 
. 0 

The 0 
FRDA 1
gene 0 
encodes 0 
a 0 
widely 0 
expressed 0 
210-aa 0 
protein 0 
, 0 
frataxin 0 
, 0 
which 0 
is 0 
located 0 
in 0 
mitochondria 0 
and 0 
is 0 
severely 0 
reduced 0 
in 0 
FRDA 1
patients 0 
. 0 

Frataxin 0 
function 0 
is 0 
still 0 
unknown 0 
but 0 
the 0 
knockout 0 
of 0 
the 0 
yeast 0 
frataxin 0 
homologue 0 
gene 0 
-LRB- 0 
YFH1 0 
-RRB- 0 
showed 0 
a 0 
severe 0 
defect 0 
of 0 
mitochondrial 0 
respiration 0 
and 0 
loss 0 
of 0 
mtDNA 0 
associated 0 
with 0 
elevated 0 
intramitochondrial 0 
iron 0 
. 0 

Here 0 
we 0 
report 0 
in 0 
vivo 0 
evidence 0 
of 0 
impaired 0 
mitochondrial 0 
respiration 0 
in 0 
skeletal 0 
muscle 0 
of 0 
FRDA 1
patients 0 
. 0 

Using 0 
phosphorus 0 
magnetic 0 
resonance 0 
spectroscopy 0 
we 0 
demonstrated 0 
a 0 
maximum 0 
rate 0 
of 0 
muscle 0 
mitochondrial 0 
ATP 0 
production 0 
-LRB- 0 
V 0 
-LRB- 0 
max 0 
-RRB- 0 
-RRB- 0 
below 0 
the 0 
normal 0 
range 0 
in 0 
all 0 
_NUM2 0 
FRDA 1
patients 0 
and 0 
a 0 
strong 0 
negative 0 
correlation 0 
between 0 
mitochondrial 0 
V 0 
-LRB- 0 
max 0 
-RRB- 0 
and 0 
the 0 
number 0 
of 0 
_DS 0 
repeats 0 
in 0 
the 0 
smaller 0 
allele 0 
. 0 

Our 0 
results 0 
show 0 
that 0 
FRDA 1
is 0 
a 0 
nuclear-encoded 0 
mitochondrial 1
disorder 1
affecting 0 
oxidative 0 
phosphorylation 0 
and 0 
give 0 
a 0 
rationale 0 
for 0 
treatments 0 
aimed 0 
to 0 
improve 0 
mitochondrial 0 
function 0 
in 0 
this 0 
condition 0 
. 0 
. 0 

Chronic 1
nonspherocytic 1
hemolytic 1
anemia 1
-LRB- 0 
CNSHA 1
-RRB- 0 
and 0 
glucose 1
_NUM1 1
phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
a 0 
patient 0 
with 0 
familial 1
amyloidotic 1
polyneuropathy 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

Molecular 0 
study 0 
of 0 
a 0 
new 0 
variant 0 
-LRB- 0 
G6PD 0 
Clinic 0 
-RRB- 0 
with 0 
markedly 0 
acidic 0 
pH 0 
optimum 0 
. 0 

A 0 
new 0 
glucose-6-phosphate 0 
dehydrogenase 0 
-LRB- 0 
G6PD 0 
-RRB- 0 
variant 0 
with 0 
severe 0 
erythrocytic 1
G6PD 1
deficiency 1
and 0 
a 0 
unique 0 
pH 0 
optimum 0 
is 0 
described 0 
in 0 
a 0 
young 0 
patient 0 
with 0 
chronic 1
nonspherocytic 1
hemolytic 1
anemia 1
-LRB- 0 
CNSHA 1
-RRB- 0 
and 0 
familial 1
amyloidotic 1
polyneuropathy 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

Chronic 1
hemolysis 1
was 0 
present 0 
in 0 
the 0 
absence 0 
of 0 
infections 0 
, 0 
oxidant 0 
drugs 0 
or 0 
ingestion 0 
of 0 
faba 0 
beans 0 
. 0 

Residual 0 
enzyme 0 
activity 0 
was 0 
about 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
and 0 
_NUM2 0 
% 0 
of 0 
normal 0 
activity 0 
in 0 
erythrocytes 0 
and 0 
leucocytes 0 
, 0 
respectively 0 
. 0 

A 0 
molecular 0 
study 0 
using 0 
standard 0 
methods 0 
showed 0 
G6PD 0 
in 0 
the 0 
patient 0 
to 0 
have 0 
normal 0 
electrophoretic 0 
mobility 0 
-LRB- 0 
at 0 
pH 0 
_NUM1 0 
. 0 

_NUM1 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
normal 0 
apparent 0 
affinity 0 
for 0 
substrates 0 
-LRB- 0 
Km 0 
, 0 
G6P 0 
and 0 
NADP 0 
-RRB- 0 
and 0 
a 0 
slightly 0 
abnormal 0 
utilization 0 
of 0 
substrate 0 
analogues 0 
-LRB- 0 
decreased 0 
deamino-NADP 0 
and 0 
increased 0 
2-deoxyglucose-6-phosphate 0 
utilization 0 
-RRB- 0 
. 0 

Heat 0 
stability 0 
was 0 
found 0 
to 0 
be 0 
markedly 0 
decreased 0 
-LRB- 0 
_NUM1 0 
% 0 
of 0 
residual 0 
activity 0 
after 0 
_NUM2 0 
min 0 
of 0 
incubation 0 
at 0 
_NUM2 0 
degrees 0 
C 0 
-RRB- 0 
and 0 
a 0 
particular 0 
characteristic 0 
of 0 
this 0 
enzyme 0 
was 0 
a 0 
biphasic 0 
pH 0 
curve 0 
with 0 
a 0 
greatly 0 
increased 0 
activity 0 
at 0 
low 0 
pH. 0 
Although 0 
molecular 0 
characteristics 0 
of 0 
this 0 
variant 0 
closely 0 
resemble 0 
those 0 
of 0 
G6PD 0 
Bangkok 0 
and 0 
G6PD 0 
Duarte 0 
, 0 
it 0 
can 0 
be 0 
distinguished 0 
from 0 
these 0 
and 0 
all 0 
other 0 
previously 0 
reported 0 
variants 0 
by 0 
virtue 0 
of 0 
its 0 
unusual 0 
pH 0 
curve 0 
. 0 

Therefore 0 
the 0 
present 0 
variant 0 
has 0 
been 0 
designated 0 
G6PD 0 
Clinic 0 
to 0 
distinguish 0 
it 0 
from 0 
other 0 
G6PD 0 
variants 0 
previously 0 
described 0 
Regional 0 
localization 0 
of 0 
polymorphic 0 
DNA 0 
loci 0 
on 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
using 0 
deletions 0 
associated 0 
with 0 
choroideremia 1
. 0 

In 0 
two 0 
unrelated 0 
families 0 
, 0 
males 0 
have 0 
been 0 
identified 0 
who 0 
suffer 0 
from 0 
choroideremia 1
and 0 
at 0 
the 0 
same 0 
time 0 
have 0 
an 0 
interstitial 0 
deletion 0 
on 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
the 0 
X 0 
chromosome 0 
. 0 

By 0 
high-resolution 0 
banding 0 
we 0 
have 0 
characterized 0 
the 0 
deletion 0 
chromosomes 0 
as 0 
del 0 
-LRB- 0 
X 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

1-q21 0 
1-q21 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
del 0 
-LRB- 0 
X 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

2-q21 0 
2-q21 0 
. 0 

_NUM2 0 
-RRB- 0 
respectively 0 
. 0 

By 0 
Southern 0 
blot 0 
analysis 0 
we 0 
have 0 
mapped 0 
ten 0 
different 0 
polymorphic 0 
DNA 0 
loci 0 
relative 0 
to 0 
the 0 
position 0 
of 0 
the 0 
deletion 0 
and 0 
the 0 
choroideremia 1
locus 0 
TCD 0 
. 0 

One 0 
probe 0 
, 0 
_AN 0 
, 0 
was 0 
shown 0 
to 0 
cover 0 
one 0 
of 0 
the 0 
breakpoints 0 
of 0 
the 0 
smallest 0 
deletion 0 
. 0 

The 0 
following 0 
order 0 
of 0 
the 0 
loci 0 
was 0 
suggested 0 
by 0 
deletion 0 
mapping 0 
cen-DXS106-DXS72-TCD 0 
- 0 
-LRB- 0 
DXYS1 0 
/ 0 
DXYS23 0 
/ 0 
DXYS5 0 
-RRB- 0 
- 0 
DXYS2 0 
- 0 
-LRB- 0 
DXYS12 0 
/ 0 
DXS3 0 
-RRB- 0 
- 0 
-LRB- 0 
DXS17 0 
/ 0 
DXS101 0 
-RRB- 0 
- 0 
Xqter 0 
. 0 

A 0 
de 0 
novo 0 
unbalanced 0 
reciprocal 0 
translocation 0 
identified 0 
as 0 
paternal 0 
in 0 
origin 0 
in 0 
the 0 
Prader-Willi 1
syndrome 1
. 0 

Interstitial 0 
cytogenetic 0 
deletions 0 
involving 0 
the 0 
paternally 0 
derived 0 
chromosome 0 
15q11-13 0 
have 0 
been 0 
described 0 
in 0 
patients 0 
with 0 
the 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

We 0 
report 0 
a 0 
child 0 
with 0 
PWS 1
and 0 
a 0 
de 0 
novo 0 
unbalanced 0 
karyotype 0 
-45 0 
, 0 
XY 0 
, 0 
-9 0 
, 0 
-15 0 
, 0 
+ 0 
der 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
-RRB- 0 
. 0 

Molecular 0 
studies 0 
with 0 
the 0 
DNA 0 
probe 0 
pML34 0 
confirmed 0 
that 0 
only 0 
a 0 
single 0 
Prader 1
Willi 1
critical 0 
region 0 
-LRB- 0 
PWCR 0 
15q11 0 
. 0 

2-q12 0 
-RRB- 0 
copy 0 
was 0 
present 0 
. 0 

Hybridisation 0 
of 0 
patient 0 
and 0 
parental 0 
DNA 0 
with 0 
the 0 
multi-allelic 0 
probe 0 
CMW1 0 
, 0 
which 0 
maps 0 
to 0 
pter-15q13 0 
, 0 
showed 0 
that 0 
the 0 
chromosome 0 
involved 0 
in 0 
the 0 
translocation 0 
was 0 
paternal 0 
in 0 
origin 0 
. 0 

This 0 
is 0 
the 0 
first 0 
example 0 
of 0 
a 0 
paternally-derived 0 
PWCR 0 
allele 0 
loss 0 
caused 0 
by 0 
an 0 
unbalanced 0 
translocation 0 
that 0 
has 0 
arisen 0 
de 0 
novo 0 
. 0 

Clinicopathologic 0 
features 0 
of 0 
BRCA-linked 1
and 1
sporadic 1
ovarian 1
cancer 1
. 0 

CONTEXT 0 
Most 0 
hereditary 1
ovarian 1
cancers 1
are 0 
associated 0 
with 0 
germline 0 
mutations 0 
in 0 
BRCA1 0 
or 0 
BRCA2 0 
. 0 

Attempts 0 
to 0 
define 0 
the 0 
clinical 0 
significance 0 
of 0 
BRCA 0 
mutation 0 
status 0 
in 0 
ovarian 1
cancer 1
have 0 
produced 0 
conflicting 0 
results 0 
, 0 
especially 0 
regarding 0 
survival 0 
. 0 

OBJECTIVE 0 
To 0 
determine 0 
whether 0 
hereditary 1
ovarian 1
cancers 1
have 0 
distinct 0 
clinical 0 
and 0 
pathological 0 
features 0 
compared 0 
with 0 
sporadic 1
-LRB- 1
nonhereditary 1
-RRB- 1
ovarian 1
cancers 1
. 0 

DESIGN 0 
AND 0 
SETTING 0 
Retrospective 0 
cohort 0 
study 0 
of 0 
a 0 
consecutive 0 
series 0 
of 0 
_NUM3 0 
ovarian 1
cancers 1
diagnosed 0 
and 0 
treated 0 
at 0 
our 0 
institution 0 
, 0 
which 0 
is 0 
a 0 
comprehensive 0 
cancer 1
center 0 
as 0 
designated 0 
by 0 
the 0 
National 0 
Cancer 1
Institute 0 
, 0 
over 0 
a 0 
12-year 0 
period 0 
-LRB- 0 
December 0 
_NUM4 0 
to 0 
August 0 
_NUM4 0 
-RRB- 0 
. 0 

PATIENTS 0 
The 0 
study 0 
was 0 
restricted 0 
to 0 
patients 0 
of 0 
Jewish 0 
origin 0 
because 0 
of 0 
the 0 
ease 0 
of 0 
BRCA1 0 
and 0 
BRCA2 0 
genotyping 0 
in 0 
this 0 
ethnic 0 
group 0 
. 0 

From 0 
the 0 
_NUM3 0 
patients 0 
who 0 
identified 0 
themselves 0 
as 0 
Jewish 0 
, 0 
_NUM2 0 
hereditary 0 
cases 0 
were 0 
identified 0 
with 0 
the 0 
presence 0 
of 0 
a 0 
germline 0 
founder 0 
mutation 0 
in 0 
BRCA1 0 
or 0 
BRCA2 0 
. 0 

The 0 
remaining 0 
_NUM3 0 
cases 0 
from 0 
the 0 
same 0 
series 0 
not 0 
associated 0 
with 0 
a 0 
BRCA 0 
mutation 0 
and 0 
_NUM1 0 
additional 0 
groups 0 
-LRB- 0 
Gynecologic 0 
Oncology 0 
Group 0 
protocols 0 
_NUM2 0 
and 0 
_NUM3 0 
-RRB- 0 
with 0 
ovarian 1
cancer 1
from 0 
clinical 0 
trials 0 
-LRB- 0 
for 0 
the 0 
survival 0 
analysis 0 
-RRB- 0 
were 0 
included 0 
for 0 
comparison 0 
. 0 

MAIN 0 
OUTCOME 0 
MEASURES 0 
Age 0 
at 0 
diagnosis 0 
, 0 
surgical 0 
stage 0 
, 0 
histologic 0 
cell 0 
type 0 
and 0 
grade 0 
, 0 
and 0 
surgical 0 
outcome 0 
; 0 
and 0 
response 0 
to 0 
chemotherapy 0 
and 0 
survival 0 
for 0 
advanced-stage 0 
-LRB- 0 
II 0 
and 0 
IV 0 
-RRB- 0 
cases 0 
. 0 

RESULTS 0 
Hereditary 1
cancers 1
were 0 
rarely 0 
diagnosed 0 
before 0 
age 0 
_NUM2 0 
years 0 
and 0 
were 0 
common 0 
after 0 
age 0 
_NUM2 0 
years 0 
, 0 
with 0 
mean 0 
age 0 
at 0 
diagnosis 0 
being 0 
significantly 0 
younger 0 
for 0 
BRCA1 0 
- 0 
vs 0 
BRCA2-linked 0 
patients 0 
-LRB- 0 
_NUM2 0 
vs 0 
_NUM2 0 
years 0 
; 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Histology 0 
, 0 
grade 0 
, 0 
stage 0 
, 0 
and 0 
success 0 
of 0 
cytoreductive 0 
surgery 0 
were 0 
similar 0 
for 0 
hereditary 0
and 0 
sporadic 0 
cases 0 
. 0 

The 0 
hereditary 0
group 0 
had 0 
a 0 
longer 0 
disease-free 0 
interval 0 
following 0 
primary 0 
chemotherapy 0 
in 0 
comparison 0 
with 0 
the 0 
nonhereditary 0 
group 0 
, 0 
with 0 
a 0 
median 0 
time 0 
to 0 
recurrence 0 
of 0 
_NUM2 0 
months 0 
and 0 
_NUM1 0 
months 0 
, 0 
respectively 0 
-LRB- 0 
P 0 
< 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

Those 0 
with 0 
hereditary 1
cancers 1
had 0 
improved 0 
survival 0 
compared 0 
with 0 
the 0 
nonhereditary 0 
group 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

For 0 
stage 1
III 1
cancers 1
, 0 
BRCA 0 
mutation 0 
status 0 
was 0 
an 0 
independent 0 
prognostic 0 
variable 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

CONCLUSIONS 0 
Although 0 
BRCA-associated 1
hereditary 1
ovarian 1
cancers 1
in 0 
this 0 
population 0 
have 0 
surgical 0 
and 0 
pathological 0 
characteristics 0 
similar 0 
to 0 
those 0 
of 0 
sporadic 1
cancers 1
, 0 
advanced-stage 1
hereditary 1
cancer 1
patients 0 
survive 0 
longer 0 
than 0 
nonhereditary 1
cancer 1
patients 0 
. 0 

Age 0 
penetrance 0 
is 0 
greater 0 
for 0 
BRCA1-linked 1
than 1
for 1
BRCA2-linked 1
cancers 1
in 0 
this 0 
population 0 
. 0 

Germline 0 
intronic 0 
and 0 
exonic 0 
mutations 0 
in 0 
the 0 
Wilms 1
' 1
tumour 1
gene 0 
-LRB- 0 
WT1 0 
-RRB- 0 
affecting 0 
urogenital 0 
development 0 
. 0 

Denys-Drash 1
syndrome 1
is 0 
a 0 
rare 0 
human 0 
developmental 1
disorder 1
affecting 0 
the 0 
urogenital 0 
system 0 
and 0 
leading 0 
to 0 
renal 1
failure 1
, 0 
intersex 1
disorders 1
and 0 
Wilms 1
tumour 1
. 0 

In 0 
this 0 
report 0 
, 0 
four 0 
individuals 0 
with 0 
this 0 
syndrome 0 
are 0 
described 0 
carrying 0 
germline 0 
point 0 
mutations 0 
in 0 
the 0 
Wilms 1
tumour 1
suppressor 0 
gene 0 
, 0 
WT1 0 
. 0 

Three 0 
of 0 
these 0 
mutations 0 
were 0 
in 0 
the 0 
zinc 0 
finger 0 
domains 0 
of 0 
WT1 0 
. 0 

The 0 
fourth 0 
occurred 0 
within 0 
intron 0 
_NUM1 0 
, 0 
preventing 0 
splicing 0 
at 0 
one 0 
of 0 
the 0 
alternatively 0 
chosen 0 
splice 0 
donor 0 
sites 0 
of 0 
exon 0 
_NUM1 0 
when 0 
assayed 0 
in 0 
vitro 0 
. 0 

These 0 
results 0 
provide 0 
genetic 0 
evidence 0 
for 0 
distinct 0 
functional 0 
roles 0 
of 0 
the 0 
WT1 0 
isoforms 0 
in 0 
urogenital 0 
development 0 
. 0 
. 0 

Analysis 0 
of 0 
deletions 0 
in 0 
DNA 0 
from 0 
patients 0 
with 0 
Becker 1
and 1
Duchenne 1
muscular 1
dystrophy 1
. 0 

Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
is 0 
an 0 
X-linked 1
recessive 1
genetic 1
disorder 1
for 0 
which 0 
the 0 
biochemical 0 
defect 0 
is 0 
as 0 
yet 0 
unknown 0 
. 0 

Recently 0 
, 0 
two 0 
cloned 0 
segments 0 
of 0 
human 0 
X-chromosome 0 
DNA 0 
have 0 
been 0 
described 0 
which 0 
detect 0 
structural 0 
alterations 0 
within 0 
or 0 
near 0 
the 0 
genetic 0 
locus 0 
responsible 0 
for 0 
the 0 
disorder 0 
. 0 

Both 0 
of 0 
these 0 
cloned 0 
segments 0 
were 0 
described 0 
as 0 
tightly 0 
linked 0 
to 0 
the 0 
locus 0 
and 0 
were 0 
capable 0 
of 0 
detecting 0 
deletions 0 
in 0 
the 0 
DNA 0 
of 0 
boys 0 
affected 0 
with 0 
DMD 1
. 0 

In 0 
an 0 
attempt 0 
to 0 
determine 0 
more 0 
precisely 0 
the 0 
occurrence 0 
of 0 
these 0 
deletions 0 
within 0 
a 0 
large 0 
population 0 
of 0 
DMD 1
patients 0 
and 0 
the 0 
accuracy 0 
of 0 
one 0 
of 0 
the 0 
segments 0 
, 0 
DXS164 0 
-LRB- 0 
pERT87 0 
-RRB- 0 
, 0 
in 0 
determining 0 
the 0 
inheritance 0 
of 0 
the 0 
DMD 1
X 0 
chromosome 0 
, 0 
the 0 
subclones 0 
_NUM1 0 
, 0 
_NUM1 0 
and 0 
_NUM2 0 
were 0 
made 0 
available 0 
to 0 
many 0 
investigators 0 
throughout 0 
the 0 
world 0 
. 0 

Here 0 
we 0 
describe 0 
the 0 
combined 0 
results 0 
of 0 
more 0 
than 0 
_NUM2 0 
research 0 
laboratories 0 
with 0 
respect 0 
to 0 
the 0 
occurrence 0 
of 0 
deletions 0 
at 0 
the 0 
DXS164 0 
locus 0 
in 0 
DNA 0 
samples 0 
isolated 0 
from 0 
patients 0 
with 0 
DMD 1
and 0 
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
BMD 1
-RRB- 0 
. 0 

The 0 
results 0 
indicate 0 
that 0 
the 0 
DXS164 0 
locus 0 
apparently 0 
recombines 0 
with 0 
DMD 1
_NUM1 0 
% 0 
of 0 
the 0 
time 0 
, 0 
but 0 
is 0 
probably 0 
located 0 
between 0 
independent 0 
sites 0 
of 0 
mutation 0 
which 0 
yield 0 
DMD 1
. 0 

The 0 
breakpoints 0 
of 0 
some 0 
deletions 0 
are 0 
delineated 0 
within 0 
the 0 
DXS164 0 
locus 0 
, 0 
and 0 
it 0 
is 0 
evident 0 
that 0 
the 0 
deletions 0 
at 0 
the 0 
DMD 1
locus 0 
are 0 
frequent 0 
and 0 
extremely 0 
large 0 
. 0 
. 0 

Additional 0 
case 0 
of 0 
female 0 
monozygotic 0 
twins 0 
discordant 0 
for 0 
the 0 
clinical 0 
manifestations 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
due 0 
to 0 
opposite 0 
X-chromosome 0 
inactivation 0 
. 0 

A 0 
pair 0 
of 0 
female 0 
monozygotic 0 
-LRB- 0 
MZ 0 
-RRB- 0 
twins 0 
, 0 
heterozygous 0 
carriers 0 
for 0 
a 0 
deletion 0 
in 0 
the 0 
DMD 1
gene 0 
and 0 
discordant 0 
for 0 
the 0 
clinical 0 
manifestations 0 
of 0 
Duchenne 1
muscular 1
dystrophy 1
, 0 
were 0 
analyzed 0 
by 0 
molecular 0 
studies 0 
, 0 
in 0 
situ 0 
hybridization 0 
, 0 
and 0 
methylation 0 
pattern 0 
of 0 
X 0 
chromosomes 0 
to 0 
search 0 
for 0 
opposite 0 
X 0 
inactivation 0 
as 0 
an 0 
explanation 0 
of 0 
their 0 
clinical 0 
discordance 0 
. 0 

Results 0 
in 0 
lymphocytes 0 
and 0 
skin 0 
fibroblast 0 
cell 0 
lines 0 
suggest 0 
a 0 
partial 0 
mirror 0 
inactivation 0 
with 0 
the 0 
normal 0 
X 0 
chromosome 0 
preferentially 0 
active 0 
in 0 
the 0 
unaffected 0 
twin 0 
, 0 
and 0 
the 0 
maternal 0 
deleted 0 
X 0 
chromosome 0 
preferentially 0 
active 0 
in 0 
the 0 
affected 0 
twin 0 
. 0 

A 0 
review 0 
shows 0 
that 0 
MZ 0 
female 0 
twins 0 
discordant 0 
for 0 
X-linked 1
diseases 1
are 0 
not 0 
uncommon 0 
. 0 

Twinning 0 
and 0 
X 0 
inactivation 0 
may 0 
be 0 
interrelated 0 
and 0 
could 0 
explain 0 
the 0 
female 0 
twins 0 
discordant 0 
for 0 
X-linked 0 
traits 0 
. 0 
. 0 

Analbuminemia 1
in 0 
a 0 
neonate 0 
. 0 

A 0 
small-for-gestational-age 0 
infant 0 
, 0 
found 0 
to 0 
have 0 
analbuminemia 1
in 0 
the 0 
neonatal 0 
period 0 
, 0 
is 0 
reported 0 
and 0 
the 0 
twelve 0 
cases 0 
recorded 0 
in 0 
the 0 
world 0 
literature 0 
are 0 
reviewed 0 
. 0 

Patients 0 
lacking 0 
this 0 
serum 0 
protein 0 
are 0 
essentially 0 
asymptomatic 0 
, 0 
apart 0 
from 0 
minimal 0 
ankle 1
edema 1
and 0 
ease 1
of 1
fatigue 1
. 0 

Apparent 0 
compensatory 0 
mechanisms 0 
which 0 
come 0 
into 0 
play 0 
when 0 
serum 0 
albumin 0 
is 0 
low 0 
include 0 
prolonged 0 
half-life 0 
of 0 
albumin 0 
and 0 
transferrin 0 
, 0 
an 0 
increase 0 
in 0 
serum 0 
globulins 0 
, 0 
beta 0 
lipoprotein 0 
, 0 
and 0 
glycoproteins 0 
, 0 
arterial 1
hypotension 1
with 0 
reduced 0 
capillary 0 
hydrostatic 0 
pressure 0 
, 0 
and 0 
the 0 
ability 0 
to 0 
respond 0 
with 0 
rapid 0 
sodium 0 
and 0 
chloride 0 
diuresis 0 
in 0 
response 0 
to 0 
small 0 
volume 0 
changes 0 
. 0 

Examination 0 
of 0 
plasma 0 
amino 0 
acids 0 
, 0 
an 0 
investigation 0 
not 0 
previously 0 
reported 0 
, 0 
revealed 0 
an 0 
extremely 0 
low 0 
plasma 0 
tryptophan 0 
level 0 
, 0 
a 0 
finding 0 
which 0 
may 0 
be 0 
important 0 
in 0 
view 0 
of 0 
the 0 
role 0 
of 0 
tryptophan 0 
in 0 
albumin 0 
synthesis 0 
. 0 
. 0 

Homozygous 0 
presence 0 
of 0 
the 0 
crossover 0 
-LRB- 0 
fusion 0 
gene 0 
-RRB- 0 
mutation 0 
identified 0 
in 0 
a 0 
type 1
II 1
Gaucher 1
disease 1
fetus 0 
: 0 
is 0 
this 0 
analogous 0 
to 0 
the 0 
Gaucher 0
knock-out 0 
mouse 0 
model 0 
? 0 

Gaucher 1
disease 1
-LRB- 0 
GD 1
-RRB- 0 
is 0 
an 0 
inherited 0 
deficiency 1
of 1
beta-glucocerebrosidase 1
-LRB- 0 
EC 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM1 0 
. 0 

_NUM2 0 
, 0 
gene 0 
symbol 0 
GBA 0 
-RRB- 0 
. 0 

In 0 
type 1
I 1
GD 1
, 0 
the 0 
CNS 0 
is 0 
not 0 
involved 0 
-LRB- 0 
nonneuronopathic 0 
-RRB- 0 
, 0 
whereas 0 
in 0 
type 1
II 1
GD 1
-LRB- 0 
acute 0 
neuronopathic 0 
-RRB- 0 
CNS 0 
involvement 0 
is 0 
early 0 
and 0 
rapidly 0 
progressive 0 
, 0 
while 0 
in 0 
type 1
III 1
GD 1
-LRB- 0 
subacute 0 
neuronopathic 0 
-RRB- 0 
CNS 0 
involvement 0 
occurs 0 
later 0 
and 0 
is 0 
slowly 0 
progressive 0 
. 0 

The 0 
T6433C 0 
-LRB- 0 
L444P 0 
-RRB- 0 
substitution 0 
is 0 
prevalent 0 
in 0 
type 1
GD 1
II 1
. 0 

It 0 
may 0 
occur 0 
alone 0 
as 0 
a 0 
single 0 
base-pair 0 
mutation 0 
but 0 
often 0 
is 0 
found 0 
as 0 
part 0 
of 0 
a 0 
complex 0 
allele 0 
containing 0 
additional 0 
GBA 0 
nucleotide 0 
substitutions 0 
, 0 
G6468C 0 
-LRB- 0 
A456P 0 
-RRB- 0 
and 0 
G6482C 0 
-LRB- 0 
V460V 0 
-RRB- 0 
, 0 
without 0 
-LRB- 0 
recNciI 0 
-RRB- 0 
or 0 
with 0 
-LRB- 0 
recTL 0 
-RRB- 0 
G5957C 0 
-LRB- 0 
D409H 0 
-RRB- 0 
. 0 

This 0 
complex 0 
allele 0 
is 0 
presumed 0 
to 0 
have 0 
formed 0 
by 0 
recombination 0 
-LRB- 0 
crossover 0 
, 0 
fusion 0 
-RRB- 0 
of 0 
the 0 
structural 0 
gene 0 
with 0 
the 0 
pseudogene 0 
, 0 
which 0 
contains 0 
the 0 
mutated 0 
sequences 0 
. 0 

Two 0 
complex 0 
alleles 0 
have 0 
never 0 
been 0 
demonstrated 0 
to 0 
coexist 0 
in 0 
any 0 
individual 0 
. 0 

We 0 
devised 0 
a 0 
selective 0 
PCR 0 
method 0 
for 0 
the 0 
specific 0 
amplification 0 
of 0 
the 0 
normal 0 
and 0 
/ 0 
or 0 
fusion 0 
gene 0 
. 0 

Using 0 
this 0 
procedure 0 
we 0 
demonstrated 0 
the 0 
fusion 0 
gene 0 
in 0 
homozygous 0 
form 0 
for 0 
the 0 
first 0 
time 0 
, 0 
in 0 
a 0 
Macedonian 0 
/ 0 
Ashkenazi 0 
Jewish 0 
GD 1
type 1
II 1
fetus 0 
. 0 

Both 0 
parents 0 
were 0 
carriers 0 
of 0 
the 0 
recombination 0 
. 0 

This 0 
was 0 
confirmed 0 
by 0 
direct 0 
sequence 0 
analysis 0 
. 0 

A 0 
previous 0 
conceptus 0 
in 0 
this 0 
family 0 
was 0 
stillborn 1
at 0 
_NUM2 0 
weeks 0 
, 0 
with 0 
features 0 
of 0 
severe 0 
type 1
II 1
GD 1
. 0 

Neonates 0 
showing 0 
a 0 
severe 0 
clinical 0 
phenotype 0 
, 0 
analogous 0 
to 0 
the 0 
early 0 
neonatal 0 
lethal 0 
disease 0 
occurring 0 
in 0 
mice 0 
homozygous 0 
for 0 
a 0 
null 0 
allele 0 
produced 0 
by 0 
targeted 0 
disruption 0 
of 0 
GBA 0 
, 0 
have 0 
been 0 
described 0 
elsewhere 0 
, 0 
but 0 
the 0 
specific 0 
mutations 0 
in 0 
these 0 
cases 0 
have 0 
not 0 
yet 0 
been 0 
characterized 0 
. 0 

-LRB- 0 
ABSTRACT 0 
TRUNCATED 0 
_DS 0 
_NUM3 0 
WORDS 0 
-RRB- 0 
Decrease 0 
in 0 
GTP 0 
cyclohydrolase 0 
I 0 
gene 0 
expression 0 
caused 0 
by 0 
inactivation 0 
of 0 
one 0 
allele 0 
in 0 
hereditary 1
progressive 1
dystonia 1
with 0 
marked 0 
diurnal 0 
fluctuation 0 
. 0 

Hereditary 1
progressive 1
dystonia 1
with 0 
marked 0 
diurnal 0 
fluctuation 0 
-LRB- 0 
HPD 1
; 0 
dopa-responsive 1
dystonia 1
, 0 
DRD 1
-RRB- 0 
have 0 
been 0 
recently 0 
found 0 
to 0 
be 0 
caused 0 
by 0 
a 0 
genetic 1
defect 1
in 0 
the 0 
GTP 0 
cyclohydrolase 0 
I 0 
-LRB- 0 
GCH1 0 
-RRB- 0 
gene 0 
. 0 

In 0 
this 0 
study 0 
, 0 
we 0 
quantified 0 
the 0 
mRNA 0 
level 0 
of 0 
GCH1 0 
in 0 
phytohemagglutinin 0 
-LRB- 0 
PHA 0 
-RRB- 0 
- 0 
stimulated 0 
mononuclear 0 
blood 0 
cells 0 
from 0 
one 0 
Japanese 0 
family 0 
that 0 
do 0 
not 0 
have 0 
a 0 
mutation 0 
in 0 
the 0 
coding 0 
region 0 
or 0 
splice 0 
junctions 0 
of 0 
the 0 
gene 0 
. 0 

The 0 
results 0 
showed 0 
that 0 
the 0 
amounts 0 
of 0 
the 0 
GCH1 0 
mRNA 0 
were 0 
decreased 0 
to 0 
about 0 
_NUM2 0 
% 0 
of 0 
the 0 
normal 0 
level 0 
in 0 
both 0 
patients 0 
and 0 
carriers 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
found 0 
that 0 
the 0 
GCH1 0 
mRNA 0 
was 0 
transcribed 0 
from 0 
only 0 
one 0 
allele 0 
, 0 
indicating 0 
that 0 
the 0 
other 0 
allele 0 
was 0 
in 0 
an 0 
inactive 0 
state 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
some 0 
novel 0 
mutations 0 
should 0 
exist 0 
on 0 
one 0 
of 0 
the 0 
alleles 0 
in 0 
some 0 
unknown 0 
region 0 
of 0 
the 0 
GCH1 0 
gene 0 
, 0 
and 0 
may 0 
decrease 0 
the 0 
GCH1 0 
mRNA 0 
causing 0 
the 0 
HPD 1
/ 0 
DRD 1
symptoms 0 
. 0 
. 0 

Novel 0 
mutations 0 
in 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
protein 0 
gene 0 
and 0 
their 0 
effects 0 
on 0 
transcriptional 0 
, 0 
translational 0 
, 0 
and 0 
clinical 0 
phenotypes 0 
. 0 

Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
is 0 
an 0 
X-linked 1
recessive 1
immunodeficiency 1
characterized 0 
by 0 
thrombocytopenia 1
, 0 
eczema 1
, 0 
and 0 
recurrent 0 
infections 0 
, 0 
and 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
WAS 1
protein 0 
-LRB- 0 
WASP 0 
-RRB- 0 
gene 0 
. 0 

WASP 0 
contains 0 
several 0 
functional 0 
domains 0 
through 0 
which 0 
it 0 
interacts 0 
with 0 
proteins 0 
involved 0 
in 0 
intracellular 0 
signaling 0 
and 0 
regulation 0 
of 0 
the 0 
actin 0 
cytoskeleton 0 
. 0 

In 0 
this 0 
report 0 
, 0 
_NUM2 0 
WASP 0 
gene 0 
mutations 0 
were 0 
identified 0 
, 0 
_NUM2 0 
of 0 
which 0 
are 0 
novel 0 
. 0 

DNA 0 
of 0 
affected 0 
males 0 
and 0 
obligate 0 
carriers 0 
was 0 
PCR 0 
amplified 0 
and 0 
analyzed 0 
by 0 
SSCA 0 
, 0 
heteroduplex 0 
analysis 0 
, 0 
and 0 
direct 0 
sequencing 0 
. 0 

The 0 
effects 0 
of 0 
the 0 
mutations 0 
at 0 
the 0 
mRNA 0 
and 0 
protein 0 
level 0 
were 0 
ascertained 0 
by 0 
RT-PCR 0 
and 0 
Western 0 
blot 0 
analyses 0 
. 0 

All 0 
missense 0 
mutations 0 
were 0 
located 0 
in 0 
exons 0 
1-4 0 
. 0 

Most 0 
of 0 
the 0 
nonsense 0 
, 0 
frameshift 0 
and 0 
splice 0 
site 0 
mutations 0 
were 0 
found 0 
in 0 
exons 0 
6-11 0 
. 0 

Mutations 0 
that 0 
alter 0 
splice 0 
sites 0 
led 0 
to 0 
the 0 
synthesis 0 
of 0 
several 0 
types 0 
of 0 
mRNAs 0 
, 0 
a 0 
fraction 0 
of 0 
which 0 
represented 0 
the 0 
normally 0 
spliced 0 
product 0 
. 0 

The 0 
presence 0 
of 0 
normally 0 
spliced 0 
transcripts 0 
was 0 
correlated 0 
with 0 
a 0 
milder 0 
phenotype 0 
. 0 

When 0 
one 0 
such 0 
case 0 
was 0 
studied 0 
by 0 
Western 0 
blotting 0 
, 0 
reduced 0 
amounts 0 
of 0 
normal-size 0 
WASP 0 
were 0 
present 0 
. 0 

In 0 
other 0 
cases 0 
as 0 
well 0 
, 0 
a 0 
correlation 0 
was 0 
found 0 
between 0 
the 0 
amount 0 
of 0 
normal 0 
or 0 
mutant 0 
WASP 0 
present 0 
and 0 
the 0 
phenotypes 0 
of 0 
the 0 
affected 0 
individuals 0 
. 0 

No 0 
protein 0 
was 0 
detected 0 
in 0 
two 0 
individuals 0 
with 0 
severe 0 
WAS 1
. 0 

Reduced 0 
levels 0 
of 0 
a 0 
normal-size 0 
WASP 0 
with 0 
a 0 
missense 0 
mutation 0 
were 0 
seen 0 
in 0 
two 0 
individuals 0 
with 0 
XLT 1
. 0 

It 0 
is 0 
concluded 0 
that 0 
mutation 0 
analysis 0 
at 0 
the 0 
DNA 0 
level 0 
is 0 
not 0 
sufficient 0 
for 0 
predicting 0 
clinical 0 
course 0 
. 0 

Studies 0 
at 0 
the 0 
transcript 0 
and 0 
protein 0 
level 0 
are 0 
needed 0 
for 0 
a 0 
better 0 
assessment 0 
. 0 
. 0 

Incidence 0 
and 0 
characteristics 0 
of 0 
glucose-6-phosphate 0
dehydrogenase 0 
variants 0 
in 0 
Japan 0 
. 0 

A 0 
total 0 
of 0 
_NUM4 0 
men 0 
living 0 
in 0 
Yamaguchi 0 
were 0 
screened 0 
for 0 
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
using 0 
Beutlers 0 
spot 0 
test 0 
and 0 
three 0 
types 0 
of 0 
starch 0 
gel 0 
electrophoresis 0 
. 0 

These 0 
electrophoresis 0 
used 0 
a 0 
phosphate 0 
buffer 0 
system 0 
at 0 
pH 0 
_NUM1 0 
. 0 

_NUM1 0 
, 0 
a 0 
TRIS-EDTA-borate 0 
buffer 0 
system 0 
at 0 
pH 0 
_NUM1 0 
. 0 

_NUM1 0 
, 0 
and 0 
a 0 
TRIS-hydrochloride 0 
buffer 0 
system 0 
at 0 
pH 0 
_NUM1 0 
. 0 
. 0 

Fifteen 0 
G6PD-deficient 1
variants 0 
were 0 
found 0 
at 0 
the 0 
rate 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
and 0 
classified 0 
into 0 
four 0 
groups 0 
. 0 

As 0 
new 0 
variants 0 
, 0 
G6PD 0
Konan 0 
, 0 
Kamiube 0 
, 0 
and 0 
Kiwa 0 
were 0 
identified 0 
. 0 

These 0 
three 0 
variants 0 
had 0 
a 0 
mild 0 
to 0 
moderate 0 
G6PD 1
deficiency 1
and 0 
were 0 
not 0 
associated 0 
with 0 
any 0 
clinical 0 
signs 0 
. 0 

G6PD 0 
Konan 0 
had 0 
fast 0 
electrophoretic 0 
mobility 0 
as 0 
compared 0 
with 0 
normal 0 
levels 0 
, 0 
G6PD 0 
Kiwa 0 
had 0 
slightly 0 
elevated 0 
electrophoretic 0 
mobility 0 
, 0 
and 0 
G6PD 0 
Kamiube 0 
had 0 
normal 0 
electrophoretic 0 
mobility 0 
. 0 

These 0 
three 0 
variants 0 
had 0 
normal 0 
levels 0 
of 0 
Km 0 
G6P 0 
, 0 
Km 0 
NADP 0 
, 0 
and 0 
Ki 0 
NADPH 0 
, 0 
normal 0 
utilizations 0 
of 0 
both 0 
2-deoxy-G6P 0 
and 0 
deamino-NAPD 0 
, 0 
normal 0 
heat 0 
stability 0 
, 0 
and 0 
a 0 
normal 0 
pH 0 
curve 0 
. 0 

The 0 
other 0 
variant 0 
was 0 
G6PD 0 
Ube 0 
, 0 
which 0 
we 0 
had 0 
previously 0 
found 0 
in 0 
Yamaguchi 0 
-LRB- 0 
Nakashima 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

One 0 
boy 0 
with 0 
G6PD 0 
Ube 0 
was 0 
Korean 0 
Difference 0 
in 0 
methylation 0 
patterns 0 
within 0 
the 0 
D15S9 0 
region 0 
of 0 
chromosome 0 
15q11-13 0 
in 0 
first 0 
cousins 0 
with 0 
Angelman 1
syndrome 1
and 0 
Prader-Willi 1
syndrome 1
. 0 

Abnormalities 0 
of 0 
chromosome 0 
region 0 
15q11-13 0 
are 0 
associated 0 
with 0 
Angelman 1
syndrome 1
-LRB- 0 
AS 1
-RRB- 0 
and 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

Differences 0 
between 0 
the 0 
methylation 0 
patterns 0 
of 0 
the 0 
region 0 
of 0 
chromosome 0 
15q11-13 0 
which 0 
hybridizes 0 
to 0 
the 0 
highly 0 
conserved 0 
DNA 0 
, 0 
DN34 0 
, 0 
in 0 
normal 0 
individuals 0 
and 0 
in 0 
patients 0 
with 0 
AS 1
and 0 
PWS 1
have 0 
been 0 
described 0 
. 0 

We 0 
report 0 
on 0 
a 0 
family 0 
in 0 
which 0 
first 0 
cousins 0 
are 0 
affected 0 
by 0 
AS 1
and 0 
PWS 1
as 0 
a 0 
result 0 
of 0 
a 0 
familial 0 
paracentric 0 
inversion 0 
of 0 
15q11-q13 0 
. 0 

The 0 
results 0 
of 0 
the 0 
studies 0 
on 0 
this 0 
family 0 
demonstrate 0 
the 0 
differences 0 
in 0 
the 0 
methylation 0 
patterns 0 
in 0 
the 0 
_NUM1 0 
conditions 0 
and 0 
the 0 
phenomenon 0 
of 0 
genomic 0 
imprinting 0 
, 0 
whereby 0 
genetic 0 
information 0 
is 0 
expressed 0 
differently 0 
dependent 0 
on 0 
the 0 
parent 0 
of 0 
origin 0 
. 0 
. 0 

Mutations 0 
in 0 
the 0 
candidate 0 
gene 0 
for 0 
Norrie 1
disease 1
. 0 

Recently 0 
, 0 
we 0 
and 0 
others 0 
have 0 
isolated 0 
a 0 
candidate 0 
gene 0 
for 0 
X 1
linked 1
Norrie 1
disease 1
-LRB- 0 
ND 1
-RRB- 0 
which 0 
was 0 
found 0 
to 0 
be 0 
deleted 0 
or 0 
disrupted 0 
in 0 
several 0 
patients 0 
. 0 

As 0 
a 0 
prerequisite 0 
for 0 
the 0 
identification 0 
of 0 
point 0 
mutations 0 
in 0 
the 0 
ND 1
gene 0 
we 0 
have 0 
established 0 
the 0 
exon-intron 0 
structure 0 
of 0 
this 0 
gene 0 
. 0 

In 0 
_NUM2 0 
unrelated 0 
patients 0 
and 0 
_NUM2 0 
controls 0 
, 0 
PCR 0 
products 0 
derived 0 
from 0 
the 0 
promoter 0 
region 0 
, 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
as 0 
well 0 
as 0 
the 0 
coding 0 
part 0 
of 0 
exon 0 
_NUM1 0 
were 0 
analysed 0 
with 0 
the 0 
single 0 
strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
technique 0 
. 0 

In 0 
_NUM2 0 
patients 0 
altered 0 
PCR 0 
fragments 0 
were 0 
detected 0 
which 0 
were 0 
studied 0 
in 0 
detail 0 
by 0 
direct 0 
sequencing 0 
. 0 

Eleven 0 
different 0 
mutations 0 
were 0 
found 0 
, 0 
and 0 
all 0 
but 0 
one 0 
are 0 
likely 0 
to 0 
give 0 
rise 0 
to 0 
significant 0 
structural 0 
changes 0 
in 0 
the 0 
predicted 0 
protein 0 
. 0 

These 0 
findings 0 
, 0 
and 0 
the 0 
absence 0 
of 0 
functionally 0 
relevant 0 
base 0 
changes 0 
in 0 
healthy 0 
controls 0 
, 0 
emphasize 0 
the 0 
causal 0 
role 0 
of 0 
this 0 
candidate 0 
gene 0 
in 0 
Norrie 1
disease 1
and 0 
pave 0 
the 0 
way 0 
for 0 
reliable 0 
diagnosis 0 
and 0 
carrier 0 
detection 0 
. 0 
. 0 

A 0 
single 0 
amino 0 
acid 0 
substitution 0 
-LRB- 0 
G103D 0 
-RRB- 0 
in 0 
the 0 
type 0 
II 0 
collagen 0 
triple 0 
helix 0 
produces 0 
Kniest 1
dysplasia 1
. 0 

Kniest 1
dysplasia 1
is 0 
a 0 
moderately 0 
severe 0 
chondrodysplasia 1
phenotype 0 
that 0 
results 0 
from 0 
mutations 0 
in 0 
the 0 
gene 0 
for 0 
type 0 
II 0 
collagen 0 
, 0 
COL2A1 0 
. 0 

Characteristics 0 
of 0 
the 0 
disorder 0 
include 0 
a 0 
short 1
trunk 1
and 1
extremities 1
, 0 
mid-face 1
hypoplasia 1
, 0 
cleft 1
palate 1
, 0 
myopia 1
, 0 
retinal 1
detachment 1
, 0 
and 0 
hearing 1
loss 1
. 0 

Recently 0 
, 0 
deletions 0 
of 0 
all 0 
or 0 
part 0 
of 0 
exon 0 
_NUM2 0 
have 0 
been 0 
identified 0 
in 0 
individuals 0 
with 0 
Kniest 1
dysplasia 1
, 0 
suggesting 0 
that 0 
mutations 0 
within 0 
this 0 
region 0 
of 0 
the 0 
protein 0 
may 0 
primarily 0 
result 0 
in 0 
the 0 
Kniest 1
dysplasia 1
phenotype 0 
. 0 

We 0 
used 0 
SSCP 0 
to 0 
analyze 0 
an 0 
amplified 0 
genomic 0 
DNA 0 
fragment 0 
containing 0 
exon 0 
_NUM2 0 
from 0 
seven 0 
individuals 0 
with 0 
Kniest 1
dysplasia 1
. 0 

An 0 
abnormality 0 
was 0 
identified 0 
in 0 
one 0 
patient 0 
. 0 

DNA 0 
sequence 0 
analysis 0 
demonstrated 0 
that 0 
the 0 
patient 0 
was 0 
heterozygous 0 
for 0 
a 0 
G 0 
to 0 
A 0 
transition 0 
that 0 
implied 0 
substitution 0 
of 0 
glycine103 0 
of 0 
the 0 
triple 0 
helical 0 
domain 0 
by 0 
aspartate 0 
. 0 

The 0 
mutation 0 
was 0 
not 0 
observed 0 
in 0 
DNA 0 
from 0 
either 0 
of 0 
the 0 
clinically 0 
unaffected 0 
parents 0 
of 0 
the 0 
proband 0 
. 0 

Protein 0 
microsequencing 0 
demonstrated 0 
expression 0 
of 0 
the 0 
abnormal 0 
allele 0 
in 0 
cartilage 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
point 0 
mutations 0 
which 0 
result 0 
in 0 
single 0 
amino 0 
acid 0 
substitutions 0 
can 0 
produce 0 
Kniest 1
dysplasia 1
and 0 
further 0 
support 0 
the 0 
hypothesis 0 
that 0 
alteration 0 
of 0 
a 0 
domain 0 
, 0 
which 0 
includes 0 
the 0 
region 0 
encoded 0 
by 0 
exon 0 
_NUM2 0 
, 0 
in 0 
the 0 
type 0 
II 0 
collagen 0 
protein 0 
leads 0 
to 0 
this 0 
disorder 0 
. 0 
. 0 

Linkage 0 
analysis 0 
of 0 
_NUM1 0 
novel 0 
van 1
der 1
Woude 1
syndrome 1
kindreds 0 
to 0 
1q32-q41 0 
markers 0 
further 0 
supports 0 
locus 0 
homogeneity 0 
of 0 
the 0 
disease 0 
trait 0 
. 0 

van 1
der 1
Woude 1
syndrome 1
-LRB- 0 
vWS 1
, 0 
MIM 0 
_NUM6 0 
-RRB- 0 
is 0 
a 0 
rare 0 
autosomal 1
dominant 1
clefting 1
condition 1
with 0 
cardinal 0 
features 0 
of 0 
mucous 1
cysts 1
-LRB- 0 
lower-lip 1
pits 1
-RRB- 0 
and 0 
clefts 1
to 1
the 1
lip 1
and 1
/ 1
or 1
palate 1
. 0 

The 0 
vWS 1
gene 0 
has 0 
been 0 
assigned 0 
to 0 
a 0 
locus 0 
in 0 
1q32-q41 0 
by 0 
linkage 0 
analysis 0 
and 0 
physical 0 
mapping 0 
. 0 

We 0 
have 0 
investigated 0 
_NUM1 0 
novel 0 
vWS 1
families 0 
through 0 
probands 0 
attended 0 
for 0 
cleft 1
lip 1
and 1
/ 1
or 1
palate 1
repair 0 
at 0 
the 0 
Department 0 
of 0 
Maxillofacial 0 
Surgery 0 
of 0 
Hopital 0 
Trousseau 0 
, 0 
Paris 0 
, 0 
in 0 
order 0 
to 0 
tentatively 0 
refine 0 
the 0 
genetic 0 
map 0 
of 0 
the 0 
vWS 1
region 0 
in 0 
1q32-q41 0 
and 0 
possibly 0 
identify 0 
unlinked 0 
pedigrees 0 
. 0 

Linkage 0 
analysis 0 
was 0 
carried 0 
out 0 
to 0 
_NUM1 0 
microsatellite 0 
markers 0 
-LRB- 0 
D1S249 0 
, 0 
D1S425 0 
, 0 
D1S491 0 
, 0 
D1S205 0 
, 0 
D1S414 0 
, 0 
D1S425 0 
-RRB- 0 
, 0 
yielding 0 
a 0 
maximum 0 
cumulative 0 
LOD 0 
score 0 
of 0 
Z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
for 0 
D1S245 0 
. 0 

The 0 
innermost 0 
four 0 
markers 0 
were 0 
found 0 
to 0 
be 0 
tightly 0 
linked 0 
to 0 
one 0 
another 0 
, 0 
with 0 
no 0 
evidence 0 
for 0 
recombination 0 
. 0 

Our 0 
results 0 
support 0 
linkage 0 
of 0 
vWS 1
within 0 
a 0 
region 0 
of 0 
tightly 0 
linked 0 
markers 0 
and 0 
do 0 
not 0 
favour 0 
locus 0 
heterogeneity 0 
of 0 
the 0 
disease 0 
trait 0 
. 0 

Hypopigmentation 1
in 0 
the 0 
Prader-Willi 1
syndrome 1
. 0 

Cutaneous 1
and 1
ocular 1
pigmentation 1
were 0 
evaluated 0 
in 0 
_NUM2 0 
individuals 0 
with 0 
the 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

Criteria 0 
for 0 
hypopigmentation 1
included 0 
the 0 
presence 0 
of 0 
type 0 
I 0 
or 0 
II 0 
skin 0 
, 0 
the 0 
lightest 0 
skin 0 
type 0 
in 0 
the 0 
family 0 
by 0 
history 0 
, 0 
and 0 
iris 0 
translucency 0 
on 0 
globe 0 
transillumination 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
these 0 
criteria 0 
, 0 
_NUM2 0 
% 0 
of 0 
the 0 
PWS 1
individuals 0 
were 0 
hypopigmented 1
. 0 

The 0 
presence 0 
of 0 
hypopigmentation 1
correlated 0 
with 0 
a 0 
small 0 
interstitial 0 
deletion 0 
on 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
; 0 
however 0 
, 0 
this 0 
deletion 0 
was 0 
also 0 
found 0 
in 0 
individuals 0 
who 0 
did 0 
not 0 
meet 0 
the 0 
full 0 
criteria 0 
for 0 
hypopigmentation 1
. 0 

Hairbulb 0 
tyrosinase 0 
activity 0 
and 0 
glutathione 0 
content 0 
, 0 
as 0 
well 0 
as 0 
urine 0 
cysteinyldopa 0 
excretion 0 
, 0 
were 0 
low 0 
in 0 
PWS 1
individuals 0 
with 0 
and 0 
without 0 
hypopigmentation 1
and 0 
did 0 
not 0 
separate 0 
these 0 
two 0 
groups 0 
. 0 

We 0 
conclude 0 
that 0 
hypopigmentation 1
is 0 
found 0 
in 0 
a 0 
significant 0 
proportion 0 
of 0 
individuals 0 
with 0 
PWS 1
and 0 
that 0 
the 0 
hypopigmentation 1
may 0 
be 0 
associated 0 
with 0 
a 0 
deletion 0 
of 0 
the 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
mechanism 0 
for 0 
the 0 
hypopigmentation 1
is 0 
unknown 0 
. 0 
. 0 

Deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
in 0 
human 0 
subjects 0 
. 0 

Clinical 0 
, 0 
genetic 0 
and 0 
immunologic 0 
studies 0 
in 0 
a 0 
large 0 
kindred 0 
. 0 

The 0 
discovery 0 
of 0 
a 0 
large 0 
kindred 0 
with 0 
a 0 
heritable 0 
deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
-LRB- 0 
C5 0 
-RRB- 0 
has 0 
permitted 0 
the 0 
accumulation 0 
of 0 
new 0 
clinical 0 
, 0 
genetic 0 
and 0 
immunologic 0 
data 0 
concerning 0 
the 0 
role 0 
of 0 
C5 0 
in 0 
human 0 
subjects 0 
. 0 

The 0 
proband 0 
, 0 
who 0 
has 0 
had 0 
nine 0 
episodes 0 
of 0 
disseminated 0 
gonococcal 1
infection 1
, 0 
has 0 
a 0 
hemolytic 0 
C5 0 
level 0 
of 0 
approximately 0 
_NUM1 0 
. 0 

_NUM1 0 
per 0 
cent 0 
of 0 
normal 0 
. 0 

No 0 
C5 0 
protein 0 
was 0 
detectable 0 
, 0 
but 0 
low 0 
levels 0 
of 0 
functional 0 
C5 0 
activity 0 
could 0 
be 0 
found 0 
using 0 
a 0 
sensitive 0 
bactericidal 0 
assay 0 
. 0 

The 0 
probands 0 
twin 0 
as 0 
well 0 
as 0 
another 0 
sister 0 
also 0 
had 0 
extremely 0 
low 0 
levels 0 
of 0 
hemolytic 0 
C5 0 
-LRB- 0 
approximately 0 
_NUM1 0 
. 0 

_NUM1 0 
per 0 
cent 0 
normal 0 
-RRB- 0 
, 0 
but 0 
both 0 
these 0 
subjects 0 
have 0 
been 0 
healthy 0 
. 0 

Hemolytic 0 
complement 0 
and 0 
bacteriolytic 0 
activity 0 
could 0 
be 0 
restored 0 
by 0 
the 0 
addition 0 
of 0 
purified 0 
C5 0 
. 0 

No 0 
chemotactic 0 
activity 0 
for 0 
polymorphonuclear 0 
leukocytes 0 
could 0 
be 0 
generated 0 
in 0 
the 0 
C5-deficient 1
serums 0 
upon 0 
activation 0 
of 0 
either 0 
the 0 
classic 0 
or 0 
alternative 0 
pathways 0 
, 0 
again 0 
demonstrating 0 
the 0 
importance 0 
of 0 
C5 0
in 0 
human 0 
subjects 0 
for 0 
the 0 
production 0 
of 0 
chemotactic 0 
factors 0 
. 0 

The 0 
chemotactic 0 
responsiveness 0 
of 0 
the 0 
patients 0 
polymorphonuclear 0 
leukocytes 0 
and 0 
monocytes 0 
to 0 
preformed 0 
chemotactic 0 
factors 0 
was 0 
not 0 
depressed 0 
. 0 

Twenty-two 0 
of 0 
_NUM2 0 
other 0 
family 0 
members 0 
from 0 
three 0 
generations 0 
had 0 
depressed 0 
whole 0 
hemolytic 0 
complement 0 
levels 0 
. 0 

In 0 
_NUM2 0 
of 0 
_NUM2 0 
family 0 
members 0 
, 0 
levels 0 
of 0 
hemolytic 0 
C5 0
ranged 0 
from 0 
_NUM2 0 
to 0 
_NUM2 0 
per 0 
cent 0 
of 0 
normal 0 
. 0 

No 0 
linkage 0 
for 0 
C5 1
deficiency 1
and 0 
the 0 
A 0 
or 0 
B 0 
loci 0 
of 0 
the 0 
major 0 
histocompatibility 0 
complex 0 
could 0 
be 0 
found 0 
. 0 

These 0 
data 0 
suggest 0 
an 0 
autosomal 0 
codominant 0 
mode 0 
of 0 
inheritance 0 
of 0 
C5 1
deficiency 1
. 0 

Deficiency 1
of 1
C5 1
is 0 
compatible 0 
with 0 
good 0 
health 0 
, 0 
but 0 
it 0 
can 0 
be 0 
associated 0 
with 0 
repeated 0 
disseminated 0 
gonococcal 1
infection 1
A 0 
new 0 
glucose-6-phosphate 0 
dehydrogenase 0 
variant 0 
, 0 
G6PD 0 
Orissa 0 
-LRB- 0 
_NUM2 0 
Ala 0 
-- 0 
> 0 
Gly 0 
-RRB- 0 
, 0 
is 0 
the 0 
major 0 
polymorphic 0 
variant 0 
in 0 
tribal 0 
populations 0 
in 0 
India 0 
. 0 

Deficiency 1
of 1
glucose-6-phosphate 1
dehydrogenase 1
-LRB- 0 
G6PD 0 
-RRB- 0 
is 0 
usually 0 
found 0 
at 0 
high 0 
frequencies 0 
in 0 
areas 0 
of 0 
the 0 
world 0 
where 0 
malaria 1
has 0 
been 0 
endemic 0 
. 0 

The 0 
frequency 0 
and 0 
genetic 0 
basis 0 
of 0 
G6PD 1
deficiency 1
have 0 
been 0 
studied 0 
in 0 
Africa 0 
, 0 
around 0 
the 0 
Mediterranean 0 
, 0 
and 0 
in 0 
the 0 
Far 0 
East 0 
, 0 
but 0 
little 0 
such 0 
information 0 
is 0 
available 0 
about 0 
the 0 
situation 0 
in 0 
India 0 
. 0 

To 0 
determine 0 
the 0 
extent 0 
of 0 
heterogeneity 0 
of 0 
G6PD 0
, 0 
we 0 
have 0 
studied 0 
several 0 
different 0 
Indian 0 
populations 0 
by 0 
screening 0 
for 0 
G6PD 1
deficiency 1
, 0 
followed 0 
by 0 
molecular 0 
analysis 0 
of 0 
deficient 0 
alleles 0 
. 0 

The 0 
frequency 0 
of 0 
G6PD 1
deficiency 1
varies 0 
between 0 
_NUM1 0 
% 0 
and 0 
_NUM2 0 
% 0 
in 0 
different 0 
tribal 0 
and 0 
urban 0 
groups 0 
. 0 

Remarkably 0 
, 0 
a 0 
previously 0 
unreported 0 
deficient 0 
variant 0 
, 0 
G6PD 0
Orissa 0 
-LRB- 0 
_NUM2 0 
Ala 0 
-- 0 
> 0 
Gly 0 
-RRB- 0 
, 0 
is 0 
responsible 0 
for 0 
most 0 
of 0 
the 0 
G6PD 1
deficiency 1
in 0 
tribal 0 
Indian 0 
populations 0 
but 0 
is 0 
not 0 
found 0 
in 0 
urban 0 
populations 0 
, 0 
where 0 
most 0 
of 0 
the 0 
G6PD 1
deficiency 1
is 0 
due 0 
to 0 
the 0 
G6PD 0 
Mediterranean 0 
-LRB- 0 
_NUM3 0 
Ser 0 
-- 0 
> 0 
Phe 0 
-RRB- 0 
variant 0 
. 0 

The 0 
KmNADP 0 
of 0 
G6PD 0 
Orissa 0 
is 0 
fivefold 0 
higher 0 
than 0 
that 0 
of 0 
the 0 
normal 0 
enzyme 0 
. 0 

This 0 
may 0 
be 0 
due 0 
to 0 
the 0 
fact 0 
that 0 
the 0 
alanine 0 
residue 0 
that 0 
is 0 
replaced 0 
by 0 
glycine 0 
is 0 
part 0 
of 0 
a 0 
putative 0 
coenzyme-binding 0 
site 0 
. 0 
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
Wilms 1
' 1
tumor 1
suppressor 0 
gene 0 
are 0 
associated 0 
with 0 
abnormal 0 
urogenital 0 
development 0 
in 0 
Denys-Drash 1
syndrome 1
. 0 

Denys-Drash 1
syndrome 1
is 0 
a 0 
rare 0 
human 0 
condition 0 
in 0 
which 0 
severe 0 
urogenital 1
aberrations 1
result 0 
in 0 
renal 1
failure 1
, 0 
pseudohermaphroditism 1
, 0 
and 0 
Wilms 1
tumor 1
-LRB- 0 
nephroblastoma 1
-RRB- 0 
. 0 

To 0 
investigate 0 
its 0 
possible 0 
role 0 
, 0 
we 0 
have 0 
analyzed 0 
the 0 
coding 0 
exons 0 
of 0 
the 0 
Wilms 1
tumor 1
suppressor 0 
gene 0 
-LRB- 0 
WT1 0 
-RRB- 0 
for 0 
germline 0 
mutations 0 
. 0 

In 0 
ten 0 
independent 0 
cases 0 
of 0 
Denys-Drash 1
syndrome 1
, 0 
point 0 
mutations 0 
in 0 
the 0 
zinc 0 
finger 0 
domains 0 
of 0 
one 0 
WT1 0 
gene 0 
copy 0 
were 0 
found 0 
. 0 

Nine 0 
of 0 
these 0 
mutations 0 
are 0 
found 0 
within 0 
exon 0 
_NUM1 0 
-LRB- 0 
zinc 0 
finger 0 
III 0 
-RRB- 0 
; 0 
the 0 
remaining 0 
mutation 0 
is 0 
in 0 
exon 0 
_NUM1 0 
-LRB- 0 
zinc 0 
finger 0 
II 0 
-RRB- 0 
. 0 

These 0 
mutations 0 
directly 0 
affect 0 
DNA 0 
sequence 0 
recognition 0 
. 0 

In 0 
two 0 
families 0 
analyzed 0 
, 0 
the 0 
mutations 0 
were 0 
shown 0 
to 0 
arise 0 
de 0 
novo 0 
. 0 

Wilms 1
tumors 1
from 0 
three 0 
individuals 0 
and 0 
one 0 
juvenile 0 
granulosa 0 
cell 0 
tumor 1
demonstrate 0 
reduction 0 
to 0 
homozygosity 0 
for 0 
the 0 
mutated 0 
WT1 0 
allele 0 
. 0 

Our 0 
results 0 
provide 0 
evidence 0 
of 0 
a 0 
direct 0 
role 0 
for 0 
WT1 0 
in 0 
Denys-Drash 1
syndrome 1
and 0 
thus 0 
urogenital 0 
system 0 
development 0 
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
feline 0 
beta-glucuronidase 1
deficiency 1
: 0 
an 0 
animal 0 
model 0 
of 0 
mucopolysaccharidosis 1
VII 1
. 0 

A 0 
family 0 
of 0 
domestic 0 
cats 0 
was 0 
found 0 
that 0 
exhibited 0 
clinical 0 
and 0 
biochemical 0 
abnormalities 0 
consistent 0 
with 0 
mucopolysaccharidosis 1
VII 1
, 0 
an 0 
autosomal 1
recessive 1
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
beta-glucuronidase 1
deficiency 1
. 0 

beta-Glucuronidase 0 
activity 0 
was 0 
undetectable 0 
in 0 
affected 0 
cat 0 
fibroblasts 0 
and 0 
restored 0 
by 0 
retroviral 0 
gene 0 
transfer 0 
of 0 
rat 0 
beta-glucuronidase 0 
cDNA 0 
. 0 

beta-Glucuronidase 0 
mRNA 0 
was 0 
normal 0 
in 0 
affected 0 
cat 0 
testis 0 
by 0 
Northern 0 
blot 0 
analysis 0 
. 0 

Normal 0 
feline 0 
beta-glucuronidase 0 
cDNA 0 
was 0 
cloned 0 
and 0 
characterized 0 
, 0 
and 0 
amplified 0 
from 0 
affected 0 
cat 0 
fibroblasts 0 
by 0 
reverse 0 
transcription 0 
coupled 0 
polymerase 0 
chain 0 
reaction 0 
. 0 

There 0 
was 0 
a 0 
G-to-A 0 
transition 0 
in 0 
the 0 
affected 0 
cat 0 
cDNA 0 
that 0 
predicted 0 
an 0 
E351K 0 
substitution 0 
, 0 
destroyed 0 
a 0 
BssSI 0 
site 0 
, 0 
and 0 
eliminated 0 
GUSB 0 
enzymatic 0 
activity 0 
in 0 
expression 0 
studies 0 
. 0 

Multiple 0 
species 0 
comparison 0 
and 0 
the 0 
crystal 0 
structure 0 
of 0 
human 0 
beta-glucuronidase 0 
indicated 0 
that 0 
_AN 0 
is 0 
a 0 
highly 0 
conserved 0 
residue 0 
most 0 
likely 0 
essential 0 
in 0 
maintenance 0 
of 0 
the 0 
enzymes 0 
conformation 0 
. 0 

BssSI 0 
digestion 0 
of 0 
polymerase 0 
chain 0 
reaction 0 
products 0 
amplified 0 
from 0 
genomic 0 
DNA 0 
indicated 0 
that 0 
affected 0 
cats 0 
were 0 
homozygous 0 
and 0 
cats 0 
with 0 
half-normal 0 
beta-glucuronidase 0 
activity 0 
were 0 
heterozygous 0 
for 0 
the 0 
missense 0 
mutation 0 
. 0 

Carriers 0 
identified 0 
in 0 
this 0 
manner 0 
produced 0 
affected 0 
kittens 0 
in 0 
prospective 0 
breedings 0 
, 0 
and 0 
a 0 
feline 0 
MPS 1
VII 1
breeding 0 
colony 0 
has 0 
been 0 
established 0 
. 0 
. 0 

Loss-of-function 0 
mutations 0 
in 0 
the 0 
cathepsin 0 
C 0 
gene 0 
result 0 
in 0 
periodontal 1
disease 1
and 0 
palmoplantar 1
keratosis 1
. 0 

Papillon-Lefevre 1
syndrome 1
, 0 
or 0 
keratosis 1
palmoplantaris 1
with 0 
periodontopathia 1
-LRB- 0 
PLS 1
, 0 
MIM 0 
_NUM6 0 
-RRB- 0 
, 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
that 0 
is 0 
mainly 0 
ascertained 0 
by 0 
dentists 0 
because 0 
of 0 
the 0 
severe 0 
periodontitis 1
that 0 
afflicts 0 
patients 0 
. 0 

Both 0 
the 0 
deciduous 0 
and 0 
permanent 0 
dentitions 0 
are 0 
affected 0 
, 0 
resulting 0 
in 0 
premature 0 
tooth 1
loss 1
. 0 

Palmoplantar 1
keratosis 1
, 0 
varying 0 
from 0 
mild 0 
psoriasiform 0 
scaly 0 
skin 0 
to 0 
overt 0 
hyperkeratosis 1
, 0 
typically 0 
develops 0 
within 0 
the 0 
first 0 
three 0 
years 0 
of 0 
life 0 
. 0 

Keratosis 1
also 0 
affects 0 
other 0 
sites 0 
such 0 
as 0 
elbows 0 
and 0 
knees 0 
. 0 

Most 0 
PLS 1
patients 0 
display 0 
both 0 
periodontitis 1
and 0 
hyperkeratosis 1
. 0 

Some 0 
patients 0 
have 0 
only 0 
palmoplantar 1
keratosis 1
or 0 
periodontitis 1
, 0 
and 0 
in 0 
rare 0 
individuals 0 
the 0 
periodontitis 1
is 0 
mild 0 
and 0 
of 0 
late 0 
onset 0 
. 0 

The 0 
PLS 1
locus 0 
has 0 
been 0 
mapped 0 
to 0 
chromosome 0 
11q14-q21 0 
-LRB- 0 
refs 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM1 0 
-RRB- 0 
. 0 

Using 0 
homozygosity 0 
mapping 0 
in 0 
eight 0 
small 0 
consanguineous 0 
families 0 
, 0 
we 0 
have 0 
narrowed 0 
the 0 
candidate 0 
region 0 
to 0 
a 0 
_NUM1 0 
. 0 

2-cM 0 
interval 0 
between 0 
D11S4082 0 
and 0 
D11S931 0 
. 0 

The 0 
gene 0 
-LRB- 0 
CTSC 0 
-RRB- 0 
encoding 0 
the 0 
lysosomal 0 
protease 0 
cathepsin 0 
C 0 
-LRB- 0 
or 0 
dipeptidyl 0 
aminopeptidase 0 
I 0 
-RRB- 0 
lies 0 
within 0 
this 0 
interval 0 
. 0 

We 0 
defined 0 
the 0 
genomic 0 
structure 0 
of 0 
CTSC 0 
and 0 
found 0 
mutations 0 
in 0 
all 0 
eight 0 
families 0 
. 0 

In 0 
two 0 
of 0 
these 0 
families 0 
we 0 
used 0 
a 0 
functional 0 
assay 0 
to 0 
demonstrate 0 
an 0 
almost 0 
total 0 
loss 0 
of 0 
cathepsin 0 
C 0 
activity 0 
in 0 
PLS 0 
patients 0 
and 0 
reduced 0 
activity 0 
in 0 
obligate 0 
carriers 0 
. 0 

Brca1 1
deficiency 1
results 0 
in 0 
early 0 
embryonic 1
lethality 1
characterized 0 
by 0 
neuroepithelial 1
abnormalities 1
. 0 

The 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
gene 0 
, 0 
BRCA1 0 
, 0 
has 0 
been 0 
cloned 0 
and 0 
shown 0 
to 0 
encode 0 
a 0 
zinc-finger 0 
protein 0 
of 0 
unknown 0 
function 0 
. 0 

Mutations 0 
in 0 
BRCA1 0 
account 0 
for 0 
at 0 
least 0 
_NUM2 0 
% 0 
of 0 
families 0 
with 0 
both 0 
breast 1
and 1
ovarian 1
cancer 1
, 0 
as 0 
well 0 
as 0 
some 0 
non-familial 0 
sporadic 0 
ovarian 1
cancers 1
. 0 

The 0 
loss 0 
of 0 
wild-type 0 
BRCA1 0 
in 0 
tumours 1
of 0 
individuals 0 
carrying 0 
one 0 
nonfunctional 0 
BRCA1 0 
allele 0 
suggests 0 
that 0 
BRCA1 0 
encodes 0 
a 0 
tumour 1
suppressor 0 
that 0 
may 0 
inhibit 0 
the 0 
proliferation 0 
of 0 
mammary 0 
epithelial 0 
cells 0 
. 0 

To 0 
examine 0 
the 0 
role 0 
of 0 
BRCA1 0 
in 0 
normal 0 
tissue 0 
growth 0 
and 0 
differentiation 0 
, 0 
and 0 
to 0 
generate 0 
a 0 
potential 0 
model 0 
for 0 
the 0 
cancer 1
susceptibility 0 
associated 0 
with 0 
loss 0 
of 0 
BRCA1 0 
function 0 
, 0 
we 0 
have 0 
created 0 
a 0 
mouse 0 
line 0 
carrying 0 
a 0 
mutation 0 
in 0 
one 0 
Brca1 0 
allele 0 
. 0 

Analysis 0 
of 0 
mice 0 
homozygous 0 
for 0 
the 0 
mutant 0 
allele 0 
indicate 0 
that 0 
Brca1 0 
is 0 
critical 0 
for 0 
normal 0 
development 0 
, 0 
as 0 
these 0 
mice 0 
died 0 
in 0 
utero 0 
between 0 
_NUM2 0 
and 0 
_NUM2 0 
days 0 
of 0 
gestation 0 
-LRB- 0 
E10-E13 0 
-RRB- 0 
. 0 

Abnormalities 0 
in 0 
Brca1-deficient 1
embryos 0 
were 0 
most 0 
evident 0 
in 0 
the 0 
neural 0 
tube 0 
, 0 
with 0 
_NUM2 0 
% 0 
of 0 
the 0 
embryos 0 
presenting 0 
with 0 
varying 0 
degrees 0 
of 0 
spina 1
bifida 1
and 0 
anencephaly 1
. 0 

In 0 
addition 0 
, 0 
the 0 
neuroepithelium 0 
in 0 
Brca1-deficient 1
embryos 0 
appeared 0 
disorganized 0 
, 0 
with 0 
signs 0 
of 0 
both 0 
rapid 0 
proliferation 0 
and 0 
excessive 0 
cell 0 
death 0 
. 0 
. 0 

X 1
linked 1
recessive 1
thrombocytopenia 1
. 0 

A 0 
Saudi 0 
Arab 0 
boy 0 
presented 0 
in 0 
early 0 
childhood 0 
with 0 
thrombocytopenia 1
, 0 
morphologically 0 
large 0 
and 0 
normal 0 
sized 0 
platelets 0 
, 0 
increased 0 
mean 0 
platelet 0 
volume 0 
, 0 
and 0 
a 0 
hypermegakaryocytic 0 
bone 0 
marrow 0 
. 0 

There 0 
was 0 
no 0 
clinical 0 
and 0 
laboratory 0 
evidence 0 
of 0 
any 0 
significant 0 
immunological 1
abnormalities 1
. 0 

Similar 0 
findings 0 
in 0 
two 0 
other 0 
brothers 0 
suggested 0 
strongly 0 
that 0 
they 0 
were 0 
all 0 
suffering 0 
from 0 
an 0 
X 1
linked 1
recessive 1
thrombocytopenic 1
disorder 1
. 0 

Results 0 
of 0 
DNA 0 
analysis 0 
with 0 
the 0 
probe 0 
_AN 0 
beta 0 
are 0 
consistent 0 
with 0 
X 0 
linkage 0 
and 0 
indicate 0 
also 0 
that 0 
the 0 
locus 0 
of 0 
the 0 
relevant 0 
gene 0 
lies 0 
close 0 
to 0 
or 0 
is 0 
identical 0 
to 0 
the 0 
locus 0 
of 0 
the 0 
gene 0 
for 0 
the 0 
Wiskott-Aldrich 1
syndrome 1
-LRB- 0 
WAS 1
-RRB- 0 
. 0 

Because 0 
of 0 
various 0 
features 0 
which 0 
include 0 
the 0 
presence 0 
of 0 
large 0 
and 0 
normal 0 
sized 0 
platelets 0 
-LRB- 0 
rather 0 
than 0 
small 0 
platelets 0 
-RRB- 0 
and 0 
freedom 0 
from 0 
significant 0 
immune 1
deficiencies 1
, 0 
it 0 
is 0 
likely 0 
that 0 
the 0 
X 1
linked 1
recessive 1
thrombocytopenia 1
in 0 
this 0 
family 0 
is 0 
an 0 
isolated 0 
entity 0 
quite 0 
distinct 0 
from 0 
the 0 
classical 0 
WAS 1
phenotype 0 
. 0 

However 0 
, 0 
a 0 
modified 0 
expression 0 
of 0 
the 0 
WAS 1
gene 0 
producing 0 
a 0 
mild 0 
phenotypic 0 
variant 0 
can 0 
not 0 
be 0 
excluded 0 
entirely 0 
. 0 
. 0 

Genetics 0 
of 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
: 0 
an 0 
autosomal 0 
recessive 0 
trait 0 
with 0 
high 0 
gene 0 
frequency 0 
in 0 
Sephardim 0 
of 0 
Moroccan 0 
origin 0 
. 0 

We 0 
described 0 
_NUM1 0 
patients 0 
-LRB- 0 
from 0 
_NUM1 0 
families 0 
-RRB- 0 
affected 0 
with 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
. 0 

All 0 
are 0 
Sephardic 0 
Jews 0 
of 0 
Moroccan 0 
extraction 0 
. 0 

In 0 
view 0 
of 0 
the 0 
small 0 
number 0 
of 0 
CTX 1
patients 0 
diagnosed 0 
in 0 
the 0 
world 0 
-LRB- 0 
a 0 
total 0 
of 0 
_NUM2 0 
including 0 
our 0 
_NUM1 0 
patients 0 
-RRB- 0 
, 0 
we 0 
are 0 
probably 0 
dealing 0 
with 0 
an 0 
ethnic 0 
subgroup 0 
with 0 
a 0 
high 0 
CTX 0 
gene 0 
frequency 0 
, 0 
which 0 
we 0 
have 0 
estimated 0 
to 0 
be 0 
1 0 
/ 0 
108 0 
. 0 

Since 0 
there 0 
are 0 
differences 0 
in 0 
expression 0 
in 0 
this 0 
disease 0 
, 0 
we 0 
recommend 0 
cholestanol 0 
study 0 
in 0 
cases 0 
of 0 
undiagnosed 0 
cataract 1
or 0 
tendinous 1
xanthomas 1
in 0 
childhood 0 
or 0 
early 0 
adolescence 0 
. 0 

The 0 
diagnosis 0 
in 0 
CTX 1
is 0 
important 0 
not 0 
only 0 
for 0 
genetic 0 
counseling 0 
, 0 
but 0 
also 0 
in 0 
veiw 0 
of 0 
possible 0 
treatment 0 
. 0 
. 0 

A 0 
missense 0 
mutation 0 
in 0 
the 0 
cholesteryl 0 
ester 0 
transfer 0 
protein 0 
gene 0 
with 0 
possible 0 
dominant 0 
effects 0 
on 0 
plasma 0 
high 0 
density 0 
lipoproteins 0 
. 0 

Plasma 0 
HDL 0 
are 0 
a 0 
negative 0 
risk 0 
factor 0 
for 0 
atherosclerosis 1
. 0 

Cholesteryl 0 
ester 0 
transfer 0 
protein 0 
-LRB- 0 
CETP 0
; 0 
_NUM3 0 
amino 0 
acids 0 
-RRB- 0 
transfers 0 
cholesteryl 0 
ester 0 
from 0 
HDL 0 
to 0 
other 0 
lipoproteins 0 
. 0 

Subjects 0 
with 0 
homozygous 0 
CETP 1
deficiency 1
caused 0 
by 0 
a 0 
gene 0 
splicing 0 
defect 0 
have 0 
markedly 0 
elevated 0 
HDL 0 
; 0 
however 0 
, 0 
heterozygotes 0 
have 0 
only 0 
mild 0 
increases 0 
in 0 
HDL 0 
. 0 

We 0 
describe 0 
two 0 
probands 0 
with 0 
a 0 
CETP 0 
missense 0 
mutation 0 
-LRB- 0 
_NUM3 0 
D 0 
G 0 
-RRB- 0 
. 0 

Although 0 
heterozygous 0 
, 0 
they 0 
have 0 
threefold 0 
increases 0 
in 0 
HDL 0 
concentration 0 
and 0 
markedly 0 
decreased 0 
plasma 0 
CETP 0 
mass 0 
and 0 
activity 0 
, 0 
suggesting 0 
that 0 
the 0 
mutation 0 
has 0 
dominant 0 
effects 0 
on 0 
CETP 0 
and 0 
HDL 0 
in 0 
vivo 0 
. 0 

Cellular 0 
expression 0 
of 0 
mutant 0 
cDNA 0 
results 0 
in 0 
secretion 0 
of 0 
only 0 
_NUM2 0 
% 0 
of 0 
wild 0 
type 0 
CETP 0 
activity 0 
. 0 

Moreover 0 
, 0 
coexpression 0 
of 0 
wild 0 
type 0 
and 0 
mutant 0 
cDNAs 0 
leads 0 
to 0 
inhibition 0 
of 0 
wild 0 
type 0 
secretion 0 
and 0 
activity 0 
. 0 

The 0 
dominant 0 
effects 0 
of 0 
the 0 
CETP 0 
missense 0 
mutation 0 
during 0 
cellular 0 
expression 0 
probably 0 
explains 0 
why 0 
the 0 
probands 0 
have 0 
markedly 0 
increased 0 
HDL 0 
in 0 
the 0 
heterozygous 0 
state 0 
, 0 
and 0 
suggests 0 
that 0 
the 0 
active 0 
molecular 0 
species 0 
of 0 
CETP 0 
may 0 
be 0 
multimeric 0 
. 0 
. 0 

Huntington 1
disease 1
: 0 
no 0 
evidence 0 
for 0 
locus 0 
heterogeneity 0 
. 0 

A 0 
total 0 
of 0 
_NUM2 0 
families 0 
with 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
were 0 
examined 0 
for 0 
linkage 0 
between 0 
HD 1
and 0 
G8 0 
-LRB- 0 
D4S10 0 
-RRB- 0 
. 0 

The 0 
families 0 
included 0 
_NUM2 0 
Caucasian 0 
, 0 
four 0 
Black 0 
American 0 
, 0 
and 0 
two 0 
Japanese 0 
. 0 

The 0 
combined 0 
maximum 0 
lod 0 
score 0 
was 0 
_NUM2 0 
. 0 

_NUM2 0 
at 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
_NUM1 0 
. 0 

018-0 0 
. 0 

_NUM3 0 
-RRB- 0 
. 0 

The 0 
maximum 0 
frequency 0 
of 0 
recombination 0 
was 0 
_NUM1 0 
. 0 

_NUM2 0 
in 0 
males 0 
and 0 
_NUM1 0 
. 0 

_NUM2 0 
in 0 
females 0 
. 0 

Fifty-seven 0 
families 0 
gave 0 
positive 0 
lod 0 
scores 0 
; 0 
five 0 
small 0 
families 0 
gave 0 
mildly 0 
negative 0 
lod 0 
scores 0 
. 0 

The 0 
maximum 0 
likelihood 0 
estimate 0 
of 0 
alpha 0 
, 0 
the 0 
proportion 0 
of 0 
linked 0 
loci 0 
, 0 
was 0 
_NUM1 0 
. 0 

_NUM1 0 
with 0 
a 0 
lower 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
there 0 
is 0 
only 0 
one 0 
HD 1
locus 0 
, 0 
although 0 
a 0 
second 0 
rare 0 
locus 0 
can 0 
not 0 
be 0 
ruled 0 
out 0 
. 0 

Homozygous 0 
and 0 
heterozygous 0 
deletions 0 
of 0 
the 0 
von 1
Willebrand 1
factor 0 
gene 0 
in 0 
patients 0 
and 0 
carriers 0 
of 0 
severe 1
von 1
Willebrand 1
disease 1
. 0 

Severe 1
von 1
Willebrand 1
disease 1
is 0 
characterized 0 
by 0 
undetectable 0 
or 0 
trace 0 
quantities 0 
of 0 
von 1
Willebrand 1
factor 0 
in 0 
plasma 0 
and 0 
tissue 0 
stores 0 
. 0 

We 0 
have 0 
studied 0 
the 0 
genomic 0 
DNA 0 
of 0 
_NUM2 0 
affected 0 
individuals 0 
from 0 
six 0 
families 0 
with 0 
this 0 
disorder 0 
using 0 
probes 0 
from 0 
the 0 
_NUM1 0 
and 0 
_NUM1 0 
ends 0 
of 0 
the 0 
vWF 0 
cDNA 0 
and 0 
with 0 
a 0 
probe 0 
extending 0 
from 0 
the 0 
_NUM1 0 
end 0 
into 0 
the 0 
central 0 
region 0 
. 0 

Southern 0 
blots 0 
of 0 
restriction 0 
endonuclease 0 
digests 0 
and 0 
gene 0 
dosage 0 
analysis 0 
measurements 0 
carried 0 
out 0 
with 0 
quantitative 0 
slot 0 
blots 0 
of 0 
undigested 0 
genomic 0 
DNA 0 
separated 0 
these 0 
patients 0 
into 0 
three 0 
groups 0 
. 0 

The 0 
first 0 
group 0 
consisted 0 
of 0 
a 0 
family 0 
with 0 
complete 0 
homozygous 0 
deletions 0 
of 0 
the 0 
vWF 0 
gene 0 
in 0 
the 0 
four 0 
probands 0 
. 0 

Gene 0 
dosage 0 
analysis 0 
was 0 
consistent 0 
with 0 
heterozygous 0 
deletions 0 
in 0 
both 0 
of 0 
the 0 
asymptomatic 0 
parents 0 
and 0 
four 0 
asymptomatic 0 
siblings 0 
of 0 
this 0 
kindred 0 
-LRB- 0 
P 0 
less 0 
than 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

The 0 
second 0 
group 0 
was 0 
comprised 0 
of 0 
a 0 
family 0 
in 0 
which 0 
there 0 
was 0 
a 0 
complete 0 
heterozygous 0 
deletion 0 
of 0 
the 0 
vWF 0 
gene 0 
in 0 
the 0 
proband 0 
and 0 
one 0 
asymptomatic 0 
parent 0 
, 0 
suggesting 0 
that 0 
a 0 
different 0 
type 0 
of 0 
genetic 1
abnormality 1
was 0 
inherited 0 
from 0 
the 0 
other 0 
parent 0 
. 0 

Thus 0 
, 0 
the 0 
patient 0 
appeared 0 
to 0 
be 0 
doubly 0 
heterozygous 0 
for 0 
interacting 0 
genetic 1
abnormalities 1
affecting 0 
vWF 0 
expression 0 
. 0 

In 0 
the 0 
third 0 
group 0 
, 0 
no 0 
gene 0 
deletions 0 
could 0 
be 0 
detected 0 
. 0 

Alloantibodies 0 
developed 0 
only 0 
in 0 
the 0 
kindred 0 
with 0 
homozygous 0 
deletions 0 
. 0 

These 0 
techniques 0 
should 0 
prove 0 
useful 0 
in 0 
identifying 0 
carriers 0 
of 0 
severe 1
von 1
Willebrand 1
disease 1
and 0 
also 0 
in 0 
defining 0 
patients 0 
predictably 0 
at 0 
risk 0 
of 0 
developing 0 
alloantibodies 0 
to 0 
vWF 0 
. 0 

Spectrum 0 
of 0 
germline 0 
mutations 0 
in 0 
the 0 
RB1 0 
gene 0 
: 0 
a 0 
study 0 
of 0 
_NUM3 0 
patients 0 
with 0 
hereditary 1
and 1
non 1
hereditary 1
retinoblastoma 1
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
RB1 0 
gene 0 
confer 0 
hereditary 0 
predisposition 0 
to 0 
retinoblastoma 1
. 0 

We 0 
have 0 
performed 0 
a 0 
mutation 0 
survey 0 
of 0 
the 0 
RB1 0 
gene 0 
in 0 
_NUM3 0 
patients 0 
with 0 
hereditary 1
or 1
non 1
hereditary 1
retinoblastoma 1
. 0 

We 0 
systematically 0 
explored 0 
all 0 
_NUM2 0 
exons 0 
and 0 
flanking 0 
sequences 0 
as 0 
well 0 
as 0 
the 0 
promotor 0 
. 0 

All 0 
types 0 
of 0 
point 0 
mutations 0 
are 0 
represented 0 
and 0 
are 0 
found 0 
unequally 0 
distributed 0 
along 0 
the 0 
RB1 0 
gene 0 
sequence 0 
. 0 

In 0 
the 0 
population 0 
we 0 
studied 0 
, 0 
exons 0 
_NUM1 0 
, 0 
_NUM1 0 
, 0 
_NUM2 0 
and 0 
_NUM2 0 
are 0 
preferentially 0 
altered 0 
. 0 

The 0 
range 0 
of 0 
frequency 0 
of 0 
detection 0 
of 0 
germline 0 
mutations 0 
is 0 
about 0 
_NUM2 0 
% 0 
, 0 
indicating 0 
that 0 
other 0 
mechanisms 0 
of 0 
inactivation 0 
of 0 
RB1 0 
should 0 
be 0 
involved 0 
. 0 

The 0 
spectrum 0 
of 0 
mutations 0 
presented 0 
here 0 
should 0 
help 0 
to 0 
improve 0 
the 0 
clinical 0 
management 0 
of 0 
retinoblastoma 1
and 0 
to 0 
understand 0 
the 0 
molecular 0 
mechanisms 0 
leading 0 
to 0 
tumorigenesis 0 
. 0 
. 0 

Pelizaeus-Merzbacher 1
disease 1
: 0 
an 0 
X-linked 1
neurologic 1
disorder 1
of 1
myelin 1
metabolism 1
with 0 
a 0 
novel 0 
mutation 0 
in 0 
the 0 
gene 0 
encoding 0 
proteolipid 0 
protein 0 
. 0 

The 0 
nosology 0 
of 0 
the 0 
inborn 1
errors 1
of 1
myelin 1
metabolism 1
has 0 
been 0 
stymied 0 
by 0 
the 0 
lack 0 
of 0 
molecular 0 
genetic 0 
analysis 0 
. 0 

Historically 0 
, 0 
Pelizaeus-Merzbacher 1
disease 1
has 0 
encompassed 0 
a 0 
host 0 
of 0 
neurologic 1
disorders 1
that 0 
present 0 
with 0 
a 0 
deficit 1
of 1
myelin 1
, 0 
the 0 
membrane 0 
elaborated 0 
by 0 
glial 0 
cells 0 
that 0 
encircles 0 
and 0 
successively 0 
enwraps 0 
axons 0 
. 0 

We 0 
describe 0 
here 0 
a 0 
Pelizaeus-Merzbacher 1
pedigree 0 
of 0 
the 0 
classical 0 
type 0 
, 0 
with 0 
X-linked 0 
inheritance 0 
, 0 
a 0 
typical 0 
clinical 0 
progression 0 
, 0 
and 0 
a 0 
pathologic 0 
loss 0 
of 0 
myelinating 0 
cells 0 
and 0 
myelin 0 
in 0 
the 0 
central 0 
nervous 0 
system 0 
. 0 

To 0 
discriminate 0 
variants 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
, 0 
a 0 
set 0 
of 0 
oligonucleotide 0 
primers 0 
was 0 
constructed 0 
to 0 
polymerase-chain-reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
amplify 0 
and 0 
sequence 0 
the 0 
gene 0 
encoding 0 
proteolipid 0 
protein 0 
-LRB- 0 
PLP 0 
-RRB- 0 
, 0 
a 0 
structural 0 
protein 0 
that 0 
comprises 0 
half 0 
of 0 
the 0 
protein 0 
of 0 
the 0 
myelin 0 
sheath 0 
. 0 

The 0 
PLP 0 
gene 0 
in 0 
one 0 
of 0 
two 0 
affected 0 
males 0 
and 0 
the 0 
carrier 0 
mother 0 
of 0 
this 0 
family 0 
exhibited 0 
a 0 
single 0 
base 0 
difference 0 
in 0 
the 0 
more 0 
than 0 
_NUM1 0 
kb 0 
of 0 
the 0 
PLP 0 
gene 0 
sequenced 0 
, 0 
a 0 
C 0 
-- 0 
T 0 
transition 0 
that 0 
would 0 
create 0 
a 0 
serine 0 
substitution 0 
for 0 
proline 0 
at 0 
the 0 
carboxy 0 
end 0 
of 0 
the 0 
protein 0 
. 0 

Our 0 
results 0 
delineate 0 
the 0 
clinical 0 
features 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
, 0 
define 0 
the 0 
possible 0 
molecular 0 
pathology 0 
of 0 
this 0 
dysmyelinating 1
disorder 1
, 0 
and 0 
address 0 
the 0 
molecular 0 
classification 0 
of 0 
inborn 1
errors 1
of 1
myelin 1
metabolism 1
. 0 

Patients 0 
with 0 
the 0 
classical 0 
form 0 
-LRB- 0 
type 0 
I 0 
-RRB- 0 
and 0 
the 0 
more 0 
severely 0 
affected 0 
, 0 
connatal 0 
variant 0 
of 0 
Pelizaeus-Merzbacher 1
disease 1
-LRB- 1
type 1
II 1
-RRB- 1
would 0 
be 0 
predicted 0 
to 0 
display 0 
mutation 0 
at 0 
the 0 
PLP 0 
locus 0 
. 0 

The 0 
other 0 
variants 0 
-LRB- 0 
types 0 
III-VI 0 
-RRB- 0 
, 0 
which 0 
have 0 
sometimes 0 
been 0 
categorized 0 
as 0 
Pelizaeus-Merzbacher 1
disease 1
, 0 
may 0 
represent 0 
mutations 0 
in 0 
genes 0 
encoding 0 
other 0 
structural 0 
myelin 0 
proteins 0 
or 0 
proteins 0 
critical 0 
to 0 
myelination 0 
. 0 
. 0 

_DS 0 
expansions 0 
in 0 
a 0 
novel 0 
gene 0 
for 0 
Machado-Joseph 1
disease 1
at 0 
chromosome 0 
14q32 0 
.1 0 
. 0 

We 0 
have 0 
identified 0 
a 0 
novel 0 
gene 0 
containing 0 
_DS 0 
repeats 0 
and 0 
mapped 0 
it 0 
to 0 
chromosome 0 
14q32 0 
. 0 

_NUM1 0 
, 0 
the 0 
genetic 0 
locus 0 
for 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
. 0 

In 0 
normal 0 
individuals 0 
the 0 
gene 0 
contains 0 
between 0 
_NUM2 0 
and 0 
_NUM2 0 
_DS 0 
repeats 0 
, 0 
whereas 0 
most 0 
of 0 
the 0 
clinically 0 
diagnosed 0 
patients 0 
and 0 
all 0 
of 0 
the 0 
affected 0 
members 0 
of 0 
a 0 
family 0 
with 0 
the 0 
clinical 0 
and 0 
pathological 0 
diagnosis 0 
of 0 
MJD 1
show 0 
expansion 0 
of 0 
the 0 
repeat-number 0 
-LRB- 0 
from 0 
68-79 0 
-RRB- 0 
. 0 

Southern 0 
blot 0 
analyses 0 
and 0 
genomic 0 
cloning 0 
demonstrates 0 
the 0 
existence 0 
of 0 
related 0 
genes 0 
. 0 

These 0 
results 0 
raise 0 
the 0 
possibility 0 
that 0 
similar 0 
abnormalities 0 
in 0 
related 0 
genes 0 
may 0 
give 0 
rise 0 
to 0 
diseases 0 
similar 0 
to 0 
MJD 1
. 0 

Conservation 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
gene 0 
in 0 
mice 0 
and 0 
humans 0 
. 0 

A 0 
portion 0 
of 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
transcript 0 
from 0 
human 0 
fetal 0 
skeletal 0 
muscle 0 
and 0 
mouse 0 
adult 0 
heart 0 
was 0 
sequenced 0 
, 0 
representing 0 
approximately 0 
_NUM2 0 
percent 0 
of 0 
the 0 
total 0 
, 0 
14-kb 0 
DMD 1
transcript 0 
. 0 

The 0 
nucleic 0 
acid 0 
and 0 
predicted 0 
amino 0 
acid 0 
sequences 0 
from 0 
the 0 
two 0 
species 0 
are 0 
nearly 0 
_NUM2 0 
percent 0 
homologous 0 
. 0 

The 0 
amino 0 
acid 0 
sequence 0 
that 0 
is 0 
predicted 0 
from 0 
this 0 
portion 0 
of 0 
the 0 
DMD 1
gene 0 
indicates 0 
that 0 
the 0 
protein 0 
product 0 
might 0 
serve 0 
a 0 
structural 0 
role 0 
in 0 
muscle 0 
, 0 
but 0 
the 0 
abundance 0 
and 0 
tissue 0 
distribution 0 
of 0 
the 0 
messenger 0 
RNA 0 
suggests 0 
that 0 
the 0 
DMD 1
protein 0 
is 0 
not 0 
nebulin 0 
. 0 
. 0 

Deficiency 1
of 1
the 1
murine 1
fifth 1
complement 1
component 1
-LRB- 1
C5 1
-RRB- 1
. 0 

A 0 
2-base 0 
pair 0 
gene 0 
deletion 0 
in 0 
a 0 
_NUM1 0 
' 0 
- 0 
exon 0 
. 0 

To 0 
ascertain 0 
the 0 
molecular 0 
mechanism 0 
that 0 
causes 0 
murine 0 
C5 1
deficiency 1
, 0 
genomic 0 
and 0 
cDNA 0 
libraries 0 
were 0 
constructed 0 
from 0 
mouse 0 
liver 0 
DNA 0 
and 0 
mRNA 0 
employing 0 
the 0 
congenic 0 
strains 0 
_AN 0 
. 0 

D2 0 
/ 0 
nSnJ 0 
and 0 
_AN 0 
. 0 

D2 0 
/ 0 
oSnJ 0 
that 0 
are 0 
sufficient 0 
and 0 
deficient 1
for 1
C5 1
, 0 
respectively 0 
. 0 

Genomic 0 
fragments 0 
were 0 
isolated 0 
which 0 
correspond 0 
to 0 
PvuII 0 
and 0 
HindIII 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
associated 0 
with 0 
C5 1
deficiency 1
. 0 

Sequence 0 
analyses 0 
demonstrated 0 
that 0 
each 0 
of 0 
these 0 
polymorphisms 0 
resulted 0 
from 0 
single 0 
base 0 
pair 0 
substitutions 0 
and 0 
that 0 
neither 0 
substitution 0 
would 0 
probably 0 
cause 0 
or 0 
contribute 0 
to 0 
the 0 
C5 1
deficiency 1
. 0 

Sequence 0 
analyses 0 
of 0 
C5 0 
sufficient 0 
and 0 
deficient 0 
cDNAs 0 
revealed 0 
a 0 
_NUM1 0 
base-pair 0 
deletion 0 
in 0 
the 0 
deficient 0 
cDNAs 0 
. 0 

The 0 
'' 0 
_DS 0 
'' 0 
deletion 0 
was 0 
located 0 
near 0 
the 0 
_NUM1 0 
end 0 
of 0 
the 0 
cDNA 0 
. 0 

This 0 
deletion 0 
shifts 0 
the 0 
reading 0 
frame 0 
of 0 
the 0 
C5 0 
mRNA 0 
so 0 
that 0 
the 0 
termination 0 
codon 0 
UGA 0 
is 0 
present 0 
_NUM1 0 
base 0 
pairs 0 
downstream 0 
from 0 
the 0 
deletion 0 
. 0 

Genomic 0 
DNA 0 
was 0 
amplified 0 
and 0 
sequenced 0 
corresponding 0 
to 0 
the 0 
area 0 
surrounding 0 
the 0 
2-base 0 
pair 0 
deletion 0 
. 0 

Six 0 
C5-deficient 1
strains 0 
, 0 
A 0 
/ 0 
HeJ 0 
, 0 
AKR 0 
/ 0 
J 0 
, 0 
DBA 0 
/ 0 
2J 0 
, 0 
NZB 0 
/ 0 
B1NJ 0 
, 0 
SWR 0 
/ 0 
J 0 
, 0 
and 0 
_AN 0 
. 0 

D2 0 
/ 0 
oSnJ 0 
, 0 
and 0 
four 0 
C5-sufficient 0 
strains 0 
, 0 
Balb 0 
/ 0 
CJ 0 
, 0 
C57Bl 0 
/ 0 
6J 0 
, 0 
DBA 0 
/ 0 
1J 0 
, 0 
and 0 
_AN 0 
. 0 

D2 0 
/ 0 
nSnJ 0 
, 0 
were 0 
analyzed 0 
. 0 

The 0 
sequencing 0 
data 0 
revealed 0 
that 0 
the 0 
_NUM1 0 
base 0 
pairs 0 
were 0 
deleted 0 
from 0 
the 0 
C5 0 
gene 0 
of 0 
each 0 
deficient 0 
mouse 0 
tested 0 
but 0 
not 0 
from 0 
the 0 
C5 0 
gene 0 
of 0 
any 0 
sufficient 0 
mouse 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
_NUM1 0 
-RRB- 0 
there 0 
is 0 
an 0 
identical 0 
2-base 0 
pair 0 
deletion 0 
in 0 
an 0 
exon 0 
of 0 
the 0 
C5 0 
gene 0 
in 0 
several 0 
different 0 
C5-deficient 1
mouse 0 
strains 0 
; 0 
_NUM1 0 
-RRB- 0 
the 0 
mRNA 0 
transcribed 0 
from 0 
the 0 
C5D 0 
gene 0 
retains 0 
this 0 
deletion 0 
; 0 
and 0 
_NUM1 0 
-RRB- 0 
this 0 
mutation 0 
should 0 
result 0 
in 0 
C5 1
protein 1
deficiency 1
. 0 

Recurrent 0 
meningitis 1
in 0 
a 0 
patient 0 
with 0 
congenital 1
deficiency 1
of 1
the 1
C9 1
component 1
of 1
complement 1
. 0 

First 0 
case 0 
of 0 
C9 1
deficiency 1
in 0 
Europe 0 
. 0 

We 0 
describe 0 
the 0 
first 0 
cases 0 
, 0 
to 0 
our 0 
knowledge 0 
, 0 
of 0 
C9 1
deficiency 1
in 0 
Europe 0 
that 0 
were 0 
detected 0 
in 0 
a 0 
Swiss 0 
family 0 
, 0 
of 0 
which 0 
two 0 
members 0 
-- 0 
one 0 
with 0 
a 0 
complete 0 
deficiency 0 
and 0 
the 0 
other 0 
with 0 
approximately 0 
half-normal 0 
C9 0 
levels 0 
-- 0 
experienced 0 
bacterial 1
meningitis 1
. 0 

The 0 
index 0 
patient 0 
, 0 
a 0 
56-year-old 0 
white 0 
man 0 
with 0 
a 0 
history 0 
of 0 
purulent 1
meningitis 1
at 0 
the 0 
age 0 
of 0 
_NUM2 0 
years 0 
, 0 
presented 0 
with 0 
an 0 
acute 1
meningococcal 1
meningitis 1
. 0 

No 0 
impairment 1
of 1
cellular 1
immunity 1
or 0 
immunoglobulin 1
deficiency 1
could 0 
be 0 
found 0 
. 0 

Complement 0 
assays 0 
showed 0 
a 0 
complete 1
deficiency 1
of 1
the 1
C9 1
component 1
, 0 
while 0 
the 0 
other 0 
individual 0 
component 0 
levels 0 
were 0 
normal 0 
and 0 
the 0 
hemolytic 0 
activity 0 
-LRB- 0 
measured 0 
using 0 
the 0 
CH50 0 
assay 0 
-RRB- 0 
was 0 
only 0 
slightly 0 
reduced 0 
. 0 

A 0 
family 0 
study 0 
revealed 0 
complete 1
C9 1
deficiency 1
in 0 
the 0 
patients 0 
healthy 0 
brother 0 
and 0 
half-normal 0 
C9 0 
concentrations 0 
in 0 
his 0 
sister 0 
, 0 
his 0 
son 0 
-LRB- 0 
who 0 
also 0 
had 0 
experienced 0 
an 0 
episode 0 
of 0 
bacterial 1
meningitis 1
-RRB- 0 
, 0 
and 0 
his 0 
niece 0 
, 0 
consistent 0 
with 0 
an 0 
inherited 0 
C9 1
deficiency 1
. 0 

This 0 
first 0 
case 0 
of 0 
recurrent 1
meningitis 1
in 0 
a 0 
white 0 
patient 0 
with 0 
complete 1
C9 1
deficiency 1
suggests 0 
that 0 
this 0 
complement 1
defect 1
may 0 
also 0 
be 0 
a 0 
risk 0 
factor 0 
for 0 
bacterial 1
, 1
especially 1
neisserial 1
, 1
infections 1
. 0 
. 0 

Bone 0 
marrow 0 
transplant 0 
in 0 
adrenoleukodystrophy 1
. 0 

An 0 
allogeneic 0 
bone 0 
marrow 0 
transplant 0 
-LRB- 0 
BMT 0 
-RRB- 0 
from 0 
a 0 
normal 0 
HLA 0 
identical 0 
sibling 0 
donor 0 
was 0 
performed 0 
in 0 
a 0 
13-year-old 0 
boy 0 
with 0 
rapidly 0 
progressive 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
. 0 

Engraftment 0 
and 0 
complete 0 
hematologic 0 
recovery 0 
occurred 0 
within 0 
_NUM1 0 
weeks 0 
, 0 
but 0 
neurologic 1
deterioration 1
continued 0 
. 0 

The 0 
patient 0 
died 0 
of 0 
an 0 
adenovirus 1
infection 1
_NUM3 0 
days 0 
after 0 
BMT 0 
. 0 

ALD 1
is 0 
characterized 0 
by 0 
abnormally 0 
high 0 
plasma 0 
levels 0 
of 0 
very 0 
long 0 
chain 0 
fatty 0 
acids 0 
-LRB- 0 
VLCFA 0 
-RRB- 0 
as 0 
a 0 
result 0 
of 0 
impaired 0 
capacity 0 
to 0 
degrade 0 
them 0 
. 0 

Ten 0 
days 0 
after 0 
BMT 0 
, 0 
the 0 
white 0 
blood 0 
cell 0 
VLCFA 0 
levels 0 
and 0 
enzyme 0 
activity 0 
became 0 
normal 0 
; 0 
after 0 
_NUM1 0 
months 0 
, 0 
there 0 
was 0 
progressive 0 
reduction 0 
of 0 
plasma 0 
VLCFA 0 
to 0 
levels 0 
only 0 
slightly 0 
above 0 
normal 0 
. 0 
. 0 

Increased 0 
incidence 0 
of 0 
cataracts 1
in 0 
male 0 
subjects 0 
deficient 1
in 1
glucose-6-phosphate 1
dehydrogenase 1
. 0 

Glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
RBCs 0 
was 0 
found 0 
significantly 0 
more 0 
frequently 0 
in 0 
_NUM3 0 
male 0 
cataractous 1
patients 0 
than 0 
in 0 
_NUM3 0 
control 0 
subjects 0 
of 0 
Sardinian 0 
origin 0 
. 0 

The 0 
frequency 0 
of 0 
the 0 
deficiency 0 
was 0 
increasingly 0 
higher 0 
in 0 
presenile 0 
cataracts 1
. 0 

In 0 
the 0 
G6PD-deficient 1
group 0 
, 0 
the 0 
incidence 0 
of 0 
cortical 1
and 1
total 1
cataracts 1
was 0 
also 0 
increased 0 
. 0 

It 0 
is 0 
suggested 0 
that 0 
decrease 0 
of 0 
the 0 
G6PD 0
activity 0 
in 0 
the 0 
lens 0 
, 0 
which 0 
accompanies 0 
its 0 
deficiency 0 
in 0 
the 0 
erythrocyte 0 
, 0 
might 0 
play 0 
a 0 
role 0 
in 0 
the 0 
cataracto-genesis 0 
of 0 
these 0 
patients 0 
. 0 

Moreover 0 
, 0 
G6PD 1
deficiency 1
should 0 
be 0 
added 0 
to 0 
other 0 
conditions 0 
, 0 
such 0 
as 0 
the 0 
galactosemic 1
states 0 
and 0 
riboflavin 1
deficiency 1
, 0 
where 0 
cataracts 1
represent 0 
a 0 
sensitive 0 
indicator 0 
of 0 
metabolic 1
abnormalities 1
of 0 
the 0 
RBC 0 
. 0 
. 0 

Von 1
Hippel-Lindau 1
disease 1
maps 0 
to 0 
the 0 
region 0 
of 0 
chromosome 0 
_NUM1 0 
associated 0 
with 0 
renal 1
cell 1
carcinoma 1
. 0 

Von 1
Hippel-Lindau 1
disease 1
-LRB- 0 
VHL 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disorder 1
with 0 
inherited 0 
susceptibility 0 
to 0 
various 0 
forms 0 
of 0 
cancer 1
, 0 
including 0 
hemangioblastomas 1
of 0 
the 0 
central 0 
nervous 0 
system 0 
, 0 
phaeochromocytomas 1
, 0 
pancreatic 1
malignancies 1
, 0 
and 0 
renal 1
cell 1
carcinomas 1
. 0 

Renal 1
cell 1
carcinomas 1
constitute 0 
a 0 
particularly 0 
frequent 0 
cause 0 
of 0 
death 0 
in 0 
this 0 
disorder 0 
, 0 
occurring 0 
as 0 
bilateral 1
and 1
multifocal 1
tumours 1
, 0 
and 0 
presenting 0 
at 0 
an 0 
earlier 0 
age 0 
than 0 
in 0 
sporadic 0 
, 0 
non-familial 0 
cases 0 
of 0 
this 0 
tumour 1
type 0 
. 0 

We 0 
report 0 
here 0 
that 0 
the 0 
VHL 1
gene 0 
is 0 
linked 0 
to 0 
the 0 
locus 0 
encoding 0 
the 0 
human 0 
homologoue 0 
of 0 
the 0 
RAF1 0 
oncogene 0 
, 0 
which 0 
maps 0 
to 0 
chromosome 0 
3p25 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

Crossovers 0 
with 0 
the 0 
VHL 1
locus 0 
suggest 0 
that 0 
the 0 
defect 0 
responsible 0 
for 0 
the 0 
VHL 1
phenotype 0 
is 0 
not 0 
a 0 
mutation 0 
in 0 
the 0 
RAF1 0 
gene 0 
itself 0 
. 0 

An 0 
alternative 0 
or 0 
prior 0 
event 0 
to 0 
oncogene 0 
activation 0 
in 0 
tumour 1
formation 0 
may 0 
be 0 
the 0 
inactivation 0 
of 0 
a 0 
putative 0 
tumour 1
suppressor 0 
which 0 
can 0 
be 0 
associated 0 
with 0 
both 0 
the 0 
inherited 1
and 1
sporadic 1
forms 1
of 1
the 1
cancer 1
. 0 

Sporadic 1
renal 1
cell 1
carcinomas 1
have 0 
previously 0 
been 0 
associated 0 
with 0 
the 0 
loss 0 
of 0 
regions 0 
on 0 
chromosome 0 
3p 0 
-LRB- 0 
refs 0 
_NUM1 0 
, 0 
_NUM1 0 
-RRB- 0 
. 0 

Consequently 0 
, 0 
sporadic 0 
and 0 
VHL-associated 0 
forms 0 
of 0 
renal 1
cell 1
carcinoma 1
might 0 
both 0 
result 0 
from 0 
alterations 0 
causing 0 
loss 0 
of 0 
function 0 
of 0 
the 0 
same 0 
tumour 1
suppressor 0 
gene 0 
on 0 
this 0 
chromosome 0 
. 0 
. 0 

Tightly 0 
linked 0 
flanking 0 
markers 0 
for 0 
the 0 
Lowe 1
oculocerebrorenal 1
syndrome 1
, 0 
with 0 
application 0 
to 0 
carrier 0 
assessment 0 
. 0 

The 0 
Lowe 1
oculocerebrorenal 1
syndrome 1
-LRB- 0 
OCRL 1
-RRB- 0 
is 0 
characterized 0 
by 0 
congenital 0 
cataract 1
, 0 
mental 1
retardation 1
, 0 
and 0 
defective 1
renal 1
tubular 1
function 1
. 0 

A 0 
map 0 
assignment 0 
of 0 
OCRL 1
to 0 
Xq24-q26 0 
has 0 
been 0 
made 0 
previously 0 
by 0 
linkage 0 
analysis 0 
with 0 
DXS42 0 
at 0 
Xq24-q26 0 
-LRB- 0 
theta 0 
= 0 
_NUM1 0 
, 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
with 0 
DXS10 0 
at 0 
Xq26 0 
-LRB- 0 
theta 0 
= 0 
_NUM1 0 
, 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Two 0 
additional 0 
families 0 
were 0 
studied 0 
and 0 
three 0 
additional 0 
polymorphisms 0 
were 0 
identified 0 
at 0 
DXS42 0 
by 0 
using 0 
a 0 
35-kb 0 
sequence 0 
isolated 0 
with 0 
the 0 
probe 0 
detecting 0 
the 0 
original 0 
polymorphism 0 
at 0 
DXS42 0 
. 0 

With 0 
additional 0 
OCRL 1
families 0 
made 0 
informative 0 
for 0 
DXS42 0 
, 0 
theta 0 
remained 0 
_NUM1 0 
with 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
; 0 
and 0 
for 0 
DXS10 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
and 0 
z 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

Evidence 0 
for 0 
placing 0 
OCRL 0 
at 0 
Xq25 0 
also 0 
comes 0 
from 0 
a 0 
female 0 
with 0 
Lowe 1
syndrome 1
and 0 
an 0 
X 0 
; 0 
_NUM1 0 
translocation 0 
. 0 

We 0 
have 0 
used 0 
the 0 
Xq25 0 
breakpoint 0 
in 0 
this 0 
patient 0 
to 0 
determine 0 
the 0 
position 0 
of 0 
OCRL 1
relative 0 
to 0 
the 0 
two 0 
linked 0 
markers 0 
. 0 

Each 0 
derivative 0 
chromosome 0 
was 0 
isolated 0 
away 0 
from 0 
its 0 
normal 0 
counterpart 0 
in 0 
somatic 0 
cell 0 
hybrids 0 
. 0 

DXS42 0 
was 0 
mapped 0 
to 0 
the 0 
derivative 0 
chromosome 0 
X 0 
containing 0 
Xpterq25 0 
, 0 
and 0 
DXS10 0 
was 0 
mapped 0 
to 0 
the 0 
derivative 0 
chromosome 0 
_NUM1 0 
containing 0 
Xq25-qter 0 
. 0 

The 0 
markers 0 
DXS10 0 
and 0 
DXS42 0 
therefore 0 
show 0 
tight 0 
linkage 0 
with 0 
OCRL 1
in 0 
six 0 
families 0 
and 0 
flank 0 
the 0 
Xq25 0 
breakpoint 0 
in 0 
a 0 
female 0 
patient 0 
with 0 
an 0 
X 0 
; 0 
_NUM1 0 
translocation 0 
. 0 

Linkage 0 
analysis 0 
with 0 
flanking 0 
markers 0 
was 0 
used 0 
to 0 
assess 0 
OCRL 0 
carrier 0 
status 0 
in 0 
women 0 
at 0 
risk 0 
. 0 

Results 0 
, 0 
when 0 
compared 0 
with 0 
carrier 0 
determination 0 
by 0 
ophthalmologic 0 
examination 0 
, 0 
indicated 0 
that 0 
the 0 
slit-lamp 0 
exam 0 
can 0 
be 0 
a 0 
sensitive 0 
and 0 
specific 0 
method 0 
of 0 
carrier 0 
determination 0 
in 0 
many 0 
cases 0 
Abnormal 0 
development 0 
of 0 
Purkinje 0 
cells 0 
and 0 
lymphocytes 0 
in 0 
Atm 0 
mutant 0 
mice 0 
. 0 

Motor 1
incoordination 1
, 0 
immune 1
deficiencies 1
, 0 
and 0 
an 0 
increased 0 
risk 0 
of 0 
cancer 1
are 0 
the 0 
characteristic 0 
features 0 
of 0 
the 0 
hereditary 1
disease 1
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
, 0 
which 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
. 0 

Through 0 
gene 0 
targeting 0 
, 0 
we 0 
have 0 
generated 0 
a 0 
line 0 
of 0 
Atm 0 
mutant 0 
mice 0 
, 0 
Atm 0 
-LRB- 0 
y 0 
/ 0 
y 0 
-RRB- 0 
mice 0 
. 0 

In 0 
contrast 0 
to 0 
other 0 
Atm 0 
mutant 0 
mice 0 
, 0 
Atm 0 
-LRB- 0 
y 0 
/ 0 
y 0 
-RRB- 0 
mice 0 
show 0 
a 0 
lower 0 
incidence 0 
of 0 
thymic 1
lymphoma 1
and 0 
survive 0 
beyond 0 
a 0 
few 0 
months 0 
of 0 
age 0 
. 0 

Atm 0 
-LRB- 0 
y 0 
/ 0 
y 0 
-RRB- 0 
mice 0 
exhibit 0 
deficits 0 
in 0 
motor 0 
learning 0 
indicative 0 
of 0 
cerebellar 1
dysfunction 1
. 0 

Even 0 
though 0 
we 0 
found 0 
no 0 
gross 0 
cerebellar 1
degeneration 1
in 0 
older 0 
Atm 0 
-LRB- 0 
y 0 
/ 0 
y 0 
-RRB- 0 
animals 0 
, 0 
ectopic 0 
and 0 
abnormally 0 
differentiated 0 
Purkinje 0 
cells 0 
were 0 
apparent 0 
in 0 
mutant 0 
mice 0 
of 0 
all 0 
ages 0 
. 0 

These 0 
findings 0 
establish 0 
that 0 
some 0 
neuropathological 1
abnormalities 1
seen 0 
in 0 
A-T 1
patients 0 
also 0 
are 0 
present 0 
in 0 
Atm 0
mutant 0 
mice 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
report 0 
a 0 
previously 0 
unrecognized 0 
effect 0 
of 0 
Atm 1
deficiency 1
on 0 
development 0 
or 0 
maintenance 0 
of 0 
CD4 0 
-LRB- 0 
+ 0 
-RRB- 0 
_NUM1 0 
-LRB- 0 
+ 0 
-RRB- 0 
thymocytes 0 
. 0 

We 0 
discuss 0 
these 0 
findings 0 
in 0 
the 0 
context 0 
of 0 
the 0 
hypothesis 0 
that 0 
abnormal 0 
development 0 
of 0 
Purkinje 0 
cells 0 
and 0 
lymphocytes 0 
contributes 0 
to 0 
the 0 
pathogenesis 0 
of 0 
A-T 1
. 0 
. 0 

Both 0 
mutations 0 
in 0 
G6PD 0
A 0 
- 0 
are 0 
necessary 0 
to 0 
produce 0 
the 0 
G6PD 1
deficient 1
phenotype 0 
. 0 

The 0 
high 0 
prevalence 0 
of 0 
glucose 1
6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
in 0 
African 0 
populations 0 
is 0 
due 0 
almost 0 
entirely 0 
to 0 
the 0 
enzyme 0 
variant 0 
A 0 
- 0 
, 0 
which 0 
differs 0 
from 0 
the 0 
wild-type 0 
G6PD 0
B 0 
by 0 
two 0 
amino 0 
acid 0 
replacements 0 
, 0 
_NUM2 0 
Val 0 
-- 0 
> 0 
Met 0 
and 0 
_NUM3 0 
Asn 0 
-- 0 
> 0 
Asp 0 
. 0 

The 0 
non-deficient 0 
polymorphic 0 
variant 0 
G6PD 0
A 0 
contains 0 
only 0 
the 0 
mutation 0 
_NUM3 0 
Asn 0 
-- 0 
> 0 
Asp 0 
. 0 

The 0 
frequencies 0 
of 0 
the 0 
G6PD 0
A 0 
and 0 
of 0 
the 0 
G6PD 0
A 0 
- 0 
genes 0 
in 0 
parts 0 
of 0 
Africa 0 
are 0 
both 0 
about 0 
_NUM1 0 
. 0 

_NUM1 0 
. 0 

The 0 
_NUM2 0 
Val 0 
-- 0 
> 0 
Met 0 
mutation 0 
has 0 
not 0 
been 0 
found 0 
in 0 
a 0 
B 0 
background 0 
. 0 

This 0 
could 0 
be 0 
because 0 
the 0 
_NUM2 0 
Val 0 
-- 0 
> 0 
Met 0 
mutation 0 
happened 0 
to 0 
arise 0 
in 0 
an 0 
A 0 
gene 0 
in 0 
the 0 
first 0 
instance 0 
, 0 
or 0 
because 0 
the 0 
_NUM2 0 
Val 0 
-- 0 
> 0 
Met 0 
mutation 0 
alone 0 
is 0 
not 0 
sufficient 0 
to 0 
cause 0 
G6PD 1
deficiency 1
. 0 

We 0 
have 0 
approached 0 
this 0 
question 0 
by 0 
producing 0 
G6PD 0 
B 0 
, 0 
A 0 
, 0 
A 0 
- 0 
, 0 
and 0 
G6PD 0 
_NUM2 0 
Val 0 
-- 0 
> 0 
Met 0 
in 0 
a 0 
bacterial 0 
expression 0 
system 0 
and 0 
analysing 0 
their 0 
biochemical 0 
properties 0 
. 0 

With 0 
each 0 
single 0 
mutation 0 
we 0 
found 0 
a 0 
slight 0 
decrease 0 
in 0 
both 0 
the 0 
specific 0 
activity 0 
and 0 
the 0 
yield 0 
of 0 
enzyme 0
when 0 
compared 0 
to 0 
G6PD 0 
B 0 
. 0 

When 0 
both 0 
mutations 0 
were 0 
introduced 0 
together 0 
, 0 
there 0 
was 0 
a 0 
roughly 0 
additive 0 
effect 0 
on 0 
specific 0 
activity 0 
, 0 
but 0 
a 0 
much 0 
more 0 
drastic 0 
effect 0 
on 0 
enzyme 0
yield 0 
-LRB- 0 
_NUM1 0 
% 0 
of 0 
normal 0 
-RRB- 0 
. 0 

This 0 
synergistic 0 
effect 0 
was 0 
also 0 
demonstrated 0 
on 0 
thermal 0 
stability 0 
, 0 
especially 0 
at 0 
low 0 
NADP 0 
concentrations 0 
. 0 

Comparable 0 
results 0 
were 0 
produced 0 
when 0 
the 0 
replacement 0 
_NUM3 0 
Gln 0 
-- 0 
> 0 
Glu 0 
was 0 
studied 0 
instead 0 
of 0 
_NUM3 0 
Asn 0 
-- 0 
> 0 
Asp 0 
. 0 

We 0 
infer 0 
that 0 
the 0 
coexistence 0 
of 0 
the 0 
two 0 
mutations 0 
is 0 
responsible 0 
for 0 
enzyme 1
deficiency 1
in 1
G6PD 1
A 0 
- 0 
because 0 
they 0 
act 0 
synergistically 0 
in 0 
causing 0 
instability 0 
of 0 
the 0 
enzyme 0 
. 0 

Detection 0 
of 0 
_NUM2 0 
% 0 
of 0 
DMD 1
/ 0 
BMD 1
gene 0 
deletions 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
. 0 

We 0 
describe 0 
oligonucleotide 0 
primer 0 
sequences 0 
that 0 
can 0 
be 0 
used 0 
to 0 
amplify 0 
eight 0 
exons 0 
plus 0 
the 0 
muscle 0 
promoter 0 
of 0 
the 0 
dystrophin 0 
gene 0 
in 0 
a 0 
single 0 
multiplex 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
. 0 

When 0 
used 0 
in 0 
conjunction 0 
with 0 
an 0 
existing 0 
primer 0 
set 0 
, 0 
these 0 
two 0 
multiplex 0 
reactions 0 
detect 0 
about 0 
_NUM2 0 
% 0 
of 0 
deletions 0 
in 0 
patients 0 
with 0 
Duchenne 1
or 1
Becker 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
, 0 
BMD 1
-RRB- 0 
. 0 

Furthermore 0 
, 0 
these 0 
primers 0 
amplify 0 
most 0 
of 0 
the 0 
exons 0 
in 0 
the 0 
deletion 0 
prone 0 
'' 0 
hot 0 
spot 0 
'' 0 
region 0 
around 0 
exons 0 
_NUM2 0 
to 0 
_NUM2 0 
, 0 
allowing 0 
determination 0 
of 0 
deletion 0 
endpoints 0 
and 0 
prediction 0 
of 0 
mutational 0 
effects 0 
on 0 
the 0 
translational 0 
reading 0 
frame 0 
. 0 

Thus 0 
, 0 
use 0 
of 0 
these 0 
PCR-based 0 
assays 0 
will 0 
allow 0 
deletion 0 
detection 0 
and 0 
prenatal 0 
diagnosis 0 
for 0 
most 0 
DMD 1
/ 0 
BMD 1
patients 0 
in 0 
a 0 
fraction 0 
of 0 
the 0 
time 0 
required 0 
for 0 
Southern 0 
blot 0 
analysis 0 
. 0 
. 0 

Recombination 0 
events 0 
that 0 
locate 0 
myotonic 1
dystrophy 1
distal 0 
to 0 
APOC2 0 
on 0 
19q 0 
. 0 

We 0 
previously 0 
reported 0 
a 0 
recombination 0 
in 0 
an 0 
individual 0 
with 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
which 0 
placed 0 
the 0 
markers 0 
D19S19 0 
and 0 
APOC2 0 
on 0 
the 0 
same 0 
side 0 
of 0 
the 0 
DM 1
locus 0 
. 0 

Haplotyping 0 
of 0 
this 0 
family 0 
with 0 
more 0 
recently 0 
characterized 0 
probes 0 
which 0 
are 0 
either 0 
tightly 0 
linked 0 
to 0 
DM 1
or 0 
distal 0 
to 0 
the 0 
linkage 0 
group 0 
at 0 
_AN 0 
. 0 

_NUM1 0 
shows 0 
that 0 
the 0 
DM 1
locus 0 
is 0 
distal 0 
to 0 
APOC2 0 
. 0 

This 0 
is 0 
confirmed 0 
by 0 
other 0 
recombinants 0 
where 0 
DM 1
segregates 0 
with 0 
distal 0 
probes 0 
. 0 

Additional 0 
marker 0 
to 0 
marker 0 
recombinations 0 
in 0 
unaffected 0 
individuals 0 
are 0 
reported 0 
and 0 
support 0 
the 0 
order 0 
and 0 
orientation 0 
of 0 
the 0 
DM 1
linkage 0 
group 0 
as 0 
pter 0 
- 0 
-LRB- 0 
INSR 0 
, 0 
LDLR 0 
, 0 
S9 0 
-RRB- 0 
- 0 
-LRB- 0 
_AN 0 
, 0 
BCL3 0 
, 0 
APOC2 0 
-RRB- 0 
- 0 
-LRB- 0 
CKMM 0 
, 0 
DM 1
-RRB- 0 
- 0 
-LRB- 0 
_AN 0 
, 0 
+ 0 
+ 0 
+ 0 
PRKCG 0 
-RRB- 0 
- 0 
qter 0 
. 0 

The 0 
data 0 
presented 0 
here 0 
can 0 
not 0 
determine 0 
whether 0 
DM 1
is 0 
proximal 0 
or 0 
distal 0 
to 0 
CKMM 0 
. 0 

The 0 
consequences 0 
of 0 
this 0 
probe 0 
order 0 
for 0 
antenatal 0 
diagnosis 0 
and 0 
future 0 
research 0 
aiming 0 
to 0 
isolate 0 
the 0 
gene 0 
which 0 
is 0 
affected 0 
in 0 
DM 0 
are 0 
discussed 0 
. 0 

New 0 
mutations 0 
, 0 
polymorphisms 0 
, 0 
and 0 
rare 0 
variants 0 
in 0 
the 0 
ATM 0 
gene 0 
detected 0 
by 0 
a 0 
novel 0 
SSCP 0 
strategy 0 
. 0 

The 0 
gene 0 
for 0 
ataxia-telangiectasia 1
, 0 
ATM 0 
, 0 
spans 0 
about 0 
_NUM3 0 
kb 0 
of 0 
genomic 0 
DNA 0 
. 0 

ATM 0 
mutations 0 
are 0 
found 0 
along 0 
the 0 
entire 0 
gene 0 
, 0 
with 0 
no 0 
evidence 0 
of 0 
a 0 
mutational 0 
hot 0 
spot 0 
. 0 

Using 0 
DNA 0 
as 0 
the 0 
starting 0 
material 0 
, 0 
we 0 
screened 0 
the 0 
ATM 0 
gene 0 
in 0 
_NUM2 0 
A-T 1
patients 0 
, 0 
using 0 
an 0 
optimized 0 
single-strand 0 
conformation 0 
polymorphism 0 
-LRB- 0 
SSCP 0 
-RRB- 0 
technique 0 
that 0 
detected 0 
all 0 
previously 0 
known 0 
mutations 0 
in 0 
the 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
segments 0 
being 0 
analyzed 0 
. 0 

To 0 
expedite 0 
screening 0 
, 0 
we 0 
sequentially 0 
loaded 0 
the 0 
SSCP 0 
gels 0 
with 0 
three 0 
different 0 
sets 0 
of 0 
PCR 0 
products 0 
that 0 
were 0 
pretested 0 
to 0 
avoid 0 
overlapping 0 
patterns 0 
. 0 

Many 0 
of 0 
the 0 
DNA 0 
changes 0 
we 0 
detected 0 
were 0 
intragenic 0 
polymorphisms 0 
. 0 

Of 0 
an 0 
expected 0 
_NUM3 0 
unknown 0 
mutations 0 
, 0 
we 0 
detected 0 
approximately 0 
_NUM2 0 
% 0 
, 0 
mostly 0 
protein 0 
truncating 0 
mutations 0 
-LRB- 0 
that 0 
would 0 
have 0 
been 0 
detectable 0 
by 0 
protein 0 
truncation 0 
testing 0 
if 0 
RNA 0 
starting 0 
material 0 
had 0 
been 0 
available 0 
-RRB- 0 
. 0 

Mutations 0 
have 0 
now 0 
been 0 
defined 0 
for 0 
every 0 
exon 0 
of 0 
the 0 
ATM 0 
gene 0 
. 0 

Herein 0 
, 0 
we 0 
present 0 
_NUM2 0 
new 0 
mutations 0 
and 0 
_NUM2 0 
new 0 
intragenic 0 
polymorphisms 0 
or 0 
rare 0 
variants 0 
within 0 
the 0 
ATM 0 
gene 0 
. 0 

This 0 
is 0 
the 0 
most 0 
comprehensive 0 
compilation 0 
of 0 
ATM 0 
polymorphisms 0 
assembled 0 
to 0 
date 0 
. 0 

Defining 0 
polymorphic 0 
sites 0 
as 0 
well 0 
as 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
will 0 
be 0 
of 0 
great 0 
importance 0 
in 0 
designing 0 
automated 0 
methods 0 
for 0 
detecting 0 
mutations 0 
. 0 
. 0 

Chromosome 0 
breakage 0 
in 0 
the 0 
Prader-Willi 1
and 1
Angelman 1
syndromes 1
involves 0 
recombination 0 
between 0 
large 0 
, 0 
transcribed 0 
repeats 0 
at 0 
proximal 0 
and 0 
distal 0 
breakpoints 0 
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
and 0 
Angelman 1
syndrome 1
-LRB- 0 
AS 1
-RRB- 0 
are 0 
distinct 0 
neurobehavioral 1
disorders 1
that 0 
most 0 
often 0 
arise 0 
from 0 
a 0 
4-Mb 0 
deletion 0 
of 0 
chromosome 0 
15q11-q13 0 
during 0 
paternal 0 
or 0 
maternal 0 
gametogenesis 0 
, 0 
respectively 0 
. 0 

At 0 
a 0 
de 0 
novo 0 
frequency 0 
of 0 
approximately 0 
. 0 

67-1 0 
/ 0 
10 0 
, 0 
_NUM3 0 
births 0 
, 0 
these 0 
deletions 0 
represent 0 
a 0 
common 0 
structural 0 
chromosome 0 
change 0 
in 0 
the 0 
human 0 
genome 0 
. 0 

To 0 
elucidate 0 
the 0 
mechanism 0 
underlying 0 
these 0 
events 0 
, 0 
we 0 
characterized 0 
the 0 
regions 0 
that 0 
contain 0 
two 0 
proximal 0 
breakpoint 0 
clusters 0 
and 0 
a 0 
distal 0 
cluster 0 
. 0 

Novel 0 
DNA 0 
sequences 0 
potentially 0 
associated 0 
with 0 
the 0 
breakpoints 0 
were 0 
positionally 0 
cloned 0 
from 0 
YACs 0 
within 0 
or 0 
near 0 
these 0 
regions 0 
. 0 

Analyses 0 
of 0 
rodent-human 0 
somatic-cell 0 
hybrids 0 
, 0 
YAC 0 
contigs 0 
, 0 
and 0 
FISH 0 
of 0 
normal 0 
or 0 
rearranged 0 
chromosomes 0 
_NUM2 0 
identified 0 
duplicated 0 
sequences 0 
-LRB- 0 
the 0 
END 0 
repeats 0 
-RRB- 0 
at 0 
or 0 
near 0 
the 0 
breakpoints 0 
. 0 

The 0 
END-repeat 0 
units 0 
are 0 
derived 0 
from 0 
large 0 
genomic 0 
duplications 0 
of 0 
a 0 
novel 0 
gene 0 
-LRB- 0 
HERC2 0 
-RRB- 0 
, 0 
many 0 
copies 0 
of 0 
which 0 
are 0 
transcriptionally 0 
active 0 
in 0 
germline 0 
tissues 0 
. 0 

One 0 
of 0 
five 0 
PWS 1
/ 0 
AS 1
patients 0 
analyzed 0 
to 0 
date 0 
has 0 
an 0 
identifiable 0 
, 0 
rearranged 0 
HERC2 0 
transcript 0 
derived 0 
from 0 
the 0 
deletion 0 
event 0 
. 0 

We 0 
postulate 0 
that 0 
the 0 
END 0 
repeats 0 
flanking 0 
15q11-q13 0 
mediate 0 
homologous 0 
recombination 0 
resulting 0 
in 0 
deletion 0 
. 0 

Furthermore 0 
, 0 
we 0 
propose 0 
that 0 
active 0 
transcription 0 
of 0 
these 0 
repeats 0 
in 0 
male 0 
and 0 
female 0 
germ 0 
cells 0 
may 0 
facilitate 0 
the 0 
homologous 0 
recombination 0 
process 0 
. 0 

A 0 
4-megabase 0 
YAC 0 
contig 0 
that 0 
spans 0 
the 0 
Langer-Giedion 1
syndrome 1
region 0 
on 0 
human 0 
chromosome 0 
8q24 0 
.1 0 
: 0 
use 0 
in 0 
refining 0 
the 0 
location 0 
of 0 
the 0 
trichorhinophalangeal 1
syndrome 1
and 0 
multiple 0 
exostoses 0 
genes 0 
-LRB- 0 
TRPS1 0 
and 0 
EXT1 0 
-RRB- 0 
. 0 

We 0 
have 0 
constructed 0 
a 0 
physical 0 
map 0 
covering 0 
over 0 
_NUM1 0 
Mb 0 
of 0 
human 0 
chromosome 0 
8q24 0 
. 0 

_NUM1 0 
and 0 
used 0 
this 0 
map 0 
to 0 
refine 0 
the 0 
locations 0 
of 0 
the 0 
genes 0 
responsible 0 
for 0 
Langer-Giedion 1
syndrome 1
. 0 

The 0 
map 0 
is 0 
composed 0 
of 0 
overlapping 0 
YAC 0 
clones 0 
that 0 
were 0 
identified 0 
and 0 
ordered 0 
in 0 
relation 0 
to 0 
sequence 0 
tagged 0 
sites 0 
mapped 0 
to 0 
the 0 
Langer-Giedion 0
chromosomal 0 
region 0 
on 0 
somatic 0 
cell 0 
hybrids 0 
. 0 

The 0 
minimal 0 
region 0 
of 0 
overlap 0 
of 0 
Langer-Giedion 1
syndrome 1
deletions 0 
, 0 
previously 0 
identified 0 
by 0 
analysis 0 
of 0 
_NUM2 0 
patients 0 
, 0 
was 0 
placed 0 
on 0 
the 0 
map 0 
by 0 
analysis 0 
of 0 
_NUM1 0 
patients 0 
whose 0 
deletions 0 
define 0 
the 0 
endpoints 0 
. 0 

The 0 
chromosome 0 
_NUM1 0 
breakpoint 0 
of 0 
a 0 
balanced 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM1 0 
-RRB- 0 
-LRB- 0 
_AN 0 
. 0 

_NUM2 0 
; 0 
_AN 0 
. 0 

_NUM1 0 
-RRB- 0 
translocation 0 
from 0 
a 0 
patient 0 
with 0 
trichorhinophalangeal 1
syndrome 1
-LRB- 0 
TRPS 1
I 0 
-RRB- 0 
was 0 
found 0 
to 0 
be 0 
located 0 
just 0 
within 0 
the 0 
proximal 0 
end 0 
of 0 
the 0 
minimal 0 
deletion 0 
region 0 
. 0 

A 0 
deletion 0 
of 0 
8q24 0 
. 0 

11-q24 0 
. 0 

_NUM1 0 
in 0 
a 0 
patient 0 
with 0 
multiple 0 
exostoses 0 
was 0 
found 0 
to 0 
overlap 0 
the 0 
distal 0 
end 0 
of 0 
the 0 
LGS 1
deletion 0 
region 0 
, 0 
indicating 0 
that 0 
the 0 
EXT1 0 
gene 0 
is 0 
distal 0 
to 0 
the 0 
TRPS1 0 
gene 0 
and 0 
supporting 0 
the 0 
hypothesis 0 
that 0 
Langer-Giedion 1
syndrome 1
is 0 
due 0 
to 0 
loss 0 
of 0 
functional 0 
copies 0 
of 0 
both 0 
the 0 
TRPS1 0 
and 0 
the 0 
EXT1 0 
genes 0 
Genetic 0 
mapping 0 
of 0 
the 0 
breast-ovarian 1
cancer 1
syndrome 1
to 0 
a 0 
small 0 
interval 0 
on 0 
chromosome 0 
17q12-21 0 
: 0 
exclusion 0 
of 0 
candidate 0 
genes 0 
EDH17B2 0 
and 0 
RARA 0 
. 0 

A 0 
susceptibility 0 
gene 0 
for 0 
hereditary 1
breast-ovarian 1
cancer 1
, 0 
BRCA1 0 
, 0 
has 0 
been 0 
assigned 0 
by 0 
linkage 0 
analysis 0 
to 0 
chromosome 0 
17q21 0 
. 0 

Candidate 0 
genes 0 
in 0 
this 0 
region 0 
include 0 
EDH17B2 0 
, 0 
which 0 
encodes 0 
estradiol 0 
_NUM2 0 
beta-hydroxysteroid 0 
dehydrogenase 0 
II 0 
-LRB- 0 
_NUM2 0 
beta-HSD 0 
II 0 
-RRB- 0 
, 0 
and 0 
RARA 0 
, 0 
the 0 
gene 0 
for 0 
retinoic 0 
acid 0 
receptor 0 
alpha 0 
. 0 

We 0 
have 0 
typed 0 
_NUM2 0 
breast 1
and 1
breast-ovarian 1
cancer 1
families 0 
with 0 
eight 0 
polymorphisms 0 
from 0 
the 0 
chromosome 0 
17q12-21 0 
region 0 
, 0 
including 0 
two 0 
in 0 
the 0 
EDH17B2 0 
gene 0 
. 0 

Genetic 0 
recombination 0 
with 0 
the 0 
breast 1
cancer 1
trait 0 
excludes 0 
RARA 0 
from 0 
further 0 
consideration 0 
as 0 
a 0 
candidate 0 
gene 0 
for 0 
BRCA1 0 
. 0 

Both 0 
BRCA1 0 
and 0 
EDH17B2 0 
map 0 
to 0 
a 0 
_NUM1 0 
cM 0 
interval 0 
-LRB- 0 
between 0 
THRA1 0 
and 0 
D17S579 0 
-RRB- 0 
and 0 
no 0 
recombination 0 
was 0 
observed 0 
between 0 
the 0 
two 0 
genes 0 
. 0 

However 0 
, 0 
direct 0 
sequencing 0 
of 0 
overlapping 0 
PCR 0 
products 0 
containing 0 
the 0 
entire 0 
EDH17B2 0 
gene 0 
in 0 
four 0 
unrelated 0 
affected 0 
women 0 
did 0 
not 0 
uncover 0 
any 0 
sequence 0 
variation 0 
, 0 
other 0 
than 0 
previously 0 
described 0 
polymorphisms 0 
. 0 

Mutations 0 
in 0 
the 0 
EDH17B2 0 
gene 0 
, 0 
therefore 0 
do 0 
not 0 
appear 0 
to 0 
be 0 
responsible 0 
for 0 
the 0 
hereditary 1
breast-ovarian 1
cancer 1
syndrome 1
. 0 

Single 0 
meiotic 0 
crossovers 0 
in 0 
affected 0 
women 0 
suggest 0 
that 0 
BRCA1 0 
is 0 
flanked 0 
by 0 
the 0 
loci 0 
RARA 0 
and 0 
D17S78 0 
. 0 
. 0 

Hereditary 1
C2 1
deficiency 1
associated 0 
with 0 
common 0 
variable 0 
immunodeficiency 1
. 0 

Homozygous 0 
C2 1
deficiency 1
in 0 
a 0 
19-year-old 0 
boy 0 
was 0 
associated 0 
with 0 
variable 0 
immunodeficiency 1
manifested 0 
by 0 
marked 0 
hypoimmunoglobulinemia 1
and 0 
impaired 0 
antibody 0 
responses 0 
, 0 
normal 0 
circulating 0 
B 0 
lymphocytes 0 
, 0 
and 0 
subnormal 0 
T-cell 0 
functions 0 
. 0 

Neither 0 
antilymphocytic 0 
autoantibodies 0 
nor 0 
chromosomal 1
abnormalities 1
were 0 
found 0 
. 0 

Serum 0 
immunoglobulin 0 
levels 0 
were 0 
within 0 
normal 0 
limits 0 
in 0 
his 0 
parents 0 
and 0 
brother 0 
who 0 
were 0 
heterozygous 0 
for 0 
C2 1
deficiency 1
. 0 

The 0 
patients 0 
lymphocytes 0 
were 0 
homozygous 0 
at 0 
the 0 
HLA-D 0 
locus 0 
but 0 
expressed 0 
an 0 
antigen 0 
different 0 
from 0 
DW2 0 
. 0 
. 0 

Isolation 0 
of 0 
molecular 0 
probes 0 
associated 0 
with 0 
the 0 
chromosome 0 
_NUM2 0 
instability 0 
in 0 
the 0 
Prader-Willi 1
syndrome 1
. 0 

Flow 0 
cytometry 0 
and 0 
recombinant 0 
DNA 0 
techniques 0 
have 0 
been 0 
used 0 
to 0 
obtain 0 
reagents 0 
for 0 
a 0 
molecular 0 
analysis 0 
of 0 
the 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

HindIII 0 
total-digest 0 
libraries 0 
were 0 
prepared 0 
in 0 
lambda 0 
phage 0 
Charon 0 
21A 0 
from 0 
flow-sorted 0 
inverted 0 
duplicated 0 
no. 0 
_NUM2 0 
human 0 
chromosomes 0 
and 0 
propagated 0 
on 0 
recombination-proficient 0 
-LRB- 0 
LE392 0 
-RRB- 0 
and 0 
recBC 0 
- 0 
, 0 
sbcB 0 
- 0 
-LRB- 0 
DB1257 0 
-RRB- 0 
bacteria 0 
. 0 

Twelve 0 
distinct 0 
chromosome 0 
15-specific 0 
probes 0 
have 0 
been 0 
isolated 0 
. 0 

Eight 0 
localized 0 
to 0 
the 0 
region 0 
15q11 0 
-- 0 
_NUM2 0 
. 0 

Four 0 
of 0 
these 0 
eight 0 
sublocalized 0 
to 0 
band 0 
15q11 0 
. 0 

_NUM1 0 
and 0 
are 0 
shown 0 
to 0 
be 0 
deleted 0 
in 0 
DNA 0 
of 0 
one 0 
of 0 
two 0 
patients 0 
examined 0 
with 0 
the 0 
PWS 1
. 0 

Heteroduplex 0 
analysis 0 
of 0 
two 0 
of 0 
these 0 
clones 0 
, 0 
which 0 
grew 0 
on 0 
DB1257 0 
but 0 
not 0 
on 0 
LE392 0 
, 0 
revealed 0 
stem-loop 0 
structures 0 
in 0 
the 0 
inserts 0 
, 0 
indicative 0 
of 0 
inverted 0 
, 0 
repeated 0 
DNA 0 
elements 0 
. 0 

Such 0 
DNA 0 
repeats 0 
might 0 
account 0 
for 0 
some 0 
of 0 
the 0 
cloning 0 
instability 0 
of 0 
DNA 0 
segments 0 
from 0 
proximal 0 
15q 0 
. 0 

Analysis 0 
of 0 
the 0 
genetic 0 
and 0 
physical 0 
instability 0 
associated 0 
with 0 
the 0 
repeated 0 
sequences 0 
we 0 
have 0 
isolated 0 
from 0 
band 0 
15q11 0 
. 0 

_NUM1 0 
may 0 
elucidate 0 
the 0 
molecular 0 
basis 0 
for 0 
the 0 
instability 0 
of 0 
this 0 
chromosomal 0 
region 0 
in 0 
patients 0 
with 0 
the 0 
PWS 1
or 0 
other 0 
diseases 0 
associated 0 
with 0 
chromosomal 1
abnormalities 1
in 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
human 0 
chromosome 0 
_NUM2 0 
Myotonic 1
dystrophy 1
: 0 
evidence 0 
for 0 
a 0 
possible 0 
dominant-negative 0 
RNA 0 
mutation 0 
. 0 

The 0 
trinucleotide 0 
expansion 0 
mutation 0 
causing 0 
myotonic 1
dystrophy 1
is 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
a 0 
protein 0 
kinase 0 
gene 0 
. 0 

The 0 
molecular 0 
mechanisms 0 
by 0 
which 0 
the 0 
expanded 0 
repeat 0 
causes 0 
the 0 
clinically 0 
variable 0 
and 0 
multisystemic 1
disease 1
, 0 
myotonic 1
dystrophy 1
, 0 
are 0 
not 0 
understood 0 
. 0 

It 0 
has 0 
been 0 
particularly 0 
difficult 0 
to 0 
rationalize 0 
the 0 
dominant 0 
inheritance 0 
with 0 
the 0 
fact 0 
that 0 
the 0 
expansion 0 
mutation 0 
lies 0 
outside 0 
of 0 
the 0 
protein-encoding 0 
gene 0 
elements 0 
, 0 
and 0 
should 0 
not 0 
be 0 
translated 0 
into 0 
protein 0 
. 0 

Here 0 
we 0 
use 0 
muscle 0 
biopsies 0 
from 0 
classical 0 
adult-onset 0 
myotonic 1
dystrophy 1
patients 0 
to 0 
study 0 
the 0 
accumulation 0 
of 0 
transcripts 0 
from 0 
both 0 
the 0 
normal 0 
and 0 
expanded 0 
DM 1
kinase 0 
genes 0 
in 0 
patient 0 
muscle 0 
, 0 
and 0 
compare 0 
the 0 
results 0 
to 0 
normal 0 
and 0 
myopathic 1
controls 0 
. 0 

We 0 
found 0 
relatively 0 
small 0 
decreases 0 
of 0 
DM 1
kinase 0 
RNA 0 
in 0 
the 0 
total 0 
RNA 0 
pool 0 
from 0 
muscle 0 
; 0 
however 0 
, 0 
these 0 
reductions 0 
were 0 
not 0 
disease 0 
specific 0 
. 0 

Analysis 0 
of 0 
poly 0 
-LRB- 0 
A 0 
-RRB- 0 
+ 0 
RNA 0 
showed 0 
dramatic 0 
decreases 0 
of 0 
both 0 
the 0 
mutant 0 
and 0 
normal 0 
DM 1
kinase 0 
RNAs 0 
, 0 
and 0 
these 0 
changes 0 
were 0 
disease-specific 0 
. 0 

Our 0 
findings 0 
are 0 
consistent 0 
with 0 
a 0 
novel 0 
molecular 0 
pathogenetic 0 
mechanism 0 
for 0 
myotonic 1
dystrophy 1
both 0 
the 0 
normal 0 
and 0 
expanded 0 
DM 1
kinase 0 
genes 0 
are 0 
transcribed 0 
in 0 
patient 0 
muscle 0 
, 0 
but 0 
the 0 
abnormal 0 
expansion-containing 0 
RNA 0 
has 0 
a 0 
dominant 0 
effect 0 
on 0 
RNA 0 
metabolism 0 
by 0 
preventing 0 
the 0 
accumulation 0 
of 0 
poly 0 
-LRB- 0 
A 0 
-RRB- 0 
+ 0 
RNA 0 
. 0 

The 0 
ability 0 
of 0 
the 0 
expansion 0 
mutation 0 
to 0 
alter 0 
accumulation 0 
of 0 
poly 0 
-LRB- 0 
A 0 
-RRB- 0 
+ 0 
RNA 0 
in 0 
trans 0 
suggests 0 
that 0 
myotonic 1
dystrophy 1
may 0 
be 0 
the 0 
first 0 
example 0 
of 0 
a 0 
dominant-negative 0 
mutation 0 
manifested 0 
at 0 
the 0 
RNA 0 
level 0 
. 0 
. 0 

Isolation 0 
of 0 
the 0 
gene 0 
for 0 
McLeod 1
syndrome 1
that 0 
encodes 0 
a 0 
novel 0 
membrane 0 
transport 0 
protein 0 
. 0 

McLeod 1
syndrome 1
is 0 
an 0 
X-linked 1
multisystem 1
disorder 1
characterized 0 
by 0 
abnormalities 0 
in 0 
the 0 
neuromuscular 0 
and 0 
hematopoietic 0 
systems 0 
. 0 

We 0 
have 0 
assembled 0 
a 0 
cosmid 0 
contig 0 
of 0 
_NUM3 0 
kb 0 
that 0 
encompasses 0 
the 0 
McLeod 1
gene 0 
locus 0 
. 0 

A 0 
_NUM2 0 
kb 0 
deletion 0 
was 0 
detected 0 
by 0 
screening 0 
DNA 0 
from 0 
patients 0 
with 0 
radiolabeled 0 
whole 0 
cosmids 0 
, 0 
and 0 
two 0 
transcription 0 
units 0 
were 0 
identified 0 
within 0 
this 0 
deletion 0 
. 0 

The 0 
mRNA 0 
expression 0 
pattern 0 
of 0 
one 0 
of 0 
them 0 
, 0 
designated 0 
as 0 
XK 0 
, 0 
correlates 0 
closely 0 
to 0 
the 0 
McLeod 1
phenotype 0 
. 0 

XK 0 
encodes 0 
a 0 
novel 0 
protein 0 
with 0 
structural 0 
characteristics 0 
of 0 
prokaryotic 0 
and 0 
eukaryotic 0 
membrane 0 
transport 0 
proteins 0 
. 0 

Nucleotide 0 
sequence 0 
analysis 0 
of 0 
XK 0 
from 0 
two 0 
unrelated 0 
McLeod 1
patients 0 
has 0 
identified 0 
point 0 
mutations 0 
at 0 
conserved 0 
splice 0 
donor 0 
and 0 
acceptor 0 
sites 0 
. 0 

These 0 
findings 0 
provide 0 
direct 0 
evidence 0 
that 0 
XK 0 
is 0 
responsible 0 
for 0 
McLeod 1
syndrome 1
. 0 
. 0 

Molecular 0 
basis 0 
of 0 
very 1
long 1
chain 1
acyl-CoA 1
dehydrogenase 1
deficiency 1
in 0 
three 0 
Israeli 0 
patients 0 
: 0 
identification 0 
of 0 
a 0 
complex 0 
mutant 0 
allele 0 
with 0 
P65L 0 
and 0 
K247Q 0 
mutations 0 
, 0 
the 0 
former 0 
being 0 
an 0 
exonic 0 
mutation 0 
causing 0 
exon 0 
_NUM1 0 
skipping 0 
. 0 

Very 1
long 1
chain 1
acyl-CoA 1
dehydrogenase 1
-LRB- 1
VLCAD 1
-RRB- 1
deficiency 1
is 0 
a 0 
life-threatening 0 
disorder 0 
of 0 
mitochondrial 0 
fatty 0 
acid 0 
beta-oxidation 0 
. 0 

We 0 
identified 0 
four 0 
novel 0 
mutations 0 
in 0 
three 0 
unrelated 0 
patients 0 
. 0 

All 0 
patients 0 
had 0 
the 0 
severe 0 
childhood 0 
form 0 
of 0 
VLCAD 1
deficiency 1
with 0 
early 0 
onset 0 
and 0 
high 0 
mortality 0 
. 0 

Immunoblot 0 
analysis 0 
revealed 0 
that 0 
VLCAD 0 
protein 0 
was 0 
undetectable 0 
in 0 
patients 0 
_NUM1 0 
and 0 
_NUM1 0 
, 0 
whereas 0 
normal-size 0 
VLCAD 0 
protein 0 
and 0 
an 0 
aberrant 0 
form 0 
of 0 
VLCAD 0 
-LRB- 0 
4kDa 0 
smaller 0 
-RRB- 0 
were 0 
detected 0 
in 0 
patient 0 
_NUM1 0 
. 0 

As 0 
expected 0 
, 0 
null 0 
mutations 0 
were 0 
found 0 
in 0 
patients 0 
_NUM1 0 
and 0 
_NUM1 0 
patient 0 
_NUM1 0 
is 0 
homozygous 0 
for 0 
a 0 
frameshift 0 
mutation 0 
, 0 
del 0 
_NUM1 0 
bp 0 
at 0 
798-801 0 
, 0 
and 0 
patient 0 
_NUM1 0 
is 0 
homozygous 0 
for 0 
a 0 
nonsense 0 
mutation 0 
65C 0 
> 0 
A 0 
-LRB- 0 
S22X 0 
-RRB- 0 
. 0 

Patient 0 
_NUM1 0 
was 0 
homozygous 0 
for 0 
a 0 
complex 0 
mutant 0 
allele 0 
containing 0 
two 0 
alterations 0 
, 0 
including 0 
a 0 
194C 0 
> 0 
T 0 
transition 0 
-LRB- 0 
P65L 0 
-RRB- 0 
and 0 
739A 0 
> 0 
C 0 
transversion 0 
-LRB- 0 
K247Q 0 
-RRB- 0 
; 0 
in 0 
the 0 
case 0 
of 0 
P65L 0 
, 0 
the 0 
amino 0 
acid 0 
change 0 
does 0 
not 0 
reduce 0 
enzyme 0 
activity 0 
. 0 

However 0 
, 0 
the 0 
nucleotide 0 
change 0 
resulted 0 
in 0 
exon 0 
_NUM1 0 
skipping 0 
, 0 
whereas 0 
the 0 
latter 0 
K247Q 0 
mutation 0 
had 0 
a 0 
drastic 0 
effect 0 
on 0 
enzyme 0 
activity 0 
. 0 

We 0 
verified 0 
these 0 
events 0 
by 0 
in 0 
vivo 0 
splicing 0 
experiments 0 
and 0 
transient 0 
expression 0 
analysis 0 
of 0 
mutant 0 
cDNAs 0 
. 0 

The 0 
P65L 0 
mutation 0 
locates 0 
_NUM2 0 
bases 0 
upstream 0 
of 0 
a 0 
splice 0 
donor 0 
site 0 
of 0 
intron 0 
_NUM1 0 
. 0 

This 0 
is 0 
an 0 
example 0 
of 0 
an 0 
exonic 0 
mutation 0 
which 0 
affects 0 
exon-splicing 0 
. 0 
. 0 

Amino-terminal 0 
fragments 0 
of 0 
mutant 0 
huntingtin 0 
show 0 
selective 0 
accumulation 0 
in 0 
striatal 0 
neurons 0 
and 0 
synaptic 0 
toxicity 0 
. 0 

Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
is 0 
caused 0 
by 0 
expansion 0 
of 0 
a 0 
glutamine 0 
repeat 0 
in 0 
the 0 
amino-terminal 0 
region 0 
of 0 
huntingtin 0 
. 0 

Despite 0 
its 0 
widespread 0 
expression 0 
, 0 
mutant 0 
huntingtin 0 
induces 0 
selective 0 
neuronal 0 
loss 0 
in 0 
striatal 0 
neurons 0 
. 0 

Here 0 
we 0 
report 0 
that 0 
, 0 
in 0 
mutant 0 
mice 0 
expressing 0 
HD 1
repeats 0 
, 0 
the 0 
production 0 
and 0 
aggregation 0 
of 0 
N-terminal 0 
huntingtin 0 
fragments 0 
preferentially 0 
occur 0 
in 0 
HD 1
affected 0 
neurons 0 
and 0 
their 0 
processes 0 
and 0 
axonal 0 
terminals 0 
. 0 

N-terminal 0 
fragments 0 
of 0 
mutant 0 
huntingtin 0 
form 0 
aggregates 0 
and 0 
induce 0 
neuritic 1
degeneration 1
in 0 
cultured 0 
striatal 0 
neurons 0 
. 0 

N-terminal 0 
mutant 0 
huntingtin 0 
also 0 
binds 0 
to 0 
synaptic 0 
vesicles 0 
and 0 
inhibits 0 
their 0 
glutamate 0 
uptake 0 
in 0 
vitro 0 
. 0 

The 0 
specific 0 
processing 0 
and 0 
accumulation 0 
of 0 
toxic 0 
fragments 0 
of 0 
N-terminal 0 
huntingtin 0 
in 0 
HD 1
affected 0 
striatal 0 
neurons 0 
, 0 
especially 0 
in 0 
their 0 
neuronal 0 
processes 0 
and 0 
axonal 0 
terminals 0 
, 0 
may 0 
contribute 0 
to 0 
the 0 
selective 0 
neuropathology 0 
of 0 
HD 1
. 0 
. 0 

Phenotypic 0 
variation 0 
including 0 
retinitis 1
pigmentosa 1
, 0 
pattern 1
dystrophy 1
, 0 
and 0 
fundus 1
flavimaculatus 1
in 0 
a 0 
single 0 
family 0 
with 0 
a 0 
deletion 0 
of 0 
codon 0 
_NUM3 0 
or 0 
_NUM3 0 
of 0 
the 0 
peripherin 0 
/ 0 
RDS 0 
gene 0 
. 0 

BACKGROUND 0 
AND 0 
OBJECTIVES 0 
Mutations 0 
of 0 
the 0 
peripherin 0 
/ 0 
RDS 0 
gene 0 
have 0 
been 0 
reported 0 
in 0 
autosomal 1
dominant 1
retinitis 1
pigmentosa 1
, 0 
pattern 0 
macular 1
dystrophy 1
, 0 
and 0 
retinitis 1
punctata 1
albescens 1
. 0 

We 0 
report 0 
herein 0 
the 0 
occurrence 0 
of 0 
three 0 
separate 0 
phenotypes 0 
within 0 
a 0 
single 0 
family 0 
with 0 
a 0 
novel 0 
3-base 0 
pair 0 
deletion 0 
of 0 
codon 0 
_NUM3 0 
or 0 
_NUM3 0 
of 0 
the 0 
peripherin 0 
/ 0 
RDS 0 
gene 0 
. 0 

DESIGN 0 
Case 0 
reports 0 
with 0 
clinical 0 
features 0 
, 0 
fluorescein 0 
angiography 0 
, 0 
kinetic 0 
perimetry 0 
, 0 
electrophysiological 0 
studies 0 
, 0 
and 0 
molecular 0 
genetics 0 
. 0 

SETTING 0 
University 0 
medical 0 
centers 0 
. 0 

PATIENTS 0 
A 0 
75-year-old 0 
woman 0 
, 0 
her 0 
two 0 
daughters 0 
-LRB- 0 
aged 0 
_NUM2 0 
and 0 
_NUM2 0 
years 0 
-RRB- 0 
, 0 
and 0 
her 0 
49-year-old 0 
son 0 
were 0 
screened 0 
for 0 
peripherin 0 
/ 0 
RDS 0 
mutations 0 
because 0 
of 0 
the 0 
presence 0 
of 0 
multiple 0 
phenotypes 0 
within 0 
the 0 
same 0 
family 0 
. 0 

RESULTS 0 
The 0 
mother 0 
presented 0 
at 0 
age 0 
_NUM2 0 
years 0 
with 0 
a 0 
profoundly 0 
abnormal 0 
electroretinogram 0 
-LRB- 0 
ERG 0 
-RRB- 0 
and 0 
adult-onset 0 
retinitis 1
pigmentosa 1
that 0 
progressed 0 
dramatically 0 
over 0 
_NUM2 0 
years 0 
, 0 
with 0 
marked 0 
loss 0 
of 0 
peripheral 0 
visual 0 
field 0 
. 0 

One 0 
daughter 0 
developed 0 
pattern 1
macular 1
dystrophy 1
at 0 
age 0 
_NUM2 0 
years 0 
. 0 

At 0 
age 0 
_NUM2 0 
years 0 
, 0 
her 0 
ERG 0 
was 0 
moderately 0 
abnormal 0 
but 0 
her 0 
clinical 0 
disease 0 
was 0 
limited 0 
to 0 
the 0 
macula 0 
. 0 

Another 0 
daughter 0 
presented 0 
at 0 
age 0 
_NUM2 0 
years 0 
with 0 
macular 1
degeneration 1
and 0 
over 0 
_NUM2 0 
years 0 
developed 0 
the 0 
clinical 0 
picture 0 
of 0 
fundus 1
flavimaculatus 1
. 0 

Her 0 
peripheral 0 
visual 0 
field 0 
was 0 
preserved 0 
but 0 
her 0 
ERG 0 
was 0 
moderately 0 
abnormal 0 
. 0 

The 0 
son 0 
had 0 
onset 0 
of 0 
macular 1
degeneration 1
at 0 
age 0 
_NUM2 0 
years 0 
. 0 

Pericentral 1
scotomas 1
were 0 
present 0 
and 0 
the 0 
ERG 0 
was 0 
markedly 0 
abnormal 0 
. 0 

Fluorescein 0 
angiography 0 
revealed 0 
punctate 0 
pigment 0 
epithelial 0 
transmission 0 
defects 0 
. 0 

CONCLUSIONS 0 
A 0 
3-base 0 
pair 0 
deletion 0 
of 0 
codon 0 
_NUM3 0 
or 0 
_NUM3 0 
of 0 
the 0 
peripherin 0 
/ 0 
RDS 0 
gene 0 
can 0 
produce 0 
clinically 0 
disparate 0 
phenotypes 0 
even 0 
within 0 
the 0 
same 0 
family 0 
. 0 
. 0 

Missense 0 
mutation 0 
in 0 
the 0 
alternative 0 
splice 0 
region 0 
of 0 
the 0 
PAX6 0 
gene 0 
in 0 
eye 1
anomalies 1
. 0 

The 0 
PAX6 0 
gene 0 
is 0 
involved 0 
in 0 
ocular 0
morphogenesis 0 
, 0 
and 0 
PAX6 0 
mutations 0 
have 0 
been 0 
detected 0 
in 0 
various 0 
types 0 
of 0 
ocular 1
anomalies 1
, 0 
including 0 
aniridia 1
, 0 
Peters 1
anomaly 1
, 0 
corneal 1
dystrophy 1
, 0 
congenital 1
cataract 1
, 0 
and 0 
foveal 1
hypoplasia 1
. 0 

The 0 
gene 0 
encodes 0 
a 0 
transcriptional 0 
regulator 0 
that 0 
recognizes 0 
target 0 
genes 0 
through 0 
its 0 
paired-type 0 
DNA-binding 0 
domain 0 
. 0 

The 0 
paired 0 
domain 0 
is 0 
composed 0 
of 0 
two 0 
distinct 0 
DNA-binding 0 
subdomains 0 
, 0 
the 0 
N-terminal 0 
subdomain 0 
-LRB- 0 
NTS 0 
-RRB- 0 
and 0 
the 0 
C-terminal 0 
subdomain 0 
-LRB- 0 
CTS 0 
-RRB- 0 
, 0 
which 0 
bind 0 
respective 0 
consensus 0 
DNA 0 
sequences 0 
. 0 

The 0 
human 0 
PAX6 0 
gene 0 
produces 0 
two 0 
alternative 0 
splice 0 
isoforms 0 
that 0 
have 0 
the 0 
distinct 0 
structure 0 
of 0 
the 0 
paired 0 
domain 0 
. 0 

The 0 
insertion 0 
, 0 
into 0 
the 0 
NTS 0 
, 0 
of 0 
_NUM2 0 
additional 0 
amino 0 
acids 0 
encoded 0 
by 0 
exon 0 
5a 0 
abolishes 0 
the 0 
DNA-binding 0 
activity 0 
of 0 
the 0 
NTS 0 
and 0 
unmasks 0 
the 0 
DNA-binding 0 
ability 0 
of 0 
the 0 
CTS 0 
. 0 

Thus 0 
, 0 
exon 0 
5a 0 
appears 0 
to 0 
function 0 
as 0 
a 0 
molecular 0 
switch 0 
that 0 
specifies 0 
target 0 
genes 0 
. 0 

We 0 
ascertained 0 
a 0 
novel 0 
missense 0 
mutation 0 
in 0 
four 0 
pedigrees 0 
with 0 
Peters 1
anomaly 1
, 0 
congenital 1
cataract 1
, 0 
Axenfeldt 1
anomaly 1
, 0 
and 0 
/ 0 
or 0 
foveal 1
hypoplasia 1
, 0 
which 0 
, 0 
to 0 
our 0 
knowledge 0 
, 0 
is 0 
the 0 
first 0 
mutation 0 
identified 0 
in 0 
the 0 
splice-variant 0 
region 0 
. 0 

A 0 
T 0 
-- 0 
> 0 
A 0 
transition 0 
at 0 
the 0 
20th 0 
nucleotide 0 
position 0 
of 0 
exon 0 
5a 0 
results 0 
in 0 
a 0 
Val 0 
-- 0 
> 0 
Asp 0 
-LRB- 0 
_DS 0 
-- 0 
> 0 
_DS 0 
-RRB- 0 
substitution 0 
at 0 
the 0 
7th 0 
codon 0 
of 0 
the 0 
alternative 0 
splice 0 
region 0 
. 0 

Functional 0 
analyses 0 
demonstrated 0 
that 0 
the 0 
V54D 0 
mutation 0 
slightly 0 
increased 0 
NTS 0 
binding 0 
and 0 
decreased 0 
CTS 0 
transactivation 0 
activity 0 
to 0 
almost 0 
half 0 
. 0 
. 0 

A 0 
detailed 0 
multipoint 0 
map 0 
of 0 
human 0 
chromosome 0 
_NUM1 0 
provides 0 
evidence 0 
for 0 
linkage 0 
heterogeneity 0 
and 0 
position-specific 0 
recombination 0 
rates 0 
. 0 

Utilizing 0 
the 0 
CEPH 0 
reference 0 
panel 0 
and 0 
genotypic 0 
data 0 
for 0 
_NUM2 0 
markers 0 
, 0 
we 0 
have 0 
constructed 0 
a 0 
20-locus 0 
multipoint 0 
genetic 0 
map 0 
of 0 
human 0 
chromosome 0 
_NUM1 0 
. 0 

New 0 
RFLPs 0 
are 0 
reported 0 
for 0 
four 0 
loci 0 
. 0 

The 0 
map 0 
integrates 0 
a 0 
high-resolution 0 
genetic 0 
map 0 
of 0 
4p16 0 
into 0 
a 0 
continuous 0 
map 0 
extending 0 
to 0 
4q31 0 
and 0 
an 0 
unlinked 0 
cluster 0 
of 0 
three 0 
loci 0 
at 0 
4q35 0 
. 0 

The 0 
_NUM2 0 
linked 0 
markers 0 
form 0 
a 0 
continuous 0 
linkage 0 
group 0 
of 0 
_NUM3 0 
cM 0 
in 0 
males 0 
and 0 
_NUM3 0 
cM 0 
in 0 
females 0 
. 0 

Likely 0 
genetic 0 
locations 0 
are 0 
provided 0 
for 0 
_NUM2 0 
polymorphic 0 
anonymous 0 
sequences 0 
and 0 
_NUM2 0 
gene-specific 0 
RFLPs 0 
. 0 

The 0 
map 0 
was 0 
constructed 0 
employing 0 
the 0 
LINKAGE 0 
and 0 
CRIMAP 0 
computational 0 
methodologies 0 
to 0 
build 0 
the 0 
multipoint 0 
map 0 
via 0 
a 0 
stepwise 0 
algorithm 0 
. 0 

A 0 
detailed 0 
10-point 0 
map 0 
of 0 
the 0 
4p16 0 
region 0 
constructed 0 
from 0 
the 0 
CEPH 0 
panel 0 
provides 0 
evidence 0 
for 0 
heterogeneity 0 
in 0 
the 0 
linkage 0 
maps 0 
constructed 0 
from 0 
families 0 
segregating 0 
for 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
. 0 

It 0 
additionally 0 
provides 0 
evidence 0 
for 0 
position-specific 0 
recombination 0 
frequencies 0 
in 0 
the 0 
telomeric 0 
region 0 
of 0 
4p 0 
. 0 
. 0 

The 0 
murine 0 
homolog 0 
of 0 
the 0 
human 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
gene 0 
Brca1 0 
maps 0 
to 0 
mouse 0 
chromosome 0 
11D 0 
. 0 

The 0 
recently 0 
cloned 0 
human 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
gene 0 
, 0 
BRCA1 0 
, 0 
is 0 
located 0 
on 0 
human 0 
chromosome 0 
17q21 0 
. 0 

We 0 
have 0 
isolated 0 
murine 0 
genomic 0 
clones 0 
containing 0 
Brca1 0 
as 0 
a 0 
first 0 
step 0 
in 0 
generating 0 
a 0 
mouse 0 
model 0 
for 0 
the 0 
loss 0 
of 0 
BRCA1 0 
function 0 
. 0 

A 0 
mouse 0 
genomic 0 
library 0 
was 0 
screened 0 
using 0 
probes 0 
corresponding 0 
to 0 
exon 0 
_NUM2 0 
of 0 
the 0 
human 0 
BRCA1 0 
gene 0 
. 0 

Two 0 
overlapping 0 
mouse 0 
clones 0 
were 0 
identified 0 
that 0 
hybridized 0 
to 0 
human 0 
BRCA1 0 
exons 0 
9-12 0 
. 0 

Sequence 0 
analysis 0 
of 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
of 0 
the 0 
region 0 
of 0 
these 0 
clones 0 
corresponding 0 
to 0 
part 0 
of 0 
human 0 
exon 0 
_NUM2 0 
revealed 0 
_NUM2 0 
% 0 
nucleic 0 
acid 0 
identity 0 
but 0 
only 0 
_NUM2 0 
% 0 
amino 0 
acid 0 
identity 0 
with 0 
the 0 
human 0 
gene 0 
. 0 

The 0 
longest 0 
of 0 
the 0 
mouse 0 
Brca1 0 
genomic 0 
clones 0 
maps 0 
to 0 
chromosome 0 
11D 0 
, 0 
as 0 
determined 0 
by 0 
two-color 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
. 0 

The 0 
synteny 0 
to 0 
human 0 
chromosome 0 
_NUM2 0 
was 0 
confirmed 0 
by 0 
cohybridization 0 
with 0 
the 0 
mouse 0 
probe 0 
for 0 
the 0 
NF1-gene 0 
. 0 

This 0 
comparative 0 
study 0 
confirms 0 
that 0 
the 0 
relative 0 
location 0 
of 0 
the 0 
BRCA1 0 
gene 0 
has 0 
been 0 
conserved 0 
between 0 
mice 0 
and 0 
humans 0 
. 0 

High 0 
residual 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
activity 0 
in 0 
a 0 
patient 0 
with 0 
late-infantile 1
metachromatic 1
leukodystrophy 1
. 0 

We 0 
identified 0 
a 0 
patient 0 
suffering 0 
from 0 
late-infantile 1
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
who 0 
has 0 
a 0 
residual 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
activity 0 
of 0 
about 0 
_NUM2 0 
% 0 
. 0 

Fibroblasts 0 
of 0 
the 0 
patient 0 
show 0 
significant 0 
sulfatide 0 
degradation 0 
activity 0 
exceeding 0 
that 0 
of 0 
adult 1
MLD 1
patients 0 
. 0 

Analysis 0 
of 0 
the 0 
ARSA 0 
gene 0 
in 0 
this 0 
patient 0 
revealed 0 
heterozygosity 0 
for 0 
two 0 
new 0 
mutant 0 
alleles 0 
in 0 
one 0 
allele 0 
, 0 
deletion 0 
of 0 
C 0 
_NUM3 0 
in 0 
exon 0 
_NUM1 0 
leads 0 
to 0 
a 0 
frameshift 0 
and 0 
to 0 
a 0 
premature 0 
stop 0 
codon 0 
at 0 
amino 0 
acid 0 
position 0 
_NUM3 0 
; 0 
in 0 
the 0 
second 0 
allele 0 
, 0 
a 0 
G 0 
-- 0 
> 0 
A 0 
transition 0 
in 0 
exon 0 
_NUM1 0 
causes 0 
a 0 
Gly309 0 
-- 0 
> 0 
Ser 0 
substitution 0 
. 0 

Transient 0 
expression 0 
of 0 
the 0 
mutant 0 
Ser309-ARSA 0 
resulted 0 
in 0 
only 0 
_NUM2 0 
% 0 
enzyme 0 
activity 0 
of 0 
that 0 
observed 0 
in 0 
cells 0 
expressing 0 
normal 0 
ARSA 0 
. 0 

The 0 
mutant 0 
ARSA 0 
is 0 
correctly 0 
targeted 0 
to 0 
the 0 
lysosomes 0 
but 0 
is 0 
unstable 0 
. 0 

These 0 
findings 0 
are 0 
in 0 
contrast 0 
to 0 
previous 0 
results 0 
showing 0 
that 0 
the 0 
late-infantile 1
type 1
of 1
MLD 1
is 0 
always 0 
associated 0 
with 0 
the 0 
complete 0 
absence 0 
of 0 
ARSA 0 
activity 0 
. 0 

The 0 
expression 0 
of 0 
the 0 
mutant 0 
ARSA 0 
protein 0 
may 0 
be 0 
influenced 0 
by 0 
particular 0 
features 0 
of 0 
oligodendrocytes 0 
, 0 
such 0 
that 0 
the 0 
level 0 
of 0 
mutant 0 
enzyme 0 
is 0 
lower 0 
in 0 
these 0 
cells 0 
than 0 
in 0 
others 0 
. 0 
. 0 

De 0 
novo 0 
deletions 0 
of 0 
SNRPN 0 
exon 0 
_NUM1 0 
in 0 
early 0 
human 0 
and 0 
mouse 0 
embryos 0 
result 0 
in 0 
a 0 
paternal 0 
to 0 
maternal 0 
imprint 0 
switch 0 
. 0 

Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
is 0 
a 0 
neurogenetic 1
disease 1
characterized 0 
by 0 
infantile 1
hypotonia 1
, 0 
gonadal 1
hypoplasia 1
, 0 
obsessive 0 
behaviour 0 
and 0 
neonatal 0 
feeding 0 
difficulties 0 
followed 0 
by 0 
hyperphagia 1
, 0 
leading 0 
to 0 
profound 0 
obesity 1
. 0 

PWS 1
is 0 
due 0 
to 0 
a 0 
lack 0 
of 0 
paternal 0 
genetic 0 
information 0 
at 0 
15q11-q13 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

Five 0 
imprinted 0 
, 0 
paternally 0 
expressed 0 
genes 0 
map 0 
to 0 
the 0 
PWS 1
region 0 
, 0 
MKRN3 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
NDN 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
NDNL1 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
SNRPN 0 
-LRB- 0 
refs 0 
6-8 0 
-RRB- 0 
and 0 
IPW 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
as 0 
well 0 
as 0 
two 0 
poorly 0 
characterized 0 
framents 0 
designated 0 
PAR-1 0 
and 0 
PAR-5 0 
-LRB- 0 
ref 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Imprinting 0 
of 0 
this 0 
region 0 
involves 0 
a 0 
bipartite 0 
imprinting 0 
centre 0 
-LRB- 0 
IC 0 
-RRB- 0 
, 0 
which 0 
overlaps 0 
SNRPN 0 
-LRB- 0 
refs 0 
_NUM2 0 
, 0 
_NUM2 0 
-RRB- 0 
. 0 

Deletion 0 
of 0 
the 0 
SNRPN 0 
promoter 0 
/ 0 
exon 0 
_NUM1 0 
region 0 
-LRB- 0 
the 0 
PWS 1
IC 0 
element 0 
-RRB- 0 
appears 0 
to 0 
impair 0 
the 0 
establishment 0 
of 0 
the 0 
paternal 0 
imprint 0 
in 0 
the 0 
male 0 
germ 0 
line 0 
and 0 
leads 0 
to 0 
PWS 1
. 0 

Here 0 
we 0 
report 0 
a 0 
PWS 1
family 0 
in 0 
which 0 
the 0 
father 0 
is 0 
mosaic 0 
for 0 
an 0 
IC 0 
deletion 0 
on 0 
his 0 
paternal 0 
chromosome 0 
. 0 

The 0 
deletion 0 
chromosome 0 
has 0 
acquired 0 
a 0 
maternal 0 
methylation 0 
imprint 0 
in 0 
his 0 
somatic 0 
cells 0 
. 0 

We 0 
have 0 
made 0 
identical 0 
findings 0 
in 0 
chimaeric 0 
mice 0 
generated 0 
from 0 
two 0 
independent 0 
embryonic 0 
stem 0 
-LRB- 0 
ES 0 
-RRB- 0 
cell 0 
lines 0 
harbouring 0 
a 0 
similar 0 
deletion 0 
. 0 

Our 0 
studies 0 
demonstrate 0 
that 0 
the 0 
PWS 1
IC 0 
element 0 
is 0 
not 0 
only 0 
required 0 
for 0 
the 0 
establishment 0 
of 0 
the 0 
paternal 0 
imprint 0 
, 0 
but 0 
also 0 
for 0 
its 0 
postzygotic 0 
maintenance 0 
. 0 
. 0 

Molecular 0 
characterization 0 
of 0 
two 0 
galactosemia 1
mutations 0 
: 0 
correlation 0 
of 0 
mutations 0 
with 0 
highly 0 
conserved 0 
domains 0 
in 0 
galactose-1-phosphate 0 
uridyl 0 
transferase 0 
. 0 

Galactosemia 1
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
of 1
human 1
galactose 1
metabolism 1
caused 0 
by 0 
deficiency 1
of 1
the 1
enzyme 1
galactose-1-phosphate 1
uridyl 1
transferase 1
-LRB- 0 
GALT 0 
-RRB- 0 
. 0 

The 0 
molecular 0 
basis 0 
of 0 
this 0 
disorder 0 
is 0 
at 0 
present 0 
not 0 
well 0 
understood 0 
. 0 

We 0 
report 0 
here 0 
two 0 
missense 0 
mutations 0 
which 0 
result 0 
in 0 
low 0 
or 0 
undetectable 0 
enzymatic 0 
activity 0 
. 0 

First 0 
, 0 
we 0 
identified 0 
at 0 
nucleotide 0 
_NUM3 0 
a 0 
transition 0 
which 0 
substitutes 0 
glutamine 0 
_NUM3 0 
by 0 
arginine 0 
. 0 

The 0 
mutated 0 
glutamine 0 
is 0 
not 0 
only 0 
highly 0 
conserved 0 
in 0 
evolution 0 
-LRB- 0 
conserved 0 
also 0 
in 0 
Escherichia 0 
coli 0 
and 0 
Saccharomyces 0 
cerevisiae 0 
-RRB- 0 
, 0 
but 0 
is 0 
also 0 
two 0 
amino 0 
acid 0 
residues 0 
downstream 0 
from 0 
the 0 
active 0 
site 0 
histidine-proline-histidine 0 
triad 0 
and 0 
results 0 
in 0 
about 0 
_NUM2 0 
% 0 
of 0 
normal 0 
enzymatic 0 
activity 0 
. 0 

The 0 
arginine 0 
_NUM3 0 
mutation 0 
is 0 
the 0 
most 0 
common 0 
galactosemia 1
mutation 0 
characterized 0 
to 0 
date 0 
. 0 

It 0 
accounts 0 
for 0 
one-fourth 0 
of 0 
the 0 
galactosemia 1
alleles 0 
studied 0 
. 0 

Second 0 
, 0 
we 0 
report 0 
the 0 
substitution 0 
of 0 
arginine 0 
_NUM3 0 
by 0 
tryptophan 0 
, 0 
caused 0 
by 0 
a 0 
transition 0 
at 0 
nucleotide 0 
_NUM4 0 
. 0 

The 0 
area 0 
surrounding 0 
this 0 
missense 0 
mutation 0 
is 0 
the 0 
most 0 
highly 0 
conserved 0 
domain 0 
in 0 
the 0 
homologous 0 
enzymes 0 
from 0 
E. 0 
coli 0 
, 0 
yeast 0 
, 0 
and 0 
humans 0 
, 0 
and 0 
this 0 
mutation 0 
results 0 
in 0 
undetectable 0 
enzymatic 0 
activity 0 
, 0 
suggesting 0 
that 0 
this 0 
is 0 
a 0 
severe 0 
mutation 0 
. 0 

This 0 
second 0 
mutation 0 
appears 0 
to 0 
be 0 
rare 0 
, 0 
since 0 
it 0 
was 0 
found 0 
only 0 
in 0 
the 0 
patient 0 
we 0 
sequenced 0 
. 0 

Our 0 
data 0 
provide 0 
further 0 
evidence 0 
for 0 
the 0 
heterogeneity 0 
of 0 
galactosemia 1
at 0 
the 0 
molecular 0 
level 0 
, 0 
heterogeneity 0 
which 0 
might 0 
be 0 
related 0 
to 0 
the 0 
variable 0 
clinical 0 
outcome 0 
observed 0 
in 0 
this 0 
disorder 0 
. 0 
. 0 

Neurophysiologic 0 
follow-up 0 
of 0 
long-term 0 
dietary 0 
treatment 0 
in 0 
adult-onset 0 
adrenoleukodystrophy 1
. 0 

OBJECTIVE 0 
To 0 
monitor 0 
the 0 
effects 0 
of 0 
dietary 0 
treatment 0 
in 0 
adult-onset 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
by 0 
means 0 
of 0 
somatosensory 0 
evoked 0 
potentials 0 
-LRB- 0 
SEPs 0 
-RRB- 0 
and 0 
motor 0 
evoked 0 
potentials 0 
-LRB- 0 
MEPs 0 
-RRB- 0 
. 0 

BACKGROUND 0 
SEPs 0 
and 0 
MEPs 0 
have 0 
proved 0 
useful 0 
in 0 
revealing 0 
signs 0 
of 0 
progressively 0 
severe 0 
, 0 
central 0 
dying-back 1
axonopathy 1
in 0 
early 0 
stages 0 
of 0 
adult-onset 0 
ALD 1
. 0 

METHODS 0 
Eight 0 
patients 0 
with 0 
adult-onset 0 
ALD 1
underwent 0 
clinical 0 
examination 0 
, 0 
brain 0 
and 0 
spine 0 
MRI 0 
, 0 
and 0 
SEP 0 
and 0 
MEP 0 
studies 0 
before 0 
and 0 
after 0 
_NUM1 0 
years 0 
of 0 
Lorenzos 0 
oil 0 
dietary 0 
therapy 0 
. 0 

RESULTS 0 
Before 0 
treatment 0 
, 0 
brain 0 
MRI 0 
was 0 
normal 0 
in 0 
five 0 
patients 0 
. 0 

Three 0 
of 0 
these 0 
patients 0 
had 0 
pure 0 
spinal 1
SEP 1
abnormalities 1
and 0 
in 0 
the 0 
remaining 0 
two 0 
patients 0 
SEPs 0 
showed 0 
signs 0 
of 0 
involvement 0 
of 0 
both 0 
the 0 
spinal 0
and 0 
cerebral 0 
somatosensory 0 
tracts 0 
. 0 

After 0 
treatment 0 
, 0 
the 0 
three 0 
patients 0 
with 0 
pure 0 
spinal 1
abnormalities 1
showed 0 
clinical 0 
and 0 
neurophysiologic 0 
worsening 0 
, 0 
whereas 0 
the 0 
two 0 
patients 0 
with 0 
a 0 
more 0 
advanced 0 
stage 0 
of 0 
disease 0 
-LRB- 0 
exhibited 0 
by 0 
SEPs 0 
-RRB- 0 
showed 0 
substantially 0 
unchanged 0 
clinical 0 
and 0 
neurophysiologic 0 
features 0 
. 0 

The 0 
patients 0 
with 0 
abnormal 0 
brain 0 
MRI 0 
at 0 
the 0 
onset 0 
of 0 
treatment 0 
showed 0 
clinical 0 
and 0 
neurophysiologic 0 
worsening 0 
. 0 

CONCLUSIONS 0 
Lorenzos 0 
oil 0 
therapy 0 
had 0 
no 0 
effect 0 
on 0 
patients 0 
with 0 
evidence 0 
of 0 
inflammatory 1
brain 1
lesions 1
. 0 

Moreover 0 
, 0 
in 0 
patients 0 
without 0 
clear 0 
signs 0 
of 0 
inflammatory 0 
damage 0 
, 0 
this 0 
treatment 0 
does 0 
not 0 
modify 0 
significantly 0 
the 0 
natural 0 
course 0 
of 0 
the 0 
disease 0 
. 0 

However 0 
, 0 
because 0 
effective 0 
treatments 0 
should 0 
begin 0 
before 0 
the 0 
onset 0 
of 0 
severe 0 
neurologic 0 
symptoms 0 
, 0 
SEPs 0 
and 0 
MEPs 0 
should 0 
be 0 
considered 0 
to 0 
evaluate 0 
the 0 
effectiveness 0 
of 0 
other 0 
experimental 0 
treatments 0 
in 0 
the 0 
patient 0 
with 0 
a 0 
negative 0 
brain 0 
MRI 0 
. 0 

The 0 
molecular 0 
basis 0 
of 0 
Sjogren-Larsson 1
syndrome 1
: 0 
mutation 0 
analysis 0 
of 0 
the 0 
fatty 0 
aldehyde 0 
dehydrogenase 0 
gene 0 
. 0 

Sjogren-Larsson 1
syndrome 1
-LRB- 0 
SLS 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
ichthyosis 1
, 0 
mental 1
retardation 1
, 0 
spasticity 1
, 0 
and 0 
deficient 1
activity 1
of 1
fatty 1
aldehyde 1
dehydrogenase 1
-LRB- 0 
FALDH 0 
-RRB- 0 
. 0 

To 0 
define 0 
the 0 
molecular 0 
defects 0 
causing 0 
SLS 1
, 0 
we 0 
performed 0 
mutation 0 
analysis 0 
of 0 
the 0 
FALDH 0 
gene 0 
in 0 
probands 0 
from 0 
_NUM2 0 
kindreds 0 
with 0 
SLS 1
. 0 

Among 0 
these 0 
patients 0 
, 0 
_NUM2 0 
different 0 
mutations-including 0 
_NUM2 0 
deletions 0 
, 0 
_NUM1 0 
insertions 0 
, 0 
_NUM2 0 
amino 0 
acid 0 
substitutions 0 
, 0 
_NUM1 0 
nonsense 0 
mutations 0 
, 0 
_NUM1 0 
splice-site 0 
defects 0 
, 0 
and 0 
_NUM1 0 
complex 0 
mutations-were 0 
found 0 
. 0 

All 0 
of 0 
the 0 
patients 0 
with 0 
SLS 1
were 0 
found 0 
to 0 
carry 0 
mutations 0 
. 0 

Nineteen 0 
of 0 
the 0 
missense 0 
mutations 0 
resulted 0 
in 0 
a 0 
severe 0 
reduction 0 
of 0 
FALDH 0 
enzyme 0 
catalytic 0 
activity 0 
when 0 
expressed 0 
in 0 
mammalian 0 
cells 0 
, 0 
but 0 
one 0 
mutation 0 
-LRB- 0 
798G 0 
-- 0 
> 0 
C 0 
-LSB- 0 
K266N 0 
-RSB- 0 
-RRB- 0 
seemed 0 
to 0 
have 0 
a 0 
greater 0 
effect 0 
on 0 
mRNA 0 
stability 0 
. 0 

The 0 
splice-site 0 
mutations 0 
led 0 
to 0 
exon 0 
skipping 0 
or 0 
utilization 0 
of 0 
cryptic 0 
acceptor-splice 0 
sites 0 
. 0 

Thirty-seven 0 
mutations 0 
were 0 
private 0 
, 0 
and 0 
_NUM2 0 
mutations 0 
were 0 
seen 0 
in 0 
two 0 
or 0 
more 0 
probands 0 
of 0 
European 0 
or 0 
Middle 0 
Eastern 0 
descent 0 
. 0 

Four 0 
single-nucleotide 0 
polymorphisms 0 
-LRB- 0 
SNPs 0 
-RRB- 0 
were 0 
found 0 
in 0 
the 0 
FALDH 0 
gene 0 
. 0 

At 0 
least 0 
four 0 
of 0 
the 0 
common 0 
mutations 0 
-LRB- 0 
551C 0 
-- 0 
> 0 
T 0 
, 0 
682C 0 
-- 0 
> 0 
T 0 
, 0 
733G 0 
-- 0 
> 0 
A 0 
, 0 
and 0 
_NUM3 0 
+ 0 
1delG 0 
-RRB- 0 
were 0 
associated 0 
with 0 
multiple 0 
SNP 0 
haplotypes 0 
, 0 
suggesting 0 
that 0 
these 0 
mutations 0 
originated 0 
independently 0 
on 0 
more 0 
than 0 
one 0 
occasion 0 
or 0 
were 0 
ancient 0 
SLS 1
genes 0 
that 0 
had 0 
undergone 0 
intragenic 0 
recombination 0 
. 0 

Our 0 
results 0 
demonstrate 0 
that 0 
SLS 1
is 0 
caused 0 
by 0 
a 0 
strikingly 0 
heterogeneous 0 
group 0 
of 0 
mutations 0 
in 0 
the 0 
FALDH 0 
gene 0 
and 0 
provide 0 
a 0 
framework 0 
for 0 
understanding 0 
the 0 
genetic 0 
basis 0 
of 0 
SLS 1
and 0 
the 0 
development 0 
of 0 
DNA-based 0 
diagnostic 0 
tests 0 
. 0 
. 0 

Severe-glucose-6-phosphate 1
dehydrogenase 1
-LRB- 1
G6PD 1
-RRB- 1
deficiency 1
associated 0 
with 0 
chronic 0 
hemolytic 1
anemia 1
, 0 
granulocyte 1
dysfunction 1
, 0 
and 0 
increased 0 
susceptibility 0 
to 0 
infections 0 
: 0 
description 0 
of 0 
a 0 
new 0 
molecular 0 
variant 0 
-LRB- 0 
G6PD 0
Barcelona 0 
-RRB- 0 
. 0 

Molecular 0 
, 0 
kinetic 0 
, 0 
and 0 
functional 0 
studies 0 
were 0 
carried 0 
out 0 
on 0 
erythrocytes 0 
and 0 
leukocytes 0 
in 0 
a 0 
Spanish 0 
male 0 
with 0 
G6PD 1
deficiency 1
, 0 
congenital 1
nonspherocytic 1
hemolytic 1
anemia 1
-LRB- 0 
CNSHA 1
-RRB- 0 
, 0 
and 0 
increased 0 
susceptibility 0 
to 0 
infections 0 
. 0 

G6PD 0 
activity 0 
was 0 
absent 0 
in 0 
patients 0 
red 0 
cells 0 
and 0 
was 0 
about 0 
_NUM1 0 
% 0 
of 0 
normal 0 
in 0 
leukocytes 0 
. 0 

Molecular 0 
studies 0 
using 0 
standard 0 
methods 0 
-LRB- 0 
WHO 0 
, 0 
_NUM4 0 
-RRB- 0 
showed 0 
G6PD 0 
in 0 
the 0 
patient 0 
to 0 
have 0 
a 0 
slightly 0 
fast 0 
electrophoretic 0 
mobility 0 
at 0 
pH 0 
_NUM1 0 
. 0 

_NUM1 0 
with 0 
otherwise 0 
normal 0 
properties 0 
-LRB- 0 
heat 0 
stability 0 
at 0 
_NUM2 0 
degrees 0 
C 0 
, 0 
apparent 0 
affinity 0 
for 0 
substrates 0 
, 0 
optimum 0 
pH 0 
, 0 
and 0 
utilization 0 
of 0 
substrate 0 
analogues 0 
-RRB- 0 
. 0 

Other 0 
tests 0 
showed 0 
the 0 
patients 0 
granulocytes 0 
to 0 
engulf 0 
latex 0 
particles 0 
normally 0 
, 0 
but 0 
to 0 
have 0 
impaired 0 
reduction 0 
of 0 
nitroblue 0 
tetrazolium 0 
and 0 
ferricytochrome-c 0 
as 0 
well 0 
as 0 
reduced 0 
iodination 0 
. 0 

Chemotaxis 0 
and 0 
random 0 
migration 0 
of 0 
the 0 
patients 0 
granulocytes 0 
were 0 
normal 0 
as 0 
were 0 
myeloperoxidase 0 
, 0 
leukocyte 0 
alkaline 0 
phosphatase 0 
-LRB- 0 
LAP 0 
-RRB- 0 
, 0 
and 0 
ultrastructural 0 
features 0 
. 0 

The 0 
molecular 0 
characteristics 0 
of 0 
G6PD 0 
in 0 
the 0 
patient 0 
differed 0 
from 0 
those 0 
of 0 
all 0 
previously 0 
reported 0 
variants 0 
associated 0 
with 0 
CNSHA 1
, 0 
so 0 
the 0 
present 0 
variant 0 
was 0 
provisionally 0 
called 0 
G6PD 0 
Barcelona 0 
to 0 
distinguish 0 
it 0 
from 0 
other 0 
G6PD 0 
variants 0 
previously 0 
described 0 
. 0 

Possible 0 
mechanisms 0 
for 0 
the 0 
severe 0 
deficiency 1
of 1
G6PD 1
in 0 
erythrocytes 0 
and 0 
granulocytes 0 
was 0 
investigated 0 
by 0 
studies 0 
on 0 
the 0 
immunologic 0 
specific 0 
activity 0 
of 0 
the 0 
mutant 0 
enzyme 0 
. 0 

Mutations 0 
at 0 
the 0 
PAX6 0 
locus 0 
are 0 
found 0 
in 0 
heterogeneous 0 
anterior 1
segment 1
malformations 1
including 0 
Peters 1
' 1
anomaly 1
. 0 

Mutation 0 
or 0 
deletion 0 
of 0 
the 0 
PAX6 0 
gene 0 
underlies 0 
many 0 
cases 0 
of 0 
aniridia 1
. 0 

Three 0 
lines 0 
of 0 
evidence 0 
now 0 
converge 0 
to 0 
implicate 0 
PAX6 0 
more 0 
widely 0 
in 0 
anterior 1
segment 1
malformations 1
including 0 
Peters 1
anomaly 1
. 0 

First 0 
, 0 
a 0 
child 0 
with 0 
Peters 1
anomaly 1
is 0 
deleted 0 
for 0 
one 0 
copy 0 
of 0 
PAX6 0 
. 0 

Second 0 
, 0 
affected 0 
members 0 
of 0 
a 0 
family 0 
with 0 
dominantly 0 
inherited 0 
anterior 1
segment 1
malformations 1
, 0 
including 0 
Peters 1
anomaly 1
are 0 
heterozygous 0 
for 0 
an 0 
R26G 0 
mutation 0 
in 0 
the 0 
PAX6 0 
paired 0 
box 0 
. 0 

Third 0 
, 0 
a 0 
proportion 0 
of 0 
Sey 0 
/ 0 
+ 0 
Smalleye 0 
mice 0 
, 0 
heterozygous 0 
for 0 
a 0 
nonsense 0 
mutation 0 
in 0 
murine 0 
Pax-6 0 
, 0 
have 0 
an 0 
ocular 0 
phenotype 0 
resembling 0 
Peters 1
anomaly 1
. 0 

We 0 
therefore 0 
propose 0 
that 0 
a 0 
variety 0 
of 0 
anterior 1
segment 1
anomalies 1
may 0 
be 0 
associated 0 
with 0 
PAX6 0 
mutations 0 
. 0 
. 0 

In 0 
Swedish 0 
families 0 
with 0 
hereditary 1
prostate 1
cancer 1
, 0 
linkage 0 
to 0 
the 0 
HPC1 0 
locus 0 
on 0 
chromosome 0 
1q24-25 0 
is 0 
restricted 0 
to 0 
families 0 
with 0 
early-onset 0 
prostate 1
cancer 1
. 0 

Prostate 1
cancer 1
clusters 0 
in 0 
some 0 
families 0 
, 0 
and 0 
an 0 
estimated 0 
_NUM1 0 
% 0 
-10 0 
% 0 
of 0 
all 0 
cases 0 
are 0 
estimated 0 
to 0 
result 0 
from 0 
inheritance 0 
of 0 
prostate 0
cancer-susceptibility 0 
genes 0 
. 0 

We 0 
previously 0 
reported 0 
evidence 0 
of 0 
linkage 0 
to 0 
the 0 
1q24-25 0 
region 0 
-LRB- 0 
HPC1 0 
-RRB- 0 
in 0 
_NUM2 0 
North 0 
American 0 
and 0 
Swedish 0 
families 0 
each 0 
with 0 
multiple 0 
cases 0 
of 0 
prostate 1
cancer 1
-LRB- 0 
Smith 0 
et 0 
al. 0 
_NUM4 0 
-RRB- 0 
. 0 

In 0 
the 0 
present 0 
report 0 
we 0 
analyze 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
original 0 
and 0 
_NUM2 0 
newly 0 
identified 0 
-RRB- 0 
Swedish 0 
families 0 
with 0 
hereditary 1
prostate 1
cancer 1
-LRB- 0 
HPC 1
-RRB- 0 
that 0 
, 0 
on 0 
the 0 
basis 0 
of 0 
_NUM2 0 
markers 0 
spanning 0 
a 0 
25-cM 0 
interval 0 
within 0 
1q24-25 0 
, 0 
have 0 
evidence 0 
of 0 
linkage 0 
. 0 

In 0 
the 0 
complete 0 
set 0 
of 0 
families 0 
, 0 
a 0 
maximum 0 
two-point 0 
LOD 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
was 0 
observed 0 
at 0 
D1S413 0 
-LRB- 0 
at 0 
a 0 
recombination 0 
fraction 0 
-LSB- 0 
theta 0 
-RSB- 0 
of 0 
. 0 

_NUM1 0 
-RRB- 0 
, 0 
with 0 
a 0 
maximum 0 
NPL 0 
-LRB- 0 
nonparametric 0 
linkage 0 
-RRB- 0 
Z 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
D1S202 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

The 0 
evidence 0 
of 0 
linkage 0 
to 0 
this 0 
region 0 
originated 0 
almost 0 
exclusively 0 
from 0 
the 0 
subset 0 
of 0 
_NUM2 0 
early-onset 0 
-LRB- 0 
age 0 
< 0 
_NUM2 0 
years 0 
-RRB- 0 
families 0 
, 0 
which 0 
yielded 0 
a 0 
maximum 0 
LOD 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
D1S413 0 
-LRB- 0 
straight 0 
theta 0 
= 0 
_NUM1 0 
-RRB- 0 
and 0 
an 0 
NPL 0 
Z 0 
score 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
at 0 
D1S422 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Estimates 0 
from 0 
heterogeneity 0 
tests 0 
suggest 0 
that 0 
, 0 
within 0 
Sweden 0 
, 0 
as 0 
many 0 
as 0 
_NUM2 0 
% 0 
of 0 
early-onset 0 
families 0 
had 0 
evidence 0 
of 0 
linkage 0 
to 0 
the 0 
HPC1 0 
region 0 
. 0 

These 0 
results 0 
are 0 
consistent 0 
with 0 
the 0 
hypothesis 0 
of 0 
linkage 0 
to 0 
HPC1 0 
in 0 
a 0 
subset 0 
of 0 
families 0 
with 0 
prostate 1
cancer 1
, 0 
particularly 0 
those 0 
with 0 
an 0 
early 0 
age 0 
at 0 
diagnosis 0 
. 0 

Localisation 0 
of 0 
the 0 
myotonic 1
dystrophy 1
locus 0 
to 0 
19q13.2-19q13 0 
.3 0 
and 0 
its 0 
relationship 0 
to 0 
twelve 0 
polymorphic 0 
loci 0 
on 0 
19q 0 
. 0 

The 0 
order 0 
of 0 
fourteen 0 
polymorphic 0 
markers 0 
localised 0 
to 0 
the 0 
long 0 
arm 0 
of 0 
human 0 
chromosome 0 
_NUM2 0 
has 0 
been 0 
established 0 
by 0 
multipoint 0 
mapping 0 
in 0 
a 0 
set 0 
of 0 
_NUM2 0 
CEPH 0 
-LRB- 0 
Centre 0 
dEtude 0 
de 0 
Polymorphisme 0 
Humain 0 
, 0 
Paris 0 
-RRB- 0 
reference 0 
families 0 
. 0 

We 0 
report 0 
here 0 
the 0 
linkage 0 
relationship 0 
of 0 
the 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
locus 0 
to 0 
twelve 0 
of 0 
these 0 
markers 0 
as 0 
studied 0 
in 0 
_NUM2 0 
families 0 
with 0 
DM 1
. 0 

The 0 
resulting 0 
genetic 0 
map 0 
is 0 
supported 0 
by 0 
the 0 
localisation 0 
of 0 
the 0 
DNA 0 
markers 0 
in 0 
a 0 
panel 0 
of 0 
somatic 0 
cell 0 
hybrids 0 
. 0 

Ten 0 
of 0 
the 0 
twelve 0 
markers 0 
have 0 
been 0 
shown 0 
to 0 
be 0 
proximal 0 
to 0 
the 0 
DM 1
gene 0 
and 0 
two 0 
, 0 
PRKCG 0 
and 0 
D19S22 0 
, 0 
distal 0 
but 0 
at 0 
distances 0 
of 0 
approximately 0 
_NUM2 0 
cM 0 
and 0 
_NUM2 0 
cM 0 
, 0 
respectively 0 
. 0 

The 0 
closest 0 
proximal 0 
markers 0 
are 0 
APOC2 0 
-LRB- 0 
apolipoprotein 0 
C-II 0 
-RRB- 0 
and 0 
CKM 0 
-LRB- 0 
creatine 0 
kinase 0 
, 0 
muscle 0 
-RRB- 0 
approximately 0 
_NUM1 0 
cM 0 
and 0 
_NUM1 0 
cM 0 
from 0 
the 0 
DM 1
gene 0 
respectively 0 
, 0 
in 0 
the 0 
order 0 
APOC2-CKM-DM 0 
. 0 

The 0 
distance 0 
between 0 
APOC2 0 
, 0 
CKM 0 
and 0 
DM 1
-LRB- 0 
of 0 
the 0 
order 0 
of 0 
_NUM1 0 
million 0 
base 0 
pairs 0 
-RRB- 0 
and 0 
their 0 
known 0 
orientation 0 
should 0 
permit 0 
directional 0 
chromosome 0 
walking 0 
and 0 
jumping 0 
. 0 

The 0 
data 0 
presented 0 
here 0 
should 0 
enable 0 
us 0 
to 0 
determine 0 
whether 0 
or 0 
not 0 
new 0 
markers 0 
are 0 
distal 0 
to 0 
APOC2 0 
/ 0 
CKM 0 
and 0 
thus 0 
potentially 0 
flank 0 
the 0 
DM 1
gene 0 
. 0 
. 0 

A 0 
recurrent 0 
expansion 0 
of 0 
a 0 
maternal 0 
allele 0 
with 0 
_NUM2 0 
_DS 0 
repeats 0 
causes 0 
Huntington 1
disease 1
in 0 
two 0 
sisters 0 
. 0 

Large 0 
intergenerational 0 
repeat 0 
expansions 0 
of 0 
the 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
the 0 
HD 1
gene 0 
have 0 
been 0 
well 0 
documented 0 
for 0 
the 0 
male 0 
germline 0 
. 0 

We 0 
describe 0 
a 0 
recurrent 0 
large 0 
expansion 0 
of 0 
a 0 
maternal 0 
allele 0 
with 0 
_NUM2 0 
_DS 0 
repeats 0 
-LRB- 0 
to 0 
_NUM2 0 
and 0 
_NUM2 0 
repeats 0 
, 0 
respectively 0 
, 0 
in 0 
two 0 
daughters 0 
-RRB- 0 
associated 0 
with 0 
onset 0 
of 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
in 0 
the 0 
second 0 
and 0 
third 0 
decade 0 
in 0 
a 0 
family 0 
without 0 
history 0 
of 0 
HD 1
. 0 

Our 0 
findings 0 
give 0 
evidence 0 
of 0 
a 0 
gonadal 0 
mosaicism 0 
in 0 
the 0 
unaffected 0 
mother 0 
. 0 

We 0 
hypothesize 0 
that 0 
large 0 
expansions 0 
also 0 
occur 0 
in 0 
the 0 
female 0 
germline 0 
and 0 
that 0 
a 0 
negative 0 
selection 0 
of 0 
oocytes 0 
with 0 
long 0 
repeats 0 
might 0 
explain 0 
the 0 
different 0 
instability 0 
behavior 0 
of 0 
the 0 
male 0 
and 0 
the 0 
female 0 
germlines 0 
. 0 
. 0 

Germline 0 
E-cadherin 0 
gene 0 
-LRB- 0 
CDH1 0 
-RRB- 0 
mutations 0 
predispose 0 
to 0 
familial 1
gastric 1
cancer 1
and 0 
colorectal 1
cancer 1
. 0 

Inherited 0 
mutations 0 
in 0 
the 0 
E-cadherin 0 
gene 0 
-LRB- 0 
CDH1 0 
-RRB- 0 
were 0 
described 0 
recently 0 
in 0 
three 0 
Maori 0 
kindreds 0 
with 0 
familial 1
gastric 1
cancer 1
. 0 

Familial 1
gastric 1
cancer 1
is 0 
genetically 0 
heterogeneous 0 
and 0 
it 0 
is 0 
not 0 
clear 0 
what 0 
proportion 0 
of 0 
gastric 1
cancer 1
susceptibility 0 
in 0 
non-Maori 0 
populations 0 
is 0 
due 0 
to 0 
germline 0 
CDH1 0 
mutations 0 
. 0 

Therefore 0 
, 0 
we 0 
screened 0 
eight 0 
familial 1
gastric 1
cancer 1
kindreds 0 
of 0 
British 0 
and 0 
Irish 0 
origin 0 
for 0 
germline 0 
CDH1 0 
mutations 0 
, 0 
by 0 
SSCP 0 
analysis 0 
of 0 
all 0 
_NUM2 0 
exons 0 
and 0 
flanking 0 
sequences 0 
. 0 

Each 0 
family 0 
contained 0 
-LRB- 0 
i 0 
-RRB- 0 
two 0 
cases 0 
of 0 
gastric 1
cancer 1
in 0 
first 0 
degree 0 
relatives 0 
with 0 
one 0 
affected 0 
before 0 
age 0 
_NUM2 0 
years 0 
; 0 
or 0 
-LRB- 0 
ii 0 
-RRB- 0 
three 0 
or 0 
more 0 
cases 0 
of 0 
gastric 1
cancer 1
. 0 

Novel 0 
germline 0 
CDH1 0 
mutations 0 
-LRB- 0 
a 0 
nonsense 0 
and 0 
a 0 
splice 0 
site 0 
-RRB- 0 
were 0 
detected 0 
in 0 
two 0 
families 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

Both 0 
mutations 0 
were 0 
predicted 0 
to 0 
truncate 0 
the 0 
E-cadherin 0 
protein 0 
in 0 
the 0 
signal 0 
peptide 0 
domain 0 
. 0 

In 0 
one 0 
family 0 
there 0 
was 0 
evidence 0 
of 0 
non-penetrance 0 
and 0 
susceptibility 0 
to 0 
both 0 
gastric 1
and 1
colorectal 1
cancer 1
; 0 
thus 0 
, 0 
in 0 
addition 0 
to 0 
six 0 
cases 0 
of 0 
gastric 1
cancer 1
, 0 
a 0 
CDH1 0 
mutation 0 
carrier 0 
developed 0 
colorectal 1
cancer 1
at 0 
age 0 
_NUM2 0 
years 0 
. 0 

We 0 
have 0 
confirmed 0 
that 0 
germline 0 
mutations 0 
in 0 
the 0 
CDH1 0 
gene 0 
cause 0 
familial 1
gastric 1
cancer 1
in 0 
non-Maori 0 
populations 0 
. 0 

However 0 
, 0 
only 0 
a 0 
minority 0 
of 0 
familial 0 
gastric 1
cancers 1
can 0 
be 0 
accounted 0 
for 0 
by 0 
CDH1 0 
mutations 0 
. 0 

Loss 0 
of 0 
E-cadherin 0 
function 0 
has 0 
been 0 
implicated 0 
in 0 
the 0 
pathogenesis 0 
of 0 
sporadic 0 
colorectal 1
and 1
other 1
cancers 1
, 0 
and 0 
our 0 
findings 0 
provide 0 
evidence 0 
that 0 
germline 0 
CDH1 0 
mutations 0 
predispose 0 
to 0 
early 0 
onset 0 
colorectal 1
cancer 1
. 0 

Thus 0 
, 0 
CDH1 0 
should 0 
be 0 
investigated 0 
as 0 
a 0 
cause 0 
of 0 
inherited 0 
susceptibility 0 
to 0 
both 0 
gastric 1
and 1
colorectal 1
cancers 1
. 0 

Germinal 0 
mosaicism 0 
in 0 
Duchenne 1
muscular 1
dystrophy 1
. 0 

We 0 
have 0 
identified 0 
a 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
pedigree 0 
where 0 
the 0 
disease 0 
is 0 
associated 0 
with 0 
a 0 
molecular 0 
deletion 0 
within 0 
the 0 
DMD 1
locus 0 
. 0 

We 0 
have 0 
examined 0 
the 0 
meiotic 0 
segregation 0 
products 0 
of 0 
the 0 
common 0 
female 0 
ancestor 0 
using 0 
marker 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
-LRB- 0 
RFLPs 0 
-RRB- 0 
detected 0 
by 0 
probes 0 
that 0 
lie 0 
within 0 
this 0 
deletion 0 
. 0 

These 0 
studies 0 
show 0 
that 0 
this 0 
female 0 
has 0 
transmitted 0 
three 0 
distinct 0 
types 0 
of 0 
X 0 
chromosome 0 
to 0 
her 0 
offspring 0 
. 0 

This 0 
observation 0 
may 0 
be 0 
explained 0 
by 0 
postulating 0 
that 0 
the 0 
mutation 0 
arose 0 
as 0 
a 0 
postzygotic 0 
deletion 0 
within 0 
this 0 
common 0 
ancestor 0 
, 0 
who 0 
was 0 
consequently 0 
germinally 0 
mosaic 0 
. 0 
. 0 

Expression 0 
of 0 
the 0 
murine 0 
Duchenne 1
muscular 1
dystrophy 1
gene 0 
in 0 
muscle 0 
and 0 
brain 0 
. 0 

Complementary 0 
DNA 0 
clones 0 
were 0 
isolated 0 
that 0 
represent 0 
the 0 
_NUM1 0 
terminal 0 
_NUM1 0 
. 0 

_NUM1 0 
kilobases 0 
of 0 
the 0 
murine 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
Dmd 0 
-RRB- 0 
messenger 0 
RNA 0 
-LRB- 0 
mRNA 0 
-RRB- 0 
. 0 

Mouse 0 
Dmd 0 
mRNA 0 
was 0 
detectable 0 
in 0 
skeletal 0 
and 0 
cardiac 0 
muscle 0 
and 0 
at 0 
a 0 
level 0 
approximately 0 
_NUM2 0 
percent 0 
lower 0 
in 0 
brain 0 
. 0 

Dmd 0 
mRNA 0 
is 0 
also 0 
present 0 
, 0 
but 0 
at 0 
much 0 
lower 0 
than 0 
normal 0 
levels 0 
, 0 
in 0 
both 0 
the 0 
muscle 0 
and 0 
brain 0 
of 0 
three 0 
different 0 
strains 0 
of 0 
dystrophic 1
mdx 0 
mice 0 
. 0 

The 0 
identification 0 
of 0 
Dmd 0 
mRNA 0 
in 0 
brain 0 
raises 0 
the 0 
possibility 0 
of 0 
a 0 
relation 0 
between 0 
human 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
gene 0 
expression 0 
and 0 
the 0 
mental 1
retardation 1
found 0 
in 0 
some 0 
DMD 1
males 0 
. 0 

These 0 
results 0 
also 0 
provide 0 
evidence 0 
that 0 
the 0 
mdx 0 
mutations 0 
are 0 
allelic 0 
variants 0 
of 0 
mouse 0 
Dmd 0 
gene 0 
mutations 0 
. 0 

Human 0 
peroxisomal 0
targeting 0 
signal-1 0 
receptor 0 
restores 0 
peroxisomal 0
protein 0 
import 0 
in 0 
cells 0 
from 0 
patients 0 
with 0 
fatal 0 
peroxisomal 1
disorders 1
. 0 

Two 0 
peroxisomal 0
targeting 0 
signals 0 
, 0 
PTS1 0 
and 0 
PTS2 0 
, 0 
are 0 
involved 0 
in 0 
the 0 
import 0 
of 0 
proteins 0 
into 0 
the 0 
peroxisome 0 
matrix 0 
. 0 

Human 0 
patients 0 
with 0 
fatal 0 
generalized 0 
peroxisomal 1
deficiency 1
disorders 1
fall 0 
into 0 
at 0 
least 0 
nine 0 
genetic 0 
complementation 0 
groups 0 
. 0 

Cells 0 
from 0 
many 0 
of 0 
these 0 
patients 0 
are 0 
deficient 0 
in 0 
the 0 
import 0 
of 0 
PTS1-containing 0 
proteins 0 
, 0 
but 0 
the 0 
causes 0 
of 0 
the 0 
protein-import 0 
defect 0 
in 0 
these 0 
patients 0 
are 0 
unknown 0 
. 0 

We 0 
have 0 
cloned 0 
and 0 
sequenced 0 
the 0 
human 0 
cDNA 0 
homologue 0 
-LRB- 0 
PTS1R 0 
-RRB- 0 
of 0 
the 0 
Pichia 0 
pastoris 0 
PAS8 0 
gene 0 
, 0 
the 0 
PTS1 0
receptor 0 
-LRB- 0 
McCollum 0 
, 0 
D. 0 
, 0 
E. 0 
Monosov 0 
, 0 
and 0 
S. 0 
Subramani 0 
. 0 

_NUM4 0 
. 0 

J. 0 
Cell 0 
Biol 0 
. 0 

_NUM3 0 
761-774 0 
-RRB- 0 
. 0 

The 0 
PTS1R 0 
mRNA 0 
is 0 
expressed 0 
in 0 
all 0 
human 0 
tissues 0 
examined 0 
. 0 

Antibodies 0 
to 0 
the 0 
human 0 
PTS1R 0 
recognize 0 
this 0 
protein 0 
in 0 
human 0 
, 0 
monkey 0 
, 0 
rat 0 
, 0 
and 0 
hamster 0 
cells 0 
. 0 

The 0 
protein 0 
is 0 
localized 0 
mainly 0 
in 0 
the 0 
cytosol 0 
but 0 
is 0 
also 0 
found 0 
to 0 
be 0 
associated 0 
with 0 
peroxisomes 0 
. 0 

Part 0 
of 0 
the 0 
peroxisomal 0 
PTS1R 0 
protein 0 
is 0 
tightly 0 
bound 0 
to 0 
the 0 
peroxisomal 0 
membrane 0 
. 0 

Antibodies 0 
to 0 
PTS1R 0 
inhibit 0 
peroxisomal 0 
protein-import 0 
of 0 
PTS1-containing 0 
proteins 0 
in 0 
a 0 
permeabilized 0 
CHO 0 
cell 0 
system 0 
. 0 

In 0 
vitro-translated 0 
PTS1R 0 
protein 0 
specifically 0 
binds 0 
a 0 
serine-lysine-leucine-peptide 0 
. 0 

A 0 
PAS8-PTS1R 0 
fusion 0 
protein 0 
complements 0 
the 0 
P. 0 
pastoris 0 
pas8 0 
mutant 0 
. 0 

The 0 
PTS1R 0 
cDNA 0 
also 0 
complements 0 
the 0 
PTS1 1
protein-import 1
defect 1
in 0 
skin 0 
fibroblasts 0 
from 0 
patients 0 
-- 0 
belonging 0 
to 0 
complementation 0 
group 0 
two 0 
-- 0 
diagnosed 0 
as 0 
having 0 
neonatal 1
adrenoleukodystrophy 1
or 0 
Zellweger 1
syndrome 1
. 0 

The 0 
PTS1R 0 
gene 0 
has 0 
been 0 
localized 0 
to 0 
a 0 
chromosomal 0 
location 0 
where 0 
no 0 
other 0 
peroxisomal 1
disorder 1
genes 0 
are 0 
known 0 
to 0 
map 0 
. 0 

Our 0 
findings 0 
represent 0 
the 0 
only 0 
case 0 
in 0 
which 0 
the 0 
molecular 0 
basis 0 
of 0 
the 0 
protein-import 1
deficiency 1
in 0 
human 0 
peroxisomal 1
disorders 1
is 0 
understood 0 
. 0 

X-linked 1
spastic 1
paraplegia 1
and 0 
Pelizaeus-Merzbacher 1
disease 1
are 0 
allelic 1
disorders 1
at 0 
the 0 
proteolipid 0 
protein 0 
locus 0 
. 0 

Three 0 
forms 0 
of 0 
X-linked 1
spastic 1
paraplegia 1
-LRB- 0 
SPG 1
-RRB- 0 
have 0 
been 0 
defined 0 
. 0 

One 0 
locus 0 
-LRB- 0 
SPG 0 
_NUM1 0 
-RRB- 0 
maps 0 
to 0 
Xq28 0 
while 0 
two 0 
clinically 0 
distinct 0 
forms 0 
map 0 
to 0 
Xq22 0 
-LRB- 0 
SPG2 0 
-RRB- 0 
. 0 

A 0 
rare 0 
X-linked 1
dysmyelinating 1
disorder 1
of 0 
the 0 
central 0 
nervous 0 
system 0 
, 0 
Pelizaeus-Merzbacher 1
disease 1
-LRB- 0 
PMD 1
-RRB- 0 
, 0 
has 0 
also 0 
been 0 
mapped 0 
to 0 
Xq21-q22 0 
, 0 
and 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
the 0 
proteolipid 0 
protein 0 
gene 0 
-LRB- 0 
PLP 0 
-RRB- 0 
which 0 
encodes 0 
two 0 
myelin 0 
proteins 0 
, 0 
PLP 0 
and 0 
DM20 0 
. 0 

While 0 
narrowing 0 
the 0 
genetic 0 
interval 0 
containing 0 
SPG2 0 
in 0 
a 0 
large 0 
pedigree 0 
, 0 
we 0 
found 0 
that 0 
PLP 0 
was 0 
the 0 
closest 0 
marker 0 
to 0 
the 0 
disease 0 
locus 0 
, 0 
implicating 0 
PLP 0 
as 0 
a 0 
possible 0 
candidate 0 
gene 0 
. 0 

We 0 
have 0 
found 0 
that 0 
a 0 
point 0 
mutation 0 
-LRB- 0 
His139Tyr 0 
-RRB- 0 
in 0 
exon 0 
3B 0 
of 0 
an 0 
affected 0 
male 0 
produces 0 
a 0 
mutant 0 
PLP 0 
but 0 
a 0 
normal 0 
DM20 0 
, 0 
and 0 
segregates 0 
with 0 
the 0 
disease 0 
-LRB- 0 
Zmax 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
theta 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

It 0 
appears 0 
, 0 
therefore 0 
, 0 
that 0 
SPG2 0 
and 0 
PMD 1
are 0 
allelic 0
disorders 0 
